Province, Autonomous City and Community of hospitalization;Main diagnosis (ICD-9-CM) reduced list;Sex;Total TOTAL NATIONAL;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Both sexes;4,637,427 TOTAL NATIONAL;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Men;2,186,003 TOTAL NATIONAL;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Women;2,451,424 TOTAL NATIONAL;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Both sexes;95,264 TOTAL NATIONAL;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Men;53,244 TOTAL NATIONAL;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Women;42,020 TOTAL NATIONAL;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Both sexes;14,484 TOTAL NATIONAL;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Men;7,651 TOTAL NATIONAL;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Women;6,833 TOTAL NATIONAL;Group 0102 Imprecise intestinal infections 009;Both sexes;8,144 TOTAL NATIONAL;Group 0102 Imprecise intestinal infections 009;Men;3,904 TOTAL NATIONAL;Group 0102 Imprecise intestinal infections 009;Women;4,241 TOTAL NATIONAL;Group 0103 Tuberculosis 010-018, 137;Both sexes;4,103 TOTAL NATIONAL;Group 0103 Tuberculosis 010-018, 137;Men;2,649 TOTAL NATIONAL;Group 0103 Tuberculosis 010-018, 137;Women;1,454 TOTAL NATIONAL;Group 0104 Septicaemia 038;Both sexes;33,326 TOTAL NATIONAL;Group 0104 Septicaemia 038;Men;17,945 TOTAL NATIONAL;Group 0104 Septicaemia 038;Women;15,381 TOTAL NATIONAL;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Both sexes;3,823 TOTAL NATIONAL;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Men;2,850 TOTAL NATIONAL;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Women;973 TOTAL NATIONAL;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Both sexes;31,384 TOTAL NATIONAL;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Men;18,245 TOTAL NATIONAL;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Women;13,138 TOTAL NATIONAL;Group 0200 Neoplasms 140-239;Both sexes;452,013 TOTAL NATIONAL;Group 0200 Neoplasms 140-239;Men;236,183 TOTAL NATIONAL;Group 0200 Neoplasms 140-239;Women;215,829 TOTAL NATIONAL;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Both sexes;46,083 TOTAL NATIONAL;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Men;28,009 TOTAL NATIONAL;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Women;18,074 TOTAL NATIONAL;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Both sexes;33,805 TOTAL NATIONAL;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Men;26,840 TOTAL NATIONAL;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Women;6,965 TOTAL NATIONAL;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Both sexes;8,500 TOTAL NATIONAL;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Men;4,847 TOTAL NATIONAL;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Women;3,653 TOTAL NATIONAL;Group 0204 Malignant neoplasm of breast 174-175;Both sexes;35,439 TOTAL NATIONAL;Group 0204 Malignant neoplasm of breast 174-175;Men;293 TOTAL NATIONAL;Group 0204 Malignant neoplasm of breast 174-175;Women;35,146 TOTAL NATIONAL;Group 0205 Malignant neoplasm of uterus 179-180, 182;Both sexes;9,517 TOTAL NATIONAL;Group 0205 Malignant neoplasm of uterus 179-180, 182;Men;.. TOTAL NATIONAL;Group 0205 Malignant neoplasm of uterus 179-180, 182;Women;9,517 TOTAL NATIONAL;Group 0206 Malignant neoplasm of ovary 1830;Both sexes;5,074 TOTAL NATIONAL;Group 0206 Malignant neoplasm of ovary 1830;Men;.. TOTAL NATIONAL;Group 0206 Malignant neoplasm of ovary 1830;Women;5,074 TOTAL NATIONAL;Group 0207 Malignant neoplasm of prostate 185;Both sexes;17,784 TOTAL NATIONAL;Group 0207 Malignant neoplasm of prostate 185;Men;17,784 TOTAL NATIONAL;Group 0207 Malignant neoplasm of prostate 185;Women;.. TOTAL NATIONAL;Group 0208 Malignant neoplasm of bladder 188;Both sexes;41,195 TOTAL NATIONAL;Group 0208 Malignant neoplasm of bladder 188;Men;34,694 TOTAL NATIONAL;Group 0208 Malignant neoplasm of bladder 188;Women;6,501 TOTAL NATIONAL;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Both sexes;157,237 TOTAL NATIONAL;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Men;91,774 TOTAL NATIONAL;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Women;65,463 TOTAL NATIONAL;Group 0210 Carcinoma in situ 230-234;Both sexes;7,277 TOTAL NATIONAL;Group 0210 Carcinoma in situ 230-234;Men;2,513 TOTAL NATIONAL;Group 0210 Carcinoma in situ 230-234;Women;4,764 TOTAL NATIONAL;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Both sexes;5,078 TOTAL NATIONAL;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Men;3,094 TOTAL NATIONAL;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Women;1,985 TOTAL NATIONAL;Grupo 0212 Leiomyoma of uterus 218;Both sexes;23,643 TOTAL NATIONAL;Grupo 0212 Leiomyoma of uterus 218;Men;.. TOTAL NATIONAL;Grupo 0212 Leiomyoma of uterus 218;Women;23,643 TOTAL NATIONAL;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Both sexes;61,379 TOTAL NATIONAL;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Men;26,336 TOTAL NATIONAL;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Women;35,043 TOTAL NATIONAL;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Both sexes;42,321 TOTAL NATIONAL;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Men;20,815 TOTAL NATIONAL;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Women;21,505 TOTAL NATIONAL;Group 0301 Anaemias 280-285;Both sexes;24,840 TOTAL NATIONAL;Group 0301 Anaemias 280-285;Men;11,801 TOTAL NATIONAL;Group 0301 Anaemias 280-285;Women;13,039 TOTAL NATIONAL;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Both sexes;17,481 TOTAL NATIONAL;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Men;9,015 TOTAL NATIONAL;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Women;8,466 TOTAL NATIONAL;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Both sexes;84,351 TOTAL NATIONAL;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Men;33,703 TOTAL NATIONAL;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Women;50,648 TOTAL NATIONAL;Group 0401 Diabetes mellitus 249-250;Both sexes;27,400 TOTAL NATIONAL;Group 0401 Diabetes mellitus 249-250;Men;15,732 TOTAL NATIONAL;Group 0401 Diabetes mellitus 249-250;Women;11,668 TOTAL NATIONAL;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Both sexes;56,950 TOTAL NATIONAL;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Men;17,971 TOTAL NATIONAL;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Women;38,980 TOTAL NATIONAL;Group 0500 Mental disorders 290-319;Both sexes;116,000 TOTAL NATIONAL;Group 0500 Mental disorders 290-319;Men;60,390 TOTAL NATIONAL;Group 0500 Mental disorders 290-319;Women;55,610 TOTAL NATIONAL;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Both sexes;3,968 TOTAL NATIONAL;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Men;1,750 TOTAL NATIONAL;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Women;2,218 TOTAL NATIONAL;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Both sexes;8,794 TOTAL NATIONAL;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Men;6,496 TOTAL NATIONAL;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Women;2,298 TOTAL NATIONAL;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Both sexes;6,972 TOTAL NATIONAL;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Men;5,175 TOTAL NATIONAL;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Women;1,798 TOTAL NATIONAL;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Both sexes;33,536 TOTAL NATIONAL;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Men;20,677 TOTAL NATIONAL;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Women;12,859 TOTAL NATIONAL;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Both sexes;26,351 TOTAL NATIONAL;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Men;10,535 TOTAL NATIONAL;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Women;15,816 TOTAL NATIONAL;Group 0506 Other mental and behavioural disorders Rest of (290-319);Both sexes;36,379 TOTAL NATIONAL;Group 0506 Other mental and behavioural disorders Rest of (290-319);Men;15,758 TOTAL NATIONAL;Group 0506 Other mental and behavioural disorders Rest of (290-319);Women;20,621 TOTAL NATIONAL;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Both sexes;106,908 TOTAL NATIONAL;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Men;54,099 TOTAL NATIONAL;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Women;52,808 TOTAL NATIONAL;Group 0601 Alzheimer's disease 3310;Both sexes;3,100 TOTAL NATIONAL;Group 0601 Alzheimer's disease 3310;Men;1,097 TOTAL NATIONAL;Group 0601 Alzheimer's disease 3310;Women;2,003 TOTAL NATIONAL;Group 0602 Multiple sclerosis 340;Both sexes;2,510 TOTAL NATIONAL;Group 0602 Multiple sclerosis 340;Men;806 TOTAL NATIONAL;Group 0602 Multiple sclerosis 340;Women;1,704 TOTAL NATIONAL;Group 0603 Epilepsy 345;Both sexes;17,674 TOTAL NATIONAL;Group 0603 Epilepsy 345;Men;9,429 TOTAL NATIONAL;Group 0603 Epilepsy 345;Women;8,245 TOTAL NATIONAL;Group 0604 Transient cerebral ischemia 435;Both sexes;15,811 TOTAL NATIONAL;Group 0604 Transient cerebral ischemia 435;Men;8,029 TOTAL NATIONAL;Group 0604 Transient cerebral ischemia 435;Women;7,782 TOTAL NATIONAL;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Both sexes;67,813 TOTAL NATIONAL;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Men;34,739 TOTAL NATIONAL;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Women;33,073 TOTAL NATIONAL;Grupo 0700 Diseases of the eye and adnexa 360-379;Both sexes;29,864 TOTAL NATIONAL;Grupo 0700 Diseases of the eye and adnexa 360-379;Men;15,307 TOTAL NATIONAL;Grupo 0700 Diseases of the eye and adnexa 360-379;Women;14,557 TOTAL NATIONAL;Grupo 0701 Cataract 366;Both sexes;6,253 TOTAL NATIONAL;Grupo 0701 Cataract 366;Men;2,921 TOTAL NATIONAL;Grupo 0701 Cataract 366;Women;3,332 TOTAL NATIONAL;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Both sexes;23,611 TOTAL NATIONAL;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Men;12,386 TOTAL NATIONAL;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Women;11,225 TOTAL NATIONAL;Group 0800 Diseases of the ear and the mastoid 380-389;Both sexes;23,824 TOTAL NATIONAL;Group 0800 Diseases of the ear and the mastoid 380-389;Men;11,706 TOTAL NATIONAL;Group 0800 Diseases of the ear and the mastoid 380-389;Women;12,118 TOTAL NATIONAL;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Both sexes;602,427 TOTAL NATIONAL;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Men;337,470 TOTAL NATIONAL;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Women;264,957 TOTAL NATIONAL;Group 0901 Hypertensive disease 401-405;Both sexes;30,229 TOTAL NATIONAL;Group 0901 Hypertensive disease 401-405;Men;12,961 TOTAL NATIONAL;Group 0901 Hypertensive disease 401-405;Women;17,269 TOTAL NATIONAL;Group 0902 Angina pectoris 4111, 413;Both sexes;26,392 TOTAL NATIONAL;Group 0902 Angina pectoris 4111, 413;Men;16,493 TOTAL NATIONAL;Group 0902 Angina pectoris 4111, 413;Women;9,898 TOTAL NATIONAL;Group 0903 Acute myocardial infarction 410;Both sexes;54,144 TOTAL NATIONAL;Group 0903 Acute myocardial infarction 410;Men;38,145 TOTAL NATIONAL;Group 0903 Acute myocardial infarction 410;Women;16,000 TOTAL NATIONAL;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Both sexes;44,059 TOTAL NATIONAL;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Men;33,732 TOTAL NATIONAL;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Women;10,328 TOTAL NATIONAL;Group 0905 Diseases of the lungs circulation 415-417;Both sexes;19,315 TOTAL NATIONAL;Group 0905 Diseases of the lungs circulation 415-417;Men;8,804 TOTAL NATIONAL;Group 0905 Diseases of the lungs circulation 415-417;Women;10,511 TOTAL NATIONAL;Group 0906 Heart conduction disorders and arrhytmias 426-427;Both sexes;76,600 TOTAL NATIONAL;Group 0906 Heart conduction disorders and arrhytmias 426-427;Men;41,565 TOTAL NATIONAL;Group 0906 Heart conduction disorders and arrhytmias 426-427;Women;35,035 TOTAL NATIONAL;Grupo 0907 Heart failure 428;Both sexes;116,369 TOTAL NATIONAL;Grupo 0907 Heart failure 428;Men;54,463 TOTAL NATIONAL;Grupo 0907 Heart failure 428;Women;61,906 TOTAL NATIONAL;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Both sexes;102,498 TOTAL NATIONAL;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Men;54,686 TOTAL NATIONAL;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Women;47,812 TOTAL NATIONAL;Grupo 0909 Atherosclerosis 440;Both sexes;20,052 TOTAL NATIONAL;Grupo 0909 Atherosclerosis 440;Men;14,930 TOTAL NATIONAL;Grupo 0909 Atherosclerosis 440;Women;5,122 TOTAL NATIONAL;Group 0910 Varicose veins of lower extremities 454;Both sexes;17,847 TOTAL NATIONAL;Group 0910 Varicose veins of lower extremities 454;Men;6,239 TOTAL NATIONAL;Group 0910 Varicose veins of lower extremities 454;Women;11,608 TOTAL NATIONAL;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Both sexes;94,922 TOTAL NATIONAL;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Men;55,453 TOTAL NATIONAL;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Women;39,470 TOTAL NATIONAL;Group 1000 Diseases of the respiratory system 0340, 460-519;Both sexes;506,939 TOTAL NATIONAL;Group 1000 Diseases of the respiratory system 0340, 460-519;Men;291,126 TOTAL NATIONAL;Group 1000 Diseases of the respiratory system 0340, 460-519;Women;215,813 TOTAL NATIONAL;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Both sexes;19,506 TOTAL NATIONAL;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Men;10,415 TOTAL NATIONAL;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Women;9,091 TOTAL NATIONAL;Group 1002 Pneumonia 480-486;Both sexes;108,555 TOTAL NATIONAL;Group 1002 Pneumonia 480-486;Men;64,247 TOTAL NATIONAL;Group 1002 Pneumonia 480-486;Women;44,308 TOTAL NATIONAL;Group 1003 Acute bronchitis and bronchiolitis 466;Both sexes;45,733 TOTAL NATIONAL;Group 1003 Acute bronchitis and bronchiolitis 466;Men;22,260 TOTAL NATIONAL;Group 1003 Acute bronchitis and bronchiolitis 466;Women;23,473 TOTAL NATIONAL;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Both sexes;26,459 TOTAL NATIONAL;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Men;13,830 TOTAL NATIONAL;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Women;12,629 TOTAL NATIONAL;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Both sexes;42,252 TOTAL NATIONAL;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Men;26,235 TOTAL NATIONAL;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Women;16,017 TOTAL NATIONAL;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Both sexes;82,442 TOTAL NATIONAL;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Men;62,801 TOTAL NATIONAL;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Women;19,641 TOTAL NATIONAL;Group 1007 Asthma 4930-4931,4938-4939;Both sexes;21,626 TOTAL NATIONAL;Group 1007 Asthma 4930-4931,4938-4939;Men;6,934 TOTAL NATIONAL;Group 1007 Asthma 4930-4931,4938-4939;Women;14,692 TOTAL NATIONAL;Group 1008 Other diseases of the respiratory system Resto of (460-519);Both sexes;160,366 TOTAL NATIONAL;Group 1008 Other diseases of the respiratory system Resto of (460-519);Men;84,404 TOTAL NATIONAL;Group 1008 Other diseases of the respiratory system Resto of (460-519);Women;75,962 TOTAL NATIONAL;Group 1100 Diseases of the digestive system 520-579;Both sexes;565,782 TOTAL NATIONAL;Group 1100 Diseases of the digestive system 520-579;Men;315,624 TOTAL NATIONAL;Group 1100 Diseases of the digestive system 520-579;Women;250,158 TOTAL NATIONAL;Group 1101 Disorders of the teeth and supporting structures 520-525;Both sexes;9,426 TOTAL NATIONAL;Group 1101 Disorders of the teeth and supporting structures 520-525;Men;4,400 TOTAL NATIONAL;Group 1101 Disorders of the teeth and supporting structures 520-525;Women;5,026 TOTAL NATIONAL;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Both sexes;7,950 TOTAL NATIONAL;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Men;4,426 TOTAL NATIONAL;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Women;3,524 TOTAL NATIONAL;Group 1103 Diseases of the esophagus 530;Both sexes;10,864 TOTAL NATIONAL;Group 1103 Diseases of the esophagus 530;Men;6,491 TOTAL NATIONAL;Group 1103 Diseases of the esophagus 530;Women;4,372 TOTAL NATIONAL;Group 1104 Peptic ulcer 531-534;Both sexes;10,473 TOTAL NATIONAL;Group 1104 Peptic ulcer 531-534;Men;7,224 TOTAL NATIONAL;Group 1104 Peptic ulcer 531-534;Women;3,249 TOTAL NATIONAL;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Both sexes;13,948 TOTAL NATIONAL;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Men;6,891 TOTAL NATIONAL;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Women;7,058 TOTAL NATIONAL;Group 1106 Appendicitis 540-543;Both sexes;48,684 TOTAL NATIONAL;Group 1106 Appendicitis 540-543;Men;27,687 TOTAL NATIONAL;Group 1106 Appendicitis 540-543;Women;20,998 TOTAL NATIONAL;Group 1107 Inguinal hernia 550;Both sexes;58,546 TOTAL NATIONAL;Group 1107 Inguinal hernia 550;Men;52,066 TOTAL NATIONAL;Group 1107 Inguinal hernia 550;Women;6,480 TOTAL NATIONAL;Group 1108 Other abdominal hernia 551-553;Both sexes;46,789 TOTAL NATIONAL;Group 1108 Other abdominal hernia 551-553;Men;22,036 TOTAL NATIONAL;Group 1108 Other abdominal hernia 551-553;Women;24,754 TOTAL NATIONAL;Group 1109 Crohn's disease and ulcerative colitis 555-556;Both sexes;11,280 TOTAL NATIONAL;Group 1109 Crohn's disease and ulcerative colitis 555-556;Men;5,860 TOTAL NATIONAL;Group 1109 Crohn's disease and ulcerative colitis 555-556;Women;5,420 TOTAL NATIONAL;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Both sexes;31,715 TOTAL NATIONAL;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Men;14,937 TOTAL NATIONAL;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Women;16,778 TOTAL NATIONAL;Group 1111 Intestinal obstruction without hernia 560;Both sexes;26,520 TOTAL NATIONAL;Group 1111 Intestinal obstruction without hernia 560;Men;13,718 TOTAL NATIONAL;Group 1111 Intestinal obstruction without hernia 560;Women;12,802 TOTAL NATIONAL;Group 1112 Intestinal diverticulosis 562;Both sexes;22,906 TOTAL NATIONAL;Group 1112 Intestinal diverticulosis 562;Men;11,382 TOTAL NATIONAL;Group 1112 Intestinal diverticulosis 562;Women;11,525 TOTAL NATIONAL;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Both sexes;34,023 TOTAL NATIONAL;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Men;21,783 TOTAL NATIONAL;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Women;12,240 TOTAL NATIONAL;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Both sexes;18,969 TOTAL NATIONAL;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Men;8,636 TOTAL NATIONAL;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Women;10,333 TOTAL NATIONAL;Group 1115 Alcoholic hepatitis 5710-5713;Both sexes;10,248 TOTAL NATIONAL;Group 1115 Alcoholic hepatitis 5710-5713;Men;8,668 TOTAL NATIONAL;Group 1115 Alcoholic hepatitis 5710-5713;Women;1,581 TOTAL NATIONAL;Group 1116 Other diseases of the liver 570,5714-573;Both sexes;20,112 TOTAL NATIONAL;Group 1116 Other diseases of the liver 570,5714-573;Men;12,301 TOTAL NATIONAL;Group 1116 Other diseases of the liver 570,5714-573;Women;7,811 TOTAL NATIONAL;Group 1117 Cholelithiasis 574;Both sexes;102,313 TOTAL NATIONAL;Group 1117 Cholelithiasis 574;Men;42,951 TOTAL NATIONAL;Group 1117 Cholelithiasis 574;Women;59,362 TOTAL NATIONAL;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Both sexes;27,233 TOTAL NATIONAL;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Men;14,444 TOTAL NATIONAL;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Women;12,790 TOTAL NATIONAL;Group 1119 Pancreatic diseases 577;Both sexes;30,623 TOTAL NATIONAL;Group 1119 Pancreatic diseases 577;Men;16,950 TOTAL NATIONAL;Group 1119 Pancreatic diseases 577;Women;13,673 TOTAL NATIONAL;Group 1120 Other diseases of the digestive system Rest of (520-579);Both sexes;23,158 TOTAL NATIONAL;Group 1120 Other diseases of the digestive system Rest of (520-579);Men;12,775 TOTAL NATIONAL;Group 1120 Other diseases of the digestive system Rest of (520-579);Women;10,383 TOTAL NATIONAL;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Both sexes;46,728 TOTAL NATIONAL;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Men;25,232 TOTAL NATIONAL;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Women;21,496 TOTAL NATIONAL;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Both sexes;28,615 TOTAL NATIONAL;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Men;16,861 TOTAL NATIONAL;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Women;11,753 TOTAL NATIONAL;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Both sexes;2,234 TOTAL NATIONAL;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Men;1,092 TOTAL NATIONAL;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Women;1,142 TOTAL NATIONAL;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Both sexes;15,879 TOTAL NATIONAL;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Men;7,278 TOTAL NATIONAL;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Women;8,601 TOTAL NATIONAL;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Both sexes;344,660 TOTAL NATIONAL;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Men;164,683 TOTAL NATIONAL;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Women;179,977 TOTAL NATIONAL;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Both sexes;.. TOTAL NATIONAL;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Men;.. TOTAL NATIONAL;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Women;.. TOTAL NATIONAL;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Both sexes;.. TOTAL NATIONAL;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Men;.. TOTAL NATIONAL;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Women;.. TOTAL NATIONAL;Group 1303 Internal derangement of knee 717;Both sexes;48,912 TOTAL NATIONAL;Group 1303 Internal derangement of knee 717;Men;33,249 TOTAL NATIONAL;Group 1303 Internal derangement of knee 717;Women;15,663 TOTAL NATIONAL;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Both sexes;124,326 TOTAL NATIONAL;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Men;53,013 TOTAL NATIONAL;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Women;71,313 TOTAL NATIONAL;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Both sexes;6,432 TOTAL NATIONAL;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Men;2,315 TOTAL NATIONAL;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Women;4,117 TOTAL NATIONAL;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Both sexes;16,165 TOTAL NATIONAL;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Men;7,829 TOTAL NATIONAL;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Women;8,336 TOTAL NATIONAL;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Both sexes;31,545 TOTAL NATIONAL;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Men;16,884 TOTAL NATIONAL;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Women;14,661 TOTAL NATIONAL;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Both sexes;9,848 TOTAL NATIONAL;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Men;4,419 TOTAL NATIONAL;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Women;5,429 TOTAL NATIONAL;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Both sexes;51,036 TOTAL NATIONAL;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Men;26,557 TOTAL NATIONAL;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Women;24,479 TOTAL NATIONAL;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Both sexes;56,396 TOTAL NATIONAL;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Men;20,417 TOTAL NATIONAL;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Women;35,979 TOTAL NATIONAL;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Both sexes;301,718 TOTAL NATIONAL;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Men;137,321 TOTAL NATIONAL;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Women;164,398 TOTAL NATIONAL;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Both sexes;30,855 TOTAL NATIONAL;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Men;10,886 TOTAL NATIONAL;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Women;19,969 TOTAL NATIONAL;Group 1402 Renal failure 5836-5837, 584-586;Both sexes;26,971 TOTAL NATIONAL;Group 1402 Renal failure 5836-5837, 584-586;Men;15,346 TOTAL NATIONAL;Group 1402 Renal failure 5836-5837, 584-586;Women;11,625 TOTAL NATIONAL;Group 1403 Urolithiasis 592, 594, 7880;Both sexes;37,320 TOTAL NATIONAL;Group 1403 Urolithiasis 592, 594, 7880;Men;22,353 TOTAL NATIONAL;Group 1403 Urolithiasis 592, 594, 7880;Women;14,967 TOTAL NATIONAL;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Both sexes;78,234 TOTAL NATIONAL;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Men;37,945 TOTAL NATIONAL;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Women;40,288 TOTAL NATIONAL;Group 1405 Prostatic hyperplasia 600;Both sexes;25,630 TOTAL NATIONAL;Group 1405 Prostatic hyperplasia 600;Men;25,630 TOTAL NATIONAL;Group 1405 Prostatic hyperplasia 600;Women;.. TOTAL NATIONAL;Group 1406 Other diseases of the male genital organs 601-608;Both sexes;22,564 TOTAL NATIONAL;Group 1406 Other diseases of the male genital organs 601-608;Men;22,564 TOTAL NATIONAL;Group 1406 Other diseases of the male genital organs 601-608;Women;.. TOTAL NATIONAL;Group 1407 Disorders of breast 610-612;Both sexes;18,281 TOTAL NATIONAL;Group 1407 Disorders of breast 610-612;Men;1,946 TOTAL NATIONAL;Group 1407 Disorders of breast 610-612;Women;16,335 TOTAL NATIONAL;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Both sexes;8,153 TOTAL NATIONAL;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Men;.. TOTAL NATIONAL;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Women;8,153 TOTAL NATIONAL;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Both sexes;4,490 TOTAL NATIONAL;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Men;.. TOTAL NATIONAL;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Women;4,490 TOTAL NATIONAL;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Both sexes;49,221 TOTAL NATIONAL;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Men;651 TOTAL NATIONAL;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Women;48,570 TOTAL NATIONAL;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Both sexes;492,606 TOTAL NATIONAL;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Men;.. TOTAL NATIONAL;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Women;492,606 TOTAL NATIONAL;Group 1501 Legally induced abortion 635;Both sexes;2,064 TOTAL NATIONAL;Group 1501 Legally induced abortion 635;Men;.. TOTAL NATIONAL;Group 1501 Legally induced abortion 635;Women;2,064 TOTAL NATIONAL;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Both sexes;29,764 TOTAL NATIONAL;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Men;.. TOTAL NATIONAL;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Women;29,764 TOTAL NATIONAL;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Both sexes;287,414 TOTAL NATIONAL;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Men;.. TOTAL NATIONAL;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Women;287,414 TOTAL NATIONAL;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Both sexes;85,835 TOTAL NATIONAL;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Men;.. TOTAL NATIONAL;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Women;85,835 TOTAL NATIONAL;Group 1505 Single spontaneous delivery 650;Both sexes;35,924 TOTAL NATIONAL;Group 1505 Single spontaneous delivery 650;Men;.. TOTAL NATIONAL;Group 1505 Single spontaneous delivery 650;Women;35,924 TOTAL NATIONAL;Group 1506 Other deliveries 6695-6697;Both sexes;17,506 TOTAL NATIONAL;Group 1506 Other deliveries 6695-6697;Men;.. TOTAL NATIONAL;Group 1506 Other deliveries 6695-6697;Women;17,506 TOTAL NATIONAL;Group 1507 Complications related to the puerperium 670-676;Both sexes;3,885 TOTAL NATIONAL;Group 1507 Complications related to the puerperium 670-676;Men;.. TOTAL NATIONAL;Group 1507 Complications related to the puerperium 670-676;Women;3,885 TOTAL NATIONAL;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Both sexes;30,214 TOTAL NATIONAL;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Men;.. TOTAL NATIONAL;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Women;30,214 TOTAL NATIONAL;Group 1600 Some disorders originating in the perinatal period 760-779;Both sexes;64,004 TOTAL NATIONAL;Group 1600 Some disorders originating in the perinatal period 760-779;Men;35,147 TOTAL NATIONAL;Group 1600 Some disorders originating in the perinatal period 760-779;Women;28,856 TOTAL NATIONAL;Group 1601 Disorders related with premature delivery and a low birth weight 765;Both sexes;17,044 TOTAL NATIONAL;Group 1601 Disorders related with premature delivery and a low birth weight 765;Men;9,089 TOTAL NATIONAL;Group 1601 Disorders related with premature delivery and a low birth weight 765;Women;7,955 TOTAL NATIONAL;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Both sexes;46,960 TOTAL NATIONAL;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Men;26,058 TOTAL NATIONAL;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Women;20,902 TOTAL NATIONAL;Grupo 1700 Congenital abnormalities 740-759;Both sexes;39,059 TOTAL NATIONAL;Grupo 1700 Congenital abnormalities 740-759;Men;21,999 TOTAL NATIONAL;Grupo 1700 Congenital abnormalities 740-759;Women;17,061 TOTAL NATIONAL;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Both sexes;210,840 TOTAL NATIONAL;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Men;112,879 TOTAL NATIONAL;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Women;97,960 TOTAL NATIONAL;Group 1801 Pain in throat and chest 7841, 7865;Both sexes;25,693 TOTAL NATIONAL;Group 1801 Pain in throat and chest 7841, 7865;Men;14,323 TOTAL NATIONAL;Group 1801 Pain in throat and chest 7841, 7865;Women;11,370 TOTAL NATIONAL;Group 1802 Abdominal pain 7890;Both sexes;24,265 TOTAL NATIONAL;Group 1802 Abdominal pain 7890;Men;9,579 TOTAL NATIONAL;Group 1802 Abdominal pain 7890;Women;14,686 TOTAL NATIONAL;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Both sexes;17,888 TOTAL NATIONAL;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Men;9,008 TOTAL NATIONAL;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Women;8,880 TOTAL NATIONAL;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Both sexes;142,994 TOTAL NATIONAL;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Men;79,969 TOTAL NATIONAL;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Women;63,025 TOTAL NATIONAL;Group 1900 Injuries and poisoning 800-999;Both sexes;411,709 TOTAL NATIONAL;Group 1900 Injuries and poisoning 800-999;Men;210,163 TOTAL NATIONAL;Group 1900 Injuries and poisoning 800-999;Women;201,546 TOTAL NATIONAL;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Both sexes;22,942 TOTAL NATIONAL;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Men;13,119 TOTAL NATIONAL;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Women;9,823 TOTAL NATIONAL;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Both sexes;11,495 TOTAL NATIONAL;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Men;8,015 TOTAL NATIONAL;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Women;3,480 TOTAL NATIONAL;Group 1903 Radius and ulna fracture 813;Both sexes;24,441 TOTAL NATIONAL;Group 1903 Radius and ulna fracture 813;Men;11,546 TOTAL NATIONAL;Group 1903 Radius and ulna fracture 813;Women;12,896 TOTAL NATIONAL;Group 1904 Femur fracture 820-821;Both sexes;67,721 TOTAL NATIONAL;Group 1904 Femur fracture 820-821;Men;18,735 TOTAL NATIONAL;Group 1904 Femur fracture 820-821;Women;48,986 TOTAL NATIONAL;Group 1905 Leg fracture, including the ankle 823-824;Both sexes;30,540 TOTAL NATIONAL;Group 1905 Leg fracture, including the ankle 823-824;Men;15,552 TOTAL NATIONAL;Group 1905 Leg fracture, including the ankle 823-824;Women;14,989 TOTAL NATIONAL;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Both sexes;119,535 TOTAL NATIONAL;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Men;71,845 TOTAL NATIONAL;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Women;47,690 TOTAL NATIONAL;Group 1907 Burns 940-949;Both sexes;3,335 TOTAL NATIONAL;Group 1907 Burns 940-949;Men;2,095 TOTAL NATIONAL;Group 1907 Burns 940-949;Women;1,240 TOTAL NATIONAL;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Both sexes;11,746 TOTAL NATIONAL;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Men;5,348 TOTAL NATIONAL;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Women;6,397 TOTAL NATIONAL;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Both sexes;106,874 TOTAL NATIONAL;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Men;56,988 TOTAL NATIONAL;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Women;49,887 TOTAL NATIONAL;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Both sexes;1,194 TOTAL NATIONAL;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Men;729 TOTAL NATIONAL;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Women;465 TOTAL NATIONAL;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Both sexes;11,885 TOTAL NATIONAL;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Men;6,191 TOTAL NATIONAL;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Women;5,694 TOTAL NATIONAL;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Both sexes;100,412 TOTAL NATIONAL;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Men;48,911 TOTAL NATIONAL;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Women;51,501 TOTAL NATIONAL;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Both sexes;5,223 TOTAL NATIONAL;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Men;2,993 TOTAL NATIONAL;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Women;2,230 TOTAL NATIONAL;Group 2102 Contraceptive management V25;Both sexes;1,820 TOTAL NATIONAL;Group 2102 Contraceptive management V25;Men;120 TOTAL NATIONAL;Group 2102 Contraceptive management V25;Women;1,699 TOTAL NATIONAL;Group 2103 Living newborns by type of delivery V30-V39;Both sexes;.. TOTAL NATIONAL;Group 2103 Living newborns by type of delivery V30-V39;Men;.. TOTAL NATIONAL;Group 2103 Living newborns by type of delivery V30-V39;Women;.. TOTAL NATIONAL;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Both sexes;32,187 TOTAL NATIONAL;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Men;19,126 TOTAL NATIONAL;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Women;13,061 TOTAL NATIONAL;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Both sexes;61,182 TOTAL NATIONAL;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Men;26,672 TOTAL NATIONAL;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Women;34,510 ANDALUC═A;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Both sexes;680,537 ANDALUC═A;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Men;304,190 ANDALUC═A;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Women;376,347 ANDALUC═A;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Both sexes;15,898 ANDALUC═A;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Men;8,939 ANDALUC═A;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Women;6,959 ANDALUC═A;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Both sexes;1,906 ANDALUC═A;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Men;1,036 ANDALUC═A;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Women;870 ANDALUC═A;Group 0102 Imprecise intestinal infections 009;Both sexes;1,626 ANDALUC═A;Group 0102 Imprecise intestinal infections 009;Men;776 ANDALUC═A;Group 0102 Imprecise intestinal infections 009;Women;850 ANDALUC═A;Group 0103 Tuberculosis 010-018, 137;Both sexes;615 ANDALUC═A;Group 0103 Tuberculosis 010-018, 137;Men;423 ANDALUC═A;Group 0103 Tuberculosis 010-018, 137;Women;192 ANDALUC═A;Group 0104 Septicaemia 038;Both sexes;6,030 ANDALUC═A;Group 0104 Septicaemia 038;Men;3,261 ANDALUC═A;Group 0104 Septicaemia 038;Women;2,770 ANDALUC═A;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Both sexes;699 ANDALUC═A;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Men;541 ANDALUC═A;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Women;157 ANDALUC═A;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Both sexes;5,022 ANDALUC═A;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Men;2,903 ANDALUC═A;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Women;2,119 ANDALUC═A;Group 0200 Neoplasms 140-239;Both sexes;63,786 ANDALUC═A;Group 0200 Neoplasms 140-239;Men;32,518 ANDALUC═A;Group 0200 Neoplasms 140-239;Women;31,267 ANDALUC═A;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Both sexes;6,289 ANDALUC═A;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Men;3,867 ANDALUC═A;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Women;2,423 ANDALUC═A;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Both sexes;4,430 ANDALUC═A;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Men;3,638 ANDALUC═A;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Women;792 ANDALUC═A;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Both sexes;1,527 ANDALUC═A;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Men;881 ANDALUC═A;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Women;645 ANDALUC═A;Group 0204 Malignant neoplasm of breast 174-175;Both sexes;5,389 ANDALUC═A;Group 0204 Malignant neoplasm of breast 174-175;Men;39 ANDALUC═A;Group 0204 Malignant neoplasm of breast 174-175;Women;5,350 ANDALUC═A;Group 0205 Malignant neoplasm of uterus 179-180, 182;Both sexes;1,466 ANDALUC═A;Group 0205 Malignant neoplasm of uterus 179-180, 182;Men;.. ANDALUC═A;Group 0205 Malignant neoplasm of uterus 179-180, 182;Women;1,466 ANDALUC═A;Group 0206 Malignant neoplasm of ovary 1830;Both sexes;892 ANDALUC═A;Group 0206 Malignant neoplasm of ovary 1830;Men;.. ANDALUC═A;Group 0206 Malignant neoplasm of ovary 1830;Women;892 ANDALUC═A;Group 0207 Malignant neoplasm of prostate 185;Both sexes;1,724 ANDALUC═A;Group 0207 Malignant neoplasm of prostate 185;Men;1,724 ANDALUC═A;Group 0207 Malignant neoplasm of prostate 185;Women;.. ANDALUC═A;Group 0208 Malignant neoplasm of bladder 188;Both sexes;5,593 ANDALUC═A;Group 0208 Malignant neoplasm of bladder 188;Men;4,784 ANDALUC═A;Group 0208 Malignant neoplasm of bladder 188;Women;809 ANDALUC═A;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Both sexes;21,871 ANDALUC═A;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Men;12,889 ANDALUC═A;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Women;8,982 ANDALUC═A;Group 0210 Carcinoma in situ 230-234;Both sexes;744 ANDALUC═A;Group 0210 Carcinoma in situ 230-234;Men;269 ANDALUC═A;Group 0210 Carcinoma in situ 230-234;Women;474 ANDALUC═A;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Both sexes;502 ANDALUC═A;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Men;309 ANDALUC═A;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Women;192 ANDALUC═A;Grupo 0212 Leiomyoma of uterus 218;Both sexes;3,936 ANDALUC═A;Grupo 0212 Leiomyoma of uterus 218;Men;.. ANDALUC═A;Grupo 0212 Leiomyoma of uterus 218;Women;3,936 ANDALUC═A;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Both sexes;9,423 ANDALUC═A;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Men;4,118 ANDALUC═A;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Women;5,306 ANDALUC═A;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Both sexes;6,287 ANDALUC═A;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Men;3,023 ANDALUC═A;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Women;3,264 ANDALUC═A;Group 0301 Anaemias 280-285;Both sexes;3,398 ANDALUC═A;Group 0301 Anaemias 280-285;Men;1,653 ANDALUC═A;Group 0301 Anaemias 280-285;Women;1,745 ANDALUC═A;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Both sexes;2,888 ANDALUC═A;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Men;1,369 ANDALUC═A;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Women;1,519 ANDALUC═A;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Both sexes;12,441 ANDALUC═A;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Men;4,832 ANDALUC═A;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Women;7,609 ANDALUC═A;Group 0401 Diabetes mellitus 249-250;Both sexes;3,766 ANDALUC═A;Group 0401 Diabetes mellitus 249-250;Men;2,252 ANDALUC═A;Group 0401 Diabetes mellitus 249-250;Women;1,514 ANDALUC═A;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Both sexes;8,675 ANDALUC═A;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Men;2,580 ANDALUC═A;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Women;6,095 ANDALUC═A;Group 0500 Mental disorders 290-319;Both sexes;13,098 ANDALUC═A;Group 0500 Mental disorders 290-319;Men;7,245 ANDALUC═A;Group 0500 Mental disorders 290-319;Women;5,854 ANDALUC═A;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Both sexes;216 ANDALUC═A;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Men;102 ANDALUC═A;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Women;113 ANDALUC═A;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Both sexes;567 ANDALUC═A;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Men;458 ANDALUC═A;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Women;109 ANDALUC═A;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Both sexes;820 ANDALUC═A;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Men;628 ANDALUC═A;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Women;192 ANDALUC═A;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Both sexes;4,272 ANDALUC═A;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Men;2,807 ANDALUC═A;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Women;1,465 ANDALUC═A;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Both sexes;2,909 ANDALUC═A;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Men;1,284 ANDALUC═A;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Women;1,625 ANDALUC═A;Group 0506 Other mental and behavioural disorders Rest of (290-319);Both sexes;4,315 ANDALUC═A;Group 0506 Other mental and behavioural disorders Rest of (290-319);Men;1,965 ANDALUC═A;Group 0506 Other mental and behavioural disorders Rest of (290-319);Women;2,350 ANDALUC═A;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Both sexes;13,101 ANDALUC═A;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Men;6,455 ANDALUC═A;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Women;6,645 ANDALUC═A;Group 0601 Alzheimer's disease 3310;Both sexes;194 ANDALUC═A;Group 0601 Alzheimer's disease 3310;Men;75 ANDALUC═A;Group 0601 Alzheimer's disease 3310;Women;120 ANDALUC═A;Group 0602 Multiple sclerosis 340;Both sexes;340 ANDALUC═A;Group 0602 Multiple sclerosis 340;Men;110 ANDALUC═A;Group 0602 Multiple sclerosis 340;Women;230 ANDALUC═A;Group 0603 Epilepsy 345;Both sexes;2,370 ANDALUC═A;Group 0603 Epilepsy 345;Men;1,266 ANDALUC═A;Group 0603 Epilepsy 345;Women;1,104 ANDALUC═A;Group 0604 Transient cerebral ischemia 435;Both sexes;2,453 ANDALUC═A;Group 0604 Transient cerebral ischemia 435;Men;1,246 ANDALUC═A;Group 0604 Transient cerebral ischemia 435;Women;1,207 ANDALUC═A;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Both sexes;7,744 ANDALUC═A;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Men;3,758 ANDALUC═A;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Women;3,985 ANDALUC═A;Grupo 0700 Diseases of the eye and adnexa 360-379;Both sexes;5,029 ANDALUC═A;Grupo 0700 Diseases of the eye and adnexa 360-379;Men;2,712 ANDALUC═A;Grupo 0700 Diseases of the eye and adnexa 360-379;Women;2,318 ANDALUC═A;Grupo 0701 Cataract 366;Both sexes;835 ANDALUC═A;Grupo 0701 Cataract 366;Men;438 ANDALUC═A;Grupo 0701 Cataract 366;Women;397 ANDALUC═A;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Both sexes;4,194 ANDALUC═A;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Men;2,273 ANDALUC═A;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Women;1,921 ANDALUC═A;Group 0800 Diseases of the ear and the mastoid 380-389;Both sexes;3,338 ANDALUC═A;Group 0800 Diseases of the ear and the mastoid 380-389;Men;1,643 ANDALUC═A;Group 0800 Diseases of the ear and the mastoid 380-389;Women;1,695 ANDALUC═A;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Both sexes;90,974 ANDALUC═A;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Men;51,733 ANDALUC═A;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Women;39,241 ANDALUC═A;Group 0901 Hypertensive disease 401-405;Both sexes;5,761 ANDALUC═A;Group 0901 Hypertensive disease 401-405;Men;2,392 ANDALUC═A;Group 0901 Hypertensive disease 401-405;Women;3,369 ANDALUC═A;Group 0902 Angina pectoris 4111, 413;Both sexes;5,881 ANDALUC═A;Group 0902 Angina pectoris 4111, 413;Men;3,570 ANDALUC═A;Group 0902 Angina pectoris 4111, 413;Women;2,311 ANDALUC═A;Group 0903 Acute myocardial infarction 410;Both sexes;9,988 ANDALUC═A;Group 0903 Acute myocardial infarction 410;Men;6,911 ANDALUC═A;Group 0903 Acute myocardial infarction 410;Women;3,077 ANDALUC═A;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Both sexes;7,411 ANDALUC═A;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Men;5,457 ANDALUC═A;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Women;1,954 ANDALUC═A;Group 0905 Diseases of the lungs circulation 415-417;Both sexes;2,554 ANDALUC═A;Group 0905 Diseases of the lungs circulation 415-417;Men;1,156 ANDALUC═A;Group 0905 Diseases of the lungs circulation 415-417;Women;1,399 ANDALUC═A;Group 0906 Heart conduction disorders and arrhytmias 426-427;Both sexes;10,752 ANDALUC═A;Group 0906 Heart conduction disorders and arrhytmias 426-427;Men;5,745 ANDALUC═A;Group 0906 Heart conduction disorders and arrhytmias 426-427;Women;5,007 ANDALUC═A;Grupo 0907 Heart failure 428;Both sexes;14,904 ANDALUC═A;Grupo 0907 Heart failure 428;Men;6,969 ANDALUC═A;Grupo 0907 Heart failure 428;Women;7,935 ANDALUC═A;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Both sexes;15,493 ANDALUC═A;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Men;8,584 ANDALUC═A;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Women;6,910 ANDALUC═A;Grupo 0909 Atherosclerosis 440;Both sexes;2,983 ANDALUC═A;Grupo 0909 Atherosclerosis 440;Men;2,273 ANDALUC═A;Grupo 0909 Atherosclerosis 440;Women;710 ANDALUC═A;Group 0910 Varicose veins of lower extremities 454;Both sexes;1,697 ANDALUC═A;Group 0910 Varicose veins of lower extremities 454;Men;633 ANDALUC═A;Group 0910 Varicose veins of lower extremities 454;Women;1,064 ANDALUC═A;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Both sexes;13,548 ANDALUC═A;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Men;8,042 ANDALUC═A;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Women;5,506 ANDALUC═A;Group 1000 Diseases of the respiratory system 0340, 460-519;Both sexes;60,629 ANDALUC═A;Group 1000 Diseases of the respiratory system 0340, 460-519;Men;35,595 ANDALUC═A;Group 1000 Diseases of the respiratory system 0340, 460-519;Women;25,034 ANDALUC═A;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Both sexes;3,114 ANDALUC═A;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Men;1,658 ANDALUC═A;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Women;1,456 ANDALUC═A;Group 1002 Pneumonia 480-486;Both sexes;13,088 ANDALUC═A;Group 1002 Pneumonia 480-486;Men;7,818 ANDALUC═A;Group 1002 Pneumonia 480-486;Women;5,270 ANDALUC═A;Group 1003 Acute bronchitis and bronchiolitis 466;Both sexes;5,470 ANDALUC═A;Group 1003 Acute bronchitis and bronchiolitis 466;Men;2,866 ANDALUC═A;Group 1003 Acute bronchitis and bronchiolitis 466;Women;2,604 ANDALUC═A;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Both sexes;2,795 ANDALUC═A;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Men;1,426 ANDALUC═A;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Women;1,369 ANDALUC═A;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Both sexes;5,802 ANDALUC═A;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Men;3,590 ANDALUC═A;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Women;2,212 ANDALUC═A;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Both sexes;7,414 ANDALUC═A;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Men;5,834 ANDALUC═A;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Women;1,580 ANDALUC═A;Group 1007 Asthma 4930-4931,4938-4939;Both sexes;2,027 ANDALUC═A;Group 1007 Asthma 4930-4931,4938-4939;Men;673 ANDALUC═A;Group 1007 Asthma 4930-4931,4938-4939;Women;1,354 ANDALUC═A;Group 1008 Other diseases of the respiratory system Resto of (460-519);Both sexes;20,920 ANDALUC═A;Group 1008 Other diseases of the respiratory system Resto of (460-519);Men;11,730 ANDALUC═A;Group 1008 Other diseases of the respiratory system Resto of (460-519);Women;9,190 ANDALUC═A;Group 1100 Diseases of the digestive system 520-579;Both sexes;85,941 ANDALUC═A;Group 1100 Diseases of the digestive system 520-579;Men;46,822 ANDALUC═A;Group 1100 Diseases of the digestive system 520-579;Women;39,119 ANDALUC═A;Group 1101 Disorders of the teeth and supporting structures 520-525;Both sexes;1,306 ANDALUC═A;Group 1101 Disorders of the teeth and supporting structures 520-525;Men;616 ANDALUC═A;Group 1101 Disorders of the teeth and supporting structures 520-525;Women;690 ANDALUC═A;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Both sexes;1,302 ANDALUC═A;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Men;719 ANDALUC═A;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Women;582 ANDALUC═A;Group 1103 Diseases of the esophagus 530;Both sexes;1,820 ANDALUC═A;Group 1103 Diseases of the esophagus 530;Men;1,078 ANDALUC═A;Group 1103 Diseases of the esophagus 530;Women;742 ANDALUC═A;Group 1104 Peptic ulcer 531-534;Both sexes;1,704 ANDALUC═A;Group 1104 Peptic ulcer 531-534;Men;1,254 ANDALUC═A;Group 1104 Peptic ulcer 531-534;Women;449 ANDALUC═A;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Both sexes;2,190 ANDALUC═A;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Men;1,042 ANDALUC═A;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Women;1,148 ANDALUC═A;Group 1106 Appendicitis 540-543;Both sexes;7,973 ANDALUC═A;Group 1106 Appendicitis 540-543;Men;4,582 ANDALUC═A;Group 1106 Appendicitis 540-543;Women;3,391 ANDALUC═A;Group 1107 Inguinal hernia 550;Both sexes;6,572 ANDALUC═A;Group 1107 Inguinal hernia 550;Men;5,727 ANDALUC═A;Group 1107 Inguinal hernia 550;Women;845 ANDALUC═A;Group 1108 Other abdominal hernia 551-553;Both sexes;7,024 ANDALUC═A;Group 1108 Other abdominal hernia 551-553;Men;3,148 ANDALUC═A;Group 1108 Other abdominal hernia 551-553;Women;3,876 ANDALUC═A;Group 1109 Crohn's disease and ulcerative colitis 555-556;Both sexes;2,101 ANDALUC═A;Group 1109 Crohn's disease and ulcerative colitis 555-556;Men;1,101 ANDALUC═A;Group 1109 Crohn's disease and ulcerative colitis 555-556;Women;1,000 ANDALUC═A;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Both sexes;4,506 ANDALUC═A;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Men;2,151 ANDALUC═A;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Women;2,355 ANDALUC═A;Group 1111 Intestinal obstruction without hernia 560;Both sexes;3,397 ANDALUC═A;Group 1111 Intestinal obstruction without hernia 560;Men;1,824 ANDALUC═A;Group 1111 Intestinal obstruction without hernia 560;Women;1,573 ANDALUC═A;Group 1112 Intestinal diverticulosis 562;Both sexes;3,159 ANDALUC═A;Group 1112 Intestinal diverticulosis 562;Men;1,613 ANDALUC═A;Group 1112 Intestinal diverticulosis 562;Women;1,545 ANDALUC═A;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Both sexes;5,186 ANDALUC═A;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Men;3,278 ANDALUC═A;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Women;1,908 ANDALUC═A;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Both sexes;2,595 ANDALUC═A;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Men;1,268 ANDALUC═A;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Women;1,327 ANDALUC═A;Group 1115 Alcoholic hepatitis 5710-5713;Both sexes;1,836 ANDALUC═A;Group 1115 Alcoholic hepatitis 5710-5713;Men;1,574 ANDALUC═A;Group 1115 Alcoholic hepatitis 5710-5713;Women;262 ANDALUC═A;Group 1116 Other diseases of the liver 570,5714-573;Both sexes;2,981 ANDALUC═A;Group 1116 Other diseases of the liver 570,5714-573;Men;1,786 ANDALUC═A;Group 1116 Other diseases of the liver 570,5714-573;Women;1,195 ANDALUC═A;Group 1117 Cholelithiasis 574;Both sexes;16,874 ANDALUC═A;Group 1117 Cholelithiasis 574;Men;6,868 ANDALUC═A;Group 1117 Cholelithiasis 574;Women;10,005 ANDALUC═A;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Both sexes;3,951 ANDALUC═A;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Men;2,055 ANDALUC═A;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Women;1,896 ANDALUC═A;Group 1119 Pancreatic diseases 577;Both sexes;5,965 ANDALUC═A;Group 1119 Pancreatic diseases 577;Men;3,218 ANDALUC═A;Group 1119 Pancreatic diseases 577;Women;2,747 ANDALUC═A;Group 1120 Other diseases of the digestive system Rest of (520-579);Both sexes;3,500 ANDALUC═A;Group 1120 Other diseases of the digestive system Rest of (520-579);Men;1,918 ANDALUC═A;Group 1120 Other diseases of the digestive system Rest of (520-579);Women;1,582 ANDALUC═A;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Both sexes;6,260 ANDALUC═A;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Men;3,428 ANDALUC═A;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Women;2,831 ANDALUC═A;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Both sexes;3,714 ANDALUC═A;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Men;2,206 ANDALUC═A;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Women;1,508 ANDALUC═A;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Both sexes;300 ANDALUC═A;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Men;161 ANDALUC═A;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Women;138 ANDALUC═A;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Both sexes;2,246 ANDALUC═A;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Men;1,061 ANDALUC═A;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Women;1,185 ANDALUC═A;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Both sexes;43,546 ANDALUC═A;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Men;19,938 ANDALUC═A;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Women;23,608 ANDALUC═A;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Both sexes;.. ANDALUC═A;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Men;.. ANDALUC═A;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Women;.. ANDALUC═A;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Both sexes;.. ANDALUC═A;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Men;.. ANDALUC═A;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Women;.. ANDALUC═A;Group 1303 Internal derangement of knee 717;Both sexes;4,239 ANDALUC═A;Group 1303 Internal derangement of knee 717;Men;2,849 ANDALUC═A;Group 1303 Internal derangement of knee 717;Women;1,390 ANDALUC═A;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Both sexes;18,455 ANDALUC═A;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Men;7,450 ANDALUC═A;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Women;11,005 ANDALUC═A;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Both sexes;939 ANDALUC═A;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Men;357 ANDALUC═A;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Women;581 ANDALUC═A;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Both sexes;2,208 ANDALUC═A;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Men;1,091 ANDALUC═A;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Women;1,117 ANDALUC═A;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Both sexes;4,505 ANDALUC═A;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Men;2,294 ANDALUC═A;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Women;2,211 ANDALUC═A;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Both sexes;1,140 ANDALUC═A;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Men;418 ANDALUC═A;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Women;721 ANDALUC═A;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Both sexes;5,448 ANDALUC═A;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Men;2,759 ANDALUC═A;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Women;2,689 ANDALUC═A;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Both sexes;6,612 ANDALUC═A;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Men;2,718 ANDALUC═A;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Women;3,894 ANDALUC═A;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Both sexes;41,603 ANDALUC═A;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Men;17,544 ANDALUC═A;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Women;24,059 ANDALUC═A;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Both sexes;4,470 ANDALUC═A;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Men;1,770 ANDALUC═A;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Women;2,700 ANDALUC═A;Group 1402 Renal failure 5836-5837, 584-586;Both sexes;4,106 ANDALUC═A;Group 1402 Renal failure 5836-5837, 584-586;Men;2,295 ANDALUC═A;Group 1402 Renal failure 5836-5837, 584-586;Women;1,812 ANDALUC═A;Group 1403 Urolithiasis 592, 594, 7880;Both sexes;5,410 ANDALUC═A;Group 1403 Urolithiasis 592, 594, 7880;Men;3,059 ANDALUC═A;Group 1403 Urolithiasis 592, 594, 7880;Women;2,350 ANDALUC═A;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Both sexes;8,366 ANDALUC═A;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Men;4,250 ANDALUC═A;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Women;4,117 ANDALUC═A;Group 1405 Prostatic hyperplasia 600;Both sexes;2,794 ANDALUC═A;Group 1405 Prostatic hyperplasia 600;Men;2,794 ANDALUC═A;Group 1405 Prostatic hyperplasia 600;Women;.. ANDALUC═A;Group 1406 Other diseases of the male genital organs 601-608;Both sexes;3,010 ANDALUC═A;Group 1406 Other diseases of the male genital organs 601-608;Men;3,010 ANDALUC═A;Group 1406 Other diseases of the male genital organs 601-608;Women;.. ANDALUC═A;Group 1407 Disorders of breast 610-612;Both sexes;3,350 ANDALUC═A;Group 1407 Disorders of breast 610-612;Men;306 ANDALUC═A;Group 1407 Disorders of breast 610-612;Women;3,044 ANDALUC═A;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Both sexes;1,396 ANDALUC═A;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Men;.. ANDALUC═A;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Women;1,396 ANDALUC═A;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Both sexes;822 ANDALUC═A;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Men;.. ANDALUC═A;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Women;822 ANDALUC═A;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Both sexes;7,880 ANDALUC═A;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Men;60 ANDALUC═A;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Women;7,819 ANDALUC═A;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Both sexes;98,141 ANDALUC═A;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Men;.. ANDALUC═A;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Women;98,141 ANDALUC═A;Group 1501 Legally induced abortion 635;Both sexes;155 ANDALUC═A;Group 1501 Legally induced abortion 635;Men;.. ANDALUC═A;Group 1501 Legally induced abortion 635;Women;155 ANDALUC═A;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Both sexes;6,464 ANDALUC═A;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Men;.. ANDALUC═A;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Women;6,464 ANDALUC═A;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Both sexes;61,928 ANDALUC═A;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Men;.. ANDALUC═A;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Women;61,928 ANDALUC═A;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Both sexes;12,699 ANDALUC═A;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Men;.. ANDALUC═A;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Women;12,699 ANDALUC═A;Group 1505 Single spontaneous delivery 650;Both sexes;6,662 ANDALUC═A;Group 1505 Single spontaneous delivery 650;Men;.. ANDALUC═A;Group 1505 Single spontaneous delivery 650;Women;6,662 ANDALUC═A;Group 1506 Other deliveries 6695-6697;Both sexes;3,989 ANDALUC═A;Group 1506 Other deliveries 6695-6697;Men;.. ANDALUC═A;Group 1506 Other deliveries 6695-6697;Women;3,989 ANDALUC═A;Group 1507 Complications related to the puerperium 670-676;Both sexes;673 ANDALUC═A;Group 1507 Complications related to the puerperium 670-676;Men;.. ANDALUC═A;Group 1507 Complications related to the puerperium 670-676;Women;673 ANDALUC═A;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Both sexes;5,571 ANDALUC═A;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Men;.. ANDALUC═A;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Women;5,571 ANDALUC═A;Group 1600 Some disorders originating in the perinatal period 760-779;Both sexes;9,592 ANDALUC═A;Group 1600 Some disorders originating in the perinatal period 760-779;Men;5,283 ANDALUC═A;Group 1600 Some disorders originating in the perinatal period 760-779;Women;4,310 ANDALUC═A;Group 1601 Disorders related with premature delivery and a low birth weight 765;Both sexes;3,129 ANDALUC═A;Group 1601 Disorders related with premature delivery and a low birth weight 765;Men;1,683 ANDALUC═A;Group 1601 Disorders related with premature delivery and a low birth weight 765;Women;1,446 ANDALUC═A;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Both sexes;6,463 ANDALUC═A;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Men;3,599 ANDALUC═A;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Women;2,864 ANDALUC═A;Grupo 1700 Congenital abnormalities 740-759;Both sexes;6,381 ANDALUC═A;Grupo 1700 Congenital abnormalities 740-759;Men;3,511 ANDALUC═A;Grupo 1700 Congenital abnormalities 740-759;Women;2,870 ANDALUC═A;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Both sexes;31,968 ANDALUC═A;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Men;16,803 ANDALUC═A;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Women;15,165 ANDALUC═A;Group 1801 Pain in throat and chest 7841, 7865;Both sexes;4,695 ANDALUC═A;Group 1801 Pain in throat and chest 7841, 7865;Men;2,566 ANDALUC═A;Group 1801 Pain in throat and chest 7841, 7865;Women;2,129 ANDALUC═A;Group 1802 Abdominal pain 7890;Both sexes;4,459 ANDALUC═A;Group 1802 Abdominal pain 7890;Men;1,727 ANDALUC═A;Group 1802 Abdominal pain 7890;Women;2,731 ANDALUC═A;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Both sexes;1,875 ANDALUC═A;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Men;933 ANDALUC═A;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Women;941 ANDALUC═A;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Both sexes;20,940 ANDALUC═A;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Men;11,576 ANDALUC═A;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Women;9,364 ANDALUC═A;Group 1900 Injuries and poisoning 800-999;Both sexes;60,976 ANDALUC═A;Group 1900 Injuries and poisoning 800-999;Men;30,967 ANDALUC═A;Group 1900 Injuries and poisoning 800-999;Women;30,009 ANDALUC═A;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Both sexes;2,682 ANDALUC═A;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Men;1,621 ANDALUC═A;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Women;1,061 ANDALUC═A;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Both sexes;1,783 ANDALUC═A;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Men;1,263 ANDALUC═A;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Women;520 ANDALUC═A;Group 1903 Radius and ulna fracture 813;Both sexes;4,110 ANDALUC═A;Group 1903 Radius and ulna fracture 813;Men;2,079 ANDALUC═A;Group 1903 Radius and ulna fracture 813;Women;2,031 ANDALUC═A;Group 1904 Femur fracture 820-821;Both sexes;10,138 ANDALUC═A;Group 1904 Femur fracture 820-821;Men;2,902 ANDALUC═A;Group 1904 Femur fracture 820-821;Women;7,236 ANDALUC═A;Group 1905 Leg fracture, including the ankle 823-824;Both sexes;5,208 ANDALUC═A;Group 1905 Leg fracture, including the ankle 823-824;Men;2,659 ANDALUC═A;Group 1905 Leg fracture, including the ankle 823-824;Women;2,549 ANDALUC═A;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Both sexes;17,718 ANDALUC═A;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Men;10,339 ANDALUC═A;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Women;7,379 ANDALUC═A;Group 1907 Burns 940-949;Both sexes;577 ANDALUC═A;Group 1907 Burns 940-949;Men;339 ANDALUC═A;Group 1907 Burns 940-949;Women;238 ANDALUC═A;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Both sexes;1,933 ANDALUC═A;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Men;907 ANDALUC═A;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Women;1,026 ANDALUC═A;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Both sexes;15,390 ANDALUC═A;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Men;8,054 ANDALUC═A;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Women;7,336 ANDALUC═A;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Both sexes;225 ANDALUC═A;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Men;132 ANDALUC═A;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Women;93 ANDALUC═A;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Both sexes;1,212 ANDALUC═A;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Men;672 ANDALUC═A;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Women;540 ANDALUC═A;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Both sexes;11,547 ANDALUC═A;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Men;5,199 ANDALUC═A;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Women;6,349 ANDALUC═A;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Both sexes;723 ANDALUC═A;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Men;349 ANDALUC═A;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Women;374 ANDALUC═A;Group 2102 Contraceptive management V25;Both sexes;228 ANDALUC═A;Group 2102 Contraceptive management V25;Men;34 ANDALUC═A;Group 2102 Contraceptive management V25;Women;194 ANDALUC═A;Group 2103 Living newborns by type of delivery V30-V39;Both sexes;.. ANDALUC═A;Group 2103 Living newborns by type of delivery V30-V39;Men;.. ANDALUC═A;Group 2103 Living newborns by type of delivery V30-V39;Women;.. ANDALUC═A;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Both sexes;4,032 ANDALUC═A;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Men;2,531 ANDALUC═A;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Women;1,501 ANDALUC═A;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Both sexes;6,563 ANDALUC═A;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Men;2,284 ANDALUC═A;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Women;4,279 AlmerÝa;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Both sexes;52,222 AlmerÝa;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Men;22,943 AlmerÝa;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Women;29,279 AlmerÝa;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Both sexes;1,315 AlmerÝa;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Men;751 AlmerÝa;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Women;564 AlmerÝa;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Both sexes;229 AlmerÝa;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Men;118 AlmerÝa;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Women;111 AlmerÝa;Group 0102 Imprecise intestinal infections 009;Both sexes;152 AlmerÝa;Group 0102 Imprecise intestinal infections 009;Men;76 AlmerÝa;Group 0102 Imprecise intestinal infections 009;Women;76 AlmerÝa;Group 0103 Tuberculosis 010-018, 137;Both sexes;102 AlmerÝa;Group 0103 Tuberculosis 010-018, 137;Men;70 AlmerÝa;Group 0103 Tuberculosis 010-018, 137;Women;32 AlmerÝa;Group 0104 Septicaemia 038;Both sexes;408 AlmerÝa;Group 0104 Septicaemia 038;Men;227 AlmerÝa;Group 0104 Septicaemia 038;Women;181 AlmerÝa;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Both sexes;29 AlmerÝa;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Men;26 AlmerÝa;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Women;3 AlmerÝa;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Both sexes;395 AlmerÝa;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Men;234 AlmerÝa;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Women;161 AlmerÝa;Group 0200 Neoplasms 140-239;Both sexes;4,218 AlmerÝa;Group 0200 Neoplasms 140-239;Men;2,259 AlmerÝa;Group 0200 Neoplasms 140-239;Women;1,959 AlmerÝa;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Both sexes;505 AlmerÝa;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Men;328 AlmerÝa;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Women;177 AlmerÝa;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Both sexes;372 AlmerÝa;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Men;290 AlmerÝa;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Women;82 AlmerÝa;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Both sexes;26 AlmerÝa;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Men;13 AlmerÝa;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Women;13 AlmerÝa;Group 0204 Malignant neoplasm of breast 174-175;Both sexes;326 AlmerÝa;Group 0204 Malignant neoplasm of breast 174-175;Men;1 AlmerÝa;Group 0204 Malignant neoplasm of breast 174-175;Women;325 AlmerÝa;Group 0205 Malignant neoplasm of uterus 179-180, 182;Both sexes;88 AlmerÝa;Group 0205 Malignant neoplasm of uterus 179-180, 182;Men;.. AlmerÝa;Group 0205 Malignant neoplasm of uterus 179-180, 182;Women;88 AlmerÝa;Group 0206 Malignant neoplasm of ovary 1830;Both sexes;64 AlmerÝa;Group 0206 Malignant neoplasm of ovary 1830;Men;.. AlmerÝa;Group 0206 Malignant neoplasm of ovary 1830;Women;64 AlmerÝa;Group 0207 Malignant neoplasm of prostate 185;Both sexes;100 AlmerÝa;Group 0207 Malignant neoplasm of prostate 185;Men;100 AlmerÝa;Group 0207 Malignant neoplasm of prostate 185;Women;.. AlmerÝa;Group 0208 Malignant neoplasm of bladder 188;Both sexes;376 AlmerÝa;Group 0208 Malignant neoplasm of bladder 188;Men;322 AlmerÝa;Group 0208 Malignant neoplasm of bladder 188;Women;54 AlmerÝa;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Both sexes;1,452 AlmerÝa;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Men;913 AlmerÝa;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Women;539 AlmerÝa;Group 0210 Carcinoma in situ 230-234;Both sexes;29 AlmerÝa;Group 0210 Carcinoma in situ 230-234;Men;9 AlmerÝa;Group 0210 Carcinoma in situ 230-234;Women;20 AlmerÝa;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Both sexes;19 AlmerÝa;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Men;17 AlmerÝa;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Women;2 AlmerÝa;Grupo 0212 Leiomyoma of uterus 218;Both sexes;261 AlmerÝa;Grupo 0212 Leiomyoma of uterus 218;Men;.. AlmerÝa;Grupo 0212 Leiomyoma of uterus 218;Women;261 AlmerÝa;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Both sexes;600 AlmerÝa;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Men;266 AlmerÝa;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Women;334 AlmerÝa;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Both sexes;426 AlmerÝa;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Men;199 AlmerÝa;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Women;227 AlmerÝa;Group 0301 Anaemias 280-285;Both sexes;231 AlmerÝa;Group 0301 Anaemias 280-285;Men;114 AlmerÝa;Group 0301 Anaemias 280-285;Women;117 AlmerÝa;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Both sexes;195 AlmerÝa;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Men;85 AlmerÝa;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Women;110 AlmerÝa;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Both sexes;862 AlmerÝa;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Men;365 AlmerÝa;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Women;497 AlmerÝa;Group 0401 Diabetes mellitus 249-250;Both sexes;320 AlmerÝa;Group 0401 Diabetes mellitus 249-250;Men;205 AlmerÝa;Group 0401 Diabetes mellitus 249-250;Women;115 AlmerÝa;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Both sexes;542 AlmerÝa;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Men;160 AlmerÝa;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Women;382 AlmerÝa;Group 0500 Mental disorders 290-319;Both sexes;980 AlmerÝa;Group 0500 Mental disorders 290-319;Men;540 AlmerÝa;Group 0500 Mental disorders 290-319;Women;440 AlmerÝa;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Both sexes;12 AlmerÝa;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Men;7 AlmerÝa;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Women;5 AlmerÝa;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Both sexes;33 AlmerÝa;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Men;28 AlmerÝa;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Women;5 AlmerÝa;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Both sexes;61 AlmerÝa;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Men;48 AlmerÝa;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Women;13 AlmerÝa;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Both sexes;354 AlmerÝa;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Men;220 AlmerÝa;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Women;134 AlmerÝa;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Both sexes;180 AlmerÝa;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Men;87 AlmerÝa;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Women;93 AlmerÝa;Group 0506 Other mental and behavioural disorders Rest of (290-319);Both sexes;340 AlmerÝa;Group 0506 Other mental and behavioural disorders Rest of (290-319);Men;150 AlmerÝa;Group 0506 Other mental and behavioural disorders Rest of (290-319);Women;190 AlmerÝa;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Both sexes;768 AlmerÝa;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Men;390 AlmerÝa;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Women;378 AlmerÝa;Group 0601 Alzheimer's disease 3310;Both sexes;27 AlmerÝa;Group 0601 Alzheimer's disease 3310;Men;5 AlmerÝa;Group 0601 Alzheimer's disease 3310;Women;22 AlmerÝa;Group 0602 Multiple sclerosis 340;Both sexes;28 AlmerÝa;Group 0602 Multiple sclerosis 340;Men;7 AlmerÝa;Group 0602 Multiple sclerosis 340;Women;21 AlmerÝa;Group 0603 Epilepsy 345;Both sexes;123 AlmerÝa;Group 0603 Epilepsy 345;Men;69 AlmerÝa;Group 0603 Epilepsy 345;Women;54 AlmerÝa;Group 0604 Transient cerebral ischemia 435;Both sexes;162 AlmerÝa;Group 0604 Transient cerebral ischemia 435;Men;80 AlmerÝa;Group 0604 Transient cerebral ischemia 435;Women;82 AlmerÝa;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Both sexes;428 AlmerÝa;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Men;229 AlmerÝa;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Women;199 AlmerÝa;Grupo 0700 Diseases of the eye and adnexa 360-379;Both sexes;242 AlmerÝa;Grupo 0700 Diseases of the eye and adnexa 360-379;Men;125 AlmerÝa;Grupo 0700 Diseases of the eye and adnexa 360-379;Women;117 AlmerÝa;Grupo 0701 Cataract 366;Both sexes;19 AlmerÝa;Grupo 0701 Cataract 366;Men;10 AlmerÝa;Grupo 0701 Cataract 366;Women;9 AlmerÝa;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Both sexes;223 AlmerÝa;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Men;115 AlmerÝa;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Women;108 AlmerÝa;Group 0800 Diseases of the ear and the mastoid 380-389;Both sexes;248 AlmerÝa;Group 0800 Diseases of the ear and the mastoid 380-389;Men;123 AlmerÝa;Group 0800 Diseases of the ear and the mastoid 380-389;Women;125 AlmerÝa;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Both sexes;5,800 AlmerÝa;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Men;3,371 AlmerÝa;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Women;2,429 AlmerÝa;Group 0901 Hypertensive disease 401-405;Both sexes;351 AlmerÝa;Group 0901 Hypertensive disease 401-405;Men;129 AlmerÝa;Group 0901 Hypertensive disease 401-405;Women;222 AlmerÝa;Group 0902 Angina pectoris 4111, 413;Both sexes;301 AlmerÝa;Group 0902 Angina pectoris 4111, 413;Men;216 AlmerÝa;Group 0902 Angina pectoris 4111, 413;Women;85 AlmerÝa;Group 0903 Acute myocardial infarction 410;Both sexes;868 AlmerÝa;Group 0903 Acute myocardial infarction 410;Men;644 AlmerÝa;Group 0903 Acute myocardial infarction 410;Women;224 AlmerÝa;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Both sexes;393 AlmerÝa;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Men;293 AlmerÝa;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Women;100 AlmerÝa;Group 0905 Diseases of the lungs circulation 415-417;Both sexes;162 AlmerÝa;Group 0905 Diseases of the lungs circulation 415-417;Men;72 AlmerÝa;Group 0905 Diseases of the lungs circulation 415-417;Women;90 AlmerÝa;Group 0906 Heart conduction disorders and arrhytmias 426-427;Both sexes;648 AlmerÝa;Group 0906 Heart conduction disorders and arrhytmias 426-427;Men;327 AlmerÝa;Group 0906 Heart conduction disorders and arrhytmias 426-427;Women;321 AlmerÝa;Grupo 0907 Heart failure 428;Both sexes;1,051 AlmerÝa;Grupo 0907 Heart failure 428;Men;524 AlmerÝa;Grupo 0907 Heart failure 428;Women;527 AlmerÝa;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Both sexes;1,155 AlmerÝa;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Men;630 AlmerÝa;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Women;525 AlmerÝa;Grupo 0909 Atherosclerosis 440;Both sexes;214 AlmerÝa;Grupo 0909 Atherosclerosis 440;Men;140 AlmerÝa;Grupo 0909 Atherosclerosis 440;Women;74 AlmerÝa;Group 0910 Varicose veins of lower extremities 454;Both sexes;22 AlmerÝa;Group 0910 Varicose veins of lower extremities 454;Men;8 AlmerÝa;Group 0910 Varicose veins of lower extremities 454;Women;14 AlmerÝa;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Both sexes;635 AlmerÝa;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Men;388 AlmerÝa;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Women;247 AlmerÝa;Group 1000 Diseases of the respiratory system 0340, 460-519;Both sexes;5,829 AlmerÝa;Group 1000 Diseases of the respiratory system 0340, 460-519;Men;3,458 AlmerÝa;Group 1000 Diseases of the respiratory system 0340, 460-519;Women;2,371 AlmerÝa;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Both sexes;315 AlmerÝa;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Men;171 AlmerÝa;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Women;144 AlmerÝa;Group 1002 Pneumonia 480-486;Both sexes;1,234 AlmerÝa;Group 1002 Pneumonia 480-486;Men;759 AlmerÝa;Group 1002 Pneumonia 480-486;Women;475 AlmerÝa;Group 1003 Acute bronchitis and bronchiolitis 466;Both sexes;817 AlmerÝa;Group 1003 Acute bronchitis and bronchiolitis 466;Men;407 AlmerÝa;Group 1003 Acute bronchitis and bronchiolitis 466;Women;410 AlmerÝa;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Both sexes;216 AlmerÝa;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Men;110 AlmerÝa;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Women;106 AlmerÝa;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Both sexes;359 AlmerÝa;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Men;249 AlmerÝa;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Women;110 AlmerÝa;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Both sexes;790 AlmerÝa;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Men;681 AlmerÝa;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Women;109 AlmerÝa;Group 1007 Asthma 4930-4931,4938-4939;Both sexes;297 AlmerÝa;Group 1007 Asthma 4930-4931,4938-4939;Men;107 AlmerÝa;Group 1007 Asthma 4930-4931,4938-4939;Women;190 AlmerÝa;Group 1008 Other diseases of the respiratory system Resto of (460-519);Both sexes;1,801 AlmerÝa;Group 1008 Other diseases of the respiratory system Resto of (460-519);Men;974 AlmerÝa;Group 1008 Other diseases of the respiratory system Resto of (460-519);Women;827 AlmerÝa;Group 1100 Diseases of the digestive system 520-579;Both sexes;6,279 AlmerÝa;Group 1100 Diseases of the digestive system 520-579;Men;3,467 AlmerÝa;Group 1100 Diseases of the digestive system 520-579;Women;2,812 AlmerÝa;Group 1101 Disorders of the teeth and supporting structures 520-525;Both sexes;92 AlmerÝa;Group 1101 Disorders of the teeth and supporting structures 520-525;Men;42 AlmerÝa;Group 1101 Disorders of the teeth and supporting structures 520-525;Women;50 AlmerÝa;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Both sexes;131 AlmerÝa;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Men;79 AlmerÝa;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Women;52 AlmerÝa;Group 1103 Diseases of the esophagus 530;Both sexes;153 AlmerÝa;Group 1103 Diseases of the esophagus 530;Men;84 AlmerÝa;Group 1103 Diseases of the esophagus 530;Women;69 AlmerÝa;Group 1104 Peptic ulcer 531-534;Both sexes;158 AlmerÝa;Group 1104 Peptic ulcer 531-534;Men;117 AlmerÝa;Group 1104 Peptic ulcer 531-534;Women;41 AlmerÝa;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Both sexes;145 AlmerÝa;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Men;76 AlmerÝa;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Women;69 AlmerÝa;Group 1106 Appendicitis 540-543;Both sexes;756 AlmerÝa;Group 1106 Appendicitis 540-543;Men;457 AlmerÝa;Group 1106 Appendicitis 540-543;Women;299 AlmerÝa;Group 1107 Inguinal hernia 550;Both sexes;315 AlmerÝa;Group 1107 Inguinal hernia 550;Men;285 AlmerÝa;Group 1107 Inguinal hernia 550;Women;30 AlmerÝa;Group 1108 Other abdominal hernia 551-553;Both sexes;372 AlmerÝa;Group 1108 Other abdominal hernia 551-553;Men;162 AlmerÝa;Group 1108 Other abdominal hernia 551-553;Women;210 AlmerÝa;Group 1109 Crohn's disease and ulcerative colitis 555-556;Both sexes;160 AlmerÝa;Group 1109 Crohn's disease and ulcerative colitis 555-556;Men;80 AlmerÝa;Group 1109 Crohn's disease and ulcerative colitis 555-556;Women;80 AlmerÝa;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Both sexes;333 AlmerÝa;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Men;165 AlmerÝa;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Women;168 AlmerÝa;Group 1111 Intestinal obstruction without hernia 560;Both sexes;287 AlmerÝa;Group 1111 Intestinal obstruction without hernia 560;Men;155 AlmerÝa;Group 1111 Intestinal obstruction without hernia 560;Women;132 AlmerÝa;Group 1112 Intestinal diverticulosis 562;Both sexes;310 AlmerÝa;Group 1112 Intestinal diverticulosis 562;Men;181 AlmerÝa;Group 1112 Intestinal diverticulosis 562;Women;129 AlmerÝa;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Both sexes;286 AlmerÝa;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Men;189 AlmerÝa;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Women;97 AlmerÝa;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Both sexes;181 AlmerÝa;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Men;92 AlmerÝa;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Women;89 AlmerÝa;Group 1115 Alcoholic hepatitis 5710-5713;Both sexes;120 AlmerÝa;Group 1115 Alcoholic hepatitis 5710-5713;Men;104 AlmerÝa;Group 1115 Alcoholic hepatitis 5710-5713;Women;16 AlmerÝa;Group 1116 Other diseases of the liver 570,5714-573;Both sexes;191 AlmerÝa;Group 1116 Other diseases of the liver 570,5714-573;Men;112 AlmerÝa;Group 1116 Other diseases of the liver 570,5714-573;Women;79 AlmerÝa;Group 1117 Cholelithiasis 574;Both sexes;1,304 AlmerÝa;Group 1117 Cholelithiasis 574;Men;552 AlmerÝa;Group 1117 Cholelithiasis 574;Women;752 AlmerÝa;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Both sexes;301 AlmerÝa;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Men;166 AlmerÝa;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Women;135 AlmerÝa;Group 1119 Pancreatic diseases 577;Both sexes;464 AlmerÝa;Group 1119 Pancreatic diseases 577;Men;254 AlmerÝa;Group 1119 Pancreatic diseases 577;Women;210 AlmerÝa;Group 1120 Other diseases of the digestive system Rest of (520-579);Both sexes;220 AlmerÝa;Group 1120 Other diseases of the digestive system Rest of (520-579);Men;115 AlmerÝa;Group 1120 Other diseases of the digestive system Rest of (520-579);Women;105 AlmerÝa;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Both sexes;440 AlmerÝa;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Men;256 AlmerÝa;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Women;184 AlmerÝa;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Both sexes;293 AlmerÝa;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Men;183 AlmerÝa;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Women;110 AlmerÝa;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Both sexes;30 AlmerÝa;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Men;19 AlmerÝa;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Women;11 AlmerÝa;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Both sexes;117 AlmerÝa;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Men;54 AlmerÝa;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Women;63 AlmerÝa;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Both sexes;3,286 AlmerÝa;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Men;1,599 AlmerÝa;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Women;1,687 AlmerÝa;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Both sexes;.. AlmerÝa;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Men;.. AlmerÝa;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Women;.. AlmerÝa;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Both sexes;.. AlmerÝa;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Men;.. AlmerÝa;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Women;.. AlmerÝa;Group 1303 Internal derangement of knee 717;Both sexes;371 AlmerÝa;Group 1303 Internal derangement of knee 717;Men;255 AlmerÝa;Group 1303 Internal derangement of knee 717;Women;116 AlmerÝa;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Both sexes;1,296 AlmerÝa;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Men;521 AlmerÝa;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Women;775 AlmerÝa;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Both sexes;71 AlmerÝa;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Men;23 AlmerÝa;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Women;48 AlmerÝa;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Both sexes;112 AlmerÝa;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Men;61 AlmerÝa;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Women;51 AlmerÝa;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Both sexes;315 AlmerÝa;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Men;177 AlmerÝa;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Women;138 AlmerÝa;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Both sexes;52 AlmerÝa;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Men;20 AlmerÝa;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Women;32 AlmerÝa;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Both sexes;627 AlmerÝa;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Men;319 AlmerÝa;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Women;308 AlmerÝa;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Both sexes;442 AlmerÝa;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Men;223 AlmerÝa;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Women;219 AlmerÝa;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Both sexes;3,165 AlmerÝa;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Men;1,337 AlmerÝa;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Women;1,828 AlmerÝa;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Both sexes;383 AlmerÝa;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Men;150 AlmerÝa;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Women;233 AlmerÝa;Group 1402 Renal failure 5836-5837, 584-586;Both sexes;300 AlmerÝa;Group 1402 Renal failure 5836-5837, 584-586;Men;168 AlmerÝa;Group 1402 Renal failure 5836-5837, 584-586;Women;132 AlmerÝa;Group 1403 Urolithiasis 592, 594, 7880;Both sexes;333 AlmerÝa;Group 1403 Urolithiasis 592, 594, 7880;Men;204 AlmerÝa;Group 1403 Urolithiasis 592, 594, 7880;Women;129 AlmerÝa;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Both sexes;752 AlmerÝa;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Men;381 AlmerÝa;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Women;371 AlmerÝa;Group 1405 Prostatic hyperplasia 600;Both sexes;230 AlmerÝa;Group 1405 Prostatic hyperplasia 600;Men;230 AlmerÝa;Group 1405 Prostatic hyperplasia 600;Women;.. AlmerÝa;Group 1406 Other diseases of the male genital organs 601-608;Both sexes;179 AlmerÝa;Group 1406 Other diseases of the male genital organs 601-608;Men;179 AlmerÝa;Group 1406 Other diseases of the male genital organs 601-608;Women;.. AlmerÝa;Group 1407 Disorders of breast 610-612;Both sexes;222 AlmerÝa;Group 1407 Disorders of breast 610-612;Men;21 AlmerÝa;Group 1407 Disorders of breast 610-612;Women;201 AlmerÝa;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Both sexes;141 AlmerÝa;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Men;.. AlmerÝa;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Women;141 AlmerÝa;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Both sexes;55 AlmerÝa;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Men;.. AlmerÝa;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Women;55 AlmerÝa;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Both sexes;570 AlmerÝa;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Men;4 AlmerÝa;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Women;566 AlmerÝa;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Both sexes;9,766 AlmerÝa;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Men;.. AlmerÝa;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Women;9,766 AlmerÝa;Group 1501 Legally induced abortion 635;Both sexes;17 AlmerÝa;Group 1501 Legally induced abortion 635;Men;.. AlmerÝa;Group 1501 Legally induced abortion 635;Women;17 AlmerÝa;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Both sexes;809 AlmerÝa;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Men;.. AlmerÝa;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Women;809 AlmerÝa;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Both sexes;6,483 AlmerÝa;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Men;.. AlmerÝa;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Women;6,483 AlmerÝa;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Both sexes;1,089 AlmerÝa;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Men;.. AlmerÝa;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Women;1,089 AlmerÝa;Group 1505 Single spontaneous delivery 650;Both sexes;482 AlmerÝa;Group 1505 Single spontaneous delivery 650;Men;.. AlmerÝa;Group 1505 Single spontaneous delivery 650;Women;482 AlmerÝa;Group 1506 Other deliveries 6695-6697;Both sexes;264 AlmerÝa;Group 1506 Other deliveries 6695-6697;Men;.. AlmerÝa;Group 1506 Other deliveries 6695-6697;Women;264 AlmerÝa;Group 1507 Complications related to the puerperium 670-676;Both sexes;39 AlmerÝa;Group 1507 Complications related to the puerperium 670-676;Men;.. AlmerÝa;Group 1507 Complications related to the puerperium 670-676;Women;39 AlmerÝa;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Both sexes;583 AlmerÝa;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Men;.. AlmerÝa;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Women;583 AlmerÝa;Group 1600 Some disorders originating in the perinatal period 760-779;Both sexes;891 AlmerÝa;Group 1600 Some disorders originating in the perinatal period 760-779;Men;475 AlmerÝa;Group 1600 Some disorders originating in the perinatal period 760-779;Women;416 AlmerÝa;Group 1601 Disorders related with premature delivery and a low birth weight 765;Both sexes;287 AlmerÝa;Group 1601 Disorders related with premature delivery and a low birth weight 765;Men;148 AlmerÝa;Group 1601 Disorders related with premature delivery and a low birth weight 765;Women;139 AlmerÝa;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Both sexes;604 AlmerÝa;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Men;327 AlmerÝa;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Women;277 AlmerÝa;Grupo 1700 Congenital abnormalities 740-759;Both sexes;413 AlmerÝa;Grupo 1700 Congenital abnormalities 740-759;Men;233 AlmerÝa;Grupo 1700 Congenital abnormalities 740-759;Women;180 AlmerÝa;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Both sexes;2,187 AlmerÝa;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Men;1,180 AlmerÝa;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Women;1,007 AlmerÝa;Group 1801 Pain in throat and chest 7841, 7865;Both sexes;321 AlmerÝa;Group 1801 Pain in throat and chest 7841, 7865;Men;189 AlmerÝa;Group 1801 Pain in throat and chest 7841, 7865;Women;132 AlmerÝa;Group 1802 Abdominal pain 7890;Both sexes;268 AlmerÝa;Group 1802 Abdominal pain 7890;Men;94 AlmerÝa;Group 1802 Abdominal pain 7890;Women;174 AlmerÝa;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Both sexes;134 AlmerÝa;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Men;71 AlmerÝa;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Women;63 AlmerÝa;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Both sexes;1,464 AlmerÝa;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Men;826 AlmerÝa;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Women;638 AlmerÝa;Group 1900 Injuries and poisoning 800-999;Both sexes;4,355 AlmerÝa;Group 1900 Injuries and poisoning 800-999;Men;2,401 AlmerÝa;Group 1900 Injuries and poisoning 800-999;Women;1,954 AlmerÝa;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Both sexes;201 AlmerÝa;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Men;122 AlmerÝa;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Women;79 AlmerÝa;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Both sexes;161 AlmerÝa;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Men;129 AlmerÝa;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Women;32 AlmerÝa;Group 1903 Radius and ulna fracture 813;Both sexes;384 AlmerÝa;Group 1903 Radius and ulna fracture 813;Men;213 AlmerÝa;Group 1903 Radius and ulna fracture 813;Women;171 AlmerÝa;Group 1904 Femur fracture 820-821;Both sexes;747 AlmerÝa;Group 1904 Femur fracture 820-821;Men;241 AlmerÝa;Group 1904 Femur fracture 820-821;Women;506 AlmerÝa;Group 1905 Leg fracture, including the ankle 823-824;Both sexes;402 AlmerÝa;Group 1905 Leg fracture, including the ankle 823-824;Men;215 AlmerÝa;Group 1905 Leg fracture, including the ankle 823-824;Women;187 AlmerÝa;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Both sexes;1,293 AlmerÝa;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Men;886 AlmerÝa;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Women;407 AlmerÝa;Group 1907 Burns 940-949;Both sexes;51 AlmerÝa;Group 1907 Burns 940-949;Men;30 AlmerÝa;Group 1907 Burns 940-949;Women;21 AlmerÝa;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Both sexes;132 AlmerÝa;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Men;57 AlmerÝa;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Women;75 AlmerÝa;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Both sexes;883 AlmerÝa;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Men;464 AlmerÝa;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Women;419 AlmerÝa;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Both sexes;13 AlmerÝa;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Men;8 AlmerÝa;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Women;5 AlmerÝa;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Both sexes;88 AlmerÝa;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Men;36 AlmerÝa;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Women;52 AlmerÝa;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Both sexes;752 AlmerÝa;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Men;414 AlmerÝa;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Women;338 AlmerÝa;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Both sexes;31 AlmerÝa;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Men;14 AlmerÝa;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Women;17 AlmerÝa;Group 2102 Contraceptive management V25;Both sexes;14 AlmerÝa;Group 2102 Contraceptive management V25;Men;.. AlmerÝa;Group 2102 Contraceptive management V25;Women;14 AlmerÝa;Group 2103 Living newborns by type of delivery V30-V39;Both sexes;.. AlmerÝa;Group 2103 Living newborns by type of delivery V30-V39;Men;.. AlmerÝa;Group 2103 Living newborns by type of delivery V30-V39;Women;.. AlmerÝa;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Both sexes;386 AlmerÝa;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Men;231 AlmerÝa;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Women;155 AlmerÝa;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Both sexes;321 AlmerÝa;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Men;169 AlmerÝa;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Women;152 Cßdiz;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Both sexes;102,319 Cßdiz;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Men;46,102 Cßdiz;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Women;56,217 Cßdiz;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Both sexes;3,558 Cßdiz;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Men;1,926 Cßdiz;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Women;1,632 Cßdiz;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Both sexes;219 Cßdiz;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Men;117 Cßdiz;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Women;102 Cßdiz;Group 0102 Imprecise intestinal infections 009;Both sexes;534 Cßdiz;Group 0102 Imprecise intestinal infections 009;Men;272 Cßdiz;Group 0102 Imprecise intestinal infections 009;Women;262 Cßdiz;Group 0103 Tuberculosis 010-018, 137;Both sexes;69 Cßdiz;Group 0103 Tuberculosis 010-018, 137;Men;44 Cßdiz;Group 0103 Tuberculosis 010-018, 137;Women;25 Cßdiz;Group 0104 Septicaemia 038;Both sexes;1,620 Cßdiz;Group 0104 Septicaemia 038;Men;818 Cßdiz;Group 0104 Septicaemia 038;Women;802 Cßdiz;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Both sexes;165 Cßdiz;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Men;129 Cßdiz;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Women;36 Cßdiz;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Both sexes;951 Cßdiz;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Men;545 Cßdiz;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Women;405 Cßdiz;Group 0200 Neoplasms 140-239;Both sexes;8,595 Cßdiz;Group 0200 Neoplasms 140-239;Men;4,529 Cßdiz;Group 0200 Neoplasms 140-239;Women;4,066 Cßdiz;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Both sexes;904 Cßdiz;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Men;543 Cßdiz;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Women;361 Cßdiz;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Both sexes;655 Cßdiz;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Men;532 Cßdiz;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Women;123 Cßdiz;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Both sexes;145 Cßdiz;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Men;84 Cßdiz;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Women;61 Cßdiz;Group 0204 Malignant neoplasm of breast 174-175;Both sexes;773 Cßdiz;Group 0204 Malignant neoplasm of breast 174-175;Men;5 Cßdiz;Group 0204 Malignant neoplasm of breast 174-175;Women;767 Cßdiz;Group 0205 Malignant neoplasm of uterus 179-180, 182;Both sexes;183 Cßdiz;Group 0205 Malignant neoplasm of uterus 179-180, 182;Men;.. Cßdiz;Group 0205 Malignant neoplasm of uterus 179-180, 182;Women;183 Cßdiz;Group 0206 Malignant neoplasm of ovary 1830;Both sexes;100 Cßdiz;Group 0206 Malignant neoplasm of ovary 1830;Men;.. Cßdiz;Group 0206 Malignant neoplasm of ovary 1830;Women;100 Cßdiz;Group 0207 Malignant neoplasm of prostate 185;Both sexes;227 Cßdiz;Group 0207 Malignant neoplasm of prostate 185;Men;227 Cßdiz;Group 0207 Malignant neoplasm of prostate 185;Women;.. Cßdiz;Group 0208 Malignant neoplasm of bladder 188;Both sexes;786 Cßdiz;Group 0208 Malignant neoplasm of bladder 188;Men;696 Cßdiz;Group 0208 Malignant neoplasm of bladder 188;Women;90 Cßdiz;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Both sexes;2,949 Cßdiz;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Men;1,794 Cßdiz;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Women;1,154 Cßdiz;Group 0210 Carcinoma in situ 230-234;Both sexes;161 Cßdiz;Group 0210 Carcinoma in situ 230-234;Men;119 Cßdiz;Group 0210 Carcinoma in situ 230-234;Women;42 Cßdiz;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Both sexes;66 Cßdiz;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Men;33 Cßdiz;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Women;33 Cßdiz;Grupo 0212 Leiomyoma of uterus 218;Both sexes;539 Cßdiz;Grupo 0212 Leiomyoma of uterus 218;Men;.. Cßdiz;Grupo 0212 Leiomyoma of uterus 218;Women;539 Cßdiz;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Both sexes;1,108 Cßdiz;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Men;496 Cßdiz;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Women;611 Cßdiz;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Both sexes;1,137 Cßdiz;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Men;548 Cßdiz;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Women;589 Cßdiz;Group 0301 Anaemias 280-285;Both sexes;723 Cßdiz;Group 0301 Anaemias 280-285;Men;337 Cßdiz;Group 0301 Anaemias 280-285;Women;386 Cßdiz;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Both sexes;414 Cßdiz;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Men;211 Cßdiz;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Women;203 Cßdiz;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Both sexes;1,986 Cßdiz;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Men;722 Cßdiz;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Women;1,264 Cßdiz;Group 0401 Diabetes mellitus 249-250;Both sexes;595 Cßdiz;Group 0401 Diabetes mellitus 249-250;Men;322 Cßdiz;Group 0401 Diabetes mellitus 249-250;Women;273 Cßdiz;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Both sexes;1,391 Cßdiz;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Men;400 Cßdiz;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Women;991 Cßdiz;Group 0500 Mental disorders 290-319;Both sexes;1,936 Cßdiz;Group 0500 Mental disorders 290-319;Men;1,077 Cßdiz;Group 0500 Mental disorders 290-319;Women;859 Cßdiz;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Both sexes;61 Cßdiz;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Men;31 Cßdiz;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Women;30 Cßdiz;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Both sexes;118 Cßdiz;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Men;95 Cßdiz;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Women;23 Cßdiz;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Both sexes;144 Cßdiz;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Men;97 Cßdiz;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Women;47 Cßdiz;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Both sexes;623 Cßdiz;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Men;414 Cßdiz;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Women;209 Cßdiz;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Both sexes;371 Cßdiz;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Men;177 Cßdiz;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Women;194 Cßdiz;Group 0506 Other mental and behavioural disorders Rest of (290-319);Both sexes;620 Cßdiz;Group 0506 Other mental and behavioural disorders Rest of (290-319);Men;263 Cßdiz;Group 0506 Other mental and behavioural disorders Rest of (290-319);Women;357 Cßdiz;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Both sexes;2,122 Cßdiz;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Men;1,049 Cßdiz;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Women;1,074 Cßdiz;Group 0601 Alzheimer's disease 3310;Both sexes;36 Cßdiz;Group 0601 Alzheimer's disease 3310;Men;13 Cßdiz;Group 0601 Alzheimer's disease 3310;Women;23 Cßdiz;Group 0602 Multiple sclerosis 340;Both sexes;71 Cßdiz;Group 0602 Multiple sclerosis 340;Men;23 Cßdiz;Group 0602 Multiple sclerosis 340;Women;49 Cßdiz;Group 0603 Epilepsy 345;Both sexes;396 Cßdiz;Group 0603 Epilepsy 345;Men;217 Cßdiz;Group 0603 Epilepsy 345;Women;179 Cßdiz;Group 0604 Transient cerebral ischemia 435;Both sexes;473 Cßdiz;Group 0604 Transient cerebral ischemia 435;Men;231 Cßdiz;Group 0604 Transient cerebral ischemia 435;Women;242 Cßdiz;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Both sexes;1,146 Cßdiz;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Men;565 Cßdiz;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Women;581 Cßdiz;Grupo 0700 Diseases of the eye and adnexa 360-379;Both sexes;617 Cßdiz;Grupo 0700 Diseases of the eye and adnexa 360-379;Men;323 Cßdiz;Grupo 0700 Diseases of the eye and adnexa 360-379;Women;295 Cßdiz;Grupo 0701 Cataract 366;Both sexes;90 Cßdiz;Grupo 0701 Cataract 366;Men;52 Cßdiz;Grupo 0701 Cataract 366;Women;38 Cßdiz;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Both sexes;527 Cßdiz;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Men;271 Cßdiz;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Women;257 Cßdiz;Group 0800 Diseases of the ear and the mastoid 380-389;Both sexes;430 Cßdiz;Group 0800 Diseases of the ear and the mastoid 380-389;Men;217 Cßdiz;Group 0800 Diseases of the ear and the mastoid 380-389;Women;213 Cßdiz;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Both sexes;14,652 Cßdiz;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Men;8,153 Cßdiz;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Women;6,498 Cßdiz;Group 0901 Hypertensive disease 401-405;Both sexes;724 Cßdiz;Group 0901 Hypertensive disease 401-405;Men;312 Cßdiz;Group 0901 Hypertensive disease 401-405;Women;412 Cßdiz;Group 0902 Angina pectoris 4111, 413;Both sexes;1,057 Cßdiz;Group 0902 Angina pectoris 4111, 413;Men;631 Cßdiz;Group 0902 Angina pectoris 4111, 413;Women;426 Cßdiz;Group 0903 Acute myocardial infarction 410;Both sexes;1,363 Cßdiz;Group 0903 Acute myocardial infarction 410;Men;923 Cßdiz;Group 0903 Acute myocardial infarction 410;Women;441 Cßdiz;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Both sexes;1,509 Cßdiz;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Men;1,070 Cßdiz;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Women;439 Cßdiz;Group 0905 Diseases of the lungs circulation 415-417;Both sexes;283 Cßdiz;Group 0905 Diseases of the lungs circulation 415-417;Men;134 Cßdiz;Group 0905 Diseases of the lungs circulation 415-417;Women;149 Cßdiz;Group 0906 Heart conduction disorders and arrhytmias 426-427;Both sexes;1,858 Cßdiz;Group 0906 Heart conduction disorders and arrhytmias 426-427;Men;960 Cßdiz;Group 0906 Heart conduction disorders and arrhytmias 426-427;Women;898 Cßdiz;Grupo 0907 Heart failure 428;Both sexes;2,736 Cßdiz;Grupo 0907 Heart failure 428;Men;1,194 Cßdiz;Grupo 0907 Heart failure 428;Women;1,542 Cßdiz;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Both sexes;2,440 Cßdiz;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Men;1,335 Cßdiz;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Women;1,105 Cßdiz;Grupo 0909 Atherosclerosis 440;Both sexes;501 Cßdiz;Grupo 0909 Atherosclerosis 440;Men;375 Cßdiz;Grupo 0909 Atherosclerosis 440;Women;125 Cßdiz;Group 0910 Varicose veins of lower extremities 454;Both sexes;190 Cßdiz;Group 0910 Varicose veins of lower extremities 454;Men;72 Cßdiz;Group 0910 Varicose veins of lower extremities 454;Women;118 Cßdiz;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Both sexes;1,991 Cßdiz;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Men;1,146 Cßdiz;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Women;845 Cßdiz;Group 1000 Diseases of the respiratory system 0340, 460-519;Both sexes;9,473 Cßdiz;Group 1000 Diseases of the respiratory system 0340, 460-519;Men;5,498 Cßdiz;Group 1000 Diseases of the respiratory system 0340, 460-519;Women;3,975 Cßdiz;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Both sexes;674 Cßdiz;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Men;357 Cßdiz;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Women;318 Cßdiz;Group 1002 Pneumonia 480-486;Both sexes;1,857 Cßdiz;Group 1002 Pneumonia 480-486;Men;1,051 Cßdiz;Group 1002 Pneumonia 480-486;Women;806 Cßdiz;Group 1003 Acute bronchitis and bronchiolitis 466;Both sexes;1,297 Cßdiz;Group 1003 Acute bronchitis and bronchiolitis 466;Men;652 Cßdiz;Group 1003 Acute bronchitis and bronchiolitis 466;Women;645 Cßdiz;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Both sexes;358 Cßdiz;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Men;182 Cßdiz;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Women;176 Cßdiz;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Both sexes;795 Cßdiz;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Men;532 Cßdiz;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Women;264 Cßdiz;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Both sexes;1,168 Cßdiz;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Men;905 Cßdiz;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Women;263 Cßdiz;Group 1007 Asthma 4930-4931,4938-4939;Both sexes;285 Cßdiz;Group 1007 Asthma 4930-4931,4938-4939;Men;95 Cßdiz;Group 1007 Asthma 4930-4931,4938-4939;Women;190 Cßdiz;Group 1008 Other diseases of the respiratory system Resto of (460-519);Both sexes;3,039 Cßdiz;Group 1008 Other diseases of the respiratory system Resto of (460-519);Men;1,725 Cßdiz;Group 1008 Other diseases of the respiratory system Resto of (460-519);Women;1,314 Cßdiz;Group 1100 Diseases of the digestive system 520-579;Both sexes;12,756 Cßdiz;Group 1100 Diseases of the digestive system 520-579;Men;7,087 Cßdiz;Group 1100 Diseases of the digestive system 520-579;Women;5,669 Cßdiz;Group 1101 Disorders of the teeth and supporting structures 520-525;Both sexes;124 Cßdiz;Group 1101 Disorders of the teeth and supporting structures 520-525;Men;62 Cßdiz;Group 1101 Disorders of the teeth and supporting structures 520-525;Women;62 Cßdiz;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Both sexes;202 Cßdiz;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Men;113 Cßdiz;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Women;89 Cßdiz;Group 1103 Diseases of the esophagus 530;Both sexes;219 Cßdiz;Group 1103 Diseases of the esophagus 530;Men;125 Cßdiz;Group 1103 Diseases of the esophagus 530;Women;94 Cßdiz;Group 1104 Peptic ulcer 531-534;Both sexes;227 Cßdiz;Group 1104 Peptic ulcer 531-534;Men;173 Cßdiz;Group 1104 Peptic ulcer 531-534;Women;54 Cßdiz;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Both sexes;501 Cßdiz;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Men;239 Cßdiz;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Women;262 Cßdiz;Group 1106 Appendicitis 540-543;Both sexes;1,150 Cßdiz;Group 1106 Appendicitis 540-543;Men;641 Cßdiz;Group 1106 Appendicitis 540-543;Women;509 Cßdiz;Group 1107 Inguinal hernia 550;Both sexes;1,012 Cßdiz;Group 1107 Inguinal hernia 550;Men;909 Cßdiz;Group 1107 Inguinal hernia 550;Women;102 Cßdiz;Group 1108 Other abdominal hernia 551-553;Both sexes;968 Cßdiz;Group 1108 Other abdominal hernia 551-553;Men;449 Cßdiz;Group 1108 Other abdominal hernia 551-553;Women;519 Cßdiz;Group 1109 Crohn's disease and ulcerative colitis 555-556;Both sexes;344 Cßdiz;Group 1109 Crohn's disease and ulcerative colitis 555-556;Men;175 Cßdiz;Group 1109 Crohn's disease and ulcerative colitis 555-556;Women;170 Cßdiz;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Both sexes;795 Cßdiz;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Men;365 Cßdiz;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Women;430 Cßdiz;Group 1111 Intestinal obstruction without hernia 560;Both sexes;532 Cßdiz;Group 1111 Intestinal obstruction without hernia 560;Men;290 Cßdiz;Group 1111 Intestinal obstruction without hernia 560;Women;242 Cßdiz;Group 1112 Intestinal diverticulosis 562;Both sexes;455 Cßdiz;Group 1112 Intestinal diverticulosis 562;Men;232 Cßdiz;Group 1112 Intestinal diverticulosis 562;Women;223 Cßdiz;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Both sexes;703 Cßdiz;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Men;429 Cßdiz;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Women;274 Cßdiz;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Both sexes;440 Cßdiz;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Men;236 Cßdiz;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Women;204 Cßdiz;Group 1115 Alcoholic hepatitis 5710-5713;Both sexes;368 Cßdiz;Group 1115 Alcoholic hepatitis 5710-5713;Men;326 Cßdiz;Group 1115 Alcoholic hepatitis 5710-5713;Women;42 Cßdiz;Group 1116 Other diseases of the liver 570,5714-573;Both sexes;482 Cßdiz;Group 1116 Other diseases of the liver 570,5714-573;Men;307 Cßdiz;Group 1116 Other diseases of the liver 570,5714-573;Women;175 Cßdiz;Group 1117 Cholelithiasis 574;Both sexes;2,360 Cßdiz;Group 1117 Cholelithiasis 574;Men;941 Cßdiz;Group 1117 Cholelithiasis 574;Women;1,419 Cßdiz;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Both sexes;562 Cßdiz;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Men;280 Cßdiz;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Women;281 Cßdiz;Group 1119 Pancreatic diseases 577;Both sexes;770 Cßdiz;Group 1119 Pancreatic diseases 577;Men;465 Cßdiz;Group 1119 Pancreatic diseases 577;Women;304 Cßdiz;Group 1120 Other diseases of the digestive system Rest of (520-579);Both sexes;543 Cßdiz;Group 1120 Other diseases of the digestive system Rest of (520-579);Men;330 Cßdiz;Group 1120 Other diseases of the digestive system Rest of (520-579);Women;213 Cßdiz;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Both sexes;1,186 Cßdiz;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Men;610 Cßdiz;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Women;576 Cßdiz;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Both sexes;658 Cßdiz;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Men;383 Cßdiz;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Women;275 Cßdiz;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Both sexes;73 Cßdiz;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Men;38 Cßdiz;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Women;35 Cßdiz;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Both sexes;455 Cßdiz;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Men;189 Cßdiz;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Women;266 Cßdiz;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Both sexes;5,690 Cßdiz;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Men;2,492 Cßdiz;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Women;3,198 Cßdiz;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Both sexes;.. Cßdiz;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Men;.. Cßdiz;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Women;.. Cßdiz;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Both sexes;.. Cßdiz;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Men;.. Cßdiz;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Women;.. Cßdiz;Group 1303 Internal derangement of knee 717;Both sexes;502 Cßdiz;Group 1303 Internal derangement of knee 717;Men;342 Cßdiz;Group 1303 Internal derangement of knee 717;Women;159 Cßdiz;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Both sexes;2,285 Cßdiz;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Men;869 Cßdiz;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Women;1,416 Cßdiz;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Both sexes;173 Cßdiz;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Men;64 Cßdiz;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Women;109 Cßdiz;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Both sexes;253 Cßdiz;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Men;138 Cßdiz;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Women;116 Cßdiz;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Both sexes;551 Cßdiz;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Men;296 Cßdiz;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Women;255 Cßdiz;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Both sexes;266 Cßdiz;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Men;115 Cßdiz;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Women;151 Cßdiz;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Both sexes;559 Cßdiz;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Men;296 Cßdiz;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Women;263 Cßdiz;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Both sexes;1,102 Cßdiz;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Men;372 Cßdiz;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Women;729 Cßdiz;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Both sexes;7,622 Cßdiz;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Men;2,996 Cßdiz;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Women;4,625 Cßdiz;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Both sexes;692 Cßdiz;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Men;253 Cßdiz;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Women;439 Cßdiz;Group 1402 Renal failure 5836-5837, 584-586;Both sexes;613 Cßdiz;Group 1402 Renal failure 5836-5837, 584-586;Men;316 Cßdiz;Group 1402 Renal failure 5836-5837, 584-586;Women;297 Cßdiz;Group 1403 Urolithiasis 592, 594, 7880;Both sexes;1,226 Cßdiz;Group 1403 Urolithiasis 592, 594, 7880;Men;677 Cßdiz;Group 1403 Urolithiasis 592, 594, 7880;Women;548 Cßdiz;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Both sexes;1,787 Cßdiz;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Men;859 Cßdiz;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Women;928 Cßdiz;Group 1405 Prostatic hyperplasia 600;Both sexes;385 Cßdiz;Group 1405 Prostatic hyperplasia 600;Men;385 Cßdiz;Group 1405 Prostatic hyperplasia 600;Women;.. Cßdiz;Group 1406 Other diseases of the male genital organs 601-608;Both sexes;441 Cßdiz;Group 1406 Other diseases of the male genital organs 601-608;Men;441 Cßdiz;Group 1406 Other diseases of the male genital organs 601-608;Women;.. Cßdiz;Group 1407 Disorders of breast 610-612;Both sexes;622 Cßdiz;Group 1407 Disorders of breast 610-612;Men;56 Cßdiz;Group 1407 Disorders of breast 610-612;Women;566 Cßdiz;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Both sexes;199 Cßdiz;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Men;.. Cßdiz;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Women;199 Cßdiz;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Both sexes;234 Cßdiz;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Men;.. Cßdiz;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Women;234 Cßdiz;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Both sexes;1,424 Cßdiz;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Men;8 Cßdiz;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Women;1,416 Cßdiz;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Both sexes;13,589 Cßdiz;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Men;.. Cßdiz;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Women;13,589 Cßdiz;Group 1501 Legally induced abortion 635;Both sexes;30 Cßdiz;Group 1501 Legally induced abortion 635;Men;.. Cßdiz;Group 1501 Legally induced abortion 635;Women;30 Cßdiz;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Both sexes;859 Cßdiz;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Men;.. Cßdiz;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Women;859 Cßdiz;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Both sexes;7,647 Cßdiz;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Men;.. Cßdiz;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Women;7,647 Cßdiz;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Both sexes;1,597 Cßdiz;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Men;.. Cßdiz;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Women;1,597 Cßdiz;Group 1505 Single spontaneous delivery 650;Both sexes;1,411 Cßdiz;Group 1505 Single spontaneous delivery 650;Men;.. Cßdiz;Group 1505 Single spontaneous delivery 650;Women;1,411 Cßdiz;Group 1506 Other deliveries 6695-6697;Both sexes;1,294 Cßdiz;Group 1506 Other deliveries 6695-6697;Men;.. Cßdiz;Group 1506 Other deliveries 6695-6697;Women;1,294 Cßdiz;Group 1507 Complications related to the puerperium 670-676;Both sexes;50 Cßdiz;Group 1507 Complications related to the puerperium 670-676;Men;.. Cßdiz;Group 1507 Complications related to the puerperium 670-676;Women;50 Cßdiz;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Both sexes;701 Cßdiz;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Men;.. Cßdiz;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Women;701 Cßdiz;Group 1600 Some disorders originating in the perinatal period 760-779;Both sexes;1,521 Cßdiz;Group 1600 Some disorders originating in the perinatal period 760-779;Men;841 Cßdiz;Group 1600 Some disorders originating in the perinatal period 760-779;Women;681 Cßdiz;Group 1601 Disorders related with premature delivery and a low birth weight 765;Both sexes;464 Cßdiz;Group 1601 Disorders related with premature delivery and a low birth weight 765;Men;250 Cßdiz;Group 1601 Disorders related with premature delivery and a low birth weight 765;Women;214 Cßdiz;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Both sexes;1,057 Cßdiz;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Men;591 Cßdiz;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Women;466 Cßdiz;Grupo 1700 Congenital abnormalities 740-759;Both sexes;804 Cßdiz;Grupo 1700 Congenital abnormalities 740-759;Men;458 Cßdiz;Grupo 1700 Congenital abnormalities 740-759;Women;345 Cßdiz;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Both sexes;5,582 Cßdiz;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Men;2,907 Cßdiz;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Women;2,675 Cßdiz;Group 1801 Pain in throat and chest 7841, 7865;Both sexes;838 Cßdiz;Group 1801 Pain in throat and chest 7841, 7865;Men;476 Cßdiz;Group 1801 Pain in throat and chest 7841, 7865;Women;362 Cßdiz;Group 1802 Abdominal pain 7890;Both sexes;1,038 Cßdiz;Group 1802 Abdominal pain 7890;Men;433 Cßdiz;Group 1802 Abdominal pain 7890;Women;605 Cßdiz;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Both sexes;220 Cßdiz;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Men;112 Cßdiz;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Women;109 Cßdiz;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Both sexes;3,486 Cßdiz;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Men;1,887 Cßdiz;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Women;1,599 Cßdiz;Group 1900 Injuries and poisoning 800-999;Both sexes;7,552 Cßdiz;Group 1900 Injuries and poisoning 800-999;Men;3,960 Cßdiz;Group 1900 Injuries and poisoning 800-999;Women;3,592 Cßdiz;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Both sexes;484 Cßdiz;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Men;314 Cßdiz;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Women;170 Cßdiz;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Both sexes;268 Cßdiz;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Men;189 Cßdiz;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Women;79 Cßdiz;Group 1903 Radius and ulna fracture 813;Both sexes;463 Cßdiz;Group 1903 Radius and ulna fracture 813;Men;259 Cßdiz;Group 1903 Radius and ulna fracture 813;Women;205 Cßdiz;Group 1904 Femur fracture 820-821;Both sexes;1,214 Cßdiz;Group 1904 Femur fracture 820-821;Men;371 Cßdiz;Group 1904 Femur fracture 820-821;Women;843 Cßdiz;Group 1905 Leg fracture, including the ankle 823-824;Both sexes;667 Cßdiz;Group 1905 Leg fracture, including the ankle 823-824;Men;358 Cßdiz;Group 1905 Leg fracture, including the ankle 823-824;Women;309 Cßdiz;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Both sexes;2,091 Cßdiz;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Men;1,269 Cßdiz;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Women;822 Cßdiz;Group 1907 Burns 940-949;Both sexes;24 Cßdiz;Group 1907 Burns 940-949;Men;16 Cßdiz;Group 1907 Burns 940-949;Women;8 Cßdiz;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Both sexes;280 Cßdiz;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Men;137 Cßdiz;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Women;144 Cßdiz;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Both sexes;1,843 Cßdiz;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Men;933 Cßdiz;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Women;910 Cßdiz;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Both sexes;47 Cßdiz;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Men;21 Cßdiz;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Women;26 Cßdiz;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Both sexes;171 Cßdiz;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Men;94 Cßdiz;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Women;77 Cßdiz;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Both sexes;1,511 Cßdiz;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Men;708 Cßdiz;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Women;803 Cßdiz;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Both sexes;59 Cßdiz;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Men;25 Cßdiz;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Women;34 Cßdiz;Group 2102 Contraceptive management V25;Both sexes;16 Cßdiz;Group 2102 Contraceptive management V25;Men;2 Cßdiz;Group 2102 Contraceptive management V25;Women;13 Cßdiz;Group 2103 Living newborns by type of delivery V30-V39;Both sexes;.. Cßdiz;Group 2103 Living newborns by type of delivery V30-V39;Men;.. Cßdiz;Group 2103 Living newborns by type of delivery V30-V39;Women;.. Cßdiz;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Both sexes;597 Cßdiz;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Men;392 Cßdiz;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Women;205 Cßdiz;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Both sexes;840 Cßdiz;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Men;290 Cßdiz;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Women;550 C¾rdoba;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Both sexes;70,371 C¾rdoba;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Men;32,576 C¾rdoba;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Women;37,795 C¾rdoba;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Both sexes;1,069 C¾rdoba;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Men;617 C¾rdoba;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Women;452 C¾rdoba;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Both sexes;141 C¾rdoba;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Men;69 C¾rdoba;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Women;72 C¾rdoba;Group 0102 Imprecise intestinal infections 009;Both sexes;37 C¾rdoba;Group 0102 Imprecise intestinal infections 009;Men;18 C¾rdoba;Group 0102 Imprecise intestinal infections 009;Women;19 C¾rdoba;Group 0103 Tuberculosis 010-018, 137;Both sexes;51 C¾rdoba;Group 0103 Tuberculosis 010-018, 137;Men;35 C¾rdoba;Group 0103 Tuberculosis 010-018, 137;Women;16 C¾rdoba;Group 0104 Septicaemia 038;Both sexes;309 C¾rdoba;Group 0104 Septicaemia 038;Men;179 C¾rdoba;Group 0104 Septicaemia 038;Women;130 C¾rdoba;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Both sexes;40 C¾rdoba;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Men;30 C¾rdoba;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Women;10 C¾rdoba;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Both sexes;491 C¾rdoba;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Men;286 C¾rdoba;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Women;205 C¾rdoba;Group 0200 Neoplasms 140-239;Both sexes;7,138 C¾rdoba;Group 0200 Neoplasms 140-239;Men;3,603 C¾rdoba;Group 0200 Neoplasms 140-239;Women;3,535 C¾rdoba;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Both sexes;686 C¾rdoba;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Men;406 C¾rdoba;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Women;280 C¾rdoba;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Both sexes;413 C¾rdoba;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Men;357 C¾rdoba;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Women;56 C¾rdoba;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Both sexes;265 C¾rdoba;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Men;153 C¾rdoba;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Women;112 C¾rdoba;Group 0204 Malignant neoplasm of breast 174-175;Both sexes;542 C¾rdoba;Group 0204 Malignant neoplasm of breast 174-175;Men;3 C¾rdoba;Group 0204 Malignant neoplasm of breast 174-175;Women;539 C¾rdoba;Group 0205 Malignant neoplasm of uterus 179-180, 182;Both sexes;179 C¾rdoba;Group 0205 Malignant neoplasm of uterus 179-180, 182;Men;.. C¾rdoba;Group 0205 Malignant neoplasm of uterus 179-180, 182;Women;179 C¾rdoba;Group 0206 Malignant neoplasm of ovary 1830;Both sexes;74 C¾rdoba;Group 0206 Malignant neoplasm of ovary 1830;Men;.. C¾rdoba;Group 0206 Malignant neoplasm of ovary 1830;Women;74 C¾rdoba;Group 0207 Malignant neoplasm of prostate 185;Both sexes;181 C¾rdoba;Group 0207 Malignant neoplasm of prostate 185;Men;181 C¾rdoba;Group 0207 Malignant neoplasm of prostate 185;Women;.. C¾rdoba;Group 0208 Malignant neoplasm of bladder 188;Both sexes;580 C¾rdoba;Group 0208 Malignant neoplasm of bladder 188;Men;482 C¾rdoba;Group 0208 Malignant neoplasm of bladder 188;Women;98 C¾rdoba;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Both sexes;2,470 C¾rdoba;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Men;1,393 C¾rdoba;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Women;1,077 C¾rdoba;Group 0210 Carcinoma in situ 230-234;Both sexes;68 C¾rdoba;Group 0210 Carcinoma in situ 230-234;Men;8 C¾rdoba;Group 0210 Carcinoma in situ 230-234;Women;60 C¾rdoba;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Both sexes;64 C¾rdoba;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Men;39 C¾rdoba;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Women;25 C¾rdoba;Grupo 0212 Leiomyoma of uterus 218;Both sexes;355 C¾rdoba;Grupo 0212 Leiomyoma of uterus 218;Men;.. C¾rdoba;Grupo 0212 Leiomyoma of uterus 218;Women;355 C¾rdoba;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Both sexes;1,261 C¾rdoba;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Men;581 C¾rdoba;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Women;680 C¾rdoba;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Both sexes;732 C¾rdoba;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Men;331 C¾rdoba;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Women;401 C¾rdoba;Group 0301 Anaemias 280-285;Both sexes;480 C¾rdoba;Group 0301 Anaemias 280-285;Men;215 C¾rdoba;Group 0301 Anaemias 280-285;Women;265 C¾rdoba;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Both sexes;252 C¾rdoba;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Men;116 C¾rdoba;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Women;136 C¾rdoba;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Both sexes;1,165 C¾rdoba;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Men;466 C¾rdoba;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Women;699 C¾rdoba;Group 0401 Diabetes mellitus 249-250;Both sexes;251 C¾rdoba;Group 0401 Diabetes mellitus 249-250;Men;136 C¾rdoba;Group 0401 Diabetes mellitus 249-250;Women;115 C¾rdoba;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Both sexes;914 C¾rdoba;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Men;330 C¾rdoba;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Women;584 C¾rdoba;Group 0500 Mental disorders 290-319;Both sexes;995 C¾rdoba;Group 0500 Mental disorders 290-319;Men;514 C¾rdoba;Group 0500 Mental disorders 290-319;Women;481 C¾rdoba;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Both sexes;14 C¾rdoba;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Men;6 C¾rdoba;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Women;8 C¾rdoba;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Both sexes;31 C¾rdoba;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Men;25 C¾rdoba;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Women;6 C¾rdoba;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Both sexes;75 C¾rdoba;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Men;48 C¾rdoba;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Women;27 C¾rdoba;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Both sexes;274 C¾rdoba;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Men;161 C¾rdoba;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Women;113 C¾rdoba;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Both sexes;252 C¾rdoba;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Men;123 C¾rdoba;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Women;129 C¾rdoba;Group 0506 Other mental and behavioural disorders Rest of (290-319);Both sexes;349 C¾rdoba;Group 0506 Other mental and behavioural disorders Rest of (290-319);Men;151 C¾rdoba;Group 0506 Other mental and behavioural disorders Rest of (290-319);Women;198 C¾rdoba;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Both sexes;1,274 C¾rdoba;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Men;606 C¾rdoba;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Women;668 C¾rdoba;Group 0601 Alzheimer's disease 3310;Both sexes;13 C¾rdoba;Group 0601 Alzheimer's disease 3310;Men;4 C¾rdoba;Group 0601 Alzheimer's disease 3310;Women;9 C¾rdoba;Group 0602 Multiple sclerosis 340;Both sexes;27 C¾rdoba;Group 0602 Multiple sclerosis 340;Men;18 C¾rdoba;Group 0602 Multiple sclerosis 340;Women;9 C¾rdoba;Group 0603 Epilepsy 345;Both sexes;172 C¾rdoba;Group 0603 Epilepsy 345;Men;92 C¾rdoba;Group 0603 Epilepsy 345;Women;80 C¾rdoba;Group 0604 Transient cerebral ischemia 435;Both sexes;253 C¾rdoba;Group 0604 Transient cerebral ischemia 435;Men;125 C¾rdoba;Group 0604 Transient cerebral ischemia 435;Women;128 C¾rdoba;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Both sexes;809 C¾rdoba;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Men;367 C¾rdoba;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Women;442 C¾rdoba;Grupo 0700 Diseases of the eye and adnexa 360-379;Both sexes;926 C¾rdoba;Grupo 0700 Diseases of the eye and adnexa 360-379;Men;503 C¾rdoba;Grupo 0700 Diseases of the eye and adnexa 360-379;Women;423 C¾rdoba;Grupo 0701 Cataract 366;Both sexes;194 C¾rdoba;Grupo 0701 Cataract 366;Men;111 C¾rdoba;Grupo 0701 Cataract 366;Women;83 C¾rdoba;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Both sexes;732 C¾rdoba;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Men;392 C¾rdoba;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Women;340 C¾rdoba;Group 0800 Diseases of the ear and the mastoid 380-389;Both sexes;255 C¾rdoba;Group 0800 Diseases of the ear and the mastoid 380-389;Men;111 C¾rdoba;Group 0800 Diseases of the ear and the mastoid 380-389;Women;144 C¾rdoba;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Both sexes;10,068 C¾rdoba;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Men;5,776 C¾rdoba;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Women;4,292 C¾rdoba;Group 0901 Hypertensive disease 401-405;Both sexes;407 C¾rdoba;Group 0901 Hypertensive disease 401-405;Men;175 C¾rdoba;Group 0901 Hypertensive disease 401-405;Women;232 C¾rdoba;Group 0902 Angina pectoris 4111, 413;Both sexes;576 C¾rdoba;Group 0902 Angina pectoris 4111, 413;Men;357 C¾rdoba;Group 0902 Angina pectoris 4111, 413;Women;219 C¾rdoba;Group 0903 Acute myocardial infarction 410;Both sexes;850 C¾rdoba;Group 0903 Acute myocardial infarction 410;Men;620 C¾rdoba;Group 0903 Acute myocardial infarction 410;Women;230 C¾rdoba;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Both sexes;704 C¾rdoba;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Men;551 C¾rdoba;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Women;153 C¾rdoba;Group 0905 Diseases of the lungs circulation 415-417;Both sexes;307 C¾rdoba;Group 0905 Diseases of the lungs circulation 415-417;Men;136 C¾rdoba;Group 0905 Diseases of the lungs circulation 415-417;Women;171 C¾rdoba;Group 0906 Heart conduction disorders and arrhytmias 426-427;Both sexes;1,229 C¾rdoba;Group 0906 Heart conduction disorders and arrhytmias 426-427;Men;668 C¾rdoba;Group 0906 Heart conduction disorders and arrhytmias 426-427;Women;561 C¾rdoba;Grupo 0907 Heart failure 428;Both sexes;1,901 C¾rdoba;Grupo 0907 Heart failure 428;Men;887 C¾rdoba;Grupo 0907 Heart failure 428;Women;1,014 C¾rdoba;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Both sexes;1,688 C¾rdoba;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Men;916 C¾rdoba;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Women;772 C¾rdoba;Grupo 0909 Atherosclerosis 440;Both sexes;281 C¾rdoba;Grupo 0909 Atherosclerosis 440;Men;237 C¾rdoba;Grupo 0909 Atherosclerosis 440;Women;44 C¾rdoba;Group 0910 Varicose veins of lower extremities 454;Both sexes;220 C¾rdoba;Group 0910 Varicose veins of lower extremities 454;Men;85 C¾rdoba;Group 0910 Varicose veins of lower extremities 454;Women;135 C¾rdoba;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Both sexes;1,905 C¾rdoba;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Men;1,144 C¾rdoba;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Women;761 C¾rdoba;Group 1000 Diseases of the respiratory system 0340, 460-519;Both sexes;6,909 C¾rdoba;Group 1000 Diseases of the respiratory system 0340, 460-519;Men;4,029 C¾rdoba;Group 1000 Diseases of the respiratory system 0340, 460-519;Women;2,880 C¾rdoba;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Both sexes;200 C¾rdoba;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Men;110 C¾rdoba;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Women;90 C¾rdoba;Group 1002 Pneumonia 480-486;Both sexes;1,751 C¾rdoba;Group 1002 Pneumonia 480-486;Men;1,030 C¾rdoba;Group 1002 Pneumonia 480-486;Women;721 C¾rdoba;Group 1003 Acute bronchitis and bronchiolitis 466;Both sexes;330 C¾rdoba;Group 1003 Acute bronchitis and bronchiolitis 466;Men;172 C¾rdoba;Group 1003 Acute bronchitis and bronchiolitis 466;Women;158 C¾rdoba;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Both sexes;140 C¾rdoba;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Men;75 C¾rdoba;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Women;65 C¾rdoba;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Both sexes;368 C¾rdoba;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Men;220 C¾rdoba;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Women;148 C¾rdoba;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Both sexes;1,018 C¾rdoba;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Men;830 C¾rdoba;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Women;188 C¾rdoba;Group 1007 Asthma 4930-4931,4938-4939;Both sexes;133 C¾rdoba;Group 1007 Asthma 4930-4931,4938-4939;Men;54 C¾rdoba;Group 1007 Asthma 4930-4931,4938-4939;Women;79 C¾rdoba;Group 1008 Other diseases of the respiratory system Resto of (460-519);Both sexes;2,969 C¾rdoba;Group 1008 Other diseases of the respiratory system Resto of (460-519);Men;1,538 C¾rdoba;Group 1008 Other diseases of the respiratory system Resto of (460-519);Women;1,431 C¾rdoba;Group 1100 Diseases of the digestive system 520-579;Both sexes;10,390 C¾rdoba;Group 1100 Diseases of the digestive system 520-579;Men;5,771 C¾rdoba;Group 1100 Diseases of the digestive system 520-579;Women;4,619 C¾rdoba;Group 1101 Disorders of the teeth and supporting structures 520-525;Both sexes;186 C¾rdoba;Group 1101 Disorders of the teeth and supporting structures 520-525;Men;83 C¾rdoba;Group 1101 Disorders of the teeth and supporting structures 520-525;Women;103 C¾rdoba;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Both sexes;164 C¾rdoba;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Men;77 C¾rdoba;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Women;87 C¾rdoba;Group 1103 Diseases of the esophagus 530;Both sexes;259 C¾rdoba;Group 1103 Diseases of the esophagus 530;Men;140 C¾rdoba;Group 1103 Diseases of the esophagus 530;Women;119 C¾rdoba;Group 1104 Peptic ulcer 531-534;Both sexes;171 C¾rdoba;Group 1104 Peptic ulcer 531-534;Men;132 C¾rdoba;Group 1104 Peptic ulcer 531-534;Women;39 C¾rdoba;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Both sexes;160 C¾rdoba;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Men;85 C¾rdoba;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Women;75 C¾rdoba;Group 1106 Appendicitis 540-543;Both sexes;838 C¾rdoba;Group 1106 Appendicitis 540-543;Men;474 C¾rdoba;Group 1106 Appendicitis 540-543;Women;364 C¾rdoba;Group 1107 Inguinal hernia 550;Both sexes;1,018 C¾rdoba;Group 1107 Inguinal hernia 550;Men;878 C¾rdoba;Group 1107 Inguinal hernia 550;Women;140 C¾rdoba;Group 1108 Other abdominal hernia 551-553;Both sexes;1,065 C¾rdoba;Group 1108 Other abdominal hernia 551-553;Men;480 C¾rdoba;Group 1108 Other abdominal hernia 551-553;Women;585 C¾rdoba;Group 1109 Crohn's disease and ulcerative colitis 555-556;Both sexes;187 C¾rdoba;Group 1109 Crohn's disease and ulcerative colitis 555-556;Men;99 C¾rdoba;Group 1109 Crohn's disease and ulcerative colitis 555-556;Women;88 C¾rdoba;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Both sexes;444 C¾rdoba;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Men;224 C¾rdoba;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Women;220 C¾rdoba;Group 1111 Intestinal obstruction without hernia 560;Both sexes;510 C¾rdoba;Group 1111 Intestinal obstruction without hernia 560;Men;288 C¾rdoba;Group 1111 Intestinal obstruction without hernia 560;Women;222 C¾rdoba;Group 1112 Intestinal diverticulosis 562;Both sexes;364 C¾rdoba;Group 1112 Intestinal diverticulosis 562;Men;196 C¾rdoba;Group 1112 Intestinal diverticulosis 562;Women;168 C¾rdoba;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Both sexes;618 C¾rdoba;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Men;393 C¾rdoba;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Women;225 C¾rdoba;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Both sexes;287 C¾rdoba;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Men;166 C¾rdoba;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Women;121 C¾rdoba;Group 1115 Alcoholic hepatitis 5710-5713;Both sexes;219 C¾rdoba;Group 1115 Alcoholic hepatitis 5710-5713;Men;192 C¾rdoba;Group 1115 Alcoholic hepatitis 5710-5713;Women;27 C¾rdoba;Group 1116 Other diseases of the liver 570,5714-573;Both sexes;267 C¾rdoba;Group 1116 Other diseases of the liver 570,5714-573;Men;156 C¾rdoba;Group 1116 Other diseases of the liver 570,5714-573;Women;111 C¾rdoba;Group 1117 Cholelithiasis 574;Both sexes;2,172 C¾rdoba;Group 1117 Cholelithiasis 574;Men;909 C¾rdoba;Group 1117 Cholelithiasis 574;Women;1,263 C¾rdoba;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Both sexes;409 C¾rdoba;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Men;233 C¾rdoba;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Women;176 C¾rdoba;Group 1119 Pancreatic diseases 577;Both sexes;644 C¾rdoba;Group 1119 Pancreatic diseases 577;Men;350 C¾rdoba;Group 1119 Pancreatic diseases 577;Women;294 C¾rdoba;Group 1120 Other diseases of the digestive system Rest of (520-579);Both sexes;408 C¾rdoba;Group 1120 Other diseases of the digestive system Rest of (520-579);Men;216 C¾rdoba;Group 1120 Other diseases of the digestive system Rest of (520-579);Women;192 C¾rdoba;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Both sexes;692 C¾rdoba;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Men;400 C¾rdoba;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Women;292 C¾rdoba;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Both sexes;379 C¾rdoba;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Men;248 C¾rdoba;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Women;131 C¾rdoba;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Both sexes;26 C¾rdoba;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Men;9 C¾rdoba;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Women;17 C¾rdoba;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Both sexes;287 C¾rdoba;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Men;143 C¾rdoba;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Women;144 C¾rdoba;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Both sexes;4,675 C¾rdoba;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Men;1,973 C¾rdoba;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Women;2,702 C¾rdoba;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Both sexes;.. C¾rdoba;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Men;.. C¾rdoba;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Women;.. C¾rdoba;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Both sexes;.. C¾rdoba;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Men;.. C¾rdoba;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Women;.. C¾rdoba;Group 1303 Internal derangement of knee 717;Both sexes;356 C¾rdoba;Group 1303 Internal derangement of knee 717;Men;271 C¾rdoba;Group 1303 Internal derangement of knee 717;Women;85 C¾rdoba;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Both sexes;2,044 C¾rdoba;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Men;763 C¾rdoba;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Women;1,281 C¾rdoba;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Both sexes;71 C¾rdoba;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Men;27 C¾rdoba;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Women;44 C¾rdoba;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Both sexes;278 C¾rdoba;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Men;138 C¾rdoba;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Women;140 C¾rdoba;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Both sexes;361 C¾rdoba;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Men;191 C¾rdoba;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Women;170 C¾rdoba;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Both sexes;34 C¾rdoba;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Men;13 C¾rdoba;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Women;21 C¾rdoba;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Both sexes;527 C¾rdoba;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Men;257 C¾rdoba;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Women;270 C¾rdoba;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Both sexes;1,004 C¾rdoba;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Men;313 C¾rdoba;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Women;691 C¾rdoba;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Both sexes;3,775 C¾rdoba;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Men;1,721 C¾rdoba;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Women;2,054 C¾rdoba;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Both sexes;401 C¾rdoba;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Men;176 C¾rdoba;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Women;225 C¾rdoba;Group 1402 Renal failure 5836-5837, 584-586;Both sexes;506 C¾rdoba;Group 1402 Renal failure 5836-5837, 584-586;Men;271 C¾rdoba;Group 1402 Renal failure 5836-5837, 584-586;Women;235 C¾rdoba;Group 1403 Urolithiasis 592, 594, 7880;Both sexes;532 C¾rdoba;Group 1403 Urolithiasis 592, 594, 7880;Men;316 C¾rdoba;Group 1403 Urolithiasis 592, 594, 7880;Women;216 C¾rdoba;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Both sexes;601 C¾rdoba;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Men;329 C¾rdoba;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Women;272 C¾rdoba;Group 1405 Prostatic hyperplasia 600;Both sexes;281 C¾rdoba;Group 1405 Prostatic hyperplasia 600;Men;281 C¾rdoba;Group 1405 Prostatic hyperplasia 600;Women;.. C¾rdoba;Group 1406 Other diseases of the male genital organs 601-608;Both sexes;296 C¾rdoba;Group 1406 Other diseases of the male genital organs 601-608;Men;296 C¾rdoba;Group 1406 Other diseases of the male genital organs 601-608;Women;.. C¾rdoba;Group 1407 Disorders of breast 610-612;Both sexes;378 C¾rdoba;Group 1407 Disorders of breast 610-612;Men;46 C¾rdoba;Group 1407 Disorders of breast 610-612;Women;332 C¾rdoba;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Both sexes;106 C¾rdoba;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Men;.. C¾rdoba;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Women;106 C¾rdoba;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Both sexes;69 C¾rdoba;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Men;.. C¾rdoba;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Women;69 C¾rdoba;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Both sexes;605 C¾rdoba;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Men;6 C¾rdoba;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Women;599 C¾rdoba;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Both sexes;8,507 C¾rdoba;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Men;.. C¾rdoba;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Women;8,507 C¾rdoba;Group 1501 Legally induced abortion 635;Both sexes;6 C¾rdoba;Group 1501 Legally induced abortion 635;Men;.. C¾rdoba;Group 1501 Legally induced abortion 635;Women;6 C¾rdoba;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Both sexes;391 C¾rdoba;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Men;.. C¾rdoba;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Women;391 C¾rdoba;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Both sexes;5,296 C¾rdoba;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Men;.. C¾rdoba;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Women;5,296 C¾rdoba;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Both sexes;946 C¾rdoba;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Men;.. C¾rdoba;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Women;946 C¾rdoba;Group 1505 Single spontaneous delivery 650;Both sexes;829 C¾rdoba;Group 1505 Single spontaneous delivery 650;Men;.. C¾rdoba;Group 1505 Single spontaneous delivery 650;Women;829 C¾rdoba;Group 1506 Other deliveries 6695-6697;Both sexes;592 C¾rdoba;Group 1506 Other deliveries 6695-6697;Men;.. C¾rdoba;Group 1506 Other deliveries 6695-6697;Women;592 C¾rdoba;Group 1507 Complications related to the puerperium 670-676;Both sexes;36 C¾rdoba;Group 1507 Complications related to the puerperium 670-676;Men;.. C¾rdoba;Group 1507 Complications related to the puerperium 670-676;Women;36 C¾rdoba;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Both sexes;411 C¾rdoba;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Men;.. C¾rdoba;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Women;411 C¾rdoba;Group 1600 Some disorders originating in the perinatal period 760-779;Both sexes;896 C¾rdoba;Group 1600 Some disorders originating in the perinatal period 760-779;Men;460 C¾rdoba;Group 1600 Some disorders originating in the perinatal period 760-779;Women;436 C¾rdoba;Group 1601 Disorders related with premature delivery and a low birth weight 765;Both sexes;318 C¾rdoba;Group 1601 Disorders related with premature delivery and a low birth weight 765;Men;156 C¾rdoba;Group 1601 Disorders related with premature delivery and a low birth weight 765;Women;162 C¾rdoba;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Both sexes;578 C¾rdoba;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Men;304 C¾rdoba;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Women;274 C¾rdoba;Grupo 1700 Congenital abnormalities 740-759;Both sexes;999 C¾rdoba;Grupo 1700 Congenital abnormalities 740-759;Men;477 C¾rdoba;Grupo 1700 Congenital abnormalities 740-759;Women;522 C¾rdoba;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Both sexes;2,826 C¾rdoba;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Men;1,506 C¾rdoba;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Women;1,320 C¾rdoba;Group 1801 Pain in throat and chest 7841, 7865;Both sexes;463 C¾rdoba;Group 1801 Pain in throat and chest 7841, 7865;Men;265 C¾rdoba;Group 1801 Pain in throat and chest 7841, 7865;Women;198 C¾rdoba;Group 1802 Abdominal pain 7890;Both sexes;582 C¾rdoba;Group 1802 Abdominal pain 7890;Men;231 C¾rdoba;Group 1802 Abdominal pain 7890;Women;351 C¾rdoba;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Both sexes;19 C¾rdoba;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Men;13 C¾rdoba;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Women;6 C¾rdoba;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Both sexes;1,762 C¾rdoba;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Men;997 C¾rdoba;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Women;765 C¾rdoba;Group 1900 Injuries and poisoning 800-999;Both sexes;6,119 C¾rdoba;Group 1900 Injuries and poisoning 800-999;Men;3,135 C¾rdoba;Group 1900 Injuries and poisoning 800-999;Women;2,984 C¾rdoba;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Both sexes;361 C¾rdoba;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Men;214 C¾rdoba;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Women;147 C¾rdoba;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Both sexes;199 C¾rdoba;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Men;138 C¾rdoba;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Women;61 C¾rdoba;Group 1903 Radius and ulna fracture 813;Both sexes;331 C¾rdoba;Group 1903 Radius and ulna fracture 813;Men;168 C¾rdoba;Group 1903 Radius and ulna fracture 813;Women;163 C¾rdoba;Group 1904 Femur fracture 820-821;Both sexes;1,204 C¾rdoba;Group 1904 Femur fracture 820-821;Men;351 C¾rdoba;Group 1904 Femur fracture 820-821;Women;853 C¾rdoba;Group 1905 Leg fracture, including the ankle 823-824;Both sexes;408 C¾rdoba;Group 1905 Leg fracture, including the ankle 823-824;Men;220 C¾rdoba;Group 1905 Leg fracture, including the ankle 823-824;Women;188 C¾rdoba;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Both sexes;1,235 C¾rdoba;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Men;768 C¾rdoba;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Women;467 C¾rdoba;Group 1907 Burns 940-949;Both sexes;78 C¾rdoba;Group 1907 Burns 940-949;Men;47 C¾rdoba;Group 1907 Burns 940-949;Women;31 C¾rdoba;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Both sexes;192 C¾rdoba;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Men;91 C¾rdoba;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Women;101 C¾rdoba;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Both sexes;1,963 C¾rdoba;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Men;1,053 C¾rdoba;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Women;910 C¾rdoba;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Both sexes;7 C¾rdoba;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Men;4 C¾rdoba;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Women;3 C¾rdoba;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Both sexes;141 C¾rdoba;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Men;81 C¾rdoba;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Women;60 C¾rdoba;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Both sexes;961 C¾rdoba;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Men;577 C¾rdoba;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Women;384 C¾rdoba;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Both sexes;115 C¾rdoba;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Men;46 C¾rdoba;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Women;69 C¾rdoba;Group 2102 Contraceptive management V25;Both sexes;8 C¾rdoba;Group 2102 Contraceptive management V25;Men;3 C¾rdoba;Group 2102 Contraceptive management V25;Women;5 C¾rdoba;Group 2103 Living newborns by type of delivery V30-V39;Both sexes;.. C¾rdoba;Group 2103 Living newborns by type of delivery V30-V39;Men;.. C¾rdoba;Group 2103 Living newborns by type of delivery V30-V39;Women;.. C¾rdoba;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Both sexes;540 C¾rdoba;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Men;376 C¾rdoba;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Women;164 C¾rdoba;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Both sexes;298 C¾rdoba;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Men;152 C¾rdoba;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Women;146 Granada;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Both sexes;69,876 Granada;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Men;31,857 Granada;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Women;38,019 Granada;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Both sexes;1,775 Granada;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Men;987 Granada;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Women;788 Granada;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Both sexes;180 Granada;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Men;91 Granada;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Women;89 Granada;Group 0102 Imprecise intestinal infections 009;Both sexes;55 Granada;Group 0102 Imprecise intestinal infections 009;Men;24 Granada;Group 0102 Imprecise intestinal infections 009;Women;31 Granada;Group 0103 Tuberculosis 010-018, 137;Both sexes;65 Granada;Group 0103 Tuberculosis 010-018, 137;Men;50 Granada;Group 0103 Tuberculosis 010-018, 137;Women;15 Granada;Group 0104 Septicaemia 038;Both sexes;944 Granada;Group 0104 Septicaemia 038;Men;515 Granada;Group 0104 Septicaemia 038;Women;429 Granada;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Both sexes;55 Granada;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Men;44 Granada;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Women;11 Granada;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Both sexes;476 Granada;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Men;263 Granada;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Women;213 Granada;Group 0200 Neoplasms 140-239;Both sexes;7,293 Granada;Group 0200 Neoplasms 140-239;Men;3,753 Granada;Group 0200 Neoplasms 140-239;Women;3,540 Granada;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Both sexes;709 Granada;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Men;441 Granada;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Women;268 Granada;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Both sexes;507 Granada;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Men;405 Granada;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Women;102 Granada;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Both sexes;294 Granada;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Men;171 Granada;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Women;123 Granada;Group 0204 Malignant neoplasm of breast 174-175;Both sexes;638 Granada;Group 0204 Malignant neoplasm of breast 174-175;Men;6 Granada;Group 0204 Malignant neoplasm of breast 174-175;Women;632 Granada;Group 0205 Malignant neoplasm of uterus 179-180, 182;Both sexes;193 Granada;Group 0205 Malignant neoplasm of uterus 179-180, 182;Men;.. Granada;Group 0205 Malignant neoplasm of uterus 179-180, 182;Women;193 Granada;Group 0206 Malignant neoplasm of ovary 1830;Both sexes;96 Granada;Group 0206 Malignant neoplasm of ovary 1830;Men;.. Granada;Group 0206 Malignant neoplasm of ovary 1830;Women;96 Granada;Group 0207 Malignant neoplasm of prostate 185;Both sexes;198 Granada;Group 0207 Malignant neoplasm of prostate 185;Men;198 Granada;Group 0207 Malignant neoplasm of prostate 185;Women;.. Granada;Group 0208 Malignant neoplasm of bladder 188;Both sexes;640 Granada;Group 0208 Malignant neoplasm of bladder 188;Men;535 Granada;Group 0208 Malignant neoplasm of bladder 188;Women;105 Granada;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Both sexes;2,480 Granada;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Men;1,495 Granada;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Women;985 Granada;Group 0210 Carcinoma in situ 230-234;Both sexes;48 Granada;Group 0210 Carcinoma in situ 230-234;Men;13 Granada;Group 0210 Carcinoma in situ 230-234;Women;35 Granada;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Both sexes;47 Granada;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Men;25 Granada;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Women;22 Granada;Grupo 0212 Leiomyoma of uterus 218;Both sexes;474 Granada;Grupo 0212 Leiomyoma of uterus 218;Men;.. Granada;Grupo 0212 Leiomyoma of uterus 218;Women;474 Granada;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Both sexes;969 Granada;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Men;464 Granada;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Women;505 Granada;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Both sexes;553 Granada;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Men;249 Granada;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Women;304 Granada;Group 0301 Anaemias 280-285;Both sexes;207 Granada;Group 0301 Anaemias 280-285;Men;99 Granada;Group 0301 Anaemias 280-285;Women;108 Granada;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Both sexes;346 Granada;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Men;150 Granada;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Women;196 Granada;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Both sexes;1,341 Granada;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Men;572 Granada;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Women;769 Granada;Group 0401 Diabetes mellitus 249-250;Both sexes;524 Granada;Group 0401 Diabetes mellitus 249-250;Men;300 Granada;Group 0401 Diabetes mellitus 249-250;Women;224 Granada;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Both sexes;817 Granada;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Men;272 Granada;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Women;545 Granada;Group 0500 Mental disorders 290-319;Both sexes;1,309 Granada;Group 0500 Mental disorders 290-319;Men;710 Granada;Group 0500 Mental disorders 290-319;Women;599 Granada;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Both sexes;19 Granada;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Men;8 Granada;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Women;11 Granada;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Both sexes;72 Granada;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Men;54 Granada;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Women;18 Granada;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Both sexes;106 Granada;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Men;80 Granada;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Women;26 Granada;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Both sexes;491 Granada;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Men;315 Granada;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Women;176 Granada;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Both sexes;262 Granada;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Men;109 Granada;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Women;153 Granada;Group 0506 Other mental and behavioural disorders Rest of (290-319);Both sexes;359 Granada;Group 0506 Other mental and behavioural disorders Rest of (290-319);Men;144 Granada;Group 0506 Other mental and behavioural disorders Rest of (290-319);Women;215 Granada;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Both sexes;1,505 Granada;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Men;742 Granada;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Women;763 Granada;Group 0601 Alzheimer's disease 3310;Both sexes;21 Granada;Group 0601 Alzheimer's disease 3310;Men;8 Granada;Group 0601 Alzheimer's disease 3310;Women;13 Granada;Group 0602 Multiple sclerosis 340;Both sexes;20 Granada;Group 0602 Multiple sclerosis 340;Men;9 Granada;Group 0602 Multiple sclerosis 340;Women;11 Granada;Group 0603 Epilepsy 345;Both sexes;223 Granada;Group 0603 Epilepsy 345;Men;109 Granada;Group 0603 Epilepsy 345;Women;114 Granada;Group 0604 Transient cerebral ischemia 435;Both sexes;237 Granada;Group 0604 Transient cerebral ischemia 435;Men;124 Granada;Group 0604 Transient cerebral ischemia 435;Women;113 Granada;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Both sexes;1,004 Granada;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Men;492 Granada;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Women;512 Granada;Grupo 0700 Diseases of the eye and adnexa 360-379;Both sexes;487 Granada;Grupo 0700 Diseases of the eye and adnexa 360-379;Men;298 Granada;Grupo 0700 Diseases of the eye and adnexa 360-379;Women;189 Granada;Grupo 0701 Cataract 366;Both sexes;96 Granada;Grupo 0701 Cataract 366;Men;55 Granada;Grupo 0701 Cataract 366;Women;41 Granada;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Both sexes;391 Granada;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Men;243 Granada;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Women;148 Granada;Group 0800 Diseases of the ear and the mastoid 380-389;Both sexes;327 Granada;Group 0800 Diseases of the ear and the mastoid 380-389;Men;173 Granada;Group 0800 Diseases of the ear and the mastoid 380-389;Women;154 Granada;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Both sexes;9,266 Granada;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Men;5,318 Granada;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Women;3,948 Granada;Group 0901 Hypertensive disease 401-405;Both sexes;500 Granada;Group 0901 Hypertensive disease 401-405;Men;207 Granada;Group 0901 Hypertensive disease 401-405;Women;293 Granada;Group 0902 Angina pectoris 4111, 413;Both sexes;505 Granada;Group 0902 Angina pectoris 4111, 413;Men;317 Granada;Group 0902 Angina pectoris 4111, 413;Women;188 Granada;Group 0903 Acute myocardial infarction 410;Both sexes;1,165 Granada;Group 0903 Acute myocardial infarction 410;Men;785 Granada;Group 0903 Acute myocardial infarction 410;Women;380 Granada;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Both sexes;508 Granada;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Men;384 Granada;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Women;124 Granada;Group 0905 Diseases of the lungs circulation 415-417;Both sexes;464 Granada;Group 0905 Diseases of the lungs circulation 415-417;Men;206 Granada;Group 0905 Diseases of the lungs circulation 415-417;Women;258 Granada;Group 0906 Heart conduction disorders and arrhytmias 426-427;Both sexes;964 Granada;Group 0906 Heart conduction disorders and arrhytmias 426-427;Men;521 Granada;Group 0906 Heart conduction disorders and arrhytmias 426-427;Women;443 Granada;Grupo 0907 Heart failure 428;Both sexes;1,444 Granada;Grupo 0907 Heart failure 428;Men;680 Granada;Grupo 0907 Heart failure 428;Women;764 Granada;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Both sexes;1,868 Granada;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Men;1,029 Granada;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Women;839 Granada;Grupo 0909 Atherosclerosis 440;Both sexes;383 Granada;Grupo 0909 Atherosclerosis 440;Men;288 Granada;Grupo 0909 Atherosclerosis 440;Women;95 Granada;Group 0910 Varicose veins of lower extremities 454;Both sexes;73 Granada;Group 0910 Varicose veins of lower extremities 454;Men;29 Granada;Group 0910 Varicose veins of lower extremities 454;Women;44 Granada;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Both sexes;1,392 Granada;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Men;872 Granada;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Women;520 Granada;Group 1000 Diseases of the respiratory system 0340, 460-519;Both sexes;6,583 Granada;Group 1000 Diseases of the respiratory system 0340, 460-519;Men;3,898 Granada;Group 1000 Diseases of the respiratory system 0340, 460-519;Women;2,685 Granada;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Both sexes;305 Granada;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Men;172 Granada;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Women;133 Granada;Group 1002 Pneumonia 480-486;Both sexes;1,563 Granada;Group 1002 Pneumonia 480-486;Men;994 Granada;Group 1002 Pneumonia 480-486;Women;569 Granada;Group 1003 Acute bronchitis and bronchiolitis 466;Both sexes;512 Granada;Group 1003 Acute bronchitis and bronchiolitis 466;Men;290 Granada;Group 1003 Acute bronchitis and bronchiolitis 466;Women;222 Granada;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Both sexes;274 Granada;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Men;133 Granada;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Women;141 Granada;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Both sexes;489 Granada;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Men;309 Granada;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Women;180 Granada;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Both sexes;820 Granada;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Men;666 Granada;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Women;154 Granada;Group 1007 Asthma 4930-4931,4938-4939;Both sexes;382 Granada;Group 1007 Asthma 4930-4931,4938-4939;Men;101 Granada;Group 1007 Asthma 4930-4931,4938-4939;Women;281 Granada;Group 1008 Other diseases of the respiratory system Resto of (460-519);Both sexes;2,238 Granada;Group 1008 Other diseases of the respiratory system Resto of (460-519);Men;1,233 Granada;Group 1008 Other diseases of the respiratory system Resto of (460-519);Women;1,005 Granada;Group 1100 Diseases of the digestive system 520-579;Both sexes;8,844 Granada;Group 1100 Diseases of the digestive system 520-579;Men;4,772 Granada;Group 1100 Diseases of the digestive system 520-579;Women;4,072 Granada;Group 1101 Disorders of the teeth and supporting structures 520-525;Both sexes;245 Granada;Group 1101 Disorders of the teeth and supporting structures 520-525;Men;101 Granada;Group 1101 Disorders of the teeth and supporting structures 520-525;Women;144 Granada;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Both sexes;157 Granada;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Men;90 Granada;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Women;67 Granada;Group 1103 Diseases of the esophagus 530;Both sexes;119 Granada;Group 1103 Diseases of the esophagus 530;Men;69 Granada;Group 1103 Diseases of the esophagus 530;Women;50 Granada;Group 1104 Peptic ulcer 531-534;Both sexes;185 Granada;Group 1104 Peptic ulcer 531-534;Men;129 Granada;Group 1104 Peptic ulcer 531-534;Women;56 Granada;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Both sexes;172 Granada;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Men;83 Granada;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Women;89 Granada;Group 1106 Appendicitis 540-543;Both sexes;1,014 Granada;Group 1106 Appendicitis 540-543;Men;573 Granada;Group 1106 Appendicitis 540-543;Women;441 Granada;Group 1107 Inguinal hernia 550;Both sexes;448 Granada;Group 1107 Inguinal hernia 550;Men;404 Granada;Group 1107 Inguinal hernia 550;Women;44 Granada;Group 1108 Other abdominal hernia 551-553;Both sexes;633 Granada;Group 1108 Other abdominal hernia 551-553;Men;285 Granada;Group 1108 Other abdominal hernia 551-553;Women;348 Granada;Group 1109 Crohn's disease and ulcerative colitis 555-556;Both sexes;199 Granada;Group 1109 Crohn's disease and ulcerative colitis 555-556;Men;109 Granada;Group 1109 Crohn's disease and ulcerative colitis 555-556;Women;90 Granada;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Both sexes;380 Granada;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Men;183 Granada;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Women;197 Granada;Group 1111 Intestinal obstruction without hernia 560;Both sexes;392 Granada;Group 1111 Intestinal obstruction without hernia 560;Men;208 Granada;Group 1111 Intestinal obstruction without hernia 560;Women;184 Granada;Group 1112 Intestinal diverticulosis 562;Both sexes;282 Granada;Group 1112 Intestinal diverticulosis 562;Men;144 Granada;Group 1112 Intestinal diverticulosis 562;Women;138 Granada;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Both sexes;597 Granada;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Men;391 Granada;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Women;206 Granada;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Both sexes;237 Granada;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Men;126 Granada;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Women;111 Granada;Group 1115 Alcoholic hepatitis 5710-5713;Both sexes;178 Granada;Group 1115 Alcoholic hepatitis 5710-5713;Men;159 Granada;Group 1115 Alcoholic hepatitis 5710-5713;Women;19 Granada;Group 1116 Other diseases of the liver 570,5714-573;Both sexes;427 Granada;Group 1116 Other diseases of the liver 570,5714-573;Men;280 Granada;Group 1116 Other diseases of the liver 570,5714-573;Women;147 Granada;Group 1117 Cholelithiasis 574;Both sexes;1,583 Granada;Group 1117 Cholelithiasis 574;Men;625 Granada;Group 1117 Cholelithiasis 574;Women;958 Granada;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Both sexes;514 Granada;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Men;260 Granada;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Women;254 Granada;Group 1119 Pancreatic diseases 577;Both sexes;735 Granada;Group 1119 Pancreatic diseases 577;Men;360 Granada;Group 1119 Pancreatic diseases 577;Women;375 Granada;Group 1120 Other diseases of the digestive system Rest of (520-579);Both sexes;347 Granada;Group 1120 Other diseases of the digestive system Rest of (520-579);Men;193 Granada;Group 1120 Other diseases of the digestive system Rest of (520-579);Women;154 Granada;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Both sexes;604 Granada;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Men;351 Granada;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Women;253 Granada;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Both sexes;354 Granada;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Men;201 Granada;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Women;153 Granada;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Both sexes;31 Granada;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Men;13 Granada;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Women;18 Granada;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Both sexes;219 Granada;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Men;137 Granada;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Women;82 Granada;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Both sexes;3,951 Granada;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Men;1,875 Granada;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Women;2,076 Granada;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Both sexes;.. Granada;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Men;.. Granada;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Women;.. Granada;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Both sexes;.. Granada;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Men;.. Granada;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Women;.. Granada;Group 1303 Internal derangement of knee 717;Both sexes;203 Granada;Group 1303 Internal derangement of knee 717;Men;146 Granada;Group 1303 Internal derangement of knee 717;Women;57 Granada;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Both sexes;1,986 Granada;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Men;848 Granada;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Women;1,138 Granada;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Both sexes;165 Granada;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Men;53 Granada;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Women;112 Granada;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Both sexes;335 Granada;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Men;175 Granada;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Women;160 Granada;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Both sexes;307 Granada;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Men;170 Granada;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Women;137 Granada;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Both sexes;32 Granada;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Men;15 Granada;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Women;17 Granada;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Both sexes;365 Granada;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Men;188 Granada;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Women;177 Granada;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Both sexes;558 Granada;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Men;280 Granada;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Women;278 Granada;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Both sexes;3,964 Granada;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Men;1,804 Granada;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Women;2,160 Granada;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Both sexes;531 Granada;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Men;249 Granada;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Women;282 Granada;Group 1402 Renal failure 5836-5837, 584-586;Both sexes;673 Granada;Group 1402 Renal failure 5836-5837, 584-586;Men;408 Granada;Group 1402 Renal failure 5836-5837, 584-586;Women;265 Granada;Group 1403 Urolithiasis 592, 594, 7880;Both sexes;286 Granada;Group 1403 Urolithiasis 592, 594, 7880;Men;163 Granada;Group 1403 Urolithiasis 592, 594, 7880;Women;123 Granada;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Both sexes;646 Granada;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Men;365 Granada;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Women;281 Granada;Group 1405 Prostatic hyperplasia 600;Both sexes;309 Granada;Group 1405 Prostatic hyperplasia 600;Men;309 Granada;Group 1405 Prostatic hyperplasia 600;Women;.. Granada;Group 1406 Other diseases of the male genital organs 601-608;Both sexes;282 Granada;Group 1406 Other diseases of the male genital organs 601-608;Men;282 Granada;Group 1406 Other diseases of the male genital organs 601-608;Women;.. Granada;Group 1407 Disorders of breast 610-612;Both sexes;154 Granada;Group 1407 Disorders of breast 610-612;Men;23 Granada;Group 1407 Disorders of breast 610-612;Women;131 Granada;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Both sexes;144 Granada;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Men;.. Granada;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Women;144 Granada;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Both sexes;88 Granada;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Men;.. Granada;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Women;88 Granada;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Both sexes;851 Granada;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Men;5 Granada;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Women;846 Granada;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Both sexes;9,831 Granada;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Men;.. Granada;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Women;9,831 Granada;Group 1501 Legally induced abortion 635;Both sexes;8 Granada;Group 1501 Legally induced abortion 635;Men;.. Granada;Group 1501 Legally induced abortion 635;Women;8 Granada;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Both sexes;548 Granada;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Men;.. Granada;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Women;548 Granada;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Both sexes;6,517 Granada;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Men;.. Granada;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Women;6,517 Granada;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Both sexes;1,077 Granada;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Men;.. Granada;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Women;1,077 Granada;Group 1505 Single spontaneous delivery 650;Both sexes;633 Granada;Group 1505 Single spontaneous delivery 650;Men;.. Granada;Group 1505 Single spontaneous delivery 650;Women;633 Granada;Group 1506 Other deliveries 6695-6697;Both sexes;453 Granada;Group 1506 Other deliveries 6695-6697;Men;.. Granada;Group 1506 Other deliveries 6695-6697;Women;453 Granada;Group 1507 Complications related to the puerperium 670-676;Both sexes;56 Granada;Group 1507 Complications related to the puerperium 670-676;Men;.. Granada;Group 1507 Complications related to the puerperium 670-676;Women;56 Granada;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Both sexes;539 Granada;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Men;.. Granada;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Women;539 Granada;Group 1600 Some disorders originating in the perinatal period 760-779;Both sexes;957 Granada;Group 1600 Some disorders originating in the perinatal period 760-779;Men;520 Granada;Group 1600 Some disorders originating in the perinatal period 760-779;Women;437 Granada;Group 1601 Disorders related with premature delivery and a low birth weight 765;Both sexes;310 Granada;Group 1601 Disorders related with premature delivery and a low birth weight 765;Men;163 Granada;Group 1601 Disorders related with premature delivery and a low birth weight 765;Women;147 Granada;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Both sexes;647 Granada;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Men;357 Granada;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Women;290 Granada;Grupo 1700 Congenital abnormalities 740-759;Both sexes;592 Granada;Grupo 1700 Congenital abnormalities 740-759;Men;349 Granada;Grupo 1700 Congenital abnormalities 740-759;Women;243 Granada;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Both sexes;1,848 Granada;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Men;948 Granada;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Women;900 Granada;Group 1801 Pain in throat and chest 7841, 7865;Both sexes;196 Granada;Group 1801 Pain in throat and chest 7841, 7865;Men;92 Granada;Group 1801 Pain in throat and chest 7841, 7865;Women;104 Granada;Group 1802 Abdominal pain 7890;Both sexes;183 Granada;Group 1802 Abdominal pain 7890;Men;62 Granada;Group 1802 Abdominal pain 7890;Women;121 Granada;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Both sexes;194 Granada;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Men;77 Granada;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Women;117 Granada;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Both sexes;1,275 Granada;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Men;717 Granada;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Women;558 Granada;Group 1900 Injuries and poisoning 800-999;Both sexes;7,575 Granada;Group 1900 Injuries and poisoning 800-999;Men;3,973 Granada;Group 1900 Injuries and poisoning 800-999;Women;3,602 Granada;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Both sexes;251 Granada;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Men;149 Granada;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Women;102 Granada;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Both sexes;201 Granada;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Men;146 Granada;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Women;55 Granada;Group 1903 Radius and ulna fracture 813;Both sexes;611 Granada;Group 1903 Radius and ulna fracture 813;Men;284 Granada;Group 1903 Radius and ulna fracture 813;Women;327 Granada;Group 1904 Femur fracture 820-821;Both sexes;1,242 Granada;Group 1904 Femur fracture 820-821;Men;364 Granada;Group 1904 Femur fracture 820-821;Women;878 Granada;Group 1905 Leg fracture, including the ankle 823-824;Both sexes;739 Granada;Group 1905 Leg fracture, including the ankle 823-824;Men;398 Granada;Group 1905 Leg fracture, including the ankle 823-824;Women;341 Granada;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Both sexes;2,319 Granada;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Men;1,438 Granada;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Women;881 Granada;Group 1907 Burns 940-949;Both sexes;64 Granada;Group 1907 Burns 940-949;Men;34 Granada;Group 1907 Burns 940-949;Women;30 Granada;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Both sexes;213 Granada;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Men;95 Granada;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Women;118 Granada;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Both sexes;1,772 Granada;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Men;960 Granada;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Women;812 Granada;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Both sexes;24 Granada;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Men;17 Granada;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Women;7 Granada;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Both sexes;139 Granada;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Men;88 Granada;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Women;51 Granada;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Both sexes;1,271 Granada;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Men;565 Granada;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Women;706 Granada;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Both sexes;42 Granada;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Men;26 Granada;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Women;16 Granada;Group 2102 Contraceptive management V25;Both sexes;12 Granada;Group 2102 Contraceptive management V25;Men;.. Granada;Group 2102 Contraceptive management V25;Women;12 Granada;Group 2103 Living newborns by type of delivery V30-V39;Both sexes;.. Granada;Group 2103 Living newborns by type of delivery V30-V39;Men;.. Granada;Group 2103 Living newborns by type of delivery V30-V39;Women;.. Granada;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Both sexes;456 Granada;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Men;276 Granada;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Women;180 Granada;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Both sexes;761 Granada;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Men;263 Granada;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Women;498 Huelva;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Both sexes;39,976 Huelva;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Men;17,844 Huelva;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Women;22,132 Huelva;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Both sexes;811 Huelva;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Men;477 Huelva;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Women;334 Huelva;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Both sexes;89 Huelva;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Men;51 Huelva;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Women;38 Huelva;Group 0102 Imprecise intestinal infections 009;Both sexes;116 Huelva;Group 0102 Imprecise intestinal infections 009;Men;58 Huelva;Group 0102 Imprecise intestinal infections 009;Women;58 Huelva;Group 0103 Tuberculosis 010-018, 137;Both sexes;64 Huelva;Group 0103 Tuberculosis 010-018, 137;Men;44 Huelva;Group 0103 Tuberculosis 010-018, 137;Women;20 Huelva;Group 0104 Septicaemia 038;Both sexes;208 Huelva;Group 0104 Septicaemia 038;Men;120 Huelva;Group 0104 Septicaemia 038;Women;87 Huelva;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Both sexes;54 Huelva;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Men;44 Huelva;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Women;10 Huelva;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Both sexes;281 Huelva;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Men;161 Huelva;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Women;120 Huelva;Group 0200 Neoplasms 140-239;Both sexes;3,177 Huelva;Group 0200 Neoplasms 140-239;Men;1,670 Huelva;Group 0200 Neoplasms 140-239;Women;1,508 Huelva;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Both sexes;423 Huelva;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Men;275 Huelva;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Women;148 Huelva;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Both sexes;185 Huelva;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Men;161 Huelva;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Women;24 Huelva;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Both sexes;9 Huelva;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Men;4 Huelva;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Women;5 Huelva;Group 0204 Malignant neoplasm of breast 174-175;Both sexes;331 Huelva;Group 0204 Malignant neoplasm of breast 174-175;Men;2 Huelva;Group 0204 Malignant neoplasm of breast 174-175;Women;329 Huelva;Group 0205 Malignant neoplasm of uterus 179-180, 182;Both sexes;74 Huelva;Group 0205 Malignant neoplasm of uterus 179-180, 182;Men;.. Huelva;Group 0205 Malignant neoplasm of uterus 179-180, 182;Women;74 Huelva;Group 0206 Malignant neoplasm of ovary 1830;Both sexes;47 Huelva;Group 0206 Malignant neoplasm of ovary 1830;Men;.. Huelva;Group 0206 Malignant neoplasm of ovary 1830;Women;47 Huelva;Group 0207 Malignant neoplasm of prostate 185;Both sexes;96 Huelva;Group 0207 Malignant neoplasm of prostate 185;Men;96 Huelva;Group 0207 Malignant neoplasm of prostate 185;Women;.. Huelva;Group 0208 Malignant neoplasm of bladder 188;Both sexes;341 Huelva;Group 0208 Malignant neoplasm of bladder 188;Men;293 Huelva;Group 0208 Malignant neoplasm of bladder 188;Women;48 Huelva;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Both sexes;1,065 Huelva;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Men;662 Huelva;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Women;402 Huelva;Group 0210 Carcinoma in situ 230-234;Both sexes;27 Huelva;Group 0210 Carcinoma in situ 230-234;Men;11 Huelva;Group 0210 Carcinoma in situ 230-234;Women;15 Huelva;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Both sexes;22 Huelva;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Men;13 Huelva;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Women;9 Huelva;Grupo 0212 Leiomyoma of uterus 218;Both sexes;186 Huelva;Grupo 0212 Leiomyoma of uterus 218;Men;.. Huelva;Grupo 0212 Leiomyoma of uterus 218;Women;186 Huelva;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Both sexes;371 Huelva;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Men;152 Huelva;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Women;219 Huelva;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Both sexes;569 Huelva;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Men;256 Huelva;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Women;313 Huelva;Group 0301 Anaemias 280-285;Both sexes;390 Huelva;Group 0301 Anaemias 280-285;Men;186 Huelva;Group 0301 Anaemias 280-285;Women;205 Huelva;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Both sexes;179 Huelva;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Men;71 Huelva;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Women;108 Huelva;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Both sexes;624 Huelva;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Men;264 Huelva;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Women;360 Huelva;Group 0401 Diabetes mellitus 249-250;Both sexes;252 Huelva;Group 0401 Diabetes mellitus 249-250;Men;165 Huelva;Group 0401 Diabetes mellitus 249-250;Women;86 Huelva;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Both sexes;372 Huelva;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Men;99 Huelva;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Women;273 Huelva;Group 0500 Mental disorders 290-319;Both sexes;835 Huelva;Group 0500 Mental disorders 290-319;Men;402 Huelva;Group 0500 Mental disorders 290-319;Women;433 Huelva;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Both sexes;25 Huelva;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Men;7 Huelva;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Women;17 Huelva;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Both sexes;28 Huelva;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Men;16 Huelva;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Women;11 Huelva;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Both sexes;49 Huelva;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Men;42 Huelva;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Women;6 Huelva;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Both sexes;260 Huelva;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Men;157 Huelva;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Women;103 Huelva;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Both sexes;158 Huelva;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Men;47 Huelva;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Women;110 Huelva;Group 0506 Other mental and behavioural disorders Rest of (290-319);Both sexes;317 Huelva;Group 0506 Other mental and behavioural disorders Rest of (290-319);Men;131 Huelva;Group 0506 Other mental and behavioural disorders Rest of (290-319);Women;185 Huelva;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Both sexes;962 Huelva;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Men;477 Huelva;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Women;485 Huelva;Group 0601 Alzheimer's disease 3310;Both sexes;16 Huelva;Group 0601 Alzheimer's disease 3310;Men;4 Huelva;Group 0601 Alzheimer's disease 3310;Women;12 Huelva;Group 0602 Multiple sclerosis 340;Both sexes;29 Huelva;Group 0602 Multiple sclerosis 340;Men;9 Huelva;Group 0602 Multiple sclerosis 340;Women;20 Huelva;Group 0603 Epilepsy 345;Both sexes;193 Huelva;Group 0603 Epilepsy 345;Men;114 Huelva;Group 0603 Epilepsy 345;Women;79 Huelva;Group 0604 Transient cerebral ischemia 435;Both sexes;203 Huelva;Group 0604 Transient cerebral ischemia 435;Men;97 Huelva;Group 0604 Transient cerebral ischemia 435;Women;106 Huelva;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Both sexes;520 Huelva;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Men;253 Huelva;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Women;267 Huelva;Grupo 0700 Diseases of the eye and adnexa 360-379;Both sexes;133 Huelva;Grupo 0700 Diseases of the eye and adnexa 360-379;Men;65 Huelva;Grupo 0700 Diseases of the eye and adnexa 360-379;Women;68 Huelva;Grupo 0701 Cataract 366;Both sexes;12 Huelva;Grupo 0701 Cataract 366;Men;4 Huelva;Grupo 0701 Cataract 366;Women;8 Huelva;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Both sexes;120 Huelva;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Men;61 Huelva;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Women;60 Huelva;Group 0800 Diseases of the ear and the mastoid 380-389;Both sexes;317 Huelva;Group 0800 Diseases of the ear and the mastoid 380-389;Men;155 Huelva;Group 0800 Diseases of the ear and the mastoid 380-389;Women;162 Huelva;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Both sexes;6,080 Huelva;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Men;3,358 Huelva;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Women;2,722 Huelva;Group 0901 Hypertensive disease 401-405;Both sexes;640 Huelva;Group 0901 Hypertensive disease 401-405;Men;277 Huelva;Group 0901 Hypertensive disease 401-405;Women;363 Huelva;Group 0902 Angina pectoris 4111, 413;Both sexes;577 Huelva;Group 0902 Angina pectoris 4111, 413;Men;339 Huelva;Group 0902 Angina pectoris 4111, 413;Women;238 Huelva;Group 0903 Acute myocardial infarction 410;Both sexes;508 Huelva;Group 0903 Acute myocardial infarction 410;Men;341 Huelva;Group 0903 Acute myocardial infarction 410;Women;167 Huelva;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Both sexes;406 Huelva;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Men;303 Huelva;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Women;103 Huelva;Group 0905 Diseases of the lungs circulation 415-417;Both sexes;144 Huelva;Group 0905 Diseases of the lungs circulation 415-417;Men;65 Huelva;Group 0905 Diseases of the lungs circulation 415-417;Women;79 Huelva;Group 0906 Heart conduction disorders and arrhytmias 426-427;Both sexes;815 Huelva;Group 0906 Heart conduction disorders and arrhytmias 426-427;Men;421 Huelva;Group 0906 Heart conduction disorders and arrhytmias 426-427;Women;393 Huelva;Grupo 0907 Heart failure 428;Both sexes;975 Huelva;Grupo 0907 Heart failure 428;Men;432 Huelva;Grupo 0907 Heart failure 428;Women;543 Huelva;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Both sexes;1,033 Huelva;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Men;596 Huelva;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Women;437 Huelva;Grupo 0909 Atherosclerosis 440;Both sexes;161 Huelva;Grupo 0909 Atherosclerosis 440;Men;120 Huelva;Grupo 0909 Atherosclerosis 440;Women;40 Huelva;Group 0910 Varicose veins of lower extremities 454;Both sexes;121 Huelva;Group 0910 Varicose veins of lower extremities 454;Men;48 Huelva;Group 0910 Varicose veins of lower extremities 454;Women;73 Huelva;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Both sexes;701 Huelva;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Men;417 Huelva;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Women;284 Huelva;Group 1000 Diseases of the respiratory system 0340, 460-519;Both sexes;3,517 Huelva;Group 1000 Diseases of the respiratory system 0340, 460-519;Men;2,117 Huelva;Group 1000 Diseases of the respiratory system 0340, 460-519;Women;1,399 Huelva;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Both sexes;204 Huelva;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Men;111 Huelva;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Women;93 Huelva;Group 1002 Pneumonia 480-486;Both sexes;729 Huelva;Group 1002 Pneumonia 480-486;Men;455 Huelva;Group 1002 Pneumonia 480-486;Women;274 Huelva;Group 1003 Acute bronchitis and bronchiolitis 466;Both sexes;352 Huelva;Group 1003 Acute bronchitis and bronchiolitis 466;Men;177 Huelva;Group 1003 Acute bronchitis and bronchiolitis 466;Women;175 Huelva;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Both sexes;242 Huelva;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Men;115 Huelva;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Women;127 Huelva;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Both sexes;430 Huelva;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Men;280 Huelva;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Women;149 Huelva;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Both sexes;437 Huelva;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Men;358 Huelva;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Women;79 Huelva;Group 1007 Asthma 4930-4931,4938-4939;Both sexes;108 Huelva;Group 1007 Asthma 4930-4931,4938-4939;Men;21 Huelva;Group 1007 Asthma 4930-4931,4938-4939;Women;87 Huelva;Group 1008 Other diseases of the respiratory system Resto of (460-519);Both sexes;1,014 Huelva;Group 1008 Other diseases of the respiratory system Resto of (460-519);Men;599 Huelva;Group 1008 Other diseases of the respiratory system Resto of (460-519);Women;416 Huelva;Group 1100 Diseases of the digestive system 520-579;Both sexes;4,799 Huelva;Group 1100 Diseases of the digestive system 520-579;Men;2,680 Huelva;Group 1100 Diseases of the digestive system 520-579;Women;2,119 Huelva;Group 1101 Disorders of the teeth and supporting structures 520-525;Both sexes;22 Huelva;Group 1101 Disorders of the teeth and supporting structures 520-525;Men;10 Huelva;Group 1101 Disorders of the teeth and supporting structures 520-525;Women;12 Huelva;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Both sexes;47 Huelva;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Men;31 Huelva;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Women;15 Huelva;Group 1103 Diseases of the esophagus 530;Both sexes;100 Huelva;Group 1103 Diseases of the esophagus 530;Men;59 Huelva;Group 1103 Diseases of the esophagus 530;Women;41 Huelva;Group 1104 Peptic ulcer 531-534;Both sexes;128 Huelva;Group 1104 Peptic ulcer 531-534;Men;94 Huelva;Group 1104 Peptic ulcer 531-534;Women;33 Huelva;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Both sexes;166 Huelva;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Men;74 Huelva;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Women;92 Huelva;Group 1106 Appendicitis 540-543;Both sexes;390 Huelva;Group 1106 Appendicitis 540-543;Men;228 Huelva;Group 1106 Appendicitis 540-543;Women;162 Huelva;Group 1107 Inguinal hernia 550;Both sexes;312 Huelva;Group 1107 Inguinal hernia 550;Men;285 Huelva;Group 1107 Inguinal hernia 550;Women;27 Huelva;Group 1108 Other abdominal hernia 551-553;Both sexes;353 Huelva;Group 1108 Other abdominal hernia 551-553;Men;157 Huelva;Group 1108 Other abdominal hernia 551-553;Women;196 Huelva;Group 1109 Crohn's disease and ulcerative colitis 555-556;Both sexes;139 Huelva;Group 1109 Crohn's disease and ulcerative colitis 555-556;Men;74 Huelva;Group 1109 Crohn's disease and ulcerative colitis 555-556;Women;65 Huelva;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Both sexes;296 Huelva;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Men;147 Huelva;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Women;149 Huelva;Group 1111 Intestinal obstruction without hernia 560;Both sexes;174 Huelva;Group 1111 Intestinal obstruction without hernia 560;Men;105 Huelva;Group 1111 Intestinal obstruction without hernia 560;Women;68 Huelva;Group 1112 Intestinal diverticulosis 562;Both sexes;125 Huelva;Group 1112 Intestinal diverticulosis 562;Men;56 Huelva;Group 1112 Intestinal diverticulosis 562;Women;70 Huelva;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Both sexes;442 Huelva;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Men;286 Huelva;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Women;156 Huelva;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Both sexes;148 Huelva;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Men;60 Huelva;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Women;88 Huelva;Group 1115 Alcoholic hepatitis 5710-5713;Both sexes;110 Huelva;Group 1115 Alcoholic hepatitis 5710-5713;Men;101 Huelva;Group 1115 Alcoholic hepatitis 5710-5713;Women;9 Huelva;Group 1116 Other diseases of the liver 570,5714-573;Both sexes;164 Huelva;Group 1116 Other diseases of the liver 570,5714-573;Men;101 Huelva;Group 1116 Other diseases of the liver 570,5714-573;Women;63 Huelva;Group 1117 Cholelithiasis 574;Both sexes;929 Huelva;Group 1117 Cholelithiasis 574;Men;390 Huelva;Group 1117 Cholelithiasis 574;Women;538 Huelva;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Both sexes;182 Huelva;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Men;103 Huelva;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Women;80 Huelva;Group 1119 Pancreatic diseases 577;Both sexes;320 Huelva;Group 1119 Pancreatic diseases 577;Men;168 Huelva;Group 1119 Pancreatic diseases 577;Women;151 Huelva;Group 1120 Other diseases of the digestive system Rest of (520-579);Both sexes;253 Huelva;Group 1120 Other diseases of the digestive system Rest of (520-579);Men;151 Huelva;Group 1120 Other diseases of the digestive system Rest of (520-579);Women;102 Huelva;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Both sexes;367 Huelva;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Men;200 Huelva;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Women;167 Huelva;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Both sexes;238 Huelva;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Men;136 Huelva;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Women;102 Huelva;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Both sexes;12 Huelva;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Men;8 Huelva;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Women;4 Huelva;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Both sexes;117 Huelva;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Men;56 Huelva;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Women;61 Huelva;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Both sexes;2,464 Huelva;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Men;1,079 Huelva;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Women;1,385 Huelva;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Both sexes;.. Huelva;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Men;.. Huelva;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Women;.. Huelva;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Both sexes;.. Huelva;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Men;.. Huelva;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Women;.. Huelva;Group 1303 Internal derangement of knee 717;Both sexes;180 Huelva;Group 1303 Internal derangement of knee 717;Men;118 Huelva;Group 1303 Internal derangement of knee 717;Women;62 Huelva;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Both sexes;1,189 Huelva;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Men;441 Huelva;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Women;748 Huelva;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Both sexes;42 Huelva;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Men;19 Huelva;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Women;23 Huelva;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Both sexes;107 Huelva;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Men;48 Huelva;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Women;59 Huelva;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Both sexes;193 Huelva;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Men;105 Huelva;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Women;88 Huelva;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Both sexes;102 Huelva;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Men;40 Huelva;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Women;62 Huelva;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Both sexes;301 Huelva;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Men;158 Huelva;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Women;143 Huelva;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Both sexes;350 Huelva;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Men;150 Huelva;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Women;200 Huelva;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Both sexes;2,157 Huelva;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Men;935 Huelva;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Women;1,222 Huelva;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Both sexes;287 Huelva;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Men;103 Huelva;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Women;184 Huelva;Group 1402 Renal failure 5836-5837, 584-586;Both sexes;162 Huelva;Group 1402 Renal failure 5836-5837, 584-586;Men;99 Huelva;Group 1402 Renal failure 5836-5837, 584-586;Women;63 Huelva;Group 1403 Urolithiasis 592, 594, 7880;Both sexes;356 Huelva;Group 1403 Urolithiasis 592, 594, 7880;Men;186 Huelva;Group 1403 Urolithiasis 592, 594, 7880;Women;170 Huelva;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Both sexes;610 Huelva;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Men;267 Huelva;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Women;343 Huelva;Group 1405 Prostatic hyperplasia 600;Both sexes;126 Huelva;Group 1405 Prostatic hyperplasia 600;Men;126 Huelva;Group 1405 Prostatic hyperplasia 600;Women;.. Huelva;Group 1406 Other diseases of the male genital organs 601-608;Both sexes;140 Huelva;Group 1406 Other diseases of the male genital organs 601-608;Men;140 Huelva;Group 1406 Other diseases of the male genital organs 601-608;Women;.. Huelva;Group 1407 Disorders of breast 610-612;Both sexes;47 Huelva;Group 1407 Disorders of breast 610-612;Men;13 Huelva;Group 1407 Disorders of breast 610-612;Women;34 Huelva;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Both sexes;63 Huelva;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Men;.. Huelva;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Women;63 Huelva;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Both sexes;37 Huelva;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Men;.. Huelva;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Women;37 Huelva;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Both sexes;329 Huelva;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Men;.. Huelva;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Women;329 Huelva;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Both sexes;6,070 Huelva;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Men;.. Huelva;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Women;6,070 Huelva;Group 1501 Legally induced abortion 635;Both sexes;9 Huelva;Group 1501 Legally induced abortion 635;Men;.. Huelva;Group 1501 Legally induced abortion 635;Women;9 Huelva;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Both sexes;571 Huelva;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Men;.. Huelva;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Women;571 Huelva;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Both sexes;4,118 Huelva;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Men;.. Huelva;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Women;4,118 Huelva;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Both sexes;345 Huelva;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Men;.. Huelva;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Women;345 Huelva;Group 1505 Single spontaneous delivery 650;Both sexes;404 Huelva;Group 1505 Single spontaneous delivery 650;Men;.. Huelva;Group 1505 Single spontaneous delivery 650;Women;404 Huelva;Group 1506 Other deliveries 6695-6697;Both sexes;87 Huelva;Group 1506 Other deliveries 6695-6697;Men;.. Huelva;Group 1506 Other deliveries 6695-6697;Women;87 Huelva;Group 1507 Complications related to the puerperium 670-676;Both sexes;74 Huelva;Group 1507 Complications related to the puerperium 670-676;Men;.. Huelva;Group 1507 Complications related to the puerperium 670-676;Women;74 Huelva;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Both sexes;463 Huelva;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Men;.. Huelva;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Women;463 Huelva;Group 1600 Some disorders originating in the perinatal period 760-779;Both sexes;488 Huelva;Group 1600 Some disorders originating in the perinatal period 760-779;Men;285 Huelva;Group 1600 Some disorders originating in the perinatal period 760-779;Women;203 Huelva;Group 1601 Disorders related with premature delivery and a low birth weight 765;Both sexes;237 Huelva;Group 1601 Disorders related with premature delivery and a low birth weight 765;Men;127 Huelva;Group 1601 Disorders related with premature delivery and a low birth weight 765;Women;110 Huelva;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Both sexes;251 Huelva;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Men;158 Huelva;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Women;93 Huelva;Grupo 1700 Congenital abnormalities 740-759;Both sexes;147 Huelva;Grupo 1700 Congenital abnormalities 740-759;Men;87 Huelva;Grupo 1700 Congenital abnormalities 740-759;Women;60 Huelva;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Both sexes;2,676 Huelva;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Men;1,429 Huelva;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Women;1,248 Huelva;Group 1801 Pain in throat and chest 7841, 7865;Both sexes;503 Huelva;Group 1801 Pain in throat and chest 7841, 7865;Men;272 Huelva;Group 1801 Pain in throat and chest 7841, 7865;Women;231 Huelva;Group 1802 Abdominal pain 7890;Both sexes;307 Huelva;Group 1802 Abdominal pain 7890;Men;134 Huelva;Group 1802 Abdominal pain 7890;Women;173 Huelva;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Both sexes;59 Huelva;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Men;27 Huelva;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Women;32 Huelva;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Both sexes;1,807 Huelva;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Men;996 Huelva;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Women;811 Huelva;Group 1900 Injuries and poisoning 800-999;Both sexes;3,235 Huelva;Group 1900 Injuries and poisoning 800-999;Men;1,600 Huelva;Group 1900 Injuries and poisoning 800-999;Women;1,635 Huelva;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Both sexes;136 Huelva;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Men;81 Huelva;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Women;55 Huelva;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Both sexes;52 Huelva;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Men;35 Huelva;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Women;16 Huelva;Group 1903 Radius and ulna fracture 813;Both sexes;284 Huelva;Group 1903 Radius and ulna fracture 813;Men;130 Huelva;Group 1903 Radius and ulna fracture 813;Women;154 Huelva;Group 1904 Femur fracture 820-821;Both sexes;535 Huelva;Group 1904 Femur fracture 820-821;Men;130 Huelva;Group 1904 Femur fracture 820-821;Women;405 Huelva;Group 1905 Leg fracture, including the ankle 823-824;Both sexes;272 Huelva;Group 1905 Leg fracture, including the ankle 823-824;Men;153 Huelva;Group 1905 Leg fracture, including the ankle 823-824;Women;119 Huelva;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Both sexes;1,011 Huelva;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Men;580 Huelva;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Women;431 Huelva;Group 1907 Burns 940-949;Both sexes;5 Huelva;Group 1907 Burns 940-949;Men;4 Huelva;Group 1907 Burns 940-949;Women;1 Huelva;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Both sexes;175 Huelva;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Men;83 Huelva;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Women;92 Huelva;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Both sexes;695 Huelva;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Men;354 Huelva;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Women;341 Huelva;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Both sexes;3 Huelva;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Men;2 Huelva;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Women;1 Huelva;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Both sexes;68 Huelva;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Men;47 Huelva;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Women;21 Huelva;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Both sexes;548 Huelva;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Men;307 Huelva;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Women;241 Huelva;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Both sexes;16 Huelva;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Men;10 Huelva;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Women;6 Huelva;Group 2102 Contraceptive management V25;Both sexes;15 Huelva;Group 2102 Contraceptive management V25;Men;.. Huelva;Group 2102 Contraceptive management V25;Women;15 Huelva;Group 2103 Living newborns by type of delivery V30-V39;Both sexes;.. Huelva;Group 2103 Living newborns by type of delivery V30-V39;Men;.. Huelva;Group 2103 Living newborns by type of delivery V30-V39;Women;.. Huelva;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Both sexes;215 Huelva;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Men;133 Huelva;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Women;82 Huelva;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Both sexes;302 Huelva;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Men;164 Huelva;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Women;138 JaÚn;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Both sexes;47,680 JaÚn;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Men;21,951 JaÚn;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Women;25,729 JaÚn;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Both sexes;868 JaÚn;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Men;510 JaÚn;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Women;358 JaÚn;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Both sexes;99 JaÚn;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Men;56 JaÚn;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Women;43 JaÚn;Group 0102 Imprecise intestinal infections 009;Both sexes;44 JaÚn;Group 0102 Imprecise intestinal infections 009;Men;21 JaÚn;Group 0102 Imprecise intestinal infections 009;Women;23 JaÚn;Group 0103 Tuberculosis 010-018, 137;Both sexes;28 JaÚn;Group 0103 Tuberculosis 010-018, 137;Men;17 JaÚn;Group 0103 Tuberculosis 010-018, 137;Women;11 JaÚn;Group 0104 Septicaemia 038;Both sexes;297 JaÚn;Group 0104 Septicaemia 038;Men;170 JaÚn;Group 0104 Septicaemia 038;Women;127 JaÚn;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Both sexes;57 JaÚn;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Men;41 JaÚn;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Women;16 JaÚn;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Both sexes;343 JaÚn;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Men;205 JaÚn;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Women;138 JaÚn;Group 0200 Neoplasms 140-239;Both sexes;4,081 JaÚn;Group 0200 Neoplasms 140-239;Men;2,135 JaÚn;Group 0200 Neoplasms 140-239;Women;1,946 JaÚn;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Both sexes;489 JaÚn;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Men;290 JaÚn;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Women;199 JaÚn;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Both sexes;293 JaÚn;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Men;260 JaÚn;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Women;33 JaÚn;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Both sexes;41 JaÚn;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Men;29 JaÚn;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Women;12 JaÚn;Group 0204 Malignant neoplasm of breast 174-175;Both sexes;363 JaÚn;Group 0204 Malignant neoplasm of breast 174-175;Men;3 JaÚn;Group 0204 Malignant neoplasm of breast 174-175;Women;360 JaÚn;Group 0205 Malignant neoplasm of uterus 179-180, 182;Both sexes;132 JaÚn;Group 0205 Malignant neoplasm of uterus 179-180, 182;Men;.. JaÚn;Group 0205 Malignant neoplasm of uterus 179-180, 182;Women;132 JaÚn;Group 0206 Malignant neoplasm of ovary 1830;Both sexes;61 JaÚn;Group 0206 Malignant neoplasm of ovary 1830;Men;.. JaÚn;Group 0206 Malignant neoplasm of ovary 1830;Women;61 JaÚn;Group 0207 Malignant neoplasm of prostate 185;Both sexes;79 JaÚn;Group 0207 Malignant neoplasm of prostate 185;Men;79 JaÚn;Group 0207 Malignant neoplasm of prostate 185;Women;.. JaÚn;Group 0208 Malignant neoplasm of bladder 188;Both sexes;426 JaÚn;Group 0208 Malignant neoplasm of bladder 188;Men;368 JaÚn;Group 0208 Malignant neoplasm of bladder 188;Women;58 JaÚn;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Both sexes;1,302 JaÚn;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Men;790 JaÚn;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Women;512 JaÚn;Group 0210 Carcinoma in situ 230-234;Both sexes;58 JaÚn;Group 0210 Carcinoma in situ 230-234;Men;26 JaÚn;Group 0210 Carcinoma in situ 230-234;Women;32 JaÚn;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Both sexes;41 JaÚn;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Men;29 JaÚn;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Women;12 JaÚn;Grupo 0212 Leiomyoma of uterus 218;Both sexes;225 JaÚn;Grupo 0212 Leiomyoma of uterus 218;Men;.. JaÚn;Grupo 0212 Leiomyoma of uterus 218;Women;225 JaÚn;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Both sexes;571 JaÚn;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Men;261 JaÚn;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Women;310 JaÚn;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Both sexes;499 JaÚn;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Men;283 JaÚn;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Women;216 JaÚn;Group 0301 Anaemias 280-285;Both sexes;276 JaÚn;Group 0301 Anaemias 280-285;Men;164 JaÚn;Group 0301 Anaemias 280-285;Women;112 JaÚn;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Both sexes;223 JaÚn;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Men;119 JaÚn;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Women;104 JaÚn;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Both sexes;989 JaÚn;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Men;510 JaÚn;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Women;479 JaÚn;Group 0401 Diabetes mellitus 249-250;Both sexes;397 JaÚn;Group 0401 Diabetes mellitus 249-250;Men;261 JaÚn;Group 0401 Diabetes mellitus 249-250;Women;136 JaÚn;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Both sexes;592 JaÚn;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Men;249 JaÚn;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Women;343 JaÚn;Group 0500 Mental disorders 290-319;Both sexes;1,218 JaÚn;Group 0500 Mental disorders 290-319;Men;645 JaÚn;Group 0500 Mental disorders 290-319;Women;573 JaÚn;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Both sexes;11 JaÚn;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Men;7 JaÚn;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Women;4 JaÚn;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Both sexes;43 JaÚn;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Men;39 JaÚn;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Women;4 JaÚn;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Both sexes;37 JaÚn;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Men;32 JaÚn;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Women;5 JaÚn;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Both sexes;328 JaÚn;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Men;220 JaÚn;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Women;108 JaÚn;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Both sexes;322 JaÚn;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Men;140 JaÚn;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Women;182 JaÚn;Group 0506 Other mental and behavioural disorders Rest of (290-319);Both sexes;477 JaÚn;Group 0506 Other mental and behavioural disorders Rest of (290-319);Men;207 JaÚn;Group 0506 Other mental and behavioural disorders Rest of (290-319);Women;270 JaÚn;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Both sexes;949 JaÚn;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Men;489 JaÚn;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Women;460 JaÚn;Group 0601 Alzheimer's disease 3310;Both sexes;15 JaÚn;Group 0601 Alzheimer's disease 3310;Men;9 JaÚn;Group 0601 Alzheimer's disease 3310;Women;6 JaÚn;Group 0602 Multiple sclerosis 340;Both sexes;29 JaÚn;Group 0602 Multiple sclerosis 340;Men;4 JaÚn;Group 0602 Multiple sclerosis 340;Women;25 JaÚn;Group 0603 Epilepsy 345;Both sexes;194 JaÚn;Group 0603 Epilepsy 345;Men;115 JaÚn;Group 0603 Epilepsy 345;Women;79 JaÚn;Group 0604 Transient cerebral ischemia 435;Both sexes;243 JaÚn;Group 0604 Transient cerebral ischemia 435;Men;136 JaÚn;Group 0604 Transient cerebral ischemia 435;Women;107 JaÚn;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Both sexes;468 JaÚn;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Men;225 JaÚn;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Women;243 JaÚn;Grupo 0700 Diseases of the eye and adnexa 360-379;Both sexes;669 JaÚn;Grupo 0700 Diseases of the eye and adnexa 360-379;Men;350 JaÚn;Grupo 0700 Diseases of the eye and adnexa 360-379;Women;319 JaÚn;Grupo 0701 Cataract 366;Both sexes;86 JaÚn;Grupo 0701 Cataract 366;Men;43 JaÚn;Grupo 0701 Cataract 366;Women;43 JaÚn;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Both sexes;583 JaÚn;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Men;307 JaÚn;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Women;276 JaÚn;Group 0800 Diseases of the ear and the mastoid 380-389;Both sexes;139 JaÚn;Group 0800 Diseases of the ear and the mastoid 380-389;Men;61 JaÚn;Group 0800 Diseases of the ear and the mastoid 380-389;Women;78 JaÚn;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Both sexes;6,657 JaÚn;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Men;3,823 JaÚn;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Women;2,834 JaÚn;Group 0901 Hypertensive disease 401-405;Both sexes;409 JaÚn;Group 0901 Hypertensive disease 401-405;Men;141 JaÚn;Group 0901 Hypertensive disease 401-405;Women;268 JaÚn;Group 0902 Angina pectoris 4111, 413;Both sexes;383 JaÚn;Group 0902 Angina pectoris 4111, 413;Men;225 JaÚn;Group 0902 Angina pectoris 4111, 413;Women;158 JaÚn;Group 0903 Acute myocardial infarction 410;Both sexes;997 JaÚn;Group 0903 Acute myocardial infarction 410;Men;709 JaÚn;Group 0903 Acute myocardial infarction 410;Women;288 JaÚn;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Both sexes;346 JaÚn;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Men;248 JaÚn;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Women;98 JaÚn;Group 0905 Diseases of the lungs circulation 415-417;Both sexes;252 JaÚn;Group 0905 Diseases of the lungs circulation 415-417;Men;115 JaÚn;Group 0905 Diseases of the lungs circulation 415-417;Women;137 JaÚn;Group 0906 Heart conduction disorders and arrhytmias 426-427;Both sexes;729 JaÚn;Group 0906 Heart conduction disorders and arrhytmias 426-427;Men;394 JaÚn;Group 0906 Heart conduction disorders and arrhytmias 426-427;Women;335 JaÚn;Grupo 0907 Heart failure 428;Both sexes;1,218 JaÚn;Grupo 0907 Heart failure 428;Men;553 JaÚn;Grupo 0907 Heart failure 428;Women;665 JaÚn;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Both sexes;1,274 JaÚn;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Men;745 JaÚn;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Women;529 JaÚn;Grupo 0909 Atherosclerosis 440;Both sexes;174 JaÚn;Grupo 0909 Atherosclerosis 440;Men;151 JaÚn;Grupo 0909 Atherosclerosis 440;Women;23 JaÚn;Group 0910 Varicose veins of lower extremities 454;Both sexes;40 JaÚn;Group 0910 Varicose veins of lower extremities 454;Men;9 JaÚn;Group 0910 Varicose veins of lower extremities 454;Women;31 JaÚn;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Both sexes;835 JaÚn;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Men;533 JaÚn;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Women;302 JaÚn;Group 1000 Diseases of the respiratory system 0340, 460-519;Both sexes;5,053 JaÚn;Group 1000 Diseases of the respiratory system 0340, 460-519;Men;3,097 JaÚn;Group 1000 Diseases of the respiratory system 0340, 460-519;Women;1,956 JaÚn;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Both sexes;174 JaÚn;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Men;109 JaÚn;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Women;65 JaÚn;Group 1002 Pneumonia 480-486;Both sexes;1,141 JaÚn;Group 1002 Pneumonia 480-486;Men;707 JaÚn;Group 1002 Pneumonia 480-486;Women;434 JaÚn;Group 1003 Acute bronchitis and bronchiolitis 466;Both sexes;332 JaÚn;Group 1003 Acute bronchitis and bronchiolitis 466;Men;184 JaÚn;Group 1003 Acute bronchitis and bronchiolitis 466;Women;148 JaÚn;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Both sexes;102 JaÚn;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Men;51 JaÚn;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Women;51 JaÚn;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Both sexes;352 JaÚn;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Men;219 JaÚn;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Women;133 JaÚn;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Both sexes;646 JaÚn;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Men;541 JaÚn;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Women;105 JaÚn;Group 1007 Asthma 4930-4931,4938-4939;Both sexes;131 JaÚn;Group 1007 Asthma 4930-4931,4938-4939;Men;68 JaÚn;Group 1007 Asthma 4930-4931,4938-4939;Women;63 JaÚn;Group 1008 Other diseases of the respiratory system Resto of (460-519);Both sexes;2,175 JaÚn;Group 1008 Other diseases of the respiratory system Resto of (460-519);Men;1,218 JaÚn;Group 1008 Other diseases of the respiratory system Resto of (460-519);Women;957 JaÚn;Group 1100 Diseases of the digestive system 520-579;Both sexes;6,088 JaÚn;Group 1100 Diseases of the digestive system 520-579;Men;3,349 JaÚn;Group 1100 Diseases of the digestive system 520-579;Women;2,739 JaÚn;Group 1101 Disorders of the teeth and supporting structures 520-525;Both sexes;65 JaÚn;Group 1101 Disorders of the teeth and supporting structures 520-525;Men;31 JaÚn;Group 1101 Disorders of the teeth and supporting structures 520-525;Women;34 JaÚn;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Both sexes;101 JaÚn;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Men;57 JaÚn;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Women;44 JaÚn;Group 1103 Diseases of the esophagus 530;Both sexes;92 JaÚn;Group 1103 Diseases of the esophagus 530;Men;67 JaÚn;Group 1103 Diseases of the esophagus 530;Women;25 JaÚn;Group 1104 Peptic ulcer 531-534;Both sexes;162 JaÚn;Group 1104 Peptic ulcer 531-534;Men;121 JaÚn;Group 1104 Peptic ulcer 531-534;Women;41 JaÚn;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Both sexes;149 JaÚn;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Men;82 JaÚn;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Women;67 JaÚn;Group 1106 Appendicitis 540-543;Both sexes;447 JaÚn;Group 1106 Appendicitis 540-543;Men;279 JaÚn;Group 1106 Appendicitis 540-543;Women;168 JaÚn;Group 1107 Inguinal hernia 550;Both sexes;331 JaÚn;Group 1107 Inguinal hernia 550;Men;296 JaÚn;Group 1107 Inguinal hernia 550;Women;35 JaÚn;Group 1108 Other abdominal hernia 551-553;Both sexes;421 JaÚn;Group 1108 Other abdominal hernia 551-553;Men;174 JaÚn;Group 1108 Other abdominal hernia 551-553;Women;247 JaÚn;Group 1109 Crohn's disease and ulcerative colitis 555-556;Both sexes;146 JaÚn;Group 1109 Crohn's disease and ulcerative colitis 555-556;Men;85 JaÚn;Group 1109 Crohn's disease and ulcerative colitis 555-556;Women;61 JaÚn;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Both sexes;229 JaÚn;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Men;114 JaÚn;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Women;115 JaÚn;Group 1111 Intestinal obstruction without hernia 560;Both sexes;257 JaÚn;Group 1111 Intestinal obstruction without hernia 560;Men;152 JaÚn;Group 1111 Intestinal obstruction without hernia 560;Women;105 JaÚn;Group 1112 Intestinal diverticulosis 562;Both sexes;201 JaÚn;Group 1112 Intestinal diverticulosis 562;Men;97 JaÚn;Group 1112 Intestinal diverticulosis 562;Women;104 JaÚn;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Both sexes;453 JaÚn;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Men;294 JaÚn;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Women;159 JaÚn;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Both sexes;166 JaÚn;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Men;70 JaÚn;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Women;96 JaÚn;Group 1115 Alcoholic hepatitis 5710-5713;Both sexes;151 JaÚn;Group 1115 Alcoholic hepatitis 5710-5713;Men;133 JaÚn;Group 1115 Alcoholic hepatitis 5710-5713;Women;18 JaÚn;Group 1116 Other diseases of the liver 570,5714-573;Both sexes;229 JaÚn;Group 1116 Other diseases of the liver 570,5714-573;Men;124 JaÚn;Group 1116 Other diseases of the liver 570,5714-573;Women;105 JaÚn;Group 1117 Cholelithiasis 574;Both sexes;1,322 JaÚn;Group 1117 Cholelithiasis 574;Men;563 JaÚn;Group 1117 Cholelithiasis 574;Women;759 JaÚn;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Both sexes;230 JaÚn;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Men;115 JaÚn;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Women;115 JaÚn;Group 1119 Pancreatic diseases 577;Both sexes;617 JaÚn;Group 1119 Pancreatic diseases 577;Men;322 JaÚn;Group 1119 Pancreatic diseases 577;Women;295 JaÚn;Group 1120 Other diseases of the digestive system Rest of (520-579);Both sexes;319 JaÚn;Group 1120 Other diseases of the digestive system Rest of (520-579);Men;173 JaÚn;Group 1120 Other diseases of the digestive system Rest of (520-579);Women;146 JaÚn;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Both sexes;365 JaÚn;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Men;221 JaÚn;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Women;144 JaÚn;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Both sexes;263 JaÚn;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Men;160 JaÚn;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Women;103 JaÚn;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Both sexes;15 JaÚn;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Men;9 JaÚn;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Women;6 JaÚn;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Both sexes;87 JaÚn;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Men;52 JaÚn;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Women;35 JaÚn;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Both sexes;2,483 JaÚn;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Men;1,123 JaÚn;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Women;1,360 JaÚn;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Both sexes;.. JaÚn;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Men;.. JaÚn;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Women;.. JaÚn;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Both sexes;.. JaÚn;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Men;.. JaÚn;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Women;.. JaÚn;Group 1303 Internal derangement of knee 717;Both sexes;159 JaÚn;Group 1303 Internal derangement of knee 717;Men;117 JaÚn;Group 1303 Internal derangement of knee 717;Women;42 JaÚn;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Both sexes;1,409 JaÚn;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Men;532 JaÚn;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Women;877 JaÚn;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Both sexes;61 JaÚn;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Men;35 JaÚn;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Women;26 JaÚn;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Both sexes;104 JaÚn;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Men;57 JaÚn;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Women;47 JaÚn;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Both sexes;161 JaÚn;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Men;90 JaÚn;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Women;71 JaÚn;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Both sexes;19 JaÚn;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Men;5 JaÚn;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Women;14 JaÚn;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Both sexes;281 JaÚn;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Men;150 JaÚn;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Women;131 JaÚn;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Both sexes;289 JaÚn;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Men;137 JaÚn;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Women;152 JaÚn;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Both sexes;2,475 JaÚn;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Men;1,034 JaÚn;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Women;1,441 JaÚn;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Both sexes;240 JaÚn;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Men;101 JaÚn;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Women;139 JaÚn;Group 1402 Renal failure 5836-5837, 584-586;Both sexes;329 JaÚn;Group 1402 Renal failure 5836-5837, 584-586;Men;188 JaÚn;Group 1402 Renal failure 5836-5837, 584-586;Women;141 JaÚn;Group 1403 Urolithiasis 592, 594, 7880;Both sexes;329 JaÚn;Group 1403 Urolithiasis 592, 594, 7880;Men;173 JaÚn;Group 1403 Urolithiasis 592, 594, 7880;Women;156 JaÚn;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Both sexes;413 JaÚn;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Men;195 JaÚn;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Women;218 JaÚn;Group 1405 Prostatic hyperplasia 600;Both sexes;140 JaÚn;Group 1405 Prostatic hyperplasia 600;Men;140 JaÚn;Group 1405 Prostatic hyperplasia 600;Women;.. JaÚn;Group 1406 Other diseases of the male genital organs 601-608;Both sexes;220 JaÚn;Group 1406 Other diseases of the male genital organs 601-608;Men;220 JaÚn;Group 1406 Other diseases of the male genital organs 601-608;Women;.. JaÚn;Group 1407 Disorders of breast 610-612;Both sexes;70 JaÚn;Group 1407 Disorders of breast 610-612;Men;11 JaÚn;Group 1407 Disorders of breast 610-612;Women;59 JaÚn;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Both sexes;81 JaÚn;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Men;.. JaÚn;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Women;81 JaÚn;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Both sexes;48 JaÚn;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Men;.. JaÚn;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Women;48 JaÚn;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Both sexes;605 JaÚn;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Men;6 JaÚn;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Women;599 JaÚn;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Both sexes;6,562 JaÚn;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Men;.. JaÚn;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Women;6,562 JaÚn;Group 1501 Legally induced abortion 635;Both sexes;1 JaÚn;Group 1501 Legally induced abortion 635;Men;.. JaÚn;Group 1501 Legally induced abortion 635;Women;1 JaÚn;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Both sexes;373 JaÚn;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Men;.. JaÚn;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Women;373 JaÚn;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Both sexes;4,281 JaÚn;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Men;.. JaÚn;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Women;4,281 JaÚn;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Both sexes;1,041 JaÚn;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Men;.. JaÚn;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Women;1,041 JaÚn;Group 1505 Single spontaneous delivery 650;Both sexes;334 JaÚn;Group 1505 Single spontaneous delivery 650;Men;.. JaÚn;Group 1505 Single spontaneous delivery 650;Women;334 JaÚn;Group 1506 Other deliveries 6695-6697;Both sexes;217 JaÚn;Group 1506 Other deliveries 6695-6697;Men;.. JaÚn;Group 1506 Other deliveries 6695-6697;Women;217 JaÚn;Group 1507 Complications related to the puerperium 670-676;Both sexes;38 JaÚn;Group 1507 Complications related to the puerperium 670-676;Men;.. JaÚn;Group 1507 Complications related to the puerperium 670-676;Women;38 JaÚn;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Both sexes;277 JaÚn;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Men;.. JaÚn;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Women;277 JaÚn;Group 1600 Some disorders originating in the perinatal period 760-779;Both sexes;599 JaÚn;Group 1600 Some disorders originating in the perinatal period 760-779;Men;334 JaÚn;Group 1600 Some disorders originating in the perinatal period 760-779;Women;265 JaÚn;Group 1601 Disorders related with premature delivery and a low birth weight 765;Both sexes;210 JaÚn;Group 1601 Disorders related with premature delivery and a low birth weight 765;Men;114 JaÚn;Group 1601 Disorders related with premature delivery and a low birth weight 765;Women;96 JaÚn;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Both sexes;389 JaÚn;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Men;220 JaÚn;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Women;169 JaÚn;Grupo 1700 Congenital abnormalities 740-759;Both sexes;173 JaÚn;Grupo 1700 Congenital abnormalities 740-759;Men;97 JaÚn;Grupo 1700 Congenital abnormalities 740-759;Women;76 JaÚn;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Both sexes;2,335 JaÚn;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Men;1,154 JaÚn;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Women;1,181 JaÚn;Group 1801 Pain in throat and chest 7841, 7865;Both sexes;359 JaÚn;Group 1801 Pain in throat and chest 7841, 7865;Men;176 JaÚn;Group 1801 Pain in throat and chest 7841, 7865;Women;183 JaÚn;Group 1802 Abdominal pain 7890;Both sexes;225 JaÚn;Group 1802 Abdominal pain 7890;Men;83 JaÚn;Group 1802 Abdominal pain 7890;Women;142 JaÚn;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Both sexes;469 JaÚn;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Men;216 JaÚn;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Women;253 JaÚn;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Both sexes;1,282 JaÚn;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Men;679 JaÚn;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Women;603 JaÚn;Group 1900 Injuries and poisoning 800-999;Both sexes;4,727 JaÚn;Group 1900 Injuries and poisoning 800-999;Men;2,403 JaÚn;Group 1900 Injuries and poisoning 800-999;Women;2,324 JaÚn;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Both sexes;188 JaÚn;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Men;114 JaÚn;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Women;74 JaÚn;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Both sexes;121 JaÚn;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Men;88 JaÚn;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Women;33 JaÚn;Group 1903 Radius and ulna fracture 813;Both sexes;344 JaÚn;Group 1903 Radius and ulna fracture 813;Men;179 JaÚn;Group 1903 Radius and ulna fracture 813;Women;165 JaÚn;Group 1904 Femur fracture 820-821;Both sexes;965 JaÚn;Group 1904 Femur fracture 820-821;Men;261 JaÚn;Group 1904 Femur fracture 820-821;Women;704 JaÚn;Group 1905 Leg fracture, including the ankle 823-824;Both sexes;422 JaÚn;Group 1905 Leg fracture, including the ankle 823-824;Men;217 JaÚn;Group 1905 Leg fracture, including the ankle 823-824;Women;205 JaÚn;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Both sexes;1,406 JaÚn;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Men;890 JaÚn;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Women;516 JaÚn;Group 1907 Burns 940-949;Both sexes;13 JaÚn;Group 1907 Burns 940-949;Men;8 JaÚn;Group 1907 Burns 940-949;Women;5 JaÚn;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Both sexes;148 JaÚn;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Men;71 JaÚn;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Women;77 JaÚn;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Both sexes;995 JaÚn;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Men;513 JaÚn;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Women;482 JaÚn;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Both sexes;14 JaÚn;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Men;6 JaÚn;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Women;8 JaÚn;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Both sexes;111 JaÚn;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Men;56 JaÚn;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Women;55 JaÚn;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Both sexes;751 JaÚn;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Men;333 JaÚn;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Women;418 JaÚn;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Both sexes;40 JaÚn;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Men;20 JaÚn;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Women;20 JaÚn;Group 2102 Contraceptive management V25;Both sexes;35 JaÚn;Group 2102 Contraceptive management V25;Men;5 JaÚn;Group 2102 Contraceptive management V25;Women;30 JaÚn;Group 2103 Living newborns by type of delivery V30-V39;Both sexes;.. JaÚn;Group 2103 Living newborns by type of delivery V30-V39;Men;.. JaÚn;Group 2103 Living newborns by type of delivery V30-V39;Women;.. JaÚn;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Both sexes;354 JaÚn;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Men;193 JaÚn;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Women;161 JaÚn;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Both sexes;322 JaÚn;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Men;115 JaÚn;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Women;207 Mßlaga;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Both sexes;135,272 Mßlaga;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Men;59,707 Mßlaga;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Women;75,565 Mßlaga;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Both sexes;2,858 Mßlaga;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Men;1,601 Mßlaga;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Women;1,257 Mßlaga;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Both sexes;329 Mßlaga;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Men;185 Mßlaga;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Women;143 Mßlaga;Group 0102 Imprecise intestinal infections 009;Both sexes;398 Mßlaga;Group 0102 Imprecise intestinal infections 009;Men;185 Mßlaga;Group 0102 Imprecise intestinal infections 009;Women;213 Mßlaga;Group 0103 Tuberculosis 010-018, 137;Both sexes;99 Mßlaga;Group 0103 Tuberculosis 010-018, 137;Men;66 Mßlaga;Group 0103 Tuberculosis 010-018, 137;Women;33 Mßlaga;Group 0104 Septicaemia 038;Both sexes;826 Mßlaga;Group 0104 Septicaemia 038;Men;451 Mßlaga;Group 0104 Septicaemia 038;Women;375 Mßlaga;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Both sexes;164 Mßlaga;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Men;127 Mßlaga;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Women;37 Mßlaga;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Both sexes;1,042 Mßlaga;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Men;585 Mßlaga;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Women;456 Mßlaga;Group 0200 Neoplasms 140-239;Both sexes;13,413 Mßlaga;Group 0200 Neoplasms 140-239;Men;6,476 Mßlaga;Group 0200 Neoplasms 140-239;Women;6,938 Mßlaga;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Both sexes;1,167 Mßlaga;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Men;690 Mßlaga;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Women;477 Mßlaga;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Both sexes;896 Mßlaga;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Men;705 Mßlaga;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Women;191 Mßlaga;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Both sexes;377 Mßlaga;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Men;212 Mßlaga;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Women;165 Mßlaga;Group 0204 Malignant neoplasm of breast 174-175;Both sexes;1,025 Mßlaga;Group 0204 Malignant neoplasm of breast 174-175;Men;12 Mßlaga;Group 0204 Malignant neoplasm of breast 174-175;Women;1,013 Mßlaga;Group 0205 Malignant neoplasm of uterus 179-180, 182;Both sexes;295 Mßlaga;Group 0205 Malignant neoplasm of uterus 179-180, 182;Men;.. Mßlaga;Group 0205 Malignant neoplasm of uterus 179-180, 182;Women;295 Mßlaga;Group 0206 Malignant neoplasm of ovary 1830;Both sexes;208 Mßlaga;Group 0206 Malignant neoplasm of ovary 1830;Men;.. Mßlaga;Group 0206 Malignant neoplasm of ovary 1830;Women;208 Mßlaga;Group 0207 Malignant neoplasm of prostate 185;Both sexes;427 Mßlaga;Group 0207 Malignant neoplasm of prostate 185;Men;427 Mßlaga;Group 0207 Malignant neoplasm of prostate 185;Women;.. Mßlaga;Group 0208 Malignant neoplasm of bladder 188;Both sexes;913 Mßlaga;Group 0208 Malignant neoplasm of bladder 188;Men;788 Mßlaga;Group 0208 Malignant neoplasm of bladder 188;Women;125 Mßlaga;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Both sexes;4,545 Mßlaga;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Men;2,607 Mßlaga;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Women;1,938 Mßlaga;Group 0210 Carcinoma in situ 230-234;Both sexes;222 Mßlaga;Group 0210 Carcinoma in situ 230-234;Men;51 Mßlaga;Group 0210 Carcinoma in situ 230-234;Women;170 Mßlaga;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Both sexes;97 Mßlaga;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Men;65 Mßlaga;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Women;32 Mßlaga;Grupo 0212 Leiomyoma of uterus 218;Both sexes;1,004 Mßlaga;Grupo 0212 Leiomyoma of uterus 218;Men;.. Mßlaga;Grupo 0212 Leiomyoma of uterus 218;Women;1,004 Mßlaga;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Both sexes;2,236 Mßlaga;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Men;919 Mßlaga;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Women;1,317 Mßlaga;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Both sexes;1,060 Mßlaga;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Men;495 Mßlaga;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Women;564 Mßlaga;Group 0301 Anaemias 280-285;Both sexes;398 Mßlaga;Group 0301 Anaemias 280-285;Men;205 Mßlaga;Group 0301 Anaemias 280-285;Women;193 Mßlaga;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Both sexes;662 Mßlaga;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Men;291 Mßlaga;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Women;371 Mßlaga;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Both sexes;2,347 Mßlaga;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Men;814 Mßlaga;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Women;1,533 Mßlaga;Group 0401 Diabetes mellitus 249-250;Both sexes;574 Mßlaga;Group 0401 Diabetes mellitus 249-250;Men;359 Mßlaga;Group 0401 Diabetes mellitus 249-250;Women;216 Mßlaga;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Both sexes;1,772 Mßlaga;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Men;455 Mßlaga;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Women;1,317 Mßlaga;Group 0500 Mental disorders 290-319;Both sexes;2,390 Mßlaga;Group 0500 Mental disorders 290-319;Men;1,319 Mßlaga;Group 0500 Mental disorders 290-319;Women;1,071 Mßlaga;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Both sexes;32 Mßlaga;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Men;15 Mßlaga;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Women;17 Mßlaga;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Both sexes;88 Mßlaga;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Men;69 Mßlaga;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Women;19 Mßlaga;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Both sexes;152 Mßlaga;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Men;122 Mßlaga;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Women;30 Mßlaga;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Both sexes;799 Mßlaga;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Men;495 Mßlaga;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Women;304 Mßlaga;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Both sexes;593 Mßlaga;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Men;270 Mßlaga;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Women;323 Mßlaga;Group 0506 Other mental and behavioural disorders Rest of (290-319);Both sexes;726 Mßlaga;Group 0506 Other mental and behavioural disorders Rest of (290-319);Men;348 Mßlaga;Group 0506 Other mental and behavioural disorders Rest of (290-319);Women;379 Mßlaga;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Both sexes;2,429 Mßlaga;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Men;1,195 Mßlaga;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Women;1,234 Mßlaga;Group 0601 Alzheimer's disease 3310;Both sexes;17 Mßlaga;Group 0601 Alzheimer's disease 3310;Men;8 Mßlaga;Group 0601 Alzheimer's disease 3310;Women;9 Mßlaga;Group 0602 Multiple sclerosis 340;Both sexes;80 Mßlaga;Group 0602 Multiple sclerosis 340;Men;23 Mßlaga;Group 0602 Multiple sclerosis 340;Women;57 Mßlaga;Group 0603 Epilepsy 345;Both sexes;426 Mßlaga;Group 0603 Epilepsy 345;Men;218 Mßlaga;Group 0603 Epilepsy 345;Women;209 Mßlaga;Group 0604 Transient cerebral ischemia 435;Both sexes;412 Mßlaga;Group 0604 Transient cerebral ischemia 435;Men;230 Mßlaga;Group 0604 Transient cerebral ischemia 435;Women;182 Mßlaga;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Both sexes;1,494 Mßlaga;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Men;717 Mßlaga;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Women;777 Mßlaga;Grupo 0700 Diseases of the eye and adnexa 360-379;Both sexes;916 Mßlaga;Grupo 0700 Diseases of the eye and adnexa 360-379;Men;487 Mßlaga;Grupo 0700 Diseases of the eye and adnexa 360-379;Women;429 Mßlaga;Grupo 0701 Cataract 366;Both sexes;256 Mßlaga;Grupo 0701 Cataract 366;Men;127 Mßlaga;Grupo 0701 Cataract 366;Women;128 Mßlaga;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Both sexes;661 Mßlaga;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Men;360 Mßlaga;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Women;301 Mßlaga;Group 0800 Diseases of the ear and the mastoid 380-389;Both sexes;796 Mßlaga;Group 0800 Diseases of the ear and the mastoid 380-389;Men;379 Mßlaga;Group 0800 Diseases of the ear and the mastoid 380-389;Women;417 Mßlaga;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Both sexes;17,510 Mßlaga;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Men;10,300 Mßlaga;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Women;7,210 Mßlaga;Group 0901 Hypertensive disease 401-405;Both sexes;1,083 Mßlaga;Group 0901 Hypertensive disease 401-405;Men;449 Mßlaga;Group 0901 Hypertensive disease 401-405;Women;634 Mßlaga;Group 0902 Angina pectoris 4111, 413;Both sexes;987 Mßlaga;Group 0902 Angina pectoris 4111, 413;Men;602 Mßlaga;Group 0902 Angina pectoris 4111, 413;Women;385 Mßlaga;Group 0903 Acute myocardial infarction 410;Both sexes;2,010 Mßlaga;Group 0903 Acute myocardial infarction 410;Men;1,455 Mßlaga;Group 0903 Acute myocardial infarction 410;Women;555 Mßlaga;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Both sexes;2,172 Mßlaga;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Men;1,609 Mßlaga;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Women;563 Mßlaga;Group 0905 Diseases of the lungs circulation 415-417;Both sexes;458 Mßlaga;Group 0905 Diseases of the lungs circulation 415-417;Men;220 Mßlaga;Group 0905 Diseases of the lungs circulation 415-417;Women;239 Mßlaga;Group 0906 Heart conduction disorders and arrhytmias 426-427;Both sexes;1,650 Mßlaga;Group 0906 Heart conduction disorders and arrhytmias 426-427;Men;918 Mßlaga;Group 0906 Heart conduction disorders and arrhytmias 426-427;Women;732 Mßlaga;Grupo 0907 Heart failure 428;Both sexes;2,275 Mßlaga;Grupo 0907 Heart failure 428;Men;1,127 Mßlaga;Grupo 0907 Heart failure 428;Women;1,148 Mßlaga;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Both sexes;2,706 Mßlaga;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Men;1,604 Mßlaga;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Women;1,102 Mßlaga;Grupo 0909 Atherosclerosis 440;Both sexes;473 Mßlaga;Grupo 0909 Atherosclerosis 440;Men;349 Mßlaga;Grupo 0909 Atherosclerosis 440;Women;124 Mßlaga;Group 0910 Varicose veins of lower extremities 454;Both sexes;585 Mßlaga;Group 0910 Varicose veins of lower extremities 454;Men;218 Mßlaga;Group 0910 Varicose veins of lower extremities 454;Women;368 Mßlaga;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Both sexes;3,111 Mßlaga;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Men;1,750 Mßlaga;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Women;1,360 Mßlaga;Group 1000 Diseases of the respiratory system 0340, 460-519;Both sexes;11,347 Mßlaga;Group 1000 Diseases of the respiratory system 0340, 460-519;Men;6,474 Mßlaga;Group 1000 Diseases of the respiratory system 0340, 460-519;Women;4,874 Mßlaga;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Both sexes;682 Mßlaga;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Men;335 Mßlaga;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Women;347 Mßlaga;Group 1002 Pneumonia 480-486;Both sexes;2,495 Mßlaga;Group 1002 Pneumonia 480-486;Men;1,483 Mßlaga;Group 1002 Pneumonia 480-486;Women;1,012 Mßlaga;Group 1003 Acute bronchitis and bronchiolitis 466;Both sexes;607 Mßlaga;Group 1003 Acute bronchitis and bronchiolitis 466;Men;330 Mßlaga;Group 1003 Acute bronchitis and bronchiolitis 466;Women;278 Mßlaga;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Both sexes;768 Mßlaga;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Men;385 Mßlaga;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Women;383 Mßlaga;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Both sexes;1,609 Mßlaga;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Men;941 Mßlaga;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Women;668 Mßlaga;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Both sexes;1,360 Mßlaga;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Men;937 Mßlaga;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Women;423 Mßlaga;Group 1007 Asthma 4930-4931,4938-4939;Both sexes;379 Mßlaga;Group 1007 Asthma 4930-4931,4938-4939;Men;106 Mßlaga;Group 1007 Asthma 4930-4931,4938-4939;Women;273 Mßlaga;Group 1008 Other diseases of the respiratory system Resto of (460-519);Both sexes;3,447 Mßlaga;Group 1008 Other diseases of the respiratory system Resto of (460-519);Men;1,957 Mßlaga;Group 1008 Other diseases of the respiratory system Resto of (460-519);Women;1,490 Mßlaga;Group 1100 Diseases of the digestive system 520-579;Both sexes;17,086 Mßlaga;Group 1100 Diseases of the digestive system 520-579;Men;9,227 Mßlaga;Group 1100 Diseases of the digestive system 520-579;Women;7,859 Mßlaga;Group 1101 Disorders of the teeth and supporting structures 520-525;Both sexes;214 Mßlaga;Group 1101 Disorders of the teeth and supporting structures 520-525;Men;105 Mßlaga;Group 1101 Disorders of the teeth and supporting structures 520-525;Women;108 Mßlaga;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Both sexes;215 Mßlaga;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Men;119 Mßlaga;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Women;95 Mßlaga;Group 1103 Diseases of the esophagus 530;Both sexes;263 Mßlaga;Group 1103 Diseases of the esophagus 530;Men;164 Mßlaga;Group 1103 Diseases of the esophagus 530;Women;98 Mßlaga;Group 1104 Peptic ulcer 531-534;Both sexes;324 Mßlaga;Group 1104 Peptic ulcer 531-534;Men;236 Mßlaga;Group 1104 Peptic ulcer 531-534;Women;88 Mßlaga;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Both sexes;466 Mßlaga;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Men;210 Mßlaga;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Women;257 Mßlaga;Group 1106 Appendicitis 540-543;Both sexes;1,657 Mßlaga;Group 1106 Appendicitis 540-543;Men;967 Mßlaga;Group 1106 Appendicitis 540-543;Women;690 Mßlaga;Group 1107 Inguinal hernia 550;Both sexes;1,507 Mßlaga;Group 1107 Inguinal hernia 550;Men;1,355 Mßlaga;Group 1107 Inguinal hernia 550;Women;151 Mßlaga;Group 1108 Other abdominal hernia 551-553;Both sexes;1,615 Mßlaga;Group 1108 Other abdominal hernia 551-553;Men;748 Mßlaga;Group 1108 Other abdominal hernia 551-553;Women;867 Mßlaga;Group 1109 Crohn's disease and ulcerative colitis 555-556;Both sexes;373 Mßlaga;Group 1109 Crohn's disease and ulcerative colitis 555-556;Men;194 Mßlaga;Group 1109 Crohn's disease and ulcerative colitis 555-556;Women;178 Mßlaga;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Both sexes;948 Mßlaga;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Men;445 Mßlaga;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Women;503 Mßlaga;Group 1111 Intestinal obstruction without hernia 560;Both sexes;575 Mßlaga;Group 1111 Intestinal obstruction without hernia 560;Men;287 Mßlaga;Group 1111 Intestinal obstruction without hernia 560;Women;289 Mßlaga;Group 1112 Intestinal diverticulosis 562;Both sexes;872 Mßlaga;Group 1112 Intestinal diverticulosis 562;Men;427 Mßlaga;Group 1112 Intestinal diverticulosis 562;Women;445 Mßlaga;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Both sexes;1,036 Mßlaga;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Men;651 Mßlaga;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Women;385 Mßlaga;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Both sexes;455 Mßlaga;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Men;202 Mßlaga;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Women;253 Mßlaga;Group 1115 Alcoholic hepatitis 5710-5713;Both sexes;259 Mßlaga;Group 1115 Alcoholic hepatitis 5710-5713;Men;198 Mßlaga;Group 1115 Alcoholic hepatitis 5710-5713;Women;60 Mßlaga;Group 1116 Other diseases of the liver 570,5714-573;Both sexes;488 Mßlaga;Group 1116 Other diseases of the liver 570,5714-573;Men;283 Mßlaga;Group 1116 Other diseases of the liver 570,5714-573;Women;206 Mßlaga;Group 1117 Cholelithiasis 574;Both sexes;3,531 Mßlaga;Group 1117 Cholelithiasis 574;Men;1,433 Mßlaga;Group 1117 Cholelithiasis 574;Women;2,098 Mßlaga;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Both sexes;742 Mßlaga;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Men;376 Mßlaga;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Women;366 Mßlaga;Group 1119 Pancreatic diseases 577;Both sexes;1,017 Mßlaga;Group 1119 Pancreatic diseases 577;Men;544 Mßlaga;Group 1119 Pancreatic diseases 577;Women;473 Mßlaga;Group 1120 Other diseases of the digestive system Rest of (520-579);Both sexes;530 Mßlaga;Group 1120 Other diseases of the digestive system Rest of (520-579);Men;282 Mßlaga;Group 1120 Other diseases of the digestive system Rest of (520-579);Women;249 Mßlaga;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Both sexes;1,277 Mßlaga;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Men;702 Mßlaga;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Women;575 Mßlaga;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Both sexes;804 Mßlaga;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Men;482 Mßlaga;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Women;322 Mßlaga;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Both sexes;47 Mßlaga;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Men;23 Mßlaga;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Women;24 Mßlaga;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Both sexes;426 Mßlaga;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Men;196 Mßlaga;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Women;230 Mßlaga;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Both sexes;8,873 Mßlaga;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Men;4,203 Mßlaga;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Women;4,669 Mßlaga;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Both sexes;.. Mßlaga;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Men;.. Mßlaga;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Women;.. Mßlaga;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Both sexes;.. Mßlaga;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Men;.. Mßlaga;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Women;.. Mßlaga;Group 1303 Internal derangement of knee 717;Both sexes;842 Mßlaga;Group 1303 Internal derangement of knee 717;Men;608 Mßlaga;Group 1303 Internal derangement of knee 717;Women;234 Mßlaga;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Both sexes;3,591 Mßlaga;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Men;1,537 Mßlaga;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Women;2,054 Mßlaga;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Both sexes;155 Mßlaga;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Men;62 Mßlaga;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Women;93 Mßlaga;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Both sexes;395 Mßlaga;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Men;171 Mßlaga;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Women;224 Mßlaga;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Both sexes;1,047 Mßlaga;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Men;532 Mßlaga;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Women;514 Mßlaga;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Both sexes;289 Mßlaga;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Men;96 Mßlaga;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Women;192 Mßlaga;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Both sexes;1,315 Mßlaga;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Men;684 Mßlaga;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Women;632 Mßlaga;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Both sexes;1,239 Mßlaga;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Men;512 Mßlaga;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Women;727 Mßlaga;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Both sexes;9,111 Mßlaga;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Men;3,770 Mßlaga;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Women;5,341 Mßlaga;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Both sexes;994 Mßlaga;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Men;373 Mßlaga;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Women;622 Mßlaga;Group 1402 Renal failure 5836-5837, 584-586;Both sexes;701 Mßlaga;Group 1402 Renal failure 5836-5837, 584-586;Men;392 Mßlaga;Group 1402 Renal failure 5836-5837, 584-586;Women;309 Mßlaga;Group 1403 Urolithiasis 592, 594, 7880;Both sexes;1,156 Mßlaga;Group 1403 Urolithiasis 592, 594, 7880;Men;677 Mßlaga;Group 1403 Urolithiasis 592, 594, 7880;Women;479 Mßlaga;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Both sexes;1,699 Mßlaga;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Men;901 Mßlaga;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Women;798 Mßlaga;Group 1405 Prostatic hyperplasia 600;Both sexes;749 Mßlaga;Group 1405 Prostatic hyperplasia 600;Men;749 Mßlaga;Group 1405 Prostatic hyperplasia 600;Women;.. Mßlaga;Group 1406 Other diseases of the male genital organs 601-608;Both sexes;592 Mßlaga;Group 1406 Other diseases of the male genital organs 601-608;Men;592 Mßlaga;Group 1406 Other diseases of the male genital organs 601-608;Women;.. Mßlaga;Group 1407 Disorders of breast 610-612;Both sexes;1,146 Mßlaga;Group 1407 Disorders of breast 610-612;Men;73 Mßlaga;Group 1407 Disorders of breast 610-612;Women;1,073 Mßlaga;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Both sexes;331 Mßlaga;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Men;.. Mßlaga;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Women;331 Mßlaga;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Both sexes;158 Mßlaga;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Men;.. Mßlaga;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Women;158 Mßlaga;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Both sexes;1,585 Mßlaga;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Men;13 Mßlaga;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Women;1,572 Mßlaga;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Both sexes;19,750 Mßlaga;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Men;.. Mßlaga;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Women;19,750 Mßlaga;Group 1501 Legally induced abortion 635;Both sexes;48 Mßlaga;Group 1501 Legally induced abortion 635;Men;.. Mßlaga;Group 1501 Legally induced abortion 635;Women;48 Mßlaga;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Both sexes;1,520 Mßlaga;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Men;.. Mßlaga;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Women;1,520 Mßlaga;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Both sexes;13,007 Mßlaga;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Men;.. Mßlaga;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Women;13,007 Mßlaga;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Both sexes;2,709 Mßlaga;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Men;.. Mßlaga;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Women;2,709 Mßlaga;Group 1505 Single spontaneous delivery 650;Both sexes;737 Mßlaga;Group 1505 Single spontaneous delivery 650;Men;.. Mßlaga;Group 1505 Single spontaneous delivery 650;Women;737 Mßlaga;Group 1506 Other deliveries 6695-6697;Both sexes;482 Mßlaga;Group 1506 Other deliveries 6695-6697;Men;.. Mßlaga;Group 1506 Other deliveries 6695-6697;Women;482 Mßlaga;Group 1507 Complications related to the puerperium 670-676;Both sexes;175 Mßlaga;Group 1507 Complications related to the puerperium 670-676;Men;.. Mßlaga;Group 1507 Complications related to the puerperium 670-676;Women;175 Mßlaga;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Both sexes;1,073 Mßlaga;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Men;.. Mßlaga;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Women;1,073 Mßlaga;Group 1600 Some disorders originating in the perinatal period 760-779;Both sexes;1,998 Mßlaga;Group 1600 Some disorders originating in the perinatal period 760-779;Men;1,104 Mßlaga;Group 1600 Some disorders originating in the perinatal period 760-779;Women;894 Mßlaga;Group 1601 Disorders related with premature delivery and a low birth weight 765;Both sexes;518 Mßlaga;Group 1601 Disorders related with premature delivery and a low birth weight 765;Men;285 Mßlaga;Group 1601 Disorders related with premature delivery and a low birth weight 765;Women;234 Mßlaga;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Both sexes;1,480 Mßlaga;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Men;819 Mßlaga;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Women;661 Mßlaga;Grupo 1700 Congenital abnormalities 740-759;Both sexes;1,190 Mßlaga;Grupo 1700 Congenital abnormalities 740-759;Men;644 Mßlaga;Grupo 1700 Congenital abnormalities 740-759;Women;546 Mßlaga;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Both sexes;5,353 Mßlaga;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Men;2,954 Mßlaga;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Women;2,399 Mßlaga;Group 1801 Pain in throat and chest 7841, 7865;Both sexes;528 Mßlaga;Group 1801 Pain in throat and chest 7841, 7865;Men;311 Mßlaga;Group 1801 Pain in throat and chest 7841, 7865;Women;218 Mßlaga;Group 1802 Abdominal pain 7890;Both sexes;640 Mßlaga;Group 1802 Abdominal pain 7890;Men;227 Mßlaga;Group 1802 Abdominal pain 7890;Women;414 Mßlaga;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Both sexes;352 Mßlaga;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Men;204 Mßlaga;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Women;147 Mßlaga;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Both sexes;3,832 Mßlaga;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Men;2,212 Mßlaga;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Women;1,620 Mßlaga;Group 1900 Injuries and poisoning 800-999;Both sexes;12,643 Mßlaga;Group 1900 Injuries and poisoning 800-999;Men;6,505 Mßlaga;Group 1900 Injuries and poisoning 800-999;Women;6,138 Mßlaga;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Both sexes;540 Mßlaga;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Men;330 Mßlaga;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Women;211 Mßlaga;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Both sexes;383 Mßlaga;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Men;263 Mßlaga;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Women;120 Mßlaga;Group 1903 Radius and ulna fracture 813;Both sexes;721 Mßlaga;Group 1903 Radius and ulna fracture 813;Men;361 Mßlaga;Group 1903 Radius and ulna fracture 813;Women;360 Mßlaga;Group 1904 Femur fracture 820-821;Both sexes;2,014 Mßlaga;Group 1904 Femur fracture 820-821;Men;584 Mßlaga;Group 1904 Femur fracture 820-821;Women;1,430 Mßlaga;Group 1905 Leg fracture, including the ankle 823-824;Both sexes;1,059 Mßlaga;Group 1905 Leg fracture, including the ankle 823-824;Men;532 Mßlaga;Group 1905 Leg fracture, including the ankle 823-824;Women;526 Mßlaga;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Both sexes;3,950 Mßlaga;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Men;2,372 Mßlaga;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Women;1,578 Mßlaga;Group 1907 Burns 940-949;Both sexes;179 Mßlaga;Group 1907 Burns 940-949;Men;98 Mßlaga;Group 1907 Burns 940-949;Women;81 Mßlaga;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Both sexes;356 Mßlaga;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Men;162 Mßlaga;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Women;193 Mßlaga;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Both sexes;3,152 Mßlaga;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Men;1,638 Mßlaga;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Women;1,514 Mßlaga;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Both sexes;50 Mßlaga;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Men;30 Mßlaga;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Women;20 Mßlaga;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Both sexes;240 Mßlaga;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Men;134 Mßlaga;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Women;105 Mßlaga;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Both sexes;2,925 Mßlaga;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Men;1,059 Mßlaga;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Women;1,866 Mßlaga;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Both sexes;145 Mßlaga;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Men;71 Mßlaga;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Women;74 Mßlaga;Group 2102 Contraceptive management V25;Both sexes;76 Mßlaga;Group 2102 Contraceptive management V25;Men;13 Mßlaga;Group 2102 Contraceptive management V25;Women;63 Mßlaga;Group 2103 Living newborns by type of delivery V30-V39;Both sexes;.. Mßlaga;Group 2103 Living newborns by type of delivery V30-V39;Men;.. Mßlaga;Group 2103 Living newborns by type of delivery V30-V39;Women;.. Mßlaga;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Both sexes;651 Mßlaga;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Men;387 Mßlaga;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Women;264 Mßlaga;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Both sexes;2,053 Mßlaga;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Men;587 Mßlaga;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Women;1,465 Sevilla;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Both sexes;162,821 Sevilla;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Men;71,210 Sevilla;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Women;91,611 Sevilla;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Both sexes;3,644 Sevilla;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Men;2,070 Sevilla;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Women;1,574 Sevilla;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Both sexes;620 Sevilla;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Men;349 Sevilla;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Women;271 Sevilla;Group 0102 Imprecise intestinal infections 009;Both sexes;290 Sevilla;Group 0102 Imprecise intestinal infections 009;Men;121 Sevilla;Group 0102 Imprecise intestinal infections 009;Women;169 Sevilla;Group 0103 Tuberculosis 010-018, 137;Both sexes;137 Sevilla;Group 0103 Tuberculosis 010-018, 137;Men;97 Sevilla;Group 0103 Tuberculosis 010-018, 137;Women;40 Sevilla;Group 0104 Septicaemia 038;Both sexes;1,419 Sevilla;Group 0104 Septicaemia 038;Men;780 Sevilla;Group 0104 Septicaemia 038;Women;639 Sevilla;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Both sexes;134 Sevilla;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Men;100 Sevilla;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Women;34 Sevilla;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Both sexes;1,044 Sevilla;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Men;623 Sevilla;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Women;421 Sevilla;Group 0200 Neoplasms 140-239;Both sexes;15,870 Sevilla;Group 0200 Neoplasms 140-239;Men;8,094 Sevilla;Group 0200 Neoplasms 140-239;Women;7,776 Sevilla;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Both sexes;1,407 Sevilla;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Men;894 Sevilla;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Women;513 Sevilla;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Both sexes;1,109 Sevilla;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Men;929 Sevilla;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Women;180 Sevilla;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Both sexes;370 Sevilla;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Men;216 Sevilla;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Women;154 Sevilla;Group 0204 Malignant neoplasm of breast 174-175;Both sexes;1,391 Sevilla;Group 0204 Malignant neoplasm of breast 174-175;Men;7 Sevilla;Group 0204 Malignant neoplasm of breast 174-175;Women;1,384 Sevilla;Group 0205 Malignant neoplasm of uterus 179-180, 182;Both sexes;322 Sevilla;Group 0205 Malignant neoplasm of uterus 179-180, 182;Men;.. Sevilla;Group 0205 Malignant neoplasm of uterus 179-180, 182;Women;322 Sevilla;Group 0206 Malignant neoplasm of ovary 1830;Both sexes;241 Sevilla;Group 0206 Malignant neoplasm of ovary 1830;Men;.. Sevilla;Group 0206 Malignant neoplasm of ovary 1830;Women;241 Sevilla;Group 0207 Malignant neoplasm of prostate 185;Both sexes;416 Sevilla;Group 0207 Malignant neoplasm of prostate 185;Men;416 Sevilla;Group 0207 Malignant neoplasm of prostate 185;Women;.. Sevilla;Group 0208 Malignant neoplasm of bladder 188;Both sexes;1,530 Sevilla;Group 0208 Malignant neoplasm of bladder 188;Men;1,300 Sevilla;Group 0208 Malignant neoplasm of bladder 188;Women;230 Sevilla;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Both sexes;5,609 Sevilla;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Men;3,234 Sevilla;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Women;2,375 Sevilla;Group 0210 Carcinoma in situ 230-234;Both sexes;131 Sevilla;Group 0210 Carcinoma in situ 230-234;Men;32 Sevilla;Group 0210 Carcinoma in situ 230-234;Women;99 Sevilla;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Both sexes;145 Sevilla;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Men;88 Sevilla;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Women;57 Sevilla;Grupo 0212 Leiomyoma of uterus 218;Both sexes;892 Sevilla;Grupo 0212 Leiomyoma of uterus 218;Men;.. Sevilla;Grupo 0212 Leiomyoma of uterus 218;Women;892 Sevilla;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Both sexes;2,307 Sevilla;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Men;978 Sevilla;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Women;1,329 Sevilla;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Both sexes;1,311 Sevilla;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Men;661 Sevilla;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Women;650 Sevilla;Group 0301 Anaemias 280-285;Both sexes;693 Sevilla;Group 0301 Anaemias 280-285;Men;334 Sevilla;Group 0301 Anaemias 280-285;Women;359 Sevilla;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Both sexes;618 Sevilla;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Men;327 Sevilla;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Women;291 Sevilla;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Both sexes;3,128 Sevilla;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Men;1,119 Sevilla;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Women;2,009 Sevilla;Group 0401 Diabetes mellitus 249-250;Both sexes;853 Sevilla;Group 0401 Diabetes mellitus 249-250;Men;504 Sevilla;Group 0401 Diabetes mellitus 249-250;Women;349 Sevilla;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Both sexes;2,275 Sevilla;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Men;615 Sevilla;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Women;1,660 Sevilla;Group 0500 Mental disorders 290-319;Both sexes;3,435 Sevilla;Group 0500 Mental disorders 290-319;Men;2,038 Sevilla;Group 0500 Mental disorders 290-319;Women;1,397 Sevilla;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Both sexes;42 Sevilla;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Men;21 Sevilla;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Women;21 Sevilla;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Both sexes;154 Sevilla;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Men;131 Sevilla;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Women;23 Sevilla;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Both sexes;196 Sevilla;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Men;158 Sevilla;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Women;38 Sevilla;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Both sexes;1,144 Sevilla;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Men;826 Sevilla;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Women;318 Sevilla;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Both sexes;771 Sevilla;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Men;330 Sevilla;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Women;441 Sevilla;Group 0506 Other mental and behavioural disorders Rest of (290-319);Both sexes;1,128 Sevilla;Group 0506 Other mental and behavioural disorders Rest of (290-319);Men;572 Sevilla;Group 0506 Other mental and behavioural disorders Rest of (290-319);Women;556 Sevilla;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Both sexes;3,092 Sevilla;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Men;1,508 Sevilla;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Women;1,584 Sevilla;Group 0601 Alzheimer's disease 3310;Both sexes;49 Sevilla;Group 0601 Alzheimer's disease 3310;Men;23 Sevilla;Group 0601 Alzheimer's disease 3310;Women;26 Sevilla;Group 0602 Multiple sclerosis 340;Both sexes;55 Sevilla;Group 0602 Multiple sclerosis 340;Men;17 Sevilla;Group 0602 Multiple sclerosis 340;Women;38 Sevilla;Group 0603 Epilepsy 345;Both sexes;643 Sevilla;Group 0603 Epilepsy 345;Men;333 Sevilla;Group 0603 Epilepsy 345;Women;310 Sevilla;Group 0604 Transient cerebral ischemia 435;Both sexes;470 Sevilla;Group 0604 Transient cerebral ischemia 435;Men;224 Sevilla;Group 0604 Transient cerebral ischemia 435;Women;246 Sevilla;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Both sexes;1,875 Sevilla;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Men;911 Sevilla;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Women;964 Sevilla;Grupo 0700 Diseases of the eye and adnexa 360-379;Both sexes;1,039 Sevilla;Grupo 0700 Diseases of the eye and adnexa 360-379;Men;561 Sevilla;Grupo 0700 Diseases of the eye and adnexa 360-379;Women;478 Sevilla;Grupo 0701 Cataract 366;Both sexes;82 Sevilla;Grupo 0701 Cataract 366;Men;36 Sevilla;Grupo 0701 Cataract 366;Women;46 Sevilla;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Both sexes;957 Sevilla;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Men;525 Sevilla;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Women;432 Sevilla;Group 0800 Diseases of the ear and the mastoid 380-389;Both sexes;826 Sevilla;Group 0800 Diseases of the ear and the mastoid 380-389;Men;424 Sevilla;Group 0800 Diseases of the ear and the mastoid 380-389;Women;402 Sevilla;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Both sexes;20,941 Sevilla;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Men;11,633 Sevilla;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Women;9,308 Sevilla;Group 0901 Hypertensive disease 401-405;Both sexes;1,648 Sevilla;Group 0901 Hypertensive disease 401-405;Men;702 Sevilla;Group 0901 Hypertensive disease 401-405;Women;946 Sevilla;Group 0902 Angina pectoris 4111, 413;Both sexes;1,495 Sevilla;Group 0902 Angina pectoris 4111, 413;Men;883 Sevilla;Group 0902 Angina pectoris 4111, 413;Women;612 Sevilla;Group 0903 Acute myocardial infarction 410;Both sexes;2,227 Sevilla;Group 0903 Acute myocardial infarction 410;Men;1,435 Sevilla;Group 0903 Acute myocardial infarction 410;Women;792 Sevilla;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Both sexes;1,373 Sevilla;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Men;999 Sevilla;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Women;374 Sevilla;Group 0905 Diseases of the lungs circulation 415-417;Both sexes;484 Sevilla;Group 0905 Diseases of the lungs circulation 415-417;Men;208 Sevilla;Group 0905 Diseases of the lungs circulation 415-417;Women;276 Sevilla;Group 0906 Heart conduction disorders and arrhytmias 426-427;Both sexes;2,860 Sevilla;Group 0906 Heart conduction disorders and arrhytmias 426-427;Men;1,536 Sevilla;Group 0906 Heart conduction disorders and arrhytmias 426-427;Women;1,324 Sevilla;Grupo 0907 Heart failure 428;Both sexes;3,305 Sevilla;Grupo 0907 Heart failure 428;Men;1,573 Sevilla;Grupo 0907 Heart failure 428;Women;1,732 Sevilla;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Both sexes;3,330 Sevilla;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Men;1,729 Sevilla;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Women;1,601 Sevilla;Grupo 0909 Atherosclerosis 440;Both sexes;796 Sevilla;Grupo 0909 Atherosclerosis 440;Men;612 Sevilla;Grupo 0909 Atherosclerosis 440;Women;184 Sevilla;Group 0910 Varicose veins of lower extremities 454;Both sexes;445 Sevilla;Group 0910 Varicose veins of lower extremities 454;Men;164 Sevilla;Group 0910 Varicose veins of lower extremities 454;Women;281 Sevilla;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Both sexes;2,978 Sevilla;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Men;1,792 Sevilla;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Women;1,186 Sevilla;Group 1000 Diseases of the respiratory system 0340, 460-519;Both sexes;11,918 Sevilla;Group 1000 Diseases of the respiratory system 0340, 460-519;Men;7,024 Sevilla;Group 1000 Diseases of the respiratory system 0340, 460-519;Women;4,894 Sevilla;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Both sexes;560 Sevilla;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Men;293 Sevilla;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Women;267 Sevilla;Group 1002 Pneumonia 480-486;Both sexes;2,318 Sevilla;Group 1002 Pneumonia 480-486;Men;1,339 Sevilla;Group 1002 Pneumonia 480-486;Women;979 Sevilla;Group 1003 Acute bronchitis and bronchiolitis 466;Both sexes;1,222 Sevilla;Group 1003 Acute bronchitis and bronchiolitis 466;Men;654 Sevilla;Group 1003 Acute bronchitis and bronchiolitis 466;Women;568 Sevilla;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Both sexes;695 Sevilla;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Men;375 Sevilla;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Women;320 Sevilla;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Both sexes;1,400 Sevilla;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Men;840 Sevilla;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Women;560 Sevilla;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Both sexes;1,175 Sevilla;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Men;916 Sevilla;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Women;259 Sevilla;Group 1007 Asthma 4930-4931,4938-4939;Both sexes;311 Sevilla;Group 1007 Asthma 4930-4931,4938-4939;Men;120 Sevilla;Group 1007 Asthma 4930-4931,4938-4939;Women;191 Sevilla;Group 1008 Other diseases of the respiratory system Resto of (460-519);Both sexes;4,237 Sevilla;Group 1008 Other diseases of the respiratory system Resto of (460-519);Men;2,487 Sevilla;Group 1008 Other diseases of the respiratory system Resto of (460-519);Women;1,750 Sevilla;Group 1100 Diseases of the digestive system 520-579;Both sexes;19,699 Sevilla;Group 1100 Diseases of the digestive system 520-579;Men;10,469 Sevilla;Group 1100 Diseases of the digestive system 520-579;Women;9,230 Sevilla;Group 1101 Disorders of the teeth and supporting structures 520-525;Both sexes;358 Sevilla;Group 1101 Disorders of the teeth and supporting structures 520-525;Men;181 Sevilla;Group 1101 Disorders of the teeth and supporting structures 520-525;Women;177 Sevilla;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Both sexes;286 Sevilla;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Men;153 Sevilla;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Women;133 Sevilla;Group 1103 Diseases of the esophagus 530;Both sexes;615 Sevilla;Group 1103 Diseases of the esophagus 530;Men;370 Sevilla;Group 1103 Diseases of the esophagus 530;Women;245 Sevilla;Group 1104 Peptic ulcer 531-534;Both sexes;350 Sevilla;Group 1104 Peptic ulcer 531-534;Men;253 Sevilla;Group 1104 Peptic ulcer 531-534;Women;97 Sevilla;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Both sexes;431 Sevilla;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Men;193 Sevilla;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Women;238 Sevilla;Group 1106 Appendicitis 540-543;Both sexes;1,721 Sevilla;Group 1106 Appendicitis 540-543;Men;963 Sevilla;Group 1106 Appendicitis 540-543;Women;758 Sevilla;Group 1107 Inguinal hernia 550;Both sexes;1,630 Sevilla;Group 1107 Inguinal hernia 550;Men;1,315 Sevilla;Group 1107 Inguinal hernia 550;Women;315 Sevilla;Group 1108 Other abdominal hernia 551-553;Both sexes;1,597 Sevilla;Group 1108 Other abdominal hernia 551-553;Men;694 Sevilla;Group 1108 Other abdominal hernia 551-553;Women;903 Sevilla;Group 1109 Crohn's disease and ulcerative colitis 555-556;Both sexes;553 Sevilla;Group 1109 Crohn's disease and ulcerative colitis 555-556;Men;285 Sevilla;Group 1109 Crohn's disease and ulcerative colitis 555-556;Women;268 Sevilla;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Both sexes;1,080 Sevilla;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Men;507 Sevilla;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Women;573 Sevilla;Group 1111 Intestinal obstruction without hernia 560;Both sexes;670 Sevilla;Group 1111 Intestinal obstruction without hernia 560;Men;339 Sevilla;Group 1111 Intestinal obstruction without hernia 560;Women;331 Sevilla;Group 1112 Intestinal diverticulosis 562;Both sexes;549 Sevilla;Group 1112 Intestinal diverticulosis 562;Men;281 Sevilla;Group 1112 Intestinal diverticulosis 562;Women;268 Sevilla;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Both sexes;1,052 Sevilla;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Men;646 Sevilla;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Women;406 Sevilla;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Both sexes;681 Sevilla;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Men;316 Sevilla;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Women;365 Sevilla;Group 1115 Alcoholic hepatitis 5710-5713;Both sexes;431 Sevilla;Group 1115 Alcoholic hepatitis 5710-5713;Men;361 Sevilla;Group 1115 Alcoholic hepatitis 5710-5713;Women;70 Sevilla;Group 1116 Other diseases of the liver 570,5714-573;Both sexes;733 Sevilla;Group 1116 Other diseases of the liver 570,5714-573;Men;423 Sevilla;Group 1116 Other diseases of the liver 570,5714-573;Women;310 Sevilla;Group 1117 Cholelithiasis 574;Both sexes;3,673 Sevilla;Group 1117 Cholelithiasis 574;Men;1,455 Sevilla;Group 1117 Cholelithiasis 574;Women;2,218 Sevilla;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Both sexes;1,011 Sevilla;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Men;522 Sevilla;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Women;489 Sevilla;Group 1119 Pancreatic diseases 577;Both sexes;1,398 Sevilla;Group 1119 Pancreatic diseases 577;Men;754 Sevilla;Group 1119 Pancreatic diseases 577;Women;644 Sevilla;Group 1120 Other diseases of the digestive system Rest of (520-579);Both sexes;880 Sevilla;Group 1120 Other diseases of the digestive system Rest of (520-579);Men;458 Sevilla;Group 1120 Other diseases of the digestive system Rest of (520-579);Women;422 Sevilla;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Both sexes;1,328 Sevilla;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Men;688 Sevilla;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Women;640 Sevilla;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Both sexes;725 Sevilla;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Men;413 Sevilla;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Women;312 Sevilla;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Both sexes;65 Sevilla;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Men;42 Sevilla;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Women;23 Sevilla;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Both sexes;538 Sevilla;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Men;233 Sevilla;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Women;305 Sevilla;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Both sexes;12,125 Sevilla;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Men;5,594 Sevilla;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Women;6,531 Sevilla;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Both sexes;.. Sevilla;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Men;.. Sevilla;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Women;.. Sevilla;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Both sexes;.. Sevilla;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Men;.. Sevilla;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Women;.. Sevilla;Group 1303 Internal derangement of knee 717;Both sexes;1,627 Sevilla;Group 1303 Internal derangement of knee 717;Men;992 Sevilla;Group 1303 Internal derangement of knee 717;Women;635 Sevilla;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Both sexes;4,655 Sevilla;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Men;1,939 Sevilla;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Women;2,716 Sevilla;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Both sexes;200 Sevilla;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Men;74 Sevilla;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Women;126 Sevilla;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Both sexes;624 Sevilla;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Men;303 Sevilla;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Women;321 Sevilla;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Both sexes;1,570 Sevilla;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Men;733 Sevilla;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Women;837 Sevilla;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Both sexes;346 Sevilla;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Men;114 Sevilla;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Women;232 Sevilla;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Both sexes;1,474 Sevilla;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Men;708 Sevilla;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Women;766 Sevilla;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Both sexes;1,629 Sevilla;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Men;731 Sevilla;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Women;898 Sevilla;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Both sexes;9,335 Sevilla;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Men;3,947 Sevilla;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Women;5,388 Sevilla;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Both sexes;942 Sevilla;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Men;365 Sevilla;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Women;577 Sevilla;Group 1402 Renal failure 5836-5837, 584-586;Both sexes;822 Sevilla;Group 1402 Renal failure 5836-5837, 584-586;Men;452 Sevilla;Group 1402 Renal failure 5836-5837, 584-586;Women;370 Sevilla;Group 1403 Urolithiasis 592, 594, 7880;Both sexes;1,192 Sevilla;Group 1403 Urolithiasis 592, 594, 7880;Men;663 Sevilla;Group 1403 Urolithiasis 592, 594, 7880;Women;529 Sevilla;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Both sexes;1,858 Sevilla;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Men;952 Sevilla;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Women;906 Sevilla;Group 1405 Prostatic hyperplasia 600;Both sexes;574 Sevilla;Group 1405 Prostatic hyperplasia 600;Men;574 Sevilla;Group 1405 Prostatic hyperplasia 600;Women;.. Sevilla;Group 1406 Other diseases of the male genital organs 601-608;Both sexes;860 Sevilla;Group 1406 Other diseases of the male genital organs 601-608;Men;860 Sevilla;Group 1406 Other diseases of the male genital organs 601-608;Women;.. Sevilla;Group 1407 Disorders of breast 610-612;Both sexes;711 Sevilla;Group 1407 Disorders of breast 610-612;Men;63 Sevilla;Group 1407 Disorders of breast 610-612;Women;648 Sevilla;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Both sexes;332 Sevilla;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Men;.. Sevilla;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Women;332 Sevilla;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Both sexes;133 Sevilla;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Men;.. Sevilla;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Women;133 Sevilla;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Both sexes;1,911 Sevilla;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Men;18 Sevilla;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Women;1,893 Sevilla;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Both sexes;24,066 Sevilla;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Men;.. Sevilla;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Women;24,066 Sevilla;Group 1501 Legally induced abortion 635;Both sexes;36 Sevilla;Group 1501 Legally induced abortion 635;Men;.. Sevilla;Group 1501 Legally induced abortion 635;Women;36 Sevilla;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Both sexes;1,393 Sevilla;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Men;.. Sevilla;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Women;1,393 Sevilla;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Both sexes;14,579 Sevilla;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Men;.. Sevilla;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Women;14,579 Sevilla;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Both sexes;3,896 Sevilla;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Men;.. Sevilla;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Women;3,896 Sevilla;Group 1505 Single spontaneous delivery 650;Both sexes;1,833 Sevilla;Group 1505 Single spontaneous delivery 650;Men;.. Sevilla;Group 1505 Single spontaneous delivery 650;Women;1,833 Sevilla;Group 1506 Other deliveries 6695-6697;Both sexes;600 Sevilla;Group 1506 Other deliveries 6695-6697;Men;.. Sevilla;Group 1506 Other deliveries 6695-6697;Women;600 Sevilla;Group 1507 Complications related to the puerperium 670-676;Both sexes;205 Sevilla;Group 1507 Complications related to the puerperium 670-676;Men;.. Sevilla;Group 1507 Complications related to the puerperium 670-676;Women;205 Sevilla;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Both sexes;1,524 Sevilla;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Men;.. Sevilla;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Women;1,524 Sevilla;Group 1600 Some disorders originating in the perinatal period 760-779;Both sexes;2,242 Sevilla;Group 1600 Some disorders originating in the perinatal period 760-779;Men;1,264 Sevilla;Group 1600 Some disorders originating in the perinatal period 760-779;Women;978 Sevilla;Group 1601 Disorders related with premature delivery and a low birth weight 765;Both sexes;784 Sevilla;Group 1601 Disorders related with premature delivery and a low birth weight 765;Men;440 Sevilla;Group 1601 Disorders related with premature delivery and a low birth weight 765;Women;344 Sevilla;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Both sexes;1,458 Sevilla;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Men;824 Sevilla;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Women;634 Sevilla;Grupo 1700 Congenital abnormalities 740-759;Both sexes;2,063 Sevilla;Grupo 1700 Congenital abnormalities 740-759;Men;1,166 Sevilla;Grupo 1700 Congenital abnormalities 740-759;Women;897 Sevilla;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Both sexes;9,161 Sevilla;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Men;4,725 Sevilla;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Women;4,436 Sevilla;Group 1801 Pain in throat and chest 7841, 7865;Both sexes;1,487 Sevilla;Group 1801 Pain in throat and chest 7841, 7865;Men;786 Sevilla;Group 1801 Pain in throat and chest 7841, 7865;Women;701 Sevilla;Group 1802 Abdominal pain 7890;Both sexes;1,215 Sevilla;Group 1802 Abdominal pain 7890;Men;464 Sevilla;Group 1802 Abdominal pain 7890;Women;751 Sevilla;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Both sexes;427 Sevilla;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Men;213 Sevilla;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Women;214 Sevilla;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Both sexes;6,032 Sevilla;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Men;3,262 Sevilla;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Women;2,770 Sevilla;Group 1900 Injuries and poisoning 800-999;Both sexes;14,770 Sevilla;Group 1900 Injuries and poisoning 800-999;Men;6,990 Sevilla;Group 1900 Injuries and poisoning 800-999;Women;7,780 Sevilla;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Both sexes;521 Sevilla;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Men;297 Sevilla;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Women;224 Sevilla;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Both sexes;399 Sevilla;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Men;275 Sevilla;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Women;124 Sevilla;Group 1903 Radius and ulna fracture 813;Both sexes;972 Sevilla;Group 1903 Radius and ulna fracture 813;Men;485 Sevilla;Group 1903 Radius and ulna fracture 813;Women;487 Sevilla;Group 1904 Femur fracture 820-821;Both sexes;2,217 Sevilla;Group 1904 Femur fracture 820-821;Men;599 Sevilla;Group 1904 Femur fracture 820-821;Women;1,618 Sevilla;Group 1905 Leg fracture, including the ankle 823-824;Both sexes;1,239 Sevilla;Group 1905 Leg fracture, including the ankle 823-824;Men;566 Sevilla;Group 1905 Leg fracture, including the ankle 823-824;Women;673 Sevilla;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Both sexes;4,413 Sevilla;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Men;2,136 Sevilla;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Women;2,277 Sevilla;Group 1907 Burns 940-949;Both sexes;163 Sevilla;Group 1907 Burns 940-949;Men;102 Sevilla;Group 1907 Burns 940-949;Women;61 Sevilla;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Both sexes;437 Sevilla;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Men;211 Sevilla;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Women;226 Sevilla;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Both sexes;4,087 Sevilla;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Men;2,139 Sevilla;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Women;1,948 Sevilla;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Both sexes;67 Sevilla;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Men;44 Sevilla;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Women;23 Sevilla;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Both sexes;255 Sevilla;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Men;136 Sevilla;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Women;119 Sevilla;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Both sexes;2,828 Sevilla;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Men;1,235 Sevilla;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Women;1,593 Sevilla;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Both sexes;275 Sevilla;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Men;137 Sevilla;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Women;138 Sevilla;Group 2102 Contraceptive management V25;Both sexes;52 Sevilla;Group 2102 Contraceptive management V25;Men;11 Sevilla;Group 2102 Contraceptive management V25;Women;41 Sevilla;Group 2103 Living newborns by type of delivery V30-V39;Both sexes;.. Sevilla;Group 2103 Living newborns by type of delivery V30-V39;Men;.. Sevilla;Group 2103 Living newborns by type of delivery V30-V39;Women;.. Sevilla;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Both sexes;834 Sevilla;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Men;543 Sevilla;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Women;291 Sevilla;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Both sexes;1,667 Sevilla;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Men;544 Sevilla;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Women;1,123 ARAGËN;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Both sexes;150,365 ARAGËN;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Men;73,468 ARAGËN;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Women;76,897 ARAGËN;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Both sexes;3,024 ARAGËN;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Men;1,674 ARAGËN;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Women;1,350 ARAGËN;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Both sexes;588 ARAGËN;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Men;321 ARAGËN;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Women;267 ARAGËN;Group 0102 Imprecise intestinal infections 009;Both sexes;207 ARAGËN;Group 0102 Imprecise intestinal infections 009;Men;107 ARAGËN;Group 0102 Imprecise intestinal infections 009;Women;100 ARAGËN;Group 0103 Tuberculosis 010-018, 137;Both sexes;179 ARAGËN;Group 0103 Tuberculosis 010-018, 137;Men;107 ARAGËN;Group 0103 Tuberculosis 010-018, 137;Women;72 ARAGËN;Group 0104 Septicaemia 038;Both sexes;1,072 ARAGËN;Group 0104 Septicaemia 038;Men;583 ARAGËN;Group 0104 Septicaemia 038;Women;489 ARAGËN;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Both sexes;47 ARAGËN;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Men;30 ARAGËN;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Women;17 ARAGËN;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Both sexes;931 ARAGËN;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Men;526 ARAGËN;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Women;405 ARAGËN;Group 0200 Neoplasms 140-239;Both sexes;14,845 ARAGËN;Group 0200 Neoplasms 140-239;Men;7,811 ARAGËN;Group 0200 Neoplasms 140-239;Women;7,034 ARAGËN;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Both sexes;1,353 ARAGËN;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Men;862 ARAGËN;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Women;491 ARAGËN;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Both sexes;1,022 ARAGËN;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Men;830 ARAGËN;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Women;192 ARAGËN;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Both sexes;452 ARAGËN;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Men;294 ARAGËN;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Women;158 ARAGËN;Group 0204 Malignant neoplasm of breast 174-175;Both sexes;996 ARAGËN;Group 0204 Malignant neoplasm of breast 174-175;Men;5 ARAGËN;Group 0204 Malignant neoplasm of breast 174-175;Women;991 ARAGËN;Group 0205 Malignant neoplasm of uterus 179-180, 182;Both sexes;272 ARAGËN;Group 0205 Malignant neoplasm of uterus 179-180, 182;Men;.. ARAGËN;Group 0205 Malignant neoplasm of uterus 179-180, 182;Women;272 ARAGËN;Group 0206 Malignant neoplasm of ovary 1830;Both sexes;129 ARAGËN;Group 0206 Malignant neoplasm of ovary 1830;Men;.. ARAGËN;Group 0206 Malignant neoplasm of ovary 1830;Women;129 ARAGËN;Group 0207 Malignant neoplasm of prostate 185;Both sexes;564 ARAGËN;Group 0207 Malignant neoplasm of prostate 185;Men;564 ARAGËN;Group 0207 Malignant neoplasm of prostate 185;Women;.. ARAGËN;Group 0208 Malignant neoplasm of bladder 188;Both sexes;1,312 ARAGËN;Group 0208 Malignant neoplasm of bladder 188;Men;1,099 ARAGËN;Group 0208 Malignant neoplasm of bladder 188;Women;213 ARAGËN;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Both sexes;4,882 ARAGËN;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Men;2,892 ARAGËN;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Women;1,991 ARAGËN;Group 0210 Carcinoma in situ 230-234;Both sexes;614 ARAGËN;Group 0210 Carcinoma in situ 230-234;Men;199 ARAGËN;Group 0210 Carcinoma in situ 230-234;Women;415 ARAGËN;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Both sexes;132 ARAGËN;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Men;74 ARAGËN;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Women;58 ARAGËN;Grupo 0212 Leiomyoma of uterus 218;Both sexes;707 ARAGËN;Grupo 0212 Leiomyoma of uterus 218;Men;.. ARAGËN;Grupo 0212 Leiomyoma of uterus 218;Women;707 ARAGËN;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Both sexes;2,408 ARAGËN;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Men;992 ARAGËN;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Women;1,416 ARAGËN;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Both sexes;1,551 ARAGËN;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Men;753 ARAGËN;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Women;798 ARAGËN;Group 0301 Anaemias 280-285;Both sexes;1,028 ARAGËN;Group 0301 Anaemias 280-285;Men;470 ARAGËN;Group 0301 Anaemias 280-285;Women;558 ARAGËN;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Both sexes;523 ARAGËN;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Men;283 ARAGËN;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Women;240 ARAGËN;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Both sexes;3,008 ARAGËN;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Men;1,240 ARAGËN;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Women;1,767 ARAGËN;Group 0401 Diabetes mellitus 249-250;Both sexes;939 ARAGËN;Group 0401 Diabetes mellitus 249-250;Men;553 ARAGËN;Group 0401 Diabetes mellitus 249-250;Women;386 ARAGËN;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Both sexes;2,069 ARAGËN;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Men;687 ARAGËN;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Women;1,381 ARAGËN;Group 0500 Mental disorders 290-319;Both sexes;3,434 ARAGËN;Group 0500 Mental disorders 290-319;Men;1,740 ARAGËN;Group 0500 Mental disorders 290-319;Women;1,694 ARAGËN;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Both sexes;115 ARAGËN;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Men;45 ARAGËN;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Women;70 ARAGËN;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Both sexes;219 ARAGËN;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Men;153 ARAGËN;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Women;66 ARAGËN;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Both sexes;120 ARAGËN;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Men;80 ARAGËN;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Women;40 ARAGËN;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Both sexes;845 ARAGËN;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Men;545 ARAGËN;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Women;300 ARAGËN;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Both sexes;785 ARAGËN;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Men;323 ARAGËN;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Women;462 ARAGËN;Group 0506 Other mental and behavioural disorders Rest of (290-319);Both sexes;1,349 ARAGËN;Group 0506 Other mental and behavioural disorders Rest of (290-319);Men;594 ARAGËN;Group 0506 Other mental and behavioural disorders Rest of (290-319);Women;756 ARAGËN;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Both sexes;3,796 ARAGËN;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Men;1,928 ARAGËN;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Women;1,869 ARAGËN;Group 0601 Alzheimer's disease 3310;Both sexes;76 ARAGËN;Group 0601 Alzheimer's disease 3310;Men;31 ARAGËN;Group 0601 Alzheimer's disease 3310;Women;45 ARAGËN;Group 0602 Multiple sclerosis 340;Both sexes;71 ARAGËN;Group 0602 Multiple sclerosis 340;Men;23 ARAGËN;Group 0602 Multiple sclerosis 340;Women;48 ARAGËN;Group 0603 Epilepsy 345;Both sexes;414 ARAGËN;Group 0603 Epilepsy 345;Men;219 ARAGËN;Group 0603 Epilepsy 345;Women;195 ARAGËN;Group 0604 Transient cerebral ischemia 435;Both sexes;515 ARAGËN;Group 0604 Transient cerebral ischemia 435;Men;260 ARAGËN;Group 0604 Transient cerebral ischemia 435;Women;255 ARAGËN;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Both sexes;2,720 ARAGËN;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Men;1,394 ARAGËN;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Women;1,325 ARAGËN;Grupo 0700 Diseases of the eye and adnexa 360-379;Both sexes;1,411 ARAGËN;Grupo 0700 Diseases of the eye and adnexa 360-379;Men;721 ARAGËN;Grupo 0700 Diseases of the eye and adnexa 360-379;Women;690 ARAGËN;Grupo 0701 Cataract 366;Both sexes;436 ARAGËN;Grupo 0701 Cataract 366;Men;213 ARAGËN;Grupo 0701 Cataract 366;Women;223 ARAGËN;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Both sexes;975 ARAGËN;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Men;508 ARAGËN;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Women;467 ARAGËN;Group 0800 Diseases of the ear and the mastoid 380-389;Both sexes;687 ARAGËN;Group 0800 Diseases of the ear and the mastoid 380-389;Men;346 ARAGËN;Group 0800 Diseases of the ear and the mastoid 380-389;Women;341 ARAGËN;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Both sexes;18,920 ARAGËN;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Men;10,410 ARAGËN;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Women;8,510 ARAGËN;Group 0901 Hypertensive disease 401-405;Both sexes;569 ARAGËN;Group 0901 Hypertensive disease 401-405;Men;258 ARAGËN;Group 0901 Hypertensive disease 401-405;Women;311 ARAGËN;Group 0902 Angina pectoris 4111, 413;Both sexes;857 ARAGËN;Group 0902 Angina pectoris 4111, 413;Men;551 ARAGËN;Group 0902 Angina pectoris 4111, 413;Women;306 ARAGËN;Group 0903 Acute myocardial infarction 410;Both sexes;1,345 ARAGËN;Group 0903 Acute myocardial infarction 410;Men;939 ARAGËN;Group 0903 Acute myocardial infarction 410;Women;406 ARAGËN;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Both sexes;1,296 ARAGËN;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Men;988 ARAGËN;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Women;308 ARAGËN;Group 0905 Diseases of the lungs circulation 415-417;Both sexes;640 ARAGËN;Group 0905 Diseases of the lungs circulation 415-417;Men;313 ARAGËN;Group 0905 Diseases of the lungs circulation 415-417;Women;327 ARAGËN;Group 0906 Heart conduction disorders and arrhytmias 426-427;Both sexes;2,611 ARAGËN;Group 0906 Heart conduction disorders and arrhytmias 426-427;Men;1,371 ARAGËN;Group 0906 Heart conduction disorders and arrhytmias 426-427;Women;1,240 ARAGËN;Grupo 0907 Heart failure 428;Both sexes;4,331 ARAGËN;Grupo 0907 Heart failure 428;Men;2,090 ARAGËN;Grupo 0907 Heart failure 428;Women;2,241 ARAGËN;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Both sexes;3,052 ARAGËN;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Men;1,615 ARAGËN;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Women;1,437 ARAGËN;Grupo 0909 Atherosclerosis 440;Both sexes;509 ARAGËN;Grupo 0909 Atherosclerosis 440;Men;394 ARAGËN;Grupo 0909 Atherosclerosis 440;Women;115 ARAGËN;Group 0910 Varicose veins of lower extremities 454;Both sexes;967 ARAGËN;Group 0910 Varicose veins of lower extremities 454;Men;318 ARAGËN;Group 0910 Varicose veins of lower extremities 454;Women;649 ARAGËN;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Both sexes;2,742 ARAGËN;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Men;1,573 ARAGËN;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Women;1,170 ARAGËN;Group 1000 Diseases of the respiratory system 0340, 460-519;Both sexes;15,217 ARAGËN;Group 1000 Diseases of the respiratory system 0340, 460-519;Men;8,896 ARAGËN;Group 1000 Diseases of the respiratory system 0340, 460-519;Women;6,321 ARAGËN;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Both sexes;691 ARAGËN;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Men;380 ARAGËN;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Women;311 ARAGËN;Group 1002 Pneumonia 480-486;Both sexes;3,034 ARAGËN;Group 1002 Pneumonia 480-486;Men;1,790 ARAGËN;Group 1002 Pneumonia 480-486;Women;1,244 ARAGËN;Group 1003 Acute bronchitis and bronchiolitis 466;Both sexes;1,541 ARAGËN;Group 1003 Acute bronchitis and bronchiolitis 466;Men;759 ARAGËN;Group 1003 Acute bronchitis and bronchiolitis 466;Women;782 ARAGËN;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Both sexes;809 ARAGËN;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Men;452 ARAGËN;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Women;357 ARAGËN;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Both sexes;1,707 ARAGËN;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Men;1,106 ARAGËN;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Women;601 ARAGËN;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Both sexes;2,380 ARAGËN;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Men;1,892 ARAGËN;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Women;488 ARAGËN;Group 1007 Asthma 4930-4931,4938-4939;Both sexes;477 ARAGËN;Group 1007 Asthma 4930-4931,4938-4939;Men;124 ARAGËN;Group 1007 Asthma 4930-4931,4938-4939;Women;352 ARAGËN;Group 1008 Other diseases of the respiratory system Resto of (460-519);Both sexes;4,578 ARAGËN;Group 1008 Other diseases of the respiratory system Resto of (460-519);Men;2,392 ARAGËN;Group 1008 Other diseases of the respiratory system Resto of (460-519);Women;2,186 ARAGËN;Group 1100 Diseases of the digestive system 520-579;Both sexes;17,853 ARAGËN;Group 1100 Diseases of the digestive system 520-579;Men;10,406 ARAGËN;Group 1100 Diseases of the digestive system 520-579;Women;7,446 ARAGËN;Group 1101 Disorders of the teeth and supporting structures 520-525;Both sexes;210 ARAGËN;Group 1101 Disorders of the teeth and supporting structures 520-525;Men;117 ARAGËN;Group 1101 Disorders of the teeth and supporting structures 520-525;Women;93 ARAGËN;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Both sexes;220 ARAGËN;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Men;130 ARAGËN;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Women;90 ARAGËN;Group 1103 Diseases of the esophagus 530;Both sexes;350 ARAGËN;Group 1103 Diseases of the esophagus 530;Men;231 ARAGËN;Group 1103 Diseases of the esophagus 530;Women;119 ARAGËN;Group 1104 Peptic ulcer 531-534;Both sexes;401 ARAGËN;Group 1104 Peptic ulcer 531-534;Men;275 ARAGËN;Group 1104 Peptic ulcer 531-534;Women;126 ARAGËN;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Both sexes;428 ARAGËN;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Men;208 ARAGËN;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Women;220 ARAGËN;Group 1106 Appendicitis 540-543;Both sexes;1,268 ARAGËN;Group 1106 Appendicitis 540-543;Men;723 ARAGËN;Group 1106 Appendicitis 540-543;Women;545 ARAGËN;Group 1107 Inguinal hernia 550;Both sexes;2,536 ARAGËN;Group 1107 Inguinal hernia 550;Men;2,223 ARAGËN;Group 1107 Inguinal hernia 550;Women;313 ARAGËN;Group 1108 Other abdominal hernia 551-553;Both sexes;1,547 ARAGËN;Group 1108 Other abdominal hernia 551-553;Men;742 ARAGËN;Group 1108 Other abdominal hernia 551-553;Women;805 ARAGËN;Group 1109 Crohn's disease and ulcerative colitis 555-556;Both sexes;307 ARAGËN;Group 1109 Crohn's disease and ulcerative colitis 555-556;Men;175 ARAGËN;Group 1109 Crohn's disease and ulcerative colitis 555-556;Women;132 ARAGËN;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Both sexes;958 ARAGËN;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Men;467 ARAGËN;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Women;491 ARAGËN;Group 1111 Intestinal obstruction without hernia 560;Both sexes;930 ARAGËN;Group 1111 Intestinal obstruction without hernia 560;Men;506 ARAGËN;Group 1111 Intestinal obstruction without hernia 560;Women;423 ARAGËN;Group 1112 Intestinal diverticulosis 562;Both sexes;664 ARAGËN;Group 1112 Intestinal diverticulosis 562;Men;332 ARAGËN;Group 1112 Intestinal diverticulosis 562;Women;332 ARAGËN;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Both sexes;1,153 ARAGËN;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Men;721 ARAGËN;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Women;432 ARAGËN;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Both sexes;687 ARAGËN;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Men;315 ARAGËN;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Women;372 ARAGËN;Group 1115 Alcoholic hepatitis 5710-5713;Both sexes;306 ARAGËN;Group 1115 Alcoholic hepatitis 5710-5713;Men;278 ARAGËN;Group 1115 Alcoholic hepatitis 5710-5713;Women;28 ARAGËN;Group 1116 Other diseases of the liver 570,5714-573;Both sexes;526 ARAGËN;Group 1116 Other diseases of the liver 570,5714-573;Men;331 ARAGËN;Group 1116 Other diseases of the liver 570,5714-573;Women;194 ARAGËN;Group 1117 Cholelithiasis 574;Both sexes;3,150 ARAGËN;Group 1117 Cholelithiasis 574;Men;1,384 ARAGËN;Group 1117 Cholelithiasis 574;Women;1,766 ARAGËN;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Both sexes;729 ARAGËN;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Men;402 ARAGËN;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Women;327 ARAGËN;Group 1119 Pancreatic diseases 577;Both sexes;793 ARAGËN;Group 1119 Pancreatic diseases 577;Men;461 ARAGËN;Group 1119 Pancreatic diseases 577;Women;332 ARAGËN;Group 1120 Other diseases of the digestive system Rest of (520-579);Both sexes;689 ARAGËN;Group 1120 Other diseases of the digestive system Rest of (520-579);Men;384 ARAGËN;Group 1120 Other diseases of the digestive system Rest of (520-579);Women;305 ARAGËN;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Both sexes;1,519 ARAGËN;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Men;874 ARAGËN;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Women;645 ARAGËN;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Both sexes;862 ARAGËN;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Men;544 ARAGËN;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Women;318 ARAGËN;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Both sexes;91 ARAGËN;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Men;52 ARAGËN;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Women;39 ARAGËN;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Both sexes;566 ARAGËN;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Men;278 ARAGËN;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Women;288 ARAGËN;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Both sexes;11,680 ARAGËN;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Men;5,850 ARAGËN;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Women;5,830 ARAGËN;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Both sexes;.. ARAGËN;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Men;.. ARAGËN;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Women;.. ARAGËN;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Both sexes;.. ARAGËN;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Men;.. ARAGËN;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Women;.. ARAGËN;Group 1303 Internal derangement of knee 717;Both sexes;1,716 ARAGËN;Group 1303 Internal derangement of knee 717;Men;1,123 ARAGËN;Group 1303 Internal derangement of knee 717;Women;593 ARAGËN;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Both sexes;3,814 ARAGËN;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Men;1,807 ARAGËN;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Women;2,007 ARAGËN;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Both sexes;225 ARAGËN;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Men;65 ARAGËN;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Women;160 ARAGËN;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Both sexes;440 ARAGËN;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Men;241 ARAGËN;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Women;199 ARAGËN;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Both sexes;1,065 ARAGËN;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Men;640 ARAGËN;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Women;425 ARAGËN;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Both sexes;409 ARAGËN;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Men;209 ARAGËN;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Women;200 ARAGËN;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Both sexes;2,103 ARAGËN;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Men;1,195 ARAGËN;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Women;909 ARAGËN;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Both sexes;1,908 ARAGËN;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Men;571 ARAGËN;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Women;1,337 ARAGËN;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Both sexes;10,016 ARAGËN;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Men;4,725 ARAGËN;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Women;5,291 ARAGËN;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Both sexes;663 ARAGËN;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Men;257 ARAGËN;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Women;406 ARAGËN;Group 1402 Renal failure 5836-5837, 584-586;Both sexes;821 ARAGËN;Group 1402 Renal failure 5836-5837, 584-586;Men;472 ARAGËN;Group 1402 Renal failure 5836-5837, 584-586;Women;350 ARAGËN;Group 1403 Urolithiasis 592, 594, 7880;Both sexes;1,356 ARAGËN;Group 1403 Urolithiasis 592, 594, 7880;Men;809 ARAGËN;Group 1403 Urolithiasis 592, 594, 7880;Women;547 ARAGËN;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Both sexes;2,362 ARAGËN;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Men;1,164 ARAGËN;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Women;1,198 ARAGËN;Group 1405 Prostatic hyperplasia 600;Both sexes;1,114 ARAGËN;Group 1405 Prostatic hyperplasia 600;Men;1,114 ARAGËN;Group 1405 Prostatic hyperplasia 600;Women;.. ARAGËN;Group 1406 Other diseases of the male genital organs 601-608;Both sexes;821 ARAGËN;Group 1406 Other diseases of the male genital organs 601-608;Men;821 ARAGËN;Group 1406 Other diseases of the male genital organs 601-608;Women;.. ARAGËN;Group 1407 Disorders of breast 610-612;Both sexes;538 ARAGËN;Group 1407 Disorders of breast 610-612;Men;74 ARAGËN;Group 1407 Disorders of breast 610-612;Women;464 ARAGËN;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Both sexes;224 ARAGËN;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Men;.. ARAGËN;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Women;224 ARAGËN;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Both sexes;174 ARAGËN;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Men;.. ARAGËN;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Women;174 ARAGËN;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Both sexes;1,943 ARAGËN;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Men;15 ARAGËN;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Women;1,928 ARAGËN;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Both sexes;13,372 ARAGËN;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Men;.. ARAGËN;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Women;13,372 ARAGËN;Group 1501 Legally induced abortion 635;Both sexes;3 ARAGËN;Group 1501 Legally induced abortion 635;Men;.. ARAGËN;Group 1501 Legally induced abortion 635;Women;3 ARAGËN;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Both sexes;1,089 ARAGËN;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Men;.. ARAGËN;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Women;1,089 ARAGËN;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Both sexes;6,466 ARAGËN;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Men;.. ARAGËN;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Women;6,466 ARAGËN;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Both sexes;3,103 ARAGËN;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Men;.. ARAGËN;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Women;3,103 ARAGËN;Group 1505 Single spontaneous delivery 650;Both sexes;1,361 ARAGËN;Group 1505 Single spontaneous delivery 650;Men;.. ARAGËN;Group 1505 Single spontaneous delivery 650;Women;1,361 ARAGËN;Group 1506 Other deliveries 6695-6697;Both sexes;340 ARAGËN;Group 1506 Other deliveries 6695-6697;Men;.. ARAGËN;Group 1506 Other deliveries 6695-6697;Women;340 ARAGËN;Group 1507 Complications related to the puerperium 670-676;Both sexes;113 ARAGËN;Group 1507 Complications related to the puerperium 670-676;Men;.. ARAGËN;Group 1507 Complications related to the puerperium 670-676;Women;113 ARAGËN;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Both sexes;897 ARAGËN;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Men;.. ARAGËN;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Women;897 ARAGËN;Group 1600 Some disorders originating in the perinatal period 760-779;Both sexes;2,081 ARAGËN;Group 1600 Some disorders originating in the perinatal period 760-779;Men;1,141 ARAGËN;Group 1600 Some disorders originating in the perinatal period 760-779;Women;940 ARAGËN;Group 1601 Disorders related with premature delivery and a low birth weight 765;Both sexes;381 ARAGËN;Group 1601 Disorders related with premature delivery and a low birth weight 765;Men;193 ARAGËN;Group 1601 Disorders related with premature delivery and a low birth weight 765;Women;188 ARAGËN;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Both sexes;1,700 ARAGËN;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Men;948 ARAGËN;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Women;752 ARAGËN;Grupo 1700 Congenital abnormalities 740-759;Both sexes;1,291 ARAGËN;Grupo 1700 Congenital abnormalities 740-759;Men;754 ARAGËN;Grupo 1700 Congenital abnormalities 740-759;Women;537 ARAGËN;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Both sexes;8,142 ARAGËN;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Men;4,441 ARAGËN;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Women;3,701 ARAGËN;Group 1801 Pain in throat and chest 7841, 7865;Both sexes;1,065 ARAGËN;Group 1801 Pain in throat and chest 7841, 7865;Men;598 ARAGËN;Group 1801 Pain in throat and chest 7841, 7865;Women;467 ARAGËN;Group 1802 Abdominal pain 7890;Both sexes;923 ARAGËN;Group 1802 Abdominal pain 7890;Men;385 ARAGËN;Group 1802 Abdominal pain 7890;Women;538 ARAGËN;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Both sexes;738 ARAGËN;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Men;378 ARAGËN;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Women;360 ARAGËN;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Both sexes;5,415 ARAGËN;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Men;3,079 ARAGËN;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Women;2,336 ARAGËN;Group 1900 Injuries and poisoning 800-999;Both sexes;13,748 ARAGËN;Group 1900 Injuries and poisoning 800-999;Men;7,321 ARAGËN;Group 1900 Injuries and poisoning 800-999;Women;6,427 ARAGËN;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Both sexes;651 ARAGËN;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Men;385 ARAGËN;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Women;266 ARAGËN;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Both sexes;398 ARAGËN;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Men;274 ARAGËN;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Women;124 ARAGËN;Group 1903 Radius and ulna fracture 813;Both sexes;735 ARAGËN;Group 1903 Radius and ulna fracture 813;Men;355 ARAGËN;Group 1903 Radius and ulna fracture 813;Women;380 ARAGËN;Group 1904 Femur fracture 820-821;Both sexes;2,414 ARAGËN;Group 1904 Femur fracture 820-821;Men;665 ARAGËN;Group 1904 Femur fracture 820-821;Women;1,749 ARAGËN;Group 1905 Leg fracture, including the ankle 823-824;Both sexes;860 ARAGËN;Group 1905 Leg fracture, including the ankle 823-824;Men;458 ARAGËN;Group 1905 Leg fracture, including the ankle 823-824;Women;402 ARAGËN;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Both sexes;4,919 ARAGËN;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Men;3,120 ARAGËN;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Women;1,799 ARAGËN;Group 1907 Burns 940-949;Both sexes;115 ARAGËN;Group 1907 Burns 940-949;Men;76 ARAGËN;Group 1907 Burns 940-949;Women;39 ARAGËN;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Both sexes;248 ARAGËN;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Men;119 ARAGËN;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Women;129 ARAGËN;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Both sexes;3,020 ARAGËN;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Men;1,659 ARAGËN;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Women;1,361 ARAGËN;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Both sexes;13 ARAGËN;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Men;5 ARAGËN;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Women;8 ARAGËN;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Both sexes;375 ARAGËN;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Men;205 ARAGËN;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Women;170 ARAGËN;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Both sexes;4,769 ARAGËN;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Men;2,436 ARAGËN;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Women;2,333 ARAGËN;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Both sexes;313 ARAGËN;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Men;205 ARAGËN;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Women;108 ARAGËN;Group 2102 Contraceptive management V25;Both sexes;74 ARAGËN;Group 2102 Contraceptive management V25;Men;2 ARAGËN;Group 2102 Contraceptive management V25;Women;72 ARAGËN;Group 2103 Living newborns by type of delivery V30-V39;Both sexes;.. ARAGËN;Group 2103 Living newborns by type of delivery V30-V39;Men;.. ARAGËN;Group 2103 Living newborns by type of delivery V30-V39;Women;.. ARAGËN;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Both sexes;1,192 ARAGËN;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Men;556 ARAGËN;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Women;636 ARAGËN;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Both sexes;3,190 ARAGËN;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Men;1,673 ARAGËN;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Women;1,517 Huesca;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Both sexes;21,605 Huesca;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Men;10,321 Huesca;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Women;11,284 Huesca;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Both sexes;625 Huesca;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Men;345 Huesca;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Women;280 Huesca;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Both sexes;118 Huesca;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Men;68 Huesca;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Women;50 Huesca;Group 0102 Imprecise intestinal infections 009;Both sexes;85 Huesca;Group 0102 Imprecise intestinal infections 009;Men;42 Huesca;Group 0102 Imprecise intestinal infections 009;Women;43 Huesca;Group 0103 Tuberculosis 010-018, 137;Both sexes;28 Huesca;Group 0103 Tuberculosis 010-018, 137;Men;16 Huesca;Group 0103 Tuberculosis 010-018, 137;Women;12 Huesca;Group 0104 Septicaemia 038;Both sexes;236 Huesca;Group 0104 Septicaemia 038;Men;144 Huesca;Group 0104 Septicaemia 038;Women;92 Huesca;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Both sexes;7 Huesca;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Men;6 Huesca;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Women;1 Huesca;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Both sexes;151 Huesca;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Men;69 Huesca;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Women;82 Huesca;Group 0200 Neoplasms 140-239;Both sexes;1,680 Huesca;Group 0200 Neoplasms 140-239;Men;878 Huesca;Group 0200 Neoplasms 140-239;Women;802 Huesca;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Both sexes;210 Huesca;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Men;139 Huesca;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Women;71 Huesca;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Both sexes;142 Huesca;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Men;118 Huesca;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Women;24 Huesca;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Both sexes;21 Huesca;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Men;12 Huesca;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Women;9 Huesca;Group 0204 Malignant neoplasm of breast 174-175;Both sexes;144 Huesca;Group 0204 Malignant neoplasm of breast 174-175;Men;2 Huesca;Group 0204 Malignant neoplasm of breast 174-175;Women;142 Huesca;Group 0205 Malignant neoplasm of uterus 179-180, 182;Both sexes;38 Huesca;Group 0205 Malignant neoplasm of uterus 179-180, 182;Men;.. Huesca;Group 0205 Malignant neoplasm of uterus 179-180, 182;Women;38 Huesca;Group 0206 Malignant neoplasm of ovary 1830;Both sexes;21 Huesca;Group 0206 Malignant neoplasm of ovary 1830;Men;.. Huesca;Group 0206 Malignant neoplasm of ovary 1830;Women;21 Huesca;Group 0207 Malignant neoplasm of prostate 185;Both sexes;65 Huesca;Group 0207 Malignant neoplasm of prostate 185;Men;65 Huesca;Group 0207 Malignant neoplasm of prostate 185;Women;.. Huesca;Group 0208 Malignant neoplasm of bladder 188;Both sexes;161 Huesca;Group 0208 Malignant neoplasm of bladder 188;Men;130 Huesca;Group 0208 Malignant neoplasm of bladder 188;Women;31 Huesca;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Both sexes;533 Huesca;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Men;329 Huesca;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Women;204 Huesca;Group 0210 Carcinoma in situ 230-234;Both sexes;48 Huesca;Group 0210 Carcinoma in situ 230-234;Men;8 Huesca;Group 0210 Carcinoma in situ 230-234;Women;40 Huesca;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Both sexes;15 Huesca;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Men;6 Huesca;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Women;9 Huesca;Grupo 0212 Leiomyoma of uterus 218;Both sexes;95 Huesca;Grupo 0212 Leiomyoma of uterus 218;Men;.. Huesca;Grupo 0212 Leiomyoma of uterus 218;Women;95 Huesca;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Both sexes;187 Huesca;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Men;69 Huesca;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Women;118 Huesca;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Both sexes;243 Huesca;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Men;115 Huesca;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Women;128 Huesca;Group 0301 Anaemias 280-285;Both sexes;180 Huesca;Group 0301 Anaemias 280-285;Men;88 Huesca;Group 0301 Anaemias 280-285;Women;92 Huesca;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Both sexes;63 Huesca;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Men;27 Huesca;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Women;36 Huesca;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Both sexes;369 Huesca;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Men;160 Huesca;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Women;209 Huesca;Group 0401 Diabetes mellitus 249-250;Both sexes;145 Huesca;Group 0401 Diabetes mellitus 249-250;Men;77 Huesca;Group 0401 Diabetes mellitus 249-250;Women;68 Huesca;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Both sexes;224 Huesca;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Men;83 Huesca;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Women;141 Huesca;Group 0500 Mental disorders 290-319;Both sexes;723 Huesca;Group 0500 Mental disorders 290-319;Men;394 Huesca;Group 0500 Mental disorders 290-319;Women;329 Huesca;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Both sexes;23 Huesca;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Men;12 Huesca;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Women;11 Huesca;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Both sexes;36 Huesca;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Men;30 Huesca;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Women;6 Huesca;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Both sexes;25 Huesca;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Men;19 Huesca;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Women;6 Huesca;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Both sexes;178 Huesca;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Men;120 Huesca;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Women;58 Huesca;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Both sexes;203 Huesca;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Men;88 Huesca;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Women;115 Huesca;Group 0506 Other mental and behavioural disorders Rest of (290-319);Both sexes;258 Huesca;Group 0506 Other mental and behavioural disorders Rest of (290-319);Men;125 Huesca;Group 0506 Other mental and behavioural disorders Rest of (290-319);Women;133 Huesca;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Both sexes;458 Huesca;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Men;219 Huesca;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Women;239 Huesca;Group 0601 Alzheimer's disease 3310;Both sexes;17 Huesca;Group 0601 Alzheimer's disease 3310;Men;12 Huesca;Group 0601 Alzheimer's disease 3310;Women;5 Huesca;Group 0602 Multiple sclerosis 340;Both sexes;3 Huesca;Group 0602 Multiple sclerosis 340;Men;.. Huesca;Group 0602 Multiple sclerosis 340;Women;3 Huesca;Group 0603 Epilepsy 345;Both sexes;75 Huesca;Group 0603 Epilepsy 345;Men;39 Huesca;Group 0603 Epilepsy 345;Women;36 Huesca;Group 0604 Transient cerebral ischemia 435;Both sexes;121 Huesca;Group 0604 Transient cerebral ischemia 435;Men;59 Huesca;Group 0604 Transient cerebral ischemia 435;Women;62 Huesca;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Both sexes;242 Huesca;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Men;109 Huesca;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Women;133 Huesca;Grupo 0700 Diseases of the eye and adnexa 360-379;Both sexes;284 Huesca;Grupo 0700 Diseases of the eye and adnexa 360-379;Men;140 Huesca;Grupo 0700 Diseases of the eye and adnexa 360-379;Women;144 Huesca;Grupo 0701 Cataract 366;Both sexes;203 Huesca;Grupo 0701 Cataract 366;Men;105 Huesca;Grupo 0701 Cataract 366;Women;98 Huesca;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Both sexes;81 Huesca;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Men;35 Huesca;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Women;46 Huesca;Group 0800 Diseases of the ear and the mastoid 380-389;Both sexes;95 Huesca;Group 0800 Diseases of the ear and the mastoid 380-389;Men;48 Huesca;Group 0800 Diseases of the ear and the mastoid 380-389;Women;47 Huesca;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Both sexes;2,912 Huesca;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Men;1,551 Huesca;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Women;1,361 Huesca;Group 0901 Hypertensive disease 401-405;Both sexes;131 Huesca;Group 0901 Hypertensive disease 401-405;Men;62 Huesca;Group 0901 Hypertensive disease 401-405;Women;69 Huesca;Group 0902 Angina pectoris 4111, 413;Both sexes;140 Huesca;Group 0902 Angina pectoris 4111, 413;Men;91 Huesca;Group 0902 Angina pectoris 4111, 413;Women;49 Huesca;Group 0903 Acute myocardial infarction 410;Both sexes;169 Huesca;Group 0903 Acute myocardial infarction 410;Men;115 Huesca;Group 0903 Acute myocardial infarction 410;Women;54 Huesca;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Both sexes;80 Huesca;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Men;60 Huesca;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Women;20 Huesca;Group 0905 Diseases of the lungs circulation 415-417;Both sexes;96 Huesca;Group 0905 Diseases of the lungs circulation 415-417;Men;59 Huesca;Group 0905 Diseases of the lungs circulation 415-417;Women;37 Huesca;Group 0906 Heart conduction disorders and arrhytmias 426-427;Both sexes;442 Huesca;Group 0906 Heart conduction disorders and arrhytmias 426-427;Men;226 Huesca;Group 0906 Heart conduction disorders and arrhytmias 426-427;Women;216 Huesca;Grupo 0907 Heart failure 428;Both sexes;775 Huesca;Grupo 0907 Heart failure 428;Men;393 Huesca;Grupo 0907 Heart failure 428;Women;382 Huesca;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Both sexes;523 Huesca;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Men;285 Huesca;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Women;238 Huesca;Grupo 0909 Atherosclerosis 440;Both sexes;66 Huesca;Grupo 0909 Atherosclerosis 440;Men;39 Huesca;Grupo 0909 Atherosclerosis 440;Women;27 Huesca;Group 0910 Varicose veins of lower extremities 454;Both sexes;172 Huesca;Group 0910 Varicose veins of lower extremities 454;Men;47 Huesca;Group 0910 Varicose veins of lower extremities 454;Women;125 Huesca;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Both sexes;318 Huesca;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Men;174 Huesca;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Women;144 Huesca;Group 1000 Diseases of the respiratory system 0340, 460-519;Both sexes;2,455 Huesca;Group 1000 Diseases of the respiratory system 0340, 460-519;Men;1,408 Huesca;Group 1000 Diseases of the respiratory system 0340, 460-519;Women;1,047 Huesca;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Both sexes;146 Huesca;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Men;81 Huesca;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Women;65 Huesca;Group 1002 Pneumonia 480-486;Both sexes;445 Huesca;Group 1002 Pneumonia 480-486;Men;273 Huesca;Group 1002 Pneumonia 480-486;Women;172 Huesca;Group 1003 Acute bronchitis and bronchiolitis 466;Both sexes;337 Huesca;Group 1003 Acute bronchitis and bronchiolitis 466;Men;152 Huesca;Group 1003 Acute bronchitis and bronchiolitis 466;Women;185 Huesca;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Both sexes;41 Huesca;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Men;12 Huesca;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Women;29 Huesca;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Both sexes;225 Huesca;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Men;142 Huesca;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Women;83 Huesca;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Both sexes;397 Huesca;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Men;329 Huesca;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Women;68 Huesca;Group 1007 Asthma 4930-4931,4938-4939;Both sexes;71 Huesca;Group 1007 Asthma 4930-4931,4938-4939;Men;20 Huesca;Group 1007 Asthma 4930-4931,4938-4939;Women;51 Huesca;Group 1008 Other diseases of the respiratory system Resto of (460-519);Both sexes;793 Huesca;Group 1008 Other diseases of the respiratory system Resto of (460-519);Men;399 Huesca;Group 1008 Other diseases of the respiratory system Resto of (460-519);Women;394 Huesca;Group 1100 Diseases of the digestive system 520-579;Both sexes;2,814 Huesca;Group 1100 Diseases of the digestive system 520-579;Men;1,655 Huesca;Group 1100 Diseases of the digestive system 520-579;Women;1,159 Huesca;Group 1101 Disorders of the teeth and supporting structures 520-525;Both sexes;27 Huesca;Group 1101 Disorders of the teeth and supporting structures 520-525;Men;15 Huesca;Group 1101 Disorders of the teeth and supporting structures 520-525;Women;12 Huesca;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Both sexes;26 Huesca;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Men;13 Huesca;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Women;13 Huesca;Group 1103 Diseases of the esophagus 530;Both sexes;54 Huesca;Group 1103 Diseases of the esophagus 530;Men;35 Huesca;Group 1103 Diseases of the esophagus 530;Women;19 Huesca;Group 1104 Peptic ulcer 531-534;Both sexes;63 Huesca;Group 1104 Peptic ulcer 531-534;Men;39 Huesca;Group 1104 Peptic ulcer 531-534;Women;24 Huesca;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Both sexes;85 Huesca;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Men;51 Huesca;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Women;34 Huesca;Group 1106 Appendicitis 540-543;Both sexes;193 Huesca;Group 1106 Appendicitis 540-543;Men;110 Huesca;Group 1106 Appendicitis 540-543;Women;83 Huesca;Group 1107 Inguinal hernia 550;Both sexes;354 Huesca;Group 1107 Inguinal hernia 550;Men;311 Huesca;Group 1107 Inguinal hernia 550;Women;43 Huesca;Group 1108 Other abdominal hernia 551-553;Both sexes;209 Huesca;Group 1108 Other abdominal hernia 551-553;Men;98 Huesca;Group 1108 Other abdominal hernia 551-553;Women;111 Huesca;Group 1109 Crohn's disease and ulcerative colitis 555-556;Both sexes;52 Huesca;Group 1109 Crohn's disease and ulcerative colitis 555-556;Men;28 Huesca;Group 1109 Crohn's disease and ulcerative colitis 555-556;Women;24 Huesca;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Both sexes;152 Huesca;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Men;79 Huesca;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Women;73 Huesca;Group 1111 Intestinal obstruction without hernia 560;Both sexes;147 Huesca;Group 1111 Intestinal obstruction without hernia 560;Men;80 Huesca;Group 1111 Intestinal obstruction without hernia 560;Women;67 Huesca;Group 1112 Intestinal diverticulosis 562;Both sexes;85 Huesca;Group 1112 Intestinal diverticulosis 562;Men;34 Huesca;Group 1112 Intestinal diverticulosis 562;Women;51 Huesca;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Both sexes;163 Huesca;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Men;104 Huesca;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Women;59 Huesca;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Both sexes;115 Huesca;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Men;56 Huesca;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Women;59 Huesca;Group 1115 Alcoholic hepatitis 5710-5713;Both sexes;63 Huesca;Group 1115 Alcoholic hepatitis 5710-5713;Men;56 Huesca;Group 1115 Alcoholic hepatitis 5710-5713;Women;7 Huesca;Group 1116 Other diseases of the liver 570,5714-573;Both sexes;89 Huesca;Group 1116 Other diseases of the liver 570,5714-573;Men;61 Huesca;Group 1116 Other diseases of the liver 570,5714-573;Women;28 Huesca;Group 1117 Cholelithiasis 574;Both sexes;580 Huesca;Group 1117 Cholelithiasis 574;Men;268 Huesca;Group 1117 Cholelithiasis 574;Women;312 Huesca;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Both sexes;141 Huesca;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Men;83 Huesca;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Women;58 Huesca;Group 1119 Pancreatic diseases 577;Both sexes;115 Huesca;Group 1119 Pancreatic diseases 577;Men;78 Huesca;Group 1119 Pancreatic diseases 577;Women;37 Huesca;Group 1120 Other diseases of the digestive system Rest of (520-579);Both sexes;101 Huesca;Group 1120 Other diseases of the digestive system Rest of (520-579);Men;56 Huesca;Group 1120 Other diseases of the digestive system Rest of (520-579);Women;45 Huesca;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Both sexes;265 Huesca;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Men;142 Huesca;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Women;123 Huesca;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Both sexes;163 Huesca;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Men;97 Huesca;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Women;66 Huesca;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Both sexes;11 Huesca;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Men;5 Huesca;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Women;6 Huesca;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Both sexes;91 Huesca;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Men;40 Huesca;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Women;51 Huesca;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Both sexes;1,185 Huesca;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Men;547 Huesca;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Women;638 Huesca;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Both sexes;.. Huesca;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Men;.. Huesca;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Women;.. Huesca;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Both sexes;.. Huesca;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Men;.. Huesca;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Women;.. Huesca;Group 1303 Internal derangement of knee 717;Both sexes;232 Huesca;Group 1303 Internal derangement of knee 717;Men;143 Huesca;Group 1303 Internal derangement of knee 717;Women;89 Huesca;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Both sexes;395 Huesca;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Men;160 Huesca;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Women;235 Huesca;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Both sexes;18 Huesca;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Men;4 Huesca;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Women;14 Huesca;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Both sexes;9 Huesca;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Men;5 Huesca;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Women;4 Huesca;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Both sexes;70 Huesca;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Men;34 Huesca;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Women;36 Huesca;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Both sexes;69 Huesca;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Men;34 Huesca;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Women;35 Huesca;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Both sexes;212 Huesca;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Men;122 Huesca;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Women;90 Huesca;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Both sexes;180 Huesca;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Men;45 Huesca;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Women;135 Huesca;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Both sexes;1,331 Huesca;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Men;631 Huesca;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Women;700 Huesca;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Both sexes;88 Huesca;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Men;25 Huesca;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Women;63 Huesca;Group 1402 Renal failure 5836-5837, 584-586;Both sexes;146 Huesca;Group 1402 Renal failure 5836-5837, 584-586;Men;82 Huesca;Group 1402 Renal failure 5836-5837, 584-586;Women;64 Huesca;Group 1403 Urolithiasis 592, 594, 7880;Both sexes;184 Huesca;Group 1403 Urolithiasis 592, 594, 7880;Men;104 Huesca;Group 1403 Urolithiasis 592, 594, 7880;Women;80 Huesca;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Both sexes;407 Huesca;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Men;223 Huesca;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Women;184 Huesca;Group 1405 Prostatic hyperplasia 600;Both sexes;127 Huesca;Group 1405 Prostatic hyperplasia 600;Men;127 Huesca;Group 1405 Prostatic hyperplasia 600;Women;.. Huesca;Group 1406 Other diseases of the male genital organs 601-608;Both sexes;65 Huesca;Group 1406 Other diseases of the male genital organs 601-608;Men;65 Huesca;Group 1406 Other diseases of the male genital organs 601-608;Women;.. Huesca;Group 1407 Disorders of breast 610-612;Both sexes;41 Huesca;Group 1407 Disorders of breast 610-612;Men;3 Huesca;Group 1407 Disorders of breast 610-612;Women;38 Huesca;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Both sexes;30 Huesca;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Men;.. Huesca;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Women;30 Huesca;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Both sexes;24 Huesca;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Men;.. Huesca;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Women;24 Huesca;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Both sexes;219 Huesca;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Men;2 Huesca;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Women;217 Huesca;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Both sexes;1,998 Huesca;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Men;.. Huesca;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Women;1,998 Huesca;Group 1501 Legally induced abortion 635;Both sexes;.. Huesca;Group 1501 Legally induced abortion 635;Men;.. Huesca;Group 1501 Legally induced abortion 635;Women;.. Huesca;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Both sexes;181 Huesca;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Men;.. Huesca;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Women;181 Huesca;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Both sexes;1,183 Huesca;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Men;.. Huesca;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Women;1,183 Huesca;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Both sexes;303 Huesca;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Men;.. Huesca;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Women;303 Huesca;Group 1505 Single spontaneous delivery 650;Both sexes;83 Huesca;Group 1505 Single spontaneous delivery 650;Men;.. Huesca;Group 1505 Single spontaneous delivery 650;Women;83 Huesca;Group 1506 Other deliveries 6695-6697;Both sexes;50 Huesca;Group 1506 Other deliveries 6695-6697;Men;.. Huesca;Group 1506 Other deliveries 6695-6697;Women;50 Huesca;Group 1507 Complications related to the puerperium 670-676;Both sexes;24 Huesca;Group 1507 Complications related to the puerperium 670-676;Men;.. Huesca;Group 1507 Complications related to the puerperium 670-676;Women;24 Huesca;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Both sexes;174 Huesca;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Men;.. Huesca;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Women;174 Huesca;Group 1600 Some disorders originating in the perinatal period 760-779;Both sexes;308 Huesca;Group 1600 Some disorders originating in the perinatal period 760-779;Men;150 Huesca;Group 1600 Some disorders originating in the perinatal period 760-779;Women;158 Huesca;Group 1601 Disorders related with premature delivery and a low birth weight 765;Both sexes;72 Huesca;Group 1601 Disorders related with premature delivery and a low birth weight 765;Men;32 Huesca;Group 1601 Disorders related with premature delivery and a low birth weight 765;Women;40 Huesca;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Both sexes;236 Huesca;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Men;118 Huesca;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Women;118 Huesca;Grupo 1700 Congenital abnormalities 740-759;Both sexes;57 Huesca;Grupo 1700 Congenital abnormalities 740-759;Men;31 Huesca;Grupo 1700 Congenital abnormalities 740-759;Women;26 Huesca;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Both sexes;1,213 Huesca;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Men;663 Huesca;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Women;550 Huesca;Group 1801 Pain in throat and chest 7841, 7865;Both sexes;165 Huesca;Group 1801 Pain in throat and chest 7841, 7865;Men;90 Huesca;Group 1801 Pain in throat and chest 7841, 7865;Women;75 Huesca;Group 1802 Abdominal pain 7890;Both sexes;223 Huesca;Group 1802 Abdominal pain 7890;Men;107 Huesca;Group 1802 Abdominal pain 7890;Women;116 Huesca;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Both sexes;1 Huesca;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Men;1 Huesca;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Women;.. Huesca;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Both sexes;824 Huesca;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Men;465 Huesca;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Women;359 Huesca;Group 1900 Injuries and poisoning 800-999;Both sexes;1,835 Huesca;Group 1900 Injuries and poisoning 800-999;Men;889 Huesca;Group 1900 Injuries and poisoning 800-999;Women;946 Huesca;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Both sexes;144 Huesca;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Men;89 Huesca;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Women;55 Huesca;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Both sexes;23 Huesca;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Men;18 Huesca;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Women;5 Huesca;Group 1903 Radius and ulna fracture 813;Both sexes;98 Huesca;Group 1903 Radius and ulna fracture 813;Men;41 Huesca;Group 1903 Radius and ulna fracture 813;Women;57 Huesca;Group 1904 Femur fracture 820-821;Both sexes;399 Huesca;Group 1904 Femur fracture 820-821;Men;107 Huesca;Group 1904 Femur fracture 820-821;Women;292 Huesca;Group 1905 Leg fracture, including the ankle 823-824;Both sexes;152 Huesca;Group 1905 Leg fracture, including the ankle 823-824;Men;86 Huesca;Group 1905 Leg fracture, including the ankle 823-824;Women;66 Huesca;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Both sexes;539 Huesca;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Men;302 Huesca;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Women;237 Huesca;Group 1907 Burns 940-949;Both sexes;.. Huesca;Group 1907 Burns 940-949;Men;.. Huesca;Group 1907 Burns 940-949;Women;.. Huesca;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Both sexes;60 Huesca;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Men;33 Huesca;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Women;27 Huesca;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Both sexes;370 Huesca;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Men;186 Huesca;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Women;184 Huesca;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Both sexes;1 Huesca;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Men;.. Huesca;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Women;1 Huesca;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Both sexes;49 Huesca;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Men;27 Huesca;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Women;22 Huesca;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Both sexes;755 Huesca;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Men;355 Huesca;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Women;400 Huesca;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Both sexes;20 Huesca;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Men;16 Huesca;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Women;4 Huesca;Group 2102 Contraceptive management V25;Both sexes;41 Huesca;Group 2102 Contraceptive management V25;Men;.. Huesca;Group 2102 Contraceptive management V25;Women;41 Huesca;Group 2103 Living newborns by type of delivery V30-V39;Both sexes;.. Huesca;Group 2103 Living newborns by type of delivery V30-V39;Men;.. Huesca;Group 2103 Living newborns by type of delivery V30-V39;Women;.. Huesca;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Both sexes;113 Huesca;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Men;68 Huesca;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Women;45 Huesca;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Both sexes;581 Huesca;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Men;271 Huesca;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Women;310 Teruel;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Both sexes;13,950 Teruel;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Men;6,964 Teruel;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Women;6,986 Teruel;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Both sexes;262 Teruel;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Men;149 Teruel;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Women;113 Teruel;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Both sexes;94 Teruel;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Men;48 Teruel;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Women;46 Teruel;Group 0102 Imprecise intestinal infections 009;Both sexes;19 Teruel;Group 0102 Imprecise intestinal infections 009;Men;9 Teruel;Group 0102 Imprecise intestinal infections 009;Women;10 Teruel;Group 0103 Tuberculosis 010-018, 137;Both sexes;11 Teruel;Group 0103 Tuberculosis 010-018, 137;Men;6 Teruel;Group 0103 Tuberculosis 010-018, 137;Women;5 Teruel;Group 0104 Septicaemia 038;Both sexes;49 Teruel;Group 0104 Septicaemia 038;Men;25 Teruel;Group 0104 Septicaemia 038;Women;24 Teruel;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Both sexes;3 Teruel;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Men;3 Teruel;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Women;.. Teruel;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Both sexes;86 Teruel;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Men;58 Teruel;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Women;28 Teruel;Group 0200 Neoplasms 140-239;Both sexes;1,036 Teruel;Group 0200 Neoplasms 140-239;Men;563 Teruel;Group 0200 Neoplasms 140-239;Women;473 Teruel;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Both sexes;159 Teruel;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Men;93 Teruel;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Women;66 Teruel;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Both sexes;85 Teruel;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Men;76 Teruel;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Women;9 Teruel;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Both sexes;8 Teruel;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Men;4 Teruel;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Women;4 Teruel;Group 0204 Malignant neoplasm of breast 174-175;Both sexes;71 Teruel;Group 0204 Malignant neoplasm of breast 174-175;Men;.. Teruel;Group 0204 Malignant neoplasm of breast 174-175;Women;71 Teruel;Group 0205 Malignant neoplasm of uterus 179-180, 182;Both sexes;23 Teruel;Group 0205 Malignant neoplasm of uterus 179-180, 182;Men;.. Teruel;Group 0205 Malignant neoplasm of uterus 179-180, 182;Women;23 Teruel;Group 0206 Malignant neoplasm of ovary 1830;Both sexes;8 Teruel;Group 0206 Malignant neoplasm of ovary 1830;Men;.. Teruel;Group 0206 Malignant neoplasm of ovary 1830;Women;8 Teruel;Group 0207 Malignant neoplasm of prostate 185;Both sexes;45 Teruel;Group 0207 Malignant neoplasm of prostate 185;Men;45 Teruel;Group 0207 Malignant neoplasm of prostate 185;Women;.. Teruel;Group 0208 Malignant neoplasm of bladder 188;Both sexes;111 Teruel;Group 0208 Malignant neoplasm of bladder 188;Men;84 Teruel;Group 0208 Malignant neoplasm of bladder 188;Women;27 Teruel;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Both sexes;317 Teruel;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Men;193 Teruel;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Women;125 Teruel;Group 0210 Carcinoma in situ 230-234;Both sexes;33 Teruel;Group 0210 Carcinoma in situ 230-234;Men;5 Teruel;Group 0210 Carcinoma in situ 230-234;Women;28 Teruel;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Both sexes;20 Teruel;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Men;16 Teruel;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Women;4 Teruel;Grupo 0212 Leiomyoma of uterus 218;Both sexes;25 Teruel;Grupo 0212 Leiomyoma of uterus 218;Men;.. Teruel;Grupo 0212 Leiomyoma of uterus 218;Women;25 Teruel;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Both sexes;129 Teruel;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Men;47 Teruel;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Women;82 Teruel;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Both sexes;158 Teruel;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Men;79 Teruel;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Women;79 Teruel;Group 0301 Anaemias 280-285;Both sexes;96 Teruel;Group 0301 Anaemias 280-285;Men;45 Teruel;Group 0301 Anaemias 280-285;Women;51 Teruel;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Both sexes;62 Teruel;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Men;34 Teruel;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Women;28 Teruel;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Both sexes;167 Teruel;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Men;97 Teruel;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Women;69 Teruel;Group 0401 Diabetes mellitus 249-250;Both sexes;79 Teruel;Group 0401 Diabetes mellitus 249-250;Men;53 Teruel;Group 0401 Diabetes mellitus 249-250;Women;26 Teruel;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Both sexes;88 Teruel;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Men;44 Teruel;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Women;43 Teruel;Group 0500 Mental disorders 290-319;Both sexes;299 Teruel;Group 0500 Mental disorders 290-319;Men;179 Teruel;Group 0500 Mental disorders 290-319;Women;120 Teruel;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Both sexes;6 Teruel;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Men;2 Teruel;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Women;4 Teruel;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Both sexes;35 Teruel;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Men;22 Teruel;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Women;13 Teruel;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Both sexes;6 Teruel;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Men;4 Teruel;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Women;2 Teruel;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Both sexes;109 Teruel;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Men;72 Teruel;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Women;37 Teruel;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Both sexes;53 Teruel;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Men;31 Teruel;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Women;22 Teruel;Group 0506 Other mental and behavioural disorders Rest of (290-319);Both sexes;90 Teruel;Group 0506 Other mental and behavioural disorders Rest of (290-319);Men;47 Teruel;Group 0506 Other mental and behavioural disorders Rest of (290-319);Women;42 Teruel;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Both sexes;228 Teruel;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Men;110 Teruel;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Women;119 Teruel;Group 0601 Alzheimer's disease 3310;Both sexes;6 Teruel;Group 0601 Alzheimer's disease 3310;Men;.. Teruel;Group 0601 Alzheimer's disease 3310;Women;6 Teruel;Group 0602 Multiple sclerosis 340;Both sexes;3 Teruel;Group 0602 Multiple sclerosis 340;Men;2 Teruel;Group 0602 Multiple sclerosis 340;Women;1 Teruel;Group 0603 Epilepsy 345;Both sexes;46 Teruel;Group 0603 Epilepsy 345;Men;25 Teruel;Group 0603 Epilepsy 345;Women;21 Teruel;Group 0604 Transient cerebral ischemia 435;Both sexes;65 Teruel;Group 0604 Transient cerebral ischemia 435;Men;30 Teruel;Group 0604 Transient cerebral ischemia 435;Women;35 Teruel;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Both sexes;108 Teruel;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Men;52 Teruel;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Women;55 Teruel;Grupo 0700 Diseases of the eye and adnexa 360-379;Both sexes;59 Teruel;Grupo 0700 Diseases of the eye and adnexa 360-379;Men;31 Teruel;Grupo 0700 Diseases of the eye and adnexa 360-379;Women;28 Teruel;Grupo 0701 Cataract 366;Both sexes;29 Teruel;Grupo 0701 Cataract 366;Men;13 Teruel;Grupo 0701 Cataract 366;Women;16 Teruel;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Both sexes;30 Teruel;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Men;18 Teruel;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Women;12 Teruel;Group 0800 Diseases of the ear and the mastoid 380-389;Both sexes;61 Teruel;Group 0800 Diseases of the ear and the mastoid 380-389;Men;24 Teruel;Group 0800 Diseases of the ear and the mastoid 380-389;Women;37 Teruel;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Both sexes;1,655 Teruel;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Men;869 Teruel;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Women;786 Teruel;Group 0901 Hypertensive disease 401-405;Both sexes;31 Teruel;Group 0901 Hypertensive disease 401-405;Men;12 Teruel;Group 0901 Hypertensive disease 401-405;Women;19 Teruel;Group 0902 Angina pectoris 4111, 413;Both sexes;132 Teruel;Group 0902 Angina pectoris 4111, 413;Men;94 Teruel;Group 0902 Angina pectoris 4111, 413;Women;38 Teruel;Group 0903 Acute myocardial infarction 410;Both sexes;97 Teruel;Group 0903 Acute myocardial infarction 410;Men;66 Teruel;Group 0903 Acute myocardial infarction 410;Women;31 Teruel;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Both sexes;46 Teruel;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Men;34 Teruel;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Women;12 Teruel;Group 0905 Diseases of the lungs circulation 415-417;Both sexes;75 Teruel;Group 0905 Diseases of the lungs circulation 415-417;Men;40 Teruel;Group 0905 Diseases of the lungs circulation 415-417;Women;35 Teruel;Group 0906 Heart conduction disorders and arrhytmias 426-427;Both sexes;219 Teruel;Group 0906 Heart conduction disorders and arrhytmias 426-427;Men;116 Teruel;Group 0906 Heart conduction disorders and arrhytmias 426-427;Women;103 Teruel;Grupo 0907 Heart failure 428;Both sexes;490 Teruel;Grupo 0907 Heart failure 428;Men;244 Teruel;Grupo 0907 Heart failure 428;Women;246 Teruel;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Both sexes;294 Teruel;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Men;136 Teruel;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Women;158 Teruel;Grupo 0909 Atherosclerosis 440;Both sexes;16 Teruel;Grupo 0909 Atherosclerosis 440;Men;13 Teruel;Grupo 0909 Atherosclerosis 440;Women;3 Teruel;Group 0910 Varicose veins of lower extremities 454;Both sexes;53 Teruel;Group 0910 Varicose veins of lower extremities 454;Men;15 Teruel;Group 0910 Varicose veins of lower extremities 454;Women;38 Teruel;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Both sexes;201 Teruel;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Men;99 Teruel;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Women;103 Teruel;Group 1000 Diseases of the respiratory system 0340, 460-519;Both sexes;1,858 Teruel;Group 1000 Diseases of the respiratory system 0340, 460-519;Men;1,111 Teruel;Group 1000 Diseases of the respiratory system 0340, 460-519;Women;747 Teruel;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Both sexes;88 Teruel;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Men;51 Teruel;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Women;37 Teruel;Group 1002 Pneumonia 480-486;Both sexes;403 Teruel;Group 1002 Pneumonia 480-486;Men;230 Teruel;Group 1002 Pneumonia 480-486;Women;173 Teruel;Group 1003 Acute bronchitis and bronchiolitis 466;Both sexes;214 Teruel;Group 1003 Acute bronchitis and bronchiolitis 466;Men;99 Teruel;Group 1003 Acute bronchitis and bronchiolitis 466;Women;115 Teruel;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Both sexes;60 Teruel;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Men;29 Teruel;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Women;31 Teruel;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Both sexes;121 Teruel;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Men;87 Teruel;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Women;34 Teruel;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Both sexes;349 Teruel;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Men;293 Teruel;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Women;56 Teruel;Group 1007 Asthma 4930-4931,4938-4939;Both sexes;85 Teruel;Group 1007 Asthma 4930-4931,4938-4939;Men;21 Teruel;Group 1007 Asthma 4930-4931,4938-4939;Women;63 Teruel;Group 1008 Other diseases of the respiratory system Resto of (460-519);Both sexes;538 Teruel;Group 1008 Other diseases of the respiratory system Resto of (460-519);Men;300 Teruel;Group 1008 Other diseases of the respiratory system Resto of (460-519);Women;238 Teruel;Group 1100 Diseases of the digestive system 520-579;Both sexes;2,075 Teruel;Group 1100 Diseases of the digestive system 520-579;Men;1,273 Teruel;Group 1100 Diseases of the digestive system 520-579;Women;801 Teruel;Group 1101 Disorders of the teeth and supporting structures 520-525;Both sexes;8 Teruel;Group 1101 Disorders of the teeth and supporting structures 520-525;Men;3 Teruel;Group 1101 Disorders of the teeth and supporting structures 520-525;Women;5 Teruel;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Both sexes;12 Teruel;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Men;9 Teruel;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Women;3 Teruel;Group 1103 Diseases of the esophagus 530;Both sexes;28 Teruel;Group 1103 Diseases of the esophagus 530;Men;21 Teruel;Group 1103 Diseases of the esophagus 530;Women;7 Teruel;Group 1104 Peptic ulcer 531-534;Both sexes;48 Teruel;Group 1104 Peptic ulcer 531-534;Men;36 Teruel;Group 1104 Peptic ulcer 531-534;Women;12 Teruel;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Both sexes;47 Teruel;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Men;25 Teruel;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Women;22 Teruel;Group 1106 Appendicitis 540-543;Both sexes;145 Teruel;Group 1106 Appendicitis 540-543;Men;85 Teruel;Group 1106 Appendicitis 540-543;Women;60 Teruel;Group 1107 Inguinal hernia 550;Both sexes;351 Teruel;Group 1107 Inguinal hernia 550;Men;315 Teruel;Group 1107 Inguinal hernia 550;Women;36 Teruel;Group 1108 Other abdominal hernia 551-553;Both sexes;179 Teruel;Group 1108 Other abdominal hernia 551-553;Men;89 Teruel;Group 1108 Other abdominal hernia 551-553;Women;90 Teruel;Group 1109 Crohn's disease and ulcerative colitis 555-556;Both sexes;25 Teruel;Group 1109 Crohn's disease and ulcerative colitis 555-556;Men;18 Teruel;Group 1109 Crohn's disease and ulcerative colitis 555-556;Women;7 Teruel;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Both sexes;138 Teruel;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Men;70 Teruel;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Women;68 Teruel;Group 1111 Intestinal obstruction without hernia 560;Both sexes;132 Teruel;Group 1111 Intestinal obstruction without hernia 560;Men;80 Teruel;Group 1111 Intestinal obstruction without hernia 560;Women;51 Teruel;Group 1112 Intestinal diverticulosis 562;Both sexes;81 Teruel;Group 1112 Intestinal diverticulosis 562;Men;43 Teruel;Group 1112 Intestinal diverticulosis 562;Women;38 Teruel;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Both sexes;109 Teruel;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Men;73 Teruel;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Women;36 Teruel;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Both sexes;77 Teruel;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Men;37 Teruel;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Women;40 Teruel;Group 1115 Alcoholic hepatitis 5710-5713;Both sexes;18 Teruel;Group 1115 Alcoholic hepatitis 5710-5713;Men;16 Teruel;Group 1115 Alcoholic hepatitis 5710-5713;Women;2 Teruel;Group 1116 Other diseases of the liver 570,5714-573;Both sexes;53 Teruel;Group 1116 Other diseases of the liver 570,5714-573;Men;30 Teruel;Group 1116 Other diseases of the liver 570,5714-573;Women;22 Teruel;Group 1117 Cholelithiasis 574;Both sexes;347 Teruel;Group 1117 Cholelithiasis 574;Men;150 Teruel;Group 1117 Cholelithiasis 574;Women;197 Teruel;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Both sexes;102 Teruel;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Men;64 Teruel;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Women;38 Teruel;Group 1119 Pancreatic diseases 577;Both sexes;100 Teruel;Group 1119 Pancreatic diseases 577;Men;63 Teruel;Group 1119 Pancreatic diseases 577;Women;37 Teruel;Group 1120 Other diseases of the digestive system Rest of (520-579);Both sexes;74 Teruel;Group 1120 Other diseases of the digestive system Rest of (520-579);Men;45 Teruel;Group 1120 Other diseases of the digestive system Rest of (520-579);Women;29 Teruel;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Both sexes;168 Teruel;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Men;113 Teruel;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Women;55 Teruel;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Both sexes;129 Teruel;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Men;85 Teruel;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Women;44 Teruel;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Both sexes;3 Teruel;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Men;3 Teruel;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Women;.. Teruel;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Both sexes;36 Teruel;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Men;25 Teruel;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Women;11 Teruel;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Both sexes;992 Teruel;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Men;487 Teruel;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Women;505 Teruel;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Both sexes;.. Teruel;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Men;.. Teruel;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Women;.. Teruel;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Both sexes;.. Teruel;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Men;.. Teruel;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Women;.. Teruel;Group 1303 Internal derangement of knee 717;Both sexes;115 Teruel;Group 1303 Internal derangement of knee 717;Men;77 Teruel;Group 1303 Internal derangement of knee 717;Women;38 Teruel;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Both sexes;461 Teruel;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Men;219 Teruel;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Women;242 Teruel;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Both sexes;30 Teruel;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Men;11 Teruel;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Women;19 Teruel;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Both sexes;9 Teruel;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Men;7 Teruel;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Women;2 Teruel;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Both sexes;27 Teruel;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Men;17 Teruel;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Women;10 Teruel;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Both sexes;19 Teruel;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Men;9 Teruel;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Women;10 Teruel;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Both sexes;218 Teruel;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Men;109 Teruel;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Women;110 Teruel;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Both sexes;113 Teruel;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Men;39 Teruel;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Women;74 Teruel;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Both sexes;757 Teruel;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Men;416 Teruel;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Women;341 Teruel;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Both sexes;60 Teruel;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Men;25 Teruel;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Women;35 Teruel;Group 1402 Renal failure 5836-5837, 584-586;Both sexes;101 Teruel;Group 1402 Renal failure 5836-5837, 584-586;Men;66 Teruel;Group 1402 Renal failure 5836-5837, 584-586;Women;36 Teruel;Group 1403 Urolithiasis 592, 594, 7880;Both sexes;92 Teruel;Group 1403 Urolithiasis 592, 594, 7880;Men;63 Teruel;Group 1403 Urolithiasis 592, 594, 7880;Women;29 Teruel;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Both sexes;147 Teruel;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Men;72 Teruel;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Women;75 Teruel;Group 1405 Prostatic hyperplasia 600;Both sexes;129 Teruel;Group 1405 Prostatic hyperplasia 600;Men;129 Teruel;Group 1405 Prostatic hyperplasia 600;Women;.. Teruel;Group 1406 Other diseases of the male genital organs 601-608;Both sexes;60 Teruel;Group 1406 Other diseases of the male genital organs 601-608;Men;60 Teruel;Group 1406 Other diseases of the male genital organs 601-608;Women;.. Teruel;Group 1407 Disorders of breast 610-612;Both sexes;14 Teruel;Group 1407 Disorders of breast 610-612;Men;2 Teruel;Group 1407 Disorders of breast 610-612;Women;12 Teruel;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Both sexes;19 Teruel;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Men;.. Teruel;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Women;19 Teruel;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Both sexes;7 Teruel;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Men;.. Teruel;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Women;7 Teruel;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Both sexes;128 Teruel;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Men;.. Teruel;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Women;128 Teruel;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Both sexes;1,264 Teruel;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Men;.. Teruel;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Women;1,264 Teruel;Group 1501 Legally induced abortion 635;Both sexes;.. Teruel;Group 1501 Legally induced abortion 635;Men;.. Teruel;Group 1501 Legally induced abortion 635;Women;.. Teruel;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Both sexes;108 Teruel;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Men;.. Teruel;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Women;108 Teruel;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Both sexes;628 Teruel;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Men;.. Teruel;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Women;628 Teruel;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Both sexes;282 Teruel;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Men;.. Teruel;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Women;282 Teruel;Group 1505 Single spontaneous delivery 650;Both sexes;134 Teruel;Group 1505 Single spontaneous delivery 650;Men;.. Teruel;Group 1505 Single spontaneous delivery 650;Women;134 Teruel;Group 1506 Other deliveries 6695-6697;Both sexes;16 Teruel;Group 1506 Other deliveries 6695-6697;Men;.. Teruel;Group 1506 Other deliveries 6695-6697;Women;16 Teruel;Group 1507 Complications related to the puerperium 670-676;Both sexes;7 Teruel;Group 1507 Complications related to the puerperium 670-676;Men;.. Teruel;Group 1507 Complications related to the puerperium 670-676;Women;7 Teruel;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Both sexes;89 Teruel;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Men;.. Teruel;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Women;89 Teruel;Group 1600 Some disorders originating in the perinatal period 760-779;Both sexes;510 Teruel;Group 1600 Some disorders originating in the perinatal period 760-779;Men;271 Teruel;Group 1600 Some disorders originating in the perinatal period 760-779;Women;239 Teruel;Group 1601 Disorders related with premature delivery and a low birth weight 765;Both sexes;15 Teruel;Group 1601 Disorders related with premature delivery and a low birth weight 765;Men;10 Teruel;Group 1601 Disorders related with premature delivery and a low birth weight 765;Women;5 Teruel;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Both sexes;495 Teruel;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Men;261 Teruel;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Women;234 Teruel;Grupo 1700 Congenital abnormalities 740-759;Both sexes;33 Teruel;Grupo 1700 Congenital abnormalities 740-759;Men;16 Teruel;Grupo 1700 Congenital abnormalities 740-759;Women;17 Teruel;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Both sexes;832 Teruel;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Men;456 Teruel;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Women;376 Teruel;Group 1801 Pain in throat and chest 7841, 7865;Both sexes;73 Teruel;Group 1801 Pain in throat and chest 7841, 7865;Men;43 Teruel;Group 1801 Pain in throat and chest 7841, 7865;Women;30 Teruel;Group 1802 Abdominal pain 7890;Both sexes;110 Teruel;Group 1802 Abdominal pain 7890;Men;49 Teruel;Group 1802 Abdominal pain 7890;Women;61 Teruel;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Both sexes;119 Teruel;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Men;66 Teruel;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Women;53 Teruel;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Both sexes;529 Teruel;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Men;297 Teruel;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Women;232 Teruel;Group 1900 Injuries and poisoning 800-999;Both sexes;1,220 Teruel;Group 1900 Injuries and poisoning 800-999;Men;549 Teruel;Group 1900 Injuries and poisoning 800-999;Women;671 Teruel;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Both sexes;61 Teruel;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Men;37 Teruel;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Women;24 Teruel;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Both sexes;10 Teruel;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Men;6 Teruel;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Women;4 Teruel;Group 1903 Radius and ulna fracture 813;Both sexes;71 Teruel;Group 1903 Radius and ulna fracture 813;Men;30 Teruel;Group 1903 Radius and ulna fracture 813;Women;41 Teruel;Group 1904 Femur fracture 820-821;Both sexes;389 Teruel;Group 1904 Femur fracture 820-821;Men;124 Teruel;Group 1904 Femur fracture 820-821;Women;265 Teruel;Group 1905 Leg fracture, including the ankle 823-824;Both sexes;77 Teruel;Group 1905 Leg fracture, including the ankle 823-824;Men;42 Teruel;Group 1905 Leg fracture, including the ankle 823-824;Women;35 Teruel;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Both sexes;307 Teruel;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Men;165 Teruel;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Women;142 Teruel;Group 1907 Burns 940-949;Both sexes;1 Teruel;Group 1907 Burns 940-949;Men;1 Teruel;Group 1907 Burns 940-949;Women;.. Teruel;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Both sexes;34 Teruel;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Men;16 Teruel;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Women;18 Teruel;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Both sexes;198 Teruel;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Men;98 Teruel;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Women;100 Teruel;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Both sexes;.. Teruel;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Men;.. Teruel;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Women;.. Teruel;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Both sexes;72 Teruel;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Men;30 Teruel;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Women;42 Teruel;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Both sexes;315 Teruel;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Men;171 Teruel;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Women;144 Teruel;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Both sexes;18 Teruel;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Men;16 Teruel;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Women;2 Teruel;Group 2102 Contraceptive management V25;Both sexes;8 Teruel;Group 2102 Contraceptive management V25;Men;.. Teruel;Group 2102 Contraceptive management V25;Women;8 Teruel;Group 2103 Living newborns by type of delivery V30-V39;Both sexes;.. Teruel;Group 2103 Living newborns by type of delivery V30-V39;Men;.. Teruel;Group 2103 Living newborns by type of delivery V30-V39;Women;.. Teruel;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Both sexes;48 Teruel;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Men;20 Teruel;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Women;28 Teruel;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Both sexes;241 Teruel;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Men;135 Teruel;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Women;106 Zaragoza;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Both sexes;114,810 Zaragoza;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Men;56,183 Zaragoza;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Women;58,627 Zaragoza;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Both sexes;2,137 Zaragoza;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Men;1,180 Zaragoza;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Women;957 Zaragoza;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Both sexes;376 Zaragoza;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Men;205 Zaragoza;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Women;171 Zaragoza;Group 0102 Imprecise intestinal infections 009;Both sexes;103 Zaragoza;Group 0102 Imprecise intestinal infections 009;Men;56 Zaragoza;Group 0102 Imprecise intestinal infections 009;Women;47 Zaragoza;Group 0103 Tuberculosis 010-018, 137;Both sexes;140 Zaragoza;Group 0103 Tuberculosis 010-018, 137;Men;85 Zaragoza;Group 0103 Tuberculosis 010-018, 137;Women;55 Zaragoza;Group 0104 Septicaemia 038;Both sexes;787 Zaragoza;Group 0104 Septicaemia 038;Men;414 Zaragoza;Group 0104 Septicaemia 038;Women;373 Zaragoza;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Both sexes;37 Zaragoza;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Men;21 Zaragoza;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Women;16 Zaragoza;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Both sexes;694 Zaragoza;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Men;399 Zaragoza;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Women;295 Zaragoza;Group 0200 Neoplasms 140-239;Both sexes;12,129 Zaragoza;Group 0200 Neoplasms 140-239;Men;6,370 Zaragoza;Group 0200 Neoplasms 140-239;Women;5,759 Zaragoza;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Both sexes;984 Zaragoza;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Men;630 Zaragoza;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Women;354 Zaragoza;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Both sexes;795 Zaragoza;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Men;636 Zaragoza;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Women;159 Zaragoza;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Both sexes;423 Zaragoza;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Men;278 Zaragoza;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Women;145 Zaragoza;Group 0204 Malignant neoplasm of breast 174-175;Both sexes;781 Zaragoza;Group 0204 Malignant neoplasm of breast 174-175;Men;3 Zaragoza;Group 0204 Malignant neoplasm of breast 174-175;Women;778 Zaragoza;Group 0205 Malignant neoplasm of uterus 179-180, 182;Both sexes;211 Zaragoza;Group 0205 Malignant neoplasm of uterus 179-180, 182;Men;.. Zaragoza;Group 0205 Malignant neoplasm of uterus 179-180, 182;Women;211 Zaragoza;Group 0206 Malignant neoplasm of ovary 1830;Both sexes;100 Zaragoza;Group 0206 Malignant neoplasm of ovary 1830;Men;.. Zaragoza;Group 0206 Malignant neoplasm of ovary 1830;Women;100 Zaragoza;Group 0207 Malignant neoplasm of prostate 185;Both sexes;454 Zaragoza;Group 0207 Malignant neoplasm of prostate 185;Men;454 Zaragoza;Group 0207 Malignant neoplasm of prostate 185;Women;.. Zaragoza;Group 0208 Malignant neoplasm of bladder 188;Both sexes;1,040 Zaragoza;Group 0208 Malignant neoplasm of bladder 188;Men;885 Zaragoza;Group 0208 Malignant neoplasm of bladder 188;Women;155 Zaragoza;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Both sexes;4,032 Zaragoza;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Men;2,370 Zaragoza;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Women;1,662 Zaragoza;Group 0210 Carcinoma in situ 230-234;Both sexes;533 Zaragoza;Group 0210 Carcinoma in situ 230-234;Men;186 Zaragoza;Group 0210 Carcinoma in situ 230-234;Women;347 Zaragoza;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Both sexes;97 Zaragoza;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Men;52 Zaragoza;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Women;45 Zaragoza;Grupo 0212 Leiomyoma of uterus 218;Both sexes;587 Zaragoza;Grupo 0212 Leiomyoma of uterus 218;Men;.. Zaragoza;Grupo 0212 Leiomyoma of uterus 218;Women;587 Zaragoza;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Both sexes;2,092 Zaragoza;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Men;876 Zaragoza;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Women;1,216 Zaragoza;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Both sexes;1,150 Zaragoza;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Men;559 Zaragoza;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Women;591 Zaragoza;Group 0301 Anaemias 280-285;Both sexes;752 Zaragoza;Group 0301 Anaemias 280-285;Men;337 Zaragoza;Group 0301 Anaemias 280-285;Women;415 Zaragoza;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Both sexes;398 Zaragoza;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Men;222 Zaragoza;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Women;176 Zaragoza;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Both sexes;2,472 Zaragoza;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Men;983 Zaragoza;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Women;1,489 Zaragoza;Group 0401 Diabetes mellitus 249-250;Both sexes;715 Zaragoza;Group 0401 Diabetes mellitus 249-250;Men;423 Zaragoza;Group 0401 Diabetes mellitus 249-250;Women;292 Zaragoza;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Both sexes;1,757 Zaragoza;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Men;560 Zaragoza;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Women;1,197 Zaragoza;Group 0500 Mental disorders 290-319;Both sexes;2,412 Zaragoza;Group 0500 Mental disorders 290-319;Men;1,168 Zaragoza;Group 0500 Mental disorders 290-319;Women;1,244 Zaragoza;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Both sexes;86 Zaragoza;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Men;31 Zaragoza;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Women;55 Zaragoza;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Both sexes;148 Zaragoza;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Men;101 Zaragoza;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Women;47 Zaragoza;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Both sexes;89 Zaragoza;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Men;57 Zaragoza;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Women;32 Zaragoza;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Both sexes;558 Zaragoza;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Men;353 Zaragoza;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Women;205 Zaragoza;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Both sexes;529 Zaragoza;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Men;204 Zaragoza;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Women;325 Zaragoza;Group 0506 Other mental and behavioural disorders Rest of (290-319);Both sexes;1,001 Zaragoza;Group 0506 Other mental and behavioural disorders Rest of (290-319);Men;421 Zaragoza;Group 0506 Other mental and behavioural disorders Rest of (290-319);Women;580 Zaragoza;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Both sexes;3,110 Zaragoza;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Men;1,599 Zaragoza;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Women;1,511 Zaragoza;Group 0601 Alzheimer's disease 3310;Both sexes;53 Zaragoza;Group 0601 Alzheimer's disease 3310;Men;19 Zaragoza;Group 0601 Alzheimer's disease 3310;Women;34 Zaragoza;Group 0602 Multiple sclerosis 340;Both sexes;65 Zaragoza;Group 0602 Multiple sclerosis 340;Men;21 Zaragoza;Group 0602 Multiple sclerosis 340;Women;44 Zaragoza;Group 0603 Epilepsy 345;Both sexes;293 Zaragoza;Group 0603 Epilepsy 345;Men;155 Zaragoza;Group 0603 Epilepsy 345;Women;138 Zaragoza;Group 0604 Transient cerebral ischemia 435;Both sexes;329 Zaragoza;Group 0604 Transient cerebral ischemia 435;Men;171 Zaragoza;Group 0604 Transient cerebral ischemia 435;Women;158 Zaragoza;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Both sexes;2,370 Zaragoza;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Men;1,233 Zaragoza;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Women;1,137 Zaragoza;Grupo 0700 Diseases of the eye and adnexa 360-379;Both sexes;1,068 Zaragoza;Grupo 0700 Diseases of the eye and adnexa 360-379;Men;550 Zaragoza;Grupo 0700 Diseases of the eye and adnexa 360-379;Women;518 Zaragoza;Grupo 0701 Cataract 366;Both sexes;204 Zaragoza;Grupo 0701 Cataract 366;Men;95 Zaragoza;Grupo 0701 Cataract 366;Women;109 Zaragoza;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Both sexes;864 Zaragoza;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Men;455 Zaragoza;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Women;409 Zaragoza;Group 0800 Diseases of the ear and the mastoid 380-389;Both sexes;531 Zaragoza;Group 0800 Diseases of the ear and the mastoid 380-389;Men;274 Zaragoza;Group 0800 Diseases of the ear and the mastoid 380-389;Women;257 Zaragoza;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Both sexes;14,353 Zaragoza;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Men;7,990 Zaragoza;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Women;6,363 Zaragoza;Group 0901 Hypertensive disease 401-405;Both sexes;407 Zaragoza;Group 0901 Hypertensive disease 401-405;Men;184 Zaragoza;Group 0901 Hypertensive disease 401-405;Women;223 Zaragoza;Group 0902 Angina pectoris 4111, 413;Both sexes;585 Zaragoza;Group 0902 Angina pectoris 4111, 413;Men;366 Zaragoza;Group 0902 Angina pectoris 4111, 413;Women;219 Zaragoza;Group 0903 Acute myocardial infarction 410;Both sexes;1,079 Zaragoza;Group 0903 Acute myocardial infarction 410;Men;758 Zaragoza;Group 0903 Acute myocardial infarction 410;Women;321 Zaragoza;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Both sexes;1,170 Zaragoza;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Men;894 Zaragoza;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Women;276 Zaragoza;Group 0905 Diseases of the lungs circulation 415-417;Both sexes;469 Zaragoza;Group 0905 Diseases of the lungs circulation 415-417;Men;214 Zaragoza;Group 0905 Diseases of the lungs circulation 415-417;Women;255 Zaragoza;Group 0906 Heart conduction disorders and arrhytmias 426-427;Both sexes;1,950 Zaragoza;Group 0906 Heart conduction disorders and arrhytmias 426-427;Men;1,029 Zaragoza;Group 0906 Heart conduction disorders and arrhytmias 426-427;Women;921 Zaragoza;Grupo 0907 Heart failure 428;Both sexes;3,066 Zaragoza;Grupo 0907 Heart failure 428;Men;1,453 Zaragoza;Grupo 0907 Heart failure 428;Women;1,613 Zaragoza;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Both sexes;2,235 Zaragoza;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Men;1,194 Zaragoza;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Women;1,041 Zaragoza;Grupo 0909 Atherosclerosis 440;Both sexes;427 Zaragoza;Grupo 0909 Atherosclerosis 440;Men;342 Zaragoza;Grupo 0909 Atherosclerosis 440;Women;85 Zaragoza;Group 0910 Varicose veins of lower extremities 454;Both sexes;742 Zaragoza;Group 0910 Varicose veins of lower extremities 454;Men;256 Zaragoza;Group 0910 Varicose veins of lower extremities 454;Women;486 Zaragoza;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Both sexes;2,223 Zaragoza;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Men;1,300 Zaragoza;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Women;923 Zaragoza;Group 1000 Diseases of the respiratory system 0340, 460-519;Both sexes;10,904 Zaragoza;Group 1000 Diseases of the respiratory system 0340, 460-519;Men;6,377 Zaragoza;Group 1000 Diseases of the respiratory system 0340, 460-519;Women;4,527 Zaragoza;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Both sexes;457 Zaragoza;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Men;248 Zaragoza;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Women;209 Zaragoza;Group 1002 Pneumonia 480-486;Both sexes;2,186 Zaragoza;Group 1002 Pneumonia 480-486;Men;1,287 Zaragoza;Group 1002 Pneumonia 480-486;Women;899 Zaragoza;Group 1003 Acute bronchitis and bronchiolitis 466;Both sexes;990 Zaragoza;Group 1003 Acute bronchitis and bronchiolitis 466;Men;508 Zaragoza;Group 1003 Acute bronchitis and bronchiolitis 466;Women;482 Zaragoza;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Both sexes;708 Zaragoza;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Men;411 Zaragoza;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Women;297 Zaragoza;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Both sexes;1,361 Zaragoza;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Men;877 Zaragoza;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Women;484 Zaragoza;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Both sexes;1,634 Zaragoza;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Men;1,270 Zaragoza;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Women;364 Zaragoza;Group 1007 Asthma 4930-4931,4938-4939;Both sexes;321 Zaragoza;Group 1007 Asthma 4930-4931,4938-4939;Men;83 Zaragoza;Group 1007 Asthma 4930-4931,4938-4939;Women;238 Zaragoza;Group 1008 Other diseases of the respiratory system Resto of (460-519);Both sexes;3,247 Zaragoza;Group 1008 Other diseases of the respiratory system Resto of (460-519);Men;1,693 Zaragoza;Group 1008 Other diseases of the respiratory system Resto of (460-519);Women;1,554 Zaragoza;Group 1100 Diseases of the digestive system 520-579;Both sexes;12,964 Zaragoza;Group 1100 Diseases of the digestive system 520-579;Men;7,478 Zaragoza;Group 1100 Diseases of the digestive system 520-579;Women;5,486 Zaragoza;Group 1101 Disorders of the teeth and supporting structures 520-525;Both sexes;175 Zaragoza;Group 1101 Disorders of the teeth and supporting structures 520-525;Men;99 Zaragoza;Group 1101 Disorders of the teeth and supporting structures 520-525;Women;76 Zaragoza;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Both sexes;182 Zaragoza;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Men;108 Zaragoza;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Women;74 Zaragoza;Group 1103 Diseases of the esophagus 530;Both sexes;268 Zaragoza;Group 1103 Diseases of the esophagus 530;Men;175 Zaragoza;Group 1103 Diseases of the esophagus 530;Women;93 Zaragoza;Group 1104 Peptic ulcer 531-534;Both sexes;290 Zaragoza;Group 1104 Peptic ulcer 531-534;Men;200 Zaragoza;Group 1104 Peptic ulcer 531-534;Women;90 Zaragoza;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Both sexes;296 Zaragoza;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Men;132 Zaragoza;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Women;164 Zaragoza;Group 1106 Appendicitis 540-543;Both sexes;930 Zaragoza;Group 1106 Appendicitis 540-543;Men;528 Zaragoza;Group 1106 Appendicitis 540-543;Women;402 Zaragoza;Group 1107 Inguinal hernia 550;Both sexes;1,831 Zaragoza;Group 1107 Inguinal hernia 550;Men;1,597 Zaragoza;Group 1107 Inguinal hernia 550;Women;234 Zaragoza;Group 1108 Other abdominal hernia 551-553;Both sexes;1,159 Zaragoza;Group 1108 Other abdominal hernia 551-553;Men;555 Zaragoza;Group 1108 Other abdominal hernia 551-553;Women;604 Zaragoza;Group 1109 Crohn's disease and ulcerative colitis 555-556;Both sexes;230 Zaragoza;Group 1109 Crohn's disease and ulcerative colitis 555-556;Men;129 Zaragoza;Group 1109 Crohn's disease and ulcerative colitis 555-556;Women;101 Zaragoza;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Both sexes;668 Zaragoza;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Men;318 Zaragoza;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Women;350 Zaragoza;Group 1111 Intestinal obstruction without hernia 560;Both sexes;651 Zaragoza;Group 1111 Intestinal obstruction without hernia 560;Men;346 Zaragoza;Group 1111 Intestinal obstruction without hernia 560;Women;305 Zaragoza;Group 1112 Intestinal diverticulosis 562;Both sexes;498 Zaragoza;Group 1112 Intestinal diverticulosis 562;Men;255 Zaragoza;Group 1112 Intestinal diverticulosis 562;Women;243 Zaragoza;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Both sexes;881 Zaragoza;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Men;544 Zaragoza;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Women;337 Zaragoza;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Both sexes;495 Zaragoza;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Men;222 Zaragoza;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Women;273 Zaragoza;Group 1115 Alcoholic hepatitis 5710-5713;Both sexes;225 Zaragoza;Group 1115 Alcoholic hepatitis 5710-5713;Men;206 Zaragoza;Group 1115 Alcoholic hepatitis 5710-5713;Women;19 Zaragoza;Group 1116 Other diseases of the liver 570,5714-573;Both sexes;384 Zaragoza;Group 1116 Other diseases of the liver 570,5714-573;Men;240 Zaragoza;Group 1116 Other diseases of the liver 570,5714-573;Women;144 Zaragoza;Group 1117 Cholelithiasis 574;Both sexes;2,223 Zaragoza;Group 1117 Cholelithiasis 574;Men;966 Zaragoza;Group 1117 Cholelithiasis 574;Women;1,257 Zaragoza;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Both sexes;486 Zaragoza;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Men;255 Zaragoza;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Women;231 Zaragoza;Group 1119 Pancreatic diseases 577;Both sexes;578 Zaragoza;Group 1119 Pancreatic diseases 577;Men;320 Zaragoza;Group 1119 Pancreatic diseases 577;Women;258 Zaragoza;Group 1120 Other diseases of the digestive system Rest of (520-579);Both sexes;514 Zaragoza;Group 1120 Other diseases of the digestive system Rest of (520-579);Men;283 Zaragoza;Group 1120 Other diseases of the digestive system Rest of (520-579);Women;231 Zaragoza;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Both sexes;1,086 Zaragoza;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Men;619 Zaragoza;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Women;467 Zaragoza;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Both sexes;570 Zaragoza;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Men;362 Zaragoza;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Women;208 Zaragoza;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Both sexes;77 Zaragoza;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Men;44 Zaragoza;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Women;33 Zaragoza;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Both sexes;439 Zaragoza;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Men;213 Zaragoza;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Women;226 Zaragoza;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Both sexes;9,503 Zaragoza;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Men;4,816 Zaragoza;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Women;4,687 Zaragoza;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Both sexes;.. Zaragoza;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Men;.. Zaragoza;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Women;.. Zaragoza;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Both sexes;.. Zaragoza;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Men;.. Zaragoza;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Women;.. Zaragoza;Group 1303 Internal derangement of knee 717;Both sexes;1,369 Zaragoza;Group 1303 Internal derangement of knee 717;Men;903 Zaragoza;Group 1303 Internal derangement of knee 717;Women;466 Zaragoza;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Both sexes;2,958 Zaragoza;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Men;1,428 Zaragoza;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Women;1,530 Zaragoza;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Both sexes;177 Zaragoza;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Men;50 Zaragoza;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Women;127 Zaragoza;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Both sexes;422 Zaragoza;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Men;229 Zaragoza;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Women;193 Zaragoza;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Both sexes;968 Zaragoza;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Men;589 Zaragoza;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Women;379 Zaragoza;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Both sexes;321 Zaragoza;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Men;166 Zaragoza;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Women;155 Zaragoza;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Both sexes;1,673 Zaragoza;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Men;964 Zaragoza;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Women;709 Zaragoza;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Both sexes;1,615 Zaragoza;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Men;487 Zaragoza;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Women;1,128 Zaragoza;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Both sexes;7,928 Zaragoza;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Men;3,678 Zaragoza;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Women;4,250 Zaragoza;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Both sexes;515 Zaragoza;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Men;207 Zaragoza;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Women;308 Zaragoza;Group 1402 Renal failure 5836-5837, 584-586;Both sexes;574 Zaragoza;Group 1402 Renal failure 5836-5837, 584-586;Men;324 Zaragoza;Group 1402 Renal failure 5836-5837, 584-586;Women;250 Zaragoza;Group 1403 Urolithiasis 592, 594, 7880;Both sexes;1,080 Zaragoza;Group 1403 Urolithiasis 592, 594, 7880;Men;642 Zaragoza;Group 1403 Urolithiasis 592, 594, 7880;Women;438 Zaragoza;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Both sexes;1,808 Zaragoza;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Men;869 Zaragoza;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Women;939 Zaragoza;Group 1405 Prostatic hyperplasia 600;Both sexes;858 Zaragoza;Group 1405 Prostatic hyperplasia 600;Men;858 Zaragoza;Group 1405 Prostatic hyperplasia 600;Women;.. Zaragoza;Group 1406 Other diseases of the male genital organs 601-608;Both sexes;696 Zaragoza;Group 1406 Other diseases of the male genital organs 601-608;Men;696 Zaragoza;Group 1406 Other diseases of the male genital organs 601-608;Women;.. Zaragoza;Group 1407 Disorders of breast 610-612;Both sexes;483 Zaragoza;Group 1407 Disorders of breast 610-612;Men;69 Zaragoza;Group 1407 Disorders of breast 610-612;Women;414 Zaragoza;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Both sexes;175 Zaragoza;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Men;.. Zaragoza;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Women;175 Zaragoza;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Both sexes;143 Zaragoza;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Men;.. Zaragoza;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Women;143 Zaragoza;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Both sexes;1,596 Zaragoza;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Men;13 Zaragoza;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Women;1,583 Zaragoza;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Both sexes;10,110 Zaragoza;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Men;.. Zaragoza;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Women;10,110 Zaragoza;Group 1501 Legally induced abortion 635;Both sexes;3 Zaragoza;Group 1501 Legally induced abortion 635;Men;.. Zaragoza;Group 1501 Legally induced abortion 635;Women;3 Zaragoza;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Both sexes;800 Zaragoza;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Men;.. Zaragoza;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Women;800 Zaragoza;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Both sexes;4,655 Zaragoza;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Men;.. Zaragoza;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Women;4,655 Zaragoza;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Both sexes;2,518 Zaragoza;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Men;.. Zaragoza;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Women;2,518 Zaragoza;Group 1505 Single spontaneous delivery 650;Both sexes;1,144 Zaragoza;Group 1505 Single spontaneous delivery 650;Men;.. Zaragoza;Group 1505 Single spontaneous delivery 650;Women;1,144 Zaragoza;Group 1506 Other deliveries 6695-6697;Both sexes;274 Zaragoza;Group 1506 Other deliveries 6695-6697;Men;.. Zaragoza;Group 1506 Other deliveries 6695-6697;Women;274 Zaragoza;Group 1507 Complications related to the puerperium 670-676;Both sexes;82 Zaragoza;Group 1507 Complications related to the puerperium 670-676;Men;.. Zaragoza;Group 1507 Complications related to the puerperium 670-676;Women;82 Zaragoza;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Both sexes;634 Zaragoza;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Men;.. Zaragoza;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Women;634 Zaragoza;Group 1600 Some disorders originating in the perinatal period 760-779;Both sexes;1,263 Zaragoza;Group 1600 Some disorders originating in the perinatal period 760-779;Men;720 Zaragoza;Group 1600 Some disorders originating in the perinatal period 760-779;Women;543 Zaragoza;Group 1601 Disorders related with premature delivery and a low birth weight 765;Both sexes;294 Zaragoza;Group 1601 Disorders related with premature delivery and a low birth weight 765;Men;151 Zaragoza;Group 1601 Disorders related with premature delivery and a low birth weight 765;Women;143 Zaragoza;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Both sexes;969 Zaragoza;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Men;569 Zaragoza;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Women;400 Zaragoza;Grupo 1700 Congenital abnormalities 740-759;Both sexes;1,201 Zaragoza;Grupo 1700 Congenital abnormalities 740-759;Men;707 Zaragoza;Grupo 1700 Congenital abnormalities 740-759;Women;494 Zaragoza;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Both sexes;6,097 Zaragoza;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Men;3,322 Zaragoza;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Women;2,775 Zaragoza;Group 1801 Pain in throat and chest 7841, 7865;Both sexes;827 Zaragoza;Group 1801 Pain in throat and chest 7841, 7865;Men;465 Zaragoza;Group 1801 Pain in throat and chest 7841, 7865;Women;362 Zaragoza;Group 1802 Abdominal pain 7890;Both sexes;590 Zaragoza;Group 1802 Abdominal pain 7890;Men;229 Zaragoza;Group 1802 Abdominal pain 7890;Women;361 Zaragoza;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Both sexes;618 Zaragoza;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Men;311 Zaragoza;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Women;307 Zaragoza;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Both sexes;4,062 Zaragoza;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Men;2,317 Zaragoza;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Women;1,745 Zaragoza;Group 1900 Injuries and poisoning 800-999;Both sexes;10,693 Zaragoza;Group 1900 Injuries and poisoning 800-999;Men;5,883 Zaragoza;Group 1900 Injuries and poisoning 800-999;Women;4,810 Zaragoza;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Both sexes;446 Zaragoza;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Men;259 Zaragoza;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Women;187 Zaragoza;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Both sexes;365 Zaragoza;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Men;250 Zaragoza;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Women;115 Zaragoza;Group 1903 Radius and ulna fracture 813;Both sexes;566 Zaragoza;Group 1903 Radius and ulna fracture 813;Men;284 Zaragoza;Group 1903 Radius and ulna fracture 813;Women;282 Zaragoza;Group 1904 Femur fracture 820-821;Both sexes;1,626 Zaragoza;Group 1904 Femur fracture 820-821;Men;434 Zaragoza;Group 1904 Femur fracture 820-821;Women;1,192 Zaragoza;Group 1905 Leg fracture, including the ankle 823-824;Both sexes;631 Zaragoza;Group 1905 Leg fracture, including the ankle 823-824;Men;330 Zaragoza;Group 1905 Leg fracture, including the ankle 823-824;Women;301 Zaragoza;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Both sexes;4,073 Zaragoza;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Men;2,653 Zaragoza;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Women;1,420 Zaragoza;Group 1907 Burns 940-949;Both sexes;114 Zaragoza;Group 1907 Burns 940-949;Men;75 Zaragoza;Group 1907 Burns 940-949;Women;39 Zaragoza;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Both sexes;154 Zaragoza;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Men;70 Zaragoza;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Women;84 Zaragoza;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Both sexes;2,452 Zaragoza;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Men;1,375 Zaragoza;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Women;1,077 Zaragoza;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Both sexes;12 Zaragoza;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Men;5 Zaragoza;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Women;7 Zaragoza;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Both sexes;254 Zaragoza;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Men;148 Zaragoza;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Women;106 Zaragoza;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Both sexes;3,699 Zaragoza;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Men;1,910 Zaragoza;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Women;1,789 Zaragoza;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Both sexes;275 Zaragoza;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Men;173 Zaragoza;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Women;102 Zaragoza;Group 2102 Contraceptive management V25;Both sexes;25 Zaragoza;Group 2102 Contraceptive management V25;Men;2 Zaragoza;Group 2102 Contraceptive management V25;Women;23 Zaragoza;Group 2103 Living newborns by type of delivery V30-V39;Both sexes;.. Zaragoza;Group 2103 Living newborns by type of delivery V30-V39;Men;.. Zaragoza;Group 2103 Living newborns by type of delivery V30-V39;Women;.. Zaragoza;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Both sexes;1,031 Zaragoza;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Men;468 Zaragoza;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Women;563 Zaragoza;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Both sexes;2,368 Zaragoza;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Men;1,267 Zaragoza;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Women;1,101 ASTURIAS, PRINCIPADO DE;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Both sexes;118,031 ASTURIAS, PRINCIPADO DE;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Men;58,016 ASTURIAS, PRINCIPADO DE;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Women;60,015 ASTURIAS, PRINCIPADO DE;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Both sexes;2,184 ASTURIAS, PRINCIPADO DE;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Men;1,169 ASTURIAS, PRINCIPADO DE;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Women;1,015 ASTURIAS, PRINCIPADO DE;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Both sexes;215 ASTURIAS, PRINCIPADO DE;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Men;107 ASTURIAS, PRINCIPADO DE;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Women;108 ASTURIAS, PRINCIPADO DE;Group 0102 Imprecise intestinal infections 009;Both sexes;113 ASTURIAS, PRINCIPADO DE;Group 0102 Imprecise intestinal infections 009;Men;60 ASTURIAS, PRINCIPADO DE;Group 0102 Imprecise intestinal infections 009;Women;53 ASTURIAS, PRINCIPADO DE;Group 0103 Tuberculosis 010-018, 137;Both sexes;100 ASTURIAS, PRINCIPADO DE;Group 0103 Tuberculosis 010-018, 137;Men;65 ASTURIAS, PRINCIPADO DE;Group 0103 Tuberculosis 010-018, 137;Women;35 ASTURIAS, PRINCIPADO DE;Group 0104 Septicaemia 038;Both sexes;926 ASTURIAS, PRINCIPADO DE;Group 0104 Septicaemia 038;Men;475 ASTURIAS, PRINCIPADO DE;Group 0104 Septicaemia 038;Women;451 ASTURIAS, PRINCIPADO DE;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Both sexes;73 ASTURIAS, PRINCIPADO DE;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Men;48 ASTURIAS, PRINCIPADO DE;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Women;25 ASTURIAS, PRINCIPADO DE;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Both sexes;757 ASTURIAS, PRINCIPADO DE;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Men;414 ASTURIAS, PRINCIPADO DE;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Women;343 ASTURIAS, PRINCIPADO DE;Group 0200 Neoplasms 140-239;Both sexes;11,182 ASTURIAS, PRINCIPADO DE;Group 0200 Neoplasms 140-239;Men;6,188 ASTURIAS, PRINCIPADO DE;Group 0200 Neoplasms 140-239;Women;4,994 ASTURIAS, PRINCIPADO DE;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Both sexes;1,309 ASTURIAS, PRINCIPADO DE;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Men;821 ASTURIAS, PRINCIPADO DE;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Women;488 ASTURIAS, PRINCIPADO DE;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Both sexes;1,082 ASTURIAS, PRINCIPADO DE;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Men;857 ASTURIAS, PRINCIPADO DE;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Women;225 ASTURIAS, PRINCIPADO DE;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Both sexes;85 ASTURIAS, PRINCIPADO DE;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Men;42 ASTURIAS, PRINCIPADO DE;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Women;43 ASTURIAS, PRINCIPADO DE;Group 0204 Malignant neoplasm of breast 174-175;Both sexes;743 ASTURIAS, PRINCIPADO DE;Group 0204 Malignant neoplasm of breast 174-175;Men;8 ASTURIAS, PRINCIPADO DE;Group 0204 Malignant neoplasm of breast 174-175;Women;735 ASTURIAS, PRINCIPADO DE;Group 0205 Malignant neoplasm of uterus 179-180, 182;Both sexes;241 ASTURIAS, PRINCIPADO DE;Group 0205 Malignant neoplasm of uterus 179-180, 182;Men;.. ASTURIAS, PRINCIPADO DE;Group 0205 Malignant neoplasm of uterus 179-180, 182;Women;241 ASTURIAS, PRINCIPADO DE;Group 0206 Malignant neoplasm of ovary 1830;Both sexes;142 ASTURIAS, PRINCIPADO DE;Group 0206 Malignant neoplasm of ovary 1830;Men;.. ASTURIAS, PRINCIPADO DE;Group 0206 Malignant neoplasm of ovary 1830;Women;142 ASTURIAS, PRINCIPADO DE;Group 0207 Malignant neoplasm of prostate 185;Both sexes;681 ASTURIAS, PRINCIPADO DE;Group 0207 Malignant neoplasm of prostate 185;Men;681 ASTURIAS, PRINCIPADO DE;Group 0207 Malignant neoplasm of prostate 185;Women;.. ASTURIAS, PRINCIPADO DE;Group 0208 Malignant neoplasm of bladder 188;Both sexes;854 ASTURIAS, PRINCIPADO DE;Group 0208 Malignant neoplasm of bladder 188;Men;709 ASTURIAS, PRINCIPADO DE;Group 0208 Malignant neoplasm of bladder 188;Women;145 ASTURIAS, PRINCIPADO DE;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Both sexes;3,844 ASTURIAS, PRINCIPADO DE;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Men;2,252 ASTURIAS, PRINCIPADO DE;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Women;1,592 ASTURIAS, PRINCIPADO DE;Group 0210 Carcinoma in situ 230-234;Both sexes;284 ASTURIAS, PRINCIPADO DE;Group 0210 Carcinoma in situ 230-234;Men;171 ASTURIAS, PRINCIPADO DE;Group 0210 Carcinoma in situ 230-234;Women;113 ASTURIAS, PRINCIPADO DE;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Both sexes;110 ASTURIAS, PRINCIPADO DE;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Men;61 ASTURIAS, PRINCIPADO DE;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Women;49 ASTURIAS, PRINCIPADO DE;Grupo 0212 Leiomyoma of uterus 218;Both sexes;483 ASTURIAS, PRINCIPADO DE;Grupo 0212 Leiomyoma of uterus 218;Men;.. ASTURIAS, PRINCIPADO DE;Grupo 0212 Leiomyoma of uterus 218;Women;483 ASTURIAS, PRINCIPADO DE;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Both sexes;1,324 ASTURIAS, PRINCIPADO DE;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Men;586 ASTURIAS, PRINCIPADO DE;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Women;738 ASTURIAS, PRINCIPADO DE;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Both sexes;1,066 ASTURIAS, PRINCIPADO DE;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Men;475 ASTURIAS, PRINCIPADO DE;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Women;591 ASTURIAS, PRINCIPADO DE;Group 0301 Anaemias 280-285;Both sexes;767 ASTURIAS, PRINCIPADO DE;Group 0301 Anaemias 280-285;Men;312 ASTURIAS, PRINCIPADO DE;Group 0301 Anaemias 280-285;Women;455 ASTURIAS, PRINCIPADO DE;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Both sexes;299 ASTURIAS, PRINCIPADO DE;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Men;163 ASTURIAS, PRINCIPADO DE;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Women;136 ASTURIAS, PRINCIPADO DE;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Both sexes;1,897 ASTURIAS, PRINCIPADO DE;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Men;749 ASTURIAS, PRINCIPADO DE;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Women;1,148 ASTURIAS, PRINCIPADO DE;Group 0401 Diabetes mellitus 249-250;Both sexes;595 ASTURIAS, PRINCIPADO DE;Group 0401 Diabetes mellitus 249-250;Men;316 ASTURIAS, PRINCIPADO DE;Group 0401 Diabetes mellitus 249-250;Women;279 ASTURIAS, PRINCIPADO DE;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Both sexes;1,302 ASTURIAS, PRINCIPADO DE;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Men;433 ASTURIAS, PRINCIPADO DE;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Women;869 ASTURIAS, PRINCIPADO DE;Group 0500 Mental disorders 290-319;Both sexes;2,994 ASTURIAS, PRINCIPADO DE;Group 0500 Mental disorders 290-319;Men;1,480 ASTURIAS, PRINCIPADO DE;Group 0500 Mental disorders 290-319;Women;1,514 ASTURIAS, PRINCIPADO DE;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Both sexes;88 ASTURIAS, PRINCIPADO DE;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Men;52 ASTURIAS, PRINCIPADO DE;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Women;36 ASTURIAS, PRINCIPADO DE;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Both sexes;245 ASTURIAS, PRINCIPADO DE;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Men;193 ASTURIAS, PRINCIPADO DE;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Women;52 ASTURIAS, PRINCIPADO DE;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Both sexes;119 ASTURIAS, PRINCIPADO DE;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Men;81 ASTURIAS, PRINCIPADO DE;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Women;38 ASTURIAS, PRINCIPADO DE;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Both sexes;623 ASTURIAS, PRINCIPADO DE;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Men;367 ASTURIAS, PRINCIPADO DE;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Women;256 ASTURIAS, PRINCIPADO DE;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Both sexes;719 ASTURIAS, PRINCIPADO DE;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Men;244 ASTURIAS, PRINCIPADO DE;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Women;475 ASTURIAS, PRINCIPADO DE;Group 0506 Other mental and behavioural disorders Rest of (290-319);Both sexes;1,200 ASTURIAS, PRINCIPADO DE;Group 0506 Other mental and behavioural disorders Rest of (290-319);Men;543 ASTURIAS, PRINCIPADO DE;Group 0506 Other mental and behavioural disorders Rest of (290-319);Women;657 ASTURIAS, PRINCIPADO DE;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Both sexes;2,650 ASTURIAS, PRINCIPADO DE;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Men;1,330 ASTURIAS, PRINCIPADO DE;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Women;1,320 ASTURIAS, PRINCIPADO DE;Group 0601 Alzheimer's disease 3310;Both sexes;27 ASTURIAS, PRINCIPADO DE;Group 0601 Alzheimer's disease 3310;Men;12 ASTURIAS, PRINCIPADO DE;Group 0601 Alzheimer's disease 3310;Women;15 ASTURIAS, PRINCIPADO DE;Group 0602 Multiple sclerosis 340;Both sexes;116 ASTURIAS, PRINCIPADO DE;Group 0602 Multiple sclerosis 340;Men;48 ASTURIAS, PRINCIPADO DE;Group 0602 Multiple sclerosis 340;Women;68 ASTURIAS, PRINCIPADO DE;Group 0603 Epilepsy 345;Both sexes;486 ASTURIAS, PRINCIPADO DE;Group 0603 Epilepsy 345;Men;277 ASTURIAS, PRINCIPADO DE;Group 0603 Epilepsy 345;Women;209 ASTURIAS, PRINCIPADO DE;Group 0604 Transient cerebral ischemia 435;Both sexes;525 ASTURIAS, PRINCIPADO DE;Group 0604 Transient cerebral ischemia 435;Men;257 ASTURIAS, PRINCIPADO DE;Group 0604 Transient cerebral ischemia 435;Women;268 ASTURIAS, PRINCIPADO DE;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Both sexes;1,496 ASTURIAS, PRINCIPADO DE;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Men;736 ASTURIAS, PRINCIPADO DE;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Women;760 ASTURIAS, PRINCIPADO DE;Grupo 0700 Diseases of the eye and adnexa 360-379;Both sexes;658 ASTURIAS, PRINCIPADO DE;Grupo 0700 Diseases of the eye and adnexa 360-379;Men;299 ASTURIAS, PRINCIPADO DE;Grupo 0700 Diseases of the eye and adnexa 360-379;Women;359 ASTURIAS, PRINCIPADO DE;Grupo 0701 Cataract 366;Both sexes;261 ASTURIAS, PRINCIPADO DE;Grupo 0701 Cataract 366;Men;109 ASTURIAS, PRINCIPADO DE;Grupo 0701 Cataract 366;Women;152 ASTURIAS, PRINCIPADO DE;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Both sexes;397 ASTURIAS, PRINCIPADO DE;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Men;190 ASTURIAS, PRINCIPADO DE;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Women;207 ASTURIAS, PRINCIPADO DE;Group 0800 Diseases of the ear and the mastoid 380-389;Both sexes;545 ASTURIAS, PRINCIPADO DE;Group 0800 Diseases of the ear and the mastoid 380-389;Men;271 ASTURIAS, PRINCIPADO DE;Group 0800 Diseases of the ear and the mastoid 380-389;Women;274 ASTURIAS, PRINCIPADO DE;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Both sexes;20,576 ASTURIAS, PRINCIPADO DE;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Men;11,104 ASTURIAS, PRINCIPADO DE;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Women;9,472 ASTURIAS, PRINCIPADO DE;Group 0901 Hypertensive disease 401-405;Both sexes;1,153 ASTURIAS, PRINCIPADO DE;Group 0901 Hypertensive disease 401-405;Men;468 ASTURIAS, PRINCIPADO DE;Group 0901 Hypertensive disease 401-405;Women;685 ASTURIAS, PRINCIPADO DE;Group 0902 Angina pectoris 4111, 413;Both sexes;1,277 ASTURIAS, PRINCIPADO DE;Group 0902 Angina pectoris 4111, 413;Men;766 ASTURIAS, PRINCIPADO DE;Group 0902 Angina pectoris 4111, 413;Women;511 ASTURIAS, PRINCIPADO DE;Group 0903 Acute myocardial infarction 410;Both sexes;1,201 ASTURIAS, PRINCIPADO DE;Group 0903 Acute myocardial infarction 410;Men;803 ASTURIAS, PRINCIPADO DE;Group 0903 Acute myocardial infarction 410;Women;398 ASTURIAS, PRINCIPADO DE;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Both sexes;1,640 ASTURIAS, PRINCIPADO DE;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Men;1,209 ASTURIAS, PRINCIPADO DE;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Women;431 ASTURIAS, PRINCIPADO DE;Group 0905 Diseases of the lungs circulation 415-417;Both sexes;771 ASTURIAS, PRINCIPADO DE;Group 0905 Diseases of the lungs circulation 415-417;Men;322 ASTURIAS, PRINCIPADO DE;Group 0905 Diseases of the lungs circulation 415-417;Women;449 ASTURIAS, PRINCIPADO DE;Group 0906 Heart conduction disorders and arrhytmias 426-427;Both sexes;2,458 ASTURIAS, PRINCIPADO DE;Group 0906 Heart conduction disorders and arrhytmias 426-427;Men;1,322 ASTURIAS, PRINCIPADO DE;Group 0906 Heart conduction disorders and arrhytmias 426-427;Women;1,136 ASTURIAS, PRINCIPADO DE;Grupo 0907 Heart failure 428;Both sexes;3,798 ASTURIAS, PRINCIPADO DE;Grupo 0907 Heart failure 428;Men;1,886 ASTURIAS, PRINCIPADO DE;Grupo 0907 Heart failure 428;Women;1,912 ASTURIAS, PRINCIPADO DE;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Both sexes;3,648 ASTURIAS, PRINCIPADO DE;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Men;1,832 ASTURIAS, PRINCIPADO DE;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Women;1,816 ASTURIAS, PRINCIPADO DE;Grupo 0909 Atherosclerosis 440;Both sexes;789 ASTURIAS, PRINCIPADO DE;Grupo 0909 Atherosclerosis 440;Men;565 ASTURIAS, PRINCIPADO DE;Grupo 0909 Atherosclerosis 440;Women;224 ASTURIAS, PRINCIPADO DE;Group 0910 Varicose veins of lower extremities 454;Both sexes;1,441 ASTURIAS, PRINCIPADO DE;Group 0910 Varicose veins of lower extremities 454;Men;491 ASTURIAS, PRINCIPADO DE;Group 0910 Varicose veins of lower extremities 454;Women;950 ASTURIAS, PRINCIPADO DE;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Both sexes;2,400 ASTURIAS, PRINCIPADO DE;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Men;1,440 ASTURIAS, PRINCIPADO DE;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Women;960 ASTURIAS, PRINCIPADO DE;Group 1000 Diseases of the respiratory system 0340, 460-519;Both sexes;14,955 ASTURIAS, PRINCIPADO DE;Group 1000 Diseases of the respiratory system 0340, 460-519;Men;8,682 ASTURIAS, PRINCIPADO DE;Group 1000 Diseases of the respiratory system 0340, 460-519;Women;6,273 ASTURIAS, PRINCIPADO DE;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Both sexes;429 ASTURIAS, PRINCIPADO DE;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Men;211 ASTURIAS, PRINCIPADO DE;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Women;218 ASTURIAS, PRINCIPADO DE;Group 1002 Pneumonia 480-486;Both sexes;3,131 ASTURIAS, PRINCIPADO DE;Group 1002 Pneumonia 480-486;Men;1,858 ASTURIAS, PRINCIPADO DE;Group 1002 Pneumonia 480-486;Women;1,273 ASTURIAS, PRINCIPADO DE;Group 1003 Acute bronchitis and bronchiolitis 466;Both sexes;608 ASTURIAS, PRINCIPADO DE;Group 1003 Acute bronchitis and bronchiolitis 466;Men;281 ASTURIAS, PRINCIPADO DE;Group 1003 Acute bronchitis and bronchiolitis 466;Women;327 ASTURIAS, PRINCIPADO DE;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Both sexes;199 ASTURIAS, PRINCIPADO DE;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Men;88 ASTURIAS, PRINCIPADO DE;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Women;111 ASTURIAS, PRINCIPADO DE;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Both sexes;857 ASTURIAS, PRINCIPADO DE;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Men;553 ASTURIAS, PRINCIPADO DE;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Women;304 ASTURIAS, PRINCIPADO DE;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Both sexes;2,642 ASTURIAS, PRINCIPADO DE;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Men;2,106 ASTURIAS, PRINCIPADO DE;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Women;536 ASTURIAS, PRINCIPADO DE;Group 1007 Asthma 4930-4931,4938-4939;Both sexes;1,634 ASTURIAS, PRINCIPADO DE;Group 1007 Asthma 4930-4931,4938-4939;Men;679 ASTURIAS, PRINCIPADO DE;Group 1007 Asthma 4930-4931,4938-4939;Women;955 ASTURIAS, PRINCIPADO DE;Group 1008 Other diseases of the respiratory system Resto of (460-519);Both sexes;5,455 ASTURIAS, PRINCIPADO DE;Group 1008 Other diseases of the respiratory system Resto of (460-519);Men;2,906 ASTURIAS, PRINCIPADO DE;Group 1008 Other diseases of the respiratory system Resto of (460-519);Women;2,549 ASTURIAS, PRINCIPADO DE;Group 1100 Diseases of the digestive system 520-579;Both sexes;13,597 ASTURIAS, PRINCIPADO DE;Group 1100 Diseases of the digestive system 520-579;Men;7,667 ASTURIAS, PRINCIPADO DE;Group 1100 Diseases of the digestive system 520-579;Women;5,930 ASTURIAS, PRINCIPADO DE;Group 1101 Disorders of the teeth and supporting structures 520-525;Both sexes;116 ASTURIAS, PRINCIPADO DE;Group 1101 Disorders of the teeth and supporting structures 520-525;Men;59 ASTURIAS, PRINCIPADO DE;Group 1101 Disorders of the teeth and supporting structures 520-525;Women;57 ASTURIAS, PRINCIPADO DE;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Both sexes;175 ASTURIAS, PRINCIPADO DE;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Men;87 ASTURIAS, PRINCIPADO DE;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Women;88 ASTURIAS, PRINCIPADO DE;Group 1103 Diseases of the esophagus 530;Both sexes;225 ASTURIAS, PRINCIPADO DE;Group 1103 Diseases of the esophagus 530;Men;138 ASTURIAS, PRINCIPADO DE;Group 1103 Diseases of the esophagus 530;Women;87 ASTURIAS, PRINCIPADO DE;Group 1104 Peptic ulcer 531-534;Both sexes;140 ASTURIAS, PRINCIPADO DE;Group 1104 Peptic ulcer 531-534;Men;91 ASTURIAS, PRINCIPADO DE;Group 1104 Peptic ulcer 531-534;Women;49 ASTURIAS, PRINCIPADO DE;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Both sexes;318 ASTURIAS, PRINCIPADO DE;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Men;148 ASTURIAS, PRINCIPADO DE;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Women;170 ASTURIAS, PRINCIPADO DE;Group 1106 Appendicitis 540-543;Both sexes;1,076 ASTURIAS, PRINCIPADO DE;Group 1106 Appendicitis 540-543;Men;588 ASTURIAS, PRINCIPADO DE;Group 1106 Appendicitis 540-543;Women;488 ASTURIAS, PRINCIPADO DE;Group 1107 Inguinal hernia 550;Both sexes;1,430 ASTURIAS, PRINCIPADO DE;Group 1107 Inguinal hernia 550;Men;1,309 ASTURIAS, PRINCIPADO DE;Group 1107 Inguinal hernia 550;Women;121 ASTURIAS, PRINCIPADO DE;Group 1108 Other abdominal hernia 551-553;Both sexes;976 ASTURIAS, PRINCIPADO DE;Group 1108 Other abdominal hernia 551-553;Men;499 ASTURIAS, PRINCIPADO DE;Group 1108 Other abdominal hernia 551-553;Women;477 ASTURIAS, PRINCIPADO DE;Group 1109 Crohn's disease and ulcerative colitis 555-556;Both sexes;289 ASTURIAS, PRINCIPADO DE;Group 1109 Crohn's disease and ulcerative colitis 555-556;Men;137 ASTURIAS, PRINCIPADO DE;Group 1109 Crohn's disease and ulcerative colitis 555-556;Women;152 ASTURIAS, PRINCIPADO DE;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Both sexes;720 ASTURIAS, PRINCIPADO DE;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Men;326 ASTURIAS, PRINCIPADO DE;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Women;394 ASTURIAS, PRINCIPADO DE;Group 1111 Intestinal obstruction without hernia 560;Both sexes;982 ASTURIAS, PRINCIPADO DE;Group 1111 Intestinal obstruction without hernia 560;Men;487 ASTURIAS, PRINCIPADO DE;Group 1111 Intestinal obstruction without hernia 560;Women;495 ASTURIAS, PRINCIPADO DE;Group 1112 Intestinal diverticulosis 562;Both sexes;686 ASTURIAS, PRINCIPADO DE;Group 1112 Intestinal diverticulosis 562;Men;307 ASTURIAS, PRINCIPADO DE;Group 1112 Intestinal diverticulosis 562;Women;379 ASTURIAS, PRINCIPADO DE;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Both sexes;718 ASTURIAS, PRINCIPADO DE;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Men;443 ASTURIAS, PRINCIPADO DE;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Women;275 ASTURIAS, PRINCIPADO DE;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Both sexes;528 ASTURIAS, PRINCIPADO DE;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Men;207 ASTURIAS, PRINCIPADO DE;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Women;321 ASTURIAS, PRINCIPADO DE;Group 1115 Alcoholic hepatitis 5710-5713;Both sexes;315 ASTURIAS, PRINCIPADO DE;Group 1115 Alcoholic hepatitis 5710-5713;Men;264 ASTURIAS, PRINCIPADO DE;Group 1115 Alcoholic hepatitis 5710-5713;Women;51 ASTURIAS, PRINCIPADO DE;Group 1116 Other diseases of the liver 570,5714-573;Both sexes;453 ASTURIAS, PRINCIPADO DE;Group 1116 Other diseases of the liver 570,5714-573;Men;308 ASTURIAS, PRINCIPADO DE;Group 1116 Other diseases of the liver 570,5714-573;Women;145 ASTURIAS, PRINCIPADO DE;Group 1117 Cholelithiasis 574;Both sexes;2,165 ASTURIAS, PRINCIPADO DE;Group 1117 Cholelithiasis 574;Men;984 ASTURIAS, PRINCIPADO DE;Group 1117 Cholelithiasis 574;Women;1,181 ASTURIAS, PRINCIPADO DE;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Both sexes;915 ASTURIAS, PRINCIPADO DE;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Men;505 ASTURIAS, PRINCIPADO DE;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Women;410 ASTURIAS, PRINCIPADO DE;Group 1119 Pancreatic diseases 577;Both sexes;752 ASTURIAS, PRINCIPADO DE;Group 1119 Pancreatic diseases 577;Men;427 ASTURIAS, PRINCIPADO DE;Group 1119 Pancreatic diseases 577;Women;325 ASTURIAS, PRINCIPADO DE;Group 1120 Other diseases of the digestive system Rest of (520-579);Both sexes;618 ASTURIAS, PRINCIPADO DE;Group 1120 Other diseases of the digestive system Rest of (520-579);Men;353 ASTURIAS, PRINCIPADO DE;Group 1120 Other diseases of the digestive system Rest of (520-579);Women;265 ASTURIAS, PRINCIPADO DE;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Both sexes;1,147 ASTURIAS, PRINCIPADO DE;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Men;618 ASTURIAS, PRINCIPADO DE;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Women;529 ASTURIAS, PRINCIPADO DE;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Both sexes;769 ASTURIAS, PRINCIPADO DE;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Men;454 ASTURIAS, PRINCIPADO DE;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Women;315 ASTURIAS, PRINCIPADO DE;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Both sexes;53 ASTURIAS, PRINCIPADO DE;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Men;20 ASTURIAS, PRINCIPADO DE;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Women;33 ASTURIAS, PRINCIPADO DE;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Both sexes;325 ASTURIAS, PRINCIPADO DE;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Men;144 ASTURIAS, PRINCIPADO DE;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Women;181 ASTURIAS, PRINCIPADO DE;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Both sexes;8,515 ASTURIAS, PRINCIPADO DE;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Men;4,168 ASTURIAS, PRINCIPADO DE;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Women;4,347 ASTURIAS, PRINCIPADO DE;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Both sexes;.. ASTURIAS, PRINCIPADO DE;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Men;.. ASTURIAS, PRINCIPADO DE;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Women;.. ASTURIAS, PRINCIPADO DE;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Both sexes;.. ASTURIAS, PRINCIPADO DE;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Men;.. ASTURIAS, PRINCIPADO DE;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Women;.. ASTURIAS, PRINCIPADO DE;Group 1303 Internal derangement of knee 717;Both sexes;704 ASTURIAS, PRINCIPADO DE;Group 1303 Internal derangement of knee 717;Men;472 ASTURIAS, PRINCIPADO DE;Group 1303 Internal derangement of knee 717;Women;232 ASTURIAS, PRINCIPADO DE;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Both sexes;4,356 ASTURIAS, PRINCIPADO DE;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Men;2,085 ASTURIAS, PRINCIPADO DE;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Women;2,271 ASTURIAS, PRINCIPADO DE;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Both sexes;150 ASTURIAS, PRINCIPADO DE;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Men;59 ASTURIAS, PRINCIPADO DE;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Women;91 ASTURIAS, PRINCIPADO DE;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Both sexes;300 ASTURIAS, PRINCIPADO DE;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Men;135 ASTURIAS, PRINCIPADO DE;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Women;165 ASTURIAS, PRINCIPADO DE;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Both sexes;756 ASTURIAS, PRINCIPADO DE;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Men;440 ASTURIAS, PRINCIPADO DE;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Women;316 ASTURIAS, PRINCIPADO DE;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Both sexes;305 ASTURIAS, PRINCIPADO DE;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Men;162 ASTURIAS, PRINCIPADO DE;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Women;143 ASTURIAS, PRINCIPADO DE;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Both sexes;989 ASTURIAS, PRINCIPADO DE;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Men;482 ASTURIAS, PRINCIPADO DE;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Women;507 ASTURIAS, PRINCIPADO DE;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Both sexes;955 ASTURIAS, PRINCIPADO DE;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Men;333 ASTURIAS, PRINCIPADO DE;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Women;622 ASTURIAS, PRINCIPADO DE;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Both sexes;7,486 ASTURIAS, PRINCIPADO DE;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Men;3,417 ASTURIAS, PRINCIPADO DE;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Women;4,069 ASTURIAS, PRINCIPADO DE;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Both sexes;580 ASTURIAS, PRINCIPADO DE;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Men;207 ASTURIAS, PRINCIPADO DE;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Women;373 ASTURIAS, PRINCIPADO DE;Group 1402 Renal failure 5836-5837, 584-586;Both sexes;803 ASTURIAS, PRINCIPADO DE;Group 1402 Renal failure 5836-5837, 584-586;Men;442 ASTURIAS, PRINCIPADO DE;Group 1402 Renal failure 5836-5837, 584-586;Women;361 ASTURIAS, PRINCIPADO DE;Group 1403 Urolithiasis 592, 594, 7880;Both sexes;858 ASTURIAS, PRINCIPADO DE;Group 1403 Urolithiasis 592, 594, 7880;Men;531 ASTURIAS, PRINCIPADO DE;Group 1403 Urolithiasis 592, 594, 7880;Women;327 ASTURIAS, PRINCIPADO DE;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Both sexes;2,558 ASTURIAS, PRINCIPADO DE;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Men;1,048 ASTURIAS, PRINCIPADO DE;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Women;1,510 ASTURIAS, PRINCIPADO DE;Group 1405 Prostatic hyperplasia 600;Both sexes;642 ASTURIAS, PRINCIPADO DE;Group 1405 Prostatic hyperplasia 600;Men;642 ASTURIAS, PRINCIPADO DE;Group 1405 Prostatic hyperplasia 600;Women;.. ASTURIAS, PRINCIPADO DE;Group 1406 Other diseases of the male genital organs 601-608;Both sexes;494 ASTURIAS, PRINCIPADO DE;Group 1406 Other diseases of the male genital organs 601-608;Men;494 ASTURIAS, PRINCIPADO DE;Group 1406 Other diseases of the male genital organs 601-608;Women;.. ASTURIAS, PRINCIPADO DE;Group 1407 Disorders of breast 610-612;Both sexes;282 ASTURIAS, PRINCIPADO DE;Group 1407 Disorders of breast 610-612;Men;35 ASTURIAS, PRINCIPADO DE;Group 1407 Disorders of breast 610-612;Women;247 ASTURIAS, PRINCIPADO DE;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Both sexes;153 ASTURIAS, PRINCIPADO DE;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Men;.. ASTURIAS, PRINCIPADO DE;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Women;153 ASTURIAS, PRINCIPADO DE;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Both sexes;77 ASTURIAS, PRINCIPADO DE;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Men;.. ASTURIAS, PRINCIPADO DE;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Women;77 ASTURIAS, PRINCIPADO DE;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Both sexes;1,039 ASTURIAS, PRINCIPADO DE;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Men;18 ASTURIAS, PRINCIPADO DE;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Women;1,021 ASTURIAS, PRINCIPADO DE;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Both sexes;7,347 ASTURIAS, PRINCIPADO DE;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Men;.. ASTURIAS, PRINCIPADO DE;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Women;7,347 ASTURIAS, PRINCIPADO DE;Group 1501 Legally induced abortion 635;Both sexes;34 ASTURIAS, PRINCIPADO DE;Group 1501 Legally induced abortion 635;Men;.. ASTURIAS, PRINCIPADO DE;Group 1501 Legally induced abortion 635;Women;34 ASTURIAS, PRINCIPADO DE;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Both sexes;335 ASTURIAS, PRINCIPADO DE;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Men;.. ASTURIAS, PRINCIPADO DE;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Women;335 ASTURIAS, PRINCIPADO DE;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Both sexes;4,355 ASTURIAS, PRINCIPADO DE;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Men;.. ASTURIAS, PRINCIPADO DE;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Women;4,355 ASTURIAS, PRINCIPADO DE;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Both sexes;820 ASTURIAS, PRINCIPADO DE;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Men;.. ASTURIAS, PRINCIPADO DE;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Women;820 ASTURIAS, PRINCIPADO DE;Group 1505 Single spontaneous delivery 650;Both sexes;1,154 ASTURIAS, PRINCIPADO DE;Group 1505 Single spontaneous delivery 650;Men;.. ASTURIAS, PRINCIPADO DE;Group 1505 Single spontaneous delivery 650;Women;1,154 ASTURIAS, PRINCIPADO DE;Group 1506 Other deliveries 6695-6697;Both sexes;316 ASTURIAS, PRINCIPADO DE;Group 1506 Other deliveries 6695-6697;Men;.. ASTURIAS, PRINCIPADO DE;Group 1506 Other deliveries 6695-6697;Women;316 ASTURIAS, PRINCIPADO DE;Group 1507 Complications related to the puerperium 670-676;Both sexes;66 ASTURIAS, PRINCIPADO DE;Group 1507 Complications related to the puerperium 670-676;Men;.. ASTURIAS, PRINCIPADO DE;Group 1507 Complications related to the puerperium 670-676;Women;66 ASTURIAS, PRINCIPADO DE;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Both sexes;267 ASTURIAS, PRINCIPADO DE;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Men;.. ASTURIAS, PRINCIPADO DE;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Women;267 ASTURIAS, PRINCIPADO DE;Group 1600 Some disorders originating in the perinatal period 760-779;Both sexes;1,068 ASTURIAS, PRINCIPADO DE;Group 1600 Some disorders originating in the perinatal period 760-779;Men;571 ASTURIAS, PRINCIPADO DE;Group 1600 Some disorders originating in the perinatal period 760-779;Women;497 ASTURIAS, PRINCIPADO DE;Group 1601 Disorders related with premature delivery and a low birth weight 765;Both sexes;134 ASTURIAS, PRINCIPADO DE;Group 1601 Disorders related with premature delivery and a low birth weight 765;Men;70 ASTURIAS, PRINCIPADO DE;Group 1601 Disorders related with premature delivery and a low birth weight 765;Women;64 ASTURIAS, PRINCIPADO DE;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Both sexes;934 ASTURIAS, PRINCIPADO DE;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Men;501 ASTURIAS, PRINCIPADO DE;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Women;433 ASTURIAS, PRINCIPADO DE;Grupo 1700 Congenital abnormalities 740-759;Both sexes;593 ASTURIAS, PRINCIPADO DE;Grupo 1700 Congenital abnormalities 740-759;Men;337 ASTURIAS, PRINCIPADO DE;Grupo 1700 Congenital abnormalities 740-759;Women;256 ASTURIAS, PRINCIPADO DE;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Both sexes;7,744 ASTURIAS, PRINCIPADO DE;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Men;3,729 ASTURIAS, PRINCIPADO DE;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Women;4,015 ASTURIAS, PRINCIPADO DE;Group 1801 Pain in throat and chest 7841, 7865;Both sexes;733 ASTURIAS, PRINCIPADO DE;Group 1801 Pain in throat and chest 7841, 7865;Men;391 ASTURIAS, PRINCIPADO DE;Group 1801 Pain in throat and chest 7841, 7865;Women;342 ASTURIAS, PRINCIPADO DE;Group 1802 Abdominal pain 7890;Both sexes;887 ASTURIAS, PRINCIPADO DE;Group 1802 Abdominal pain 7890;Men;331 ASTURIAS, PRINCIPADO DE;Group 1802 Abdominal pain 7890;Women;556 ASTURIAS, PRINCIPADO DE;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Both sexes;786 ASTURIAS, PRINCIPADO DE;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Men;346 ASTURIAS, PRINCIPADO DE;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Women;440 ASTURIAS, PRINCIPADO DE;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Both sexes;5,338 ASTURIAS, PRINCIPADO DE;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Men;2,661 ASTURIAS, PRINCIPADO DE;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Women;2,677 ASTURIAS, PRINCIPADO DE;Group 1900 Injuries and poisoning 800-999;Both sexes;9,748 ASTURIAS, PRINCIPADO DE;Group 1900 Injuries and poisoning 800-999;Men;4,685 ASTURIAS, PRINCIPADO DE;Group 1900 Injuries and poisoning 800-999;Women;5,063 ASTURIAS, PRINCIPADO DE;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Both sexes;286 ASTURIAS, PRINCIPADO DE;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Men;160 ASTURIAS, PRINCIPADO DE;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Women;126 ASTURIAS, PRINCIPADO DE;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Both sexes;308 ASTURIAS, PRINCIPADO DE;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Men;206 ASTURIAS, PRINCIPADO DE;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Women;102 ASTURIAS, PRINCIPADO DE;Group 1903 Radius and ulna fracture 813;Both sexes;333 ASTURIAS, PRINCIPADO DE;Group 1903 Radius and ulna fracture 813;Men;147 ASTURIAS, PRINCIPADO DE;Group 1903 Radius and ulna fracture 813;Women;186 ASTURIAS, PRINCIPADO DE;Group 1904 Femur fracture 820-821;Both sexes;1,833 ASTURIAS, PRINCIPADO DE;Group 1904 Femur fracture 820-821;Men;447 ASTURIAS, PRINCIPADO DE;Group 1904 Femur fracture 820-821;Women;1,386 ASTURIAS, PRINCIPADO DE;Group 1905 Leg fracture, including the ankle 823-824;Both sexes;735 ASTURIAS, PRINCIPADO DE;Group 1905 Leg fracture, including the ankle 823-824;Men;337 ASTURIAS, PRINCIPADO DE;Group 1905 Leg fracture, including the ankle 823-824;Women;398 ASTURIAS, PRINCIPADO DE;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Both sexes;2,898 ASTURIAS, PRINCIPADO DE;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Men;1,677 ASTURIAS, PRINCIPADO DE;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Women;1,221 ASTURIAS, PRINCIPADO DE;Group 1907 Burns 940-949;Both sexes;59 ASTURIAS, PRINCIPADO DE;Group 1907 Burns 940-949;Men;31 ASTURIAS, PRINCIPADO DE;Group 1907 Burns 940-949;Women;28 ASTURIAS, PRINCIPADO DE;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Both sexes;340 ASTURIAS, PRINCIPADO DE;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Men;153 ASTURIAS, PRINCIPADO DE;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Women;187 ASTURIAS, PRINCIPADO DE;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Both sexes;2,614 ASTURIAS, PRINCIPADO DE;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Men;1,366 ASTURIAS, PRINCIPADO DE;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Women;1,248 ASTURIAS, PRINCIPADO DE;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Both sexes;70 ASTURIAS, PRINCIPADO DE;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Men;44 ASTURIAS, PRINCIPADO DE;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Women;26 ASTURIAS, PRINCIPADO DE;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Both sexes;272 ASTURIAS, PRINCIPADO DE;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Men;117 ASTURIAS, PRINCIPADO DE;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Women;155 ASTURIAS, PRINCIPADO DE;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Both sexes;2,079 ASTURIAS, PRINCIPADO DE;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Men;1,077 ASTURIAS, PRINCIPADO DE;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Women;1,002 ASTURIAS, PRINCIPADO DE;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Both sexes;68 ASTURIAS, PRINCIPADO DE;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Men;43 ASTURIAS, PRINCIPADO DE;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Women;25 ASTURIAS, PRINCIPADO DE;Group 2102 Contraceptive management V25;Both sexes;22 ASTURIAS, PRINCIPADO DE;Group 2102 Contraceptive management V25;Men;2 ASTURIAS, PRINCIPADO DE;Group 2102 Contraceptive management V25;Women;20 ASTURIAS, PRINCIPADO DE;Group 2103 Living newborns by type of delivery V30-V39;Both sexes;.. ASTURIAS, PRINCIPADO DE;Group 2103 Living newborns by type of delivery V30-V39;Men;.. ASTURIAS, PRINCIPADO DE;Group 2103 Living newborns by type of delivery V30-V39;Women;.. ASTURIAS, PRINCIPADO DE;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Both sexes;1,038 ASTURIAS, PRINCIPADO DE;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Men;612 ASTURIAS, PRINCIPADO DE;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Women;426 ASTURIAS, PRINCIPADO DE;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Both sexes;951 ASTURIAS, PRINCIPADO DE;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Men;420 ASTURIAS, PRINCIPADO DE;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Women;531 BALEARS, ILLES;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Both sexes;123,000 BALEARS, ILLES;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Men;57,945 BALEARS, ILLES;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Women;65,055 BALEARS, ILLES;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Both sexes;2,941 BALEARS, ILLES;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Men;1,602 BALEARS, ILLES;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Women;1,339 BALEARS, ILLES;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Both sexes;493 BALEARS, ILLES;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Men;252 BALEARS, ILLES;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Women;241 BALEARS, ILLES;Group 0102 Imprecise intestinal infections 009;Both sexes;513 BALEARS, ILLES;Group 0102 Imprecise intestinal infections 009;Men;227 BALEARS, ILLES;Group 0102 Imprecise intestinal infections 009;Women;286 BALEARS, ILLES;Group 0103 Tuberculosis 010-018, 137;Both sexes;97 BALEARS, ILLES;Group 0103 Tuberculosis 010-018, 137;Men;67 BALEARS, ILLES;Group 0103 Tuberculosis 010-018, 137;Women;30 BALEARS, ILLES;Group 0104 Septicaemia 038;Both sexes;754 BALEARS, ILLES;Group 0104 Septicaemia 038;Men;400 BALEARS, ILLES;Group 0104 Septicaemia 038;Women;353 BALEARS, ILLES;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Both sexes;140 BALEARS, ILLES;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Men;96 BALEARS, ILLES;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Women;44 BALEARS, ILLES;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Both sexes;945 BALEARS, ILLES;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Men;560 BALEARS, ILLES;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Women;385 BALEARS, ILLES;Group 0200 Neoplasms 140-239;Both sexes;8,279 BALEARS, ILLES;Group 0200 Neoplasms 140-239;Men;4,357 BALEARS, ILLES;Group 0200 Neoplasms 140-239;Women;3,923 BALEARS, ILLES;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Both sexes;825 BALEARS, ILLES;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Men;484 BALEARS, ILLES;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Women;341 BALEARS, ILLES;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Both sexes;703 BALEARS, ILLES;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Men;536 BALEARS, ILLES;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Women;166 BALEARS, ILLES;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Both sexes;125 BALEARS, ILLES;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Men;71 BALEARS, ILLES;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Women;54 BALEARS, ILLES;Group 0204 Malignant neoplasm of breast 174-175;Both sexes;653 BALEARS, ILLES;Group 0204 Malignant neoplasm of breast 174-175;Men;7 BALEARS, ILLES;Group 0204 Malignant neoplasm of breast 174-175;Women;646 BALEARS, ILLES;Group 0205 Malignant neoplasm of uterus 179-180, 182;Both sexes;169 BALEARS, ILLES;Group 0205 Malignant neoplasm of uterus 179-180, 182;Men;.. BALEARS, ILLES;Group 0205 Malignant neoplasm of uterus 179-180, 182;Women;169 BALEARS, ILLES;Group 0206 Malignant neoplasm of ovary 1830;Both sexes;114 BALEARS, ILLES;Group 0206 Malignant neoplasm of ovary 1830;Men;.. BALEARS, ILLES;Group 0206 Malignant neoplasm of ovary 1830;Women;114 BALEARS, ILLES;Group 0207 Malignant neoplasm of prostate 185;Both sexes;319 BALEARS, ILLES;Group 0207 Malignant neoplasm of prostate 185;Men;319 BALEARS, ILLES;Group 0207 Malignant neoplasm of prostate 185;Women;.. BALEARS, ILLES;Group 0208 Malignant neoplasm of bladder 188;Both sexes;732 BALEARS, ILLES;Group 0208 Malignant neoplasm of bladder 188;Men;604 BALEARS, ILLES;Group 0208 Malignant neoplasm of bladder 188;Women;128 BALEARS, ILLES;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Both sexes;2,676 BALEARS, ILLES;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Men;1,573 BALEARS, ILLES;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Women;1,103 BALEARS, ILLES;Group 0210 Carcinoma in situ 230-234;Both sexes;232 BALEARS, ILLES;Group 0210 Carcinoma in situ 230-234;Men;128 BALEARS, ILLES;Group 0210 Carcinoma in situ 230-234;Women;103 BALEARS, ILLES;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Both sexes;97 BALEARS, ILLES;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Men;54 BALEARS, ILLES;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Women;43 BALEARS, ILLES;Grupo 0212 Leiomyoma of uterus 218;Both sexes;399 BALEARS, ILLES;Grupo 0212 Leiomyoma of uterus 218;Men;.. BALEARS, ILLES;Grupo 0212 Leiomyoma of uterus 218;Women;399 BALEARS, ILLES;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Both sexes;1,234 BALEARS, ILLES;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Men;579 BALEARS, ILLES;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Women;655 BALEARS, ILLES;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Both sexes;891 BALEARS, ILLES;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Men;417 BALEARS, ILLES;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Women;474 BALEARS, ILLES;Group 0301 Anaemias 280-285;Both sexes;607 BALEARS, ILLES;Group 0301 Anaemias 280-285;Men;265 BALEARS, ILLES;Group 0301 Anaemias 280-285;Women;342 BALEARS, ILLES;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Both sexes;284 BALEARS, ILLES;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Men;153 BALEARS, ILLES;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Women;131 BALEARS, ILLES;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Both sexes;1,956 BALEARS, ILLES;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Men;882 BALEARS, ILLES;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Women;1,074 BALEARS, ILLES;Group 0401 Diabetes mellitus 249-250;Both sexes;801 BALEARS, ILLES;Group 0401 Diabetes mellitus 249-250;Men;478 BALEARS, ILLES;Group 0401 Diabetes mellitus 249-250;Women;322 BALEARS, ILLES;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Both sexes;1,156 BALEARS, ILLES;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Men;404 BALEARS, ILLES;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Women;751 BALEARS, ILLES;Group 0500 Mental disorders 290-319;Both sexes;3,250 BALEARS, ILLES;Group 0500 Mental disorders 290-319;Men;1,626 BALEARS, ILLES;Group 0500 Mental disorders 290-319;Women;1,625 BALEARS, ILLES;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Both sexes;64 BALEARS, ILLES;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Men;30 BALEARS, ILLES;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Women;34 BALEARS, ILLES;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Both sexes;427 BALEARS, ILLES;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Men;298 BALEARS, ILLES;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Women;129 BALEARS, ILLES;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Both sexes;138 BALEARS, ILLES;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Men;89 BALEARS, ILLES;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Women;49 BALEARS, ILLES;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Both sexes;839 BALEARS, ILLES;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Men;503 BALEARS, ILLES;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Women;336 BALEARS, ILLES;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Both sexes;705 BALEARS, ILLES;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Men;253 BALEARS, ILLES;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Women;452 BALEARS, ILLES;Group 0506 Other mental and behavioural disorders Rest of (290-319);Both sexes;1,076 BALEARS, ILLES;Group 0506 Other mental and behavioural disorders Rest of (290-319);Men;452 BALEARS, ILLES;Group 0506 Other mental and behavioural disorders Rest of (290-319);Women;623 BALEARS, ILLES;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Both sexes;3,774 BALEARS, ILLES;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Men;1,998 BALEARS, ILLES;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Women;1,776 BALEARS, ILLES;Group 0601 Alzheimer's disease 3310;Both sexes;54 BALEARS, ILLES;Group 0601 Alzheimer's disease 3310;Men;23 BALEARS, ILLES;Group 0601 Alzheimer's disease 3310;Women;31 BALEARS, ILLES;Group 0602 Multiple sclerosis 340;Both sexes;42 BALEARS, ILLES;Group 0602 Multiple sclerosis 340;Men;13 BALEARS, ILLES;Group 0602 Multiple sclerosis 340;Women;29 BALEARS, ILLES;Group 0603 Epilepsy 345;Both sexes;559 BALEARS, ILLES;Group 0603 Epilepsy 345;Men;305 BALEARS, ILLES;Group 0603 Epilepsy 345;Women;254 BALEARS, ILLES;Group 0604 Transient cerebral ischemia 435;Both sexes;350 BALEARS, ILLES;Group 0604 Transient cerebral ischemia 435;Men;207 BALEARS, ILLES;Group 0604 Transient cerebral ischemia 435;Women;143 BALEARS, ILLES;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Both sexes;2,769 BALEARS, ILLES;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Men;1,451 BALEARS, ILLES;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Women;1,318 BALEARS, ILLES;Grupo 0700 Diseases of the eye and adnexa 360-379;Both sexes;525 BALEARS, ILLES;Grupo 0700 Diseases of the eye and adnexa 360-379;Men;265 BALEARS, ILLES;Grupo 0700 Diseases of the eye and adnexa 360-379;Women;260 BALEARS, ILLES;Grupo 0701 Cataract 366;Both sexes;41 BALEARS, ILLES;Grupo 0701 Cataract 366;Men;19 BALEARS, ILLES;Grupo 0701 Cataract 366;Women;21 BALEARS, ILLES;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Both sexes;484 BALEARS, ILLES;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Men;246 BALEARS, ILLES;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Women;238 BALEARS, ILLES;Group 0800 Diseases of the ear and the mastoid 380-389;Both sexes;864 BALEARS, ILLES;Group 0800 Diseases of the ear and the mastoid 380-389;Men;416 BALEARS, ILLES;Group 0800 Diseases of the ear and the mastoid 380-389;Women;447 BALEARS, ILLES;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Both sexes;13,738 BALEARS, ILLES;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Men;7,691 BALEARS, ILLES;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Women;6,048 BALEARS, ILLES;Group 0901 Hypertensive disease 401-405;Both sexes;701 BALEARS, ILLES;Group 0901 Hypertensive disease 401-405;Men;323 BALEARS, ILLES;Group 0901 Hypertensive disease 401-405;Women;378 BALEARS, ILLES;Group 0902 Angina pectoris 4111, 413;Both sexes;941 BALEARS, ILLES;Group 0902 Angina pectoris 4111, 413;Men;598 BALEARS, ILLES;Group 0902 Angina pectoris 4111, 413;Women;343 BALEARS, ILLES;Group 0903 Acute myocardial infarction 410;Both sexes;1,154 BALEARS, ILLES;Group 0903 Acute myocardial infarction 410;Men;815 BALEARS, ILLES;Group 0903 Acute myocardial infarction 410;Women;339 BALEARS, ILLES;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Both sexes;712 BALEARS, ILLES;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Men;553 BALEARS, ILLES;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Women;160 BALEARS, ILLES;Group 0905 Diseases of the lungs circulation 415-417;Both sexes;337 BALEARS, ILLES;Group 0905 Diseases of the lungs circulation 415-417;Men;155 BALEARS, ILLES;Group 0905 Diseases of the lungs circulation 415-417;Women;183 BALEARS, ILLES;Group 0906 Heart conduction disorders and arrhytmias 426-427;Both sexes;1,916 BALEARS, ILLES;Group 0906 Heart conduction disorders and arrhytmias 426-427;Men;1,051 BALEARS, ILLES;Group 0906 Heart conduction disorders and arrhytmias 426-427;Women;865 BALEARS, ILLES;Grupo 0907 Heart failure 428;Both sexes;2,692 BALEARS, ILLES;Grupo 0907 Heart failure 428;Men;1,262 BALEARS, ILLES;Grupo 0907 Heart failure 428;Women;1,430 BALEARS, ILLES;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Both sexes;2,211 BALEARS, ILLES;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Men;1,203 BALEARS, ILLES;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Women;1,008 BALEARS, ILLES;Grupo 0909 Atherosclerosis 440;Both sexes;297 BALEARS, ILLES;Grupo 0909 Atherosclerosis 440;Men;230 BALEARS, ILLES;Grupo 0909 Atherosclerosis 440;Women;67 BALEARS, ILLES;Group 0910 Varicose veins of lower extremities 454;Both sexes;580 BALEARS, ILLES;Group 0910 Varicose veins of lower extremities 454;Men;210 BALEARS, ILLES;Group 0910 Varicose veins of lower extremities 454;Women;369 BALEARS, ILLES;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Both sexes;2,198 BALEARS, ILLES;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Men;1,292 BALEARS, ILLES;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Women;906 BALEARS, ILLES;Group 1000 Diseases of the respiratory system 0340, 460-519;Both sexes;14,359 BALEARS, ILLES;Group 1000 Diseases of the respiratory system 0340, 460-519;Men;8,036 BALEARS, ILLES;Group 1000 Diseases of the respiratory system 0340, 460-519;Women;6,323 BALEARS, ILLES;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Both sexes;863 BALEARS, ILLES;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Men;493 BALEARS, ILLES;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Women;370 BALEARS, ILLES;Group 1002 Pneumonia 480-486;Both sexes;3,291 BALEARS, ILLES;Group 1002 Pneumonia 480-486;Men;1,920 BALEARS, ILLES;Group 1002 Pneumonia 480-486;Women;1,371 BALEARS, ILLES;Group 1003 Acute bronchitis and bronchiolitis 466;Both sexes;2,608 BALEARS, ILLES;Group 1003 Acute bronchitis and bronchiolitis 466;Men;1,152 BALEARS, ILLES;Group 1003 Acute bronchitis and bronchiolitis 466;Women;1,456 BALEARS, ILLES;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Both sexes;498 BALEARS, ILLES;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Men;254 BALEARS, ILLES;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Women;244 BALEARS, ILLES;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Both sexes;1,102 BALEARS, ILLES;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Men;661 BALEARS, ILLES;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Women;442 BALEARS, ILLES;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Both sexes;2,455 BALEARS, ILLES;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Men;1,796 BALEARS, ILLES;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Women;659 BALEARS, ILLES;Group 1007 Asthma 4930-4931,4938-4939;Both sexes;680 BALEARS, ILLES;Group 1007 Asthma 4930-4931,4938-4939;Men;225 BALEARS, ILLES;Group 1007 Asthma 4930-4931,4938-4939;Women;455 BALEARS, ILLES;Group 1008 Other diseases of the respiratory system Resto of (460-519);Both sexes;2,863 BALEARS, ILLES;Group 1008 Other diseases of the respiratory system Resto of (460-519);Men;1,537 BALEARS, ILLES;Group 1008 Other diseases of the respiratory system Resto of (460-519);Women;1,326 BALEARS, ILLES;Group 1100 Diseases of the digestive system 520-579;Both sexes;14,990 BALEARS, ILLES;Group 1100 Diseases of the digestive system 520-579;Men;7,997 BALEARS, ILLES;Group 1100 Diseases of the digestive system 520-579;Women;6,993 BALEARS, ILLES;Group 1101 Disorders of the teeth and supporting structures 520-525;Both sexes;200 BALEARS, ILLES;Group 1101 Disorders of the teeth and supporting structures 520-525;Men;89 BALEARS, ILLES;Group 1101 Disorders of the teeth and supporting structures 520-525;Women;110 BALEARS, ILLES;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Both sexes;223 BALEARS, ILLES;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Men;130 BALEARS, ILLES;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Women;93 BALEARS, ILLES;Group 1103 Diseases of the esophagus 530;Both sexes;234 BALEARS, ILLES;Group 1103 Diseases of the esophagus 530;Men;132 BALEARS, ILLES;Group 1103 Diseases of the esophagus 530;Women;101 BALEARS, ILLES;Group 1104 Peptic ulcer 531-534;Both sexes;259 BALEARS, ILLES;Group 1104 Peptic ulcer 531-534;Men;182 BALEARS, ILLES;Group 1104 Peptic ulcer 531-534;Women;77 BALEARS, ILLES;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Both sexes;569 BALEARS, ILLES;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Men;256 BALEARS, ILLES;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Women;313 BALEARS, ILLES;Group 1106 Appendicitis 540-543;Both sexes;1,399 BALEARS, ILLES;Group 1106 Appendicitis 540-543;Men;769 BALEARS, ILLES;Group 1106 Appendicitis 540-543;Women;630 BALEARS, ILLES;Group 1107 Inguinal hernia 550;Both sexes;1,285 BALEARS, ILLES;Group 1107 Inguinal hernia 550;Men;1,148 BALEARS, ILLES;Group 1107 Inguinal hernia 550;Women;136 BALEARS, ILLES;Group 1108 Other abdominal hernia 551-553;Both sexes;1,174 BALEARS, ILLES;Group 1108 Other abdominal hernia 551-553;Men;535 BALEARS, ILLES;Group 1108 Other abdominal hernia 551-553;Women;639 BALEARS, ILLES;Group 1109 Crohn's disease and ulcerative colitis 555-556;Both sexes;287 BALEARS, ILLES;Group 1109 Crohn's disease and ulcerative colitis 555-556;Men;137 BALEARS, ILLES;Group 1109 Crohn's disease and ulcerative colitis 555-556;Women;150 BALEARS, ILLES;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Both sexes;1,797 BALEARS, ILLES;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Men;773 BALEARS, ILLES;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Women;1,024 BALEARS, ILLES;Group 1111 Intestinal obstruction without hernia 560;Both sexes;632 BALEARS, ILLES;Group 1111 Intestinal obstruction without hernia 560;Men;285 BALEARS, ILLES;Group 1111 Intestinal obstruction without hernia 560;Women;347 BALEARS, ILLES;Group 1112 Intestinal diverticulosis 562;Both sexes;695 BALEARS, ILLES;Group 1112 Intestinal diverticulosis 562;Men;358 BALEARS, ILLES;Group 1112 Intestinal diverticulosis 562;Women;337 BALEARS, ILLES;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Both sexes;768 BALEARS, ILLES;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Men;470 BALEARS, ILLES;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Women;298 BALEARS, ILLES;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Both sexes;462 BALEARS, ILLES;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Men;206 BALEARS, ILLES;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Women;256 BALEARS, ILLES;Group 1115 Alcoholic hepatitis 5710-5713;Both sexes;175 BALEARS, ILLES;Group 1115 Alcoholic hepatitis 5710-5713;Men;134 BALEARS, ILLES;Group 1115 Alcoholic hepatitis 5710-5713;Women;40 BALEARS, ILLES;Group 1116 Other diseases of the liver 570,5714-573;Both sexes;388 BALEARS, ILLES;Group 1116 Other diseases of the liver 570,5714-573;Men;235 BALEARS, ILLES;Group 1116 Other diseases of the liver 570,5714-573;Women;153 BALEARS, ILLES;Group 1117 Cholelithiasis 574;Both sexes;2,490 BALEARS, ILLES;Group 1117 Cholelithiasis 574;Men;1,114 BALEARS, ILLES;Group 1117 Cholelithiasis 574;Women;1,377 BALEARS, ILLES;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Both sexes;759 BALEARS, ILLES;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Men;377 BALEARS, ILLES;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Women;383 BALEARS, ILLES;Group 1119 Pancreatic diseases 577;Both sexes;674 BALEARS, ILLES;Group 1119 Pancreatic diseases 577;Men;394 BALEARS, ILLES;Group 1119 Pancreatic diseases 577;Women;280 BALEARS, ILLES;Group 1120 Other diseases of the digestive system Rest of (520-579);Both sexes;521 BALEARS, ILLES;Group 1120 Other diseases of the digestive system Rest of (520-579);Men;273 BALEARS, ILLES;Group 1120 Other diseases of the digestive system Rest of (520-579);Women;248 BALEARS, ILLES;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Both sexes;1,377 BALEARS, ILLES;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Men;732 BALEARS, ILLES;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Women;645 BALEARS, ILLES;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Both sexes;934 BALEARS, ILLES;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Men;552 BALEARS, ILLES;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Women;382 BALEARS, ILLES;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Both sexes;50 BALEARS, ILLES;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Men;19 BALEARS, ILLES;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Women;30 BALEARS, ILLES;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Both sexes;393 BALEARS, ILLES;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Men;160 BALEARS, ILLES;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Women;232 BALEARS, ILLES;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Both sexes;10,235 BALEARS, ILLES;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Men;4,691 BALEARS, ILLES;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Women;5,544 BALEARS, ILLES;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Both sexes;.. BALEARS, ILLES;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Men;.. BALEARS, ILLES;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Women;.. BALEARS, ILLES;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Both sexes;.. BALEARS, ILLES;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Men;.. BALEARS, ILLES;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Women;.. BALEARS, ILLES;Group 1303 Internal derangement of knee 717;Both sexes;1,016 BALEARS, ILLES;Group 1303 Internal derangement of knee 717;Men;663 BALEARS, ILLES;Group 1303 Internal derangement of knee 717;Women;353 BALEARS, ILLES;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Both sexes;3,796 BALEARS, ILLES;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Men;1,716 BALEARS, ILLES;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Women;2,080 BALEARS, ILLES;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Both sexes;128 BALEARS, ILLES;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Men;53 BALEARS, ILLES;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Women;75 BALEARS, ILLES;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Both sexes;331 BALEARS, ILLES;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Men;160 BALEARS, ILLES;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Women;172 BALEARS, ILLES;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Both sexes;899 BALEARS, ILLES;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Men;462 BALEARS, ILLES;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Women;437 BALEARS, ILLES;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Both sexes;868 BALEARS, ILLES;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Men;352 BALEARS, ILLES;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Women;516 BALEARS, ILLES;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Both sexes;1,678 BALEARS, ILLES;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Men;769 BALEARS, ILLES;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Women;909 BALEARS, ILLES;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Both sexes;1,519 BALEARS, ILLES;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Men;517 BALEARS, ILLES;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Women;1,002 BALEARS, ILLES;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Both sexes;8,511 BALEARS, ILLES;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Men;4,132 BALEARS, ILLES;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Women;4,379 BALEARS, ILLES;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Both sexes;884 BALEARS, ILLES;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Men;256 BALEARS, ILLES;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Women;628 BALEARS, ILLES;Group 1402 Renal failure 5836-5837, 584-586;Both sexes;492 BALEARS, ILLES;Group 1402 Renal failure 5836-5837, 584-586;Men;298 BALEARS, ILLES;Group 1402 Renal failure 5836-5837, 584-586;Women;194 BALEARS, ILLES;Group 1403 Urolithiasis 592, 594, 7880;Both sexes;1,768 BALEARS, ILLES;Group 1403 Urolithiasis 592, 594, 7880;Men;1,104 BALEARS, ILLES;Group 1403 Urolithiasis 592, 594, 7880;Women;664 BALEARS, ILLES;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Both sexes;2,350 BALEARS, ILLES;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Men;1,166 BALEARS, ILLES;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Women;1,184 BALEARS, ILLES;Group 1405 Prostatic hyperplasia 600;Both sexes;560 BALEARS, ILLES;Group 1405 Prostatic hyperplasia 600;Men;560 BALEARS, ILLES;Group 1405 Prostatic hyperplasia 600;Women;.. BALEARS, ILLES;Group 1406 Other diseases of the male genital organs 601-608;Both sexes;675 BALEARS, ILLES;Group 1406 Other diseases of the male genital organs 601-608;Men;675 BALEARS, ILLES;Group 1406 Other diseases of the male genital organs 601-608;Women;.. BALEARS, ILLES;Group 1407 Disorders of breast 610-612;Both sexes;292 BALEARS, ILLES;Group 1407 Disorders of breast 610-612;Men;55 BALEARS, ILLES;Group 1407 Disorders of breast 610-612;Women;237 BALEARS, ILLES;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Both sexes;222 BALEARS, ILLES;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Men;.. BALEARS, ILLES;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Women;222 BALEARS, ILLES;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Both sexes;116 BALEARS, ILLES;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Men;.. BALEARS, ILLES;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Women;116 BALEARS, ILLES;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Both sexes;1,152 BALEARS, ILLES;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Men;17 BALEARS, ILLES;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Women;1,135 BALEARS, ILLES;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Both sexes;11,377 BALEARS, ILLES;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Men;.. BALEARS, ILLES;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Women;11,377 BALEARS, ILLES;Group 1501 Legally induced abortion 635;Both sexes;181 BALEARS, ILLES;Group 1501 Legally induced abortion 635;Men;.. BALEARS, ILLES;Group 1501 Legally induced abortion 635;Women;181 BALEARS, ILLES;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Both sexes;571 BALEARS, ILLES;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Men;.. BALEARS, ILLES;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Women;571 BALEARS, ILLES;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Both sexes;4,894 BALEARS, ILLES;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Men;.. BALEARS, ILLES;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Women;4,894 BALEARS, ILLES;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Both sexes;3,183 BALEARS, ILLES;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Men;.. BALEARS, ILLES;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Women;3,183 BALEARS, ILLES;Group 1505 Single spontaneous delivery 650;Both sexes;1,502 BALEARS, ILLES;Group 1505 Single spontaneous delivery 650;Men;.. BALEARS, ILLES;Group 1505 Single spontaneous delivery 650;Women;1,502 BALEARS, ILLES;Group 1506 Other deliveries 6695-6697;Both sexes;422 BALEARS, ILLES;Group 1506 Other deliveries 6695-6697;Men;.. BALEARS, ILLES;Group 1506 Other deliveries 6695-6697;Women;422 BALEARS, ILLES;Group 1507 Complications related to the puerperium 670-676;Both sexes;83 BALEARS, ILLES;Group 1507 Complications related to the puerperium 670-676;Men;.. BALEARS, ILLES;Group 1507 Complications related to the puerperium 670-676;Women;83 BALEARS, ILLES;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Both sexes;542 BALEARS, ILLES;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Men;.. BALEARS, ILLES;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Women;542 BALEARS, ILLES;Group 1600 Some disorders originating in the perinatal period 760-779;Both sexes;1,499 BALEARS, ILLES;Group 1600 Some disorders originating in the perinatal period 760-779;Men;785 BALEARS, ILLES;Group 1600 Some disorders originating in the perinatal period 760-779;Women;714 BALEARS, ILLES;Group 1601 Disorders related with premature delivery and a low birth weight 765;Both sexes;320 BALEARS, ILLES;Group 1601 Disorders related with premature delivery and a low birth weight 765;Men;156 BALEARS, ILLES;Group 1601 Disorders related with premature delivery and a low birth weight 765;Women;165 BALEARS, ILLES;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Both sexes;1,179 BALEARS, ILLES;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Men;630 BALEARS, ILLES;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Women;550 BALEARS, ILLES;Grupo 1700 Congenital abnormalities 740-759;Both sexes;891 BALEARS, ILLES;Grupo 1700 Congenital abnormalities 740-759;Men;483 BALEARS, ILLES;Grupo 1700 Congenital abnormalities 740-759;Women;408 BALEARS, ILLES;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Both sexes;8,588 BALEARS, ILLES;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Men;4,434 BALEARS, ILLES;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Women;4,154 BALEARS, ILLES;Group 1801 Pain in throat and chest 7841, 7865;Both sexes;990 BALEARS, ILLES;Group 1801 Pain in throat and chest 7841, 7865;Men;549 BALEARS, ILLES;Group 1801 Pain in throat and chest 7841, 7865;Women;441 BALEARS, ILLES;Group 1802 Abdominal pain 7890;Both sexes;1,369 BALEARS, ILLES;Group 1802 Abdominal pain 7890;Men;503 BALEARS, ILLES;Group 1802 Abdominal pain 7890;Women;866 BALEARS, ILLES;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Both sexes;580 BALEARS, ILLES;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Men;292 BALEARS, ILLES;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Women;288 BALEARS, ILLES;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Both sexes;5,649 BALEARS, ILLES;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Men;3,090 BALEARS, ILLES;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Women;2,559 BALEARS, ILLES;Group 1900 Injuries and poisoning 800-999;Both sexes;12,669 BALEARS, ILLES;Group 1900 Injuries and poisoning 800-999;Men;6,438 BALEARS, ILLES;Group 1900 Injuries and poisoning 800-999;Women;6,231 BALEARS, ILLES;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Both sexes;1,018 BALEARS, ILLES;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Men;580 BALEARS, ILLES;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Women;438 BALEARS, ILLES;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Both sexes;436 BALEARS, ILLES;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Men;303 BALEARS, ILLES;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Women;132 BALEARS, ILLES;Group 1903 Radius and ulna fracture 813;Both sexes;818 BALEARS, ILLES;Group 1903 Radius and ulna fracture 813;Men;327 BALEARS, ILLES;Group 1903 Radius and ulna fracture 813;Women;491 BALEARS, ILLES;Group 1904 Femur fracture 820-821;Both sexes;1,789 BALEARS, ILLES;Group 1904 Femur fracture 820-821;Men;546 BALEARS, ILLES;Group 1904 Femur fracture 820-821;Women;1,243 BALEARS, ILLES;Group 1905 Leg fracture, including the ankle 823-824;Both sexes;983 BALEARS, ILLES;Group 1905 Leg fracture, including the ankle 823-824;Men;464 BALEARS, ILLES;Group 1905 Leg fracture, including the ankle 823-824;Women;520 BALEARS, ILLES;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Both sexes;4,738 BALEARS, ILLES;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Men;2,680 BALEARS, ILLES;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Women;2,058 BALEARS, ILLES;Group 1907 Burns 940-949;Both sexes;101 BALEARS, ILLES;Group 1907 Burns 940-949;Men;75 BALEARS, ILLES;Group 1907 Burns 940-949;Women;26 BALEARS, ILLES;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Both sexes;401 BALEARS, ILLES;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Men;192 BALEARS, ILLES;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Women;210 BALEARS, ILLES;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Both sexes;1,930 BALEARS, ILLES;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Men;1,031 BALEARS, ILLES;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Women;899 BALEARS, ILLES;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Both sexes;5 BALEARS, ILLES;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Men;3 BALEARS, ILLES;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Women;2 BALEARS, ILLES;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Both sexes;451 BALEARS, ILLES;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Men;238 BALEARS, ILLES;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Women;213 BALEARS, ILLES;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Both sexes;2,283 BALEARS, ILLES;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Men;962 BALEARS, ILLES;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Women;1,321 BALEARS, ILLES;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Both sexes;214 BALEARS, ILLES;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Men;98 BALEARS, ILLES;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Women;115 BALEARS, ILLES;Group 2102 Contraceptive management V25;Both sexes;60 BALEARS, ILLES;Group 2102 Contraceptive management V25;Men;6 BALEARS, ILLES;Group 2102 Contraceptive management V25;Women;54 BALEARS, ILLES;Group 2103 Living newborns by type of delivery V30-V39;Both sexes;.. BALEARS, ILLES;Group 2103 Living newborns by type of delivery V30-V39;Men;.. BALEARS, ILLES;Group 2103 Living newborns by type of delivery V30-V39;Women;.. BALEARS, ILLES;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Both sexes;333 BALEARS, ILLES;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Men;199 BALEARS, ILLES;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Women;134 BALEARS, ILLES;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Both sexes;1,676 BALEARS, ILLES;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Men;659 BALEARS, ILLES;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Women;1,017 CANARIAS;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Both sexes;179,504 CANARIAS;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Men;83,925 CANARIAS;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Women;95,579 CANARIAS;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Both sexes;3,345 CANARIAS;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Men;1,789 CANARIAS;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Women;1,556 CANARIAS;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Both sexes;363 CANARIAS;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Men;191 CANARIAS;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Women;172 CANARIAS;Group 0102 Imprecise intestinal infections 009;Both sexes;193 CANARIAS;Group 0102 Imprecise intestinal infections 009;Men;89 CANARIAS;Group 0102 Imprecise intestinal infections 009;Women;104 CANARIAS;Group 0103 Tuberculosis 010-018, 137;Both sexes;86 CANARIAS;Group 0103 Tuberculosis 010-018, 137;Men;61 CANARIAS;Group 0103 Tuberculosis 010-018, 137;Women;25 CANARIAS;Group 0104 Septicaemia 038;Both sexes;1,466 CANARIAS;Group 0104 Septicaemia 038;Men;741 CANARIAS;Group 0104 Septicaemia 038;Women;725 CANARIAS;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Both sexes;96 CANARIAS;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Men;72 CANARIAS;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Women;24 CANARIAS;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Both sexes;1,142 CANARIAS;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Men;636 CANARIAS;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Women;506 CANARIAS;Group 0200 Neoplasms 140-239;Both sexes;16,428 CANARIAS;Group 0200 Neoplasms 140-239;Men;7,871 CANARIAS;Group 0200 Neoplasms 140-239;Women;8,556 CANARIAS;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Both sexes;1,395 CANARIAS;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Men;804 CANARIAS;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Women;590 CANARIAS;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Both sexes;1,153 CANARIAS;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Men;866 CANARIAS;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Women;287 CANARIAS;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Both sexes;380 CANARIAS;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Men;217 CANARIAS;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Women;163 CANARIAS;Group 0204 Malignant neoplasm of breast 174-175;Both sexes;1,426 CANARIAS;Group 0204 Malignant neoplasm of breast 174-175;Men;11 CANARIAS;Group 0204 Malignant neoplasm of breast 174-175;Women;1,415 CANARIAS;Group 0205 Malignant neoplasm of uterus 179-180, 182;Both sexes;498 CANARIAS;Group 0205 Malignant neoplasm of uterus 179-180, 182;Men;.. CANARIAS;Group 0205 Malignant neoplasm of uterus 179-180, 182;Women;498 CANARIAS;Group 0206 Malignant neoplasm of ovary 1830;Both sexes;130 CANARIAS;Group 0206 Malignant neoplasm of ovary 1830;Men;.. CANARIAS;Group 0206 Malignant neoplasm of ovary 1830;Women;130 CANARIAS;Group 0207 Malignant neoplasm of prostate 185;Both sexes;675 CANARIAS;Group 0207 Malignant neoplasm of prostate 185;Men;675 CANARIAS;Group 0207 Malignant neoplasm of prostate 185;Women;.. CANARIAS;Group 0208 Malignant neoplasm of bladder 188;Both sexes;1,142 CANARIAS;Group 0208 Malignant neoplasm of bladder 188;Men;949 CANARIAS;Group 0208 Malignant neoplasm of bladder 188;Women;193 CANARIAS;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Both sexes;5,589 CANARIAS;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Men;3,170 CANARIAS;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Women;2,419 CANARIAS;Group 0210 Carcinoma in situ 230-234;Both sexes;407 CANARIAS;Group 0210 Carcinoma in situ 230-234;Men;141 CANARIAS;Group 0210 Carcinoma in situ 230-234;Women;266 CANARIAS;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Both sexes;164 CANARIAS;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Men;91 CANARIAS;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Women;73 CANARIAS;Grupo 0212 Leiomyoma of uterus 218;Both sexes;1,093 CANARIAS;Grupo 0212 Leiomyoma of uterus 218;Men;.. CANARIAS;Grupo 0212 Leiomyoma of uterus 218;Women;1,093 CANARIAS;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Both sexes;2,375 CANARIAS;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Men;946 CANARIAS;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Women;1,429 CANARIAS;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Both sexes;1,248 CANARIAS;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Men;622 CANARIAS;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Women;626 CANARIAS;Group 0301 Anaemias 280-285;Both sexes;643 CANARIAS;Group 0301 Anaemias 280-285;Men;326 CANARIAS;Group 0301 Anaemias 280-285;Women;317 CANARIAS;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Both sexes;605 CANARIAS;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Men;296 CANARIAS;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Women;309 CANARIAS;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Both sexes;3,972 CANARIAS;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Men;1,567 CANARIAS;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Women;2,405 CANARIAS;Group 0401 Diabetes mellitus 249-250;Both sexes;1,269 CANARIAS;Group 0401 Diabetes mellitus 249-250;Men;736 CANARIAS;Group 0401 Diabetes mellitus 249-250;Women;533 CANARIAS;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Both sexes;2,703 CANARIAS;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Men;831 CANARIAS;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Women;1,872 CANARIAS;Group 0500 Mental disorders 290-319;Both sexes;3,737 CANARIAS;Group 0500 Mental disorders 290-319;Men;2,156 CANARIAS;Group 0500 Mental disorders 290-319;Women;1,581 CANARIAS;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Both sexes;78 CANARIAS;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Men;40 CANARIAS;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Women;37 CANARIAS;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Both sexes;378 CANARIAS;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Men;292 CANARIAS;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Women;86 CANARIAS;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Both sexes;500 CANARIAS;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Men;383 CANARIAS;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Women;117 CANARIAS;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Both sexes;1,193 CANARIAS;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Men;724 CANARIAS;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Women;470 CANARIAS;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Both sexes;789 CANARIAS;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Men;347 CANARIAS;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Women;442 CANARIAS;Group 0506 Other mental and behavioural disorders Rest of (290-319);Both sexes;798 CANARIAS;Group 0506 Other mental and behavioural disorders Rest of (290-319);Men;370 CANARIAS;Group 0506 Other mental and behavioural disorders Rest of (290-319);Women;429 CANARIAS;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Both sexes;4,291 CANARIAS;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Men;2,319 CANARIAS;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Women;1,972 CANARIAS;Group 0601 Alzheimer's disease 3310;Both sexes;75 CANARIAS;Group 0601 Alzheimer's disease 3310;Men;24 CANARIAS;Group 0601 Alzheimer's disease 3310;Women;51 CANARIAS;Group 0602 Multiple sclerosis 340;Both sexes;210 CANARIAS;Group 0602 Multiple sclerosis 340;Men;63 CANARIAS;Group 0602 Multiple sclerosis 340;Women;147 CANARIAS;Group 0603 Epilepsy 345;Both sexes;403 CANARIAS;Group 0603 Epilepsy 345;Men;228 CANARIAS;Group 0603 Epilepsy 345;Women;175 CANARIAS;Group 0604 Transient cerebral ischemia 435;Both sexes;435 CANARIAS;Group 0604 Transient cerebral ischemia 435;Men;240 CANARIAS;Group 0604 Transient cerebral ischemia 435;Women;195 CANARIAS;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Both sexes;3,168 CANARIAS;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Men;1,764 CANARIAS;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Women;1,403 CANARIAS;Grupo 0700 Diseases of the eye and adnexa 360-379;Both sexes;1,150 CANARIAS;Grupo 0700 Diseases of the eye and adnexa 360-379;Men;575 CANARIAS;Grupo 0700 Diseases of the eye and adnexa 360-379;Women;575 CANARIAS;Grupo 0701 Cataract 366;Both sexes;151 CANARIAS;Grupo 0701 Cataract 366;Men;62 CANARIAS;Grupo 0701 Cataract 366;Women;89 CANARIAS;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Both sexes;1,000 CANARIAS;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Men;513 CANARIAS;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Women;486 CANARIAS;Group 0800 Diseases of the ear and the mastoid 380-389;Both sexes;953 CANARIAS;Group 0800 Diseases of the ear and the mastoid 380-389;Men;494 CANARIAS;Group 0800 Diseases of the ear and the mastoid 380-389;Women;459 CANARIAS;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Both sexes;23,218 CANARIAS;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Men;13,207 CANARIAS;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Women;10,011 CANARIAS;Group 0901 Hypertensive disease 401-405;Both sexes;1,523 CANARIAS;Group 0901 Hypertensive disease 401-405;Men;693 CANARIAS;Group 0901 Hypertensive disease 401-405;Women;830 CANARIAS;Group 0902 Angina pectoris 4111, 413;Both sexes;907 CANARIAS;Group 0902 Angina pectoris 4111, 413;Men;554 CANARIAS;Group 0902 Angina pectoris 4111, 413;Women;352 CANARIAS;Group 0903 Acute myocardial infarction 410;Both sexes;2,540 CANARIAS;Group 0903 Acute myocardial infarction 410;Men;1,779 CANARIAS;Group 0903 Acute myocardial infarction 410;Women;761 CANARIAS;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Both sexes;1,693 CANARIAS;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Men;1,259 CANARIAS;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Women;434 CANARIAS;Group 0905 Diseases of the lungs circulation 415-417;Both sexes;538 CANARIAS;Group 0905 Diseases of the lungs circulation 415-417;Men;225 CANARIAS;Group 0905 Diseases of the lungs circulation 415-417;Women;313 CANARIAS;Group 0906 Heart conduction disorders and arrhytmias 426-427;Both sexes;2,657 CANARIAS;Group 0906 Heart conduction disorders and arrhytmias 426-427;Men;1,557 CANARIAS;Group 0906 Heart conduction disorders and arrhytmias 426-427;Women;1,100 CANARIAS;Grupo 0907 Heart failure 428;Both sexes;3,088 CANARIAS;Grupo 0907 Heart failure 428;Men;1,524 CANARIAS;Grupo 0907 Heart failure 428;Women;1,564 CANARIAS;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Both sexes;3,822 CANARIAS;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Men;2,106 CANARIAS;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Women;1,715 CANARIAS;Grupo 0909 Atherosclerosis 440;Both sexes;722 CANARIAS;Grupo 0909 Atherosclerosis 440;Men;570 CANARIAS;Grupo 0909 Atherosclerosis 440;Women;152 CANARIAS;Group 0910 Varicose veins of lower extremities 454;Both sexes;1,553 CANARIAS;Group 0910 Varicose veins of lower extremities 454;Men;527 CANARIAS;Group 0910 Varicose veins of lower extremities 454;Women;1,026 CANARIAS;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Both sexes;4,176 CANARIAS;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Men;2,413 CANARIAS;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Women;1,763 CANARIAS;Group 1000 Diseases of the respiratory system 0340, 460-519;Both sexes;18,199 CANARIAS;Group 1000 Diseases of the respiratory system 0340, 460-519;Men;9,866 CANARIAS;Group 1000 Diseases of the respiratory system 0340, 460-519;Women;8,333 CANARIAS;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Both sexes;634 CANARIAS;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Men;345 CANARIAS;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Women;289 CANARIAS;Group 1002 Pneumonia 480-486;Both sexes;4,096 CANARIAS;Group 1002 Pneumonia 480-486;Men;2,263 CANARIAS;Group 1002 Pneumonia 480-486;Women;1,832 CANARIAS;Group 1003 Acute bronchitis and bronchiolitis 466;Both sexes;1,821 CANARIAS;Group 1003 Acute bronchitis and bronchiolitis 466;Men;867 CANARIAS;Group 1003 Acute bronchitis and bronchiolitis 466;Women;954 CANARIAS;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Both sexes;1,803 CANARIAS;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Men;883 CANARIAS;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Women;920 CANARIAS;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Both sexes;2,003 CANARIAS;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Men;1,241 CANARIAS;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Women;762 CANARIAS;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Both sexes;2,314 CANARIAS;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Men;1,551 CANARIAS;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Women;763 CANARIAS;Group 1007 Asthma 4930-4931,4938-4939;Both sexes;765 CANARIAS;Group 1007 Asthma 4930-4931,4938-4939;Men;248 CANARIAS;Group 1007 Asthma 4930-4931,4938-4939;Women;517 CANARIAS;Group 1008 Other diseases of the respiratory system Resto of (460-519);Both sexes;4,765 CANARIAS;Group 1008 Other diseases of the respiratory system Resto of (460-519);Men;2,469 CANARIAS;Group 1008 Other diseases of the respiratory system Resto of (460-519);Women;2,296 CANARIAS;Group 1100 Diseases of the digestive system 520-579;Both sexes;23,132 CANARIAS;Group 1100 Diseases of the digestive system 520-579;Men;13,203 CANARIAS;Group 1100 Diseases of the digestive system 520-579;Women;9,929 CANARIAS;Group 1101 Disorders of the teeth and supporting structures 520-525;Both sexes;370 CANARIAS;Group 1101 Disorders of the teeth and supporting structures 520-525;Men;155 CANARIAS;Group 1101 Disorders of the teeth and supporting structures 520-525;Women;215 CANARIAS;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Both sexes;355 CANARIAS;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Men;211 CANARIAS;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Women;144 CANARIAS;Group 1103 Diseases of the esophagus 530;Both sexes;417 CANARIAS;Group 1103 Diseases of the esophagus 530;Men;260 CANARIAS;Group 1103 Diseases of the esophagus 530;Women;157 CANARIAS;Group 1104 Peptic ulcer 531-534;Both sexes;371 CANARIAS;Group 1104 Peptic ulcer 531-534;Men;266 CANARIAS;Group 1104 Peptic ulcer 531-534;Women;106 CANARIAS;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Both sexes;567 CANARIAS;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Men;280 CANARIAS;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Women;287 CANARIAS;Group 1106 Appendicitis 540-543;Both sexes;1,900 CANARIAS;Group 1106 Appendicitis 540-543;Men;1,118 CANARIAS;Group 1106 Appendicitis 540-543;Women;782 CANARIAS;Group 1107 Inguinal hernia 550;Both sexes;2,938 CANARIAS;Group 1107 Inguinal hernia 550;Men;2,666 CANARIAS;Group 1107 Inguinal hernia 550;Women;272 CANARIAS;Group 1108 Other abdominal hernia 551-553;Both sexes;2,577 CANARIAS;Group 1108 Other abdominal hernia 551-553;Men;1,409 CANARIAS;Group 1108 Other abdominal hernia 551-553;Women;1,168 CANARIAS;Group 1109 Crohn's disease and ulcerative colitis 555-556;Both sexes;511 CANARIAS;Group 1109 Crohn's disease and ulcerative colitis 555-556;Men;284 CANARIAS;Group 1109 Crohn's disease and ulcerative colitis 555-556;Women;227 CANARIAS;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Both sexes;1,770 CANARIAS;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Men;844 CANARIAS;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Women;926 CANARIAS;Group 1111 Intestinal obstruction without hernia 560;Both sexes;797 CANARIAS;Group 1111 Intestinal obstruction without hernia 560;Men;412 CANARIAS;Group 1111 Intestinal obstruction without hernia 560;Women;385 CANARIAS;Group 1112 Intestinal diverticulosis 562;Both sexes;1,003 CANARIAS;Group 1112 Intestinal diverticulosis 562;Men;512 CANARIAS;Group 1112 Intestinal diverticulosis 562;Women;491 CANARIAS;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Both sexes;1,227 CANARIAS;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Men;842 CANARIAS;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Women;385 CANARIAS;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Both sexes;773 CANARIAS;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Men;336 CANARIAS;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Women;437 CANARIAS;Group 1115 Alcoholic hepatitis 5710-5713;Both sexes;563 CANARIAS;Group 1115 Alcoholic hepatitis 5710-5713;Men;492 CANARIAS;Group 1115 Alcoholic hepatitis 5710-5713;Women;71 CANARIAS;Group 1116 Other diseases of the liver 570,5714-573;Both sexes;708 CANARIAS;Group 1116 Other diseases of the liver 570,5714-573;Men;400 CANARIAS;Group 1116 Other diseases of the liver 570,5714-573;Women;308 CANARIAS;Group 1117 Cholelithiasis 574;Both sexes;3,666 CANARIAS;Group 1117 Cholelithiasis 574;Men;1,354 CANARIAS;Group 1117 Cholelithiasis 574;Women;2,313 CANARIAS;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Both sexes;962 CANARIAS;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Men;436 CANARIAS;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Women;525 CANARIAS;Group 1119 Pancreatic diseases 577;Both sexes;1,045 CANARIAS;Group 1119 Pancreatic diseases 577;Men;586 CANARIAS;Group 1119 Pancreatic diseases 577;Women;459 CANARIAS;Group 1120 Other diseases of the digestive system Rest of (520-579);Both sexes;611 CANARIAS;Group 1120 Other diseases of the digestive system Rest of (520-579);Men;339 CANARIAS;Group 1120 Other diseases of the digestive system Rest of (520-579);Women;272 CANARIAS;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Both sexes;2,507 CANARIAS;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Men;1,397 CANARIAS;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Women;1,109 CANARIAS;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Both sexes;1,748 CANARIAS;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Men;1,071 CANARIAS;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Women;677 CANARIAS;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Both sexes;94 CANARIAS;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Men;40 CANARIAS;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Women;54 CANARIAS;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Both sexes;665 CANARIAS;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Men;286 CANARIAS;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Women;378 CANARIAS;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Both sexes;13,004 CANARIAS;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Men;6,317 CANARIAS;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Women;6,687 CANARIAS;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Both sexes;.. CANARIAS;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Men;.. CANARIAS;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Women;.. CANARIAS;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Both sexes;.. CANARIAS;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Men;.. CANARIAS;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Women;.. CANARIAS;Group 1303 Internal derangement of knee 717;Both sexes;2,143 CANARIAS;Group 1303 Internal derangement of knee 717;Men;1,401 CANARIAS;Group 1303 Internal derangement of knee 717;Women;741 CANARIAS;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Both sexes;4,612 CANARIAS;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Men;1,815 CANARIAS;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Women;2,797 CANARIAS;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Both sexes;297 CANARIAS;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Men;106 CANARIAS;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Women;191 CANARIAS;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Both sexes;540 CANARIAS;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Men;276 CANARIAS;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Women;263 CANARIAS;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Both sexes;1,550 CANARIAS;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Men;800 CANARIAS;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Women;750 CANARIAS;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Both sexes;341 CANARIAS;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Men;146 CANARIAS;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Women;195 CANARIAS;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Both sexes;1,783 CANARIAS;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Men;1,040 CANARIAS;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Women;743 CANARIAS;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Both sexes;1,738 CANARIAS;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Men;732 CANARIAS;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Women;1,006 CANARIAS;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Both sexes;10,624 CANARIAS;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Men;4,168 CANARIAS;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Women;6,455 CANARIAS;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Both sexes;1,048 CANARIAS;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Men;386 CANARIAS;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Women;662 CANARIAS;Group 1402 Renal failure 5836-5837, 584-586;Both sexes;647 CANARIAS;Group 1402 Renal failure 5836-5837, 584-586;Men;350 CANARIAS;Group 1402 Renal failure 5836-5837, 584-586;Women;297 CANARIAS;Group 1403 Urolithiasis 592, 594, 7880;Both sexes;1,056 CANARIAS;Group 1403 Urolithiasis 592, 594, 7880;Men;634 CANARIAS;Group 1403 Urolithiasis 592, 594, 7880;Women;422 CANARIAS;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Both sexes;2,571 CANARIAS;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Men;1,094 CANARIAS;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Women;1,477 CANARIAS;Group 1405 Prostatic hyperplasia 600;Both sexes;834 CANARIAS;Group 1405 Prostatic hyperplasia 600;Men;834 CANARIAS;Group 1405 Prostatic hyperplasia 600;Women;.. CANARIAS;Group 1406 Other diseases of the male genital organs 601-608;Both sexes;742 CANARIAS;Group 1406 Other diseases of the male genital organs 601-608;Men;742 CANARIAS;Group 1406 Other diseases of the male genital organs 601-608;Women;.. CANARIAS;Group 1407 Disorders of breast 610-612;Both sexes;985 CANARIAS;Group 1407 Disorders of breast 610-612;Men;119 CANARIAS;Group 1407 Disorders of breast 610-612;Women;865 CANARIAS;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Both sexes;399 CANARIAS;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Men;.. CANARIAS;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Women;399 CANARIAS;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Both sexes;199 CANARIAS;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Men;.. CANARIAS;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Women;199 CANARIAS;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Both sexes;2,143 CANARIAS;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Men;8 CANARIAS;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Women;2,135 CANARIAS;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Both sexes;18,950 CANARIAS;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Men;.. CANARIAS;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Women;18,950 CANARIAS;Group 1501 Legally induced abortion 635;Both sexes;180 CANARIAS;Group 1501 Legally induced abortion 635;Men;.. CANARIAS;Group 1501 Legally induced abortion 635;Women;180 CANARIAS;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Both sexes;1,101 CANARIAS;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Men;.. CANARIAS;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Women;1,101 CANARIAS;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Both sexes;12,999 CANARIAS;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Men;.. CANARIAS;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Women;12,999 CANARIAS;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Both sexes;3,141 CANARIAS;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Men;.. CANARIAS;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Women;3,141 CANARIAS;Group 1505 Single spontaneous delivery 650;Both sexes;463 CANARIAS;Group 1505 Single spontaneous delivery 650;Men;.. CANARIAS;Group 1505 Single spontaneous delivery 650;Women;463 CANARIAS;Group 1506 Other deliveries 6695-6697;Both sexes;106 CANARIAS;Group 1506 Other deliveries 6695-6697;Men;.. CANARIAS;Group 1506 Other deliveries 6695-6697;Women;106 CANARIAS;Group 1507 Complications related to the puerperium 670-676;Both sexes;102 CANARIAS;Group 1507 Complications related to the puerperium 670-676;Men;.. CANARIAS;Group 1507 Complications related to the puerperium 670-676;Women;102 CANARIAS;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Both sexes;858 CANARIAS;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Men;.. CANARIAS;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Women;858 CANARIAS;Group 1600 Some disorders originating in the perinatal period 760-779;Both sexes;2,694 CANARIAS;Group 1600 Some disorders originating in the perinatal period 760-779;Men;1,461 CANARIAS;Group 1600 Some disorders originating in the perinatal period 760-779;Women;1,233 CANARIAS;Group 1601 Disorders related with premature delivery and a low birth weight 765;Both sexes;679 CANARIAS;Group 1601 Disorders related with premature delivery and a low birth weight 765;Men;331 CANARIAS;Group 1601 Disorders related with premature delivery and a low birth weight 765;Women;347 CANARIAS;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Both sexes;2,015 CANARIAS;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Men;1,130 CANARIAS;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Women;885 CANARIAS;Grupo 1700 Congenital abnormalities 740-759;Both sexes;1,529 CANARIAS;Grupo 1700 Congenital abnormalities 740-759;Men;905 CANARIAS;Grupo 1700 Congenital abnormalities 740-759;Women;625 CANARIAS;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Both sexes;9,095 CANARIAS;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Men;4,770 CANARIAS;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Women;4,325 CANARIAS;Group 1801 Pain in throat and chest 7841, 7865;Both sexes;829 CANARIAS;Group 1801 Pain in throat and chest 7841, 7865;Men;438 CANARIAS;Group 1801 Pain in throat and chest 7841, 7865;Women;391 CANARIAS;Group 1802 Abdominal pain 7890;Both sexes;756 CANARIAS;Group 1802 Abdominal pain 7890;Men;319 CANARIAS;Group 1802 Abdominal pain 7890;Women;437 CANARIAS;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Both sexes;2,479 CANARIAS;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Men;1,184 CANARIAS;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Women;1,295 CANARIAS;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Both sexes;5,031 CANARIAS;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Men;2,829 CANARIAS;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Women;2,202 CANARIAS;Group 1900 Injuries and poisoning 800-999;Both sexes;16,682 CANARIAS;Group 1900 Injuries and poisoning 800-999;Men;8,972 CANARIAS;Group 1900 Injuries and poisoning 800-999;Women;7,710 CANARIAS;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Both sexes;1,168 CANARIAS;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Men;703 CANARIAS;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Women;465 CANARIAS;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Both sexes;682 CANARIAS;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Men;465 CANARIAS;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Women;217 CANARIAS;Group 1903 Radius and ulna fracture 813;Both sexes;1,296 CANARIAS;Group 1903 Radius and ulna fracture 813;Men;583 CANARIAS;Group 1903 Radius and ulna fracture 813;Women;713 CANARIAS;Group 1904 Femur fracture 820-821;Both sexes;1,812 CANARIAS;Group 1904 Femur fracture 820-821;Men;593 CANARIAS;Group 1904 Femur fracture 820-821;Women;1,219 CANARIAS;Group 1905 Leg fracture, including the ankle 823-824;Both sexes;1,570 CANARIAS;Group 1905 Leg fracture, including the ankle 823-824;Men;740 CANARIAS;Group 1905 Leg fracture, including the ankle 823-824;Women;831 CANARIAS;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Both sexes;4,870 CANARIAS;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Men;2,939 CANARIAS;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Women;1,931 CANARIAS;Group 1907 Burns 940-949;Both sexes;143 CANARIAS;Group 1907 Burns 940-949;Men;78 CANARIAS;Group 1907 Burns 940-949;Women;64 CANARIAS;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Both sexes;311 CANARIAS;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Men;179 CANARIAS;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Women;132 CANARIAS;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Both sexes;4,395 CANARIAS;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Men;2,463 CANARIAS;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Women;1,933 CANARIAS;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Both sexes;29 CANARIAS;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Men;15 CANARIAS;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Women;14 CANARIAS;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Both sexes;404 CANARIAS;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Men;213 CANARIAS;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Women;192 CANARIAS;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Both sexes;4,748 CANARIAS;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Men;2,265 CANARIAS;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Women;2,483 CANARIAS;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Both sexes;371 CANARIAS;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Men;200 CANARIAS;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Women;171 CANARIAS;Group 2102 Contraceptive management V25;Both sexes;304 CANARIAS;Group 2102 Contraceptive management V25;Men;3 CANARIAS;Group 2102 Contraceptive management V25;Women;301 CANARIAS;Group 2103 Living newborns by type of delivery V30-V39;Both sexes;.. CANARIAS;Group 2103 Living newborns by type of delivery V30-V39;Men;.. CANARIAS;Group 2103 Living newborns by type of delivery V30-V39;Women;.. CANARIAS;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Both sexes;1,374 CANARIAS;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Men;897 CANARIAS;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Women;477 CANARIAS;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Both sexes;2,699 CANARIAS;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Men;1,165 CANARIAS;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Women;1,534 Palmas, Las;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Both sexes;83,636 Palmas, Las;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Men;38,924 Palmas, Las;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Women;44,712 Palmas, Las;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Both sexes;1,486 Palmas, Las;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Men;843 Palmas, Las;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Women;643 Palmas, Las;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Both sexes;230 Palmas, Las;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Men;126 Palmas, Las;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Women;104 Palmas, Las;Group 0102 Imprecise intestinal infections 009;Both sexes;65 Palmas, Las;Group 0102 Imprecise intestinal infections 009;Men;33 Palmas, Las;Group 0102 Imprecise intestinal infections 009;Women;32 Palmas, Las;Group 0103 Tuberculosis 010-018, 137;Both sexes;52 Palmas, Las;Group 0103 Tuberculosis 010-018, 137;Men;37 Palmas, Las;Group 0103 Tuberculosis 010-018, 137;Women;15 Palmas, Las;Group 0104 Septicaemia 038;Both sexes;625 Palmas, Las;Group 0104 Septicaemia 038;Men;332 Palmas, Las;Group 0104 Septicaemia 038;Women;293 Palmas, Las;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Both sexes;38 Palmas, Las;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Men;28 Palmas, Las;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Women;10 Palmas, Las;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Both sexes;476 Palmas, Las;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Men;287 Palmas, Las;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Women;189 Palmas, Las;Group 0200 Neoplasms 140-239;Both sexes;7,510 Palmas, Las;Group 0200 Neoplasms 140-239;Men;3,659 Palmas, Las;Group 0200 Neoplasms 140-239;Women;3,851 Palmas, Las;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Both sexes;609 Palmas, Las;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Men;357 Palmas, Las;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Women;252 Palmas, Las;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Both sexes;559 Palmas, Las;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Men;416 Palmas, Las;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Women;143 Palmas, Las;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Both sexes;120 Palmas, Las;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Men;67 Palmas, Las;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Women;53 Palmas, Las;Group 0204 Malignant neoplasm of breast 174-175;Both sexes;634 Palmas, Las;Group 0204 Malignant neoplasm of breast 174-175;Men;2 Palmas, Las;Group 0204 Malignant neoplasm of breast 174-175;Women;632 Palmas, Las;Group 0205 Malignant neoplasm of uterus 179-180, 182;Both sexes;237 Palmas, Las;Group 0205 Malignant neoplasm of uterus 179-180, 182;Men;.. Palmas, Las;Group 0205 Malignant neoplasm of uterus 179-180, 182;Women;237 Palmas, Las;Group 0206 Malignant neoplasm of ovary 1830;Both sexes;62 Palmas, Las;Group 0206 Malignant neoplasm of ovary 1830;Men;.. Palmas, Las;Group 0206 Malignant neoplasm of ovary 1830;Women;62 Palmas, Las;Group 0207 Malignant neoplasm of prostate 185;Both sexes;233 Palmas, Las;Group 0207 Malignant neoplasm of prostate 185;Men;233 Palmas, Las;Group 0207 Malignant neoplasm of prostate 185;Women;.. Palmas, Las;Group 0208 Malignant neoplasm of bladder 188;Both sexes;532 Palmas, Las;Group 0208 Malignant neoplasm of bladder 188;Men;458 Palmas, Las;Group 0208 Malignant neoplasm of bladder 188;Women;74 Palmas, Las;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Both sexes;2,586 Palmas, Las;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Men;1,520 Palmas, Las;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Women;1,066 Palmas, Las;Group 0210 Carcinoma in situ 230-234;Both sexes;213 Palmas, Las;Group 0210 Carcinoma in situ 230-234;Men;105 Palmas, Las;Group 0210 Carcinoma in situ 230-234;Women;108 Palmas, Las;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Both sexes;76 Palmas, Las;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Men;37 Palmas, Las;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Women;39 Palmas, Las;Grupo 0212 Leiomyoma of uterus 218;Both sexes;483 Palmas, Las;Grupo 0212 Leiomyoma of uterus 218;Men;.. Palmas, Las;Grupo 0212 Leiomyoma of uterus 218;Women;483 Palmas, Las;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Both sexes;1,166 Palmas, Las;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Men;464 Palmas, Las;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Women;702 Palmas, Las;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Both sexes;501 Palmas, Las;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Men;264 Palmas, Las;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Women;237 Palmas, Las;Group 0301 Anaemias 280-285;Both sexes;234 Palmas, Las;Group 0301 Anaemias 280-285;Men;131 Palmas, Las;Group 0301 Anaemias 280-285;Women;103 Palmas, Las;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Both sexes;267 Palmas, Las;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Men;133 Palmas, Las;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Women;134 Palmas, Las;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Both sexes;1,993 Palmas, Las;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Men;757 Palmas, Las;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Women;1,236 Palmas, Las;Group 0401 Diabetes mellitus 249-250;Both sexes;638 Palmas, Las;Group 0401 Diabetes mellitus 249-250;Men;356 Palmas, Las;Group 0401 Diabetes mellitus 249-250;Women;282 Palmas, Las;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Both sexes;1,355 Palmas, Las;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Men;401 Palmas, Las;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Women;954 Palmas, Las;Group 0500 Mental disorders 290-319;Both sexes;1,922 Palmas, Las;Group 0500 Mental disorders 290-319;Men;1,110 Palmas, Las;Group 0500 Mental disorders 290-319;Women;812 Palmas, Las;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Both sexes;42 Palmas, Las;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Men;18 Palmas, Las;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Women;24 Palmas, Las;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Both sexes;146 Palmas, Las;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Men;120 Palmas, Las;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Women;26 Palmas, Las;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Both sexes;199 Palmas, Las;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Men;149 Palmas, Las;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Women;50 Palmas, Las;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Both sexes;669 Palmas, Las;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Men;417 Palmas, Las;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Women;252 Palmas, Las;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Both sexes;429 Palmas, Las;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Men;190 Palmas, Las;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Women;239 Palmas, Las;Group 0506 Other mental and behavioural disorders Rest of (290-319);Both sexes;437 Palmas, Las;Group 0506 Other mental and behavioural disorders Rest of (290-319);Men;216 Palmas, Las;Group 0506 Other mental and behavioural disorders Rest of (290-319);Women;221 Palmas, Las;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Both sexes;1,527 Palmas, Las;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Men;840 Palmas, Las;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Women;687 Palmas, Las;Group 0601 Alzheimer's disease 3310;Both sexes;24 Palmas, Las;Group 0601 Alzheimer's disease 3310;Men;10 Palmas, Las;Group 0601 Alzheimer's disease 3310;Women;14 Palmas, Las;Group 0602 Multiple sclerosis 340;Both sexes;36 Palmas, Las;Group 0602 Multiple sclerosis 340;Men;12 Palmas, Las;Group 0602 Multiple sclerosis 340;Women;24 Palmas, Las;Group 0603 Epilepsy 345;Both sexes;178 Palmas, Las;Group 0603 Epilepsy 345;Men;99 Palmas, Las;Group 0603 Epilepsy 345;Women;79 Palmas, Las;Group 0604 Transient cerebral ischemia 435;Both sexes;196 Palmas, Las;Group 0604 Transient cerebral ischemia 435;Men;115 Palmas, Las;Group 0604 Transient cerebral ischemia 435;Women;81 Palmas, Las;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Both sexes;1,093 Palmas, Las;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Men;604 Palmas, Las;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Women;489 Palmas, Las;Grupo 0700 Diseases of the eye and adnexa 360-379;Both sexes;309 Palmas, Las;Grupo 0700 Diseases of the eye and adnexa 360-379;Men;158 Palmas, Las;Grupo 0700 Diseases of the eye and adnexa 360-379;Women;151 Palmas, Las;Grupo 0701 Cataract 366;Both sexes;17 Palmas, Las;Grupo 0701 Cataract 366;Men;10 Palmas, Las;Grupo 0701 Cataract 366;Women;7 Palmas, Las;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Both sexes;292 Palmas, Las;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Men;148 Palmas, Las;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Women;144 Palmas, Las;Group 0800 Diseases of the ear and the mastoid 380-389;Both sexes;481 Palmas, Las;Group 0800 Diseases of the ear and the mastoid 380-389;Men;244 Palmas, Las;Group 0800 Diseases of the ear and the mastoid 380-389;Women;237 Palmas, Las;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Both sexes;11,241 Palmas, Las;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Men;6,495 Palmas, Las;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Women;4,746 Palmas, Las;Group 0901 Hypertensive disease 401-405;Both sexes;707 Palmas, Las;Group 0901 Hypertensive disease 401-405;Men;352 Palmas, Las;Group 0901 Hypertensive disease 401-405;Women;355 Palmas, Las;Group 0902 Angina pectoris 4111, 413;Both sexes;519 Palmas, Las;Group 0902 Angina pectoris 4111, 413;Men;286 Palmas, Las;Group 0902 Angina pectoris 4111, 413;Women;233 Palmas, Las;Group 0903 Acute myocardial infarction 410;Both sexes;1,481 Palmas, Las;Group 0903 Acute myocardial infarction 410;Men;1,044 Palmas, Las;Group 0903 Acute myocardial infarction 410;Women;437 Palmas, Las;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Both sexes;807 Palmas, Las;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Men;607 Palmas, Las;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Women;200 Palmas, Las;Group 0905 Diseases of the lungs circulation 415-417;Both sexes;273 Palmas, Las;Group 0905 Diseases of the lungs circulation 415-417;Men;116 Palmas, Las;Group 0905 Diseases of the lungs circulation 415-417;Women;157 Palmas, Las;Group 0906 Heart conduction disorders and arrhytmias 426-427;Both sexes;1,278 Palmas, Las;Group 0906 Heart conduction disorders and arrhytmias 426-427;Men;761 Palmas, Las;Group 0906 Heart conduction disorders and arrhytmias 426-427;Women;517 Palmas, Las;Grupo 0907 Heart failure 428;Both sexes;1,500 Palmas, Las;Grupo 0907 Heart failure 428;Men;754 Palmas, Las;Grupo 0907 Heart failure 428;Women;746 Palmas, Las;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Both sexes;1,779 Palmas, Las;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Men;1,015 Palmas, Las;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Women;764 Palmas, Las;Grupo 0909 Atherosclerosis 440;Both sexes;337 Palmas, Las;Grupo 0909 Atherosclerosis 440;Men;269 Palmas, Las;Grupo 0909 Atherosclerosis 440;Women;68 Palmas, Las;Group 0910 Varicose veins of lower extremities 454;Both sexes;682 Palmas, Las;Group 0910 Varicose veins of lower extremities 454;Men;228 Palmas, Las;Group 0910 Varicose veins of lower extremities 454;Women;454 Palmas, Las;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Both sexes;1,878 Palmas, Las;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Men;1,063 Palmas, Las;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Women;815 Palmas, Las;Group 1000 Diseases of the respiratory system 0340, 460-519;Both sexes;7,957 Palmas, Las;Group 1000 Diseases of the respiratory system 0340, 460-519;Men;4,425 Palmas, Las;Group 1000 Diseases of the respiratory system 0340, 460-519;Women;3,532 Palmas, Las;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Both sexes;301 Palmas, Las;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Men;164 Palmas, Las;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Women;137 Palmas, Las;Group 1002 Pneumonia 480-486;Both sexes;1,988 Palmas, Las;Group 1002 Pneumonia 480-486;Men;1,125 Palmas, Las;Group 1002 Pneumonia 480-486;Women;863 Palmas, Las;Group 1003 Acute bronchitis and bronchiolitis 466;Both sexes;618 Palmas, Las;Group 1003 Acute bronchitis and bronchiolitis 466;Men;290 Palmas, Las;Group 1003 Acute bronchitis and bronchiolitis 466;Women;328 Palmas, Las;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Both sexes;1,016 Palmas, Las;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Men;510 Palmas, Las;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Women;506 Palmas, Las;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Both sexes;955 Palmas, Las;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Men;598 Palmas, Las;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Women;357 Palmas, Las;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Both sexes;876 Palmas, Las;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Men;610 Palmas, Las;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Women;266 Palmas, Las;Group 1007 Asthma 4930-4931,4938-4939;Both sexes;352 Palmas, Las;Group 1007 Asthma 4930-4931,4938-4939;Men;123 Palmas, Las;Group 1007 Asthma 4930-4931,4938-4939;Women;229 Palmas, Las;Group 1008 Other diseases of the respiratory system Resto of (460-519);Both sexes;1,851 Palmas, Las;Group 1008 Other diseases of the respiratory system Resto of (460-519);Men;1,005 Palmas, Las;Group 1008 Other diseases of the respiratory system Resto of (460-519);Women;846 Palmas, Las;Group 1100 Diseases of the digestive system 520-579;Both sexes;10,075 Palmas, Las;Group 1100 Diseases of the digestive system 520-579;Men;5,728 Palmas, Las;Group 1100 Diseases of the digestive system 520-579;Women;4,347 Palmas, Las;Group 1101 Disorders of the teeth and supporting structures 520-525;Both sexes;111 Palmas, Las;Group 1101 Disorders of the teeth and supporting structures 520-525;Men;55 Palmas, Las;Group 1101 Disorders of the teeth and supporting structures 520-525;Women;56 Palmas, Las;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Both sexes;109 Palmas, Las;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Men;62 Palmas, Las;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Women;47 Palmas, Las;Group 1103 Diseases of the esophagus 530;Both sexes;168 Palmas, Las;Group 1103 Diseases of the esophagus 530;Men;97 Palmas, Las;Group 1103 Diseases of the esophagus 530;Women;71 Palmas, Las;Group 1104 Peptic ulcer 531-534;Both sexes;192 Palmas, Las;Group 1104 Peptic ulcer 531-534;Men;133 Palmas, Las;Group 1104 Peptic ulcer 531-534;Women;59 Palmas, Las;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Both sexes;204 Palmas, Las;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Men;109 Palmas, Las;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Women;95 Palmas, Las;Group 1106 Appendicitis 540-543;Both sexes;943 Palmas, Las;Group 1106 Appendicitis 540-543;Men;564 Palmas, Las;Group 1106 Appendicitis 540-543;Women;379 Palmas, Las;Group 1107 Inguinal hernia 550;Both sexes;1,382 Palmas, Las;Group 1107 Inguinal hernia 550;Men;1,253 Palmas, Las;Group 1107 Inguinal hernia 550;Women;129 Palmas, Las;Group 1108 Other abdominal hernia 551-553;Both sexes;1,290 Palmas, Las;Group 1108 Other abdominal hernia 551-553;Men;683 Palmas, Las;Group 1108 Other abdominal hernia 551-553;Women;607 Palmas, Las;Group 1109 Crohn's disease and ulcerative colitis 555-556;Both sexes;236 Palmas, Las;Group 1109 Crohn's disease and ulcerative colitis 555-556;Men;122 Palmas, Las;Group 1109 Crohn's disease and ulcerative colitis 555-556;Women;114 Palmas, Las;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Both sexes;577 Palmas, Las;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Men;284 Palmas, Las;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Women;293 Palmas, Las;Group 1111 Intestinal obstruction without hernia 560;Both sexes;383 Palmas, Las;Group 1111 Intestinal obstruction without hernia 560;Men;196 Palmas, Las;Group 1111 Intestinal obstruction without hernia 560;Women;187 Palmas, Las;Group 1112 Intestinal diverticulosis 562;Both sexes;401 Palmas, Las;Group 1112 Intestinal diverticulosis 562;Men;226 Palmas, Las;Group 1112 Intestinal diverticulosis 562;Women;175 Palmas, Las;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Both sexes;411 Palmas, Las;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Men;275 Palmas, Las;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Women;136 Palmas, Las;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Both sexes;335 Palmas, Las;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Men;139 Palmas, Las;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Women;196 Palmas, Las;Group 1115 Alcoholic hepatitis 5710-5713;Both sexes;173 Palmas, Las;Group 1115 Alcoholic hepatitis 5710-5713;Men;144 Palmas, Las;Group 1115 Alcoholic hepatitis 5710-5713;Women;29 Palmas, Las;Group 1116 Other diseases of the liver 570,5714-573;Both sexes;342 Palmas, Las;Group 1116 Other diseases of the liver 570,5714-573;Men;196 Palmas, Las;Group 1116 Other diseases of the liver 570,5714-573;Women;146 Palmas, Las;Group 1117 Cholelithiasis 574;Both sexes;1,676 Palmas, Las;Group 1117 Cholelithiasis 574;Men;568 Palmas, Las;Group 1117 Cholelithiasis 574;Women;1,108 Palmas, Las;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Both sexes;329 Palmas, Las;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Men;170 Palmas, Las;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Women;159 Palmas, Las;Group 1119 Pancreatic diseases 577;Both sexes;550 Palmas, Las;Group 1119 Pancreatic diseases 577;Men;308 Palmas, Las;Group 1119 Pancreatic diseases 577;Women;242 Palmas, Las;Group 1120 Other diseases of the digestive system Rest of (520-579);Both sexes;263 Palmas, Las;Group 1120 Other diseases of the digestive system Rest of (520-579);Men;144 Palmas, Las;Group 1120 Other diseases of the digestive system Rest of (520-579);Women;119 Palmas, Las;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Both sexes;1,115 Palmas, Las;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Men;622 Palmas, Las;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Women;493 Palmas, Las;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Both sexes;717 Palmas, Las;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Men;439 Palmas, Las;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Women;278 Palmas, Las;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Both sexes;34 Palmas, Las;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Men;18 Palmas, Las;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Women;16 Palmas, Las;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Both sexes;364 Palmas, Las;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Men;165 Palmas, Las;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Women;199 Palmas, Las;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Both sexes;6,280 Palmas, Las;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Men;3,135 Palmas, Las;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Women;3,145 Palmas, Las;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Both sexes;.. Palmas, Las;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Men;.. Palmas, Las;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Women;.. Palmas, Las;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Both sexes;.. Palmas, Las;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Men;.. Palmas, Las;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Women;.. Palmas, Las;Group 1303 Internal derangement of knee 717;Both sexes;926 Palmas, Las;Group 1303 Internal derangement of knee 717;Men;628 Palmas, Las;Group 1303 Internal derangement of knee 717;Women;298 Palmas, Las;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Both sexes;2,139 Palmas, Las;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Men;884 Palmas, Las;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Women;1,255 Palmas, Las;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Both sexes;177 Palmas, Las;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Men;67 Palmas, Las;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Women;110 Palmas, Las;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Both sexes;287 Palmas, Las;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Men;145 Palmas, Las;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Women;142 Palmas, Las;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Both sexes;888 Palmas, Las;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Men;470 Palmas, Las;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Women;418 Palmas, Las;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Both sexes;204 Palmas, Las;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Men;85 Palmas, Las;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Women;119 Palmas, Las;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Both sexes;783 Palmas, Las;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Men;479 Palmas, Las;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Women;304 Palmas, Las;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Both sexes;876 Palmas, Las;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Men;377 Palmas, Las;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Women;499 Palmas, Las;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Both sexes;5,149 Palmas, Las;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Men;2,007 Palmas, Las;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Women;3,142 Palmas, Las;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Both sexes;524 Palmas, Las;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Men;183 Palmas, Las;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Women;341 Palmas, Las;Group 1402 Renal failure 5836-5837, 584-586;Both sexes;361 Palmas, Las;Group 1402 Renal failure 5836-5837, 584-586;Men;188 Palmas, Las;Group 1402 Renal failure 5836-5837, 584-586;Women;173 Palmas, Las;Group 1403 Urolithiasis 592, 594, 7880;Both sexes;405 Palmas, Las;Group 1403 Urolithiasis 592, 594, 7880;Men;257 Palmas, Las;Group 1403 Urolithiasis 592, 594, 7880;Women;148 Palmas, Las;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Both sexes;1,081 Palmas, Las;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Men;490 Palmas, Las;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Women;591 Palmas, Las;Group 1405 Prostatic hyperplasia 600;Both sexes;477 Palmas, Las;Group 1405 Prostatic hyperplasia 600;Men;477 Palmas, Las;Group 1405 Prostatic hyperplasia 600;Women;.. Palmas, Las;Group 1406 Other diseases of the male genital organs 601-608;Both sexes;324 Palmas, Las;Group 1406 Other diseases of the male genital organs 601-608;Men;324 Palmas, Las;Group 1406 Other diseases of the male genital organs 601-608;Women;.. Palmas, Las;Group 1407 Disorders of breast 610-612;Both sexes;598 Palmas, Las;Group 1407 Disorders of breast 610-612;Men;86 Palmas, Las;Group 1407 Disorders of breast 610-612;Women;512 Palmas, Las;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Both sexes;173 Palmas, Las;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Men;.. Palmas, Las;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Women;173 Palmas, Las;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Both sexes;120 Palmas, Las;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Men;.. Palmas, Las;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Women;120 Palmas, Las;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Both sexes;1,086 Palmas, Las;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Men;2 Palmas, Las;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Women;1,084 Palmas, Las;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Both sexes;10,021 Palmas, Las;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Men;.. Palmas, Las;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Women;10,021 Palmas, Las;Group 1501 Legally induced abortion 635;Both sexes;85 Palmas, Las;Group 1501 Legally induced abortion 635;Men;.. Palmas, Las;Group 1501 Legally induced abortion 635;Women;85 Palmas, Las;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Both sexes;494 Palmas, Las;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Men;.. Palmas, Las;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Women;494 Palmas, Las;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Both sexes;6,906 Palmas, Las;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Men;.. Palmas, Las;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Women;6,906 Palmas, Las;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Both sexes;1,895 Palmas, Las;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Men;.. Palmas, Las;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Women;1,895 Palmas, Las;Group 1505 Single spontaneous delivery 650;Both sexes;170 Palmas, Las;Group 1505 Single spontaneous delivery 650;Men;.. Palmas, Las;Group 1505 Single spontaneous delivery 650;Women;170 Palmas, Las;Group 1506 Other deliveries 6695-6697;Both sexes;66 Palmas, Las;Group 1506 Other deliveries 6695-6697;Men;.. Palmas, Las;Group 1506 Other deliveries 6695-6697;Women;66 Palmas, Las;Group 1507 Complications related to the puerperium 670-676;Both sexes;36 Palmas, Las;Group 1507 Complications related to the puerperium 670-676;Men;.. Palmas, Las;Group 1507 Complications related to the puerperium 670-676;Women;36 Palmas, Las;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Both sexes;369 Palmas, Las;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Men;.. Palmas, Las;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Women;369 Palmas, Las;Group 1600 Some disorders originating in the perinatal period 760-779;Both sexes;1,303 Palmas, Las;Group 1600 Some disorders originating in the perinatal period 760-779;Men;694 Palmas, Las;Group 1600 Some disorders originating in the perinatal period 760-779;Women;609 Palmas, Las;Group 1601 Disorders related with premature delivery and a low birth weight 765;Both sexes;294 Palmas, Las;Group 1601 Disorders related with premature delivery and a low birth weight 765;Men;127 Palmas, Las;Group 1601 Disorders related with premature delivery and a low birth weight 765;Women;167 Palmas, Las;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Both sexes;1,009 Palmas, Las;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Men;567 Palmas, Las;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Women;442 Palmas, Las;Grupo 1700 Congenital abnormalities 740-759;Both sexes;843 Palmas, Las;Grupo 1700 Congenital abnormalities 740-759;Men;518 Palmas, Las;Grupo 1700 Congenital abnormalities 740-759;Women;325 Palmas, Las;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Both sexes;4,951 Palmas, Las;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Men;2,625 Palmas, Las;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Women;2,326 Palmas, Las;Group 1801 Pain in throat and chest 7841, 7865;Both sexes;372 Palmas, Las;Group 1801 Pain in throat and chest 7841, 7865;Men;194 Palmas, Las;Group 1801 Pain in throat and chest 7841, 7865;Women;178 Palmas, Las;Group 1802 Abdominal pain 7890;Both sexes;264 Palmas, Las;Group 1802 Abdominal pain 7890;Men;124 Palmas, Las;Group 1802 Abdominal pain 7890;Women;140 Palmas, Las;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Both sexes;1,744 Palmas, Las;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Men;790 Palmas, Las;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Women;954 Palmas, Las;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Both sexes;2,571 Palmas, Las;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Men;1,517 Palmas, Las;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Women;1,054 Palmas, Las;Group 1900 Injuries and poisoning 800-999;Both sexes;7,254 Palmas, Las;Group 1900 Injuries and poisoning 800-999;Men;3,981 Palmas, Las;Group 1900 Injuries and poisoning 800-999;Women;3,273 Palmas, Las;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Both sexes;572 Palmas, Las;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Men;343 Palmas, Las;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Women;229 Palmas, Las;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Both sexes;255 Palmas, Las;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Men;187 Palmas, Las;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Women;68 Palmas, Las;Group 1903 Radius and ulna fracture 813;Both sexes;462 Palmas, Las;Group 1903 Radius and ulna fracture 813;Men;237 Palmas, Las;Group 1903 Radius and ulna fracture 813;Women;225 Palmas, Las;Group 1904 Femur fracture 820-821;Both sexes;729 Palmas, Las;Group 1904 Femur fracture 820-821;Men;241 Palmas, Las;Group 1904 Femur fracture 820-821;Women;488 Palmas, Las;Group 1905 Leg fracture, including the ankle 823-824;Both sexes;719 Palmas, Las;Group 1905 Leg fracture, including the ankle 823-824;Men;354 Palmas, Las;Group 1905 Leg fracture, including the ankle 823-824;Women;365 Palmas, Las;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Both sexes;2,142 Palmas, Las;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Men;1,296 Palmas, Las;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Women;846 Palmas, Las;Group 1907 Burns 940-949;Both sexes;74 Palmas, Las;Group 1907 Burns 940-949;Men;39 Palmas, Las;Group 1907 Burns 940-949;Women;35 Palmas, Las;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Both sexes;165 Palmas, Las;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Men;101 Palmas, Las;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Women;64 Palmas, Las;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Both sexes;1,972 Palmas, Las;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Men;1,093 Palmas, Las;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Women;879 Palmas, Las;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Both sexes;12 Palmas, Las;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Men;7 Palmas, Las;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Women;5 Palmas, Las;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Both sexes;152 Palmas, Las;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Men;83 Palmas, Las;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Women;69 Palmas, Las;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Both sexes;1,718 Palmas, Las;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Men;819 Palmas, Las;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Women;899 Palmas, Las;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Both sexes;148 Palmas, Las;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Men;76 Palmas, Las;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Women;72 Palmas, Las;Group 2102 Contraceptive management V25;Both sexes;111 Palmas, Las;Group 2102 Contraceptive management V25;Men;.. Palmas, Las;Group 2102 Contraceptive management V25;Women;111 Palmas, Las;Group 2103 Living newborns by type of delivery V30-V39;Both sexes;.. Palmas, Las;Group 2103 Living newborns by type of delivery V30-V39;Men;.. Palmas, Las;Group 2103 Living newborns by type of delivery V30-V39;Women;.. Palmas, Las;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Both sexes;471 Palmas, Las;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Men;308 Palmas, Las;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Women;163 Palmas, Las;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Both sexes;988 Palmas, Las;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Men;435 Palmas, Las;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Women;553 Santa Cruz de Tenerife;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Both sexes;95,868 Santa Cruz de Tenerife;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Men;45,001 Santa Cruz de Tenerife;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Women;50,867 Santa Cruz de Tenerife;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Both sexes;1,859 Santa Cruz de Tenerife;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Men;946 Santa Cruz de Tenerife;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Women;913 Santa Cruz de Tenerife;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Both sexes;133 Santa Cruz de Tenerife;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Men;65 Santa Cruz de Tenerife;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Women;68 Santa Cruz de Tenerife;Group 0102 Imprecise intestinal infections 009;Both sexes;128 Santa Cruz de Tenerife;Group 0102 Imprecise intestinal infections 009;Men;56 Santa Cruz de Tenerife;Group 0102 Imprecise intestinal infections 009;Women;72 Santa Cruz de Tenerife;Group 0103 Tuberculosis 010-018, 137;Both sexes;34 Santa Cruz de Tenerife;Group 0103 Tuberculosis 010-018, 137;Men;24 Santa Cruz de Tenerife;Group 0103 Tuberculosis 010-018, 137;Women;10 Santa Cruz de Tenerife;Group 0104 Septicaemia 038;Both sexes;841 Santa Cruz de Tenerife;Group 0104 Septicaemia 038;Men;409 Santa Cruz de Tenerife;Group 0104 Septicaemia 038;Women;432 Santa Cruz de Tenerife;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Both sexes;58 Santa Cruz de Tenerife;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Men;44 Santa Cruz de Tenerife;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Women;14 Santa Cruz de Tenerife;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Both sexes;666 Santa Cruz de Tenerife;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Men;349 Santa Cruz de Tenerife;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Women;317 Santa Cruz de Tenerife;Group 0200 Neoplasms 140-239;Both sexes;8,918 Santa Cruz de Tenerife;Group 0200 Neoplasms 140-239;Men;4,212 Santa Cruz de Tenerife;Group 0200 Neoplasms 140-239;Women;4,705 Santa Cruz de Tenerife;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Both sexes;786 Santa Cruz de Tenerife;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Men;447 Santa Cruz de Tenerife;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Women;338 Santa Cruz de Tenerife;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Both sexes;594 Santa Cruz de Tenerife;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Men;450 Santa Cruz de Tenerife;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Women;144 Santa Cruz de Tenerife;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Both sexes;260 Santa Cruz de Tenerife;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Men;150 Santa Cruz de Tenerife;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Women;110 Santa Cruz de Tenerife;Group 0204 Malignant neoplasm of breast 174-175;Both sexes;792 Santa Cruz de Tenerife;Group 0204 Malignant neoplasm of breast 174-175;Men;9 Santa Cruz de Tenerife;Group 0204 Malignant neoplasm of breast 174-175;Women;783 Santa Cruz de Tenerife;Group 0205 Malignant neoplasm of uterus 179-180, 182;Both sexes;261 Santa Cruz de Tenerife;Group 0205 Malignant neoplasm of uterus 179-180, 182;Men;.. Santa Cruz de Tenerife;Group 0205 Malignant neoplasm of uterus 179-180, 182;Women;261 Santa Cruz de Tenerife;Group 0206 Malignant neoplasm of ovary 1830;Both sexes;68 Santa Cruz de Tenerife;Group 0206 Malignant neoplasm of ovary 1830;Men;.. Santa Cruz de Tenerife;Group 0206 Malignant neoplasm of ovary 1830;Women;68 Santa Cruz de Tenerife;Group 0207 Malignant neoplasm of prostate 185;Both sexes;442 Santa Cruz de Tenerife;Group 0207 Malignant neoplasm of prostate 185;Men;442 Santa Cruz de Tenerife;Group 0207 Malignant neoplasm of prostate 185;Women;.. Santa Cruz de Tenerife;Group 0208 Malignant neoplasm of bladder 188;Both sexes;610 Santa Cruz de Tenerife;Group 0208 Malignant neoplasm of bladder 188;Men;491 Santa Cruz de Tenerife;Group 0208 Malignant neoplasm of bladder 188;Women;119 Santa Cruz de Tenerife;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Both sexes;3,003 Santa Cruz de Tenerife;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Men;1,650 Santa Cruz de Tenerife;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Women;1,353 Santa Cruz de Tenerife;Group 0210 Carcinoma in situ 230-234;Both sexes;194 Santa Cruz de Tenerife;Group 0210 Carcinoma in situ 230-234;Men;36 Santa Cruz de Tenerife;Group 0210 Carcinoma in situ 230-234;Women;158 Santa Cruz de Tenerife;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Both sexes;88 Santa Cruz de Tenerife;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Men;54 Santa Cruz de Tenerife;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Women;34 Santa Cruz de Tenerife;Grupo 0212 Leiomyoma of uterus 218;Both sexes;610 Santa Cruz de Tenerife;Grupo 0212 Leiomyoma of uterus 218;Men;.. Santa Cruz de Tenerife;Grupo 0212 Leiomyoma of uterus 218;Women;610 Santa Cruz de Tenerife;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Both sexes;1,209 Santa Cruz de Tenerife;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Men;482 Santa Cruz de Tenerife;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Women;727 Santa Cruz de Tenerife;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Both sexes;747 Santa Cruz de Tenerife;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Men;358 Santa Cruz de Tenerife;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Women;389 Santa Cruz de Tenerife;Group 0301 Anaemias 280-285;Both sexes;409 Santa Cruz de Tenerife;Group 0301 Anaemias 280-285;Men;195 Santa Cruz de Tenerife;Group 0301 Anaemias 280-285;Women;214 Santa Cruz de Tenerife;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Both sexes;338 Santa Cruz de Tenerife;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Men;163 Santa Cruz de Tenerife;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Women;175 Santa Cruz de Tenerife;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Both sexes;1,979 Santa Cruz de Tenerife;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Men;810 Santa Cruz de Tenerife;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Women;1,169 Santa Cruz de Tenerife;Group 0401 Diabetes mellitus 249-250;Both sexes;631 Santa Cruz de Tenerife;Group 0401 Diabetes mellitus 249-250;Men;380 Santa Cruz de Tenerife;Group 0401 Diabetes mellitus 249-250;Women;251 Santa Cruz de Tenerife;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Both sexes;1,348 Santa Cruz de Tenerife;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Men;430 Santa Cruz de Tenerife;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Women;918 Santa Cruz de Tenerife;Group 0500 Mental disorders 290-319;Both sexes;1,815 Santa Cruz de Tenerife;Group 0500 Mental disorders 290-319;Men;1,046 Santa Cruz de Tenerife;Group 0500 Mental disorders 290-319;Women;769 Santa Cruz de Tenerife;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Both sexes;36 Santa Cruz de Tenerife;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Men;22 Santa Cruz de Tenerife;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Women;13 Santa Cruz de Tenerife;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Both sexes;232 Santa Cruz de Tenerife;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Men;172 Santa Cruz de Tenerife;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Women;60 Santa Cruz de Tenerife;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Both sexes;301 Santa Cruz de Tenerife;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Men;234 Santa Cruz de Tenerife;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Women;67 Santa Cruz de Tenerife;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Both sexes;524 Santa Cruz de Tenerife;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Men;307 Santa Cruz de Tenerife;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Women;218 Santa Cruz de Tenerife;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Both sexes;360 Santa Cruz de Tenerife;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Men;157 Santa Cruz de Tenerife;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Women;203 Santa Cruz de Tenerife;Group 0506 Other mental and behavioural disorders Rest of (290-319);Both sexes;361 Santa Cruz de Tenerife;Group 0506 Other mental and behavioural disorders Rest of (290-319);Men;154 Santa Cruz de Tenerife;Group 0506 Other mental and behavioural disorders Rest of (290-319);Women;208 Santa Cruz de Tenerife;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Both sexes;2,764 Santa Cruz de Tenerife;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Men;1,479 Santa Cruz de Tenerife;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Women;1,285 Santa Cruz de Tenerife;Group 0601 Alzheimer's disease 3310;Both sexes;51 Santa Cruz de Tenerife;Group 0601 Alzheimer's disease 3310;Men;14 Santa Cruz de Tenerife;Group 0601 Alzheimer's disease 3310;Women;37 Santa Cruz de Tenerife;Group 0602 Multiple sclerosis 340;Both sexes;174 Santa Cruz de Tenerife;Group 0602 Multiple sclerosis 340;Men;51 Santa Cruz de Tenerife;Group 0602 Multiple sclerosis 340;Women;123 Santa Cruz de Tenerife;Group 0603 Epilepsy 345;Both sexes;225 Santa Cruz de Tenerife;Group 0603 Epilepsy 345;Men;129 Santa Cruz de Tenerife;Group 0603 Epilepsy 345;Women;96 Santa Cruz de Tenerife;Group 0604 Transient cerebral ischemia 435;Both sexes;239 Santa Cruz de Tenerife;Group 0604 Transient cerebral ischemia 435;Men;125 Santa Cruz de Tenerife;Group 0604 Transient cerebral ischemia 435;Women;114 Santa Cruz de Tenerife;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Both sexes;2,075 Santa Cruz de Tenerife;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Men;1,160 Santa Cruz de Tenerife;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Women;914 Santa Cruz de Tenerife;Grupo 0700 Diseases of the eye and adnexa 360-379;Both sexes;841 Santa Cruz de Tenerife;Grupo 0700 Diseases of the eye and adnexa 360-379;Men;417 Santa Cruz de Tenerife;Grupo 0700 Diseases of the eye and adnexa 360-379;Women;424 Santa Cruz de Tenerife;Grupo 0701 Cataract 366;Both sexes;134 Santa Cruz de Tenerife;Grupo 0701 Cataract 366;Men;52 Santa Cruz de Tenerife;Grupo 0701 Cataract 366;Women;82 Santa Cruz de Tenerife;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Both sexes;708 Santa Cruz de Tenerife;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Men;365 Santa Cruz de Tenerife;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Women;342 Santa Cruz de Tenerife;Group 0800 Diseases of the ear and the mastoid 380-389;Both sexes;472 Santa Cruz de Tenerife;Group 0800 Diseases of the ear and the mastoid 380-389;Men;250 Santa Cruz de Tenerife;Group 0800 Diseases of the ear and the mastoid 380-389;Women;222 Santa Cruz de Tenerife;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Both sexes;11,977 Santa Cruz de Tenerife;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Men;6,712 Santa Cruz de Tenerife;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Women;5,265 Santa Cruz de Tenerife;Group 0901 Hypertensive disease 401-405;Both sexes;816 Santa Cruz de Tenerife;Group 0901 Hypertensive disease 401-405;Men;341 Santa Cruz de Tenerife;Group 0901 Hypertensive disease 401-405;Women;475 Santa Cruz de Tenerife;Group 0902 Angina pectoris 4111, 413;Both sexes;388 Santa Cruz de Tenerife;Group 0902 Angina pectoris 4111, 413;Men;268 Santa Cruz de Tenerife;Group 0902 Angina pectoris 4111, 413;Women;119 Santa Cruz de Tenerife;Group 0903 Acute myocardial infarction 410;Both sexes;1,059 Santa Cruz de Tenerife;Group 0903 Acute myocardial infarction 410;Men;735 Santa Cruz de Tenerife;Group 0903 Acute myocardial infarction 410;Women;324 Santa Cruz de Tenerife;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Both sexes;886 Santa Cruz de Tenerife;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Men;652 Santa Cruz de Tenerife;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Women;234 Santa Cruz de Tenerife;Group 0905 Diseases of the lungs circulation 415-417;Both sexes;265 Santa Cruz de Tenerife;Group 0905 Diseases of the lungs circulation 415-417;Men;109 Santa Cruz de Tenerife;Group 0905 Diseases of the lungs circulation 415-417;Women;156 Santa Cruz de Tenerife;Group 0906 Heart conduction disorders and arrhytmias 426-427;Both sexes;1,379 Santa Cruz de Tenerife;Group 0906 Heart conduction disorders and arrhytmias 426-427;Men;796 Santa Cruz de Tenerife;Group 0906 Heart conduction disorders and arrhytmias 426-427;Women;583 Santa Cruz de Tenerife;Grupo 0907 Heart failure 428;Both sexes;1,588 Santa Cruz de Tenerife;Grupo 0907 Heart failure 428;Men;770 Santa Cruz de Tenerife;Grupo 0907 Heart failure 428;Women;818 Santa Cruz de Tenerife;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Both sexes;2,043 Santa Cruz de Tenerife;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Men;1,091 Santa Cruz de Tenerife;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Women;951 Santa Cruz de Tenerife;Grupo 0909 Atherosclerosis 440;Both sexes;385 Santa Cruz de Tenerife;Grupo 0909 Atherosclerosis 440;Men;301 Santa Cruz de Tenerife;Grupo 0909 Atherosclerosis 440;Women;84 Santa Cruz de Tenerife;Group 0910 Varicose veins of lower extremities 454;Both sexes;871 Santa Cruz de Tenerife;Group 0910 Varicose veins of lower extremities 454;Men;299 Santa Cruz de Tenerife;Group 0910 Varicose veins of lower extremities 454;Women;572 Santa Cruz de Tenerife;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Both sexes;2,298 Santa Cruz de Tenerife;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Men;1,350 Santa Cruz de Tenerife;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Women;948 Santa Cruz de Tenerife;Group 1000 Diseases of the respiratory system 0340, 460-519;Both sexes;10,242 Santa Cruz de Tenerife;Group 1000 Diseases of the respiratory system 0340, 460-519;Men;5,441 Santa Cruz de Tenerife;Group 1000 Diseases of the respiratory system 0340, 460-519;Women;4,801 Santa Cruz de Tenerife;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Both sexes;333 Santa Cruz de Tenerife;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Men;181 Santa Cruz de Tenerife;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Women;152 Santa Cruz de Tenerife;Group 1002 Pneumonia 480-486;Both sexes;2,108 Santa Cruz de Tenerife;Group 1002 Pneumonia 480-486;Men;1,138 Santa Cruz de Tenerife;Group 1002 Pneumonia 480-486;Women;969 Santa Cruz de Tenerife;Group 1003 Acute bronchitis and bronchiolitis 466;Both sexes;1,203 Santa Cruz de Tenerife;Group 1003 Acute bronchitis and bronchiolitis 466;Men;577 Santa Cruz de Tenerife;Group 1003 Acute bronchitis and bronchiolitis 466;Women;626 Santa Cruz de Tenerife;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Both sexes;787 Santa Cruz de Tenerife;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Men;373 Santa Cruz de Tenerife;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Women;414 Santa Cruz de Tenerife;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Both sexes;1,048 Santa Cruz de Tenerife;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Men;643 Santa Cruz de Tenerife;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Women;405 Santa Cruz de Tenerife;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Both sexes;1,438 Santa Cruz de Tenerife;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Men;941 Santa Cruz de Tenerife;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Women;497 Santa Cruz de Tenerife;Group 1007 Asthma 4930-4931,4938-4939;Both sexes;413 Santa Cruz de Tenerife;Group 1007 Asthma 4930-4931,4938-4939;Men;125 Santa Cruz de Tenerife;Group 1007 Asthma 4930-4931,4938-4939;Women;288 Santa Cruz de Tenerife;Group 1008 Other diseases of the respiratory system Resto of (460-519);Both sexes;2,914 Santa Cruz de Tenerife;Group 1008 Other diseases of the respiratory system Resto of (460-519);Men;1,464 Santa Cruz de Tenerife;Group 1008 Other diseases of the respiratory system Resto of (460-519);Women;1,450 Santa Cruz de Tenerife;Group 1100 Diseases of the digestive system 520-579;Both sexes;13,057 Santa Cruz de Tenerife;Group 1100 Diseases of the digestive system 520-579;Men;7,475 Santa Cruz de Tenerife;Group 1100 Diseases of the digestive system 520-579;Women;5,582 Santa Cruz de Tenerife;Group 1101 Disorders of the teeth and supporting structures 520-525;Both sexes;259 Santa Cruz de Tenerife;Group 1101 Disorders of the teeth and supporting structures 520-525;Men;100 Santa Cruz de Tenerife;Group 1101 Disorders of the teeth and supporting structures 520-525;Women;159 Santa Cruz de Tenerife;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Both sexes;246 Santa Cruz de Tenerife;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Men;149 Santa Cruz de Tenerife;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Women;97 Santa Cruz de Tenerife;Group 1103 Diseases of the esophagus 530;Both sexes;249 Santa Cruz de Tenerife;Group 1103 Diseases of the esophagus 530;Men;163 Santa Cruz de Tenerife;Group 1103 Diseases of the esophagus 530;Women;86 Santa Cruz de Tenerife;Group 1104 Peptic ulcer 531-534;Both sexes;179 Santa Cruz de Tenerife;Group 1104 Peptic ulcer 531-534;Men;133 Santa Cruz de Tenerife;Group 1104 Peptic ulcer 531-534;Women;47 Santa Cruz de Tenerife;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Both sexes;363 Santa Cruz de Tenerife;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Men;171 Santa Cruz de Tenerife;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Women;192 Santa Cruz de Tenerife;Group 1106 Appendicitis 540-543;Both sexes;957 Santa Cruz de Tenerife;Group 1106 Appendicitis 540-543;Men;554 Santa Cruz de Tenerife;Group 1106 Appendicitis 540-543;Women;403 Santa Cruz de Tenerife;Group 1107 Inguinal hernia 550;Both sexes;1,556 Santa Cruz de Tenerife;Group 1107 Inguinal hernia 550;Men;1,413 Santa Cruz de Tenerife;Group 1107 Inguinal hernia 550;Women;143 Santa Cruz de Tenerife;Group 1108 Other abdominal hernia 551-553;Both sexes;1,287 Santa Cruz de Tenerife;Group 1108 Other abdominal hernia 551-553;Men;726 Santa Cruz de Tenerife;Group 1108 Other abdominal hernia 551-553;Women;561 Santa Cruz de Tenerife;Group 1109 Crohn's disease and ulcerative colitis 555-556;Both sexes;275 Santa Cruz de Tenerife;Group 1109 Crohn's disease and ulcerative colitis 555-556;Men;162 Santa Cruz de Tenerife;Group 1109 Crohn's disease and ulcerative colitis 555-556;Women;113 Santa Cruz de Tenerife;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Both sexes;1,193 Santa Cruz de Tenerife;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Men;560 Santa Cruz de Tenerife;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Women;633 Santa Cruz de Tenerife;Group 1111 Intestinal obstruction without hernia 560;Both sexes;414 Santa Cruz de Tenerife;Group 1111 Intestinal obstruction without hernia 560;Men;216 Santa Cruz de Tenerife;Group 1111 Intestinal obstruction without hernia 560;Women;198 Santa Cruz de Tenerife;Group 1112 Intestinal diverticulosis 562;Both sexes;602 Santa Cruz de Tenerife;Group 1112 Intestinal diverticulosis 562;Men;286 Santa Cruz de Tenerife;Group 1112 Intestinal diverticulosis 562;Women;316 Santa Cruz de Tenerife;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Both sexes;816 Santa Cruz de Tenerife;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Men;567 Santa Cruz de Tenerife;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Women;249 Santa Cruz de Tenerife;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Both sexes;438 Santa Cruz de Tenerife;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Men;197 Santa Cruz de Tenerife;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Women;241 Santa Cruz de Tenerife;Group 1115 Alcoholic hepatitis 5710-5713;Both sexes;390 Santa Cruz de Tenerife;Group 1115 Alcoholic hepatitis 5710-5713;Men;348 Santa Cruz de Tenerife;Group 1115 Alcoholic hepatitis 5710-5713;Women;42 Santa Cruz de Tenerife;Group 1116 Other diseases of the liver 570,5714-573;Both sexes;366 Santa Cruz de Tenerife;Group 1116 Other diseases of the liver 570,5714-573;Men;204 Santa Cruz de Tenerife;Group 1116 Other diseases of the liver 570,5714-573;Women;162 Santa Cruz de Tenerife;Group 1117 Cholelithiasis 574;Both sexes;1,990 Santa Cruz de Tenerife;Group 1117 Cholelithiasis 574;Men;786 Santa Cruz de Tenerife;Group 1117 Cholelithiasis 574;Women;1,205 Santa Cruz de Tenerife;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Both sexes;633 Santa Cruz de Tenerife;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Men;266 Santa Cruz de Tenerife;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Women;366 Santa Cruz de Tenerife;Group 1119 Pancreatic diseases 577;Both sexes;495 Santa Cruz de Tenerife;Group 1119 Pancreatic diseases 577;Men;278 Santa Cruz de Tenerife;Group 1119 Pancreatic diseases 577;Women;217 Santa Cruz de Tenerife;Group 1120 Other diseases of the digestive system Rest of (520-579);Both sexes;348 Santa Cruz de Tenerife;Group 1120 Other diseases of the digestive system Rest of (520-579);Men;195 Santa Cruz de Tenerife;Group 1120 Other diseases of the digestive system Rest of (520-579);Women;153 Santa Cruz de Tenerife;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Both sexes;1,392 Santa Cruz de Tenerife;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Men;775 Santa Cruz de Tenerife;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Women;616 Santa Cruz de Tenerife;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Both sexes;1,031 Santa Cruz de Tenerife;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Men;632 Santa Cruz de Tenerife;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Women;399 Santa Cruz de Tenerife;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Both sexes;60 Santa Cruz de Tenerife;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Men;22 Santa Cruz de Tenerife;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Women;38 Santa Cruz de Tenerife;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Both sexes;301 Santa Cruz de Tenerife;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Men;121 Santa Cruz de Tenerife;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Women;179 Santa Cruz de Tenerife;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Both sexes;6,724 Santa Cruz de Tenerife;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Men;3,182 Santa Cruz de Tenerife;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Women;3,542 Santa Cruz de Tenerife;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Both sexes;.. Santa Cruz de Tenerife;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Men;.. Santa Cruz de Tenerife;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Women;.. Santa Cruz de Tenerife;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Both sexes;.. Santa Cruz de Tenerife;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Men;.. Santa Cruz de Tenerife;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Women;.. Santa Cruz de Tenerife;Group 1303 Internal derangement of knee 717;Both sexes;1,217 Santa Cruz de Tenerife;Group 1303 Internal derangement of knee 717;Men;773 Santa Cruz de Tenerife;Group 1303 Internal derangement of knee 717;Women;443 Santa Cruz de Tenerife;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Both sexes;2,473 Santa Cruz de Tenerife;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Men;931 Santa Cruz de Tenerife;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Women;1,542 Santa Cruz de Tenerife;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Both sexes;120 Santa Cruz de Tenerife;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Men;39 Santa Cruz de Tenerife;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Women;81 Santa Cruz de Tenerife;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Both sexes;253 Santa Cruz de Tenerife;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Men;131 Santa Cruz de Tenerife;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Women;121 Santa Cruz de Tenerife;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Both sexes;662 Santa Cruz de Tenerife;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Men;330 Santa Cruz de Tenerife;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Women;332 Santa Cruz de Tenerife;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Both sexes;137 Santa Cruz de Tenerife;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Men;61 Santa Cruz de Tenerife;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Women;76 Santa Cruz de Tenerife;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Both sexes;1,000 Santa Cruz de Tenerife;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Men;561 Santa Cruz de Tenerife;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Women;439 Santa Cruz de Tenerife;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Both sexes;862 Santa Cruz de Tenerife;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Men;355 Santa Cruz de Tenerife;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Women;507 Santa Cruz de Tenerife;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Both sexes;5,475 Santa Cruz de Tenerife;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Men;2,161 Santa Cruz de Tenerife;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Women;3,313 Santa Cruz de Tenerife;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Both sexes;524 Santa Cruz de Tenerife;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Men;203 Santa Cruz de Tenerife;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Women;321 Santa Cruz de Tenerife;Group 1402 Renal failure 5836-5837, 584-586;Both sexes;286 Santa Cruz de Tenerife;Group 1402 Renal failure 5836-5837, 584-586;Men;162 Santa Cruz de Tenerife;Group 1402 Renal failure 5836-5837, 584-586;Women;124 Santa Cruz de Tenerife;Group 1403 Urolithiasis 592, 594, 7880;Both sexes;651 Santa Cruz de Tenerife;Group 1403 Urolithiasis 592, 594, 7880;Men;377 Santa Cruz de Tenerife;Group 1403 Urolithiasis 592, 594, 7880;Women;274 Santa Cruz de Tenerife;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Both sexes;1,490 Santa Cruz de Tenerife;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Men;604 Santa Cruz de Tenerife;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Women;886 Santa Cruz de Tenerife;Group 1405 Prostatic hyperplasia 600;Both sexes;357 Santa Cruz de Tenerife;Group 1405 Prostatic hyperplasia 600;Men;357 Santa Cruz de Tenerife;Group 1405 Prostatic hyperplasia 600;Women;.. Santa Cruz de Tenerife;Group 1406 Other diseases of the male genital organs 601-608;Both sexes;418 Santa Cruz de Tenerife;Group 1406 Other diseases of the male genital organs 601-608;Men;418 Santa Cruz de Tenerife;Group 1406 Other diseases of the male genital organs 601-608;Women;.. Santa Cruz de Tenerife;Group 1407 Disorders of breast 610-612;Both sexes;387 Santa Cruz de Tenerife;Group 1407 Disorders of breast 610-612;Men;33 Santa Cruz de Tenerife;Group 1407 Disorders of breast 610-612;Women;353 Santa Cruz de Tenerife;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Both sexes;226 Santa Cruz de Tenerife;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Men;.. Santa Cruz de Tenerife;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Women;226 Santa Cruz de Tenerife;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Both sexes;79 Santa Cruz de Tenerife;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Men;.. Santa Cruz de Tenerife;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Women;79 Santa Cruz de Tenerife;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Both sexes;1,057 Santa Cruz de Tenerife;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Men;6 Santa Cruz de Tenerife;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Women;1,051 Santa Cruz de Tenerife;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Both sexes;8,929 Santa Cruz de Tenerife;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Men;.. Santa Cruz de Tenerife;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Women;8,929 Santa Cruz de Tenerife;Group 1501 Legally induced abortion 635;Both sexes;95 Santa Cruz de Tenerife;Group 1501 Legally induced abortion 635;Men;.. Santa Cruz de Tenerife;Group 1501 Legally induced abortion 635;Women;95 Santa Cruz de Tenerife;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Both sexes;607 Santa Cruz de Tenerife;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Men;.. Santa Cruz de Tenerife;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Women;607 Santa Cruz de Tenerife;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Both sexes;6,093 Santa Cruz de Tenerife;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Men;.. Santa Cruz de Tenerife;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Women;6,093 Santa Cruz de Tenerife;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Both sexes;1,246 Santa Cruz de Tenerife;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Men;.. Santa Cruz de Tenerife;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Women;1,246 Santa Cruz de Tenerife;Group 1505 Single spontaneous delivery 650;Both sexes;293 Santa Cruz de Tenerife;Group 1505 Single spontaneous delivery 650;Men;.. Santa Cruz de Tenerife;Group 1505 Single spontaneous delivery 650;Women;293 Santa Cruz de Tenerife;Group 1506 Other deliveries 6695-6697;Both sexes;40 Santa Cruz de Tenerife;Group 1506 Other deliveries 6695-6697;Men;.. Santa Cruz de Tenerife;Group 1506 Other deliveries 6695-6697;Women;40 Santa Cruz de Tenerife;Group 1507 Complications related to the puerperium 670-676;Both sexes;66 Santa Cruz de Tenerife;Group 1507 Complications related to the puerperium 670-676;Men;.. Santa Cruz de Tenerife;Group 1507 Complications related to the puerperium 670-676;Women;66 Santa Cruz de Tenerife;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Both sexes;489 Santa Cruz de Tenerife;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Men;.. Santa Cruz de Tenerife;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Women;489 Santa Cruz de Tenerife;Group 1600 Some disorders originating in the perinatal period 760-779;Both sexes;1,391 Santa Cruz de Tenerife;Group 1600 Some disorders originating in the perinatal period 760-779;Men;767 Santa Cruz de Tenerife;Group 1600 Some disorders originating in the perinatal period 760-779;Women;624 Santa Cruz de Tenerife;Group 1601 Disorders related with premature delivery and a low birth weight 765;Both sexes;385 Santa Cruz de Tenerife;Group 1601 Disorders related with premature delivery and a low birth weight 765;Men;204 Santa Cruz de Tenerife;Group 1601 Disorders related with premature delivery and a low birth weight 765;Women;180 Santa Cruz de Tenerife;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Both sexes;1,006 Santa Cruz de Tenerife;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Men;563 Santa Cruz de Tenerife;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Women;443 Santa Cruz de Tenerife;Grupo 1700 Congenital abnormalities 740-759;Both sexes;686 Santa Cruz de Tenerife;Grupo 1700 Congenital abnormalities 740-759;Men;387 Santa Cruz de Tenerife;Grupo 1700 Congenital abnormalities 740-759;Women;300 Santa Cruz de Tenerife;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Both sexes;4,144 Santa Cruz de Tenerife;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Men;2,145 Santa Cruz de Tenerife;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Women;1,999 Santa Cruz de Tenerife;Group 1801 Pain in throat and chest 7841, 7865;Both sexes;457 Santa Cruz de Tenerife;Group 1801 Pain in throat and chest 7841, 7865;Men;244 Santa Cruz de Tenerife;Group 1801 Pain in throat and chest 7841, 7865;Women;213 Santa Cruz de Tenerife;Group 1802 Abdominal pain 7890;Both sexes;492 Santa Cruz de Tenerife;Group 1802 Abdominal pain 7890;Men;195 Santa Cruz de Tenerife;Group 1802 Abdominal pain 7890;Women;297 Santa Cruz de Tenerife;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Both sexes;735 Santa Cruz de Tenerife;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Men;394 Santa Cruz de Tenerife;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Women;341 Santa Cruz de Tenerife;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Both sexes;2,460 Santa Cruz de Tenerife;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Men;1,312 Santa Cruz de Tenerife;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Women;1,148 Santa Cruz de Tenerife;Group 1900 Injuries and poisoning 800-999;Both sexes;9,428 Santa Cruz de Tenerife;Group 1900 Injuries and poisoning 800-999;Men;4,991 Santa Cruz de Tenerife;Group 1900 Injuries and poisoning 800-999;Women;4,437 Santa Cruz de Tenerife;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Both sexes;596 Santa Cruz de Tenerife;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Men;360 Santa Cruz de Tenerife;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Women;236 Santa Cruz de Tenerife;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Both sexes;427 Santa Cruz de Tenerife;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Men;278 Santa Cruz de Tenerife;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Women;149 Santa Cruz de Tenerife;Group 1903 Radius and ulna fracture 813;Both sexes;834 Santa Cruz de Tenerife;Group 1903 Radius and ulna fracture 813;Men;346 Santa Cruz de Tenerife;Group 1903 Radius and ulna fracture 813;Women;488 Santa Cruz de Tenerife;Group 1904 Femur fracture 820-821;Both sexes;1,083 Santa Cruz de Tenerife;Group 1904 Femur fracture 820-821;Men;352 Santa Cruz de Tenerife;Group 1904 Femur fracture 820-821;Women;731 Santa Cruz de Tenerife;Group 1905 Leg fracture, including the ankle 823-824;Both sexes;851 Santa Cruz de Tenerife;Group 1905 Leg fracture, including the ankle 823-824;Men;386 Santa Cruz de Tenerife;Group 1905 Leg fracture, including the ankle 823-824;Women;466 Santa Cruz de Tenerife;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Both sexes;2,728 Santa Cruz de Tenerife;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Men;1,643 Santa Cruz de Tenerife;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Women;1,085 Santa Cruz de Tenerife;Group 1907 Burns 940-949;Both sexes;69 Santa Cruz de Tenerife;Group 1907 Burns 940-949;Men;39 Santa Cruz de Tenerife;Group 1907 Burns 940-949;Women;29 Santa Cruz de Tenerife;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Both sexes;146 Santa Cruz de Tenerife;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Men;78 Santa Cruz de Tenerife;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Women;68 Santa Cruz de Tenerife;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Both sexes;2,423 Santa Cruz de Tenerife;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Men;1,370 Santa Cruz de Tenerife;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Women;1,054 Santa Cruz de Tenerife;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Both sexes;17 Santa Cruz de Tenerife;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Men;8 Santa Cruz de Tenerife;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Women;9 Santa Cruz de Tenerife;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Both sexes;252 Santa Cruz de Tenerife;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Men;130 Santa Cruz de Tenerife;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Women;123 Santa Cruz de Tenerife;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Both sexes;3,030 Santa Cruz de Tenerife;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Men;1,446 Santa Cruz de Tenerife;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Women;1,584 Santa Cruz de Tenerife;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Both sexes;223 Santa Cruz de Tenerife;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Men;124 Santa Cruz de Tenerife;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Women;99 Santa Cruz de Tenerife;Group 2102 Contraceptive management V25;Both sexes;193 Santa Cruz de Tenerife;Group 2102 Contraceptive management V25;Men;3 Santa Cruz de Tenerife;Group 2102 Contraceptive management V25;Women;190 Santa Cruz de Tenerife;Group 2103 Living newborns by type of delivery V30-V39;Both sexes;.. Santa Cruz de Tenerife;Group 2103 Living newborns by type of delivery V30-V39;Men;.. Santa Cruz de Tenerife;Group 2103 Living newborns by type of delivery V30-V39;Women;.. Santa Cruz de Tenerife;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Both sexes;903 Santa Cruz de Tenerife;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Men;589 Santa Cruz de Tenerife;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Women;314 Santa Cruz de Tenerife;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Both sexes;1,711 Santa Cruz de Tenerife;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Men;730 Santa Cruz de Tenerife;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Women;981 CANTABRIA;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Both sexes;58,590 CANTABRIA;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Men;28,307 CANTABRIA;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Women;30,283 CANTABRIA;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Both sexes;1,296 CANTABRIA;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Men;766 CANTABRIA;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Women;530 CANTABRIA;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Both sexes;178 CANTABRIA;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Men;106 CANTABRIA;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Women;72 CANTABRIA;Group 0102 Imprecise intestinal infections 009;Both sexes;25 CANTABRIA;Group 0102 Imprecise intestinal infections 009;Men;16 CANTABRIA;Group 0102 Imprecise intestinal infections 009;Women;9 CANTABRIA;Group 0103 Tuberculosis 010-018, 137;Both sexes;47 CANTABRIA;Group 0103 Tuberculosis 010-018, 137;Men;25 CANTABRIA;Group 0103 Tuberculosis 010-018, 137;Women;22 CANTABRIA;Group 0104 Septicaemia 038;Both sexes;646 CANTABRIA;Group 0104 Septicaemia 038;Men;379 CANTABRIA;Group 0104 Septicaemia 038;Women;267 CANTABRIA;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Both sexes;24 CANTABRIA;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Men;20 CANTABRIA;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Women;4 CANTABRIA;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Both sexes;376 CANTABRIA;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Men;220 CANTABRIA;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Women;156 CANTABRIA;Group 0200 Neoplasms 140-239;Both sexes;5,659 CANTABRIA;Group 0200 Neoplasms 140-239;Men;2,936 CANTABRIA;Group 0200 Neoplasms 140-239;Women;2,723 CANTABRIA;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Both sexes;580 CANTABRIA;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Men;372 CANTABRIA;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Women;208 CANTABRIA;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Both sexes;407 CANTABRIA;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Men;305 CANTABRIA;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Women;102 CANTABRIA;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Both sexes;118 CANTABRIA;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Men;49 CANTABRIA;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Women;69 CANTABRIA;Group 0204 Malignant neoplasm of breast 174-175;Both sexes;375 CANTABRIA;Group 0204 Malignant neoplasm of breast 174-175;Men;1 CANTABRIA;Group 0204 Malignant neoplasm of breast 174-175;Women;374 CANTABRIA;Group 0205 Malignant neoplasm of uterus 179-180, 182;Both sexes;124 CANTABRIA;Group 0205 Malignant neoplasm of uterus 179-180, 182;Men;.. CANTABRIA;Group 0205 Malignant neoplasm of uterus 179-180, 182;Women;124 CANTABRIA;Group 0206 Malignant neoplasm of ovary 1830;Both sexes;40 CANTABRIA;Group 0206 Malignant neoplasm of ovary 1830;Men;.. CANTABRIA;Group 0206 Malignant neoplasm of ovary 1830;Women;40 CANTABRIA;Group 0207 Malignant neoplasm of prostate 185;Both sexes;184 CANTABRIA;Group 0207 Malignant neoplasm of prostate 185;Men;184 CANTABRIA;Group 0207 Malignant neoplasm of prostate 185;Women;.. CANTABRIA;Group 0208 Malignant neoplasm of bladder 188;Both sexes;458 CANTABRIA;Group 0208 Malignant neoplasm of bladder 188;Men;391 CANTABRIA;Group 0208 Malignant neoplasm of bladder 188;Women;67 CANTABRIA;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Both sexes;1,902 CANTABRIA;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Men;1,076 CANTABRIA;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Women;826 CANTABRIA;Group 0210 Carcinoma in situ 230-234;Both sexes;107 CANTABRIA;Group 0210 Carcinoma in situ 230-234;Men;33 CANTABRIA;Group 0210 Carcinoma in situ 230-234;Women;74 CANTABRIA;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Both sexes;73 CANTABRIA;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Men;45 CANTABRIA;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Women;28 CANTABRIA;Grupo 0212 Leiomyoma of uterus 218;Both sexes;283 CANTABRIA;Grupo 0212 Leiomyoma of uterus 218;Men;.. CANTABRIA;Grupo 0212 Leiomyoma of uterus 218;Women;283 CANTABRIA;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Both sexes;1,008 CANTABRIA;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Men;480 CANTABRIA;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Women;528 CANTABRIA;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Both sexes;600 CANTABRIA;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Men;311 CANTABRIA;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Women;289 CANTABRIA;Group 0301 Anaemias 280-285;Both sexes;381 CANTABRIA;Group 0301 Anaemias 280-285;Men;195 CANTABRIA;Group 0301 Anaemias 280-285;Women;186 CANTABRIA;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Both sexes;219 CANTABRIA;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Men;116 CANTABRIA;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Women;103 CANTABRIA;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Both sexes;1,091 CANTABRIA;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Men;403 CANTABRIA;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Women;688 CANTABRIA;Group 0401 Diabetes mellitus 249-250;Both sexes;308 CANTABRIA;Group 0401 Diabetes mellitus 249-250;Men;161 CANTABRIA;Group 0401 Diabetes mellitus 249-250;Women;147 CANTABRIA;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Both sexes;783 CANTABRIA;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Men;242 CANTABRIA;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Women;541 CANTABRIA;Group 0500 Mental disorders 290-319;Both sexes;1,212 CANTABRIA;Group 0500 Mental disorders 290-319;Men;591 CANTABRIA;Group 0500 Mental disorders 290-319;Women;621 CANTABRIA;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Both sexes;48 CANTABRIA;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Men;16 CANTABRIA;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Women;32 CANTABRIA;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Both sexes;94 CANTABRIA;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Men;71 CANTABRIA;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Women;23 CANTABRIA;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Both sexes;57 CANTABRIA;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Men;28 CANTABRIA;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Women;29 CANTABRIA;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Both sexes;417 CANTABRIA;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Men;225 CANTABRIA;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Women;192 CANTABRIA;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Both sexes;265 CANTABRIA;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Men;101 CANTABRIA;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Women;164 CANTABRIA;Group 0506 Other mental and behavioural disorders Rest of (290-319);Both sexes;331 CANTABRIA;Group 0506 Other mental and behavioural disorders Rest of (290-319);Men;150 CANTABRIA;Group 0506 Other mental and behavioural disorders Rest of (290-319);Women;181 CANTABRIA;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Both sexes;1,111 CANTABRIA;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Men;544 CANTABRIA;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Women;567 CANTABRIA;Group 0601 Alzheimer's disease 3310;Both sexes;28 CANTABRIA;Group 0601 Alzheimer's disease 3310;Men;7 CANTABRIA;Group 0601 Alzheimer's disease 3310;Women;21 CANTABRIA;Group 0602 Multiple sclerosis 340;Both sexes;25 CANTABRIA;Group 0602 Multiple sclerosis 340;Men;10 CANTABRIA;Group 0602 Multiple sclerosis 340;Women;15 CANTABRIA;Group 0603 Epilepsy 345;Both sexes;152 CANTABRIA;Group 0603 Epilepsy 345;Men;85 CANTABRIA;Group 0603 Epilepsy 345;Women;67 CANTABRIA;Group 0604 Transient cerebral ischemia 435;Both sexes;206 CANTABRIA;Group 0604 Transient cerebral ischemia 435;Men;93 CANTABRIA;Group 0604 Transient cerebral ischemia 435;Women;113 CANTABRIA;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Both sexes;700 CANTABRIA;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Men;349 CANTABRIA;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Women;351 CANTABRIA;Grupo 0700 Diseases of the eye and adnexa 360-379;Both sexes;197 CANTABRIA;Grupo 0700 Diseases of the eye and adnexa 360-379;Men;97 CANTABRIA;Grupo 0700 Diseases of the eye and adnexa 360-379;Women;100 CANTABRIA;Grupo 0701 Cataract 366;Both sexes;54 CANTABRIA;Grupo 0701 Cataract 366;Men;27 CANTABRIA;Grupo 0701 Cataract 366;Women;27 CANTABRIA;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Both sexes;143 CANTABRIA;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Men;70 CANTABRIA;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Women;73 CANTABRIA;Group 0800 Diseases of the ear and the mastoid 380-389;Both sexes;292 CANTABRIA;Group 0800 Diseases of the ear and the mastoid 380-389;Men;154 CANTABRIA;Group 0800 Diseases of the ear and the mastoid 380-389;Women;138 CANTABRIA;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Both sexes;8,317 CANTABRIA;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Men;4,898 CANTABRIA;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Women;3,419 CANTABRIA;Group 0901 Hypertensive disease 401-405;Both sexes;383 CANTABRIA;Group 0901 Hypertensive disease 401-405;Men;176 CANTABRIA;Group 0901 Hypertensive disease 401-405;Women;207 CANTABRIA;Group 0902 Angina pectoris 4111, 413;Both sexes;377 CANTABRIA;Group 0902 Angina pectoris 4111, 413;Men;235 CANTABRIA;Group 0902 Angina pectoris 4111, 413;Women;142 CANTABRIA;Group 0903 Acute myocardial infarction 410;Both sexes;640 CANTABRIA;Group 0903 Acute myocardial infarction 410;Men;420 CANTABRIA;Group 0903 Acute myocardial infarction 410;Women;220 CANTABRIA;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Both sexes;616 CANTABRIA;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Men;478 CANTABRIA;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Women;138 CANTABRIA;Group 0905 Diseases of the lungs circulation 415-417;Both sexes;281 CANTABRIA;Group 0905 Diseases of the lungs circulation 415-417;Men;109 CANTABRIA;Group 0905 Diseases of the lungs circulation 415-417;Women;172 CANTABRIA;Group 0906 Heart conduction disorders and arrhytmias 426-427;Both sexes;1,162 CANTABRIA;Group 0906 Heart conduction disorders and arrhytmias 426-427;Men;677 CANTABRIA;Group 0906 Heart conduction disorders and arrhytmias 426-427;Women;485 CANTABRIA;Grupo 0907 Heart failure 428;Both sexes;1,262 CANTABRIA;Grupo 0907 Heart failure 428;Men;670 CANTABRIA;Grupo 0907 Heart failure 428;Women;592 CANTABRIA;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Both sexes;1,421 CANTABRIA;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Men;739 CANTABRIA;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Women;682 CANTABRIA;Grupo 0909 Atherosclerosis 440;Both sexes;443 CANTABRIA;Grupo 0909 Atherosclerosis 440;Men;356 CANTABRIA;Grupo 0909 Atherosclerosis 440;Women;87 CANTABRIA;Group 0910 Varicose veins of lower extremities 454;Both sexes;41 CANTABRIA;Group 0910 Varicose veins of lower extremities 454;Men;11 CANTABRIA;Group 0910 Varicose veins of lower extremities 454;Women;30 CANTABRIA;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Both sexes;1,691 CANTABRIA;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Men;1,027 CANTABRIA;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Women;664 CANTABRIA;Group 1000 Diseases of the respiratory system 0340, 460-519;Both sexes;6,230 CANTABRIA;Group 1000 Diseases of the respiratory system 0340, 460-519;Men;3,627 CANTABRIA;Group 1000 Diseases of the respiratory system 0340, 460-519;Women;2,603 CANTABRIA;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Both sexes;172 CANTABRIA;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Men;98 CANTABRIA;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Women;74 CANTABRIA;Group 1002 Pneumonia 480-486;Both sexes;1,221 CANTABRIA;Group 1002 Pneumonia 480-486;Men;748 CANTABRIA;Group 1002 Pneumonia 480-486;Women;473 CANTABRIA;Group 1003 Acute bronchitis and bronchiolitis 466;Both sexes;202 CANTABRIA;Group 1003 Acute bronchitis and bronchiolitis 466;Men;112 CANTABRIA;Group 1003 Acute bronchitis and bronchiolitis 466;Women;90 CANTABRIA;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Both sexes;474 CANTABRIA;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Men;269 CANTABRIA;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Women;205 CANTABRIA;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Both sexes;385 CANTABRIA;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Men;240 CANTABRIA;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Women;145 CANTABRIA;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Both sexes;1,293 CANTABRIA;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Men;970 CANTABRIA;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Women;323 CANTABRIA;Group 1007 Asthma 4930-4931,4938-4939;Both sexes;426 CANTABRIA;Group 1007 Asthma 4930-4931,4938-4939;Men;158 CANTABRIA;Group 1007 Asthma 4930-4931,4938-4939;Women;268 CANTABRIA;Group 1008 Other diseases of the respiratory system Resto of (460-519);Both sexes;2,057 CANTABRIA;Group 1008 Other diseases of the respiratory system Resto of (460-519);Men;1,032 CANTABRIA;Group 1008 Other diseases of the respiratory system Resto of (460-519);Women;1,025 CANTABRIA;Group 1100 Diseases of the digestive system 520-579;Both sexes;6,463 CANTABRIA;Group 1100 Diseases of the digestive system 520-579;Men;3,555 CANTABRIA;Group 1100 Diseases of the digestive system 520-579;Women;2,908 CANTABRIA;Group 1101 Disorders of the teeth and supporting structures 520-525;Both sexes;68 CANTABRIA;Group 1101 Disorders of the teeth and supporting structures 520-525;Men;35 CANTABRIA;Group 1101 Disorders of the teeth and supporting structures 520-525;Women;33 CANTABRIA;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Both sexes;96 CANTABRIA;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Men;56 CANTABRIA;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Women;40 CANTABRIA;Group 1103 Diseases of the esophagus 530;Both sexes;130 CANTABRIA;Group 1103 Diseases of the esophagus 530;Men;83 CANTABRIA;Group 1103 Diseases of the esophagus 530;Women;47 CANTABRIA;Group 1104 Peptic ulcer 531-534;Both sexes;180 CANTABRIA;Group 1104 Peptic ulcer 531-534;Men;122 CANTABRIA;Group 1104 Peptic ulcer 531-534;Women;58 CANTABRIA;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Both sexes;148 CANTABRIA;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Men;80 CANTABRIA;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Women;68 CANTABRIA;Group 1106 Appendicitis 540-543;Both sexes;631 CANTABRIA;Group 1106 Appendicitis 540-543;Men;377 CANTABRIA;Group 1106 Appendicitis 540-543;Women;254 CANTABRIA;Group 1107 Inguinal hernia 550;Both sexes;507 CANTABRIA;Group 1107 Inguinal hernia 550;Men;437 CANTABRIA;Group 1107 Inguinal hernia 550;Women;70 CANTABRIA;Group 1108 Other abdominal hernia 551-553;Both sexes;563 CANTABRIA;Group 1108 Other abdominal hernia 551-553;Men;258 CANTABRIA;Group 1108 Other abdominal hernia 551-553;Women;305 CANTABRIA;Group 1109 Crohn's disease and ulcerative colitis 555-556;Both sexes;177 CANTABRIA;Group 1109 Crohn's disease and ulcerative colitis 555-556;Men;88 CANTABRIA;Group 1109 Crohn's disease and ulcerative colitis 555-556;Women;89 CANTABRIA;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Both sexes;266 CANTABRIA;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Men;117 CANTABRIA;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Women;149 CANTABRIA;Group 1111 Intestinal obstruction without hernia 560;Both sexes;299 CANTABRIA;Group 1111 Intestinal obstruction without hernia 560;Men;151 CANTABRIA;Group 1111 Intestinal obstruction without hernia 560;Women;148 CANTABRIA;Group 1112 Intestinal diverticulosis 562;Both sexes;300 CANTABRIA;Group 1112 Intestinal diverticulosis 562;Men;116 CANTABRIA;Group 1112 Intestinal diverticulosis 562;Women;184 CANTABRIA;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Both sexes;313 CANTABRIA;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Men;203 CANTABRIA;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Women;110 CANTABRIA;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Both sexes;234 CANTABRIA;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Men;92 CANTABRIA;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Women;142 CANTABRIA;Group 1115 Alcoholic hepatitis 5710-5713;Both sexes;133 CANTABRIA;Group 1115 Alcoholic hepatitis 5710-5713;Men;116 CANTABRIA;Group 1115 Alcoholic hepatitis 5710-5713;Women;17 CANTABRIA;Group 1116 Other diseases of the liver 570,5714-573;Both sexes;235 CANTABRIA;Group 1116 Other diseases of the liver 570,5714-573;Men;173 CANTABRIA;Group 1116 Other diseases of the liver 570,5714-573;Women;62 CANTABRIA;Group 1117 Cholelithiasis 574;Both sexes;1,275 CANTABRIA;Group 1117 Cholelithiasis 574;Men;556 CANTABRIA;Group 1117 Cholelithiasis 574;Women;719 CANTABRIA;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Both sexes;303 CANTABRIA;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Men;166 CANTABRIA;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Women;137 CANTABRIA;Group 1119 Pancreatic diseases 577;Both sexes;323 CANTABRIA;Group 1119 Pancreatic diseases 577;Men;179 CANTABRIA;Group 1119 Pancreatic diseases 577;Women;144 CANTABRIA;Group 1120 Other diseases of the digestive system Rest of (520-579);Both sexes;282 CANTABRIA;Group 1120 Other diseases of the digestive system Rest of (520-579);Men;150 CANTABRIA;Group 1120 Other diseases of the digestive system Rest of (520-579);Women;132 CANTABRIA;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Both sexes;592 CANTABRIA;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Men;300 CANTABRIA;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Women;292 CANTABRIA;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Both sexes;306 CANTABRIA;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Men;172 CANTABRIA;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Women;134 CANTABRIA;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Both sexes;34 CANTABRIA;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Men;15 CANTABRIA;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Women;19 CANTABRIA;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Both sexes;252 CANTABRIA;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Men;113 CANTABRIA;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Women;139 CANTABRIA;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Both sexes;4,815 CANTABRIA;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Men;2,314 CANTABRIA;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Women;2,501 CANTABRIA;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Both sexes;.. CANTABRIA;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Men;.. CANTABRIA;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Women;.. CANTABRIA;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Both sexes;.. CANTABRIA;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Men;.. CANTABRIA;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Women;.. CANTABRIA;Group 1303 Internal derangement of knee 717;Both sexes;454 CANTABRIA;Group 1303 Internal derangement of knee 717;Men;302 CANTABRIA;Group 1303 Internal derangement of knee 717;Women;152 CANTABRIA;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Both sexes;2,226 CANTABRIA;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Men;1,078 CANTABRIA;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Women;1,148 CANTABRIA;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Both sexes;97 CANTABRIA;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Men;38 CANTABRIA;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Women;59 CANTABRIA;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Both sexes;78 CANTABRIA;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Men;38 CANTABRIA;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Women;40 CANTABRIA;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Both sexes;207 CANTABRIA;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Men;106 CANTABRIA;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Women;101 CANTABRIA;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Both sexes;55 CANTABRIA;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Men;21 CANTABRIA;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Women;34 CANTABRIA;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Both sexes;652 CANTABRIA;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Men;397 CANTABRIA;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Women;255 CANTABRIA;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Both sexes;1,046 CANTABRIA;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Men;334 CANTABRIA;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Women;712 CANTABRIA;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Both sexes;3,179 CANTABRIA;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Men;1,437 CANTABRIA;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Women;1,742 CANTABRIA;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Both sexes;270 CANTABRIA;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Men;99 CANTABRIA;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Women;171 CANTABRIA;Group 1402 Renal failure 5836-5837, 584-586;Both sexes;297 CANTABRIA;Group 1402 Renal failure 5836-5837, 584-586;Men;174 CANTABRIA;Group 1402 Renal failure 5836-5837, 584-586;Women;123 CANTABRIA;Group 1403 Urolithiasis 592, 594, 7880;Both sexes;281 CANTABRIA;Group 1403 Urolithiasis 592, 594, 7880;Men;178 CANTABRIA;Group 1403 Urolithiasis 592, 594, 7880;Women;103 CANTABRIA;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Both sexes;910 CANTABRIA;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Men;404 CANTABRIA;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Women;506 CANTABRIA;Group 1405 Prostatic hyperplasia 600;Both sexes;257 CANTABRIA;Group 1405 Prostatic hyperplasia 600;Men;257 CANTABRIA;Group 1405 Prostatic hyperplasia 600;Women;.. CANTABRIA;Group 1406 Other diseases of the male genital organs 601-608;Both sexes;309 CANTABRIA;Group 1406 Other diseases of the male genital organs 601-608;Men;309 CANTABRIA;Group 1406 Other diseases of the male genital organs 601-608;Women;.. CANTABRIA;Group 1407 Disorders of breast 610-612;Both sexes;111 CANTABRIA;Group 1407 Disorders of breast 610-612;Men;11 CANTABRIA;Group 1407 Disorders of breast 610-612;Women;100 CANTABRIA;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Both sexes;113 CANTABRIA;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Men;.. CANTABRIA;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Women;113 CANTABRIA;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Both sexes;71 CANTABRIA;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Men;.. CANTABRIA;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Women;71 CANTABRIA;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Both sexes;560 CANTABRIA;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Men;5 CANTABRIA;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Women;555 CANTABRIA;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Both sexes;5,647 CANTABRIA;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Men;.. CANTABRIA;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Women;5,647 CANTABRIA;Group 1501 Legally induced abortion 635;Both sexes;15 CANTABRIA;Group 1501 Legally induced abortion 635;Men;.. CANTABRIA;Group 1501 Legally induced abortion 635;Women;15 CANTABRIA;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Both sexes;535 CANTABRIA;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Men;.. CANTABRIA;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Women;535 CANTABRIA;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Both sexes;3,674 CANTABRIA;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Men;.. CANTABRIA;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Women;3,674 CANTABRIA;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Both sexes;816 CANTABRIA;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Men;.. CANTABRIA;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Women;816 CANTABRIA;Group 1505 Single spontaneous delivery 650;Both sexes;128 CANTABRIA;Group 1505 Single spontaneous delivery 650;Men;.. CANTABRIA;Group 1505 Single spontaneous delivery 650;Women;128 CANTABRIA;Group 1506 Other deliveries 6695-6697;Both sexes;78 CANTABRIA;Group 1506 Other deliveries 6695-6697;Men;.. CANTABRIA;Group 1506 Other deliveries 6695-6697;Women;78 CANTABRIA;Group 1507 Complications related to the puerperium 670-676;Both sexes;61 CANTABRIA;Group 1507 Complications related to the puerperium 670-676;Men;.. CANTABRIA;Group 1507 Complications related to the puerperium 670-676;Women;61 CANTABRIA;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Both sexes;340 CANTABRIA;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Men;.. CANTABRIA;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Women;340 CANTABRIA;Group 1600 Some disorders originating in the perinatal period 760-779;Both sexes;684 CANTABRIA;Group 1600 Some disorders originating in the perinatal period 760-779;Men;391 CANTABRIA;Group 1600 Some disorders originating in the perinatal period 760-779;Women;293 CANTABRIA;Group 1601 Disorders related with premature delivery and a low birth weight 765;Both sexes;168 CANTABRIA;Group 1601 Disorders related with premature delivery and a low birth weight 765;Men;97 CANTABRIA;Group 1601 Disorders related with premature delivery and a low birth weight 765;Women;71 CANTABRIA;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Both sexes;516 CANTABRIA;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Men;294 CANTABRIA;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Women;222 CANTABRIA;Grupo 1700 Congenital abnormalities 740-759;Both sexes;452 CANTABRIA;Grupo 1700 Congenital abnormalities 740-759;Men;256 CANTABRIA;Grupo 1700 Congenital abnormalities 740-759;Women;196 CANTABRIA;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Both sexes;2,854 CANTABRIA;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Men;1,470 CANTABRIA;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Women;1,384 CANTABRIA;Group 1801 Pain in throat and chest 7841, 7865;Both sexes;341 CANTABRIA;Group 1801 Pain in throat and chest 7841, 7865;Men;196 CANTABRIA;Group 1801 Pain in throat and chest 7841, 7865;Women;145 CANTABRIA;Group 1802 Abdominal pain 7890;Both sexes;187 CANTABRIA;Group 1802 Abdominal pain 7890;Men;87 CANTABRIA;Group 1802 Abdominal pain 7890;Women;100 CANTABRIA;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Both sexes;591 CANTABRIA;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Men;261 CANTABRIA;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Women;330 CANTABRIA;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Both sexes;1,735 CANTABRIA;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Men;926 CANTABRIA;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Women;809 CANTABRIA;Group 1900 Injuries and poisoning 800-999;Both sexes;6,546 CANTABRIA;Group 1900 Injuries and poisoning 800-999;Men;3,544 CANTABRIA;Group 1900 Injuries and poisoning 800-999;Women;3,002 CANTABRIA;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Both sexes;273 CANTABRIA;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Men;153 CANTABRIA;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Women;120 CANTABRIA;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Both sexes;130 CANTABRIA;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Men;90 CANTABRIA;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Women;40 CANTABRIA;Group 1903 Radius and ulna fracture 813;Both sexes;435 CANTABRIA;Group 1903 Radius and ulna fracture 813;Men;160 CANTABRIA;Group 1903 Radius and ulna fracture 813;Women;275 CANTABRIA;Group 1904 Femur fracture 820-821;Both sexes;817 CANTABRIA;Group 1904 Femur fracture 820-821;Men;239 CANTABRIA;Group 1904 Femur fracture 820-821;Women;578 CANTABRIA;Group 1905 Leg fracture, including the ankle 823-824;Both sexes;613 CANTABRIA;Group 1905 Leg fracture, including the ankle 823-824;Men;353 CANTABRIA;Group 1905 Leg fracture, including the ankle 823-824;Women;260 CANTABRIA;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Both sexes;1,857 CANTABRIA;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Men;1,226 CANTABRIA;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Women;631 CANTABRIA;Group 1907 Burns 940-949;Both sexes;24 CANTABRIA;Group 1907 Burns 940-949;Men;17 CANTABRIA;Group 1907 Burns 940-949;Women;7 CANTABRIA;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Both sexes;100 CANTABRIA;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Men;50 CANTABRIA;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Women;50 CANTABRIA;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Both sexes;1,928 CANTABRIA;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Men;1,061 CANTABRIA;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Women;867 CANTABRIA;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Both sexes;25 CANTABRIA;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Men;17 CANTABRIA;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Women;8 CANTABRIA;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Both sexes;344 CANTABRIA;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Men;178 CANTABRIA;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Women;166 CANTABRIA;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Both sexes;1,353 CANTABRIA;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Men;713 CANTABRIA;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Women;640 CANTABRIA;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Both sexes;54 CANTABRIA;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Men;27 CANTABRIA;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Women;27 CANTABRIA;Group 2102 Contraceptive management V25;Both sexes;17 CANTABRIA;Group 2102 Contraceptive management V25;Men;1 CANTABRIA;Group 2102 Contraceptive management V25;Women;16 CANTABRIA;Group 2103 Living newborns by type of delivery V30-V39;Both sexes;.. CANTABRIA;Group 2103 Living newborns by type of delivery V30-V39;Men;.. CANTABRIA;Group 2103 Living newborns by type of delivery V30-V39;Women;.. CANTABRIA;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Both sexes;422 CANTABRIA;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Men;272 CANTABRIA;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Women;150 CANTABRIA;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Both sexes;860 CANTABRIA;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Men;413 CANTABRIA;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Women;447 CASTILLA Y LEËN;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Both sexes;268,186 CASTILLA Y LEËN;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Men;133,901 CASTILLA Y LEËN;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Women;134,285 CASTILLA Y LEËN;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Both sexes;5,393 CASTILLA Y LEËN;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Men;3,074 CASTILLA Y LEËN;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Women;2,320 CASTILLA Y LEËN;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Both sexes;1,018 CASTILLA Y LEËN;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Men;559 CASTILLA Y LEËN;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Women;460 CASTILLA Y LEËN;Group 0102 Imprecise intestinal infections 009;Both sexes;308 CASTILLA Y LEËN;Group 0102 Imprecise intestinal infections 009;Men;152 CASTILLA Y LEËN;Group 0102 Imprecise intestinal infections 009;Women;156 CASTILLA Y LEËN;Group 0103 Tuberculosis 010-018, 137;Both sexes;237 CASTILLA Y LEËN;Group 0103 Tuberculosis 010-018, 137;Men;158 CASTILLA Y LEËN;Group 0103 Tuberculosis 010-018, 137;Women;79 CASTILLA Y LEËN;Group 0104 Septicaemia 038;Both sexes;2,119 CASTILLA Y LEËN;Group 0104 Septicaemia 038;Men;1,179 CASTILLA Y LEËN;Group 0104 Septicaemia 038;Women;940 CASTILLA Y LEËN;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Both sexes;120 CASTILLA Y LEËN;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Men;81 CASTILLA Y LEËN;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Women;39 CASTILLA Y LEËN;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Both sexes;1,591 CASTILLA Y LEËN;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Men;945 CASTILLA Y LEËN;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Women;646 CASTILLA Y LEËN;Group 0200 Neoplasms 140-239;Both sexes;28,311 CASTILLA Y LEËN;Group 0200 Neoplasms 140-239;Men;15,380 CASTILLA Y LEËN;Group 0200 Neoplasms 140-239;Women;12,931 CASTILLA Y LEËN;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Both sexes;3,293 CASTILLA Y LEËN;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Men;2,037 CASTILLA Y LEËN;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Women;1,256 CASTILLA Y LEËN;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Both sexes;2,086 CASTILLA Y LEËN;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Men;1,691 CASTILLA Y LEËN;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Women;395 CASTILLA Y LEËN;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Both sexes;596 CASTILLA Y LEËN;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Men;317 CASTILLA Y LEËN;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Women;279 CASTILLA Y LEËN;Group 0204 Malignant neoplasm of breast 174-175;Both sexes;1,806 CASTILLA Y LEËN;Group 0204 Malignant neoplasm of breast 174-175;Men;15 CASTILLA Y LEËN;Group 0204 Malignant neoplasm of breast 174-175;Women;1,791 CASTILLA Y LEËN;Group 0205 Malignant neoplasm of uterus 179-180, 182;Both sexes;510 CASTILLA Y LEËN;Group 0205 Malignant neoplasm of uterus 179-180, 182;Men;.. CASTILLA Y LEËN;Group 0205 Malignant neoplasm of uterus 179-180, 182;Women;510 CASTILLA Y LEËN;Group 0206 Malignant neoplasm of ovary 1830;Both sexes;334 CASTILLA Y LEËN;Group 0206 Malignant neoplasm of ovary 1830;Men;.. CASTILLA Y LEËN;Group 0206 Malignant neoplasm of ovary 1830;Women;334 CASTILLA Y LEËN;Group 0207 Malignant neoplasm of prostate 185;Both sexes;1,161 CASTILLA Y LEËN;Group 0207 Malignant neoplasm of prostate 185;Men;1,161 CASTILLA Y LEËN;Group 0207 Malignant neoplasm of prostate 185;Women;.. CASTILLA Y LEËN;Group 0208 Malignant neoplasm of bladder 188;Both sexes;2,538 CASTILLA Y LEËN;Group 0208 Malignant neoplasm of bladder 188;Men;2,101 CASTILLA Y LEËN;Group 0208 Malignant neoplasm of bladder 188;Women;437 CASTILLA Y LEËN;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Both sexes;10,288 CASTILLA Y LEËN;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Men;6,081 CASTILLA Y LEËN;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Women;4,207 CASTILLA Y LEËN;Group 0210 Carcinoma in situ 230-234;Both sexes;492 CASTILLA Y LEËN;Group 0210 Carcinoma in situ 230-234;Men;175 CASTILLA Y LEËN;Group 0210 Carcinoma in situ 230-234;Women;317 CASTILLA Y LEËN;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Both sexes;253 CASTILLA Y LEËN;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Men;168 CASTILLA Y LEËN;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Women;85 CASTILLA Y LEËN;Grupo 0212 Leiomyoma of uterus 218;Both sexes;1,229 CASTILLA Y LEËN;Grupo 0212 Leiomyoma of uterus 218;Men;.. CASTILLA Y LEËN;Grupo 0212 Leiomyoma of uterus 218;Women;1,229 CASTILLA Y LEËN;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Both sexes;3,726 CASTILLA Y LEËN;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Men;1,634 CASTILLA Y LEËN;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Women;2,092 CASTILLA Y LEËN;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Both sexes;2,688 CASTILLA Y LEËN;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Men;1,316 CASTILLA Y LEËN;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Women;1,372 CASTILLA Y LEËN;Group 0301 Anaemias 280-285;Both sexes;1,793 CASTILLA Y LEËN;Group 0301 Anaemias 280-285;Men;838 CASTILLA Y LEËN;Group 0301 Anaemias 280-285;Women;955 CASTILLA Y LEËN;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Both sexes;895 CASTILLA Y LEËN;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Men;478 CASTILLA Y LEËN;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Women;417 CASTILLA Y LEËN;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Both sexes;5,307 CASTILLA Y LEËN;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Men;2,238 CASTILLA Y LEËN;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Women;3,069 CASTILLA Y LEËN;Group 0401 Diabetes mellitus 249-250;Both sexes;1,968 CASTILLA Y LEËN;Group 0401 Diabetes mellitus 249-250;Men;1,087 CASTILLA Y LEËN;Group 0401 Diabetes mellitus 249-250;Women;882 CASTILLA Y LEËN;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Both sexes;3,338 CASTILLA Y LEËN;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Men;1,151 CASTILLA Y LEËN;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Women;2,187 CASTILLA Y LEËN;Group 0500 Mental disorders 290-319;Both sexes;6,080 CASTILLA Y LEËN;Group 0500 Mental disorders 290-319;Men;3,102 CASTILLA Y LEËN;Group 0500 Mental disorders 290-319;Women;2,978 CASTILLA Y LEËN;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Both sexes;139 CASTILLA Y LEËN;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Men;54 CASTILLA Y LEËN;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Women;85 CASTILLA Y LEËN;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Both sexes;461 CASTILLA Y LEËN;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Men;362 CASTILLA Y LEËN;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Women;99 CASTILLA Y LEËN;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Both sexes;409 CASTILLA Y LEËN;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Men;324 CASTILLA Y LEËN;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Women;85 CASTILLA Y LEËN;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Both sexes;1,670 CASTILLA Y LEËN;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Men;1,009 CASTILLA Y LEËN;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Women;661 CASTILLA Y LEËN;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Both sexes;1,472 CASTILLA Y LEËN;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Men;529 CASTILLA Y LEËN;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Women;943 CASTILLA Y LEËN;Group 0506 Other mental and behavioural disorders Rest of (290-319);Both sexes;1,929 CASTILLA Y LEËN;Group 0506 Other mental and behavioural disorders Rest of (290-319);Men;824 CASTILLA Y LEËN;Group 0506 Other mental and behavioural disorders Rest of (290-319);Women;1,105 CASTILLA Y LEËN;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Both sexes;5,446 CASTILLA Y LEËN;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Men;2,608 CASTILLA Y LEËN;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Women;2,837 CASTILLA Y LEËN;Group 0601 Alzheimer's disease 3310;Both sexes;176 CASTILLA Y LEËN;Group 0601 Alzheimer's disease 3310;Men;58 CASTILLA Y LEËN;Group 0601 Alzheimer's disease 3310;Women;118 CASTILLA Y LEËN;Group 0602 Multiple sclerosis 340;Both sexes;189 CASTILLA Y LEËN;Group 0602 Multiple sclerosis 340;Men;71 CASTILLA Y LEËN;Group 0602 Multiple sclerosis 340;Women;118 CASTILLA Y LEËN;Group 0603 Epilepsy 345;Both sexes;751 CASTILLA Y LEËN;Group 0603 Epilepsy 345;Men;431 CASTILLA Y LEËN;Group 0603 Epilepsy 345;Women;320 CASTILLA Y LEËN;Group 0604 Transient cerebral ischemia 435;Both sexes;1,042 CASTILLA Y LEËN;Group 0604 Transient cerebral ischemia 435;Men;521 CASTILLA Y LEËN;Group 0604 Transient cerebral ischemia 435;Women;521 CASTILLA Y LEËN;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Both sexes;3,288 CASTILLA Y LEËN;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Men;1,527 CASTILLA Y LEËN;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Women;1,761 CASTILLA Y LEËN;Grupo 0700 Diseases of the eye and adnexa 360-379;Both sexes;2,141 CASTILLA Y LEËN;Grupo 0700 Diseases of the eye and adnexa 360-379;Men;1,114 CASTILLA Y LEËN;Grupo 0700 Diseases of the eye and adnexa 360-379;Women;1,027 CASTILLA Y LEËN;Grupo 0701 Cataract 366;Both sexes;508 CASTILLA Y LEËN;Grupo 0701 Cataract 366;Men;264 CASTILLA Y LEËN;Grupo 0701 Cataract 366;Women;244 CASTILLA Y LEËN;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Both sexes;1,633 CASTILLA Y LEËN;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Men;850 CASTILLA Y LEËN;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Women;783 CASTILLA Y LEËN;Group 0800 Diseases of the ear and the mastoid 380-389;Both sexes;1,742 CASTILLA Y LEËN;Group 0800 Diseases of the ear and the mastoid 380-389;Men;824 CASTILLA Y LEËN;Group 0800 Diseases of the ear and the mastoid 380-389;Women;918 CASTILLA Y LEËN;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Both sexes;38,058 CASTILLA Y LEËN;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Men;21,368 CASTILLA Y LEËN;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Women;16,691 CASTILLA Y LEËN;Group 0901 Hypertensive disease 401-405;Both sexes;2,249 CASTILLA Y LEËN;Group 0901 Hypertensive disease 401-405;Men;972 CASTILLA Y LEËN;Group 0901 Hypertensive disease 401-405;Women;1,277 CASTILLA Y LEËN;Group 0902 Angina pectoris 4111, 413;Both sexes;1,353 CASTILLA Y LEËN;Group 0902 Angina pectoris 4111, 413;Men;869 CASTILLA Y LEËN;Group 0902 Angina pectoris 4111, 413;Women;484 CASTILLA Y LEËN;Group 0903 Acute myocardial infarction 410;Both sexes;3,441 CASTILLA Y LEËN;Group 0903 Acute myocardial infarction 410;Men;2,473 CASTILLA Y LEËN;Group 0903 Acute myocardial infarction 410;Women;968 CASTILLA Y LEËN;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Both sexes;1,808 CASTILLA Y LEËN;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Men;1,459 CASTILLA Y LEËN;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Women;349 CASTILLA Y LEËN;Group 0905 Diseases of the lungs circulation 415-417;Both sexes;1,553 CASTILLA Y LEËN;Group 0905 Diseases of the lungs circulation 415-417;Men;726 CASTILLA Y LEËN;Group 0905 Diseases of the lungs circulation 415-417;Women;827 CASTILLA Y LEËN;Group 0906 Heart conduction disorders and arrhytmias 426-427;Both sexes;4,766 CASTILLA Y LEËN;Group 0906 Heart conduction disorders and arrhytmias 426-427;Men;2,592 CASTILLA Y LEËN;Group 0906 Heart conduction disorders and arrhytmias 426-427;Women;2,174 CASTILLA Y LEËN;Grupo 0907 Heart failure 428;Both sexes;7,765 CASTILLA Y LEËN;Grupo 0907 Heart failure 428;Men;3,782 CASTILLA Y LEËN;Grupo 0907 Heart failure 428;Women;3,983 CASTILLA Y LEËN;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Both sexes;6,371 CASTILLA Y LEËN;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Men;3,441 CASTILLA Y LEËN;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Women;2,930 CASTILLA Y LEËN;Grupo 0909 Atherosclerosis 440;Both sexes;1,083 CASTILLA Y LEËN;Grupo 0909 Atherosclerosis 440;Men;821 CASTILLA Y LEËN;Grupo 0909 Atherosclerosis 440;Women;262 CASTILLA Y LEËN;Group 0910 Varicose veins of lower extremities 454;Both sexes;1,489 CASTILLA Y LEËN;Group 0910 Varicose veins of lower extremities 454;Men;563 CASTILLA Y LEËN;Group 0910 Varicose veins of lower extremities 454;Women;926 CASTILLA Y LEËN;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Both sexes;6,180 CASTILLA Y LEËN;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Men;3,669 CASTILLA Y LEËN;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Women;2,511 CASTILLA Y LEËN;Group 1000 Diseases of the respiratory system 0340, 460-519;Both sexes;32,089 CASTILLA Y LEËN;Group 1000 Diseases of the respiratory system 0340, 460-519;Men;19,008 CASTILLA Y LEËN;Group 1000 Diseases of the respiratory system 0340, 460-519;Women;13,080 CASTILLA Y LEËN;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Both sexes;1,142 CASTILLA Y LEËN;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Men;621 CASTILLA Y LEËN;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Women;521 CASTILLA Y LEËN;Group 1002 Pneumonia 480-486;Both sexes;6,705 CASTILLA Y LEËN;Group 1002 Pneumonia 480-486;Men;4,117 CASTILLA Y LEËN;Group 1002 Pneumonia 480-486;Women;2,588 CASTILLA Y LEËN;Group 1003 Acute bronchitis and bronchiolitis 466;Both sexes;2,352 CASTILLA Y LEËN;Group 1003 Acute bronchitis and bronchiolitis 466;Men;1,116 CASTILLA Y LEËN;Group 1003 Acute bronchitis and bronchiolitis 466;Women;1,236 CASTILLA Y LEËN;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Both sexes;1,927 CASTILLA Y LEËN;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Men;995 CASTILLA Y LEËN;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Women;932 CASTILLA Y LEËN;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Both sexes;3,441 CASTILLA Y LEËN;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Men;2,261 CASTILLA Y LEËN;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Women;1,179 CASTILLA Y LEËN;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Both sexes;5,356 CASTILLA Y LEËN;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Men;4,277 CASTILLA Y LEËN;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Women;1,079 CASTILLA Y LEËN;Group 1007 Asthma 4930-4931,4938-4939;Both sexes;1,236 CASTILLA Y LEËN;Group 1007 Asthma 4930-4931,4938-4939;Men;397 CASTILLA Y LEËN;Group 1007 Asthma 4930-4931,4938-4939;Women;840 CASTILLA Y LEËN;Group 1008 Other diseases of the respiratory system Resto of (460-519);Both sexes;9,930 CASTILLA Y LEËN;Group 1008 Other diseases of the respiratory system Resto of (460-519);Men;5,224 CASTILLA Y LEËN;Group 1008 Other diseases of the respiratory system Resto of (460-519);Women;4,705 CASTILLA Y LEËN;Group 1100 Diseases of the digestive system 520-579;Both sexes;36,618 CASTILLA Y LEËN;Group 1100 Diseases of the digestive system 520-579;Men;21,434 CASTILLA Y LEËN;Group 1100 Diseases of the digestive system 520-579;Women;15,185 CASTILLA Y LEËN;Group 1101 Disorders of the teeth and supporting structures 520-525;Both sexes;441 CASTILLA Y LEËN;Group 1101 Disorders of the teeth and supporting structures 520-525;Men;216 CASTILLA Y LEËN;Group 1101 Disorders of the teeth and supporting structures 520-525;Women;225 CASTILLA Y LEËN;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Both sexes;493 CASTILLA Y LEËN;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Men;277 CASTILLA Y LEËN;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Women;216 CASTILLA Y LEËN;Group 1103 Diseases of the esophagus 530;Both sexes;553 CASTILLA Y LEËN;Group 1103 Diseases of the esophagus 530;Men;333 CASTILLA Y LEËN;Group 1103 Diseases of the esophagus 530;Women;220 CASTILLA Y LEËN;Group 1104 Peptic ulcer 531-534;Both sexes;739 CASTILLA Y LEËN;Group 1104 Peptic ulcer 531-534;Men;493 CASTILLA Y LEËN;Group 1104 Peptic ulcer 531-534;Women;246 CASTILLA Y LEËN;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Both sexes;923 CASTILLA Y LEËN;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Men;447 CASTILLA Y LEËN;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Women;476 CASTILLA Y LEËN;Group 1106 Appendicitis 540-543;Both sexes;2,782 CASTILLA Y LEËN;Group 1106 Appendicitis 540-543;Men;1,572 CASTILLA Y LEËN;Group 1106 Appendicitis 540-543;Women;1,210 CASTILLA Y LEËN;Group 1107 Inguinal hernia 550;Both sexes;5,453 CASTILLA Y LEËN;Group 1107 Inguinal hernia 550;Men;4,902 CASTILLA Y LEËN;Group 1107 Inguinal hernia 550;Women;551 CASTILLA Y LEËN;Group 1108 Other abdominal hernia 551-553;Both sexes;2,808 CASTILLA Y LEËN;Group 1108 Other abdominal hernia 551-553;Men;1,431 CASTILLA Y LEËN;Group 1108 Other abdominal hernia 551-553;Women;1,376 CASTILLA Y LEËN;Group 1109 Crohn's disease and ulcerative colitis 555-556;Both sexes;560 CASTILLA Y LEËN;Group 1109 Crohn's disease and ulcerative colitis 555-556;Men;302 CASTILLA Y LEËN;Group 1109 Crohn's disease and ulcerative colitis 555-556;Women;258 CASTILLA Y LEËN;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Both sexes;2,209 CASTILLA Y LEËN;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Men;1,032 CASTILLA Y LEËN;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Women;1,177 CASTILLA Y LEËN;Group 1111 Intestinal obstruction without hernia 560;Both sexes;2,187 CASTILLA Y LEËN;Group 1111 Intestinal obstruction without hernia 560;Men;1,135 CASTILLA Y LEËN;Group 1111 Intestinal obstruction without hernia 560;Women;1,052 CASTILLA Y LEËN;Group 1112 Intestinal diverticulosis 562;Both sexes;1,432 CASTILLA Y LEËN;Group 1112 Intestinal diverticulosis 562;Men;693 CASTILLA Y LEËN;Group 1112 Intestinal diverticulosis 562;Women;739 CASTILLA Y LEËN;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Both sexes;1,925 CASTILLA Y LEËN;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Men;1,244 CASTILLA Y LEËN;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Women;681 CASTILLA Y LEËN;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Both sexes;1,360 CASTILLA Y LEËN;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Men;607 CASTILLA Y LEËN;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Women;753 CASTILLA Y LEËN;Group 1115 Alcoholic hepatitis 5710-5713;Both sexes;564 CASTILLA Y LEËN;Group 1115 Alcoholic hepatitis 5710-5713;Men;480 CASTILLA Y LEËN;Group 1115 Alcoholic hepatitis 5710-5713;Women;84 CASTILLA Y LEËN;Group 1116 Other diseases of the liver 570,5714-573;Both sexes;1,142 CASTILLA Y LEËN;Group 1116 Other diseases of the liver 570,5714-573;Men;747 CASTILLA Y LEËN;Group 1116 Other diseases of the liver 570,5714-573;Women;396 CASTILLA Y LEËN;Group 1117 Cholelithiasis 574;Both sexes;6,396 CASTILLA Y LEËN;Group 1117 Cholelithiasis 574;Men;2,985 CASTILLA Y LEËN;Group 1117 Cholelithiasis 574;Women;3,411 CASTILLA Y LEËN;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Both sexes;1,587 CASTILLA Y LEËN;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Men;874 CASTILLA Y LEËN;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Women;714 CASTILLA Y LEËN;Group 1119 Pancreatic diseases 577;Both sexes;1,535 CASTILLA Y LEËN;Group 1119 Pancreatic diseases 577;Men;844 CASTILLA Y LEËN;Group 1119 Pancreatic diseases 577;Women;691 CASTILLA Y LEËN;Group 1120 Other diseases of the digestive system Rest of (520-579);Both sexes;1,532 CASTILLA Y LEËN;Group 1120 Other diseases of the digestive system Rest of (520-579);Men;822 CASTILLA Y LEËN;Group 1120 Other diseases of the digestive system Rest of (520-579);Women;710 CASTILLA Y LEËN;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Both sexes;2,761 CASTILLA Y LEËN;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Men;1,502 CASTILLA Y LEËN;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Women;1,259 CASTILLA Y LEËN;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Both sexes;1,558 CASTILLA Y LEËN;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Men;949 CASTILLA Y LEËN;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Women;608 CASTILLA Y LEËN;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Both sexes;129 CASTILLA Y LEËN;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Men;72 CASTILLA Y LEËN;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Women;57 CASTILLA Y LEËN;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Both sexes;1,075 CASTILLA Y LEËN;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Men;481 CASTILLA Y LEËN;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Women;594 CASTILLA Y LEËN;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Both sexes;17,230 CASTILLA Y LEËN;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Men;8,288 CASTILLA Y LEËN;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Women;8,942 CASTILLA Y LEËN;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Both sexes;.. CASTILLA Y LEËN;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Men;.. CASTILLA Y LEËN;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Women;.. CASTILLA Y LEËN;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Both sexes;.. CASTILLA Y LEËN;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Men;.. CASTILLA Y LEËN;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Women;.. CASTILLA Y LEËN;Group 1303 Internal derangement of knee 717;Both sexes;2,033 CASTILLA Y LEËN;Group 1303 Internal derangement of knee 717;Men;1,433 CASTILLA Y LEËN;Group 1303 Internal derangement of knee 717;Women;600 CASTILLA Y LEËN;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Both sexes;6,769 CASTILLA Y LEËN;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Men;3,141 CASTILLA Y LEËN;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Women;3,628 CASTILLA Y LEËN;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Both sexes;452 CASTILLA Y LEËN;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Men;155 CASTILLA Y LEËN;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Women;297 CASTILLA Y LEËN;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Both sexes;829 CASTILLA Y LEËN;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Men;416 CASTILLA Y LEËN;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Women;414 CASTILLA Y LEËN;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Both sexes;1,404 CASTILLA Y LEËN;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Men;752 CASTILLA Y LEËN;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Women;653 CASTILLA Y LEËN;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Both sexes;560 CASTILLA Y LEËN;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Men;267 CASTILLA Y LEËN;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Women;293 CASTILLA Y LEËN;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Both sexes;2,296 CASTILLA Y LEËN;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Men;1,254 CASTILLA Y LEËN;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Women;1,042 CASTILLA Y LEËN;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Both sexes;2,887 CASTILLA Y LEËN;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Men;871 CASTILLA Y LEËN;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Women;2,016 CASTILLA Y LEËN;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Both sexes;17,157 CASTILLA Y LEËN;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Men;8,269 CASTILLA Y LEËN;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Women;8,887 CASTILLA Y LEËN;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Both sexes;1,262 CASTILLA Y LEËN;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Men;497 CASTILLA Y LEËN;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Women;765 CASTILLA Y LEËN;Group 1402 Renal failure 5836-5837, 584-586;Both sexes;1,482 CASTILLA Y LEËN;Group 1402 Renal failure 5836-5837, 584-586;Men;854 CASTILLA Y LEËN;Group 1402 Renal failure 5836-5837, 584-586;Women;629 CASTILLA Y LEËN;Group 1403 Urolithiasis 592, 594, 7880;Both sexes;2,190 CASTILLA Y LEËN;Group 1403 Urolithiasis 592, 594, 7880;Men;1,292 CASTILLA Y LEËN;Group 1403 Urolithiasis 592, 594, 7880;Women;899 CASTILLA Y LEËN;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Both sexes;4,851 CASTILLA Y LEËN;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Men;2,352 CASTILLA Y LEËN;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Women;2,499 CASTILLA Y LEËN;Group 1405 Prostatic hyperplasia 600;Both sexes;1,517 CASTILLA Y LEËN;Group 1405 Prostatic hyperplasia 600;Men;1,517 CASTILLA Y LEËN;Group 1405 Prostatic hyperplasia 600;Women;.. CASTILLA Y LEËN;Group 1406 Other diseases of the male genital organs 601-608;Both sexes;1,600 CASTILLA Y LEËN;Group 1406 Other diseases of the male genital organs 601-608;Men;1,600 CASTILLA Y LEËN;Group 1406 Other diseases of the male genital organs 601-608;Women;.. CASTILLA Y LEËN;Group 1407 Disorders of breast 610-612;Both sexes;766 CASTILLA Y LEËN;Group 1407 Disorders of breast 610-612;Men;111 CASTILLA Y LEËN;Group 1407 Disorders of breast 610-612;Women;655 CASTILLA Y LEËN;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Both sexes;460 CASTILLA Y LEËN;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Men;.. CASTILLA Y LEËN;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Women;460 CASTILLA Y LEËN;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Both sexes;378 CASTILLA Y LEËN;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Men;.. CASTILLA Y LEËN;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Women;378 CASTILLA Y LEËN;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Both sexes;2,650 CASTILLA Y LEËN;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Men;47 CASTILLA Y LEËN;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Women;2,603 CASTILLA Y LEËN;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Both sexes;20,578 CASTILLA Y LEËN;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Men;.. CASTILLA Y LEËN;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Women;20,578 CASTILLA Y LEËN;Group 1501 Legally induced abortion 635;Both sexes;7 CASTILLA Y LEËN;Group 1501 Legally induced abortion 635;Men;.. CASTILLA Y LEËN;Group 1501 Legally induced abortion 635;Women;7 CASTILLA Y LEËN;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Both sexes;1,575 CASTILLA Y LEËN;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Men;.. CASTILLA Y LEËN;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Women;1,575 CASTILLA Y LEËN;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Both sexes;11,746 CASTILLA Y LEËN;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Men;.. CASTILLA Y LEËN;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Women;11,746 CASTILLA Y LEËN;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Both sexes;3,366 CASTILLA Y LEËN;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Men;.. CASTILLA Y LEËN;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Women;3,366 CASTILLA Y LEËN;Group 1505 Single spontaneous delivery 650;Both sexes;1,704 CASTILLA Y LEËN;Group 1505 Single spontaneous delivery 650;Men;.. CASTILLA Y LEËN;Group 1505 Single spontaneous delivery 650;Women;1,704 CASTILLA Y LEËN;Group 1506 Other deliveries 6695-6697;Both sexes;914 CASTILLA Y LEËN;Group 1506 Other deliveries 6695-6697;Men;.. CASTILLA Y LEËN;Group 1506 Other deliveries 6695-6697;Women;914 CASTILLA Y LEËN;Group 1507 Complications related to the puerperium 670-676;Both sexes;153 CASTILLA Y LEËN;Group 1507 Complications related to the puerperium 670-676;Men;.. CASTILLA Y LEËN;Group 1507 Complications related to the puerperium 670-676;Women;153 CASTILLA Y LEËN;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Both sexes;1,114 CASTILLA Y LEËN;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Men;.. CASTILLA Y LEËN;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Women;1,114 CASTILLA Y LEËN;Group 1600 Some disorders originating in the perinatal period 760-779;Both sexes;2,732 CASTILLA Y LEËN;Group 1600 Some disorders originating in the perinatal period 760-779;Men;1,500 CASTILLA Y LEËN;Group 1600 Some disorders originating in the perinatal period 760-779;Women;1,232 CASTILLA Y LEËN;Group 1601 Disorders related with premature delivery and a low birth weight 765;Both sexes;742 CASTILLA Y LEËN;Group 1601 Disorders related with premature delivery and a low birth weight 765;Men;388 CASTILLA Y LEËN;Group 1601 Disorders related with premature delivery and a low birth weight 765;Women;354 CASTILLA Y LEËN;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Both sexes;1,990 CASTILLA Y LEËN;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Men;1,112 CASTILLA Y LEËN;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Women;878 CASTILLA Y LEËN;Grupo 1700 Congenital abnormalities 740-759;Both sexes;1,657 CASTILLA Y LEËN;Grupo 1700 Congenital abnormalities 740-759;Men;1,048 CASTILLA Y LEËN;Grupo 1700 Congenital abnormalities 740-759;Women;609 CASTILLA Y LEËN;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Both sexes;12,731 CASTILLA Y LEËN;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Men;6,859 CASTILLA Y LEËN;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Women;5,872 CASTILLA Y LEËN;Group 1801 Pain in throat and chest 7841, 7865;Both sexes;1,348 CASTILLA Y LEËN;Group 1801 Pain in throat and chest 7841, 7865;Men;757 CASTILLA Y LEËN;Group 1801 Pain in throat and chest 7841, 7865;Women;591 CASTILLA Y LEËN;Group 1802 Abdominal pain 7890;Both sexes;1,582 CASTILLA Y LEËN;Group 1802 Abdominal pain 7890;Men;636 CASTILLA Y LEËN;Group 1802 Abdominal pain 7890;Women;947 CASTILLA Y LEËN;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Both sexes;1,786 CASTILLA Y LEËN;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Men;975 CASTILLA Y LEËN;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Women;811 CASTILLA Y LEËN;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Both sexes;8,015 CASTILLA Y LEËN;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Men;4,491 CASTILLA Y LEËN;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Women;3,524 CASTILLA Y LEËN;Group 1900 Injuries and poisoning 800-999;Both sexes;24,291 CASTILLA Y LEËN;Group 1900 Injuries and poisoning 800-999;Men;12,341 CASTILLA Y LEËN;Group 1900 Injuries and poisoning 800-999;Women;11,950 CASTILLA Y LEËN;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Both sexes;1,437 CASTILLA Y LEËN;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Men;817 CASTILLA Y LEËN;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Women;620 CASTILLA Y LEËN;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Both sexes;808 CASTILLA Y LEËN;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Men;563 CASTILLA Y LEËN;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Women;245 CASTILLA Y LEËN;Group 1903 Radius and ulna fracture 813;Both sexes;1,070 CASTILLA Y LEËN;Group 1903 Radius and ulna fracture 813;Men;489 CASTILLA Y LEËN;Group 1903 Radius and ulna fracture 813;Women;581 CASTILLA Y LEËN;Group 1904 Femur fracture 820-821;Both sexes;4,593 CASTILLA Y LEËN;Group 1904 Femur fracture 820-821;Men;1,138 CASTILLA Y LEËN;Group 1904 Femur fracture 820-821;Women;3,455 CASTILLA Y LEËN;Group 1905 Leg fracture, including the ankle 823-824;Both sexes;1,491 CASTILLA Y LEËN;Group 1905 Leg fracture, including the ankle 823-824;Men;753 CASTILLA Y LEËN;Group 1905 Leg fracture, including the ankle 823-824;Women;738 CASTILLA Y LEËN;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Both sexes;6,527 CASTILLA Y LEËN;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Men;3,960 CASTILLA Y LEËN;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Women;2,567 CASTILLA Y LEËN;Group 1907 Burns 940-949;Both sexes;173 CASTILLA Y LEËN;Group 1907 Burns 940-949;Men;122 CASTILLA Y LEËN;Group 1907 Burns 940-949;Women;51 CASTILLA Y LEËN;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Both sexes;705 CASTILLA Y LEËN;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Men;335 CASTILLA Y LEËN;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Women;370 CASTILLA Y LEËN;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Both sexes;6,675 CASTILLA Y LEËN;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Men;3,740 CASTILLA Y LEËN;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Women;2,935 CASTILLA Y LEËN;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Both sexes;36 CASTILLA Y LEËN;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Men;27 CASTILLA Y LEËN;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Women;9 CASTILLA Y LEËN;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Both sexes;777 CASTILLA Y LEËN;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Men;397 CASTILLA Y LEËN;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Women;380 CASTILLA Y LEËN;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Both sexes;5,177 CASTILLA Y LEËN;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Men;2,628 CASTILLA Y LEËN;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Women;2,549 CASTILLA Y LEËN;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Both sexes;276 CASTILLA Y LEËN;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Men;160 CASTILLA Y LEËN;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Women;116 CASTILLA Y LEËN;Group 2102 Contraceptive management V25;Both sexes;124 CASTILLA Y LEËN;Group 2102 Contraceptive management V25;Men;17 CASTILLA Y LEËN;Group 2102 Contraceptive management V25;Women;107 CASTILLA Y LEËN;Group 2103 Living newborns by type of delivery V30-V39;Both sexes;.. CASTILLA Y LEËN;Group 2103 Living newborns by type of delivery V30-V39;Men;.. CASTILLA Y LEËN;Group 2103 Living newborns by type of delivery V30-V39;Women;.. CASTILLA Y LEËN;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Both sexes;2,058 CASTILLA Y LEËN;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Men;1,108 CASTILLA Y LEËN;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Women;950 CASTILLA Y LEËN;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Both sexes;2,719 CASTILLA Y LEËN;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Men;1,343 CASTILLA Y LEËN;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Women;1,376 ┴vila;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Both sexes;14,652 ┴vila;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Men;7,336 ┴vila;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Women;7,316 ┴vila;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Both sexes;381 ┴vila;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Men;228 ┴vila;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Women;154 ┴vila;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Both sexes;88 ┴vila;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Men;55 ┴vila;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Women;34 ┴vila;Group 0102 Imprecise intestinal infections 009;Both sexes;4 ┴vila;Group 0102 Imprecise intestinal infections 009;Men;1 ┴vila;Group 0102 Imprecise intestinal infections 009;Women;3 ┴vila;Group 0103 Tuberculosis 010-018, 137;Both sexes;8 ┴vila;Group 0103 Tuberculosis 010-018, 137;Men;7 ┴vila;Group 0103 Tuberculosis 010-018, 137;Women;1 ┴vila;Group 0104 Septicaemia 038;Both sexes;153 ┴vila;Group 0104 Septicaemia 038;Men;87 ┴vila;Group 0104 Septicaemia 038;Women;66 ┴vila;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Both sexes;7 ┴vila;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Men;6 ┴vila;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Women;1 ┴vila;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Both sexes;121 ┴vila;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Men;72 ┴vila;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Women;49 ┴vila;Group 0200 Neoplasms 140-239;Both sexes;1,471 ┴vila;Group 0200 Neoplasms 140-239;Men;830 ┴vila;Group 0200 Neoplasms 140-239;Women;641 ┴vila;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Both sexes;171 ┴vila;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Men;109 ┴vila;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Women;62 ┴vila;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Both sexes;102 ┴vila;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Men;87 ┴vila;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Women;15 ┴vila;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Both sexes;58 ┴vila;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Men;30 ┴vila;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Women;28 ┴vila;Group 0204 Malignant neoplasm of breast 174-175;Both sexes;100 ┴vila;Group 0204 Malignant neoplasm of breast 174-175;Men;.. ┴vila;Group 0204 Malignant neoplasm of breast 174-175;Women;100 ┴vila;Group 0205 Malignant neoplasm of uterus 179-180, 182;Both sexes;19 ┴vila;Group 0205 Malignant neoplasm of uterus 179-180, 182;Men;.. ┴vila;Group 0205 Malignant neoplasm of uterus 179-180, 182;Women;19 ┴vila;Group 0206 Malignant neoplasm of ovary 1830;Both sexes;39 ┴vila;Group 0206 Malignant neoplasm of ovary 1830;Men;.. ┴vila;Group 0206 Malignant neoplasm of ovary 1830;Women;39 ┴vila;Group 0207 Malignant neoplasm of prostate 185;Both sexes;63 ┴vila;Group 0207 Malignant neoplasm of prostate 185;Men;63 ┴vila;Group 0207 Malignant neoplasm of prostate 185;Women;.. ┴vila;Group 0208 Malignant neoplasm of bladder 188;Both sexes;144 ┴vila;Group 0208 Malignant neoplasm of bladder 188;Men;130 ┴vila;Group 0208 Malignant neoplasm of bladder 188;Women;14 ┴vila;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Both sexes;492 ┴vila;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Men;330 ┴vila;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Women;162 ┴vila;Group 0210 Carcinoma in situ 230-234;Both sexes;31 ┴vila;Group 0210 Carcinoma in situ 230-234;Men;9 ┴vila;Group 0210 Carcinoma in situ 230-234;Women;22 ┴vila;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Both sexes;6 ┴vila;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Men;2 ┴vila;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Women;4 ┴vila;Grupo 0212 Leiomyoma of uterus 218;Both sexes;84 ┴vila;Grupo 0212 Leiomyoma of uterus 218;Men;.. ┴vila;Grupo 0212 Leiomyoma of uterus 218;Women;84 ┴vila;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Both sexes;162 ┴vila;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Men;70 ┴vila;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Women;92 ┴vila;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Both sexes;172 ┴vila;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Men;92 ┴vila;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Women;80 ┴vila;Group 0301 Anaemias 280-285;Both sexes;121 ┴vila;Group 0301 Anaemias 280-285;Men;59 ┴vila;Group 0301 Anaemias 280-285;Women;62 ┴vila;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Both sexes;51 ┴vila;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Men;33 ┴vila;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Women;18 ┴vila;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Both sexes;315 ┴vila;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Men;124 ┴vila;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Women;191 ┴vila;Group 0401 Diabetes mellitus 249-250;Both sexes;102 ┴vila;Group 0401 Diabetes mellitus 249-250;Men;48 ┴vila;Group 0401 Diabetes mellitus 249-250;Women;54 ┴vila;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Both sexes;213 ┴vila;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Men;76 ┴vila;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Women;137 ┴vila;Group 0500 Mental disorders 290-319;Both sexes;356 ┴vila;Group 0500 Mental disorders 290-319;Men;192 ┴vila;Group 0500 Mental disorders 290-319;Women;164 ┴vila;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Both sexes;4 ┴vila;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Men;4 ┴vila;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Women;.. ┴vila;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Both sexes;26 ┴vila;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Men;21 ┴vila;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Women;5 ┴vila;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Both sexes;11 ┴vila;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Men;9 ┴vila;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Women;2 ┴vila;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Both sexes;88 ┴vila;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Men;60 ┴vila;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Women;28 ┴vila;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Both sexes;73 ┴vila;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Men;30 ┴vila;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Women;43 ┴vila;Group 0506 Other mental and behavioural disorders Rest of (290-319);Both sexes;154 ┴vila;Group 0506 Other mental and behavioural disorders Rest of (290-319);Men;69 ┴vila;Group 0506 Other mental and behavioural disorders Rest of (290-319);Women;86 ┴vila;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Both sexes;291 ┴vila;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Men;131 ┴vila;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Women;160 ┴vila;Group 0601 Alzheimer's disease 3310;Both sexes;1 ┴vila;Group 0601 Alzheimer's disease 3310;Men;1 ┴vila;Group 0601 Alzheimer's disease 3310;Women;.. ┴vila;Group 0602 Multiple sclerosis 340;Both sexes;10 ┴vila;Group 0602 Multiple sclerosis 340;Men;6 ┴vila;Group 0602 Multiple sclerosis 340;Women;4 ┴vila;Group 0603 Epilepsy 345;Both sexes;52 ┴vila;Group 0603 Epilepsy 345;Men;29 ┴vila;Group 0603 Epilepsy 345;Women;23 ┴vila;Group 0604 Transient cerebral ischemia 435;Both sexes;70 ┴vila;Group 0604 Transient cerebral ischemia 435;Men;33 ┴vila;Group 0604 Transient cerebral ischemia 435;Women;37 ┴vila;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Both sexes;158 ┴vila;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Men;61 ┴vila;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Women;96 ┴vila;Grupo 0700 Diseases of the eye and adnexa 360-379;Both sexes;142 ┴vila;Grupo 0700 Diseases of the eye and adnexa 360-379;Men;83 ┴vila;Grupo 0700 Diseases of the eye and adnexa 360-379;Women;59 ┴vila;Grupo 0701 Cataract 366;Both sexes;32 ┴vila;Grupo 0701 Cataract 366;Men;18 ┴vila;Grupo 0701 Cataract 366;Women;14 ┴vila;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Both sexes;110 ┴vila;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Men;65 ┴vila;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Women;45 ┴vila;Group 0800 Diseases of the ear and the mastoid 380-389;Both sexes;59 ┴vila;Group 0800 Diseases of the ear and the mastoid 380-389;Men;25 ┴vila;Group 0800 Diseases of the ear and the mastoid 380-389;Women;34 ┴vila;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Both sexes;2,122 ┴vila;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Men;1,081 ┴vila;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Women;1,041 ┴vila;Group 0901 Hypertensive disease 401-405;Both sexes;91 ┴vila;Group 0901 Hypertensive disease 401-405;Men;33 ┴vila;Group 0901 Hypertensive disease 401-405;Women;58 ┴vila;Group 0902 Angina pectoris 4111, 413;Both sexes;108 ┴vila;Group 0902 Angina pectoris 4111, 413;Men;75 ┴vila;Group 0902 Angina pectoris 4111, 413;Women;33 ┴vila;Group 0903 Acute myocardial infarction 410;Both sexes;170 ┴vila;Group 0903 Acute myocardial infarction 410;Men;116 ┴vila;Group 0903 Acute myocardial infarction 410;Women;54 ┴vila;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Both sexes;9 ┴vila;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Men;9 ┴vila;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Women;.. ┴vila;Group 0905 Diseases of the lungs circulation 415-417;Both sexes;108 ┴vila;Group 0905 Diseases of the lungs circulation 415-417;Men;47 ┴vila;Group 0905 Diseases of the lungs circulation 415-417;Women;61 ┴vila;Group 0906 Heart conduction disorders and arrhytmias 426-427;Both sexes;313 ┴vila;Group 0906 Heart conduction disorders and arrhytmias 426-427;Men;147 ┴vila;Group 0906 Heart conduction disorders and arrhytmias 426-427;Women;166 ┴vila;Grupo 0907 Heart failure 428;Both sexes;633 ┴vila;Grupo 0907 Heart failure 428;Men;285 ┴vila;Grupo 0907 Heart failure 428;Women;348 ┴vila;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Both sexes;389 ┴vila;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Men;213 ┴vila;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Women;176 ┴vila;Grupo 0909 Atherosclerosis 440;Both sexes;3 ┴vila;Grupo 0909 Atherosclerosis 440;Men;1 ┴vila;Grupo 0909 Atherosclerosis 440;Women;2 ┴vila;Group 0910 Varicose veins of lower extremities 454;Both sexes;85 ┴vila;Group 0910 Varicose veins of lower extremities 454;Men;30 ┴vila;Group 0910 Varicose veins of lower extremities 454;Women;55 ┴vila;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Both sexes;212 ┴vila;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Men;125 ┴vila;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Women;87 ┴vila;Group 1000 Diseases of the respiratory system 0340, 460-519;Both sexes;1,680 ┴vila;Group 1000 Diseases of the respiratory system 0340, 460-519;Men;1,099 ┴vila;Group 1000 Diseases of the respiratory system 0340, 460-519;Women;581 ┴vila;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Both sexes;54 ┴vila;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Men;38 ┴vila;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Women;16 ┴vila;Group 1002 Pneumonia 480-486;Both sexes;312 ┴vila;Group 1002 Pneumonia 480-486;Men;225 ┴vila;Group 1002 Pneumonia 480-486;Women;86 ┴vila;Group 1003 Acute bronchitis and bronchiolitis 466;Both sexes;65 ┴vila;Group 1003 Acute bronchitis and bronchiolitis 466;Men;29 ┴vila;Group 1003 Acute bronchitis and bronchiolitis 466;Women;36 ┴vila;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Both sexes;106 ┴vila;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Men;50 ┴vila;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Women;56 ┴vila;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Both sexes;194 ┴vila;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Men;139 ┴vila;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Women;56 ┴vila;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Both sexes;260 ┴vila;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Men;221 ┴vila;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Women;39 ┴vila;Group 1007 Asthma 4930-4931,4938-4939;Both sexes;57 ┴vila;Group 1007 Asthma 4930-4931,4938-4939;Men;23 ┴vila;Group 1007 Asthma 4930-4931,4938-4939;Women;35 ┴vila;Group 1008 Other diseases of the respiratory system Resto of (460-519);Both sexes;631 ┴vila;Group 1008 Other diseases of the respiratory system Resto of (460-519);Men;374 ┴vila;Group 1008 Other diseases of the respiratory system Resto of (460-519);Women;257 ┴vila;Group 1100 Diseases of the digestive system 520-579;Both sexes;2,153 ┴vila;Group 1100 Diseases of the digestive system 520-579;Men;1,278 ┴vila;Group 1100 Diseases of the digestive system 520-579;Women;874 ┴vila;Group 1101 Disorders of the teeth and supporting structures 520-525;Both sexes;25 ┴vila;Group 1101 Disorders of the teeth and supporting structures 520-525;Men;12 ┴vila;Group 1101 Disorders of the teeth and supporting structures 520-525;Women;13 ┴vila;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Both sexes;25 ┴vila;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Men;17 ┴vila;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Women;8 ┴vila;Group 1103 Diseases of the esophagus 530;Both sexes;24 ┴vila;Group 1103 Diseases of the esophagus 530;Men;19 ┴vila;Group 1103 Diseases of the esophagus 530;Women;5 ┴vila;Group 1104 Peptic ulcer 531-534;Both sexes;27 ┴vila;Group 1104 Peptic ulcer 531-534;Men;16 ┴vila;Group 1104 Peptic ulcer 531-534;Women;11 ┴vila;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Both sexes;56 ┴vila;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Men;32 ┴vila;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Women;24 ┴vila;Group 1106 Appendicitis 540-543;Both sexes;157 ┴vila;Group 1106 Appendicitis 540-543;Men;91 ┴vila;Group 1106 Appendicitis 540-543;Women;66 ┴vila;Group 1107 Inguinal hernia 550;Both sexes;381 ┴vila;Group 1107 Inguinal hernia 550;Men;329 ┴vila;Group 1107 Inguinal hernia 550;Women;52 ┴vila;Group 1108 Other abdominal hernia 551-553;Both sexes;195 ┴vila;Group 1108 Other abdominal hernia 551-553;Men;101 ┴vila;Group 1108 Other abdominal hernia 551-553;Women;94 ┴vila;Group 1109 Crohn's disease and ulcerative colitis 555-556;Both sexes;36 ┴vila;Group 1109 Crohn's disease and ulcerative colitis 555-556;Men;20 ┴vila;Group 1109 Crohn's disease and ulcerative colitis 555-556;Women;16 ┴vila;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Both sexes;159 ┴vila;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Men;72 ┴vila;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Women;87 ┴vila;Group 1111 Intestinal obstruction without hernia 560;Both sexes;118 ┴vila;Group 1111 Intestinal obstruction without hernia 560;Men;57 ┴vila;Group 1111 Intestinal obstruction without hernia 560;Women;60 ┴vila;Group 1112 Intestinal diverticulosis 562;Both sexes;57 ┴vila;Group 1112 Intestinal diverticulosis 562;Men;25 ┴vila;Group 1112 Intestinal diverticulosis 562;Women;32 ┴vila;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Both sexes;143 ┴vila;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Men;84 ┴vila;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Women;59 ┴vila;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Both sexes;56 ┴vila;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Men;26 ┴vila;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Women;30 ┴vila;Group 1115 Alcoholic hepatitis 5710-5713;Both sexes;27 ┴vila;Group 1115 Alcoholic hepatitis 5710-5713;Men;24 ┴vila;Group 1115 Alcoholic hepatitis 5710-5713;Women;3 ┴vila;Group 1116 Other diseases of the liver 570,5714-573;Both sexes;63 ┴vila;Group 1116 Other diseases of the liver 570,5714-573;Men;37 ┴vila;Group 1116 Other diseases of the liver 570,5714-573;Women;27 ┴vila;Group 1117 Cholelithiasis 574;Both sexes;302 ┴vila;Group 1117 Cholelithiasis 574;Men;146 ┴vila;Group 1117 Cholelithiasis 574;Women;156 ┴vila;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Both sexes;82 ┴vila;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Men;51 ┴vila;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Women;31 ┴vila;Group 1119 Pancreatic diseases 577;Both sexes;110 ┴vila;Group 1119 Pancreatic diseases 577;Men;66 ┴vila;Group 1119 Pancreatic diseases 577;Women;44 ┴vila;Group 1120 Other diseases of the digestive system Rest of (520-579);Both sexes;111 ┴vila;Group 1120 Other diseases of the digestive system Rest of (520-579);Men;54 ┴vila;Group 1120 Other diseases of the digestive system Rest of (520-579);Women;57 ┴vila;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Both sexes;178 ┴vila;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Men;89 ┴vila;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Women;89 ┴vila;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Both sexes;101 ┴vila;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Men;59 ┴vila;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Women;42 ┴vila;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Both sexes;3 ┴vila;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Men;2 ┴vila;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Women;1 ┴vila;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Both sexes;74 ┴vila;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Men;28 ┴vila;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Women;46 ┴vila;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Both sexes;602 ┴vila;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Men;273 ┴vila;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Women;329 ┴vila;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Both sexes;.. ┴vila;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Men;.. ┴vila;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Women;.. ┴vila;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Both sexes;.. ┴vila;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Men;.. ┴vila;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Women;.. ┴vila;Group 1303 Internal derangement of knee 717;Both sexes;110 ┴vila;Group 1303 Internal derangement of knee 717;Men;71 ┴vila;Group 1303 Internal derangement of knee 717;Women;39 ┴vila;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Both sexes;254 ┴vila;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Men;108 ┴vila;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Women;147 ┴vila;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Both sexes;11 ┴vila;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Men;9 ┴vila;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Women;2 ┴vila;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Both sexes;9 ┴vila;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Men;6 ┴vila;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Women;4 ┴vila;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Both sexes;30 ┴vila;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Men;19 ┴vila;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Women;12 ┴vila;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Both sexes;7 ┴vila;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Men;1 ┴vila;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Women;6 ┴vila;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Both sexes;75 ┴vila;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Men;41 ┴vila;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Women;34 ┴vila;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Both sexes;104 ┴vila;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Men;19 ┴vila;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Women;86 ┴vila;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Both sexes;948 ┴vila;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Men;497 ┴vila;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Women;451 ┴vila;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Both sexes;53 ┴vila;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Men;23 ┴vila;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Women;30 ┴vila;Group 1402 Renal failure 5836-5837, 584-586;Both sexes;81 ┴vila;Group 1402 Renal failure 5836-5837, 584-586;Men;50 ┴vila;Group 1402 Renal failure 5836-5837, 584-586;Women;31 ┴vila;Group 1403 Urolithiasis 592, 594, 7880;Both sexes;90 ┴vila;Group 1403 Urolithiasis 592, 594, 7880;Men;54 ┴vila;Group 1403 Urolithiasis 592, 594, 7880;Women;36 ┴vila;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Both sexes;278 ┴vila;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Men;138 ┴vila;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Women;140 ┴vila;Group 1405 Prostatic hyperplasia 600;Both sexes;104 ┴vila;Group 1405 Prostatic hyperplasia 600;Men;104 ┴vila;Group 1405 Prostatic hyperplasia 600;Women;.. ┴vila;Group 1406 Other diseases of the male genital organs 601-608;Both sexes;123 ┴vila;Group 1406 Other diseases of the male genital organs 601-608;Men;123 ┴vila;Group 1406 Other diseases of the male genital organs 601-608;Women;.. ┴vila;Group 1407 Disorders of breast 610-612;Both sexes;15 ┴vila;Group 1407 Disorders of breast 610-612;Men;6 ┴vila;Group 1407 Disorders of breast 610-612;Women;9 ┴vila;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Both sexes;27 ┴vila;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Men;.. ┴vila;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Women;27 ┴vila;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Both sexes;23 ┴vila;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Men;.. ┴vila;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Women;23 ┴vila;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Both sexes;155 ┴vila;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Men;.. ┴vila;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Women;155 ┴vila;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Both sexes;1,227 ┴vila;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Men;.. ┴vila;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Women;1,227 ┴vila;Group 1501 Legally induced abortion 635;Both sexes;2 ┴vila;Group 1501 Legally induced abortion 635;Men;.. ┴vila;Group 1501 Legally induced abortion 635;Women;2 ┴vila;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Both sexes;103 ┴vila;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Men;.. ┴vila;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Women;103 ┴vila;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Both sexes;653 ┴vila;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Men;.. ┴vila;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Women;653 ┴vila;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Both sexes;306 ┴vila;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Men;.. ┴vila;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Women;306 ┴vila;Group 1505 Single spontaneous delivery 650;Both sexes;70 ┴vila;Group 1505 Single spontaneous delivery 650;Men;.. ┴vila;Group 1505 Single spontaneous delivery 650;Women;70 ┴vila;Group 1506 Other deliveries 6695-6697;Both sexes;27 ┴vila;Group 1506 Other deliveries 6695-6697;Men;.. ┴vila;Group 1506 Other deliveries 6695-6697;Women;27 ┴vila;Group 1507 Complications related to the puerperium 670-676;Both sexes;10 ┴vila;Group 1507 Complications related to the puerperium 670-676;Men;.. ┴vila;Group 1507 Complications related to the puerperium 670-676;Women;10 ┴vila;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Both sexes;57 ┴vila;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Men;.. ┴vila;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Women;57 ┴vila;Group 1600 Some disorders originating in the perinatal period 760-779;Both sexes;279 ┴vila;Group 1600 Some disorders originating in the perinatal period 760-779;Men;171 ┴vila;Group 1600 Some disorders originating in the perinatal period 760-779;Women;108 ┴vila;Group 1601 Disorders related with premature delivery and a low birth weight 765;Both sexes;45 ┴vila;Group 1601 Disorders related with premature delivery and a low birth weight 765;Men;29 ┴vila;Group 1601 Disorders related with premature delivery and a low birth weight 765;Women;16 ┴vila;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Both sexes;234 ┴vila;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Men;142 ┴vila;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Women;92 ┴vila;Grupo 1700 Congenital abnormalities 740-759;Both sexes;118 ┴vila;Grupo 1700 Congenital abnormalities 740-759;Men;59 ┴vila;Grupo 1700 Congenital abnormalities 740-759;Women;59 ┴vila;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Both sexes;889 ┴vila;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Men;469 ┴vila;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Women;420 ┴vila;Group 1801 Pain in throat and chest 7841, 7865;Both sexes;130 ┴vila;Group 1801 Pain in throat and chest 7841, 7865;Men;74 ┴vila;Group 1801 Pain in throat and chest 7841, 7865;Women;55 ┴vila;Group 1802 Abdominal pain 7890;Both sexes;181 ┴vila;Group 1802 Abdominal pain 7890;Men;79 ┴vila;Group 1802 Abdominal pain 7890;Women;102 ┴vila;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Both sexes;.. ┴vila;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Men;.. ┴vila;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Women;.. ┴vila;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Both sexes;578 ┴vila;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Men;315 ┴vila;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Women;263 ┴vila;Group 1900 Injuries and poisoning 800-999;Both sexes;1,154 ┴vila;Group 1900 Injuries and poisoning 800-999;Men;551 ┴vila;Group 1900 Injuries and poisoning 800-999;Women;603 ┴vila;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Both sexes;71 ┴vila;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Men;41 ┴vila;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Women;30 ┴vila;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Both sexes;40 ┴vila;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Men;26 ┴vila;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Women;14 ┴vila;Group 1903 Radius and ulna fracture 813;Both sexes;41 ┴vila;Group 1903 Radius and ulna fracture 813;Men;19 ┴vila;Group 1903 Radius and ulna fracture 813;Women;22 ┴vila;Group 1904 Femur fracture 820-821;Both sexes;273 ┴vila;Group 1904 Femur fracture 820-821;Men;81 ┴vila;Group 1904 Femur fracture 820-821;Women;192 ┴vila;Group 1905 Leg fracture, including the ankle 823-824;Both sexes;69 ┴vila;Group 1905 Leg fracture, including the ankle 823-824;Men;28 ┴vila;Group 1905 Leg fracture, including the ankle 823-824;Women;41 ┴vila;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Both sexes;215 ┴vila;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Men;129 ┴vila;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Women;85 ┴vila;Group 1907 Burns 940-949;Both sexes;3 ┴vila;Group 1907 Burns 940-949;Men;1 ┴vila;Group 1907 Burns 940-949;Women;2 ┴vila;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Both sexes;26 ┴vila;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Men;13 ┴vila;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Women;13 ┴vila;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Both sexes;349 ┴vila;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Men;181 ┴vila;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Women;168 ┴vila;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Both sexes;3 ┴vila;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Men;3 ┴vila;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Women;.. ┴vila;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Both sexes;65 ┴vila;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Men;29 ┴vila;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Women;36 ┴vila;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Both sexes;116 ┴vila;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Men;63 ┴vila;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Women;53 ┴vila;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Both sexes;6 ┴vila;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Men;3 ┴vila;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Women;3 ┴vila;Group 2102 Contraceptive management V25;Both sexes;7 ┴vila;Group 2102 Contraceptive management V25;Men;.. ┴vila;Group 2102 Contraceptive management V25;Women;7 ┴vila;Group 2103 Living newborns by type of delivery V30-V39;Both sexes;.. ┴vila;Group 2103 Living newborns by type of delivery V30-V39;Men;.. ┴vila;Group 2103 Living newborns by type of delivery V30-V39;Women;.. ┴vila;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Both sexes;44 ┴vila;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Men;31 ┴vila;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Women;13 ┴vila;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Both sexes;59 ┴vila;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Men;29 ┴vila;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Women;30 Burgos;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Both sexes;42,058 Burgos;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Men;21,102 Burgos;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Women;20,956 Burgos;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Both sexes;933 Burgos;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Men;539 Burgos;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Women;394 Burgos;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Both sexes;124 Burgos;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Men;63 Burgos;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Women;61 Burgos;Group 0102 Imprecise intestinal infections 009;Both sexes;69 Burgos;Group 0102 Imprecise intestinal infections 009;Men;33 Burgos;Group 0102 Imprecise intestinal infections 009;Women;36 Burgos;Group 0103 Tuberculosis 010-018, 137;Both sexes;35 Burgos;Group 0103 Tuberculosis 010-018, 137;Men;17 Burgos;Group 0103 Tuberculosis 010-018, 137;Women;18 Burgos;Group 0104 Septicaemia 038;Both sexes;415 Burgos;Group 0104 Septicaemia 038;Men;256 Burgos;Group 0104 Septicaemia 038;Women;159 Burgos;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Both sexes;24 Burgos;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Men;16 Burgos;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Women;8 Burgos;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Both sexes;266 Burgos;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Men;154 Burgos;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Women;112 Burgos;Group 0200 Neoplasms 140-239;Both sexes;4,336 Burgos;Group 0200 Neoplasms 140-239;Men;2,399 Burgos;Group 0200 Neoplasms 140-239;Women;1,937 Burgos;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Both sexes;516 Burgos;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Men;326 Burgos;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Women;190 Burgos;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Both sexes;257 Burgos;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Men;185 Burgos;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Women;72 Burgos;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Both sexes;79 Burgos;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Men;47 Burgos;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Women;32 Burgos;Group 0204 Malignant neoplasm of breast 174-175;Both sexes;254 Burgos;Group 0204 Malignant neoplasm of breast 174-175;Men;7 Burgos;Group 0204 Malignant neoplasm of breast 174-175;Women;247 Burgos;Group 0205 Malignant neoplasm of uterus 179-180, 182;Both sexes;63 Burgos;Group 0205 Malignant neoplasm of uterus 179-180, 182;Men;.. Burgos;Group 0205 Malignant neoplasm of uterus 179-180, 182;Women;63 Burgos;Group 0206 Malignant neoplasm of ovary 1830;Both sexes;31 Burgos;Group 0206 Malignant neoplasm of ovary 1830;Men;.. Burgos;Group 0206 Malignant neoplasm of ovary 1830;Women;31 Burgos;Group 0207 Malignant neoplasm of prostate 185;Both sexes;192 Burgos;Group 0207 Malignant neoplasm of prostate 185;Men;192 Burgos;Group 0207 Malignant neoplasm of prostate 185;Women;.. Burgos;Group 0208 Malignant neoplasm of bladder 188;Both sexes;351 Burgos;Group 0208 Malignant neoplasm of bladder 188;Men;277 Burgos;Group 0208 Malignant neoplasm of bladder 188;Women;74 Burgos;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Both sexes;1,764 Burgos;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Men;1,069 Burgos;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Women;695 Burgos;Group 0210 Carcinoma in situ 230-234;Both sexes;70 Burgos;Group 0210 Carcinoma in situ 230-234;Men;29 Burgos;Group 0210 Carcinoma in situ 230-234;Women;41 Burgos;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Both sexes;69 Burgos;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Men;48 Burgos;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Women;21 Burgos;Grupo 0212 Leiomyoma of uterus 218;Both sexes;129 Burgos;Grupo 0212 Leiomyoma of uterus 218;Men;.. Burgos;Grupo 0212 Leiomyoma of uterus 218;Women;129 Burgos;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Both sexes;561 Burgos;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Men;219 Burgos;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Women;342 Burgos;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Both sexes;443 Burgos;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Men;233 Burgos;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Women;210 Burgos;Group 0301 Anaemias 280-285;Both sexes;311 Burgos;Group 0301 Anaemias 280-285;Men;167 Burgos;Group 0301 Anaemias 280-285;Women;144 Burgos;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Both sexes;132 Burgos;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Men;66 Burgos;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Women;66 Burgos;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Both sexes;765 Burgos;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Men;329 Burgos;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Women;436 Burgos;Group 0401 Diabetes mellitus 249-250;Both sexes;267 Burgos;Group 0401 Diabetes mellitus 249-250;Men;140 Burgos;Group 0401 Diabetes mellitus 249-250;Women;127 Burgos;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Both sexes;498 Burgos;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Men;189 Burgos;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Women;309 Burgos;Group 0500 Mental disorders 290-319;Both sexes;1,020 Burgos;Group 0500 Mental disorders 290-319;Men;497 Burgos;Group 0500 Mental disorders 290-319;Women;523 Burgos;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Both sexes;10 Burgos;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Men;3 Burgos;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Women;7 Burgos;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Both sexes;81 Burgos;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Men;62 Burgos;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Women;19 Burgos;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Both sexes;27 Burgos;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Men;21 Burgos;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Women;6 Burgos;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Both sexes;259 Burgos;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Men;176 Burgos;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Women;83 Burgos;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Both sexes;381 Burgos;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Men;126 Burgos;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Women;255 Burgos;Group 0506 Other mental and behavioural disorders Rest of (290-319);Both sexes;262 Burgos;Group 0506 Other mental and behavioural disorders Rest of (290-319);Men;109 Burgos;Group 0506 Other mental and behavioural disorders Rest of (290-319);Women;153 Burgos;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Both sexes;752 Burgos;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Men;384 Burgos;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Women;368 Burgos;Group 0601 Alzheimer's disease 3310;Both sexes;14 Burgos;Group 0601 Alzheimer's disease 3310;Men;4 Burgos;Group 0601 Alzheimer's disease 3310;Women;10 Burgos;Group 0602 Multiple sclerosis 340;Both sexes;6 Burgos;Group 0602 Multiple sclerosis 340;Men;3 Burgos;Group 0602 Multiple sclerosis 340;Women;3 Burgos;Group 0603 Epilepsy 345;Both sexes;118 Burgos;Group 0603 Epilepsy 345;Men;82 Burgos;Group 0603 Epilepsy 345;Women;36 Burgos;Group 0604 Transient cerebral ischemia 435;Both sexes;138 Burgos;Group 0604 Transient cerebral ischemia 435;Men;63 Burgos;Group 0604 Transient cerebral ischemia 435;Women;75 Burgos;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Both sexes;476 Burgos;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Men;232 Burgos;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Women;244 Burgos;Grupo 0700 Diseases of the eye and adnexa 360-379;Both sexes;530 Burgos;Grupo 0700 Diseases of the eye and adnexa 360-379;Men;278 Burgos;Grupo 0700 Diseases of the eye and adnexa 360-379;Women;252 Burgos;Grupo 0701 Cataract 366;Both sexes;224 Burgos;Grupo 0701 Cataract 366;Men;115 Burgos;Grupo 0701 Cataract 366;Women;109 Burgos;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Both sexes;306 Burgos;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Men;163 Burgos;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Women;143 Burgos;Group 0800 Diseases of the ear and the mastoid 380-389;Both sexes;227 Burgos;Group 0800 Diseases of the ear and the mastoid 380-389;Men;103 Burgos;Group 0800 Diseases of the ear and the mastoid 380-389;Women;124 Burgos;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Both sexes;5,076 Burgos;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Men;2,901 Burgos;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Women;2,175 Burgos;Group 0901 Hypertensive disease 401-405;Both sexes;244 Burgos;Group 0901 Hypertensive disease 401-405;Men;126 Burgos;Group 0901 Hypertensive disease 401-405;Women;118 Burgos;Group 0902 Angina pectoris 4111, 413;Both sexes;154 Burgos;Group 0902 Angina pectoris 4111, 413;Men;108 Burgos;Group 0902 Angina pectoris 4111, 413;Women;46 Burgos;Group 0903 Acute myocardial infarction 410;Both sexes;322 Burgos;Group 0903 Acute myocardial infarction 410;Men;224 Burgos;Group 0903 Acute myocardial infarction 410;Women;98 Burgos;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Both sexes;198 Burgos;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Men;166 Burgos;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Women;32 Burgos;Group 0905 Diseases of the lungs circulation 415-417;Both sexes;185 Burgos;Group 0905 Diseases of the lungs circulation 415-417;Men;85 Burgos;Group 0905 Diseases of the lungs circulation 415-417;Women;100 Burgos;Group 0906 Heart conduction disorders and arrhytmias 426-427;Both sexes;726 Burgos;Group 0906 Heart conduction disorders and arrhytmias 426-427;Men;405 Burgos;Group 0906 Heart conduction disorders and arrhytmias 426-427;Women;321 Burgos;Grupo 0907 Heart failure 428;Both sexes;1,330 Burgos;Grupo 0907 Heart failure 428;Men;644 Burgos;Grupo 0907 Heart failure 428;Women;686 Burgos;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Both sexes;965 Burgos;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Men;524 Burgos;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Women;441 Burgos;Grupo 0909 Atherosclerosis 440;Both sexes;202 Burgos;Grupo 0909 Atherosclerosis 440;Men;160 Burgos;Grupo 0909 Atherosclerosis 440;Women;42 Burgos;Group 0910 Varicose veins of lower extremities 454;Both sexes;31 Burgos;Group 0910 Varicose veins of lower extremities 454;Men;15 Burgos;Group 0910 Varicose veins of lower extremities 454;Women;16 Burgos;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Both sexes;719 Burgos;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Men;444 Burgos;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Women;275 Burgos;Group 1000 Diseases of the respiratory system 0340, 460-519;Both sexes;5,345 Burgos;Group 1000 Diseases of the respiratory system 0340, 460-519;Men;3,101 Burgos;Group 1000 Diseases of the respiratory system 0340, 460-519;Women;2,244 Burgos;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Both sexes;235 Burgos;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Men;112 Burgos;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Women;123 Burgos;Group 1002 Pneumonia 480-486;Both sexes;1,249 Burgos;Group 1002 Pneumonia 480-486;Men;768 Burgos;Group 1002 Pneumonia 480-486;Women;481 Burgos;Group 1003 Acute bronchitis and bronchiolitis 466;Both sexes;311 Burgos;Group 1003 Acute bronchitis and bronchiolitis 466;Men;143 Burgos;Group 1003 Acute bronchitis and bronchiolitis 466;Women;168 Burgos;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Both sexes;339 Burgos;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Men;170 Burgos;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Women;169 Burgos;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Both sexes;579 Burgos;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Men;401 Burgos;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Women;178 Burgos;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Both sexes;984 Burgos;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Men;725 Burgos;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Women;259 Burgos;Group 1007 Asthma 4930-4931,4938-4939;Both sexes;265 Burgos;Group 1007 Asthma 4930-4931,4938-4939;Men;100 Burgos;Group 1007 Asthma 4930-4931,4938-4939;Women;165 Burgos;Group 1008 Other diseases of the respiratory system Resto of (460-519);Both sexes;1,383 Burgos;Group 1008 Other diseases of the respiratory system Resto of (460-519);Men;682 Burgos;Group 1008 Other diseases of the respiratory system Resto of (460-519);Women;701 Burgos;Group 1100 Diseases of the digestive system 520-579;Both sexes;5,449 Burgos;Group 1100 Diseases of the digestive system 520-579;Men;3,212 Burgos;Group 1100 Diseases of the digestive system 520-579;Women;2,237 Burgos;Group 1101 Disorders of the teeth and supporting structures 520-525;Both sexes;79 Burgos;Group 1101 Disorders of the teeth and supporting structures 520-525;Men;45 Burgos;Group 1101 Disorders of the teeth and supporting structures 520-525;Women;34 Burgos;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Both sexes;84 Burgos;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Men;48 Burgos;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Women;36 Burgos;Group 1103 Diseases of the esophagus 530;Both sexes;82 Burgos;Group 1103 Diseases of the esophagus 530;Men;51 Burgos;Group 1103 Diseases of the esophagus 530;Women;31 Burgos;Group 1104 Peptic ulcer 531-534;Both sexes;115 Burgos;Group 1104 Peptic ulcer 531-534;Men;74 Burgos;Group 1104 Peptic ulcer 531-534;Women;41 Burgos;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Both sexes;127 Burgos;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Men;63 Burgos;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Women;64 Burgos;Group 1106 Appendicitis 540-543;Both sexes;461 Burgos;Group 1106 Appendicitis 540-543;Men;262 Burgos;Group 1106 Appendicitis 540-543;Women;199 Burgos;Group 1107 Inguinal hernia 550;Both sexes;752 Burgos;Group 1107 Inguinal hernia 550;Men;667 Burgos;Group 1107 Inguinal hernia 550;Women;85 Burgos;Group 1108 Other abdominal hernia 551-553;Both sexes;390 Burgos;Group 1108 Other abdominal hernia 551-553;Men;191 Burgos;Group 1108 Other abdominal hernia 551-553;Women;199 Burgos;Group 1109 Crohn's disease and ulcerative colitis 555-556;Both sexes;80 Burgos;Group 1109 Crohn's disease and ulcerative colitis 555-556;Men;53 Burgos;Group 1109 Crohn's disease and ulcerative colitis 555-556;Women;27 Burgos;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Both sexes;404 Burgos;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Men;195 Burgos;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Women;209 Burgos;Group 1111 Intestinal obstruction without hernia 560;Both sexes;425 Burgos;Group 1111 Intestinal obstruction without hernia 560;Men;232 Burgos;Group 1111 Intestinal obstruction without hernia 560;Women;193 Burgos;Group 1112 Intestinal diverticulosis 562;Both sexes;160 Burgos;Group 1112 Intestinal diverticulosis 562;Men;76 Burgos;Group 1112 Intestinal diverticulosis 562;Women;84 Burgos;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Both sexes;305 Burgos;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Men;180 Burgos;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Women;125 Burgos;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Both sexes;182 Burgos;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Men;81 Burgos;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Women;101 Burgos;Group 1115 Alcoholic hepatitis 5710-5713;Both sexes;94 Burgos;Group 1115 Alcoholic hepatitis 5710-5713;Men;82 Burgos;Group 1115 Alcoholic hepatitis 5710-5713;Women;12 Burgos;Group 1116 Other diseases of the liver 570,5714-573;Both sexes;192 Burgos;Group 1116 Other diseases of the liver 570,5714-573;Men;124 Burgos;Group 1116 Other diseases of the liver 570,5714-573;Women;68 Burgos;Group 1117 Cholelithiasis 574;Both sexes;777 Burgos;Group 1117 Cholelithiasis 574;Men;359 Burgos;Group 1117 Cholelithiasis 574;Women;418 Burgos;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Both sexes;258 Burgos;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Men;144 Burgos;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Women;114 Burgos;Group 1119 Pancreatic diseases 577;Both sexes;245 Burgos;Group 1119 Pancreatic diseases 577;Men;137 Burgos;Group 1119 Pancreatic diseases 577;Women;108 Burgos;Group 1120 Other diseases of the digestive system Rest of (520-579);Both sexes;237 Burgos;Group 1120 Other diseases of the digestive system Rest of (520-579);Men;148 Burgos;Group 1120 Other diseases of the digestive system Rest of (520-579);Women;89 Burgos;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Both sexes;504 Burgos;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Men;263 Burgos;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Women;241 Burgos;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Both sexes;265 Burgos;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Men;156 Burgos;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Women;109 Burgos;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Both sexes;18 Burgos;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Men;12 Burgos;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Women;6 Burgos;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Both sexes;221 Burgos;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Men;95 Burgos;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Women;126 Burgos;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Both sexes;2,858 Burgos;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Men;1,419 Burgos;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Women;1,439 Burgos;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Both sexes;.. Burgos;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Men;.. Burgos;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Women;.. Burgos;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Both sexes;.. Burgos;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Men;.. Burgos;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Women;.. Burgos;Group 1303 Internal derangement of knee 717;Both sexes;459 Burgos;Group 1303 Internal derangement of knee 717;Men;319 Burgos;Group 1303 Internal derangement of knee 717;Women;140 Burgos;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Both sexes;1,048 Burgos;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Men;496 Burgos;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Women;552 Burgos;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Both sexes;40 Burgos;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Men;19 Burgos;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Women;21 Burgos;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Both sexes;100 Burgos;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Men;59 Burgos;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Women;41 Burgos;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Both sexes;128 Burgos;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Men;70 Burgos;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Women;58 Burgos;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Both sexes;111 Burgos;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Men;43 Burgos;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Women;68 Burgos;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Both sexes;420 Burgos;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Men;265 Burgos;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Women;155 Burgos;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Both sexes;552 Burgos;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Men;148 Burgos;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Women;404 Burgos;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Both sexes;2,682 Burgos;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Men;1,297 Burgos;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Women;1,385 Burgos;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Both sexes;236 Burgos;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Men;98 Burgos;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Women;138 Burgos;Group 1402 Renal failure 5836-5837, 584-586;Both sexes;202 Burgos;Group 1402 Renal failure 5836-5837, 584-586;Men;122 Burgos;Group 1402 Renal failure 5836-5837, 584-586;Women;80 Burgos;Group 1403 Urolithiasis 592, 594, 7880;Both sexes;398 Burgos;Group 1403 Urolithiasis 592, 594, 7880;Men;249 Burgos;Group 1403 Urolithiasis 592, 594, 7880;Women;149 Burgos;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Both sexes;803 Burgos;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Men;394 Burgos;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Women;409 Burgos;Group 1405 Prostatic hyperplasia 600;Both sexes;184 Burgos;Group 1405 Prostatic hyperplasia 600;Men;184 Burgos;Group 1405 Prostatic hyperplasia 600;Women;.. Burgos;Group 1406 Other diseases of the male genital organs 601-608;Both sexes;216 Burgos;Group 1406 Other diseases of the male genital organs 601-608;Men;216 Burgos;Group 1406 Other diseases of the male genital organs 601-608;Women;.. Burgos;Group 1407 Disorders of breast 610-612;Both sexes;180 Burgos;Group 1407 Disorders of breast 610-612;Men;22 Burgos;Group 1407 Disorders of breast 610-612;Women;158 Burgos;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Both sexes;69 Burgos;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Men;.. Burgos;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Women;69 Burgos;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Both sexes;36 Burgos;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Men;.. Burgos;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Women;36 Burgos;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Both sexes;358 Burgos;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Men;12 Burgos;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Women;346 Burgos;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Both sexes;3,410 Burgos;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Men;.. Burgos;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Women;3,410 Burgos;Group 1501 Legally induced abortion 635;Both sexes;2 Burgos;Group 1501 Legally induced abortion 635;Men;.. Burgos;Group 1501 Legally induced abortion 635;Women;2 Burgos;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Both sexes;261 Burgos;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Men;.. Burgos;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Women;261 Burgos;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Both sexes;2,103 Burgos;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Men;.. Burgos;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Women;2,103 Burgos;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Both sexes;609 Burgos;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Men;.. Burgos;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Women;609 Burgos;Group 1505 Single spontaneous delivery 650;Both sexes;189 Burgos;Group 1505 Single spontaneous delivery 650;Men;.. Burgos;Group 1505 Single spontaneous delivery 650;Women;189 Burgos;Group 1506 Other deliveries 6695-6697;Both sexes;30 Burgos;Group 1506 Other deliveries 6695-6697;Men;.. Burgos;Group 1506 Other deliveries 6695-6697;Women;30 Burgos;Group 1507 Complications related to the puerperium 670-676;Both sexes;29 Burgos;Group 1507 Complications related to the puerperium 670-676;Men;.. Burgos;Group 1507 Complications related to the puerperium 670-676;Women;29 Burgos;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Both sexes;187 Burgos;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Men;.. Burgos;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Women;187 Burgos;Group 1600 Some disorders originating in the perinatal period 760-779;Both sexes;513 Burgos;Group 1600 Some disorders originating in the perinatal period 760-779;Men;276 Burgos;Group 1600 Some disorders originating in the perinatal period 760-779;Women;237 Burgos;Group 1601 Disorders related with premature delivery and a low birth weight 765;Both sexes;108 Burgos;Group 1601 Disorders related with premature delivery and a low birth weight 765;Men;55 Burgos;Group 1601 Disorders related with premature delivery and a low birth weight 765;Women;53 Burgos;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Both sexes;405 Burgos;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Men;221 Burgos;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Women;184 Burgos;Grupo 1700 Congenital abnormalities 740-759;Both sexes;381 Burgos;Grupo 1700 Congenital abnormalities 740-759;Men;256 Burgos;Grupo 1700 Congenital abnormalities 740-759;Women;125 Burgos;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Both sexes;2,015 Burgos;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Men;1,113 Burgos;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Women;902 Burgos;Group 1801 Pain in throat and chest 7841, 7865;Both sexes;157 Burgos;Group 1801 Pain in throat and chest 7841, 7865;Men;103 Burgos;Group 1801 Pain in throat and chest 7841, 7865;Women;54 Burgos;Group 1802 Abdominal pain 7890;Both sexes;287 Burgos;Group 1802 Abdominal pain 7890;Men;113 Burgos;Group 1802 Abdominal pain 7890;Women;174 Burgos;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Both sexes;240 Burgos;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Men;132 Burgos;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Women;108 Burgos;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Both sexes;1,331 Burgos;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Men;765 Burgos;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Women;566 Burgos;Group 1900 Injuries and poisoning 800-999;Both sexes;4,140 Burgos;Group 1900 Injuries and poisoning 800-999;Men;2,188 Burgos;Group 1900 Injuries and poisoning 800-999;Women;1,952 Burgos;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Both sexes;267 Burgos;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Men;147 Burgos;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Women;120 Burgos;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Both sexes;185 Burgos;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Men;133 Burgos;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Women;52 Burgos;Group 1903 Radius and ulna fracture 813;Both sexes;210 Burgos;Group 1903 Radius and ulna fracture 813;Men;92 Burgos;Group 1903 Radius and ulna fracture 813;Women;118 Burgos;Group 1904 Femur fracture 820-821;Both sexes;602 Burgos;Group 1904 Femur fracture 820-821;Men;137 Burgos;Group 1904 Femur fracture 820-821;Women;465 Burgos;Group 1905 Leg fracture, including the ankle 823-824;Both sexes;213 Burgos;Group 1905 Leg fracture, including the ankle 823-824;Men;115 Burgos;Group 1905 Leg fracture, including the ankle 823-824;Women;98 Burgos;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Both sexes;1,302 Burgos;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Men;799 Burgos;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Women;503 Burgos;Group 1907 Burns 940-949;Both sexes;54 Burgos;Group 1907 Burns 940-949;Men;35 Burgos;Group 1907 Burns 940-949;Women;19 Burgos;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Both sexes;89 Burgos;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Men;47 Burgos;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Women;42 Burgos;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Both sexes;1,057 Burgos;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Men;589 Burgos;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Women;468 Burgos;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Both sexes;10 Burgos;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Men;9 Burgos;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Women;1 Burgos;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Both sexes;151 Burgos;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Men;85 Burgos;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Women;66 Burgos;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Both sexes;679 Burgos;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Men;314 Burgos;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Women;365 Burgos;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Both sexes;34 Burgos;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Men;23 Burgos;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Women;11 Burgos;Group 2102 Contraceptive management V25;Both sexes;26 Burgos;Group 2102 Contraceptive management V25;Men;1 Burgos;Group 2102 Contraceptive management V25;Women;25 Burgos;Group 2103 Living newborns by type of delivery V30-V39;Both sexes;.. Burgos;Group 2103 Living newborns by type of delivery V30-V39;Men;.. Burgos;Group 2103 Living newborns by type of delivery V30-V39;Women;.. Burgos;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Both sexes;135 Burgos;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Men;85 Burgos;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Women;50 Burgos;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Both sexes;484 Burgos;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Men;205 Burgos;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Women;279 Le¾n;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Both sexes;59,325 Le¾n;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Men;29,622 Le¾n;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Women;29,703 Le¾n;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Both sexes;841 Le¾n;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Men;475 Le¾n;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Women;366 Le¾n;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Both sexes;140 Le¾n;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Men;80 Le¾n;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Women;60 Le¾n;Group 0102 Imprecise intestinal infections 009;Both sexes;99 Le¾n;Group 0102 Imprecise intestinal infections 009;Men;49 Le¾n;Group 0102 Imprecise intestinal infections 009;Women;50 Le¾n;Group 0103 Tuberculosis 010-018, 137;Both sexes;87 Le¾n;Group 0103 Tuberculosis 010-018, 137;Men;64 Le¾n;Group 0103 Tuberculosis 010-018, 137;Women;23 Le¾n;Group 0104 Septicaemia 038;Both sexes;216 Le¾n;Group 0104 Septicaemia 038;Men;113 Le¾n;Group 0104 Septicaemia 038;Women;103 Le¾n;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Both sexes;12 Le¾n;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Men;9 Le¾n;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Women;3 Le¾n;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Both sexes;287 Le¾n;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Men;160 Le¾n;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Women;127 Le¾n;Group 0200 Neoplasms 140-239;Both sexes;6,191 Le¾n;Group 0200 Neoplasms 140-239;Men;3,383 Le¾n;Group 0200 Neoplasms 140-239;Women;2,808 Le¾n;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Both sexes;718 Le¾n;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Men;409 Le¾n;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Women;309 Le¾n;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Both sexes;426 Le¾n;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Men;358 Le¾n;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Women;68 Le¾n;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Both sexes;225 Le¾n;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Men;123 Le¾n;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Women;102 Le¾n;Group 0204 Malignant neoplasm of breast 174-175;Both sexes;390 Le¾n;Group 0204 Malignant neoplasm of breast 174-175;Men;2 Le¾n;Group 0204 Malignant neoplasm of breast 174-175;Women;388 Le¾n;Group 0205 Malignant neoplasm of uterus 179-180, 182;Both sexes;122 Le¾n;Group 0205 Malignant neoplasm of uterus 179-180, 182;Men;.. Le¾n;Group 0205 Malignant neoplasm of uterus 179-180, 182;Women;122 Le¾n;Group 0206 Malignant neoplasm of ovary 1830;Both sexes;65 Le¾n;Group 0206 Malignant neoplasm of ovary 1830;Men;.. Le¾n;Group 0206 Malignant neoplasm of ovary 1830;Women;65 Le¾n;Group 0207 Malignant neoplasm of prostate 185;Both sexes;231 Le¾n;Group 0207 Malignant neoplasm of prostate 185;Men;231 Le¾n;Group 0207 Malignant neoplasm of prostate 185;Women;.. Le¾n;Group 0208 Malignant neoplasm of bladder 188;Both sexes;625 Le¾n;Group 0208 Malignant neoplasm of bladder 188;Men;511 Le¾n;Group 0208 Malignant neoplasm of bladder 188;Women;114 Le¾n;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Both sexes;2,216 Le¾n;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Men;1,310 Le¾n;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Women;906 Le¾n;Group 0210 Carcinoma in situ 230-234;Both sexes;120 Le¾n;Group 0210 Carcinoma in situ 230-234;Men;35 Le¾n;Group 0210 Carcinoma in situ 230-234;Women;85 Le¾n;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Both sexes;63 Le¾n;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Men;44 Le¾n;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Women;19 Le¾n;Grupo 0212 Leiomyoma of uterus 218;Both sexes;213 Le¾n;Grupo 0212 Leiomyoma of uterus 218;Men;.. Le¾n;Grupo 0212 Leiomyoma of uterus 218;Women;213 Le¾n;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Both sexes;777 Le¾n;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Men;360 Le¾n;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Women;417 Le¾n;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Both sexes;594 Le¾n;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Men;279 Le¾n;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Women;315 Le¾n;Group 0301 Anaemias 280-285;Both sexes;441 Le¾n;Group 0301 Anaemias 280-285;Men;197 Le¾n;Group 0301 Anaemias 280-285;Women;244 Le¾n;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Both sexes;153 Le¾n;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Men;82 Le¾n;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Women;71 Le¾n;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Both sexes;998 Le¾n;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Men;421 Le¾n;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Women;577 Le¾n;Group 0401 Diabetes mellitus 249-250;Both sexes;339 Le¾n;Group 0401 Diabetes mellitus 249-250;Men;189 Le¾n;Group 0401 Diabetes mellitus 249-250;Women;150 Le¾n;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Both sexes;659 Le¾n;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Men;232 Le¾n;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Women;427 Le¾n;Group 0500 Mental disorders 290-319;Both sexes;1,116 Le¾n;Group 0500 Mental disorders 290-319;Men;551 Le¾n;Group 0500 Mental disorders 290-319;Women;565 Le¾n;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Both sexes;37 Le¾n;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Men;14 Le¾n;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Women;23 Le¾n;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Both sexes;47 Le¾n;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Men;38 Le¾n;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Women;9 Le¾n;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Both sexes;17 Le¾n;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Men;11 Le¾n;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Women;6 Le¾n;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Both sexes;364 Le¾n;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Men;209 Le¾n;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Women;155 Le¾n;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Both sexes;241 Le¾n;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Men;90 Le¾n;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Women;151 Le¾n;Group 0506 Other mental and behavioural disorders Rest of (290-319);Both sexes;410 Le¾n;Group 0506 Other mental and behavioural disorders Rest of (290-319);Men;189 Le¾n;Group 0506 Other mental and behavioural disorders Rest of (290-319);Women;221 Le¾n;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Both sexes;1,230 Le¾n;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Men;613 Le¾n;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Women;617 Le¾n;Group 0601 Alzheimer's disease 3310;Both sexes;44 Le¾n;Group 0601 Alzheimer's disease 3310;Men;21 Le¾n;Group 0601 Alzheimer's disease 3310;Women;23 Le¾n;Group 0602 Multiple sclerosis 340;Both sexes;45 Le¾n;Group 0602 Multiple sclerosis 340;Men;20 Le¾n;Group 0602 Multiple sclerosis 340;Women;25 Le¾n;Group 0603 Epilepsy 345;Both sexes;130 Le¾n;Group 0603 Epilepsy 345;Men;76 Le¾n;Group 0603 Epilepsy 345;Women;54 Le¾n;Group 0604 Transient cerebral ischemia 435;Both sexes;307 Le¾n;Group 0604 Transient cerebral ischemia 435;Men;150 Le¾n;Group 0604 Transient cerebral ischemia 435;Women;157 Le¾n;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Both sexes;704 Le¾n;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Men;346 Le¾n;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Women;358 Le¾n;Grupo 0700 Diseases of the eye and adnexa 360-379;Both sexes;653 Le¾n;Grupo 0700 Diseases of the eye and adnexa 360-379;Men;334 Le¾n;Grupo 0700 Diseases of the eye and adnexa 360-379;Women;319 Le¾n;Grupo 0701 Cataract 366;Both sexes;128 Le¾n;Grupo 0701 Cataract 366;Men;67 Le¾n;Grupo 0701 Cataract 366;Women;61 Le¾n;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Both sexes;525 Le¾n;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Men;267 Le¾n;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Women;258 Le¾n;Group 0800 Diseases of the ear and the mastoid 380-389;Both sexes;259 Le¾n;Group 0800 Diseases of the ear and the mastoid 380-389;Men;118 Le¾n;Group 0800 Diseases of the ear and the mastoid 380-389;Women;141 Le¾n;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Both sexes;8,989 Le¾n;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Men;4,883 Le¾n;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Women;4,106 Le¾n;Group 0901 Hypertensive disease 401-405;Both sexes;698 Le¾n;Group 0901 Hypertensive disease 401-405;Men;302 Le¾n;Group 0901 Hypertensive disease 401-405;Women;396 Le¾n;Group 0902 Angina pectoris 4111, 413;Both sexes;265 Le¾n;Group 0902 Angina pectoris 4111, 413;Men;167 Le¾n;Group 0902 Angina pectoris 4111, 413;Women;98 Le¾n;Group 0903 Acute myocardial infarction 410;Both sexes;707 Le¾n;Group 0903 Acute myocardial infarction 410;Men;517 Le¾n;Group 0903 Acute myocardial infarction 410;Women;190 Le¾n;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Both sexes;414 Le¾n;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Men;327 Le¾n;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Women;87 Le¾n;Group 0905 Diseases of the lungs circulation 415-417;Both sexes;353 Le¾n;Group 0905 Diseases of the lungs circulation 415-417;Men;182 Le¾n;Group 0905 Diseases of the lungs circulation 415-417;Women;171 Le¾n;Group 0906 Heart conduction disorders and arrhytmias 426-427;Both sexes;908 Le¾n;Group 0906 Heart conduction disorders and arrhytmias 426-427;Men;456 Le¾n;Group 0906 Heart conduction disorders and arrhytmias 426-427;Women;452 Le¾n;Grupo 0907 Heart failure 428;Both sexes;1,701 Le¾n;Grupo 0907 Heart failure 428;Men;802 Le¾n;Grupo 0907 Heart failure 428;Women;899 Le¾n;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Both sexes;1,422 Le¾n;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Men;740 Le¾n;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Women;682 Le¾n;Grupo 0909 Atherosclerosis 440;Both sexes;259 Le¾n;Grupo 0909 Atherosclerosis 440;Men;184 Le¾n;Grupo 0909 Atherosclerosis 440;Women;75 Le¾n;Group 0910 Varicose veins of lower extremities 454;Both sexes;601 Le¾n;Group 0910 Varicose veins of lower extremities 454;Men;233 Le¾n;Group 0910 Varicose veins of lower extremities 454;Women;368 Le¾n;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Both sexes;1,661 Le¾n;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Men;973 Le¾n;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Women;688 Le¾n;Group 1000 Diseases of the respiratory system 0340, 460-519;Both sexes;7,078 Le¾n;Group 1000 Diseases of the respiratory system 0340, 460-519;Men;4,359 Le¾n;Group 1000 Diseases of the respiratory system 0340, 460-519;Women;2,719 Le¾n;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Both sexes;159 Le¾n;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Men;90 Le¾n;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Women;69 Le¾n;Group 1002 Pneumonia 480-486;Both sexes;1,439 Le¾n;Group 1002 Pneumonia 480-486;Men;924 Le¾n;Group 1002 Pneumonia 480-486;Women;515 Le¾n;Group 1003 Acute bronchitis and bronchiolitis 466;Both sexes;423 Le¾n;Group 1003 Acute bronchitis and bronchiolitis 466;Men;217 Le¾n;Group 1003 Acute bronchitis and bronchiolitis 466;Women;206 Le¾n;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Both sexes;235 Le¾n;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Men;129 Le¾n;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Women;106 Le¾n;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Both sexes;567 Le¾n;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Men;400 Le¾n;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Women;167 Le¾n;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Both sexes;1,380 Le¾n;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Men;1,098 Le¾n;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Women;282 Le¾n;Group 1007 Asthma 4930-4931,4938-4939;Both sexes;245 Le¾n;Group 1007 Asthma 4930-4931,4938-4939;Men;83 Le¾n;Group 1007 Asthma 4930-4931,4938-4939;Women;162 Le¾n;Group 1008 Other diseases of the respiratory system Resto of (460-519);Both sexes;2,630 Le¾n;Group 1008 Other diseases of the respiratory system Resto of (460-519);Men;1,418 Le¾n;Group 1008 Other diseases of the respiratory system Resto of (460-519);Women;1,212 Le¾n;Group 1100 Diseases of the digestive system 520-579;Both sexes;7,702 Le¾n;Group 1100 Diseases of the digestive system 520-579;Men;4,537 Le¾n;Group 1100 Diseases of the digestive system 520-579;Women;3,165 Le¾n;Group 1101 Disorders of the teeth and supporting structures 520-525;Both sexes;99 Le¾n;Group 1101 Disorders of the teeth and supporting structures 520-525;Men;45 Le¾n;Group 1101 Disorders of the teeth and supporting structures 520-525;Women;54 Le¾n;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Both sexes;73 Le¾n;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Men;39 Le¾n;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Women;34 Le¾n;Group 1103 Diseases of the esophagus 530;Both sexes;93 Le¾n;Group 1103 Diseases of the esophagus 530;Men;45 Le¾n;Group 1103 Diseases of the esophagus 530;Women;48 Le¾n;Group 1104 Peptic ulcer 531-534;Both sexes;120 Le¾n;Group 1104 Peptic ulcer 531-534;Men;83 Le¾n;Group 1104 Peptic ulcer 531-534;Women;37 Le¾n;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Both sexes;221 Le¾n;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Men;99 Le¾n;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Women;122 Le¾n;Group 1106 Appendicitis 540-543;Both sexes;570 Le¾n;Group 1106 Appendicitis 540-543;Men;317 Le¾n;Group 1106 Appendicitis 540-543;Women;253 Le¾n;Group 1107 Inguinal hernia 550;Both sexes;1,275 Le¾n;Group 1107 Inguinal hernia 550;Men;1,137 Le¾n;Group 1107 Inguinal hernia 550;Women;138 Le¾n;Group 1108 Other abdominal hernia 551-553;Both sexes;623 Le¾n;Group 1108 Other abdominal hernia 551-553;Men;329 Le¾n;Group 1108 Other abdominal hernia 551-553;Women;294 Le¾n;Group 1109 Crohn's disease and ulcerative colitis 555-556;Both sexes;96 Le¾n;Group 1109 Crohn's disease and ulcerative colitis 555-556;Men;46 Le¾n;Group 1109 Crohn's disease and ulcerative colitis 555-556;Women;50 Le¾n;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Both sexes;471 Le¾n;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Men;216 Le¾n;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Women;255 Le¾n;Group 1111 Intestinal obstruction without hernia 560;Both sexes;389 Le¾n;Group 1111 Intestinal obstruction without hernia 560;Men;204 Le¾n;Group 1111 Intestinal obstruction without hernia 560;Women;185 Le¾n;Group 1112 Intestinal diverticulosis 562;Both sexes;347 Le¾n;Group 1112 Intestinal diverticulosis 562;Men;184 Le¾n;Group 1112 Intestinal diverticulosis 562;Women;163 Le¾n;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Both sexes;412 Le¾n;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Men;275 Le¾n;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Women;137 Le¾n;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Both sexes;323 Le¾n;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Men;146 Le¾n;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Women;177 Le¾n;Group 1115 Alcoholic hepatitis 5710-5713;Both sexes;130 Le¾n;Group 1115 Alcoholic hepatitis 5710-5713;Men;105 Le¾n;Group 1115 Alcoholic hepatitis 5710-5713;Women;25 Le¾n;Group 1116 Other diseases of the liver 570,5714-573;Both sexes;221 Le¾n;Group 1116 Other diseases of the liver 570,5714-573;Men;147 Le¾n;Group 1116 Other diseases of the liver 570,5714-573;Women;74 Le¾n;Group 1117 Cholelithiasis 574;Both sexes;1,374 Le¾n;Group 1117 Cholelithiasis 574;Men;641 Le¾n;Group 1117 Cholelithiasis 574;Women;733 Le¾n;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Both sexes;311 Le¾n;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Men;174 Le¾n;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Women;137 Le¾n;Group 1119 Pancreatic diseases 577;Both sexes;351 Le¾n;Group 1119 Pancreatic diseases 577;Men;192 Le¾n;Group 1119 Pancreatic diseases 577;Women;159 Le¾n;Group 1120 Other diseases of the digestive system Rest of (520-579);Both sexes;203 Le¾n;Group 1120 Other diseases of the digestive system Rest of (520-579);Men;113 Le¾n;Group 1120 Other diseases of the digestive system Rest of (520-579);Women;90 Le¾n;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Both sexes;752 Le¾n;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Men;409 Le¾n;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Women;343 Le¾n;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Both sexes;383 Le¾n;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Men;241 Le¾n;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Women;142 Le¾n;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Both sexes;40 Le¾n;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Men;20 Le¾n;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Women;20 Le¾n;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Both sexes;329 Le¾n;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Men;148 Le¾n;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Women;181 Le¾n;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Both sexes;4,840 Le¾n;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Men;2,337 Le¾n;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Women;2,503 Le¾n;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Both sexes;.. Le¾n;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Men;.. Le¾n;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Women;.. Le¾n;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Both sexes;.. Le¾n;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Men;.. Le¾n;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Women;.. Le¾n;Group 1303 Internal derangement of knee 717;Both sexes;567 Le¾n;Group 1303 Internal derangement of knee 717;Men;378 Le¾n;Group 1303 Internal derangement of knee 717;Women;189 Le¾n;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Both sexes;1,738 Le¾n;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Men;781 Le¾n;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Women;957 Le¾n;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Both sexes;103 Le¾n;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Men;52 Le¾n;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Women;51 Le¾n;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Both sexes;307 Le¾n;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Men;156 Le¾n;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Women;151 Le¾n;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Both sexes;453 Le¾n;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Men;248 Le¾n;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Women;205 Le¾n;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Both sexes;278 Le¾n;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Men;140 Le¾n;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Women;138 Le¾n;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Both sexes;671 Le¾n;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Men;343 Le¾n;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Women;328 Le¾n;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Both sexes;723 Le¾n;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Men;239 Le¾n;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Women;484 Le¾n;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Both sexes;3,742 Le¾n;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Men;1,568 Le¾n;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Women;2,174 Le¾n;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Both sexes;186 Le¾n;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Men;71 Le¾n;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Women;115 Le¾n;Group 1402 Renal failure 5836-5837, 584-586;Both sexes;291 Le¾n;Group 1402 Renal failure 5836-5837, 584-586;Men;153 Le¾n;Group 1402 Renal failure 5836-5837, 584-586;Women;138 Le¾n;Group 1403 Urolithiasis 592, 594, 7880;Both sexes;328 Le¾n;Group 1403 Urolithiasis 592, 594, 7880;Men;204 Le¾n;Group 1403 Urolithiasis 592, 594, 7880;Women;124 Le¾n;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Both sexes;1,172 Le¾n;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Men;485 Le¾n;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Women;687 Le¾n;Group 1405 Prostatic hyperplasia 600;Both sexes;305 Le¾n;Group 1405 Prostatic hyperplasia 600;Men;305 Le¾n;Group 1405 Prostatic hyperplasia 600;Women;.. Le¾n;Group 1406 Other diseases of the male genital organs 601-608;Both sexes;322 Le¾n;Group 1406 Other diseases of the male genital organs 601-608;Men;322 Le¾n;Group 1406 Other diseases of the male genital organs 601-608;Women;.. Le¾n;Group 1407 Disorders of breast 610-612;Both sexes;172 Le¾n;Group 1407 Disorders of breast 610-612;Men;19 Le¾n;Group 1407 Disorders of breast 610-612;Women;153 Le¾n;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Both sexes;84 Le¾n;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Men;.. Le¾n;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Women;84 Le¾n;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Both sexes;213 Le¾n;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Men;.. Le¾n;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Women;213 Le¾n;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Both sexes;669 Le¾n;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Men;9 Le¾n;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Women;660 Le¾n;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Both sexes;3,734 Le¾n;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Men;.. Le¾n;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Women;3,734 Le¾n;Group 1501 Legally induced abortion 635;Both sexes;1 Le¾n;Group 1501 Legally induced abortion 635;Men;.. Le¾n;Group 1501 Legally induced abortion 635;Women;1 Le¾n;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Both sexes;242 Le¾n;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Men;.. Le¾n;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Women;242 Le¾n;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Both sexes;1,810 Le¾n;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Men;.. Le¾n;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Women;1,810 Le¾n;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Both sexes;668 Le¾n;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Men;.. Le¾n;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Women;668 Le¾n;Group 1505 Single spontaneous delivery 650;Both sexes;537 Le¾n;Group 1505 Single spontaneous delivery 650;Men;.. Le¾n;Group 1505 Single spontaneous delivery 650;Women;537 Le¾n;Group 1506 Other deliveries 6695-6697;Both sexes;210 Le¾n;Group 1506 Other deliveries 6695-6697;Men;.. Le¾n;Group 1506 Other deliveries 6695-6697;Women;210 Le¾n;Group 1507 Complications related to the puerperium 670-676;Both sexes;24 Le¾n;Group 1507 Complications related to the puerperium 670-676;Men;.. Le¾n;Group 1507 Complications related to the puerperium 670-676;Women;24 Le¾n;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Both sexes;242 Le¾n;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Men;.. Le¾n;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Women;242 Le¾n;Group 1600 Some disorders originating in the perinatal period 760-779;Both sexes;409 Le¾n;Group 1600 Some disorders originating in the perinatal period 760-779;Men;218 Le¾n;Group 1600 Some disorders originating in the perinatal period 760-779;Women;191 Le¾n;Group 1601 Disorders related with premature delivery and a low birth weight 765;Both sexes;141 Le¾n;Group 1601 Disorders related with premature delivery and a low birth weight 765;Men;73 Le¾n;Group 1601 Disorders related with premature delivery and a low birth weight 765;Women;68 Le¾n;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Both sexes;268 Le¾n;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Men;145 Le¾n;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Women;123 Le¾n;Grupo 1700 Congenital abnormalities 740-759;Both sexes;249 Le¾n;Grupo 1700 Congenital abnormalities 740-759;Men;149 Le¾n;Grupo 1700 Congenital abnormalities 740-759;Women;100 Le¾n;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Both sexes;2,953 Le¾n;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Men;1,518 Le¾n;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Women;1,435 Le¾n;Group 1801 Pain in throat and chest 7841, 7865;Both sexes;239 Le¾n;Group 1801 Pain in throat and chest 7841, 7865;Men;131 Le¾n;Group 1801 Pain in throat and chest 7841, 7865;Women;108 Le¾n;Group 1802 Abdominal pain 7890;Both sexes;318 Le¾n;Group 1802 Abdominal pain 7890;Men;125 Le¾n;Group 1802 Abdominal pain 7890;Women;193 Le¾n;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Both sexes;436 Le¾n;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Men;208 Le¾n;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Women;228 Le¾n;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Both sexes;1,960 Le¾n;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Men;1,054 Le¾n;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Women;906 Le¾n;Group 1900 Injuries and poisoning 800-999;Both sexes;5,493 Le¾n;Group 1900 Injuries and poisoning 800-999;Men;2,669 Le¾n;Group 1900 Injuries and poisoning 800-999;Women;2,824 Le¾n;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Both sexes;361 Le¾n;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Men;194 Le¾n;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Women;167 Le¾n;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Both sexes;157 Le¾n;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Men;103 Le¾n;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Women;54 Le¾n;Group 1903 Radius and ulna fracture 813;Both sexes;172 Le¾n;Group 1903 Radius and ulna fracture 813;Men;78 Le¾n;Group 1903 Radius and ulna fracture 813;Women;94 Le¾n;Group 1904 Femur fracture 820-821;Both sexes;1,151 Le¾n;Group 1904 Femur fracture 820-821;Men;282 Le¾n;Group 1904 Femur fracture 820-821;Women;869 Le¾n;Group 1905 Leg fracture, including the ankle 823-824;Both sexes;326 Le¾n;Group 1905 Leg fracture, including the ankle 823-824;Men;150 Le¾n;Group 1905 Leg fracture, including the ankle 823-824;Women;176 Le¾n;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Both sexes;1,611 Le¾n;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Men;929 Le¾n;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Women;682 Le¾n;Group 1907 Burns 940-949;Both sexes;35 Le¾n;Group 1907 Burns 940-949;Men;26 Le¾n;Group 1907 Burns 940-949;Women;9 Le¾n;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Both sexes;135 Le¾n;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Men;68 Le¾n;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Women;67 Le¾n;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Both sexes;1,349 Le¾n;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Men;747 Le¾n;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Women;602 Le¾n;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Both sexes;6 Le¾n;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Men;4 Le¾n;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Women;2 Le¾n;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Both sexes;190 Le¾n;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Men;88 Le¾n;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Women;102 Le¾n;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Both sexes;1,502 Le¾n;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Men;801 Le¾n;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Women;701 Le¾n;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Both sexes;40 Le¾n;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Men;26 Le¾n;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Women;14 Le¾n;Group 2102 Contraceptive management V25;Both sexes;22 Le¾n;Group 2102 Contraceptive management V25;Men;3 Le¾n;Group 2102 Contraceptive management V25;Women;19 Le¾n;Group 2103 Living newborns by type of delivery V30-V39;Both sexes;.. Le¾n;Group 2103 Living newborns by type of delivery V30-V39;Men;.. Le¾n;Group 2103 Living newborns by type of delivery V30-V39;Women;.. Le¾n;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Both sexes;267 Le¾n;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Men;170 Le¾n;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Women;97 Le¾n;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Both sexes;1,173 Le¾n;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Men;602 Le¾n;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Women;571 Palencia;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Both sexes;17,921 Palencia;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Men;9,086 Palencia;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Women;8,835 Palencia;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Both sexes;357 Palencia;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Men;217 Palencia;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Women;140 Palencia;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Both sexes;104 Palencia;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Men;57 Palencia;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Women;47 Palencia;Group 0102 Imprecise intestinal infections 009;Both sexes;8 Palencia;Group 0102 Imprecise intestinal infections 009;Men;5 Palencia;Group 0102 Imprecise intestinal infections 009;Women;3 Palencia;Group 0103 Tuberculosis 010-018, 137;Both sexes;11 Palencia;Group 0103 Tuberculosis 010-018, 137;Men;9 Palencia;Group 0103 Tuberculosis 010-018, 137;Women;2 Palencia;Group 0104 Septicaemia 038;Both sexes;90 Palencia;Group 0104 Septicaemia 038;Men;56 Palencia;Group 0104 Septicaemia 038;Women;34 Palencia;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Both sexes;14 Palencia;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Men;11 Palencia;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Women;3 Palencia;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Both sexes;130 Palencia;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Men;79 Palencia;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Women;51 Palencia;Group 0200 Neoplasms 140-239;Both sexes;1,601 Palencia;Group 0200 Neoplasms 140-239;Men;824 Palencia;Group 0200 Neoplasms 140-239;Women;777 Palencia;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Both sexes;210 Palencia;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Men;114 Palencia;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Women;96 Palencia;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Both sexes;110 Palencia;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Men;89 Palencia;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Women;21 Palencia;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Both sexes;2 Palencia;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Men;.. Palencia;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Women;2 Palencia;Group 0204 Malignant neoplasm of breast 174-175;Both sexes;119 Palencia;Group 0204 Malignant neoplasm of breast 174-175;Men;2 Palencia;Group 0204 Malignant neoplasm of breast 174-175;Women;117 Palencia;Group 0205 Malignant neoplasm of uterus 179-180, 182;Both sexes;31 Palencia;Group 0205 Malignant neoplasm of uterus 179-180, 182;Men;.. Palencia;Group 0205 Malignant neoplasm of uterus 179-180, 182;Women;31 Palencia;Group 0206 Malignant neoplasm of ovary 1830;Both sexes;15 Palencia;Group 0206 Malignant neoplasm of ovary 1830;Men;.. Palencia;Group 0206 Malignant neoplasm of ovary 1830;Women;15 Palencia;Group 0207 Malignant neoplasm of prostate 185;Both sexes;41 Palencia;Group 0207 Malignant neoplasm of prostate 185;Men;41 Palencia;Group 0207 Malignant neoplasm of prostate 185;Women;.. Palencia;Group 0208 Malignant neoplasm of bladder 188;Both sexes;175 Palencia;Group 0208 Malignant neoplasm of bladder 188;Men;142 Palencia;Group 0208 Malignant neoplasm of bladder 188;Women;33 Palencia;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Both sexes;563 Palencia;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Men;337 Palencia;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Women;226 Palencia;Group 0210 Carcinoma in situ 230-234;Both sexes;26 Palencia;Group 0210 Carcinoma in situ 230-234;Men;5 Palencia;Group 0210 Carcinoma in situ 230-234;Women;21 Palencia;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Both sexes;13 Palencia;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Men;10 Palencia;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Women;3 Palencia;Grupo 0212 Leiomyoma of uterus 218;Both sexes;93 Palencia;Grupo 0212 Leiomyoma of uterus 218;Men;.. Palencia;Grupo 0212 Leiomyoma of uterus 218;Women;93 Palencia;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Both sexes;204 Palencia;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Men;84 Palencia;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Women;120 Palencia;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Both sexes;156 Palencia;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Men;86 Palencia;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Women;70 Palencia;Group 0301 Anaemias 280-285;Both sexes;112 Palencia;Group 0301 Anaemias 280-285;Men;62 Palencia;Group 0301 Anaemias 280-285;Women;50 Palencia;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Both sexes;44 Palencia;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Men;24 Palencia;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Women;20 Palencia;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Both sexes;334 Palencia;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Men;144 Palencia;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Women;190 Palencia;Group 0401 Diabetes mellitus 249-250;Both sexes;130 Palencia;Group 0401 Diabetes mellitus 249-250;Men;64 Palencia;Group 0401 Diabetes mellitus 249-250;Women;66 Palencia;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Both sexes;205 Palencia;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Men;80 Palencia;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Women;125 Palencia;Group 0500 Mental disorders 290-319;Both sexes;723 Palencia;Group 0500 Mental disorders 290-319;Men;390 Palencia;Group 0500 Mental disorders 290-319;Women;333 Palencia;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Both sexes;34 Palencia;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Men;11 Palencia;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Women;23 Palencia;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Both sexes;67 Palencia;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Men;48 Palencia;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Women;19 Palencia;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Both sexes;100 Palencia;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Men;87 Palencia;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Women;13 Palencia;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Both sexes;181 Palencia;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Men;104 Palencia;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Women;77 Palencia;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Both sexes;157 Palencia;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Men;58 Palencia;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Women;99 Palencia;Group 0506 Other mental and behavioural disorders Rest of (290-319);Both sexes;184 Palencia;Group 0506 Other mental and behavioural disorders Rest of (290-319);Men;82 Palencia;Group 0506 Other mental and behavioural disorders Rest of (290-319);Women;102 Palencia;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Both sexes;338 Palencia;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Men;159 Palencia;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Women;180 Palencia;Group 0601 Alzheimer's disease 3310;Both sexes;16 Palencia;Group 0601 Alzheimer's disease 3310;Men;3 Palencia;Group 0601 Alzheimer's disease 3310;Women;13 Palencia;Group 0602 Multiple sclerosis 340;Both sexes;45 Palencia;Group 0602 Multiple sclerosis 340;Men;14 Palencia;Group 0602 Multiple sclerosis 340;Women;31 Palencia;Group 0603 Epilepsy 345;Both sexes;55 Palencia;Group 0603 Epilepsy 345;Men;30 Palencia;Group 0603 Epilepsy 345;Women;25 Palencia;Group 0604 Transient cerebral ischemia 435;Both sexes;61 Palencia;Group 0604 Transient cerebral ischemia 435;Men;24 Palencia;Group 0604 Transient cerebral ischemia 435;Women;37 Palencia;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Both sexes;161 Palencia;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Men;88 Palencia;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Women;74 Palencia;Grupo 0700 Diseases of the eye and adnexa 360-379;Both sexes;78 Palencia;Grupo 0700 Diseases of the eye and adnexa 360-379;Men;40 Palencia;Grupo 0700 Diseases of the eye and adnexa 360-379;Women;38 Palencia;Grupo 0701 Cataract 366;Both sexes;25 Palencia;Grupo 0701 Cataract 366;Men;16 Palencia;Grupo 0701 Cataract 366;Women;9 Palencia;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Both sexes;53 Palencia;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Men;24 Palencia;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Women;29 Palencia;Group 0800 Diseases of the ear and the mastoid 380-389;Both sexes;117 Palencia;Group 0800 Diseases of the ear and the mastoid 380-389;Men;61 Palencia;Group 0800 Diseases of the ear and the mastoid 380-389;Women;56 Palencia;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Both sexes;2,330 Palencia;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Men;1,240 Palencia;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Women;1,090 Palencia;Group 0901 Hypertensive disease 401-405;Both sexes;222 Palencia;Group 0901 Hypertensive disease 401-405;Men;93 Palencia;Group 0901 Hypertensive disease 401-405;Women;129 Palencia;Group 0902 Angina pectoris 4111, 413;Both sexes;99 Palencia;Group 0902 Angina pectoris 4111, 413;Men;59 Palencia;Group 0902 Angina pectoris 4111, 413;Women;40 Palencia;Group 0903 Acute myocardial infarction 410;Both sexes;226 Palencia;Group 0903 Acute myocardial infarction 410;Men;172 Palencia;Group 0903 Acute myocardial infarction 410;Women;54 Palencia;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Both sexes;65 Palencia;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Men;47 Palencia;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Women;18 Palencia;Group 0905 Diseases of the lungs circulation 415-417;Both sexes;78 Palencia;Group 0905 Diseases of the lungs circulation 415-417;Men;22 Palencia;Group 0905 Diseases of the lungs circulation 415-417;Women;56 Palencia;Group 0906 Heart conduction disorders and arrhytmias 426-427;Both sexes;466 Palencia;Group 0906 Heart conduction disorders and arrhytmias 426-427;Men;219 Palencia;Group 0906 Heart conduction disorders and arrhytmias 426-427;Women;247 Palencia;Grupo 0907 Heart failure 428;Both sexes;468 Palencia;Grupo 0907 Heart failure 428;Men;252 Palencia;Grupo 0907 Heart failure 428;Women;216 Palencia;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Both sexes;352 Palencia;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Men;172 Palencia;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Women;180 Palencia;Grupo 0909 Atherosclerosis 440;Both sexes;15 Palencia;Grupo 0909 Atherosclerosis 440;Men;12 Palencia;Grupo 0909 Atherosclerosis 440;Women;3 Palencia;Group 0910 Varicose veins of lower extremities 454;Both sexes;2 Palencia;Group 0910 Varicose veins of lower extremities 454;Men;1 Palencia;Group 0910 Varicose veins of lower extremities 454;Women;1 Palencia;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Both sexes;338 Palencia;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Men;191 Palencia;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Women;147 Palencia;Group 1000 Diseases of the respiratory system 0340, 460-519;Both sexes;2,558 Palencia;Group 1000 Diseases of the respiratory system 0340, 460-519;Men;1,479 Palencia;Group 1000 Diseases of the respiratory system 0340, 460-519;Women;1,079 Palencia;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Both sexes;71 Palencia;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Men;34 Palencia;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Women;37 Palencia;Group 1002 Pneumonia 480-486;Both sexes;454 Palencia;Group 1002 Pneumonia 480-486;Men;280 Palencia;Group 1002 Pneumonia 480-486;Women;174 Palencia;Group 1003 Acute bronchitis and bronchiolitis 466;Both sexes;204 Palencia;Group 1003 Acute bronchitis and bronchiolitis 466;Men;98 Palencia;Group 1003 Acute bronchitis and bronchiolitis 466;Women;106 Palencia;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Both sexes;194 Palencia;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Men;96 Palencia;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Women;98 Palencia;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Both sexes;319 Palencia;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Men;229 Palencia;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Women;91 Palencia;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Both sexes;517 Palencia;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Men;400 Palencia;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Women;117 Palencia;Group 1007 Asthma 4930-4931,4938-4939;Both sexes;99 Palencia;Group 1007 Asthma 4930-4931,4938-4939;Men;17 Palencia;Group 1007 Asthma 4930-4931,4938-4939;Women;82 Palencia;Group 1008 Other diseases of the respiratory system Resto of (460-519);Both sexes;701 Palencia;Group 1008 Other diseases of the respiratory system Resto of (460-519);Men;326 Palencia;Group 1008 Other diseases of the respiratory system Resto of (460-519);Women;375 Palencia;Group 1100 Diseases of the digestive system 520-579;Both sexes;2,546 Palencia;Group 1100 Diseases of the digestive system 520-579;Men;1,555 Palencia;Group 1100 Diseases of the digestive system 520-579;Women;990 Palencia;Group 1101 Disorders of the teeth and supporting structures 520-525;Both sexes;5 Palencia;Group 1101 Disorders of the teeth and supporting structures 520-525;Men;3 Palencia;Group 1101 Disorders of the teeth and supporting structures 520-525;Women;2 Palencia;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Both sexes;11 Palencia;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Men;9 Palencia;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Women;2 Palencia;Group 1103 Diseases of the esophagus 530;Both sexes;35 Palencia;Group 1103 Diseases of the esophagus 530;Men;20 Palencia;Group 1103 Diseases of the esophagus 530;Women;15 Palencia;Group 1104 Peptic ulcer 531-534;Both sexes;65 Palencia;Group 1104 Peptic ulcer 531-534;Men;50 Palencia;Group 1104 Peptic ulcer 531-534;Women;15 Palencia;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Both sexes;43 Palencia;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Men;27 Palencia;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Women;16 Palencia;Group 1106 Appendicitis 540-543;Both sexes;178 Palencia;Group 1106 Appendicitis 540-543;Men;100 Palencia;Group 1106 Appendicitis 540-543;Women;78 Palencia;Group 1107 Inguinal hernia 550;Both sexes;421 Palencia;Group 1107 Inguinal hernia 550;Men;388 Palencia;Group 1107 Inguinal hernia 550;Women;33 Palencia;Group 1108 Other abdominal hernia 551-553;Both sexes;180 Palencia;Group 1108 Other abdominal hernia 551-553;Men;97 Palencia;Group 1108 Other abdominal hernia 551-553;Women;83 Palencia;Group 1109 Crohn's disease and ulcerative colitis 555-556;Both sexes;35 Palencia;Group 1109 Crohn's disease and ulcerative colitis 555-556;Men;18 Palencia;Group 1109 Crohn's disease and ulcerative colitis 555-556;Women;17 Palencia;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Both sexes;197 Palencia;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Men;103 Palencia;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Women;94 Palencia;Group 1111 Intestinal obstruction without hernia 560;Both sexes;113 Palencia;Group 1111 Intestinal obstruction without hernia 560;Men;57 Palencia;Group 1111 Intestinal obstruction without hernia 560;Women;57 Palencia;Group 1112 Intestinal diverticulosis 562;Both sexes;93 Palencia;Group 1112 Intestinal diverticulosis 562;Men;41 Palencia;Group 1112 Intestinal diverticulosis 562;Women;52 Palencia;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Both sexes;116 Palencia;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Men;71 Palencia;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Women;45 Palencia;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Both sexes;100 Palencia;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Men;49 Palencia;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Women;51 Palencia;Group 1115 Alcoholic hepatitis 5710-5713;Both sexes;46 Palencia;Group 1115 Alcoholic hepatitis 5710-5713;Men;41 Palencia;Group 1115 Alcoholic hepatitis 5710-5713;Women;5 Palencia;Group 1116 Other diseases of the liver 570,5714-573;Both sexes;76 Palencia;Group 1116 Other diseases of the liver 570,5714-573;Men;52 Palencia;Group 1116 Other diseases of the liver 570,5714-573;Women;24 Palencia;Group 1117 Cholelithiasis 574;Both sexes;442 Palencia;Group 1117 Cholelithiasis 574;Men;220 Palencia;Group 1117 Cholelithiasis 574;Women;222 Palencia;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Both sexes;173 Palencia;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Men;88 Palencia;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Women;85 Palencia;Group 1119 Pancreatic diseases 577;Both sexes;119 Palencia;Group 1119 Pancreatic diseases 577;Men;57 Palencia;Group 1119 Pancreatic diseases 577;Women;62 Palencia;Group 1120 Other diseases of the digestive system Rest of (520-579);Both sexes;101 Palencia;Group 1120 Other diseases of the digestive system Rest of (520-579);Men;67 Palencia;Group 1120 Other diseases of the digestive system Rest of (520-579);Women;34 Palencia;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Both sexes;187 Palencia;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Men;108 Palencia;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Women;80 Palencia;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Both sexes;123 Palencia;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Men;75 Palencia;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Women;48 Palencia;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Both sexes;5 Palencia;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Men;3 Palencia;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Women;2 Palencia;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Both sexes;60 Palencia;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Men;30 Palencia;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Women;30 Palencia;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Both sexes;1,048 Palencia;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Men;555 Palencia;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Women;494 Palencia;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Both sexes;.. Palencia;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Men;.. Palencia;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Women;.. Palencia;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Both sexes;.. Palencia;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Men;.. Palencia;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Women;.. Palencia;Group 1303 Internal derangement of knee 717;Both sexes;81 Palencia;Group 1303 Internal derangement of knee 717;Men;58 Palencia;Group 1303 Internal derangement of knee 717;Women;23 Palencia;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Both sexes;484 Palencia;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Men;281 Palencia;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Women;203 Palencia;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Both sexes;20 Palencia;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Men;8 Palencia;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Women;12 Palencia;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Both sexes;16 Palencia;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Men;7 Palencia;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Women;9 Palencia;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Both sexes;38 Palencia;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Men;19 Palencia;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Women;19 Palencia;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Both sexes;24 Palencia;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Men;11 Palencia;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Women;13 Palencia;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Both sexes;217 Palencia;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Men;119 Palencia;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Women;98 Palencia;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Both sexes;169 Palencia;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Men;51 Palencia;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Women;118 Palencia;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Both sexes;1,272 Palencia;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Men;613 Palencia;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Women;659 Palencia;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Both sexes;94 Palencia;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Men;26 Palencia;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Women;68 Palencia;Group 1402 Renal failure 5836-5837, 584-586;Both sexes;132 Palencia;Group 1402 Renal failure 5836-5837, 584-586;Men;78 Palencia;Group 1402 Renal failure 5836-5837, 584-586;Women;54 Palencia;Group 1403 Urolithiasis 592, 594, 7880;Both sexes;198 Palencia;Group 1403 Urolithiasis 592, 594, 7880;Men;106 Palencia;Group 1403 Urolithiasis 592, 594, 7880;Women;93 Palencia;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Both sexes;373 Palencia;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Men;189 Palencia;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Women;184 Palencia;Group 1405 Prostatic hyperplasia 600;Both sexes;108 Palencia;Group 1405 Prostatic hyperplasia 600;Men;108 Palencia;Group 1405 Prostatic hyperplasia 600;Women;.. Palencia;Group 1406 Other diseases of the male genital organs 601-608;Both sexes;99 Palencia;Group 1406 Other diseases of the male genital organs 601-608;Men;99 Palencia;Group 1406 Other diseases of the male genital organs 601-608;Women;.. Palencia;Group 1407 Disorders of breast 610-612;Both sexes;25 Palencia;Group 1407 Disorders of breast 610-612;Men;6 Palencia;Group 1407 Disorders of breast 610-612;Women;19 Palencia;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Both sexes;29 Palencia;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Men;.. Palencia;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Women;29 Palencia;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Both sexes;14 Palencia;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Men;.. Palencia;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Women;14 Palencia;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Both sexes;201 Palencia;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Men;2 Palencia;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Women;199 Palencia;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Both sexes;1,271 Palencia;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Men;.. Palencia;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Women;1,271 Palencia;Group 1501 Legally induced abortion 635;Both sexes;.. Palencia;Group 1501 Legally induced abortion 635;Men;.. Palencia;Group 1501 Legally induced abortion 635;Women;.. Palencia;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Both sexes;152 Palencia;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Men;.. Palencia;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Women;152 Palencia;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Both sexes;621 Palencia;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Men;.. Palencia;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Women;621 Palencia;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Both sexes;284 Palencia;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Men;.. Palencia;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Women;284 Palencia;Group 1505 Single spontaneous delivery 650;Both sexes;61 Palencia;Group 1505 Single spontaneous delivery 650;Men;.. Palencia;Group 1505 Single spontaneous delivery 650;Women;61 Palencia;Group 1506 Other deliveries 6695-6697;Both sexes;65 Palencia;Group 1506 Other deliveries 6695-6697;Men;.. Palencia;Group 1506 Other deliveries 6695-6697;Women;65 Palencia;Group 1507 Complications related to the puerperium 670-676;Both sexes;9 Palencia;Group 1507 Complications related to the puerperium 670-676;Men;.. Palencia;Group 1507 Complications related to the puerperium 670-676;Women;9 Palencia;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Both sexes;79 Palencia;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Men;.. Palencia;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Women;79 Palencia;Group 1600 Some disorders originating in the perinatal period 760-779;Both sexes;211 Palencia;Group 1600 Some disorders originating in the perinatal period 760-779;Men;116 Palencia;Group 1600 Some disorders originating in the perinatal period 760-779;Women;95 Palencia;Group 1601 Disorders related with premature delivery and a low birth weight 765;Both sexes;44 Palencia;Group 1601 Disorders related with premature delivery and a low birth weight 765;Men;24 Palencia;Group 1601 Disorders related with premature delivery and a low birth weight 765;Women;20 Palencia;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Both sexes;167 Palencia;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Men;92 Palencia;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Women;75 Palencia;Grupo 1700 Congenital abnormalities 740-759;Both sexes;58 Palencia;Grupo 1700 Congenital abnormalities 740-759;Men;36 Palencia;Grupo 1700 Congenital abnormalities 740-759;Women;22 Palencia;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Both sexes;924 Palencia;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Men;516 Palencia;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Women;408 Palencia;Group 1801 Pain in throat and chest 7841, 7865;Both sexes;193 Palencia;Group 1801 Pain in throat and chest 7841, 7865;Men;106 Palencia;Group 1801 Pain in throat and chest 7841, 7865;Women;87 Palencia;Group 1802 Abdominal pain 7890;Both sexes;81 Palencia;Group 1802 Abdominal pain 7890;Men;36 Palencia;Group 1802 Abdominal pain 7890;Women;46 Palencia;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Both sexes;41 Palencia;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Men;25 Palencia;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Women;16 Palencia;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Both sexes;609 Palencia;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Men;350 Palencia;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Women;259 Palencia;Group 1900 Injuries and poisoning 800-999;Both sexes;1,540 Palencia;Group 1900 Injuries and poisoning 800-999;Men;764 Palencia;Group 1900 Injuries and poisoning 800-999;Women;776 Palencia;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Both sexes;114 Palencia;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Men;58 Palencia;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Women;56 Palencia;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Both sexes;25 Palencia;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Men;15 Palencia;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Women;10 Palencia;Group 1903 Radius and ulna fracture 813;Both sexes;96 Palencia;Group 1903 Radius and ulna fracture 813;Men;42 Palencia;Group 1903 Radius and ulna fracture 813;Women;54 Palencia;Group 1904 Femur fracture 820-821;Both sexes;298 Palencia;Group 1904 Femur fracture 820-821;Men;79 Palencia;Group 1904 Femur fracture 820-821;Women;219 Palencia;Group 1905 Leg fracture, including the ankle 823-824;Both sexes;102 Palencia;Group 1905 Leg fracture, including the ankle 823-824;Men;55 Palencia;Group 1905 Leg fracture, including the ankle 823-824;Women;47 Palencia;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Both sexes;407 Palencia;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Men;250 Palencia;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Women;157 Palencia;Group 1907 Burns 940-949;Both sexes;5 Palencia;Group 1907 Burns 940-949;Men;5 Palencia;Group 1907 Burns 940-949;Women;.. Palencia;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Both sexes;75 Palencia;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Men;36 Palencia;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Women;39 Palencia;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Both sexes;380 Palencia;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Men;202 Palencia;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Women;178 Palencia;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Both sexes;1 Palencia;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Men;1 Palencia;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Women;.. Palencia;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Both sexes;38 Palencia;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Men;21 Palencia;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Women;17 Palencia;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Both sexes;273 Palencia;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Men;184 Palencia;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Women;89 Palencia;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Both sexes;3 Palencia;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Men;.. Palencia;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Women;3 Palencia;Group 2102 Contraceptive management V25;Both sexes;2 Palencia;Group 2102 Contraceptive management V25;Men;1 Palencia;Group 2102 Contraceptive management V25;Women;1 Palencia;Group 2103 Living newborns by type of delivery V30-V39;Both sexes;.. Palencia;Group 2103 Living newborns by type of delivery V30-V39;Men;.. Palencia;Group 2103 Living newborns by type of delivery V30-V39;Women;.. Palencia;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Both sexes;154 Palencia;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Men;122 Palencia;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Women;32 Palencia;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Both sexes;114 Palencia;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Men;61 Palencia;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Women;53 Salamanca;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Both sexes;34,998 Salamanca;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Men;17,383 Salamanca;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Women;17,615 Salamanca;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Both sexes;814 Salamanca;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Men;474 Salamanca;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Women;340 Salamanca;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Both sexes;108 Salamanca;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Men;57 Salamanca;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Women;51 Salamanca;Group 0102 Imprecise intestinal infections 009;Both sexes;36 Salamanca;Group 0102 Imprecise intestinal infections 009;Men;24 Salamanca;Group 0102 Imprecise intestinal infections 009;Women;12 Salamanca;Group 0103 Tuberculosis 010-018, 137;Both sexes;24 Salamanca;Group 0103 Tuberculosis 010-018, 137;Men;17 Salamanca;Group 0103 Tuberculosis 010-018, 137;Women;7 Salamanca;Group 0104 Septicaemia 038;Both sexes;427 Salamanca;Group 0104 Septicaemia 038;Men;238 Salamanca;Group 0104 Septicaemia 038;Women;189 Salamanca;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Both sexes;33 Salamanca;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Men;21 Salamanca;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Women;12 Salamanca;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Both sexes;186 Salamanca;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Men;117 Salamanca;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Women;69 Salamanca;Group 0200 Neoplasms 140-239;Both sexes;3,901 Salamanca;Group 0200 Neoplasms 140-239;Men;2,148 Salamanca;Group 0200 Neoplasms 140-239;Women;1,753 Salamanca;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Both sexes;406 Salamanca;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Men;238 Salamanca;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Women;168 Salamanca;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Both sexes;324 Salamanca;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Men;276 Salamanca;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Women;48 Salamanca;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Both sexes;115 Salamanca;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Men;64 Salamanca;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Women;51 Salamanca;Group 0204 Malignant neoplasm of breast 174-175;Both sexes;207 Salamanca;Group 0204 Malignant neoplasm of breast 174-175;Men;2 Salamanca;Group 0204 Malignant neoplasm of breast 174-175;Women;205 Salamanca;Group 0205 Malignant neoplasm of uterus 179-180, 182;Both sexes;63 Salamanca;Group 0205 Malignant neoplasm of uterus 179-180, 182;Men;.. Salamanca;Group 0205 Malignant neoplasm of uterus 179-180, 182;Women;63 Salamanca;Group 0206 Malignant neoplasm of ovary 1830;Both sexes;44 Salamanca;Group 0206 Malignant neoplasm of ovary 1830;Men;.. Salamanca;Group 0206 Malignant neoplasm of ovary 1830;Women;44 Salamanca;Group 0207 Malignant neoplasm of prostate 185;Both sexes;152 Salamanca;Group 0207 Malignant neoplasm of prostate 185;Men;152 Salamanca;Group 0207 Malignant neoplasm of prostate 185;Women;.. Salamanca;Group 0208 Malignant neoplasm of bladder 188;Both sexes;368 Salamanca;Group 0208 Malignant neoplasm of bladder 188;Men;307 Salamanca;Group 0208 Malignant neoplasm of bladder 188;Women;61 Salamanca;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Both sexes;1,462 Salamanca;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Men;834 Salamanca;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Women;628 Salamanca;Group 0210 Carcinoma in situ 230-234;Both sexes;39 Salamanca;Group 0210 Carcinoma in situ 230-234;Men;13 Salamanca;Group 0210 Carcinoma in situ 230-234;Women;26 Salamanca;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Both sexes;33 Salamanca;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Men;21 Salamanca;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Women;12 Salamanca;Grupo 0212 Leiomyoma of uterus 218;Both sexes;177 Salamanca;Grupo 0212 Leiomyoma of uterus 218;Men;.. Salamanca;Grupo 0212 Leiomyoma of uterus 218;Women;177 Salamanca;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Both sexes;511 Salamanca;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Men;241 Salamanca;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Women;270 Salamanca;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Both sexes;334 Salamanca;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Men;160 Salamanca;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Women;174 Salamanca;Group 0301 Anaemias 280-285;Both sexes;200 Salamanca;Group 0301 Anaemias 280-285;Men;81 Salamanca;Group 0301 Anaemias 280-285;Women;119 Salamanca;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Both sexes;134 Salamanca;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Men;79 Salamanca;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Women;55 Salamanca;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Both sexes;822 Salamanca;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Men;371 Salamanca;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Women;451 Salamanca;Group 0401 Diabetes mellitus 249-250;Both sexes;394 Salamanca;Group 0401 Diabetes mellitus 249-250;Men;236 Salamanca;Group 0401 Diabetes mellitus 249-250;Women;158 Salamanca;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Both sexes;428 Salamanca;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Men;135 Salamanca;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Women;293 Salamanca;Group 0500 Mental disorders 290-319;Both sexes;756 Salamanca;Group 0500 Mental disorders 290-319;Men;438 Salamanca;Group 0500 Mental disorders 290-319;Women;318 Salamanca;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Both sexes;12 Salamanca;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Men;6 Salamanca;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Women;6 Salamanca;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Both sexes;78 Salamanca;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Men;58 Salamanca;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Women;20 Salamanca;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Both sexes;167 Salamanca;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Men;134 Salamanca;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Women;33 Salamanca;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Both sexes;197 Salamanca;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Men;120 Salamanca;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Women;77 Salamanca;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Both sexes;146 Salamanca;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Men;55 Salamanca;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Women;91 Salamanca;Group 0506 Other mental and behavioural disorders Rest of (290-319);Both sexes;156 Salamanca;Group 0506 Other mental and behavioural disorders Rest of (290-319);Men;65 Salamanca;Group 0506 Other mental and behavioural disorders Rest of (290-319);Women;91 Salamanca;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Both sexes;847 Salamanca;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Men;344 Salamanca;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Women;503 Salamanca;Group 0601 Alzheimer's disease 3310;Both sexes;2 Salamanca;Group 0601 Alzheimer's disease 3310;Men;2 Salamanca;Group 0601 Alzheimer's disease 3310;Women;.. Salamanca;Group 0602 Multiple sclerosis 340;Both sexes;5 Salamanca;Group 0602 Multiple sclerosis 340;Men;3 Salamanca;Group 0602 Multiple sclerosis 340;Women;2 Salamanca;Group 0603 Epilepsy 345;Both sexes;59 Salamanca;Group 0603 Epilepsy 345;Men;31 Salamanca;Group 0603 Epilepsy 345;Women;28 Salamanca;Group 0604 Transient cerebral ischemia 435;Both sexes;99 Salamanca;Group 0604 Transient cerebral ischemia 435;Men;49 Salamanca;Group 0604 Transient cerebral ischemia 435;Women;50 Salamanca;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Both sexes;682 Salamanca;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Men;259 Salamanca;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Women;423 Salamanca;Grupo 0700 Diseases of the eye and adnexa 360-379;Both sexes;136 Salamanca;Grupo 0700 Diseases of the eye and adnexa 360-379;Men;66 Salamanca;Grupo 0700 Diseases of the eye and adnexa 360-379;Women;70 Salamanca;Grupo 0701 Cataract 366;Both sexes;11 Salamanca;Grupo 0701 Cataract 366;Men;6 Salamanca;Grupo 0701 Cataract 366;Women;5 Salamanca;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Both sexes;125 Salamanca;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Men;60 Salamanca;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Women;65 Salamanca;Group 0800 Diseases of the ear and the mastoid 380-389;Both sexes;276 Salamanca;Group 0800 Diseases of the ear and the mastoid 380-389;Men;128 Salamanca;Group 0800 Diseases of the ear and the mastoid 380-389;Women;148 Salamanca;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Both sexes;5,337 Salamanca;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Men;3,033 Salamanca;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Women;2,304 Salamanca;Group 0901 Hypertensive disease 401-405;Both sexes;278 Salamanca;Group 0901 Hypertensive disease 401-405;Men;116 Salamanca;Group 0901 Hypertensive disease 401-405;Women;162 Salamanca;Group 0902 Angina pectoris 4111, 413;Both sexes;107 Salamanca;Group 0902 Angina pectoris 4111, 413;Men;84 Salamanca;Group 0902 Angina pectoris 4111, 413;Women;23 Salamanca;Group 0903 Acute myocardial infarction 410;Both sexes;702 Salamanca;Group 0903 Acute myocardial infarction 410;Men;508 Salamanca;Group 0903 Acute myocardial infarction 410;Women;194 Salamanca;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Both sexes;244 Salamanca;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Men;205 Salamanca;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Women;39 Salamanca;Group 0905 Diseases of the lungs circulation 415-417;Both sexes;216 Salamanca;Group 0905 Diseases of the lungs circulation 415-417;Men;102 Salamanca;Group 0905 Diseases of the lungs circulation 415-417;Women;114 Salamanca;Group 0906 Heart conduction disorders and arrhytmias 426-427;Both sexes;565 Salamanca;Group 0906 Heart conduction disorders and arrhytmias 426-427;Men;332 Salamanca;Group 0906 Heart conduction disorders and arrhytmias 426-427;Women;233 Salamanca;Grupo 0907 Heart failure 428;Both sexes;932 Salamanca;Grupo 0907 Heart failure 428;Men;452 Salamanca;Grupo 0907 Heart failure 428;Women;480 Salamanca;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Both sexes;886 Salamanca;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Men;469 Salamanca;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Women;417 Salamanca;Grupo 0909 Atherosclerosis 440;Both sexes;116 Salamanca;Grupo 0909 Atherosclerosis 440;Men;85 Salamanca;Grupo 0909 Atherosclerosis 440;Women;31 Salamanca;Group 0910 Varicose veins of lower extremities 454;Both sexes;348 Salamanca;Group 0910 Varicose veins of lower extremities 454;Men;103 Salamanca;Group 0910 Varicose veins of lower extremities 454;Women;245 Salamanca;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Both sexes;943 Salamanca;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Men;577 Salamanca;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Women;366 Salamanca;Group 1000 Diseases of the respiratory system 0340, 460-519;Both sexes;3,485 Salamanca;Group 1000 Diseases of the respiratory system 0340, 460-519;Men;2,096 Salamanca;Group 1000 Diseases of the respiratory system 0340, 460-519;Women;1,389 Salamanca;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Both sexes;81 Salamanca;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Men;50 Salamanca;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Women;31 Salamanca;Group 1002 Pneumonia 480-486;Both sexes;705 Salamanca;Group 1002 Pneumonia 480-486;Men;415 Salamanca;Group 1002 Pneumonia 480-486;Women;290 Salamanca;Group 1003 Acute bronchitis and bronchiolitis 466;Both sexes;441 Salamanca;Group 1003 Acute bronchitis and bronchiolitis 466;Men;209 Salamanca;Group 1003 Acute bronchitis and bronchiolitis 466;Women;232 Salamanca;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Both sexes;114 Salamanca;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Men;59 Salamanca;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Women;55 Salamanca;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Both sexes;381 Salamanca;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Men;249 Salamanca;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Women;132 Salamanca;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Both sexes;492 Salamanca;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Men;427 Salamanca;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Women;65 Salamanca;Group 1007 Asthma 4930-4931,4938-4939;Both sexes;121 Salamanca;Group 1007 Asthma 4930-4931,4938-4939;Men;39 Salamanca;Group 1007 Asthma 4930-4931,4938-4939;Women;82 Salamanca;Group 1008 Other diseases of the respiratory system Resto of (460-519);Both sexes;1,150 Salamanca;Group 1008 Other diseases of the respiratory system Resto of (460-519);Men;648 Salamanca;Group 1008 Other diseases of the respiratory system Resto of (460-519);Women;502 Salamanca;Group 1100 Diseases of the digestive system 520-579;Both sexes;4,611 Salamanca;Group 1100 Diseases of the digestive system 520-579;Men;2,587 Salamanca;Group 1100 Diseases of the digestive system 520-579;Women;2,024 Salamanca;Group 1101 Disorders of the teeth and supporting structures 520-525;Both sexes;60 Salamanca;Group 1101 Disorders of the teeth and supporting structures 520-525;Men;29 Salamanca;Group 1101 Disorders of the teeth and supporting structures 520-525;Women;31 Salamanca;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Both sexes;107 Salamanca;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Men;63 Salamanca;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Women;44 Salamanca;Group 1103 Diseases of the esophagus 530;Both sexes;79 Salamanca;Group 1103 Diseases of the esophagus 530;Men;52 Salamanca;Group 1103 Diseases of the esophagus 530;Women;27 Salamanca;Group 1104 Peptic ulcer 531-534;Both sexes;92 Salamanca;Group 1104 Peptic ulcer 531-534;Men;60 Salamanca;Group 1104 Peptic ulcer 531-534;Women;32 Salamanca;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Both sexes;121 Salamanca;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Men;55 Salamanca;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Women;66 Salamanca;Group 1106 Appendicitis 540-543;Both sexes;349 Salamanca;Group 1106 Appendicitis 540-543;Men;186 Salamanca;Group 1106 Appendicitis 540-543;Women;163 Salamanca;Group 1107 Inguinal hernia 550;Both sexes;494 Salamanca;Group 1107 Inguinal hernia 550;Men;436 Salamanca;Group 1107 Inguinal hernia 550;Women;58 Salamanca;Group 1108 Other abdominal hernia 551-553;Both sexes;354 Salamanca;Group 1108 Other abdominal hernia 551-553;Men;155 Salamanca;Group 1108 Other abdominal hernia 551-553;Women;199 Salamanca;Group 1109 Crohn's disease and ulcerative colitis 555-556;Both sexes;66 Salamanca;Group 1109 Crohn's disease and ulcerative colitis 555-556;Men;38 Salamanca;Group 1109 Crohn's disease and ulcerative colitis 555-556;Women;28 Salamanca;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Both sexes;183 Salamanca;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Men;80 Salamanca;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Women;103 Salamanca;Group 1111 Intestinal obstruction without hernia 560;Both sexes;358 Salamanca;Group 1111 Intestinal obstruction without hernia 560;Men;186 Salamanca;Group 1111 Intestinal obstruction without hernia 560;Women;172 Salamanca;Group 1112 Intestinal diverticulosis 562;Both sexes;190 Salamanca;Group 1112 Intestinal diverticulosis 562;Men;92 Salamanca;Group 1112 Intestinal diverticulosis 562;Women;98 Salamanca;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Both sexes;224 Salamanca;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Men;165 Salamanca;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Women;59 Salamanca;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Both sexes;171 Salamanca;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Men;75 Salamanca;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Women;96 Salamanca;Group 1115 Alcoholic hepatitis 5710-5713;Both sexes;58 Salamanca;Group 1115 Alcoholic hepatitis 5710-5713;Men;49 Salamanca;Group 1115 Alcoholic hepatitis 5710-5713;Women;9 Salamanca;Group 1116 Other diseases of the liver 570,5714-573;Both sexes;166 Salamanca;Group 1116 Other diseases of the liver 570,5714-573;Men;123 Salamanca;Group 1116 Other diseases of the liver 570,5714-573;Women;43 Salamanca;Group 1117 Cholelithiasis 574;Both sexes;938 Salamanca;Group 1117 Cholelithiasis 574;Men;409 Salamanca;Group 1117 Cholelithiasis 574;Women;529 Salamanca;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Both sexes;203 Salamanca;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Men;116 Salamanca;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Women;87 Salamanca;Group 1119 Pancreatic diseases 577;Both sexes;154 Salamanca;Group 1119 Pancreatic diseases 577;Men;90 Salamanca;Group 1119 Pancreatic diseases 577;Women;64 Salamanca;Group 1120 Other diseases of the digestive system Rest of (520-579);Both sexes;244 Salamanca;Group 1120 Other diseases of the digestive system Rest of (520-579);Men;128 Salamanca;Group 1120 Other diseases of the digestive system Rest of (520-579);Women;116 Salamanca;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Both sexes;259 Salamanca;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Men;132 Salamanca;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Women;127 Salamanca;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Both sexes;130 Salamanca;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Men;73 Salamanca;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Women;57 Salamanca;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Both sexes;17 Salamanca;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Men;12 Salamanca;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Women;5 Salamanca;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Both sexes;112 Salamanca;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Men;47 Salamanca;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Women;65 Salamanca;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Both sexes;1,714 Salamanca;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Men;784 Salamanca;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Women;930 Salamanca;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Both sexes;.. Salamanca;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Men;.. Salamanca;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Women;.. Salamanca;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Both sexes;.. Salamanca;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Men;.. Salamanca;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Women;.. Salamanca;Group 1303 Internal derangement of knee 717;Both sexes;66 Salamanca;Group 1303 Internal derangement of knee 717;Men;44 Salamanca;Group 1303 Internal derangement of knee 717;Women;22 Salamanca;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Both sexes;784 Salamanca;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Men;345 Salamanca;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Women;439 Salamanca;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Both sexes;48 Salamanca;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Men;15 Salamanca;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Women;33 Salamanca;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Both sexes;129 Salamanca;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Men;58 Salamanca;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Women;71 Salamanca;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Both sexes;261 Salamanca;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Men;136 Salamanca;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Women;125 Salamanca;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Both sexes;32 Salamanca;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Men;16 Salamanca;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Women;16 Salamanca;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Both sexes;152 Salamanca;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Men;78 Salamanca;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Women;74 Salamanca;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Both sexes;242 Salamanca;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Men;92 Salamanca;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Women;150 Salamanca;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Both sexes;2,105 Salamanca;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Men;997 Salamanca;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Women;1,108 Salamanca;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Both sexes;173 Salamanca;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Men;76 Salamanca;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Women;97 Salamanca;Group 1402 Renal failure 5836-5837, 584-586;Both sexes;225 Salamanca;Group 1402 Renal failure 5836-5837, 584-586;Men;122 Salamanca;Group 1402 Renal failure 5836-5837, 584-586;Women;103 Salamanca;Group 1403 Urolithiasis 592, 594, 7880;Both sexes;259 Salamanca;Group 1403 Urolithiasis 592, 594, 7880;Men;147 Salamanca;Group 1403 Urolithiasis 592, 594, 7880;Women;112 Salamanca;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Both sexes;426 Salamanca;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Men;227 Salamanca;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Women;199 Salamanca;Group 1405 Prostatic hyperplasia 600;Both sexes;194 Salamanca;Group 1405 Prostatic hyperplasia 600;Men;194 Salamanca;Group 1405 Prostatic hyperplasia 600;Women;.. Salamanca;Group 1406 Other diseases of the male genital organs 601-608;Both sexes;205 Salamanca;Group 1406 Other diseases of the male genital organs 601-608;Men;205 Salamanca;Group 1406 Other diseases of the male genital organs 601-608;Women;.. Salamanca;Group 1407 Disorders of breast 610-612;Both sexes;119 Salamanca;Group 1407 Disorders of breast 610-612;Men;8 Salamanca;Group 1407 Disorders of breast 610-612;Women;111 Salamanca;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Both sexes;81 Salamanca;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Men;.. Salamanca;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Women;81 Salamanca;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Both sexes;33 Salamanca;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Men;.. Salamanca;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Women;33 Salamanca;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Both sexes;390 Salamanca;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Men;18 Salamanca;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Women;372 Salamanca;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Both sexes;2,835 Salamanca;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Men;.. Salamanca;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Women;2,835 Salamanca;Group 1501 Legally induced abortion 635;Both sexes;.. Salamanca;Group 1501 Legally induced abortion 635;Men;.. Salamanca;Group 1501 Legally induced abortion 635;Women;.. Salamanca;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Both sexes;251 Salamanca;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Men;.. Salamanca;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Women;251 Salamanca;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Both sexes;1,615 Salamanca;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Men;.. Salamanca;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Women;1,615 Salamanca;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Both sexes;532 Salamanca;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Men;.. Salamanca;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Women;532 Salamanca;Group 1505 Single spontaneous delivery 650;Both sexes;197 Salamanca;Group 1505 Single spontaneous delivery 650;Men;.. Salamanca;Group 1505 Single spontaneous delivery 650;Women;197 Salamanca;Group 1506 Other deliveries 6695-6697;Both sexes;83 Salamanca;Group 1506 Other deliveries 6695-6697;Men;.. Salamanca;Group 1506 Other deliveries 6695-6697;Women;83 Salamanca;Group 1507 Complications related to the puerperium 670-676;Both sexes;14 Salamanca;Group 1507 Complications related to the puerperium 670-676;Men;.. Salamanca;Group 1507 Complications related to the puerperium 670-676;Women;14 Salamanca;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Both sexes;143 Salamanca;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Men;.. Salamanca;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Women;143 Salamanca;Group 1600 Some disorders originating in the perinatal period 760-779;Both sexes;373 Salamanca;Group 1600 Some disorders originating in the perinatal period 760-779;Men;197 Salamanca;Group 1600 Some disorders originating in the perinatal period 760-779;Women;176 Salamanca;Group 1601 Disorders related with premature delivery and a low birth weight 765;Both sexes;143 Salamanca;Group 1601 Disorders related with premature delivery and a low birth weight 765;Men;81 Salamanca;Group 1601 Disorders related with premature delivery and a low birth weight 765;Women;62 Salamanca;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Both sexes;230 Salamanca;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Men;116 Salamanca;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Women;114 Salamanca;Grupo 1700 Congenital abnormalities 740-759;Both sexes;319 Salamanca;Grupo 1700 Congenital abnormalities 740-759;Men;244 Salamanca;Grupo 1700 Congenital abnormalities 740-759;Women;75 Salamanca;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Both sexes;1,946 Salamanca;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Men;1,049 Salamanca;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Women;897 Salamanca;Group 1801 Pain in throat and chest 7841, 7865;Both sexes;98 Salamanca;Group 1801 Pain in throat and chest 7841, 7865;Men;46 Salamanca;Group 1801 Pain in throat and chest 7841, 7865;Women;52 Salamanca;Group 1802 Abdominal pain 7890;Both sexes;204 Salamanca;Group 1802 Abdominal pain 7890;Men;92 Salamanca;Group 1802 Abdominal pain 7890;Women;112 Salamanca;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Both sexes;791 Salamanca;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Men;435 Salamanca;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Women;356 Salamanca;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Both sexes;853 Salamanca;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Men;476 Salamanca;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Women;377 Salamanca;Group 1900 Injuries and poisoning 800-999;Both sexes;3,415 Salamanca;Group 1900 Injuries and poisoning 800-999;Men;1,765 Salamanca;Group 1900 Injuries and poisoning 800-999;Women;1,650 Salamanca;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Both sexes;208 Salamanca;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Men;126 Salamanca;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Women;82 Salamanca;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Both sexes;91 Salamanca;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Men;68 Salamanca;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Women;23 Salamanca;Group 1903 Radius and ulna fracture 813;Both sexes;140 Salamanca;Group 1903 Radius and ulna fracture 813;Men;64 Salamanca;Group 1903 Radius and ulna fracture 813;Women;76 Salamanca;Group 1904 Femur fracture 820-821;Both sexes;604 Salamanca;Group 1904 Femur fracture 820-821;Men;140 Salamanca;Group 1904 Femur fracture 820-821;Women;464 Salamanca;Group 1905 Leg fracture, including the ankle 823-824;Both sexes;244 Salamanca;Group 1905 Leg fracture, including the ankle 823-824;Men;123 Salamanca;Group 1905 Leg fracture, including the ankle 823-824;Women;121 Salamanca;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Both sexes;898 Salamanca;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Men;569 Salamanca;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Women;329 Salamanca;Group 1907 Burns 940-949;Both sexes;24 Salamanca;Group 1907 Burns 940-949;Men;17 Salamanca;Group 1907 Burns 940-949;Women;7 Salamanca;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Both sexes;122 Salamanca;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Men;61 Salamanca;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Women;61 Salamanca;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Both sexes;984 Salamanca;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Men;542 Salamanca;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Women;442 Salamanca;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Both sexes;.. Salamanca;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Men;.. Salamanca;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Women;.. Salamanca;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Both sexes;100 Salamanca;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Men;55 Salamanca;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Women;45 Salamanca;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Both sexes;713 Salamanca;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Men;370 Salamanca;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Women;343 Salamanca;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Both sexes;41 Salamanca;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Men;14 Salamanca;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Women;27 Salamanca;Group 2102 Contraceptive management V25;Both sexes;8 Salamanca;Group 2102 Contraceptive management V25;Men;1 Salamanca;Group 2102 Contraceptive management V25;Women;7 Salamanca;Group 2103 Living newborns by type of delivery V30-V39;Both sexes;.. Salamanca;Group 2103 Living newborns by type of delivery V30-V39;Men;.. Salamanca;Group 2103 Living newborns by type of delivery V30-V39;Women;.. Salamanca;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Both sexes;494 Salamanca;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Men;273 Salamanca;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Women;221 Salamanca;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Both sexes;170 Salamanca;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Men;82 Salamanca;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Women;88 Segovia;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Both sexes;12,876 Segovia;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Men;6,567 Segovia;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Women;6,309 Segovia;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Both sexes;327 Segovia;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Men;189 Segovia;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Women;138 Segovia;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Both sexes;77 Segovia;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Men;44 Segovia;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Women;33 Segovia;Group 0102 Imprecise intestinal infections 009;Both sexes;17 Segovia;Group 0102 Imprecise intestinal infections 009;Men;6 Segovia;Group 0102 Imprecise intestinal infections 009;Women;11 Segovia;Group 0103 Tuberculosis 010-018, 137;Both sexes;5 Segovia;Group 0103 Tuberculosis 010-018, 137;Men;4 Segovia;Group 0103 Tuberculosis 010-018, 137;Women;1 Segovia;Group 0104 Septicaemia 038;Both sexes;124 Segovia;Group 0104 Septicaemia 038;Men;64 Segovia;Group 0104 Septicaemia 038;Women;60 Segovia;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Both sexes;5 Segovia;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Men;4 Segovia;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Women;1 Segovia;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Both sexes;99 Segovia;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Men;67 Segovia;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Women;32 Segovia;Group 0200 Neoplasms 140-239;Both sexes;1,080 Segovia;Group 0200 Neoplasms 140-239;Men;581 Segovia;Group 0200 Neoplasms 140-239;Women;499 Segovia;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Both sexes;117 Segovia;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Men;75 Segovia;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Women;42 Segovia;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Both sexes;60 Segovia;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Men;46 Segovia;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Women;14 Segovia;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Both sexes;34 Segovia;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Men;17 Segovia;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Women;17 Segovia;Group 0204 Malignant neoplasm of breast 174-175;Both sexes;83 Segovia;Group 0204 Malignant neoplasm of breast 174-175;Men;.. Segovia;Group 0204 Malignant neoplasm of breast 174-175;Women;83 Segovia;Group 0205 Malignant neoplasm of uterus 179-180, 182;Both sexes;23 Segovia;Group 0205 Malignant neoplasm of uterus 179-180, 182;Men;.. Segovia;Group 0205 Malignant neoplasm of uterus 179-180, 182;Women;23 Segovia;Group 0206 Malignant neoplasm of ovary 1830;Both sexes;17 Segovia;Group 0206 Malignant neoplasm of ovary 1830;Men;.. Segovia;Group 0206 Malignant neoplasm of ovary 1830;Women;17 Segovia;Group 0207 Malignant neoplasm of prostate 185;Both sexes;53 Segovia;Group 0207 Malignant neoplasm of prostate 185;Men;53 Segovia;Group 0207 Malignant neoplasm of prostate 185;Women;.. Segovia;Group 0208 Malignant neoplasm of bladder 188;Both sexes;123 Segovia;Group 0208 Malignant neoplasm of bladder 188;Men;94 Segovia;Group 0208 Malignant neoplasm of bladder 188;Women;29 Segovia;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Both sexes;362 Segovia;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Men;213 Segovia;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Women;149 Segovia;Group 0210 Carcinoma in situ 230-234;Both sexes;50 Segovia;Group 0210 Carcinoma in situ 230-234;Men;23 Segovia;Group 0210 Carcinoma in situ 230-234;Women;27 Segovia;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Both sexes;6 Segovia;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Men;4 Segovia;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Women;2 Segovia;Grupo 0212 Leiomyoma of uterus 218;Both sexes;37 Segovia;Grupo 0212 Leiomyoma of uterus 218;Men;.. Segovia;Grupo 0212 Leiomyoma of uterus 218;Women;37 Segovia;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Both sexes;115 Segovia;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Men;56 Segovia;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Women;59 Segovia;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Both sexes;102 Segovia;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Men;53 Segovia;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Women;49 Segovia;Group 0301 Anaemias 280-285;Both sexes;59 Segovia;Group 0301 Anaemias 280-285;Men;29 Segovia;Group 0301 Anaemias 280-285;Women;30 Segovia;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Both sexes;43 Segovia;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Men;24 Segovia;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Women;19 Segovia;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Both sexes;229 Segovia;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Men;115 Segovia;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Women;114 Segovia;Group 0401 Diabetes mellitus 249-250;Both sexes;77 Segovia;Group 0401 Diabetes mellitus 249-250;Men;53 Segovia;Group 0401 Diabetes mellitus 249-250;Women;24 Segovia;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Both sexes;152 Segovia;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Men;62 Segovia;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Women;90 Segovia;Group 0500 Mental disorders 290-319;Both sexes;334 Segovia;Group 0500 Mental disorders 290-319;Men;179 Segovia;Group 0500 Mental disorders 290-319;Women;155 Segovia;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Both sexes;2 Segovia;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Men;.. Segovia;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Women;2 Segovia;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Both sexes;30 Segovia;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Men;25 Segovia;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Women;5 Segovia;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Both sexes;13 Segovia;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Men;7 Segovia;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Women;6 Segovia;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Both sexes;79 Segovia;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Men;48 Segovia;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Women;31 Segovia;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Both sexes;104 Segovia;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Men;45 Segovia;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Women;59 Segovia;Group 0506 Other mental and behavioural disorders Rest of (290-319);Both sexes;106 Segovia;Group 0506 Other mental and behavioural disorders Rest of (290-319);Men;54 Segovia;Group 0506 Other mental and behavioural disorders Rest of (290-319);Women;52 Segovia;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Both sexes;210 Segovia;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Men;104 Segovia;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Women;106 Segovia;Group 0601 Alzheimer's disease 3310;Both sexes;10 Segovia;Group 0601 Alzheimer's disease 3310;Men;1 Segovia;Group 0601 Alzheimer's disease 3310;Women;9 Segovia;Group 0602 Multiple sclerosis 340;Both sexes;17 Segovia;Group 0602 Multiple sclerosis 340;Men;6 Segovia;Group 0602 Multiple sclerosis 340;Women;11 Segovia;Group 0603 Epilepsy 345;Both sexes;31 Segovia;Group 0603 Epilepsy 345;Men;12 Segovia;Group 0603 Epilepsy 345;Women;19 Segovia;Group 0604 Transient cerebral ischemia 435;Both sexes;33 Segovia;Group 0604 Transient cerebral ischemia 435;Men;18 Segovia;Group 0604 Transient cerebral ischemia 435;Women;15 Segovia;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Both sexes;119 Segovia;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Men;67 Segovia;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Women;52 Segovia;Grupo 0700 Diseases of the eye and adnexa 360-379;Both sexes;200 Segovia;Grupo 0700 Diseases of the eye and adnexa 360-379;Men;103 Segovia;Grupo 0700 Diseases of the eye and adnexa 360-379;Women;97 Segovia;Grupo 0701 Cataract 366;Both sexes;46 Segovia;Grupo 0701 Cataract 366;Men;23 Segovia;Grupo 0701 Cataract 366;Women;23 Segovia;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Both sexes;154 Segovia;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Men;80 Segovia;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Women;74 Segovia;Group 0800 Diseases of the ear and the mastoid 380-389;Both sexes;72 Segovia;Group 0800 Diseases of the ear and the mastoid 380-389;Men;35 Segovia;Group 0800 Diseases of the ear and the mastoid 380-389;Women;37 Segovia;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Both sexes;1,711 Segovia;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Men;963 Segovia;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Women;748 Segovia;Group 0901 Hypertensive disease 401-405;Both sexes;42 Segovia;Group 0901 Hypertensive disease 401-405;Men;16 Segovia;Group 0901 Hypertensive disease 401-405;Women;26 Segovia;Group 0902 Angina pectoris 4111, 413;Both sexes;63 Segovia;Group 0902 Angina pectoris 4111, 413;Men;39 Segovia;Group 0902 Angina pectoris 4111, 413;Women;24 Segovia;Group 0903 Acute myocardial infarction 410;Both sexes;181 Segovia;Group 0903 Acute myocardial infarction 410;Men;123 Segovia;Group 0903 Acute myocardial infarction 410;Women;58 Segovia;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Both sexes;61 Segovia;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Men;54 Segovia;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Women;7 Segovia;Group 0905 Diseases of the lungs circulation 415-417;Both sexes;71 Segovia;Group 0905 Diseases of the lungs circulation 415-417;Men;40 Segovia;Group 0905 Diseases of the lungs circulation 415-417;Women;31 Segovia;Group 0906 Heart conduction disorders and arrhytmias 426-427;Both sexes;237 Segovia;Group 0906 Heart conduction disorders and arrhytmias 426-427;Men;121 Segovia;Group 0906 Heart conduction disorders and arrhytmias 426-427;Women;116 Segovia;Grupo 0907 Heart failure 428;Both sexes;423 Segovia;Grupo 0907 Heart failure 428;Men;196 Segovia;Grupo 0907 Heart failure 428;Women;227 Segovia;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Both sexes;343 Segovia;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Men;207 Segovia;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Women;136 Segovia;Grupo 0909 Atherosclerosis 440;Both sexes;32 Segovia;Grupo 0909 Atherosclerosis 440;Men;19 Segovia;Grupo 0909 Atherosclerosis 440;Women;13 Segovia;Group 0910 Varicose veins of lower extremities 454;Both sexes;32 Segovia;Group 0910 Varicose veins of lower extremities 454;Men;14 Segovia;Group 0910 Varicose veins of lower extremities 454;Women;18 Segovia;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Both sexes;226 Segovia;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Men;134 Segovia;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Women;92 Segovia;Group 1000 Diseases of the respiratory system 0340, 460-519;Both sexes;1,519 Segovia;Group 1000 Diseases of the respiratory system 0340, 460-519;Men;869 Segovia;Group 1000 Diseases of the respiratory system 0340, 460-519;Women;650 Segovia;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Both sexes;127 Segovia;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Men;71 Segovia;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Women;56 Segovia;Group 1002 Pneumonia 480-486;Both sexes;355 Segovia;Group 1002 Pneumonia 480-486;Men;207 Segovia;Group 1002 Pneumonia 480-486;Women;148 Segovia;Group 1003 Acute bronchitis and bronchiolitis 466;Both sexes;74 Segovia;Group 1003 Acute bronchitis and bronchiolitis 466;Men;40 Segovia;Group 1003 Acute bronchitis and bronchiolitis 466;Women;34 Segovia;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Both sexes;68 Segovia;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Men;25 Segovia;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Women;43 Segovia;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Both sexes;139 Segovia;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Men;86 Segovia;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Women;53 Segovia;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Both sexes;270 Segovia;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Men;227 Segovia;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Women;43 Segovia;Group 1007 Asthma 4930-4931,4938-4939;Both sexes;66 Segovia;Group 1007 Asthma 4930-4931,4938-4939;Men;24 Segovia;Group 1007 Asthma 4930-4931,4938-4939;Women;42 Segovia;Group 1008 Other diseases of the respiratory system Resto of (460-519);Both sexes;420 Segovia;Group 1008 Other diseases of the respiratory system Resto of (460-519);Men;189 Segovia;Group 1008 Other diseases of the respiratory system Resto of (460-519);Women;231 Segovia;Group 1100 Diseases of the digestive system 520-579;Both sexes;1,896 Segovia;Group 1100 Diseases of the digestive system 520-579;Men;1,134 Segovia;Group 1100 Diseases of the digestive system 520-579;Women;762 Segovia;Group 1101 Disorders of the teeth and supporting structures 520-525;Both sexes;21 Segovia;Group 1101 Disorders of the teeth and supporting structures 520-525;Men;9 Segovia;Group 1101 Disorders of the teeth and supporting structures 520-525;Women;12 Segovia;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Both sexes;29 Segovia;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Men;16 Segovia;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Women;13 Segovia;Group 1103 Diseases of the esophagus 530;Both sexes;37 Segovia;Group 1103 Diseases of the esophagus 530;Men;27 Segovia;Group 1103 Diseases of the esophagus 530;Women;10 Segovia;Group 1104 Peptic ulcer 531-534;Both sexes;58 Segovia;Group 1104 Peptic ulcer 531-534;Men;41 Segovia;Group 1104 Peptic ulcer 531-534;Women;17 Segovia;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Both sexes;39 Segovia;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Men;17 Segovia;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Women;22 Segovia;Group 1106 Appendicitis 540-543;Both sexes;175 Segovia;Group 1106 Appendicitis 540-543;Men;103 Segovia;Group 1106 Appendicitis 540-543;Women;72 Segovia;Group 1107 Inguinal hernia 550;Both sexes;266 Segovia;Group 1107 Inguinal hernia 550;Men;241 Segovia;Group 1107 Inguinal hernia 550;Women;25 Segovia;Group 1108 Other abdominal hernia 551-553;Both sexes;147 Segovia;Group 1108 Other abdominal hernia 551-553;Men;76 Segovia;Group 1108 Other abdominal hernia 551-553;Women;71 Segovia;Group 1109 Crohn's disease and ulcerative colitis 555-556;Both sexes;24 Segovia;Group 1109 Crohn's disease and ulcerative colitis 555-556;Men;11 Segovia;Group 1109 Crohn's disease and ulcerative colitis 555-556;Women;13 Segovia;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Both sexes;107 Segovia;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Men;61 Segovia;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Women;46 Segovia;Group 1111 Intestinal obstruction without hernia 560;Both sexes;118 Segovia;Group 1111 Intestinal obstruction without hernia 560;Men;72 Segovia;Group 1111 Intestinal obstruction without hernia 560;Women;46 Segovia;Group 1112 Intestinal diverticulosis 562;Both sexes;73 Segovia;Group 1112 Intestinal diverticulosis 562;Men;35 Segovia;Group 1112 Intestinal diverticulosis 562;Women;38 Segovia;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Both sexes;123 Segovia;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Men;83 Segovia;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Women;40 Segovia;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Both sexes;77 Segovia;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Men;30 Segovia;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Women;47 Segovia;Group 1115 Alcoholic hepatitis 5710-5713;Both sexes;10 Segovia;Group 1115 Alcoholic hepatitis 5710-5713;Men;7 Segovia;Group 1115 Alcoholic hepatitis 5710-5713;Women;3 Segovia;Group 1116 Other diseases of the liver 570,5714-573;Both sexes;40 Segovia;Group 1116 Other diseases of the liver 570,5714-573;Men;29 Segovia;Group 1116 Other diseases of the liver 570,5714-573;Women;11 Segovia;Group 1117 Cholelithiasis 574;Both sexes;305 Segovia;Group 1117 Cholelithiasis 574;Men;135 Segovia;Group 1117 Cholelithiasis 574;Women;170 Segovia;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Both sexes;89 Segovia;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Men;53 Segovia;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Women;36 Segovia;Group 1119 Pancreatic diseases 577;Both sexes;85 Segovia;Group 1119 Pancreatic diseases 577;Men;49 Segovia;Group 1119 Pancreatic diseases 577;Women;36 Segovia;Group 1120 Other diseases of the digestive system Rest of (520-579);Both sexes;73 Segovia;Group 1120 Other diseases of the digestive system Rest of (520-579);Men;39 Segovia;Group 1120 Other diseases of the digestive system Rest of (520-579);Women;34 Segovia;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Both sexes;177 Segovia;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Men;101 Segovia;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Women;76 Segovia;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Both sexes;128 Segovia;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Men;80 Segovia;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Women;48 Segovia;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Both sexes;3 Segovia;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Men;2 Segovia;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Women;1 Segovia;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Both sexes;46 Segovia;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Men;19 Segovia;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Women;27 Segovia;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Both sexes;783 Segovia;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Men;406 Segovia;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Women;377 Segovia;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Both sexes;.. Segovia;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Men;.. Segovia;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Women;.. Segovia;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Both sexes;.. Segovia;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Men;.. Segovia;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Women;.. Segovia;Group 1303 Internal derangement of knee 717;Both sexes;155 Segovia;Group 1303 Internal derangement of knee 717;Men;122 Segovia;Group 1303 Internal derangement of knee 717;Women;33 Segovia;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Both sexes;398 Segovia;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Men;190 Segovia;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Women;208 Segovia;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Both sexes;11 Segovia;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Men;5 Segovia;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Women;6 Segovia;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Both sexes;4 Segovia;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Men;2 Segovia;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Women;2 Segovia;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Both sexes;12 Segovia;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Men;7 Segovia;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Women;5 Segovia;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Both sexes;5 Segovia;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Men;5 Segovia;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Women;.. Segovia;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Both sexes;89 Segovia;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Men;43 Segovia;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Women;46 Segovia;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Both sexes;109 Segovia;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Men;32 Segovia;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Women;77 Segovia;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Both sexes;988 Segovia;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Men;551 Segovia;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Women;437 Segovia;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Both sexes;103 Segovia;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Men;24 Segovia;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Women;79 Segovia;Group 1402 Renal failure 5836-5837, 584-586;Both sexes;80 Segovia;Group 1402 Renal failure 5836-5837, 584-586;Men;48 Segovia;Group 1402 Renal failure 5836-5837, 584-586;Women;32 Segovia;Group 1403 Urolithiasis 592, 594, 7880;Both sexes;177 Segovia;Group 1403 Urolithiasis 592, 594, 7880;Men;98 Segovia;Group 1403 Urolithiasis 592, 594, 7880;Women;79 Segovia;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Both sexes;221 Segovia;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Men;127 Segovia;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Women;94 Segovia;Group 1405 Prostatic hyperplasia 600;Both sexes;114 Segovia;Group 1405 Prostatic hyperplasia 600;Men;114 Segovia;Group 1405 Prostatic hyperplasia 600;Women;.. Segovia;Group 1406 Other diseases of the male genital organs 601-608;Both sexes;134 Segovia;Group 1406 Other diseases of the male genital organs 601-608;Men;134 Segovia;Group 1406 Other diseases of the male genital organs 601-608;Women;.. Segovia;Group 1407 Disorders of breast 610-612;Both sexes;8 Segovia;Group 1407 Disorders of breast 610-612;Men;4 Segovia;Group 1407 Disorders of breast 610-612;Women;4 Segovia;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Both sexes;17 Segovia;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Men;.. Segovia;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Women;17 Segovia;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Both sexes;5 Segovia;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Men;.. Segovia;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Women;5 Segovia;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Both sexes;129 Segovia;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Men;2 Segovia;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Women;127 Segovia;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Both sexes;1,089 Segovia;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Men;.. Segovia;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Women;1,089 Segovia;Group 1501 Legally induced abortion 635;Both sexes;.. Segovia;Group 1501 Legally induced abortion 635;Men;.. Segovia;Group 1501 Legally induced abortion 635;Women;.. Segovia;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Both sexes;59 Segovia;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Men;.. Segovia;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Women;59 Segovia;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Both sexes;567 Segovia;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Men;.. Segovia;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Women;567 Segovia;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Both sexes;271 Segovia;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Men;.. Segovia;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Women;271 Segovia;Group 1505 Single spontaneous delivery 650;Both sexes;75 Segovia;Group 1505 Single spontaneous delivery 650;Men;.. Segovia;Group 1505 Single spontaneous delivery 650;Women;75 Segovia;Group 1506 Other deliveries 6695-6697;Both sexes;2 Segovia;Group 1506 Other deliveries 6695-6697;Men;.. Segovia;Group 1506 Other deliveries 6695-6697;Women;2 Segovia;Group 1507 Complications related to the puerperium 670-676;Both sexes;12 Segovia;Group 1507 Complications related to the puerperium 670-676;Men;.. Segovia;Group 1507 Complications related to the puerperium 670-676;Women;12 Segovia;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Both sexes;103 Segovia;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Men;.. Segovia;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Women;103 Segovia;Group 1600 Some disorders originating in the perinatal period 760-779;Both sexes;134 Segovia;Group 1600 Some disorders originating in the perinatal period 760-779;Men;70 Segovia;Group 1600 Some disorders originating in the perinatal period 760-779;Women;64 Segovia;Group 1601 Disorders related with premature delivery and a low birth weight 765;Both sexes;42 Segovia;Group 1601 Disorders related with premature delivery and a low birth weight 765;Men;20 Segovia;Group 1601 Disorders related with premature delivery and a low birth weight 765;Women;22 Segovia;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Both sexes;92 Segovia;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Men;50 Segovia;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Women;42 Segovia;Grupo 1700 Congenital abnormalities 740-759;Both sexes;51 Segovia;Grupo 1700 Congenital abnormalities 740-759;Men;35 Segovia;Grupo 1700 Congenital abnormalities 740-759;Women;16 Segovia;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Both sexes;516 Segovia;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Men;295 Segovia;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Women;221 Segovia;Group 1801 Pain in throat and chest 7841, 7865;Both sexes;53 Segovia;Group 1801 Pain in throat and chest 7841, 7865;Men;38 Segovia;Group 1801 Pain in throat and chest 7841, 7865;Women;15 Segovia;Group 1802 Abdominal pain 7890;Both sexes;101 Segovia;Group 1802 Abdominal pain 7890;Men;39 Segovia;Group 1802 Abdominal pain 7890;Women;62 Segovia;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Both sexes;.. Segovia;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Men;.. Segovia;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Women;.. Segovia;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Both sexes;362 Segovia;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Men;218 Segovia;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Women;144 Segovia;Group 1900 Injuries and poisoning 800-999;Both sexes;1,201 Segovia;Group 1900 Injuries and poisoning 800-999;Men;619 Segovia;Group 1900 Injuries and poisoning 800-999;Women;582 Segovia;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Both sexes;77 Segovia;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Men;47 Segovia;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Women;30 Segovia;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Both sexes;14 Segovia;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Men;11 Segovia;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Women;3 Segovia;Group 1903 Radius and ulna fracture 813;Both sexes;70 Segovia;Group 1903 Radius and ulna fracture 813;Men;31 Segovia;Group 1903 Radius and ulna fracture 813;Women;39 Segovia;Group 1904 Femur fracture 820-821;Both sexes;286 Segovia;Group 1904 Femur fracture 820-821;Men;84 Segovia;Group 1904 Femur fracture 820-821;Women;202 Segovia;Group 1905 Leg fracture, including the ankle 823-824;Both sexes;77 Segovia;Group 1905 Leg fracture, including the ankle 823-824;Men;37 Segovia;Group 1905 Leg fracture, including the ankle 823-824;Women;40 Segovia;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Both sexes;294 Segovia;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Men;190 Segovia;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Women;104 Segovia;Group 1907 Burns 940-949;Both sexes;1 Segovia;Group 1907 Burns 940-949;Men;.. Segovia;Group 1907 Burns 940-949;Women;1 Segovia;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Both sexes;23 Segovia;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Men;12 Segovia;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Women;11 Segovia;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Both sexes;300 Segovia;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Men;176 Segovia;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Women;124 Segovia;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Both sexes;1 Segovia;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Men;1 Segovia;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Women;.. Segovia;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Both sexes;58 Segovia;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Men;30 Segovia;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Women;28 Segovia;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Both sexes;257 Segovia;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Men;165 Segovia;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Women;92 Segovia;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Both sexes;11 Segovia;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Men;7 Segovia;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Women;4 Segovia;Group 2102 Contraceptive management V25;Both sexes;11 Segovia;Group 2102 Contraceptive management V25;Men;.. Segovia;Group 2102 Contraceptive management V25;Women;11 Segovia;Group 2103 Living newborns by type of delivery V30-V39;Both sexes;.. Segovia;Group 2103 Living newborns by type of delivery V30-V39;Men;.. Segovia;Group 2103 Living newborns by type of delivery V30-V39;Women;.. Segovia;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Both sexes;172 Segovia;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Men;121 Segovia;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Women;51 Segovia;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Both sexes;63 Segovia;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Men;37 Segovia;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Women;26 Soria;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Both sexes;8,606 Soria;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Men;4,435 Soria;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Women;4,171 Soria;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Both sexes;201 Soria;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Men;122 Soria;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Women;79 Soria;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Both sexes;37 Soria;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Men;19 Soria;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Women;18 Soria;Group 0102 Imprecise intestinal infections 009;Both sexes;6 Soria;Group 0102 Imprecise intestinal infections 009;Men;3 Soria;Group 0102 Imprecise intestinal infections 009;Women;3 Soria;Group 0103 Tuberculosis 010-018, 137;Both sexes;5 Soria;Group 0103 Tuberculosis 010-018, 137;Men;2 Soria;Group 0103 Tuberculosis 010-018, 137;Women;3 Soria;Group 0104 Septicaemia 038;Both sexes;117 Soria;Group 0104 Septicaemia 038;Men;72 Soria;Group 0104 Septicaemia 038;Women;45 Soria;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Both sexes;6 Soria;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Men;3 Soria;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Women;3 Soria;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Both sexes;30 Soria;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Men;23 Soria;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Women;7 Soria;Group 0200 Neoplasms 140-239;Both sexes;840 Soria;Group 0200 Neoplasms 140-239;Men;496 Soria;Group 0200 Neoplasms 140-239;Women;344 Soria;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Both sexes;110 Soria;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Men;77 Soria;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Women;33 Soria;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Both sexes;50 Soria;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Men;38 Soria;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Women;12 Soria;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Both sexes;2 Soria;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Men;2 Soria;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Women;.. Soria;Group 0204 Malignant neoplasm of breast 174-175;Both sexes;67 Soria;Group 0204 Malignant neoplasm of breast 174-175;Men;.. Soria;Group 0204 Malignant neoplasm of breast 174-175;Women;67 Soria;Group 0205 Malignant neoplasm of uterus 179-180, 182;Both sexes;15 Soria;Group 0205 Malignant neoplasm of uterus 179-180, 182;Men;.. Soria;Group 0205 Malignant neoplasm of uterus 179-180, 182;Women;15 Soria;Group 0206 Malignant neoplasm of ovary 1830;Both sexes;17 Soria;Group 0206 Malignant neoplasm of ovary 1830;Men;.. Soria;Group 0206 Malignant neoplasm of ovary 1830;Women;17 Soria;Group 0207 Malignant neoplasm of prostate 185;Both sexes;80 Soria;Group 0207 Malignant neoplasm of prostate 185;Men;80 Soria;Group 0207 Malignant neoplasm of prostate 185;Women;.. Soria;Group 0208 Malignant neoplasm of bladder 188;Both sexes;83 Soria;Group 0208 Malignant neoplasm of bladder 188;Men;74 Soria;Group 0208 Malignant neoplasm of bladder 188;Women;9 Soria;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Both sexes;261 Soria;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Men;167 Soria;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Women;94 Soria;Group 0210 Carcinoma in situ 230-234;Both sexes;15 Soria;Group 0210 Carcinoma in situ 230-234;Men;8 Soria;Group 0210 Carcinoma in situ 230-234;Women;7 Soria;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Both sexes;6 Soria;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Men;4 Soria;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Women;2 Soria;Grupo 0212 Leiomyoma of uterus 218;Both sexes;43 Soria;Grupo 0212 Leiomyoma of uterus 218;Men;.. Soria;Grupo 0212 Leiomyoma of uterus 218;Women;43 Soria;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Both sexes;91 Soria;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Men;46 Soria;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Women;45 Soria;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Both sexes;95 Soria;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Men;39 Soria;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Women;56 Soria;Group 0301 Anaemias 280-285;Both sexes;60 Soria;Group 0301 Anaemias 280-285;Men;27 Soria;Group 0301 Anaemias 280-285;Women;33 Soria;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Both sexes;35 Soria;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Men;12 Soria;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Women;23 Soria;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Both sexes;153 Soria;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Men;81 Soria;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Women;72 Soria;Group 0401 Diabetes mellitus 249-250;Both sexes;79 Soria;Group 0401 Diabetes mellitus 249-250;Men;47 Soria;Group 0401 Diabetes mellitus 249-250;Women;32 Soria;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Both sexes;74 Soria;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Men;34 Soria;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Women;40 Soria;Group 0500 Mental disorders 290-319;Both sexes;303 Soria;Group 0500 Mental disorders 290-319;Men;152 Soria;Group 0500 Mental disorders 290-319;Women;151 Soria;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Both sexes;4 Soria;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Men;2 Soria;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Women;2 Soria;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Both sexes;20 Soria;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Men;18 Soria;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Women;2 Soria;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Both sexes;8 Soria;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Men;8 Soria;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Women;.. Soria;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Both sexes;112 Soria;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Men;67 Soria;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Women;45 Soria;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Both sexes;57 Soria;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Men;23 Soria;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Women;34 Soria;Group 0506 Other mental and behavioural disorders Rest of (290-319);Both sexes;102 Soria;Group 0506 Other mental and behavioural disorders Rest of (290-319);Men;34 Soria;Group 0506 Other mental and behavioural disorders Rest of (290-319);Women;68 Soria;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Both sexes;187 Soria;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Men;93 Soria;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Women;94 Soria;Group 0601 Alzheimer's disease 3310;Both sexes;8 Soria;Group 0601 Alzheimer's disease 3310;Men;2 Soria;Group 0601 Alzheimer's disease 3310;Women;6 Soria;Group 0602 Multiple sclerosis 340;Both sexes;2 Soria;Group 0602 Multiple sclerosis 340;Men;1 Soria;Group 0602 Multiple sclerosis 340;Women;1 Soria;Group 0603 Epilepsy 345;Both sexes;26 Soria;Group 0603 Epilepsy 345;Men;15 Soria;Group 0603 Epilepsy 345;Women;11 Soria;Group 0604 Transient cerebral ischemia 435;Both sexes;58 Soria;Group 0604 Transient cerebral ischemia 435;Men;37 Soria;Group 0604 Transient cerebral ischemia 435;Women;21 Soria;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Both sexes;93 Soria;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Men;38 Soria;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Women;55 Soria;Grupo 0700 Diseases of the eye and adnexa 360-379;Both sexes;21 Soria;Grupo 0700 Diseases of the eye and adnexa 360-379;Men;15 Soria;Grupo 0700 Diseases of the eye and adnexa 360-379;Women;6 Soria;Grupo 0701 Cataract 366;Both sexes;1 Soria;Grupo 0701 Cataract 366;Men;1 Soria;Grupo 0701 Cataract 366;Women;.. Soria;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Both sexes;20 Soria;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Men;14 Soria;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Women;6 Soria;Group 0800 Diseases of the ear and the mastoid 380-389;Both sexes;36 Soria;Group 0800 Diseases of the ear and the mastoid 380-389;Men;23 Soria;Group 0800 Diseases of the ear and the mastoid 380-389;Women;13 Soria;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Both sexes;1,470 Soria;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Men;829 Soria;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Women;641 Soria;Group 0901 Hypertensive disease 401-405;Both sexes;66 Soria;Group 0901 Hypertensive disease 401-405;Men;35 Soria;Group 0901 Hypertensive disease 401-405;Women;31 Soria;Group 0902 Angina pectoris 4111, 413;Both sexes;69 Soria;Group 0902 Angina pectoris 4111, 413;Men;43 Soria;Group 0902 Angina pectoris 4111, 413;Women;26 Soria;Group 0903 Acute myocardial infarction 410;Both sexes;133 Soria;Group 0903 Acute myocardial infarction 410;Men;91 Soria;Group 0903 Acute myocardial infarction 410;Women;42 Soria;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Both sexes;40 Soria;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Men;26 Soria;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Women;14 Soria;Group 0905 Diseases of the lungs circulation 415-417;Both sexes;76 Soria;Group 0905 Diseases of the lungs circulation 415-417;Men;34 Soria;Group 0905 Diseases of the lungs circulation 415-417;Women;42 Soria;Group 0906 Heart conduction disorders and arrhytmias 426-427;Both sexes;242 Soria;Group 0906 Heart conduction disorders and arrhytmias 426-427;Men;141 Soria;Group 0906 Heart conduction disorders and arrhytmias 426-427;Women;101 Soria;Grupo 0907 Heart failure 428;Both sexes;363 Soria;Grupo 0907 Heart failure 428;Men;213 Soria;Grupo 0907 Heart failure 428;Women;150 Soria;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Both sexes;238 Soria;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Men;125 Soria;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Women;113 Soria;Grupo 0909 Atherosclerosis 440;Both sexes;17 Soria;Grupo 0909 Atherosclerosis 440;Men;8 Soria;Grupo 0909 Atherosclerosis 440;Women;9 Soria;Group 0910 Varicose veins of lower extremities 454;Both sexes;97 Soria;Group 0910 Varicose veins of lower extremities 454;Men;41 Soria;Group 0910 Varicose veins of lower extremities 454;Women;56 Soria;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Both sexes;129 Soria;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Men;72 Soria;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Women;57 Soria;Group 1000 Diseases of the respiratory system 0340, 460-519;Both sexes;1,122 Soria;Group 1000 Diseases of the respiratory system 0340, 460-519;Men;669 Soria;Group 1000 Diseases of the respiratory system 0340, 460-519;Women;453 Soria;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Both sexes;18 Soria;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Men;12 Soria;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Women;6 Soria;Group 1002 Pneumonia 480-486;Both sexes;269 Soria;Group 1002 Pneumonia 480-486;Men;160 Soria;Group 1002 Pneumonia 480-486;Women;109 Soria;Group 1003 Acute bronchitis and bronchiolitis 466;Both sexes;22 Soria;Group 1003 Acute bronchitis and bronchiolitis 466;Men;11 Soria;Group 1003 Acute bronchitis and bronchiolitis 466;Women;11 Soria;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Both sexes;81 Soria;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Men;42 Soria;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Women;39 Soria;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Both sexes;110 Soria;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Men;75 Soria;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Women;35 Soria;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Both sexes;122 Soria;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Men;104 Soria;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Women;18 Soria;Group 1007 Asthma 4930-4931,4938-4939;Both sexes;25 Soria;Group 1007 Asthma 4930-4931,4938-4939;Men;4 Soria;Group 1007 Asthma 4930-4931,4938-4939;Women;21 Soria;Group 1008 Other diseases of the respiratory system Resto of (460-519);Both sexes;475 Soria;Group 1008 Other diseases of the respiratory system Resto of (460-519);Men;261 Soria;Group 1008 Other diseases of the respiratory system Resto of (460-519);Women;214 Soria;Group 1100 Diseases of the digestive system 520-579;Both sexes;1,195 Soria;Group 1100 Diseases of the digestive system 520-579;Men;688 Soria;Group 1100 Diseases of the digestive system 520-579;Women;507 Soria;Group 1101 Disorders of the teeth and supporting structures 520-525;Both sexes;2 Soria;Group 1101 Disorders of the teeth and supporting structures 520-525;Men;.. Soria;Group 1101 Disorders of the teeth and supporting structures 520-525;Women;2 Soria;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Both sexes;17 Soria;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Men;10 Soria;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Women;7 Soria;Group 1103 Diseases of the esophagus 530;Both sexes;29 Soria;Group 1103 Diseases of the esophagus 530;Men;20 Soria;Group 1103 Diseases of the esophagus 530;Women;9 Soria;Group 1104 Peptic ulcer 531-534;Both sexes;31 Soria;Group 1104 Peptic ulcer 531-534;Men;19 Soria;Group 1104 Peptic ulcer 531-534;Women;12 Soria;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Both sexes;21 Soria;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Men;12 Soria;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Women;9 Soria;Group 1106 Appendicitis 540-543;Both sexes;83 Soria;Group 1106 Appendicitis 540-543;Men;46 Soria;Group 1106 Appendicitis 540-543;Women;37 Soria;Group 1107 Inguinal hernia 550;Both sexes;145 Soria;Group 1107 Inguinal hernia 550;Men;134 Soria;Group 1107 Inguinal hernia 550;Women;11 Soria;Group 1108 Other abdominal hernia 551-553;Both sexes;85 Soria;Group 1108 Other abdominal hernia 551-553;Men;33 Soria;Group 1108 Other abdominal hernia 551-553;Women;52 Soria;Group 1109 Crohn's disease and ulcerative colitis 555-556;Both sexes;13 Soria;Group 1109 Crohn's disease and ulcerative colitis 555-556;Men;5 Soria;Group 1109 Crohn's disease and ulcerative colitis 555-556;Women;8 Soria;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Both sexes;53 Soria;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Men;21 Soria;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Women;32 Soria;Group 1111 Intestinal obstruction without hernia 560;Both sexes;87 Soria;Group 1111 Intestinal obstruction without hernia 560;Men;39 Soria;Group 1111 Intestinal obstruction without hernia 560;Women;48 Soria;Group 1112 Intestinal diverticulosis 562;Both sexes;41 Soria;Group 1112 Intestinal diverticulosis 562;Men;22 Soria;Group 1112 Intestinal diverticulosis 562;Women;19 Soria;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Both sexes;62 Soria;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Men;45 Soria;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Women;17 Soria;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Both sexes;48 Soria;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Men;26 Soria;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Women;22 Soria;Group 1115 Alcoholic hepatitis 5710-5713;Both sexes;14 Soria;Group 1115 Alcoholic hepatitis 5710-5713;Men;12 Soria;Group 1115 Alcoholic hepatitis 5710-5713;Women;2 Soria;Group 1116 Other diseases of the liver 570,5714-573;Both sexes;43 Soria;Group 1116 Other diseases of the liver 570,5714-573;Men;30 Soria;Group 1116 Other diseases of the liver 570,5714-573;Women;13 Soria;Group 1117 Cholelithiasis 574;Both sexes;197 Soria;Group 1117 Cholelithiasis 574;Men;96 Soria;Group 1117 Cholelithiasis 574;Women;101 Soria;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Both sexes;65 Soria;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Men;35 Soria;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Women;30 Soria;Group 1119 Pancreatic diseases 577;Both sexes;63 Soria;Group 1119 Pancreatic diseases 577;Men;39 Soria;Group 1119 Pancreatic diseases 577;Women;24 Soria;Group 1120 Other diseases of the digestive system Rest of (520-579);Both sexes;96 Soria;Group 1120 Other diseases of the digestive system Rest of (520-579);Men;44 Soria;Group 1120 Other diseases of the digestive system Rest of (520-579);Women;52 Soria;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Both sexes;65 Soria;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Men;42 Soria;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Women;23 Soria;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Both sexes;43 Soria;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Men;29 Soria;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Women;14 Soria;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Both sexes;3 Soria;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Men;3 Soria;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Women;.. Soria;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Both sexes;19 Soria;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Men;10 Soria;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Women;9 Soria;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Both sexes;525 Soria;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Men;267 Soria;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Women;258 Soria;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Both sexes;.. Soria;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Men;.. Soria;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Women;.. Soria;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Both sexes;.. Soria;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Men;.. Soria;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Women;.. Soria;Group 1303 Internal derangement of knee 717;Both sexes;115 Soria;Group 1303 Internal derangement of knee 717;Men;79 Soria;Group 1303 Internal derangement of knee 717;Women;36 Soria;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Both sexes;209 Soria;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Men;100 Soria;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Women;109 Soria;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Both sexes;10 Soria;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Men;3 Soria;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Women;7 Soria;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Both sexes;8 Soria;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Men;5 Soria;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Women;3 Soria;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Both sexes;12 Soria;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Men;6 Soria;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Women;6 Soria;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Both sexes;12 Soria;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Men;5 Soria;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Women;7 Soria;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Both sexes;74 Soria;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Men;45 Soria;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Women;29 Soria;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Both sexes;85 Soria;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Men;24 Soria;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Women;61 Soria;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Both sexes;459 Soria;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Men;260 Soria;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Women;199 Soria;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Both sexes;36 Soria;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Men;14 Soria;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Women;22 Soria;Group 1402 Renal failure 5836-5837, 584-586;Both sexes;51 Soria;Group 1402 Renal failure 5836-5837, 584-586;Men;33 Soria;Group 1402 Renal failure 5836-5837, 584-586;Women;18 Soria;Group 1403 Urolithiasis 592, 594, 7880;Both sexes;36 Soria;Group 1403 Urolithiasis 592, 594, 7880;Men;25 Soria;Group 1403 Urolithiasis 592, 594, 7880;Women;11 Soria;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Both sexes;160 Soria;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Men;71 Soria;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Women;89 Soria;Group 1405 Prostatic hyperplasia 600;Both sexes;58 Soria;Group 1405 Prostatic hyperplasia 600;Men;58 Soria;Group 1405 Prostatic hyperplasia 600;Women;.. Soria;Group 1406 Other diseases of the male genital organs 601-608;Both sexes;59 Soria;Group 1406 Other diseases of the male genital organs 601-608;Men;59 Soria;Group 1406 Other diseases of the male genital organs 601-608;Women;.. Soria;Group 1407 Disorders of breast 610-612;Both sexes;11 Soria;Group 1407 Disorders of breast 610-612;Men;.. Soria;Group 1407 Disorders of breast 610-612;Women;11 Soria;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Both sexes;10 Soria;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Men;.. Soria;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Women;10 Soria;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Both sexes;5 Soria;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Men;.. Soria;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Women;5 Soria;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Both sexes;33 Soria;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Men;.. Soria;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Women;33 Soria;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Both sexes;703 Soria;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Men;.. Soria;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Women;703 Soria;Group 1501 Legally induced abortion 635;Both sexes;1 Soria;Group 1501 Legally induced abortion 635;Men;.. Soria;Group 1501 Legally induced abortion 635;Women;1 Soria;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Both sexes;39 Soria;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Men;.. Soria;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Women;39 Soria;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Both sexes;479 Soria;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Men;.. Soria;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Women;479 Soria;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Both sexes;137 Soria;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Men;.. Soria;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Women;137 Soria;Group 1505 Single spontaneous delivery 650;Both sexes;9 Soria;Group 1505 Single spontaneous delivery 650;Men;.. Soria;Group 1505 Single spontaneous delivery 650;Women;9 Soria;Group 1506 Other deliveries 6695-6697;Both sexes;16 Soria;Group 1506 Other deliveries 6695-6697;Men;.. Soria;Group 1506 Other deliveries 6695-6697;Women;16 Soria;Group 1507 Complications related to the puerperium 670-676;Both sexes;7 Soria;Group 1507 Complications related to the puerperium 670-676;Men;.. Soria;Group 1507 Complications related to the puerperium 670-676;Women;7 Soria;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Both sexes;15 Soria;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Men;.. Soria;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Women;15 Soria;Group 1600 Some disorders originating in the perinatal period 760-779;Both sexes;87 Soria;Group 1600 Some disorders originating in the perinatal period 760-779;Men;41 Soria;Group 1600 Some disorders originating in the perinatal period 760-779;Women;46 Soria;Group 1601 Disorders related with premature delivery and a low birth weight 765;Both sexes;18 Soria;Group 1601 Disorders related with premature delivery and a low birth weight 765;Men;7 Soria;Group 1601 Disorders related with premature delivery and a low birth weight 765;Women;11 Soria;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Both sexes;69 Soria;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Men;34 Soria;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Women;35 Soria;Grupo 1700 Congenital abnormalities 740-759;Both sexes;33 Soria;Grupo 1700 Congenital abnormalities 740-759;Men;22 Soria;Grupo 1700 Congenital abnormalities 740-759;Women;11 Soria;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Both sexes;308 Soria;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Men;182 Soria;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Women;126 Soria;Group 1801 Pain in throat and chest 7841, 7865;Both sexes;51 Soria;Group 1801 Pain in throat and chest 7841, 7865;Men;32 Soria;Group 1801 Pain in throat and chest 7841, 7865;Women;19 Soria;Group 1802 Abdominal pain 7890;Both sexes;51 Soria;Group 1802 Abdominal pain 7890;Men;17 Soria;Group 1802 Abdominal pain 7890;Women;34 Soria;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Both sexes;7 Soria;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Men;5 Soria;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Women;2 Soria;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Both sexes;199 Soria;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Men;128 Soria;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Women;71 Soria;Group 1900 Injuries and poisoning 800-999;Both sexes;687 Soria;Group 1900 Injuries and poisoning 800-999;Men;339 Soria;Group 1900 Injuries and poisoning 800-999;Women;348 Soria;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Both sexes;38 Soria;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Men;22 Soria;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Women;16 Soria;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Both sexes;10 Soria;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Men;9 Soria;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Women;1 Soria;Group 1903 Radius and ulna fracture 813;Both sexes;33 Soria;Group 1903 Radius and ulna fracture 813;Men;16 Soria;Group 1903 Radius and ulna fracture 813;Women;17 Soria;Group 1904 Femur fracture 820-821;Both sexes;205 Soria;Group 1904 Femur fracture 820-821;Men;59 Soria;Group 1904 Femur fracture 820-821;Women;146 Soria;Group 1905 Leg fracture, including the ankle 823-824;Both sexes;46 Soria;Group 1905 Leg fracture, including the ankle 823-824;Men;23 Soria;Group 1905 Leg fracture, including the ankle 823-824;Women;23 Soria;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Both sexes;153 Soria;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Men;87 Soria;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Women;66 Soria;Group 1907 Burns 940-949;Both sexes;3 Soria;Group 1907 Burns 940-949;Men;2 Soria;Group 1907 Burns 940-949;Women;1 Soria;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Both sexes;18 Soria;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Men;6 Soria;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Women;12 Soria;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Both sexes;162 Soria;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Men;104 Soria;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Women;58 Soria;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Both sexes;2 Soria;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Men;2 Soria;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Women;.. Soria;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Both sexes;17 Soria;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Men;9 Soria;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Women;8 Soria;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Both sexes;116 Soria;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Men;75 Soria;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Women;41 Soria;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Both sexes;5 Soria;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Men;3 Soria;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Women;2 Soria;Group 2102 Contraceptive management V25;Both sexes;9 Soria;Group 2102 Contraceptive management V25;Men;8 Soria;Group 2102 Contraceptive management V25;Women;1 Soria;Group 2103 Living newborns by type of delivery V30-V39;Both sexes;.. Soria;Group 2103 Living newborns by type of delivery V30-V39;Men;.. Soria;Group 2103 Living newborns by type of delivery V30-V39;Women;.. Soria;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Both sexes;54 Soria;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Men;31 Soria;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Women;23 Soria;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Both sexes;48 Soria;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Men;33 Soria;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Women;15 Valladolid;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Both sexes;59,242 Valladolid;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Men;29,267 Valladolid;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Women;29,975 Valladolid;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Both sexes;992 Valladolid;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Men;530 Valladolid;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Women;462 Valladolid;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Both sexes;207 Valladolid;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Men;112 Valladolid;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Women;95 Valladolid;Group 0102 Imprecise intestinal infections 009;Both sexes;32 Valladolid;Group 0102 Imprecise intestinal infections 009;Men;16 Valladolid;Group 0102 Imprecise intestinal infections 009;Women;16 Valladolid;Group 0103 Tuberculosis 010-018, 137;Both sexes;38 Valladolid;Group 0103 Tuberculosis 010-018, 137;Men;26 Valladolid;Group 0103 Tuberculosis 010-018, 137;Women;12 Valladolid;Group 0104 Septicaemia 038;Both sexes;405 Valladolid;Group 0104 Septicaemia 038;Men;195 Valladolid;Group 0104 Septicaemia 038;Women;210 Valladolid;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Both sexes;14 Valladolid;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Men;9 Valladolid;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Women;5 Valladolid;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Both sexes;296 Valladolid;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Men;172 Valladolid;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Women;124 Valladolid;Group 0200 Neoplasms 140-239;Both sexes;6,788 Valladolid;Group 0200 Neoplasms 140-239;Men;3,567 Valladolid;Group 0200 Neoplasms 140-239;Women;3,221 Valladolid;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Both sexes;725 Valladolid;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Men;484 Valladolid;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Women;241 Valladolid;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Both sexes;590 Valladolid;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Men;466 Valladolid;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Women;124 Valladolid;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Both sexes;73 Valladolid;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Men;32 Valladolid;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Women;41 Valladolid;Group 0204 Malignant neoplasm of breast 174-175;Both sexes;440 Valladolid;Group 0204 Malignant neoplasm of breast 174-175;Men;1 Valladolid;Group 0204 Malignant neoplasm of breast 174-175;Women;439 Valladolid;Group 0205 Malignant neoplasm of uterus 179-180, 182;Both sexes;130 Valladolid;Group 0205 Malignant neoplasm of uterus 179-180, 182;Men;.. Valladolid;Group 0205 Malignant neoplasm of uterus 179-180, 182;Women;130 Valladolid;Group 0206 Malignant neoplasm of ovary 1830;Both sexes;77 Valladolid;Group 0206 Malignant neoplasm of ovary 1830;Men;.. Valladolid;Group 0206 Malignant neoplasm of ovary 1830;Women;77 Valladolid;Group 0207 Malignant neoplasm of prostate 185;Both sexes;289 Valladolid;Group 0207 Malignant neoplasm of prostate 185;Men;289 Valladolid;Group 0207 Malignant neoplasm of prostate 185;Women;.. Valladolid;Group 0208 Malignant neoplasm of bladder 188;Both sexes;498 Valladolid;Group 0208 Malignant neoplasm of bladder 188;Men;424 Valladolid;Group 0208 Malignant neoplasm of bladder 188;Women;74 Valladolid;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Both sexes;2,345 Valladolid;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Men;1,328 Valladolid;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Women;1,017 Valladolid;Group 0210 Carcinoma in situ 230-234;Both sexes;116 Valladolid;Group 0210 Carcinoma in situ 230-234;Men;47 Valladolid;Group 0210 Carcinoma in situ 230-234;Women;69 Valladolid;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Both sexes;38 Valladolid;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Men;21 Valladolid;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Women;17 Valladolid;Grupo 0212 Leiomyoma of uterus 218;Both sexes;379 Valladolid;Grupo 0212 Leiomyoma of uterus 218;Men;.. Valladolid;Grupo 0212 Leiomyoma of uterus 218;Women;379 Valladolid;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Both sexes;1,088 Valladolid;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Men;475 Valladolid;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Women;613 Valladolid;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Both sexes;632 Valladolid;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Men;287 Valladolid;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Women;345 Valladolid;Group 0301 Anaemias 280-285;Both sexes;400 Valladolid;Group 0301 Anaemias 280-285;Men;171 Valladolid;Group 0301 Anaemias 280-285;Women;229 Valladolid;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Both sexes;232 Valladolid;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Men;116 Valladolid;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Women;116 Valladolid;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Both sexes;1,238 Valladolid;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Men;493 Valladolid;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Women;745 Valladolid;Group 0401 Diabetes mellitus 249-250;Both sexes;421 Valladolid;Group 0401 Diabetes mellitus 249-250;Men;239 Valladolid;Group 0401 Diabetes mellitus 249-250;Women;182 Valladolid;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Both sexes;817 Valladolid;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Men;254 Valladolid;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Women;563 Valladolid;Group 0500 Mental disorders 290-319;Both sexes;1,183 Valladolid;Group 0500 Mental disorders 290-319;Men;552 Valladolid;Group 0500 Mental disorders 290-319;Women;631 Valladolid;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Both sexes;23 Valladolid;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Men;11 Valladolid;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Women;12 Valladolid;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Both sexes;88 Valladolid;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Men;69 Valladolid;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Women;19 Valladolid;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Both sexes;50 Valladolid;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Men;36 Valladolid;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Women;14 Valladolid;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Both sexes;300 Valladolid;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Men;162 Valladolid;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Women;138 Valladolid;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Both sexes;275 Valladolid;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Men;89 Valladolid;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Women;186 Valladolid;Group 0506 Other mental and behavioural disorders Rest of (290-319);Both sexes;447 Valladolid;Group 0506 Other mental and behavioural disorders Rest of (290-319);Men;185 Valladolid;Group 0506 Other mental and behavioural disorders Rest of (290-319);Women;262 Valladolid;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Both sexes;1,169 Valladolid;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Men;557 Valladolid;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Women;612 Valladolid;Group 0601 Alzheimer's disease 3310;Both sexes;73 Valladolid;Group 0601 Alzheimer's disease 3310;Men;20 Valladolid;Group 0601 Alzheimer's disease 3310;Women;53 Valladolid;Group 0602 Multiple sclerosis 340;Both sexes;53 Valladolid;Group 0602 Multiple sclerosis 340;Men;16 Valladolid;Group 0602 Multiple sclerosis 340;Women;37 Valladolid;Group 0603 Epilepsy 345;Both sexes;202 Valladolid;Group 0603 Epilepsy 345;Men;114 Valladolid;Group 0603 Epilepsy 345;Women;88 Valladolid;Group 0604 Transient cerebral ischemia 435;Both sexes;155 Valladolid;Group 0604 Transient cerebral ischemia 435;Men;84 Valladolid;Group 0604 Transient cerebral ischemia 435;Women;71 Valladolid;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Both sexes;686 Valladolid;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Men;323 Valladolid;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Women;363 Valladolid;Grupo 0700 Diseases of the eye and adnexa 360-379;Both sexes;339 Valladolid;Grupo 0700 Diseases of the eye and adnexa 360-379;Men;178 Valladolid;Grupo 0700 Diseases of the eye and adnexa 360-379;Women;161 Valladolid;Grupo 0701 Cataract 366;Both sexes;36 Valladolid;Grupo 0701 Cataract 366;Men;16 Valladolid;Grupo 0701 Cataract 366;Women;20 Valladolid;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Both sexes;303 Valladolid;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Men;162 Valladolid;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Women;141 Valladolid;Group 0800 Diseases of the ear and the mastoid 380-389;Both sexes;519 Valladolid;Group 0800 Diseases of the ear and the mastoid 380-389;Men;253 Valladolid;Group 0800 Diseases of the ear and the mastoid 380-389;Women;266 Valladolid;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Both sexes;8,639 Valladolid;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Men;5,140 Valladolid;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Women;3,499 Valladolid;Group 0901 Hypertensive disease 401-405;Both sexes;500 Valladolid;Group 0901 Hypertensive disease 401-405;Men;213 Valladolid;Group 0901 Hypertensive disease 401-405;Women;287 Valladolid;Group 0902 Angina pectoris 4111, 413;Both sexes;447 Valladolid;Group 0902 Angina pectoris 4111, 413;Men;263 Valladolid;Group 0902 Angina pectoris 4111, 413;Women;184 Valladolid;Group 0903 Acute myocardial infarction 410;Both sexes;789 Valladolid;Group 0903 Acute myocardial infarction 410;Men;584 Valladolid;Group 0903 Acute myocardial infarction 410;Women;205 Valladolid;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Both sexes;679 Valladolid;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Men;544 Valladolid;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Women;135 Valladolid;Group 0905 Diseases of the lungs circulation 415-417;Both sexes;344 Valladolid;Group 0905 Diseases of the lungs circulation 415-417;Men;157 Valladolid;Group 0905 Diseases of the lungs circulation 415-417;Women;187 Valladolid;Group 0906 Heart conduction disorders and arrhytmias 426-427;Both sexes;1,011 Valladolid;Group 0906 Heart conduction disorders and arrhytmias 426-427;Men;604 Valladolid;Group 0906 Heart conduction disorders and arrhytmias 426-427;Women;407 Valladolid;Grupo 0907 Heart failure 428;Both sexes;1,278 Valladolid;Grupo 0907 Heart failure 428;Men;634 Valladolid;Grupo 0907 Heart failure 428;Women;644 Valladolid;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Both sexes;1,330 Valladolid;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Men;745 Valladolid;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Women;585 Valladolid;Grupo 0909 Atherosclerosis 440;Both sexes;424 Valladolid;Grupo 0909 Atherosclerosis 440;Men;346 Valladolid;Grupo 0909 Atherosclerosis 440;Women;78 Valladolid;Group 0910 Varicose veins of lower extremities 454;Both sexes;225 Valladolid;Group 0910 Varicose veins of lower extremities 454;Men;94 Valladolid;Group 0910 Varicose veins of lower extremities 454;Women;131 Valladolid;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Both sexes;1,612 Valladolid;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Men;956 Valladolid;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Women;656 Valladolid;Group 1000 Diseases of the respiratory system 0340, 460-519;Both sexes;6,561 Valladolid;Group 1000 Diseases of the respiratory system 0340, 460-519;Men;3,753 Valladolid;Group 1000 Diseases of the respiratory system 0340, 460-519;Women;2,808 Valladolid;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Both sexes;245 Valladolid;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Men;138 Valladolid;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Women;107 Valladolid;Group 1002 Pneumonia 480-486;Both sexes;1,329 Valladolid;Group 1002 Pneumonia 480-486;Men;765 Valladolid;Group 1002 Pneumonia 480-486;Women;564 Valladolid;Group 1003 Acute bronchitis and bronchiolitis 466;Both sexes;595 Valladolid;Group 1003 Acute bronchitis and bronchiolitis 466;Men;277 Valladolid;Group 1003 Acute bronchitis and bronchiolitis 466;Women;318 Valladolid;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Both sexes;608 Valladolid;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Men;331 Valladolid;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Women;277 Valladolid;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Both sexes;863 Valladolid;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Men;516 Valladolid;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Women;347 Valladolid;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Both sexes;897 Valladolid;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Men;692 Valladolid;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Women;205 Valladolid;Group 1007 Asthma 4930-4931,4938-4939;Both sexes;236 Valladolid;Group 1007 Asthma 4930-4931,4938-4939;Men;69 Valladolid;Group 1007 Asthma 4930-4931,4938-4939;Women;167 Valladolid;Group 1008 Other diseases of the respiratory system Resto of (460-519);Both sexes;1,788 Valladolid;Group 1008 Other diseases of the respiratory system Resto of (460-519);Men;965 Valladolid;Group 1008 Other diseases of the respiratory system Resto of (460-519);Women;823 Valladolid;Group 1100 Diseases of the digestive system 520-579;Both sexes;8,287 Valladolid;Group 1100 Diseases of the digestive system 520-579;Men;4,866 Valladolid;Group 1100 Diseases of the digestive system 520-579;Women;3,421 Valladolid;Group 1101 Disorders of the teeth and supporting structures 520-525;Both sexes;143 Valladolid;Group 1101 Disorders of the teeth and supporting structures 520-525;Men;69 Valladolid;Group 1101 Disorders of the teeth and supporting structures 520-525;Women;74 Valladolid;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Both sexes;101 Valladolid;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Men;50 Valladolid;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Women;51 Valladolid;Group 1103 Diseases of the esophagus 530;Both sexes;125 Valladolid;Group 1103 Diseases of the esophagus 530;Men;69 Valladolid;Group 1103 Diseases of the esophagus 530;Women;56 Valladolid;Group 1104 Peptic ulcer 531-534;Both sexes;165 Valladolid;Group 1104 Peptic ulcer 531-534;Men;109 Valladolid;Group 1104 Peptic ulcer 531-534;Women;56 Valladolid;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Both sexes;216 Valladolid;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Men;100 Valladolid;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Women;116 Valladolid;Group 1106 Appendicitis 540-543;Both sexes;611 Valladolid;Group 1106 Appendicitis 540-543;Men;351 Valladolid;Group 1106 Appendicitis 540-543;Women;260 Valladolid;Group 1107 Inguinal hernia 550;Both sexes;1,374 Valladolid;Group 1107 Inguinal hernia 550;Men;1,251 Valladolid;Group 1107 Inguinal hernia 550;Women;123 Valladolid;Group 1108 Other abdominal hernia 551-553;Both sexes;670 Valladolid;Group 1108 Other abdominal hernia 551-553;Men;373 Valladolid;Group 1108 Other abdominal hernia 551-553;Women;297 Valladolid;Group 1109 Crohn's disease and ulcerative colitis 555-556;Both sexes;163 Valladolid;Group 1109 Crohn's disease and ulcerative colitis 555-556;Men;83 Valladolid;Group 1109 Crohn's disease and ulcerative colitis 555-556;Women;80 Valladolid;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Both sexes;408 Valladolid;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Men;179 Valladolid;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Women;229 Valladolid;Group 1111 Intestinal obstruction without hernia 560;Both sexes;422 Valladolid;Group 1111 Intestinal obstruction without hernia 560;Men;210 Valladolid;Group 1111 Intestinal obstruction without hernia 560;Women;212 Valladolid;Group 1112 Intestinal diverticulosis 562;Both sexes;327 Valladolid;Group 1112 Intestinal diverticulosis 562;Men;145 Valladolid;Group 1112 Intestinal diverticulosis 562;Women;182 Valladolid;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Both sexes;457 Valladolid;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Men;290 Valladolid;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Women;167 Valladolid;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Both sexes;297 Valladolid;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Men;123 Valladolid;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Women;174 Valladolid;Group 1115 Alcoholic hepatitis 5710-5713;Both sexes;152 Valladolid;Group 1115 Alcoholic hepatitis 5710-5713;Men;129 Valladolid;Group 1115 Alcoholic hepatitis 5710-5713;Women;23 Valladolid;Group 1116 Other diseases of the liver 570,5714-573;Both sexes;260 Valladolid;Group 1116 Other diseases of the liver 570,5714-573;Men;155 Valladolid;Group 1116 Other diseases of the liver 570,5714-573;Women;105 Valladolid;Group 1117 Cholelithiasis 574;Both sexes;1,466 Valladolid;Group 1117 Cholelithiasis 574;Men;697 Valladolid;Group 1117 Cholelithiasis 574;Women;769 Valladolid;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Both sexes;311 Valladolid;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Men;169 Valladolid;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Women;142 Valladolid;Group 1119 Pancreatic diseases 577;Both sexes;295 Valladolid;Group 1119 Pancreatic diseases 577;Men;146 Valladolid;Group 1119 Pancreatic diseases 577;Women;149 Valladolid;Group 1120 Other diseases of the digestive system Rest of (520-579);Both sexes;324 Valladolid;Group 1120 Other diseases of the digestive system Rest of (520-579);Men;168 Valladolid;Group 1120 Other diseases of the digestive system Rest of (520-579);Women;156 Valladolid;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Both sexes;503 Valladolid;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Men;276 Valladolid;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Women;227 Valladolid;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Both sexes;295 Valladolid;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Men;176 Valladolid;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Women;119 Valladolid;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Both sexes;35 Valladolid;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Men;16 Valladolid;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Women;19 Valladolid;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Both sexes;173 Valladolid;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Men;84 Valladolid;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Women;89 Valladolid;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Both sexes;3,877 Valladolid;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Men;1,817 Valladolid;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Women;2,060 Valladolid;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Both sexes;.. Valladolid;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Men;.. Valladolid;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Women;.. Valladolid;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Both sexes;.. Valladolid;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Men;.. Valladolid;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Women;.. Valladolid;Group 1303 Internal derangement of knee 717;Both sexes;399 Valladolid;Group 1303 Internal derangement of knee 717;Men;300 Valladolid;Group 1303 Internal derangement of knee 717;Women;99 Valladolid;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Both sexes;1,330 Valladolid;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Men;606 Valladolid;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Women;724 Valladolid;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Both sexes;174 Valladolid;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Men;34 Valladolid;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Women;140 Valladolid;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Both sexes;249 Valladolid;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Men;117 Valladolid;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Women;132 Valladolid;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Both sexes;449 Valladolid;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Men;237 Valladolid;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Women;212 Valladolid;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Both sexes;87 Valladolid;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Men;44 Valladolid;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Women;43 Valladolid;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Both sexes;491 Valladolid;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Men;259 Valladolid;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Women;232 Valladolid;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Both sexes;698 Valladolid;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Men;220 Valladolid;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Women;478 Valladolid;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Both sexes;3,891 Valladolid;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Men;1,917 Valladolid;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Women;1,974 Valladolid;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Both sexes;304 Valladolid;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Men;139 Valladolid;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Women;165 Valladolid;Group 1402 Renal failure 5836-5837, 584-586;Both sexes;308 Valladolid;Group 1402 Renal failure 5836-5837, 584-586;Men;182 Valladolid;Group 1402 Renal failure 5836-5837, 584-586;Women;126 Valladolid;Group 1403 Urolithiasis 592, 594, 7880;Both sexes;580 Valladolid;Group 1403 Urolithiasis 592, 594, 7880;Men;324 Valladolid;Group 1403 Urolithiasis 592, 594, 7880;Women;256 Valladolid;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Both sexes;1,034 Valladolid;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Men;514 Valladolid;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Women;520 Valladolid;Group 1405 Prostatic hyperplasia 600;Both sexes;335 Valladolid;Group 1405 Prostatic hyperplasia 600;Men;335 Valladolid;Group 1405 Prostatic hyperplasia 600;Women;.. Valladolid;Group 1406 Other diseases of the male genital organs 601-608;Both sexes;377 Valladolid;Group 1406 Other diseases of the male genital organs 601-608;Men;377 Valladolid;Group 1406 Other diseases of the male genital organs 601-608;Women;.. Valladolid;Group 1407 Disorders of breast 610-612;Both sexes;217 Valladolid;Group 1407 Disorders of breast 610-612;Men;43 Valladolid;Group 1407 Disorders of breast 610-612;Women;174 Valladolid;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Both sexes;114 Valladolid;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Men;.. Valladolid;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Women;114 Valladolid;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Both sexes;38 Valladolid;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Men;.. Valladolid;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Women;38 Valladolid;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Both sexes;584 Valladolid;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Men;3 Valladolid;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Women;581 Valladolid;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Both sexes;5,037 Valladolid;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Men;.. Valladolid;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Women;5,037 Valladolid;Group 1501 Legally induced abortion 635;Both sexes;1 Valladolid;Group 1501 Legally induced abortion 635;Men;.. Valladolid;Group 1501 Legally induced abortion 635;Women;1 Valladolid;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Both sexes;335 Valladolid;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Men;.. Valladolid;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Women;335 Valladolid;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Both sexes;3,032 Valladolid;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Men;.. Valladolid;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Women;3,032 Valladolid;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Both sexes;397 Valladolid;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Men;.. Valladolid;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Women;397 Valladolid;Group 1505 Single spontaneous delivery 650;Both sexes;530 Valladolid;Group 1505 Single spontaneous delivery 650;Men;.. Valladolid;Group 1505 Single spontaneous delivery 650;Women;530 Valladolid;Group 1506 Other deliveries 6695-6697;Both sexes;464 Valladolid;Group 1506 Other deliveries 6695-6697;Men;.. Valladolid;Group 1506 Other deliveries 6695-6697;Women;464 Valladolid;Group 1507 Complications related to the puerperium 670-676;Both sexes;29 Valladolid;Group 1507 Complications related to the puerperium 670-676;Men;.. Valladolid;Group 1507 Complications related to the puerperium 670-676;Women;29 Valladolid;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Both sexes;249 Valladolid;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Men;.. Valladolid;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Women;249 Valladolid;Group 1600 Some disorders originating in the perinatal period 760-779;Both sexes;604 Valladolid;Group 1600 Some disorders originating in the perinatal period 760-779;Men;351 Valladolid;Group 1600 Some disorders originating in the perinatal period 760-779;Women;253 Valladolid;Group 1601 Disorders related with premature delivery and a low birth weight 765;Both sexes;167 Valladolid;Group 1601 Disorders related with premature delivery and a low birth weight 765;Men;86 Valladolid;Group 1601 Disorders related with premature delivery and a low birth weight 765;Women;81 Valladolid;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Both sexes;437 Valladolid;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Men;265 Valladolid;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Women;172 Valladolid;Grupo 1700 Congenital abnormalities 740-759;Both sexes;390 Valladolid;Grupo 1700 Congenital abnormalities 740-759;Men;228 Valladolid;Grupo 1700 Congenital abnormalities 740-759;Women;162 Valladolid;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Both sexes;2,573 Valladolid;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Men;1,387 Valladolid;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Women;1,186 Valladolid;Group 1801 Pain in throat and chest 7841, 7865;Both sexes;320 Valladolid;Group 1801 Pain in throat and chest 7841, 7865;Men;165 Valladolid;Group 1801 Pain in throat and chest 7841, 7865;Women;155 Valladolid;Group 1802 Abdominal pain 7890;Both sexes;287 Valladolid;Group 1802 Abdominal pain 7890;Men;112 Valladolid;Group 1802 Abdominal pain 7890;Women;175 Valladolid;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Both sexes;235 Valladolid;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Men;145 Valladolid;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Women;90 Valladolid;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Both sexes;1,731 Valladolid;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Men;965 Valladolid;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Women;766 Valladolid;Group 1900 Injuries and poisoning 800-999;Both sexes;5,107 Valladolid;Group 1900 Injuries and poisoning 800-999;Men;2,706 Valladolid;Group 1900 Injuries and poisoning 800-999;Women;2,401 Valladolid;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Both sexes;190 Valladolid;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Men;122 Valladolid;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Women;68 Valladolid;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Both sexes;223 Valladolid;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Men;157 Valladolid;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Women;66 Valladolid;Group 1903 Radius and ulna fracture 813;Both sexes;221 Valladolid;Group 1903 Radius and ulna fracture 813;Men;111 Valladolid;Group 1903 Radius and ulna fracture 813;Women;110 Valladolid;Group 1904 Femur fracture 820-821;Both sexes;850 Valladolid;Group 1904 Femur fracture 820-821;Men;195 Valladolid;Group 1904 Femur fracture 820-821;Women;655 Valladolid;Group 1905 Leg fracture, including the ankle 823-824;Both sexes;326 Valladolid;Group 1905 Leg fracture, including the ankle 823-824;Men;177 Valladolid;Group 1905 Leg fracture, including the ankle 823-824;Women;149 Valladolid;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Both sexes;1,339 Valladolid;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Men;811 Valladolid;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Women;528 Valladolid;Group 1907 Burns 940-949;Both sexes;45 Valladolid;Group 1907 Burns 940-949;Men;33 Valladolid;Group 1907 Burns 940-949;Women;12 Valladolid;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Both sexes;158 Valladolid;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Men;69 Valladolid;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Women;89 Valladolid;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Both sexes;1,655 Valladolid;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Men;972 Valladolid;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Women;683 Valladolid;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Both sexes;10 Valladolid;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Men;6 Valladolid;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Women;4 Valladolid;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Both sexes;90 Valladolid;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Men;53 Valladolid;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Women;37 Valladolid;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Both sexes;913 Valladolid;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Men;409 Valladolid;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Women;504 Valladolid;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Both sexes;127 Valladolid;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Men;80 Valladolid;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Women;47 Valladolid;Group 2102 Contraceptive management V25;Both sexes;36 Valladolid;Group 2102 Contraceptive management V25;Men;3 Valladolid;Group 2102 Contraceptive management V25;Women;33 Valladolid;Group 2103 Living newborns by type of delivery V30-V39;Both sexes;.. Valladolid;Group 2103 Living newborns by type of delivery V30-V39;Men;.. Valladolid;Group 2103 Living newborns by type of delivery V30-V39;Women;.. Valladolid;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Both sexes;388 Valladolid;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Men;166 Valladolid;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Women;222 Valladolid;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Both sexes;362 Valladolid;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Men;160 Valladolid;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Women;202 Zamora;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Both sexes;18,508 Zamora;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Men;9,104 Zamora;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Women;9,404 Zamora;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Both sexes;547 Zamora;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Men;300 Zamora;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Women;247 Zamora;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Both sexes;133 Zamora;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Men;72 Zamora;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Women;61 Zamora;Group 0102 Imprecise intestinal infections 009;Both sexes;37 Zamora;Group 0102 Imprecise intestinal infections 009;Men;15 Zamora;Group 0102 Imprecise intestinal infections 009;Women;22 Zamora;Group 0103 Tuberculosis 010-018, 137;Both sexes;24 Zamora;Group 0103 Tuberculosis 010-018, 137;Men;12 Zamora;Group 0103 Tuberculosis 010-018, 137;Women;12 Zamora;Group 0104 Septicaemia 038;Both sexes;172 Zamora;Group 0104 Septicaemia 038;Men;98 Zamora;Group 0104 Septicaemia 038;Women;74 Zamora;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Both sexes;5 Zamora;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Men;2 Zamora;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Women;3 Zamora;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Both sexes;176 Zamora;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Men;101 Zamora;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Women;75 Zamora;Group 0200 Neoplasms 140-239;Both sexes;2,103 Zamora;Group 0200 Neoplasms 140-239;Men;1,152 Zamora;Group 0200 Neoplasms 140-239;Women;951 Zamora;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Both sexes;320 Zamora;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Men;205 Zamora;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Women;115 Zamora;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Both sexes;167 Zamora;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Men;146 Zamora;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Women;21 Zamora;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Both sexes;8 Zamora;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Men;2 Zamora;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Women;6 Zamora;Group 0204 Malignant neoplasm of breast 174-175;Both sexes;146 Zamora;Group 0204 Malignant neoplasm of breast 174-175;Men;1 Zamora;Group 0204 Malignant neoplasm of breast 174-175;Women;145 Zamora;Group 0205 Malignant neoplasm of uterus 179-180, 182;Both sexes;44 Zamora;Group 0205 Malignant neoplasm of uterus 179-180, 182;Men;.. Zamora;Group 0205 Malignant neoplasm of uterus 179-180, 182;Women;44 Zamora;Group 0206 Malignant neoplasm of ovary 1830;Both sexes;29 Zamora;Group 0206 Malignant neoplasm of ovary 1830;Men;.. Zamora;Group 0206 Malignant neoplasm of ovary 1830;Women;29 Zamora;Group 0207 Malignant neoplasm of prostate 185;Both sexes;60 Zamora;Group 0207 Malignant neoplasm of prostate 185;Men;60 Zamora;Group 0207 Malignant neoplasm of prostate 185;Women;.. Zamora;Group 0208 Malignant neoplasm of bladder 188;Both sexes;171 Zamora;Group 0208 Malignant neoplasm of bladder 188;Men;142 Zamora;Group 0208 Malignant neoplasm of bladder 188;Women;29 Zamora;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Both sexes;823 Zamora;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Men;493 Zamora;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Women;330 Zamora;Group 0210 Carcinoma in situ 230-234;Both sexes;25 Zamora;Group 0210 Carcinoma in situ 230-234;Men;6 Zamora;Group 0210 Carcinoma in situ 230-234;Women;19 Zamora;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Both sexes;19 Zamora;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Men;14 Zamora;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Women;5 Zamora;Grupo 0212 Leiomyoma of uterus 218;Both sexes;74 Zamora;Grupo 0212 Leiomyoma of uterus 218;Men;.. Zamora;Grupo 0212 Leiomyoma of uterus 218;Women;74 Zamora;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Both sexes;217 Zamora;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Men;83 Zamora;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Women;134 Zamora;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Both sexes;160 Zamora;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Men;87 Zamora;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Women;73 Zamora;Group 0301 Anaemias 280-285;Both sexes;89 Zamora;Group 0301 Anaemias 280-285;Men;45 Zamora;Group 0301 Anaemias 280-285;Women;44 Zamora;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Both sexes;71 Zamora;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Men;42 Zamora;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Women;29 Zamora;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Both sexes;453 Zamora;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Men;160 Zamora;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Women;293 Zamora;Group 0401 Diabetes mellitus 249-250;Both sexes;160 Zamora;Group 0401 Diabetes mellitus 249-250;Men;71 Zamora;Group 0401 Diabetes mellitus 249-250;Women;89 Zamora;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Both sexes;293 Zamora;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Men;89 Zamora;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Women;204 Zamora;Group 0500 Mental disorders 290-319;Both sexes;289 Zamora;Group 0500 Mental disorders 290-319;Men;151 Zamora;Group 0500 Mental disorders 290-319;Women;138 Zamora;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Both sexes;13 Zamora;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Men;3 Zamora;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Women;10 Zamora;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Both sexes;24 Zamora;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Men;23 Zamora;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Women;1 Zamora;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Both sexes;16 Zamora;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Men;11 Zamora;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Women;5 Zamora;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Both sexes;90 Zamora;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Men;63 Zamora;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Women;27 Zamora;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Both sexes;38 Zamora;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Men;13 Zamora;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Women;25 Zamora;Group 0506 Other mental and behavioural disorders Rest of (290-319);Both sexes;108 Zamora;Group 0506 Other mental and behavioural disorders Rest of (290-319);Men;38 Zamora;Group 0506 Other mental and behavioural disorders Rest of (290-319);Women;70 Zamora;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Both sexes;422 Zamora;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Men;224 Zamora;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Women;198 Zamora;Group 0601 Alzheimer's disease 3310;Both sexes;8 Zamora;Group 0601 Alzheimer's disease 3310;Men;4 Zamora;Group 0601 Alzheimer's disease 3310;Women;4 Zamora;Group 0602 Multiple sclerosis 340;Both sexes;6 Zamora;Group 0602 Multiple sclerosis 340;Men;2 Zamora;Group 0602 Multiple sclerosis 340;Women;4 Zamora;Group 0603 Epilepsy 345;Both sexes;78 Zamora;Group 0603 Epilepsy 345;Men;42 Zamora;Group 0603 Epilepsy 345;Women;36 Zamora;Group 0604 Transient cerebral ischemia 435;Both sexes;121 Zamora;Group 0604 Transient cerebral ischemia 435;Men;63 Zamora;Group 0604 Transient cerebral ischemia 435;Women;58 Zamora;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Both sexes;209 Zamora;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Men;113 Zamora;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Women;96 Zamora;Grupo 0700 Diseases of the eye and adnexa 360-379;Both sexes;42 Zamora;Grupo 0700 Diseases of the eye and adnexa 360-379;Men;17 Zamora;Grupo 0700 Diseases of the eye and adnexa 360-379;Women;25 Zamora;Grupo 0701 Cataract 366;Both sexes;5 Zamora;Grupo 0701 Cataract 366;Men;2 Zamora;Grupo 0701 Cataract 366;Women;3 Zamora;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Both sexes;37 Zamora;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Men;15 Zamora;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Women;22 Zamora;Group 0800 Diseases of the ear and the mastoid 380-389;Both sexes;177 Zamora;Group 0800 Diseases of the ear and the mastoid 380-389;Men;78 Zamora;Group 0800 Diseases of the ear and the mastoid 380-389;Women;99 Zamora;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Both sexes;2,385 Zamora;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Men;1,298 Zamora;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Women;1,087 Zamora;Group 0901 Hypertensive disease 401-405;Both sexes;108 Zamora;Group 0901 Hypertensive disease 401-405;Men;38 Zamora;Group 0901 Hypertensive disease 401-405;Women;70 Zamora;Group 0902 Angina pectoris 4111, 413;Both sexes;41 Zamora;Group 0902 Angina pectoris 4111, 413;Men;31 Zamora;Group 0902 Angina pectoris 4111, 413;Women;10 Zamora;Group 0903 Acute myocardial infarction 410;Both sexes;211 Zamora;Group 0903 Acute myocardial infarction 410;Men;138 Zamora;Group 0903 Acute myocardial infarction 410;Women;73 Zamora;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Both sexes;98 Zamora;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Men;81 Zamora;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Women;17 Zamora;Group 0905 Diseases of the lungs circulation 415-417;Both sexes;122 Zamora;Group 0905 Diseases of the lungs circulation 415-417;Men;57 Zamora;Group 0905 Diseases of the lungs circulation 415-417;Women;65 Zamora;Group 0906 Heart conduction disorders and arrhytmias 426-427;Both sexes;298 Zamora;Group 0906 Heart conduction disorders and arrhytmias 426-427;Men;167 Zamora;Group 0906 Heart conduction disorders and arrhytmias 426-427;Women;131 Zamora;Grupo 0907 Heart failure 428;Both sexes;637 Zamora;Grupo 0907 Heart failure 428;Men;304 Zamora;Grupo 0907 Heart failure 428;Women;333 Zamora;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Both sexes;446 Zamora;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Men;246 Zamora;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Women;200 Zamora;Grupo 0909 Atherosclerosis 440;Both sexes;15 Zamora;Grupo 0909 Atherosclerosis 440;Men;6 Zamora;Grupo 0909 Atherosclerosis 440;Women;9 Zamora;Group 0910 Varicose veins of lower extremities 454;Both sexes;68 Zamora;Group 0910 Varicose veins of lower extremities 454;Men;32 Zamora;Group 0910 Varicose veins of lower extremities 454;Women;36 Zamora;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Both sexes;341 Zamora;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Men;198 Zamora;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Women;143 Zamora;Group 1000 Diseases of the respiratory system 0340, 460-519;Both sexes;2,741 Zamora;Group 1000 Diseases of the respiratory system 0340, 460-519;Men;1,583 Zamora;Group 1000 Diseases of the respiratory system 0340, 460-519;Women;1,158 Zamora;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Both sexes;152 Zamora;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Men;76 Zamora;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Women;76 Zamora;Group 1002 Pneumonia 480-486;Both sexes;594 Zamora;Group 1002 Pneumonia 480-486;Men;373 Zamora;Group 1002 Pneumonia 480-486;Women;221 Zamora;Group 1003 Acute bronchitis and bronchiolitis 466;Both sexes;217 Zamora;Group 1003 Acute bronchitis and bronchiolitis 466;Men;92 Zamora;Group 1003 Acute bronchitis and bronchiolitis 466;Women;125 Zamora;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Both sexes;182 Zamora;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Men;93 Zamora;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Women;89 Zamora;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Both sexes;288 Zamora;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Men;167 Zamora;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Women;121 Zamora;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Both sexes;434 Zamora;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Men;383 Zamora;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Women;51 Zamora;Group 1007 Asthma 4930-4931,4938-4939;Both sexes;122 Zamora;Group 1007 Asthma 4930-4931,4938-4939;Men;38 Zamora;Group 1007 Asthma 4930-4931,4938-4939;Women;84 Zamora;Group 1008 Other diseases of the respiratory system Resto of (460-519);Both sexes;752 Zamora;Group 1008 Other diseases of the respiratory system Resto of (460-519);Men;361 Zamora;Group 1008 Other diseases of the respiratory system Resto of (460-519);Women;391 Zamora;Group 1100 Diseases of the digestive system 520-579;Both sexes;2,780 Zamora;Group 1100 Diseases of the digestive system 520-579;Men;1,576 Zamora;Group 1100 Diseases of the digestive system 520-579;Women;1,204 Zamora;Group 1101 Disorders of the teeth and supporting structures 520-525;Both sexes;7 Zamora;Group 1101 Disorders of the teeth and supporting structures 520-525;Men;4 Zamora;Group 1101 Disorders of the teeth and supporting structures 520-525;Women;3 Zamora;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Both sexes;46 Zamora;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Men;25 Zamora;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Women;21 Zamora;Group 1103 Diseases of the esophagus 530;Both sexes;49 Zamora;Group 1103 Diseases of the esophagus 530;Men;30 Zamora;Group 1103 Diseases of the esophagus 530;Women;19 Zamora;Group 1104 Peptic ulcer 531-534;Both sexes;66 Zamora;Group 1104 Peptic ulcer 531-534;Men;41 Zamora;Group 1104 Peptic ulcer 531-534;Women;25 Zamora;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Both sexes;79 Zamora;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Men;42 Zamora;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Women;37 Zamora;Group 1106 Appendicitis 540-543;Both sexes;198 Zamora;Group 1106 Appendicitis 540-543;Men;116 Zamora;Group 1106 Appendicitis 540-543;Women;82 Zamora;Group 1107 Inguinal hernia 550;Both sexes;345 Zamora;Group 1107 Inguinal hernia 550;Men;319 Zamora;Group 1107 Inguinal hernia 550;Women;26 Zamora;Group 1108 Other abdominal hernia 551-553;Both sexes;164 Zamora;Group 1108 Other abdominal hernia 551-553;Men;77 Zamora;Group 1108 Other abdominal hernia 551-553;Women;87 Zamora;Group 1109 Crohn's disease and ulcerative colitis 555-556;Both sexes;47 Zamora;Group 1109 Crohn's disease and ulcerative colitis 555-556;Men;28 Zamora;Group 1109 Crohn's disease and ulcerative colitis 555-556;Women;19 Zamora;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Both sexes;227 Zamora;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Men;105 Zamora;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Women;122 Zamora;Group 1111 Intestinal obstruction without hernia 560;Both sexes;157 Zamora;Group 1111 Intestinal obstruction without hernia 560;Men;78 Zamora;Group 1111 Intestinal obstruction without hernia 560;Women;79 Zamora;Group 1112 Intestinal diverticulosis 562;Both sexes;144 Zamora;Group 1112 Intestinal diverticulosis 562;Men;73 Zamora;Group 1112 Intestinal diverticulosis 562;Women;71 Zamora;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Both sexes;83 Zamora;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Men;51 Zamora;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Women;32 Zamora;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Both sexes;107 Zamora;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Men;51 Zamora;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Women;56 Zamora;Group 1115 Alcoholic hepatitis 5710-5713;Both sexes;33 Zamora;Group 1115 Alcoholic hepatitis 5710-5713;Men;31 Zamora;Group 1115 Alcoholic hepatitis 5710-5713;Women;2 Zamora;Group 1116 Other diseases of the liver 570,5714-573;Both sexes;81 Zamora;Group 1116 Other diseases of the liver 570,5714-573;Men;50 Zamora;Group 1116 Other diseases of the liver 570,5714-573;Women;31 Zamora;Group 1117 Cholelithiasis 574;Both sexes;595 Zamora;Group 1117 Cholelithiasis 574;Men;282 Zamora;Group 1117 Cholelithiasis 574;Women;313 Zamora;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Both sexes;96 Zamora;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Men;44 Zamora;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Women;52 Zamora;Group 1119 Pancreatic diseases 577;Both sexes;113 Zamora;Group 1119 Pancreatic diseases 577;Men;68 Zamora;Group 1119 Pancreatic diseases 577;Women;45 Zamora;Group 1120 Other diseases of the digestive system Rest of (520-579);Both sexes;143 Zamora;Group 1120 Other diseases of the digestive system Rest of (520-579);Men;61 Zamora;Group 1120 Other diseases of the digestive system Rest of (520-579);Women;82 Zamora;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Both sexes;136 Zamora;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Men;82 Zamora;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Women;54 Zamora;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Both sexes;90 Zamora;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Men;60 Zamora;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Women;30 Zamora;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Both sexes;5 Zamora;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Men;2 Zamora;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Women;3 Zamora;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Both sexes;41 Zamora;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Men;20 Zamora;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Women;21 Zamora;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Both sexes;983 Zamora;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Men;431 Zamora;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Women;552 Zamora;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Both sexes;.. Zamora;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Men;.. Zamora;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Women;.. Zamora;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Both sexes;.. Zamora;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Men;.. Zamora;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Women;.. Zamora;Group 1303 Internal derangement of knee 717;Both sexes;81 Zamora;Group 1303 Internal derangement of knee 717;Men;62 Zamora;Group 1303 Internal derangement of knee 717;Women;19 Zamora;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Both sexes;523 Zamora;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Men;234 Zamora;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Women;289 Zamora;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Both sexes;35 Zamora;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Men;10 Zamora;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Women;25 Zamora;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Both sexes;7 Zamora;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Men;6 Zamora;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Women;1 Zamora;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Both sexes;21 Zamora;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Men;10 Zamora;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Women;11 Zamora;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Both sexes;4 Zamora;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Men;2 Zamora;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Women;2 Zamora;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Both sexes;107 Zamora;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Men;61 Zamora;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Women;46 Zamora;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Both sexes;205 Zamora;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Men;46 Zamora;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Women;159 Zamora;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Both sexes;1,069 Zamora;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Men;569 Zamora;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Women;500 Zamora;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Both sexes;77 Zamora;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Men;26 Zamora;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Women;51 Zamora;Group 1402 Renal failure 5836-5837, 584-586;Both sexes;113 Zamora;Group 1402 Renal failure 5836-5837, 584-586;Men;66 Zamora;Group 1402 Renal failure 5836-5837, 584-586;Women;47 Zamora;Group 1403 Urolithiasis 592, 594, 7880;Both sexes;124 Zamora;Group 1403 Urolithiasis 592, 594, 7880;Men;85 Zamora;Group 1403 Urolithiasis 592, 594, 7880;Women;39 Zamora;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Both sexes;384 Zamora;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Men;207 Zamora;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Women;177 Zamora;Group 1405 Prostatic hyperplasia 600;Both sexes;115 Zamora;Group 1405 Prostatic hyperplasia 600;Men;115 Zamora;Group 1405 Prostatic hyperplasia 600;Women;.. Zamora;Group 1406 Other diseases of the male genital organs 601-608;Both sexes;66 Zamora;Group 1406 Other diseases of the male genital organs 601-608;Men;66 Zamora;Group 1406 Other diseases of the male genital organs 601-608;Women;.. Zamora;Group 1407 Disorders of breast 610-612;Both sexes;19 Zamora;Group 1407 Disorders of breast 610-612;Men;3 Zamora;Group 1407 Disorders of breast 610-612;Women;16 Zamora;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Both sexes;29 Zamora;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Men;.. Zamora;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Women;29 Zamora;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Both sexes;11 Zamora;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Men;.. Zamora;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Women;11 Zamora;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Both sexes;131 Zamora;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Men;1 Zamora;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Women;130 Zamora;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Both sexes;1,272 Zamora;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Men;.. Zamora;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Women;1,272 Zamora;Group 1501 Legally induced abortion 635;Both sexes;.. Zamora;Group 1501 Legally induced abortion 635;Men;.. Zamora;Group 1501 Legally induced abortion 635;Women;.. Zamora;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Both sexes;133 Zamora;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Men;.. Zamora;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Women;133 Zamora;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Both sexes;866 Zamora;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Men;.. Zamora;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Women;866 Zamora;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Both sexes;162 Zamora;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Men;.. Zamora;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Women;162 Zamora;Group 1505 Single spontaneous delivery 650;Both sexes;36 Zamora;Group 1505 Single spontaneous delivery 650;Men;.. Zamora;Group 1505 Single spontaneous delivery 650;Women;36 Zamora;Group 1506 Other deliveries 6695-6697;Both sexes;17 Zamora;Group 1506 Other deliveries 6695-6697;Men;.. Zamora;Group 1506 Other deliveries 6695-6697;Women;17 Zamora;Group 1507 Complications related to the puerperium 670-676;Both sexes;19 Zamora;Group 1507 Complications related to the puerperium 670-676;Men;.. Zamora;Group 1507 Complications related to the puerperium 670-676;Women;19 Zamora;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Both sexes;39 Zamora;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Men;.. Zamora;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Women;39 Zamora;Group 1600 Some disorders originating in the perinatal period 760-779;Both sexes;122 Zamora;Group 1600 Some disorders originating in the perinatal period 760-779;Men;60 Zamora;Group 1600 Some disorders originating in the perinatal period 760-779;Women;62 Zamora;Group 1601 Disorders related with premature delivery and a low birth weight 765;Both sexes;34 Zamora;Group 1601 Disorders related with premature delivery and a low birth weight 765;Men;13 Zamora;Group 1601 Disorders related with premature delivery and a low birth weight 765;Women;21 Zamora;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Both sexes;88 Zamora;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Men;47 Zamora;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Women;41 Zamora;Grupo 1700 Congenital abnormalities 740-759;Both sexes;58 Zamora;Grupo 1700 Congenital abnormalities 740-759;Men;19 Zamora;Grupo 1700 Congenital abnormalities 740-759;Women;39 Zamora;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Both sexes;607 Zamora;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Men;330 Zamora;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Women;277 Zamora;Group 1801 Pain in throat and chest 7841, 7865;Both sexes;107 Zamora;Group 1801 Pain in throat and chest 7841, 7865;Men;62 Zamora;Group 1801 Pain in throat and chest 7841, 7865;Women;45 Zamora;Group 1802 Abdominal pain 7890;Both sexes;72 Zamora;Group 1802 Abdominal pain 7890;Men;23 Zamora;Group 1802 Abdominal pain 7890;Women;49 Zamora;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Both sexes;36 Zamora;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Men;25 Zamora;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Women;11 Zamora;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Both sexes;392 Zamora;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Men;220 Zamora;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Women;172 Zamora;Group 1900 Injuries and poisoning 800-999;Both sexes;1,554 Zamora;Group 1900 Injuries and poisoning 800-999;Men;740 Zamora;Group 1900 Injuries and poisoning 800-999;Women;814 Zamora;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Both sexes;111 Zamora;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Men;60 Zamora;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Women;51 Zamora;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Both sexes;63 Zamora;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Men;41 Zamora;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Women;22 Zamora;Group 1903 Radius and ulna fracture 813;Both sexes;87 Zamora;Group 1903 Radius and ulna fracture 813;Men;36 Zamora;Group 1903 Radius and ulna fracture 813;Women;51 Zamora;Group 1904 Femur fracture 820-821;Both sexes;324 Zamora;Group 1904 Femur fracture 820-821;Men;81 Zamora;Group 1904 Femur fracture 820-821;Women;243 Zamora;Group 1905 Leg fracture, including the ankle 823-824;Both sexes;88 Zamora;Group 1905 Leg fracture, including the ankle 823-824;Men;45 Zamora;Group 1905 Leg fracture, including the ankle 823-824;Women;43 Zamora;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Both sexes;309 Zamora;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Men;196 Zamora;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Women;113 Zamora;Group 1907 Burns 940-949;Both sexes;3 Zamora;Group 1907 Burns 940-949;Men;3 Zamora;Group 1907 Burns 940-949;Women;.. Zamora;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Both sexes;59 Zamora;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Men;23 Zamora;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Women;36 Zamora;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Both sexes;439 Zamora;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Men;227 Zamora;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Women;212 Zamora;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Both sexes;3 Zamora;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Men;1 Zamora;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Women;2 Zamora;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Both sexes;68 Zamora;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Men;27 Zamora;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Women;41 Zamora;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Both sexes;608 Zamora;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Men;247 Zamora;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Women;361 Zamora;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Both sexes;9 Zamora;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Men;4 Zamora;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Women;5 Zamora;Group 2102 Contraceptive management V25;Both sexes;3 Zamora;Group 2102 Contraceptive management V25;Men;.. Zamora;Group 2102 Contraceptive management V25;Women;3 Zamora;Group 2103 Living newborns by type of delivery V30-V39;Both sexes;.. Zamora;Group 2103 Living newborns by type of delivery V30-V39;Men;.. Zamora;Group 2103 Living newborns by type of delivery V30-V39;Women;.. Zamora;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Both sexes;350 Zamora;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Men;109 Zamora;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Women;241 Zamora;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Both sexes;246 Zamora;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Men;134 Zamora;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Women;112 CASTILLA - LA MANCHA;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Both sexes;170,036 CASTILLA - LA MANCHA;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Men;80,786 CASTILLA - LA MANCHA;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Women;89,250 CASTILLA - LA MANCHA;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Both sexes;4,049 CASTILLA - LA MANCHA;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Men;2,274 CASTILLA - LA MANCHA;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Women;1,775 CASTILLA - LA MANCHA;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Both sexes;715 CASTILLA - LA MANCHA;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Men;374 CASTILLA - LA MANCHA;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Women;341 CASTILLA - LA MANCHA;Group 0102 Imprecise intestinal infections 009;Both sexes;233 CASTILLA - LA MANCHA;Group 0102 Imprecise intestinal infections 009;Men;112 CASTILLA - LA MANCHA;Group 0102 Imprecise intestinal infections 009;Women;121 CASTILLA - LA MANCHA;Group 0103 Tuberculosis 010-018, 137;Both sexes;122 CASTILLA - LA MANCHA;Group 0103 Tuberculosis 010-018, 137;Men;78 CASTILLA - LA MANCHA;Group 0103 Tuberculosis 010-018, 137;Women;44 CASTILLA - LA MANCHA;Group 0104 Septicaemia 038;Both sexes;1,704 CASTILLA - LA MANCHA;Group 0104 Septicaemia 038;Men;949 CASTILLA - LA MANCHA;Group 0104 Septicaemia 038;Women;755 CASTILLA - LA MANCHA;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Both sexes;79 CASTILLA - LA MANCHA;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Men;65 CASTILLA - LA MANCHA;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Women;14 CASTILLA - LA MANCHA;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Both sexes;1,196 CASTILLA - LA MANCHA;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Men;696 CASTILLA - LA MANCHA;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Women;500 CASTILLA - LA MANCHA;Group 0200 Neoplasms 140-239;Both sexes;15,794 CASTILLA - LA MANCHA;Group 0200 Neoplasms 140-239;Men;8,766 CASTILLA - LA MANCHA;Group 0200 Neoplasms 140-239;Women;7,028 CASTILLA - LA MANCHA;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Both sexes;1,678 CASTILLA - LA MANCHA;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Men;1,051 CASTILLA - LA MANCHA;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Women;627 CASTILLA - LA MANCHA;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Both sexes;1,396 CASTILLA - LA MANCHA;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Men;1,217 CASTILLA - LA MANCHA;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Women;179 CASTILLA - LA MANCHA;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Both sexes;383 CASTILLA - LA MANCHA;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Men;221 CASTILLA - LA MANCHA;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Women;162 CASTILLA - LA MANCHA;Group 0204 Malignant neoplasm of breast 174-175;Both sexes;1,124 CASTILLA - LA MANCHA;Group 0204 Malignant neoplasm of breast 174-175;Men;17 CASTILLA - LA MANCHA;Group 0204 Malignant neoplasm of breast 174-175;Women;1,107 CASTILLA - LA MANCHA;Group 0205 Malignant neoplasm of uterus 179-180, 182;Both sexes;345 CASTILLA - LA MANCHA;Group 0205 Malignant neoplasm of uterus 179-180, 182;Men;.. CASTILLA - LA MANCHA;Group 0205 Malignant neoplasm of uterus 179-180, 182;Women;345 CASTILLA - LA MANCHA;Group 0206 Malignant neoplasm of ovary 1830;Both sexes;162 CASTILLA - LA MANCHA;Group 0206 Malignant neoplasm of ovary 1830;Men;.. CASTILLA - LA MANCHA;Group 0206 Malignant neoplasm of ovary 1830;Women;162 CASTILLA - LA MANCHA;Group 0207 Malignant neoplasm of prostate 185;Both sexes;460 CASTILLA - LA MANCHA;Group 0207 Malignant neoplasm of prostate 185;Men;460 CASTILLA - LA MANCHA;Group 0207 Malignant neoplasm of prostate 185;Women;.. CASTILLA - LA MANCHA;Group 0208 Malignant neoplasm of bladder 188;Both sexes;1,229 CASTILLA - LA MANCHA;Group 0208 Malignant neoplasm of bladder 188;Men;1,070 CASTILLA - LA MANCHA;Group 0208 Malignant neoplasm of bladder 188;Women;159 CASTILLA - LA MANCHA;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Both sexes;5,467 CASTILLA - LA MANCHA;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Men;3,287 CASTILLA - LA MANCHA;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Women;2,180 CASTILLA - LA MANCHA;Group 0210 Carcinoma in situ 230-234;Both sexes;188 CASTILLA - LA MANCHA;Group 0210 Carcinoma in situ 230-234;Men;75 CASTILLA - LA MANCHA;Group 0210 Carcinoma in situ 230-234;Women;113 CASTILLA - LA MANCHA;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Both sexes;206 CASTILLA - LA MANCHA;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Men;117 CASTILLA - LA MANCHA;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Women;89 CASTILLA - LA MANCHA;Grupo 0212 Leiomyoma of uterus 218;Both sexes;715 CASTILLA - LA MANCHA;Grupo 0212 Leiomyoma of uterus 218;Men;.. CASTILLA - LA MANCHA;Grupo 0212 Leiomyoma of uterus 218;Women;715 CASTILLA - LA MANCHA;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Both sexes;2,441 CASTILLA - LA MANCHA;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Men;1,251 CASTILLA - LA MANCHA;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Women;1,190 CASTILLA - LA MANCHA;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Both sexes;1,500 CASTILLA - LA MANCHA;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Men;776 CASTILLA - LA MANCHA;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Women;724 CASTILLA - LA MANCHA;Group 0301 Anaemias 280-285;Both sexes;864 CASTILLA - LA MANCHA;Group 0301 Anaemias 280-285;Men;435 CASTILLA - LA MANCHA;Group 0301 Anaemias 280-285;Women;429 CASTILLA - LA MANCHA;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Both sexes;636 CASTILLA - LA MANCHA;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Men;341 CASTILLA - LA MANCHA;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Women;295 CASTILLA - LA MANCHA;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Both sexes;2,603 CASTILLA - LA MANCHA;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Men;1,088 CASTILLA - LA MANCHA;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Women;1,515 CASTILLA - LA MANCHA;Group 0401 Diabetes mellitus 249-250;Both sexes;913 CASTILLA - LA MANCHA;Group 0401 Diabetes mellitus 249-250;Men;514 CASTILLA - LA MANCHA;Group 0401 Diabetes mellitus 249-250;Women;399 CASTILLA - LA MANCHA;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Both sexes;1,690 CASTILLA - LA MANCHA;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Men;574 CASTILLA - LA MANCHA;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Women;1,116 CASTILLA - LA MANCHA;Group 0500 Mental disorders 290-319;Both sexes;4,122 CASTILLA - LA MANCHA;Group 0500 Mental disorders 290-319;Men;2,185 CASTILLA - LA MANCHA;Group 0500 Mental disorders 290-319;Women;1,937 CASTILLA - LA MANCHA;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Both sexes;53 CASTILLA - LA MANCHA;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Men;30 CASTILLA - LA MANCHA;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Women;23 CASTILLA - LA MANCHA;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Both sexes;255 CASTILLA - LA MANCHA;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Men;198 CASTILLA - LA MANCHA;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Women;57 CASTILLA - LA MANCHA;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Both sexes;182 CASTILLA - LA MANCHA;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Men;143 CASTILLA - LA MANCHA;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Women;39 CASTILLA - LA MANCHA;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Both sexes;1,261 CASTILLA - LA MANCHA;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Men;838 CASTILLA - LA MANCHA;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Women;423 CASTILLA - LA MANCHA;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Both sexes;843 CASTILLA - LA MANCHA;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Men;354 CASTILLA - LA MANCHA;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Women;489 CASTILLA - LA MANCHA;Group 0506 Other mental and behavioural disorders Rest of (290-319);Both sexes;1,528 CASTILLA - LA MANCHA;Group 0506 Other mental and behavioural disorders Rest of (290-319);Men;622 CASTILLA - LA MANCHA;Group 0506 Other mental and behavioural disorders Rest of (290-319);Women;906 CASTILLA - LA MANCHA;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Both sexes;4,291 CASTILLA - LA MANCHA;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Men;2,343 CASTILLA - LA MANCHA;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Women;1,948 CASTILLA - LA MANCHA;Group 0601 Alzheimer's disease 3310;Both sexes;53 CASTILLA - LA MANCHA;Group 0601 Alzheimer's disease 3310;Men;16 CASTILLA - LA MANCHA;Group 0601 Alzheimer's disease 3310;Women;37 CASTILLA - LA MANCHA;Group 0602 Multiple sclerosis 340;Both sexes;159 CASTILLA - LA MANCHA;Group 0602 Multiple sclerosis 340;Men;51 CASTILLA - LA MANCHA;Group 0602 Multiple sclerosis 340;Women;108 CASTILLA - LA MANCHA;Group 0603 Epilepsy 345;Both sexes;508 CASTILLA - LA MANCHA;Group 0603 Epilepsy 345;Men;282 CASTILLA - LA MANCHA;Group 0603 Epilepsy 345;Women;226 CASTILLA - LA MANCHA;Group 0604 Transient cerebral ischemia 435;Both sexes;751 CASTILLA - LA MANCHA;Group 0604 Transient cerebral ischemia 435;Men;396 CASTILLA - LA MANCHA;Group 0604 Transient cerebral ischemia 435;Women;355 CASTILLA - LA MANCHA;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Both sexes;2,820 CASTILLA - LA MANCHA;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Men;1,598 CASTILLA - LA MANCHA;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Women;1,222 CASTILLA - LA MANCHA;Grupo 0700 Diseases of the eye and adnexa 360-379;Both sexes;1,102 CASTILLA - LA MANCHA;Grupo 0700 Diseases of the eye and adnexa 360-379;Men;610 CASTILLA - LA MANCHA;Grupo 0700 Diseases of the eye and adnexa 360-379;Women;492 CASTILLA - LA MANCHA;Grupo 0701 Cataract 366;Both sexes;252 CASTILLA - LA MANCHA;Grupo 0701 Cataract 366;Men;125 CASTILLA - LA MANCHA;Grupo 0701 Cataract 366;Women;127 CASTILLA - LA MANCHA;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Both sexes;850 CASTILLA - LA MANCHA;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Men;485 CASTILLA - LA MANCHA;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Women;365 CASTILLA - LA MANCHA;Group 0800 Diseases of the ear and the mastoid 380-389;Both sexes;753 CASTILLA - LA MANCHA;Group 0800 Diseases of the ear and the mastoid 380-389;Men;390 CASTILLA - LA MANCHA;Group 0800 Diseases of the ear and the mastoid 380-389;Women;363 CASTILLA - LA MANCHA;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Both sexes;22,516 CASTILLA - LA MANCHA;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Men;12,678 CASTILLA - LA MANCHA;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Women;9,838 CASTILLA - LA MANCHA;Group 0901 Hypertensive disease 401-405;Both sexes;1,017 CASTILLA - LA MANCHA;Group 0901 Hypertensive disease 401-405;Men;444 CASTILLA - LA MANCHA;Group 0901 Hypertensive disease 401-405;Women;573 CASTILLA - LA MANCHA;Group 0902 Angina pectoris 4111, 413;Both sexes;1,232 CASTILLA - LA MANCHA;Group 0902 Angina pectoris 4111, 413;Men;772 CASTILLA - LA MANCHA;Group 0902 Angina pectoris 4111, 413;Women;460 CASTILLA - LA MANCHA;Group 0903 Acute myocardial infarction 410;Both sexes;2,244 CASTILLA - LA MANCHA;Group 0903 Acute myocardial infarction 410;Men;1,637 CASTILLA - LA MANCHA;Group 0903 Acute myocardial infarction 410;Women;607 CASTILLA - LA MANCHA;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Both sexes;1,433 CASTILLA - LA MANCHA;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Men;1,099 CASTILLA - LA MANCHA;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Women;334 CASTILLA - LA MANCHA;Group 0905 Diseases of the lungs circulation 415-417;Both sexes;774 CASTILLA - LA MANCHA;Group 0905 Diseases of the lungs circulation 415-417;Men;381 CASTILLA - LA MANCHA;Group 0905 Diseases of the lungs circulation 415-417;Women;393 CASTILLA - LA MANCHA;Group 0906 Heart conduction disorders and arrhytmias 426-427;Both sexes;2,865 CASTILLA - LA MANCHA;Group 0906 Heart conduction disorders and arrhytmias 426-427;Men;1,580 CASTILLA - LA MANCHA;Group 0906 Heart conduction disorders and arrhytmias 426-427;Women;1,285 CASTILLA - LA MANCHA;Grupo 0907 Heart failure 428;Both sexes;4,602 CASTILLA - LA MANCHA;Grupo 0907 Heart failure 428;Men;1,970 CASTILLA - LA MANCHA;Grupo 0907 Heart failure 428;Women;2,632 CASTILLA - LA MANCHA;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Both sexes;4,014 CASTILLA - LA MANCHA;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Men;2,223 CASTILLA - LA MANCHA;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Women;1,791 CASTILLA - LA MANCHA;Grupo 0909 Atherosclerosis 440;Both sexes;762 CASTILLA - LA MANCHA;Grupo 0909 Atherosclerosis 440;Men;564 CASTILLA - LA MANCHA;Grupo 0909 Atherosclerosis 440;Women;198 CASTILLA - LA MANCHA;Group 0910 Varicose veins of lower extremities 454;Both sexes;251 CASTILLA - LA MANCHA;Group 0910 Varicose veins of lower extremities 454;Men;74 CASTILLA - LA MANCHA;Group 0910 Varicose veins of lower extremities 454;Women;177 CASTILLA - LA MANCHA;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Both sexes;3,322 CASTILLA - LA MANCHA;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Men;1,934 CASTILLA - LA MANCHA;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Women;1,388 CASTILLA - LA MANCHA;Group 1000 Diseases of the respiratory system 0340, 460-519;Both sexes;20,082 CASTILLA - LA MANCHA;Group 1000 Diseases of the respiratory system 0340, 460-519;Men;11,828 CASTILLA - LA MANCHA;Group 1000 Diseases of the respiratory system 0340, 460-519;Women;8,254 CASTILLA - LA MANCHA;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Both sexes;812 CASTILLA - LA MANCHA;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Men;448 CASTILLA - LA MANCHA;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Women;364 CASTILLA - LA MANCHA;Group 1002 Pneumonia 480-486;Both sexes;4,730 CASTILLA - LA MANCHA;Group 1002 Pneumonia 480-486;Men;2,907 CASTILLA - LA MANCHA;Group 1002 Pneumonia 480-486;Women;1,823 CASTILLA - LA MANCHA;Group 1003 Acute bronchitis and bronchiolitis 466;Both sexes;1,420 CASTILLA - LA MANCHA;Group 1003 Acute bronchitis and bronchiolitis 466;Men;652 CASTILLA - LA MANCHA;Group 1003 Acute bronchitis and bronchiolitis 466;Women;768 CASTILLA - LA MANCHA;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Both sexes;777 CASTILLA - LA MANCHA;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Men;390 CASTILLA - LA MANCHA;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Women;387 CASTILLA - LA MANCHA;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Both sexes;1,318 CASTILLA - LA MANCHA;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Men;866 CASTILLA - LA MANCHA;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Women;452 CASTILLA - LA MANCHA;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Both sexes;2,905 CASTILLA - LA MANCHA;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Men;2,434 CASTILLA - LA MANCHA;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Women;471 CASTILLA - LA MANCHA;Group 1007 Asthma 4930-4931,4938-4939;Both sexes;714 CASTILLA - LA MANCHA;Group 1007 Asthma 4930-4931,4938-4939;Men;258 CASTILLA - LA MANCHA;Group 1007 Asthma 4930-4931,4938-4939;Women;456 CASTILLA - LA MANCHA;Group 1008 Other diseases of the respiratory system Resto of (460-519);Both sexes;7,406 CASTILLA - LA MANCHA;Group 1008 Other diseases of the respiratory system Resto of (460-519);Men;3,873 CASTILLA - LA MANCHA;Group 1008 Other diseases of the respiratory system Resto of (460-519);Women;3,533 CASTILLA - LA MANCHA;Group 1100 Diseases of the digestive system 520-579;Both sexes;22,071 CASTILLA - LA MANCHA;Group 1100 Diseases of the digestive system 520-579;Men;12,314 CASTILLA - LA MANCHA;Group 1100 Diseases of the digestive system 520-579;Women;9,757 CASTILLA - LA MANCHA;Group 1101 Disorders of the teeth and supporting structures 520-525;Both sexes;252 CASTILLA - LA MANCHA;Group 1101 Disorders of the teeth and supporting structures 520-525;Men;120 CASTILLA - LA MANCHA;Group 1101 Disorders of the teeth and supporting structures 520-525;Women;132 CASTILLA - LA MANCHA;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Both sexes;289 CASTILLA - LA MANCHA;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Men;150 CASTILLA - LA MANCHA;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Women;139 CASTILLA - LA MANCHA;Group 1103 Diseases of the esophagus 530;Both sexes;435 CASTILLA - LA MANCHA;Group 1103 Diseases of the esophagus 530;Men;293 CASTILLA - LA MANCHA;Group 1103 Diseases of the esophagus 530;Women;142 CASTILLA - LA MANCHA;Group 1104 Peptic ulcer 531-534;Both sexes;533 CASTILLA - LA MANCHA;Group 1104 Peptic ulcer 531-534;Men;362 CASTILLA - LA MANCHA;Group 1104 Peptic ulcer 531-534;Women;171 CASTILLA - LA MANCHA;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Both sexes;508 CASTILLA - LA MANCHA;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Men;277 CASTILLA - LA MANCHA;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Women;231 CASTILLA - LA MANCHA;Group 1106 Appendicitis 540-543;Both sexes;1,860 CASTILLA - LA MANCHA;Group 1106 Appendicitis 540-543;Men;1,117 CASTILLA - LA MANCHA;Group 1106 Appendicitis 540-543;Women;743 CASTILLA - LA MANCHA;Group 1107 Inguinal hernia 550;Both sexes;1,669 CASTILLA - LA MANCHA;Group 1107 Inguinal hernia 550;Men;1,478 CASTILLA - LA MANCHA;Group 1107 Inguinal hernia 550;Women;191 CASTILLA - LA MANCHA;Group 1108 Other abdominal hernia 551-553;Both sexes;1,686 CASTILLA - LA MANCHA;Group 1108 Other abdominal hernia 551-553;Men;739 CASTILLA - LA MANCHA;Group 1108 Other abdominal hernia 551-553;Women;947 CASTILLA - LA MANCHA;Group 1109 Crohn's disease and ulcerative colitis 555-556;Both sexes;410 CASTILLA - LA MANCHA;Group 1109 Crohn's disease and ulcerative colitis 555-556;Men;224 CASTILLA - LA MANCHA;Group 1109 Crohn's disease and ulcerative colitis 555-556;Women;186 CASTILLA - LA MANCHA;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Both sexes;1,191 CASTILLA - LA MANCHA;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Men;540 CASTILLA - LA MANCHA;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Women;651 CASTILLA - LA MANCHA;Group 1111 Intestinal obstruction without hernia 560;Both sexes;1,243 CASTILLA - LA MANCHA;Group 1111 Intestinal obstruction without hernia 560;Men;665 CASTILLA - LA MANCHA;Group 1111 Intestinal obstruction without hernia 560;Women;578 CASTILLA - LA MANCHA;Group 1112 Intestinal diverticulosis 562;Both sexes;747 CASTILLA - LA MANCHA;Group 1112 Intestinal diverticulosis 562;Men;387 CASTILLA - LA MANCHA;Group 1112 Intestinal diverticulosis 562;Women;360 CASTILLA - LA MANCHA;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Both sexes;1,246 CASTILLA - LA MANCHA;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Men;800 CASTILLA - LA MANCHA;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Women;446 CASTILLA - LA MANCHA;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Both sexes;835 CASTILLA - LA MANCHA;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Men;412 CASTILLA - LA MANCHA;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Women;423 CASTILLA - LA MANCHA;Group 1115 Alcoholic hepatitis 5710-5713;Both sexes;275 CASTILLA - LA MANCHA;Group 1115 Alcoholic hepatitis 5710-5713;Men;246 CASTILLA - LA MANCHA;Group 1115 Alcoholic hepatitis 5710-5713;Women;29 CASTILLA - LA MANCHA;Group 1116 Other diseases of the liver 570,5714-573;Both sexes;755 CASTILLA - LA MANCHA;Group 1116 Other diseases of the liver 570,5714-573;Men;496 CASTILLA - LA MANCHA;Group 1116 Other diseases of the liver 570,5714-573;Women;259 CASTILLA - LA MANCHA;Group 1117 Cholelithiasis 574;Both sexes;4,472 CASTILLA - LA MANCHA;Group 1117 Cholelithiasis 574;Men;1,940 CASTILLA - LA MANCHA;Group 1117 Cholelithiasis 574;Women;2,532 CASTILLA - LA MANCHA;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Both sexes;1,260 CASTILLA - LA MANCHA;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Men;717 CASTILLA - LA MANCHA;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Women;543 CASTILLA - LA MANCHA;Group 1119 Pancreatic diseases 577;Both sexes;1,485 CASTILLA - LA MANCHA;Group 1119 Pancreatic diseases 577;Men;825 CASTILLA - LA MANCHA;Group 1119 Pancreatic diseases 577;Women;660 CASTILLA - LA MANCHA;Group 1120 Other diseases of the digestive system Rest of (520-579);Both sexes;920 CASTILLA - LA MANCHA;Group 1120 Other diseases of the digestive system Rest of (520-579);Men;526 CASTILLA - LA MANCHA;Group 1120 Other diseases of the digestive system Rest of (520-579);Women;394 CASTILLA - LA MANCHA;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Both sexes;1,292 CASTILLA - LA MANCHA;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Men;685 CASTILLA - LA MANCHA;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Women;607 CASTILLA - LA MANCHA;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Both sexes;780 CASTILLA - LA MANCHA;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Men;433 CASTILLA - LA MANCHA;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Women;347 CASTILLA - LA MANCHA;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Both sexes;54 CASTILLA - LA MANCHA;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Men;24 CASTILLA - LA MANCHA;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Women;30 CASTILLA - LA MANCHA;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Both sexes;458 CASTILLA - LA MANCHA;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Men;228 CASTILLA - LA MANCHA;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Women;230 CASTILLA - LA MANCHA;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Both sexes;9,803 CASTILLA - LA MANCHA;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Men;4,670 CASTILLA - LA MANCHA;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Women;5,133 CASTILLA - LA MANCHA;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Both sexes;.. CASTILLA - LA MANCHA;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Men;.. CASTILLA - LA MANCHA;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Women;.. CASTILLA - LA MANCHA;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Both sexes;.. CASTILLA - LA MANCHA;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Men;.. CASTILLA - LA MANCHA;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Women;.. CASTILLA - LA MANCHA;Group 1303 Internal derangement of knee 717;Both sexes;899 CASTILLA - LA MANCHA;Group 1303 Internal derangement of knee 717;Men;620 CASTILLA - LA MANCHA;Group 1303 Internal derangement of knee 717;Women;279 CASTILLA - LA MANCHA;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Both sexes;4,333 CASTILLA - LA MANCHA;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Men;1,924 CASTILLA - LA MANCHA;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Women;2,409 CASTILLA - LA MANCHA;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Both sexes;168 CASTILLA - LA MANCHA;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Men;67 CASTILLA - LA MANCHA;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Women;101 CASTILLA - LA MANCHA;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Both sexes;499 CASTILLA - LA MANCHA;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Men;251 CASTILLA - LA MANCHA;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Women;248 CASTILLA - LA MANCHA;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Both sexes;823 CASTILLA - LA MANCHA;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Men;440 CASTILLA - LA MANCHA;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Women;383 CASTILLA - LA MANCHA;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Both sexes;176 CASTILLA - LA MANCHA;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Men;82 CASTILLA - LA MANCHA;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Women;94 CASTILLA - LA MANCHA;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Both sexes;1,286 CASTILLA - LA MANCHA;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Men;686 CASTILLA - LA MANCHA;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Women;600 CASTILLA - LA MANCHA;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Both sexes;1,619 CASTILLA - LA MANCHA;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Men;600 CASTILLA - LA MANCHA;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Women;1,019 CASTILLA - LA MANCHA;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Both sexes;10,931 CASTILLA - LA MANCHA;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Men;5,013 CASTILLA - LA MANCHA;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Women;5,918 CASTILLA - LA MANCHA;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Both sexes;1,024 CASTILLA - LA MANCHA;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Men;370 CASTILLA - LA MANCHA;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Women;654 CASTILLA - LA MANCHA;Group 1402 Renal failure 5836-5837, 584-586;Both sexes;1,043 CASTILLA - LA MANCHA;Group 1402 Renal failure 5836-5837, 584-586;Men;568 CASTILLA - LA MANCHA;Group 1402 Renal failure 5836-5837, 584-586;Women;475 CASTILLA - LA MANCHA;Group 1403 Urolithiasis 592, 594, 7880;Both sexes;1,432 CASTILLA - LA MANCHA;Group 1403 Urolithiasis 592, 594, 7880;Men;820 CASTILLA - LA MANCHA;Group 1403 Urolithiasis 592, 594, 7880;Women;612 CASTILLA - LA MANCHA;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Both sexes;3,326 CASTILLA - LA MANCHA;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Men;1,628 CASTILLA - LA MANCHA;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Women;1,698 CASTILLA - LA MANCHA;Group 1405 Prostatic hyperplasia 600;Both sexes;712 CASTILLA - LA MANCHA;Group 1405 Prostatic hyperplasia 600;Men;712 CASTILLA - LA MANCHA;Group 1405 Prostatic hyperplasia 600;Women;.. CASTILLA - LA MANCHA;Group 1406 Other diseases of the male genital organs 601-608;Both sexes;867 CASTILLA - LA MANCHA;Group 1406 Other diseases of the male genital organs 601-608;Men;867 CASTILLA - LA MANCHA;Group 1406 Other diseases of the male genital organs 601-608;Women;.. CASTILLA - LA MANCHA;Group 1407 Disorders of breast 610-612;Both sexes;376 CASTILLA - LA MANCHA;Group 1407 Disorders of breast 610-612;Men;42 CASTILLA - LA MANCHA;Group 1407 Disorders of breast 610-612;Women;334 CASTILLA - LA MANCHA;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Both sexes;279 CASTILLA - LA MANCHA;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Men;.. CASTILLA - LA MANCHA;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Women;279 CASTILLA - LA MANCHA;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Both sexes;219 CASTILLA - LA MANCHA;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Men;.. CASTILLA - LA MANCHA;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Women;219 CASTILLA - LA MANCHA;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Both sexes;1,653 CASTILLA - LA MANCHA;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Men;6 CASTILLA - LA MANCHA;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Women;1,647 CASTILLA - LA MANCHA;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Both sexes;20,129 CASTILLA - LA MANCHA;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Men;.. CASTILLA - LA MANCHA;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Women;20,129 CASTILLA - LA MANCHA;Group 1501 Legally induced abortion 635;Both sexes;20 CASTILLA - LA MANCHA;Group 1501 Legally induced abortion 635;Men;.. CASTILLA - LA MANCHA;Group 1501 Legally induced abortion 635;Women;20 CASTILLA - LA MANCHA;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Both sexes;1,818 CASTILLA - LA MANCHA;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Men;.. CASTILLA - LA MANCHA;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Women;1,818 CASTILLA - LA MANCHA;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Both sexes;12,201 CASTILLA - LA MANCHA;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Men;.. CASTILLA - LA MANCHA;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Women;12,201 CASTILLA - LA MANCHA;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Both sexes;2,692 CASTILLA - LA MANCHA;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Men;.. CASTILLA - LA MANCHA;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Women;2,692 CASTILLA - LA MANCHA;Group 1505 Single spontaneous delivery 650;Both sexes;1,332 CASTILLA - LA MANCHA;Group 1505 Single spontaneous delivery 650;Men;.. CASTILLA - LA MANCHA;Group 1505 Single spontaneous delivery 650;Women;1,332 CASTILLA - LA MANCHA;Group 1506 Other deliveries 6695-6697;Both sexes;768 CASTILLA - LA MANCHA;Group 1506 Other deliveries 6695-6697;Men;.. CASTILLA - LA MANCHA;Group 1506 Other deliveries 6695-6697;Women;768 CASTILLA - LA MANCHA;Group 1507 Complications related to the puerperium 670-676;Both sexes;130 CASTILLA - LA MANCHA;Group 1507 Complications related to the puerperium 670-676;Men;.. CASTILLA - LA MANCHA;Group 1507 Complications related to the puerperium 670-676;Women;130 CASTILLA - LA MANCHA;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Both sexes;1,168 CASTILLA - LA MANCHA;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Men;.. CASTILLA - LA MANCHA;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Women;1,168 CASTILLA - LA MANCHA;Group 1600 Some disorders originating in the perinatal period 760-779;Both sexes;3,013 CASTILLA - LA MANCHA;Group 1600 Some disorders originating in the perinatal period 760-779;Men;1,633 CASTILLA - LA MANCHA;Group 1600 Some disorders originating in the perinatal period 760-779;Women;1,380 CASTILLA - LA MANCHA;Group 1601 Disorders related with premature delivery and a low birth weight 765;Both sexes;766 CASTILLA - LA MANCHA;Group 1601 Disorders related with premature delivery and a low birth weight 765;Men;394 CASTILLA - LA MANCHA;Group 1601 Disorders related with premature delivery and a low birth weight 765;Women;372 CASTILLA - LA MANCHA;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Both sexes;2,247 CASTILLA - LA MANCHA;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Men;1,239 CASTILLA - LA MANCHA;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Women;1,008 CASTILLA - LA MANCHA;Grupo 1700 Congenital abnormalities 740-759;Both sexes;1,107 CASTILLA - LA MANCHA;Grupo 1700 Congenital abnormalities 740-759;Men;640 CASTILLA - LA MANCHA;Grupo 1700 Congenital abnormalities 740-759;Women;467 CASTILLA - LA MANCHA;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Both sexes;7,516 CASTILLA - LA MANCHA;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Men;3,996 CASTILLA - LA MANCHA;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Women;3,520 CASTILLA - LA MANCHA;Group 1801 Pain in throat and chest 7841, 7865;Both sexes;876 CASTILLA - LA MANCHA;Group 1801 Pain in throat and chest 7841, 7865;Men;490 CASTILLA - LA MANCHA;Group 1801 Pain in throat and chest 7841, 7865;Women;386 CASTILLA - LA MANCHA;Group 1802 Abdominal pain 7890;Both sexes;882 CASTILLA - LA MANCHA;Group 1802 Abdominal pain 7890;Men;358 CASTILLA - LA MANCHA;Group 1802 Abdominal pain 7890;Women;524 CASTILLA - LA MANCHA;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Both sexes;673 CASTILLA - LA MANCHA;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Men;307 CASTILLA - LA MANCHA;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Women;366 CASTILLA - LA MANCHA;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Both sexes;5,085 CASTILLA - LA MANCHA;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Men;2,841 CASTILLA - LA MANCHA;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Women;2,244 CASTILLA - LA MANCHA;Group 1900 Injuries and poisoning 800-999;Both sexes;14,491 CASTILLA - LA MANCHA;Group 1900 Injuries and poisoning 800-999;Men;7,291 CASTILLA - LA MANCHA;Group 1900 Injuries and poisoning 800-999;Women;7,200 CASTILLA - LA MANCHA;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Both sexes;848 CASTILLA - LA MANCHA;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Men;500 CASTILLA - LA MANCHA;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Women;348 CASTILLA - LA MANCHA;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Both sexes;347 CASTILLA - LA MANCHA;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Men;273 CASTILLA - LA MANCHA;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Women;74 CASTILLA - LA MANCHA;Group 1903 Radius and ulna fracture 813;Both sexes;791 CASTILLA - LA MANCHA;Group 1903 Radius and ulna fracture 813;Men;358 CASTILLA - LA MANCHA;Group 1903 Radius and ulna fracture 813;Women;433 CASTILLA - LA MANCHA;Group 1904 Femur fracture 820-821;Both sexes;3,026 CASTILLA - LA MANCHA;Group 1904 Femur fracture 820-821;Men;853 CASTILLA - LA MANCHA;Group 1904 Femur fracture 820-821;Women;2,173 CASTILLA - LA MANCHA;Group 1905 Leg fracture, including the ankle 823-824;Both sexes;1,082 CASTILLA - LA MANCHA;Group 1905 Leg fracture, including the ankle 823-824;Men;580 CASTILLA - LA MANCHA;Group 1905 Leg fracture, including the ankle 823-824;Women;502 CASTILLA - LA MANCHA;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Both sexes;3,899 CASTILLA - LA MANCHA;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Men;2,403 CASTILLA - LA MANCHA;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Women;1,496 CASTILLA - LA MANCHA;Group 1907 Burns 940-949;Both sexes;45 CASTILLA - LA MANCHA;Group 1907 Burns 940-949;Men;38 CASTILLA - LA MANCHA;Group 1907 Burns 940-949;Women;7 CASTILLA - LA MANCHA;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Both sexes;428 CASTILLA - LA MANCHA;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Men;192 CASTILLA - LA MANCHA;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Women;236 CASTILLA - LA MANCHA;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Both sexes;3,467 CASTILLA - LA MANCHA;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Men;1,823 CASTILLA - LA MANCHA;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Women;1,644 CASTILLA - LA MANCHA;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Both sexes;14 CASTILLA - LA MANCHA;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Men;8 CASTILLA - LA MANCHA;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Women;6 CASTILLA - LA MANCHA;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Both sexes;544 CASTILLA - LA MANCHA;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Men;263 CASTILLA - LA MANCHA;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Women;281 CASTILLA - LA MANCHA;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Both sexes;2,871 CASTILLA - LA MANCHA;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Men;1,606 CASTILLA - LA MANCHA;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Women;1,265 CASTILLA - LA MANCHA;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Both sexes;182 CASTILLA - LA MANCHA;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Men;120 CASTILLA - LA MANCHA;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Women;62 CASTILLA - LA MANCHA;Group 2102 Contraceptive management V25;Both sexes;55 CASTILLA - LA MANCHA;Group 2102 Contraceptive management V25;Men;8 CASTILLA - LA MANCHA;Group 2102 Contraceptive management V25;Women;47 CASTILLA - LA MANCHA;Group 2103 Living newborns by type of delivery V30-V39;Both sexes;.. CASTILLA - LA MANCHA;Group 2103 Living newborns by type of delivery V30-V39;Men;.. CASTILLA - LA MANCHA;Group 2103 Living newborns by type of delivery V30-V39;Women;.. CASTILLA - LA MANCHA;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Both sexes;1,354 CASTILLA - LA MANCHA;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Men;797 CASTILLA - LA MANCHA;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Women;557 CASTILLA - LA MANCHA;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Both sexes;1,280 CASTILLA - LA MANCHA;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Men;681 CASTILLA - LA MANCHA;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Women;599 Albacete;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Both sexes;38,954 Albacete;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Men;18,255 Albacete;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Women;20,699 Albacete;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Both sexes;893 Albacete;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Men;523 Albacete;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Women;370 Albacete;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Both sexes;124 Albacete;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Men;62 Albacete;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Women;62 Albacete;Group 0102 Imprecise intestinal infections 009;Both sexes;89 Albacete;Group 0102 Imprecise intestinal infections 009;Men;53 Albacete;Group 0102 Imprecise intestinal infections 009;Women;36 Albacete;Group 0103 Tuberculosis 010-018, 137;Both sexes;25 Albacete;Group 0103 Tuberculosis 010-018, 137;Men;16 Albacete;Group 0103 Tuberculosis 010-018, 137;Women;9 Albacete;Group 0104 Septicaemia 038;Both sexes;395 Albacete;Group 0104 Septicaemia 038;Men;235 Albacete;Group 0104 Septicaemia 038;Women;160 Albacete;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Both sexes;19 Albacete;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Men;18 Albacete;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Women;1 Albacete;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Both sexes;241 Albacete;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Men;139 Albacete;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Women;102 Albacete;Group 0200 Neoplasms 140-239;Both sexes;3,337 Albacete;Group 0200 Neoplasms 140-239;Men;1,868 Albacete;Group 0200 Neoplasms 140-239;Women;1,469 Albacete;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Both sexes;331 Albacete;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Men;198 Albacete;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Women;133 Albacete;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Both sexes;307 Albacete;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Men;265 Albacete;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Women;42 Albacete;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Both sexes;71 Albacete;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Men;43 Albacete;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Women;28 Albacete;Group 0204 Malignant neoplasm of breast 174-175;Both sexes;165 Albacete;Group 0204 Malignant neoplasm of breast 174-175;Men;3 Albacete;Group 0204 Malignant neoplasm of breast 174-175;Women;162 Albacete;Group 0205 Malignant neoplasm of uterus 179-180, 182;Both sexes;56 Albacete;Group 0205 Malignant neoplasm of uterus 179-180, 182;Men;.. Albacete;Group 0205 Malignant neoplasm of uterus 179-180, 182;Women;56 Albacete;Group 0206 Malignant neoplasm of ovary 1830;Both sexes;22 Albacete;Group 0206 Malignant neoplasm of ovary 1830;Men;.. Albacete;Group 0206 Malignant neoplasm of ovary 1830;Women;22 Albacete;Group 0207 Malignant neoplasm of prostate 185;Both sexes;86 Albacete;Group 0207 Malignant neoplasm of prostate 185;Men;86 Albacete;Group 0207 Malignant neoplasm of prostate 185;Women;.. Albacete;Group 0208 Malignant neoplasm of bladder 188;Both sexes;328 Albacete;Group 0208 Malignant neoplasm of bladder 188;Men;279 Albacete;Group 0208 Malignant neoplasm of bladder 188;Women;49 Albacete;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Both sexes;1,285 Albacete;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Men;761 Albacete;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Women;524 Albacete;Group 0210 Carcinoma in situ 230-234;Both sexes;50 Albacete;Group 0210 Carcinoma in situ 230-234;Men;20 Albacete;Group 0210 Carcinoma in situ 230-234;Women;30 Albacete;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Both sexes;32 Albacete;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Men;15 Albacete;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Women;17 Albacete;Grupo 0212 Leiomyoma of uterus 218;Both sexes;175 Albacete;Grupo 0212 Leiomyoma of uterus 218;Men;.. Albacete;Grupo 0212 Leiomyoma of uterus 218;Women;175 Albacete;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Both sexes;429 Albacete;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Men;198 Albacete;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Women;231 Albacete;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Both sexes;336 Albacete;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Men;178 Albacete;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Women;158 Albacete;Group 0301 Anaemias 280-285;Both sexes;167 Albacete;Group 0301 Anaemias 280-285;Men;87 Albacete;Group 0301 Anaemias 280-285;Women;80 Albacete;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Both sexes;169 Albacete;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Men;91 Albacete;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Women;78 Albacete;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Both sexes;584 Albacete;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Men;285 Albacete;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Women;299 Albacete;Group 0401 Diabetes mellitus 249-250;Both sexes;209 Albacete;Group 0401 Diabetes mellitus 249-250;Men;136 Albacete;Group 0401 Diabetes mellitus 249-250;Women;73 Albacete;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Both sexes;375 Albacete;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Men;149 Albacete;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Women;226 Albacete;Group 0500 Mental disorders 290-319;Both sexes;835 Albacete;Group 0500 Mental disorders 290-319;Men;367 Albacete;Group 0500 Mental disorders 290-319;Women;468 Albacete;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Both sexes;5 Albacete;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Men;4 Albacete;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Women;1 Albacete;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Both sexes;41 Albacete;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Men;32 Albacete;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Women;9 Albacete;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Both sexes;30 Albacete;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Men;25 Albacete;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Women;5 Albacete;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Both sexes;247 Albacete;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Men;140 Albacete;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Women;107 Albacete;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Both sexes;200 Albacete;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Men;83 Albacete;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Women;117 Albacete;Group 0506 Other mental and behavioural disorders Rest of (290-319);Both sexes;312 Albacete;Group 0506 Other mental and behavioural disorders Rest of (290-319);Men;83 Albacete;Group 0506 Other mental and behavioural disorders Rest of (290-319);Women;229 Albacete;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Both sexes;554 Albacete;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Men;311 Albacete;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Women;243 Albacete;Group 0601 Alzheimer's disease 3310;Both sexes;7 Albacete;Group 0601 Alzheimer's disease 3310;Men;1 Albacete;Group 0601 Alzheimer's disease 3310;Women;6 Albacete;Group 0602 Multiple sclerosis 340;Both sexes;5 Albacete;Group 0602 Multiple sclerosis 340;Men;2 Albacete;Group 0602 Multiple sclerosis 340;Women;3 Albacete;Group 0603 Epilepsy 345;Both sexes;90 Albacete;Group 0603 Epilepsy 345;Men;51 Albacete;Group 0603 Epilepsy 345;Women;39 Albacete;Group 0604 Transient cerebral ischemia 435;Both sexes;135 Albacete;Group 0604 Transient cerebral ischemia 435;Men;73 Albacete;Group 0604 Transient cerebral ischemia 435;Women;62 Albacete;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Both sexes;317 Albacete;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Men;184 Albacete;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Women;133 Albacete;Grupo 0700 Diseases of the eye and adnexa 360-379;Both sexes;234 Albacete;Grupo 0700 Diseases of the eye and adnexa 360-379;Men;130 Albacete;Grupo 0700 Diseases of the eye and adnexa 360-379;Women;104 Albacete;Grupo 0701 Cataract 366;Both sexes;119 Albacete;Grupo 0701 Cataract 366;Men;64 Albacete;Grupo 0701 Cataract 366;Women;55 Albacete;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Both sexes;115 Albacete;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Men;66 Albacete;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Women;49 Albacete;Group 0800 Diseases of the ear and the mastoid 380-389;Both sexes;140 Albacete;Group 0800 Diseases of the ear and the mastoid 380-389;Men;86 Albacete;Group 0800 Diseases of the ear and the mastoid 380-389;Women;54 Albacete;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Both sexes;5,166 Albacete;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Men;2,948 Albacete;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Women;2,218 Albacete;Group 0901 Hypertensive disease 401-405;Both sexes;229 Albacete;Group 0901 Hypertensive disease 401-405;Men;105 Albacete;Group 0901 Hypertensive disease 401-405;Women;124 Albacete;Group 0902 Angina pectoris 4111, 413;Both sexes;211 Albacete;Group 0902 Angina pectoris 4111, 413;Men;122 Albacete;Group 0902 Angina pectoris 4111, 413;Women;89 Albacete;Group 0903 Acute myocardial infarction 410;Both sexes;554 Albacete;Group 0903 Acute myocardial infarction 410;Men;418 Albacete;Group 0903 Acute myocardial infarction 410;Women;136 Albacete;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Both sexes;362 Albacete;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Men;271 Albacete;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Women;91 Albacete;Group 0905 Diseases of the lungs circulation 415-417;Both sexes;206 Albacete;Group 0905 Diseases of the lungs circulation 415-417;Men;108 Albacete;Group 0905 Diseases of the lungs circulation 415-417;Women;98 Albacete;Group 0906 Heart conduction disorders and arrhytmias 426-427;Both sexes;562 Albacete;Group 0906 Heart conduction disorders and arrhytmias 426-427;Men;314 Albacete;Group 0906 Heart conduction disorders and arrhytmias 426-427;Women;248 Albacete;Grupo 0907 Heart failure 428;Both sexes;954 Albacete;Grupo 0907 Heart failure 428;Men;437 Albacete;Grupo 0907 Heart failure 428;Women;517 Albacete;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Both sexes;1,000 Albacete;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Men;541 Albacete;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Women;459 Albacete;Grupo 0909 Atherosclerosis 440;Both sexes;152 Albacete;Grupo 0909 Atherosclerosis 440;Men;118 Albacete;Grupo 0909 Atherosclerosis 440;Women;34 Albacete;Group 0910 Varicose veins of lower extremities 454;Both sexes;68 Albacete;Group 0910 Varicose veins of lower extremities 454;Men;22 Albacete;Group 0910 Varicose veins of lower extremities 454;Women;46 Albacete;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Both sexes;868 Albacete;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Men;492 Albacete;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Women;376 Albacete;Group 1000 Diseases of the respiratory system 0340, 460-519;Both sexes;4,249 Albacete;Group 1000 Diseases of the respiratory system 0340, 460-519;Men;2,458 Albacete;Group 1000 Diseases of the respiratory system 0340, 460-519;Women;1,791 Albacete;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Both sexes;194 Albacete;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Men;114 Albacete;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Women;80 Albacete;Group 1002 Pneumonia 480-486;Both sexes;829 Albacete;Group 1002 Pneumonia 480-486;Men;509 Albacete;Group 1002 Pneumonia 480-486;Women;320 Albacete;Group 1003 Acute bronchitis and bronchiolitis 466;Both sexes;428 Albacete;Group 1003 Acute bronchitis and bronchiolitis 466;Men;216 Albacete;Group 1003 Acute bronchitis and bronchiolitis 466;Women;212 Albacete;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Both sexes;163 Albacete;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Men;77 Albacete;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Women;86 Albacete;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Both sexes;216 Albacete;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Men;134 Albacete;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Women;82 Albacete;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Both sexes;443 Albacete;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Men;346 Albacete;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Women;97 Albacete;Group 1007 Asthma 4930-4931,4938-4939;Both sexes;114 Albacete;Group 1007 Asthma 4930-4931,4938-4939;Men;49 Albacete;Group 1007 Asthma 4930-4931,4938-4939;Women;65 Albacete;Group 1008 Other diseases of the respiratory system Resto of (460-519);Both sexes;1,862 Albacete;Group 1008 Other diseases of the respiratory system Resto of (460-519);Men;1,013 Albacete;Group 1008 Other diseases of the respiratory system Resto of (460-519);Women;849 Albacete;Group 1100 Diseases of the digestive system 520-579;Both sexes;4,530 Albacete;Group 1100 Diseases of the digestive system 520-579;Men;2,543 Albacete;Group 1100 Diseases of the digestive system 520-579;Women;1,987 Albacete;Group 1101 Disorders of the teeth and supporting structures 520-525;Both sexes;32 Albacete;Group 1101 Disorders of the teeth and supporting structures 520-525;Men;16 Albacete;Group 1101 Disorders of the teeth and supporting structures 520-525;Women;16 Albacete;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Both sexes;61 Albacete;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Men;39 Albacete;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Women;22 Albacete;Group 1103 Diseases of the esophagus 530;Both sexes;98 Albacete;Group 1103 Diseases of the esophagus 530;Men;66 Albacete;Group 1103 Diseases of the esophagus 530;Women;32 Albacete;Group 1104 Peptic ulcer 531-534;Both sexes;152 Albacete;Group 1104 Peptic ulcer 531-534;Men;96 Albacete;Group 1104 Peptic ulcer 531-534;Women;56 Albacete;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Both sexes;111 Albacete;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Men;68 Albacete;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Women;43 Albacete;Group 1106 Appendicitis 540-543;Both sexes;413 Albacete;Group 1106 Appendicitis 540-543;Men;272 Albacete;Group 1106 Appendicitis 540-543;Women;141 Albacete;Group 1107 Inguinal hernia 550;Both sexes;247 Albacete;Group 1107 Inguinal hernia 550;Men;218 Albacete;Group 1107 Inguinal hernia 550;Women;29 Albacete;Group 1108 Other abdominal hernia 551-553;Both sexes;271 Albacete;Group 1108 Other abdominal hernia 551-553;Men;116 Albacete;Group 1108 Other abdominal hernia 551-553;Women;155 Albacete;Group 1109 Crohn's disease and ulcerative colitis 555-556;Both sexes;79 Albacete;Group 1109 Crohn's disease and ulcerative colitis 555-556;Men;45 Albacete;Group 1109 Crohn's disease and ulcerative colitis 555-556;Women;34 Albacete;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Both sexes;213 Albacete;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Men;102 Albacete;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Women;111 Albacete;Group 1111 Intestinal obstruction without hernia 560;Both sexes;283 Albacete;Group 1111 Intestinal obstruction without hernia 560;Men;148 Albacete;Group 1111 Intestinal obstruction without hernia 560;Women;135 Albacete;Group 1112 Intestinal diverticulosis 562;Both sexes;148 Albacete;Group 1112 Intestinal diverticulosis 562;Men;73 Albacete;Group 1112 Intestinal diverticulosis 562;Women;75 Albacete;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Both sexes;312 Albacete;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Men;184 Albacete;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Women;128 Albacete;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Both sexes;134 Albacete;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Men;61 Albacete;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Women;73 Albacete;Group 1115 Alcoholic hepatitis 5710-5713;Both sexes;57 Albacete;Group 1115 Alcoholic hepatitis 5710-5713;Men;49 Albacete;Group 1115 Alcoholic hepatitis 5710-5713;Women;8 Albacete;Group 1116 Other diseases of the liver 570,5714-573;Both sexes;171 Albacete;Group 1116 Other diseases of the liver 570,5714-573;Men;114 Albacete;Group 1116 Other diseases of the liver 570,5714-573;Women;57 Albacete;Group 1117 Cholelithiasis 574;Both sexes;905 Albacete;Group 1117 Cholelithiasis 574;Men;406 Albacete;Group 1117 Cholelithiasis 574;Women;499 Albacete;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Both sexes;339 Albacete;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Men;182 Albacete;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Women;157 Albacete;Group 1119 Pancreatic diseases 577;Both sexes;295 Albacete;Group 1119 Pancreatic diseases 577;Men;152 Albacete;Group 1119 Pancreatic diseases 577;Women;143 Albacete;Group 1120 Other diseases of the digestive system Rest of (520-579);Both sexes;209 Albacete;Group 1120 Other diseases of the digestive system Rest of (520-579);Men;136 Albacete;Group 1120 Other diseases of the digestive system Rest of (520-579);Women;73 Albacete;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Both sexes;303 Albacete;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Men;165 Albacete;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Women;138 Albacete;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Both sexes;169 Albacete;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Men;100 Albacete;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Women;69 Albacete;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Both sexes;13 Albacete;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Men;6 Albacete;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Women;7 Albacete;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Both sexes;121 Albacete;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Men;59 Albacete;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Women;62 Albacete;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Both sexes;2,172 Albacete;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Men;1,091 Albacete;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Women;1,081 Albacete;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Both sexes;.. Albacete;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Men;.. Albacete;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Women;.. Albacete;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Both sexes;.. Albacete;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Men;.. Albacete;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Women;.. Albacete;Group 1303 Internal derangement of knee 717;Both sexes;74 Albacete;Group 1303 Internal derangement of knee 717;Men;54 Albacete;Group 1303 Internal derangement of knee 717;Women;20 Albacete;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Both sexes;1,069 Albacete;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Men;486 Albacete;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Women;583 Albacete;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Both sexes;30 Albacete;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Men;10 Albacete;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Women;20 Albacete;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Both sexes;139 Albacete;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Men;63 Albacete;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Women;76 Albacete;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Both sexes;290 Albacete;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Men;158 Albacete;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Women;132 Albacete;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Both sexes;31 Albacete;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Men;13 Albacete;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Women;18 Albacete;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Both sexes;256 Albacete;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Men;157 Albacete;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Women;99 Albacete;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Both sexes;283 Albacete;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Men;150 Albacete;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Women;133 Albacete;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Both sexes;2,785 Albacete;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Men;1,206 Albacete;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Women;1,579 Albacete;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Both sexes;190 Albacete;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Men;75 Albacete;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Women;115 Albacete;Group 1402 Renal failure 5836-5837, 584-586;Both sexes;215 Albacete;Group 1402 Renal failure 5836-5837, 584-586;Men;101 Albacete;Group 1402 Renal failure 5836-5837, 584-586;Women;114 Albacete;Group 1403 Urolithiasis 592, 594, 7880;Both sexes;496 Albacete;Group 1403 Urolithiasis 592, 594, 7880;Men;274 Albacete;Group 1403 Urolithiasis 592, 594, 7880;Women;222 Albacete;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Both sexes;872 Albacete;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Men;407 Albacete;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Women;465 Albacete;Group 1405 Prostatic hyperplasia 600;Both sexes;174 Albacete;Group 1405 Prostatic hyperplasia 600;Men;174 Albacete;Group 1405 Prostatic hyperplasia 600;Women;.. Albacete;Group 1406 Other diseases of the male genital organs 601-608;Both sexes;165 Albacete;Group 1406 Other diseases of the male genital organs 601-608;Men;165 Albacete;Group 1406 Other diseases of the male genital organs 601-608;Women;.. Albacete;Group 1407 Disorders of breast 610-612;Both sexes;107 Albacete;Group 1407 Disorders of breast 610-612;Men;5 Albacete;Group 1407 Disorders of breast 610-612;Women;102 Albacete;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Both sexes;71 Albacete;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Men;.. Albacete;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Women;71 Albacete;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Both sexes;33 Albacete;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Men;.. Albacete;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Women;33 Albacete;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Both sexes;462 Albacete;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Men;5 Albacete;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Women;457 Albacete;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Both sexes;5,152 Albacete;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Men;.. Albacete;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Women;5,152 Albacete;Group 1501 Legally induced abortion 635;Both sexes;19 Albacete;Group 1501 Legally induced abortion 635;Men;.. Albacete;Group 1501 Legally induced abortion 635;Women;19 Albacete;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Both sexes;535 Albacete;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Men;.. Albacete;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Women;535 Albacete;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Both sexes;2,499 Albacete;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Men;.. Albacete;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Women;2,499 Albacete;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Both sexes;992 Albacete;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Men;.. Albacete;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Women;992 Albacete;Group 1505 Single spontaneous delivery 650;Both sexes;584 Albacete;Group 1505 Single spontaneous delivery 650;Men;.. Albacete;Group 1505 Single spontaneous delivery 650;Women;584 Albacete;Group 1506 Other deliveries 6695-6697;Both sexes;328 Albacete;Group 1506 Other deliveries 6695-6697;Men;.. Albacete;Group 1506 Other deliveries 6695-6697;Women;328 Albacete;Group 1507 Complications related to the puerperium 670-676;Both sexes;32 Albacete;Group 1507 Complications related to the puerperium 670-676;Men;.. Albacete;Group 1507 Complications related to the puerperium 670-676;Women;32 Albacete;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Both sexes;163 Albacete;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Men;.. Albacete;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Women;163 Albacete;Group 1600 Some disorders originating in the perinatal period 760-779;Both sexes;643 Albacete;Group 1600 Some disorders originating in the perinatal period 760-779;Men;361 Albacete;Group 1600 Some disorders originating in the perinatal period 760-779;Women;282 Albacete;Group 1601 Disorders related with premature delivery and a low birth weight 765;Both sexes;188 Albacete;Group 1601 Disorders related with premature delivery and a low birth weight 765;Men;101 Albacete;Group 1601 Disorders related with premature delivery and a low birth weight 765;Women;87 Albacete;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Both sexes;455 Albacete;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Men;260 Albacete;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Women;195 Albacete;Grupo 1700 Congenital abnormalities 740-759;Both sexes;358 Albacete;Grupo 1700 Congenital abnormalities 740-759;Men;212 Albacete;Grupo 1700 Congenital abnormalities 740-759;Women;146 Albacete;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Both sexes;2,204 Albacete;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Men;1,158 Albacete;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Women;1,046 Albacete;Group 1801 Pain in throat and chest 7841, 7865;Both sexes;173 Albacete;Group 1801 Pain in throat and chest 7841, 7865;Men;98 Albacete;Group 1801 Pain in throat and chest 7841, 7865;Women;75 Albacete;Group 1802 Abdominal pain 7890;Both sexes;281 Albacete;Group 1802 Abdominal pain 7890;Men;117 Albacete;Group 1802 Abdominal pain 7890;Women;164 Albacete;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Both sexes;614 Albacete;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Men;281 Albacete;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Women;333 Albacete;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Both sexes;1,136 Albacete;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Men;662 Albacete;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Women;474 Albacete;Group 1900 Injuries and poisoning 800-999;Both sexes;3,603 Albacete;Group 1900 Injuries and poisoning 800-999;Men;1,905 Albacete;Group 1900 Injuries and poisoning 800-999;Women;1,698 Albacete;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Both sexes;217 Albacete;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Men;132 Albacete;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Women;85 Albacete;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Both sexes;75 Albacete;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Men;66 Albacete;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Women;9 Albacete;Group 1903 Radius and ulna fracture 813;Both sexes;190 Albacete;Group 1903 Radius and ulna fracture 813;Men;98 Albacete;Group 1903 Radius and ulna fracture 813;Women;92 Albacete;Group 1904 Femur fracture 820-821;Both sexes;666 Albacete;Group 1904 Femur fracture 820-821;Men;206 Albacete;Group 1904 Femur fracture 820-821;Women;460 Albacete;Group 1905 Leg fracture, including the ankle 823-824;Both sexes;240 Albacete;Group 1905 Leg fracture, including the ankle 823-824;Men;134 Albacete;Group 1905 Leg fracture, including the ankle 823-824;Women;106 Albacete;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Both sexes;975 Albacete;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Men;625 Albacete;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Women;350 Albacete;Group 1907 Burns 940-949;Both sexes;23 Albacete;Group 1907 Burns 940-949;Men;22 Albacete;Group 1907 Burns 940-949;Women;1 Albacete;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Both sexes;92 Albacete;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Men;45 Albacete;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Women;47 Albacete;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Both sexes;937 Albacete;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Men;484 Albacete;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Women;453 Albacete;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Both sexes;5 Albacete;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Men;4 Albacete;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Women;1 Albacete;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Both sexes;183 Albacete;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Men;89 Albacete;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Women;94 Albacete;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Both sexes;876 Albacete;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Men;460 Albacete;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Women;416 Albacete;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Both sexes;80 Albacete;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Men;58 Albacete;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Women;22 Albacete;Group 2102 Contraceptive management V25;Both sexes;7 Albacete;Group 2102 Contraceptive management V25;Men;.. Albacete;Group 2102 Contraceptive management V25;Women;7 Albacete;Group 2103 Living newborns by type of delivery V30-V39;Both sexes;.. Albacete;Group 2103 Living newborns by type of delivery V30-V39;Men;.. Albacete;Group 2103 Living newborns by type of delivery V30-V39;Women;.. Albacete;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Both sexes;459 Albacete;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Men;261 Albacete;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Women;198 Albacete;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Both sexes;330 Albacete;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Men;141 Albacete;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Women;189 Ciudad Real;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Both sexes;52,510 Ciudad Real;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Men;24,298 Ciudad Real;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Women;28,212 Ciudad Real;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Both sexes;1,210 Ciudad Real;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Men;667 Ciudad Real;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Women;543 Ciudad Real;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Both sexes;329 Ciudad Real;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Men;180 Ciudad Real;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Women;149 Ciudad Real;Group 0102 Imprecise intestinal infections 009;Both sexes;21 Ciudad Real;Group 0102 Imprecise intestinal infections 009;Men;8 Ciudad Real;Group 0102 Imprecise intestinal infections 009;Women;13 Ciudad Real;Group 0103 Tuberculosis 010-018, 137;Both sexes;24 Ciudad Real;Group 0103 Tuberculosis 010-018, 137;Men;18 Ciudad Real;Group 0103 Tuberculosis 010-018, 137;Women;6 Ciudad Real;Group 0104 Septicaemia 038;Both sexes;433 Ciudad Real;Group 0104 Septicaemia 038;Men;223 Ciudad Real;Group 0104 Septicaemia 038;Women;210 Ciudad Real;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Both sexes;26 Ciudad Real;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Men;24 Ciudad Real;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Women;2 Ciudad Real;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Both sexes;377 Ciudad Real;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Men;214 Ciudad Real;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Women;163 Ciudad Real;Group 0200 Neoplasms 140-239;Both sexes;5,109 Ciudad Real;Group 0200 Neoplasms 140-239;Men;2,762 Ciudad Real;Group 0200 Neoplasms 140-239;Women;2,347 Ciudad Real;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Both sexes;545 Ciudad Real;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Men;325 Ciudad Real;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Women;220 Ciudad Real;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Both sexes;475 Ciudad Real;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Men;410 Ciudad Real;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Women;65 Ciudad Real;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Both sexes;78 Ciudad Real;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Men;47 Ciudad Real;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Women;31 Ciudad Real;Group 0204 Malignant neoplasm of breast 174-175;Both sexes;383 Ciudad Real;Group 0204 Malignant neoplasm of breast 174-175;Men;8 Ciudad Real;Group 0204 Malignant neoplasm of breast 174-175;Women;375 Ciudad Real;Group 0205 Malignant neoplasm of uterus 179-180, 182;Both sexes;117 Ciudad Real;Group 0205 Malignant neoplasm of uterus 179-180, 182;Men;.. Ciudad Real;Group 0205 Malignant neoplasm of uterus 179-180, 182;Women;117 Ciudad Real;Group 0206 Malignant neoplasm of ovary 1830;Both sexes;54 Ciudad Real;Group 0206 Malignant neoplasm of ovary 1830;Men;.. Ciudad Real;Group 0206 Malignant neoplasm of ovary 1830;Women;54 Ciudad Real;Group 0207 Malignant neoplasm of prostate 185;Both sexes;167 Ciudad Real;Group 0207 Malignant neoplasm of prostate 185;Men;167 Ciudad Real;Group 0207 Malignant neoplasm of prostate 185;Women;.. Ciudad Real;Group 0208 Malignant neoplasm of bladder 188;Both sexes;479 Ciudad Real;Group 0208 Malignant neoplasm of bladder 188;Men;417 Ciudad Real;Group 0208 Malignant neoplasm of bladder 188;Women;62 Ciudad Real;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Both sexes;1,799 Ciudad Real;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Men;1,033 Ciudad Real;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Women;766 Ciudad Real;Group 0210 Carcinoma in situ 230-234;Both sexes;38 Ciudad Real;Group 0210 Carcinoma in situ 230-234;Men;20 Ciudad Real;Group 0210 Carcinoma in situ 230-234;Women;18 Ciudad Real;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Both sexes;91 Ciudad Real;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Men;56 Ciudad Real;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Women;35 Ciudad Real;Grupo 0212 Leiomyoma of uterus 218;Both sexes;252 Ciudad Real;Grupo 0212 Leiomyoma of uterus 218;Men;.. Ciudad Real;Grupo 0212 Leiomyoma of uterus 218;Women;252 Ciudad Real;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Both sexes;631 Ciudad Real;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Men;279 Ciudad Real;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Women;352 Ciudad Real;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Both sexes;461 Ciudad Real;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Men;227 Ciudad Real;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Women;234 Ciudad Real;Group 0301 Anaemias 280-285;Both sexes;269 Ciudad Real;Group 0301 Anaemias 280-285;Men;131 Ciudad Real;Group 0301 Anaemias 280-285;Women;138 Ciudad Real;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Both sexes;192 Ciudad Real;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Men;96 Ciudad Real;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Women;96 Ciudad Real;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Both sexes;779 Ciudad Real;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Men;284 Ciudad Real;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Women;495 Ciudad Real;Group 0401 Diabetes mellitus 249-250;Both sexes;269 Ciudad Real;Group 0401 Diabetes mellitus 249-250;Men;136 Ciudad Real;Group 0401 Diabetes mellitus 249-250;Women;133 Ciudad Real;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Both sexes;510 Ciudad Real;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Men;148 Ciudad Real;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Women;362 Ciudad Real;Group 0500 Mental disorders 290-319;Both sexes;1,027 Ciudad Real;Group 0500 Mental disorders 290-319;Men;511 Ciudad Real;Group 0500 Mental disorders 290-319;Women;516 Ciudad Real;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Both sexes;24 Ciudad Real;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Men;15 Ciudad Real;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Women;9 Ciudad Real;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Both sexes;30 Ciudad Real;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Men;24 Ciudad Real;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Women;6 Ciudad Real;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Both sexes;36 Ciudad Real;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Men;27 Ciudad Real;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Women;9 Ciudad Real;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Both sexes;205 Ciudad Real;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Men;131 Ciudad Real;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Women;74 Ciudad Real;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Both sexes;211 Ciudad Real;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Men;95 Ciudad Real;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Women;116 Ciudad Real;Group 0506 Other mental and behavioural disorders Rest of (290-319);Both sexes;521 Ciudad Real;Group 0506 Other mental and behavioural disorders Rest of (290-319);Men;219 Ciudad Real;Group 0506 Other mental and behavioural disorders Rest of (290-319);Women;302 Ciudad Real;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Both sexes;1,367 Ciudad Real;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Men;668 Ciudad Real;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Women;699 Ciudad Real;Group 0601 Alzheimer's disease 3310;Both sexes;31 Ciudad Real;Group 0601 Alzheimer's disease 3310;Men;11 Ciudad Real;Group 0601 Alzheimer's disease 3310;Women;20 Ciudad Real;Group 0602 Multiple sclerosis 340;Both sexes;49 Ciudad Real;Group 0602 Multiple sclerosis 340;Men;13 Ciudad Real;Group 0602 Multiple sclerosis 340;Women;36 Ciudad Real;Group 0603 Epilepsy 345;Both sexes;139 Ciudad Real;Group 0603 Epilepsy 345;Men;75 Ciudad Real;Group 0603 Epilepsy 345;Women;64 Ciudad Real;Group 0604 Transient cerebral ischemia 435;Both sexes;208 Ciudad Real;Group 0604 Transient cerebral ischemia 435;Men;110 Ciudad Real;Group 0604 Transient cerebral ischemia 435;Women;98 Ciudad Real;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Both sexes;940 Ciudad Real;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Men;459 Ciudad Real;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Women;481 Ciudad Real;Grupo 0700 Diseases of the eye and adnexa 360-379;Both sexes;335 Ciudad Real;Grupo 0700 Diseases of the eye and adnexa 360-379;Men;199 Ciudad Real;Grupo 0700 Diseases of the eye and adnexa 360-379;Women;136 Ciudad Real;Grupo 0701 Cataract 366;Both sexes;27 Ciudad Real;Grupo 0701 Cataract 366;Men;14 Ciudad Real;Grupo 0701 Cataract 366;Women;13 Ciudad Real;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Both sexes;308 Ciudad Real;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Men;185 Ciudad Real;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Women;123 Ciudad Real;Group 0800 Diseases of the ear and the mastoid 380-389;Both sexes;262 Ciudad Real;Group 0800 Diseases of the ear and the mastoid 380-389;Men;134 Ciudad Real;Group 0800 Diseases of the ear and the mastoid 380-389;Women;128 Ciudad Real;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Both sexes;6,800 Ciudad Real;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Men;3,647 Ciudad Real;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Women;3,153 Ciudad Real;Group 0901 Hypertensive disease 401-405;Both sexes;268 Ciudad Real;Group 0901 Hypertensive disease 401-405;Men;100 Ciudad Real;Group 0901 Hypertensive disease 401-405;Women;168 Ciudad Real;Group 0902 Angina pectoris 4111, 413;Both sexes;457 Ciudad Real;Group 0902 Angina pectoris 4111, 413;Men;278 Ciudad Real;Group 0902 Angina pectoris 4111, 413;Women;179 Ciudad Real;Group 0903 Acute myocardial infarction 410;Both sexes;642 Ciudad Real;Group 0903 Acute myocardial infarction 410;Men;459 Ciudad Real;Group 0903 Acute myocardial infarction 410;Women;183 Ciudad Real;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Both sexes;442 Ciudad Real;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Men;350 Ciudad Real;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Women;92 Ciudad Real;Group 0905 Diseases of the lungs circulation 415-417;Both sexes;263 Ciudad Real;Group 0905 Diseases of the lungs circulation 415-417;Men;115 Ciudad Real;Group 0905 Diseases of the lungs circulation 415-417;Women;148 Ciudad Real;Group 0906 Heart conduction disorders and arrhytmias 426-427;Both sexes;865 Ciudad Real;Group 0906 Heart conduction disorders and arrhytmias 426-427;Men;453 Ciudad Real;Group 0906 Heart conduction disorders and arrhytmias 426-427;Women;412 Ciudad Real;Grupo 0907 Heart failure 428;Both sexes;1,447 Ciudad Real;Grupo 0907 Heart failure 428;Men;581 Ciudad Real;Grupo 0907 Heart failure 428;Women;866 Ciudad Real;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Both sexes;1,131 Ciudad Real;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Men;622 Ciudad Real;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Women;509 Ciudad Real;Grupo 0909 Atherosclerosis 440;Both sexes;295 Ciudad Real;Grupo 0909 Atherosclerosis 440;Men;207 Ciudad Real;Grupo 0909 Atherosclerosis 440;Women;88 Ciudad Real;Group 0910 Varicose veins of lower extremities 454;Both sexes;71 Ciudad Real;Group 0910 Varicose veins of lower extremities 454;Men;24 Ciudad Real;Group 0910 Varicose veins of lower extremities 454;Women;47 Ciudad Real;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Both sexes;919 Ciudad Real;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Men;458 Ciudad Real;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Women;461 Ciudad Real;Group 1000 Diseases of the respiratory system 0340, 460-519;Both sexes;6,766 Ciudad Real;Group 1000 Diseases of the respiratory system 0340, 460-519;Men;3,975 Ciudad Real;Group 1000 Diseases of the respiratory system 0340, 460-519;Women;2,791 Ciudad Real;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Both sexes;247 Ciudad Real;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Men;140 Ciudad Real;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Women;107 Ciudad Real;Group 1002 Pneumonia 480-486;Both sexes;1,387 Ciudad Real;Group 1002 Pneumonia 480-486;Men;875 Ciudad Real;Group 1002 Pneumonia 480-486;Women;512 Ciudad Real;Group 1003 Acute bronchitis and bronchiolitis 466;Both sexes;566 Ciudad Real;Group 1003 Acute bronchitis and bronchiolitis 466;Men;234 Ciudad Real;Group 1003 Acute bronchitis and bronchiolitis 466;Women;332 Ciudad Real;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Both sexes;301 Ciudad Real;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Men;150 Ciudad Real;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Women;151 Ciudad Real;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Both sexes;487 Ciudad Real;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Men;320 Ciudad Real;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Women;167 Ciudad Real;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Both sexes;1,186 Ciudad Real;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Men;989 Ciudad Real;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Women;197 Ciudad Real;Group 1007 Asthma 4930-4931,4938-4939;Both sexes;217 Ciudad Real;Group 1007 Asthma 4930-4931,4938-4939;Men;52 Ciudad Real;Group 1007 Asthma 4930-4931,4938-4939;Women;165 Ciudad Real;Group 1008 Other diseases of the respiratory system Resto of (460-519);Both sexes;2,375 Ciudad Real;Group 1008 Other diseases of the respiratory system Resto of (460-519);Men;1,215 Ciudad Real;Group 1008 Other diseases of the respiratory system Resto of (460-519);Women;1,160 Ciudad Real;Group 1100 Diseases of the digestive system 520-579;Both sexes;7,405 Ciudad Real;Group 1100 Diseases of the digestive system 520-579;Men;4,011 Ciudad Real;Group 1100 Diseases of the digestive system 520-579;Women;3,394 Ciudad Real;Group 1101 Disorders of the teeth and supporting structures 520-525;Both sexes;106 Ciudad Real;Group 1101 Disorders of the teeth and supporting structures 520-525;Men;48 Ciudad Real;Group 1101 Disorders of the teeth and supporting structures 520-525;Women;58 Ciudad Real;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Both sexes;112 Ciudad Real;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Men;52 Ciudad Real;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Women;60 Ciudad Real;Group 1103 Diseases of the esophagus 530;Both sexes;175 Ciudad Real;Group 1103 Diseases of the esophagus 530;Men;116 Ciudad Real;Group 1103 Diseases of the esophagus 530;Women;59 Ciudad Real;Group 1104 Peptic ulcer 531-534;Both sexes;170 Ciudad Real;Group 1104 Peptic ulcer 531-534;Men;116 Ciudad Real;Group 1104 Peptic ulcer 531-534;Women;54 Ciudad Real;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Both sexes;200 Ciudad Real;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Men;101 Ciudad Real;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Women;99 Ciudad Real;Group 1106 Appendicitis 540-543;Both sexes;547 Ciudad Real;Group 1106 Appendicitis 540-543;Men;317 Ciudad Real;Group 1106 Appendicitis 540-543;Women;230 Ciudad Real;Group 1107 Inguinal hernia 550;Both sexes;574 Ciudad Real;Group 1107 Inguinal hernia 550;Men;495 Ciudad Real;Group 1107 Inguinal hernia 550;Women;79 Ciudad Real;Group 1108 Other abdominal hernia 551-553;Both sexes;679 Ciudad Real;Group 1108 Other abdominal hernia 551-553;Men;289 Ciudad Real;Group 1108 Other abdominal hernia 551-553;Women;390 Ciudad Real;Group 1109 Crohn's disease and ulcerative colitis 555-556;Both sexes;136 Ciudad Real;Group 1109 Crohn's disease and ulcerative colitis 555-556;Men;72 Ciudad Real;Group 1109 Crohn's disease and ulcerative colitis 555-556;Women;64 Ciudad Real;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Both sexes;352 Ciudad Real;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Men;147 Ciudad Real;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Women;205 Ciudad Real;Group 1111 Intestinal obstruction without hernia 560;Both sexes;388 Ciudad Real;Group 1111 Intestinal obstruction without hernia 560;Men;216 Ciudad Real;Group 1111 Intestinal obstruction without hernia 560;Women;172 Ciudad Real;Group 1112 Intestinal diverticulosis 562;Both sexes;205 Ciudad Real;Group 1112 Intestinal diverticulosis 562;Men;98 Ciudad Real;Group 1112 Intestinal diverticulosis 562;Women;107 Ciudad Real;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Both sexes;336 Ciudad Real;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Men;225 Ciudad Real;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Women;111 Ciudad Real;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Both sexes;262 Ciudad Real;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Men;134 Ciudad Real;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Women;128 Ciudad Real;Group 1115 Alcoholic hepatitis 5710-5713;Both sexes;106 Ciudad Real;Group 1115 Alcoholic hepatitis 5710-5713;Men;100 Ciudad Real;Group 1115 Alcoholic hepatitis 5710-5713;Women;6 Ciudad Real;Group 1116 Other diseases of the liver 570,5714-573;Both sexes;218 Ciudad Real;Group 1116 Other diseases of the liver 570,5714-573;Men;143 Ciudad Real;Group 1116 Other diseases of the liver 570,5714-573;Women;75 Ciudad Real;Group 1117 Cholelithiasis 574;Both sexes;1,678 Ciudad Real;Group 1117 Cholelithiasis 574;Men;697 Ciudad Real;Group 1117 Cholelithiasis 574;Women;981 Ciudad Real;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Both sexes;341 Ciudad Real;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Men;199 Ciudad Real;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Women;142 Ciudad Real;Group 1119 Pancreatic diseases 577;Both sexes;524 Ciudad Real;Group 1119 Pancreatic diseases 577;Men;290 Ciudad Real;Group 1119 Pancreatic diseases 577;Women;234 Ciudad Real;Group 1120 Other diseases of the digestive system Rest of (520-579);Both sexes;296 Ciudad Real;Group 1120 Other diseases of the digestive system Rest of (520-579);Men;156 Ciudad Real;Group 1120 Other diseases of the digestive system Rest of (520-579);Women;140 Ciudad Real;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Both sexes;345 Ciudad Real;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Men;172 Ciudad Real;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Women;173 Ciudad Real;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Both sexes;212 Ciudad Real;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Men;113 Ciudad Real;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Women;99 Ciudad Real;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Both sexes;11 Ciudad Real;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Men;4 Ciudad Real;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Women;7 Ciudad Real;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Both sexes;122 Ciudad Real;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Men;55 Ciudad Real;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Women;67 Ciudad Real;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Both sexes;3,084 Ciudad Real;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Men;1,382 Ciudad Real;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Women;1,702 Ciudad Real;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Both sexes;.. Ciudad Real;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Men;.. Ciudad Real;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Women;.. Ciudad Real;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Both sexes;.. Ciudad Real;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Men;.. Ciudad Real;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Women;.. Ciudad Real;Group 1303 Internal derangement of knee 717;Both sexes;312 Ciudad Real;Group 1303 Internal derangement of knee 717;Men;210 Ciudad Real;Group 1303 Internal derangement of knee 717;Women;102 Ciudad Real;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Both sexes;1,357 Ciudad Real;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Men;585 Ciudad Real;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Women;772 Ciudad Real;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Both sexes;63 Ciudad Real;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Men;24 Ciudad Real;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Women;39 Ciudad Real;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Both sexes;156 Ciudad Real;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Men;79 Ciudad Real;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Women;77 Ciudad Real;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Both sexes;189 Ciudad Real;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Men;99 Ciudad Real;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Women;90 Ciudad Real;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Both sexes;38 Ciudad Real;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Men;15 Ciudad Real;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Women;23 Ciudad Real;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Both sexes;397 Ciudad Real;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Men;199 Ciudad Real;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Women;198 Ciudad Real;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Both sexes;572 Ciudad Real;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Men;171 Ciudad Real;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Women;401 Ciudad Real;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Both sexes;3,336 Ciudad Real;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Men;1,500 Ciudad Real;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Women;1,836 Ciudad Real;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Both sexes;241 Ciudad Real;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Men;89 Ciudad Real;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Women;152 Ciudad Real;Group 1402 Renal failure 5836-5837, 584-586;Both sexes;351 Ciudad Real;Group 1402 Renal failure 5836-5837, 584-586;Men;178 Ciudad Real;Group 1402 Renal failure 5836-5837, 584-586;Women;173 Ciudad Real;Group 1403 Urolithiasis 592, 594, 7880;Both sexes;340 Ciudad Real;Group 1403 Urolithiasis 592, 594, 7880;Men;197 Ciudad Real;Group 1403 Urolithiasis 592, 594, 7880;Women;143 Ciudad Real;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Both sexes;1,053 Ciudad Real;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Men;503 Ciudad Real;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Women;550 Ciudad Real;Group 1405 Prostatic hyperplasia 600;Both sexes;243 Ciudad Real;Group 1405 Prostatic hyperplasia 600;Men;243 Ciudad Real;Group 1405 Prostatic hyperplasia 600;Women;.. Ciudad Real;Group 1406 Other diseases of the male genital organs 601-608;Both sexes;276 Ciudad Real;Group 1406 Other diseases of the male genital organs 601-608;Men;276 Ciudad Real;Group 1406 Other diseases of the male genital organs 601-608;Women;.. Ciudad Real;Group 1407 Disorders of breast 610-612;Both sexes;110 Ciudad Real;Group 1407 Disorders of breast 610-612;Men;13 Ciudad Real;Group 1407 Disorders of breast 610-612;Women;97 Ciudad Real;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Both sexes;90 Ciudad Real;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Men;.. Ciudad Real;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Women;90 Ciudad Real;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Both sexes;93 Ciudad Real;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Men;.. Ciudad Real;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Women;93 Ciudad Real;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Both sexes;539 Ciudad Real;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Men;1 Ciudad Real;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Women;538 Ciudad Real;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Both sexes;6,136 Ciudad Real;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Men;.. Ciudad Real;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Women;6,136 Ciudad Real;Group 1501 Legally induced abortion 635;Both sexes;.. Ciudad Real;Group 1501 Legally induced abortion 635;Men;.. Ciudad Real;Group 1501 Legally induced abortion 635;Women;.. Ciudad Real;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Both sexes;555 Ciudad Real;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Men;.. Ciudad Real;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Women;555 Ciudad Real;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Both sexes;3,990 Ciudad Real;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Men;.. Ciudad Real;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Women;3,990 Ciudad Real;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Both sexes;928 Ciudad Real;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Men;.. Ciudad Real;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Women;928 Ciudad Real;Group 1505 Single spontaneous delivery 650;Both sexes;227 Ciudad Real;Group 1505 Single spontaneous delivery 650;Men;.. Ciudad Real;Group 1505 Single spontaneous delivery 650;Women;227 Ciudad Real;Group 1506 Other deliveries 6695-6697;Both sexes;24 Ciudad Real;Group 1506 Other deliveries 6695-6697;Men;.. Ciudad Real;Group 1506 Other deliveries 6695-6697;Women;24 Ciudad Real;Group 1507 Complications related to the puerperium 670-676;Both sexes;38 Ciudad Real;Group 1507 Complications related to the puerperium 670-676;Men;.. Ciudad Real;Group 1507 Complications related to the puerperium 670-676;Women;38 Ciudad Real;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Both sexes;374 Ciudad Real;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Men;.. Ciudad Real;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Women;374 Ciudad Real;Group 1600 Some disorders originating in the perinatal period 760-779;Both sexes;1,128 Ciudad Real;Group 1600 Some disorders originating in the perinatal period 760-779;Men;606 Ciudad Real;Group 1600 Some disorders originating in the perinatal period 760-779;Women;522 Ciudad Real;Group 1601 Disorders related with premature delivery and a low birth weight 765;Both sexes;239 Ciudad Real;Group 1601 Disorders related with premature delivery and a low birth weight 765;Men;120 Ciudad Real;Group 1601 Disorders related with premature delivery and a low birth weight 765;Women;119 Ciudad Real;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Both sexes;889 Ciudad Real;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Men;486 Ciudad Real;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Women;403 Ciudad Real;Grupo 1700 Congenital abnormalities 740-759;Both sexes;268 Ciudad Real;Grupo 1700 Congenital abnormalities 740-759;Men;172 Ciudad Real;Grupo 1700 Congenital abnormalities 740-759;Women;96 Ciudad Real;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Both sexes;2,019 Ciudad Real;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Men;1,085 Ciudad Real;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Women;934 Ciudad Real;Group 1801 Pain in throat and chest 7841, 7865;Both sexes;317 Ciudad Real;Group 1801 Pain in throat and chest 7841, 7865;Men;178 Ciudad Real;Group 1801 Pain in throat and chest 7841, 7865;Women;139 Ciudad Real;Group 1802 Abdominal pain 7890;Both sexes;160 Ciudad Real;Group 1802 Abdominal pain 7890;Men;63 Ciudad Real;Group 1802 Abdominal pain 7890;Women;97 Ciudad Real;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Both sexes;3 Ciudad Real;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Men;1 Ciudad Real;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Women;2 Ciudad Real;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Both sexes;1,539 Ciudad Real;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Men;843 Ciudad Real;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Women;696 Ciudad Real;Group 1900 Injuries and poisoning 800-999;Both sexes;3,819 Ciudad Real;Group 1900 Injuries and poisoning 800-999;Men;1,823 Ciudad Real;Group 1900 Injuries and poisoning 800-999;Women;1,996 Ciudad Real;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Both sexes;198 Ciudad Real;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Men;119 Ciudad Real;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Women;79 Ciudad Real;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Both sexes;118 Ciudad Real;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Men;92 Ciudad Real;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Women;26 Ciudad Real;Group 1903 Radius and ulna fracture 813;Both sexes;249 Ciudad Real;Group 1903 Radius and ulna fracture 813;Men;108 Ciudad Real;Group 1903 Radius and ulna fracture 813;Women;141 Ciudad Real;Group 1904 Femur fracture 820-821;Both sexes;926 Ciudad Real;Group 1904 Femur fracture 820-821;Men;251 Ciudad Real;Group 1904 Femur fracture 820-821;Women;675 Ciudad Real;Group 1905 Leg fracture, including the ankle 823-824;Both sexes;288 Ciudad Real;Group 1905 Leg fracture, including the ankle 823-824;Men;150 Ciudad Real;Group 1905 Leg fracture, including the ankle 823-824;Women;138 Ciudad Real;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Both sexes;879 Ciudad Real;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Men;514 Ciudad Real;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Women;365 Ciudad Real;Group 1907 Burns 940-949;Both sexes;9 Ciudad Real;Group 1907 Burns 940-949;Men;6 Ciudad Real;Group 1907 Burns 940-949;Women;3 Ciudad Real;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Both sexes;113 Ciudad Real;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Men;50 Ciudad Real;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Women;63 Ciudad Real;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Both sexes;926 Ciudad Real;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Men;476 Ciudad Real;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Women;450 Ciudad Real;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Both sexes;5 Ciudad Real;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Men;2 Ciudad Real;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Women;3 Ciudad Real;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Both sexes;108 Ciudad Real;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Men;55 Ciudad Real;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Women;53 Ciudad Real;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Both sexes;854 Ciudad Real;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Men;473 Ciudad Real;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Women;381 Ciudad Real;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Both sexes;38 Ciudad Real;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Men;23 Ciudad Real;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Women;15 Ciudad Real;Group 2102 Contraceptive management V25;Both sexes;25 Ciudad Real;Group 2102 Contraceptive management V25;Men;1 Ciudad Real;Group 2102 Contraceptive management V25;Women;24 Ciudad Real;Group 2103 Living newborns by type of delivery V30-V39;Both sexes;.. Ciudad Real;Group 2103 Living newborns by type of delivery V30-V39;Men;.. Ciudad Real;Group 2103 Living newborns by type of delivery V30-V39;Women;.. Ciudad Real;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Both sexes;448 Ciudad Real;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Men;240 Ciudad Real;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Women;208 Ciudad Real;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Both sexes;343 Ciudad Real;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Men;209 Ciudad Real;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Women;134 Cuenca;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Both sexes;13,284 Cuenca;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Men;6,478 Cuenca;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Women;6,806 Cuenca;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Both sexes;326 Cuenca;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Men;179 Cuenca;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Women;147 Cuenca;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Both sexes;53 Cuenca;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Men;27 Cuenca;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Women;26 Cuenca;Group 0102 Imprecise intestinal infections 009;Both sexes;10 Cuenca;Group 0102 Imprecise intestinal infections 009;Men;4 Cuenca;Group 0102 Imprecise intestinal infections 009;Women;6 Cuenca;Group 0103 Tuberculosis 010-018, 137;Both sexes;15 Cuenca;Group 0103 Tuberculosis 010-018, 137;Men;10 Cuenca;Group 0103 Tuberculosis 010-018, 137;Women;5 Cuenca;Group 0104 Septicaemia 038;Both sexes;154 Cuenca;Group 0104 Septicaemia 038;Men;81 Cuenca;Group 0104 Septicaemia 038;Women;73 Cuenca;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Both sexes;7 Cuenca;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Men;6 Cuenca;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Women;1 Cuenca;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Both sexes;87 Cuenca;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Men;51 Cuenca;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Women;36 Cuenca;Group 0200 Neoplasms 140-239;Both sexes;1,023 Cuenca;Group 0200 Neoplasms 140-239;Men;592 Cuenca;Group 0200 Neoplasms 140-239;Women;431 Cuenca;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Both sexes;151 Cuenca;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Men;103 Cuenca;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Women;48 Cuenca;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Both sexes;61 Cuenca;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Men;53 Cuenca;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Women;8 Cuenca;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Both sexes;20 Cuenca;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Men;12 Cuenca;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Women;8 Cuenca;Group 0204 Malignant neoplasm of breast 174-175;Both sexes;80 Cuenca;Group 0204 Malignant neoplasm of breast 174-175;Men;.. Cuenca;Group 0204 Malignant neoplasm of breast 174-175;Women;80 Cuenca;Group 0205 Malignant neoplasm of uterus 179-180, 182;Both sexes;14 Cuenca;Group 0205 Malignant neoplasm of uterus 179-180, 182;Men;.. Cuenca;Group 0205 Malignant neoplasm of uterus 179-180, 182;Women;14 Cuenca;Group 0206 Malignant neoplasm of ovary 1830;Both sexes;9 Cuenca;Group 0206 Malignant neoplasm of ovary 1830;Men;.. Cuenca;Group 0206 Malignant neoplasm of ovary 1830;Women;9 Cuenca;Group 0207 Malignant neoplasm of prostate 185;Both sexes;27 Cuenca;Group 0207 Malignant neoplasm of prostate 185;Men;27 Cuenca;Group 0207 Malignant neoplasm of prostate 185;Women;.. Cuenca;Group 0208 Malignant neoplasm of bladder 188;Both sexes;50 Cuenca;Group 0208 Malignant neoplasm of bladder 188;Men;46 Cuenca;Group 0208 Malignant neoplasm of bladder 188;Women;4 Cuenca;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Both sexes;307 Cuenca;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Men;208 Cuenca;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Women;99 Cuenca;Group 0210 Carcinoma in situ 230-234;Both sexes;10 Cuenca;Group 0210 Carcinoma in situ 230-234;Men;4 Cuenca;Group 0210 Carcinoma in situ 230-234;Women;6 Cuenca;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Both sexes;18 Cuenca;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Men;10 Cuenca;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Women;8 Cuenca;Grupo 0212 Leiomyoma of uterus 218;Both sexes;47 Cuenca;Grupo 0212 Leiomyoma of uterus 218;Men;.. Cuenca;Grupo 0212 Leiomyoma of uterus 218;Women;47 Cuenca;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Both sexes;229 Cuenca;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Men;129 Cuenca;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Women;100 Cuenca;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Both sexes;117 Cuenca;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Men;52 Cuenca;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Women;65 Cuenca;Group 0301 Anaemias 280-285;Both sexes;86 Cuenca;Group 0301 Anaemias 280-285;Men;36 Cuenca;Group 0301 Anaemias 280-285;Women;50 Cuenca;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Both sexes;31 Cuenca;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Men;16 Cuenca;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Women;15 Cuenca;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Both sexes;185 Cuenca;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Men;91 Cuenca;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Women;94 Cuenca;Group 0401 Diabetes mellitus 249-250;Both sexes;62 Cuenca;Group 0401 Diabetes mellitus 249-250;Men;38 Cuenca;Group 0401 Diabetes mellitus 249-250;Women;24 Cuenca;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Both sexes;123 Cuenca;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Men;53 Cuenca;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Women;70 Cuenca;Group 0500 Mental disorders 290-319;Both sexes;458 Cuenca;Group 0500 Mental disorders 290-319;Men;247 Cuenca;Group 0500 Mental disorders 290-319;Women;211 Cuenca;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Both sexes;10 Cuenca;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Men;4 Cuenca;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Women;6 Cuenca;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Both sexes;54 Cuenca;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Men;46 Cuenca;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Women;8 Cuenca;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Both sexes;24 Cuenca;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Men;18 Cuenca;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Women;6 Cuenca;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Both sexes;161 Cuenca;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Men;110 Cuenca;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Women;51 Cuenca;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Both sexes;77 Cuenca;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Men;20 Cuenca;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Women;57 Cuenca;Group 0506 Other mental and behavioural disorders Rest of (290-319);Both sexes;132 Cuenca;Group 0506 Other mental and behavioural disorders Rest of (290-319);Men;49 Cuenca;Group 0506 Other mental and behavioural disorders Rest of (290-319);Women;83 Cuenca;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Both sexes;411 Cuenca;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Men;230 Cuenca;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Women;181 Cuenca;Group 0601 Alzheimer's disease 3310;Both sexes;6 Cuenca;Group 0601 Alzheimer's disease 3310;Men;1 Cuenca;Group 0601 Alzheimer's disease 3310;Women;5 Cuenca;Group 0602 Multiple sclerosis 340;Both sexes;40 Cuenca;Group 0602 Multiple sclerosis 340;Men;17 Cuenca;Group 0602 Multiple sclerosis 340;Women;23 Cuenca;Group 0603 Epilepsy 345;Both sexes;55 Cuenca;Group 0603 Epilepsy 345;Men;36 Cuenca;Group 0603 Epilepsy 345;Women;19 Cuenca;Group 0604 Transient cerebral ischemia 435;Both sexes;115 Cuenca;Group 0604 Transient cerebral ischemia 435;Men;61 Cuenca;Group 0604 Transient cerebral ischemia 435;Women;54 Cuenca;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Both sexes;195 Cuenca;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Men;115 Cuenca;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Women;80 Cuenca;Grupo 0700 Diseases of the eye and adnexa 360-379;Both sexes;134 Cuenca;Grupo 0700 Diseases of the eye and adnexa 360-379;Men;76 Cuenca;Grupo 0700 Diseases of the eye and adnexa 360-379;Women;58 Cuenca;Grupo 0701 Cataract 366;Both sexes;9 Cuenca;Grupo 0701 Cataract 366;Men;7 Cuenca;Grupo 0701 Cataract 366;Women;2 Cuenca;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Both sexes;125 Cuenca;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Men;69 Cuenca;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Women;56 Cuenca;Group 0800 Diseases of the ear and the mastoid 380-389;Both sexes;68 Cuenca;Group 0800 Diseases of the ear and the mastoid 380-389;Men;33 Cuenca;Group 0800 Diseases of the ear and the mastoid 380-389;Women;35 Cuenca;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Both sexes;1,806 Cuenca;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Men;976 Cuenca;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Women;830 Cuenca;Group 0901 Hypertensive disease 401-405;Both sexes;105 Cuenca;Group 0901 Hypertensive disease 401-405;Men;42 Cuenca;Group 0901 Hypertensive disease 401-405;Women;63 Cuenca;Group 0902 Angina pectoris 4111, 413;Both sexes;143 Cuenca;Group 0902 Angina pectoris 4111, 413;Men;101 Cuenca;Group 0902 Angina pectoris 4111, 413;Women;42 Cuenca;Group 0903 Acute myocardial infarction 410;Both sexes;106 Cuenca;Group 0903 Acute myocardial infarction 410;Men;65 Cuenca;Group 0903 Acute myocardial infarction 410;Women;41 Cuenca;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Both sexes;26 Cuenca;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Men;19 Cuenca;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Women;7 Cuenca;Group 0905 Diseases of the lungs circulation 415-417;Both sexes;52 Cuenca;Group 0905 Diseases of the lungs circulation 415-417;Men;29 Cuenca;Group 0905 Diseases of the lungs circulation 415-417;Women;23 Cuenca;Group 0906 Heart conduction disorders and arrhytmias 426-427;Both sexes;211 Cuenca;Group 0906 Heart conduction disorders and arrhytmias 426-427;Men;105 Cuenca;Group 0906 Heart conduction disorders and arrhytmias 426-427;Women;106 Cuenca;Grupo 0907 Heart failure 428;Both sexes;465 Cuenca;Grupo 0907 Heart failure 428;Men;208 Cuenca;Grupo 0907 Heart failure 428;Women;257 Cuenca;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Both sexes;370 Cuenca;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Men;207 Cuenca;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Women;163 Cuenca;Grupo 0909 Atherosclerosis 440;Both sexes;44 Cuenca;Grupo 0909 Atherosclerosis 440;Men;35 Cuenca;Grupo 0909 Atherosclerosis 440;Women;9 Cuenca;Group 0910 Varicose veins of lower extremities 454;Both sexes;29 Cuenca;Group 0910 Varicose veins of lower extremities 454;Men;10 Cuenca;Group 0910 Varicose veins of lower extremities 454;Women;19 Cuenca;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Both sexes;255 Cuenca;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Men;155 Cuenca;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Women;100 Cuenca;Group 1000 Diseases of the respiratory system 0340, 460-519;Both sexes;1,612 Cuenca;Group 1000 Diseases of the respiratory system 0340, 460-519;Men;929 Cuenca;Group 1000 Diseases of the respiratory system 0340, 460-519;Women;683 Cuenca;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Both sexes;67 Cuenca;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Men;33 Cuenca;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Women;34 Cuenca;Group 1002 Pneumonia 480-486;Both sexes;355 Cuenca;Group 1002 Pneumonia 480-486;Men;218 Cuenca;Group 1002 Pneumonia 480-486;Women;137 Cuenca;Group 1003 Acute bronchitis and bronchiolitis 466;Both sexes;52 Cuenca;Group 1003 Acute bronchitis and bronchiolitis 466;Men;18 Cuenca;Group 1003 Acute bronchitis and bronchiolitis 466;Women;34 Cuenca;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Both sexes;33 Cuenca;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Men;13 Cuenca;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Women;20 Cuenca;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Both sexes;67 Cuenca;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Men;39 Cuenca;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Women;28 Cuenca;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Both sexes;206 Cuenca;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Men;177 Cuenca;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Women;29 Cuenca;Group 1007 Asthma 4930-4931,4938-4939;Both sexes;53 Cuenca;Group 1007 Asthma 4930-4931,4938-4939;Men;18 Cuenca;Group 1007 Asthma 4930-4931,4938-4939;Women;35 Cuenca;Group 1008 Other diseases of the respiratory system Resto of (460-519);Both sexes;779 Cuenca;Group 1008 Other diseases of the respiratory system Resto of (460-519);Men;413 Cuenca;Group 1008 Other diseases of the respiratory system Resto of (460-519);Women;366 Cuenca;Group 1100 Diseases of the digestive system 520-579;Both sexes;2,019 Cuenca;Group 1100 Diseases of the digestive system 520-579;Men;1,182 Cuenca;Group 1100 Diseases of the digestive system 520-579;Women;837 Cuenca;Group 1101 Disorders of the teeth and supporting structures 520-525;Both sexes;32 Cuenca;Group 1101 Disorders of the teeth and supporting structures 520-525;Men;16 Cuenca;Group 1101 Disorders of the teeth and supporting structures 520-525;Women;16 Cuenca;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Both sexes;25 Cuenca;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Men;9 Cuenca;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Women;16 Cuenca;Group 1103 Diseases of the esophagus 530;Both sexes;36 Cuenca;Group 1103 Diseases of the esophagus 530;Men;26 Cuenca;Group 1103 Diseases of the esophagus 530;Women;10 Cuenca;Group 1104 Peptic ulcer 531-534;Both sexes;50 Cuenca;Group 1104 Peptic ulcer 531-534;Men;38 Cuenca;Group 1104 Peptic ulcer 531-534;Women;12 Cuenca;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Both sexes;42 Cuenca;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Men;25 Cuenca;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Women;17 Cuenca;Group 1106 Appendicitis 540-543;Both sexes;165 Cuenca;Group 1106 Appendicitis 540-543;Men;95 Cuenca;Group 1106 Appendicitis 540-543;Women;70 Cuenca;Group 1107 Inguinal hernia 550;Both sexes;204 Cuenca;Group 1107 Inguinal hernia 550;Men;186 Cuenca;Group 1107 Inguinal hernia 550;Women;18 Cuenca;Group 1108 Other abdominal hernia 551-553;Both sexes;131 Cuenca;Group 1108 Other abdominal hernia 551-553;Men;59 Cuenca;Group 1108 Other abdominal hernia 551-553;Women;72 Cuenca;Group 1109 Crohn's disease and ulcerative colitis 555-556;Both sexes;29 Cuenca;Group 1109 Crohn's disease and ulcerative colitis 555-556;Men;12 Cuenca;Group 1109 Crohn's disease and ulcerative colitis 555-556;Women;17 Cuenca;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Both sexes;166 Cuenca;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Men;86 Cuenca;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Women;80 Cuenca;Group 1111 Intestinal obstruction without hernia 560;Both sexes;111 Cuenca;Group 1111 Intestinal obstruction without hernia 560;Men;56 Cuenca;Group 1111 Intestinal obstruction without hernia 560;Women;55 Cuenca;Group 1112 Intestinal diverticulosis 562;Both sexes;56 Cuenca;Group 1112 Intestinal diverticulosis 562;Men;32 Cuenca;Group 1112 Intestinal diverticulosis 562;Women;24 Cuenca;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Both sexes;146 Cuenca;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Men;92 Cuenca;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Women;54 Cuenca;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Both sexes;83 Cuenca;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Men;42 Cuenca;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Women;41 Cuenca;Group 1115 Alcoholic hepatitis 5710-5713;Both sexes;19 Cuenca;Group 1115 Alcoholic hepatitis 5710-5713;Men;17 Cuenca;Group 1115 Alcoholic hepatitis 5710-5713;Women;2 Cuenca;Group 1116 Other diseases of the liver 570,5714-573;Both sexes;62 Cuenca;Group 1116 Other diseases of the liver 570,5714-573;Men;47 Cuenca;Group 1116 Other diseases of the liver 570,5714-573;Women;15 Cuenca;Group 1117 Cholelithiasis 574;Both sexes;350 Cuenca;Group 1117 Cholelithiasis 574;Men;152 Cuenca;Group 1117 Cholelithiasis 574;Women;198 Cuenca;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Both sexes;97 Cuenca;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Men;62 Cuenca;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Women;35 Cuenca;Group 1119 Pancreatic diseases 577;Both sexes;109 Cuenca;Group 1119 Pancreatic diseases 577;Men;62 Cuenca;Group 1119 Pancreatic diseases 577;Women;47 Cuenca;Group 1120 Other diseases of the digestive system Rest of (520-579);Both sexes;106 Cuenca;Group 1120 Other diseases of the digestive system Rest of (520-579);Men;68 Cuenca;Group 1120 Other diseases of the digestive system Rest of (520-579);Women;38 Cuenca;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Both sexes;108 Cuenca;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Men;65 Cuenca;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Women;43 Cuenca;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Both sexes;72 Cuenca;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Men;43 Cuenca;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Women;29 Cuenca;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Both sexes;6 Cuenca;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Men;4 Cuenca;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Women;2 Cuenca;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Both sexes;30 Cuenca;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Men;18 Cuenca;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Women;12 Cuenca;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Both sexes;655 Cuenca;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Men;328 Cuenca;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Women;327 Cuenca;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Both sexes;.. Cuenca;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Men;.. Cuenca;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Women;.. Cuenca;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Both sexes;.. Cuenca;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Men;.. Cuenca;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Women;.. Cuenca;Group 1303 Internal derangement of knee 717;Both sexes;59 Cuenca;Group 1303 Internal derangement of knee 717;Men;35 Cuenca;Group 1303 Internal derangement of knee 717;Women;24 Cuenca;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Both sexes;315 Cuenca;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Men;150 Cuenca;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Women;165 Cuenca;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Both sexes;15 Cuenca;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Men;8 Cuenca;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Women;7 Cuenca;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Both sexes;23 Cuenca;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Men;15 Cuenca;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Women;8 Cuenca;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Both sexes;27 Cuenca;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Men;18 Cuenca;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Women;9 Cuenca;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Both sexes;29 Cuenca;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Men;12 Cuenca;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Women;17 Cuenca;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Both sexes;68 Cuenca;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Men;44 Cuenca;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Women;24 Cuenca;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Both sexes;119 Cuenca;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Men;46 Cuenca;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Women;73 Cuenca;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Both sexes;768 Cuenca;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Men;326 Cuenca;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Women;442 Cuenca;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Both sexes;80 Cuenca;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Men;25 Cuenca;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Women;55 Cuenca;Group 1402 Renal failure 5836-5837, 584-586;Both sexes;77 Cuenca;Group 1402 Renal failure 5836-5837, 584-586;Men;43 Cuenca;Group 1402 Renal failure 5836-5837, 584-586;Women;34 Cuenca;Group 1403 Urolithiasis 592, 594, 7880;Both sexes;81 Cuenca;Group 1403 Urolithiasis 592, 594, 7880;Men;45 Cuenca;Group 1403 Urolithiasis 592, 594, 7880;Women;36 Cuenca;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Both sexes;221 Cuenca;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Men;98 Cuenca;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Women;123 Cuenca;Group 1405 Prostatic hyperplasia 600;Both sexes;53 Cuenca;Group 1405 Prostatic hyperplasia 600;Men;53 Cuenca;Group 1405 Prostatic hyperplasia 600;Women;.. Cuenca;Group 1406 Other diseases of the male genital organs 601-608;Both sexes;60 Cuenca;Group 1406 Other diseases of the male genital organs 601-608;Men;60 Cuenca;Group 1406 Other diseases of the male genital organs 601-608;Women;.. Cuenca;Group 1407 Disorders of breast 610-612;Both sexes;17 Cuenca;Group 1407 Disorders of breast 610-612;Men;2 Cuenca;Group 1407 Disorders of breast 610-612;Women;15 Cuenca;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Both sexes;26 Cuenca;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Men;.. Cuenca;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Women;26 Cuenca;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Both sexes;18 Cuenca;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Men;.. Cuenca;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Women;18 Cuenca;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Both sexes;135 Cuenca;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Men;.. Cuenca;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Women;135 Cuenca;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Both sexes;1,204 Cuenca;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Men;.. Cuenca;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Women;1,204 Cuenca;Group 1501 Legally induced abortion 635;Both sexes;.. Cuenca;Group 1501 Legally induced abortion 635;Men;.. Cuenca;Group 1501 Legally induced abortion 635;Women;.. Cuenca;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Both sexes;167 Cuenca;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Men;.. Cuenca;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Women;167 Cuenca;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Both sexes;619 Cuenca;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Men;.. Cuenca;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Women;619 Cuenca;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Both sexes;184 Cuenca;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Men;.. Cuenca;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Women;184 Cuenca;Group 1505 Single spontaneous delivery 650;Both sexes;52 Cuenca;Group 1505 Single spontaneous delivery 650;Men;.. Cuenca;Group 1505 Single spontaneous delivery 650;Women;52 Cuenca;Group 1506 Other deliveries 6695-6697;Both sexes;102 Cuenca;Group 1506 Other deliveries 6695-6697;Men;.. Cuenca;Group 1506 Other deliveries 6695-6697;Women;102 Cuenca;Group 1507 Complications related to the puerperium 670-676;Both sexes;3 Cuenca;Group 1507 Complications related to the puerperium 670-676;Men;.. Cuenca;Group 1507 Complications related to the puerperium 670-676;Women;3 Cuenca;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Both sexes;77 Cuenca;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Men;.. Cuenca;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Women;77 Cuenca;Group 1600 Some disorders originating in the perinatal period 760-779;Both sexes;111 Cuenca;Group 1600 Some disorders originating in the perinatal period 760-779;Men;57 Cuenca;Group 1600 Some disorders originating in the perinatal period 760-779;Women;54 Cuenca;Group 1601 Disorders related with premature delivery and a low birth weight 765;Both sexes;33 Cuenca;Group 1601 Disorders related with premature delivery and a low birth weight 765;Men;15 Cuenca;Group 1601 Disorders related with premature delivery and a low birth weight 765;Women;18 Cuenca;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Both sexes;78 Cuenca;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Men;42 Cuenca;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Women;36 Cuenca;Grupo 1700 Congenital abnormalities 740-759;Both sexes;49 Cuenca;Grupo 1700 Congenital abnormalities 740-759;Men;23 Cuenca;Grupo 1700 Congenital abnormalities 740-759;Women;26 Cuenca;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Both sexes;893 Cuenca;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Men;438 Cuenca;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Women;455 Cuenca;Group 1801 Pain in throat and chest 7841, 7865;Both sexes;100 Cuenca;Group 1801 Pain in throat and chest 7841, 7865;Men;54 Cuenca;Group 1801 Pain in throat and chest 7841, 7865;Women;46 Cuenca;Group 1802 Abdominal pain 7890;Both sexes;143 Cuenca;Group 1802 Abdominal pain 7890;Men;55 Cuenca;Group 1802 Abdominal pain 7890;Women;88 Cuenca;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Both sexes;47 Cuenca;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Men;20 Cuenca;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Women;27 Cuenca;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Both sexes;603 Cuenca;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Men;309 Cuenca;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Women;294 Cuenca;Group 1900 Injuries and poisoning 800-999;Both sexes;1,158 Cuenca;Group 1900 Injuries and poisoning 800-999;Men;541 Cuenca;Group 1900 Injuries and poisoning 800-999;Women;617 Cuenca;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Both sexes;80 Cuenca;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Men;38 Cuenca;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Women;42 Cuenca;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Both sexes;21 Cuenca;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Men;15 Cuenca;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Women;6 Cuenca;Group 1903 Radius and ulna fracture 813;Both sexes;42 Cuenca;Group 1903 Radius and ulna fracture 813;Men;22 Cuenca;Group 1903 Radius and ulna fracture 813;Women;20 Cuenca;Group 1904 Femur fracture 820-821;Both sexes;258 Cuenca;Group 1904 Femur fracture 820-821;Men;62 Cuenca;Group 1904 Femur fracture 820-821;Women;196 Cuenca;Group 1905 Leg fracture, including the ankle 823-824;Both sexes;81 Cuenca;Group 1905 Leg fracture, including the ankle 823-824;Men;37 Cuenca;Group 1905 Leg fracture, including the ankle 823-824;Women;44 Cuenca;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Both sexes;407 Cuenca;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Men;238 Cuenca;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Women;169 Cuenca;Group 1907 Burns 940-949;Both sexes;3 Cuenca;Group 1907 Burns 940-949;Men;3 Cuenca;Group 1907 Burns 940-949;Women;.. Cuenca;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Both sexes;51 Cuenca;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Men;18 Cuenca;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Women;33 Cuenca;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Both sexes;178 Cuenca;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Men;90 Cuenca;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Women;88 Cuenca;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Both sexes;2 Cuenca;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Men;1 Cuenca;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Women;1 Cuenca;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Both sexes;35 Cuenca;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Men;17 Cuenca;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Women;18 Cuenca;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Both sexes;179 Cuenca;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Men;113 Cuenca;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Women;66 Cuenca;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Both sexes;7 Cuenca;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Men;2 Cuenca;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Women;5 Cuenca;Group 2102 Contraceptive management V25;Both sexes;6 Cuenca;Group 2102 Contraceptive management V25;Men;.. Cuenca;Group 2102 Contraceptive management V25;Women;6 Cuenca;Group 2103 Living newborns by type of delivery V30-V39;Both sexes;.. Cuenca;Group 2103 Living newborns by type of delivery V30-V39;Men;.. Cuenca;Group 2103 Living newborns by type of delivery V30-V39;Women;.. Cuenca;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Both sexes;68 Cuenca;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Men;47 Cuenca;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Women;21 Cuenca;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Both sexes;98 Cuenca;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Men;64 Cuenca;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Women;34 Guadalajara;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Both sexes;18,508 Guadalajara;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Men;9,001 Guadalajara;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Women;9,507 Guadalajara;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Both sexes;641 Guadalajara;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Men;363 Guadalajara;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Women;278 Guadalajara;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Both sexes;113 Guadalajara;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Men;58 Guadalajara;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Women;55 Guadalajara;Group 0102 Imprecise intestinal infections 009;Both sexes;18 Guadalajara;Group 0102 Imprecise intestinal infections 009;Men;7 Guadalajara;Group 0102 Imprecise intestinal infections 009;Women;11 Guadalajara;Group 0103 Tuberculosis 010-018, 137;Both sexes;19 Guadalajara;Group 0103 Tuberculosis 010-018, 137;Men;11 Guadalajara;Group 0103 Tuberculosis 010-018, 137;Women;8 Guadalajara;Group 0104 Septicaemia 038;Both sexes;263 Guadalajara;Group 0104 Septicaemia 038;Men;144 Guadalajara;Group 0104 Septicaemia 038;Women;119 Guadalajara;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Both sexes;13 Guadalajara;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Men;6 Guadalajara;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Women;7 Guadalajara;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Both sexes;215 Guadalajara;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Men;137 Guadalajara;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Women;78 Guadalajara;Group 0200 Neoplasms 140-239;Both sexes;1,526 Guadalajara;Group 0200 Neoplasms 140-239;Men;863 Guadalajara;Group 0200 Neoplasms 140-239;Women;663 Guadalajara;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Both sexes;173 Guadalajara;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Men;112 Guadalajara;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Women;61 Guadalajara;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Both sexes;98 Guadalajara;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Men;82 Guadalajara;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Women;16 Guadalajara;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Both sexes;102 Guadalajara;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Men;56 Guadalajara;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Women;46 Guadalajara;Group 0204 Malignant neoplasm of breast 174-175;Both sexes;88 Guadalajara;Group 0204 Malignant neoplasm of breast 174-175;Men;1 Guadalajara;Group 0204 Malignant neoplasm of breast 174-175;Women;87 Guadalajara;Group 0205 Malignant neoplasm of uterus 179-180, 182;Both sexes;36 Guadalajara;Group 0205 Malignant neoplasm of uterus 179-180, 182;Men;.. Guadalajara;Group 0205 Malignant neoplasm of uterus 179-180, 182;Women;36 Guadalajara;Group 0206 Malignant neoplasm of ovary 1830;Both sexes;13 Guadalajara;Group 0206 Malignant neoplasm of ovary 1830;Men;.. Guadalajara;Group 0206 Malignant neoplasm of ovary 1830;Women;13 Guadalajara;Group 0207 Malignant neoplasm of prostate 185;Both sexes;61 Guadalajara;Group 0207 Malignant neoplasm of prostate 185;Men;61 Guadalajara;Group 0207 Malignant neoplasm of prostate 185;Women;.. Guadalajara;Group 0208 Malignant neoplasm of bladder 188;Both sexes;130 Guadalajara;Group 0208 Malignant neoplasm of bladder 188;Men;117 Guadalajara;Group 0208 Malignant neoplasm of bladder 188;Women;13 Guadalajara;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Both sexes;536 Guadalajara;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Men;335 Guadalajara;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Women;201 Guadalajara;Group 0210 Carcinoma in situ 230-234;Both sexes;28 Guadalajara;Group 0210 Carcinoma in situ 230-234;Men;16 Guadalajara;Group 0210 Carcinoma in situ 230-234;Women;12 Guadalajara;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Both sexes;14 Guadalajara;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Men;8 Guadalajara;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Women;6 Guadalajara;Grupo 0212 Leiomyoma of uterus 218;Both sexes;69 Guadalajara;Grupo 0212 Leiomyoma of uterus 218;Men;.. Guadalajara;Grupo 0212 Leiomyoma of uterus 218;Women;69 Guadalajara;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Both sexes;178 Guadalajara;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Men;75 Guadalajara;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Women;103 Guadalajara;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Both sexes;186 Guadalajara;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Men;107 Guadalajara;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Women;79 Guadalajara;Group 0301 Anaemias 280-285;Both sexes;111 Guadalajara;Group 0301 Anaemias 280-285;Men;62 Guadalajara;Group 0301 Anaemias 280-285;Women;49 Guadalajara;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Both sexes;75 Guadalajara;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Men;45 Guadalajara;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Women;30 Guadalajara;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Both sexes;325 Guadalajara;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Men;142 Guadalajara;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Women;183 Guadalajara;Group 0401 Diabetes mellitus 249-250;Both sexes;142 Guadalajara;Group 0401 Diabetes mellitus 249-250;Men;71 Guadalajara;Group 0401 Diabetes mellitus 249-250;Women;71 Guadalajara;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Both sexes;183 Guadalajara;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Men;71 Guadalajara;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Women;112 Guadalajara;Group 0500 Mental disorders 290-319;Both sexes;408 Guadalajara;Group 0500 Mental disorders 290-319;Men;212 Guadalajara;Group 0500 Mental disorders 290-319;Women;196 Guadalajara;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Both sexes;7 Guadalajara;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Men;2 Guadalajara;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Women;5 Guadalajara;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Both sexes;40 Guadalajara;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Men;30 Guadalajara;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Women;10 Guadalajara;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Both sexes;20 Guadalajara;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Men;11 Guadalajara;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Women;9 Guadalajara;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Both sexes;167 Guadalajara;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Men;99 Guadalajara;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Women;68 Guadalajara;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Both sexes;87 Guadalajara;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Men;25 Guadalajara;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Women;62 Guadalajara;Group 0506 Other mental and behavioural disorders Rest of (290-319);Both sexes;87 Guadalajara;Group 0506 Other mental and behavioural disorders Rest of (290-319);Men;45 Guadalajara;Group 0506 Other mental and behavioural disorders Rest of (290-319);Women;42 Guadalajara;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Both sexes;362 Guadalajara;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Men;176 Guadalajara;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Women;186 Guadalajara;Group 0601 Alzheimer's disease 3310;Both sexes;3 Guadalajara;Group 0601 Alzheimer's disease 3310;Men;.. Guadalajara;Group 0601 Alzheimer's disease 3310;Women;3 Guadalajara;Group 0602 Multiple sclerosis 340;Both sexes;19 Guadalajara;Group 0602 Multiple sclerosis 340;Men;6 Guadalajara;Group 0602 Multiple sclerosis 340;Women;13 Guadalajara;Group 0603 Epilepsy 345;Both sexes;74 Guadalajara;Group 0603 Epilepsy 345;Men;38 Guadalajara;Group 0603 Epilepsy 345;Women;36 Guadalajara;Group 0604 Transient cerebral ischemia 435;Both sexes;76 Guadalajara;Group 0604 Transient cerebral ischemia 435;Men;43 Guadalajara;Group 0604 Transient cerebral ischemia 435;Women;33 Guadalajara;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Both sexes;190 Guadalajara;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Men;89 Guadalajara;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Women;101 Guadalajara;Grupo 0700 Diseases of the eye and adnexa 360-379;Both sexes;103 Guadalajara;Grupo 0700 Diseases of the eye and adnexa 360-379;Men;57 Guadalajara;Grupo 0700 Diseases of the eye and adnexa 360-379;Women;46 Guadalajara;Grupo 0701 Cataract 366;Both sexes;40 Guadalajara;Grupo 0701 Cataract 366;Men;19 Guadalajara;Grupo 0701 Cataract 366;Women;21 Guadalajara;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Both sexes;63 Guadalajara;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Men;38 Guadalajara;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Women;25 Guadalajara;Group 0800 Diseases of the ear and the mastoid 380-389;Both sexes;94 Guadalajara;Group 0800 Diseases of the ear and the mastoid 380-389;Men;48 Guadalajara;Group 0800 Diseases of the ear and the mastoid 380-389;Women;46 Guadalajara;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Both sexes;2,538 Guadalajara;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Men;1,480 Guadalajara;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Women;1,058 Guadalajara;Group 0901 Hypertensive disease 401-405;Both sexes;221 Guadalajara;Group 0901 Hypertensive disease 401-405;Men;106 Guadalajara;Group 0901 Hypertensive disease 401-405;Women;115 Guadalajara;Group 0902 Angina pectoris 4111, 413;Both sexes;59 Guadalajara;Group 0902 Angina pectoris 4111, 413;Men;32 Guadalajara;Group 0902 Angina pectoris 4111, 413;Women;27 Guadalajara;Group 0903 Acute myocardial infarction 410;Both sexes;209 Guadalajara;Group 0903 Acute myocardial infarction 410;Men;158 Guadalajara;Group 0903 Acute myocardial infarction 410;Women;51 Guadalajara;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Both sexes;189 Guadalajara;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Men;145 Guadalajara;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Women;44 Guadalajara;Group 0905 Diseases of the lungs circulation 415-417;Both sexes;61 Guadalajara;Group 0905 Diseases of the lungs circulation 415-417;Men;28 Guadalajara;Group 0905 Diseases of the lungs circulation 415-417;Women;33 Guadalajara;Group 0906 Heart conduction disorders and arrhytmias 426-427;Both sexes;448 Guadalajara;Group 0906 Heart conduction disorders and arrhytmias 426-427;Men;280 Guadalajara;Group 0906 Heart conduction disorders and arrhytmias 426-427;Women;168 Guadalajara;Grupo 0907 Heart failure 428;Both sexes;570 Guadalajara;Grupo 0907 Heart failure 428;Men;244 Guadalajara;Grupo 0907 Heart failure 428;Women;326 Guadalajara;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Both sexes;337 Guadalajara;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Men;202 Guadalajara;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Women;135 Guadalajara;Grupo 0909 Atherosclerosis 440;Both sexes;88 Guadalajara;Grupo 0909 Atherosclerosis 440;Men;76 Guadalajara;Grupo 0909 Atherosclerosis 440;Women;12 Guadalajara;Group 0910 Varicose veins of lower extremities 454;Both sexes;58 Guadalajara;Group 0910 Varicose veins of lower extremities 454;Men;14 Guadalajara;Group 0910 Varicose veins of lower extremities 454;Women;44 Guadalajara;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Both sexes;298 Guadalajara;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Men;195 Guadalajara;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Women;103 Guadalajara;Group 1000 Diseases of the respiratory system 0340, 460-519;Both sexes;2,119 Guadalajara;Group 1000 Diseases of the respiratory system 0340, 460-519;Men;1,287 Guadalajara;Group 1000 Diseases of the respiratory system 0340, 460-519;Women;832 Guadalajara;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Both sexes;84 Guadalajara;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Men;46 Guadalajara;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Women;38 Guadalajara;Group 1002 Pneumonia 480-486;Both sexes;712 Guadalajara;Group 1002 Pneumonia 480-486;Men;430 Guadalajara;Group 1002 Pneumonia 480-486;Women;282 Guadalajara;Group 1003 Acute bronchitis and bronchiolitis 466;Both sexes;140 Guadalajara;Group 1003 Acute bronchitis and bronchiolitis 466;Men;68 Guadalajara;Group 1003 Acute bronchitis and bronchiolitis 466;Women;72 Guadalajara;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Both sexes;76 Guadalajara;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Men;46 Guadalajara;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Women;30 Guadalajara;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Both sexes;105 Guadalajara;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Men;64 Guadalajara;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Women;41 Guadalajara;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Both sexes;284 Guadalajara;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Men;232 Guadalajara;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Women;52 Guadalajara;Group 1007 Asthma 4930-4931,4938-4939;Both sexes;103 Guadalajara;Group 1007 Asthma 4930-4931,4938-4939;Men;42 Guadalajara;Group 1007 Asthma 4930-4931,4938-4939;Women;61 Guadalajara;Group 1008 Other diseases of the respiratory system Resto of (460-519);Both sexes;615 Guadalajara;Group 1008 Other diseases of the respiratory system Resto of (460-519);Men;359 Guadalajara;Group 1008 Other diseases of the respiratory system Resto of (460-519);Women;256 Guadalajara;Group 1100 Diseases of the digestive system 520-579;Both sexes;2,658 Guadalajara;Group 1100 Diseases of the digestive system 520-579;Men;1,511 Guadalajara;Group 1100 Diseases of the digestive system 520-579;Women;1,147 Guadalajara;Group 1101 Disorders of the teeth and supporting structures 520-525;Both sexes;22 Guadalajara;Group 1101 Disorders of the teeth and supporting structures 520-525;Men;10 Guadalajara;Group 1101 Disorders of the teeth and supporting structures 520-525;Women;12 Guadalajara;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Both sexes;22 Guadalajara;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Men;15 Guadalajara;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Women;7 Guadalajara;Group 1103 Diseases of the esophagus 530;Both sexes;58 Guadalajara;Group 1103 Diseases of the esophagus 530;Men;37 Guadalajara;Group 1103 Diseases of the esophagus 530;Women;21 Guadalajara;Group 1104 Peptic ulcer 531-534;Both sexes;66 Guadalajara;Group 1104 Peptic ulcer 531-534;Men;48 Guadalajara;Group 1104 Peptic ulcer 531-534;Women;18 Guadalajara;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Both sexes;55 Guadalajara;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Men;31 Guadalajara;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Women;24 Guadalajara;Group 1106 Appendicitis 540-543;Both sexes;234 Guadalajara;Group 1106 Appendicitis 540-543;Men;139 Guadalajara;Group 1106 Appendicitis 540-543;Women;95 Guadalajara;Group 1107 Inguinal hernia 550;Both sexes;303 Guadalajara;Group 1107 Inguinal hernia 550;Men;272 Guadalajara;Group 1107 Inguinal hernia 550;Women;31 Guadalajara;Group 1108 Other abdominal hernia 551-553;Both sexes;169 Guadalajara;Group 1108 Other abdominal hernia 551-553;Men;72 Guadalajara;Group 1108 Other abdominal hernia 551-553;Women;97 Guadalajara;Group 1109 Crohn's disease and ulcerative colitis 555-556;Both sexes;47 Guadalajara;Group 1109 Crohn's disease and ulcerative colitis 555-556;Men;29 Guadalajara;Group 1109 Crohn's disease and ulcerative colitis 555-556;Women;18 Guadalajara;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Both sexes;189 Guadalajara;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Men;79 Guadalajara;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Women;110 Guadalajara;Group 1111 Intestinal obstruction without hernia 560;Both sexes;111 Guadalajara;Group 1111 Intestinal obstruction without hernia 560;Men;58 Guadalajara;Group 1111 Intestinal obstruction without hernia 560;Women;53 Guadalajara;Group 1112 Intestinal diverticulosis 562;Both sexes;96 Guadalajara;Group 1112 Intestinal diverticulosis 562;Men;57 Guadalajara;Group 1112 Intestinal diverticulosis 562;Women;39 Guadalajara;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Both sexes;103 Guadalajara;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Men;74 Guadalajara;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Women;29 Guadalajara;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Both sexes;129 Guadalajara;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Men;69 Guadalajara;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Women;60 Guadalajara;Group 1115 Alcoholic hepatitis 5710-5713;Both sexes;38 Guadalajara;Group 1115 Alcoholic hepatitis 5710-5713;Men;34 Guadalajara;Group 1115 Alcoholic hepatitis 5710-5713;Women;4 Guadalajara;Group 1116 Other diseases of the liver 570,5714-573;Both sexes;88 Guadalajara;Group 1116 Other diseases of the liver 570,5714-573;Men;55 Guadalajara;Group 1116 Other diseases of the liver 570,5714-573;Women;33 Guadalajara;Group 1117 Cholelithiasis 574;Both sexes;508 Guadalajara;Group 1117 Cholelithiasis 574;Men;207 Guadalajara;Group 1117 Cholelithiasis 574;Women;301 Guadalajara;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Both sexes;163 Guadalajara;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Men;83 Guadalajara;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Women;80 Guadalajara;Group 1119 Pancreatic diseases 577;Both sexes;143 Guadalajara;Group 1119 Pancreatic diseases 577;Men;86 Guadalajara;Group 1119 Pancreatic diseases 577;Women;57 Guadalajara;Group 1120 Other diseases of the digestive system Rest of (520-579);Both sexes;114 Guadalajara;Group 1120 Other diseases of the digestive system Rest of (520-579);Men;56 Guadalajara;Group 1120 Other diseases of the digestive system Rest of (520-579);Women;58 Guadalajara;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Both sexes;161 Guadalajara;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Men;80 Guadalajara;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Women;81 Guadalajara;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Both sexes;99 Guadalajara;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Men;51 Guadalajara;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Women;48 Guadalajara;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Both sexes;10 Guadalajara;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Men;1 Guadalajara;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Women;9 Guadalajara;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Both sexes;52 Guadalajara;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Men;28 Guadalajara;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Women;24 Guadalajara;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Both sexes;1,296 Guadalajara;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Men;603 Guadalajara;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Women;693 Guadalajara;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Both sexes;.. Guadalajara;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Men;.. Guadalajara;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Women;.. Guadalajara;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Both sexes;.. Guadalajara;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Men;.. Guadalajara;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Women;.. Guadalajara;Group 1303 Internal derangement of knee 717;Both sexes;139 Guadalajara;Group 1303 Internal derangement of knee 717;Men;98 Guadalajara;Group 1303 Internal derangement of knee 717;Women;41 Guadalajara;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Both sexes;466 Guadalajara;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Men;220 Guadalajara;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Women;246 Guadalajara;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Both sexes;15 Guadalajara;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Men;5 Guadalajara;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Women;10 Guadalajara;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Both sexes;59 Guadalajara;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Men;37 Guadalajara;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Women;22 Guadalajara;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Both sexes;94 Guadalajara;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Men;51 Guadalajara;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Women;43 Guadalajara;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Both sexes;31 Guadalajara;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Men;18 Guadalajara;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Women;13 Guadalajara;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Both sexes;203 Guadalajara;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Men;86 Guadalajara;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Women;117 Guadalajara;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Both sexes;289 Guadalajara;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Men;88 Guadalajara;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Women;201 Guadalajara;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Both sexes;1,086 Guadalajara;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Men;517 Guadalajara;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Women;569 Guadalajara;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Both sexes;181 Guadalajara;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Men;50 Guadalajara;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Women;131 Guadalajara;Group 1402 Renal failure 5836-5837, 584-586;Both sexes;122 Guadalajara;Group 1402 Renal failure 5836-5837, 584-586;Men;87 Guadalajara;Group 1402 Renal failure 5836-5837, 584-586;Women;35 Guadalajara;Group 1403 Urolithiasis 592, 594, 7880;Both sexes;96 Guadalajara;Group 1403 Urolithiasis 592, 594, 7880;Men;57 Guadalajara;Group 1403 Urolithiasis 592, 594, 7880;Women;39 Guadalajara;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Both sexes;369 Guadalajara;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Men;172 Guadalajara;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Women;197 Guadalajara;Group 1405 Prostatic hyperplasia 600;Both sexes;73 Guadalajara;Group 1405 Prostatic hyperplasia 600;Men;73 Guadalajara;Group 1405 Prostatic hyperplasia 600;Women;.. Guadalajara;Group 1406 Other diseases of the male genital organs 601-608;Both sexes;72 Guadalajara;Group 1406 Other diseases of the male genital organs 601-608;Men;72 Guadalajara;Group 1406 Other diseases of the male genital organs 601-608;Women;.. Guadalajara;Group 1407 Disorders of breast 610-612;Both sexes;32 Guadalajara;Group 1407 Disorders of breast 610-612;Men;6 Guadalajara;Group 1407 Disorders of breast 610-612;Women;26 Guadalajara;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Both sexes;22 Guadalajara;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Men;.. Guadalajara;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Women;22 Guadalajara;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Both sexes;6 Guadalajara;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Men;.. Guadalajara;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Women;6 Guadalajara;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Both sexes;113 Guadalajara;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Men;.. Guadalajara;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Women;113 Guadalajara;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Both sexes;2,076 Guadalajara;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Men;.. Guadalajara;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Women;2,076 Guadalajara;Group 1501 Legally induced abortion 635;Both sexes;.. Guadalajara;Group 1501 Legally induced abortion 635;Men;.. Guadalajara;Group 1501 Legally induced abortion 635;Women;.. Guadalajara;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Both sexes;172 Guadalajara;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Men;.. Guadalajara;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Women;172 Guadalajara;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Both sexes;1,324 Guadalajara;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Men;.. Guadalajara;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Women;1,324 Guadalajara;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Both sexes;213 Guadalajara;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Men;.. Guadalajara;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Women;213 Guadalajara;Group 1505 Single spontaneous delivery 650;Both sexes;81 Guadalajara;Group 1505 Single spontaneous delivery 650;Men;.. Guadalajara;Group 1505 Single spontaneous delivery 650;Women;81 Guadalajara;Group 1506 Other deliveries 6695-6697;Both sexes;103 Guadalajara;Group 1506 Other deliveries 6695-6697;Men;.. Guadalajara;Group 1506 Other deliveries 6695-6697;Women;103 Guadalajara;Group 1507 Complications related to the puerperium 670-676;Both sexes;12 Guadalajara;Group 1507 Complications related to the puerperium 670-676;Men;.. Guadalajara;Group 1507 Complications related to the puerperium 670-676;Women;12 Guadalajara;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Both sexes;171 Guadalajara;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Men;.. Guadalajara;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Women;171 Guadalajara;Group 1600 Some disorders originating in the perinatal period 760-779;Both sexes;163 Guadalajara;Group 1600 Some disorders originating in the perinatal period 760-779;Men;91 Guadalajara;Group 1600 Some disorders originating in the perinatal period 760-779;Women;72 Guadalajara;Group 1601 Disorders related with premature delivery and a low birth weight 765;Both sexes;62 Guadalajara;Group 1601 Disorders related with premature delivery and a low birth weight 765;Men;35 Guadalajara;Group 1601 Disorders related with premature delivery and a low birth weight 765;Women;27 Guadalajara;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Both sexes;101 Guadalajara;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Men;56 Guadalajara;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Women;45 Guadalajara;Grupo 1700 Congenital abnormalities 740-759;Both sexes;72 Guadalajara;Grupo 1700 Congenital abnormalities 740-759;Men;35 Guadalajara;Grupo 1700 Congenital abnormalities 740-759;Women;37 Guadalajara;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Both sexes;825 Guadalajara;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Men;451 Guadalajara;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Women;374 Guadalajara;Group 1801 Pain in throat and chest 7841, 7865;Both sexes;134 Guadalajara;Group 1801 Pain in throat and chest 7841, 7865;Men;75 Guadalajara;Group 1801 Pain in throat and chest 7841, 7865;Women;59 Guadalajara;Group 1802 Abdominal pain 7890;Both sexes;109 Guadalajara;Group 1802 Abdominal pain 7890;Men;47 Guadalajara;Group 1802 Abdominal pain 7890;Women;62 Guadalajara;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Both sexes;1 Guadalajara;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Men;1 Guadalajara;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Women;.. Guadalajara;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Both sexes;581 Guadalajara;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Men;328 Guadalajara;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Women;253 Guadalajara;Group 1900 Injuries and poisoning 800-999;Both sexes;1,497 Guadalajara;Group 1900 Injuries and poisoning 800-999;Men;762 Guadalajara;Group 1900 Injuries and poisoning 800-999;Women;735 Guadalajara;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Both sexes;86 Guadalajara;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Men;45 Guadalajara;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Women;41 Guadalajara;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Both sexes;41 Guadalajara;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Men;30 Guadalajara;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Women;11 Guadalajara;Group 1903 Radius and ulna fracture 813;Both sexes;62 Guadalajara;Group 1903 Radius and ulna fracture 813;Men;33 Guadalajara;Group 1903 Radius and ulna fracture 813;Women;29 Guadalajara;Group 1904 Femur fracture 820-821;Both sexes;322 Guadalajara;Group 1904 Femur fracture 820-821;Men;100 Guadalajara;Group 1904 Femur fracture 820-821;Women;222 Guadalajara;Group 1905 Leg fracture, including the ankle 823-824;Both sexes;73 Guadalajara;Group 1905 Leg fracture, including the ankle 823-824;Men;41 Guadalajara;Group 1905 Leg fracture, including the ankle 823-824;Women;32 Guadalajara;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Both sexes;297 Guadalajara;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Men;190 Guadalajara;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Women;107 Guadalajara;Group 1907 Burns 940-949;Both sexes;.. Guadalajara;Group 1907 Burns 940-949;Men;.. Guadalajara;Group 1907 Burns 940-949;Women;.. Guadalajara;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Both sexes;59 Guadalajara;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Men;26 Guadalajara;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Women;33 Guadalajara;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Both sexes;460 Guadalajara;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Men;250 Guadalajara;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Women;210 Guadalajara;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Both sexes;.. Guadalajara;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Men;.. Guadalajara;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Women;.. Guadalajara;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Both sexes;97 Guadalajara;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Men;47 Guadalajara;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Women;50 Guadalajara;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Both sexes;372 Guadalajara;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Men;216 Guadalajara;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Women;156 Guadalajara;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Both sexes;51 Guadalajara;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Men;33 Guadalajara;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Women;18 Guadalajara;Group 2102 Contraceptive management V25;Both sexes;8 Guadalajara;Group 2102 Contraceptive management V25;Men;2 Guadalajara;Group 2102 Contraceptive management V25;Women;6 Guadalajara;Group 2103 Living newborns by type of delivery V30-V39;Both sexes;.. Guadalajara;Group 2103 Living newborns by type of delivery V30-V39;Men;.. Guadalajara;Group 2103 Living newborns by type of delivery V30-V39;Women;.. Guadalajara;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Both sexes;100 Guadalajara;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Men;56 Guadalajara;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Women;44 Guadalajara;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Both sexes;213 Guadalajara;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Men;125 Guadalajara;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Women;88 Toledo;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Both sexes;46,780 Toledo;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Men;22,754 Toledo;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Women;24,026 Toledo;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Both sexes;979 Toledo;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Men;542 Toledo;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Women;437 Toledo;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Both sexes;96 Toledo;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Men;47 Toledo;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Women;49 Toledo;Group 0102 Imprecise intestinal infections 009;Both sexes;95 Toledo;Group 0102 Imprecise intestinal infections 009;Men;40 Toledo;Group 0102 Imprecise intestinal infections 009;Women;55 Toledo;Group 0103 Tuberculosis 010-018, 137;Both sexes;39 Toledo;Group 0103 Tuberculosis 010-018, 137;Men;23 Toledo;Group 0103 Tuberculosis 010-018, 137;Women;16 Toledo;Group 0104 Septicaemia 038;Both sexes;459 Toledo;Group 0104 Septicaemia 038;Men;266 Toledo;Group 0104 Septicaemia 038;Women;193 Toledo;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Both sexes;14 Toledo;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Men;11 Toledo;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Women;3 Toledo;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Both sexes;276 Toledo;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Men;155 Toledo;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Women;121 Toledo;Group 0200 Neoplasms 140-239;Both sexes;4,799 Toledo;Group 0200 Neoplasms 140-239;Men;2,681 Toledo;Group 0200 Neoplasms 140-239;Women;2,118 Toledo;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Both sexes;478 Toledo;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Men;313 Toledo;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Women;165 Toledo;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Both sexes;455 Toledo;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Men;407 Toledo;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Women;48 Toledo;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Both sexes;112 Toledo;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Men;63 Toledo;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Women;49 Toledo;Group 0204 Malignant neoplasm of breast 174-175;Both sexes;408 Toledo;Group 0204 Malignant neoplasm of breast 174-175;Men;5 Toledo;Group 0204 Malignant neoplasm of breast 174-175;Women;403 Toledo;Group 0205 Malignant neoplasm of uterus 179-180, 182;Both sexes;122 Toledo;Group 0205 Malignant neoplasm of uterus 179-180, 182;Men;.. Toledo;Group 0205 Malignant neoplasm of uterus 179-180, 182;Women;122 Toledo;Group 0206 Malignant neoplasm of ovary 1830;Both sexes;64 Toledo;Group 0206 Malignant neoplasm of ovary 1830;Men;.. Toledo;Group 0206 Malignant neoplasm of ovary 1830;Women;64 Toledo;Group 0207 Malignant neoplasm of prostate 185;Both sexes;119 Toledo;Group 0207 Malignant neoplasm of prostate 185;Men;119 Toledo;Group 0207 Malignant neoplasm of prostate 185;Women;.. Toledo;Group 0208 Malignant neoplasm of bladder 188;Both sexes;242 Toledo;Group 0208 Malignant neoplasm of bladder 188;Men;211 Toledo;Group 0208 Malignant neoplasm of bladder 188;Women;31 Toledo;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Both sexes;1,540 Toledo;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Men;950 Toledo;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Women;590 Toledo;Group 0210 Carcinoma in situ 230-234;Both sexes;62 Toledo;Group 0210 Carcinoma in situ 230-234;Men;15 Toledo;Group 0210 Carcinoma in situ 230-234;Women;47 Toledo;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Both sexes;51 Toledo;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Men;28 Toledo;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Women;23 Toledo;Grupo 0212 Leiomyoma of uterus 218;Both sexes;172 Toledo;Grupo 0212 Leiomyoma of uterus 218;Men;.. Toledo;Grupo 0212 Leiomyoma of uterus 218;Women;172 Toledo;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Both sexes;974 Toledo;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Men;570 Toledo;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Women;404 Toledo;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Both sexes;400 Toledo;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Men;212 Toledo;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Women;188 Toledo;Group 0301 Anaemias 280-285;Both sexes;231 Toledo;Group 0301 Anaemias 280-285;Men;119 Toledo;Group 0301 Anaemias 280-285;Women;112 Toledo;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Both sexes;169 Toledo;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Men;93 Toledo;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Women;76 Toledo;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Both sexes;730 Toledo;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Men;286 Toledo;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Women;444 Toledo;Group 0401 Diabetes mellitus 249-250;Both sexes;231 Toledo;Group 0401 Diabetes mellitus 249-250;Men;133 Toledo;Group 0401 Diabetes mellitus 249-250;Women;98 Toledo;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Both sexes;499 Toledo;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Men;153 Toledo;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Women;346 Toledo;Group 0500 Mental disorders 290-319;Both sexes;1,394 Toledo;Group 0500 Mental disorders 290-319;Men;848 Toledo;Group 0500 Mental disorders 290-319;Women;546 Toledo;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Both sexes;7 Toledo;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Men;5 Toledo;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Women;2 Toledo;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Both sexes;90 Toledo;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Men;66 Toledo;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Women;24 Toledo;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Both sexes;72 Toledo;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Men;62 Toledo;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Women;10 Toledo;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Both sexes;481 Toledo;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Men;358 Toledo;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Women;123 Toledo;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Both sexes;268 Toledo;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Men;131 Toledo;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Women;137 Toledo;Group 0506 Other mental and behavioural disorders Rest of (290-319);Both sexes;476 Toledo;Group 0506 Other mental and behavioural disorders Rest of (290-319);Men;226 Toledo;Group 0506 Other mental and behavioural disorders Rest of (290-319);Women;250 Toledo;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Both sexes;1,597 Toledo;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Men;958 Toledo;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Women;639 Toledo;Group 0601 Alzheimer's disease 3310;Both sexes;6 Toledo;Group 0601 Alzheimer's disease 3310;Men;3 Toledo;Group 0601 Alzheimer's disease 3310;Women;3 Toledo;Group 0602 Multiple sclerosis 340;Both sexes;46 Toledo;Group 0602 Multiple sclerosis 340;Men;13 Toledo;Group 0602 Multiple sclerosis 340;Women;33 Toledo;Group 0603 Epilepsy 345;Both sexes;150 Toledo;Group 0603 Epilepsy 345;Men;82 Toledo;Group 0603 Epilepsy 345;Women;68 Toledo;Group 0604 Transient cerebral ischemia 435;Both sexes;217 Toledo;Group 0604 Transient cerebral ischemia 435;Men;109 Toledo;Group 0604 Transient cerebral ischemia 435;Women;108 Toledo;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Both sexes;1,178 Toledo;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Men;751 Toledo;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Women;427 Toledo;Grupo 0700 Diseases of the eye and adnexa 360-379;Both sexes;296 Toledo;Grupo 0700 Diseases of the eye and adnexa 360-379;Men;148 Toledo;Grupo 0700 Diseases of the eye and adnexa 360-379;Women;148 Toledo;Grupo 0701 Cataract 366;Both sexes;57 Toledo;Grupo 0701 Cataract 366;Men;21 Toledo;Grupo 0701 Cataract 366;Women;36 Toledo;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Both sexes;239 Toledo;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Men;127 Toledo;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Women;112 Toledo;Group 0800 Diseases of the ear and the mastoid 380-389;Both sexes;189 Toledo;Group 0800 Diseases of the ear and the mastoid 380-389;Men;89 Toledo;Group 0800 Diseases of the ear and the mastoid 380-389;Women;100 Toledo;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Both sexes;6,206 Toledo;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Men;3,627 Toledo;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Women;2,579 Toledo;Group 0901 Hypertensive disease 401-405;Both sexes;194 Toledo;Group 0901 Hypertensive disease 401-405;Men;91 Toledo;Group 0901 Hypertensive disease 401-405;Women;103 Toledo;Group 0902 Angina pectoris 4111, 413;Both sexes;362 Toledo;Group 0902 Angina pectoris 4111, 413;Men;239 Toledo;Group 0902 Angina pectoris 4111, 413;Women;123 Toledo;Group 0903 Acute myocardial infarction 410;Both sexes;733 Toledo;Group 0903 Acute myocardial infarction 410;Men;537 Toledo;Group 0903 Acute myocardial infarction 410;Women;196 Toledo;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Both sexes;414 Toledo;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Men;314 Toledo;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Women;100 Toledo;Group 0905 Diseases of the lungs circulation 415-417;Both sexes;192 Toledo;Group 0905 Diseases of the lungs circulation 415-417;Men;101 Toledo;Group 0905 Diseases of the lungs circulation 415-417;Women;91 Toledo;Group 0906 Heart conduction disorders and arrhytmias 426-427;Both sexes;779 Toledo;Group 0906 Heart conduction disorders and arrhytmias 426-427;Men;428 Toledo;Group 0906 Heart conduction disorders and arrhytmias 426-427;Women;351 Toledo;Grupo 0907 Heart failure 428;Both sexes;1,166 Toledo;Grupo 0907 Heart failure 428;Men;500 Toledo;Grupo 0907 Heart failure 428;Women;666 Toledo;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Both sexes;1,176 Toledo;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Men;651 Toledo;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Women;525 Toledo;Grupo 0909 Atherosclerosis 440;Both sexes;183 Toledo;Grupo 0909 Atherosclerosis 440;Men;128 Toledo;Grupo 0909 Atherosclerosis 440;Women;55 Toledo;Group 0910 Varicose veins of lower extremities 454;Both sexes;25 Toledo;Group 0910 Varicose veins of lower extremities 454;Men;4 Toledo;Group 0910 Varicose veins of lower extremities 454;Women;21 Toledo;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Both sexes;982 Toledo;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Men;634 Toledo;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Women;348 Toledo;Group 1000 Diseases of the respiratory system 0340, 460-519;Both sexes;5,336 Toledo;Group 1000 Diseases of the respiratory system 0340, 460-519;Men;3,179 Toledo;Group 1000 Diseases of the respiratory system 0340, 460-519;Women;2,157 Toledo;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Both sexes;220 Toledo;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Men;115 Toledo;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Women;105 Toledo;Group 1002 Pneumonia 480-486;Both sexes;1,447 Toledo;Group 1002 Pneumonia 480-486;Men;875 Toledo;Group 1002 Pneumonia 480-486;Women;572 Toledo;Group 1003 Acute bronchitis and bronchiolitis 466;Both sexes;234 Toledo;Group 1003 Acute bronchitis and bronchiolitis 466;Men;116 Toledo;Group 1003 Acute bronchitis and bronchiolitis 466;Women;118 Toledo;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Both sexes;204 Toledo;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Men;104 Toledo;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Women;100 Toledo;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Both sexes;443 Toledo;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Men;309 Toledo;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Women;134 Toledo;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Both sexes;786 Toledo;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Men;690 Toledo;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Women;96 Toledo;Group 1007 Asthma 4930-4931,4938-4939;Both sexes;227 Toledo;Group 1007 Asthma 4930-4931,4938-4939;Men;97 Toledo;Group 1007 Asthma 4930-4931,4938-4939;Women;130 Toledo;Group 1008 Other diseases of the respiratory system Resto of (460-519);Both sexes;1,775 Toledo;Group 1008 Other diseases of the respiratory system Resto of (460-519);Men;873 Toledo;Group 1008 Other diseases of the respiratory system Resto of (460-519);Women;902 Toledo;Group 1100 Diseases of the digestive system 520-579;Both sexes;5,459 Toledo;Group 1100 Diseases of the digestive system 520-579;Men;3,067 Toledo;Group 1100 Diseases of the digestive system 520-579;Women;2,392 Toledo;Group 1101 Disorders of the teeth and supporting structures 520-525;Both sexes;60 Toledo;Group 1101 Disorders of the teeth and supporting structures 520-525;Men;30 Toledo;Group 1101 Disorders of the teeth and supporting structures 520-525;Women;30 Toledo;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Both sexes;69 Toledo;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Men;35 Toledo;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Women;34 Toledo;Group 1103 Diseases of the esophagus 530;Both sexes;68 Toledo;Group 1103 Diseases of the esophagus 530;Men;48 Toledo;Group 1103 Diseases of the esophagus 530;Women;20 Toledo;Group 1104 Peptic ulcer 531-534;Both sexes;95 Toledo;Group 1104 Peptic ulcer 531-534;Men;64 Toledo;Group 1104 Peptic ulcer 531-534;Women;31 Toledo;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Both sexes;100 Toledo;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Men;52 Toledo;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Women;48 Toledo;Group 1106 Appendicitis 540-543;Both sexes;501 Toledo;Group 1106 Appendicitis 540-543;Men;294 Toledo;Group 1106 Appendicitis 540-543;Women;207 Toledo;Group 1107 Inguinal hernia 550;Both sexes;341 Toledo;Group 1107 Inguinal hernia 550;Men;307 Toledo;Group 1107 Inguinal hernia 550;Women;34 Toledo;Group 1108 Other abdominal hernia 551-553;Both sexes;436 Toledo;Group 1108 Other abdominal hernia 551-553;Men;203 Toledo;Group 1108 Other abdominal hernia 551-553;Women;233 Toledo;Group 1109 Crohn's disease and ulcerative colitis 555-556;Both sexes;119 Toledo;Group 1109 Crohn's disease and ulcerative colitis 555-556;Men;66 Toledo;Group 1109 Crohn's disease and ulcerative colitis 555-556;Women;53 Toledo;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Both sexes;271 Toledo;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Men;126 Toledo;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Women;145 Toledo;Group 1111 Intestinal obstruction without hernia 560;Both sexes;350 Toledo;Group 1111 Intestinal obstruction without hernia 560;Men;187 Toledo;Group 1111 Intestinal obstruction without hernia 560;Women;163 Toledo;Group 1112 Intestinal diverticulosis 562;Both sexes;242 Toledo;Group 1112 Intestinal diverticulosis 562;Men;127 Toledo;Group 1112 Intestinal diverticulosis 562;Women;115 Toledo;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Both sexes;349 Toledo;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Men;225 Toledo;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Women;124 Toledo;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Both sexes;227 Toledo;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Men;106 Toledo;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Women;121 Toledo;Group 1115 Alcoholic hepatitis 5710-5713;Both sexes;55 Toledo;Group 1115 Alcoholic hepatitis 5710-5713;Men;46 Toledo;Group 1115 Alcoholic hepatitis 5710-5713;Women;9 Toledo;Group 1116 Other diseases of the liver 570,5714-573;Both sexes;216 Toledo;Group 1116 Other diseases of the liver 570,5714-573;Men;137 Toledo;Group 1116 Other diseases of the liver 570,5714-573;Women;79 Toledo;Group 1117 Cholelithiasis 574;Both sexes;1,031 Toledo;Group 1117 Cholelithiasis 574;Men;478 Toledo;Group 1117 Cholelithiasis 574;Women;553 Toledo;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Both sexes;320 Toledo;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Men;191 Toledo;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Women;129 Toledo;Group 1119 Pancreatic diseases 577;Both sexes;414 Toledo;Group 1119 Pancreatic diseases 577;Men;235 Toledo;Group 1119 Pancreatic diseases 577;Women;179 Toledo;Group 1120 Other diseases of the digestive system Rest of (520-579);Both sexes;195 Toledo;Group 1120 Other diseases of the digestive system Rest of (520-579);Men;110 Toledo;Group 1120 Other diseases of the digestive system Rest of (520-579);Women;85 Toledo;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Both sexes;375 Toledo;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Men;203 Toledo;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Women;172 Toledo;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Both sexes;228 Toledo;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Men;126 Toledo;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Women;102 Toledo;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Both sexes;14 Toledo;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Men;9 Toledo;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Women;5 Toledo;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Both sexes;133 Toledo;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Men;68 Toledo;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Women;65 Toledo;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Both sexes;2,596 Toledo;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Men;1,266 Toledo;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Women;1,330 Toledo;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Both sexes;.. Toledo;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Men;.. Toledo;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Women;.. Toledo;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Both sexes;.. Toledo;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Men;.. Toledo;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Women;.. Toledo;Group 1303 Internal derangement of knee 717;Both sexes;315 Toledo;Group 1303 Internal derangement of knee 717;Men;223 Toledo;Group 1303 Internal derangement of knee 717;Women;92 Toledo;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Both sexes;1,126 Toledo;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Men;483 Toledo;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Women;643 Toledo;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Both sexes;45 Toledo;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Men;20 Toledo;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Women;25 Toledo;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Both sexes;122 Toledo;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Men;57 Toledo;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Women;65 Toledo;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Both sexes;223 Toledo;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Men;114 Toledo;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Women;109 Toledo;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Both sexes;47 Toledo;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Men;24 Toledo;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Women;23 Toledo;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Both sexes;362 Toledo;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Men;200 Toledo;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Women;162 Toledo;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Both sexes;356 Toledo;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Men;145 Toledo;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Women;211 Toledo;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Both sexes;2,956 Toledo;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Men;1,464 Toledo;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Women;1,492 Toledo;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Both sexes;332 Toledo;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Men;131 Toledo;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Women;201 Toledo;Group 1402 Renal failure 5836-5837, 584-586;Both sexes;278 Toledo;Group 1402 Renal failure 5836-5837, 584-586;Men;159 Toledo;Group 1402 Renal failure 5836-5837, 584-586;Women;119 Toledo;Group 1403 Urolithiasis 592, 594, 7880;Both sexes;419 Toledo;Group 1403 Urolithiasis 592, 594, 7880;Men;247 Toledo;Group 1403 Urolithiasis 592, 594, 7880;Women;172 Toledo;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Both sexes;811 Toledo;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Men;448 Toledo;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Women;363 Toledo;Group 1405 Prostatic hyperplasia 600;Both sexes;169 Toledo;Group 1405 Prostatic hyperplasia 600;Men;169 Toledo;Group 1405 Prostatic hyperplasia 600;Women;.. Toledo;Group 1406 Other diseases of the male genital organs 601-608;Both sexes;294 Toledo;Group 1406 Other diseases of the male genital organs 601-608;Men;294 Toledo;Group 1406 Other diseases of the male genital organs 601-608;Women;.. Toledo;Group 1407 Disorders of breast 610-612;Both sexes;110 Toledo;Group 1407 Disorders of breast 610-612;Men;16 Toledo;Group 1407 Disorders of breast 610-612;Women;94 Toledo;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Both sexes;70 Toledo;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Men;.. Toledo;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Women;70 Toledo;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Both sexes;69 Toledo;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Men;.. Toledo;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Women;69 Toledo;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Both sexes;404 Toledo;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Men;.. Toledo;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Women;404 Toledo;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Both sexes;5,561 Toledo;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Men;.. Toledo;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Women;5,561 Toledo;Group 1501 Legally induced abortion 635;Both sexes;1 Toledo;Group 1501 Legally induced abortion 635;Men;.. Toledo;Group 1501 Legally induced abortion 635;Women;1 Toledo;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Both sexes;389 Toledo;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Men;.. Toledo;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Women;389 Toledo;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Both sexes;3,769 Toledo;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Men;.. Toledo;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Women;3,769 Toledo;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Both sexes;375 Toledo;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Men;.. Toledo;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Women;375 Toledo;Group 1505 Single spontaneous delivery 650;Both sexes;388 Toledo;Group 1505 Single spontaneous delivery 650;Men;.. Toledo;Group 1505 Single spontaneous delivery 650;Women;388 Toledo;Group 1506 Other deliveries 6695-6697;Both sexes;211 Toledo;Group 1506 Other deliveries 6695-6697;Men;.. Toledo;Group 1506 Other deliveries 6695-6697;Women;211 Toledo;Group 1507 Complications related to the puerperium 670-676;Both sexes;45 Toledo;Group 1507 Complications related to the puerperium 670-676;Men;.. Toledo;Group 1507 Complications related to the puerperium 670-676;Women;45 Toledo;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Both sexes;383 Toledo;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Men;.. Toledo;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Women;383 Toledo;Group 1600 Some disorders originating in the perinatal period 760-779;Both sexes;968 Toledo;Group 1600 Some disorders originating in the perinatal period 760-779;Men;518 Toledo;Group 1600 Some disorders originating in the perinatal period 760-779;Women;450 Toledo;Group 1601 Disorders related with premature delivery and a low birth weight 765;Both sexes;244 Toledo;Group 1601 Disorders related with premature delivery and a low birth weight 765;Men;123 Toledo;Group 1601 Disorders related with premature delivery and a low birth weight 765;Women;121 Toledo;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Both sexes;724 Toledo;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Men;395 Toledo;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Women;329 Toledo;Grupo 1700 Congenital abnormalities 740-759;Both sexes;360 Toledo;Grupo 1700 Congenital abnormalities 740-759;Men;198 Toledo;Grupo 1700 Congenital abnormalities 740-759;Women;162 Toledo;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Both sexes;1,575 Toledo;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Men;864 Toledo;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Women;711 Toledo;Group 1801 Pain in throat and chest 7841, 7865;Both sexes;152 Toledo;Group 1801 Pain in throat and chest 7841, 7865;Men;85 Toledo;Group 1801 Pain in throat and chest 7841, 7865;Women;67 Toledo;Group 1802 Abdominal pain 7890;Both sexes;189 Toledo;Group 1802 Abdominal pain 7890;Men;76 Toledo;Group 1802 Abdominal pain 7890;Women;113 Toledo;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Both sexes;8 Toledo;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Men;4 Toledo;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Women;4 Toledo;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Both sexes;1,226 Toledo;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Men;699 Toledo;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Women;527 Toledo;Group 1900 Injuries and poisoning 800-999;Both sexes;4,414 Toledo;Group 1900 Injuries and poisoning 800-999;Men;2,260 Toledo;Group 1900 Injuries and poisoning 800-999;Women;2,154 Toledo;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Both sexes;267 Toledo;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Men;166 Toledo;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Women;101 Toledo;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Both sexes;92 Toledo;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Men;70 Toledo;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Women;22 Toledo;Group 1903 Radius and ulna fracture 813;Both sexes;248 Toledo;Group 1903 Radius and ulna fracture 813;Men;97 Toledo;Group 1903 Radius and ulna fracture 813;Women;151 Toledo;Group 1904 Femur fracture 820-821;Both sexes;854 Toledo;Group 1904 Femur fracture 820-821;Men;234 Toledo;Group 1904 Femur fracture 820-821;Women;620 Toledo;Group 1905 Leg fracture, including the ankle 823-824;Both sexes;400 Toledo;Group 1905 Leg fracture, including the ankle 823-824;Men;218 Toledo;Group 1905 Leg fracture, including the ankle 823-824;Women;182 Toledo;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Both sexes;1,341 Toledo;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Men;836 Toledo;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Women;505 Toledo;Group 1907 Burns 940-949;Both sexes;10 Toledo;Group 1907 Burns 940-949;Men;7 Toledo;Group 1907 Burns 940-949;Women;3 Toledo;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Both sexes;113 Toledo;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Men;53 Toledo;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Women;60 Toledo;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Both sexes;966 Toledo;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Men;523 Toledo;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Women;443 Toledo;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Both sexes;2 Toledo;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Men;1 Toledo;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Women;1 Toledo;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Both sexes;121 Toledo;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Men;55 Toledo;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Women;66 Toledo;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Both sexes;590 Toledo;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Men;344 Toledo;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Women;246 Toledo;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Both sexes;6 Toledo;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Men;4 Toledo;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Women;2 Toledo;Group 2102 Contraceptive management V25;Both sexes;9 Toledo;Group 2102 Contraceptive management V25;Men;5 Toledo;Group 2102 Contraceptive management V25;Women;4 Toledo;Group 2103 Living newborns by type of delivery V30-V39;Both sexes;.. Toledo;Group 2103 Living newborns by type of delivery V30-V39;Men;.. Toledo;Group 2103 Living newborns by type of delivery V30-V39;Women;.. Toledo;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Both sexes;279 Toledo;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Men;193 Toledo;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Women;86 Toledo;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Both sexes;296 Toledo;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Men;142 Toledo;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Women;154 CATALUÐA;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Both sexes;808,410 CATALUÐA;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Men;380,712 CATALUÐA;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Women;427,698 CATALUÐA;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Both sexes;14,143 CATALUÐA;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Men;7,880 CATALUÐA;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Women;6,263 CATALUÐA;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Both sexes;2,376 CATALUÐA;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Men;1,214 CATALUÐA;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Women;1,161 CATALUÐA;Group 0102 Imprecise intestinal infections 009;Both sexes;2,121 CATALUÐA;Group 0102 Imprecise intestinal infections 009;Men;1,031 CATALUÐA;Group 0102 Imprecise intestinal infections 009;Women;1,090 CATALUÐA;Group 0103 Tuberculosis 010-018, 137;Both sexes;771 CATALUÐA;Group 0103 Tuberculosis 010-018, 137;Men;492 CATALUÐA;Group 0103 Tuberculosis 010-018, 137;Women;279 CATALUÐA;Group 0104 Septicaemia 038;Both sexes;3,350 CATALUÐA;Group 0104 Septicaemia 038;Men;1,817 CATALUÐA;Group 0104 Septicaemia 038;Women;1,533 CATALUÐA;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Both sexes;739 CATALUÐA;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Men;576 CATALUÐA;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Women;164 CATALUÐA;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Both sexes;4,786 CATALUÐA;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Men;2,751 CATALUÐA;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Women;2,035 CATALUÐA;Group 0200 Neoplasms 140-239;Both sexes;79,292 CATALUÐA;Group 0200 Neoplasms 140-239;Men;42,444 CATALUÐA;Group 0200 Neoplasms 140-239;Women;36,848 CATALUÐA;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Both sexes;8,752 CATALUÐA;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Men;5,222 CATALUÐA;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Women;3,530 CATALUÐA;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Both sexes;6,530 CATALUÐA;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Men;5,149 CATALUÐA;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Women;1,381 CATALUÐA;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Both sexes;1,054 CATALUÐA;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Men;624 CATALUÐA;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Women;431 CATALUÐA;Group 0204 Malignant neoplasm of breast 174-175;Both sexes;6,731 CATALUÐA;Group 0204 Malignant neoplasm of breast 174-175;Men;51 CATALUÐA;Group 0204 Malignant neoplasm of breast 174-175;Women;6,681 CATALUÐA;Group 0205 Malignant neoplasm of uterus 179-180, 182;Both sexes;1,579 CATALUÐA;Group 0205 Malignant neoplasm of uterus 179-180, 182;Men;.. CATALUÐA;Group 0205 Malignant neoplasm of uterus 179-180, 182;Women;1,579 CATALUÐA;Group 0206 Malignant neoplasm of ovary 1830;Both sexes;891 CATALUÐA;Group 0206 Malignant neoplasm of ovary 1830;Men;.. CATALUÐA;Group 0206 Malignant neoplasm of ovary 1830;Women;891 CATALUÐA;Group 0207 Malignant neoplasm of prostate 185;Both sexes;3,016 CATALUÐA;Group 0207 Malignant neoplasm of prostate 185;Men;3,016 CATALUÐA;Group 0207 Malignant neoplasm of prostate 185;Women;.. CATALUÐA;Group 0208 Malignant neoplasm of bladder 188;Both sexes;8,258 CATALUÐA;Group 0208 Malignant neoplasm of bladder 188;Men;7,013 CATALUÐA;Group 0208 Malignant neoplasm of bladder 188;Women;1,246 CATALUÐA;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Both sexes;28,415 CATALUÐA;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Men;16,798 CATALUÐA;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Women;11,616 CATALUÐA;Group 0210 Carcinoma in situ 230-234;Both sexes;928 CATALUÐA;Group 0210 Carcinoma in situ 230-234;Men;373 CATALUÐA;Group 0210 Carcinoma in situ 230-234;Women;555 CATALUÐA;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Both sexes;738 CATALUÐA;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Men;454 CATALUÐA;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Women;284 CATALUÐA;Grupo 0212 Leiomyoma of uterus 218;Both sexes;3,783 CATALUÐA;Grupo 0212 Leiomyoma of uterus 218;Men;.. CATALUÐA;Grupo 0212 Leiomyoma of uterus 218;Women;3,783 CATALUÐA;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Both sexes;8,617 CATALUÐA;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Men;3,745 CATALUÐA;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Women;4,872 CATALUÐA;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Both sexes;6,866 CATALUÐA;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Men;3,338 CATALUÐA;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Women;3,528 CATALUÐA;Group 0301 Anaemias 280-285;Both sexes;3,807 CATALUÐA;Group 0301 Anaemias 280-285;Men;1,762 CATALUÐA;Group 0301 Anaemias 280-285;Women;2,046 CATALUÐA;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Both sexes;3,059 CATALUÐA;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Men;1,577 CATALUÐA;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Women;1,482 CATALUÐA;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Both sexes;14,102 CATALUÐA;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Men;5,649 CATALUÐA;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Women;8,453 CATALUÐA;Group 0401 Diabetes mellitus 249-250;Both sexes;4,792 CATALUÐA;Group 0401 Diabetes mellitus 249-250;Men;2,736 CATALUÐA;Group 0401 Diabetes mellitus 249-250;Women;2,056 CATALUÐA;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Both sexes;9,310 CATALUÐA;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Men;2,913 CATALUÐA;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Women;6,397 CATALUÐA;Group 0500 Mental disorders 290-319;Both sexes;28,734 CATALUÐA;Group 0500 Mental disorders 290-319;Men;14,815 CATALUÐA;Group 0500 Mental disorders 290-319;Women;13,918 CATALUÐA;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Both sexes;1,938 CATALUÐA;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Men;813 CATALUÐA;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Women;1,125 CATALUÐA;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Both sexes;1,835 CATALUÐA;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Men;1,356 CATALUÐA;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Women;479 CATALUÐA;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Both sexes;1,624 CATALUÐA;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Men;1,188 CATALUÐA;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Women;435 CATALUÐA;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Both sexes;8,670 CATALUÐA;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Men;5,351 CATALUÐA;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Women;3,319 CATALUÐA;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Both sexes;6,578 CATALUÐA;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Men;2,660 CATALUÐA;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Women;3,918 CATALUÐA;Group 0506 Other mental and behavioural disorders Rest of (290-319);Both sexes;8,089 CATALUÐA;Group 0506 Other mental and behavioural disorders Rest of (290-319);Men;3,446 CATALUÐA;Group 0506 Other mental and behavioural disorders Rest of (290-319);Women;4,643 CATALUÐA;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Both sexes;16,551 CATALUÐA;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Men;7,883 CATALUÐA;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Women;8,669 CATALUÐA;Group 0601 Alzheimer's disease 3310;Both sexes;1,531 CATALUÐA;Group 0601 Alzheimer's disease 3310;Men;502 CATALUÐA;Group 0601 Alzheimer's disease 3310;Women;1,028 CATALUÐA;Group 0602 Multiple sclerosis 340;Both sexes;181 CATALUÐA;Group 0602 Multiple sclerosis 340;Men;66 CATALUÐA;Group 0602 Multiple sclerosis 340;Women;115 CATALUÐA;Group 0603 Epilepsy 345;Both sexes;2,762 CATALUÐA;Group 0603 Epilepsy 345;Men;1,462 CATALUÐA;Group 0603 Epilepsy 345;Women;1,300 CATALUÐA;Group 0604 Transient cerebral ischemia 435;Both sexes;2,191 CATALUÐA;Group 0604 Transient cerebral ischemia 435;Men;1,125 CATALUÐA;Group 0604 Transient cerebral ischemia 435;Women;1,066 CATALUÐA;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Both sexes;9,887 CATALUÐA;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Men;4,728 CATALUÐA;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Women;5,160 CATALUÐA;Grupo 0700 Diseases of the eye and adnexa 360-379;Both sexes;5,266 CATALUÐA;Grupo 0700 Diseases of the eye and adnexa 360-379;Men;2,623 CATALUÐA;Grupo 0700 Diseases of the eye and adnexa 360-379;Women;2,643 CATALUÐA;Grupo 0701 Cataract 366;Both sexes;1,688 CATALUÐA;Grupo 0701 Cataract 366;Men;706 CATALUÐA;Grupo 0701 Cataract 366;Women;983 CATALUÐA;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Both sexes;3,577 CATALUÐA;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Men;1,917 CATALUÐA;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Women;1,660 CATALUÐA;Group 0800 Diseases of the ear and the mastoid 380-389;Both sexes;4,157 CATALUÐA;Group 0800 Diseases of the ear and the mastoid 380-389;Men;1,993 CATALUÐA;Group 0800 Diseases of the ear and the mastoid 380-389;Women;2,164 CATALUÐA;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Both sexes;103,687 CATALUÐA;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Men;57,287 CATALUÐA;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Women;46,400 CATALUÐA;Group 0901 Hypertensive disease 401-405;Both sexes;4,191 CATALUÐA;Group 0901 Hypertensive disease 401-405;Men;1,693 CATALUÐA;Group 0901 Hypertensive disease 401-405;Women;2,499 CATALUÐA;Group 0902 Angina pectoris 4111, 413;Both sexes;3,489 CATALUÐA;Group 0902 Angina pectoris 4111, 413;Men;2,240 CATALUÐA;Group 0902 Angina pectoris 4111, 413;Women;1,249 CATALUÐA;Group 0903 Acute myocardial infarction 410;Both sexes;9,581 CATALUÐA;Group 0903 Acute myocardial infarction 410;Men;6,741 CATALUÐA;Group 0903 Acute myocardial infarction 410;Women;2,841 CATALUÐA;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Both sexes;7,473 CATALUÐA;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Men;5,740 CATALUÐA;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Women;1,732 CATALUÐA;Group 0905 Diseases of the lungs circulation 415-417;Both sexes;2,837 CATALUÐA;Group 0905 Diseases of the lungs circulation 415-417;Men;1,309 CATALUÐA;Group 0905 Diseases of the lungs circulation 415-417;Women;1,528 CATALUÐA;Group 0906 Heart conduction disorders and arrhytmias 426-427;Both sexes;12,905 CATALUÐA;Group 0906 Heart conduction disorders and arrhytmias 426-427;Men;6,960 CATALUÐA;Group 0906 Heart conduction disorders and arrhytmias 426-427;Women;5,945 CATALUÐA;Grupo 0907 Heart failure 428;Both sexes;23,624 CATALUÐA;Grupo 0907 Heart failure 428;Men;10,727 CATALUÐA;Grupo 0907 Heart failure 428;Women;12,897 CATALUÐA;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Both sexes;18,879 CATALUÐA;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Men;9,855 CATALUÐA;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Women;9,025 CATALUÐA;Grupo 0909 Atherosclerosis 440;Both sexes;4,303 CATALUÐA;Grupo 0909 Atherosclerosis 440;Men;3,066 CATALUÐA;Grupo 0909 Atherosclerosis 440;Women;1,237 CATALUÐA;Group 0910 Varicose veins of lower extremities 454;Both sexes;1,974 CATALUÐA;Group 0910 Varicose veins of lower extremities 454;Men;635 CATALUÐA;Group 0910 Varicose veins of lower extremities 454;Women;1,339 CATALUÐA;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Both sexes;14,429 CATALUÐA;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Men;8,321 CATALUÐA;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Women;6,108 CATALUÐA;Group 1000 Diseases of the respiratory system 0340, 460-519;Both sexes;90,877 CATALUÐA;Group 1000 Diseases of the respiratory system 0340, 460-519;Men;51,779 CATALUÐA;Group 1000 Diseases of the respiratory system 0340, 460-519;Women;39,098 CATALUÐA;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Both sexes;2,470 CATALUÐA;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Men;1,303 CATALUÐA;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Women;1,167 CATALUÐA;Group 1002 Pneumonia 480-486;Both sexes;18,401 CATALUÐA;Group 1002 Pneumonia 480-486;Men;10,899 CATALUÐA;Group 1002 Pneumonia 480-486;Women;7,502 CATALUÐA;Group 1003 Acute bronchitis and bronchiolitis 466;Both sexes;12,036 CATALUÐA;Group 1003 Acute bronchitis and bronchiolitis 466;Men;5,618 CATALUÐA;Group 1003 Acute bronchitis and bronchiolitis 466;Women;6,418 CATALUÐA;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Both sexes;3,487 CATALUÐA;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Men;1,790 CATALUÐA;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Women;1,697 CATALUÐA;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Both sexes;6,785 CATALUÐA;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Men;4,130 CATALUÐA;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Women;2,656 CATALUÐA;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Both sexes;17,844 CATALUÐA;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Men;13,432 CATALUÐA;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Women;4,413 CATALUÐA;Group 1007 Asthma 4930-4931,4938-4939;Both sexes;3,740 CATALUÐA;Group 1007 Asthma 4930-4931,4938-4939;Men;946 CATALUÐA;Group 1007 Asthma 4930-4931,4938-4939;Women;2,794 CATALUÐA;Group 1008 Other diseases of the respiratory system Resto of (460-519);Both sexes;26,113 CATALUÐA;Group 1008 Other diseases of the respiratory system Resto of (460-519);Men;13,662 CATALUÐA;Group 1008 Other diseases of the respiratory system Resto of (460-519);Women;12,451 CATALUÐA;Group 1100 Diseases of the digestive system 520-579;Both sexes;91,542 CATALUÐA;Group 1100 Diseases of the digestive system 520-579;Men;50,359 CATALUÐA;Group 1100 Diseases of the digestive system 520-579;Women;41,183 CATALUÐA;Group 1101 Disorders of the teeth and supporting structures 520-525;Both sexes;1,394 CATALUÐA;Group 1101 Disorders of the teeth and supporting structures 520-525;Men;653 CATALUÐA;Group 1101 Disorders of the teeth and supporting structures 520-525;Women;741 CATALUÐA;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Both sexes;1,117 CATALUÐA;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Men;636 CATALUÐA;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Women;481 CATALUÐA;Group 1103 Diseases of the esophagus 530;Both sexes;1,430 CATALUÐA;Group 1103 Diseases of the esophagus 530;Men;839 CATALUÐA;Group 1103 Diseases of the esophagus 530;Women;590 CATALUÐA;Group 1104 Peptic ulcer 531-534;Both sexes;1,743 CATALUÐA;Group 1104 Peptic ulcer 531-534;Men;1,190 CATALUÐA;Group 1104 Peptic ulcer 531-534;Women;552 CATALUÐA;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Both sexes;2,132 CATALUÐA;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Men;1,044 CATALUÐA;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Women;1,088 CATALUÐA;Group 1106 Appendicitis 540-543;Both sexes;7,749 CATALUÐA;Group 1106 Appendicitis 540-543;Men;4,453 CATALUÐA;Group 1106 Appendicitis 540-543;Women;3,296 CATALUÐA;Group 1107 Inguinal hernia 550;Both sexes;9,445 CATALUÐA;Group 1107 Inguinal hernia 550;Men;8,400 CATALUÐA;Group 1107 Inguinal hernia 550;Women;1,044 CATALUÐA;Group 1108 Other abdominal hernia 551-553;Both sexes;8,111 CATALUÐA;Group 1108 Other abdominal hernia 551-553;Men;3,573 CATALUÐA;Group 1108 Other abdominal hernia 551-553;Women;4,537 CATALUÐA;Group 1109 Crohn's disease and ulcerative colitis 555-556;Both sexes;1,582 CATALUÐA;Group 1109 Crohn's disease and ulcerative colitis 555-556;Men;783 CATALUÐA;Group 1109 Crohn's disease and ulcerative colitis 555-556;Women;799 CATALUÐA;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Both sexes;4,390 CATALUÐA;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Men;1,988 CATALUÐA;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Women;2,402 CATALUÐA;Group 1111 Intestinal obstruction without hernia 560;Both sexes;4,471 CATALUÐA;Group 1111 Intestinal obstruction without hernia 560;Men;2,236 CATALUÐA;Group 1111 Intestinal obstruction without hernia 560;Women;2,235 CATALUÐA;Group 1112 Intestinal diverticulosis 562;Both sexes;3,878 CATALUÐA;Group 1112 Intestinal diverticulosis 562;Men;1,919 CATALUÐA;Group 1112 Intestinal diverticulosis 562;Women;1,959 CATALUÐA;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Both sexes;5,281 CATALUÐA;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Men;3,311 CATALUÐA;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Women;1,970 CATALUÐA;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Both sexes;3,111 CATALUÐA;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Men;1,443 CATALUÐA;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Women;1,668 CATALUÐA;Group 1115 Alcoholic hepatitis 5710-5713;Both sexes;1,812 CATALUÐA;Group 1115 Alcoholic hepatitis 5710-5713;Men;1,452 CATALUÐA;Group 1115 Alcoholic hepatitis 5710-5713;Women;360 CATALUÐA;Group 1116 Other diseases of the liver 570,5714-573;Both sexes;3,652 CATALUÐA;Group 1116 Other diseases of the liver 570,5714-573;Men;2,068 CATALUÐA;Group 1116 Other diseases of the liver 570,5714-573;Women;1,584 CATALUÐA;Group 1117 Cholelithiasis 574;Both sexes;17,256 CATALUÐA;Group 1117 Cholelithiasis 574;Men;7,226 CATALUÐA;Group 1117 Cholelithiasis 574;Women;10,030 CATALUÐA;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Both sexes;4,445 CATALUÐA;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Men;2,420 CATALUÐA;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Women;2,025 CATALUÐA;Group 1119 Pancreatic diseases 577;Both sexes;4,929 CATALUÐA;Group 1119 Pancreatic diseases 577;Men;2,760 CATALUÐA;Group 1119 Pancreatic diseases 577;Women;2,169 CATALUÐA;Group 1120 Other diseases of the digestive system Rest of (520-579);Both sexes;3,615 CATALUÐA;Group 1120 Other diseases of the digestive system Rest of (520-579);Men;1,963 CATALUÐA;Group 1120 Other diseases of the digestive system Rest of (520-579);Women;1,652 CATALUÐA;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Both sexes;8,496 CATALUÐA;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Men;4,357 CATALUÐA;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Women;4,139 CATALUÐA;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Both sexes;5,187 CATALUÐA;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Men;2,919 CATALUÐA;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Women;2,268 CATALUÐA;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Both sexes;322 CATALUÐA;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Men;161 CATALUÐA;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Women;161 CATALUÐA;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Both sexes;2,988 CATALUÐA;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Men;1,278 CATALUÐA;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Women;1,710 CATALUÐA;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Both sexes;65,451 CATALUÐA;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Men;30,630 CATALUÐA;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Women;34,821 CATALUÐA;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Both sexes;.. CATALUÐA;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Men;.. CATALUÐA;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Women;.. CATALUÐA;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Both sexes;.. CATALUÐA;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Men;.. CATALUÐA;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Women;.. CATALUÐA;Group 1303 Internal derangement of knee 717;Both sexes;9,348 CATALUÐA;Group 1303 Internal derangement of knee 717;Men;6,185 CATALUÐA;Group 1303 Internal derangement of knee 717;Women;3,163 CATALUÐA;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Both sexes;23,521 CATALUÐA;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Men;9,612 CATALUÐA;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Women;13,909 CATALUÐA;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Both sexes;945 CATALUÐA;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Men;343 CATALUÐA;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Women;603 CATALUÐA;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Both sexes;3,141 CATALUÐA;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Men;1,404 CATALUÐA;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Women;1,737 CATALUÐA;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Both sexes;5,557 CATALUÐA;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Men;3,002 CATALUÐA;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Women;2,555 CATALUÐA;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Both sexes;1,780 CATALUÐA;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Men;815 CATALUÐA;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Women;965 CATALUÐA;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Both sexes;10,597 CATALUÐA;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Men;5,165 CATALUÐA;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Women;5,432 CATALUÐA;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Both sexes;10,561 CATALUÐA;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Men;4,104 CATALUÐA;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Women;6,457 CATALUÐA;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Both sexes;58,124 CATALUÐA;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Men;27,071 CATALUÐA;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Women;31,053 CATALUÐA;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Both sexes;7,386 CATALUÐA;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Men;2,249 CATALUÐA;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Women;5,136 CATALUÐA;Group 1402 Renal failure 5836-5837, 584-586;Both sexes;5,843 CATALUÐA;Group 1402 Renal failure 5836-5837, 584-586;Men;3,320 CATALUÐA;Group 1402 Renal failure 5836-5837, 584-586;Women;2,522 CATALUÐA;Group 1403 Urolithiasis 592, 594, 7880;Both sexes;6,920 CATALUÐA;Group 1403 Urolithiasis 592, 594, 7880;Men;4,256 CATALUÐA;Group 1403 Urolithiasis 592, 594, 7880;Women;2,664 CATALUÐA;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Both sexes;13,733 CATALUÐA;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Men;6,731 CATALUÐA;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Women;7,002 CATALUÐA;Group 1405 Prostatic hyperplasia 600;Both sexes;5,122 CATALUÐA;Group 1405 Prostatic hyperplasia 600;Men;5,122 CATALUÐA;Group 1405 Prostatic hyperplasia 600;Women;.. CATALUÐA;Group 1406 Other diseases of the male genital organs 601-608;Both sexes;4,967 CATALUÐA;Group 1406 Other diseases of the male genital organs 601-608;Men;4,967 CATALUÐA;Group 1406 Other diseases of the male genital organs 601-608;Women;.. CATALUÐA;Group 1407 Disorders of breast 610-612;Both sexes;3,907 CATALUÐA;Group 1407 Disorders of breast 610-612;Men;289 CATALUÐA;Group 1407 Disorders of breast 610-612;Women;3,618 CATALUÐA;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Both sexes;1,245 CATALUÐA;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Men;.. CATALUÐA;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Women;1,245 CATALUÐA;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Both sexes;464 CATALUÐA;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Men;.. CATALUÐA;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Women;464 CATALUÐA;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Both sexes;8,536 CATALUÐA;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Men;135 CATALUÐA;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Women;8,400 CATALUÐA;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Both sexes;78,989 CATALUÐA;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Men;.. CATALUÐA;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Women;78,989 CATALUÐA;Group 1501 Legally induced abortion 635;Both sexes;624 CATALUÐA;Group 1501 Legally induced abortion 635;Men;.. CATALUÐA;Group 1501 Legally induced abortion 635;Women;624 CATALUÐA;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Both sexes;3,051 CATALUÐA;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Men;.. CATALUÐA;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Women;3,051 CATALUÐA;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Both sexes;39,052 CATALUÐA;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Men;.. CATALUÐA;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Women;39,052 CATALUÐA;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Both sexes;18,222 CATALUÐA;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Men;.. CATALUÐA;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Women;18,222 CATALUÐA;Group 1505 Single spontaneous delivery 650;Both sexes;7,970 CATALUÐA;Group 1505 Single spontaneous delivery 650;Men;.. CATALUÐA;Group 1505 Single spontaneous delivery 650;Women;7,970 CATALUÐA;Group 1506 Other deliveries 6695-6697;Both sexes;2,823 CATALUÐA;Group 1506 Other deliveries 6695-6697;Men;.. CATALUÐA;Group 1506 Other deliveries 6695-6697;Women;2,823 CATALUÐA;Group 1507 Complications related to the puerperium 670-676;Both sexes;864 CATALUÐA;Group 1507 Complications related to the puerperium 670-676;Men;.. CATALUÐA;Group 1507 Complications related to the puerperium 670-676;Women;864 CATALUÐA;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Both sexes;6,384 CATALUÐA;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Men;.. CATALUÐA;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Women;6,384 CATALUÐA;Group 1600 Some disorders originating in the perinatal period 760-779;Both sexes;12,662 CATALUÐA;Group 1600 Some disorders originating in the perinatal period 760-779;Men;6,982 CATALUÐA;Group 1600 Some disorders originating in the perinatal period 760-779;Women;5,681 CATALUÐA;Group 1601 Disorders related with premature delivery and a low birth weight 765;Both sexes;3,724 CATALUÐA;Group 1601 Disorders related with premature delivery and a low birth weight 765;Men;2,002 CATALUÐA;Group 1601 Disorders related with premature delivery and a low birth weight 765;Women;1,722 CATALUÐA;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Both sexes;8,938 CATALUÐA;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Men;4,980 CATALUÐA;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Women;3,958 CATALUÐA;Grupo 1700 Congenital abnormalities 740-759;Both sexes;6,790 CATALUÐA;Grupo 1700 Congenital abnormalities 740-759;Men;3,769 CATALUÐA;Grupo 1700 Congenital abnormalities 740-759;Women;3,021 CATALUÐA;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Both sexes;29,898 CATALUÐA;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Men;16,378 CATALUÐA;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Women;13,520 CATALUÐA;Group 1801 Pain in throat and chest 7841, 7865;Both sexes;3,003 CATALUÐA;Group 1801 Pain in throat and chest 7841, 7865;Men;1,716 CATALUÐA;Group 1801 Pain in throat and chest 7841, 7865;Women;1,287 CATALUÐA;Group 1802 Abdominal pain 7890;Both sexes;3,587 CATALUÐA;Group 1802 Abdominal pain 7890;Men;1,390 CATALUÐA;Group 1802 Abdominal pain 7890;Women;2,197 CATALUÐA;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Both sexes;1,404 CATALUÐA;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Men;721 CATALUÐA;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Women;682 CATALUÐA;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Both sexes;21,904 CATALUÐA;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Men;12,550 CATALUÐA;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Women;9,354 CATALUÐA;Group 1900 Injuries and poisoning 800-999;Both sexes;76,634 CATALUÐA;Group 1900 Injuries and poisoning 800-999;Men;37,091 CATALUÐA;Group 1900 Injuries and poisoning 800-999;Women;39,544 CATALUÐA;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Both sexes;5,084 CATALUÐA;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Men;2,745 CATALUÐA;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Women;2,339 CATALUÐA;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Both sexes;1,666 CATALUÐA;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Men;1,107 CATALUÐA;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Women;558 CATALUÐA;Group 1903 Radius and ulna fracture 813;Both sexes;4,019 CATALUÐA;Group 1903 Radius and ulna fracture 813;Men;1,983 CATALUÐA;Group 1903 Radius and ulna fracture 813;Women;2,036 CATALUÐA;Group 1904 Femur fracture 820-821;Both sexes;15,773 CATALUÐA;Group 1904 Femur fracture 820-821;Men;4,323 CATALUÐA;Group 1904 Femur fracture 820-821;Women;11,449 CATALUÐA;Group 1905 Leg fracture, including the ankle 823-824;Both sexes;5,129 CATALUÐA;Group 1905 Leg fracture, including the ankle 823-824;Men;2,620 CATALUÐA;Group 1905 Leg fracture, including the ankle 823-824;Women;2,508 CATALUÐA;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Both sexes;21,238 CATALUÐA;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Men;12,071 CATALUÐA;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Women;9,168 CATALUÐA;Group 1907 Burns 940-949;Both sexes;596 CATALUÐA;Group 1907 Burns 940-949;Men;390 CATALUÐA;Group 1907 Burns 940-949;Women;206 CATALUÐA;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Both sexes;2,343 CATALUÐA;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Men;966 CATALUÐA;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Women;1,377 CATALUÐA;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Both sexes;18,412 CATALUÐA;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Men;9,587 CATALUÐA;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Women;8,825 CATALUÐA;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Both sexes;222 CATALUÐA;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Men;139 CATALUÐA;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Women;83 CATALUÐA;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Both sexes;2,153 CATALUÐA;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Men;1,159 CATALUÐA;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Women;994 CATALUÐA;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Both sexes;16,148 CATALUÐA;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Men;8,386 CATALUÐA;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Women;7,763 CATALUÐA;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Both sexes;342 CATALUÐA;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Men;214 CATALUÐA;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Women;129 CATALUÐA;Group 2102 Contraceptive management V25;Both sexes;267 CATALUÐA;Group 2102 Contraceptive management V25;Men;17 CATALUÐA;Group 2102 Contraceptive management V25;Women;250 CATALUÐA;Group 2103 Living newborns by type of delivery V30-V39;Both sexes;.. CATALUÐA;Group 2103 Living newborns by type of delivery V30-V39;Men;.. CATALUÐA;Group 2103 Living newborns by type of delivery V30-V39;Women;.. CATALUÐA;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Both sexes;4,225 CATALUÐA;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Men;2,547 CATALUÐA;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Women;1,678 CATALUÐA;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Both sexes;11,314 CATALUÐA;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Men;5,607 CATALUÐA;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Women;5,707 Barcelona;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Both sexes;629,644 Barcelona;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Men;296,000 Barcelona;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Women;333,644 Barcelona;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Both sexes;11,202 Barcelona;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Men;6,231 Barcelona;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Women;4,971 Barcelona;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Both sexes;1,950 Barcelona;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Men;991 Barcelona;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Women;959 Barcelona;Group 0102 Imprecise intestinal infections 009;Both sexes;1,628 Barcelona;Group 0102 Imprecise intestinal infections 009;Men;818 Barcelona;Group 0102 Imprecise intestinal infections 009;Women;810 Barcelona;Group 0103 Tuberculosis 010-018, 137;Both sexes;571 Barcelona;Group 0103 Tuberculosis 010-018, 137;Men;354 Barcelona;Group 0103 Tuberculosis 010-018, 137;Women;217 Barcelona;Group 0104 Septicaemia 038;Both sexes;2,746 Barcelona;Group 0104 Septicaemia 038;Men;1,470 Barcelona;Group 0104 Septicaemia 038;Women;1,276 Barcelona;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Both sexes;536 Barcelona;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Men;427 Barcelona;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Women;109 Barcelona;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Both sexes;3,772 Barcelona;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Men;2,171 Barcelona;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Women;1,601 Barcelona;Group 0200 Neoplasms 140-239;Both sexes;62,282 Barcelona;Group 0200 Neoplasms 140-239;Men;33,107 Barcelona;Group 0200 Neoplasms 140-239;Women;29,175 Barcelona;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Both sexes;6,557 Barcelona;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Men;3,906 Barcelona;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Women;2,651 Barcelona;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Both sexes;5,040 Barcelona;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Men;3,958 Barcelona;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Women;1,083 Barcelona;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Both sexes;824 Barcelona;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Men;474 Barcelona;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Women;350 Barcelona;Group 0204 Malignant neoplasm of breast 174-175;Both sexes;5,191 Barcelona;Group 0204 Malignant neoplasm of breast 174-175;Men;44 Barcelona;Group 0204 Malignant neoplasm of breast 174-175;Women;5,146 Barcelona;Group 0205 Malignant neoplasm of uterus 179-180, 182;Both sexes;1,280 Barcelona;Group 0205 Malignant neoplasm of uterus 179-180, 182;Men;.. Barcelona;Group 0205 Malignant neoplasm of uterus 179-180, 182;Women;1,280 Barcelona;Group 0206 Malignant neoplasm of ovary 1830;Both sexes;717 Barcelona;Group 0206 Malignant neoplasm of ovary 1830;Men;.. Barcelona;Group 0206 Malignant neoplasm of ovary 1830;Women;717 Barcelona;Group 0207 Malignant neoplasm of prostate 185;Both sexes;2,492 Barcelona;Group 0207 Malignant neoplasm of prostate 185;Men;2,492 Barcelona;Group 0207 Malignant neoplasm of prostate 185;Women;.. Barcelona;Group 0208 Malignant neoplasm of bladder 188;Both sexes;6,252 Barcelona;Group 0208 Malignant neoplasm of bladder 188;Men;5,246 Barcelona;Group 0208 Malignant neoplasm of bladder 188;Women;1,006 Barcelona;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Both sexes;22,806 Barcelona;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Men;13,416 Barcelona;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Women;9,390 Barcelona;Group 0210 Carcinoma in situ 230-234;Both sexes;782 Barcelona;Group 0210 Carcinoma in situ 230-234;Men;318 Barcelona;Group 0210 Carcinoma in situ 230-234;Women;463 Barcelona;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Both sexes;583 Barcelona;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Men;352 Barcelona;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Women;230 Barcelona;Grupo 0212 Leiomyoma of uterus 218;Both sexes;2,981 Barcelona;Grupo 0212 Leiomyoma of uterus 218;Men;.. Barcelona;Grupo 0212 Leiomyoma of uterus 218;Women;2,981 Barcelona;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Both sexes;6,778 Barcelona;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Men;2,900 Barcelona;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Women;3,877 Barcelona;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Both sexes;5,325 Barcelona;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Men;2,589 Barcelona;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Women;2,737 Barcelona;Group 0301 Anaemias 280-285;Both sexes;2,847 Barcelona;Group 0301 Anaemias 280-285;Men;1,307 Barcelona;Group 0301 Anaemias 280-285;Women;1,540 Barcelona;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Both sexes;2,478 Barcelona;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Men;1,282 Barcelona;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Women;1,197 Barcelona;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Both sexes;11,566 Barcelona;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Men;4,604 Barcelona;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Women;6,962 Barcelona;Group 0401 Diabetes mellitus 249-250;Both sexes;3,825 Barcelona;Group 0401 Diabetes mellitus 249-250;Men;2,191 Barcelona;Group 0401 Diabetes mellitus 249-250;Women;1,635 Barcelona;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Both sexes;7,741 Barcelona;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Men;2,413 Barcelona;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Women;5,328 Barcelona;Group 0500 Mental disorders 290-319;Both sexes;22,508 Barcelona;Group 0500 Mental disorders 290-319;Men;11,421 Barcelona;Group 0500 Mental disorders 290-319;Women;11,088 Barcelona;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Both sexes;1,536 Barcelona;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Men;644 Barcelona;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Women;892 Barcelona;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Both sexes;1,483 Barcelona;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Men;1,089 Barcelona;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Women;393 Barcelona;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Both sexes;1,337 Barcelona;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Men;964 Barcelona;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Women;373 Barcelona;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Both sexes;6,681 Barcelona;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Men;4,100 Barcelona;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Women;2,580 Barcelona;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Both sexes;5,294 Barcelona;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Men;2,140 Barcelona;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Women;3,154 Barcelona;Group 0506 Other mental and behavioural disorders Rest of (290-319);Both sexes;6,179 Barcelona;Group 0506 Other mental and behavioural disorders Rest of (290-319);Men;2,484 Barcelona;Group 0506 Other mental and behavioural disorders Rest of (290-319);Women;3,694 Barcelona;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Both sexes;13,299 Barcelona;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Men;6,315 Barcelona;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Women;6,983 Barcelona;Group 0601 Alzheimer's disease 3310;Both sexes;1,228 Barcelona;Group 0601 Alzheimer's disease 3310;Men;398 Barcelona;Group 0601 Alzheimer's disease 3310;Women;829 Barcelona;Group 0602 Multiple sclerosis 340;Both sexes;128 Barcelona;Group 0602 Multiple sclerosis 340;Men;46 Barcelona;Group 0602 Multiple sclerosis 340;Women;83 Barcelona;Group 0603 Epilepsy 345;Both sexes;2,236 Barcelona;Group 0603 Epilepsy 345;Men;1,183 Barcelona;Group 0603 Epilepsy 345;Women;1,053 Barcelona;Group 0604 Transient cerebral ischemia 435;Both sexes;1,717 Barcelona;Group 0604 Transient cerebral ischemia 435;Men;869 Barcelona;Group 0604 Transient cerebral ischemia 435;Women;848 Barcelona;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Both sexes;7,991 Barcelona;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Men;3,820 Barcelona;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Women;4,171 Barcelona;Grupo 0700 Diseases of the eye and adnexa 360-379;Both sexes;4,262 Barcelona;Grupo 0700 Diseases of the eye and adnexa 360-379;Men;2,143 Barcelona;Grupo 0700 Diseases of the eye and adnexa 360-379;Women;2,120 Barcelona;Grupo 0701 Cataract 366;Both sexes;1,133 Barcelona;Grupo 0701 Cataract 366;Men;465 Barcelona;Grupo 0701 Cataract 366;Women;668 Barcelona;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Both sexes;3,129 Barcelona;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Men;1,678 Barcelona;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Women;1,451 Barcelona;Group 0800 Diseases of the ear and the mastoid 380-389;Both sexes;3,301 Barcelona;Group 0800 Diseases of the ear and the mastoid 380-389;Men;1,580 Barcelona;Group 0800 Diseases of the ear and the mastoid 380-389;Women;1,721 Barcelona;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Both sexes;81,407 Barcelona;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Men;44,778 Barcelona;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Women;36,629 Barcelona;Group 0901 Hypertensive disease 401-405;Both sexes;3,718 Barcelona;Group 0901 Hypertensive disease 401-405;Men;1,513 Barcelona;Group 0901 Hypertensive disease 401-405;Women;2,205 Barcelona;Group 0902 Angina pectoris 4111, 413;Both sexes;2,389 Barcelona;Group 0902 Angina pectoris 4111, 413;Men;1,486 Barcelona;Group 0902 Angina pectoris 4111, 413;Women;902 Barcelona;Group 0903 Acute myocardial infarction 410;Both sexes;7,262 Barcelona;Group 0903 Acute myocardial infarction 410;Men;5,101 Barcelona;Group 0903 Acute myocardial infarction 410;Women;2,161 Barcelona;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Both sexes;6,405 Barcelona;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Men;4,996 Barcelona;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Women;1,409 Barcelona;Group 0905 Diseases of the lungs circulation 415-417;Both sexes;2,159 Barcelona;Group 0905 Diseases of the lungs circulation 415-417;Men;994 Barcelona;Group 0905 Diseases of the lungs circulation 415-417;Women;1,164 Barcelona;Group 0906 Heart conduction disorders and arrhytmias 426-427;Both sexes;10,148 Barcelona;Group 0906 Heart conduction disorders and arrhytmias 426-427;Men;5,485 Barcelona;Group 0906 Heart conduction disorders and arrhytmias 426-427;Women;4,663 Barcelona;Grupo 0907 Heart failure 428;Both sexes;18,726 Barcelona;Grupo 0907 Heart failure 428;Men;8,397 Barcelona;Grupo 0907 Heart failure 428;Women;10,329 Barcelona;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Both sexes;14,310 Barcelona;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Men;7,341 Barcelona;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Women;6,969 Barcelona;Grupo 0909 Atherosclerosis 440;Both sexes;3,401 Barcelona;Grupo 0909 Atherosclerosis 440;Men;2,403 Barcelona;Grupo 0909 Atherosclerosis 440;Women;998 Barcelona;Group 0910 Varicose veins of lower extremities 454;Both sexes;1,339 Barcelona;Group 0910 Varicose veins of lower extremities 454;Men;412 Barcelona;Group 0910 Varicose veins of lower extremities 454;Women;927 Barcelona;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Both sexes;11,550 Barcelona;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Men;6,649 Barcelona;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Women;4,901 Barcelona;Group 1000 Diseases of the respiratory system 0340, 460-519;Both sexes;69,796 Barcelona;Group 1000 Diseases of the respiratory system 0340, 460-519;Men;39,458 Barcelona;Group 1000 Diseases of the respiratory system 0340, 460-519;Women;30,339 Barcelona;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Both sexes;1,926 Barcelona;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Men;1,014 Barcelona;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Women;912 Barcelona;Group 1002 Pneumonia 480-486;Both sexes;13,926 Barcelona;Group 1002 Pneumonia 480-486;Men;8,160 Barcelona;Group 1002 Pneumonia 480-486;Women;5,766 Barcelona;Group 1003 Acute bronchitis and bronchiolitis 466;Both sexes;8,164 Barcelona;Group 1003 Acute bronchitis and bronchiolitis 466;Men;3,753 Barcelona;Group 1003 Acute bronchitis and bronchiolitis 466;Women;4,411 Barcelona;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Both sexes;2,411 Barcelona;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Men;1,229 Barcelona;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Women;1,183 Barcelona;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Both sexes;5,254 Barcelona;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Men;3,165 Barcelona;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Women;2,089 Barcelona;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Both sexes;13,653 Barcelona;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Men;10,292 Barcelona;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Women;3,361 Barcelona;Group 1007 Asthma 4930-4931,4938-4939;Both sexes;2,824 Barcelona;Group 1007 Asthma 4930-4931,4938-4939;Men;676 Barcelona;Group 1007 Asthma 4930-4931,4938-4939;Women;2,149 Barcelona;Group 1008 Other diseases of the respiratory system Resto of (460-519);Both sexes;21,638 Barcelona;Group 1008 Other diseases of the respiratory system Resto of (460-519);Men;11,169 Barcelona;Group 1008 Other diseases of the respiratory system Resto of (460-519);Women;10,469 Barcelona;Group 1100 Diseases of the digestive system 520-579;Both sexes;69,187 Barcelona;Group 1100 Diseases of the digestive system 520-579;Men;37,673 Barcelona;Group 1100 Diseases of the digestive system 520-579;Women;31,514 Barcelona;Group 1101 Disorders of the teeth and supporting structures 520-525;Both sexes;957 Barcelona;Group 1101 Disorders of the teeth and supporting structures 520-525;Men;438 Barcelona;Group 1101 Disorders of the teeth and supporting structures 520-525;Women;518 Barcelona;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Both sexes;919 Barcelona;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Men;523 Barcelona;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Women;396 Barcelona;Group 1103 Diseases of the esophagus 530;Both sexes;1,178 Barcelona;Group 1103 Diseases of the esophagus 530;Men;680 Barcelona;Group 1103 Diseases of the esophagus 530;Women;498 Barcelona;Group 1104 Peptic ulcer 531-534;Both sexes;1,343 Barcelona;Group 1104 Peptic ulcer 531-534;Men;906 Barcelona;Group 1104 Peptic ulcer 531-534;Women;437 Barcelona;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Both sexes;1,630 Barcelona;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Men;782 Barcelona;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Women;848 Barcelona;Group 1106 Appendicitis 540-543;Both sexes;5,877 Barcelona;Group 1106 Appendicitis 540-543;Men;3,351 Barcelona;Group 1106 Appendicitis 540-543;Women;2,526 Barcelona;Group 1107 Inguinal hernia 550;Both sexes;6,985 Barcelona;Group 1107 Inguinal hernia 550;Men;6,189 Barcelona;Group 1107 Inguinal hernia 550;Women;796 Barcelona;Group 1108 Other abdominal hernia 551-553;Both sexes;5,959 Barcelona;Group 1108 Other abdominal hernia 551-553;Men;2,576 Barcelona;Group 1108 Other abdominal hernia 551-553;Women;3,383 Barcelona;Group 1109 Crohn's disease and ulcerative colitis 555-556;Both sexes;1,230 Barcelona;Group 1109 Crohn's disease and ulcerative colitis 555-556;Men;602 Barcelona;Group 1109 Crohn's disease and ulcerative colitis 555-556;Women;627 Barcelona;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Both sexes;3,319 Barcelona;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Men;1,511 Barcelona;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Women;1,808 Barcelona;Group 1111 Intestinal obstruction without hernia 560;Both sexes;3,310 Barcelona;Group 1111 Intestinal obstruction without hernia 560;Men;1,604 Barcelona;Group 1111 Intestinal obstruction without hernia 560;Women;1,706 Barcelona;Group 1112 Intestinal diverticulosis 562;Both sexes;3,087 Barcelona;Group 1112 Intestinal diverticulosis 562;Men;1,520 Barcelona;Group 1112 Intestinal diverticulosis 562;Women;1,568 Barcelona;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Both sexes;3,834 Barcelona;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Men;2,389 Barcelona;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Women;1,445 Barcelona;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Both sexes;2,447 Barcelona;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Men;1,136 Barcelona;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Women;1,311 Barcelona;Group 1115 Alcoholic hepatitis 5710-5713;Both sexes;1,360 Barcelona;Group 1115 Alcoholic hepatitis 5710-5713;Men;1,085 Barcelona;Group 1115 Alcoholic hepatitis 5710-5713;Women;275 Barcelona;Group 1116 Other diseases of the liver 570,5714-573;Both sexes;2,995 Barcelona;Group 1116 Other diseases of the liver 570,5714-573;Men;1,666 Barcelona;Group 1116 Other diseases of the liver 570,5714-573;Women;1,329 Barcelona;Group 1117 Cholelithiasis 574;Both sexes;13,092 Barcelona;Group 1117 Cholelithiasis 574;Men;5,458 Barcelona;Group 1117 Cholelithiasis 574;Women;7,634 Barcelona;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Both sexes;3,260 Barcelona;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Men;1,757 Barcelona;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Women;1,502 Barcelona;Group 1119 Pancreatic diseases 577;Both sexes;3,693 Barcelona;Group 1119 Pancreatic diseases 577;Men;2,046 Barcelona;Group 1119 Pancreatic diseases 577;Women;1,647 Barcelona;Group 1120 Other diseases of the digestive system Rest of (520-579);Both sexes;2,711 Barcelona;Group 1120 Other diseases of the digestive system Rest of (520-579);Men;1,452 Barcelona;Group 1120 Other diseases of the digestive system Rest of (520-579);Women;1,259 Barcelona;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Both sexes;6,487 Barcelona;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Men;3,263 Barcelona;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Women;3,223 Barcelona;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Both sexes;3,854 Barcelona;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Men;2,142 Barcelona;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Women;1,712 Barcelona;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Both sexes;260 Barcelona;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Men;139 Barcelona;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Women;121 Barcelona;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Both sexes;2,372 Barcelona;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Men;982 Barcelona;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Women;1,391 Barcelona;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Both sexes;53,195 Barcelona;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Men;24,980 Barcelona;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Women;28,215 Barcelona;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Both sexes;.. Barcelona;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Men;.. Barcelona;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Women;.. Barcelona;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Both sexes;.. Barcelona;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Men;.. Barcelona;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Women;.. Barcelona;Group 1303 Internal derangement of knee 717;Both sexes;7,983 Barcelona;Group 1303 Internal derangement of knee 717;Men;5,326 Barcelona;Group 1303 Internal derangement of knee 717;Women;2,657 Barcelona;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Both sexes;18,542 Barcelona;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Men;7,548 Barcelona;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Women;10,994 Barcelona;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Both sexes;755 Barcelona;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Men;273 Barcelona;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Women;481 Barcelona;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Both sexes;2,698 Barcelona;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Men;1,164 Barcelona;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Women;1,535 Barcelona;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Both sexes;4,660 Barcelona;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Men;2,506 Barcelona;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Women;2,154 Barcelona;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Both sexes;1,268 Barcelona;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Men;589 Barcelona;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Women;679 Barcelona;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Both sexes;8,563 Barcelona;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Men;4,153 Barcelona;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Women;4,410 Barcelona;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Both sexes;8,725 Barcelona;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Men;3,421 Barcelona;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Women;5,304 Barcelona;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Both sexes;46,083 Barcelona;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Men;21,292 Barcelona;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Women;24,791 Barcelona;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Both sexes;5,802 Barcelona;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Men;1,716 Barcelona;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Women;4,085 Barcelona;Group 1402 Renal failure 5836-5837, 584-586;Both sexes;4,738 Barcelona;Group 1402 Renal failure 5836-5837, 584-586;Men;2,662 Barcelona;Group 1402 Renal failure 5836-5837, 584-586;Women;2,076 Barcelona;Group 1403 Urolithiasis 592, 594, 7880;Both sexes;5,352 Barcelona;Group 1403 Urolithiasis 592, 594, 7880;Men;3,271 Barcelona;Group 1403 Urolithiasis 592, 594, 7880;Women;2,081 Barcelona;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Both sexes;10,785 Barcelona;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Men;5,232 Barcelona;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Women;5,553 Barcelona;Group 1405 Prostatic hyperplasia 600;Both sexes;4,007 Barcelona;Group 1405 Prostatic hyperplasia 600;Men;4,007 Barcelona;Group 1405 Prostatic hyperplasia 600;Women;.. Barcelona;Group 1406 Other diseases of the male genital organs 601-608;Both sexes;4,055 Barcelona;Group 1406 Other diseases of the male genital organs 601-608;Men;4,055 Barcelona;Group 1406 Other diseases of the male genital organs 601-608;Women;.. Barcelona;Group 1407 Disorders of breast 610-612;Both sexes;3,536 Barcelona;Group 1407 Disorders of breast 610-612;Men;239 Barcelona;Group 1407 Disorders of breast 610-612;Women;3,297 Barcelona;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Both sexes;897 Barcelona;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Men;.. Barcelona;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Women;897 Barcelona;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Both sexes;294 Barcelona;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Men;.. Barcelona;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Women;294 Barcelona;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Both sexes;6,619 Barcelona;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Men;110 Barcelona;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Women;6,509 Barcelona;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Both sexes;59,019 Barcelona;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Men;.. Barcelona;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Women;59,019 Barcelona;Group 1501 Legally induced abortion 635;Both sexes;525 Barcelona;Group 1501 Legally induced abortion 635;Men;.. Barcelona;Group 1501 Legally induced abortion 635;Women;525 Barcelona;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Both sexes;1,963 Barcelona;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Men;.. Barcelona;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Women;1,963 Barcelona;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Both sexes;29,846 Barcelona;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Men;.. Barcelona;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Women;29,846 Barcelona;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Both sexes;13,702 Barcelona;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Men;.. Barcelona;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Women;13,702 Barcelona;Group 1505 Single spontaneous delivery 650;Both sexes;5,226 Barcelona;Group 1505 Single spontaneous delivery 650;Men;.. Barcelona;Group 1505 Single spontaneous delivery 650;Women;5,226 Barcelona;Group 1506 Other deliveries 6695-6697;Both sexes;2,392 Barcelona;Group 1506 Other deliveries 6695-6697;Men;.. Barcelona;Group 1506 Other deliveries 6695-6697;Women;2,392 Barcelona;Group 1507 Complications related to the puerperium 670-676;Both sexes;600 Barcelona;Group 1507 Complications related to the puerperium 670-676;Men;.. Barcelona;Group 1507 Complications related to the puerperium 670-676;Women;600 Barcelona;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Both sexes;4,765 Barcelona;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Men;.. Barcelona;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Women;4,765 Barcelona;Group 1600 Some disorders originating in the perinatal period 760-779;Both sexes;10,179 Barcelona;Group 1600 Some disorders originating in the perinatal period 760-779;Men;5,593 Barcelona;Group 1600 Some disorders originating in the perinatal period 760-779;Women;4,586 Barcelona;Group 1601 Disorders related with premature delivery and a low birth weight 765;Both sexes;2,976 Barcelona;Group 1601 Disorders related with premature delivery and a low birth weight 765;Men;1,588 Barcelona;Group 1601 Disorders related with premature delivery and a low birth weight 765;Women;1,389 Barcelona;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Both sexes;7,203 Barcelona;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Men;4,006 Barcelona;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Women;3,197 Barcelona;Grupo 1700 Congenital abnormalities 740-759;Both sexes;5,927 Barcelona;Grupo 1700 Congenital abnormalities 740-759;Men;3,270 Barcelona;Grupo 1700 Congenital abnormalities 740-759;Women;2,657 Barcelona;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Both sexes;22,266 Barcelona;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Men;12,094 Barcelona;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Women;10,172 Barcelona;Group 1801 Pain in throat and chest 7841, 7865;Both sexes;2,173 Barcelona;Group 1801 Pain in throat and chest 7841, 7865;Men;1,241 Barcelona;Group 1801 Pain in throat and chest 7841, 7865;Women;932 Barcelona;Group 1802 Abdominal pain 7890;Both sexes;2,527 Barcelona;Group 1802 Abdominal pain 7890;Men;988 Barcelona;Group 1802 Abdominal pain 7890;Women;1,539 Barcelona;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Both sexes;1,276 Barcelona;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Men;659 Barcelona;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Women;617 Barcelona;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Both sexes;16,289 Barcelona;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Men;9,206 Barcelona;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Women;7,084 Barcelona;Group 1900 Injuries and poisoning 800-999;Both sexes;58,997 Barcelona;Group 1900 Injuries and poisoning 800-999;Men;28,607 Barcelona;Group 1900 Injuries and poisoning 800-999;Women;30,390 Barcelona;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Both sexes;3,859 Barcelona;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Men;2,029 Barcelona;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Women;1,830 Barcelona;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Both sexes;1,300 Barcelona;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Men;862 Barcelona;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Women;438 Barcelona;Group 1903 Radius and ulna fracture 813;Both sexes;2,917 Barcelona;Group 1903 Radius and ulna fracture 813;Men;1,445 Barcelona;Group 1903 Radius and ulna fracture 813;Women;1,472 Barcelona;Group 1904 Femur fracture 820-821;Both sexes;11,573 Barcelona;Group 1904 Femur fracture 820-821;Men;3,145 Barcelona;Group 1904 Femur fracture 820-821;Women;8,428 Barcelona;Group 1905 Leg fracture, including the ankle 823-824;Both sexes;3,874 Barcelona;Group 1905 Leg fracture, including the ankle 823-824;Men;1,974 Barcelona;Group 1905 Leg fracture, including the ankle 823-824;Women;1,900 Barcelona;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Both sexes;16,061 Barcelona;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Men;9,149 Barcelona;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Women;6,912 Barcelona;Group 1907 Burns 940-949;Both sexes;535 Barcelona;Group 1907 Burns 940-949;Men;353 Barcelona;Group 1907 Burns 940-949;Women;183 Barcelona;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Both sexes;1,837 Barcelona;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Men;753 Barcelona;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Women;1,084 Barcelona;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Both sexes;15,195 Barcelona;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Men;7,897 Barcelona;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Women;7,298 Barcelona;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Both sexes;168 Barcelona;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Men;103 Barcelona;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Women;65 Barcelona;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Both sexes;1,676 Barcelona;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Men;896 Barcelona;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Women;780 Barcelona;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Both sexes;13,354 Barcelona;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Men;7,002 Barcelona;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Women;6,352 Barcelona;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Both sexes;303 Barcelona;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Men;185 Barcelona;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Women;117 Barcelona;Group 2102 Contraceptive management V25;Both sexes;165 Barcelona;Group 2102 Contraceptive management V25;Men;14 Barcelona;Group 2102 Contraceptive management V25;Women;150 Barcelona;Group 2103 Living newborns by type of delivery V30-V39;Both sexes;.. Barcelona;Group 2103 Living newborns by type of delivery V30-V39;Men;.. Barcelona;Group 2103 Living newborns by type of delivery V30-V39;Women;.. Barcelona;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Both sexes;3,431 Barcelona;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Men;2,071 Barcelona;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Women;1,360 Barcelona;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Both sexes;9,456 Barcelona;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Men;4,732 Barcelona;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Women;4,725 Girona;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Both sexes;67,336 Girona;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Men;31,529 Girona;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Women;35,807 Girona;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Both sexes;1,307 Girona;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Men;738 Girona;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Women;569 Girona;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Both sexes;170 Girona;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Men;89 Girona;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Women;81 Girona;Group 0102 Imprecise intestinal infections 009;Both sexes;278 Girona;Group 0102 Imprecise intestinal infections 009;Men;124 Girona;Group 0102 Imprecise intestinal infections 009;Women;155 Girona;Group 0103 Tuberculosis 010-018, 137;Both sexes;86 Girona;Group 0103 Tuberculosis 010-018, 137;Men;56 Girona;Group 0103 Tuberculosis 010-018, 137;Women;30 Girona;Group 0104 Septicaemia 038;Both sexes;314 Girona;Group 0104 Septicaemia 038;Men;194 Girona;Group 0104 Septicaemia 038;Women;119 Girona;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Both sexes;40 Girona;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Men;38 Girona;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Women;2 Girona;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Both sexes;419 Girona;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Men;238 Girona;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Women;181 Girona;Group 0200 Neoplasms 140-239;Both sexes;6,273 Girona;Group 0200 Neoplasms 140-239;Men;3,264 Girona;Group 0200 Neoplasms 140-239;Women;3,009 Girona;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Both sexes;755 Girona;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Men;443 Girona;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Women;312 Girona;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Both sexes;549 Girona;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Men;442 Girona;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Women;107 Girona;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Both sexes;93 Girona;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Men;52 Girona;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Women;41 Girona;Group 0204 Malignant neoplasm of breast 174-175;Both sexes;626 Girona;Group 0204 Malignant neoplasm of breast 174-175;Men;6 Girona;Group 0204 Malignant neoplasm of breast 174-175;Women;619 Girona;Group 0205 Malignant neoplasm of uterus 179-180, 182;Both sexes;86 Girona;Group 0205 Malignant neoplasm of uterus 179-180, 182;Men;.. Girona;Group 0205 Malignant neoplasm of uterus 179-180, 182;Women;86 Girona;Group 0206 Malignant neoplasm of ovary 1830;Both sexes;78 Girona;Group 0206 Malignant neoplasm of ovary 1830;Men;.. Girona;Group 0206 Malignant neoplasm of ovary 1830;Women;78 Girona;Group 0207 Malignant neoplasm of prostate 185;Both sexes;182 Girona;Group 0207 Malignant neoplasm of prostate 185;Men;182 Girona;Group 0207 Malignant neoplasm of prostate 185;Women;.. Girona;Group 0208 Malignant neoplasm of bladder 188;Both sexes;601 Girona;Group 0208 Malignant neoplasm of bladder 188;Men;504 Girona;Group 0208 Malignant neoplasm of bladder 188;Women;98 Girona;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Both sexes;2,135 Girona;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Men;1,260 Girona;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Women;874 Girona;Group 0210 Carcinoma in situ 230-234;Both sexes;43 Girona;Group 0210 Carcinoma in situ 230-234;Men;11 Girona;Group 0210 Carcinoma in situ 230-234;Women;32 Girona;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Both sexes;32 Girona;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Men;14 Girona;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Women;18 Girona;Grupo 0212 Leiomyoma of uterus 218;Both sexes;278 Girona;Grupo 0212 Leiomyoma of uterus 218;Men;.. Girona;Grupo 0212 Leiomyoma of uterus 218;Women;278 Girona;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Both sexes;817 Girona;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Men;350 Girona;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Women;467 Girona;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Both sexes;516 Girona;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Men;234 Girona;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Women;283 Girona;Group 0301 Anaemias 280-285;Both sexes;298 Girona;Group 0301 Anaemias 280-285;Men;136 Girona;Group 0301 Anaemias 280-285;Women;162 Girona;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Both sexes;218 Girona;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Men;98 Girona;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Women;121 Girona;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Both sexes;921 Girona;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Men;390 Girona;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Women;531 Girona;Group 0401 Diabetes mellitus 249-250;Both sexes;347 Girona;Group 0401 Diabetes mellitus 249-250;Men;201 Girona;Group 0401 Diabetes mellitus 249-250;Women;146 Girona;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Both sexes;574 Girona;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Men;189 Girona;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Women;385 Girona;Group 0500 Mental disorders 290-319;Both sexes;1,860 Girona;Group 0500 Mental disorders 290-319;Men;1,030 Girona;Group 0500 Mental disorders 290-319;Women;830 Girona;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Both sexes;129 Girona;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Men;61 Girona;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Women;67 Girona;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Both sexes;108 Girona;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Men;79 Girona;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Women;30 Girona;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Both sexes;80 Girona;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Men;61 Girona;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Women;19 Girona;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Both sexes;672 Girona;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Men;450 Girona;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Women;222 Girona;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Both sexes;422 Girona;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Men;185 Girona;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Women;236 Girona;Group 0506 Other mental and behavioural disorders Rest of (290-319);Both sexes;449 Girona;Group 0506 Other mental and behavioural disorders Rest of (290-319);Men;194 Girona;Group 0506 Other mental and behavioural disorders Rest of (290-319);Women;255 Girona;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Both sexes;1,403 Girona;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Men;682 Girona;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Women;721 Girona;Group 0601 Alzheimer's disease 3310;Both sexes;125 Girona;Group 0601 Alzheimer's disease 3310;Men;47 Girona;Group 0601 Alzheimer's disease 3310;Women;78 Girona;Group 0602 Multiple sclerosis 340;Both sexes;22 Girona;Group 0602 Multiple sclerosis 340;Men;7 Girona;Group 0602 Multiple sclerosis 340;Women;15 Girona;Group 0603 Epilepsy 345;Both sexes;241 Girona;Group 0603 Epilepsy 345;Men;140 Girona;Group 0603 Epilepsy 345;Women;101 Girona;Group 0604 Transient cerebral ischemia 435;Both sexes;138 Girona;Group 0604 Transient cerebral ischemia 435;Men;75 Girona;Group 0604 Transient cerebral ischemia 435;Women;63 Girona;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Both sexes;876 Girona;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Men;413 Girona;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Women;464 Girona;Grupo 0700 Diseases of the eye and adnexa 360-379;Both sexes;679 Girona;Grupo 0700 Diseases of the eye and adnexa 360-379;Men;313 Girona;Grupo 0700 Diseases of the eye and adnexa 360-379;Women;366 Girona;Grupo 0701 Cataract 366;Both sexes;429 Girona;Grupo 0701 Cataract 366;Men;185 Girona;Grupo 0701 Cataract 366;Women;244 Girona;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Both sexes;251 Girona;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Men;129 Girona;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Women;122 Girona;Group 0800 Diseases of the ear and the mastoid 380-389;Both sexes;287 Girona;Group 0800 Diseases of the ear and the mastoid 380-389;Men;137 Girona;Group 0800 Diseases of the ear and the mastoid 380-389;Women;150 Girona;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Both sexes;8,439 Girona;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Men;4,746 Girona;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Women;3,693 Girona;Group 0901 Hypertensive disease 401-405;Both sexes;151 Girona;Group 0901 Hypertensive disease 401-405;Men;60 Girona;Group 0901 Hypertensive disease 401-405;Women;91 Girona;Group 0902 Angina pectoris 4111, 413;Both sexes;380 Girona;Group 0902 Angina pectoris 4111, 413;Men;256 Girona;Group 0902 Angina pectoris 4111, 413;Women;125 Girona;Group 0903 Acute myocardial infarction 410;Both sexes;947 Girona;Group 0903 Acute myocardial infarction 410;Men;675 Girona;Group 0903 Acute myocardial infarction 410;Women;272 Girona;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Both sexes;381 Girona;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Men;268 Girona;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Women;113 Girona;Group 0905 Diseases of the lungs circulation 415-417;Both sexes;290 Girona;Group 0905 Diseases of the lungs circulation 415-417;Men;143 Girona;Group 0905 Diseases of the lungs circulation 415-417;Women;148 Girona;Group 0906 Heart conduction disorders and arrhytmias 426-427;Both sexes;1,028 Girona;Group 0906 Heart conduction disorders and arrhytmias 426-427;Men;568 Girona;Group 0906 Heart conduction disorders and arrhytmias 426-427;Women;461 Girona;Grupo 0907 Heart failure 428;Both sexes;1,772 Girona;Grupo 0907 Heart failure 428;Men;806 Girona;Grupo 0907 Heart failure 428;Women;966 Girona;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Both sexes;1,649 Girona;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Men;901 Girona;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Women;748 Girona;Grupo 0909 Atherosclerosis 440;Both sexes;317 Girona;Grupo 0909 Atherosclerosis 440;Men;236 Girona;Grupo 0909 Atherosclerosis 440;Women;80 Girona;Group 0910 Varicose veins of lower extremities 454;Both sexes;320 Girona;Group 0910 Varicose veins of lower extremities 454;Men;106 Girona;Group 0910 Varicose veins of lower extremities 454;Women;214 Girona;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Both sexes;1,203 Girona;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Men;728 Girona;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Women;476 Girona;Group 1000 Diseases of the respiratory system 0340, 460-519;Both sexes;7,727 Girona;Group 1000 Diseases of the respiratory system 0340, 460-519;Men;4,417 Girona;Group 1000 Diseases of the respiratory system 0340, 460-519;Women;3,310 Girona;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Both sexes;171 Girona;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Men;85 Girona;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Women;87 Girona;Group 1002 Pneumonia 480-486;Both sexes;1,660 Girona;Group 1002 Pneumonia 480-486;Men;986 Girona;Group 1002 Pneumonia 480-486;Women;675 Girona;Group 1003 Acute bronchitis and bronchiolitis 466;Both sexes;1,080 Girona;Group 1003 Acute bronchitis and bronchiolitis 466;Men;526 Girona;Group 1003 Acute bronchitis and bronchiolitis 466;Women;554 Girona;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Both sexes;538 Girona;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Men;283 Girona;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Women;256 Girona;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Both sexes;670 Girona;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Men;427 Girona;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Women;243 Girona;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Both sexes;1,269 Girona;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Men;919 Girona;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Women;350 Girona;Group 1007 Asthma 4930-4931,4938-4939;Both sexes;349 Girona;Group 1007 Asthma 4930-4931,4938-4939;Men;127 Girona;Group 1007 Asthma 4930-4931,4938-4939;Women;223 Girona;Group 1008 Other diseases of the respiratory system Resto of (460-519);Both sexes;1,988 Girona;Group 1008 Other diseases of the respiratory system Resto of (460-519);Men;1,065 Girona;Group 1008 Other diseases of the respiratory system Resto of (460-519);Women;924 Girona;Group 1100 Diseases of the digestive system 520-579;Both sexes;8,039 Girona;Group 1100 Diseases of the digestive system 520-579;Men;4,597 Girona;Group 1100 Diseases of the digestive system 520-579;Women;3,442 Girona;Group 1101 Disorders of the teeth and supporting structures 520-525;Both sexes;22 Girona;Group 1101 Disorders of the teeth and supporting structures 520-525;Men;15 Girona;Group 1101 Disorders of the teeth and supporting structures 520-525;Women;6 Girona;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Both sexes;69 Girona;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Men;41 Girona;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Women;28 Girona;Group 1103 Diseases of the esophagus 530;Both sexes;103 Girona;Group 1103 Diseases of the esophagus 530;Men;64 Girona;Group 1103 Diseases of the esophagus 530;Women;39 Girona;Group 1104 Peptic ulcer 531-534;Both sexes;145 Girona;Group 1104 Peptic ulcer 531-534;Men;98 Girona;Group 1104 Peptic ulcer 531-534;Women;47 Girona;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Both sexes;184 Girona;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Men;99 Girona;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Women;86 Girona;Group 1106 Appendicitis 540-543;Both sexes;773 Girona;Group 1106 Appendicitis 540-543;Men;459 Girona;Group 1106 Appendicitis 540-543;Women;314 Girona;Group 1107 Inguinal hernia 550;Both sexes;965 Girona;Group 1107 Inguinal hernia 550;Men;854 Girona;Group 1107 Inguinal hernia 550;Women;111 Girona;Group 1108 Other abdominal hernia 551-553;Both sexes;798 Girona;Group 1108 Other abdominal hernia 551-553;Men;400 Girona;Group 1108 Other abdominal hernia 551-553;Women;398 Girona;Group 1109 Crohn's disease and ulcerative colitis 555-556;Both sexes;147 Girona;Group 1109 Crohn's disease and ulcerative colitis 555-556;Men;69 Girona;Group 1109 Crohn's disease and ulcerative colitis 555-556;Women;78 Girona;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Both sexes;361 Girona;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Men;158 Girona;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Women;203 Girona;Group 1111 Intestinal obstruction without hernia 560;Both sexes;426 Girona;Group 1111 Intestinal obstruction without hernia 560;Men;217 Girona;Group 1111 Intestinal obstruction without hernia 560;Women;209 Girona;Group 1112 Intestinal diverticulosis 562;Both sexes;303 Girona;Group 1112 Intestinal diverticulosis 562;Men;165 Girona;Group 1112 Intestinal diverticulosis 562;Women;138 Girona;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Both sexes;526 Girona;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Men;341 Girona;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Women;184 Girona;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Both sexes;245 Girona;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Men;122 Girona;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Women;124 Girona;Group 1115 Alcoholic hepatitis 5710-5713;Both sexes;100 Girona;Group 1115 Alcoholic hepatitis 5710-5713;Men;72 Girona;Group 1115 Alcoholic hepatitis 5710-5713;Women;28 Girona;Group 1116 Other diseases of the liver 570,5714-573;Both sexes;206 Girona;Group 1116 Other diseases of the liver 570,5714-573;Men;119 Girona;Group 1116 Other diseases of the liver 570,5714-573;Women;86 Girona;Group 1117 Cholelithiasis 574;Both sexes;1,452 Girona;Group 1117 Cholelithiasis 574;Men;613 Girona;Group 1117 Cholelithiasis 574;Women;838 Girona;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Both sexes;422 Girona;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Men;226 Girona;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Women;196 Girona;Group 1119 Pancreatic diseases 577;Both sexes;448 Girona;Group 1119 Pancreatic diseases 577;Men;265 Girona;Group 1119 Pancreatic diseases 577;Women;183 Girona;Group 1120 Other diseases of the digestive system Rest of (520-579);Both sexes;344 Girona;Group 1120 Other diseases of the digestive system Rest of (520-579);Men;199 Girona;Group 1120 Other diseases of the digestive system Rest of (520-579);Women;145 Girona;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Both sexes;796 Girona;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Men;436 Girona;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Women;360 Girona;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Both sexes;523 Girona;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Men;314 Girona;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Women;209 Girona;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Both sexes;14 Girona;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Men;6 Girona;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Women;8 Girona;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Both sexes;259 Girona;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Men;116 Girona;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Women;143 Girona;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Both sexes;5,264 Girona;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Men;2,449 Girona;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Women;2,814 Girona;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Both sexes;.. Girona;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Men;.. Girona;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Women;.. Girona;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Both sexes;.. Girona;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Men;.. Girona;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Women;.. Girona;Group 1303 Internal derangement of knee 717;Both sexes;471 Girona;Group 1303 Internal derangement of knee 717;Men;306 Girona;Group 1303 Internal derangement of knee 717;Women;165 Girona;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Both sexes;2,136 Girona;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Men;921 Girona;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Women;1,215 Girona;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Both sexes;68 Girona;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Men;17 Girona;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Women;50 Girona;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Both sexes;191 Girona;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Men;100 Girona;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Women;91 Girona;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Both sexes;377 Girona;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Men;206 Girona;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Women;171 Girona;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Both sexes;236 Girona;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Men;107 Girona;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Women;129 Girona;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Both sexes;994 Girona;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Men;491 Girona;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Women;503 Girona;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Both sexes;790 Girona;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Men;301 Girona;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Women;489 Girona;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Both sexes;4,361 Girona;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Men;2,109 Girona;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Women;2,251 Girona;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Both sexes;588 Girona;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Men;239 Girona;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Women;349 Girona;Group 1402 Renal failure 5836-5837, 584-586;Both sexes;468 Girona;Group 1402 Renal failure 5836-5837, 584-586;Men;269 Girona;Group 1402 Renal failure 5836-5837, 584-586;Women;199 Girona;Group 1403 Urolithiasis 592, 594, 7880;Both sexes;468 Girona;Group 1403 Urolithiasis 592, 594, 7880;Men;299 Girona;Group 1403 Urolithiasis 592, 594, 7880;Women;169 Girona;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Both sexes;999 Girona;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Men;524 Girona;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Women;475 Girona;Group 1405 Prostatic hyperplasia 600;Both sexes;427 Girona;Group 1405 Prostatic hyperplasia 600;Men;427 Girona;Group 1405 Prostatic hyperplasia 600;Women;.. Girona;Group 1406 Other diseases of the male genital organs 601-608;Both sexes;315 Girona;Group 1406 Other diseases of the male genital organs 601-608;Men;315 Girona;Group 1406 Other diseases of the male genital organs 601-608;Women;.. Girona;Group 1407 Disorders of breast 610-612;Both sexes;167 Girona;Group 1407 Disorders of breast 610-612;Men;29 Girona;Group 1407 Disorders of breast 610-612;Women;138 Girona;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Both sexes;119 Girona;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Men;.. Girona;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Women;119 Girona;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Both sexes;44 Girona;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Men;.. Girona;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Women;44 Girona;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Both sexes;765 Girona;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Men;7 Girona;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Women;758 Girona;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Both sexes;7,497 Girona;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Men;.. Girona;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Women;7,497 Girona;Group 1501 Legally induced abortion 635;Both sexes;42 Girona;Group 1501 Legally induced abortion 635;Men;.. Girona;Group 1501 Legally induced abortion 635;Women;42 Girona;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Both sexes;359 Girona;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Men;.. Girona;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Women;359 Girona;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Both sexes;3,681 Girona;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Men;.. Girona;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Women;3,681 Girona;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Both sexes;1,656 Girona;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Men;.. Girona;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Women;1,656 Girona;Group 1505 Single spontaneous delivery 650;Both sexes;939 Girona;Group 1505 Single spontaneous delivery 650;Men;.. Girona;Group 1505 Single spontaneous delivery 650;Women;939 Girona;Group 1506 Other deliveries 6695-6697;Both sexes;218 Girona;Group 1506 Other deliveries 6695-6697;Men;.. Girona;Group 1506 Other deliveries 6695-6697;Women;218 Girona;Group 1507 Complications related to the puerperium 670-676;Both sexes;67 Girona;Group 1507 Complications related to the puerperium 670-676;Men;.. Girona;Group 1507 Complications related to the puerperium 670-676;Women;67 Girona;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Both sexes;535 Girona;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Men;.. Girona;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Women;535 Girona;Group 1600 Some disorders originating in the perinatal period 760-779;Both sexes;950 Girona;Group 1600 Some disorders originating in the perinatal period 760-779;Men;528 Girona;Group 1600 Some disorders originating in the perinatal period 760-779;Women;422 Girona;Group 1601 Disorders related with premature delivery and a low birth weight 765;Both sexes;298 Girona;Group 1601 Disorders related with premature delivery and a low birth weight 765;Men;165 Girona;Group 1601 Disorders related with premature delivery and a low birth weight 765;Women;133 Girona;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Both sexes;652 Girona;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Men;363 Girona;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Women;289 Girona;Grupo 1700 Congenital abnormalities 740-759;Both sexes;305 Girona;Grupo 1700 Congenital abnormalities 740-759;Men;179 Girona;Grupo 1700 Congenital abnormalities 740-759;Women;126 Girona;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Both sexes;2,626 Girona;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Men;1,409 Girona;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Women;1,217 Girona;Group 1801 Pain in throat and chest 7841, 7865;Both sexes;263 Girona;Group 1801 Pain in throat and chest 7841, 7865;Men;149 Girona;Group 1801 Pain in throat and chest 7841, 7865;Women;113 Girona;Group 1802 Abdominal pain 7890;Both sexes;409 Girona;Group 1802 Abdominal pain 7890;Men;152 Girona;Group 1802 Abdominal pain 7890;Women;258 Girona;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Both sexes;89 Girona;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Men;39 Girona;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Women;50 Girona;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Both sexes;1,865 Girona;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Men;1,069 Girona;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Women;796 Girona;Group 1900 Injuries and poisoning 800-999;Both sexes;6,926 Girona;Group 1900 Injuries and poisoning 800-999;Men;3,318 Girona;Group 1900 Injuries and poisoning 800-999;Women;3,608 Girona;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Both sexes;419 Girona;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Men;242 Girona;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Women;177 Girona;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Both sexes;115 Girona;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Men;70 Girona;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Women;45 Girona;Group 1903 Radius and ulna fracture 813;Both sexes;482 Girona;Group 1903 Radius and ulna fracture 813;Men;217 Girona;Group 1903 Radius and ulna fracture 813;Women;266 Girona;Group 1904 Femur fracture 820-821;Both sexes;1,599 Girona;Group 1904 Femur fracture 820-821;Men;456 Girona;Group 1904 Femur fracture 820-821;Women;1,143 Girona;Group 1905 Leg fracture, including the ankle 823-824;Both sexes;514 Girona;Group 1905 Leg fracture, including the ankle 823-824;Men;268 Girona;Group 1905 Leg fracture, including the ankle 823-824;Women;246 Girona;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Both sexes;2,086 Girona;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Men;1,204 Girona;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Women;882 Girona;Group 1907 Burns 940-949;Both sexes;28 Girona;Group 1907 Burns 940-949;Men;19 Girona;Group 1907 Burns 940-949;Women;9 Girona;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Both sexes;189 Girona;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Men;80 Girona;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Women;109 Girona;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Both sexes;1,319 Girona;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Men;666 Girona;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Women;653 Girona;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Both sexes;32 Girona;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Men;23 Girona;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Women;9 Girona;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Both sexes;143 Girona;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Men;75 Girona;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Women;68 Girona;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Both sexes;1,161 Girona;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Men;552 Girona;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Women;608 Girona;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Both sexes;10 Girona;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Men;7 Girona;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Women;3 Girona;Group 2102 Contraceptive management V25;Both sexes;33 Girona;Group 2102 Contraceptive management V25;Men;3 Girona;Group 2102 Contraceptive management V25;Women;30 Girona;Group 2103 Living newborns by type of delivery V30-V39;Both sexes;.. Girona;Group 2103 Living newborns by type of delivery V30-V39;Men;.. Girona;Group 2103 Living newborns by type of delivery V30-V39;Women;.. Girona;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Both sexes;261 Girona;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Men;149 Girona;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Women;111 Girona;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Both sexes;857 Girona;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Men;393 Girona;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Women;464 Lleida;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Both sexes;36,841 Lleida;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Men;17,639 Lleida;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Women;19,202 Lleida;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Both sexes;571 Lleida;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Men;317 Lleida;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Women;254 Lleida;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Both sexes;91 Lleida;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Men;46 Lleida;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Women;45 Lleida;Group 0102 Imprecise intestinal infections 009;Both sexes;68 Lleida;Group 0102 Imprecise intestinal infections 009;Men;29 Lleida;Group 0102 Imprecise intestinal infections 009;Women;39 Lleida;Group 0103 Tuberculosis 010-018, 137;Both sexes;57 Lleida;Group 0103 Tuberculosis 010-018, 137;Men;43 Lleida;Group 0103 Tuberculosis 010-018, 137;Women;14 Lleida;Group 0104 Septicaemia 038;Both sexes;97 Lleida;Group 0104 Septicaemia 038;Men;53 Lleida;Group 0104 Septicaemia 038;Women;44 Lleida;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Both sexes;50 Lleida;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Men;30 Lleida;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Women;20 Lleida;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Both sexes;208 Lleida;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Men;116 Lleida;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Women;92 Lleida;Group 0200 Neoplasms 140-239;Both sexes;3,540 Lleida;Group 0200 Neoplasms 140-239;Men;2,003 Lleida;Group 0200 Neoplasms 140-239;Women;1,537 Lleida;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Both sexes;481 Lleida;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Men;286 Lleida;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Women;195 Lleida;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Both sexes;198 Lleida;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Men;146 Lleida;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Women;52 Lleida;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Both sexes;31 Lleida;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Men;22 Lleida;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Women;9 Lleida;Group 0204 Malignant neoplasm of breast 174-175;Both sexes;230 Lleida;Group 0204 Malignant neoplasm of breast 174-175;Men;.. Lleida;Group 0204 Malignant neoplasm of breast 174-175;Women;230 Lleida;Group 0205 Malignant neoplasm of uterus 179-180, 182;Both sexes;61 Lleida;Group 0205 Malignant neoplasm of uterus 179-180, 182;Men;.. Lleida;Group 0205 Malignant neoplasm of uterus 179-180, 182;Women;61 Lleida;Group 0206 Malignant neoplasm of ovary 1830;Both sexes;26 Lleida;Group 0206 Malignant neoplasm of ovary 1830;Men;.. Lleida;Group 0206 Malignant neoplasm of ovary 1830;Women;26 Lleida;Group 0207 Malignant neoplasm of prostate 185;Both sexes;113 Lleida;Group 0207 Malignant neoplasm of prostate 185;Men;113 Lleida;Group 0207 Malignant neoplasm of prostate 185;Women;.. Lleida;Group 0208 Malignant neoplasm of bladder 188;Both sexes;470 Lleida;Group 0208 Malignant neoplasm of bladder 188;Men;412 Lleida;Group 0208 Malignant neoplasm of bladder 188;Women;58 Lleida;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Both sexes;1,344 Lleida;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Men;794 Lleida;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Women;550 Lleida;Group 0210 Carcinoma in situ 230-234;Both sexes;25 Lleida;Group 0210 Carcinoma in situ 230-234;Men;15 Lleida;Group 0210 Carcinoma in situ 230-234;Women;10 Lleida;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Both sexes;44 Lleida;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Men;31 Lleida;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Women;13 Lleida;Grupo 0212 Leiomyoma of uterus 218;Both sexes;138 Lleida;Grupo 0212 Leiomyoma of uterus 218;Men;.. Lleida;Grupo 0212 Leiomyoma of uterus 218;Women;138 Lleida;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Both sexes;378 Lleida;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Men;184 Lleida;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Women;194 Lleida;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Both sexes;280 Lleida;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Men;140 Lleida;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Women;140 Lleida;Group 0301 Anaemias 280-285;Both sexes;141 Lleida;Group 0301 Anaemias 280-285;Men;65 Lleida;Group 0301 Anaemias 280-285;Women;76 Lleida;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Both sexes;139 Lleida;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Men;75 Lleida;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Women;64 Lleida;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Both sexes;492 Lleida;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Men;230 Lleida;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Women;262 Lleida;Group 0401 Diabetes mellitus 249-250;Both sexes;176 Lleida;Group 0401 Diabetes mellitus 249-250;Men;109 Lleida;Group 0401 Diabetes mellitus 249-250;Women;67 Lleida;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Both sexes;316 Lleida;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Men;121 Lleida;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Women;195 Lleida;Group 0500 Mental disorders 290-319;Both sexes;1,919 Lleida;Group 0500 Mental disorders 290-319;Men;1,009 Lleida;Group 0500 Mental disorders 290-319;Women;910 Lleida;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Both sexes;62 Lleida;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Men;29 Lleida;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Women;33 Lleida;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Both sexes;118 Lleida;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Men;94 Lleida;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Women;24 Lleida;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Both sexes;122 Lleida;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Men;94 Lleida;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Women;29 Lleida;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Both sexes;637 Lleida;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Men;369 Lleida;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Women;268 Lleida;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Both sexes;426 Lleida;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Men;149 Lleida;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Women;277 Lleida;Group 0506 Other mental and behavioural disorders Rest of (290-319);Both sexes;554 Lleida;Group 0506 Other mental and behavioural disorders Rest of (290-319);Men;274 Lleida;Group 0506 Other mental and behavioural disorders Rest of (290-319);Women;279 Lleida;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Both sexes;668 Lleida;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Men;319 Lleida;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Women;349 Lleida;Group 0601 Alzheimer's disease 3310;Both sexes;64 Lleida;Group 0601 Alzheimer's disease 3310;Men;19 Lleida;Group 0601 Alzheimer's disease 3310;Women;45 Lleida;Group 0602 Multiple sclerosis 340;Both sexes;12 Lleida;Group 0602 Multiple sclerosis 340;Men;4 Lleida;Group 0602 Multiple sclerosis 340;Women;8 Lleida;Group 0603 Epilepsy 345;Both sexes;92 Lleida;Group 0603 Epilepsy 345;Men;41 Lleida;Group 0603 Epilepsy 345;Women;51 Lleida;Group 0604 Transient cerebral ischemia 435;Both sexes;151 Lleida;Group 0604 Transient cerebral ischemia 435;Men;85 Lleida;Group 0604 Transient cerebral ischemia 435;Women;66 Lleida;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Both sexes;349 Lleida;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Men;170 Lleida;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Women;179 Lleida;Grupo 0700 Diseases of the eye and adnexa 360-379;Both sexes;92 Lleida;Grupo 0700 Diseases of the eye and adnexa 360-379;Men;58 Lleida;Grupo 0700 Diseases of the eye and adnexa 360-379;Women;34 Lleida;Grupo 0701 Cataract 366;Both sexes;28 Lleida;Grupo 0701 Cataract 366;Men;15 Lleida;Grupo 0701 Cataract 366;Women;13 Lleida;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Both sexes;64 Lleida;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Men;43 Lleida;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Women;21 Lleida;Group 0800 Diseases of the ear and the mastoid 380-389;Both sexes;144 Lleida;Group 0800 Diseases of the ear and the mastoid 380-389;Men;76 Lleida;Group 0800 Diseases of the ear and the mastoid 380-389;Women;68 Lleida;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Both sexes;4,489 Lleida;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Men;2,525 Lleida;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Women;1,965 Lleida;Group 0901 Hypertensive disease 401-405;Both sexes;116 Lleida;Group 0901 Hypertensive disease 401-405;Men;48 Lleida;Group 0901 Hypertensive disease 401-405;Women;68 Lleida;Group 0902 Angina pectoris 4111, 413;Both sexes;216 Lleida;Group 0902 Angina pectoris 4111, 413;Men;168 Lleida;Group 0902 Angina pectoris 4111, 413;Women;48 Lleida;Group 0903 Acute myocardial infarction 410;Both sexes;315 Lleida;Group 0903 Acute myocardial infarction 410;Men;240 Lleida;Group 0903 Acute myocardial infarction 410;Women;75 Lleida;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Both sexes;239 Lleida;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Men;165 Lleida;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Women;74 Lleida;Group 0905 Diseases of the lungs circulation 415-417;Both sexes;120 Lleida;Group 0905 Diseases of the lungs circulation 415-417;Men;55 Lleida;Group 0905 Diseases of the lungs circulation 415-417;Women;65 Lleida;Group 0906 Heart conduction disorders and arrhytmias 426-427;Both sexes;537 Lleida;Group 0906 Heart conduction disorders and arrhytmias 426-427;Men;285 Lleida;Group 0906 Heart conduction disorders and arrhytmias 426-427;Women;252 Lleida;Grupo 0907 Heart failure 428;Both sexes;1,185 Lleida;Grupo 0907 Heart failure 428;Men;569 Lleida;Grupo 0907 Heart failure 428;Women;616 Lleida;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Both sexes;1,052 Lleida;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Men;579 Lleida;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Women;473 Lleida;Grupo 0909 Atherosclerosis 440;Both sexes;181 Lleida;Grupo 0909 Atherosclerosis 440;Men;116 Lleida;Grupo 0909 Atherosclerosis 440;Women;65 Lleida;Group 0910 Varicose veins of lower extremities 454;Both sexes;30 Lleida;Group 0910 Varicose veins of lower extremities 454;Men;12 Lleida;Group 0910 Varicose veins of lower extremities 454;Women;18 Lleida;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Both sexes;499 Lleida;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Men;288 Lleida;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Women;211 Lleida;Group 1000 Diseases of the respiratory system 0340, 460-519;Both sexes;4,560 Lleida;Group 1000 Diseases of the respiratory system 0340, 460-519;Men;2,733 Lleida;Group 1000 Diseases of the respiratory system 0340, 460-519;Women;1,827 Lleida;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Both sexes;97 Lleida;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Men;52 Lleida;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Women;45 Lleida;Group 1002 Pneumonia 480-486;Both sexes;841 Lleida;Group 1002 Pneumonia 480-486;Men;527 Lleida;Group 1002 Pneumonia 480-486;Women;314 Lleida;Group 1003 Acute bronchitis and bronchiolitis 466;Both sexes;1,105 Lleida;Group 1003 Acute bronchitis and bronchiolitis 466;Men;536 Lleida;Group 1003 Acute bronchitis and bronchiolitis 466;Women;569 Lleida;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Both sexes;167 Lleida;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Men;96 Lleida;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Women;71 Lleida;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Both sexes;236 Lleida;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Men;145 Lleida;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Women;91 Lleida;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Both sexes;1,116 Lleida;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Men;822 Lleida;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Women;294 Lleida;Group 1007 Asthma 4930-4931,4938-4939;Both sexes;135 Lleida;Group 1007 Asthma 4930-4931,4938-4939;Men;47 Lleida;Group 1007 Asthma 4930-4931,4938-4939;Women;88 Lleida;Group 1008 Other diseases of the respiratory system Resto of (460-519);Both sexes;863 Lleida;Group 1008 Other diseases of the respiratory system Resto of (460-519);Men;508 Lleida;Group 1008 Other diseases of the respiratory system Resto of (460-519);Women;355 Lleida;Group 1100 Diseases of the digestive system 520-579;Both sexes;4,429 Lleida;Group 1100 Diseases of the digestive system 520-579;Men;2,432 Lleida;Group 1100 Diseases of the digestive system 520-579;Women;1,997 Lleida;Group 1101 Disorders of the teeth and supporting structures 520-525;Both sexes;118 Lleida;Group 1101 Disorders of the teeth and supporting structures 520-525;Men;57 Lleida;Group 1101 Disorders of the teeth and supporting structures 520-525;Women;61 Lleida;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Both sexes;27 Lleida;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Men;20 Lleida;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Women;7 Lleida;Group 1103 Diseases of the esophagus 530;Both sexes;32 Lleida;Group 1103 Diseases of the esophagus 530;Men;22 Lleida;Group 1103 Diseases of the esophagus 530;Women;10 Lleida;Group 1104 Peptic ulcer 531-534;Both sexes;86 Lleida;Group 1104 Peptic ulcer 531-534;Men;66 Lleida;Group 1104 Peptic ulcer 531-534;Women;20 Lleida;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Both sexes;101 Lleida;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Men;44 Lleida;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Women;57 Lleida;Group 1106 Appendicitis 540-543;Both sexes;338 Lleida;Group 1106 Appendicitis 540-543;Men;186 Lleida;Group 1106 Appendicitis 540-543;Women;152 Lleida;Group 1107 Inguinal hernia 550;Both sexes;367 Lleida;Group 1107 Inguinal hernia 550;Men;324 Lleida;Group 1107 Inguinal hernia 550;Women;43 Lleida;Group 1108 Other abdominal hernia 551-553;Both sexes;372 Lleida;Group 1108 Other abdominal hernia 551-553;Men;159 Lleida;Group 1108 Other abdominal hernia 551-553;Women;213 Lleida;Group 1109 Crohn's disease and ulcerative colitis 555-556;Both sexes;54 Lleida;Group 1109 Crohn's disease and ulcerative colitis 555-556;Men;33 Lleida;Group 1109 Crohn's disease and ulcerative colitis 555-556;Women;21 Lleida;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Both sexes;214 Lleida;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Men;96 Lleida;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Women;118 Lleida;Group 1111 Intestinal obstruction without hernia 560;Both sexes;219 Lleida;Group 1111 Intestinal obstruction without hernia 560;Men;127 Lleida;Group 1111 Intestinal obstruction without hernia 560;Women;92 Lleida;Group 1112 Intestinal diverticulosis 562;Both sexes;159 Lleida;Group 1112 Intestinal diverticulosis 562;Men;77 Lleida;Group 1112 Intestinal diverticulosis 562;Women;82 Lleida;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Both sexes;189 Lleida;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Men;121 Lleida;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Women;68 Lleida;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Both sexes;149 Lleida;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Men;61 Lleida;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Women;88 Lleida;Group 1115 Alcoholic hepatitis 5710-5713;Both sexes;131 Lleida;Group 1115 Alcoholic hepatitis 5710-5713;Men;110 Lleida;Group 1115 Alcoholic hepatitis 5710-5713;Women;21 Lleida;Group 1116 Other diseases of the liver 570,5714-573;Both sexes;176 Lleida;Group 1116 Other diseases of the liver 570,5714-573;Men;112 Lleida;Group 1116 Other diseases of the liver 570,5714-573;Women;64 Lleida;Group 1117 Cholelithiasis 574;Both sexes;965 Lleida;Group 1117 Cholelithiasis 574;Men;404 Lleida;Group 1117 Cholelithiasis 574;Women;561 Lleida;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Both sexes;328 Lleida;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Men;177 Lleida;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Women;151 Lleida;Group 1119 Pancreatic diseases 577;Both sexes;205 Lleida;Group 1119 Pancreatic diseases 577;Men;123 Lleida;Group 1119 Pancreatic diseases 577;Women;82 Lleida;Group 1120 Other diseases of the digestive system Rest of (520-579);Both sexes;199 Lleida;Group 1120 Other diseases of the digestive system Rest of (520-579);Men;113 Lleida;Group 1120 Other diseases of the digestive system Rest of (520-579);Women;86 Lleida;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Both sexes;327 Lleida;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Men;167 Lleida;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Women;160 Lleida;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Both sexes;208 Lleida;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Men;106 Lleida;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Women;102 Lleida;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Both sexes;14 Lleida;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Men;5 Lleida;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Women;9 Lleida;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Both sexes;105 Lleida;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Men;56 Lleida;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Women;49 Lleida;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Both sexes;2,271 Lleida;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Men;1,051 Lleida;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Women;1,220 Lleida;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Both sexes;.. Lleida;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Men;.. Lleida;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Women;.. Lleida;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Both sexes;.. Lleida;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Men;.. Lleida;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Women;.. Lleida;Group 1303 Internal derangement of knee 717;Both sexes;188 Lleida;Group 1303 Internal derangement of knee 717;Men;118 Lleida;Group 1303 Internal derangement of knee 717;Women;70 Lleida;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Both sexes;932 Lleida;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Men;399 Lleida;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Women;533 Lleida;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Both sexes;48 Lleida;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Men;20 Lleida;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Women;28 Lleida;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Both sexes;92 Lleida;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Men;52 Lleida;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Women;40 Lleida;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Both sexes;204 Lleida;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Men;108 Lleida;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Women;96 Lleida;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Both sexes;93 Lleida;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Men;30 Lleida;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Women;63 Lleida;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Both sexes;359 Lleida;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Men;179 Lleida;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Women;180 Lleida;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Both sexes;355 Lleida;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Men;145 Lleida;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Women;210 Lleida;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Both sexes;2,626 Lleida;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Men;1,339 Lleida;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Women;1,287 Lleida;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Both sexes;358 Lleida;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Men;97 Lleida;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Women;261 Lleida;Group 1402 Renal failure 5836-5837, 584-586;Both sexes;189 Lleida;Group 1402 Renal failure 5836-5837, 584-586;Men;113 Lleida;Group 1402 Renal failure 5836-5837, 584-586;Women;76 Lleida;Group 1403 Urolithiasis 592, 594, 7880;Both sexes;422 Lleida;Group 1403 Urolithiasis 592, 594, 7880;Men;264 Lleida;Group 1403 Urolithiasis 592, 594, 7880;Women;158 Lleida;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Both sexes;704 Lleida;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Men;378 Lleida;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Women;326 Lleida;Group 1405 Prostatic hyperplasia 600;Both sexes;319 Lleida;Group 1405 Prostatic hyperplasia 600;Men;319 Lleida;Group 1405 Prostatic hyperplasia 600;Women;.. Lleida;Group 1406 Other diseases of the male genital organs 601-608;Both sexes;155 Lleida;Group 1406 Other diseases of the male genital organs 601-608;Men;155 Lleida;Group 1406 Other diseases of the male genital organs 601-608;Women;.. Lleida;Group 1407 Disorders of breast 610-612;Both sexes;58 Lleida;Group 1407 Disorders of breast 610-612;Men;1 Lleida;Group 1407 Disorders of breast 610-612;Women;57 Lleida;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Both sexes;63 Lleida;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Men;.. Lleida;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Women;63 Lleida;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Both sexes;32 Lleida;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Men;.. Lleida;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Women;32 Lleida;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Both sexes;326 Lleida;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Men;12 Lleida;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Women;314 Lleida;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Both sexes;4,217 Lleida;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Men;.. Lleida;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Women;4,217 Lleida;Group 1501 Legally induced abortion 635;Both sexes;24 Lleida;Group 1501 Legally induced abortion 635;Men;.. Lleida;Group 1501 Legally induced abortion 635;Women;24 Lleida;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Both sexes;238 Lleida;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Men;.. Lleida;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Women;238 Lleida;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Both sexes;2,178 Lleida;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Men;.. Lleida;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Women;2,178 Lleida;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Both sexes;896 Lleida;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Men;.. Lleida;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Women;896 Lleida;Group 1505 Single spontaneous delivery 650;Both sexes;438 Lleida;Group 1505 Single spontaneous delivery 650;Men;.. Lleida;Group 1505 Single spontaneous delivery 650;Women;438 Lleida;Group 1506 Other deliveries 6695-6697;Both sexes;101 Lleida;Group 1506 Other deliveries 6695-6697;Men;.. Lleida;Group 1506 Other deliveries 6695-6697;Women;101 Lleida;Group 1507 Complications related to the puerperium 670-676;Both sexes;56 Lleida;Group 1507 Complications related to the puerperium 670-676;Men;.. Lleida;Group 1507 Complications related to the puerperium 670-676;Women;56 Lleida;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Both sexes;286 Lleida;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Men;.. Lleida;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Women;286 Lleida;Group 1600 Some disorders originating in the perinatal period 760-779;Both sexes;380 Lleida;Group 1600 Some disorders originating in the perinatal period 760-779;Men;220 Lleida;Group 1600 Some disorders originating in the perinatal period 760-779;Women;160 Lleida;Group 1601 Disorders related with premature delivery and a low birth weight 765;Both sexes;113 Lleida;Group 1601 Disorders related with premature delivery and a low birth weight 765;Men;63 Lleida;Group 1601 Disorders related with premature delivery and a low birth weight 765;Women;50 Lleida;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Both sexes;267 Lleida;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Men;157 Lleida;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Women;110 Lleida;Grupo 1700 Congenital abnormalities 740-759;Both sexes;90 Lleida;Grupo 1700 Congenital abnormalities 740-759;Men;57 Lleida;Grupo 1700 Congenital abnormalities 740-759;Women;33 Lleida;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Both sexes;1,557 Lleida;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Men;884 Lleida;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Women;674 Lleida;Group 1801 Pain in throat and chest 7841, 7865;Both sexes;140 Lleida;Group 1801 Pain in throat and chest 7841, 7865;Men;83 Lleida;Group 1801 Pain in throat and chest 7841, 7865;Women;57 Lleida;Group 1802 Abdominal pain 7890;Both sexes;221 Lleida;Group 1802 Abdominal pain 7890;Men;88 Lleida;Group 1802 Abdominal pain 7890;Women;133 Lleida;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Both sexes;12 Lleida;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Men;8 Lleida;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Women;5 Lleida;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Both sexes;1,184 Lleida;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Men;705 Lleida;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Women;479 Lleida;Group 1900 Injuries and poisoning 800-999;Both sexes;3,699 Lleida;Group 1900 Injuries and poisoning 800-999;Men;1,809 Lleida;Group 1900 Injuries and poisoning 800-999;Women;1,890 Lleida;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Both sexes;341 Lleida;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Men;206 Lleida;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Women;135 Lleida;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Both sexes;71 Lleida;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Men;45 Lleida;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Women;26 Lleida;Group 1903 Radius and ulna fracture 813;Both sexes;152 Lleida;Group 1903 Radius and ulna fracture 813;Men;75 Lleida;Group 1903 Radius and ulna fracture 813;Women;77 Lleida;Group 1904 Femur fracture 820-821;Both sexes;892 Lleida;Group 1904 Femur fracture 820-821;Men;259 Lleida;Group 1904 Femur fracture 820-821;Women;633 Lleida;Group 1905 Leg fracture, including the ankle 823-824;Both sexes;238 Lleida;Group 1905 Leg fracture, including the ankle 823-824;Men;125 Lleida;Group 1905 Leg fracture, including the ankle 823-824;Women;113 Lleida;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Both sexes;1,205 Lleida;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Men;677 Lleida;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Women;528 Lleida;Group 1907 Burns 940-949;Both sexes;17 Lleida;Group 1907 Burns 940-949;Men;10 Lleida;Group 1907 Burns 940-949;Women;7 Lleida;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Both sexes;131 Lleida;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Men;57 Lleida;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Women;74 Lleida;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Both sexes;566 Lleida;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Men;308 Lleida;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Women;258 Lleida;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Both sexes;7 Lleida;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Men;6 Lleida;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Women;1 Lleida;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Both sexes;78 Lleida;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Men;41 Lleida;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Women;37 Lleida;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Both sexes;488 Lleida;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Men;270 Lleida;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Women;218 Lleida;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Both sexes;16 Lleida;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Men;11 Lleida;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Women;5 Lleida;Group 2102 Contraceptive management V25;Both sexes;17 Lleida;Group 2102 Contraceptive management V25;Men;.. Lleida;Group 2102 Contraceptive management V25;Women;17 Lleida;Group 2103 Living newborns by type of delivery V30-V39;Both sexes;.. Lleida;Group 2103 Living newborns by type of delivery V30-V39;Men;.. Lleida;Group 2103 Living newborns by type of delivery V30-V39;Women;.. Lleida;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Both sexes;227 Lleida;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Men;151 Lleida;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Women;76 Lleida;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Both sexes;228 Lleida;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Men;108 Lleida;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Women;120 Tarragona;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Both sexes;74,589 Tarragona;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Men;35,544 Tarragona;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Women;39,045 Tarragona;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Both sexes;1,063 Tarragona;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Men;594 Tarragona;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Women;469 Tarragona;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Both sexes;165 Tarragona;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Men;89 Tarragona;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Women;76 Tarragona;Group 0102 Imprecise intestinal infections 009;Both sexes;147 Tarragona;Group 0102 Imprecise intestinal infections 009;Men;60 Tarragona;Group 0102 Imprecise intestinal infections 009;Women;87 Tarragona;Group 0103 Tuberculosis 010-018, 137;Both sexes;58 Tarragona;Group 0103 Tuberculosis 010-018, 137;Men;39 Tarragona;Group 0103 Tuberculosis 010-018, 137;Women;18 Tarragona;Group 0104 Septicaemia 038;Both sexes;194 Tarragona;Group 0104 Septicaemia 038;Men;100 Tarragona;Group 0104 Septicaemia 038;Women;94 Tarragona;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Both sexes;113 Tarragona;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Men;81 Tarragona;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Women;33 Tarragona;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Both sexes;386 Tarragona;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Men;225 Tarragona;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Women;161 Tarragona;Group 0200 Neoplasms 140-239;Both sexes;7,197 Tarragona;Group 0200 Neoplasms 140-239;Men;4,070 Tarragona;Group 0200 Neoplasms 140-239;Women;3,127 Tarragona;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Both sexes;959 Tarragona;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Men;587 Tarragona;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Women;372 Tarragona;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Both sexes;743 Tarragona;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Men;604 Tarragona;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Women;139 Tarragona;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Both sexes;106 Tarragona;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Men;75 Tarragona;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Women;30 Tarragona;Group 0204 Malignant neoplasm of breast 174-175;Both sexes;685 Tarragona;Group 0204 Malignant neoplasm of breast 174-175;Men;.. Tarragona;Group 0204 Malignant neoplasm of breast 174-175;Women;685 Tarragona;Group 0205 Malignant neoplasm of uterus 179-180, 182;Both sexes;152 Tarragona;Group 0205 Malignant neoplasm of uterus 179-180, 182;Men;.. Tarragona;Group 0205 Malignant neoplasm of uterus 179-180, 182;Women;152 Tarragona;Group 0206 Malignant neoplasm of ovary 1830;Both sexes;70 Tarragona;Group 0206 Malignant neoplasm of ovary 1830;Men;.. Tarragona;Group 0206 Malignant neoplasm of ovary 1830;Women;70 Tarragona;Group 0207 Malignant neoplasm of prostate 185;Both sexes;229 Tarragona;Group 0207 Malignant neoplasm of prostate 185;Men;229 Tarragona;Group 0207 Malignant neoplasm of prostate 185;Women;.. Tarragona;Group 0208 Malignant neoplasm of bladder 188;Both sexes;935 Tarragona;Group 0208 Malignant neoplasm of bladder 188;Men;851 Tarragona;Group 0208 Malignant neoplasm of bladder 188;Women;84 Tarragona;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Both sexes;2,130 Tarragona;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Men;1,328 Tarragona;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Women;802 Tarragona;Group 0210 Carcinoma in situ 230-234;Both sexes;78 Tarragona;Group 0210 Carcinoma in situ 230-234;Men;29 Tarragona;Group 0210 Carcinoma in situ 230-234;Women;50 Tarragona;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Both sexes;80 Tarragona;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Men;56 Tarragona;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Women;23 Tarragona;Grupo 0212 Leiomyoma of uterus 218;Both sexes;385 Tarragona;Grupo 0212 Leiomyoma of uterus 218;Men;.. Tarragona;Grupo 0212 Leiomyoma of uterus 218;Women;385 Tarragona;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Both sexes;645 Tarragona;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Men;311 Tarragona;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Women;334 Tarragona;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Both sexes;744 Tarragona;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Men;376 Tarragona;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Women;368 Tarragona;Group 0301 Anaemias 280-285;Both sexes;521 Tarragona;Group 0301 Anaemias 280-285;Men;254 Tarragona;Group 0301 Anaemias 280-285;Women;267 Tarragona;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Both sexes;223 Tarragona;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Men;122 Tarragona;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Women;101 Tarragona;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Both sexes;1,123 Tarragona;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Men;425 Tarragona;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Women;698 Tarragona;Group 0401 Diabetes mellitus 249-250;Both sexes;444 Tarragona;Group 0401 Diabetes mellitus 249-250;Men;235 Tarragona;Group 0401 Diabetes mellitus 249-250;Women;208 Tarragona;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Both sexes;679 Tarragona;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Men;189 Tarragona;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Women;489 Tarragona;Group 0500 Mental disorders 290-319;Both sexes;2,446 Tarragona;Group 0500 Mental disorders 290-319;Men;1,355 Tarragona;Group 0500 Mental disorders 290-319;Women;1,091 Tarragona;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Both sexes;211 Tarragona;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Men;80 Tarragona;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Women;132 Tarragona;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Both sexes;126 Tarragona;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Men;94 Tarragona;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Women;32 Tarragona;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Both sexes;85 Tarragona;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Men;71 Tarragona;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Women;14 Tarragona;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Both sexes;680 Tarragona;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Men;431 Tarragona;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Women;248 Tarragona;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Both sexes;437 Tarragona;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Men;186 Tarragona;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Women;251 Tarragona;Group 0506 Other mental and behavioural disorders Rest of (290-319);Both sexes;907 Tarragona;Group 0506 Other mental and behavioural disorders Rest of (290-319);Men;493 Tarragona;Group 0506 Other mental and behavioural disorders Rest of (290-319);Women;414 Tarragona;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Both sexes;1,182 Tarragona;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Men;566 Tarragona;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Women;615 Tarragona;Group 0601 Alzheimer's disease 3310;Both sexes;114 Tarragona;Group 0601 Alzheimer's disease 3310;Men;38 Tarragona;Group 0601 Alzheimer's disease 3310;Women;76 Tarragona;Group 0602 Multiple sclerosis 340;Both sexes;18 Tarragona;Group 0602 Multiple sclerosis 340;Men;9 Tarragona;Group 0602 Multiple sclerosis 340;Women;9 Tarragona;Group 0603 Epilepsy 345;Both sexes;193 Tarragona;Group 0603 Epilepsy 345;Men;98 Tarragona;Group 0603 Epilepsy 345;Women;95 Tarragona;Group 0604 Transient cerebral ischemia 435;Both sexes;185 Tarragona;Group 0604 Transient cerebral ischemia 435;Men;96 Tarragona;Group 0604 Transient cerebral ischemia 435;Women;89 Tarragona;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Both sexes;671 Tarragona;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Men;325 Tarragona;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Women;346 Tarragona;Grupo 0700 Diseases of the eye and adnexa 360-379;Both sexes;232 Tarragona;Grupo 0700 Diseases of the eye and adnexa 360-379;Men;109 Tarragona;Grupo 0700 Diseases of the eye and adnexa 360-379;Women;123 Tarragona;Grupo 0701 Cataract 366;Both sexes;99 Tarragona;Grupo 0701 Cataract 366;Men;42 Tarragona;Grupo 0701 Cataract 366;Women;57 Tarragona;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Both sexes;133 Tarragona;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Men;68 Tarragona;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Women;66 Tarragona;Group 0800 Diseases of the ear and the mastoid 380-389;Both sexes;425 Tarragona;Group 0800 Diseases of the ear and the mastoid 380-389;Men;200 Tarragona;Group 0800 Diseases of the ear and the mastoid 380-389;Women;226 Tarragona;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Both sexes;9,351 Tarragona;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Men;5,238 Tarragona;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Women;4,113 Tarragona;Group 0901 Hypertensive disease 401-405;Both sexes;206 Tarragona;Group 0901 Hypertensive disease 401-405;Men;72 Tarragona;Group 0901 Hypertensive disease 401-405;Women;135 Tarragona;Group 0902 Angina pectoris 4111, 413;Both sexes;504 Tarragona;Group 0902 Angina pectoris 4111, 413;Men;330 Tarragona;Group 0902 Angina pectoris 4111, 413;Women;174 Tarragona;Group 0903 Acute myocardial infarction 410;Both sexes;1,057 Tarragona;Group 0903 Acute myocardial infarction 410;Men;724 Tarragona;Group 0903 Acute myocardial infarction 410;Women;333 Tarragona;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Both sexes;448 Tarragona;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Men;312 Tarragona;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Women;136 Tarragona;Group 0905 Diseases of the lungs circulation 415-417;Both sexes;268 Tarragona;Group 0905 Diseases of the lungs circulation 415-417;Men;117 Tarragona;Group 0905 Diseases of the lungs circulation 415-417;Women;151 Tarragona;Group 0906 Heart conduction disorders and arrhytmias 426-427;Both sexes;1,192 Tarragona;Group 0906 Heart conduction disorders and arrhytmias 426-427;Men;622 Tarragona;Group 0906 Heart conduction disorders and arrhytmias 426-427;Women;570 Tarragona;Grupo 0907 Heart failure 428;Both sexes;1,941 Tarragona;Grupo 0907 Heart failure 428;Men;955 Tarragona;Grupo 0907 Heart failure 428;Women;987 Tarragona;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Both sexes;1,868 Tarragona;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Men;1,034 Tarragona;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Women;834 Tarragona;Grupo 0909 Atherosclerosis 440;Both sexes;405 Tarragona;Grupo 0909 Atherosclerosis 440;Men;311 Tarragona;Grupo 0909 Atherosclerosis 440;Women;94 Tarragona;Group 0910 Varicose veins of lower extremities 454;Both sexes;285 Tarragona;Group 0910 Varicose veins of lower extremities 454;Men;105 Tarragona;Group 0910 Varicose veins of lower extremities 454;Women;179 Tarragona;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Both sexes;1,177 Tarragona;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Men;656 Tarragona;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Women;520 Tarragona;Group 1000 Diseases of the respiratory system 0340, 460-519;Both sexes;8,794 Tarragona;Group 1000 Diseases of the respiratory system 0340, 460-519;Men;5,171 Tarragona;Group 1000 Diseases of the respiratory system 0340, 460-519;Women;3,622 Tarragona;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Both sexes;276 Tarragona;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Men;152 Tarragona;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Women;124 Tarragona;Group 1002 Pneumonia 480-486;Both sexes;1,973 Tarragona;Group 1002 Pneumonia 480-486;Men;1,226 Tarragona;Group 1002 Pneumonia 480-486;Women;748 Tarragona;Group 1003 Acute bronchitis and bronchiolitis 466;Both sexes;1,688 Tarragona;Group 1003 Acute bronchitis and bronchiolitis 466;Men;803 Tarragona;Group 1003 Acute bronchitis and bronchiolitis 466;Women;884 Tarragona;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Both sexes;370 Tarragona;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Men;182 Tarragona;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Women;188 Tarragona;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Both sexes;625 Tarragona;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Men;392 Tarragona;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Women;232 Tarragona;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Both sexes;1,806 Tarragona;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Men;1,398 Tarragona;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Women;408 Tarragona;Group 1007 Asthma 4930-4931,4938-4939;Both sexes;431 Tarragona;Group 1007 Asthma 4930-4931,4938-4939;Men;97 Tarragona;Group 1007 Asthma 4930-4931,4938-4939;Women;335 Tarragona;Group 1008 Other diseases of the respiratory system Resto of (460-519);Both sexes;1,624 Tarragona;Group 1008 Other diseases of the respiratory system Resto of (460-519);Men;920 Tarragona;Group 1008 Other diseases of the respiratory system Resto of (460-519);Women;704 Tarragona;Group 1100 Diseases of the digestive system 520-579;Both sexes;9,887 Tarragona;Group 1100 Diseases of the digestive system 520-579;Men;5,657 Tarragona;Group 1100 Diseases of the digestive system 520-579;Women;4,230 Tarragona;Group 1101 Disorders of the teeth and supporting structures 520-525;Both sexes;297 Tarragona;Group 1101 Disorders of the teeth and supporting structures 520-525;Men;142 Tarragona;Group 1101 Disorders of the teeth and supporting structures 520-525;Women;155 Tarragona;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Both sexes;103 Tarragona;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Men;52 Tarragona;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Women;51 Tarragona;Group 1103 Diseases of the esophagus 530;Both sexes;116 Tarragona;Group 1103 Diseases of the esophagus 530;Men;73 Tarragona;Group 1103 Diseases of the esophagus 530;Women;43 Tarragona;Group 1104 Peptic ulcer 531-534;Both sexes;168 Tarragona;Group 1104 Peptic ulcer 531-534;Men;120 Tarragona;Group 1104 Peptic ulcer 531-534;Women;48 Tarragona;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Both sexes;217 Tarragona;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Men;119 Tarragona;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Women;98 Tarragona;Group 1106 Appendicitis 540-543;Both sexes;760 Tarragona;Group 1106 Appendicitis 540-543;Men;457 Tarragona;Group 1106 Appendicitis 540-543;Women;303 Tarragona;Group 1107 Inguinal hernia 550;Both sexes;1,127 Tarragona;Group 1107 Inguinal hernia 550;Men;1,034 Tarragona;Group 1107 Inguinal hernia 550;Women;94 Tarragona;Group 1108 Other abdominal hernia 551-553;Both sexes;981 Tarragona;Group 1108 Other abdominal hernia 551-553;Men;438 Tarragona;Group 1108 Other abdominal hernia 551-553;Women;543 Tarragona;Group 1109 Crohn's disease and ulcerative colitis 555-556;Both sexes;151 Tarragona;Group 1109 Crohn's disease and ulcerative colitis 555-556;Men;78 Tarragona;Group 1109 Crohn's disease and ulcerative colitis 555-556;Women;72 Tarragona;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Both sexes;496 Tarragona;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Men;223 Tarragona;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Women;273 Tarragona;Group 1111 Intestinal obstruction without hernia 560;Both sexes;517 Tarragona;Group 1111 Intestinal obstruction without hernia 560;Men;288 Tarragona;Group 1111 Intestinal obstruction without hernia 560;Women;229 Tarragona;Group 1112 Intestinal diverticulosis 562;Both sexes;329 Tarragona;Group 1112 Intestinal diverticulosis 562;Men;158 Tarragona;Group 1112 Intestinal diverticulosis 562;Women;171 Tarragona;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Both sexes;732 Tarragona;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Men;460 Tarragona;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Women;272 Tarragona;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Both sexes;269 Tarragona;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Men;124 Tarragona;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Women;145 Tarragona;Group 1115 Alcoholic hepatitis 5710-5713;Both sexes;221 Tarragona;Group 1115 Alcoholic hepatitis 5710-5713;Men;185 Tarragona;Group 1115 Alcoholic hepatitis 5710-5713;Women;37 Tarragona;Group 1116 Other diseases of the liver 570,5714-573;Both sexes;276 Tarragona;Group 1116 Other diseases of the liver 570,5714-573;Men;170 Tarragona;Group 1116 Other diseases of the liver 570,5714-573;Women;105 Tarragona;Group 1117 Cholelithiasis 574;Both sexes;1,747 Tarragona;Group 1117 Cholelithiasis 574;Men;750 Tarragona;Group 1117 Cholelithiasis 574;Women;996 Tarragona;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Both sexes;435 Tarragona;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Men;259 Tarragona;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Women;176 Tarragona;Group 1119 Pancreatic diseases 577;Both sexes;583 Tarragona;Group 1119 Pancreatic diseases 577;Men;327 Tarragona;Group 1119 Pancreatic diseases 577;Women;256 Tarragona;Group 1120 Other diseases of the digestive system Rest of (520-579);Both sexes;361 Tarragona;Group 1120 Other diseases of the digestive system Rest of (520-579);Men;200 Tarragona;Group 1120 Other diseases of the digestive system Rest of (520-579);Women;161 Tarragona;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Both sexes;886 Tarragona;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Men;491 Tarragona;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Women;395 Tarragona;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Both sexes;602 Tarragona;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Men;357 Tarragona;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Women;245 Tarragona;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Both sexes;33 Tarragona;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Men;10 Tarragona;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Women;22 Tarragona;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Both sexes;251 Tarragona;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Men;124 Tarragona;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Women;127 Tarragona;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Both sexes;4,721 Tarragona;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Men;2,149 Tarragona;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Women;2,572 Tarragona;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Both sexes;.. Tarragona;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Men;.. Tarragona;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Women;.. Tarragona;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Both sexes;.. Tarragona;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Men;.. Tarragona;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Women;.. Tarragona;Group 1303 Internal derangement of knee 717;Both sexes;706 Tarragona;Group 1303 Internal derangement of knee 717;Men;435 Tarragona;Group 1303 Internal derangement of knee 717;Women;271 Tarragona;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Both sexes;1,910 Tarragona;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Men;744 Tarragona;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Women;1,166 Tarragona;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Both sexes;74 Tarragona;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Men;32 Tarragona;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Women;43 Tarragona;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Both sexes;159 Tarragona;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Men;89 Tarragona;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Women;70 Tarragona;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Both sexes;316 Tarragona;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Men;182 Tarragona;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Women;134 Tarragona;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Both sexes;183 Tarragona;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Men;90 Tarragona;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Women;94 Tarragona;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Both sexes;681 Tarragona;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Men;341 Tarragona;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Women;339 Tarragona;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Both sexes;691 Tarragona;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Men;237 Tarragona;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Women;454 Tarragona;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Both sexes;5,054 Tarragona;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Men;2,331 Tarragona;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Women;2,723 Tarragona;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Both sexes;638 Tarragona;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Men;197 Tarragona;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Women;441 Tarragona;Group 1402 Renal failure 5836-5837, 584-586;Both sexes;447 Tarragona;Group 1402 Renal failure 5836-5837, 584-586;Men;276 Tarragona;Group 1402 Renal failure 5836-5837, 584-586;Women;172 Tarragona;Group 1403 Urolithiasis 592, 594, 7880;Both sexes;677 Tarragona;Group 1403 Urolithiasis 592, 594, 7880;Men;422 Tarragona;Group 1403 Urolithiasis 592, 594, 7880;Women;256 Tarragona;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Both sexes;1,245 Tarragona;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Men;598 Tarragona;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Women;648 Tarragona;Group 1405 Prostatic hyperplasia 600;Both sexes;369 Tarragona;Group 1405 Prostatic hyperplasia 600;Men;369 Tarragona;Group 1405 Prostatic hyperplasia 600;Women;.. Tarragona;Group 1406 Other diseases of the male genital organs 601-608;Both sexes;442 Tarragona;Group 1406 Other diseases of the male genital organs 601-608;Men;442 Tarragona;Group 1406 Other diseases of the male genital organs 601-608;Women;.. Tarragona;Group 1407 Disorders of breast 610-612;Both sexes;147 Tarragona;Group 1407 Disorders of breast 610-612;Men;21 Tarragona;Group 1407 Disorders of breast 610-612;Women;126 Tarragona;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Both sexes;167 Tarragona;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Men;.. Tarragona;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Women;167 Tarragona;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Both sexes;94 Tarragona;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Men;.. Tarragona;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Women;94 Tarragona;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Both sexes;826 Tarragona;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Men;6 Tarragona;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Women;820 Tarragona;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Both sexes;8,256 Tarragona;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Men;.. Tarragona;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Women;8,256 Tarragona;Group 1501 Legally induced abortion 635;Both sexes;33 Tarragona;Group 1501 Legally induced abortion 635;Men;.. Tarragona;Group 1501 Legally induced abortion 635;Women;33 Tarragona;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Both sexes;491 Tarragona;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Men;.. Tarragona;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Women;491 Tarragona;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Both sexes;3,347 Tarragona;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Men;.. Tarragona;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Women;3,347 Tarragona;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Both sexes;1,968 Tarragona;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Men;.. Tarragona;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Women;1,968 Tarragona;Group 1505 Single spontaneous delivery 650;Both sexes;1,368 Tarragona;Group 1505 Single spontaneous delivery 650;Men;.. Tarragona;Group 1505 Single spontaneous delivery 650;Women;1,368 Tarragona;Group 1506 Other deliveries 6695-6697;Both sexes;112 Tarragona;Group 1506 Other deliveries 6695-6697;Men;.. Tarragona;Group 1506 Other deliveries 6695-6697;Women;112 Tarragona;Group 1507 Complications related to the puerperium 670-676;Both sexes;142 Tarragona;Group 1507 Complications related to the puerperium 670-676;Men;.. Tarragona;Group 1507 Complications related to the puerperium 670-676;Women;142 Tarragona;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Both sexes;798 Tarragona;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Men;.. Tarragona;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Women;798 Tarragona;Group 1600 Some disorders originating in the perinatal period 760-779;Both sexes;1,154 Tarragona;Group 1600 Some disorders originating in the perinatal period 760-779;Men;641 Tarragona;Group 1600 Some disorders originating in the perinatal period 760-779;Women;513 Tarragona;Group 1601 Disorders related with premature delivery and a low birth weight 765;Both sexes;337 Tarragona;Group 1601 Disorders related with premature delivery and a low birth weight 765;Men;186 Tarragona;Group 1601 Disorders related with premature delivery and a low birth weight 765;Women;151 Tarragona;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Both sexes;817 Tarragona;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Men;454 Tarragona;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Women;363 Tarragona;Grupo 1700 Congenital abnormalities 740-759;Both sexes;468 Tarragona;Grupo 1700 Congenital abnormalities 740-759;Men;263 Tarragona;Grupo 1700 Congenital abnormalities 740-759;Women;205 Tarragona;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Both sexes;3,449 Tarragona;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Men;1,991 Tarragona;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Women;1,458 Tarragona;Group 1801 Pain in throat and chest 7841, 7865;Both sexes;428 Tarragona;Group 1801 Pain in throat and chest 7841, 7865;Men;243 Tarragona;Group 1801 Pain in throat and chest 7841, 7865;Women;185 Tarragona;Group 1802 Abdominal pain 7890;Both sexes;429 Tarragona;Group 1802 Abdominal pain 7890;Men;162 Tarragona;Group 1802 Abdominal pain 7890;Women;267 Tarragona;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Both sexes;26 Tarragona;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Men;15 Tarragona;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Women;11 Tarragona;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Both sexes;2,566 Tarragona;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Men;1,571 Tarragona;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Women;995 Tarragona;Group 1900 Injuries and poisoning 800-999;Both sexes;7,013 Tarragona;Group 1900 Injuries and poisoning 800-999;Men;3,357 Tarragona;Group 1900 Injuries and poisoning 800-999;Women;3,656 Tarragona;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Both sexes;465 Tarragona;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Men;268 Tarragona;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Women;197 Tarragona;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Both sexes;179 Tarragona;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Men;130 Tarragona;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Women;49 Tarragona;Group 1903 Radius and ulna fracture 813;Both sexes;468 Tarragona;Group 1903 Radius and ulna fracture 813;Men;246 Tarragona;Group 1903 Radius and ulna fracture 813;Women;221 Tarragona;Group 1904 Femur fracture 820-821;Both sexes;1,708 Tarragona;Group 1904 Femur fracture 820-821;Men;463 Tarragona;Group 1904 Femur fracture 820-821;Women;1,245 Tarragona;Group 1905 Leg fracture, including the ankle 823-824;Both sexes;503 Tarragona;Group 1905 Leg fracture, including the ankle 823-824;Men;254 Tarragona;Group 1905 Leg fracture, including the ankle 823-824;Women;249 Tarragona;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Both sexes;1,886 Tarragona;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Men;1,041 Tarragona;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Women;845 Tarragona;Group 1907 Burns 940-949;Both sexes;15 Tarragona;Group 1907 Burns 940-949;Men;8 Tarragona;Group 1907 Burns 940-949;Women;7 Tarragona;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Both sexes;185 Tarragona;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Men;75 Tarragona;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Women;110 Tarragona;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Both sexes;1,332 Tarragona;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Men;716 Tarragona;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Women;616 Tarragona;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Both sexes;15 Tarragona;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Men;7 Tarragona;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Women;8 Tarragona;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Both sexes;255 Tarragona;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Men;147 Tarragona;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Women;109 Tarragona;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Both sexes;1,145 Tarragona;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Men;561 Tarragona;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Women;584 Tarragona;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Both sexes;13 Tarragona;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Men;10 Tarragona;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Women;3 Tarragona;Group 2102 Contraceptive management V25;Both sexes;52 Tarragona;Group 2102 Contraceptive management V25;Men;.. Tarragona;Group 2102 Contraceptive management V25;Women;52 Tarragona;Group 2103 Living newborns by type of delivery V30-V39;Both sexes;.. Tarragona;Group 2103 Living newborns by type of delivery V30-V39;Men;.. Tarragona;Group 2103 Living newborns by type of delivery V30-V39;Women;.. Tarragona;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Both sexes;307 Tarragona;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Men;176 Tarragona;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Women;130 Tarragona;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Both sexes;773 Tarragona;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Men;375 Tarragona;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Women;398 COMUNITAT VALENCIANA;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Both sexes;494,068 COMUNITAT VALENCIANA;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Men;235,827 COMUNITAT VALENCIANA;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Women;258,241 COMUNITAT VALENCIANA;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Both sexes;10,905 COMUNITAT VALENCIANA;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Men;6,049 COMUNITAT VALENCIANA;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Women;4,856 COMUNITAT VALENCIANA;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Both sexes;1,500 COMUNITAT VALENCIANA;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Men;806 COMUNITAT VALENCIANA;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Women;694 COMUNITAT VALENCIANA;Group 0102 Imprecise intestinal infections 009;Both sexes;1,095 COMUNITAT VALENCIANA;Group 0102 Imprecise intestinal infections 009;Men;517 COMUNITAT VALENCIANA;Group 0102 Imprecise intestinal infections 009;Women;578 COMUNITAT VALENCIANA;Group 0103 Tuberculosis 010-018, 137;Both sexes;435 COMUNITAT VALENCIANA;Group 0103 Tuberculosis 010-018, 137;Men;299 COMUNITAT VALENCIANA;Group 0103 Tuberculosis 010-018, 137;Women;136 COMUNITAT VALENCIANA;Group 0104 Septicaemia 038;Both sexes;3,808 COMUNITAT VALENCIANA;Group 0104 Septicaemia 038;Men;2,037 COMUNITAT VALENCIANA;Group 0104 Septicaemia 038;Women;1,771 COMUNITAT VALENCIANA;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Both sexes;422 COMUNITAT VALENCIANA;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Men;289 COMUNITAT VALENCIANA;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Women;133 COMUNITAT VALENCIANA;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Both sexes;3,645 COMUNITAT VALENCIANA;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Men;2,101 COMUNITAT VALENCIANA;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Women;1,544 COMUNITAT VALENCIANA;Group 0200 Neoplasms 140-239;Both sexes;50,465 COMUNITAT VALENCIANA;Group 0200 Neoplasms 140-239;Men;26,698 COMUNITAT VALENCIANA;Group 0200 Neoplasms 140-239;Women;23,767 COMUNITAT VALENCIANA;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Both sexes;5,281 COMUNITAT VALENCIANA;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Men;3,180 COMUNITAT VALENCIANA;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Women;2,101 COMUNITAT VALENCIANA;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Both sexes;4,122 COMUNITAT VALENCIANA;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Men;3,248 COMUNITAT VALENCIANA;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Women;874 COMUNITAT VALENCIANA;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Both sexes;800 COMUNITAT VALENCIANA;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Men;478 COMUNITAT VALENCIANA;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Women;322 COMUNITAT VALENCIANA;Group 0204 Malignant neoplasm of breast 174-175;Both sexes;4,255 COMUNITAT VALENCIANA;Group 0204 Malignant neoplasm of breast 174-175;Men;33 COMUNITAT VALENCIANA;Group 0204 Malignant neoplasm of breast 174-175;Women;4,222 COMUNITAT VALENCIANA;Group 0205 Malignant neoplasm of uterus 179-180, 182;Both sexes;1,107 COMUNITAT VALENCIANA;Group 0205 Malignant neoplasm of uterus 179-180, 182;Men;.. COMUNITAT VALENCIANA;Group 0205 Malignant neoplasm of uterus 179-180, 182;Women;1,107 COMUNITAT VALENCIANA;Group 0206 Malignant neoplasm of ovary 1830;Both sexes;616 COMUNITAT VALENCIANA;Group 0206 Malignant neoplasm of ovary 1830;Men;.. COMUNITAT VALENCIANA;Group 0206 Malignant neoplasm of ovary 1830;Women;616 COMUNITAT VALENCIANA;Group 0207 Malignant neoplasm of prostate 185;Both sexes;2,082 COMUNITAT VALENCIANA;Group 0207 Malignant neoplasm of prostate 185;Men;2,082 COMUNITAT VALENCIANA;Group 0207 Malignant neoplasm of prostate 185;Women;.. COMUNITAT VALENCIANA;Group 0208 Malignant neoplasm of bladder 188;Both sexes;5,567 COMUNITAT VALENCIANA;Group 0208 Malignant neoplasm of bladder 188;Men;4,785 COMUNITAT VALENCIANA;Group 0208 Malignant neoplasm of bladder 188;Women;782 COMUNITAT VALENCIANA;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Both sexes;16,022 COMUNITAT VALENCIANA;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Men;9,505 COMUNITAT VALENCIANA;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Women;6,517 COMUNITAT VALENCIANA;Group 0210 Carcinoma in situ 230-234;Both sexes;761 COMUNITAT VALENCIANA;Group 0210 Carcinoma in situ 230-234;Men;194 COMUNITAT VALENCIANA;Group 0210 Carcinoma in situ 230-234;Women;567 COMUNITAT VALENCIANA;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Both sexes;656 COMUNITAT VALENCIANA;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Men;408 COMUNITAT VALENCIANA;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Women;248 COMUNITAT VALENCIANA;Grupo 0212 Leiomyoma of uterus 218;Both sexes;2,700 COMUNITAT VALENCIANA;Grupo 0212 Leiomyoma of uterus 218;Men;.. COMUNITAT VALENCIANA;Grupo 0212 Leiomyoma of uterus 218;Women;2,700 COMUNITAT VALENCIANA;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Both sexes;6,496 COMUNITAT VALENCIANA;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Men;2,785 COMUNITAT VALENCIANA;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Women;3,711 COMUNITAT VALENCIANA;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Both sexes;4,337 COMUNITAT VALENCIANA;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Men;2,129 COMUNITAT VALENCIANA;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Women;2,208 COMUNITAT VALENCIANA;Group 0301 Anaemias 280-285;Both sexes;2,349 COMUNITAT VALENCIANA;Group 0301 Anaemias 280-285;Men;1,088 COMUNITAT VALENCIANA;Group 0301 Anaemias 280-285;Women;1,261 COMUNITAT VALENCIANA;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Both sexes;1,988 COMUNITAT VALENCIANA;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Men;1,041 COMUNITAT VALENCIANA;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Women;947 COMUNITAT VALENCIANA;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Both sexes;9,273 COMUNITAT VALENCIANA;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Men;3,762 COMUNITAT VALENCIANA;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Women;5,511 COMUNITAT VALENCIANA;Group 0401 Diabetes mellitus 249-250;Both sexes;3,347 COMUNITAT VALENCIANA;Group 0401 Diabetes mellitus 249-250;Men;1,951 COMUNITAT VALENCIANA;Group 0401 Diabetes mellitus 249-250;Women;1,396 COMUNITAT VALENCIANA;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Both sexes;5,926 COMUNITAT VALENCIANA;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Men;1,811 COMUNITAT VALENCIANA;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Women;4,115 COMUNITAT VALENCIANA;Group 0500 Mental disorders 290-319;Both sexes;10,480 COMUNITAT VALENCIANA;Group 0500 Mental disorders 290-319;Men;5,648 COMUNITAT VALENCIANA;Group 0500 Mental disorders 290-319;Women;4,832 COMUNITAT VALENCIANA;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Both sexes;246 COMUNITAT VALENCIANA;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Men;115 COMUNITAT VALENCIANA;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Women;131 COMUNITAT VALENCIANA;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Both sexes;750 COMUNITAT VALENCIANA;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Men;539 COMUNITAT VALENCIANA;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Women;211 COMUNITAT VALENCIANA;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Both sexes;623 COMUNITAT VALENCIANA;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Men;476 COMUNITAT VALENCIANA;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Women;147 COMUNITAT VALENCIANA;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Both sexes;3,170 COMUNITAT VALENCIANA;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Men;2,031 COMUNITAT VALENCIANA;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Women;1,139 COMUNITAT VALENCIANA;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Both sexes;2,237 COMUNITAT VALENCIANA;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Men;971 COMUNITAT VALENCIANA;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Women;1,266 COMUNITAT VALENCIANA;Group 0506 Other mental and behavioural disorders Rest of (290-319);Both sexes;3,454 COMUNITAT VALENCIANA;Group 0506 Other mental and behavioural disorders Rest of (290-319);Men;1,516 COMUNITAT VALENCIANA;Group 0506 Other mental and behavioural disorders Rest of (290-319);Women;1,938 COMUNITAT VALENCIANA;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Both sexes;12,546 COMUNITAT VALENCIANA;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Men;6,488 COMUNITAT VALENCIANA;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Women;6,058 COMUNITAT VALENCIANA;Group 0601 Alzheimer's disease 3310;Both sexes;214 COMUNITAT VALENCIANA;Group 0601 Alzheimer's disease 3310;Men;89 COMUNITAT VALENCIANA;Group 0601 Alzheimer's disease 3310;Women;125 COMUNITAT VALENCIANA;Group 0602 Multiple sclerosis 340;Both sexes;266 COMUNITAT VALENCIANA;Group 0602 Multiple sclerosis 340;Men;69 COMUNITAT VALENCIANA;Group 0602 Multiple sclerosis 340;Women;197 COMUNITAT VALENCIANA;Group 0603 Epilepsy 345;Both sexes;2,516 COMUNITAT VALENCIANA;Group 0603 Epilepsy 345;Men;1,400 COMUNITAT VALENCIANA;Group 0603 Epilepsy 345;Women;1,116 COMUNITAT VALENCIANA;Group 0604 Transient cerebral ischemia 435;Both sexes;1,856 COMUNITAT VALENCIANA;Group 0604 Transient cerebral ischemia 435;Men;999 COMUNITAT VALENCIANA;Group 0604 Transient cerebral ischemia 435;Women;857 COMUNITAT VALENCIANA;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Both sexes;7,694 COMUNITAT VALENCIANA;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Men;3,931 COMUNITAT VALENCIANA;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Women;3,763 COMUNITAT VALENCIANA;Grupo 0700 Diseases of the eye and adnexa 360-379;Both sexes;2,774 COMUNITAT VALENCIANA;Grupo 0700 Diseases of the eye and adnexa 360-379;Men;1,458 COMUNITAT VALENCIANA;Grupo 0700 Diseases of the eye and adnexa 360-379;Women;1,316 COMUNITAT VALENCIANA;Grupo 0701 Cataract 366;Both sexes;363 COMUNITAT VALENCIANA;Grupo 0701 Cataract 366;Men;181 COMUNITAT VALENCIANA;Grupo 0701 Cataract 366;Women;182 COMUNITAT VALENCIANA;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Both sexes;2,411 COMUNITAT VALENCIANA;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Men;1,277 COMUNITAT VALENCIANA;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Women;1,134 COMUNITAT VALENCIANA;Group 0800 Diseases of the ear and the mastoid 380-389;Both sexes;2,592 COMUNITAT VALENCIANA;Group 0800 Diseases of the ear and the mastoid 380-389;Men;1,262 COMUNITAT VALENCIANA;Group 0800 Diseases of the ear and the mastoid 380-389;Women;1,330 COMUNITAT VALENCIANA;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Both sexes;63,698 COMUNITAT VALENCIANA;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Men;36,423 COMUNITAT VALENCIANA;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Women;27,275 COMUNITAT VALENCIANA;Group 0901 Hypertensive disease 401-405;Both sexes;1,947 COMUNITAT VALENCIANA;Group 0901 Hypertensive disease 401-405;Men;928 COMUNITAT VALENCIANA;Group 0901 Hypertensive disease 401-405;Women;1,019 COMUNITAT VALENCIANA;Group 0902 Angina pectoris 4111, 413;Both sexes;3,357 COMUNITAT VALENCIANA;Group 0902 Angina pectoris 4111, 413;Men;2,166 COMUNITAT VALENCIANA;Group 0902 Angina pectoris 4111, 413;Women;1,191 COMUNITAT VALENCIANA;Group 0903 Acute myocardial infarction 410;Both sexes;5,963 COMUNITAT VALENCIANA;Group 0903 Acute myocardial infarction 410;Men;4,238 COMUNITAT VALENCIANA;Group 0903 Acute myocardial infarction 410;Women;1,725 COMUNITAT VALENCIANA;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Both sexes;4,675 COMUNITAT VALENCIANA;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Men;3,608 COMUNITAT VALENCIANA;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Women;1,067 COMUNITAT VALENCIANA;Group 0905 Diseases of the lungs circulation 415-417;Both sexes;1,968 COMUNITAT VALENCIANA;Group 0905 Diseases of the lungs circulation 415-417;Men;893 COMUNITAT VALENCIANA;Group 0905 Diseases of the lungs circulation 415-417;Women;1,075 COMUNITAT VALENCIANA;Group 0906 Heart conduction disorders and arrhytmias 426-427;Both sexes;8,517 COMUNITAT VALENCIANA;Group 0906 Heart conduction disorders and arrhytmias 426-427;Men;4,556 COMUNITAT VALENCIANA;Group 0906 Heart conduction disorders and arrhytmias 426-427;Women;3,961 COMUNITAT VALENCIANA;Grupo 0907 Heart failure 428;Both sexes;12,493 COMUNITAT VALENCIANA;Grupo 0907 Heart failure 428;Men;5,934 COMUNITAT VALENCIANA;Grupo 0907 Heart failure 428;Women;6,559 COMUNITAT VALENCIANA;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Both sexes;11,694 COMUNITAT VALENCIANA;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Men;6,392 COMUNITAT VALENCIANA;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Women;5,302 COMUNITAT VALENCIANA;Grupo 0909 Atherosclerosis 440;Both sexes;1,576 COMUNITAT VALENCIANA;Grupo 0909 Atherosclerosis 440;Men;1,181 COMUNITAT VALENCIANA;Grupo 0909 Atherosclerosis 440;Women;395 COMUNITAT VALENCIANA;Group 0910 Varicose veins of lower extremities 454;Both sexes;1,058 COMUNITAT VALENCIANA;Group 0910 Varicose veins of lower extremities 454;Men;377 COMUNITAT VALENCIANA;Group 0910 Varicose veins of lower extremities 454;Women;681 COMUNITAT VALENCIANA;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Both sexes;10,450 COMUNITAT VALENCIANA;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Men;6,150 COMUNITAT VALENCIANA;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Women;4,300 COMUNITAT VALENCIANA;Group 1000 Diseases of the respiratory system 0340, 460-519;Both sexes;53,328 COMUNITAT VALENCIANA;Group 1000 Diseases of the respiratory system 0340, 460-519;Men;30,653 COMUNITAT VALENCIANA;Group 1000 Diseases of the respiratory system 0340, 460-519;Women;22,675 COMUNITAT VALENCIANA;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Both sexes;2,865 COMUNITAT VALENCIANA;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Men;1,500 COMUNITAT VALENCIANA;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Women;1,365 COMUNITAT VALENCIANA;Group 1002 Pneumonia 480-486;Both sexes;12,227 COMUNITAT VALENCIANA;Group 1002 Pneumonia 480-486;Men;7,243 COMUNITAT VALENCIANA;Group 1002 Pneumonia 480-486;Women;4,984 COMUNITAT VALENCIANA;Group 1003 Acute bronchitis and bronchiolitis 466;Both sexes;4,725 COMUNITAT VALENCIANA;Group 1003 Acute bronchitis and bronchiolitis 466;Men;2,279 COMUNITAT VALENCIANA;Group 1003 Acute bronchitis and bronchiolitis 466;Women;2,446 COMUNITAT VALENCIANA;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Both sexes;4,070 COMUNITAT VALENCIANA;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Men;2,176 COMUNITAT VALENCIANA;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Women;1,894 COMUNITAT VALENCIANA;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Both sexes;3,869 COMUNITAT VALENCIANA;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Men;2,394 COMUNITAT VALENCIANA;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Women;1,475 COMUNITAT VALENCIANA;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Both sexes;8,248 COMUNITAT VALENCIANA;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Men;6,272 COMUNITAT VALENCIANA;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Women;1,976 COMUNITAT VALENCIANA;Group 1007 Asthma 4930-4931,4938-4939;Both sexes;1,746 COMUNITAT VALENCIANA;Group 1007 Asthma 4930-4931,4938-4939;Men;486 COMUNITAT VALENCIANA;Group 1007 Asthma 4930-4931,4938-4939;Women;1,260 COMUNITAT VALENCIANA;Group 1008 Other diseases of the respiratory system Resto of (460-519);Both sexes;15,578 COMUNITAT VALENCIANA;Group 1008 Other diseases of the respiratory system Resto of (460-519);Men;8,303 COMUNITAT VALENCIANA;Group 1008 Other diseases of the respiratory system Resto of (460-519);Women;7,275 COMUNITAT VALENCIANA;Group 1100 Diseases of the digestive system 520-579;Both sexes;61,658 COMUNITAT VALENCIANA;Group 1100 Diseases of the digestive system 520-579;Men;34,271 COMUNITAT VALENCIANA;Group 1100 Diseases of the digestive system 520-579;Women;27,387 COMUNITAT VALENCIANA;Group 1101 Disorders of the teeth and supporting structures 520-525;Both sexes;1,241 COMUNITAT VALENCIANA;Group 1101 Disorders of the teeth and supporting structures 520-525;Men;562 COMUNITAT VALENCIANA;Group 1101 Disorders of the teeth and supporting structures 520-525;Women;679 COMUNITAT VALENCIANA;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Both sexes;852 COMUNITAT VALENCIANA;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Men;454 COMUNITAT VALENCIANA;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Women;398 COMUNITAT VALENCIANA;Group 1103 Diseases of the esophagus 530;Both sexes;1,306 COMUNITAT VALENCIANA;Group 1103 Diseases of the esophagus 530;Men;776 COMUNITAT VALENCIANA;Group 1103 Diseases of the esophagus 530;Women;530 COMUNITAT VALENCIANA;Group 1104 Peptic ulcer 531-534;Both sexes;1,361 COMUNITAT VALENCIANA;Group 1104 Peptic ulcer 531-534;Men;935 COMUNITAT VALENCIANA;Group 1104 Peptic ulcer 531-534;Women;426 COMUNITAT VALENCIANA;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Both sexes;2,002 COMUNITAT VALENCIANA;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Men;991 COMUNITAT VALENCIANA;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Women;1,011 COMUNITAT VALENCIANA;Group 1106 Appendicitis 540-543;Both sexes;5,430 COMUNITAT VALENCIANA;Group 1106 Appendicitis 540-543;Men;3,037 COMUNITAT VALENCIANA;Group 1106 Appendicitis 540-543;Women;2,393 COMUNITAT VALENCIANA;Group 1107 Inguinal hernia 550;Both sexes;5,170 COMUNITAT VALENCIANA;Group 1107 Inguinal hernia 550;Men;4,628 COMUNITAT VALENCIANA;Group 1107 Inguinal hernia 550;Women;542 COMUNITAT VALENCIANA;Group 1108 Other abdominal hernia 551-553;Both sexes;4,622 COMUNITAT VALENCIANA;Group 1108 Other abdominal hernia 551-553;Men;2,142 COMUNITAT VALENCIANA;Group 1108 Other abdominal hernia 551-553;Women;2,480 COMUNITAT VALENCIANA;Group 1109 Crohn's disease and ulcerative colitis 555-556;Both sexes;1,575 COMUNITAT VALENCIANA;Group 1109 Crohn's disease and ulcerative colitis 555-556;Men;833 COMUNITAT VALENCIANA;Group 1109 Crohn's disease and ulcerative colitis 555-556;Women;742 COMUNITAT VALENCIANA;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Both sexes;3,733 COMUNITAT VALENCIANA;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Men;1,790 COMUNITAT VALENCIANA;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Women;1,943 COMUNITAT VALENCIANA;Group 1111 Intestinal obstruction without hernia 560;Both sexes;2,684 COMUNITAT VALENCIANA;Group 1111 Intestinal obstruction without hernia 560;Men;1,428 COMUNITAT VALENCIANA;Group 1111 Intestinal obstruction without hernia 560;Women;1,256 COMUNITAT VALENCIANA;Group 1112 Intestinal diverticulosis 562;Both sexes;2,532 COMUNITAT VALENCIANA;Group 1112 Intestinal diverticulosis 562;Men;1,230 COMUNITAT VALENCIANA;Group 1112 Intestinal diverticulosis 562;Women;1,302 COMUNITAT VALENCIANA;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Both sexes;3,970 COMUNITAT VALENCIANA;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Men;2,569 COMUNITAT VALENCIANA;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Women;1,401 COMUNITAT VALENCIANA;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Both sexes;2,065 COMUNITAT VALENCIANA;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Men;931 COMUNITAT VALENCIANA;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Women;1,134 COMUNITAT VALENCIANA;Group 1115 Alcoholic hepatitis 5710-5713;Both sexes;1,042 COMUNITAT VALENCIANA;Group 1115 Alcoholic hepatitis 5710-5713;Men;897 COMUNITAT VALENCIANA;Group 1115 Alcoholic hepatitis 5710-5713;Women;145 COMUNITAT VALENCIANA;Group 1116 Other diseases of the liver 570,5714-573;Both sexes;2,576 COMUNITAT VALENCIANA;Group 1116 Other diseases of the liver 570,5714-573;Men;1,625 COMUNITAT VALENCIANA;Group 1116 Other diseases of the liver 570,5714-573;Women;951 COMUNITAT VALENCIANA;Group 1117 Cholelithiasis 574;Both sexes;10,202 COMUNITAT VALENCIANA;Group 1117 Cholelithiasis 574;Men;4,307 COMUNITAT VALENCIANA;Group 1117 Cholelithiasis 574;Women;5,895 COMUNITAT VALENCIANA;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Both sexes;3,000 COMUNITAT VALENCIANA;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Men;1,616 COMUNITAT VALENCIANA;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Women;1,384 COMUNITAT VALENCIANA;Group 1119 Pancreatic diseases 577;Both sexes;3,263 COMUNITAT VALENCIANA;Group 1119 Pancreatic diseases 577;Men;1,849 COMUNITAT VALENCIANA;Group 1119 Pancreatic diseases 577;Women;1,414 COMUNITAT VALENCIANA;Group 1120 Other diseases of the digestive system Rest of (520-579);Both sexes;3,032 COMUNITAT VALENCIANA;Group 1120 Other diseases of the digestive system Rest of (520-579);Men;1,671 COMUNITAT VALENCIANA;Group 1120 Other diseases of the digestive system Rest of (520-579);Women;1,361 COMUNITAT VALENCIANA;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Both sexes;4,668 COMUNITAT VALENCIANA;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Men;2,646 COMUNITAT VALENCIANA;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Women;2,022 COMUNITAT VALENCIANA;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Both sexes;3,073 COMUNITAT VALENCIANA;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Men;1,866 COMUNITAT VALENCIANA;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Women;1,207 COMUNITAT VALENCIANA;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Both sexes;205 COMUNITAT VALENCIANA;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Men;88 COMUNITAT VALENCIANA;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Women;117 COMUNITAT VALENCIANA;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Both sexes;1,390 COMUNITAT VALENCIANA;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Men;692 COMUNITAT VALENCIANA;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Women;698 COMUNITAT VALENCIANA;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Both sexes;33,937 COMUNITAT VALENCIANA;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Men;17,163 COMUNITAT VALENCIANA;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Women;16,774 COMUNITAT VALENCIANA;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Both sexes;.. COMUNITAT VALENCIANA;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Men;.. COMUNITAT VALENCIANA;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Women;.. COMUNITAT VALENCIANA;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Both sexes;.. COMUNITAT VALENCIANA;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Men;.. COMUNITAT VALENCIANA;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Women;.. COMUNITAT VALENCIANA;Group 1303 Internal derangement of knee 717;Both sexes;5,615 COMUNITAT VALENCIANA;Group 1303 Internal derangement of knee 717;Men;4,018 COMUNITAT VALENCIANA;Group 1303 Internal derangement of knee 717;Women;1,597 COMUNITAT VALENCIANA;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Both sexes;11,101 COMUNITAT VALENCIANA;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Men;4,831 COMUNITAT VALENCIANA;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Women;6,270 COMUNITAT VALENCIANA;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Both sexes;677 COMUNITAT VALENCIANA;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Men;245 COMUNITAT VALENCIANA;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Women;432 COMUNITAT VALENCIANA;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Both sexes;1,820 COMUNITAT VALENCIANA;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Men;977 COMUNITAT VALENCIANA;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Women;843 COMUNITAT VALENCIANA;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Both sexes;3,077 COMUNITAT VALENCIANA;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Men;1,631 COMUNITAT VALENCIANA;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Women;1,446 COMUNITAT VALENCIANA;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Both sexes;758 COMUNITAT VALENCIANA;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Men;337 COMUNITAT VALENCIANA;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Women;421 COMUNITAT VALENCIANA;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Both sexes;5,357 COMUNITAT VALENCIANA;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Men;2,918 COMUNITAT VALENCIANA;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Women;2,439 COMUNITAT VALENCIANA;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Both sexes;5,532 COMUNITAT VALENCIANA;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Men;2,206 COMUNITAT VALENCIANA;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Women;3,326 COMUNITAT VALENCIANA;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Both sexes;33,554 COMUNITAT VALENCIANA;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Men;14,650 COMUNITAT VALENCIANA;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Women;18,904 COMUNITAT VALENCIANA;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Both sexes;3,497 COMUNITAT VALENCIANA;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Men;1,255 COMUNITAT VALENCIANA;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Women;2,242 COMUNITAT VALENCIANA;Group 1402 Renal failure 5836-5837, 584-586;Both sexes;2,668 COMUNITAT VALENCIANA;Group 1402 Renal failure 5836-5837, 584-586;Men;1,560 COMUNITAT VALENCIANA;Group 1402 Renal failure 5836-5837, 584-586;Women;1,108 COMUNITAT VALENCIANA;Group 1403 Urolithiasis 592, 594, 7880;Both sexes;4,153 COMUNITAT VALENCIANA;Group 1403 Urolithiasis 592, 594, 7880;Men;2,481 COMUNITAT VALENCIANA;Group 1403 Urolithiasis 592, 594, 7880;Women;1,672 COMUNITAT VALENCIANA;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Both sexes;8,731 COMUNITAT VALENCIANA;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Men;4,313 COMUNITAT VALENCIANA;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Women;4,418 COMUNITAT VALENCIANA;Group 1405 Prostatic hyperplasia 600;Both sexes;2,695 COMUNITAT VALENCIANA;Group 1405 Prostatic hyperplasia 600;Men;2,695 COMUNITAT VALENCIANA;Group 1405 Prostatic hyperplasia 600;Women;.. COMUNITAT VALENCIANA;Group 1406 Other diseases of the male genital organs 601-608;Both sexes;2,068 COMUNITAT VALENCIANA;Group 1406 Other diseases of the male genital organs 601-608;Men;2,068 COMUNITAT VALENCIANA;Group 1406 Other diseases of the male genital organs 601-608;Women;.. COMUNITAT VALENCIANA;Group 1407 Disorders of breast 610-612;Both sexes;2,473 COMUNITAT VALENCIANA;Group 1407 Disorders of breast 610-612;Men;215 COMUNITAT VALENCIANA;Group 1407 Disorders of breast 610-612;Women;2,258 COMUNITAT VALENCIANA;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Both sexes;992 COMUNITAT VALENCIANA;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Men;.. COMUNITAT VALENCIANA;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Women;992 COMUNITAT VALENCIANA;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Both sexes;591 COMUNITAT VALENCIANA;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Men;.. COMUNITAT VALENCIANA;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Women;591 COMUNITAT VALENCIANA;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Both sexes;5,686 COMUNITAT VALENCIANA;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Men;63 COMUNITAT VALENCIANA;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Women;5,623 COMUNITAT VALENCIANA;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Both sexes;51,373 COMUNITAT VALENCIANA;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Men;.. COMUNITAT VALENCIANA;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Women;51,373 COMUNITAT VALENCIANA;Group 1501 Legally induced abortion 635;Both sexes;234 COMUNITAT VALENCIANA;Group 1501 Legally induced abortion 635;Men;.. COMUNITAT VALENCIANA;Group 1501 Legally induced abortion 635;Women;234 COMUNITAT VALENCIANA;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Both sexes;3,558 COMUNITAT VALENCIANA;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Men;.. COMUNITAT VALENCIANA;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Women;3,558 COMUNITAT VALENCIANA;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Both sexes;29,984 COMUNITAT VALENCIANA;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Men;.. COMUNITAT VALENCIANA;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Women;29,984 COMUNITAT VALENCIANA;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Both sexes;8,284 COMUNITAT VALENCIANA;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Men;.. COMUNITAT VALENCIANA;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Women;8,284 COMUNITAT VALENCIANA;Group 1505 Single spontaneous delivery 650;Both sexes;3,938 COMUNITAT VALENCIANA;Group 1505 Single spontaneous delivery 650;Men;.. COMUNITAT VALENCIANA;Group 1505 Single spontaneous delivery 650;Women;3,938 COMUNITAT VALENCIANA;Group 1506 Other deliveries 6695-6697;Both sexes;1,971 COMUNITAT VALENCIANA;Group 1506 Other deliveries 6695-6697;Men;.. COMUNITAT VALENCIANA;Group 1506 Other deliveries 6695-6697;Women;1,971 COMUNITAT VALENCIANA;Group 1507 Complications related to the puerperium 670-676;Both sexes;374 COMUNITAT VALENCIANA;Group 1507 Complications related to the puerperium 670-676;Men;.. COMUNITAT VALENCIANA;Group 1507 Complications related to the puerperium 670-676;Women;374 COMUNITAT VALENCIANA;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Both sexes;3,030 COMUNITAT VALENCIANA;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Men;.. COMUNITAT VALENCIANA;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Women;3,030 COMUNITAT VALENCIANA;Group 1600 Some disorders originating in the perinatal period 760-779;Both sexes;6,908 COMUNITAT VALENCIANA;Group 1600 Some disorders originating in the perinatal period 760-779;Men;3,783 COMUNITAT VALENCIANA;Group 1600 Some disorders originating in the perinatal period 760-779;Women;3,125 COMUNITAT VALENCIANA;Group 1601 Disorders related with premature delivery and a low birth weight 765;Both sexes;1,943 COMUNITAT VALENCIANA;Group 1601 Disorders related with premature delivery and a low birth weight 765;Men;1,031 COMUNITAT VALENCIANA;Group 1601 Disorders related with premature delivery and a low birth weight 765;Women;912 COMUNITAT VALENCIANA;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Both sexes;4,965 COMUNITAT VALENCIANA;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Men;2,752 COMUNITAT VALENCIANA;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Women;2,213 COMUNITAT VALENCIANA;Grupo 1700 Congenital abnormalities 740-759;Both sexes;4,078 COMUNITAT VALENCIANA;Grupo 1700 Congenital abnormalities 740-759;Men;2,394 COMUNITAT VALENCIANA;Grupo 1700 Congenital abnormalities 740-759;Women;1,684 COMUNITAT VALENCIANA;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Both sexes;22,965 COMUNITAT VALENCIANA;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Men;12,516 COMUNITAT VALENCIANA;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Women;10,450 COMUNITAT VALENCIANA;Group 1801 Pain in throat and chest 7841, 7865;Both sexes;3,415 COMUNITAT VALENCIANA;Group 1801 Pain in throat and chest 7841, 7865;Men;1,958 COMUNITAT VALENCIANA;Group 1801 Pain in throat and chest 7841, 7865;Women;1,457 COMUNITAT VALENCIANA;Group 1802 Abdominal pain 7890;Both sexes;2,420 COMUNITAT VALENCIANA;Group 1802 Abdominal pain 7890;Men;878 COMUNITAT VALENCIANA;Group 1802 Abdominal pain 7890;Women;1,542 COMUNITAT VALENCIANA;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Both sexes;569 COMUNITAT VALENCIANA;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Men;290 COMUNITAT VALENCIANA;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Women;280 COMUNITAT VALENCIANA;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Both sexes;16,561 COMUNITAT VALENCIANA;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Men;9,390 COMUNITAT VALENCIANA;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Women;7,171 COMUNITAT VALENCIANA;Group 1900 Injuries and poisoning 800-999;Both sexes;43,718 COMUNITAT VALENCIANA;Group 1900 Injuries and poisoning 800-999;Men;22,726 COMUNITAT VALENCIANA;Group 1900 Injuries and poisoning 800-999;Women;20,992 COMUNITAT VALENCIANA;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Both sexes;2,227 COMUNITAT VALENCIANA;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Men;1,311 COMUNITAT VALENCIANA;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Women;916 COMUNITAT VALENCIANA;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Both sexes;971 COMUNITAT VALENCIANA;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Men;689 COMUNITAT VALENCIANA;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Women;282 COMUNITAT VALENCIANA;Group 1903 Radius and ulna fracture 813;Both sexes;3,144 COMUNITAT VALENCIANA;Group 1903 Radius and ulna fracture 813;Men;1,444 COMUNITAT VALENCIANA;Group 1903 Radius and ulna fracture 813;Women;1,700 COMUNITAT VALENCIANA;Group 1904 Femur fracture 820-821;Both sexes;6,676 COMUNITAT VALENCIANA;Group 1904 Femur fracture 820-821;Men;1,976 COMUNITAT VALENCIANA;Group 1904 Femur fracture 820-821;Women;4,700 COMUNITAT VALENCIANA;Group 1905 Leg fracture, including the ankle 823-824;Both sexes;3,405 COMUNITAT VALENCIANA;Group 1905 Leg fracture, including the ankle 823-824;Men;1,816 COMUNITAT VALENCIANA;Group 1905 Leg fracture, including the ankle 823-824;Women;1,589 COMUNITAT VALENCIANA;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Both sexes;13,555 COMUNITAT VALENCIANA;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Men;8,440 COMUNITAT VALENCIANA;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Women;5,115 COMUNITAT VALENCIANA;Group 1907 Burns 940-949;Both sexes;303 COMUNITAT VALENCIANA;Group 1907 Burns 940-949;Men;196 COMUNITAT VALENCIANA;Group 1907 Burns 940-949;Women;107 COMUNITAT VALENCIANA;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Both sexes;1,417 COMUNITAT VALENCIANA;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Men;605 COMUNITAT VALENCIANA;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Women;812 COMUNITAT VALENCIANA;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Both sexes;10,280 COMUNITAT VALENCIANA;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Men;5,267 COMUNITAT VALENCIANA;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Women;5,013 COMUNITAT VALENCIANA;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Both sexes;230 COMUNITAT VALENCIANA;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Men;151 COMUNITAT VALENCIANA;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Women;79 COMUNITAT VALENCIANA;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Both sexes;1,510 COMUNITAT VALENCIANA;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Men;831 COMUNITAT VALENCIANA;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Women;679 COMUNITAT VALENCIANA;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Both sexes;10,811 COMUNITAT VALENCIANA;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Men;5,109 COMUNITAT VALENCIANA;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Women;5,702 COMUNITAT VALENCIANA;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Both sexes;346 COMUNITAT VALENCIANA;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Men;166 COMUNITAT VALENCIANA;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Women;180 COMUNITAT VALENCIANA;Group 2102 Contraceptive management V25;Both sexes;154 COMUNITAT VALENCIANA;Group 2102 Contraceptive management V25;Men;5 COMUNITAT VALENCIANA;Group 2102 Contraceptive management V25;Women;149 COMUNITAT VALENCIANA;Group 2103 Living newborns by type of delivery V30-V39;Both sexes;.. COMUNITAT VALENCIANA;Group 2103 Living newborns by type of delivery V30-V39;Men;.. COMUNITAT VALENCIANA;Group 2103 Living newborns by type of delivery V30-V39;Women;.. COMUNITAT VALENCIANA;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Both sexes;2,914 COMUNITAT VALENCIANA;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Men;1,695 COMUNITAT VALENCIANA;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Women;1,219 COMUNITAT VALENCIANA;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Both sexes;7,397 COMUNITAT VALENCIANA;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Men;3,243 COMUNITAT VALENCIANA;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Women;4,154 Alicante/Alacant;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Both sexes;192,531 Alicante/Alacant;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Men;91,968 Alicante/Alacant;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Women;100,563 Alicante/Alacant;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Both sexes;4,863 Alicante/Alacant;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Men;2,637 Alicante/Alacant;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Women;2,226 Alicante/Alacant;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Both sexes;550 Alicante/Alacant;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Men;291 Alicante/Alacant;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Women;259 Alicante/Alacant;Group 0102 Imprecise intestinal infections 009;Both sexes;570 Alicante/Alacant;Group 0102 Imprecise intestinal infections 009;Men;248 Alicante/Alacant;Group 0102 Imprecise intestinal infections 009;Women;322 Alicante/Alacant;Group 0103 Tuberculosis 010-018, 137;Both sexes;134 Alicante/Alacant;Group 0103 Tuberculosis 010-018, 137;Men;90 Alicante/Alacant;Group 0103 Tuberculosis 010-018, 137;Women;44 Alicante/Alacant;Group 0104 Septicaemia 038;Both sexes;2,137 Alicante/Alacant;Group 0104 Septicaemia 038;Men;1,136 Alicante/Alacant;Group 0104 Septicaemia 038;Women;1,001 Alicante/Alacant;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Both sexes;156 Alicante/Alacant;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Men;105 Alicante/Alacant;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Women;51 Alicante/Alacant;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Both sexes;1,316 Alicante/Alacant;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Men;767 Alicante/Alacant;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Women;549 Alicante/Alacant;Group 0200 Neoplasms 140-239;Both sexes;16,758 Alicante/Alacant;Group 0200 Neoplasms 140-239;Men;8,761 Alicante/Alacant;Group 0200 Neoplasms 140-239;Women;7,997 Alicante/Alacant;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Both sexes;1,929 Alicante/Alacant;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Men;1,178 Alicante/Alacant;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Women;751 Alicante/Alacant;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Both sexes;1,401 Alicante/Alacant;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Men;1,053 Alicante/Alacant;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Women;348 Alicante/Alacant;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Both sexes;199 Alicante/Alacant;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Men;131 Alicante/Alacant;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Women;68 Alicante/Alacant;Group 0204 Malignant neoplasm of breast 174-175;Both sexes;1,255 Alicante/Alacant;Group 0204 Malignant neoplasm of breast 174-175;Men;9 Alicante/Alacant;Group 0204 Malignant neoplasm of breast 174-175;Women;1,246 Alicante/Alacant;Group 0205 Malignant neoplasm of uterus 179-180, 182;Both sexes;324 Alicante/Alacant;Group 0205 Malignant neoplasm of uterus 179-180, 182;Men;.. Alicante/Alacant;Group 0205 Malignant neoplasm of uterus 179-180, 182;Women;324 Alicante/Alacant;Group 0206 Malignant neoplasm of ovary 1830;Both sexes;165 Alicante/Alacant;Group 0206 Malignant neoplasm of ovary 1830;Men;.. Alicante/Alacant;Group 0206 Malignant neoplasm of ovary 1830;Women;165 Alicante/Alacant;Group 0207 Malignant neoplasm of prostate 185;Both sexes;480 Alicante/Alacant;Group 0207 Malignant neoplasm of prostate 185;Men;480 Alicante/Alacant;Group 0207 Malignant neoplasm of prostate 185;Women;.. Alicante/Alacant;Group 0208 Malignant neoplasm of bladder 188;Both sexes;1,791 Alicante/Alacant;Group 0208 Malignant neoplasm of bladder 188;Men;1,520 Alicante/Alacant;Group 0208 Malignant neoplasm of bladder 188;Women;271 Alicante/Alacant;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Both sexes;5,342 Alicante/Alacant;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Men;3,159 Alicante/Alacant;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Women;2,183 Alicante/Alacant;Group 0210 Carcinoma in situ 230-234;Both sexes;251 Alicante/Alacant;Group 0210 Carcinoma in situ 230-234;Men;45 Alicante/Alacant;Group 0210 Carcinoma in situ 230-234;Women;206 Alicante/Alacant;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Both sexes;271 Alicante/Alacant;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Men;171 Alicante/Alacant;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Women;100 Alicante/Alacant;Grupo 0212 Leiomyoma of uterus 218;Both sexes;1,090 Alicante/Alacant;Grupo 0212 Leiomyoma of uterus 218;Men;.. Alicante/Alacant;Grupo 0212 Leiomyoma of uterus 218;Women;1,090 Alicante/Alacant;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Both sexes;2,260 Alicante/Alacant;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Men;1,015 Alicante/Alacant;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Women;1,245 Alicante/Alacant;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Both sexes;1,801 Alicante/Alacant;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Men;865 Alicante/Alacant;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Women;936 Alicante/Alacant;Group 0301 Anaemias 280-285;Both sexes;1,066 Alicante/Alacant;Group 0301 Anaemias 280-285;Men;513 Alicante/Alacant;Group 0301 Anaemias 280-285;Women;553 Alicante/Alacant;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Both sexes;735 Alicante/Alacant;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Men;352 Alicante/Alacant;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Women;383 Alicante/Alacant;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Both sexes;3,518 Alicante/Alacant;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Men;1,531 Alicante/Alacant;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Women;1,987 Alicante/Alacant;Group 0401 Diabetes mellitus 249-250;Both sexes;1,354 Alicante/Alacant;Group 0401 Diabetes mellitus 249-250;Men;827 Alicante/Alacant;Group 0401 Diabetes mellitus 249-250;Women;527 Alicante/Alacant;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Both sexes;2,164 Alicante/Alacant;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Men;704 Alicante/Alacant;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Women;1,460 Alicante/Alacant;Group 0500 Mental disorders 290-319;Both sexes;4,190 Alicante/Alacant;Group 0500 Mental disorders 290-319;Men;2,295 Alicante/Alacant;Group 0500 Mental disorders 290-319;Women;1,895 Alicante/Alacant;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Both sexes;124 Alicante/Alacant;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Men;59 Alicante/Alacant;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Women;65 Alicante/Alacant;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Both sexes;293 Alicante/Alacant;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Men;203 Alicante/Alacant;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Women;90 Alicante/Alacant;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Both sexes;253 Alicante/Alacant;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Men;201 Alicante/Alacant;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Women;52 Alicante/Alacant;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Both sexes;1,197 Alicante/Alacant;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Men;768 Alicante/Alacant;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Women;429 Alicante/Alacant;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Both sexes;840 Alicante/Alacant;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Men;347 Alicante/Alacant;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Women;493 Alicante/Alacant;Group 0506 Other mental and behavioural disorders Rest of (290-319);Both sexes;1,483 Alicante/Alacant;Group 0506 Other mental and behavioural disorders Rest of (290-319);Men;717 Alicante/Alacant;Group 0506 Other mental and behavioural disorders Rest of (290-319);Women;766 Alicante/Alacant;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Both sexes;6,184 Alicante/Alacant;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Men;3,396 Alicante/Alacant;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Women;2,788 Alicante/Alacant;Group 0601 Alzheimer's disease 3310;Both sexes;95 Alicante/Alacant;Group 0601 Alzheimer's disease 3310;Men;37 Alicante/Alacant;Group 0601 Alzheimer's disease 3310;Women;58 Alicante/Alacant;Group 0602 Multiple sclerosis 340;Both sexes;94 Alicante/Alacant;Group 0602 Multiple sclerosis 340;Men;24 Alicante/Alacant;Group 0602 Multiple sclerosis 340;Women;70 Alicante/Alacant;Group 0603 Epilepsy 345;Both sexes;1,139 Alicante/Alacant;Group 0603 Epilepsy 345;Men;660 Alicante/Alacant;Group 0603 Epilepsy 345;Women;479 Alicante/Alacant;Group 0604 Transient cerebral ischemia 435;Both sexes;987 Alicante/Alacant;Group 0604 Transient cerebral ischemia 435;Men;522 Alicante/Alacant;Group 0604 Transient cerebral ischemia 435;Women;465 Alicante/Alacant;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Both sexes;3,869 Alicante/Alacant;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Men;2,153 Alicante/Alacant;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Women;1,716 Alicante/Alacant;Grupo 0700 Diseases of the eye and adnexa 360-379;Both sexes;1,051 Alicante/Alacant;Grupo 0700 Diseases of the eye and adnexa 360-379;Men;562 Alicante/Alacant;Grupo 0700 Diseases of the eye and adnexa 360-379;Women;489 Alicante/Alacant;Grupo 0701 Cataract 366;Both sexes;139 Alicante/Alacant;Grupo 0701 Cataract 366;Men;62 Alicante/Alacant;Grupo 0701 Cataract 366;Women;77 Alicante/Alacant;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Both sexes;912 Alicante/Alacant;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Men;500 Alicante/Alacant;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Women;412 Alicante/Alacant;Group 0800 Diseases of the ear and the mastoid 380-389;Both sexes;934 Alicante/Alacant;Group 0800 Diseases of the ear and the mastoid 380-389;Men;466 Alicante/Alacant;Group 0800 Diseases of the ear and the mastoid 380-389;Women;468 Alicante/Alacant;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Both sexes;27,449 Alicante/Alacant;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Men;15,717 Alicante/Alacant;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Women;11,732 Alicante/Alacant;Group 0901 Hypertensive disease 401-405;Both sexes;975 Alicante/Alacant;Group 0901 Hypertensive disease 401-405;Men;486 Alicante/Alacant;Group 0901 Hypertensive disease 401-405;Women;489 Alicante/Alacant;Group 0902 Angina pectoris 4111, 413;Both sexes;1,672 Alicante/Alacant;Group 0902 Angina pectoris 4111, 413;Men;1,042 Alicante/Alacant;Group 0902 Angina pectoris 4111, 413;Women;630 Alicante/Alacant;Group 0903 Acute myocardial infarction 410;Both sexes;2,692 Alicante/Alacant;Group 0903 Acute myocardial infarction 410;Men;1,907 Alicante/Alacant;Group 0903 Acute myocardial infarction 410;Women;785 Alicante/Alacant;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Both sexes;2,002 Alicante/Alacant;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Men;1,561 Alicante/Alacant;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Women;441 Alicante/Alacant;Group 0905 Diseases of the lungs circulation 415-417;Both sexes;809 Alicante/Alacant;Group 0905 Diseases of the lungs circulation 415-417;Men;392 Alicante/Alacant;Group 0905 Diseases of the lungs circulation 415-417;Women;417 Alicante/Alacant;Group 0906 Heart conduction disorders and arrhytmias 426-427;Both sexes;4,118 Alicante/Alacant;Group 0906 Heart conduction disorders and arrhytmias 426-427;Men;2,224 Alicante/Alacant;Group 0906 Heart conduction disorders and arrhytmias 426-427;Women;1,894 Alicante/Alacant;Grupo 0907 Heart failure 428;Both sexes;5,585 Alicante/Alacant;Grupo 0907 Heart failure 428;Men;2,714 Alicante/Alacant;Grupo 0907 Heart failure 428;Women;2,871 Alicante/Alacant;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Both sexes;4,709 Alicante/Alacant;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Men;2,549 Alicante/Alacant;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Women;2,160 Alicante/Alacant;Grupo 0909 Atherosclerosis 440;Both sexes;588 Alicante/Alacant;Grupo 0909 Atherosclerosis 440;Men;436 Alicante/Alacant;Grupo 0909 Atherosclerosis 440;Women;152 Alicante/Alacant;Group 0910 Varicose veins of lower extremities 454;Both sexes;309 Alicante/Alacant;Group 0910 Varicose veins of lower extremities 454;Men;120 Alicante/Alacant;Group 0910 Varicose veins of lower extremities 454;Women;189 Alicante/Alacant;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Both sexes;3,990 Alicante/Alacant;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Men;2,286 Alicante/Alacant;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Women;1,704 Alicante/Alacant;Group 1000 Diseases of the respiratory system 0340, 460-519;Both sexes;20,116 Alicante/Alacant;Group 1000 Diseases of the respiratory system 0340, 460-519;Men;11,524 Alicante/Alacant;Group 1000 Diseases of the respiratory system 0340, 460-519;Women;8,592 Alicante/Alacant;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Both sexes;1,029 Alicante/Alacant;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Men;537 Alicante/Alacant;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Women;492 Alicante/Alacant;Group 1002 Pneumonia 480-486;Both sexes;4,334 Alicante/Alacant;Group 1002 Pneumonia 480-486;Men;2,568 Alicante/Alacant;Group 1002 Pneumonia 480-486;Women;1,766 Alicante/Alacant;Group 1003 Acute bronchitis and bronchiolitis 466;Both sexes;1,913 Alicante/Alacant;Group 1003 Acute bronchitis and bronchiolitis 466;Men;868 Alicante/Alacant;Group 1003 Acute bronchitis and bronchiolitis 466;Women;1,045 Alicante/Alacant;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Both sexes;1,269 Alicante/Alacant;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Men;700 Alicante/Alacant;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Women;569 Alicante/Alacant;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Both sexes;1,245 Alicante/Alacant;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Men;786 Alicante/Alacant;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Women;459 Alicante/Alacant;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Both sexes;3,265 Alicante/Alacant;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Men;2,437 Alicante/Alacant;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Women;828 Alicante/Alacant;Group 1007 Asthma 4930-4931,4938-4939;Both sexes;726 Alicante/Alacant;Group 1007 Asthma 4930-4931,4938-4939;Men;193 Alicante/Alacant;Group 1007 Asthma 4930-4931,4938-4939;Women;533 Alicante/Alacant;Group 1008 Other diseases of the respiratory system Resto of (460-519);Both sexes;6,335 Alicante/Alacant;Group 1008 Other diseases of the respiratory system Resto of (460-519);Men;3,435 Alicante/Alacant;Group 1008 Other diseases of the respiratory system Resto of (460-519);Women;2,900 Alicante/Alacant;Group 1100 Diseases of the digestive system 520-579;Both sexes;24,651 Alicante/Alacant;Group 1100 Diseases of the digestive system 520-579;Men;13,722 Alicante/Alacant;Group 1100 Diseases of the digestive system 520-579;Women;10,929 Alicante/Alacant;Group 1101 Disorders of the teeth and supporting structures 520-525;Both sexes;306 Alicante/Alacant;Group 1101 Disorders of the teeth and supporting structures 520-525;Men;133 Alicante/Alacant;Group 1101 Disorders of the teeth and supporting structures 520-525;Women;173 Alicante/Alacant;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Both sexes;287 Alicante/Alacant;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Men;151 Alicante/Alacant;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Women;136 Alicante/Alacant;Group 1103 Diseases of the esophagus 530;Both sexes;551 Alicante/Alacant;Group 1103 Diseases of the esophagus 530;Men;326 Alicante/Alacant;Group 1103 Diseases of the esophagus 530;Women;225 Alicante/Alacant;Group 1104 Peptic ulcer 531-534;Both sexes;620 Alicante/Alacant;Group 1104 Peptic ulcer 531-534;Men;437 Alicante/Alacant;Group 1104 Peptic ulcer 531-534;Women;183 Alicante/Alacant;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Both sexes;863 Alicante/Alacant;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Men;412 Alicante/Alacant;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Women;451 Alicante/Alacant;Group 1106 Appendicitis 540-543;Both sexes;2,098 Alicante/Alacant;Group 1106 Appendicitis 540-543;Men;1,192 Alicante/Alacant;Group 1106 Appendicitis 540-543;Women;906 Alicante/Alacant;Group 1107 Inguinal hernia 550;Both sexes;1,994 Alicante/Alacant;Group 1107 Inguinal hernia 550;Men;1,805 Alicante/Alacant;Group 1107 Inguinal hernia 550;Women;189 Alicante/Alacant;Group 1108 Other abdominal hernia 551-553;Both sexes;1,766 Alicante/Alacant;Group 1108 Other abdominal hernia 551-553;Men;842 Alicante/Alacant;Group 1108 Other abdominal hernia 551-553;Women;924 Alicante/Alacant;Group 1109 Crohn's disease and ulcerative colitis 555-556;Both sexes;678 Alicante/Alacant;Group 1109 Crohn's disease and ulcerative colitis 555-556;Men;378 Alicante/Alacant;Group 1109 Crohn's disease and ulcerative colitis 555-556;Women;300 Alicante/Alacant;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Both sexes;1,851 Alicante/Alacant;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Men;877 Alicante/Alacant;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Women;974 Alicante/Alacant;Group 1111 Intestinal obstruction without hernia 560;Both sexes;1,060 Alicante/Alacant;Group 1111 Intestinal obstruction without hernia 560;Men;551 Alicante/Alacant;Group 1111 Intestinal obstruction without hernia 560;Women;509 Alicante/Alacant;Group 1112 Intestinal diverticulosis 562;Both sexes;1,174 Alicante/Alacant;Group 1112 Intestinal diverticulosis 562;Men;549 Alicante/Alacant;Group 1112 Intestinal diverticulosis 562;Women;625 Alicante/Alacant;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Both sexes;1,574 Alicante/Alacant;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Men;1,011 Alicante/Alacant;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Women;563 Alicante/Alacant;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Both sexes;895 Alicante/Alacant;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Men;411 Alicante/Alacant;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Women;484 Alicante/Alacant;Group 1115 Alcoholic hepatitis 5710-5713;Both sexes;497 Alicante/Alacant;Group 1115 Alcoholic hepatitis 5710-5713;Men;428 Alicante/Alacant;Group 1115 Alcoholic hepatitis 5710-5713;Women;69 Alicante/Alacant;Group 1116 Other diseases of the liver 570,5714-573;Both sexes;999 Alicante/Alacant;Group 1116 Other diseases of the liver 570,5714-573;Men;626 Alicante/Alacant;Group 1116 Other diseases of the liver 570,5714-573;Women;373 Alicante/Alacant;Group 1117 Cholelithiasis 574;Both sexes;3,838 Alicante/Alacant;Group 1117 Cholelithiasis 574;Men;1,617 Alicante/Alacant;Group 1117 Cholelithiasis 574;Women;2,221 Alicante/Alacant;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Both sexes;1,035 Alicante/Alacant;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Men;570 Alicante/Alacant;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Women;465 Alicante/Alacant;Group 1119 Pancreatic diseases 577;Both sexes;1,415 Alicante/Alacant;Group 1119 Pancreatic diseases 577;Men;783 Alicante/Alacant;Group 1119 Pancreatic diseases 577;Women;632 Alicante/Alacant;Group 1120 Other diseases of the digestive system Rest of (520-579);Both sexes;1,150 Alicante/Alacant;Group 1120 Other diseases of the digestive system Rest of (520-579);Men;623 Alicante/Alacant;Group 1120 Other diseases of the digestive system Rest of (520-579);Women;527 Alicante/Alacant;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Both sexes;1,992 Alicante/Alacant;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Men;1,179 Alicante/Alacant;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Women;813 Alicante/Alacant;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Both sexes;1,356 Alicante/Alacant;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Men;845 Alicante/Alacant;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Women;511 Alicante/Alacant;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Both sexes;94 Alicante/Alacant;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Men;47 Alicante/Alacant;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Women;47 Alicante/Alacant;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Both sexes;542 Alicante/Alacant;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Men;287 Alicante/Alacant;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Women;255 Alicante/Alacant;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Both sexes;11,337 Alicante/Alacant;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Men;5,547 Alicante/Alacant;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Women;5,790 Alicante/Alacant;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Both sexes;.. Alicante/Alacant;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Men;.. Alicante/Alacant;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Women;.. Alicante/Alacant;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Both sexes;.. Alicante/Alacant;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Men;.. Alicante/Alacant;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Women;.. Alicante/Alacant;Group 1303 Internal derangement of knee 717;Both sexes;1,509 Alicante/Alacant;Group 1303 Internal derangement of knee 717;Men;1,065 Alicante/Alacant;Group 1303 Internal derangement of knee 717;Women;444 Alicante/Alacant;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Both sexes;3,731 Alicante/Alacant;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Men;1,631 Alicante/Alacant;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Women;2,100 Alicante/Alacant;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Both sexes;249 Alicante/Alacant;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Men;96 Alicante/Alacant;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Women;153 Alicante/Alacant;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Both sexes;699 Alicante/Alacant;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Men;392 Alicante/Alacant;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Women;307 Alicante/Alacant;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Both sexes;966 Alicante/Alacant;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Men;480 Alicante/Alacant;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Women;486 Alicante/Alacant;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Both sexes;309 Alicante/Alacant;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Men;118 Alicante/Alacant;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Women;191 Alicante/Alacant;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Both sexes;1,897 Alicante/Alacant;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Men;1,039 Alicante/Alacant;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Women;858 Alicante/Alacant;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Both sexes;1,977 Alicante/Alacant;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Men;726 Alicante/Alacant;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Women;1,251 Alicante/Alacant;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Both sexes;12,405 Alicante/Alacant;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Men;5,343 Alicante/Alacant;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Women;7,062 Alicante/Alacant;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Both sexes;1,331 Alicante/Alacant;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Men;454 Alicante/Alacant;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Women;877 Alicante/Alacant;Group 1402 Renal failure 5836-5837, 584-586;Both sexes;1,066 Alicante/Alacant;Group 1402 Renal failure 5836-5837, 584-586;Men;647 Alicante/Alacant;Group 1402 Renal failure 5836-5837, 584-586;Women;419 Alicante/Alacant;Group 1403 Urolithiasis 592, 594, 7880;Both sexes;1,689 Alicante/Alacant;Group 1403 Urolithiasis 592, 594, 7880;Men;1,050 Alicante/Alacant;Group 1403 Urolithiasis 592, 594, 7880;Women;639 Alicante/Alacant;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Both sexes;2,928 Alicante/Alacant;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Men;1,435 Alicante/Alacant;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Women;1,493 Alicante/Alacant;Group 1405 Prostatic hyperplasia 600;Both sexes;815 Alicante/Alacant;Group 1405 Prostatic hyperplasia 600;Men;815 Alicante/Alacant;Group 1405 Prostatic hyperplasia 600;Women;.. Alicante/Alacant;Group 1406 Other diseases of the male genital organs 601-608;Both sexes;815 Alicante/Alacant;Group 1406 Other diseases of the male genital organs 601-608;Men;815 Alicante/Alacant;Group 1406 Other diseases of the male genital organs 601-608;Women;.. Alicante/Alacant;Group 1407 Disorders of breast 610-612;Both sexes;1,126 Alicante/Alacant;Group 1407 Disorders of breast 610-612;Men;99 Alicante/Alacant;Group 1407 Disorders of breast 610-612;Women;1,027 Alicante/Alacant;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Both sexes;404 Alicante/Alacant;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Men;.. Alicante/Alacant;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Women;404 Alicante/Alacant;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Both sexes;286 Alicante/Alacant;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Men;.. Alicante/Alacant;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Women;286 Alicante/Alacant;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Both sexes;1,945 Alicante/Alacant;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Men;28 Alicante/Alacant;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Women;1,917 Alicante/Alacant;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Both sexes;19,602 Alicante/Alacant;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Men;.. Alicante/Alacant;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Women;19,602 Alicante/Alacant;Group 1501 Legally induced abortion 635;Both sexes;41 Alicante/Alacant;Group 1501 Legally induced abortion 635;Men;.. Alicante/Alacant;Group 1501 Legally induced abortion 635;Women;41 Alicante/Alacant;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Both sexes;2,181 Alicante/Alacant;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Men;.. Alicante/Alacant;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Women;2,181 Alicante/Alacant;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Both sexes;11,202 Alicante/Alacant;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Men;.. Alicante/Alacant;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Women;11,202 Alicante/Alacant;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Both sexes;2,676 Alicante/Alacant;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Men;.. Alicante/Alacant;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Women;2,676 Alicante/Alacant;Group 1505 Single spontaneous delivery 650;Both sexes;1,399 Alicante/Alacant;Group 1505 Single spontaneous delivery 650;Men;.. Alicante/Alacant;Group 1505 Single spontaneous delivery 650;Women;1,399 Alicante/Alacant;Group 1506 Other deliveries 6695-6697;Both sexes;978 Alicante/Alacant;Group 1506 Other deliveries 6695-6697;Men;.. Alicante/Alacant;Group 1506 Other deliveries 6695-6697;Women;978 Alicante/Alacant;Group 1507 Complications related to the puerperium 670-676;Both sexes;133 Alicante/Alacant;Group 1507 Complications related to the puerperium 670-676;Men;.. Alicante/Alacant;Group 1507 Complications related to the puerperium 670-676;Women;133 Alicante/Alacant;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Both sexes;992 Alicante/Alacant;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Men;.. Alicante/Alacant;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Women;992 Alicante/Alacant;Group 1600 Some disorders originating in the perinatal period 760-779;Both sexes;2,403 Alicante/Alacant;Group 1600 Some disorders originating in the perinatal period 760-779;Men;1,310 Alicante/Alacant;Group 1600 Some disorders originating in the perinatal period 760-779;Women;1,093 Alicante/Alacant;Group 1601 Disorders related with premature delivery and a low birth weight 765;Both sexes;597 Alicante/Alacant;Group 1601 Disorders related with premature delivery and a low birth weight 765;Men;303 Alicante/Alacant;Group 1601 Disorders related with premature delivery and a low birth weight 765;Women;294 Alicante/Alacant;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Both sexes;1,806 Alicante/Alacant;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Men;1,007 Alicante/Alacant;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Women;799 Alicante/Alacant;Grupo 1700 Congenital abnormalities 740-759;Both sexes;1,051 Alicante/Alacant;Grupo 1700 Congenital abnormalities 740-759;Men;625 Alicante/Alacant;Grupo 1700 Congenital abnormalities 740-759;Women;426 Alicante/Alacant;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Both sexes;11,259 Alicante/Alacant;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Men;5,942 Alicante/Alacant;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Women;5,318 Alicante/Alacant;Group 1801 Pain in throat and chest 7841, 7865;Both sexes;1,910 Alicante/Alacant;Group 1801 Pain in throat and chest 7841, 7865;Men;1,082 Alicante/Alacant;Group 1801 Pain in throat and chest 7841, 7865;Women;828 Alicante/Alacant;Group 1802 Abdominal pain 7890;Both sexes;1,251 Alicante/Alacant;Group 1802 Abdominal pain 7890;Men;427 Alicante/Alacant;Group 1802 Abdominal pain 7890;Women;824 Alicante/Alacant;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Both sexes;351 Alicante/Alacant;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Men;182 Alicante/Alacant;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Women;170 Alicante/Alacant;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Both sexes;7,747 Alicante/Alacant;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Men;4,251 Alicante/Alacant;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Women;3,496 Alicante/Alacant;Group 1900 Injuries and poisoning 800-999;Both sexes;16,525 Alicante/Alacant;Group 1900 Injuries and poisoning 800-999;Men;8,446 Alicante/Alacant;Group 1900 Injuries and poisoning 800-999;Women;8,079 Alicante/Alacant;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Both sexes;934 Alicante/Alacant;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Men;563 Alicante/Alacant;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Women;371 Alicante/Alacant;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Both sexes;364 Alicante/Alacant;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Men;255 Alicante/Alacant;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Women;109 Alicante/Alacant;Group 1903 Radius and ulna fracture 813;Both sexes;1,257 Alicante/Alacant;Group 1903 Radius and ulna fracture 813;Men;527 Alicante/Alacant;Group 1903 Radius and ulna fracture 813;Women;730 Alicante/Alacant;Group 1904 Femur fracture 820-821;Both sexes;2,392 Alicante/Alacant;Group 1904 Femur fracture 820-821;Men;741 Alicante/Alacant;Group 1904 Femur fracture 820-821;Women;1,651 Alicante/Alacant;Group 1905 Leg fracture, including the ankle 823-824;Both sexes;1,329 Alicante/Alacant;Group 1905 Leg fracture, including the ankle 823-824;Men;672 Alicante/Alacant;Group 1905 Leg fracture, including the ankle 823-824;Women;657 Alicante/Alacant;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Both sexes;5,078 Alicante/Alacant;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Men;2,995 Alicante/Alacant;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Women;2,083 Alicante/Alacant;Group 1907 Burns 940-949;Both sexes;143 Alicante/Alacant;Group 1907 Burns 940-949;Men;85 Alicante/Alacant;Group 1907 Burns 940-949;Women;58 Alicante/Alacant;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Both sexes;594 Alicante/Alacant;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Men;258 Alicante/Alacant;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Women;336 Alicante/Alacant;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Both sexes;3,721 Alicante/Alacant;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Men;1,931 Alicante/Alacant;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Women;1,790 Alicante/Alacant;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Both sexes;92 Alicante/Alacant;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Men;57 Alicante/Alacant;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Women;35 Alicante/Alacant;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Both sexes;621 Alicante/Alacant;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Men;362 Alicante/Alacant;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Women;259 Alicante/Alacant;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Both sexes;4,442 Alicante/Alacant;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Men;2,101 Alicante/Alacant;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Women;2,341 Alicante/Alacant;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Both sexes;154 Alicante/Alacant;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Men;71 Alicante/Alacant;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Women;83 Alicante/Alacant;Group 2102 Contraceptive management V25;Both sexes;22 Alicante/Alacant;Group 2102 Contraceptive management V25;Men;3 Alicante/Alacant;Group 2102 Contraceptive management V25;Women;19 Alicante/Alacant;Group 2103 Living newborns by type of delivery V30-V39;Both sexes;.. Alicante/Alacant;Group 2103 Living newborns by type of delivery V30-V39;Men;.. Alicante/Alacant;Group 2103 Living newborns by type of delivery V30-V39;Women;.. Alicante/Alacant;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Both sexes;938 Alicante/Alacant;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Men;546 Alicante/Alacant;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Women;392 Alicante/Alacant;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Both sexes;3,328 Alicante/Alacant;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Men;1,481 Alicante/Alacant;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Women;1,847 Castell¾n/Castell¾;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Both sexes;49,176 Castell¾n/Castell¾;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Men;23,542 Castell¾n/Castell¾;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Women;25,634 Castell¾n/Castell¾;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Both sexes;1,321 Castell¾n/Castell¾;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Men;777 Castell¾n/Castell¾;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Women;544 Castell¾n/Castell¾;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Both sexes;196 Castell¾n/Castell¾;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Men;104 Castell¾n/Castell¾;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Women;92 Castell¾n/Castell¾;Group 0102 Imprecise intestinal infections 009;Both sexes;187 Castell¾n/Castell¾;Group 0102 Imprecise intestinal infections 009;Men;92 Castell¾n/Castell¾;Group 0102 Imprecise intestinal infections 009;Women;95 Castell¾n/Castell¾;Group 0103 Tuberculosis 010-018, 137;Both sexes;56 Castell¾n/Castell¾;Group 0103 Tuberculosis 010-018, 137;Men;41 Castell¾n/Castell¾;Group 0103 Tuberculosis 010-018, 137;Women;15 Castell¾n/Castell¾;Group 0104 Septicaemia 038;Both sexes;346 Castell¾n/Castell¾;Group 0104 Septicaemia 038;Men;200 Castell¾n/Castell¾;Group 0104 Septicaemia 038;Women;146 Castell¾n/Castell¾;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Both sexes;46 Castell¾n/Castell¾;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Men;33 Castell¾n/Castell¾;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Women;13 Castell¾n/Castell¾;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Both sexes;490 Castell¾n/Castell¾;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Men;307 Castell¾n/Castell¾;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Women;183 Castell¾n/Castell¾;Group 0200 Neoplasms 140-239;Both sexes;5,055 Castell¾n/Castell¾;Group 0200 Neoplasms 140-239;Men;2,678 Castell¾n/Castell¾;Group 0200 Neoplasms 140-239;Women;2,377 Castell¾n/Castell¾;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Both sexes;657 Castell¾n/Castell¾;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Men;413 Castell¾n/Castell¾;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Women;244 Castell¾n/Castell¾;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Both sexes;404 Castell¾n/Castell¾;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Men;359 Castell¾n/Castell¾;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Women;45 Castell¾n/Castell¾;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Both sexes;57 Castell¾n/Castell¾;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Men;34 Castell¾n/Castell¾;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Women;23 Castell¾n/Castell¾;Group 0204 Malignant neoplasm of breast 174-175;Both sexes;433 Castell¾n/Castell¾;Group 0204 Malignant neoplasm of breast 174-175;Men;5 Castell¾n/Castell¾;Group 0204 Malignant neoplasm of breast 174-175;Women;428 Castell¾n/Castell¾;Group 0205 Malignant neoplasm of uterus 179-180, 182;Both sexes;164 Castell¾n/Castell¾;Group 0205 Malignant neoplasm of uterus 179-180, 182;Men;.. Castell¾n/Castell¾;Group 0205 Malignant neoplasm of uterus 179-180, 182;Women;164 Castell¾n/Castell¾;Group 0206 Malignant neoplasm of ovary 1830;Both sexes;68 Castell¾n/Castell¾;Group 0206 Malignant neoplasm of ovary 1830;Men;.. Castell¾n/Castell¾;Group 0206 Malignant neoplasm of ovary 1830;Women;68 Castell¾n/Castell¾;Group 0207 Malignant neoplasm of prostate 185;Both sexes;223 Castell¾n/Castell¾;Group 0207 Malignant neoplasm of prostate 185;Men;223 Castell¾n/Castell¾;Group 0207 Malignant neoplasm of prostate 185;Women;.. Castell¾n/Castell¾;Group 0208 Malignant neoplasm of bladder 188;Both sexes;465 Castell¾n/Castell¾;Group 0208 Malignant neoplasm of bladder 188;Men;400 Castell¾n/Castell¾;Group 0208 Malignant neoplasm of bladder 188;Women;65 Castell¾n/Castell¾;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Both sexes;1,591 Castell¾n/Castell¾;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Men;938 Castell¾n/Castell¾;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Women;653 Castell¾n/Castell¾;Group 0210 Carcinoma in situ 230-234;Both sexes;82 Castell¾n/Castell¾;Group 0210 Carcinoma in situ 230-234;Men;19 Castell¾n/Castell¾;Group 0210 Carcinoma in situ 230-234;Women;63 Castell¾n/Castell¾;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Both sexes;76 Castell¾n/Castell¾;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Men;46 Castell¾n/Castell¾;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Women;30 Castell¾n/Castell¾;Grupo 0212 Leiomyoma of uterus 218;Both sexes;219 Castell¾n/Castell¾;Grupo 0212 Leiomyoma of uterus 218;Men;.. Castell¾n/Castell¾;Grupo 0212 Leiomyoma of uterus 218;Women;219 Castell¾n/Castell¾;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Both sexes;616 Castell¾n/Castell¾;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Men;241 Castell¾n/Castell¾;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Women;375 Castell¾n/Castell¾;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Both sexes;410 Castell¾n/Castell¾;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Men;207 Castell¾n/Castell¾;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Women;203 Castell¾n/Castell¾;Group 0301 Anaemias 280-285;Both sexes;219 Castell¾n/Castell¾;Group 0301 Anaemias 280-285;Men;105 Castell¾n/Castell¾;Group 0301 Anaemias 280-285;Women;114 Castell¾n/Castell¾;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Both sexes;191 Castell¾n/Castell¾;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Men;102 Castell¾n/Castell¾;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Women;89 Castell¾n/Castell¾;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Both sexes;908 Castell¾n/Castell¾;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Men;353 Castell¾n/Castell¾;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Women;555 Castell¾n/Castell¾;Group 0401 Diabetes mellitus 249-250;Both sexes;359 Castell¾n/Castell¾;Group 0401 Diabetes mellitus 249-250;Men;199 Castell¾n/Castell¾;Group 0401 Diabetes mellitus 249-250;Women;160 Castell¾n/Castell¾;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Both sexes;549 Castell¾n/Castell¾;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Men;154 Castell¾n/Castell¾;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Women;395 Castell¾n/Castell¾;Group 0500 Mental disorders 290-319;Both sexes;727 Castell¾n/Castell¾;Group 0500 Mental disorders 290-319;Men;428 Castell¾n/Castell¾;Group 0500 Mental disorders 290-319;Women;299 Castell¾n/Castell¾;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Both sexes;11 Castell¾n/Castell¾;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Men;8 Castell¾n/Castell¾;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Women;3 Castell¾n/Castell¾;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Both sexes;61 Castell¾n/Castell¾;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Men;51 Castell¾n/Castell¾;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Women;10 Castell¾n/Castell¾;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Both sexes;59 Castell¾n/Castell¾;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Men;47 Castell¾n/Castell¾;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Women;12 Castell¾n/Castell¾;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Both sexes;208 Castell¾n/Castell¾;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Men;139 Castell¾n/Castell¾;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Women;69 Castell¾n/Castell¾;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Both sexes;186 Castell¾n/Castell¾;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Men;93 Castell¾n/Castell¾;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Women;93 Castell¾n/Castell¾;Group 0506 Other mental and behavioural disorders Rest of (290-319);Both sexes;202 Castell¾n/Castell¾;Group 0506 Other mental and behavioural disorders Rest of (290-319);Men;90 Castell¾n/Castell¾;Group 0506 Other mental and behavioural disorders Rest of (290-319);Women;112 Castell¾n/Castell¾;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Both sexes;852 Castell¾n/Castell¾;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Men;402 Castell¾n/Castell¾;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Women;450 Castell¾n/Castell¾;Group 0601 Alzheimer's disease 3310;Both sexes;13 Castell¾n/Castell¾;Group 0601 Alzheimer's disease 3310;Men;5 Castell¾n/Castell¾;Group 0601 Alzheimer's disease 3310;Women;8 Castell¾n/Castell¾;Group 0602 Multiple sclerosis 340;Both sexes;28 Castell¾n/Castell¾;Group 0602 Multiple sclerosis 340;Men;6 Castell¾n/Castell¾;Group 0602 Multiple sclerosis 340;Women;22 Castell¾n/Castell¾;Group 0603 Epilepsy 345;Both sexes;179 Castell¾n/Castell¾;Group 0603 Epilepsy 345;Men;98 Castell¾n/Castell¾;Group 0603 Epilepsy 345;Women;81 Castell¾n/Castell¾;Group 0604 Transient cerebral ischemia 435;Both sexes;160 Castell¾n/Castell¾;Group 0604 Transient cerebral ischemia 435;Men;96 Castell¾n/Castell¾;Group 0604 Transient cerebral ischemia 435;Women;64 Castell¾n/Castell¾;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Both sexes;472 Castell¾n/Castell¾;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Men;197 Castell¾n/Castell¾;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Women;275 Castell¾n/Castell¾;Grupo 0700 Diseases of the eye and adnexa 360-379;Both sexes;246 Castell¾n/Castell¾;Grupo 0700 Diseases of the eye and adnexa 360-379;Men;120 Castell¾n/Castell¾;Grupo 0700 Diseases of the eye and adnexa 360-379;Women;126 Castell¾n/Castell¾;Grupo 0701 Cataract 366;Both sexes;45 Castell¾n/Castell¾;Grupo 0701 Cataract 366;Men;21 Castell¾n/Castell¾;Grupo 0701 Cataract 366;Women;24 Castell¾n/Castell¾;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Both sexes;201 Castell¾n/Castell¾;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Men;99 Castell¾n/Castell¾;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Women;102 Castell¾n/Castell¾;Group 0800 Diseases of the ear and the mastoid 380-389;Both sexes;176 Castell¾n/Castell¾;Group 0800 Diseases of the ear and the mastoid 380-389;Men;83 Castell¾n/Castell¾;Group 0800 Diseases of the ear and the mastoid 380-389;Women;93 Castell¾n/Castell¾;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Both sexes;6,316 Castell¾n/Castell¾;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Men;3,581 Castell¾n/Castell¾;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Women;2,735 Castell¾n/Castell¾;Group 0901 Hypertensive disease 401-405;Both sexes;266 Castell¾n/Castell¾;Group 0901 Hypertensive disease 401-405;Men;130 Castell¾n/Castell¾;Group 0901 Hypertensive disease 401-405;Women;136 Castell¾n/Castell¾;Group 0902 Angina pectoris 4111, 413;Both sexes;169 Castell¾n/Castell¾;Group 0902 Angina pectoris 4111, 413;Men;113 Castell¾n/Castell¾;Group 0902 Angina pectoris 4111, 413;Women;56 Castell¾n/Castell¾;Group 0903 Acute myocardial infarction 410;Both sexes;575 Castell¾n/Castell¾;Group 0903 Acute myocardial infarction 410;Men;414 Castell¾n/Castell¾;Group 0903 Acute myocardial infarction 410;Women;161 Castell¾n/Castell¾;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Both sexes;493 Castell¾n/Castell¾;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Men;363 Castell¾n/Castell¾;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Women;130 Castell¾n/Castell¾;Group 0905 Diseases of the lungs circulation 415-417;Both sexes;117 Castell¾n/Castell¾;Group 0905 Diseases of the lungs circulation 415-417;Men;46 Castell¾n/Castell¾;Group 0905 Diseases of the lungs circulation 415-417;Women;71 Castell¾n/Castell¾;Group 0906 Heart conduction disorders and arrhytmias 426-427;Both sexes;882 Castell¾n/Castell¾;Group 0906 Heart conduction disorders and arrhytmias 426-427;Men;475 Castell¾n/Castell¾;Group 0906 Heart conduction disorders and arrhytmias 426-427;Women;407 Castell¾n/Castell¾;Grupo 0907 Heart failure 428;Both sexes;1,297 Castell¾n/Castell¾;Grupo 0907 Heart failure 428;Men;633 Castell¾n/Castell¾;Grupo 0907 Heart failure 428;Women;664 Castell¾n/Castell¾;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Both sexes;1,246 Castell¾n/Castell¾;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Men;718 Castell¾n/Castell¾;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Women;528 Castell¾n/Castell¾;Grupo 0909 Atherosclerosis 440;Both sexes;141 Castell¾n/Castell¾;Grupo 0909 Atherosclerosis 440;Men;99 Castell¾n/Castell¾;Grupo 0909 Atherosclerosis 440;Women;42 Castell¾n/Castell¾;Group 0910 Varicose veins of lower extremities 454;Both sexes;256 Castell¾n/Castell¾;Group 0910 Varicose veins of lower extremities 454;Men;87 Castell¾n/Castell¾;Group 0910 Varicose veins of lower extremities 454;Women;169 Castell¾n/Castell¾;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Both sexes;874 Castell¾n/Castell¾;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Men;503 Castell¾n/Castell¾;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Women;371 Castell¾n/Castell¾;Group 1000 Diseases of the respiratory system 0340, 460-519;Both sexes;5,742 Castell¾n/Castell¾;Group 1000 Diseases of the respiratory system 0340, 460-519;Men;3,438 Castell¾n/Castell¾;Group 1000 Diseases of the respiratory system 0340, 460-519;Women;2,304 Castell¾n/Castell¾;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Both sexes;257 Castell¾n/Castell¾;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Men;148 Castell¾n/Castell¾;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Women;109 Castell¾n/Castell¾;Group 1002 Pneumonia 480-486;Both sexes;1,439 Castell¾n/Castell¾;Group 1002 Pneumonia 480-486;Men;867 Castell¾n/Castell¾;Group 1002 Pneumonia 480-486;Women;572 Castell¾n/Castell¾;Group 1003 Acute bronchitis and bronchiolitis 466;Both sexes;740 Castell¾n/Castell¾;Group 1003 Acute bronchitis and bronchiolitis 466;Men;346 Castell¾n/Castell¾;Group 1003 Acute bronchitis and bronchiolitis 466;Women;394 Castell¾n/Castell¾;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Both sexes;508 Castell¾n/Castell¾;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Men;274 Castell¾n/Castell¾;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Women;234 Castell¾n/Castell¾;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Both sexes;309 Castell¾n/Castell¾;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Men;208 Castell¾n/Castell¾;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Women;101 Castell¾n/Castell¾;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Both sexes;1,291 Castell¾n/Castell¾;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Men;1,002 Castell¾n/Castell¾;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Women;289 Castell¾n/Castell¾;Group 1007 Asthma 4930-4931,4938-4939;Both sexes;189 Castell¾n/Castell¾;Group 1007 Asthma 4930-4931,4938-4939;Men;69 Castell¾n/Castell¾;Group 1007 Asthma 4930-4931,4938-4939;Women;120 Castell¾n/Castell¾;Group 1008 Other diseases of the respiratory system Resto of (460-519);Both sexes;1,009 Castell¾n/Castell¾;Group 1008 Other diseases of the respiratory system Resto of (460-519);Men;524 Castell¾n/Castell¾;Group 1008 Other diseases of the respiratory system Resto of (460-519);Women;485 Castell¾n/Castell¾;Group 1100 Diseases of the digestive system 520-579;Both sexes;6,366 Castell¾n/Castell¾;Group 1100 Diseases of the digestive system 520-579;Men;3,693 Castell¾n/Castell¾;Group 1100 Diseases of the digestive system 520-579;Women;2,673 Castell¾n/Castell¾;Group 1101 Disorders of the teeth and supporting structures 520-525;Both sexes;100 Castell¾n/Castell¾;Group 1101 Disorders of the teeth and supporting structures 520-525;Men;49 Castell¾n/Castell¾;Group 1101 Disorders of the teeth and supporting structures 520-525;Women;51 Castell¾n/Castell¾;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Both sexes;65 Castell¾n/Castell¾;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Men;34 Castell¾n/Castell¾;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Women;31 Castell¾n/Castell¾;Group 1103 Diseases of the esophagus 530;Both sexes;78 Castell¾n/Castell¾;Group 1103 Diseases of the esophagus 530;Men;44 Castell¾n/Castell¾;Group 1103 Diseases of the esophagus 530;Women;34 Castell¾n/Castell¾;Group 1104 Peptic ulcer 531-534;Both sexes;140 Castell¾n/Castell¾;Group 1104 Peptic ulcer 531-534;Men;99 Castell¾n/Castell¾;Group 1104 Peptic ulcer 531-534;Women;41 Castell¾n/Castell¾;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Both sexes;161 Castell¾n/Castell¾;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Men;93 Castell¾n/Castell¾;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Women;68 Castell¾n/Castell¾;Group 1106 Appendicitis 540-543;Both sexes;531 Castell¾n/Castell¾;Group 1106 Appendicitis 540-543;Men;315 Castell¾n/Castell¾;Group 1106 Appendicitis 540-543;Women;216 Castell¾n/Castell¾;Group 1107 Inguinal hernia 550;Both sexes;658 Castell¾n/Castell¾;Group 1107 Inguinal hernia 550;Men;590 Castell¾n/Castell¾;Group 1107 Inguinal hernia 550;Women;68 Castell¾n/Castell¾;Group 1108 Other abdominal hernia 551-553;Both sexes;524 Castell¾n/Castell¾;Group 1108 Other abdominal hernia 551-553;Men;260 Castell¾n/Castell¾;Group 1108 Other abdominal hernia 551-553;Women;264 Castell¾n/Castell¾;Group 1109 Crohn's disease and ulcerative colitis 555-556;Both sexes;123 Castell¾n/Castell¾;Group 1109 Crohn's disease and ulcerative colitis 555-556;Men;66 Castell¾n/Castell¾;Group 1109 Crohn's disease and ulcerative colitis 555-556;Women;57 Castell¾n/Castell¾;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Both sexes;273 Castell¾n/Castell¾;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Men;144 Castell¾n/Castell¾;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Women;129 Castell¾n/Castell¾;Group 1111 Intestinal obstruction without hernia 560;Both sexes;288 Castell¾n/Castell¾;Group 1111 Intestinal obstruction without hernia 560;Men;168 Castell¾n/Castell¾;Group 1111 Intestinal obstruction without hernia 560;Women;120 Castell¾n/Castell¾;Group 1112 Intestinal diverticulosis 562;Both sexes;206 Castell¾n/Castell¾;Group 1112 Intestinal diverticulosis 562;Men;112 Castell¾n/Castell¾;Group 1112 Intestinal diverticulosis 562;Women;94 Castell¾n/Castell¾;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Both sexes;418 Castell¾n/Castell¾;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Men;250 Castell¾n/Castell¾;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Women;168 Castell¾n/Castell¾;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Both sexes;176 Castell¾n/Castell¾;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Men;84 Castell¾n/Castell¾;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Women;92 Castell¾n/Castell¾;Group 1115 Alcoholic hepatitis 5710-5713;Both sexes;128 Castell¾n/Castell¾;Group 1115 Alcoholic hepatitis 5710-5713;Men;110 Castell¾n/Castell¾;Group 1115 Alcoholic hepatitis 5710-5713;Women;18 Castell¾n/Castell¾;Group 1116 Other diseases of the liver 570,5714-573;Both sexes;228 Castell¾n/Castell¾;Group 1116 Other diseases of the liver 570,5714-573;Men;150 Castell¾n/Castell¾;Group 1116 Other diseases of the liver 570,5714-573;Women;78 Castell¾n/Castell¾;Group 1117 Cholelithiasis 574;Both sexes;1,297 Castell¾n/Castell¾;Group 1117 Cholelithiasis 574;Men;583 Castell¾n/Castell¾;Group 1117 Cholelithiasis 574;Women;714 Castell¾n/Castell¾;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Both sexes;372 Castell¾n/Castell¾;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Men;172 Castell¾n/Castell¾;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Women;200 Castell¾n/Castell¾;Group 1119 Pancreatic diseases 577;Both sexes;338 Castell¾n/Castell¾;Group 1119 Pancreatic diseases 577;Men;209 Castell¾n/Castell¾;Group 1119 Pancreatic diseases 577;Women;129 Castell¾n/Castell¾;Group 1120 Other diseases of the digestive system Rest of (520-579);Both sexes;262 Castell¾n/Castell¾;Group 1120 Other diseases of the digestive system Rest of (520-579);Men;161 Castell¾n/Castell¾;Group 1120 Other diseases of the digestive system Rest of (520-579);Women;101 Castell¾n/Castell¾;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Both sexes;321 Castell¾n/Castell¾;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Men;184 Castell¾n/Castell¾;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Women;137 Castell¾n/Castell¾;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Both sexes;220 Castell¾n/Castell¾;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Men;136 Castell¾n/Castell¾;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Women;84 Castell¾n/Castell¾;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Both sexes;26 Castell¾n/Castell¾;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Men;9 Castell¾n/Castell¾;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Women;17 Castell¾n/Castell¾;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Both sexes;75 Castell¾n/Castell¾;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Men;39 Castell¾n/Castell¾;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Women;36 Castell¾n/Castell¾;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Both sexes;2,985 Castell¾n/Castell¾;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Men;1,521 Castell¾n/Castell¾;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Women;1,464 Castell¾n/Castell¾;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Both sexes;.. Castell¾n/Castell¾;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Men;.. Castell¾n/Castell¾;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Women;.. Castell¾n/Castell¾;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Both sexes;.. Castell¾n/Castell¾;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Men;.. Castell¾n/Castell¾;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Women;.. Castell¾n/Castell¾;Group 1303 Internal derangement of knee 717;Both sexes;548 Castell¾n/Castell¾;Group 1303 Internal derangement of knee 717;Men;390 Castell¾n/Castell¾;Group 1303 Internal derangement of knee 717;Women;158 Castell¾n/Castell¾;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Both sexes;886 Castell¾n/Castell¾;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Men;417 Castell¾n/Castell¾;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Women;469 Castell¾n/Castell¾;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Both sexes;38 Castell¾n/Castell¾;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Men;16 Castell¾n/Castell¾;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Women;22 Castell¾n/Castell¾;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Both sexes;135 Castell¾n/Castell¾;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Men;72 Castell¾n/Castell¾;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Women;63 Castell¾n/Castell¾;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Both sexes;207 Castell¾n/Castell¾;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Men;121 Castell¾n/Castell¾;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Women;86 Castell¾n/Castell¾;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Both sexes;83 Castell¾n/Castell¾;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Men;49 Castell¾n/Castell¾;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Women;34 Castell¾n/Castell¾;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Both sexes;416 Castell¾n/Castell¾;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Men;228 Castell¾n/Castell¾;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Women;188 Castell¾n/Castell¾;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Both sexes;672 Castell¾n/Castell¾;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Men;228 Castell¾n/Castell¾;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Women;444 Castell¾n/Castell¾;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Both sexes;3,475 Castell¾n/Castell¾;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Men;1,569 Castell¾n/Castell¾;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Women;1,906 Castell¾n/Castell¾;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Both sexes;374 Castell¾n/Castell¾;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Men;137 Castell¾n/Castell¾;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Women;237 Castell¾n/Castell¾;Group 1402 Renal failure 5836-5837, 584-586;Both sexes;252 Castell¾n/Castell¾;Group 1402 Renal failure 5836-5837, 584-586;Men;147 Castell¾n/Castell¾;Group 1402 Renal failure 5836-5837, 584-586;Women;105 Castell¾n/Castell¾;Group 1403 Urolithiasis 592, 594, 7880;Both sexes;446 Castell¾n/Castell¾;Group 1403 Urolithiasis 592, 594, 7880;Men;262 Castell¾n/Castell¾;Group 1403 Urolithiasis 592, 594, 7880;Women;184 Castell¾n/Castell¾;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Both sexes;808 Castell¾n/Castell¾;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Men;388 Castell¾n/Castell¾;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Women;420 Castell¾n/Castell¾;Group 1405 Prostatic hyperplasia 600;Both sexes;309 Castell¾n/Castell¾;Group 1405 Prostatic hyperplasia 600;Men;309 Castell¾n/Castell¾;Group 1405 Prostatic hyperplasia 600;Women;.. Castell¾n/Castell¾;Group 1406 Other diseases of the male genital organs 601-608;Both sexes;292 Castell¾n/Castell¾;Group 1406 Other diseases of the male genital organs 601-608;Men;292 Castell¾n/Castell¾;Group 1406 Other diseases of the male genital organs 601-608;Women;.. Castell¾n/Castell¾;Group 1407 Disorders of breast 610-612;Both sexes;179 Castell¾n/Castell¾;Group 1407 Disorders of breast 610-612;Men;19 Castell¾n/Castell¾;Group 1407 Disorders of breast 610-612;Women;160 Castell¾n/Castell¾;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Both sexes;127 Castell¾n/Castell¾;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Men;.. Castell¾n/Castell¾;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Women;127 Castell¾n/Castell¾;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Both sexes;49 Castell¾n/Castell¾;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Men;.. Castell¾n/Castell¾;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Women;49 Castell¾n/Castell¾;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Both sexes;639 Castell¾n/Castell¾;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Men;15 Castell¾n/Castell¾;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Women;624 Castell¾n/Castell¾;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Both sexes;6,086 Castell¾n/Castell¾;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Men;.. Castell¾n/Castell¾;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Women;6,086 Castell¾n/Castell¾;Group 1501 Legally induced abortion 635;Both sexes;35 Castell¾n/Castell¾;Group 1501 Legally induced abortion 635;Men;.. Castell¾n/Castell¾;Group 1501 Legally induced abortion 635;Women;35 Castell¾n/Castell¾;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Both sexes;329 Castell¾n/Castell¾;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Men;.. Castell¾n/Castell¾;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Women;329 Castell¾n/Castell¾;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Both sexes;4,071 Castell¾n/Castell¾;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Men;.. Castell¾n/Castell¾;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Women;4,071 Castell¾n/Castell¾;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Both sexes;885 Castell¾n/Castell¾;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Men;.. Castell¾n/Castell¾;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Women;885 Castell¾n/Castell¾;Group 1505 Single spontaneous delivery 650;Both sexes;246 Castell¾n/Castell¾;Group 1505 Single spontaneous delivery 650;Men;.. Castell¾n/Castell¾;Group 1505 Single spontaneous delivery 650;Women;246 Castell¾n/Castell¾;Group 1506 Other deliveries 6695-6697;Both sexes;66 Castell¾n/Castell¾;Group 1506 Other deliveries 6695-6697;Men;.. Castell¾n/Castell¾;Group 1506 Other deliveries 6695-6697;Women;66 Castell¾n/Castell¾;Group 1507 Complications related to the puerperium 670-676;Both sexes;47 Castell¾n/Castell¾;Group 1507 Complications related to the puerperium 670-676;Men;.. Castell¾n/Castell¾;Group 1507 Complications related to the puerperium 670-676;Women;47 Castell¾n/Castell¾;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Both sexes;407 Castell¾n/Castell¾;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Men;.. Castell¾n/Castell¾;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Women;407 Castell¾n/Castell¾;Group 1600 Some disorders originating in the perinatal period 760-779;Both sexes;1,036 Castell¾n/Castell¾;Group 1600 Some disorders originating in the perinatal period 760-779;Men;559 Castell¾n/Castell¾;Group 1600 Some disorders originating in the perinatal period 760-779;Women;477 Castell¾n/Castell¾;Group 1601 Disorders related with premature delivery and a low birth weight 765;Both sexes;299 Castell¾n/Castell¾;Group 1601 Disorders related with premature delivery and a low birth weight 765;Men;161 Castell¾n/Castell¾;Group 1601 Disorders related with premature delivery and a low birth weight 765;Women;138 Castell¾n/Castell¾;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Both sexes;737 Castell¾n/Castell¾;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Men;398 Castell¾n/Castell¾;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Women;339 Castell¾n/Castell¾;Grupo 1700 Congenital abnormalities 740-759;Both sexes;302 Castell¾n/Castell¾;Grupo 1700 Congenital abnormalities 740-759;Men;198 Castell¾n/Castell¾;Grupo 1700 Congenital abnormalities 740-759;Women;104 Castell¾n/Castell¾;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Both sexes;1,596 Castell¾n/Castell¾;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Men;895 Castell¾n/Castell¾;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Women;701 Castell¾n/Castell¾;Group 1801 Pain in throat and chest 7841, 7865;Both sexes;263 Castell¾n/Castell¾;Group 1801 Pain in throat and chest 7841, 7865;Men;162 Castell¾n/Castell¾;Group 1801 Pain in throat and chest 7841, 7865;Women;101 Castell¾n/Castell¾;Group 1802 Abdominal pain 7890;Both sexes;209 Castell¾n/Castell¾;Group 1802 Abdominal pain 7890;Men;82 Castell¾n/Castell¾;Group 1802 Abdominal pain 7890;Women;127 Castell¾n/Castell¾;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Both sexes;17 Castell¾n/Castell¾;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Men;11 Castell¾n/Castell¾;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Women;6 Castell¾n/Castell¾;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Both sexes;1,107 Castell¾n/Castell¾;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Men;640 Castell¾n/Castell¾;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Women;467 Castell¾n/Castell¾;Group 1900 Injuries and poisoning 800-999;Both sexes;4,106 Castell¾n/Castell¾;Group 1900 Injuries and poisoning 800-999;Men;2,192 Castell¾n/Castell¾;Group 1900 Injuries and poisoning 800-999;Women;1,914 Castell¾n/Castell¾;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Both sexes;269 Castell¾n/Castell¾;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Men;152 Castell¾n/Castell¾;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Women;117 Castell¾n/Castell¾;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Both sexes;107 Castell¾n/Castell¾;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Men;73 Castell¾n/Castell¾;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Women;34 Castell¾n/Castell¾;Group 1903 Radius and ulna fracture 813;Both sexes;291 Castell¾n/Castell¾;Group 1903 Radius and ulna fracture 813;Men;145 Castell¾n/Castell¾;Group 1903 Radius and ulna fracture 813;Women;146 Castell¾n/Castell¾;Group 1904 Femur fracture 820-821;Both sexes;683 Castell¾n/Castell¾;Group 1904 Femur fracture 820-821;Men;202 Castell¾n/Castell¾;Group 1904 Femur fracture 820-821;Women;481 Castell¾n/Castell¾;Group 1905 Leg fracture, including the ankle 823-824;Both sexes;289 Castell¾n/Castell¾;Group 1905 Leg fracture, including the ankle 823-824;Men;169 Castell¾n/Castell¾;Group 1905 Leg fracture, including the ankle 823-824;Women;120 Castell¾n/Castell¾;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Both sexes;1,213 Castell¾n/Castell¾;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Men;812 Castell¾n/Castell¾;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Women;401 Castell¾n/Castell¾;Group 1907 Burns 940-949;Both sexes;3 Castell¾n/Castell¾;Group 1907 Burns 940-949;Men;2 Castell¾n/Castell¾;Group 1907 Burns 940-949;Women;1 Castell¾n/Castell¾;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Both sexes;115 Castell¾n/Castell¾;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Men;60 Castell¾n/Castell¾;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Women;55 Castell¾n/Castell¾;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Both sexes;985 Castell¾n/Castell¾;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Men;493 Castell¾n/Castell¾;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Women;492 Castell¾n/Castell¾;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Both sexes;8 Castell¾n/Castell¾;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Men;4 Castell¾n/Castell¾;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Women;4 Castell¾n/Castell¾;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Both sexes;143 Castell¾n/Castell¾;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Men;80 Castell¾n/Castell¾;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Women;63 Castell¾n/Castell¾;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Both sexes;1,150 Castell¾n/Castell¾;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Men;664 Castell¾n/Castell¾;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Women;486 Castell¾n/Castell¾;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Both sexes;42 Castell¾n/Castell¾;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Men;32 Castell¾n/Castell¾;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Women;10 Castell¾n/Castell¾;Group 2102 Contraceptive management V25;Both sexes;50 Castell¾n/Castell¾;Group 2102 Contraceptive management V25;Men;1 Castell¾n/Castell¾;Group 2102 Contraceptive management V25;Women;49 Castell¾n/Castell¾;Group 2103 Living newborns by type of delivery V30-V39;Both sexes;.. Castell¾n/Castell¾;Group 2103 Living newborns by type of delivery V30-V39;Men;.. Castell¾n/Castell¾;Group 2103 Living newborns by type of delivery V30-V39;Women;.. Castell¾n/Castell¾;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Both sexes;488 Castell¾n/Castell¾;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Men;309 Castell¾n/Castell¾;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Women;179 Castell¾n/Castell¾;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Both sexes;570 Castell¾n/Castell¾;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Men;322 Castell¾n/Castell¾;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Women;248 Valencia/ValÞncia;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Both sexes;252,361 Valencia/ValÞncia;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Men;120,317 Valencia/ValÞncia;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Women;132,044 Valencia/ValÞncia;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Both sexes;4,721 Valencia/ValÞncia;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Men;2,635 Valencia/ValÞncia;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Women;2,086 Valencia/ValÞncia;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Both sexes;754 Valencia/ValÞncia;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Men;411 Valencia/ValÞncia;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Women;343 Valencia/ValÞncia;Group 0102 Imprecise intestinal infections 009;Both sexes;338 Valencia/ValÞncia;Group 0102 Imprecise intestinal infections 009;Men;177 Valencia/ValÞncia;Group 0102 Imprecise intestinal infections 009;Women;161 Valencia/ValÞncia;Group 0103 Tuberculosis 010-018, 137;Both sexes;245 Valencia/ValÞncia;Group 0103 Tuberculosis 010-018, 137;Men;168 Valencia/ValÞncia;Group 0103 Tuberculosis 010-018, 137;Women;77 Valencia/ValÞncia;Group 0104 Septicaemia 038;Both sexes;1,325 Valencia/ValÞncia;Group 0104 Septicaemia 038;Men;701 Valencia/ValÞncia;Group 0104 Septicaemia 038;Women;624 Valencia/ValÞncia;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Both sexes;220 Valencia/ValÞncia;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Men;151 Valencia/ValÞncia;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Women;69 Valencia/ValÞncia;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Both sexes;1,839 Valencia/ValÞncia;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Men;1,027 Valencia/ValÞncia;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Women;812 Valencia/ValÞncia;Group 0200 Neoplasms 140-239;Both sexes;28,652 Valencia/ValÞncia;Group 0200 Neoplasms 140-239;Men;15,259 Valencia/ValÞncia;Group 0200 Neoplasms 140-239;Women;13,393 Valencia/ValÞncia;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Both sexes;2,695 Valencia/ValÞncia;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Men;1,589 Valencia/ValÞncia;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Women;1,106 Valencia/ValÞncia;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Both sexes;2,317 Valencia/ValÞncia;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Men;1,836 Valencia/ValÞncia;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Women;481 Valencia/ValÞncia;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Both sexes;544 Valencia/ValÞncia;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Men;313 Valencia/ValÞncia;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Women;231 Valencia/ValÞncia;Group 0204 Malignant neoplasm of breast 174-175;Both sexes;2,567 Valencia/ValÞncia;Group 0204 Malignant neoplasm of breast 174-175;Men;19 Valencia/ValÞncia;Group 0204 Malignant neoplasm of breast 174-175;Women;2,548 Valencia/ValÞncia;Group 0205 Malignant neoplasm of uterus 179-180, 182;Both sexes;619 Valencia/ValÞncia;Group 0205 Malignant neoplasm of uterus 179-180, 182;Men;.. Valencia/ValÞncia;Group 0205 Malignant neoplasm of uterus 179-180, 182;Women;619 Valencia/ValÞncia;Group 0206 Malignant neoplasm of ovary 1830;Both sexes;383 Valencia/ValÞncia;Group 0206 Malignant neoplasm of ovary 1830;Men;.. Valencia/ValÞncia;Group 0206 Malignant neoplasm of ovary 1830;Women;383 Valencia/ValÞncia;Group 0207 Malignant neoplasm of prostate 185;Both sexes;1,379 Valencia/ValÞncia;Group 0207 Malignant neoplasm of prostate 185;Men;1,379 Valencia/ValÞncia;Group 0207 Malignant neoplasm of prostate 185;Women;.. Valencia/ValÞncia;Group 0208 Malignant neoplasm of bladder 188;Both sexes;3,311 Valencia/ValÞncia;Group 0208 Malignant neoplasm of bladder 188;Men;2,865 Valencia/ValÞncia;Group 0208 Malignant neoplasm of bladder 188;Women;446 Valencia/ValÞncia;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Both sexes;9,089 Valencia/ValÞncia;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Men;5,408 Valencia/ValÞncia;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Women;3,681 Valencia/ValÞncia;Group 0210 Carcinoma in situ 230-234;Both sexes;428 Valencia/ValÞncia;Group 0210 Carcinoma in situ 230-234;Men;130 Valencia/ValÞncia;Group 0210 Carcinoma in situ 230-234;Women;298 Valencia/ValÞncia;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Both sexes;309 Valencia/ValÞncia;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Men;191 Valencia/ValÞncia;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Women;118 Valencia/ValÞncia;Grupo 0212 Leiomyoma of uterus 218;Both sexes;1,391 Valencia/ValÞncia;Grupo 0212 Leiomyoma of uterus 218;Men;.. Valencia/ValÞncia;Grupo 0212 Leiomyoma of uterus 218;Women;1,391 Valencia/ValÞncia;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Both sexes;3,620 Valencia/ValÞncia;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Men;1,529 Valencia/ValÞncia;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Women;2,091 Valencia/ValÞncia;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Both sexes;2,126 Valencia/ValÞncia;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Men;1,057 Valencia/ValÞncia;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Women;1,069 Valencia/ValÞncia;Group 0301 Anaemias 280-285;Both sexes;1,064 Valencia/ValÞncia;Group 0301 Anaemias 280-285;Men;470 Valencia/ValÞncia;Group 0301 Anaemias 280-285;Women;594 Valencia/ValÞncia;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Both sexes;1,062 Valencia/ValÞncia;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Men;587 Valencia/ValÞncia;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Women;475 Valencia/ValÞncia;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Both sexes;4,847 Valencia/ValÞncia;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Men;1,878 Valencia/ValÞncia;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Women;2,969 Valencia/ValÞncia;Group 0401 Diabetes mellitus 249-250;Both sexes;1,634 Valencia/ValÞncia;Group 0401 Diabetes mellitus 249-250;Men;925 Valencia/ValÞncia;Group 0401 Diabetes mellitus 249-250;Women;709 Valencia/ValÞncia;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Both sexes;3,213 Valencia/ValÞncia;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Men;953 Valencia/ValÞncia;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Women;2,260 Valencia/ValÞncia;Group 0500 Mental disorders 290-319;Both sexes;5,563 Valencia/ValÞncia;Group 0500 Mental disorders 290-319;Men;2,925 Valencia/ValÞncia;Group 0500 Mental disorders 290-319;Women;2,638 Valencia/ValÞncia;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Both sexes;111 Valencia/ValÞncia;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Men;48 Valencia/ValÞncia;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Women;63 Valencia/ValÞncia;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Both sexes;396 Valencia/ValÞncia;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Men;285 Valencia/ValÞncia;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Women;111 Valencia/ValÞncia;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Both sexes;311 Valencia/ValÞncia;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Men;228 Valencia/ValÞncia;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Women;83 Valencia/ValÞncia;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Both sexes;1,765 Valencia/ValÞncia;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Men;1,124 Valencia/ValÞncia;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Women;641 Valencia/ValÞncia;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Both sexes;1,211 Valencia/ValÞncia;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Men;531 Valencia/ValÞncia;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Women;680 Valencia/ValÞncia;Group 0506 Other mental and behavioural disorders Rest of (290-319);Both sexes;1,769 Valencia/ValÞncia;Group 0506 Other mental and behavioural disorders Rest of (290-319);Men;709 Valencia/ValÞncia;Group 0506 Other mental and behavioural disorders Rest of (290-319);Women;1,060 Valencia/ValÞncia;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Both sexes;5,510 Valencia/ValÞncia;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Men;2,690 Valencia/ValÞncia;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Women;2,820 Valencia/ValÞncia;Group 0601 Alzheimer's disease 3310;Both sexes;106 Valencia/ValÞncia;Group 0601 Alzheimer's disease 3310;Men;47 Valencia/ValÞncia;Group 0601 Alzheimer's disease 3310;Women;59 Valencia/ValÞncia;Group 0602 Multiple sclerosis 340;Both sexes;144 Valencia/ValÞncia;Group 0602 Multiple sclerosis 340;Men;39 Valencia/ValÞncia;Group 0602 Multiple sclerosis 340;Women;105 Valencia/ValÞncia;Group 0603 Epilepsy 345;Both sexes;1,198 Valencia/ValÞncia;Group 0603 Epilepsy 345;Men;642 Valencia/ValÞncia;Group 0603 Epilepsy 345;Women;556 Valencia/ValÞncia;Group 0604 Transient cerebral ischemia 435;Both sexes;709 Valencia/ValÞncia;Group 0604 Transient cerebral ischemia 435;Men;381 Valencia/ValÞncia;Group 0604 Transient cerebral ischemia 435;Women;328 Valencia/ValÞncia;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Both sexes;3,353 Valencia/ValÞncia;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Men;1,581 Valencia/ValÞncia;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Women;1,772 Valencia/ValÞncia;Grupo 0700 Diseases of the eye and adnexa 360-379;Both sexes;1,477 Valencia/ValÞncia;Grupo 0700 Diseases of the eye and adnexa 360-379;Men;776 Valencia/ValÞncia;Grupo 0700 Diseases of the eye and adnexa 360-379;Women;701 Valencia/ValÞncia;Grupo 0701 Cataract 366;Both sexes;179 Valencia/ValÞncia;Grupo 0701 Cataract 366;Men;98 Valencia/ValÞncia;Grupo 0701 Cataract 366;Women;81 Valencia/ValÞncia;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Both sexes;1,298 Valencia/ValÞncia;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Men;678 Valencia/ValÞncia;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Women;620 Valencia/ValÞncia;Group 0800 Diseases of the ear and the mastoid 380-389;Both sexes;1,482 Valencia/ValÞncia;Group 0800 Diseases of the ear and the mastoid 380-389;Men;713 Valencia/ValÞncia;Group 0800 Diseases of the ear and the mastoid 380-389;Women;769 Valencia/ValÞncia;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Both sexes;29,933 Valencia/ValÞncia;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Men;17,125 Valencia/ValÞncia;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Women;12,808 Valencia/ValÞncia;Group 0901 Hypertensive disease 401-405;Both sexes;706 Valencia/ValÞncia;Group 0901 Hypertensive disease 401-405;Men;312 Valencia/ValÞncia;Group 0901 Hypertensive disease 401-405;Women;394 Valencia/ValÞncia;Group 0902 Angina pectoris 4111, 413;Both sexes;1,516 Valencia/ValÞncia;Group 0902 Angina pectoris 4111, 413;Men;1,011 Valencia/ValÞncia;Group 0902 Angina pectoris 4111, 413;Women;505 Valencia/ValÞncia;Group 0903 Acute myocardial infarction 410;Both sexes;2,696 Valencia/ValÞncia;Group 0903 Acute myocardial infarction 410;Men;1,917 Valencia/ValÞncia;Group 0903 Acute myocardial infarction 410;Women;779 Valencia/ValÞncia;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Both sexes;2,180 Valencia/ValÞncia;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Men;1,684 Valencia/ValÞncia;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Women;496 Valencia/ValÞncia;Group 0905 Diseases of the lungs circulation 415-417;Both sexes;1,042 Valencia/ValÞncia;Group 0905 Diseases of the lungs circulation 415-417;Men;455 Valencia/ValÞncia;Group 0905 Diseases of the lungs circulation 415-417;Women;587 Valencia/ValÞncia;Group 0906 Heart conduction disorders and arrhytmias 426-427;Both sexes;3,517 Valencia/ValÞncia;Group 0906 Heart conduction disorders and arrhytmias 426-427;Men;1,857 Valencia/ValÞncia;Group 0906 Heart conduction disorders and arrhytmias 426-427;Women;1,660 Valencia/ValÞncia;Grupo 0907 Heart failure 428;Both sexes;5,611 Valencia/ValÞncia;Grupo 0907 Heart failure 428;Men;2,587 Valencia/ValÞncia;Grupo 0907 Heart failure 428;Women;3,024 Valencia/ValÞncia;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Both sexes;5,739 Valencia/ValÞncia;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Men;3,125 Valencia/ValÞncia;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Women;2,614 Valencia/ValÞncia;Grupo 0909 Atherosclerosis 440;Both sexes;847 Valencia/ValÞncia;Grupo 0909 Atherosclerosis 440;Men;646 Valencia/ValÞncia;Grupo 0909 Atherosclerosis 440;Women;201 Valencia/ValÞncia;Group 0910 Varicose veins of lower extremities 454;Both sexes;493 Valencia/ValÞncia;Group 0910 Varicose veins of lower extremities 454;Men;170 Valencia/ValÞncia;Group 0910 Varicose veins of lower extremities 454;Women;323 Valencia/ValÞncia;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Both sexes;5,586 Valencia/ValÞncia;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Men;3,361 Valencia/ValÞncia;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Women;2,225 Valencia/ValÞncia;Group 1000 Diseases of the respiratory system 0340, 460-519;Both sexes;27,470 Valencia/ValÞncia;Group 1000 Diseases of the respiratory system 0340, 460-519;Men;15,691 Valencia/ValÞncia;Group 1000 Diseases of the respiratory system 0340, 460-519;Women;11,779 Valencia/ValÞncia;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Both sexes;1,579 Valencia/ValÞncia;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Men;815 Valencia/ValÞncia;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Women;764 Valencia/ValÞncia;Group 1002 Pneumonia 480-486;Both sexes;6,454 Valencia/ValÞncia;Group 1002 Pneumonia 480-486;Men;3,808 Valencia/ValÞncia;Group 1002 Pneumonia 480-486;Women;2,646 Valencia/ValÞncia;Group 1003 Acute bronchitis and bronchiolitis 466;Both sexes;2,072 Valencia/ValÞncia;Group 1003 Acute bronchitis and bronchiolitis 466;Men;1,065 Valencia/ValÞncia;Group 1003 Acute bronchitis and bronchiolitis 466;Women;1,007 Valencia/ValÞncia;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Both sexes;2,293 Valencia/ValÞncia;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Men;1,202 Valencia/ValÞncia;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Women;1,091 Valencia/ValÞncia;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Both sexes;2,315 Valencia/ValÞncia;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Men;1,400 Valencia/ValÞncia;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Women;915 Valencia/ValÞncia;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Both sexes;3,692 Valencia/ValÞncia;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Men;2,833 Valencia/ValÞncia;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Women;859 Valencia/ValÞncia;Group 1007 Asthma 4930-4931,4938-4939;Both sexes;831 Valencia/ValÞncia;Group 1007 Asthma 4930-4931,4938-4939;Men;224 Valencia/ValÞncia;Group 1007 Asthma 4930-4931,4938-4939;Women;607 Valencia/ValÞncia;Group 1008 Other diseases of the respiratory system Resto of (460-519);Both sexes;8,234 Valencia/ValÞncia;Group 1008 Other diseases of the respiratory system Resto of (460-519);Men;4,344 Valencia/ValÞncia;Group 1008 Other diseases of the respiratory system Resto of (460-519);Women;3,890 Valencia/ValÞncia;Group 1100 Diseases of the digestive system 520-579;Both sexes;30,641 Valencia/ValÞncia;Group 1100 Diseases of the digestive system 520-579;Men;16,856 Valencia/ValÞncia;Group 1100 Diseases of the digestive system 520-579;Women;13,785 Valencia/ValÞncia;Group 1101 Disorders of the teeth and supporting structures 520-525;Both sexes;835 Valencia/ValÞncia;Group 1101 Disorders of the teeth and supporting structures 520-525;Men;380 Valencia/ValÞncia;Group 1101 Disorders of the teeth and supporting structures 520-525;Women;455 Valencia/ValÞncia;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Both sexes;500 Valencia/ValÞncia;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Men;269 Valencia/ValÞncia;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Women;231 Valencia/ValÞncia;Group 1103 Diseases of the esophagus 530;Both sexes;677 Valencia/ValÞncia;Group 1103 Diseases of the esophagus 530;Men;406 Valencia/ValÞncia;Group 1103 Diseases of the esophagus 530;Women;271 Valencia/ValÞncia;Group 1104 Peptic ulcer 531-534;Both sexes;601 Valencia/ValÞncia;Group 1104 Peptic ulcer 531-534;Men;399 Valencia/ValÞncia;Group 1104 Peptic ulcer 531-534;Women;202 Valencia/ValÞncia;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Both sexes;978 Valencia/ValÞncia;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Men;486 Valencia/ValÞncia;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Women;492 Valencia/ValÞncia;Group 1106 Appendicitis 540-543;Both sexes;2,801 Valencia/ValÞncia;Group 1106 Appendicitis 540-543;Men;1,530 Valencia/ValÞncia;Group 1106 Appendicitis 540-543;Women;1,271 Valencia/ValÞncia;Group 1107 Inguinal hernia 550;Both sexes;2,518 Valencia/ValÞncia;Group 1107 Inguinal hernia 550;Men;2,233 Valencia/ValÞncia;Group 1107 Inguinal hernia 550;Women;285 Valencia/ValÞncia;Group 1108 Other abdominal hernia 551-553;Both sexes;2,332 Valencia/ValÞncia;Group 1108 Other abdominal hernia 551-553;Men;1,040 Valencia/ValÞncia;Group 1108 Other abdominal hernia 551-553;Women;1,292 Valencia/ValÞncia;Group 1109 Crohn's disease and ulcerative colitis 555-556;Both sexes;774 Valencia/ValÞncia;Group 1109 Crohn's disease and ulcerative colitis 555-556;Men;389 Valencia/ValÞncia;Group 1109 Crohn's disease and ulcerative colitis 555-556;Women;385 Valencia/ValÞncia;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Both sexes;1,609 Valencia/ValÞncia;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Men;769 Valencia/ValÞncia;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Women;840 Valencia/ValÞncia;Group 1111 Intestinal obstruction without hernia 560;Both sexes;1,336 Valencia/ValÞncia;Group 1111 Intestinal obstruction without hernia 560;Men;709 Valencia/ValÞncia;Group 1111 Intestinal obstruction without hernia 560;Women;627 Valencia/ValÞncia;Group 1112 Intestinal diverticulosis 562;Both sexes;1,152 Valencia/ValÞncia;Group 1112 Intestinal diverticulosis 562;Men;569 Valencia/ValÞncia;Group 1112 Intestinal diverticulosis 562;Women;583 Valencia/ValÞncia;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Both sexes;1,978 Valencia/ValÞncia;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Men;1,308 Valencia/ValÞncia;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Women;670 Valencia/ValÞncia;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Both sexes;994 Valencia/ValÞncia;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Men;436 Valencia/ValÞncia;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Women;558 Valencia/ValÞncia;Group 1115 Alcoholic hepatitis 5710-5713;Both sexes;417 Valencia/ValÞncia;Group 1115 Alcoholic hepatitis 5710-5713;Men;359 Valencia/ValÞncia;Group 1115 Alcoholic hepatitis 5710-5713;Women;58 Valencia/ValÞncia;Group 1116 Other diseases of the liver 570,5714-573;Both sexes;1,349 Valencia/ValÞncia;Group 1116 Other diseases of the liver 570,5714-573;Men;849 Valencia/ValÞncia;Group 1116 Other diseases of the liver 570,5714-573;Women;500 Valencia/ValÞncia;Group 1117 Cholelithiasis 574;Both sexes;5,067 Valencia/ValÞncia;Group 1117 Cholelithiasis 574;Men;2,107 Valencia/ValÞncia;Group 1117 Cholelithiasis 574;Women;2,960 Valencia/ValÞncia;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Both sexes;1,593 Valencia/ValÞncia;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Men;874 Valencia/ValÞncia;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Women;719 Valencia/ValÞncia;Group 1119 Pancreatic diseases 577;Both sexes;1,510 Valencia/ValÞncia;Group 1119 Pancreatic diseases 577;Men;857 Valencia/ValÞncia;Group 1119 Pancreatic diseases 577;Women;653 Valencia/ValÞncia;Group 1120 Other diseases of the digestive system Rest of (520-579);Both sexes;1,620 Valencia/ValÞncia;Group 1120 Other diseases of the digestive system Rest of (520-579);Men;887 Valencia/ValÞncia;Group 1120 Other diseases of the digestive system Rest of (520-579);Women;733 Valencia/ValÞncia;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Both sexes;2,355 Valencia/ValÞncia;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Men;1,283 Valencia/ValÞncia;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Women;1,072 Valencia/ValÞncia;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Both sexes;1,497 Valencia/ValÞncia;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Men;885 Valencia/ValÞncia;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Women;612 Valencia/ValÞncia;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Both sexes;85 Valencia/ValÞncia;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Men;32 Valencia/ValÞncia;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Women;53 Valencia/ValÞncia;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Both sexes;773 Valencia/ValÞncia;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Men;366 Valencia/ValÞncia;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Women;407 Valencia/ValÞncia;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Both sexes;19,615 Valencia/ValÞncia;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Men;10,095 Valencia/ValÞncia;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Women;9,520 Valencia/ValÞncia;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Both sexes;.. Valencia/ValÞncia;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Men;.. Valencia/ValÞncia;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Women;.. Valencia/ValÞncia;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Both sexes;.. Valencia/ValÞncia;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Men;.. Valencia/ValÞncia;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Women;.. Valencia/ValÞncia;Group 1303 Internal derangement of knee 717;Both sexes;3,558 Valencia/ValÞncia;Group 1303 Internal derangement of knee 717;Men;2,563 Valencia/ValÞncia;Group 1303 Internal derangement of knee 717;Women;995 Valencia/ValÞncia;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Both sexes;6,484 Valencia/ValÞncia;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Men;2,783 Valencia/ValÞncia;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Women;3,701 Valencia/ValÞncia;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Both sexes;390 Valencia/ValÞncia;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Men;133 Valencia/ValÞncia;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Women;257 Valencia/ValÞncia;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Both sexes;986 Valencia/ValÞncia;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Men;513 Valencia/ValÞncia;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Women;473 Valencia/ValÞncia;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Both sexes;1,904 Valencia/ValÞncia;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Men;1,030 Valencia/ValÞncia;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Women;874 Valencia/ValÞncia;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Both sexes;366 Valencia/ValÞncia;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Men;170 Valencia/ValÞncia;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Women;196 Valencia/ValÞncia;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Both sexes;3,044 Valencia/ValÞncia;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Men;1,651 Valencia/ValÞncia;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Women;1,393 Valencia/ValÞncia;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Both sexes;2,883 Valencia/ValÞncia;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Men;1,252 Valencia/ValÞncia;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Women;1,631 Valencia/ValÞncia;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Both sexes;17,674 Valencia/ValÞncia;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Men;7,738 Valencia/ValÞncia;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Women;9,936 Valencia/ValÞncia;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Both sexes;1,792 Valencia/ValÞncia;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Men;664 Valencia/ValÞncia;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Women;1,128 Valencia/ValÞncia;Group 1402 Renal failure 5836-5837, 584-586;Both sexes;1,350 Valencia/ValÞncia;Group 1402 Renal failure 5836-5837, 584-586;Men;766 Valencia/ValÞncia;Group 1402 Renal failure 5836-5837, 584-586;Women;584 Valencia/ValÞncia;Group 1403 Urolithiasis 592, 594, 7880;Both sexes;2,018 Valencia/ValÞncia;Group 1403 Urolithiasis 592, 594, 7880;Men;1,169 Valencia/ValÞncia;Group 1403 Urolithiasis 592, 594, 7880;Women;849 Valencia/ValÞncia;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Both sexes;4,995 Valencia/ValÞncia;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Men;2,490 Valencia/ValÞncia;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Women;2,505 Valencia/ValÞncia;Group 1405 Prostatic hyperplasia 600;Both sexes;1,571 Valencia/ValÞncia;Group 1405 Prostatic hyperplasia 600;Men;1,571 Valencia/ValÞncia;Group 1405 Prostatic hyperplasia 600;Women;.. Valencia/ValÞncia;Group 1406 Other diseases of the male genital organs 601-608;Both sexes;961 Valencia/ValÞncia;Group 1406 Other diseases of the male genital organs 601-608;Men;961 Valencia/ValÞncia;Group 1406 Other diseases of the male genital organs 601-608;Women;.. Valencia/ValÞncia;Group 1407 Disorders of breast 610-612;Both sexes;1,168 Valencia/ValÞncia;Group 1407 Disorders of breast 610-612;Men;97 Valencia/ValÞncia;Group 1407 Disorders of breast 610-612;Women;1,071 Valencia/ValÞncia;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Both sexes;461 Valencia/ValÞncia;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Men;.. Valencia/ValÞncia;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Women;461 Valencia/ValÞncia;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Both sexes;256 Valencia/ValÞncia;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Men;.. Valencia/ValÞncia;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Women;256 Valencia/ValÞncia;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Both sexes;3,102 Valencia/ValÞncia;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Men;20 Valencia/ValÞncia;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Women;3,082 Valencia/ValÞncia;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Both sexes;25,685 Valencia/ValÞncia;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Men;.. Valencia/ValÞncia;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Women;25,685 Valencia/ValÞncia;Group 1501 Legally induced abortion 635;Both sexes;158 Valencia/ValÞncia;Group 1501 Legally induced abortion 635;Men;.. Valencia/ValÞncia;Group 1501 Legally induced abortion 635;Women;158 Valencia/ValÞncia;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Both sexes;1,048 Valencia/ValÞncia;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Men;.. Valencia/ValÞncia;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Women;1,048 Valencia/ValÞncia;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Both sexes;14,711 Valencia/ValÞncia;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Men;.. Valencia/ValÞncia;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Women;14,711 Valencia/ValÞncia;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Both sexes;4,723 Valencia/ValÞncia;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Men;.. Valencia/ValÞncia;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Women;4,723 Valencia/ValÞncia;Group 1505 Single spontaneous delivery 650;Both sexes;2,293 Valencia/ValÞncia;Group 1505 Single spontaneous delivery 650;Men;.. Valencia/ValÞncia;Group 1505 Single spontaneous delivery 650;Women;2,293 Valencia/ValÞncia;Group 1506 Other deliveries 6695-6697;Both sexes;927 Valencia/ValÞncia;Group 1506 Other deliveries 6695-6697;Men;.. Valencia/ValÞncia;Group 1506 Other deliveries 6695-6697;Women;927 Valencia/ValÞncia;Group 1507 Complications related to the puerperium 670-676;Both sexes;194 Valencia/ValÞncia;Group 1507 Complications related to the puerperium 670-676;Men;.. Valencia/ValÞncia;Group 1507 Complications related to the puerperium 670-676;Women;194 Valencia/ValÞncia;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Both sexes;1,631 Valencia/ValÞncia;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Men;.. Valencia/ValÞncia;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Women;1,631 Valencia/ValÞncia;Group 1600 Some disorders originating in the perinatal period 760-779;Both sexes;3,469 Valencia/ValÞncia;Group 1600 Some disorders originating in the perinatal period 760-779;Men;1,914 Valencia/ValÞncia;Group 1600 Some disorders originating in the perinatal period 760-779;Women;1,555 Valencia/ValÞncia;Group 1601 Disorders related with premature delivery and a low birth weight 765;Both sexes;1,047 Valencia/ValÞncia;Group 1601 Disorders related with premature delivery and a low birth weight 765;Men;567 Valencia/ValÞncia;Group 1601 Disorders related with premature delivery and a low birth weight 765;Women;480 Valencia/ValÞncia;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Both sexes;2,422 Valencia/ValÞncia;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Men;1,347 Valencia/ValÞncia;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Women;1,075 Valencia/ValÞncia;Grupo 1700 Congenital abnormalities 740-759;Both sexes;2,725 Valencia/ValÞncia;Grupo 1700 Congenital abnormalities 740-759;Men;1,571 Valencia/ValÞncia;Grupo 1700 Congenital abnormalities 740-759;Women;1,154 Valencia/ValÞncia;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Both sexes;10,110 Valencia/ValÞncia;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Men;5,679 Valencia/ValÞncia;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Women;4,431 Valencia/ValÞncia;Group 1801 Pain in throat and chest 7841, 7865;Both sexes;1,242 Valencia/ValÞncia;Group 1801 Pain in throat and chest 7841, 7865;Men;714 Valencia/ValÞncia;Group 1801 Pain in throat and chest 7841, 7865;Women;528 Valencia/ValÞncia;Group 1802 Abdominal pain 7890;Both sexes;960 Valencia/ValÞncia;Group 1802 Abdominal pain 7890;Men;369 Valencia/ValÞncia;Group 1802 Abdominal pain 7890;Women;591 Valencia/ValÞncia;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Both sexes;201 Valencia/ValÞncia;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Men;97 Valencia/ValÞncia;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Women;104 Valencia/ValÞncia;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Both sexes;7,707 Valencia/ValÞncia;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Men;4,499 Valencia/ValÞncia;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Women;3,208 Valencia/ValÞncia;Group 1900 Injuries and poisoning 800-999;Both sexes;23,087 Valencia/ValÞncia;Group 1900 Injuries and poisoning 800-999;Men;12,088 Valencia/ValÞncia;Group 1900 Injuries and poisoning 800-999;Women;10,999 Valencia/ValÞncia;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Both sexes;1,024 Valencia/ValÞncia;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Men;596 Valencia/ValÞncia;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Women;428 Valencia/ValÞncia;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Both sexes;500 Valencia/ValÞncia;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Men;361 Valencia/ValÞncia;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Women;139 Valencia/ValÞncia;Group 1903 Radius and ulna fracture 813;Both sexes;1,596 Valencia/ValÞncia;Group 1903 Radius and ulna fracture 813;Men;772 Valencia/ValÞncia;Group 1903 Radius and ulna fracture 813;Women;824 Valencia/ValÞncia;Group 1904 Femur fracture 820-821;Both sexes;3,601 Valencia/ValÞncia;Group 1904 Femur fracture 820-821;Men;1,033 Valencia/ValÞncia;Group 1904 Femur fracture 820-821;Women;2,568 Valencia/ValÞncia;Group 1905 Leg fracture, including the ankle 823-824;Both sexes;1,787 Valencia/ValÞncia;Group 1905 Leg fracture, including the ankle 823-824;Men;975 Valencia/ValÞncia;Group 1905 Leg fracture, including the ankle 823-824;Women;812 Valencia/ValÞncia;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Both sexes;7,264 Valencia/ValÞncia;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Men;4,633 Valencia/ValÞncia;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Women;2,631 Valencia/ValÞncia;Group 1907 Burns 940-949;Both sexes;157 Valencia/ValÞncia;Group 1907 Burns 940-949;Men;109 Valencia/ValÞncia;Group 1907 Burns 940-949;Women;48 Valencia/ValÞncia;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Both sexes;708 Valencia/ValÞncia;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Men;287 Valencia/ValÞncia;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Women;421 Valencia/ValÞncia;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Both sexes;5,574 Valencia/ValÞncia;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Men;2,843 Valencia/ValÞncia;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Women;2,731 Valencia/ValÞncia;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Both sexes;130 Valencia/ValÞncia;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Men;90 Valencia/ValÞncia;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Women;40 Valencia/ValÞncia;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Both sexes;746 Valencia/ValÞncia;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Men;389 Valencia/ValÞncia;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Women;357 Valencia/ValÞncia;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Both sexes;5,219 Valencia/ValÞncia;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Men;2,344 Valencia/ValÞncia;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Women;2,875 Valencia/ValÞncia;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Both sexes;150 Valencia/ValÞncia;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Men;63 Valencia/ValÞncia;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Women;87 Valencia/ValÞncia;Group 2102 Contraceptive management V25;Both sexes;82 Valencia/ValÞncia;Group 2102 Contraceptive management V25;Men;1 Valencia/ValÞncia;Group 2102 Contraceptive management V25;Women;81 Valencia/ValÞncia;Group 2103 Living newborns by type of delivery V30-V39;Both sexes;.. Valencia/ValÞncia;Group 2103 Living newborns by type of delivery V30-V39;Men;.. Valencia/ValÞncia;Group 2103 Living newborns by type of delivery V30-V39;Women;.. Valencia/ValÞncia;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Both sexes;1,488 Valencia/ValÞncia;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Men;840 Valencia/ValÞncia;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Women;648 Valencia/ValÞncia;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Both sexes;3,499 Valencia/ValÞncia;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Men;1,440 Valencia/ValÞncia;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Women;2,059 EXTREMADURA;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Both sexes;111,814 EXTREMADURA;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Men;53,226 EXTREMADURA;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Women;58,588 EXTREMADURA;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Both sexes;1,761 EXTREMADURA;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Men;963 EXTREMADURA;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Women;798 EXTREMADURA;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Both sexes;318 EXTREMADURA;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Men;163 EXTREMADURA;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Women;155 EXTREMADURA;Group 0102 Imprecise intestinal infections 009;Both sexes;230 EXTREMADURA;Group 0102 Imprecise intestinal infections 009;Men;129 EXTREMADURA;Group 0102 Imprecise intestinal infections 009;Women;101 EXTREMADURA;Group 0103 Tuberculosis 010-018, 137;Both sexes;71 EXTREMADURA;Group 0103 Tuberculosis 010-018, 137;Men;44 EXTREMADURA;Group 0103 Tuberculosis 010-018, 137;Women;27 EXTREMADURA;Group 0104 Septicaemia 038;Both sexes;434 EXTREMADURA;Group 0104 Septicaemia 038;Men;220 EXTREMADURA;Group 0104 Septicaemia 038;Women;214 EXTREMADURA;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Both sexes;48 EXTREMADURA;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Men;34 EXTREMADURA;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Women;14 EXTREMADURA;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Both sexes;660 EXTREMADURA;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Men;373 EXTREMADURA;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Women;287 EXTREMADURA;Group 0200 Neoplasms 140-239;Both sexes;10,285 EXTREMADURA;Group 0200 Neoplasms 140-239;Men;5,456 EXTREMADURA;Group 0200 Neoplasms 140-239;Women;4,829 EXTREMADURA;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Both sexes;1,011 EXTREMADURA;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Men;630 EXTREMADURA;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Women;381 EXTREMADURA;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Both sexes;858 EXTREMADURA;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Men;747 EXTREMADURA;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Women;111 EXTREMADURA;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Both sexes;468 EXTREMADURA;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Men;279 EXTREMADURA;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Women;189 EXTREMADURA;Group 0204 Malignant neoplasm of breast 174-175;Both sexes;831 EXTREMADURA;Group 0204 Malignant neoplasm of breast 174-175;Men;5 EXTREMADURA;Group 0204 Malignant neoplasm of breast 174-175;Women;826 EXTREMADURA;Group 0205 Malignant neoplasm of uterus 179-180, 182;Both sexes;170 EXTREMADURA;Group 0205 Malignant neoplasm of uterus 179-180, 182;Men;.. EXTREMADURA;Group 0205 Malignant neoplasm of uterus 179-180, 182;Women;170 EXTREMADURA;Group 0206 Malignant neoplasm of ovary 1830;Both sexes;106 EXTREMADURA;Group 0206 Malignant neoplasm of ovary 1830;Men;.. EXTREMADURA;Group 0206 Malignant neoplasm of ovary 1830;Women;106 EXTREMADURA;Group 0207 Malignant neoplasm of prostate 185;Both sexes;261 EXTREMADURA;Group 0207 Malignant neoplasm of prostate 185;Men;261 EXTREMADURA;Group 0207 Malignant neoplasm of prostate 185;Women;.. EXTREMADURA;Group 0208 Malignant neoplasm of bladder 188;Both sexes;688 EXTREMADURA;Group 0208 Malignant neoplasm of bladder 188;Men;606 EXTREMADURA;Group 0208 Malignant neoplasm of bladder 188;Women;82 EXTREMADURA;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Both sexes;2,984 EXTREMADURA;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Men;1,853 EXTREMADURA;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Women;1,131 EXTREMADURA;Group 0210 Carcinoma in situ 230-234;Both sexes;273 EXTREMADURA;Group 0210 Carcinoma in situ 230-234;Men;75 EXTREMADURA;Group 0210 Carcinoma in situ 230-234;Women;198 EXTREMADURA;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Both sexes;134 EXTREMADURA;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Men;89 EXTREMADURA;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Women;45 EXTREMADURA;Grupo 0212 Leiomyoma of uterus 218;Both sexes;622 EXTREMADURA;Grupo 0212 Leiomyoma of uterus 218;Men;.. EXTREMADURA;Grupo 0212 Leiomyoma of uterus 218;Women;622 EXTREMADURA;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Both sexes;1,879 EXTREMADURA;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Men;911 EXTREMADURA;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Women;968 EXTREMADURA;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Both sexes;1,094 EXTREMADURA;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Men;540 EXTREMADURA;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Women;554 EXTREMADURA;Group 0301 Anaemias 280-285;Both sexes;714 EXTREMADURA;Group 0301 Anaemias 280-285;Men;339 EXTREMADURA;Group 0301 Anaemias 280-285;Women;375 EXTREMADURA;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Both sexes;380 EXTREMADURA;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Men;201 EXTREMADURA;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Women;179 EXTREMADURA;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Both sexes;1,655 EXTREMADURA;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Men;723 EXTREMADURA;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Women;932 EXTREMADURA;Group 0401 Diabetes mellitus 249-250;Both sexes;639 EXTREMADURA;Group 0401 Diabetes mellitus 249-250;Men;361 EXTREMADURA;Group 0401 Diabetes mellitus 249-250;Women;278 EXTREMADURA;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Both sexes;1,016 EXTREMADURA;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Men;362 EXTREMADURA;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Women;654 EXTREMADURA;Group 0500 Mental disorders 290-319;Both sexes;3,229 EXTREMADURA;Group 0500 Mental disorders 290-319;Men;1,709 EXTREMADURA;Group 0500 Mental disorders 290-319;Women;1,520 EXTREMADURA;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Both sexes;43 EXTREMADURA;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Men;21 EXTREMADURA;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Women;22 EXTREMADURA;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Both sexes;221 EXTREMADURA;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Men;171 EXTREMADURA;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Women;50 EXTREMADURA;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Both sexes;92 EXTREMADURA;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Men;64 EXTREMADURA;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Women;28 EXTREMADURA;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Both sexes;854 EXTREMADURA;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Men;510 EXTREMADURA;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Women;344 EXTREMADURA;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Both sexes;785 EXTREMADURA;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Men;331 EXTREMADURA;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Women;454 EXTREMADURA;Group 0506 Other mental and behavioural disorders Rest of (290-319);Both sexes;1,234 EXTREMADURA;Group 0506 Other mental and behavioural disorders Rest of (290-319);Men;612 EXTREMADURA;Group 0506 Other mental and behavioural disorders Rest of (290-319);Women;622 EXTREMADURA;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Both sexes;2,559 EXTREMADURA;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Men;1,238 EXTREMADURA;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Women;1,321 EXTREMADURA;Group 0601 Alzheimer's disease 3310;Both sexes;33 EXTREMADURA;Group 0601 Alzheimer's disease 3310;Men;15 EXTREMADURA;Group 0601 Alzheimer's disease 3310;Women;18 EXTREMADURA;Group 0602 Multiple sclerosis 340;Both sexes;123 EXTREMADURA;Group 0602 Multiple sclerosis 340;Men;39 EXTREMADURA;Group 0602 Multiple sclerosis 340;Women;84 EXTREMADURA;Group 0603 Epilepsy 345;Both sexes;481 EXTREMADURA;Group 0603 Epilepsy 345;Men;255 EXTREMADURA;Group 0603 Epilepsy 345;Women;226 EXTREMADURA;Group 0604 Transient cerebral ischemia 435;Both sexes;613 EXTREMADURA;Group 0604 Transient cerebral ischemia 435;Men;322 EXTREMADURA;Group 0604 Transient cerebral ischemia 435;Women;291 EXTREMADURA;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Both sexes;1,309 EXTREMADURA;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Men;607 EXTREMADURA;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Women;702 EXTREMADURA;Grupo 0700 Diseases of the eye and adnexa 360-379;Both sexes;1,813 EXTREMADURA;Grupo 0700 Diseases of the eye and adnexa 360-379;Men;931 EXTREMADURA;Grupo 0700 Diseases of the eye and adnexa 360-379;Women;882 EXTREMADURA;Grupo 0701 Cataract 366;Both sexes;792 EXTREMADURA;Grupo 0701 Cataract 366;Men;367 EXTREMADURA;Grupo 0701 Cataract 366;Women;425 EXTREMADURA;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Both sexes;1,021 EXTREMADURA;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Men;564 EXTREMADURA;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Women;457 EXTREMADURA;Group 0800 Diseases of the ear and the mastoid 380-389;Both sexes;598 EXTREMADURA;Group 0800 Diseases of the ear and the mastoid 380-389;Men;279 EXTREMADURA;Group 0800 Diseases of the ear and the mastoid 380-389;Women;319 EXTREMADURA;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Both sexes;14,752 EXTREMADURA;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Men;8,265 EXTREMADURA;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Women;6,487 EXTREMADURA;Group 0901 Hypertensive disease 401-405;Both sexes;630 EXTREMADURA;Group 0901 Hypertensive disease 401-405;Men;250 EXTREMADURA;Group 0901 Hypertensive disease 401-405;Women;380 EXTREMADURA;Group 0902 Angina pectoris 4111, 413;Both sexes;852 EXTREMADURA;Group 0902 Angina pectoris 4111, 413;Men;520 EXTREMADURA;Group 0902 Angina pectoris 4111, 413;Women;332 EXTREMADURA;Group 0903 Acute myocardial infarction 410;Both sexes;1,473 EXTREMADURA;Group 0903 Acute myocardial infarction 410;Men;1,076 EXTREMADURA;Group 0903 Acute myocardial infarction 410;Women;397 EXTREMADURA;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Both sexes;1,052 EXTREMADURA;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Men;809 EXTREMADURA;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Women;243 EXTREMADURA;Group 0905 Diseases of the lungs circulation 415-417;Both sexes;558 EXTREMADURA;Group 0905 Diseases of the lungs circulation 415-417;Men;278 EXTREMADURA;Group 0905 Diseases of the lungs circulation 415-417;Women;280 EXTREMADURA;Group 0906 Heart conduction disorders and arrhytmias 426-427;Both sexes;2,049 EXTREMADURA;Group 0906 Heart conduction disorders and arrhytmias 426-427;Men;1,050 EXTREMADURA;Group 0906 Heart conduction disorders and arrhytmias 426-427;Women;999 EXTREMADURA;Grupo 0907 Heart failure 428;Both sexes;2,655 EXTREMADURA;Grupo 0907 Heart failure 428;Men;1,190 EXTREMADURA;Grupo 0907 Heart failure 428;Women;1,465 EXTREMADURA;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Both sexes;2,650 EXTREMADURA;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Men;1,408 EXTREMADURA;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Women;1,242 EXTREMADURA;Grupo 0909 Atherosclerosis 440;Both sexes;320 EXTREMADURA;Grupo 0909 Atherosclerosis 440;Men;248 EXTREMADURA;Grupo 0909 Atherosclerosis 440;Women;72 EXTREMADURA;Group 0910 Varicose veins of lower extremities 454;Both sexes;296 EXTREMADURA;Group 0910 Varicose veins of lower extremities 454;Men;119 EXTREMADURA;Group 0910 Varicose veins of lower extremities 454;Women;177 EXTREMADURA;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Both sexes;2,217 EXTREMADURA;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Men;1,317 EXTREMADURA;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Women;900 EXTREMADURA;Group 1000 Diseases of the respiratory system 0340, 460-519;Both sexes;13,645 EXTREMADURA;Group 1000 Diseases of the respiratory system 0340, 460-519;Men;8,083 EXTREMADURA;Group 1000 Diseases of the respiratory system 0340, 460-519;Women;5,562 EXTREMADURA;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Both sexes;521 EXTREMADURA;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Men;306 EXTREMADURA;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Women;215 EXTREMADURA;Group 1002 Pneumonia 480-486;Both sexes;2,419 EXTREMADURA;Group 1002 Pneumonia 480-486;Men;1,517 EXTREMADURA;Group 1002 Pneumonia 480-486;Women;902 EXTREMADURA;Group 1003 Acute bronchitis and bronchiolitis 466;Both sexes;1,005 EXTREMADURA;Group 1003 Acute bronchitis and bronchiolitis 466;Men;542 EXTREMADURA;Group 1003 Acute bronchitis and bronchiolitis 466;Women;463 EXTREMADURA;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Both sexes;935 EXTREMADURA;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Men;496 EXTREMADURA;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Women;439 EXTREMADURA;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Both sexes;1,116 EXTREMADURA;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Men;688 EXTREMADURA;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Women;428 EXTREMADURA;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Both sexes;1,449 EXTREMADURA;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Men;1,252 EXTREMADURA;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Women;197 EXTREMADURA;Group 1007 Asthma 4930-4931,4938-4939;Both sexes;312 EXTREMADURA;Group 1007 Asthma 4930-4931,4938-4939;Men;100 EXTREMADURA;Group 1007 Asthma 4930-4931,4938-4939;Women;212 EXTREMADURA;Group 1008 Other diseases of the respiratory system Resto of (460-519);Both sexes;5,888 EXTREMADURA;Group 1008 Other diseases of the respiratory system Resto of (460-519);Men;3,182 EXTREMADURA;Group 1008 Other diseases of the respiratory system Resto of (460-519);Women;2,706 EXTREMADURA;Group 1100 Diseases of the digestive system 520-579;Both sexes;14,004 EXTREMADURA;Group 1100 Diseases of the digestive system 520-579;Men;7,962 EXTREMADURA;Group 1100 Diseases of the digestive system 520-579;Women;6,042 EXTREMADURA;Group 1101 Disorders of the teeth and supporting structures 520-525;Both sexes;156 EXTREMADURA;Group 1101 Disorders of the teeth and supporting structures 520-525;Men;72 EXTREMADURA;Group 1101 Disorders of the teeth and supporting structures 520-525;Women;84 EXTREMADURA;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Both sexes;172 EXTREMADURA;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Men;94 EXTREMADURA;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Women;78 EXTREMADURA;Group 1103 Diseases of the esophagus 530;Both sexes;292 EXTREMADURA;Group 1103 Diseases of the esophagus 530;Men;178 EXTREMADURA;Group 1103 Diseases of the esophagus 530;Women;114 EXTREMADURA;Group 1104 Peptic ulcer 531-534;Both sexes;233 EXTREMADURA;Group 1104 Peptic ulcer 531-534;Men;155 EXTREMADURA;Group 1104 Peptic ulcer 531-534;Women;78 EXTREMADURA;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Both sexes;383 EXTREMADURA;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Men;190 EXTREMADURA;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Women;193 EXTREMADURA;Group 1106 Appendicitis 540-543;Both sexes;1,077 EXTREMADURA;Group 1106 Appendicitis 540-543;Men;592 EXTREMADURA;Group 1106 Appendicitis 540-543;Women;485 EXTREMADURA;Group 1107 Inguinal hernia 550;Both sexes;1,441 EXTREMADURA;Group 1107 Inguinal hernia 550;Men;1,278 EXTREMADURA;Group 1107 Inguinal hernia 550;Women;163 EXTREMADURA;Group 1108 Other abdominal hernia 551-553;Both sexes;1,116 EXTREMADURA;Group 1108 Other abdominal hernia 551-553;Men;557 EXTREMADURA;Group 1108 Other abdominal hernia 551-553;Women;559 EXTREMADURA;Group 1109 Crohn's disease and ulcerative colitis 555-556;Both sexes;228 EXTREMADURA;Group 1109 Crohn's disease and ulcerative colitis 555-556;Men;123 EXTREMADURA;Group 1109 Crohn's disease and ulcerative colitis 555-556;Women;105 EXTREMADURA;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Both sexes;999 EXTREMADURA;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Men;514 EXTREMADURA;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Women;485 EXTREMADURA;Group 1111 Intestinal obstruction without hernia 560;Both sexes;840 EXTREMADURA;Group 1111 Intestinal obstruction without hernia 560;Men;443 EXTREMADURA;Group 1111 Intestinal obstruction without hernia 560;Women;397 EXTREMADURA;Group 1112 Intestinal diverticulosis 562;Both sexes;382 EXTREMADURA;Group 1112 Intestinal diverticulosis 562;Men;214 EXTREMADURA;Group 1112 Intestinal diverticulosis 562;Women;168 EXTREMADURA;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Both sexes;996 EXTREMADURA;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Men;639 EXTREMADURA;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Women;357 EXTREMADURA;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Both sexes;457 EXTREMADURA;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Men;219 EXTREMADURA;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Women;238 EXTREMADURA;Group 1115 Alcoholic hepatitis 5710-5713;Both sexes;200 EXTREMADURA;Group 1115 Alcoholic hepatitis 5710-5713;Men;184 EXTREMADURA;Group 1115 Alcoholic hepatitis 5710-5713;Women;16 EXTREMADURA;Group 1116 Other diseases of the liver 570,5714-573;Both sexes;389 EXTREMADURA;Group 1116 Other diseases of the liver 570,5714-573;Men;235 EXTREMADURA;Group 1116 Other diseases of the liver 570,5714-573;Women;154 EXTREMADURA;Group 1117 Cholelithiasis 574;Both sexes;2,321 EXTREMADURA;Group 1117 Cholelithiasis 574;Men;1,027 EXTREMADURA;Group 1117 Cholelithiasis 574;Women;1,294 EXTREMADURA;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Both sexes;839 EXTREMADURA;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Men;458 EXTREMADURA;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Women;381 EXTREMADURA;Group 1119 Pancreatic diseases 577;Both sexes;810 EXTREMADURA;Group 1119 Pancreatic diseases 577;Men;440 EXTREMADURA;Group 1119 Pancreatic diseases 577;Women;370 EXTREMADURA;Group 1120 Other diseases of the digestive system Rest of (520-579);Both sexes;673 EXTREMADURA;Group 1120 Other diseases of the digestive system Rest of (520-579);Men;350 EXTREMADURA;Group 1120 Other diseases of the digestive system Rest of (520-579);Women;323 EXTREMADURA;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Both sexes;1,064 EXTREMADURA;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Men;589 EXTREMADURA;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Women;475 EXTREMADURA;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Both sexes;620 EXTREMADURA;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Men;381 EXTREMADURA;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Women;239 EXTREMADURA;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Both sexes;65 EXTREMADURA;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Men;29 EXTREMADURA;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Women;36 EXTREMADURA;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Both sexes;379 EXTREMADURA;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Men;179 EXTREMADURA;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Women;200 EXTREMADURA;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Both sexes;6,179 EXTREMADURA;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Men;2,806 EXTREMADURA;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Women;3,373 EXTREMADURA;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Both sexes;.. EXTREMADURA;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Men;.. EXTREMADURA;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Women;.. EXTREMADURA;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Both sexes;.. EXTREMADURA;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Men;.. EXTREMADURA;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Women;.. EXTREMADURA;Group 1303 Internal derangement of knee 717;Both sexes;595 EXTREMADURA;Group 1303 Internal derangement of knee 717;Men;420 EXTREMADURA;Group 1303 Internal derangement of knee 717;Women;175 EXTREMADURA;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Both sexes;2,359 EXTREMADURA;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Men;956 EXTREMADURA;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Women;1,403 EXTREMADURA;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Both sexes;142 EXTREMADURA;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Men;53 EXTREMADURA;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Women;89 EXTREMADURA;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Both sexes;335 EXTREMADURA;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Men;186 EXTREMADURA;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Women;149 EXTREMADURA;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Both sexes;508 EXTREMADURA;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Men;267 EXTREMADURA;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Women;241 EXTREMADURA;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Both sexes;206 EXTREMADURA;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Men;97 EXTREMADURA;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Women;109 EXTREMADURA;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Both sexes;739 EXTREMADURA;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Men;434 EXTREMADURA;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Women;305 EXTREMADURA;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Both sexes;1,295 EXTREMADURA;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Men;393 EXTREMADURA;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Women;902 EXTREMADURA;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Both sexes;7,144 EXTREMADURA;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Men;2,919 EXTREMADURA;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Women;4,225 EXTREMADURA;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Both sexes;553 EXTREMADURA;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Men;234 EXTREMADURA;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Women;319 EXTREMADURA;Group 1402 Renal failure 5836-5837, 584-586;Both sexes;721 EXTREMADURA;Group 1402 Renal failure 5836-5837, 584-586;Men;409 EXTREMADURA;Group 1402 Renal failure 5836-5837, 584-586;Women;312 EXTREMADURA;Group 1403 Urolithiasis 592, 594, 7880;Both sexes;683 EXTREMADURA;Group 1403 Urolithiasis 592, 594, 7880;Men;360 EXTREMADURA;Group 1403 Urolithiasis 592, 594, 7880;Women;323 EXTREMADURA;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Both sexes;1,512 EXTREMADURA;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Men;707 EXTREMADURA;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Women;805 EXTREMADURA;Group 1405 Prostatic hyperplasia 600;Both sexes;420 EXTREMADURA;Group 1405 Prostatic hyperplasia 600;Men;420 EXTREMADURA;Group 1405 Prostatic hyperplasia 600;Women;.. EXTREMADURA;Group 1406 Other diseases of the male genital organs 601-608;Both sexes;745 EXTREMADURA;Group 1406 Other diseases of the male genital organs 601-608;Men;745 EXTREMADURA;Group 1406 Other diseases of the male genital organs 601-608;Women;.. EXTREMADURA;Group 1407 Disorders of breast 610-612;Both sexes;381 EXTREMADURA;Group 1407 Disorders of breast 610-612;Men;30 EXTREMADURA;Group 1407 Disorders of breast 610-612;Women;351 EXTREMADURA;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Both sexes;236 EXTREMADURA;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Men;.. EXTREMADURA;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Women;236 EXTREMADURA;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Both sexes;309 EXTREMADURA;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Men;.. EXTREMADURA;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Women;309 EXTREMADURA;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Both sexes;1,584 EXTREMADURA;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Men;14 EXTREMADURA;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Women;1,570 EXTREMADURA;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Both sexes;11,613 EXTREMADURA;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Men;.. EXTREMADURA;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Women;11,613 EXTREMADURA;Group 1501 Legally induced abortion 635;Both sexes;4 EXTREMADURA;Group 1501 Legally induced abortion 635;Men;.. EXTREMADURA;Group 1501 Legally induced abortion 635;Women;4 EXTREMADURA;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Both sexes;1,265 EXTREMADURA;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Men;.. EXTREMADURA;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Women;1,265 EXTREMADURA;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Both sexes;5,979 EXTREMADURA;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Men;.. EXTREMADURA;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Women;5,979 EXTREMADURA;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Both sexes;2,485 EXTREMADURA;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Men;.. EXTREMADURA;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Women;2,485 EXTREMADURA;Group 1505 Single spontaneous delivery 650;Both sexes;568 EXTREMADURA;Group 1505 Single spontaneous delivery 650;Men;.. EXTREMADURA;Group 1505 Single spontaneous delivery 650;Women;568 EXTREMADURA;Group 1506 Other deliveries 6695-6697;Both sexes;547 EXTREMADURA;Group 1506 Other deliveries 6695-6697;Men;.. EXTREMADURA;Group 1506 Other deliveries 6695-6697;Women;547 EXTREMADURA;Group 1507 Complications related to the puerperium 670-676;Both sexes;84 EXTREMADURA;Group 1507 Complications related to the puerperium 670-676;Men;.. EXTREMADURA;Group 1507 Complications related to the puerperium 670-676;Women;84 EXTREMADURA;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Both sexes;681 EXTREMADURA;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Men;.. EXTREMADURA;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Women;681 EXTREMADURA;Group 1600 Some disorders originating in the perinatal period 760-779;Both sexes;1,592 EXTREMADURA;Group 1600 Some disorders originating in the perinatal period 760-779;Men;848 EXTREMADURA;Group 1600 Some disorders originating in the perinatal period 760-779;Women;744 EXTREMADURA;Group 1601 Disorders related with premature delivery and a low birth weight 765;Both sexes;268 EXTREMADURA;Group 1601 Disorders related with premature delivery and a low birth weight 765;Men;138 EXTREMADURA;Group 1601 Disorders related with premature delivery and a low birth weight 765;Women;130 EXTREMADURA;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Both sexes;1,324 EXTREMADURA;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Men;710 EXTREMADURA;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Women;614 EXTREMADURA;Grupo 1700 Congenital abnormalities 740-759;Both sexes;791 EXTREMADURA;Grupo 1700 Congenital abnormalities 740-759;Men;490 EXTREMADURA;Grupo 1700 Congenital abnormalities 740-759;Women;301 EXTREMADURA;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Both sexes;8,003 EXTREMADURA;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Men;4,347 EXTREMADURA;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Women;3,656 EXTREMADURA;Group 1801 Pain in throat and chest 7841, 7865;Both sexes;655 EXTREMADURA;Group 1801 Pain in throat and chest 7841, 7865;Men;391 EXTREMADURA;Group 1801 Pain in throat and chest 7841, 7865;Women;264 EXTREMADURA;Group 1802 Abdominal pain 7890;Both sexes;715 EXTREMADURA;Group 1802 Abdominal pain 7890;Men;314 EXTREMADURA;Group 1802 Abdominal pain 7890;Women;401 EXTREMADURA;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Both sexes;1,753 EXTREMADURA;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Men;855 EXTREMADURA;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Women;898 EXTREMADURA;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Both sexes;4,880 EXTREMADURA;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Men;2,787 EXTREMADURA;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Women;2,093 EXTREMADURA;Group 1900 Injuries and poisoning 800-999;Both sexes;7,994 EXTREMADURA;Group 1900 Injuries and poisoning 800-999;Men;3,959 EXTREMADURA;Group 1900 Injuries and poisoning 800-999;Women;4,035 EXTREMADURA;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Both sexes;391 EXTREMADURA;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Men;239 EXTREMADURA;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Women;152 EXTREMADURA;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Both sexes;227 EXTREMADURA;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Men;169 EXTREMADURA;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Women;58 EXTREMADURA;Group 1903 Radius and ulna fracture 813;Both sexes;448 EXTREMADURA;Group 1903 Radius and ulna fracture 813;Men;199 EXTREMADURA;Group 1903 Radius and ulna fracture 813;Women;249 EXTREMADURA;Group 1904 Femur fracture 820-821;Both sexes;1,539 EXTREMADURA;Group 1904 Femur fracture 820-821;Men;368 EXTREMADURA;Group 1904 Femur fracture 820-821;Women;1,171 EXTREMADURA;Group 1905 Leg fracture, including the ankle 823-824;Both sexes;647 EXTREMADURA;Group 1905 Leg fracture, including the ankle 823-824;Men;308 EXTREMADURA;Group 1905 Leg fracture, including the ankle 823-824;Women;339 EXTREMADURA;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Both sexes;2,082 EXTREMADURA;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Men;1,266 EXTREMADURA;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Women;816 EXTREMADURA;Group 1907 Burns 940-949;Both sexes;109 EXTREMADURA;Group 1907 Burns 940-949;Men;71 EXTREMADURA;Group 1907 Burns 940-949;Women;38 EXTREMADURA;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Both sexes;289 EXTREMADURA;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Men;150 EXTREMADURA;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Women;139 EXTREMADURA;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Both sexes;1,960 EXTREMADURA;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Men;1,019 EXTREMADURA;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Women;941 EXTREMADURA;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Both sexes;23 EXTREMADURA;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Men;19 EXTREMADURA;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Women;4 EXTREMADURA;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Both sexes;279 EXTREMADURA;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Men;151 EXTREMADURA;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Women;128 EXTREMADURA;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Both sexes;2,039 EXTREMADURA;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Men;1,119 EXTREMADURA;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Women;920 EXTREMADURA;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Both sexes;372 EXTREMADURA;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Men;254 EXTREMADURA;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Women;118 EXTREMADURA;Group 2102 Contraceptive management V25;Both sexes;75 EXTREMADURA;Group 2102 Contraceptive management V25;Men;2 EXTREMADURA;Group 2102 Contraceptive management V25;Women;73 EXTREMADURA;Group 2103 Living newborns by type of delivery V30-V39;Both sexes;.. EXTREMADURA;Group 2103 Living newborns by type of delivery V30-V39;Men;.. EXTREMADURA;Group 2103 Living newborns by type of delivery V30-V39;Women;.. EXTREMADURA;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Both sexes;663 EXTREMADURA;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Men;387 EXTREMADURA;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Women;276 EXTREMADURA;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Both sexes;929 EXTREMADURA;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Men;476 EXTREMADURA;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Women;453 Badajoz;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Both sexes;72,329 Badajoz;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Men;34,016 Badajoz;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Women;38,313 Badajoz;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Both sexes;1,172 Badajoz;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Men;643 Badajoz;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Women;529 Badajoz;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Both sexes;160 Badajoz;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Men;82 Badajoz;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Women;78 Badajoz;Group 0102 Imprecise intestinal infections 009;Both sexes;147 Badajoz;Group 0102 Imprecise intestinal infections 009;Men;83 Badajoz;Group 0102 Imprecise intestinal infections 009;Women;64 Badajoz;Group 0103 Tuberculosis 010-018, 137;Both sexes;43 Badajoz;Group 0103 Tuberculosis 010-018, 137;Men;29 Badajoz;Group 0103 Tuberculosis 010-018, 137;Women;14 Badajoz;Group 0104 Septicaemia 038;Both sexes;319 Badajoz;Group 0104 Septicaemia 038;Men;159 Badajoz;Group 0104 Septicaemia 038;Women;160 Badajoz;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Both sexes;38 Badajoz;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Men;26 Badajoz;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Women;12 Badajoz;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Both sexes;465 Badajoz;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Men;264 Badajoz;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Women;201 Badajoz;Group 0200 Neoplasms 140-239;Both sexes;6,313 Badajoz;Group 0200 Neoplasms 140-239;Men;3,370 Badajoz;Group 0200 Neoplasms 140-239;Women;2,943 Badajoz;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Both sexes;647 Badajoz;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Men;394 Badajoz;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Women;253 Badajoz;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Both sexes;519 Badajoz;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Men;457 Badajoz;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Women;62 Badajoz;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Both sexes;60 Badajoz;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Men;34 Badajoz;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Women;26 Badajoz;Group 0204 Malignant neoplasm of breast 174-175;Both sexes;485 Badajoz;Group 0204 Malignant neoplasm of breast 174-175;Men;4 Badajoz;Group 0204 Malignant neoplasm of breast 174-175;Women;481 Badajoz;Group 0205 Malignant neoplasm of uterus 179-180, 182;Both sexes;80 Badajoz;Group 0205 Malignant neoplasm of uterus 179-180, 182;Men;.. Badajoz;Group 0205 Malignant neoplasm of uterus 179-180, 182;Women;80 Badajoz;Group 0206 Malignant neoplasm of ovary 1830;Both sexes;86 Badajoz;Group 0206 Malignant neoplasm of ovary 1830;Men;.. Badajoz;Group 0206 Malignant neoplasm of ovary 1830;Women;86 Badajoz;Group 0207 Malignant neoplasm of prostate 185;Both sexes;161 Badajoz;Group 0207 Malignant neoplasm of prostate 185;Men;161 Badajoz;Group 0207 Malignant neoplasm of prostate 185;Women;.. Badajoz;Group 0208 Malignant neoplasm of bladder 188;Both sexes;416 Badajoz;Group 0208 Malignant neoplasm of bladder 188;Men;375 Badajoz;Group 0208 Malignant neoplasm of bladder 188;Women;41 Badajoz;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Both sexes;2,009 Badajoz;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Men;1,234 Badajoz;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Women;775 Badajoz;Group 0210 Carcinoma in situ 230-234;Both sexes;165 Badajoz;Group 0210 Carcinoma in situ 230-234;Men;48 Badajoz;Group 0210 Carcinoma in situ 230-234;Women;117 Badajoz;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Both sexes;83 Badajoz;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Men;57 Badajoz;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Women;26 Badajoz;Grupo 0212 Leiomyoma of uterus 218;Both sexes;390 Badajoz;Grupo 0212 Leiomyoma of uterus 218;Men;.. Badajoz;Grupo 0212 Leiomyoma of uterus 218;Women;390 Badajoz;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Both sexes;1,212 Badajoz;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Men;606 Badajoz;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Women;606 Badajoz;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Both sexes;734 Badajoz;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Men;362 Badajoz;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Women;372 Badajoz;Group 0301 Anaemias 280-285;Both sexes;514 Badajoz;Group 0301 Anaemias 280-285;Men;242 Badajoz;Group 0301 Anaemias 280-285;Women;272 Badajoz;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Both sexes;220 Badajoz;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Men;120 Badajoz;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Women;100 Badajoz;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Both sexes;1,040 Badajoz;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Men;455 Badajoz;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Women;585 Badajoz;Group 0401 Diabetes mellitus 249-250;Both sexes;419 Badajoz;Group 0401 Diabetes mellitus 249-250;Men;227 Badajoz;Group 0401 Diabetes mellitus 249-250;Women;192 Badajoz;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Both sexes;621 Badajoz;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Men;228 Badajoz;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Women;393 Badajoz;Group 0500 Mental disorders 290-319;Both sexes;1,637 Badajoz;Group 0500 Mental disorders 290-319;Men;834 Badajoz;Group 0500 Mental disorders 290-319;Women;803 Badajoz;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Both sexes;39 Badajoz;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Men;19 Badajoz;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Women;20 Badajoz;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Both sexes;111 Badajoz;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Men;81 Badajoz;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Women;30 Badajoz;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Both sexes;61 Badajoz;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Men;46 Badajoz;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Women;15 Badajoz;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Both sexes;308 Badajoz;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Men;181 Badajoz;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Women;127 Badajoz;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Both sexes;430 Badajoz;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Men;183 Badajoz;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Women;247 Badajoz;Group 0506 Other mental and behavioural disorders Rest of (290-319);Both sexes;688 Badajoz;Group 0506 Other mental and behavioural disorders Rest of (290-319);Men;324 Badajoz;Group 0506 Other mental and behavioural disorders Rest of (290-319);Women;364 Badajoz;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Both sexes;1,949 Badajoz;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Men;950 Badajoz;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Women;999 Badajoz;Group 0601 Alzheimer's disease 3310;Both sexes;29 Badajoz;Group 0601 Alzheimer's disease 3310;Men;12 Badajoz;Group 0601 Alzheimer's disease 3310;Women;17 Badajoz;Group 0602 Multiple sclerosis 340;Both sexes;102 Badajoz;Group 0602 Multiple sclerosis 340;Men;30 Badajoz;Group 0602 Multiple sclerosis 340;Women;72 Badajoz;Group 0603 Epilepsy 345;Both sexes;372 Badajoz;Group 0603 Epilepsy 345;Men;206 Badajoz;Group 0603 Epilepsy 345;Women;166 Badajoz;Group 0604 Transient cerebral ischemia 435;Both sexes;474 Badajoz;Group 0604 Transient cerebral ischemia 435;Men;242 Badajoz;Group 0604 Transient cerebral ischemia 435;Women;232 Badajoz;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Both sexes;972 Badajoz;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Men;460 Badajoz;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Women;512 Badajoz;Grupo 0700 Diseases of the eye and adnexa 360-379;Both sexes;748 Badajoz;Grupo 0700 Diseases of the eye and adnexa 360-379;Men;400 Badajoz;Grupo 0700 Diseases of the eye and adnexa 360-379;Women;348 Badajoz;Grupo 0701 Cataract 366;Both sexes;146 Badajoz;Grupo 0701 Cataract 366;Men;69 Badajoz;Grupo 0701 Cataract 366;Women;77 Badajoz;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Both sexes;602 Badajoz;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Men;331 Badajoz;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Women;271 Badajoz;Group 0800 Diseases of the ear and the mastoid 380-389;Both sexes;358 Badajoz;Group 0800 Diseases of the ear and the mastoid 380-389;Men;170 Badajoz;Group 0800 Diseases of the ear and the mastoid 380-389;Women;188 Badajoz;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Both sexes;9,826 Badajoz;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Men;5,409 Badajoz;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Women;4,417 Badajoz;Group 0901 Hypertensive disease 401-405;Both sexes;458 Badajoz;Group 0901 Hypertensive disease 401-405;Men;184 Badajoz;Group 0901 Hypertensive disease 401-405;Women;274 Badajoz;Group 0902 Angina pectoris 4111, 413;Both sexes;617 Badajoz;Group 0902 Angina pectoris 4111, 413;Men;388 Badajoz;Group 0902 Angina pectoris 4111, 413;Women;229 Badajoz;Group 0903 Acute myocardial infarction 410;Both sexes;820 Badajoz;Group 0903 Acute myocardial infarction 410;Men;594 Badajoz;Group 0903 Acute myocardial infarction 410;Women;226 Badajoz;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Both sexes;629 Badajoz;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Men;477 Badajoz;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Women;152 Badajoz;Group 0905 Diseases of the lungs circulation 415-417;Both sexes;366 Badajoz;Group 0905 Diseases of the lungs circulation 415-417;Men;188 Badajoz;Group 0905 Diseases of the lungs circulation 415-417;Women;178 Badajoz;Group 0906 Heart conduction disorders and arrhytmias 426-427;Both sexes;1,520 Badajoz;Group 0906 Heart conduction disorders and arrhytmias 426-427;Men;782 Badajoz;Group 0906 Heart conduction disorders and arrhytmias 426-427;Women;738 Badajoz;Grupo 0907 Heart failure 428;Both sexes;1,910 Badajoz;Grupo 0907 Heart failure 428;Men;854 Badajoz;Grupo 0907 Heart failure 428;Women;1,056 Badajoz;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Both sexes;1,731 Badajoz;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Men;893 Badajoz;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Women;838 Badajoz;Grupo 0909 Atherosclerosis 440;Both sexes;135 Badajoz;Grupo 0909 Atherosclerosis 440;Men;101 Badajoz;Grupo 0909 Atherosclerosis 440;Women;34 Badajoz;Group 0910 Varicose veins of lower extremities 454;Both sexes;188 Badajoz;Group 0910 Varicose veins of lower extremities 454;Men;77 Badajoz;Group 0910 Varicose veins of lower extremities 454;Women;111 Badajoz;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Both sexes;1,452 Badajoz;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Men;871 Badajoz;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Women;581 Badajoz;Group 1000 Diseases of the respiratory system 0340, 460-519;Both sexes;9,094 Badajoz;Group 1000 Diseases of the respiratory system 0340, 460-519;Men;5,326 Badajoz;Group 1000 Diseases of the respiratory system 0340, 460-519;Women;3,768 Badajoz;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Both sexes;316 Badajoz;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Men;194 Badajoz;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Women;122 Badajoz;Group 1002 Pneumonia 480-486;Both sexes;1,490 Badajoz;Group 1002 Pneumonia 480-486;Men;927 Badajoz;Group 1002 Pneumonia 480-486;Women;563 Badajoz;Group 1003 Acute bronchitis and bronchiolitis 466;Both sexes;608 Badajoz;Group 1003 Acute bronchitis and bronchiolitis 466;Men;314 Badajoz;Group 1003 Acute bronchitis and bronchiolitis 466;Women;294 Badajoz;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Both sexes;643 Badajoz;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Men;334 Badajoz;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Women;309 Badajoz;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Both sexes;687 Badajoz;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Men;420 Badajoz;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Women;267 Badajoz;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Both sexes;979 Badajoz;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Men;837 Badajoz;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Women;142 Badajoz;Group 1007 Asthma 4930-4931,4938-4939;Both sexes;211 Badajoz;Group 1007 Asthma 4930-4931,4938-4939;Men;64 Badajoz;Group 1007 Asthma 4930-4931,4938-4939;Women;147 Badajoz;Group 1008 Other diseases of the respiratory system Resto of (460-519);Both sexes;4,160 Badajoz;Group 1008 Other diseases of the respiratory system Resto of (460-519);Men;2,236 Badajoz;Group 1008 Other diseases of the respiratory system Resto of (460-519);Women;1,924 Badajoz;Group 1100 Diseases of the digestive system 520-579;Both sexes;8,833 Badajoz;Group 1100 Diseases of the digestive system 520-579;Men;4,961 Badajoz;Group 1100 Diseases of the digestive system 520-579;Women;3,872 Badajoz;Group 1101 Disorders of the teeth and supporting structures 520-525;Both sexes;136 Badajoz;Group 1101 Disorders of the teeth and supporting structures 520-525;Men;60 Badajoz;Group 1101 Disorders of the teeth and supporting structures 520-525;Women;76 Badajoz;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Both sexes;129 Badajoz;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Men;73 Badajoz;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Women;56 Badajoz;Group 1103 Diseases of the esophagus 530;Both sexes;191 Badajoz;Group 1103 Diseases of the esophagus 530;Men;111 Badajoz;Group 1103 Diseases of the esophagus 530;Women;80 Badajoz;Group 1104 Peptic ulcer 531-534;Both sexes;158 Badajoz;Group 1104 Peptic ulcer 531-534;Men;111 Badajoz;Group 1104 Peptic ulcer 531-534;Women;47 Badajoz;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Both sexes;284 Badajoz;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Men;141 Badajoz;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Women;143 Badajoz;Group 1106 Appendicitis 540-543;Both sexes;764 Badajoz;Group 1106 Appendicitis 540-543;Men;403 Badajoz;Group 1106 Appendicitis 540-543;Women;361 Badajoz;Group 1107 Inguinal hernia 550;Both sexes;709 Badajoz;Group 1107 Inguinal hernia 550;Men;625 Badajoz;Group 1107 Inguinal hernia 550;Women;84 Badajoz;Group 1108 Other abdominal hernia 551-553;Both sexes;640 Badajoz;Group 1108 Other abdominal hernia 551-553;Men;306 Badajoz;Group 1108 Other abdominal hernia 551-553;Women;334 Badajoz;Group 1109 Crohn's disease and ulcerative colitis 555-556;Both sexes;174 Badajoz;Group 1109 Crohn's disease and ulcerative colitis 555-556;Men;94 Badajoz;Group 1109 Crohn's disease and ulcerative colitis 555-556;Women;80 Badajoz;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Both sexes;663 Badajoz;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Men;327 Badajoz;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Women;336 Badajoz;Group 1111 Intestinal obstruction without hernia 560;Both sexes;555 Badajoz;Group 1111 Intestinal obstruction without hernia 560;Men;299 Badajoz;Group 1111 Intestinal obstruction without hernia 560;Women;256 Badajoz;Group 1112 Intestinal diverticulosis 562;Both sexes;255 Badajoz;Group 1112 Intestinal diverticulosis 562;Men;142 Badajoz;Group 1112 Intestinal diverticulosis 562;Women;113 Badajoz;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Both sexes;604 Badajoz;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Men;389 Badajoz;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Women;215 Badajoz;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Both sexes;313 Badajoz;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Men;145 Badajoz;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Women;168 Badajoz;Group 1115 Alcoholic hepatitis 5710-5713;Both sexes;167 Badajoz;Group 1115 Alcoholic hepatitis 5710-5713;Men;153 Badajoz;Group 1115 Alcoholic hepatitis 5710-5713;Women;14 Badajoz;Group 1116 Other diseases of the liver 570,5714-573;Both sexes;250 Badajoz;Group 1116 Other diseases of the liver 570,5714-573;Men;151 Badajoz;Group 1116 Other diseases of the liver 570,5714-573;Women;99 Badajoz;Group 1117 Cholelithiasis 574;Both sexes;1,380 Badajoz;Group 1117 Cholelithiasis 574;Men;620 Badajoz;Group 1117 Cholelithiasis 574;Women;760 Badajoz;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Both sexes;525 Badajoz;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Men;296 Badajoz;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Women;229 Badajoz;Group 1119 Pancreatic diseases 577;Both sexes;501 Badajoz;Group 1119 Pancreatic diseases 577;Men;291 Badajoz;Group 1119 Pancreatic diseases 577;Women;210 Badajoz;Group 1120 Other diseases of the digestive system Rest of (520-579);Both sexes;435 Badajoz;Group 1120 Other diseases of the digestive system Rest of (520-579);Men;224 Badajoz;Group 1120 Other diseases of the digestive system Rest of (520-579);Women;211 Badajoz;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Both sexes;640 Badajoz;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Men;343 Badajoz;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Women;297 Badajoz;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Both sexes;350 Badajoz;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Men;207 Badajoz;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Women;143 Badajoz;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Both sexes;47 Badajoz;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Men;19 Badajoz;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Women;28 Badajoz;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Both sexes;243 Badajoz;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Men;117 Badajoz;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Women;126 Badajoz;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Both sexes;4,204 Badajoz;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Men;1,948 Badajoz;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Women;2,256 Badajoz;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Both sexes;.. Badajoz;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Men;.. Badajoz;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Women;.. Badajoz;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Both sexes;.. Badajoz;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Men;.. Badajoz;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Women;.. Badajoz;Group 1303 Internal derangement of knee 717;Both sexes;408 Badajoz;Group 1303 Internal derangement of knee 717;Men;297 Badajoz;Group 1303 Internal derangement of knee 717;Women;111 Badajoz;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Both sexes;1,527 Badajoz;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Men;610 Badajoz;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Women;917 Badajoz;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Both sexes;115 Badajoz;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Men;45 Badajoz;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Women;70 Badajoz;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Both sexes;286 Badajoz;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Men;161 Badajoz;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Women;125 Badajoz;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Both sexes;437 Badajoz;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Men;233 Badajoz;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Women;204 Badajoz;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Both sexes;107 Badajoz;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Men;53 Badajoz;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Women;54 Badajoz;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Both sexes;534 Badajoz;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Men;318 Badajoz;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Women;216 Badajoz;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Both sexes;790 Badajoz;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Men;231 Badajoz;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Women;559 Badajoz;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Both sexes;4,447 Badajoz;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Men;1,816 Badajoz;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Women;2,631 Badajoz;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Both sexes;413 Badajoz;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Men;179 Badajoz;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Women;234 Badajoz;Group 1402 Renal failure 5836-5837, 584-586;Both sexes;477 Badajoz;Group 1402 Renal failure 5836-5837, 584-586;Men;262 Badajoz;Group 1402 Renal failure 5836-5837, 584-586;Women;215 Badajoz;Group 1403 Urolithiasis 592, 594, 7880;Both sexes;449 Badajoz;Group 1403 Urolithiasis 592, 594, 7880;Men;236 Badajoz;Group 1403 Urolithiasis 592, 594, 7880;Women;213 Badajoz;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Both sexes;964 Badajoz;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Men;450 Badajoz;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Women;514 Badajoz;Group 1405 Prostatic hyperplasia 600;Both sexes;233 Badajoz;Group 1405 Prostatic hyperplasia 600;Men;233 Badajoz;Group 1405 Prostatic hyperplasia 600;Women;.. Badajoz;Group 1406 Other diseases of the male genital organs 601-608;Both sexes;421 Badajoz;Group 1406 Other diseases of the male genital organs 601-608;Men;421 Badajoz;Group 1406 Other diseases of the male genital organs 601-608;Women;.. Badajoz;Group 1407 Disorders of breast 610-612;Both sexes;240 Badajoz;Group 1407 Disorders of breast 610-612;Men;24 Badajoz;Group 1407 Disorders of breast 610-612;Women;216 Badajoz;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Both sexes;153 Badajoz;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Men;.. Badajoz;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Women;153 Badajoz;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Both sexes;208 Badajoz;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Men;.. Badajoz;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Women;208 Badajoz;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Both sexes;889 Badajoz;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Men;11 Badajoz;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Women;878 Badajoz;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Both sexes;8,114 Badajoz;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Men;.. Badajoz;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Women;8,114 Badajoz;Group 1501 Legally induced abortion 635;Both sexes;3 Badajoz;Group 1501 Legally induced abortion 635;Men;.. Badajoz;Group 1501 Legally induced abortion 635;Women;3 Badajoz;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Both sexes;862 Badajoz;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Men;.. Badajoz;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Women;862 Badajoz;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Both sexes;4,278 Badajoz;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Men;.. Badajoz;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Women;4,278 Badajoz;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Both sexes;1,681 Badajoz;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Men;.. Badajoz;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Women;1,681 Badajoz;Group 1505 Single spontaneous delivery 650;Both sexes;354 Badajoz;Group 1505 Single spontaneous delivery 650;Men;.. Badajoz;Group 1505 Single spontaneous delivery 650;Women;354 Badajoz;Group 1506 Other deliveries 6695-6697;Both sexes;448 Badajoz;Group 1506 Other deliveries 6695-6697;Men;.. Badajoz;Group 1506 Other deliveries 6695-6697;Women;448 Badajoz;Group 1507 Complications related to the puerperium 670-676;Both sexes;62 Badajoz;Group 1507 Complications related to the puerperium 670-676;Men;.. Badajoz;Group 1507 Complications related to the puerperium 670-676;Women;62 Badajoz;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Both sexes;426 Badajoz;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Men;.. Badajoz;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Women;426 Badajoz;Group 1600 Some disorders originating in the perinatal period 760-779;Both sexes;738 Badajoz;Group 1600 Some disorders originating in the perinatal period 760-779;Men;385 Badajoz;Group 1600 Some disorders originating in the perinatal period 760-779;Women;353 Badajoz;Group 1601 Disorders related with premature delivery and a low birth weight 765;Both sexes;126 Badajoz;Group 1601 Disorders related with premature delivery and a low birth weight 765;Men;65 Badajoz;Group 1601 Disorders related with premature delivery and a low birth weight 765;Women;61 Badajoz;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Both sexes;612 Badajoz;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Men;320 Badajoz;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Women;292 Badajoz;Grupo 1700 Congenital abnormalities 740-759;Both sexes;582 Badajoz;Grupo 1700 Congenital abnormalities 740-759;Men;378 Badajoz;Grupo 1700 Congenital abnormalities 740-759;Women;204 Badajoz;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Both sexes;5,708 Badajoz;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Men;3,054 Badajoz;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Women;2,654 Badajoz;Group 1801 Pain in throat and chest 7841, 7865;Both sexes;437 Badajoz;Group 1801 Pain in throat and chest 7841, 7865;Men;248 Badajoz;Group 1801 Pain in throat and chest 7841, 7865;Women;189 Badajoz;Group 1802 Abdominal pain 7890;Both sexes;460 Badajoz;Group 1802 Abdominal pain 7890;Men;202 Badajoz;Group 1802 Abdominal pain 7890;Women;258 Badajoz;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Both sexes;1,292 Badajoz;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Men;618 Badajoz;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Women;674 Badajoz;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Both sexes;3,519 Badajoz;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Men;1,986 Badajoz;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Women;1,533 Badajoz;Group 1900 Injuries and poisoning 800-999;Both sexes;4,977 Badajoz;Group 1900 Injuries and poisoning 800-999;Men;2,522 Badajoz;Group 1900 Injuries and poisoning 800-999;Women;2,455 Badajoz;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Both sexes;257 Badajoz;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Men;165 Badajoz;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Women;92 Badajoz;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Both sexes;150 Badajoz;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Men;118 Badajoz;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Women;32 Badajoz;Group 1903 Radius and ulna fracture 813;Both sexes;258 Badajoz;Group 1903 Radius and ulna fracture 813;Men;120 Badajoz;Group 1903 Radius and ulna fracture 813;Women;138 Badajoz;Group 1904 Femur fracture 820-821;Both sexes;891 Badajoz;Group 1904 Femur fracture 820-821;Men;211 Badajoz;Group 1904 Femur fracture 820-821;Women;680 Badajoz;Group 1905 Leg fracture, including the ankle 823-824;Both sexes;396 Badajoz;Group 1905 Leg fracture, including the ankle 823-824;Men;187 Badajoz;Group 1905 Leg fracture, including the ankle 823-824;Women;209 Badajoz;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Both sexes;1,277 Badajoz;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Men;782 Badajoz;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Women;495 Badajoz;Group 1907 Burns 940-949;Both sexes;12 Badajoz;Group 1907 Burns 940-949;Men;10 Badajoz;Group 1907 Burns 940-949;Women;2 Badajoz;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Both sexes;212 Badajoz;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Men;113 Badajoz;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Women;99 Badajoz;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Both sexes;1,321 Badajoz;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Men;696 Badajoz;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Women;625 Badajoz;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Both sexes;11 Badajoz;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Men;9 Badajoz;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Women;2 Badajoz;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Both sexes;192 Badajoz;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Men;111 Badajoz;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Women;81 Badajoz;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Both sexes;1,215 Badajoz;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Men;690 Badajoz;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Women;525 Badajoz;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Both sexes;357 Badajoz;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Men;246 Badajoz;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Women;111 Badajoz;Group 2102 Contraceptive management V25;Both sexes;42 Badajoz;Group 2102 Contraceptive management V25;Men;2 Badajoz;Group 2102 Contraceptive management V25;Women;40 Badajoz;Group 2103 Living newborns by type of delivery V30-V39;Both sexes;.. Badajoz;Group 2103 Living newborns by type of delivery V30-V39;Men;.. Badajoz;Group 2103 Living newborns by type of delivery V30-V39;Women;.. Badajoz;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Both sexes;313 Badajoz;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Men;180 Badajoz;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Women;133 Badajoz;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Both sexes;503 Badajoz;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Men;262 Badajoz;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Women;241 Cßceres;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Both sexes;39,485 Cßceres;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Men;19,210 Cßceres;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Women;20,275 Cßceres;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Both sexes;589 Cßceres;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Men;320 Cßceres;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Women;269 Cßceres;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Both sexes;158 Cßceres;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Men;81 Cßceres;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Women;77 Cßceres;Group 0102 Imprecise intestinal infections 009;Both sexes;83 Cßceres;Group 0102 Imprecise intestinal infections 009;Men;46 Cßceres;Group 0102 Imprecise intestinal infections 009;Women;37 Cßceres;Group 0103 Tuberculosis 010-018, 137;Both sexes;28 Cßceres;Group 0103 Tuberculosis 010-018, 137;Men;15 Cßceres;Group 0103 Tuberculosis 010-018, 137;Women;13 Cßceres;Group 0104 Septicaemia 038;Both sexes;115 Cßceres;Group 0104 Septicaemia 038;Men;61 Cßceres;Group 0104 Septicaemia 038;Women;54 Cßceres;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Both sexes;10 Cßceres;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Men;8 Cßceres;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Women;2 Cßceres;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Both sexes;195 Cßceres;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Men;109 Cßceres;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Women;86 Cßceres;Group 0200 Neoplasms 140-239;Both sexes;3,972 Cßceres;Group 0200 Neoplasms 140-239;Men;2,086 Cßceres;Group 0200 Neoplasms 140-239;Women;1,886 Cßceres;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Both sexes;364 Cßceres;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Men;236 Cßceres;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Women;128 Cßceres;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Both sexes;339 Cßceres;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Men;290 Cßceres;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Women;49 Cßceres;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Both sexes;408 Cßceres;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Men;245 Cßceres;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Women;163 Cßceres;Group 0204 Malignant neoplasm of breast 174-175;Both sexes;346 Cßceres;Group 0204 Malignant neoplasm of breast 174-175;Men;1 Cßceres;Group 0204 Malignant neoplasm of breast 174-175;Women;345 Cßceres;Group 0205 Malignant neoplasm of uterus 179-180, 182;Both sexes;90 Cßceres;Group 0205 Malignant neoplasm of uterus 179-180, 182;Men;.. Cßceres;Group 0205 Malignant neoplasm of uterus 179-180, 182;Women;90 Cßceres;Group 0206 Malignant neoplasm of ovary 1830;Both sexes;20 Cßceres;Group 0206 Malignant neoplasm of ovary 1830;Men;.. Cßceres;Group 0206 Malignant neoplasm of ovary 1830;Women;20 Cßceres;Group 0207 Malignant neoplasm of prostate 185;Both sexes;100 Cßceres;Group 0207 Malignant neoplasm of prostate 185;Men;100 Cßceres;Group 0207 Malignant neoplasm of prostate 185;Women;.. Cßceres;Group 0208 Malignant neoplasm of bladder 188;Both sexes;272 Cßceres;Group 0208 Malignant neoplasm of bladder 188;Men;231 Cßceres;Group 0208 Malignant neoplasm of bladder 188;Women;41 Cßceres;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Both sexes;975 Cßceres;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Men;619 Cßceres;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Women;356 Cßceres;Group 0210 Carcinoma in situ 230-234;Both sexes;108 Cßceres;Group 0210 Carcinoma in situ 230-234;Men;27 Cßceres;Group 0210 Carcinoma in situ 230-234;Women;81 Cßceres;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Both sexes;51 Cßceres;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Men;32 Cßceres;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Women;19 Cßceres;Grupo 0212 Leiomyoma of uterus 218;Both sexes;232 Cßceres;Grupo 0212 Leiomyoma of uterus 218;Men;.. Cßceres;Grupo 0212 Leiomyoma of uterus 218;Women;232 Cßceres;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Both sexes;667 Cßceres;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Men;305 Cßceres;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Women;362 Cßceres;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Both sexes;360 Cßceres;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Men;178 Cßceres;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Women;182 Cßceres;Group 0301 Anaemias 280-285;Both sexes;200 Cßceres;Group 0301 Anaemias 280-285;Men;97 Cßceres;Group 0301 Anaemias 280-285;Women;103 Cßceres;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Both sexes;160 Cßceres;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Men;81 Cßceres;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Women;79 Cßceres;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Both sexes;615 Cßceres;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Men;268 Cßceres;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Women;347 Cßceres;Group 0401 Diabetes mellitus 249-250;Both sexes;220 Cßceres;Group 0401 Diabetes mellitus 249-250;Men;134 Cßceres;Group 0401 Diabetes mellitus 249-250;Women;86 Cßceres;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Both sexes;395 Cßceres;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Men;134 Cßceres;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Women;261 Cßceres;Group 0500 Mental disorders 290-319;Both sexes;1,592 Cßceres;Group 0500 Mental disorders 290-319;Men;875 Cßceres;Group 0500 Mental disorders 290-319;Women;717 Cßceres;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Both sexes;4 Cßceres;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Men;2 Cßceres;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Women;2 Cßceres;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Both sexes;110 Cßceres;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Men;90 Cßceres;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Women;20 Cßceres;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Both sexes;31 Cßceres;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Men;18 Cßceres;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Women;13 Cßceres;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Both sexes;546 Cßceres;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Men;329 Cßceres;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Women;217 Cßceres;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Both sexes;355 Cßceres;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Men;148 Cßceres;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Women;207 Cßceres;Group 0506 Other mental and behavioural disorders Rest of (290-319);Both sexes;546 Cßceres;Group 0506 Other mental and behavioural disorders Rest of (290-319);Men;288 Cßceres;Group 0506 Other mental and behavioural disorders Rest of (290-319);Women;258 Cßceres;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Both sexes;610 Cßceres;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Men;288 Cßceres;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Women;322 Cßceres;Group 0601 Alzheimer's disease 3310;Both sexes;4 Cßceres;Group 0601 Alzheimer's disease 3310;Men;3 Cßceres;Group 0601 Alzheimer's disease 3310;Women;1 Cßceres;Group 0602 Multiple sclerosis 340;Both sexes;21 Cßceres;Group 0602 Multiple sclerosis 340;Men;9 Cßceres;Group 0602 Multiple sclerosis 340;Women;12 Cßceres;Group 0603 Epilepsy 345;Both sexes;109 Cßceres;Group 0603 Epilepsy 345;Men;49 Cßceres;Group 0603 Epilepsy 345;Women;60 Cßceres;Group 0604 Transient cerebral ischemia 435;Both sexes;139 Cßceres;Group 0604 Transient cerebral ischemia 435;Men;80 Cßceres;Group 0604 Transient cerebral ischemia 435;Women;59 Cßceres;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Both sexes;337 Cßceres;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Men;147 Cßceres;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Women;190 Cßceres;Grupo 0700 Diseases of the eye and adnexa 360-379;Both sexes;1,065 Cßceres;Grupo 0700 Diseases of the eye and adnexa 360-379;Men;531 Cßceres;Grupo 0700 Diseases of the eye and adnexa 360-379;Women;534 Cßceres;Grupo 0701 Cataract 366;Both sexes;646 Cßceres;Grupo 0701 Cataract 366;Men;298 Cßceres;Grupo 0701 Cataract 366;Women;348 Cßceres;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Both sexes;419 Cßceres;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Men;233 Cßceres;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Women;186 Cßceres;Group 0800 Diseases of the ear and the mastoid 380-389;Both sexes;240 Cßceres;Group 0800 Diseases of the ear and the mastoid 380-389;Men;109 Cßceres;Group 0800 Diseases of the ear and the mastoid 380-389;Women;131 Cßceres;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Both sexes;4,926 Cßceres;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Men;2,856 Cßceres;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Women;2,070 Cßceres;Group 0901 Hypertensive disease 401-405;Both sexes;172 Cßceres;Group 0901 Hypertensive disease 401-405;Men;66 Cßceres;Group 0901 Hypertensive disease 401-405;Women;106 Cßceres;Group 0902 Angina pectoris 4111, 413;Both sexes;235 Cßceres;Group 0902 Angina pectoris 4111, 413;Men;132 Cßceres;Group 0902 Angina pectoris 4111, 413;Women;103 Cßceres;Group 0903 Acute myocardial infarction 410;Both sexes;653 Cßceres;Group 0903 Acute myocardial infarction 410;Men;482 Cßceres;Group 0903 Acute myocardial infarction 410;Women;171 Cßceres;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Both sexes;423 Cßceres;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Men;332 Cßceres;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Women;91 Cßceres;Group 0905 Diseases of the lungs circulation 415-417;Both sexes;192 Cßceres;Group 0905 Diseases of the lungs circulation 415-417;Men;90 Cßceres;Group 0905 Diseases of the lungs circulation 415-417;Women;102 Cßceres;Group 0906 Heart conduction disorders and arrhytmias 426-427;Both sexes;529 Cßceres;Group 0906 Heart conduction disorders and arrhytmias 426-427;Men;268 Cßceres;Group 0906 Heart conduction disorders and arrhytmias 426-427;Women;261 Cßceres;Grupo 0907 Heart failure 428;Both sexes;745 Cßceres;Grupo 0907 Heart failure 428;Men;336 Cßceres;Grupo 0907 Heart failure 428;Women;409 Cßceres;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Both sexes;919 Cßceres;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Men;515 Cßceres;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Women;404 Cßceres;Grupo 0909 Atherosclerosis 440;Both sexes;185 Cßceres;Grupo 0909 Atherosclerosis 440;Men;147 Cßceres;Grupo 0909 Atherosclerosis 440;Women;38 Cßceres;Group 0910 Varicose veins of lower extremities 454;Both sexes;108 Cßceres;Group 0910 Varicose veins of lower extremities 454;Men;42 Cßceres;Group 0910 Varicose veins of lower extremities 454;Women;66 Cßceres;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Both sexes;765 Cßceres;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Men;446 Cßceres;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Women;319 Cßceres;Group 1000 Diseases of the respiratory system 0340, 460-519;Both sexes;4,551 Cßceres;Group 1000 Diseases of the respiratory system 0340, 460-519;Men;2,757 Cßceres;Group 1000 Diseases of the respiratory system 0340, 460-519;Women;1,794 Cßceres;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Both sexes;205 Cßceres;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Men;112 Cßceres;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Women;93 Cßceres;Group 1002 Pneumonia 480-486;Both sexes;929 Cßceres;Group 1002 Pneumonia 480-486;Men;590 Cßceres;Group 1002 Pneumonia 480-486;Women;339 Cßceres;Group 1003 Acute bronchitis and bronchiolitis 466;Both sexes;397 Cßceres;Group 1003 Acute bronchitis and bronchiolitis 466;Men;228 Cßceres;Group 1003 Acute bronchitis and bronchiolitis 466;Women;169 Cßceres;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Both sexes;292 Cßceres;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Men;162 Cßceres;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Women;130 Cßceres;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Both sexes;429 Cßceres;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Men;268 Cßceres;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Women;161 Cßceres;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Both sexes;470 Cßceres;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Men;415 Cßceres;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Women;55 Cßceres;Group 1007 Asthma 4930-4931,4938-4939;Both sexes;101 Cßceres;Group 1007 Asthma 4930-4931,4938-4939;Men;36 Cßceres;Group 1007 Asthma 4930-4931,4938-4939;Women;65 Cßceres;Group 1008 Other diseases of the respiratory system Resto of (460-519);Both sexes;1,728 Cßceres;Group 1008 Other diseases of the respiratory system Resto of (460-519);Men;946 Cßceres;Group 1008 Other diseases of the respiratory system Resto of (460-519);Women;782 Cßceres;Group 1100 Diseases of the digestive system 520-579;Both sexes;5,171 Cßceres;Group 1100 Diseases of the digestive system 520-579;Men;3,001 Cßceres;Group 1100 Diseases of the digestive system 520-579;Women;2,170 Cßceres;Group 1101 Disorders of the teeth and supporting structures 520-525;Both sexes;20 Cßceres;Group 1101 Disorders of the teeth and supporting structures 520-525;Men;12 Cßceres;Group 1101 Disorders of the teeth and supporting structures 520-525;Women;8 Cßceres;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Both sexes;43 Cßceres;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Men;21 Cßceres;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Women;22 Cßceres;Group 1103 Diseases of the esophagus 530;Both sexes;101 Cßceres;Group 1103 Diseases of the esophagus 530;Men;67 Cßceres;Group 1103 Diseases of the esophagus 530;Women;34 Cßceres;Group 1104 Peptic ulcer 531-534;Both sexes;75 Cßceres;Group 1104 Peptic ulcer 531-534;Men;44 Cßceres;Group 1104 Peptic ulcer 531-534;Women;31 Cßceres;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Both sexes;99 Cßceres;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Men;49 Cßceres;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Women;50 Cßceres;Group 1106 Appendicitis 540-543;Both sexes;313 Cßceres;Group 1106 Appendicitis 540-543;Men;189 Cßceres;Group 1106 Appendicitis 540-543;Women;124 Cßceres;Group 1107 Inguinal hernia 550;Both sexes;732 Cßceres;Group 1107 Inguinal hernia 550;Men;653 Cßceres;Group 1107 Inguinal hernia 550;Women;79 Cßceres;Group 1108 Other abdominal hernia 551-553;Both sexes;476 Cßceres;Group 1108 Other abdominal hernia 551-553;Men;251 Cßceres;Group 1108 Other abdominal hernia 551-553;Women;225 Cßceres;Group 1109 Crohn's disease and ulcerative colitis 555-556;Both sexes;54 Cßceres;Group 1109 Crohn's disease and ulcerative colitis 555-556;Men;29 Cßceres;Group 1109 Crohn's disease and ulcerative colitis 555-556;Women;25 Cßceres;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Both sexes;336 Cßceres;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Men;187 Cßceres;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Women;149 Cßceres;Group 1111 Intestinal obstruction without hernia 560;Both sexes;285 Cßceres;Group 1111 Intestinal obstruction without hernia 560;Men;144 Cßceres;Group 1111 Intestinal obstruction without hernia 560;Women;141 Cßceres;Group 1112 Intestinal diverticulosis 562;Both sexes;127 Cßceres;Group 1112 Intestinal diverticulosis 562;Men;72 Cßceres;Group 1112 Intestinal diverticulosis 562;Women;55 Cßceres;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Both sexes;392 Cßceres;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Men;250 Cßceres;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Women;142 Cßceres;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Both sexes;144 Cßceres;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Men;74 Cßceres;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Women;70 Cßceres;Group 1115 Alcoholic hepatitis 5710-5713;Both sexes;33 Cßceres;Group 1115 Alcoholic hepatitis 5710-5713;Men;31 Cßceres;Group 1115 Alcoholic hepatitis 5710-5713;Women;2 Cßceres;Group 1116 Other diseases of the liver 570,5714-573;Both sexes;139 Cßceres;Group 1116 Other diseases of the liver 570,5714-573;Men;84 Cßceres;Group 1116 Other diseases of the liver 570,5714-573;Women;55 Cßceres;Group 1117 Cholelithiasis 574;Both sexes;941 Cßceres;Group 1117 Cholelithiasis 574;Men;407 Cßceres;Group 1117 Cholelithiasis 574;Women;534 Cßceres;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Both sexes;314 Cßceres;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Men;162 Cßceres;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Women;152 Cßceres;Group 1119 Pancreatic diseases 577;Both sexes;309 Cßceres;Group 1119 Pancreatic diseases 577;Men;149 Cßceres;Group 1119 Pancreatic diseases 577;Women;160 Cßceres;Group 1120 Other diseases of the digestive system Rest of (520-579);Both sexes;238 Cßceres;Group 1120 Other diseases of the digestive system Rest of (520-579);Men;126 Cßceres;Group 1120 Other diseases of the digestive system Rest of (520-579);Women;112 Cßceres;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Both sexes;424 Cßceres;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Men;246 Cßceres;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Women;178 Cßceres;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Both sexes;270 Cßceres;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Men;174 Cßceres;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Women;96 Cßceres;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Both sexes;18 Cßceres;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Men;10 Cßceres;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Women;8 Cßceres;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Both sexes;136 Cßceres;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Men;62 Cßceres;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Women;74 Cßceres;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Both sexes;1,975 Cßceres;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Men;858 Cßceres;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Women;1,117 Cßceres;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Both sexes;.. Cßceres;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Men;.. Cßceres;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Women;.. Cßceres;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Both sexes;.. Cßceres;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Men;.. Cßceres;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Women;.. Cßceres;Group 1303 Internal derangement of knee 717;Both sexes;187 Cßceres;Group 1303 Internal derangement of knee 717;Men;123 Cßceres;Group 1303 Internal derangement of knee 717;Women;64 Cßceres;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Both sexes;832 Cßceres;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Men;346 Cßceres;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Women;486 Cßceres;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Both sexes;27 Cßceres;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Men;8 Cßceres;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Women;19 Cßceres;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Both sexes;49 Cßceres;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Men;25 Cßceres;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Women;24 Cßceres;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Both sexes;71 Cßceres;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Men;34 Cßceres;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Women;37 Cßceres;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Both sexes;99 Cßceres;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Men;44 Cßceres;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Women;55 Cßceres;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Both sexes;205 Cßceres;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Men;116 Cßceres;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Women;89 Cßceres;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Both sexes;505 Cßceres;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Men;162 Cßceres;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Women;343 Cßceres;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Both sexes;2,697 Cßceres;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Men;1,103 Cßceres;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Women;1,594 Cßceres;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Both sexes;140 Cßceres;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Men;55 Cßceres;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Women;85 Cßceres;Group 1402 Renal failure 5836-5837, 584-586;Both sexes;244 Cßceres;Group 1402 Renal failure 5836-5837, 584-586;Men;147 Cßceres;Group 1402 Renal failure 5836-5837, 584-586;Women;97 Cßceres;Group 1403 Urolithiasis 592, 594, 7880;Both sexes;234 Cßceres;Group 1403 Urolithiasis 592, 594, 7880;Men;124 Cßceres;Group 1403 Urolithiasis 592, 594, 7880;Women;110 Cßceres;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Both sexes;548 Cßceres;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Men;257 Cßceres;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Women;291 Cßceres;Group 1405 Prostatic hyperplasia 600;Both sexes;187 Cßceres;Group 1405 Prostatic hyperplasia 600;Men;187 Cßceres;Group 1405 Prostatic hyperplasia 600;Women;.. Cßceres;Group 1406 Other diseases of the male genital organs 601-608;Both sexes;324 Cßceres;Group 1406 Other diseases of the male genital organs 601-608;Men;324 Cßceres;Group 1406 Other diseases of the male genital organs 601-608;Women;.. Cßceres;Group 1407 Disorders of breast 610-612;Both sexes;141 Cßceres;Group 1407 Disorders of breast 610-612;Men;6 Cßceres;Group 1407 Disorders of breast 610-612;Women;135 Cßceres;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Both sexes;83 Cßceres;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Men;.. Cßceres;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Women;83 Cßceres;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Both sexes;101 Cßceres;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Men;.. Cßceres;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Women;101 Cßceres;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Both sexes;695 Cßceres;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Men;3 Cßceres;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Women;692 Cßceres;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Both sexes;3,499 Cßceres;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Men;.. Cßceres;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Women;3,499 Cßceres;Group 1501 Legally induced abortion 635;Both sexes;1 Cßceres;Group 1501 Legally induced abortion 635;Men;.. Cßceres;Group 1501 Legally induced abortion 635;Women;1 Cßceres;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Both sexes;403 Cßceres;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Men;.. Cßceres;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Women;403 Cßceres;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Both sexes;1,701 Cßceres;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Men;.. Cßceres;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Women;1,701 Cßceres;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Both sexes;804 Cßceres;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Men;.. Cßceres;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Women;804 Cßceres;Group 1505 Single spontaneous delivery 650;Both sexes;214 Cßceres;Group 1505 Single spontaneous delivery 650;Men;.. Cßceres;Group 1505 Single spontaneous delivery 650;Women;214 Cßceres;Group 1506 Other deliveries 6695-6697;Both sexes;99 Cßceres;Group 1506 Other deliveries 6695-6697;Men;.. Cßceres;Group 1506 Other deliveries 6695-6697;Women;99 Cßceres;Group 1507 Complications related to the puerperium 670-676;Both sexes;22 Cßceres;Group 1507 Complications related to the puerperium 670-676;Men;.. Cßceres;Group 1507 Complications related to the puerperium 670-676;Women;22 Cßceres;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Both sexes;255 Cßceres;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Men;.. Cßceres;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Women;255 Cßceres;Group 1600 Some disorders originating in the perinatal period 760-779;Both sexes;854 Cßceres;Group 1600 Some disorders originating in the perinatal period 760-779;Men;463 Cßceres;Group 1600 Some disorders originating in the perinatal period 760-779;Women;391 Cßceres;Group 1601 Disorders related with premature delivery and a low birth weight 765;Both sexes;142 Cßceres;Group 1601 Disorders related with premature delivery and a low birth weight 765;Men;73 Cßceres;Group 1601 Disorders related with premature delivery and a low birth weight 765;Women;69 Cßceres;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Both sexes;712 Cßceres;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Men;390 Cßceres;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Women;322 Cßceres;Grupo 1700 Congenital abnormalities 740-759;Both sexes;209 Cßceres;Grupo 1700 Congenital abnormalities 740-759;Men;112 Cßceres;Grupo 1700 Congenital abnormalities 740-759;Women;97 Cßceres;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Both sexes;2,295 Cßceres;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Men;1,293 Cßceres;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Women;1,002 Cßceres;Group 1801 Pain in throat and chest 7841, 7865;Both sexes;218 Cßceres;Group 1801 Pain in throat and chest 7841, 7865;Men;143 Cßceres;Group 1801 Pain in throat and chest 7841, 7865;Women;75 Cßceres;Group 1802 Abdominal pain 7890;Both sexes;255 Cßceres;Group 1802 Abdominal pain 7890;Men;112 Cßceres;Group 1802 Abdominal pain 7890;Women;143 Cßceres;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Both sexes;461 Cßceres;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Men;237 Cßceres;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Women;224 Cßceres;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Both sexes;1,361 Cßceres;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Men;801 Cßceres;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Women;560 Cßceres;Group 1900 Injuries and poisoning 800-999;Both sexes;3,017 Cßceres;Group 1900 Injuries and poisoning 800-999;Men;1,437 Cßceres;Group 1900 Injuries and poisoning 800-999;Women;1,580 Cßceres;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Both sexes;134 Cßceres;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Men;74 Cßceres;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Women;60 Cßceres;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Both sexes;77 Cßceres;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Men;51 Cßceres;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Women;26 Cßceres;Group 1903 Radius and ulna fracture 813;Both sexes;190 Cßceres;Group 1903 Radius and ulna fracture 813;Men;79 Cßceres;Group 1903 Radius and ulna fracture 813;Women;111 Cßceres;Group 1904 Femur fracture 820-821;Both sexes;648 Cßceres;Group 1904 Femur fracture 820-821;Men;157 Cßceres;Group 1904 Femur fracture 820-821;Women;491 Cßceres;Group 1905 Leg fracture, including the ankle 823-824;Both sexes;251 Cßceres;Group 1905 Leg fracture, including the ankle 823-824;Men;121 Cßceres;Group 1905 Leg fracture, including the ankle 823-824;Women;130 Cßceres;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Both sexes;805 Cßceres;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Men;484 Cßceres;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Women;321 Cßceres;Group 1907 Burns 940-949;Both sexes;97 Cßceres;Group 1907 Burns 940-949;Men;61 Cßceres;Group 1907 Burns 940-949;Women;36 Cßceres;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Both sexes;77 Cßceres;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Men;37 Cßceres;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Women;40 Cßceres;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Both sexes;639 Cßceres;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Men;323 Cßceres;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Women;316 Cßceres;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Both sexes;12 Cßceres;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Men;10 Cßceres;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Women;2 Cßceres;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Both sexes;87 Cßceres;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Men;40 Cßceres;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Women;47 Cßceres;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Both sexes;824 Cßceres;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Men;429 Cßceres;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Women;395 Cßceres;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Both sexes;15 Cßceres;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Men;8 Cßceres;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Women;7 Cßceres;Group 2102 Contraceptive management V25;Both sexes;33 Cßceres;Group 2102 Contraceptive management V25;Men;.. Cßceres;Group 2102 Contraceptive management V25;Women;33 Cßceres;Group 2103 Living newborns by type of delivery V30-V39;Both sexes;.. Cßceres;Group 2103 Living newborns by type of delivery V30-V39;Men;.. Cßceres;Group 2103 Living newborns by type of delivery V30-V39;Women;.. Cßceres;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Both sexes;350 Cßceres;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Men;207 Cßceres;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Women;143 Cßceres;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Both sexes;426 Cßceres;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Men;214 Cßceres;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Women;212 GALICIA;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Both sexes;290,460 GALICIA;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Men;141,709 GALICIA;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Women;148,751 GALICIA;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Both sexes;5,548 GALICIA;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Men;3,088 GALICIA;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Women;2,460 GALICIA;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Both sexes;699 GALICIA;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Men;369 GALICIA;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Women;330 GALICIA;Group 0102 Imprecise intestinal infections 009;Both sexes;217 GALICIA;Group 0102 Imprecise intestinal infections 009;Men;110 GALICIA;Group 0102 Imprecise intestinal infections 009;Women;107 GALICIA;Group 0103 Tuberculosis 010-018, 137;Both sexes;314 GALICIA;Group 0103 Tuberculosis 010-018, 137;Men;195 GALICIA;Group 0103 Tuberculosis 010-018, 137;Women;119 GALICIA;Group 0104 Septicaemia 038;Both sexes;1,744 GALICIA;Group 0104 Septicaemia 038;Men;884 GALICIA;Group 0104 Septicaemia 038;Women;860 GALICIA;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Both sexes;246 GALICIA;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Men;182 GALICIA;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Women;64 GALICIA;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Both sexes;2,328 GALICIA;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Men;1,348 GALICIA;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Women;980 GALICIA;Group 0200 Neoplasms 140-239;Both sexes;30,095 GALICIA;Group 0200 Neoplasms 140-239;Men;15,938 GALICIA;Group 0200 Neoplasms 140-239;Women;14,157 GALICIA;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Both sexes;3,350 GALICIA;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Men;2,037 GALICIA;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Women;1,313 GALICIA;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Both sexes;2,104 GALICIA;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Men;1,657 GALICIA;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Women;447 GALICIA;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Both sexes;480 GALICIA;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Men;233 GALICIA;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Women;247 GALICIA;Group 0204 Malignant neoplasm of breast 174-175;Both sexes;2,137 GALICIA;Group 0204 Malignant neoplasm of breast 174-175;Men;24 GALICIA;Group 0204 Malignant neoplasm of breast 174-175;Women;2,113 GALICIA;Group 0205 Malignant neoplasm of uterus 179-180, 182;Both sexes;723 GALICIA;Group 0205 Malignant neoplasm of uterus 179-180, 182;Men;.. GALICIA;Group 0205 Malignant neoplasm of uterus 179-180, 182;Women;723 GALICIA;Group 0206 Malignant neoplasm of ovary 1830;Both sexes;306 GALICIA;Group 0206 Malignant neoplasm of ovary 1830;Men;.. GALICIA;Group 0206 Malignant neoplasm of ovary 1830;Women;306 GALICIA;Group 0207 Malignant neoplasm of prostate 185;Both sexes;1,724 GALICIA;Group 0207 Malignant neoplasm of prostate 185;Men;1,724 GALICIA;Group 0207 Malignant neoplasm of prostate 185;Women;.. GALICIA;Group 0208 Malignant neoplasm of bladder 188;Both sexes;2,538 GALICIA;Group 0208 Malignant neoplasm of bladder 188;Men;2,130 GALICIA;Group 0208 Malignant neoplasm of bladder 188;Women;409 GALICIA;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Both sexes;10,915 GALICIA;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Men;6,402 GALICIA;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Women;4,513 GALICIA;Group 0210 Carcinoma in situ 230-234;Both sexes;441 GALICIA;Group 0210 Carcinoma in situ 230-234;Men;150 GALICIA;Group 0210 Carcinoma in situ 230-234;Women;291 GALICIA;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Both sexes;349 GALICIA;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Men;215 GALICIA;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Women;134 GALICIA;Grupo 0212 Leiomyoma of uterus 218;Both sexes;1,337 GALICIA;Grupo 0212 Leiomyoma of uterus 218;Men;.. GALICIA;Grupo 0212 Leiomyoma of uterus 218;Women;1,337 GALICIA;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Both sexes;3,690 GALICIA;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Men;1,367 GALICIA;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Women;2,323 GALICIA;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Both sexes;2,642 GALICIA;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Men;1,280 GALICIA;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Women;1,362 GALICIA;Group 0301 Anaemias 280-285;Both sexes;1,705 GALICIA;Group 0301 Anaemias 280-285;Men;841 GALICIA;Group 0301 Anaemias 280-285;Women;864 GALICIA;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Both sexes;937 GALICIA;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Men;439 GALICIA;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Women;498 GALICIA;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Both sexes;4,779 GALICIA;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Men;1,955 GALICIA;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Women;2,824 GALICIA;Group 0401 Diabetes mellitus 249-250;Both sexes;1,663 GALICIA;Group 0401 Diabetes mellitus 249-250;Men;929 GALICIA;Group 0401 Diabetes mellitus 249-250;Women;735 GALICIA;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Both sexes;3,116 GALICIA;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Men;1,027 GALICIA;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Women;2,089 GALICIA;Group 0500 Mental disorders 290-319;Both sexes;5,880 GALICIA;Group 0500 Mental disorders 290-319;Men;2,968 GALICIA;Group 0500 Mental disorders 290-319;Women;2,912 GALICIA;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Both sexes;169 GALICIA;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Men;68 GALICIA;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Women;101 GALICIA;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Both sexes;521 GALICIA;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Men;411 GALICIA;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Women;110 GALICIA;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Both sexes;273 GALICIA;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Men;194 GALICIA;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Women;79 GALICIA;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Both sexes;1,557 GALICIA;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Men;866 GALICIA;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Women;691 GALICIA;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Both sexes;1,376 GALICIA;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Men;503 GALICIA;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Women;873 GALICIA;Group 0506 Other mental and behavioural disorders Rest of (290-319);Both sexes;1,984 GALICIA;Group 0506 Other mental and behavioural disorders Rest of (290-319);Men;926 GALICIA;Group 0506 Other mental and behavioural disorders Rest of (290-319);Women;1,057 GALICIA;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Both sexes;5,941 GALICIA;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Men;2,884 GALICIA;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Women;3,057 GALICIA;Group 0601 Alzheimer's disease 3310;Both sexes;115 GALICIA;Group 0601 Alzheimer's disease 3310;Men;48 GALICIA;Group 0601 Alzheimer's disease 3310;Women;67 GALICIA;Group 0602 Multiple sclerosis 340;Both sexes;282 GALICIA;Group 0602 Multiple sclerosis 340;Men;88 GALICIA;Group 0602 Multiple sclerosis 340;Women;194 GALICIA;Group 0603 Epilepsy 345;Both sexes;1,003 GALICIA;Group 0603 Epilepsy 345;Men;512 GALICIA;Group 0603 Epilepsy 345;Women;491 GALICIA;Group 0604 Transient cerebral ischemia 435;Both sexes;970 GALICIA;Group 0604 Transient cerebral ischemia 435;Men;464 GALICIA;Group 0604 Transient cerebral ischemia 435;Women;506 GALICIA;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Both sexes;3,570 GALICIA;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Men;1,771 GALICIA;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Women;1,799 GALICIA;Grupo 0700 Diseases of the eye and adnexa 360-379;Both sexes;1,381 GALICIA;Grupo 0700 Diseases of the eye and adnexa 360-379;Men;684 GALICIA;Grupo 0700 Diseases of the eye and adnexa 360-379;Women;697 GALICIA;Grupo 0701 Cataract 366;Both sexes;120 GALICIA;Grupo 0701 Cataract 366;Men;49 GALICIA;Grupo 0701 Cataract 366;Women;71 GALICIA;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Both sexes;1,261 GALICIA;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Men;635 GALICIA;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Women;626 GALICIA;Group 0800 Diseases of the ear and the mastoid 380-389;Both sexes;1,341 GALICIA;Group 0800 Diseases of the ear and the mastoid 380-389;Men;667 GALICIA;Group 0800 Diseases of the ear and the mastoid 380-389;Women;674 GALICIA;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Both sexes;39,561 GALICIA;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Men;22,427 GALICIA;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Women;17,134 GALICIA;Group 0901 Hypertensive disease 401-405;Both sexes;2,211 GALICIA;Group 0901 Hypertensive disease 401-405;Men;1,047 GALICIA;Group 0901 Hypertensive disease 401-405;Women;1,164 GALICIA;Group 0902 Angina pectoris 4111, 413;Both sexes;1,492 GALICIA;Group 0902 Angina pectoris 4111, 413;Men;917 GALICIA;Group 0902 Angina pectoris 4111, 413;Women;575 GALICIA;Group 0903 Acute myocardial infarction 410;Both sexes;3,393 GALICIA;Group 0903 Acute myocardial infarction 410;Men;2,441 GALICIA;Group 0903 Acute myocardial infarction 410;Women;952 GALICIA;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Both sexes;2,804 GALICIA;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Men;2,210 GALICIA;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Women;594 GALICIA;Group 0905 Diseases of the lungs circulation 415-417;Both sexes;1,516 GALICIA;Group 0905 Diseases of the lungs circulation 415-417;Men;647 GALICIA;Group 0905 Diseases of the lungs circulation 415-417;Women;869 GALICIA;Group 0906 Heart conduction disorders and arrhytmias 426-427;Both sexes;4,552 GALICIA;Group 0906 Heart conduction disorders and arrhytmias 426-427;Men;2,546 GALICIA;Group 0906 Heart conduction disorders and arrhytmias 426-427;Women;2,006 GALICIA;Grupo 0907 Heart failure 428;Both sexes;7,329 GALICIA;Grupo 0907 Heart failure 428;Men;3,693 GALICIA;Grupo 0907 Heart failure 428;Women;3,635 GALICIA;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Both sexes;6,775 GALICIA;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Men;3,478 GALICIA;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Women;3,297 GALICIA;Grupo 0909 Atherosclerosis 440;Both sexes;1,458 GALICIA;Grupo 0909 Atherosclerosis 440;Men;1,023 GALICIA;Grupo 0909 Atherosclerosis 440;Women;435 GALICIA;Group 0910 Varicose veins of lower extremities 454;Both sexes;1,499 GALICIA;Group 0910 Varicose veins of lower extremities 454;Men;490 GALICIA;Group 0910 Varicose veins of lower extremities 454;Women;1,009 GALICIA;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Both sexes;6,532 GALICIA;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Men;3,934 GALICIA;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Women;2,598 GALICIA;Group 1000 Diseases of the respiratory system 0340, 460-519;Both sexes;36,304 GALICIA;Group 1000 Diseases of the respiratory system 0340, 460-519;Men;20,942 GALICIA;Group 1000 Diseases of the respiratory system 0340, 460-519;Women;15,362 GALICIA;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Both sexes;1,213 GALICIA;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Men;631 GALICIA;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Women;583 GALICIA;Group 1002 Pneumonia 480-486;Both sexes;7,917 GALICIA;Group 1002 Pneumonia 480-486;Men;4,685 GALICIA;Group 1002 Pneumonia 480-486;Women;3,232 GALICIA;Group 1003 Acute bronchitis and bronchiolitis 466;Both sexes;1,300 GALICIA;Group 1003 Acute bronchitis and bronchiolitis 466;Men;710 GALICIA;Group 1003 Acute bronchitis and bronchiolitis 466;Women;590 GALICIA;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Both sexes;2,104 GALICIA;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Men;1,096 GALICIA;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Women;1,008 GALICIA;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Both sexes;2,840 GALICIA;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Men;1,821 GALICIA;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Women;1,018 GALICIA;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Both sexes;6,186 GALICIA;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Men;4,634 GALICIA;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Women;1,552 GALICIA;Group 1007 Asthma 4930-4931,4938-4939;Both sexes;1,274 GALICIA;Group 1007 Asthma 4930-4931,4938-4939;Men;352 GALICIA;Group 1007 Asthma 4930-4931,4938-4939;Women;922 GALICIA;Group 1008 Other diseases of the respiratory system Resto of (460-519);Both sexes;13,469 GALICIA;Group 1008 Other diseases of the respiratory system Resto of (460-519);Men;7,012 GALICIA;Group 1008 Other diseases of the respiratory system Resto of (460-519);Women;6,457 GALICIA;Group 1100 Diseases of the digestive system 520-579;Both sexes;35,959 GALICIA;Group 1100 Diseases of the digestive system 520-579;Men;20,467 GALICIA;Group 1100 Diseases of the digestive system 520-579;Women;15,492 GALICIA;Group 1101 Disorders of the teeth and supporting structures 520-525;Both sexes;433 GALICIA;Group 1101 Disorders of the teeth and supporting structures 520-525;Men;229 GALICIA;Group 1101 Disorders of the teeth and supporting structures 520-525;Women;204 GALICIA;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Both sexes;461 GALICIA;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Men;251 GALICIA;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Women;210 GALICIA;Group 1103 Diseases of the esophagus 530;Both sexes;534 GALICIA;Group 1103 Diseases of the esophagus 530;Men;320 GALICIA;Group 1103 Diseases of the esophagus 530;Women;214 GALICIA;Group 1104 Peptic ulcer 531-534;Both sexes;526 GALICIA;Group 1104 Peptic ulcer 531-534;Men;332 GALICIA;Group 1104 Peptic ulcer 531-534;Women;194 GALICIA;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Both sexes;749 GALICIA;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Men;401 GALICIA;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Women;347 GALICIA;Group 1106 Appendicitis 540-543;Both sexes;2,984 GALICIA;Group 1106 Appendicitis 540-543;Men;1,693 GALICIA;Group 1106 Appendicitis 540-543;Women;1,291 GALICIA;Group 1107 Inguinal hernia 550;Both sexes;4,369 GALICIA;Group 1107 Inguinal hernia 550;Men;3,911 GALICIA;Group 1107 Inguinal hernia 550;Women;458 GALICIA;Group 1108 Other abdominal hernia 551-553;Both sexes;2,688 GALICIA;Group 1108 Other abdominal hernia 551-553;Men;1,332 GALICIA;Group 1108 Other abdominal hernia 551-553;Women;1,356 GALICIA;Group 1109 Crohn's disease and ulcerative colitis 555-556;Both sexes;710 GALICIA;Group 1109 Crohn's disease and ulcerative colitis 555-556;Men;355 GALICIA;Group 1109 Crohn's disease and ulcerative colitis 555-556;Women;354 GALICIA;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Both sexes;1,540 GALICIA;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Men;798 GALICIA;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Women;743 GALICIA;Group 1111 Intestinal obstruction without hernia 560;Both sexes;1,727 GALICIA;Group 1111 Intestinal obstruction without hernia 560;Men;884 GALICIA;Group 1111 Intestinal obstruction without hernia 560;Women;843 GALICIA;Group 1112 Intestinal diverticulosis 562;Both sexes;1,476 GALICIA;Group 1112 Intestinal diverticulosis 562;Men;750 GALICIA;Group 1112 Intestinal diverticulosis 562;Women;727 GALICIA;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Both sexes;2,141 GALICIA;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Men;1,392 GALICIA;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Women;749 GALICIA;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Both sexes;1,282 GALICIA;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Men;578 GALICIA;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Women;703 GALICIA;Group 1115 Alcoholic hepatitis 5710-5713;Both sexes;861 GALICIA;Group 1115 Alcoholic hepatitis 5710-5713;Men;733 GALICIA;Group 1115 Alcoholic hepatitis 5710-5713;Women;128 GALICIA;Group 1116 Other diseases of the liver 570,5714-573;Both sexes;1,486 GALICIA;Group 1116 Other diseases of the liver 570,5714-573;Men;910 GALICIA;Group 1116 Other diseases of the liver 570,5714-573;Women;576 GALICIA;Group 1117 Cholelithiasis 574;Both sexes;6,754 GALICIA;Group 1117 Cholelithiasis 574;Men;2,790 GALICIA;Group 1117 Cholelithiasis 574;Women;3,963 GALICIA;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Both sexes;1,750 GALICIA;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Men;933 GALICIA;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Women;818 GALICIA;Group 1119 Pancreatic diseases 577;Both sexes;2,023 GALICIA;Group 1119 Pancreatic diseases 577;Men;1,087 GALICIA;Group 1119 Pancreatic diseases 577;Women;935 GALICIA;Group 1120 Other diseases of the digestive system Rest of (520-579);Both sexes;1,464 GALICIA;Group 1120 Other diseases of the digestive system Rest of (520-579);Men;787 GALICIA;Group 1120 Other diseases of the digestive system Rest of (520-579);Women;677 GALICIA;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Both sexes;3,562 GALICIA;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Men;1,882 GALICIA;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Women;1,680 GALICIA;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Both sexes;2,258 GALICIA;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Men;1,277 GALICIA;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Women;981 GALICIA;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Both sexes;244 GALICIA;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Men;114 GALICIA;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Women;130 GALICIA;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Both sexes;1,060 GALICIA;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Men;491 GALICIA;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Women;569 GALICIA;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Both sexes;21,927 GALICIA;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Men;10,100 GALICIA;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Women;11,827 GALICIA;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Both sexes;.. GALICIA;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Men;.. GALICIA;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Women;.. GALICIA;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Both sexes;.. GALICIA;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Men;.. GALICIA;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Women;.. GALICIA;Group 1303 Internal derangement of knee 717;Both sexes;3,193 GALICIA;Group 1303 Internal derangement of knee 717;Men;2,163 GALICIA;Group 1303 Internal derangement of knee 717;Women;1,030 GALICIA;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Both sexes;8,366 GALICIA;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Men;3,320 GALICIA;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Women;5,047 GALICIA;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Both sexes;529 GALICIA;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Men;193 GALICIA;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Women;336 GALICIA;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Both sexes;729 GALICIA;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Men;369 GALICIA;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Women;360 GALICIA;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Both sexes;1,720 GALICIA;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Men;935 GALICIA;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Women;785 GALICIA;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Both sexes;286 GALICIA;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Men;126 GALICIA;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Women;160 GALICIA;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Both sexes;3,221 GALICIA;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Men;1,767 GALICIA;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Women;1,454 GALICIA;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Both sexes;3,882 GALICIA;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Men;1,227 GALICIA;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Women;2,655 GALICIA;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Both sexes;17,778 GALICIA;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Men;8,496 GALICIA;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Women;9,282 GALICIA;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Both sexes;1,411 GALICIA;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Men;521 GALICIA;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Women;890 GALICIA;Group 1402 Renal failure 5836-5837, 584-586;Both sexes;1,598 GALICIA;Group 1402 Renal failure 5836-5837, 584-586;Men;885 GALICIA;Group 1402 Renal failure 5836-5837, 584-586;Women;713 GALICIA;Group 1403 Urolithiasis 592, 594, 7880;Both sexes;1,749 GALICIA;Group 1403 Urolithiasis 592, 594, 7880;Men;1,064 GALICIA;Group 1403 Urolithiasis 592, 594, 7880;Women;684 GALICIA;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Both sexes;5,184 GALICIA;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Men;2,392 GALICIA;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Women;2,792 GALICIA;Group 1405 Prostatic hyperplasia 600;Both sexes;1,930 GALICIA;Group 1405 Prostatic hyperplasia 600;Men;1,930 GALICIA;Group 1405 Prostatic hyperplasia 600;Women;.. GALICIA;Group 1406 Other diseases of the male genital organs 601-608;Both sexes;1,535 GALICIA;Group 1406 Other diseases of the male genital organs 601-608;Men;1,535 GALICIA;Group 1406 Other diseases of the male genital organs 601-608;Women;.. GALICIA;Group 1407 Disorders of breast 610-612;Both sexes;669 GALICIA;Group 1407 Disorders of breast 610-612;Men;115 GALICIA;Group 1407 Disorders of breast 610-612;Women;554 GALICIA;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Both sexes;482 GALICIA;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Men;.. GALICIA;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Women;482 GALICIA;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Both sexes;318 GALICIA;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Men;.. GALICIA;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Women;318 GALICIA;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Both sexes;2,901 GALICIA;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Men;53 GALICIA;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Women;2,848 GALICIA;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Both sexes;25,325 GALICIA;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Men;.. GALICIA;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Women;25,325 GALICIA;Group 1501 Legally induced abortion 635;Both sexes;271 GALICIA;Group 1501 Legally induced abortion 635;Men;.. GALICIA;Group 1501 Legally induced abortion 635;Women;271 GALICIA;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Both sexes;2,600 GALICIA;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Men;.. GALICIA;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Women;2,600 GALICIA;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Both sexes;14,842 GALICIA;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Men;.. GALICIA;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Women;14,842 GALICIA;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Both sexes;4,006 GALICIA;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Men;.. GALICIA;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Women;4,006 GALICIA;Group 1505 Single spontaneous delivery 650;Both sexes;1,461 GALICIA;Group 1505 Single spontaneous delivery 650;Men;.. GALICIA;Group 1505 Single spontaneous delivery 650;Women;1,461 GALICIA;Group 1506 Other deliveries 6695-6697;Both sexes;663 GALICIA;Group 1506 Other deliveries 6695-6697;Men;.. GALICIA;Group 1506 Other deliveries 6695-6697;Women;663 GALICIA;Group 1507 Complications related to the puerperium 670-676;Both sexes;184 GALICIA;Group 1507 Complications related to the puerperium 670-676;Men;.. GALICIA;Group 1507 Complications related to the puerperium 670-676;Women;184 GALICIA;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Both sexes;1,298 GALICIA;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Men;.. GALICIA;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Women;1,298 GALICIA;Group 1600 Some disorders originating in the perinatal period 760-779;Both sexes;3,378 GALICIA;Group 1600 Some disorders originating in the perinatal period 760-779;Men;1,837 GALICIA;Group 1600 Some disorders originating in the perinatal period 760-779;Women;1,541 GALICIA;Group 1601 Disorders related with premature delivery and a low birth weight 765;Both sexes;733 GALICIA;Group 1601 Disorders related with premature delivery and a low birth weight 765;Men;405 GALICIA;Group 1601 Disorders related with premature delivery and a low birth weight 765;Women;328 GALICIA;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Both sexes;2,645 GALICIA;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Men;1,432 GALICIA;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Women;1,213 GALICIA;Grupo 1700 Congenital abnormalities 740-759;Both sexes;2,244 GALICIA;Grupo 1700 Congenital abnormalities 740-759;Men;1,393 GALICIA;Grupo 1700 Congenital abnormalities 740-759;Women;851 GALICIA;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Both sexes;12,205 GALICIA;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Men;6,463 GALICIA;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Women;5,742 GALICIA;Group 1801 Pain in throat and chest 7841, 7865;Both sexes;1,263 GALICIA;Group 1801 Pain in throat and chest 7841, 7865;Men;709 GALICIA;Group 1801 Pain in throat and chest 7841, 7865;Women;554 GALICIA;Group 1802 Abdominal pain 7890;Both sexes;1,220 GALICIA;Group 1802 Abdominal pain 7890;Men;476 GALICIA;Group 1802 Abdominal pain 7890;Women;744 GALICIA;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Both sexes;2,111 GALICIA;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Men;1,086 GALICIA;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Women;1,025 GALICIA;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Both sexes;7,611 GALICIA;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Men;4,192 GALICIA;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Women;3,419 GALICIA;Group 1900 Injuries and poisoning 800-999;Both sexes;28,694 GALICIA;Group 1900 Injuries and poisoning 800-999;Men;15,075 GALICIA;Group 1900 Injuries and poisoning 800-999;Women;13,618 GALICIA;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Both sexes;1,935 GALICIA;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Men;1,120 GALICIA;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Women;815 GALICIA;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Both sexes;1,023 GALICIA;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Men;735 GALICIA;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Women;288 GALICIA;Group 1903 Radius and ulna fracture 813;Both sexes;1,545 GALICIA;Group 1903 Radius and ulna fracture 813;Men;726 GALICIA;Group 1903 Radius and ulna fracture 813;Women;819 GALICIA;Group 1904 Femur fracture 820-821;Both sexes;3,924 GALICIA;Group 1904 Femur fracture 820-821;Men;973 GALICIA;Group 1904 Femur fracture 820-821;Women;2,950 GALICIA;Group 1905 Leg fracture, including the ankle 823-824;Both sexes;2,124 GALICIA;Group 1905 Leg fracture, including the ankle 823-824;Men;949 GALICIA;Group 1905 Leg fracture, including the ankle 823-824;Women;1,176 GALICIA;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Both sexes;9,098 GALICIA;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Men;5,627 GALICIA;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Women;3,472 GALICIA;Group 1907 Burns 940-949;Both sexes;324 GALICIA;Group 1907 Burns 940-949;Men;187 GALICIA;Group 1907 Burns 940-949;Women;137 GALICIA;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Both sexes;602 GALICIA;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Men;278 GALICIA;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Women;324 GALICIA;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Both sexes;7,564 GALICIA;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Men;4,210 GALICIA;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Women;3,354 GALICIA;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Both sexes;57 GALICIA;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Men;27 GALICIA;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Women;30 GALICIA;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Both sexes;497 GALICIA;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Men;243 GALICIA;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Women;254 GALICIA;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Both sexes;5,918 GALICIA;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Men;3,162 GALICIA;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Women;2,755 GALICIA;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Both sexes;271 GALICIA;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Men;151 GALICIA;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Women;120 GALICIA;Group 2102 Contraceptive management V25;Both sexes;99 GALICIA;Group 2102 Contraceptive management V25;Men;4 GALICIA;Group 2102 Contraceptive management V25;Women;95 GALICIA;Group 2103 Living newborns by type of delivery V30-V39;Both sexes;.. GALICIA;Group 2103 Living newborns by type of delivery V30-V39;Men;.. GALICIA;Group 2103 Living newborns by type of delivery V30-V39;Women;.. GALICIA;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Both sexes;2,636 GALICIA;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Men;1,635 GALICIA;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Women;1,001 GALICIA;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Both sexes;2,912 GALICIA;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Men;1,372 GALICIA;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Women;1,539 Coru±a, A;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Both sexes;125,008 Coru±a, A;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Men;60,917 Coru±a, A;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Women;64,091 Coru±a, A;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Both sexes;2,458 Coru±a, A;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Men;1,410 Coru±a, A;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Women;1,048 Coru±a, A;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Both sexes;281 Coru±a, A;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Men;149 Coru±a, A;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Women;132 Coru±a, A;Group 0102 Imprecise intestinal infections 009;Both sexes;136 Coru±a, A;Group 0102 Imprecise intestinal infections 009;Men;71 Coru±a, A;Group 0102 Imprecise intestinal infections 009;Women;65 Coru±a, A;Group 0103 Tuberculosis 010-018, 137;Both sexes;155 Coru±a, A;Group 0103 Tuberculosis 010-018, 137;Men;94 Coru±a, A;Group 0103 Tuberculosis 010-018, 137;Women;61 Coru±a, A;Group 0104 Septicaemia 038;Both sexes;720 Coru±a, A;Group 0104 Septicaemia 038;Men;399 Coru±a, A;Group 0104 Septicaemia 038;Women;321 Coru±a, A;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Both sexes;111 Coru±a, A;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Men;83 Coru±a, A;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Women;28 Coru±a, A;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Both sexes;1,055 Coru±a, A;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Men;614 Coru±a, A;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Women;441 Coru±a, A;Group 0200 Neoplasms 140-239;Both sexes;14,160 Coru±a, A;Group 0200 Neoplasms 140-239;Men;7,582 Coru±a, A;Group 0200 Neoplasms 140-239;Women;6,578 Coru±a, A;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Both sexes;1,469 Coru±a, A;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Men;893 Coru±a, A;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Women;576 Coru±a, A;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Both sexes;1,120 Coru±a, A;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Men;880 Coru±a, A;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Women;240 Coru±a, A;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Both sexes;252 Coru±a, A;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Men;132 Coru±a, A;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Women;120 Coru±a, A;Group 0204 Malignant neoplasm of breast 174-175;Both sexes;982 Coru±a, A;Group 0204 Malignant neoplasm of breast 174-175;Men;13 Coru±a, A;Group 0204 Malignant neoplasm of breast 174-175;Women;969 Coru±a, A;Group 0205 Malignant neoplasm of uterus 179-180, 182;Both sexes;363 Coru±a, A;Group 0205 Malignant neoplasm of uterus 179-180, 182;Men;.. Coru±a, A;Group 0205 Malignant neoplasm of uterus 179-180, 182;Women;363 Coru±a, A;Group 0206 Malignant neoplasm of ovary 1830;Both sexes;152 Coru±a, A;Group 0206 Malignant neoplasm of ovary 1830;Men;.. Coru±a, A;Group 0206 Malignant neoplasm of ovary 1830;Women;152 Coru±a, A;Group 0207 Malignant neoplasm of prostate 185;Both sexes;881 Coru±a, A;Group 0207 Malignant neoplasm of prostate 185;Men;881 Coru±a, A;Group 0207 Malignant neoplasm of prostate 185;Women;.. Coru±a, A;Group 0208 Malignant neoplasm of bladder 188;Both sexes;1,051 Coru±a, A;Group 0208 Malignant neoplasm of bladder 188;Men;900 Coru±a, A;Group 0208 Malignant neoplasm of bladder 188;Women;151 Coru±a, A;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Both sexes;5,137 Coru±a, A;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Men;3,026 Coru±a, A;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Women;2,111 Coru±a, A;Group 0210 Carcinoma in situ 230-234;Both sexes;173 Coru±a, A;Group 0210 Carcinoma in situ 230-234;Men;60 Coru±a, A;Group 0210 Carcinoma in situ 230-234;Women;113 Coru±a, A;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Both sexes;200 Coru±a, A;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Men;122 Coru±a, A;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Women;78 Coru±a, A;Grupo 0212 Leiomyoma of uterus 218;Both sexes;632 Coru±a, A;Grupo 0212 Leiomyoma of uterus 218;Men;.. Coru±a, A;Grupo 0212 Leiomyoma of uterus 218;Women;632 Coru±a, A;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Both sexes;1,748 Coru±a, A;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Men;675 Coru±a, A;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Women;1,073 Coru±a, A;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Both sexes;1,029 Coru±a, A;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Men;488 Coru±a, A;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Women;541 Coru±a, A;Group 0301 Anaemias 280-285;Both sexes;646 Coru±a, A;Group 0301 Anaemias 280-285;Men;318 Coru±a, A;Group 0301 Anaemias 280-285;Women;328 Coru±a, A;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Both sexes;383 Coru±a, A;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Men;170 Coru±a, A;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Women;213 Coru±a, A;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Both sexes;1,751 Coru±a, A;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Men;720 Coru±a, A;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Women;1,031 Coru±a, A;Group 0401 Diabetes mellitus 249-250;Both sexes;642 Coru±a, A;Group 0401 Diabetes mellitus 249-250;Men;367 Coru±a, A;Group 0401 Diabetes mellitus 249-250;Women;275 Coru±a, A;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Both sexes;1,109 Coru±a, A;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Men;353 Coru±a, A;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Women;756 Coru±a, A;Group 0500 Mental disorders 290-319;Both sexes;2,361 Coru±a, A;Group 0500 Mental disorders 290-319;Men;1,170 Coru±a, A;Group 0500 Mental disorders 290-319;Women;1,191 Coru±a, A;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Both sexes;66 Coru±a, A;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Men;30 Coru±a, A;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Women;36 Coru±a, A;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Both sexes;209 Coru±a, A;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Men;173 Coru±a, A;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Women;36 Coru±a, A;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Both sexes;147 Coru±a, A;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Men;106 Coru±a, A;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Women;41 Coru±a, A;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Both sexes;616 Coru±a, A;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Men;314 Coru±a, A;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Women;302 Coru±a, A;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Both sexes;585 Coru±a, A;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Men;212 Coru±a, A;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Women;373 Coru±a, A;Group 0506 Other mental and behavioural disorders Rest of (290-319);Both sexes;738 Coru±a, A;Group 0506 Other mental and behavioural disorders Rest of (290-319);Men;335 Coru±a, A;Group 0506 Other mental and behavioural disorders Rest of (290-319);Women;403 Coru±a, A;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Both sexes;2,440 Coru±a, A;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Men;1,205 Coru±a, A;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Women;1,235 Coru±a, A;Group 0601 Alzheimer's disease 3310;Both sexes;31 Coru±a, A;Group 0601 Alzheimer's disease 3310;Men;14 Coru±a, A;Group 0601 Alzheimer's disease 3310;Women;17 Coru±a, A;Group 0602 Multiple sclerosis 340;Both sexes;90 Coru±a, A;Group 0602 Multiple sclerosis 340;Men;29 Coru±a, A;Group 0602 Multiple sclerosis 340;Women;61 Coru±a, A;Group 0603 Epilepsy 345;Both sexes;385 Coru±a, A;Group 0603 Epilepsy 345;Men;196 Coru±a, A;Group 0603 Epilepsy 345;Women;189 Coru±a, A;Group 0604 Transient cerebral ischemia 435;Both sexes;389 Coru±a, A;Group 0604 Transient cerebral ischemia 435;Men;201 Coru±a, A;Group 0604 Transient cerebral ischemia 435;Women;188 Coru±a, A;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Both sexes;1,545 Coru±a, A;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Men;765 Coru±a, A;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Women;780 Coru±a, A;Grupo 0700 Diseases of the eye and adnexa 360-379;Both sexes;495 Coru±a, A;Grupo 0700 Diseases of the eye and adnexa 360-379;Men;232 Coru±a, A;Grupo 0700 Diseases of the eye and adnexa 360-379;Women;263 Coru±a, A;Grupo 0701 Cataract 366;Both sexes;44 Coru±a, A;Grupo 0701 Cataract 366;Men;15 Coru±a, A;Grupo 0701 Cataract 366;Women;29 Coru±a, A;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Both sexes;451 Coru±a, A;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Men;217 Coru±a, A;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Women;234 Coru±a, A;Group 0800 Diseases of the ear and the mastoid 380-389;Both sexes;477 Coru±a, A;Group 0800 Diseases of the ear and the mastoid 380-389;Men;241 Coru±a, A;Group 0800 Diseases of the ear and the mastoid 380-389;Women;236 Coru±a, A;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Both sexes;18,012 Coru±a, A;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Men;10,373 Coru±a, A;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Women;7,639 Coru±a, A;Group 0901 Hypertensive disease 401-405;Both sexes;1,029 Coru±a, A;Group 0901 Hypertensive disease 401-405;Men;527 Coru±a, A;Group 0901 Hypertensive disease 401-405;Women;502 Coru±a, A;Group 0902 Angina pectoris 4111, 413;Both sexes;588 Coru±a, A;Group 0902 Angina pectoris 4111, 413;Men;334 Coru±a, A;Group 0902 Angina pectoris 4111, 413;Women;254 Coru±a, A;Group 0903 Acute myocardial infarction 410;Both sexes;1,569 Coru±a, A;Group 0903 Acute myocardial infarction 410;Men;1,144 Coru±a, A;Group 0903 Acute myocardial infarction 410;Women;425 Coru±a, A;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Both sexes;1,564 Coru±a, A;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Men;1,240 Coru±a, A;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Women;324 Coru±a, A;Group 0905 Diseases of the lungs circulation 415-417;Both sexes;559 Coru±a, A;Group 0905 Diseases of the lungs circulation 415-417;Men;235 Coru±a, A;Group 0905 Diseases of the lungs circulation 415-417;Women;324 Coru±a, A;Group 0906 Heart conduction disorders and arrhytmias 426-427;Both sexes;2,083 Coru±a, A;Group 0906 Heart conduction disorders and arrhytmias 426-427;Men;1,181 Coru±a, A;Group 0906 Heart conduction disorders and arrhytmias 426-427;Women;902 Coru±a, A;Grupo 0907 Heart failure 428;Both sexes;3,009 Coru±a, A;Grupo 0907 Heart failure 428;Men;1,557 Coru±a, A;Grupo 0907 Heart failure 428;Women;1,452 Coru±a, A;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Both sexes;2,818 Coru±a, A;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Men;1,441 Coru±a, A;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Women;1,377 Coru±a, A;Grupo 0909 Atherosclerosis 440;Both sexes;619 Coru±a, A;Grupo 0909 Atherosclerosis 440;Men;456 Coru±a, A;Grupo 0909 Atherosclerosis 440;Women;163 Coru±a, A;Group 0910 Varicose veins of lower extremities 454;Both sexes;961 Coru±a, A;Group 0910 Varicose veins of lower extremities 454;Men;300 Coru±a, A;Group 0910 Varicose veins of lower extremities 454;Women;661 Coru±a, A;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Both sexes;3,213 Coru±a, A;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Men;1,958 Coru±a, A;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Women;1,255 Coru±a, A;Group 1000 Diseases of the respiratory system 0340, 460-519;Both sexes;15,222 Coru±a, A;Group 1000 Diseases of the respiratory system 0340, 460-519;Men;8,839 Coru±a, A;Group 1000 Diseases of the respiratory system 0340, 460-519;Women;6,383 Coru±a, A;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Both sexes;665 Coru±a, A;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Men;356 Coru±a, A;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Women;309 Coru±a, A;Group 1002 Pneumonia 480-486;Both sexes;3,176 Coru±a, A;Group 1002 Pneumonia 480-486;Men;1,913 Coru±a, A;Group 1002 Pneumonia 480-486;Women;1,263 Coru±a, A;Group 1003 Acute bronchitis and bronchiolitis 466;Both sexes;563 Coru±a, A;Group 1003 Acute bronchitis and bronchiolitis 466;Men;296 Coru±a, A;Group 1003 Acute bronchitis and bronchiolitis 466;Women;267 Coru±a, A;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Both sexes;766 Coru±a, A;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Men;387 Coru±a, A;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Women;379 Coru±a, A;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Both sexes;1,209 Coru±a, A;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Men;768 Coru±a, A;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Women;441 Coru±a, A;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Both sexes;2,873 Coru±a, A;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Men;2,241 Coru±a, A;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Women;632 Coru±a, A;Group 1007 Asthma 4930-4931,4938-4939;Both sexes;673 Coru±a, A;Group 1007 Asthma 4930-4931,4938-4939;Men;151 Coru±a, A;Group 1007 Asthma 4930-4931,4938-4939;Women;522 Coru±a, A;Group 1008 Other diseases of the respiratory system Resto of (460-519);Both sexes;5,297 Coru±a, A;Group 1008 Other diseases of the respiratory system Resto of (460-519);Men;2,727 Coru±a, A;Group 1008 Other diseases of the respiratory system Resto of (460-519);Women;2,570 Coru±a, A;Group 1100 Diseases of the digestive system 520-579;Both sexes;14,848 Coru±a, A;Group 1100 Diseases of the digestive system 520-579;Men;8,296 Coru±a, A;Group 1100 Diseases of the digestive system 520-579;Women;6,552 Coru±a, A;Group 1101 Disorders of the teeth and supporting structures 520-525;Both sexes;169 Coru±a, A;Group 1101 Disorders of the teeth and supporting structures 520-525;Men;76 Coru±a, A;Group 1101 Disorders of the teeth and supporting structures 520-525;Women;93 Coru±a, A;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Both sexes;174 Coru±a, A;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Men;98 Coru±a, A;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Women;76 Coru±a, A;Group 1103 Diseases of the esophagus 530;Both sexes;263 Coru±a, A;Group 1103 Diseases of the esophagus 530;Men;152 Coru±a, A;Group 1103 Diseases of the esophagus 530;Women;111 Coru±a, A;Group 1104 Peptic ulcer 531-534;Both sexes;216 Coru±a, A;Group 1104 Peptic ulcer 531-534;Men;132 Coru±a, A;Group 1104 Peptic ulcer 531-534;Women;84 Coru±a, A;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Both sexes;290 Coru±a, A;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Men;157 Coru±a, A;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Women;133 Coru±a, A;Group 1106 Appendicitis 540-543;Both sexes;1,217 Coru±a, A;Group 1106 Appendicitis 540-543;Men;664 Coru±a, A;Group 1106 Appendicitis 540-543;Women;553 Coru±a, A;Group 1107 Inguinal hernia 550;Both sexes;1,674 Coru±a, A;Group 1107 Inguinal hernia 550;Men;1,509 Coru±a, A;Group 1107 Inguinal hernia 550;Women;165 Coru±a, A;Group 1108 Other abdominal hernia 551-553;Both sexes;1,089 Coru±a, A;Group 1108 Other abdominal hernia 551-553;Men;541 Coru±a, A;Group 1108 Other abdominal hernia 551-553;Women;548 Coru±a, A;Group 1109 Crohn's disease and ulcerative colitis 555-556;Both sexes;307 Coru±a, A;Group 1109 Crohn's disease and ulcerative colitis 555-556;Men;154 Coru±a, A;Group 1109 Crohn's disease and ulcerative colitis 555-556;Women;153 Coru±a, A;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Both sexes;603 Coru±a, A;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Men;322 Coru±a, A;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Women;281 Coru±a, A;Group 1111 Intestinal obstruction without hernia 560;Both sexes;672 Coru±a, A;Group 1111 Intestinal obstruction without hernia 560;Men;338 Coru±a, A;Group 1111 Intestinal obstruction without hernia 560;Women;334 Coru±a, A;Group 1112 Intestinal diverticulosis 562;Both sexes;574 Coru±a, A;Group 1112 Intestinal diverticulosis 562;Men;295 Coru±a, A;Group 1112 Intestinal diverticulosis 562;Women;279 Coru±a, A;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Both sexes;937 Coru±a, A;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Men;601 Coru±a, A;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Women;336 Coru±a, A;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Both sexes;501 Coru±a, A;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Men;217 Coru±a, A;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Women;284 Coru±a, A;Group 1115 Alcoholic hepatitis 5710-5713;Both sexes;354 Coru±a, A;Group 1115 Alcoholic hepatitis 5710-5713;Men;302 Coru±a, A;Group 1115 Alcoholic hepatitis 5710-5713;Women;52 Coru±a, A;Group 1116 Other diseases of the liver 570,5714-573;Both sexes;632 Coru±a, A;Group 1116 Other diseases of the liver 570,5714-573;Men;346 Coru±a, A;Group 1116 Other diseases of the liver 570,5714-573;Women;286 Coru±a, A;Group 1117 Cholelithiasis 574;Both sexes;3,078 Coru±a, A;Group 1117 Cholelithiasis 574;Men;1,273 Coru±a, A;Group 1117 Cholelithiasis 574;Women;1,805 Coru±a, A;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Both sexes;602 Coru±a, A;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Men;310 Coru±a, A;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Women;292 Coru±a, A;Group 1119 Pancreatic diseases 577;Both sexes;904 Coru±a, A;Group 1119 Pancreatic diseases 577;Men;486 Coru±a, A;Group 1119 Pancreatic diseases 577;Women;418 Coru±a, A;Group 1120 Other diseases of the digestive system Rest of (520-579);Both sexes;592 Coru±a, A;Group 1120 Other diseases of the digestive system Rest of (520-579);Men;323 Coru±a, A;Group 1120 Other diseases of the digestive system Rest of (520-579);Women;269 Coru±a, A;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Both sexes;1,367 Coru±a, A;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Men;737 Coru±a, A;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Women;630 Coru±a, A;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Both sexes;857 Coru±a, A;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Men;484 Coru±a, A;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Women;373 Coru±a, A;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Both sexes;90 Coru±a, A;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Men;45 Coru±a, A;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Women;45 Coru±a, A;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Both sexes;420 Coru±a, A;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Men;208 Coru±a, A;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Women;212 Coru±a, A;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Both sexes;8,975 Coru±a, A;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Men;3,958 Coru±a, A;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Women;5,017 Coru±a, A;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Both sexes;.. Coru±a, A;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Men;.. Coru±a, A;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Women;.. Coru±a, A;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Both sexes;.. Coru±a, A;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Men;.. Coru±a, A;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Women;.. Coru±a, A;Group 1303 Internal derangement of knee 717;Both sexes;989 Coru±a, A;Group 1303 Internal derangement of knee 717;Men;684 Coru±a, A;Group 1303 Internal derangement of knee 717;Women;305 Coru±a, A;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Both sexes;3,380 Coru±a, A;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Men;1,316 Coru±a, A;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Women;2,064 Coru±a, A;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Both sexes;244 Coru±a, A;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Men;84 Coru±a, A;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Women;160 Coru±a, A;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Both sexes;284 Coru±a, A;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Men;141 Coru±a, A;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Women;143 Coru±a, A;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Both sexes;725 Coru±a, A;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Men;398 Coru±a, A;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Women;327 Coru±a, A;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Both sexes;87 Coru±a, A;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Men;43 Coru±a, A;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Women;44 Coru±a, A;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Both sexes;1,417 Coru±a, A;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Men;745 Coru±a, A;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Women;672 Coru±a, A;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Both sexes;1,849 Coru±a, A;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Men;547 Coru±a, A;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Women;1,302 Coru±a, A;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Both sexes;6,989 Coru±a, A;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Men;3,362 Coru±a, A;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Women;3,627 Coru±a, A;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Both sexes;596 Coru±a, A;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Men;223 Coru±a, A;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Women;373 Coru±a, A;Group 1402 Renal failure 5836-5837, 584-586;Both sexes;647 Coru±a, A;Group 1402 Renal failure 5836-5837, 584-586;Men;352 Coru±a, A;Group 1402 Renal failure 5836-5837, 584-586;Women;295 Coru±a, A;Group 1403 Urolithiasis 592, 594, 7880;Both sexes;638 Coru±a, A;Group 1403 Urolithiasis 592, 594, 7880;Men;376 Coru±a, A;Group 1403 Urolithiasis 592, 594, 7880;Women;262 Coru±a, A;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Both sexes;1,989 Coru±a, A;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Men;957 Coru±a, A;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Women;1,032 Coru±a, A;Group 1405 Prostatic hyperplasia 600;Both sexes;837 Coru±a, A;Group 1405 Prostatic hyperplasia 600;Men;837 Coru±a, A;Group 1405 Prostatic hyperplasia 600;Women;.. Coru±a, A;Group 1406 Other diseases of the male genital organs 601-608;Both sexes;564 Coru±a, A;Group 1406 Other diseases of the male genital organs 601-608;Men;564 Coru±a, A;Group 1406 Other diseases of the male genital organs 601-608;Women;.. Coru±a, A;Group 1407 Disorders of breast 610-612;Both sexes;293 Coru±a, A;Group 1407 Disorders of breast 610-612;Men;44 Coru±a, A;Group 1407 Disorders of breast 610-612;Women;249 Coru±a, A;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Both sexes;175 Coru±a, A;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Men;.. Coru±a, A;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Women;175 Coru±a, A;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Both sexes;130 Coru±a, A;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Men;.. Coru±a, A;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Women;130 Coru±a, A;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Both sexes;1,120 Coru±a, A;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Men;9 Coru±a, A;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Women;1,111 Coru±a, A;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Both sexes;11,693 Coru±a, A;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Men;.. Coru±a, A;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Women;11,693 Coru±a, A;Group 1501 Legally induced abortion 635;Both sexes;85 Coru±a, A;Group 1501 Legally induced abortion 635;Men;.. Coru±a, A;Group 1501 Legally induced abortion 635;Women;85 Coru±a, A;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Both sexes;1,244 Coru±a, A;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Men;.. Coru±a, A;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Women;1,244 Coru±a, A;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Both sexes;7,330 Coru±a, A;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Men;.. Coru±a, A;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Women;7,330 Coru±a, A;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Both sexes;1,372 Coru±a, A;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Men;.. Coru±a, A;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Women;1,372 Coru±a, A;Group 1505 Single spontaneous delivery 650;Both sexes;595 Coru±a, A;Group 1505 Single spontaneous delivery 650;Men;.. Coru±a, A;Group 1505 Single spontaneous delivery 650;Women;595 Coru±a, A;Group 1506 Other deliveries 6695-6697;Both sexes;282 Coru±a, A;Group 1506 Other deliveries 6695-6697;Men;.. Coru±a, A;Group 1506 Other deliveries 6695-6697;Women;282 Coru±a, A;Group 1507 Complications related to the puerperium 670-676;Both sexes;61 Coru±a, A;Group 1507 Complications related to the puerperium 670-676;Men;.. Coru±a, A;Group 1507 Complications related to the puerperium 670-676;Women;61 Coru±a, A;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Both sexes;724 Coru±a, A;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Men;.. Coru±a, A;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Women;724 Coru±a, A;Group 1600 Some disorders originating in the perinatal period 760-779;Both sexes;1,798 Coru±a, A;Group 1600 Some disorders originating in the perinatal period 760-779;Men;994 Coru±a, A;Group 1600 Some disorders originating in the perinatal period 760-779;Women;804 Coru±a, A;Group 1601 Disorders related with premature delivery and a low birth weight 765;Both sexes;326 Coru±a, A;Group 1601 Disorders related with premature delivery and a low birth weight 765;Men;186 Coru±a, A;Group 1601 Disorders related with premature delivery and a low birth weight 765;Women;140 Coru±a, A;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Both sexes;1,472 Coru±a, A;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Men;808 Coru±a, A;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Women;664 Coru±a, A;Grupo 1700 Congenital abnormalities 740-759;Both sexes;1,322 Coru±a, A;Grupo 1700 Congenital abnormalities 740-759;Men;824 Coru±a, A;Grupo 1700 Congenital abnormalities 740-759;Women;498 Coru±a, A;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Both sexes;4,907 Coru±a, A;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Men;2,596 Coru±a, A;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Women;2,311 Coru±a, A;Group 1801 Pain in throat and chest 7841, 7865;Both sexes;596 Coru±a, A;Group 1801 Pain in throat and chest 7841, 7865;Men;326 Coru±a, A;Group 1801 Pain in throat and chest 7841, 7865;Women;270 Coru±a, A;Group 1802 Abdominal pain 7890;Both sexes;460 Coru±a, A;Group 1802 Abdominal pain 7890;Men;165 Coru±a, A;Group 1802 Abdominal pain 7890;Women;295 Coru±a, A;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Both sexes;830 Coru±a, A;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Men;474 Coru±a, A;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Women;356 Coru±a, A;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Both sexes;3,021 Coru±a, A;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Men;1,631 Coru±a, A;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Women;1,390 Coru±a, A;Group 1900 Injuries and poisoning 800-999;Both sexes;11,851 Coru±a, A;Group 1900 Injuries and poisoning 800-999;Men;6,348 Coru±a, A;Group 1900 Injuries and poisoning 800-999;Women;5,503 Coru±a, A;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Both sexes;636 Coru±a, A;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Men;360 Coru±a, A;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Women;276 Coru±a, A;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Both sexes;432 Coru±a, A;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Men;310 Coru±a, A;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Women;122 Coru±a, A;Group 1903 Radius and ulna fracture 813;Both sexes;651 Coru±a, A;Group 1903 Radius and ulna fracture 813;Men;311 Coru±a, A;Group 1903 Radius and ulna fracture 813;Women;340 Coru±a, A;Group 1904 Femur fracture 820-821;Both sexes;1,594 Coru±a, A;Group 1904 Femur fracture 820-821;Men;403 Coru±a, A;Group 1904 Femur fracture 820-821;Women;1,191 Coru±a, A;Group 1905 Leg fracture, including the ankle 823-824;Both sexes;862 Coru±a, A;Group 1905 Leg fracture, including the ankle 823-824;Men;394 Coru±a, A;Group 1905 Leg fracture, including the ankle 823-824;Women;468 Coru±a, A;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Both sexes;3,337 Coru±a, A;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Men;2,127 Coru±a, A;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Women;1,210 Coru±a, A;Group 1907 Burns 940-949;Both sexes;146 Coru±a, A;Group 1907 Burns 940-949;Men;77 Coru±a, A;Group 1907 Burns 940-949;Women;69 Coru±a, A;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Both sexes;251 Coru±a, A;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Men;118 Coru±a, A;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Women;133 Coru±a, A;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Both sexes;3,694 Coru±a, A;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Men;2,124 Coru±a, A;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Women;1,570 Coru±a, A;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Both sexes;46 Coru±a, A;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Men;24 Coru±a, A;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Women;22 Coru±a, A;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Both sexes;202 Coru±a, A;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Men;100 Coru±a, A;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Women;102 Coru±a, A;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Both sexes;2,853 Coru±a, A;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Men;1,542 Coru±a, A;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Women;1,311 Coru±a, A;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Both sexes;129 Coru±a, A;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Men;67 Coru±a, A;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Women;62 Coru±a, A;Group 2102 Contraceptive management V25;Both sexes;11 Coru±a, A;Group 2102 Contraceptive management V25;Men;2 Coru±a, A;Group 2102 Contraceptive management V25;Women;9 Coru±a, A;Group 2103 Living newborns by type of delivery V30-V39;Both sexes;.. Coru±a, A;Group 2103 Living newborns by type of delivery V30-V39;Men;.. Coru±a, A;Group 2103 Living newborns by type of delivery V30-V39;Women;.. Coru±a, A;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Both sexes;1,133 Coru±a, A;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Men;732 Coru±a, A;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Women;401 Coru±a, A;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Both sexes;1,580 Coru±a, A;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Men;741 Coru±a, A;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Women;839 Lugo;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Both sexes;34,571 Lugo;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Men;17,313 Lugo;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Women;17,258 Lugo;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Both sexes;585 Lugo;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Men;315 Lugo;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Women;270 Lugo;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Both sexes;107 Lugo;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Men;59 Lugo;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Women;48 Lugo;Group 0102 Imprecise intestinal infections 009;Both sexes;19 Lugo;Group 0102 Imprecise intestinal infections 009;Men;8 Lugo;Group 0102 Imprecise intestinal infections 009;Women;11 Lugo;Group 0103 Tuberculosis 010-018, 137;Both sexes;35 Lugo;Group 0103 Tuberculosis 010-018, 137;Men;23 Lugo;Group 0103 Tuberculosis 010-018, 137;Women;12 Lugo;Group 0104 Septicaemia 038;Both sexes;81 Lugo;Group 0104 Septicaemia 038;Men;39 Lugo;Group 0104 Septicaemia 038;Women;42 Lugo;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Both sexes;14 Lugo;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Men;9 Lugo;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Women;5 Lugo;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Both sexes;329 Lugo;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Men;177 Lugo;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Women;152 Lugo;Group 0200 Neoplasms 140-239;Both sexes;3,173 Lugo;Group 0200 Neoplasms 140-239;Men;1,662 Lugo;Group 0200 Neoplasms 140-239;Women;1,511 Lugo;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Both sexes;422 Lugo;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Men;259 Lugo;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Women;163 Lugo;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Both sexes;163 Lugo;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Men;135 Lugo;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Women;28 Lugo;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Both sexes;51 Lugo;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Men;26 Lugo;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Women;25 Lugo;Group 0204 Malignant neoplasm of breast 174-175;Both sexes;221 Lugo;Group 0204 Malignant neoplasm of breast 174-175;Men;6 Lugo;Group 0204 Malignant neoplasm of breast 174-175;Women;215 Lugo;Group 0205 Malignant neoplasm of uterus 179-180, 182;Both sexes;125 Lugo;Group 0205 Malignant neoplasm of uterus 179-180, 182;Men;.. Lugo;Group 0205 Malignant neoplasm of uterus 179-180, 182;Women;125 Lugo;Group 0206 Malignant neoplasm of ovary 1830;Both sexes;40 Lugo;Group 0206 Malignant neoplasm of ovary 1830;Men;.. Lugo;Group 0206 Malignant neoplasm of ovary 1830;Women;40 Lugo;Group 0207 Malignant neoplasm of prostate 185;Both sexes;160 Lugo;Group 0207 Malignant neoplasm of prostate 185;Men;160 Lugo;Group 0207 Malignant neoplasm of prostate 185;Women;.. Lugo;Group 0208 Malignant neoplasm of bladder 188;Both sexes;369 Lugo;Group 0208 Malignant neoplasm of bladder 188;Men;313 Lugo;Group 0208 Malignant neoplasm of bladder 188;Women;57 Lugo;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Both sexes;975 Lugo;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Men;589 Lugo;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Women;386 Lugo;Group 0210 Carcinoma in situ 230-234;Both sexes;44 Lugo;Group 0210 Carcinoma in situ 230-234;Men;18 Lugo;Group 0210 Carcinoma in situ 230-234;Women;26 Lugo;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Both sexes;39 Lugo;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Men;26 Lugo;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Women;13 Lugo;Grupo 0212 Leiomyoma of uterus 218;Both sexes;175 Lugo;Grupo 0212 Leiomyoma of uterus 218;Men;.. Lugo;Grupo 0212 Leiomyoma of uterus 218;Women;175 Lugo;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Both sexes;388 Lugo;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Men;131 Lugo;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Women;257 Lugo;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Both sexes;357 Lugo;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Men;168 Lugo;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Women;189 Lugo;Group 0301 Anaemias 280-285;Both sexes;218 Lugo;Group 0301 Anaemias 280-285;Men;97 Lugo;Group 0301 Anaemias 280-285;Women;121 Lugo;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Both sexes;139 Lugo;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Men;71 Lugo;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Women;68 Lugo;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Both sexes;657 Lugo;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Men;311 Lugo;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Women;346 Lugo;Group 0401 Diabetes mellitus 249-250;Both sexes;257 Lugo;Group 0401 Diabetes mellitus 249-250;Men;159 Lugo;Group 0401 Diabetes mellitus 249-250;Women;99 Lugo;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Both sexes;400 Lugo;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Men;153 Lugo;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Women;247 Lugo;Group 0500 Mental disorders 290-319;Both sexes;656 Lugo;Group 0500 Mental disorders 290-319;Men;354 Lugo;Group 0500 Mental disorders 290-319;Women;302 Lugo;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Both sexes;45 Lugo;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Men;15 Lugo;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Women;30 Lugo;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Both sexes;58 Lugo;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Men;46 Lugo;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Women;12 Lugo;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Both sexes;30 Lugo;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Men;20 Lugo;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Women;10 Lugo;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Both sexes;193 Lugo;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Men;118 Lugo;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Women;75 Lugo;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Both sexes;129 Lugo;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Men;61 Lugo;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Women;68 Lugo;Group 0506 Other mental and behavioural disorders Rest of (290-319);Both sexes;201 Lugo;Group 0506 Other mental and behavioural disorders Rest of (290-319);Men;94 Lugo;Group 0506 Other mental and behavioural disorders Rest of (290-319);Women;106 Lugo;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Both sexes;731 Lugo;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Men;350 Lugo;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Women;381 Lugo;Group 0601 Alzheimer's disease 3310;Both sexes;27 Lugo;Group 0601 Alzheimer's disease 3310;Men;11 Lugo;Group 0601 Alzheimer's disease 3310;Women;16 Lugo;Group 0602 Multiple sclerosis 340;Both sexes;50 Lugo;Group 0602 Multiple sclerosis 340;Men;16 Lugo;Group 0602 Multiple sclerosis 340;Women;34 Lugo;Group 0603 Epilepsy 345;Both sexes;169 Lugo;Group 0603 Epilepsy 345;Men;85 Lugo;Group 0603 Epilepsy 345;Women;84 Lugo;Group 0604 Transient cerebral ischemia 435;Both sexes;82 Lugo;Group 0604 Transient cerebral ischemia 435;Men;44 Lugo;Group 0604 Transient cerebral ischemia 435;Women;38 Lugo;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Both sexes;402 Lugo;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Men;193 Lugo;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Women;209 Lugo;Grupo 0700 Diseases of the eye and adnexa 360-379;Both sexes;291 Lugo;Grupo 0700 Diseases of the eye and adnexa 360-379;Men;149 Lugo;Grupo 0700 Diseases of the eye and adnexa 360-379;Women;142 Lugo;Grupo 0701 Cataract 366;Both sexes;29 Lugo;Grupo 0701 Cataract 366;Men;14 Lugo;Grupo 0701 Cataract 366;Women;15 Lugo;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Both sexes;262 Lugo;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Men;135 Lugo;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Women;127 Lugo;Group 0800 Diseases of the ear and the mastoid 380-389;Both sexes;159 Lugo;Group 0800 Diseases of the ear and the mastoid 380-389;Men;81 Lugo;Group 0800 Diseases of the ear and the mastoid 380-389;Women;78 Lugo;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Both sexes;4,443 Lugo;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Men;2,603 Lugo;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Women;1,840 Lugo;Group 0901 Hypertensive disease 401-405;Both sexes;282 Lugo;Group 0901 Hypertensive disease 401-405;Men;128 Lugo;Group 0901 Hypertensive disease 401-405;Women;154 Lugo;Group 0902 Angina pectoris 4111, 413;Both sexes;366 Lugo;Group 0902 Angina pectoris 4111, 413;Men;246 Lugo;Group 0902 Angina pectoris 4111, 413;Women;120 Lugo;Group 0903 Acute myocardial infarction 410;Both sexes;406 Lugo;Group 0903 Acute myocardial infarction 410;Men;291 Lugo;Group 0903 Acute myocardial infarction 410;Women;115 Lugo;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Both sexes;137 Lugo;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Men;109 Lugo;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Women;28 Lugo;Group 0905 Diseases of the lungs circulation 415-417;Both sexes;223 Lugo;Group 0905 Diseases of the lungs circulation 415-417;Men;106 Lugo;Group 0905 Diseases of the lungs circulation 415-417;Women;117 Lugo;Group 0906 Heart conduction disorders and arrhytmias 426-427;Both sexes;487 Lugo;Group 0906 Heart conduction disorders and arrhytmias 426-427;Men;275 Lugo;Group 0906 Heart conduction disorders and arrhytmias 426-427;Women;212 Lugo;Grupo 0907 Heart failure 428;Both sexes;685 Lugo;Grupo 0907 Heart failure 428;Men;359 Lugo;Grupo 0907 Heart failure 428;Women;325 Lugo;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Both sexes;885 Lugo;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Men;491 Lugo;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Women;394 Lugo;Grupo 0909 Atherosclerosis 440;Both sexes;197 Lugo;Grupo 0909 Atherosclerosis 440;Men;130 Lugo;Grupo 0909 Atherosclerosis 440;Women;67 Lugo;Group 0910 Varicose veins of lower extremities 454;Both sexes;20 Lugo;Group 0910 Varicose veins of lower extremities 454;Men;10 Lugo;Group 0910 Varicose veins of lower extremities 454;Women;10 Lugo;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Both sexes;755 Lugo;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Men;457 Lugo;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Women;298 Lugo;Group 1000 Diseases of the respiratory system 0340, 460-519;Both sexes;3,640 Lugo;Group 1000 Diseases of the respiratory system 0340, 460-519;Men;2,186 Lugo;Group 1000 Diseases of the respiratory system 0340, 460-519;Women;1,454 Lugo;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Both sexes;153 Lugo;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Men;80 Lugo;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Women;74 Lugo;Group 1002 Pneumonia 480-486;Both sexes;884 Lugo;Group 1002 Pneumonia 480-486;Men;549 Lugo;Group 1002 Pneumonia 480-486;Women;335 Lugo;Group 1003 Acute bronchitis and bronchiolitis 466;Both sexes;118 Lugo;Group 1003 Acute bronchitis and bronchiolitis 466;Men;77 Lugo;Group 1003 Acute bronchitis and bronchiolitis 466;Women;41 Lugo;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Both sexes;123 Lugo;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Men;64 Lugo;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Women;59 Lugo;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Both sexes;224 Lugo;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Men;148 Lugo;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Women;75 Lugo;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Both sexes;447 Lugo;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Men;330 Lugo;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Women;117 Lugo;Group 1007 Asthma 4930-4931,4938-4939;Both sexes;114 Lugo;Group 1007 Asthma 4930-4931,4938-4939;Men;45 Lugo;Group 1007 Asthma 4930-4931,4938-4939;Women;69 Lugo;Group 1008 Other diseases of the respiratory system Resto of (460-519);Both sexes;1,576 Lugo;Group 1008 Other diseases of the respiratory system Resto of (460-519);Men;892 Lugo;Group 1008 Other diseases of the respiratory system Resto of (460-519);Women;684 Lugo;Group 1100 Diseases of the digestive system 520-579;Both sexes;5,226 Lugo;Group 1100 Diseases of the digestive system 520-579;Men;3,043 Lugo;Group 1100 Diseases of the digestive system 520-579;Women;2,183 Lugo;Group 1101 Disorders of the teeth and supporting structures 520-525;Both sexes;53 Lugo;Group 1101 Disorders of the teeth and supporting structures 520-525;Men;31 Lugo;Group 1101 Disorders of the teeth and supporting structures 520-525;Women;22 Lugo;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Both sexes;51 Lugo;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Men;27 Lugo;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Women;24 Lugo;Group 1103 Diseases of the esophagus 530;Both sexes;70 Lugo;Group 1103 Diseases of the esophagus 530;Men;51 Lugo;Group 1103 Diseases of the esophagus 530;Women;19 Lugo;Group 1104 Peptic ulcer 531-534;Both sexes;74 Lugo;Group 1104 Peptic ulcer 531-534;Men;47 Lugo;Group 1104 Peptic ulcer 531-534;Women;27 Lugo;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Both sexes;93 Lugo;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Men;50 Lugo;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Women;42 Lugo;Group 1106 Appendicitis 540-543;Both sexes;376 Lugo;Group 1106 Appendicitis 540-543;Men;216 Lugo;Group 1106 Appendicitis 540-543;Women;160 Lugo;Group 1107 Inguinal hernia 550;Both sexes;668 Lugo;Group 1107 Inguinal hernia 550;Men;599 Lugo;Group 1107 Inguinal hernia 550;Women;69 Lugo;Group 1108 Other abdominal hernia 551-553;Both sexes;411 Lugo;Group 1108 Other abdominal hernia 551-553;Men;190 Lugo;Group 1108 Other abdominal hernia 551-553;Women;221 Lugo;Group 1109 Crohn's disease and ulcerative colitis 555-556;Both sexes;66 Lugo;Group 1109 Crohn's disease and ulcerative colitis 555-556;Men;29 Lugo;Group 1109 Crohn's disease and ulcerative colitis 555-556;Women;36 Lugo;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Both sexes;235 Lugo;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Men;141 Lugo;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Women;95 Lugo;Group 1111 Intestinal obstruction without hernia 560;Both sexes;304 Lugo;Group 1111 Intestinal obstruction without hernia 560;Men;148 Lugo;Group 1111 Intestinal obstruction without hernia 560;Women;156 Lugo;Group 1112 Intestinal diverticulosis 562;Both sexes;249 Lugo;Group 1112 Intestinal diverticulosis 562;Men;131 Lugo;Group 1112 Intestinal diverticulosis 562;Women;119 Lugo;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Both sexes;282 Lugo;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Men;197 Lugo;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Women;85 Lugo;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Both sexes;222 Lugo;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Men;105 Lugo;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Women;116 Lugo;Group 1115 Alcoholic hepatitis 5710-5713;Both sexes;137 Lugo;Group 1115 Alcoholic hepatitis 5710-5713;Men;118 Lugo;Group 1115 Alcoholic hepatitis 5710-5713;Women;19 Lugo;Group 1116 Other diseases of the liver 570,5714-573;Both sexes;130 Lugo;Group 1116 Other diseases of the liver 570,5714-573;Men;79 Lugo;Group 1116 Other diseases of the liver 570,5714-573;Women;51 Lugo;Group 1117 Cholelithiasis 574;Both sexes;996 Lugo;Group 1117 Cholelithiasis 574;Men;440 Lugo;Group 1117 Cholelithiasis 574;Women;555 Lugo;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Both sexes;319 Lugo;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Men;168 Lugo;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Women;152 Lugo;Group 1119 Pancreatic diseases 577;Both sexes;295 Lugo;Group 1119 Pancreatic diseases 577;Men;169 Lugo;Group 1119 Pancreatic diseases 577;Women;125 Lugo;Group 1120 Other diseases of the digestive system Rest of (520-579);Both sexes;194 Lugo;Group 1120 Other diseases of the digestive system Rest of (520-579);Men;106 Lugo;Group 1120 Other diseases of the digestive system Rest of (520-579);Women;88 Lugo;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Both sexes;512 Lugo;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Men;273 Lugo;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Women;239 Lugo;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Both sexes;320 Lugo;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Men;181 Lugo;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Women;139 Lugo;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Both sexes;46 Lugo;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Men;19 Lugo;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Women;27 Lugo;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Both sexes;146 Lugo;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Men;73 Lugo;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Women;73 Lugo;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Both sexes;2,669 Lugo;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Men;1,229 Lugo;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Women;1,440 Lugo;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Both sexes;.. Lugo;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Men;.. Lugo;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Women;.. Lugo;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Both sexes;.. Lugo;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Men;.. Lugo;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Women;.. Lugo;Group 1303 Internal derangement of knee 717;Both sexes;266 Lugo;Group 1303 Internal derangement of knee 717;Men;184 Lugo;Group 1303 Internal derangement of knee 717;Women;82 Lugo;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Both sexes;1,190 Lugo;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Men;483 Lugo;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Women;708 Lugo;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Both sexes;72 Lugo;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Men;34 Lugo;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Women;38 Lugo;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Both sexes;94 Lugo;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Men;47 Lugo;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Women;47 Lugo;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Both sexes;169 Lugo;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Men;78 Lugo;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Women;91 Lugo;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Both sexes;60 Lugo;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Men;23 Lugo;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Women;37 Lugo;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Both sexes;432 Lugo;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Men;248 Lugo;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Women;184 Lugo;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Both sexes;385 Lugo;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Men;132 Lugo;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Women;253 Lugo;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Both sexes;2,131 Lugo;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Men;1,021 Lugo;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Women;1,110 Lugo;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Both sexes;131 Lugo;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Men;56 Lugo;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Women;75 Lugo;Group 1402 Renal failure 5836-5837, 584-586;Both sexes;216 Lugo;Group 1402 Renal failure 5836-5837, 584-586;Men;120 Lugo;Group 1402 Renal failure 5836-5837, 584-586;Women;96 Lugo;Group 1403 Urolithiasis 592, 594, 7880;Both sexes;187 Lugo;Group 1403 Urolithiasis 592, 594, 7880;Men;113 Lugo;Group 1403 Urolithiasis 592, 594, 7880;Women;73 Lugo;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Both sexes;572 Lugo;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Men;247 Lugo;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Women;325 Lugo;Group 1405 Prostatic hyperplasia 600;Both sexes;224 Lugo;Group 1405 Prostatic hyperplasia 600;Men;224 Lugo;Group 1405 Prostatic hyperplasia 600;Women;.. Lugo;Group 1406 Other diseases of the male genital organs 601-608;Both sexes;241 Lugo;Group 1406 Other diseases of the male genital organs 601-608;Men;241 Lugo;Group 1406 Other diseases of the male genital organs 601-608;Women;.. Lugo;Group 1407 Disorders of breast 610-612;Both sexes;72 Lugo;Group 1407 Disorders of breast 610-612;Men;14 Lugo;Group 1407 Disorders of breast 610-612;Women;58 Lugo;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Both sexes;59 Lugo;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Men;.. Lugo;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Women;59 Lugo;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Both sexes;60 Lugo;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Men;.. Lugo;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Women;60 Lugo;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Both sexes;368 Lugo;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Men;5 Lugo;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Women;363 Lugo;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Both sexes;2,668 Lugo;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Men;.. Lugo;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Women;2,668 Lugo;Group 1501 Legally induced abortion 635;Both sexes;15 Lugo;Group 1501 Legally induced abortion 635;Men;.. Lugo;Group 1501 Legally induced abortion 635;Women;15 Lugo;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Both sexes;320 Lugo;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Men;.. Lugo;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Women;320 Lugo;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Both sexes;1,306 Lugo;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Men;.. Lugo;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Women;1,306 Lugo;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Both sexes;710 Lugo;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Men;.. Lugo;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Women;710 Lugo;Group 1505 Single spontaneous delivery 650;Both sexes;95 Lugo;Group 1505 Single spontaneous delivery 650;Men;.. Lugo;Group 1505 Single spontaneous delivery 650;Women;95 Lugo;Group 1506 Other deliveries 6695-6697;Both sexes;63 Lugo;Group 1506 Other deliveries 6695-6697;Men;.. Lugo;Group 1506 Other deliveries 6695-6697;Women;63 Lugo;Group 1507 Complications related to the puerperium 670-676;Both sexes;12 Lugo;Group 1507 Complications related to the puerperium 670-676;Men;.. Lugo;Group 1507 Complications related to the puerperium 670-676;Women;12 Lugo;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Both sexes;147 Lugo;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Men;.. Lugo;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Women;147 Lugo;Group 1600 Some disorders originating in the perinatal period 760-779;Both sexes;413 Lugo;Group 1600 Some disorders originating in the perinatal period 760-779;Men;222 Lugo;Group 1600 Some disorders originating in the perinatal period 760-779;Women;191 Lugo;Group 1601 Disorders related with premature delivery and a low birth weight 765;Both sexes;82 Lugo;Group 1601 Disorders related with premature delivery and a low birth weight 765;Men;42 Lugo;Group 1601 Disorders related with premature delivery and a low birth weight 765;Women;40 Lugo;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Both sexes;331 Lugo;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Men;180 Lugo;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Women;151 Lugo;Grupo 1700 Congenital abnormalities 740-759;Both sexes;114 Lugo;Grupo 1700 Congenital abnormalities 740-759;Men;65 Lugo;Grupo 1700 Congenital abnormalities 740-759;Women;49 Lugo;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Both sexes;1,913 Lugo;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Men;1,066 Lugo;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Women;847 Lugo;Group 1801 Pain in throat and chest 7841, 7865;Both sexes;132 Lugo;Group 1801 Pain in throat and chest 7841, 7865;Men;77 Lugo;Group 1801 Pain in throat and chest 7841, 7865;Women;55 Lugo;Group 1802 Abdominal pain 7890;Both sexes;178 Lugo;Group 1802 Abdominal pain 7890;Men;78 Lugo;Group 1802 Abdominal pain 7890;Women;100 Lugo;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Both sexes;487 Lugo;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Men;259 Lugo;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Women;228 Lugo;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Both sexes;1,116 Lugo;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Men;652 Lugo;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Women;464 Lugo;Group 1900 Injuries and poisoning 800-999;Both sexes;3,601 Lugo;Group 1900 Injuries and poisoning 800-999;Men;1,888 Lugo;Group 1900 Injuries and poisoning 800-999;Women;1,712 Lugo;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Both sexes;246 Lugo;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Men;153 Lugo;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Women;93 Lugo;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Both sexes;113 Lugo;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Men;83 Lugo;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Women;30 Lugo;Group 1903 Radius and ulna fracture 813;Both sexes;159 Lugo;Group 1903 Radius and ulna fracture 813;Men;80 Lugo;Group 1903 Radius and ulna fracture 813;Women;79 Lugo;Group 1904 Femur fracture 820-821;Both sexes;619 Lugo;Group 1904 Femur fracture 820-821;Men;157 Lugo;Group 1904 Femur fracture 820-821;Women;461 Lugo;Group 1905 Leg fracture, including the ankle 823-824;Both sexes;257 Lugo;Group 1905 Leg fracture, including the ankle 823-824;Men;122 Lugo;Group 1905 Leg fracture, including the ankle 823-824;Women;136 Lugo;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Both sexes;1,065 Lugo;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Men;667 Lugo;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Women;399 Lugo;Group 1907 Burns 940-949;Both sexes;45 Lugo;Group 1907 Burns 940-949;Men;29 Lugo;Group 1907 Burns 940-949;Women;16 Lugo;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Both sexes;83 Lugo;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Men;41 Lugo;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Women;42 Lugo;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Both sexes;942 Lugo;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Men;518 Lugo;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Women;424 Lugo;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Both sexes;.. Lugo;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Men;.. Lugo;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Women;.. Lugo;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Both sexes;71 Lugo;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Men;38 Lugo;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Women;33 Lugo;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Both sexes;634 Lugo;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Men;326 Lugo;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Women;307 Lugo;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Both sexes;54 Lugo;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Men;34 Lugo;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Women;20 Lugo;Group 2102 Contraceptive management V25;Both sexes;19 Lugo;Group 2102 Contraceptive management V25;Men;.. Lugo;Group 2102 Contraceptive management V25;Women;19 Lugo;Group 2103 Living newborns by type of delivery V30-V39;Both sexes;.. Lugo;Group 2103 Living newborns by type of delivery V30-V39;Men;.. Lugo;Group 2103 Living newborns by type of delivery V30-V39;Women;.. Lugo;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Both sexes;218 Lugo;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Men;108 Lugo;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Women;110 Lugo;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Both sexes;343 Lugo;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Men;184 Lugo;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Women;158 Ourense;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Both sexes;37,250 Ourense;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Men;18,727 Ourense;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Women;18,523 Ourense;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Both sexes;667 Ourense;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Men;360 Ourense;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Women;307 Ourense;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Both sexes;108 Ourense;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Men;55 Ourense;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Women;53 Ourense;Group 0102 Imprecise intestinal infections 009;Both sexes;13 Ourense;Group 0102 Imprecise intestinal infections 009;Men;5 Ourense;Group 0102 Imprecise intestinal infections 009;Women;8 Ourense;Group 0103 Tuberculosis 010-018, 137;Both sexes;24 Ourense;Group 0103 Tuberculosis 010-018, 137;Men;16 Ourense;Group 0103 Tuberculosis 010-018, 137;Women;8 Ourense;Group 0104 Septicaemia 038;Both sexes;318 Ourense;Group 0104 Septicaemia 038;Men;158 Ourense;Group 0104 Septicaemia 038;Women;160 Ourense;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Both sexes;6 Ourense;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Men;4 Ourense;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Women;2 Ourense;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Both sexes;198 Ourense;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Men;122 Ourense;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Women;76 Ourense;Group 0200 Neoplasms 140-239;Both sexes;3,188 Ourense;Group 0200 Neoplasms 140-239;Men;1,783 Ourense;Group 0200 Neoplasms 140-239;Women;1,405 Ourense;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Both sexes;505 Ourense;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Men;328 Ourense;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Women;177 Ourense;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Both sexes;180 Ourense;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Men;144 Ourense;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Women;36 Ourense;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Both sexes;33 Ourense;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Men;18 Ourense;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Women;15 Ourense;Group 0204 Malignant neoplasm of breast 174-175;Both sexes;258 Ourense;Group 0204 Malignant neoplasm of breast 174-175;Men;2 Ourense;Group 0204 Malignant neoplasm of breast 174-175;Women;256 Ourense;Group 0205 Malignant neoplasm of uterus 179-180, 182;Both sexes;57 Ourense;Group 0205 Malignant neoplasm of uterus 179-180, 182;Men;.. Ourense;Group 0205 Malignant neoplasm of uterus 179-180, 182;Women;57 Ourense;Group 0206 Malignant neoplasm of ovary 1830;Both sexes;28 Ourense;Group 0206 Malignant neoplasm of ovary 1830;Men;.. Ourense;Group 0206 Malignant neoplasm of ovary 1830;Women;28 Ourense;Group 0207 Malignant neoplasm of prostate 185;Both sexes;101 Ourense;Group 0207 Malignant neoplasm of prostate 185;Men;101 Ourense;Group 0207 Malignant neoplasm of prostate 185;Women;.. Ourense;Group 0208 Malignant neoplasm of bladder 188;Both sexes;358 Ourense;Group 0208 Malignant neoplasm of bladder 188;Men;288 Ourense;Group 0208 Malignant neoplasm of bladder 188;Women;70 Ourense;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Both sexes;1,058 Ourense;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Men;660 Ourense;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Women;398 Ourense;Group 0210 Carcinoma in situ 230-234;Both sexes;44 Ourense;Group 0210 Carcinoma in situ 230-234;Men;14 Ourense;Group 0210 Carcinoma in situ 230-234;Women;30 Ourense;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Both sexes;44 Ourense;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Men;31 Ourense;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Women;13 Ourense;Grupo 0212 Leiomyoma of uterus 218;Both sexes;112 Ourense;Grupo 0212 Leiomyoma of uterus 218;Men;.. Ourense;Grupo 0212 Leiomyoma of uterus 218;Women;112 Ourense;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Both sexes;410 Ourense;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Men;197 Ourense;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Women;213 Ourense;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Both sexes;357 Ourense;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Men;189 Ourense;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Women;168 Ourense;Group 0301 Anaemias 280-285;Both sexes;270 Ourense;Group 0301 Anaemias 280-285;Men;147 Ourense;Group 0301 Anaemias 280-285;Women;123 Ourense;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Both sexes;87 Ourense;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Men;42 Ourense;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Women;45 Ourense;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Both sexes;573 Ourense;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Men;243 Ourense;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Women;330 Ourense;Group 0401 Diabetes mellitus 249-250;Both sexes;189 Ourense;Group 0401 Diabetes mellitus 249-250;Men;98 Ourense;Group 0401 Diabetes mellitus 249-250;Women;91 Ourense;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Both sexes;384 Ourense;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Men;145 Ourense;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Women;239 Ourense;Group 0500 Mental disorders 290-319;Both sexes;567 Ourense;Group 0500 Mental disorders 290-319;Men;291 Ourense;Group 0500 Mental disorders 290-319;Women;276 Ourense;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Both sexes;8 Ourense;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Men;4 Ourense;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Women;4 Ourense;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Both sexes;64 Ourense;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Men;44 Ourense;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Women;20 Ourense;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Both sexes;21 Ourense;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Men;16 Ourense;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Women;5 Ourense;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Both sexes;161 Ourense;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Men;87 Ourense;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Women;74 Ourense;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Both sexes;104 Ourense;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Men;38 Ourense;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Women;66 Ourense;Group 0506 Other mental and behavioural disorders Rest of (290-319);Both sexes;209 Ourense;Group 0506 Other mental and behavioural disorders Rest of (290-319);Men;102 Ourense;Group 0506 Other mental and behavioural disorders Rest of (290-319);Women;107 Ourense;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Both sexes;790 Ourense;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Men;391 Ourense;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Women;399 Ourense;Group 0601 Alzheimer's disease 3310;Both sexes;8 Ourense;Group 0601 Alzheimer's disease 3310;Men;4 Ourense;Group 0601 Alzheimer's disease 3310;Women;4 Ourense;Group 0602 Multiple sclerosis 340;Both sexes;35 Ourense;Group 0602 Multiple sclerosis 340;Men;11 Ourense;Group 0602 Multiple sclerosis 340;Women;24 Ourense;Group 0603 Epilepsy 345;Both sexes;95 Ourense;Group 0603 Epilepsy 345;Men;51 Ourense;Group 0603 Epilepsy 345;Women;44 Ourense;Group 0604 Transient cerebral ischemia 435;Both sexes;232 Ourense;Group 0604 Transient cerebral ischemia 435;Men;104 Ourense;Group 0604 Transient cerebral ischemia 435;Women;128 Ourense;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Both sexes;420 Ourense;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Men;221 Ourense;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Women;199 Ourense;Grupo 0700 Diseases of the eye and adnexa 360-379;Both sexes;105 Ourense;Grupo 0700 Diseases of the eye and adnexa 360-379;Men;54 Ourense;Grupo 0700 Diseases of the eye and adnexa 360-379;Women;51 Ourense;Grupo 0701 Cataract 366;Both sexes;3 Ourense;Grupo 0701 Cataract 366;Men;1 Ourense;Grupo 0701 Cataract 366;Women;2 Ourense;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Both sexes;102 Ourense;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Men;53 Ourense;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Women;49 Ourense;Group 0800 Diseases of the ear and the mastoid 380-389;Both sexes;148 Ourense;Group 0800 Diseases of the ear and the mastoid 380-389;Men;65 Ourense;Group 0800 Diseases of the ear and the mastoid 380-389;Women;83 Ourense;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Both sexes;5,000 Ourense;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Men;2,828 Ourense;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Women;2,172 Ourense;Group 0901 Hypertensive disease 401-405;Both sexes;160 Ourense;Group 0901 Hypertensive disease 401-405;Men;77 Ourense;Group 0901 Hypertensive disease 401-405;Women;83 Ourense;Group 0902 Angina pectoris 4111, 413;Both sexes;315 Ourense;Group 0902 Angina pectoris 4111, 413;Men;201 Ourense;Group 0902 Angina pectoris 4111, 413;Women;114 Ourense;Group 0903 Acute myocardial infarction 410;Both sexes;348 Ourense;Group 0903 Acute myocardial infarction 410;Men;238 Ourense;Group 0903 Acute myocardial infarction 410;Women;110 Ourense;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Both sexes;212 Ourense;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Men;167 Ourense;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Women;45 Ourense;Group 0905 Diseases of the lungs circulation 415-417;Both sexes;236 Ourense;Group 0905 Diseases of the lungs circulation 415-417;Men;119 Ourense;Group 0905 Diseases of the lungs circulation 415-417;Women;117 Ourense;Group 0906 Heart conduction disorders and arrhytmias 426-427;Both sexes;600 Ourense;Group 0906 Heart conduction disorders and arrhytmias 426-427;Men;347 Ourense;Group 0906 Heart conduction disorders and arrhytmias 426-427;Women;253 Ourense;Grupo 0907 Heart failure 428;Both sexes;1,156 Ourense;Grupo 0907 Heart failure 428;Men;570 Ourense;Grupo 0907 Heart failure 428;Women;586 Ourense;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Both sexes;1,056 Ourense;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Men;562 Ourense;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Women;494 Ourense;Grupo 0909 Atherosclerosis 440;Both sexes;169 Ourense;Grupo 0909 Atherosclerosis 440;Men;115 Ourense;Grupo 0909 Atherosclerosis 440;Women;54 Ourense;Group 0910 Varicose veins of lower extremities 454;Both sexes;54 Ourense;Group 0910 Varicose veins of lower extremities 454;Men;22 Ourense;Group 0910 Varicose veins of lower extremities 454;Women;32 Ourense;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Both sexes;694 Ourense;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Men;410 Ourense;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Women;284 Ourense;Group 1000 Diseases of the respiratory system 0340, 460-519;Both sexes;5,389 Ourense;Group 1000 Diseases of the respiratory system 0340, 460-519;Men;3,165 Ourense;Group 1000 Diseases of the respiratory system 0340, 460-519;Women;2,224 Ourense;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Both sexes;135 Ourense;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Men;71 Ourense;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Women;64 Ourense;Group 1002 Pneumonia 480-486;Both sexes;1,453 Ourense;Group 1002 Pneumonia 480-486;Men;890 Ourense;Group 1002 Pneumonia 480-486;Women;563 Ourense;Group 1003 Acute bronchitis and bronchiolitis 466;Both sexes;146 Ourense;Group 1003 Acute bronchitis and bronchiolitis 466;Men;84 Ourense;Group 1003 Acute bronchitis and bronchiolitis 466;Women;62 Ourense;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Both sexes;268 Ourense;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Men;141 Ourense;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Women;127 Ourense;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Both sexes;312 Ourense;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Men;219 Ourense;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Women;93 Ourense;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Both sexes;996 Ourense;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Men;709 Ourense;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Women;287 Ourense;Group 1007 Asthma 4930-4931,4938-4939;Both sexes;118 Ourense;Group 1007 Asthma 4930-4931,4938-4939;Men;32 Ourense;Group 1007 Asthma 4930-4931,4938-4939;Women;86 Ourense;Group 1008 Other diseases of the respiratory system Resto of (460-519);Both sexes;1,961 Ourense;Group 1008 Other diseases of the respiratory system Resto of (460-519);Men;1,019 Ourense;Group 1008 Other diseases of the respiratory system Resto of (460-519);Women;942 Ourense;Group 1100 Diseases of the digestive system 520-579;Both sexes;5,109 Ourense;Group 1100 Diseases of the digestive system 520-579;Men;2,919 Ourense;Group 1100 Diseases of the digestive system 520-579;Women;2,190 Ourense;Group 1101 Disorders of the teeth and supporting structures 520-525;Both sexes;16 Ourense;Group 1101 Disorders of the teeth and supporting structures 520-525;Men;12 Ourense;Group 1101 Disorders of the teeth and supporting structures 520-525;Women;4 Ourense;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Both sexes;38 Ourense;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Men;19 Ourense;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Women;19 Ourense;Group 1103 Diseases of the esophagus 530;Both sexes;67 Ourense;Group 1103 Diseases of the esophagus 530;Men;41 Ourense;Group 1103 Diseases of the esophagus 530;Women;26 Ourense;Group 1104 Peptic ulcer 531-534;Both sexes;91 Ourense;Group 1104 Peptic ulcer 531-534;Men;60 Ourense;Group 1104 Peptic ulcer 531-534;Women;31 Ourense;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Both sexes;111 Ourense;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Men;63 Ourense;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Women;48 Ourense;Group 1106 Appendicitis 540-543;Both sexes;285 Ourense;Group 1106 Appendicitis 540-543;Men;162 Ourense;Group 1106 Appendicitis 540-543;Women;123 Ourense;Group 1107 Inguinal hernia 550;Both sexes;689 Ourense;Group 1107 Inguinal hernia 550;Men;616 Ourense;Group 1107 Inguinal hernia 550;Women;73 Ourense;Group 1108 Other abdominal hernia 551-553;Both sexes;365 Ourense;Group 1108 Other abdominal hernia 551-553;Men;176 Ourense;Group 1108 Other abdominal hernia 551-553;Women;189 Ourense;Group 1109 Crohn's disease and ulcerative colitis 555-556;Both sexes;75 Ourense;Group 1109 Crohn's disease and ulcerative colitis 555-556;Men;34 Ourense;Group 1109 Crohn's disease and ulcerative colitis 555-556;Women;41 Ourense;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Both sexes;284 Ourense;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Men;115 Ourense;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Women;169 Ourense;Group 1111 Intestinal obstruction without hernia 560;Both sexes;283 Ourense;Group 1111 Intestinal obstruction without hernia 560;Men;161 Ourense;Group 1111 Intestinal obstruction without hernia 560;Women;122 Ourense;Group 1112 Intestinal diverticulosis 562;Both sexes;240 Ourense;Group 1112 Intestinal diverticulosis 562;Men;117 Ourense;Group 1112 Intestinal diverticulosis 562;Women;123 Ourense;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Both sexes;303 Ourense;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Men;188 Ourense;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Women;115 Ourense;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Both sexes;174 Ourense;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Men;84 Ourense;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Women;90 Ourense;Group 1115 Alcoholic hepatitis 5710-5713;Both sexes;77 Ourense;Group 1115 Alcoholic hepatitis 5710-5713;Men;58 Ourense;Group 1115 Alcoholic hepatitis 5710-5713;Women;19 Ourense;Group 1116 Other diseases of the liver 570,5714-573;Both sexes;211 Ourense;Group 1116 Other diseases of the liver 570,5714-573;Men;142 Ourense;Group 1116 Other diseases of the liver 570,5714-573;Women;69 Ourense;Group 1117 Cholelithiasis 574;Both sexes;844 Ourense;Group 1117 Cholelithiasis 574;Men;350 Ourense;Group 1117 Cholelithiasis 574;Women;494 Ourense;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Both sexes;387 Ourense;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Men;208 Ourense;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Women;179 Ourense;Group 1119 Pancreatic diseases 577;Both sexes;266 Ourense;Group 1119 Pancreatic diseases 577;Men;139 Ourense;Group 1119 Pancreatic diseases 577;Women;127 Ourense;Group 1120 Other diseases of the digestive system Rest of (520-579);Both sexes;303 Ourense;Group 1120 Other diseases of the digestive system Rest of (520-579);Men;174 Ourense;Group 1120 Other diseases of the digestive system Rest of (520-579);Women;129 Ourense;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Both sexes;485 Ourense;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Men;240 Ourense;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Women;245 Ourense;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Both sexes;345 Ourense;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Men;179 Ourense;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Women;166 Ourense;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Both sexes;15 Ourense;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Men;8 Ourense;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Women;7 Ourense;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Both sexes;125 Ourense;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Men;53 Ourense;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Women;72 Ourense;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Both sexes;2,781 Ourense;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Men;1,272 Ourense;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Women;1,509 Ourense;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Both sexes;.. Ourense;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Men;.. Ourense;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Women;.. Ourense;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Both sexes;.. Ourense;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Men;.. Ourense;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Women;.. Ourense;Group 1303 Internal derangement of knee 717;Both sexes;389 Ourense;Group 1303 Internal derangement of knee 717;Men;261 Ourense;Group 1303 Internal derangement of knee 717;Women;128 Ourense;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Both sexes;1,317 Ourense;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Men;529 Ourense;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Women;788 Ourense;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Both sexes;62 Ourense;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Men;20 Ourense;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Women;42 Ourense;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Both sexes;92 Ourense;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Men;46 Ourense;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Women;46 Ourense;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Both sexes;183 Ourense;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Men;93 Ourense;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Women;90 Ourense;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Both sexes;36 Ourense;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Men;19 Ourense;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Women;17 Ourense;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Both sexes;332 Ourense;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Men;184 Ourense;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Women;148 Ourense;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Both sexes;370 Ourense;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Men;120 Ourense;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Women;250 Ourense;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Both sexes;2,347 Ourense;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Men;1,099 Ourense;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Women;1,248 Ourense;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Both sexes;167 Ourense;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Men;58 Ourense;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Women;109 Ourense;Group 1402 Renal failure 5836-5837, 584-586;Both sexes;262 Ourense;Group 1402 Renal failure 5836-5837, 584-586;Men;158 Ourense;Group 1402 Renal failure 5836-5837, 584-586;Women;104 Ourense;Group 1403 Urolithiasis 592, 594, 7880;Both sexes;277 Ourense;Group 1403 Urolithiasis 592, 594, 7880;Men;176 Ourense;Group 1403 Urolithiasis 592, 594, 7880;Women;101 Ourense;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Both sexes;842 Ourense;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Men;359 Ourense;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Women;483 Ourense;Group 1405 Prostatic hyperplasia 600;Both sexes;205 Ourense;Group 1405 Prostatic hyperplasia 600;Men;205 Ourense;Group 1405 Prostatic hyperplasia 600;Women;.. Ourense;Group 1406 Other diseases of the male genital organs 601-608;Both sexes;124 Ourense;Group 1406 Other diseases of the male genital organs 601-608;Men;124 Ourense;Group 1406 Other diseases of the male genital organs 601-608;Women;.. Ourense;Group 1407 Disorders of breast 610-612;Both sexes;73 Ourense;Group 1407 Disorders of breast 610-612;Men;19 Ourense;Group 1407 Disorders of breast 610-612;Women;54 Ourense;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Both sexes;44 Ourense;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Men;.. Ourense;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Women;44 Ourense;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Both sexes;38 Ourense;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Men;.. Ourense;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Women;38 Ourense;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Both sexes;315 Ourense;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Men;.. Ourense;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Women;315 Ourense;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Both sexes;2,231 Ourense;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Men;.. Ourense;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Women;2,231 Ourense;Group 1501 Legally induced abortion 635;Both sexes;3 Ourense;Group 1501 Legally induced abortion 635;Men;.. Ourense;Group 1501 Legally induced abortion 635;Women;3 Ourense;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Both sexes;130 Ourense;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Men;.. Ourense;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Women;130 Ourense;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Both sexes;1,328 Ourense;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Men;.. Ourense;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Women;1,328 Ourense;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Both sexes;496 Ourense;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Men;.. Ourense;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Women;496 Ourense;Group 1505 Single spontaneous delivery 650;Both sexes;142 Ourense;Group 1505 Single spontaneous delivery 650;Men;.. Ourense;Group 1505 Single spontaneous delivery 650;Women;142 Ourense;Group 1506 Other deliveries 6695-6697;Both sexes;24 Ourense;Group 1506 Other deliveries 6695-6697;Men;.. Ourense;Group 1506 Other deliveries 6695-6697;Women;24 Ourense;Group 1507 Complications related to the puerperium 670-676;Both sexes;7 Ourense;Group 1507 Complications related to the puerperium 670-676;Men;.. Ourense;Group 1507 Complications related to the puerperium 670-676;Women;7 Ourense;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Both sexes;101 Ourense;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Men;.. Ourense;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Women;101 Ourense;Group 1600 Some disorders originating in the perinatal period 760-779;Both sexes;282 Ourense;Group 1600 Some disorders originating in the perinatal period 760-779;Men;146 Ourense;Group 1600 Some disorders originating in the perinatal period 760-779;Women;136 Ourense;Group 1601 Disorders related with premature delivery and a low birth weight 765;Both sexes;82 Ourense;Group 1601 Disorders related with premature delivery and a low birth weight 765;Men;46 Ourense;Group 1601 Disorders related with premature delivery and a low birth weight 765;Women;36 Ourense;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Both sexes;200 Ourense;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Men;100 Ourense;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Women;100 Ourense;Grupo 1700 Congenital abnormalities 740-759;Both sexes;124 Ourense;Grupo 1700 Congenital abnormalities 740-759;Men;68 Ourense;Grupo 1700 Congenital abnormalities 740-759;Women;56 Ourense;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Both sexes;2,925 Ourense;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Men;1,526 Ourense;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Women;1,399 Ourense;Group 1801 Pain in throat and chest 7841, 7865;Both sexes;252 Ourense;Group 1801 Pain in throat and chest 7841, 7865;Men;153 Ourense;Group 1801 Pain in throat and chest 7841, 7865;Women;99 Ourense;Group 1802 Abdominal pain 7890;Both sexes;268 Ourense;Group 1802 Abdominal pain 7890;Men;111 Ourense;Group 1802 Abdominal pain 7890;Women;157 Ourense;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Both sexes;782 Ourense;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Men;348 Ourense;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Women;434 Ourense;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Both sexes;1,623 Ourense;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Men;914 Ourense;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Women;709 Ourense;Group 1900 Injuries and poisoning 800-999;Both sexes;3,682 Ourense;Group 1900 Injuries and poisoning 800-999;Men;1,774 Ourense;Group 1900 Injuries and poisoning 800-999;Women;1,908 Ourense;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Both sexes;284 Ourense;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Men;167 Ourense;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Women;117 Ourense;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Both sexes;73 Ourense;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Men;50 Ourense;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Women;23 Ourense;Group 1903 Radius and ulna fracture 813;Both sexes;242 Ourense;Group 1903 Radius and ulna fracture 813;Men;105 Ourense;Group 1903 Radius and ulna fracture 813;Women;137 Ourense;Group 1904 Femur fracture 820-821;Both sexes;636 Ourense;Group 1904 Femur fracture 820-821;Men;160 Ourense;Group 1904 Femur fracture 820-821;Women;476 Ourense;Group 1905 Leg fracture, including the ankle 823-824;Both sexes;263 Ourense;Group 1905 Leg fracture, including the ankle 823-824;Men;104 Ourense;Group 1905 Leg fracture, including the ankle 823-824;Women;159 Ourense;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Both sexes;1,351 Ourense;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Men;770 Ourense;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Women;581 Ourense;Group 1907 Burns 940-949;Both sexes;12 Ourense;Group 1907 Burns 940-949;Men;6 Ourense;Group 1907 Burns 940-949;Women;6 Ourense;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Both sexes;89 Ourense;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Men;45 Ourense;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Women;44 Ourense;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Both sexes;660 Ourense;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Men;336 Ourense;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Women;324 Ourense;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Both sexes;5 Ourense;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Men;.. Ourense;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Women;5 Ourense;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Both sexes;67 Ourense;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Men;31 Ourense;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Women;36 Ourense;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Both sexes;500 Ourense;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Men;314 Ourense;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Women;186 Ourense;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Both sexes;25 Ourense;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Men;18 Ourense;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Women;7 Ourense;Group 2102 Contraceptive management V25;Both sexes;7 Ourense;Group 2102 Contraceptive management V25;Men;.. Ourense;Group 2102 Contraceptive management V25;Women;7 Ourense;Group 2103 Living newborns by type of delivery V30-V39;Both sexes;.. Ourense;Group 2103 Living newborns by type of delivery V30-V39;Men;.. Ourense;Group 2103 Living newborns by type of delivery V30-V39;Women;.. Ourense;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Both sexes;231 Ourense;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Men;167 Ourense;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Women;64 Ourense;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Both sexes;237 Ourense;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Men;129 Ourense;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Women;108 Pontevedra;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Both sexes;93,631 Pontevedra;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Men;44,752 Pontevedra;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Women;48,879 Pontevedra;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Both sexes;1,838 Pontevedra;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Men;1,003 Pontevedra;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Women;835 Pontevedra;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Both sexes;203 Pontevedra;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Men;106 Pontevedra;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Women;97 Pontevedra;Group 0102 Imprecise intestinal infections 009;Both sexes;49 Pontevedra;Group 0102 Imprecise intestinal infections 009;Men;26 Pontevedra;Group 0102 Imprecise intestinal infections 009;Women;23 Pontevedra;Group 0103 Tuberculosis 010-018, 137;Both sexes;100 Pontevedra;Group 0103 Tuberculosis 010-018, 137;Men;62 Pontevedra;Group 0103 Tuberculosis 010-018, 137;Women;38 Pontevedra;Group 0104 Septicaemia 038;Both sexes;625 Pontevedra;Group 0104 Septicaemia 038;Men;288 Pontevedra;Group 0104 Septicaemia 038;Women;337 Pontevedra;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Both sexes;115 Pontevedra;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Men;86 Pontevedra;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Women;29 Pontevedra;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Both sexes;746 Pontevedra;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Men;435 Pontevedra;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Women;311 Pontevedra;Group 0200 Neoplasms 140-239;Both sexes;9,574 Pontevedra;Group 0200 Neoplasms 140-239;Men;4,911 Pontevedra;Group 0200 Neoplasms 140-239;Women;4,663 Pontevedra;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Both sexes;954 Pontevedra;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Men;557 Pontevedra;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Women;397 Pontevedra;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Both sexes;641 Pontevedra;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Men;498 Pontevedra;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Women;143 Pontevedra;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Both sexes;144 Pontevedra;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Men;57 Pontevedra;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Women;87 Pontevedra;Group 0204 Malignant neoplasm of breast 174-175;Both sexes;676 Pontevedra;Group 0204 Malignant neoplasm of breast 174-175;Men;3 Pontevedra;Group 0204 Malignant neoplasm of breast 174-175;Women;673 Pontevedra;Group 0205 Malignant neoplasm of uterus 179-180, 182;Both sexes;178 Pontevedra;Group 0205 Malignant neoplasm of uterus 179-180, 182;Men;.. Pontevedra;Group 0205 Malignant neoplasm of uterus 179-180, 182;Women;178 Pontevedra;Group 0206 Malignant neoplasm of ovary 1830;Both sexes;86 Pontevedra;Group 0206 Malignant neoplasm of ovary 1830;Men;.. Pontevedra;Group 0206 Malignant neoplasm of ovary 1830;Women;86 Pontevedra;Group 0207 Malignant neoplasm of prostate 185;Both sexes;582 Pontevedra;Group 0207 Malignant neoplasm of prostate 185;Men;582 Pontevedra;Group 0207 Malignant neoplasm of prostate 185;Women;.. Pontevedra;Group 0208 Malignant neoplasm of bladder 188;Both sexes;760 Pontevedra;Group 0208 Malignant neoplasm of bladder 188;Men;629 Pontevedra;Group 0208 Malignant neoplasm of bladder 188;Women;131 Pontevedra;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Both sexes;3,745 Pontevedra;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Men;2,127 Pontevedra;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Women;1,618 Pontevedra;Group 0210 Carcinoma in situ 230-234;Both sexes;180 Pontevedra;Group 0210 Carcinoma in situ 230-234;Men;58 Pontevedra;Group 0210 Carcinoma in situ 230-234;Women;122 Pontevedra;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Both sexes;66 Pontevedra;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Men;36 Pontevedra;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Women;30 Pontevedra;Grupo 0212 Leiomyoma of uterus 218;Both sexes;418 Pontevedra;Grupo 0212 Leiomyoma of uterus 218;Men;.. Pontevedra;Grupo 0212 Leiomyoma of uterus 218;Women;418 Pontevedra;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Both sexes;1,144 Pontevedra;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Men;364 Pontevedra;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Women;780 Pontevedra;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Both sexes;899 Pontevedra;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Men;435 Pontevedra;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Women;464 Pontevedra;Group 0301 Anaemias 280-285;Both sexes;571 Pontevedra;Group 0301 Anaemias 280-285;Men;279 Pontevedra;Group 0301 Anaemias 280-285;Women;292 Pontevedra;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Both sexes;328 Pontevedra;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Men;156 Pontevedra;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Women;172 Pontevedra;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Both sexes;1,798 Pontevedra;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Men;681 Pontevedra;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Women;1,117 Pontevedra;Group 0401 Diabetes mellitus 249-250;Both sexes;575 Pontevedra;Group 0401 Diabetes mellitus 249-250;Men;305 Pontevedra;Group 0401 Diabetes mellitus 249-250;Women;270 Pontevedra;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Both sexes;1,223 Pontevedra;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Men;376 Pontevedra;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Women;847 Pontevedra;Group 0500 Mental disorders 290-319;Both sexes;2,296 Pontevedra;Group 0500 Mental disorders 290-319;Men;1,153 Pontevedra;Group 0500 Mental disorders 290-319;Women;1,143 Pontevedra;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Both sexes;50 Pontevedra;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Men;19 Pontevedra;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Women;31 Pontevedra;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Both sexes;190 Pontevedra;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Men;148 Pontevedra;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Women;42 Pontevedra;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Both sexes;75 Pontevedra;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Men;52 Pontevedra;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Women;23 Pontevedra;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Both sexes;587 Pontevedra;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Men;347 Pontevedra;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Women;240 Pontevedra;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Both sexes;558 Pontevedra;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Men;192 Pontevedra;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Women;366 Pontevedra;Group 0506 Other mental and behavioural disorders Rest of (290-319);Both sexes;836 Pontevedra;Group 0506 Other mental and behavioural disorders Rest of (290-319);Men;395 Pontevedra;Group 0506 Other mental and behavioural disorders Rest of (290-319);Women;441 Pontevedra;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Both sexes;1,980 Pontevedra;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Men;938 Pontevedra;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Women;1,042 Pontevedra;Group 0601 Alzheimer's disease 3310;Both sexes;49 Pontevedra;Group 0601 Alzheimer's disease 3310;Men;19 Pontevedra;Group 0601 Alzheimer's disease 3310;Women;30 Pontevedra;Group 0602 Multiple sclerosis 340;Both sexes;107 Pontevedra;Group 0602 Multiple sclerosis 340;Men;32 Pontevedra;Group 0602 Multiple sclerosis 340;Women;75 Pontevedra;Group 0603 Epilepsy 345;Both sexes;354 Pontevedra;Group 0603 Epilepsy 345;Men;180 Pontevedra;Group 0603 Epilepsy 345;Women;174 Pontevedra;Group 0604 Transient cerebral ischemia 435;Both sexes;267 Pontevedra;Group 0604 Transient cerebral ischemia 435;Men;115 Pontevedra;Group 0604 Transient cerebral ischemia 435;Women;152 Pontevedra;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Both sexes;1,203 Pontevedra;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Men;592 Pontevedra;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Women;611 Pontevedra;Grupo 0700 Diseases of the eye and adnexa 360-379;Both sexes;490 Pontevedra;Grupo 0700 Diseases of the eye and adnexa 360-379;Men;249 Pontevedra;Grupo 0700 Diseases of the eye and adnexa 360-379;Women;241 Pontevedra;Grupo 0701 Cataract 366;Both sexes;44 Pontevedra;Grupo 0701 Cataract 366;Men;19 Pontevedra;Grupo 0701 Cataract 366;Women;25 Pontevedra;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Both sexes;446 Pontevedra;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Men;230 Pontevedra;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Women;216 Pontevedra;Group 0800 Diseases of the ear and the mastoid 380-389;Both sexes;557 Pontevedra;Group 0800 Diseases of the ear and the mastoid 380-389;Men;280 Pontevedra;Group 0800 Diseases of the ear and the mastoid 380-389;Women;277 Pontevedra;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Both sexes;12,106 Pontevedra;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Men;6,623 Pontevedra;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Women;5,483 Pontevedra;Group 0901 Hypertensive disease 401-405;Both sexes;740 Pontevedra;Group 0901 Hypertensive disease 401-405;Men;315 Pontevedra;Group 0901 Hypertensive disease 401-405;Women;425 Pontevedra;Group 0902 Angina pectoris 4111, 413;Both sexes;223 Pontevedra;Group 0902 Angina pectoris 4111, 413;Men;136 Pontevedra;Group 0902 Angina pectoris 4111, 413;Women;87 Pontevedra;Group 0903 Acute myocardial infarction 410;Both sexes;1,070 Pontevedra;Group 0903 Acute myocardial infarction 410;Men;768 Pontevedra;Group 0903 Acute myocardial infarction 410;Women;302 Pontevedra;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Both sexes;891 Pontevedra;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Men;694 Pontevedra;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Women;197 Pontevedra;Group 0905 Diseases of the lungs circulation 415-417;Both sexes;498 Pontevedra;Group 0905 Diseases of the lungs circulation 415-417;Men;187 Pontevedra;Group 0905 Diseases of the lungs circulation 415-417;Women;311 Pontevedra;Group 0906 Heart conduction disorders and arrhytmias 426-427;Both sexes;1,382 Pontevedra;Group 0906 Heart conduction disorders and arrhytmias 426-427;Men;743 Pontevedra;Group 0906 Heart conduction disorders and arrhytmias 426-427;Women;639 Pontevedra;Grupo 0907 Heart failure 428;Both sexes;2,479 Pontevedra;Grupo 0907 Heart failure 428;Men;1,207 Pontevedra;Grupo 0907 Heart failure 428;Women;1,272 Pontevedra;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Both sexes;2,016 Pontevedra;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Men;984 Pontevedra;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Women;1,032 Pontevedra;Grupo 0909 Atherosclerosis 440;Both sexes;473 Pontevedra;Grupo 0909 Atherosclerosis 440;Men;322 Pontevedra;Grupo 0909 Atherosclerosis 440;Women;151 Pontevedra;Group 0910 Varicose veins of lower extremities 454;Both sexes;464 Pontevedra;Group 0910 Varicose veins of lower extremities 454;Men;158 Pontevedra;Group 0910 Varicose veins of lower extremities 454;Women;306 Pontevedra;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Both sexes;1,870 Pontevedra;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Men;1,109 Pontevedra;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Women;761 Pontevedra;Group 1000 Diseases of the respiratory system 0340, 460-519;Both sexes;12,053 Pontevedra;Group 1000 Diseases of the respiratory system 0340, 460-519;Men;6,752 Pontevedra;Group 1000 Diseases of the respiratory system 0340, 460-519;Women;5,301 Pontevedra;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Both sexes;260 Pontevedra;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Men;124 Pontevedra;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Women;136 Pontevedra;Group 1002 Pneumonia 480-486;Both sexes;2,404 Pontevedra;Group 1002 Pneumonia 480-486;Men;1,333 Pontevedra;Group 1002 Pneumonia 480-486;Women;1,071 Pontevedra;Group 1003 Acute bronchitis and bronchiolitis 466;Both sexes;473 Pontevedra;Group 1003 Acute bronchitis and bronchiolitis 466;Men;253 Pontevedra;Group 1003 Acute bronchitis and bronchiolitis 466;Women;220 Pontevedra;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Both sexes;947 Pontevedra;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Men;504 Pontevedra;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Women;443 Pontevedra;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Both sexes;1,095 Pontevedra;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Men;686 Pontevedra;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Women;409 Pontevedra;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Both sexes;1,870 Pontevedra;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Men;1,354 Pontevedra;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Women;516 Pontevedra;Group 1007 Asthma 4930-4931,4938-4939;Both sexes;369 Pontevedra;Group 1007 Asthma 4930-4931,4938-4939;Men;124 Pontevedra;Group 1007 Asthma 4930-4931,4938-4939;Women;245 Pontevedra;Group 1008 Other diseases of the respiratory system Resto of (460-519);Both sexes;4,635 Pontevedra;Group 1008 Other diseases of the respiratory system Resto of (460-519);Men;2,374 Pontevedra;Group 1008 Other diseases of the respiratory system Resto of (460-519);Women;2,261 Pontevedra;Group 1100 Diseases of the digestive system 520-579;Both sexes;10,776 Pontevedra;Group 1100 Diseases of the digestive system 520-579;Men;6,209 Pontevedra;Group 1100 Diseases of the digestive system 520-579;Women;4,567 Pontevedra;Group 1101 Disorders of the teeth and supporting structures 520-525;Both sexes;195 Pontevedra;Group 1101 Disorders of the teeth and supporting structures 520-525;Men;110 Pontevedra;Group 1101 Disorders of the teeth and supporting structures 520-525;Women;85 Pontevedra;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Both sexes;198 Pontevedra;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Men;107 Pontevedra;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Women;91 Pontevedra;Group 1103 Diseases of the esophagus 530;Both sexes;134 Pontevedra;Group 1103 Diseases of the esophagus 530;Men;76 Pontevedra;Group 1103 Diseases of the esophagus 530;Women;58 Pontevedra;Group 1104 Peptic ulcer 531-534;Both sexes;145 Pontevedra;Group 1104 Peptic ulcer 531-534;Men;93 Pontevedra;Group 1104 Peptic ulcer 531-534;Women;52 Pontevedra;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Both sexes;255 Pontevedra;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Men;131 Pontevedra;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Women;124 Pontevedra;Group 1106 Appendicitis 540-543;Both sexes;1,106 Pontevedra;Group 1106 Appendicitis 540-543;Men;651 Pontevedra;Group 1106 Appendicitis 540-543;Women;455 Pontevedra;Group 1107 Inguinal hernia 550;Both sexes;1,338 Pontevedra;Group 1107 Inguinal hernia 550;Men;1,187 Pontevedra;Group 1107 Inguinal hernia 550;Women;151 Pontevedra;Group 1108 Other abdominal hernia 551-553;Both sexes;823 Pontevedra;Group 1108 Other abdominal hernia 551-553;Men;425 Pontevedra;Group 1108 Other abdominal hernia 551-553;Women;398 Pontevedra;Group 1109 Crohn's disease and ulcerative colitis 555-556;Both sexes;262 Pontevedra;Group 1109 Crohn's disease and ulcerative colitis 555-556;Men;138 Pontevedra;Group 1109 Crohn's disease and ulcerative colitis 555-556;Women;124 Pontevedra;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Both sexes;418 Pontevedra;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Men;220 Pontevedra;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Women;198 Pontevedra;Group 1111 Intestinal obstruction without hernia 560;Both sexes;468 Pontevedra;Group 1111 Intestinal obstruction without hernia 560;Men;237 Pontevedra;Group 1111 Intestinal obstruction without hernia 560;Women;231 Pontevedra;Group 1112 Intestinal diverticulosis 562;Both sexes;413 Pontevedra;Group 1112 Intestinal diverticulosis 562;Men;207 Pontevedra;Group 1112 Intestinal diverticulosis 562;Women;206 Pontevedra;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Both sexes;619 Pontevedra;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Men;406 Pontevedra;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Women;213 Pontevedra;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Both sexes;385 Pontevedra;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Men;172 Pontevedra;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Women;213 Pontevedra;Group 1115 Alcoholic hepatitis 5710-5713;Both sexes;293 Pontevedra;Group 1115 Alcoholic hepatitis 5710-5713;Men;255 Pontevedra;Group 1115 Alcoholic hepatitis 5710-5713;Women;38 Pontevedra;Group 1116 Other diseases of the liver 570,5714-573;Both sexes;513 Pontevedra;Group 1116 Other diseases of the liver 570,5714-573;Men;343 Pontevedra;Group 1116 Other diseases of the liver 570,5714-573;Women;170 Pontevedra;Group 1117 Cholelithiasis 574;Both sexes;1,836 Pontevedra;Group 1117 Cholelithiasis 574;Men;727 Pontevedra;Group 1117 Cholelithiasis 574;Women;1,109 Pontevedra;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Both sexes;442 Pontevedra;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Men;247 Pontevedra;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Women;195 Pontevedra;Group 1119 Pancreatic diseases 577;Both sexes;558 Pontevedra;Group 1119 Pancreatic diseases 577;Men;293 Pontevedra;Group 1119 Pancreatic diseases 577;Women;265 Pontevedra;Group 1120 Other diseases of the digestive system Rest of (520-579);Both sexes;375 Pontevedra;Group 1120 Other diseases of the digestive system Rest of (520-579);Men;184 Pontevedra;Group 1120 Other diseases of the digestive system Rest of (520-579);Women;191 Pontevedra;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Both sexes;1,198 Pontevedra;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Men;632 Pontevedra;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Women;566 Pontevedra;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Both sexes;736 Pontevedra;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Men;433 Pontevedra;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Women;303 Pontevedra;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Both sexes;93 Pontevedra;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Men;42 Pontevedra;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Women;51 Pontevedra;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Both sexes;369 Pontevedra;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Men;157 Pontevedra;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Women;212 Pontevedra;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Both sexes;7,502 Pontevedra;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Men;3,641 Pontevedra;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Women;3,861 Pontevedra;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Both sexes;.. Pontevedra;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Men;.. Pontevedra;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Women;.. Pontevedra;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Both sexes;.. Pontevedra;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Men;.. Pontevedra;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Women;.. Pontevedra;Group 1303 Internal derangement of knee 717;Both sexes;1,549 Pontevedra;Group 1303 Internal derangement of knee 717;Men;1,034 Pontevedra;Group 1303 Internal derangement of knee 717;Women;515 Pontevedra;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Both sexes;2,479 Pontevedra;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Men;992 Pontevedra;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Women;1,487 Pontevedra;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Both sexes;151 Pontevedra;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Men;55 Pontevedra;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Women;96 Pontevedra;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Both sexes;259 Pontevedra;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Men;135 Pontevedra;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Women;124 Pontevedra;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Both sexes;643 Pontevedra;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Men;366 Pontevedra;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Women;277 Pontevedra;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Both sexes;103 Pontevedra;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Men;41 Pontevedra;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Women;62 Pontevedra;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Both sexes;1,040 Pontevedra;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Men;590 Pontevedra;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Women;450 Pontevedra;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Both sexes;1,278 Pontevedra;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Men;428 Pontevedra;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Women;850 Pontevedra;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Both sexes;6,311 Pontevedra;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Men;3,014 Pontevedra;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Women;3,297 Pontevedra;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Both sexes;517 Pontevedra;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Men;184 Pontevedra;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Women;333 Pontevedra;Group 1402 Renal failure 5836-5837, 584-586;Both sexes;473 Pontevedra;Group 1402 Renal failure 5836-5837, 584-586;Men;255 Pontevedra;Group 1402 Renal failure 5836-5837, 584-586;Women;218 Pontevedra;Group 1403 Urolithiasis 592, 594, 7880;Both sexes;647 Pontevedra;Group 1403 Urolithiasis 592, 594, 7880;Men;399 Pontevedra;Group 1403 Urolithiasis 592, 594, 7880;Women;248 Pontevedra;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Both sexes;1,781 Pontevedra;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Men;829 Pontevedra;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Women;952 Pontevedra;Group 1405 Prostatic hyperplasia 600;Both sexes;664 Pontevedra;Group 1405 Prostatic hyperplasia 600;Men;664 Pontevedra;Group 1405 Prostatic hyperplasia 600;Women;.. Pontevedra;Group 1406 Other diseases of the male genital organs 601-608;Both sexes;606 Pontevedra;Group 1406 Other diseases of the male genital organs 601-608;Men;606 Pontevedra;Group 1406 Other diseases of the male genital organs 601-608;Women;.. Pontevedra;Group 1407 Disorders of breast 610-612;Both sexes;231 Pontevedra;Group 1407 Disorders of breast 610-612;Men;38 Pontevedra;Group 1407 Disorders of breast 610-612;Women;193 Pontevedra;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Both sexes;204 Pontevedra;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Men;.. Pontevedra;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Women;204 Pontevedra;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Both sexes;90 Pontevedra;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Men;.. Pontevedra;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Women;90 Pontevedra;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Both sexes;1,098 Pontevedra;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Men;39 Pontevedra;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Women;1,059 Pontevedra;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Both sexes;8,733 Pontevedra;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Men;.. Pontevedra;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Women;8,733 Pontevedra;Group 1501 Legally induced abortion 635;Both sexes;168 Pontevedra;Group 1501 Legally induced abortion 635;Men;.. Pontevedra;Group 1501 Legally induced abortion 635;Women;168 Pontevedra;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Both sexes;906 Pontevedra;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Men;.. Pontevedra;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Women;906 Pontevedra;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Both sexes;4,878 Pontevedra;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Men;.. Pontevedra;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Women;4,878 Pontevedra;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Both sexes;1,428 Pontevedra;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Men;.. Pontevedra;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Women;1,428 Pontevedra;Group 1505 Single spontaneous delivery 650;Both sexes;629 Pontevedra;Group 1505 Single spontaneous delivery 650;Men;.. Pontevedra;Group 1505 Single spontaneous delivery 650;Women;629 Pontevedra;Group 1506 Other deliveries 6695-6697;Both sexes;294 Pontevedra;Group 1506 Other deliveries 6695-6697;Men;.. Pontevedra;Group 1506 Other deliveries 6695-6697;Women;294 Pontevedra;Group 1507 Complications related to the puerperium 670-676;Both sexes;104 Pontevedra;Group 1507 Complications related to the puerperium 670-676;Men;.. Pontevedra;Group 1507 Complications related to the puerperium 670-676;Women;104 Pontevedra;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Both sexes;326 Pontevedra;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Men;.. Pontevedra;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Women;326 Pontevedra;Group 1600 Some disorders originating in the perinatal period 760-779;Both sexes;885 Pontevedra;Group 1600 Some disorders originating in the perinatal period 760-779;Men;475 Pontevedra;Group 1600 Some disorders originating in the perinatal period 760-779;Women;410 Pontevedra;Group 1601 Disorders related with premature delivery and a low birth weight 765;Both sexes;243 Pontevedra;Group 1601 Disorders related with premature delivery and a low birth weight 765;Men;131 Pontevedra;Group 1601 Disorders related with premature delivery and a low birth weight 765;Women;112 Pontevedra;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Both sexes;642 Pontevedra;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Men;344 Pontevedra;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Women;298 Pontevedra;Grupo 1700 Congenital abnormalities 740-759;Both sexes;684 Pontevedra;Grupo 1700 Congenital abnormalities 740-759;Men;436 Pontevedra;Grupo 1700 Congenital abnormalities 740-759;Women;248 Pontevedra;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Both sexes;2,460 Pontevedra;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Men;1,275 Pontevedra;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Women;1,185 Pontevedra;Group 1801 Pain in throat and chest 7841, 7865;Both sexes;283 Pontevedra;Group 1801 Pain in throat and chest 7841, 7865;Men;153 Pontevedra;Group 1801 Pain in throat and chest 7841, 7865;Women;130 Pontevedra;Group 1802 Abdominal pain 7890;Both sexes;314 Pontevedra;Group 1802 Abdominal pain 7890;Men;122 Pontevedra;Group 1802 Abdominal pain 7890;Women;192 Pontevedra;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Both sexes;12 Pontevedra;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Men;5 Pontevedra;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Women;7 Pontevedra;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Both sexes;1,851 Pontevedra;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Men;995 Pontevedra;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Women;856 Pontevedra;Group 1900 Injuries and poisoning 800-999;Both sexes;9,560 Pontevedra;Group 1900 Injuries and poisoning 800-999;Men;5,065 Pontevedra;Group 1900 Injuries and poisoning 800-999;Women;4,495 Pontevedra;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Both sexes;769 Pontevedra;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Men;440 Pontevedra;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Women;329 Pontevedra;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Both sexes;405 Pontevedra;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Men;292 Pontevedra;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Women;113 Pontevedra;Group 1903 Radius and ulna fracture 813;Both sexes;493 Pontevedra;Group 1903 Radius and ulna fracture 813;Men;230 Pontevedra;Group 1903 Radius and ulna fracture 813;Women;263 Pontevedra;Group 1904 Femur fracture 820-821;Both sexes;1,075 Pontevedra;Group 1904 Femur fracture 820-821;Men;253 Pontevedra;Group 1904 Femur fracture 820-821;Women;822 Pontevedra;Group 1905 Leg fracture, including the ankle 823-824;Both sexes;742 Pontevedra;Group 1905 Leg fracture, including the ankle 823-824;Men;329 Pontevedra;Group 1905 Leg fracture, including the ankle 823-824;Women;413 Pontevedra;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Both sexes;3,345 Pontevedra;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Men;2,063 Pontevedra;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Women;1,282 Pontevedra;Group 1907 Burns 940-949;Both sexes;121 Pontevedra;Group 1907 Burns 940-949;Men;75 Pontevedra;Group 1907 Burns 940-949;Women;46 Pontevedra;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Both sexes;179 Pontevedra;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Men;74 Pontevedra;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Women;105 Pontevedra;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Both sexes;2,268 Pontevedra;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Men;1,232 Pontevedra;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Women;1,036 Pontevedra;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Both sexes;6 Pontevedra;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Men;3 Pontevedra;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Women;3 Pontevedra;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Both sexes;157 Pontevedra;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Men;74 Pontevedra;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Women;83 Pontevedra;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Both sexes;1,931 Pontevedra;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Men;980 Pontevedra;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Women;951 Pontevedra;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Both sexes;63 Pontevedra;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Men;32 Pontevedra;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Women;31 Pontevedra;Group 2102 Contraceptive management V25;Both sexes;62 Pontevedra;Group 2102 Contraceptive management V25;Men;2 Pontevedra;Group 2102 Contraceptive management V25;Women;60 Pontevedra;Group 2103 Living newborns by type of delivery V30-V39;Both sexes;.. Pontevedra;Group 2103 Living newborns by type of delivery V30-V39;Men;.. Pontevedra;Group 2103 Living newborns by type of delivery V30-V39;Women;.. Pontevedra;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Both sexes;1,054 Pontevedra;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Men;628 Pontevedra;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Women;426 Pontevedra;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Both sexes;752 Pontevedra;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Men;318 Pontevedra;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Women;434 MADRID, COMUNIDAD DE;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Both sexes;681,681 MADRID, COMUNIDAD DE;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Men;312,288 MADRID, COMUNIDAD DE;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Women;369,393 MADRID, COMUNIDAD DE;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Both sexes;15,126 MADRID, COMUNIDAD DE;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Men;8,535 MADRID, COMUNIDAD DE;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Women;6,591 MADRID, COMUNIDAD DE;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Both sexes;2,494 MADRID, COMUNIDAD DE;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Men;1,299 MADRID, COMUNIDAD DE;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Women;1,195 MADRID, COMUNIDAD DE;Group 0102 Imprecise intestinal infections 009;Both sexes;814 MADRID, COMUNIDAD DE;Group 0102 Imprecise intestinal infections 009;Men;377 MADRID, COMUNIDAD DE;Group 0102 Imprecise intestinal infections 009;Women;437 MADRID, COMUNIDAD DE;Group 0103 Tuberculosis 010-018, 137;Both sexes;548 MADRID, COMUNIDAD DE;Group 0103 Tuberculosis 010-018, 137;Men;337 MADRID, COMUNIDAD DE;Group 0103 Tuberculosis 010-018, 137;Women;211 MADRID, COMUNIDAD DE;Group 0104 Septicaemia 038;Both sexes;5,653 MADRID, COMUNIDAD DE;Group 0104 Septicaemia 038;Men;2,998 MADRID, COMUNIDAD DE;Group 0104 Septicaemia 038;Women;2,655 MADRID, COMUNIDAD DE;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Both sexes;671 MADRID, COMUNIDAD DE;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Men;542 MADRID, COMUNIDAD DE;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Women;129 MADRID, COMUNIDAD DE;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Both sexes;4,945 MADRID, COMUNIDAD DE;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Men;2,981 MADRID, COMUNIDAD DE;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Women;1,963 MADRID, COMUNIDAD DE;Group 0200 Neoplasms 140-239;Both sexes;69,837 MADRID, COMUNIDAD DE;Group 0200 Neoplasms 140-239;Men;34,425 MADRID, COMUNIDAD DE;Group 0200 Neoplasms 140-239;Women;35,413 MADRID, COMUNIDAD DE;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Both sexes;5,968 MADRID, COMUNIDAD DE;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Men;3,499 MADRID, COMUNIDAD DE;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Women;2,470 MADRID, COMUNIDAD DE;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Both sexes;4,641 MADRID, COMUNIDAD DE;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Men;3,511 MADRID, COMUNIDAD DE;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Women;1,129 MADRID, COMUNIDAD DE;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Both sexes;1,156 MADRID, COMUNIDAD DE;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Men;657 MADRID, COMUNIDAD DE;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Women;499 MADRID, COMUNIDAD DE;Group 0204 Malignant neoplasm of breast 174-175;Both sexes;5,334 MADRID, COMUNIDAD DE;Group 0204 Malignant neoplasm of breast 174-175;Men;39 MADRID, COMUNIDAD DE;Group 0204 Malignant neoplasm of breast 174-175;Women;5,295 MADRID, COMUNIDAD DE;Group 0205 Malignant neoplasm of uterus 179-180, 182;Both sexes;1,366 MADRID, COMUNIDAD DE;Group 0205 Malignant neoplasm of uterus 179-180, 182;Men;.. MADRID, COMUNIDAD DE;Group 0205 Malignant neoplasm of uterus 179-180, 182;Women;1,366 MADRID, COMUNIDAD DE;Group 0206 Malignant neoplasm of ovary 1830;Both sexes;786 MADRID, COMUNIDAD DE;Group 0206 Malignant neoplasm of ovary 1830;Men;.. MADRID, COMUNIDAD DE;Group 0206 Malignant neoplasm of ovary 1830;Women;786 MADRID, COMUNIDAD DE;Group 0207 Malignant neoplasm of prostate 185;Both sexes;2,831 MADRID, COMUNIDAD DE;Group 0207 Malignant neoplasm of prostate 185;Men;2,831 MADRID, COMUNIDAD DE;Group 0207 Malignant neoplasm of prostate 185;Women;.. MADRID, COMUNIDAD DE;Group 0208 Malignant neoplasm of bladder 188;Both sexes;6,031 MADRID, COMUNIDAD DE;Group 0208 Malignant neoplasm of bladder 188;Men;4,954 MADRID, COMUNIDAD DE;Group 0208 Malignant neoplasm of bladder 188;Women;1,076 MADRID, COMUNIDAD DE;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Both sexes;25,437 MADRID, COMUNIDAD DE;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Men;13,948 MADRID, COMUNIDAD DE;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Women;11,490 MADRID, COMUNIDAD DE;Group 0210 Carcinoma in situ 230-234;Both sexes;1,045 MADRID, COMUNIDAD DE;Group 0210 Carcinoma in situ 230-234;Men;307 MADRID, COMUNIDAD DE;Group 0210 Carcinoma in situ 230-234;Women;738 MADRID, COMUNIDAD DE;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Both sexes;994 MADRID, COMUNIDAD DE;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Men;580 MADRID, COMUNIDAD DE;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Women;413 MADRID, COMUNIDAD DE;Grupo 0212 Leiomyoma of uterus 218;Both sexes;4,040 MADRID, COMUNIDAD DE;Grupo 0212 Leiomyoma of uterus 218;Men;.. MADRID, COMUNIDAD DE;Grupo 0212 Leiomyoma of uterus 218;Women;4,040 MADRID, COMUNIDAD DE;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Both sexes;10,208 MADRID, COMUNIDAD DE;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Men;4,098 MADRID, COMUNIDAD DE;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Women;6,110 MADRID, COMUNIDAD DE;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Both sexes;6,016 MADRID, COMUNIDAD DE;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Men;3,046 MADRID, COMUNIDAD DE;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Women;2,971 MADRID, COMUNIDAD DE;Group 0301 Anaemias 280-285;Both sexes;3,364 MADRID, COMUNIDAD DE;Group 0301 Anaemias 280-285;Men;1,608 MADRID, COMUNIDAD DE;Group 0301 Anaemias 280-285;Women;1,756 MADRID, COMUNIDAD DE;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Both sexes;2,652 MADRID, COMUNIDAD DE;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Men;1,437 MADRID, COMUNIDAD DE;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Women;1,215 MADRID, COMUNIDAD DE;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Both sexes;12,974 MADRID, COMUNIDAD DE;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Men;4,734 MADRID, COMUNIDAD DE;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Women;8,240 MADRID, COMUNIDAD DE;Group 0401 Diabetes mellitus 249-250;Both sexes;2,997 MADRID, COMUNIDAD DE;Group 0401 Diabetes mellitus 249-250;Men;1,725 MADRID, COMUNIDAD DE;Group 0401 Diabetes mellitus 249-250;Women;1,272 MADRID, COMUNIDAD DE;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Both sexes;9,976 MADRID, COMUNIDAD DE;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Men;3,009 MADRID, COMUNIDAD DE;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Women;6,967 MADRID, COMUNIDAD DE;Group 0500 Mental disorders 290-319;Both sexes;16,248 MADRID, COMUNIDAD DE;Group 0500 Mental disorders 290-319;Men;7,906 MADRID, COMUNIDAD DE;Group 0500 Mental disorders 290-319;Women;8,341 MADRID, COMUNIDAD DE;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Both sexes;283 MADRID, COMUNIDAD DE;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Men;125 MADRID, COMUNIDAD DE;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Women;158 MADRID, COMUNIDAD DE;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Both sexes;1,720 MADRID, COMUNIDAD DE;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Men;1,214 MADRID, COMUNIDAD DE;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Women;506 MADRID, COMUNIDAD DE;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Both sexes;1,125 MADRID, COMUNIDAD DE;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Men;835 MADRID, COMUNIDAD DE;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Women;290 MADRID, COMUNIDAD DE;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Both sexes;4,096 MADRID, COMUNIDAD DE;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Men;2,385 MADRID, COMUNIDAD DE;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Women;1,711 MADRID, COMUNIDAD DE;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Both sexes;3,762 MADRID, COMUNIDAD DE;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Men;1,386 MADRID, COMUNIDAD DE;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Women;2,376 MADRID, COMUNIDAD DE;Group 0506 Other mental and behavioural disorders Rest of (290-319);Both sexes;5,261 MADRID, COMUNIDAD DE;Group 0506 Other mental and behavioural disorders Rest of (290-319);Men;1,961 MADRID, COMUNIDAD DE;Group 0506 Other mental and behavioural disorders Rest of (290-319);Women;3,300 MADRID, COMUNIDAD DE;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Both sexes;18,646 MADRID, COMUNIDAD DE;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Men;9,889 MADRID, COMUNIDAD DE;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Women;8,757 MADRID, COMUNIDAD DE;Group 0601 Alzheimer's disease 3310;Both sexes;234 MADRID, COMUNIDAD DE;Group 0601 Alzheimer's disease 3310;Men;91 MADRID, COMUNIDAD DE;Group 0601 Alzheimer's disease 3310;Women;143 MADRID, COMUNIDAD DE;Group 0602 Multiple sclerosis 340;Both sexes;272 MADRID, COMUNIDAD DE;Group 0602 Multiple sclerosis 340;Men;89 MADRID, COMUNIDAD DE;Group 0602 Multiple sclerosis 340;Women;183 MADRID, COMUNIDAD DE;Group 0603 Epilepsy 345;Both sexes;3,107 MADRID, COMUNIDAD DE;Group 0603 Epilepsy 345;Men;1,603 MADRID, COMUNIDAD DE;Group 0603 Epilepsy 345;Women;1,504 MADRID, COMUNIDAD DE;Group 0604 Transient cerebral ischemia 435;Both sexes;2,164 MADRID, COMUNIDAD DE;Group 0604 Transient cerebral ischemia 435;Men;1,044 MADRID, COMUNIDAD DE;Group 0604 Transient cerebral ischemia 435;Women;1,120 MADRID, COMUNIDAD DE;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Both sexes;12,868 MADRID, COMUNIDAD DE;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Men;7,061 MADRID, COMUNIDAD DE;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Women;5,807 MADRID, COMUNIDAD DE;Grupo 0700 Diseases of the eye and adnexa 360-379;Both sexes;4,505 MADRID, COMUNIDAD DE;Grupo 0700 Diseases of the eye and adnexa 360-379;Men;2,274 MADRID, COMUNIDAD DE;Grupo 0700 Diseases of the eye and adnexa 360-379;Women;2,231 MADRID, COMUNIDAD DE;Grupo 0701 Cataract 366;Both sexes;584 MADRID, COMUNIDAD DE;Grupo 0701 Cataract 366;Men;274 MADRID, COMUNIDAD DE;Grupo 0701 Cataract 366;Women;310 MADRID, COMUNIDAD DE;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Both sexes;3,921 MADRID, COMUNIDAD DE;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Men;2,000 MADRID, COMUNIDAD DE;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Women;1,921 MADRID, COMUNIDAD DE;Group 0800 Diseases of the ear and the mastoid 380-389;Both sexes;3,324 MADRID, COMUNIDAD DE;Group 0800 Diseases of the ear and the mastoid 380-389;Men;1,598 MADRID, COMUNIDAD DE;Group 0800 Diseases of the ear and the mastoid 380-389;Women;1,725 MADRID, COMUNIDAD DE;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Both sexes;79,350 MADRID, COMUNIDAD DE;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Men;42,956 MADRID, COMUNIDAD DE;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Women;36,394 MADRID, COMUNIDAD DE;Group 0901 Hypertensive disease 401-405;Both sexes;4,300 MADRID, COMUNIDAD DE;Group 0901 Hypertensive disease 401-405;Men;1,656 MADRID, COMUNIDAD DE;Group 0901 Hypertensive disease 401-405;Women;2,643 MADRID, COMUNIDAD DE;Group 0902 Angina pectoris 4111, 413;Both sexes;2,022 MADRID, COMUNIDAD DE;Group 0902 Angina pectoris 4111, 413;Men;1,276 MADRID, COMUNIDAD DE;Group 0902 Angina pectoris 4111, 413;Women;745 MADRID, COMUNIDAD DE;Group 0903 Acute myocardial infarction 410;Both sexes;5,817 MADRID, COMUNIDAD DE;Group 0903 Acute myocardial infarction 410;Men;4,086 MADRID, COMUNIDAD DE;Group 0903 Acute myocardial infarction 410;Women;1,730 MADRID, COMUNIDAD DE;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Both sexes;6,894 MADRID, COMUNIDAD DE;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Men;5,332 MADRID, COMUNIDAD DE;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Women;1,561 MADRID, COMUNIDAD DE;Group 0905 Diseases of the lungs circulation 415-417;Both sexes;2,900 MADRID, COMUNIDAD DE;Group 0905 Diseases of the lungs circulation 415-417;Men;1,358 MADRID, COMUNIDAD DE;Group 0905 Diseases of the lungs circulation 415-417;Women;1,542 MADRID, COMUNIDAD DE;Group 0906 Heart conduction disorders and arrhytmias 426-427;Both sexes;10,722 MADRID, COMUNIDAD DE;Group 0906 Heart conduction disorders and arrhytmias 426-427;Men;5,860 MADRID, COMUNIDAD DE;Group 0906 Heart conduction disorders and arrhytmias 426-427;Women;4,862 MADRID, COMUNIDAD DE;Grupo 0907 Heart failure 428;Both sexes;15,940 MADRID, COMUNIDAD DE;Grupo 0907 Heart failure 428;Men;6,833 MADRID, COMUNIDAD DE;Grupo 0907 Heart failure 428;Women;9,107 MADRID, COMUNIDAD DE;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Both sexes;11,435 MADRID, COMUNIDAD DE;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Men;5,883 MADRID, COMUNIDAD DE;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Women;5,552 MADRID, COMUNIDAD DE;Grupo 0909 Atherosclerosis 440;Both sexes;2,284 MADRID, COMUNIDAD DE;Grupo 0909 Atherosclerosis 440;Men;1,680 MADRID, COMUNIDAD DE;Grupo 0909 Atherosclerosis 440;Women;604 MADRID, COMUNIDAD DE;Group 0910 Varicose veins of lower extremities 454;Both sexes;2,368 MADRID, COMUNIDAD DE;Group 0910 Varicose veins of lower extremities 454;Men;861 MADRID, COMUNIDAD DE;Group 0910 Varicose veins of lower extremities 454;Women;1,507 MADRID, COMUNIDAD DE;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Both sexes;14,668 MADRID, COMUNIDAD DE;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Men;8,129 MADRID, COMUNIDAD DE;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Women;6,540 MADRID, COMUNIDAD DE;Group 1000 Diseases of the respiratory system 0340, 460-519;Both sexes;76,659 MADRID, COMUNIDAD DE;Group 1000 Diseases of the respiratory system 0340, 460-519;Men;42,570 MADRID, COMUNIDAD DE;Group 1000 Diseases of the respiratory system 0340, 460-519;Women;34,089 MADRID, COMUNIDAD DE;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Both sexes;2,498 MADRID, COMUNIDAD DE;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Men;1,342 MADRID, COMUNIDAD DE;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Women;1,156 MADRID, COMUNIDAD DE;Group 1002 Pneumonia 480-486;Both sexes;17,176 MADRID, COMUNIDAD DE;Group 1002 Pneumonia 480-486;Men;9,768 MADRID, COMUNIDAD DE;Group 1002 Pneumonia 480-486;Women;7,407 MADRID, COMUNIDAD DE;Group 1003 Acute bronchitis and bronchiolitis 466;Both sexes;5,860 MADRID, COMUNIDAD DE;Group 1003 Acute bronchitis and bronchiolitis 466;Men;3,036 MADRID, COMUNIDAD DE;Group 1003 Acute bronchitis and bronchiolitis 466;Women;2,823 MADRID, COMUNIDAD DE;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Both sexes;3,827 MADRID, COMUNIDAD DE;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Men;1,984 MADRID, COMUNIDAD DE;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Women;1,842 MADRID, COMUNIDAD DE;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Both sexes;6,403 MADRID, COMUNIDAD DE;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Men;3,757 MADRID, COMUNIDAD DE;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Women;2,646 MADRID, COMUNIDAD DE;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Both sexes;12,648 MADRID, COMUNIDAD DE;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Men;9,185 MADRID, COMUNIDAD DE;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Women;3,463 MADRID, COMUNIDAD DE;Group 1007 Asthma 4930-4931,4938-4939;Both sexes;3,639 MADRID, COMUNIDAD DE;Group 1007 Asthma 4930-4931,4938-4939;Men;1,272 MADRID, COMUNIDAD DE;Group 1007 Asthma 4930-4931,4938-4939;Women;2,367 MADRID, COMUNIDAD DE;Group 1008 Other diseases of the respiratory system Resto of (460-519);Both sexes;24,609 MADRID, COMUNIDAD DE;Group 1008 Other diseases of the respiratory system Resto of (460-519);Men;12,225 MADRID, COMUNIDAD DE;Group 1008 Other diseases of the respiratory system Resto of (460-519);Women;12,384 MADRID, COMUNIDAD DE;Group 1100 Diseases of the digestive system 520-579;Both sexes;80,766 MADRID, COMUNIDAD DE;Group 1100 Diseases of the digestive system 520-579;Men;44,090 MADRID, COMUNIDAD DE;Group 1100 Diseases of the digestive system 520-579;Women;36,676 MADRID, COMUNIDAD DE;Group 1101 Disorders of the teeth and supporting structures 520-525;Both sexes;2,256 MADRID, COMUNIDAD DE;Group 1101 Disorders of the teeth and supporting structures 520-525;Men;1,018 MADRID, COMUNIDAD DE;Group 1101 Disorders of the teeth and supporting structures 520-525;Women;1,238 MADRID, COMUNIDAD DE;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Both sexes;1,308 MADRID, COMUNIDAD DE;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Men;699 MADRID, COMUNIDAD DE;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Women;609 MADRID, COMUNIDAD DE;Group 1103 Diseases of the esophagus 530;Both sexes;1,918 MADRID, COMUNIDAD DE;Group 1103 Diseases of the esophagus 530;Men;1,102 MADRID, COMUNIDAD DE;Group 1103 Diseases of the esophagus 530;Women;815 MADRID, COMUNIDAD DE;Group 1104 Peptic ulcer 531-534;Both sexes;1,217 MADRID, COMUNIDAD DE;Group 1104 Peptic ulcer 531-534;Men;844 MADRID, COMUNIDAD DE;Group 1104 Peptic ulcer 531-534;Women;373 MADRID, COMUNIDAD DE;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Both sexes;1,691 MADRID, COMUNIDAD DE;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Men;787 MADRID, COMUNIDAD DE;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Women;903 MADRID, COMUNIDAD DE;Group 1106 Appendicitis 540-543;Both sexes;7,075 MADRID, COMUNIDAD DE;Group 1106 Appendicitis 540-543;Men;3,895 MADRID, COMUNIDAD DE;Group 1106 Appendicitis 540-543;Women;3,181 MADRID, COMUNIDAD DE;Group 1107 Inguinal hernia 550;Both sexes;8,933 MADRID, COMUNIDAD DE;Group 1107 Inguinal hernia 550;Men;7,866 MADRID, COMUNIDAD DE;Group 1107 Inguinal hernia 550;Women;1,067 MADRID, COMUNIDAD DE;Group 1108 Other abdominal hernia 551-553;Both sexes;6,836 MADRID, COMUNIDAD DE;Group 1108 Other abdominal hernia 551-553;Men;3,174 MADRID, COMUNIDAD DE;Group 1108 Other abdominal hernia 551-553;Women;3,662 MADRID, COMUNIDAD DE;Group 1109 Crohn's disease and ulcerative colitis 555-556;Both sexes;1,292 MADRID, COMUNIDAD DE;Group 1109 Crohn's disease and ulcerative colitis 555-556;Men;644 MADRID, COMUNIDAD DE;Group 1109 Crohn's disease and ulcerative colitis 555-556;Women;648 MADRID, COMUNIDAD DE;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Both sexes;4,315 MADRID, COMUNIDAD DE;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Men;1,976 MADRID, COMUNIDAD DE;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Women;2,339 MADRID, COMUNIDAD DE;Group 1111 Intestinal obstruction without hernia 560;Both sexes;3,205 MADRID, COMUNIDAD DE;Group 1111 Intestinal obstruction without hernia 560;Men;1,576 MADRID, COMUNIDAD DE;Group 1111 Intestinal obstruction without hernia 560;Women;1,628 MADRID, COMUNIDAD DE;Group 1112 Intestinal diverticulosis 562;Both sexes;3,197 MADRID, COMUNIDAD DE;Group 1112 Intestinal diverticulosis 562;Men;1,577 MADRID, COMUNIDAD DE;Group 1112 Intestinal diverticulosis 562;Women;1,620 MADRID, COMUNIDAD DE;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Both sexes;5,199 MADRID, COMUNIDAD DE;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Men;3,308 MADRID, COMUNIDAD DE;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Women;1,891 MADRID, COMUNIDAD DE;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Both sexes;2,546 MADRID, COMUNIDAD DE;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Men;1,083 MADRID, COMUNIDAD DE;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Women;1,462 MADRID, COMUNIDAD DE;Group 1115 Alcoholic hepatitis 5710-5713;Both sexes;1,094 MADRID, COMUNIDAD DE;Group 1115 Alcoholic hepatitis 5710-5713;Men;915 MADRID, COMUNIDAD DE;Group 1115 Alcoholic hepatitis 5710-5713;Women;179 MADRID, COMUNIDAD DE;Group 1116 Other diseases of the liver 570,5714-573;Both sexes;2,791 MADRID, COMUNIDAD DE;Group 1116 Other diseases of the liver 570,5714-573;Men;1,712 MADRID, COMUNIDAD DE;Group 1116 Other diseases of the liver 570,5714-573;Women;1,079 MADRID, COMUNIDAD DE;Group 1117 Cholelithiasis 574;Both sexes;14,777 MADRID, COMUNIDAD DE;Group 1117 Cholelithiasis 574;Men;6,028 MADRID, COMUNIDAD DE;Group 1117 Cholelithiasis 574;Women;8,749 MADRID, COMUNIDAD DE;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Both sexes;3,973 MADRID, COMUNIDAD DE;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Men;1,983 MADRID, COMUNIDAD DE;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Women;1,990 MADRID, COMUNIDAD DE;Group 1119 Pancreatic diseases 577;Both sexes;4,202 MADRID, COMUNIDAD DE;Group 1119 Pancreatic diseases 577;Men;2,290 MADRID, COMUNIDAD DE;Group 1119 Pancreatic diseases 577;Women;1,911 MADRID, COMUNIDAD DE;Group 1120 Other diseases of the digestive system Rest of (520-579);Both sexes;2,942 MADRID, COMUNIDAD DE;Group 1120 Other diseases of the digestive system Rest of (520-579);Men;1,611 MADRID, COMUNIDAD DE;Group 1120 Other diseases of the digestive system Rest of (520-579);Women;1,330 MADRID, COMUNIDAD DE;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Both sexes;6,177 MADRID, COMUNIDAD DE;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Men;3,185 MADRID, COMUNIDAD DE;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Women;2,992 MADRID, COMUNIDAD DE;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Both sexes;3,349 MADRID, COMUNIDAD DE;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Men;1,931 MADRID, COMUNIDAD DE;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Women;1,418 MADRID, COMUNIDAD DE;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Both sexes;359 MADRID, COMUNIDAD DE;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Men;179 MADRID, COMUNIDAD DE;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Women;180 MADRID, COMUNIDAD DE;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Both sexes;2,469 MADRID, COMUNIDAD DE;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Men;1,075 MADRID, COMUNIDAD DE;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Women;1,394 MADRID, COMUNIDAD DE;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Both sexes;59,196 MADRID, COMUNIDAD DE;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Men;28,198 MADRID, COMUNIDAD DE;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Women;30,998 MADRID, COMUNIDAD DE;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Both sexes;.. MADRID, COMUNIDAD DE;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Men;.. MADRID, COMUNIDAD DE;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Women;.. MADRID, COMUNIDAD DE;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Both sexes;.. MADRID, COMUNIDAD DE;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Men;.. MADRID, COMUNIDAD DE;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Women;.. MADRID, COMUNIDAD DE;Group 1303 Internal derangement of knee 717;Both sexes;10,513 MADRID, COMUNIDAD DE;Group 1303 Internal derangement of knee 717;Men;7,210 MADRID, COMUNIDAD DE;Group 1303 Internal derangement of knee 717;Women;3,303 MADRID, COMUNIDAD DE;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Both sexes;17,260 MADRID, COMUNIDAD DE;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Men;7,228 MADRID, COMUNIDAD DE;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Women;10,032 MADRID, COMUNIDAD DE;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Both sexes;1,011 MADRID, COMUNIDAD DE;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Men;335 MADRID, COMUNIDAD DE;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Women;676 MADRID, COMUNIDAD DE;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Both sexes;3,223 MADRID, COMUNIDAD DE;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Men;1,429 MADRID, COMUNIDAD DE;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Women;1,794 MADRID, COMUNIDAD DE;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Both sexes;6,128 MADRID, COMUNIDAD DE;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Men;3,285 MADRID, COMUNIDAD DE;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Women;2,843 MADRID, COMUNIDAD DE;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Both sexes;1,550 MADRID, COMUNIDAD DE;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Men;694 MADRID, COMUNIDAD DE;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Women;856 MADRID, COMUNIDAD DE;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Both sexes;8,899 MADRID, COMUNIDAD DE;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Men;4,395 MADRID, COMUNIDAD DE;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Women;4,504 MADRID, COMUNIDAD DE;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Both sexes;10,612 MADRID, COMUNIDAD DE;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Men;3,622 MADRID, COMUNIDAD DE;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Women;6,990 MADRID, COMUNIDAD DE;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Both sexes;43,280 MADRID, COMUNIDAD DE;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Men;20,274 MADRID, COMUNIDAD DE;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Women;23,006 MADRID, COMUNIDAD DE;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Both sexes;4,627 MADRID, COMUNIDAD DE;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Men;1,659 MADRID, COMUNIDAD DE;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Women;2,968 MADRID, COMUNIDAD DE;Group 1402 Renal failure 5836-5837, 584-586;Both sexes;3,698 MADRID, COMUNIDAD DE;Group 1402 Renal failure 5836-5837, 584-586;Men;2,108 MADRID, COMUNIDAD DE;Group 1402 Renal failure 5836-5837, 584-586;Women;1,589 MADRID, COMUNIDAD DE;Group 1403 Urolithiasis 592, 594, 7880;Both sexes;5,023 MADRID, COMUNIDAD DE;Group 1403 Urolithiasis 592, 594, 7880;Men;3,031 MADRID, COMUNIDAD DE;Group 1403 Urolithiasis 592, 594, 7880;Women;1,992 MADRID, COMUNIDAD DE;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Both sexes;12,620 MADRID, COMUNIDAD DE;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Men;6,265 MADRID, COMUNIDAD DE;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Women;6,355 MADRID, COMUNIDAD DE;Group 1405 Prostatic hyperplasia 600;Both sexes;4,199 MADRID, COMUNIDAD DE;Group 1405 Prostatic hyperplasia 600;Men;4,199 MADRID, COMUNIDAD DE;Group 1405 Prostatic hyperplasia 600;Women;.. MADRID, COMUNIDAD DE;Group 1406 Other diseases of the male genital organs 601-608;Both sexes;2,571 MADRID, COMUNIDAD DE;Group 1406 Other diseases of the male genital organs 601-608;Men;2,571 MADRID, COMUNIDAD DE;Group 1406 Other diseases of the male genital organs 601-608;Women;.. MADRID, COMUNIDAD DE;Group 1407 Disorders of breast 610-612;Both sexes;2,347 MADRID, COMUNIDAD DE;Group 1407 Disorders of breast 610-612;Men;331 MADRID, COMUNIDAD DE;Group 1407 Disorders of breast 610-612;Women;2,016 MADRID, COMUNIDAD DE;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Both sexes;1,105 MADRID, COMUNIDAD DE;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Men;.. MADRID, COMUNIDAD DE;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Women;1,105 MADRID, COMUNIDAD DE;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Both sexes;379 MADRID, COMUNIDAD DE;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Men;.. MADRID, COMUNIDAD DE;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Women;379 MADRID, COMUNIDAD DE;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Both sexes;6,711 MADRID, COMUNIDAD DE;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Men;109 MADRID, COMUNIDAD DE;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Women;6,602 MADRID, COMUNIDAD DE;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Both sexes;74,861 MADRID, COMUNIDAD DE;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Men;.. MADRID, COMUNIDAD DE;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Women;74,861 MADRID, COMUNIDAD DE;Group 1501 Legally induced abortion 635;Both sexes;143 MADRID, COMUNIDAD DE;Group 1501 Legally induced abortion 635;Men;.. MADRID, COMUNIDAD DE;Group 1501 Legally induced abortion 635;Women;143 MADRID, COMUNIDAD DE;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Both sexes;2,997 MADRID, COMUNIDAD DE;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Men;.. MADRID, COMUNIDAD DE;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Women;2,997 MADRID, COMUNIDAD DE;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Both sexes;45,436 MADRID, COMUNIDAD DE;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Men;.. MADRID, COMUNIDAD DE;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Women;45,436 MADRID, COMUNIDAD DE;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Both sexes;13,365 MADRID, COMUNIDAD DE;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Men;.. MADRID, COMUNIDAD DE;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Women;13,365 MADRID, COMUNIDAD DE;Group 1505 Single spontaneous delivery 650;Both sexes;4,669 MADRID, COMUNIDAD DE;Group 1505 Single spontaneous delivery 650;Men;.. MADRID, COMUNIDAD DE;Group 1505 Single spontaneous delivery 650;Women;4,669 MADRID, COMUNIDAD DE;Group 1506 Other deliveries 6695-6697;Both sexes;3,076 MADRID, COMUNIDAD DE;Group 1506 Other deliveries 6695-6697;Men;.. MADRID, COMUNIDAD DE;Group 1506 Other deliveries 6695-6697;Women;3,076 MADRID, COMUNIDAD DE;Group 1507 Complications related to the puerperium 670-676;Both sexes;591 MADRID, COMUNIDAD DE;Group 1507 Complications related to the puerperium 670-676;Men;.. MADRID, COMUNIDAD DE;Group 1507 Complications related to the puerperium 670-676;Women;591 MADRID, COMUNIDAD DE;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Both sexes;4,584 MADRID, COMUNIDAD DE;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Men;.. MADRID, COMUNIDAD DE;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Women;4,584 MADRID, COMUNIDAD DE;Group 1600 Some disorders originating in the perinatal period 760-779;Both sexes;10,847 MADRID, COMUNIDAD DE;Group 1600 Some disorders originating in the perinatal period 760-779;Men;5,967 MADRID, COMUNIDAD DE;Group 1600 Some disorders originating in the perinatal period 760-779;Women;4,881 MADRID, COMUNIDAD DE;Group 1601 Disorders related with premature delivery and a low birth weight 765;Both sexes;2,395 MADRID, COMUNIDAD DE;Group 1601 Disorders related with premature delivery and a low birth weight 765;Men;1,279 MADRID, COMUNIDAD DE;Group 1601 Disorders related with premature delivery and a low birth weight 765;Women;1,115 MADRID, COMUNIDAD DE;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Both sexes;8,453 MADRID, COMUNIDAD DE;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Men;4,687 MADRID, COMUNIDAD DE;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Women;3,765 MADRID, COMUNIDAD DE;Grupo 1700 Congenital abnormalities 740-759;Both sexes;7,818 MADRID, COMUNIDAD DE;Grupo 1700 Congenital abnormalities 740-759;Men;4,080 MADRID, COMUNIDAD DE;Grupo 1700 Congenital abnormalities 740-759;Women;3,738 MADRID, COMUNIDAD DE;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Both sexes;24,529 MADRID, COMUNIDAD DE;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Men;13,150 MADRID, COMUNIDAD DE;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Women;11,379 MADRID, COMUNIDAD DE;Group 1801 Pain in throat and chest 7841, 7865;Both sexes;2,651 MADRID, COMUNIDAD DE;Group 1801 Pain in throat and chest 7841, 7865;Men;1,418 MADRID, COMUNIDAD DE;Group 1801 Pain in throat and chest 7841, 7865;Women;1,232 MADRID, COMUNIDAD DE;Group 1802 Abdominal pain 7890;Both sexes;2,418 MADRID, COMUNIDAD DE;Group 1802 Abdominal pain 7890;Men;929 MADRID, COMUNIDAD DE;Group 1802 Abdominal pain 7890;Women;1,489 MADRID, COMUNIDAD DE;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Both sexes;1,733 MADRID, COMUNIDAD DE;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Men;934 MADRID, COMUNIDAD DE;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Women;799 MADRID, COMUNIDAD DE;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Both sexes;17,727 MADRID, COMUNIDAD DE;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Men;9,869 MADRID, COMUNIDAD DE;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Women;7,858 MADRID, COMUNIDAD DE;Group 1900 Injuries and poisoning 800-999;Both sexes;52,813 MADRID, COMUNIDAD DE;Group 1900 Injuries and poisoning 800-999;Men;27,002 MADRID, COMUNIDAD DE;Group 1900 Injuries and poisoning 800-999;Women;25,812 MADRID, COMUNIDAD DE;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Both sexes;2,331 MADRID, COMUNIDAD DE;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Men;1,267 MADRID, COMUNIDAD DE;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Women;1,064 MADRID, COMUNIDAD DE;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Both sexes;1,473 MADRID, COMUNIDAD DE;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Men;1,021 MADRID, COMUNIDAD DE;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Women;452 MADRID, COMUNIDAD DE;Group 1903 Radius and ulna fracture 813;Both sexes;3,115 MADRID, COMUNIDAD DE;Group 1903 Radius and ulna fracture 813;Men;1,549 MADRID, COMUNIDAD DE;Group 1903 Radius and ulna fracture 813;Women;1,567 MADRID, COMUNIDAD DE;Group 1904 Femur fracture 820-821;Both sexes;7,248 MADRID, COMUNIDAD DE;Group 1904 Femur fracture 820-821;Men;1,995 MADRID, COMUNIDAD DE;Group 1904 Femur fracture 820-821;Women;5,252 MADRID, COMUNIDAD DE;Group 1905 Leg fracture, including the ankle 823-824;Both sexes;3,712 MADRID, COMUNIDAD DE;Group 1905 Leg fracture, including the ankle 823-824;Men;1,963 MADRID, COMUNIDAD DE;Group 1905 Leg fracture, including the ankle 823-824;Women;1,749 MADRID, COMUNIDAD DE;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Both sexes;13,536 MADRID, COMUNIDAD DE;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Men;8,196 MADRID, COMUNIDAD DE;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Women;5,340 MADRID, COMUNIDAD DE;Group 1907 Burns 940-949;Both sexes;467 MADRID, COMUNIDAD DE;Group 1907 Burns 940-949;Men;278 MADRID, COMUNIDAD DE;Group 1907 Burns 940-949;Women;189 MADRID, COMUNIDAD DE;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Both sexes;1,492 MADRID, COMUNIDAD DE;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Men;675 MADRID, COMUNIDAD DE;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Women;817 MADRID, COMUNIDAD DE;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Both sexes;17,627 MADRID, COMUNIDAD DE;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Men;9,173 MADRID, COMUNIDAD DE;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Women;8,454 MADRID, COMUNIDAD DE;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Both sexes;146 MADRID, COMUNIDAD DE;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Men;85 MADRID, COMUNIDAD DE;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Women;61 MADRID, COMUNIDAD DE;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Both sexes;1,665 MADRID, COMUNIDAD DE;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Men;799 MADRID, COMUNIDAD DE;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Women;866 MADRID, COMUNIDAD DE;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Both sexes;18,709 MADRID, COMUNIDAD DE;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Men;8,410 MADRID, COMUNIDAD DE;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Women;10,300 MADRID, COMUNIDAD DE;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Both sexes;1,153 MADRID, COMUNIDAD DE;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Men;677 MADRID, COMUNIDAD DE;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Women;476 MADRID, COMUNIDAD DE;Group 2102 Contraceptive management V25;Both sexes;131 MADRID, COMUNIDAD DE;Group 2102 Contraceptive management V25;Men;8 MADRID, COMUNIDAD DE;Group 2102 Contraceptive management V25;Women;123 MADRID, COMUNIDAD DE;Group 2103 Living newborns by type of delivery V30-V39;Both sexes;.. MADRID, COMUNIDAD DE;Group 2103 Living newborns by type of delivery V30-V39;Men;.. MADRID, COMUNIDAD DE;Group 2103 Living newborns by type of delivery V30-V39;Women;.. MADRID, COMUNIDAD DE;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Both sexes;6,181 MADRID, COMUNIDAD DE;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Men;3,626 MADRID, COMUNIDAD DE;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Women;2,555 MADRID, COMUNIDAD DE;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Both sexes;11,244 MADRID, COMUNIDAD DE;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Men;4,098 MADRID, COMUNIDAD DE;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Women;7,145 MURCIA, REGIËN DE;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Both sexes;145,014 MURCIA, REGIËN DE;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Men;66,897 MURCIA, REGIËN DE;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Women;78,117 MURCIA, REGIËN DE;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Both sexes;3,152 MURCIA, REGIËN DE;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Men;1,796 MURCIA, REGIËN DE;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Women;1,356 MURCIA, REGIËN DE;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Both sexes;590 MURCIA, REGIËN DE;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Men;339 MURCIA, REGIËN DE;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Women;251 MURCIA, REGIËN DE;Group 0102 Imprecise intestinal infections 009;Both sexes;101 MURCIA, REGIËN DE;Group 0102 Imprecise intestinal infections 009;Men;42 MURCIA, REGIËN DE;Group 0102 Imprecise intestinal infections 009;Women;59 MURCIA, REGIËN DE;Group 0103 Tuberculosis 010-018, 137;Both sexes;139 MURCIA, REGIËN DE;Group 0103 Tuberculosis 010-018, 137;Men;90 MURCIA, REGIËN DE;Group 0103 Tuberculosis 010-018, 137;Women;49 MURCIA, REGIËN DE;Group 0104 Septicaemia 038;Both sexes;1,207 MURCIA, REGIËN DE;Group 0104 Septicaemia 038;Men;658 MURCIA, REGIËN DE;Group 0104 Septicaemia 038;Women;549 MURCIA, REGIËN DE;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Both sexes;115 MURCIA, REGIËN DE;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Men;89 MURCIA, REGIËN DE;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Women;26 MURCIA, REGIËN DE;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Both sexes;1,000 MURCIA, REGIËN DE;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Men;578 MURCIA, REGIËN DE;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Women;422 MURCIA, REGIËN DE;Group 0200 Neoplasms 140-239;Both sexes;12,135 MURCIA, REGIËN DE;Group 0200 Neoplasms 140-239;Men;6,271 MURCIA, REGIËN DE;Group 0200 Neoplasms 140-239;Women;5,864 MURCIA, REGIËN DE;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Both sexes;1,192 MURCIA, REGIËN DE;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Men;736 MURCIA, REGIËN DE;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Women;456 MURCIA, REGIËN DE;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Both sexes;824 MURCIA, REGIËN DE;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Men;690 MURCIA, REGIËN DE;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Women;134 MURCIA, REGIËN DE;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Both sexes;197 MURCIA, REGIËN DE;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Men;113 MURCIA, REGIËN DE;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Women;84 MURCIA, REGIËN DE;Group 0204 Malignant neoplasm of breast 174-175;Both sexes;997 MURCIA, REGIËN DE;Group 0204 Malignant neoplasm of breast 174-175;Men;10 MURCIA, REGIËN DE;Group 0204 Malignant neoplasm of breast 174-175;Women;987 MURCIA, REGIËN DE;Group 0205 Malignant neoplasm of uterus 179-180, 182;Both sexes;262 MURCIA, REGIËN DE;Group 0205 Malignant neoplasm of uterus 179-180, 182;Men;.. MURCIA, REGIËN DE;Group 0205 Malignant neoplasm of uterus 179-180, 182;Women;262 MURCIA, REGIËN DE;Group 0206 Malignant neoplasm of ovary 1830;Both sexes;100 MURCIA, REGIËN DE;Group 0206 Malignant neoplasm of ovary 1830;Men;.. MURCIA, REGIËN DE;Group 0206 Malignant neoplasm of ovary 1830;Women;100 MURCIA, REGIËN DE;Group 0207 Malignant neoplasm of prostate 185;Both sexes;352 MURCIA, REGIËN DE;Group 0207 Malignant neoplasm of prostate 185;Men;352 MURCIA, REGIËN DE;Group 0207 Malignant neoplasm of prostate 185;Women;.. MURCIA, REGIËN DE;Group 0208 Malignant neoplasm of bladder 188;Both sexes;1,086 MURCIA, REGIËN DE;Group 0208 Malignant neoplasm of bladder 188;Men;923 MURCIA, REGIËN DE;Group 0208 Malignant neoplasm of bladder 188;Women;163 MURCIA, REGIËN DE;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Both sexes;4,089 MURCIA, REGIËN DE;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Men;2,369 MURCIA, REGIËN DE;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Women;1,720 MURCIA, REGIËN DE;Group 0210 Carcinoma in situ 230-234;Both sexes;203 MURCIA, REGIËN DE;Group 0210 Carcinoma in situ 230-234;Men;84 MURCIA, REGIËN DE;Group 0210 Carcinoma in situ 230-234;Women;119 MURCIA, REGIËN DE;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Both sexes;126 MURCIA, REGIËN DE;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Men;83 MURCIA, REGIËN DE;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Women;43 MURCIA, REGIËN DE;Grupo 0212 Leiomyoma of uterus 218;Both sexes;710 MURCIA, REGIËN DE;Grupo 0212 Leiomyoma of uterus 218;Men;.. MURCIA, REGIËN DE;Grupo 0212 Leiomyoma of uterus 218;Women;710 MURCIA, REGIËN DE;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Both sexes;1,997 MURCIA, REGIËN DE;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Men;911 MURCIA, REGIËN DE;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Women;1,086 MURCIA, REGIËN DE;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Both sexes;1,450 MURCIA, REGIËN DE;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Men;666 MURCIA, REGIËN DE;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Women;784 MURCIA, REGIËN DE;Group 0301 Anaemias 280-285;Both sexes;739 MURCIA, REGIËN DE;Group 0301 Anaemias 280-285;Men;339 MURCIA, REGIËN DE;Group 0301 Anaemias 280-285;Women;400 MURCIA, REGIËN DE;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Both sexes;711 MURCIA, REGIËN DE;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Men;327 MURCIA, REGIËN DE;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Women;384 MURCIA, REGIËN DE;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Both sexes;3,102 MURCIA, REGIËN DE;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Men;1,275 MURCIA, REGIËN DE;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Women;1,827 MURCIA, REGIËN DE;Group 0401 Diabetes mellitus 249-250;Both sexes;1,102 MURCIA, REGIËN DE;Group 0401 Diabetes mellitus 249-250;Men;615 MURCIA, REGIËN DE;Group 0401 Diabetes mellitus 249-250;Women;487 MURCIA, REGIËN DE;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Both sexes;2,000 MURCIA, REGIËN DE;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Men;660 MURCIA, REGIËN DE;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Women;1,340 MURCIA, REGIËN DE;Group 0500 Mental disorders 290-319;Both sexes;3,246 MURCIA, REGIËN DE;Group 0500 Mental disorders 290-319;Men;1,780 MURCIA, REGIËN DE;Group 0500 Mental disorders 290-319;Women;1,466 MURCIA, REGIËN DE;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Both sexes;105 MURCIA, REGIËN DE;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Men;43 MURCIA, REGIËN DE;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Women;62 MURCIA, REGIËN DE;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Both sexes;198 MURCIA, REGIËN DE;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Men;143 MURCIA, REGIËN DE;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Women;55 MURCIA, REGIËN DE;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Both sexes;254 MURCIA, REGIËN DE;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Men;195 MURCIA, REGIËN DE;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Women;59 MURCIA, REGIËN DE;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Both sexes;1,018 MURCIA, REGIËN DE;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Men;611 MURCIA, REGIËN DE;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Women;407 MURCIA, REGIËN DE;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Both sexes;649 MURCIA, REGIËN DE;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Men;305 MURCIA, REGIËN DE;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Women;344 MURCIA, REGIËN DE;Group 0506 Other mental and behavioural disorders Rest of (290-319);Both sexes;1,022 MURCIA, REGIËN DE;Group 0506 Other mental and behavioural disorders Rest of (290-319);Men;483 MURCIA, REGIËN DE;Group 0506 Other mental and behavioural disorders Rest of (290-319);Women;539 MURCIA, REGIËN DE;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Both sexes;3,592 MURCIA, REGIËN DE;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Men;1,816 MURCIA, REGIËN DE;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Women;1,776 MURCIA, REGIËN DE;Group 0601 Alzheimer's disease 3310;Both sexes;92 MURCIA, REGIËN DE;Group 0601 Alzheimer's disease 3310;Men;28 MURCIA, REGIËN DE;Group 0601 Alzheimer's disease 3310;Women;64 MURCIA, REGIËN DE;Group 0602 Multiple sclerosis 340;Both sexes;83 MURCIA, REGIËN DE;Group 0602 Multiple sclerosis 340;Men;28 MURCIA, REGIËN DE;Group 0602 Multiple sclerosis 340;Women;55 MURCIA, REGIËN DE;Group 0603 Epilepsy 345;Both sexes;788 MURCIA, REGIËN DE;Group 0603 Epilepsy 345;Men;413 MURCIA, REGIËN DE;Group 0603 Epilepsy 345;Women;375 MURCIA, REGIËN DE;Group 0604 Transient cerebral ischemia 435;Both sexes;659 MURCIA, REGIËN DE;Group 0604 Transient cerebral ischemia 435;Men;337 MURCIA, REGIËN DE;Group 0604 Transient cerebral ischemia 435;Women;322 MURCIA, REGIËN DE;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Both sexes;1,970 MURCIA, REGIËN DE;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Men;1,010 MURCIA, REGIËN DE;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Women;960 MURCIA, REGIËN DE;Grupo 0700 Diseases of the eye and adnexa 360-379;Both sexes;469 MURCIA, REGIËN DE;Grupo 0700 Diseases of the eye and adnexa 360-379;Men;251 MURCIA, REGIËN DE;Grupo 0700 Diseases of the eye and adnexa 360-379;Women;218 MURCIA, REGIËN DE;Grupo 0701 Cataract 366;Both sexes;24 MURCIA, REGIËN DE;Grupo 0701 Cataract 366;Men;15 MURCIA, REGIËN DE;Grupo 0701 Cataract 366;Women;9 MURCIA, REGIËN DE;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Both sexes;445 MURCIA, REGIËN DE;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Men;236 MURCIA, REGIËN DE;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Women;209 MURCIA, REGIËN DE;Group 0800 Diseases of the ear and the mastoid 380-389;Both sexes;711 MURCIA, REGIËN DE;Group 0800 Diseases of the ear and the mastoid 380-389;Men;355 MURCIA, REGIËN DE;Group 0800 Diseases of the ear and the mastoid 380-389;Women;356 MURCIA, REGIËN DE;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Both sexes;18,850 MURCIA, REGIËN DE;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Men;10,545 MURCIA, REGIËN DE;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Women;8,305 MURCIA, REGIËN DE;Group 0901 Hypertensive disease 401-405;Both sexes;890 MURCIA, REGIËN DE;Group 0901 Hypertensive disease 401-405;Men;431 MURCIA, REGIËN DE;Group 0901 Hypertensive disease 401-405;Women;459 MURCIA, REGIËN DE;Group 0902 Angina pectoris 4111, 413;Both sexes;1,203 MURCIA, REGIËN DE;Group 0902 Angina pectoris 4111, 413;Men;731 MURCIA, REGIËN DE;Group 0902 Angina pectoris 4111, 413;Women;472 MURCIA, REGIËN DE;Group 0903 Acute myocardial infarction 410;Both sexes;1,982 MURCIA, REGIËN DE;Group 0903 Acute myocardial infarction 410;Men;1,389 MURCIA, REGIËN DE;Group 0903 Acute myocardial infarction 410;Women;593 MURCIA, REGIËN DE;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Both sexes;1,442 MURCIA, REGIËN DE;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Men;1,080 MURCIA, REGIËN DE;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Women;362 MURCIA, REGIËN DE;Group 0905 Diseases of the lungs circulation 415-417;Both sexes;429 MURCIA, REGIËN DE;Group 0905 Diseases of the lungs circulation 415-417;Men;204 MURCIA, REGIËN DE;Group 0905 Diseases of the lungs circulation 415-417;Women;225 MURCIA, REGIËN DE;Group 0906 Heart conduction disorders and arrhytmias 426-427;Both sexes;2,352 MURCIA, REGIËN DE;Group 0906 Heart conduction disorders and arrhytmias 426-427;Men;1,233 MURCIA, REGIËN DE;Group 0906 Heart conduction disorders and arrhytmias 426-427;Women;1,119 MURCIA, REGIËN DE;Grupo 0907 Heart failure 428;Both sexes;3,219 MURCIA, REGIËN DE;Grupo 0907 Heart failure 428;Men;1,395 MURCIA, REGIËN DE;Grupo 0907 Heart failure 428;Women;1,824 MURCIA, REGIËN DE;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Both sexes;3,293 MURCIA, REGIËN DE;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Men;1,786 MURCIA, REGIËN DE;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Women;1,507 MURCIA, REGIËN DE;Grupo 0909 Atherosclerosis 440;Both sexes;363 MURCIA, REGIËN DE;Grupo 0909 Atherosclerosis 440;Men;280 MURCIA, REGIËN DE;Grupo 0909 Atherosclerosis 440;Women;83 MURCIA, REGIËN DE;Group 0910 Varicose veins of lower extremities 454;Both sexes;670 MURCIA, REGIËN DE;Group 0910 Varicose veins of lower extremities 454;Men;218 MURCIA, REGIËN DE;Group 0910 Varicose veins of lower extremities 454;Women;452 MURCIA, REGIËN DE;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Both sexes;3,007 MURCIA, REGIËN DE;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Men;1,798 MURCIA, REGIËN DE;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Women;1,209 MURCIA, REGIËN DE;Group 1000 Diseases of the respiratory system 0340, 460-519;Both sexes;15,257 MURCIA, REGIËN DE;Group 1000 Diseases of the respiratory system 0340, 460-519;Men;8,717 MURCIA, REGIËN DE;Group 1000 Diseases of the respiratory system 0340, 460-519;Women;6,540 MURCIA, REGIËN DE;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Both sexes;795 MURCIA, REGIËN DE;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Men;403 MURCIA, REGIËN DE;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Women;392 MURCIA, REGIËN DE;Group 1002 Pneumonia 480-486;Both sexes;3,197 MURCIA, REGIËN DE;Group 1002 Pneumonia 480-486;Men;1,881 MURCIA, REGIËN DE;Group 1002 Pneumonia 480-486;Women;1,316 MURCIA, REGIËN DE;Group 1003 Acute bronchitis and bronchiolitis 466;Both sexes;1,219 MURCIA, REGIËN DE;Group 1003 Acute bronchitis and bronchiolitis 466;Men;574 MURCIA, REGIËN DE;Group 1003 Acute bronchitis and bronchiolitis 466;Women;645 MURCIA, REGIËN DE;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Both sexes;585 MURCIA, REGIËN DE;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Men;332 MURCIA, REGIËN DE;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Women;253 MURCIA, REGIËN DE;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Both sexes;1,304 MURCIA, REGIËN DE;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Men;803 MURCIA, REGIËN DE;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Women;501 MURCIA, REGIËN DE;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Both sexes;2,095 MURCIA, REGIËN DE;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Men;1,732 MURCIA, REGIËN DE;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Women;363 MURCIA, REGIËN DE;Group 1007 Asthma 4930-4931,4938-4939;Both sexes;707 MURCIA, REGIËN DE;Group 1007 Asthma 4930-4931,4938-4939;Men;225 MURCIA, REGIËN DE;Group 1007 Asthma 4930-4931,4938-4939;Women;482 MURCIA, REGIËN DE;Group 1008 Other diseases of the respiratory system Resto of (460-519);Both sexes;5,355 MURCIA, REGIËN DE;Group 1008 Other diseases of the respiratory system Resto of (460-519);Men;2,767 MURCIA, REGIËN DE;Group 1008 Other diseases of the respiratory system Resto of (460-519);Women;2,588 MURCIA, REGIËN DE;Group 1100 Diseases of the digestive system 520-579;Both sexes;17,306 MURCIA, REGIËN DE;Group 1100 Diseases of the digestive system 520-579;Men;9,761 MURCIA, REGIËN DE;Group 1100 Diseases of the digestive system 520-579;Women;7,545 MURCIA, REGIËN DE;Group 1101 Disorders of the teeth and supporting structures 520-525;Both sexes;355 MURCIA, REGIËN DE;Group 1101 Disorders of the teeth and supporting structures 520-525;Men;155 MURCIA, REGIËN DE;Group 1101 Disorders of the teeth and supporting structures 520-525;Women;200 MURCIA, REGIËN DE;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Both sexes;265 MURCIA, REGIËN DE;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Men;156 MURCIA, REGIËN DE;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Women;109 MURCIA, REGIËN DE;Group 1103 Diseases of the esophagus 530;Both sexes;339 MURCIA, REGIËN DE;Group 1103 Diseases of the esophagus 530;Men;211 MURCIA, REGIËN DE;Group 1103 Diseases of the esophagus 530;Women;128 MURCIA, REGIËN DE;Group 1104 Peptic ulcer 531-534;Both sexes;259 MURCIA, REGIËN DE;Group 1104 Peptic ulcer 531-534;Men;177 MURCIA, REGIËN DE;Group 1104 Peptic ulcer 531-534;Women;82 MURCIA, REGIËN DE;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Both sexes;374 MURCIA, REGIËN DE;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Men;197 MURCIA, REGIËN DE;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Women;177 MURCIA, REGIËN DE;Group 1106 Appendicitis 540-543;Both sexes;1,715 MURCIA, REGIËN DE;Group 1106 Appendicitis 540-543;Men;1,002 MURCIA, REGIËN DE;Group 1106 Appendicitis 540-543;Women;713 MURCIA, REGIËN DE;Group 1107 Inguinal hernia 550;Both sexes;1,583 MURCIA, REGIËN DE;Group 1107 Inguinal hernia 550;Men;1,428 MURCIA, REGIËN DE;Group 1107 Inguinal hernia 550;Women;155 MURCIA, REGIËN DE;Group 1108 Other abdominal hernia 551-553;Both sexes;1,415 MURCIA, REGIËN DE;Group 1108 Other abdominal hernia 551-553;Men;697 MURCIA, REGIËN DE;Group 1108 Other abdominal hernia 551-553;Women;718 MURCIA, REGIËN DE;Group 1109 Crohn's disease and ulcerative colitis 555-556;Both sexes;381 MURCIA, REGIËN DE;Group 1109 Crohn's disease and ulcerative colitis 555-556;Men;203 MURCIA, REGIËN DE;Group 1109 Crohn's disease and ulcerative colitis 555-556;Women;178 MURCIA, REGIËN DE;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Both sexes;1,164 MURCIA, REGIËN DE;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Men;584 MURCIA, REGIËN DE;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Women;580 MURCIA, REGIËN DE;Group 1111 Intestinal obstruction without hernia 560;Both sexes;769 MURCIA, REGIËN DE;Group 1111 Intestinal obstruction without hernia 560;Men;410 MURCIA, REGIËN DE;Group 1111 Intestinal obstruction without hernia 560;Women;359 MURCIA, REGIËN DE;Group 1112 Intestinal diverticulosis 562;Both sexes;699 MURCIA, REGIËN DE;Group 1112 Intestinal diverticulosis 562;Men;384 MURCIA, REGIËN DE;Group 1112 Intestinal diverticulosis 562;Women;315 MURCIA, REGIËN DE;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Both sexes;1,008 MURCIA, REGIËN DE;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Men;680 MURCIA, REGIËN DE;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Women;328 MURCIA, REGIËN DE;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Both sexes;500 MURCIA, REGIËN DE;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Men;251 MURCIA, REGIËN DE;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Women;249 MURCIA, REGIËN DE;Group 1115 Alcoholic hepatitis 5710-5713;Both sexes;282 MURCIA, REGIËN DE;Group 1115 Alcoholic hepatitis 5710-5713;Men;248 MURCIA, REGIËN DE;Group 1115 Alcoholic hepatitis 5710-5713;Women;34 MURCIA, REGIËN DE;Group 1116 Other diseases of the liver 570,5714-573;Both sexes;543 MURCIA, REGIËN DE;Group 1116 Other diseases of the liver 570,5714-573;Men;315 MURCIA, REGIËN DE;Group 1116 Other diseases of the liver 570,5714-573;Women;228 MURCIA, REGIËN DE;Group 1117 Cholelithiasis 574;Both sexes;3,298 MURCIA, REGIËN DE;Group 1117 Cholelithiasis 574;Men;1,295 MURCIA, REGIËN DE;Group 1117 Cholelithiasis 574;Women;2,003 MURCIA, REGIËN DE;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Both sexes;725 MURCIA, REGIËN DE;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Men;408 MURCIA, REGIËN DE;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Women;317 MURCIA, REGIËN DE;Group 1119 Pancreatic diseases 577;Both sexes;891 MURCIA, REGIËN DE;Group 1119 Pancreatic diseases 577;Men;502 MURCIA, REGIËN DE;Group 1119 Pancreatic diseases 577;Women;389 MURCIA, REGIËN DE;Group 1120 Other diseases of the digestive system Rest of (520-579);Both sexes;741 MURCIA, REGIËN DE;Group 1120 Other diseases of the digestive system Rest of (520-579);Men;458 MURCIA, REGIËN DE;Group 1120 Other diseases of the digestive system Rest of (520-579);Women;283 MURCIA, REGIËN DE;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Both sexes;1,549 MURCIA, REGIËN DE;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Men;890 MURCIA, REGIËN DE;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Women;659 MURCIA, REGIËN DE;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Both sexes;1,017 MURCIA, REGIËN DE;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Men;632 MURCIA, REGIËN DE;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Women;385 MURCIA, REGIËN DE;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Both sexes;73 MURCIA, REGIËN DE;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Men;36 MURCIA, REGIËN DE;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Women;37 MURCIA, REGIËN DE;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Both sexes;459 MURCIA, REGIËN DE;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Men;222 MURCIA, REGIËN DE;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Women;237 MURCIA, REGIËN DE;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Both sexes;9,570 MURCIA, REGIËN DE;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Men;4,580 MURCIA, REGIËN DE;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Women;4,990 MURCIA, REGIËN DE;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Both sexes;.. MURCIA, REGIËN DE;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Men;.. MURCIA, REGIËN DE;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Women;.. MURCIA, REGIËN DE;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Both sexes;.. MURCIA, REGIËN DE;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Men;.. MURCIA, REGIËN DE;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Women;.. MURCIA, REGIËN DE;Group 1303 Internal derangement of knee 717;Both sexes;1,342 MURCIA, REGIËN DE;Group 1303 Internal derangement of knee 717;Men;934 MURCIA, REGIËN DE;Group 1303 Internal derangement of knee 717;Women;408 MURCIA, REGIËN DE;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Both sexes;3,188 MURCIA, REGIËN DE;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Men;1,263 MURCIA, REGIËN DE;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Women;1,925 MURCIA, REGIËN DE;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Both sexes;185 MURCIA, REGIËN DE;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Men;66 MURCIA, REGIËN DE;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Women;119 MURCIA, REGIËN DE;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Both sexes;372 MURCIA, REGIËN DE;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Men;191 MURCIA, REGIËN DE;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Women;181 MURCIA, REGIËN DE;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Both sexes;1,133 MURCIA, REGIËN DE;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Men;626 MURCIA, REGIËN DE;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Women;507 MURCIA, REGIËN DE;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Both sexes;353 MURCIA, REGIËN DE;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Men;145 MURCIA, REGIËN DE;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Women;208 MURCIA, REGIËN DE;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Both sexes;1,480 MURCIA, REGIËN DE;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Men;746 MURCIA, REGIËN DE;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Women;734 MURCIA, REGIËN DE;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Both sexes;1,517 MURCIA, REGIËN DE;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Men;609 MURCIA, REGIËN DE;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Women;908 MURCIA, REGIËN DE;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Both sexes;10,340 MURCIA, REGIËN DE;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Men;4,666 MURCIA, REGIËN DE;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Women;5,674 MURCIA, REGIËN DE;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Both sexes;1,180 MURCIA, REGIËN DE;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Men;380 MURCIA, REGIËN DE;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Women;800 MURCIA, REGIËN DE;Group 1402 Renal failure 5836-5837, 584-586;Both sexes;902 MURCIA, REGIËN DE;Group 1402 Renal failure 5836-5837, 584-586;Men;505 MURCIA, REGIËN DE;Group 1402 Renal failure 5836-5837, 584-586;Women;397 MURCIA, REGIËN DE;Group 1403 Urolithiasis 592, 594, 7880;Both sexes;1,587 MURCIA, REGIËN DE;Group 1403 Urolithiasis 592, 594, 7880;Men;939 MURCIA, REGIËN DE;Group 1403 Urolithiasis 592, 594, 7880;Women;648 MURCIA, REGIËN DE;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Both sexes;2,850 MURCIA, REGIËN DE;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Men;1,329 MURCIA, REGIËN DE;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Women;1,521 MURCIA, REGIËN DE;Group 1405 Prostatic hyperplasia 600;Both sexes;705 MURCIA, REGIËN DE;Group 1405 Prostatic hyperplasia 600;Men;705 MURCIA, REGIËN DE;Group 1405 Prostatic hyperplasia 600;Women;.. MURCIA, REGIËN DE;Group 1406 Other diseases of the male genital organs 601-608;Both sexes;732 MURCIA, REGIËN DE;Group 1406 Other diseases of the male genital organs 601-608;Men;732 MURCIA, REGIËN DE;Group 1406 Other diseases of the male genital organs 601-608;Women;.. MURCIA, REGIËN DE;Group 1407 Disorders of breast 610-612;Both sexes;564 MURCIA, REGIËN DE;Group 1407 Disorders of breast 610-612;Men;66 MURCIA, REGIËN DE;Group 1407 Disorders of breast 610-612;Women;498 MURCIA, REGIËN DE;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Both sexes;295 MURCIA, REGIËN DE;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Men;.. MURCIA, REGIËN DE;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Women;295 MURCIA, REGIËN DE;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Both sexes;128 MURCIA, REGIËN DE;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Men;.. MURCIA, REGIËN DE;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Women;128 MURCIA, REGIËN DE;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Both sexes;1,397 MURCIA, REGIËN DE;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Men;10 MURCIA, REGIËN DE;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Women;1,387 MURCIA, REGIËN DE;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Both sexes;18,802 MURCIA, REGIËN DE;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Men;.. MURCIA, REGIËN DE;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Women;18,802 MURCIA, REGIËN DE;Group 1501 Legally induced abortion 635;Both sexes;7 MURCIA, REGIËN DE;Group 1501 Legally induced abortion 635;Men;.. MURCIA, REGIËN DE;Group 1501 Legally induced abortion 635;Women;7 MURCIA, REGIËN DE;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Both sexes;1,098 MURCIA, REGIËN DE;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Men;.. MURCIA, REGIËN DE;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Women;1,098 MURCIA, REGIËN DE;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Both sexes;12,905 MURCIA, REGIËN DE;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Men;.. MURCIA, REGIËN DE;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Women;12,905 MURCIA, REGIËN DE;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Both sexes;2,066 MURCIA, REGIËN DE;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Men;.. MURCIA, REGIËN DE;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Women;2,066 MURCIA, REGIËN DE;Group 1505 Single spontaneous delivery 650;Both sexes;654 MURCIA, REGIËN DE;Group 1505 Single spontaneous delivery 650;Men;.. MURCIA, REGIËN DE;Group 1505 Single spontaneous delivery 650;Women;654 MURCIA, REGIËN DE;Group 1506 Other deliveries 6695-6697;Both sexes;765 MURCIA, REGIËN DE;Group 1506 Other deliveries 6695-6697;Men;.. MURCIA, REGIËN DE;Group 1506 Other deliveries 6695-6697;Women;765 MURCIA, REGIËN DE;Group 1507 Complications related to the puerperium 670-676;Both sexes;111 MURCIA, REGIËN DE;Group 1507 Complications related to the puerperium 670-676;Men;.. MURCIA, REGIËN DE;Group 1507 Complications related to the puerperium 670-676;Women;111 MURCIA, REGIËN DE;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Both sexes;1,196 MURCIA, REGIËN DE;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Men;.. MURCIA, REGIËN DE;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Women;1,196 MURCIA, REGIËN DE;Group 1600 Some disorders originating in the perinatal period 760-779;Both sexes;1,748 MURCIA, REGIËN DE;Group 1600 Some disorders originating in the perinatal period 760-779;Men;1,034 MURCIA, REGIËN DE;Group 1600 Some disorders originating in the perinatal period 760-779;Women;714 MURCIA, REGIËN DE;Group 1601 Disorders related with premature delivery and a low birth weight 765;Both sexes;581 MURCIA, REGIËN DE;Group 1601 Disorders related with premature delivery and a low birth weight 765;Men;344 MURCIA, REGIËN DE;Group 1601 Disorders related with premature delivery and a low birth weight 765;Women;237 MURCIA, REGIËN DE;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Both sexes;1,167 MURCIA, REGIËN DE;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Men;690 MURCIA, REGIËN DE;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Women;477 MURCIA, REGIËN DE;Grupo 1700 Congenital abnormalities 740-759;Both sexes;1,240 MURCIA, REGIËN DE;Grupo 1700 Congenital abnormalities 740-759;Men;697 MURCIA, REGIËN DE;Grupo 1700 Congenital abnormalities 740-759;Women;543 MURCIA, REGIËN DE;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Both sexes;7,151 MURCIA, REGIËN DE;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Men;3,921 MURCIA, REGIËN DE;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Women;3,229 MURCIA, REGIËN DE;Group 1801 Pain in throat and chest 7841, 7865;Both sexes;1,149 MURCIA, REGIËN DE;Group 1801 Pain in throat and chest 7841, 7865;Men;645 MURCIA, REGIËN DE;Group 1801 Pain in throat and chest 7841, 7865;Women;504 MURCIA, REGIËN DE;Group 1802 Abdominal pain 7890;Both sexes;733 MURCIA, REGIËN DE;Group 1802 Abdominal pain 7890;Men;309 MURCIA, REGIËN DE;Group 1802 Abdominal pain 7890;Women;424 MURCIA, REGIËN DE;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Both sexes;243 MURCIA, REGIËN DE;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Men;135 MURCIA, REGIËN DE;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Women;107 MURCIA, REGIËN DE;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Both sexes;5,026 MURCIA, REGIËN DE;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Men;2,832 MURCIA, REGIËN DE;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Women;2,194 MURCIA, REGIËN DE;Group 1900 Injuries and poisoning 800-999;Both sexes;12,401 MURCIA, REGIËN DE;Group 1900 Injuries and poisoning 800-999;Men;6,713 MURCIA, REGIËN DE;Group 1900 Injuries and poisoning 800-999;Women;5,687 MURCIA, REGIËN DE;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Both sexes;661 MURCIA, REGIËN DE;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Men;405 MURCIA, REGIËN DE;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Women;256 MURCIA, REGIËN DE;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Both sexes;397 MURCIA, REGIËN DE;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Men;266 MURCIA, REGIËN DE;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Women;131 MURCIA, REGIËN DE;Group 1903 Radius and ulna fracture 813;Both sexes;738 MURCIA, REGIËN DE;Group 1903 Radius and ulna fracture 813;Men;349 MURCIA, REGIËN DE;Group 1903 Radius and ulna fracture 813;Women;389 MURCIA, REGIËN DE;Group 1904 Femur fracture 820-821;Both sexes;1,627 MURCIA, REGIËN DE;Group 1904 Femur fracture 820-821;Men;469 MURCIA, REGIËN DE;Group 1904 Femur fracture 820-821;Women;1,158 MURCIA, REGIËN DE;Group 1905 Leg fracture, including the ankle 823-824;Both sexes;834 MURCIA, REGIËN DE;Group 1905 Leg fracture, including the ankle 823-824;Men;459 MURCIA, REGIËN DE;Group 1905 Leg fracture, including the ankle 823-824;Women;375 MURCIA, REGIËN DE;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Both sexes;3,809 MURCIA, REGIËN DE;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Men;2,434 MURCIA, REGIËN DE;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Women;1,375 MURCIA, REGIËN DE;Group 1907 Burns 940-949;Both sexes;120 MURCIA, REGIËN DE;Group 1907 Burns 940-949;Men;67 MURCIA, REGIËN DE;Group 1907 Burns 940-949;Women;53 MURCIA, REGIËN DE;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Both sexes;378 MURCIA, REGIËN DE;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Men;185 MURCIA, REGIËN DE;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Women;193 MURCIA, REGIËN DE;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Both sexes;3,401 MURCIA, REGIËN DE;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Men;1,854 MURCIA, REGIËN DE;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Women;1,547 MURCIA, REGIËN DE;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Both sexes;16 MURCIA, REGIËN DE;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Men;8 MURCIA, REGIËN DE;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Women;8 MURCIA, REGIËN DE;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Both sexes;419 MURCIA, REGIËN DE;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Men;217 MURCIA, REGIËN DE;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Women;202 MURCIA, REGIËN DE;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Both sexes;2,943 MURCIA, REGIËN DE;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Men;1,162 MURCIA, REGIËN DE;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Women;1,781 MURCIA, REGIËN DE;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Both sexes;60 MURCIA, REGIËN DE;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Men;30 MURCIA, REGIËN DE;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Women;30 MURCIA, REGIËN DE;Group 2102 Contraceptive management V25;Both sexes;80 MURCIA, REGIËN DE;Group 2102 Contraceptive management V25;Men;4 MURCIA, REGIËN DE;Group 2102 Contraceptive management V25;Women;76 MURCIA, REGIËN DE;Group 2103 Living newborns by type of delivery V30-V39;Both sexes;.. MURCIA, REGIËN DE;Group 2103 Living newborns by type of delivery V30-V39;Men;.. MURCIA, REGIËN DE;Group 2103 Living newborns by type of delivery V30-V39;Women;.. MURCIA, REGIËN DE;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Both sexes;904 MURCIA, REGIËN DE;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Men;481 MURCIA, REGIËN DE;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Women;423 MURCIA, REGIËN DE;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Both sexes;1,899 MURCIA, REGIËN DE;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Men;647 MURCIA, REGIËN DE;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Women;1,252 NAVARRA, COMUNIDAD FORAL DE;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Both sexes;67,799 NAVARRA, COMUNIDAD FORAL DE;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Men;33,020 NAVARRA, COMUNIDAD FORAL DE;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Women;34,779 NAVARRA, COMUNIDAD FORAL DE;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Both sexes;1,236 NAVARRA, COMUNIDAD FORAL DE;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Men;695 NAVARRA, COMUNIDAD FORAL DE;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Women;541 NAVARRA, COMUNIDAD FORAL DE;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Both sexes;234 NAVARRA, COMUNIDAD FORAL DE;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Men;115 NAVARRA, COMUNIDAD FORAL DE;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Women;119 NAVARRA, COMUNIDAD FORAL DE;Group 0102 Imprecise intestinal infections 009;Both sexes;74 NAVARRA, COMUNIDAD FORAL DE;Group 0102 Imprecise intestinal infections 009;Men;28 NAVARRA, COMUNIDAD FORAL DE;Group 0102 Imprecise intestinal infections 009;Women;46 NAVARRA, COMUNIDAD FORAL DE;Group 0103 Tuberculosis 010-018, 137;Both sexes;41 NAVARRA, COMUNIDAD FORAL DE;Group 0103 Tuberculosis 010-018, 137;Men;24 NAVARRA, COMUNIDAD FORAL DE;Group 0103 Tuberculosis 010-018, 137;Women;17 NAVARRA, COMUNIDAD FORAL DE;Group 0104 Septicaemia 038;Both sexes;436 NAVARRA, COMUNIDAD FORAL DE;Group 0104 Septicaemia 038;Men;248 NAVARRA, COMUNIDAD FORAL DE;Group 0104 Septicaemia 038;Women;188 NAVARRA, COMUNIDAD FORAL DE;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Both sexes;43 NAVARRA, COMUNIDAD FORAL DE;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Men;26 NAVARRA, COMUNIDAD FORAL DE;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Women;17 NAVARRA, COMUNIDAD FORAL DE;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Both sexes;408 NAVARRA, COMUNIDAD FORAL DE;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Men;254 NAVARRA, COMUNIDAD FORAL DE;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Women;154 NAVARRA, COMUNIDAD FORAL DE;Group 0200 Neoplasms 140-239;Both sexes;7,838 NAVARRA, COMUNIDAD FORAL DE;Group 0200 Neoplasms 140-239;Men;4,221 NAVARRA, COMUNIDAD FORAL DE;Group 0200 Neoplasms 140-239;Women;3,617 NAVARRA, COMUNIDAD FORAL DE;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Both sexes;736 NAVARRA, COMUNIDAD FORAL DE;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Men;488 NAVARRA, COMUNIDAD FORAL DE;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Women;248 NAVARRA, COMUNIDAD FORAL DE;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Both sexes;514 NAVARRA, COMUNIDAD FORAL DE;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Men;393 NAVARRA, COMUNIDAD FORAL DE;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Women;121 NAVARRA, COMUNIDAD FORAL DE;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Both sexes;151 NAVARRA, COMUNIDAD FORAL DE;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Men;84 NAVARRA, COMUNIDAD FORAL DE;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Women;67 NAVARRA, COMUNIDAD FORAL DE;Group 0204 Malignant neoplasm of breast 174-175;Both sexes;592 NAVARRA, COMUNIDAD FORAL DE;Group 0204 Malignant neoplasm of breast 174-175;Men;2 NAVARRA, COMUNIDAD FORAL DE;Group 0204 Malignant neoplasm of breast 174-175;Women;590 NAVARRA, COMUNIDAD FORAL DE;Group 0205 Malignant neoplasm of uterus 179-180, 182;Both sexes;153 NAVARRA, COMUNIDAD FORAL DE;Group 0205 Malignant neoplasm of uterus 179-180, 182;Men;.. NAVARRA, COMUNIDAD FORAL DE;Group 0205 Malignant neoplasm of uterus 179-180, 182;Women;153 NAVARRA, COMUNIDAD FORAL DE;Group 0206 Malignant neoplasm of ovary 1830;Both sexes;64 NAVARRA, COMUNIDAD FORAL DE;Group 0206 Malignant neoplasm of ovary 1830;Men;.. NAVARRA, COMUNIDAD FORAL DE;Group 0206 Malignant neoplasm of ovary 1830;Women;64 NAVARRA, COMUNIDAD FORAL DE;Group 0207 Malignant neoplasm of prostate 185;Both sexes;294 NAVARRA, COMUNIDAD FORAL DE;Group 0207 Malignant neoplasm of prostate 185;Men;294 NAVARRA, COMUNIDAD FORAL DE;Group 0207 Malignant neoplasm of prostate 185;Women;.. NAVARRA, COMUNIDAD FORAL DE;Group 0208 Malignant neoplasm of bladder 188;Both sexes;586 NAVARRA, COMUNIDAD FORAL DE;Group 0208 Malignant neoplasm of bladder 188;Men;476 NAVARRA, COMUNIDAD FORAL DE;Group 0208 Malignant neoplasm of bladder 188;Women;110 NAVARRA, COMUNIDAD FORAL DE;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Both sexes;3,063 NAVARRA, COMUNIDAD FORAL DE;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Men;1,891 NAVARRA, COMUNIDAD FORAL DE;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Women;1,172 NAVARRA, COMUNIDAD FORAL DE;Group 0210 Carcinoma in situ 230-234;Both sexes;148 NAVARRA, COMUNIDAD FORAL DE;Group 0210 Carcinoma in situ 230-234;Men;35 NAVARRA, COMUNIDAD FORAL DE;Group 0210 Carcinoma in situ 230-234;Women;113 NAVARRA, COMUNIDAD FORAL DE;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Both sexes;94 NAVARRA, COMUNIDAD FORAL DE;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Men;63 NAVARRA, COMUNIDAD FORAL DE;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Women;31 NAVARRA, COMUNIDAD FORAL DE;Grupo 0212 Leiomyoma of uterus 218;Both sexes;343 NAVARRA, COMUNIDAD FORAL DE;Grupo 0212 Leiomyoma of uterus 218;Men;.. NAVARRA, COMUNIDAD FORAL DE;Grupo 0212 Leiomyoma of uterus 218;Women;343 NAVARRA, COMUNIDAD FORAL DE;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Both sexes;1,100 NAVARRA, COMUNIDAD FORAL DE;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Men;495 NAVARRA, COMUNIDAD FORAL DE;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Women;605 NAVARRA, COMUNIDAD FORAL DE;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Both sexes;696 NAVARRA, COMUNIDAD FORAL DE;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Men;387 NAVARRA, COMUNIDAD FORAL DE;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Women;309 NAVARRA, COMUNIDAD FORAL DE;Group 0301 Anaemias 280-285;Both sexes;410 NAVARRA, COMUNIDAD FORAL DE;Group 0301 Anaemias 280-285;Men;215 NAVARRA, COMUNIDAD FORAL DE;Group 0301 Anaemias 280-285;Women;195 NAVARRA, COMUNIDAD FORAL DE;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Both sexes;286 NAVARRA, COMUNIDAD FORAL DE;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Men;172 NAVARRA, COMUNIDAD FORAL DE;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Women;114 NAVARRA, COMUNIDAD FORAL DE;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Both sexes;1,292 NAVARRA, COMUNIDAD FORAL DE;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Men;553 NAVARRA, COMUNIDAD FORAL DE;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Women;739 NAVARRA, COMUNIDAD FORAL DE;Group 0401 Diabetes mellitus 249-250;Both sexes;418 NAVARRA, COMUNIDAD FORAL DE;Group 0401 Diabetes mellitus 249-250;Men;243 NAVARRA, COMUNIDAD FORAL DE;Group 0401 Diabetes mellitus 249-250;Women;175 NAVARRA, COMUNIDAD FORAL DE;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Both sexes;874 NAVARRA, COMUNIDAD FORAL DE;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Men;310 NAVARRA, COMUNIDAD FORAL DE;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Women;564 NAVARRA, COMUNIDAD FORAL DE;Group 0500 Mental disorders 290-319;Both sexes;1,969 NAVARRA, COMUNIDAD FORAL DE;Group 0500 Mental disorders 290-319;Men;1,006 NAVARRA, COMUNIDAD FORAL DE;Group 0500 Mental disorders 290-319;Women;963 NAVARRA, COMUNIDAD FORAL DE;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Both sexes;255 NAVARRA, COMUNIDAD FORAL DE;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Men;125 NAVARRA, COMUNIDAD FORAL DE;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Women;130 NAVARRA, COMUNIDAD FORAL DE;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Both sexes;130 NAVARRA, COMUNIDAD FORAL DE;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Men;98 NAVARRA, COMUNIDAD FORAL DE;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Women;32 NAVARRA, COMUNIDAD FORAL DE;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Both sexes;103 NAVARRA, COMUNIDAD FORAL DE;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Men;72 NAVARRA, COMUNIDAD FORAL DE;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Women;31 NAVARRA, COMUNIDAD FORAL DE;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Both sexes;466 NAVARRA, COMUNIDAD FORAL DE;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Men;264 NAVARRA, COMUNIDAD FORAL DE;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Women;202 NAVARRA, COMUNIDAD FORAL DE;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Both sexes;489 NAVARRA, COMUNIDAD FORAL DE;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Men;211 NAVARRA, COMUNIDAD FORAL DE;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Women;278 NAVARRA, COMUNIDAD FORAL DE;Group 0506 Other mental and behavioural disorders Rest of (290-319);Both sexes;526 NAVARRA, COMUNIDAD FORAL DE;Group 0506 Other mental and behavioural disorders Rest of (290-319);Men;236 NAVARRA, COMUNIDAD FORAL DE;Group 0506 Other mental and behavioural disorders Rest of (290-319);Women;290 NAVARRA, COMUNIDAD FORAL DE;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Both sexes;2,055 NAVARRA, COMUNIDAD FORAL DE;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Men;1,001 NAVARRA, COMUNIDAD FORAL DE;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Women;1,054 NAVARRA, COMUNIDAD FORAL DE;Group 0601 Alzheimer's disease 3310;Both sexes;58 NAVARRA, COMUNIDAD FORAL DE;Group 0601 Alzheimer's disease 3310;Men;26 NAVARRA, COMUNIDAD FORAL DE;Group 0601 Alzheimer's disease 3310;Women;32 NAVARRA, COMUNIDAD FORAL DE;Group 0602 Multiple sclerosis 340;Both sexes;48 NAVARRA, COMUNIDAD FORAL DE;Group 0602 Multiple sclerosis 340;Men;7 NAVARRA, COMUNIDAD FORAL DE;Group 0602 Multiple sclerosis 340;Women;41 NAVARRA, COMUNIDAD FORAL DE;Group 0603 Epilepsy 345;Both sexes;238 NAVARRA, COMUNIDAD FORAL DE;Group 0603 Epilepsy 345;Men;105 NAVARRA, COMUNIDAD FORAL DE;Group 0603 Epilepsy 345;Women;133 NAVARRA, COMUNIDAD FORAL DE;Group 0604 Transient cerebral ischemia 435;Both sexes;167 NAVARRA, COMUNIDAD FORAL DE;Group 0604 Transient cerebral ischemia 435;Men;75 NAVARRA, COMUNIDAD FORAL DE;Group 0604 Transient cerebral ischemia 435;Women;92 NAVARRA, COMUNIDAD FORAL DE;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Both sexes;1,544 NAVARRA, COMUNIDAD FORAL DE;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Men;788 NAVARRA, COMUNIDAD FORAL DE;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Women;756 NAVARRA, COMUNIDAD FORAL DE;Grupo 0700 Diseases of the eye and adnexa 360-379;Both sexes;351 NAVARRA, COMUNIDAD FORAL DE;Grupo 0700 Diseases of the eye and adnexa 360-379;Men;198 NAVARRA, COMUNIDAD FORAL DE;Grupo 0700 Diseases of the eye and adnexa 360-379;Women;153 NAVARRA, COMUNIDAD FORAL DE;Grupo 0701 Cataract 366;Both sexes;37 NAVARRA, COMUNIDAD FORAL DE;Grupo 0701 Cataract 366;Men;23 NAVARRA, COMUNIDAD FORAL DE;Grupo 0701 Cataract 366;Women;14 NAVARRA, COMUNIDAD FORAL DE;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Both sexes;314 NAVARRA, COMUNIDAD FORAL DE;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Men;175 NAVARRA, COMUNIDAD FORAL DE;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Women;139 NAVARRA, COMUNIDAD FORAL DE;Group 0800 Diseases of the ear and the mastoid 380-389;Both sexes;446 NAVARRA, COMUNIDAD FORAL DE;Group 0800 Diseases of the ear and the mastoid 380-389;Men;247 NAVARRA, COMUNIDAD FORAL DE;Group 0800 Diseases of the ear and the mastoid 380-389;Women;199 NAVARRA, COMUNIDAD FORAL DE;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Both sexes;7,728 NAVARRA, COMUNIDAD FORAL DE;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Men;4,583 NAVARRA, COMUNIDAD FORAL DE;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Women;3,145 NAVARRA, COMUNIDAD FORAL DE;Group 0901 Hypertensive disease 401-405;Both sexes;562 NAVARRA, COMUNIDAD FORAL DE;Group 0901 Hypertensive disease 401-405;Men;262 NAVARRA, COMUNIDAD FORAL DE;Group 0901 Hypertensive disease 401-405;Women;300 NAVARRA, COMUNIDAD FORAL DE;Group 0902 Angina pectoris 4111, 413;Both sexes;180 NAVARRA, COMUNIDAD FORAL DE;Group 0902 Angina pectoris 4111, 413;Men;113 NAVARRA, COMUNIDAD FORAL DE;Group 0902 Angina pectoris 4111, 413;Women;67 NAVARRA, COMUNIDAD FORAL DE;Group 0903 Acute myocardial infarction 410;Both sexes;601 NAVARRA, COMUNIDAD FORAL DE;Group 0903 Acute myocardial infarction 410;Men;430 NAVARRA, COMUNIDAD FORAL DE;Group 0903 Acute myocardial infarction 410;Women;171 NAVARRA, COMUNIDAD FORAL DE;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Both sexes;602 NAVARRA, COMUNIDAD FORAL DE;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Men;484 NAVARRA, COMUNIDAD FORAL DE;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Women;118 NAVARRA, COMUNIDAD FORAL DE;Group 0905 Diseases of the lungs circulation 415-417;Both sexes;368 NAVARRA, COMUNIDAD FORAL DE;Group 0905 Diseases of the lungs circulation 415-417;Men;172 NAVARRA, COMUNIDAD FORAL DE;Group 0905 Diseases of the lungs circulation 415-417;Women;196 NAVARRA, COMUNIDAD FORAL DE;Group 0906 Heart conduction disorders and arrhytmias 426-427;Both sexes;989 NAVARRA, COMUNIDAD FORAL DE;Group 0906 Heart conduction disorders and arrhytmias 426-427;Men;573 NAVARRA, COMUNIDAD FORAL DE;Group 0906 Heart conduction disorders and arrhytmias 426-427;Women;416 NAVARRA, COMUNIDAD FORAL DE;Grupo 0907 Heart failure 428;Both sexes;1,288 NAVARRA, COMUNIDAD FORAL DE;Grupo 0907 Heart failure 428;Men;709 NAVARRA, COMUNIDAD FORAL DE;Grupo 0907 Heart failure 428;Women;579 NAVARRA, COMUNIDAD FORAL DE;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Both sexes;1,306 NAVARRA, COMUNIDAD FORAL DE;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Men;714 NAVARRA, COMUNIDAD FORAL DE;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Women;592 NAVARRA, COMUNIDAD FORAL DE;Grupo 0909 Atherosclerosis 440;Both sexes;338 NAVARRA, COMUNIDAD FORAL DE;Grupo 0909 Atherosclerosis 440;Men;263 NAVARRA, COMUNIDAD FORAL DE;Grupo 0909 Atherosclerosis 440;Women;75 NAVARRA, COMUNIDAD FORAL DE;Group 0910 Varicose veins of lower extremities 454;Both sexes;148 NAVARRA, COMUNIDAD FORAL DE;Group 0910 Varicose veins of lower extremities 454;Men;52 NAVARRA, COMUNIDAD FORAL DE;Group 0910 Varicose veins of lower extremities 454;Women;96 NAVARRA, COMUNIDAD FORAL DE;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Both sexes;1,346 NAVARRA, COMUNIDAD FORAL DE;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Men;811 NAVARRA, COMUNIDAD FORAL DE;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Women;535 NAVARRA, COMUNIDAD FORAL DE;Group 1000 Diseases of the respiratory system 0340, 460-519;Both sexes;7,207 NAVARRA, COMUNIDAD FORAL DE;Group 1000 Diseases of the respiratory system 0340, 460-519;Men;4,185 NAVARRA, COMUNIDAD FORAL DE;Group 1000 Diseases of the respiratory system 0340, 460-519;Women;3,022 NAVARRA, COMUNIDAD FORAL DE;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Both sexes;233 NAVARRA, COMUNIDAD FORAL DE;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Men;132 NAVARRA, COMUNIDAD FORAL DE;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Women;101 NAVARRA, COMUNIDAD FORAL DE;Group 1002 Pneumonia 480-486;Both sexes;1,411 NAVARRA, COMUNIDAD FORAL DE;Group 1002 Pneumonia 480-486;Men;863 NAVARRA, COMUNIDAD FORAL DE;Group 1002 Pneumonia 480-486;Women;548 NAVARRA, COMUNIDAD FORAL DE;Group 1003 Acute bronchitis and bronchiolitis 466;Both sexes;471 NAVARRA, COMUNIDAD FORAL DE;Group 1003 Acute bronchitis and bronchiolitis 466;Men;243 NAVARRA, COMUNIDAD FORAL DE;Group 1003 Acute bronchitis and bronchiolitis 466;Women;228 NAVARRA, COMUNIDAD FORAL DE;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Both sexes;543 NAVARRA, COMUNIDAD FORAL DE;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Men;298 NAVARRA, COMUNIDAD FORAL DE;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Women;245 NAVARRA, COMUNIDAD FORAL DE;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Both sexes;829 NAVARRA, COMUNIDAD FORAL DE;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Men;506 NAVARRA, COMUNIDAD FORAL DE;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Women;323 NAVARRA, COMUNIDAD FORAL DE;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Both sexes;1,196 NAVARRA, COMUNIDAD FORAL DE;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Men;875 NAVARRA, COMUNIDAD FORAL DE;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Women;321 NAVARRA, COMUNIDAD FORAL DE;Group 1007 Asthma 4930-4931,4938-4939;Both sexes;323 NAVARRA, COMUNIDAD FORAL DE;Group 1007 Asthma 4930-4931,4938-4939;Men;101 NAVARRA, COMUNIDAD FORAL DE;Group 1007 Asthma 4930-4931,4938-4939;Women;222 NAVARRA, COMUNIDAD FORAL DE;Group 1008 Other diseases of the respiratory system Resto of (460-519);Both sexes;2,201 NAVARRA, COMUNIDAD FORAL DE;Group 1008 Other diseases of the respiratory system Resto of (460-519);Men;1,167 NAVARRA, COMUNIDAD FORAL DE;Group 1008 Other diseases of the respiratory system Resto of (460-519);Women;1,034 NAVARRA, COMUNIDAD FORAL DE;Group 1100 Diseases of the digestive system 520-579;Both sexes;7,877 NAVARRA, COMUNIDAD FORAL DE;Group 1100 Diseases of the digestive system 520-579;Men;4,564 NAVARRA, COMUNIDAD FORAL DE;Group 1100 Diseases of the digestive system 520-579;Women;3,313 NAVARRA, COMUNIDAD FORAL DE;Group 1101 Disorders of the teeth and supporting structures 520-525;Both sexes;139 NAVARRA, COMUNIDAD FORAL DE;Group 1101 Disorders of the teeth and supporting structures 520-525;Men;59 NAVARRA, COMUNIDAD FORAL DE;Group 1101 Disorders of the teeth and supporting structures 520-525;Women;80 NAVARRA, COMUNIDAD FORAL DE;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Both sexes;150 NAVARRA, COMUNIDAD FORAL DE;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Men;90 NAVARRA, COMUNIDAD FORAL DE;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Women;60 NAVARRA, COMUNIDAD FORAL DE;Group 1103 Diseases of the esophagus 530;Both sexes;185 NAVARRA, COMUNIDAD FORAL DE;Group 1103 Diseases of the esophagus 530;Men;113 NAVARRA, COMUNIDAD FORAL DE;Group 1103 Diseases of the esophagus 530;Women;72 NAVARRA, COMUNIDAD FORAL DE;Group 1104 Peptic ulcer 531-534;Both sexes;153 NAVARRA, COMUNIDAD FORAL DE;Group 1104 Peptic ulcer 531-534;Men;98 NAVARRA, COMUNIDAD FORAL DE;Group 1104 Peptic ulcer 531-534;Women;55 NAVARRA, COMUNIDAD FORAL DE;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Both sexes;231 NAVARRA, COMUNIDAD FORAL DE;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Men;140 NAVARRA, COMUNIDAD FORAL DE;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Women;91 NAVARRA, COMUNIDAD FORAL DE;Group 1106 Appendicitis 540-543;Both sexes;697 NAVARRA, COMUNIDAD FORAL DE;Group 1106 Appendicitis 540-543;Men;409 NAVARRA, COMUNIDAD FORAL DE;Group 1106 Appendicitis 540-543;Women;288 NAVARRA, COMUNIDAD FORAL DE;Group 1107 Inguinal hernia 550;Both sexes;687 NAVARRA, COMUNIDAD FORAL DE;Group 1107 Inguinal hernia 550;Men;618 NAVARRA, COMUNIDAD FORAL DE;Group 1107 Inguinal hernia 550;Women;69 NAVARRA, COMUNIDAD FORAL DE;Group 1108 Other abdominal hernia 551-553;Both sexes;625 NAVARRA, COMUNIDAD FORAL DE;Group 1108 Other abdominal hernia 551-553;Men;320 NAVARRA, COMUNIDAD FORAL DE;Group 1108 Other abdominal hernia 551-553;Women;305 NAVARRA, COMUNIDAD FORAL DE;Group 1109 Crohn's disease and ulcerative colitis 555-556;Both sexes;160 NAVARRA, COMUNIDAD FORAL DE;Group 1109 Crohn's disease and ulcerative colitis 555-556;Men;85 NAVARRA, COMUNIDAD FORAL DE;Group 1109 Crohn's disease and ulcerative colitis 555-556;Women;75 NAVARRA, COMUNIDAD FORAL DE;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Both sexes;419 NAVARRA, COMUNIDAD FORAL DE;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Men;217 NAVARRA, COMUNIDAD FORAL DE;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Women;202 NAVARRA, COMUNIDAD FORAL DE;Group 1111 Intestinal obstruction without hernia 560;Both sexes;363 NAVARRA, COMUNIDAD FORAL DE;Group 1111 Intestinal obstruction without hernia 560;Men;201 NAVARRA, COMUNIDAD FORAL DE;Group 1111 Intestinal obstruction without hernia 560;Women;162 NAVARRA, COMUNIDAD FORAL DE;Group 1112 Intestinal diverticulosis 562;Both sexes;299 NAVARRA, COMUNIDAD FORAL DE;Group 1112 Intestinal diverticulosis 562;Men;132 NAVARRA, COMUNIDAD FORAL DE;Group 1112 Intestinal diverticulosis 562;Women;167 NAVARRA, COMUNIDAD FORAL DE;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Both sexes;457 NAVARRA, COMUNIDAD FORAL DE;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Men;303 NAVARRA, COMUNIDAD FORAL DE;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Women;154 NAVARRA, COMUNIDAD FORAL DE;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Both sexes;353 NAVARRA, COMUNIDAD FORAL DE;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Men;162 NAVARRA, COMUNIDAD FORAL DE;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Women;191 NAVARRA, COMUNIDAD FORAL DE;Group 1115 Alcoholic hepatitis 5710-5713;Both sexes;179 NAVARRA, COMUNIDAD FORAL DE;Group 1115 Alcoholic hepatitis 5710-5713;Men;153 NAVARRA, COMUNIDAD FORAL DE;Group 1115 Alcoholic hepatitis 5710-5713;Women;26 NAVARRA, COMUNIDAD FORAL DE;Group 1116 Other diseases of the liver 570,5714-573;Both sexes;249 NAVARRA, COMUNIDAD FORAL DE;Group 1116 Other diseases of the liver 570,5714-573;Men;154 NAVARRA, COMUNIDAD FORAL DE;Group 1116 Other diseases of the liver 570,5714-573;Women;95 NAVARRA, COMUNIDAD FORAL DE;Group 1117 Cholelithiasis 574;Both sexes;1,370 NAVARRA, COMUNIDAD FORAL DE;Group 1117 Cholelithiasis 574;Men;625 NAVARRA, COMUNIDAD FORAL DE;Group 1117 Cholelithiasis 574;Women;745 NAVARRA, COMUNIDAD FORAL DE;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Both sexes;391 NAVARRA, COMUNIDAD FORAL DE;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Men;222 NAVARRA, COMUNIDAD FORAL DE;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Women;169 NAVARRA, COMUNIDAD FORAL DE;Group 1119 Pancreatic diseases 577;Both sexes;392 NAVARRA, COMUNIDAD FORAL DE;Group 1119 Pancreatic diseases 577;Men;242 NAVARRA, COMUNIDAD FORAL DE;Group 1119 Pancreatic diseases 577;Women;150 NAVARRA, COMUNIDAD FORAL DE;Group 1120 Other diseases of the digestive system Rest of (520-579);Both sexes;378 NAVARRA, COMUNIDAD FORAL DE;Group 1120 Other diseases of the digestive system Rest of (520-579);Men;221 NAVARRA, COMUNIDAD FORAL DE;Group 1120 Other diseases of the digestive system Rest of (520-579);Women;157 NAVARRA, COMUNIDAD FORAL DE;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Both sexes;611 NAVARRA, COMUNIDAD FORAL DE;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Men;344 NAVARRA, COMUNIDAD FORAL DE;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Women;267 NAVARRA, COMUNIDAD FORAL DE;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Both sexes;363 NAVARRA, COMUNIDAD FORAL DE;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Men;207 NAVARRA, COMUNIDAD FORAL DE;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Women;156 NAVARRA, COMUNIDAD FORAL DE;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Both sexes;25 NAVARRA, COMUNIDAD FORAL DE;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Men;11 NAVARRA, COMUNIDAD FORAL DE;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Women;14 NAVARRA, COMUNIDAD FORAL DE;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Both sexes;223 NAVARRA, COMUNIDAD FORAL DE;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Men;126 NAVARRA, COMUNIDAD FORAL DE;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Women;97 NAVARRA, COMUNIDAD FORAL DE;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Both sexes;6,351 NAVARRA, COMUNIDAD FORAL DE;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Men;3,209 NAVARRA, COMUNIDAD FORAL DE;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Women;3,142 NAVARRA, COMUNIDAD FORAL DE;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Both sexes;.. NAVARRA, COMUNIDAD FORAL DE;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Men;.. NAVARRA, COMUNIDAD FORAL DE;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Women;.. NAVARRA, COMUNIDAD FORAL DE;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Both sexes;.. NAVARRA, COMUNIDAD FORAL DE;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Men;.. NAVARRA, COMUNIDAD FORAL DE;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Women;.. NAVARRA, COMUNIDAD FORAL DE;Group 1303 Internal derangement of knee 717;Both sexes;987 NAVARRA, COMUNIDAD FORAL DE;Group 1303 Internal derangement of knee 717;Men;685 NAVARRA, COMUNIDAD FORAL DE;Group 1303 Internal derangement of knee 717;Women;302 NAVARRA, COMUNIDAD FORAL DE;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Both sexes;1,821 NAVARRA, COMUNIDAD FORAL DE;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Men;919 NAVARRA, COMUNIDAD FORAL DE;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Women;902 NAVARRA, COMUNIDAD FORAL DE;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Both sexes;151 NAVARRA, COMUNIDAD FORAL DE;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Men;52 NAVARRA, COMUNIDAD FORAL DE;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Women;99 NAVARRA, COMUNIDAD FORAL DE;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Both sexes;286 NAVARRA, COMUNIDAD FORAL DE;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Men;145 NAVARRA, COMUNIDAD FORAL DE;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Women;141 NAVARRA, COMUNIDAD FORAL DE;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Both sexes;521 NAVARRA, COMUNIDAD FORAL DE;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Men;280 NAVARRA, COMUNIDAD FORAL DE;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Women;241 NAVARRA, COMUNIDAD FORAL DE;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Both sexes;324 NAVARRA, COMUNIDAD FORAL DE;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Men;165 NAVARRA, COMUNIDAD FORAL DE;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Women;159 NAVARRA, COMUNIDAD FORAL DE;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Both sexes;1,145 NAVARRA, COMUNIDAD FORAL DE;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Men;557 NAVARRA, COMUNIDAD FORAL DE;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Women;588 NAVARRA, COMUNIDAD FORAL DE;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Both sexes;1,116 NAVARRA, COMUNIDAD FORAL DE;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Men;406 NAVARRA, COMUNIDAD FORAL DE;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Women;710 NAVARRA, COMUNIDAD FORAL DE;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Both sexes;3,428 NAVARRA, COMUNIDAD FORAL DE;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Men;1,480 NAVARRA, COMUNIDAD FORAL DE;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Women;1,948 NAVARRA, COMUNIDAD FORAL DE;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Both sexes;330 NAVARRA, COMUNIDAD FORAL DE;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Men;129 NAVARRA, COMUNIDAD FORAL DE;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Women;201 NAVARRA, COMUNIDAD FORAL DE;Group 1402 Renal failure 5836-5837, 584-586;Both sexes;283 NAVARRA, COMUNIDAD FORAL DE;Group 1402 Renal failure 5836-5837, 584-586;Men;165 NAVARRA, COMUNIDAD FORAL DE;Group 1402 Renal failure 5836-5837, 584-586;Women;118 NAVARRA, COMUNIDAD FORAL DE;Group 1403 Urolithiasis 592, 594, 7880;Both sexes;321 NAVARRA, COMUNIDAD FORAL DE;Group 1403 Urolithiasis 592, 594, 7880;Men;222 NAVARRA, COMUNIDAD FORAL DE;Group 1403 Urolithiasis 592, 594, 7880;Women;99 NAVARRA, COMUNIDAD FORAL DE;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Both sexes;973 NAVARRA, COMUNIDAD FORAL DE;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Men;429 NAVARRA, COMUNIDAD FORAL DE;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Women;544 NAVARRA, COMUNIDAD FORAL DE;Group 1405 Prostatic hyperplasia 600;Both sexes;331 NAVARRA, COMUNIDAD FORAL DE;Group 1405 Prostatic hyperplasia 600;Men;331 NAVARRA, COMUNIDAD FORAL DE;Group 1405 Prostatic hyperplasia 600;Women;.. NAVARRA, COMUNIDAD FORAL DE;Group 1406 Other diseases of the male genital organs 601-608;Both sexes;161 NAVARRA, COMUNIDAD FORAL DE;Group 1406 Other diseases of the male genital organs 601-608;Men;161 NAVARRA, COMUNIDAD FORAL DE;Group 1406 Other diseases of the male genital organs 601-608;Women;.. NAVARRA, COMUNIDAD FORAL DE;Group 1407 Disorders of breast 610-612;Both sexes;202 NAVARRA, COMUNIDAD FORAL DE;Group 1407 Disorders of breast 610-612;Men;36 NAVARRA, COMUNIDAD FORAL DE;Group 1407 Disorders of breast 610-612;Women;166 NAVARRA, COMUNIDAD FORAL DE;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Both sexes;105 NAVARRA, COMUNIDAD FORAL DE;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Men;.. NAVARRA, COMUNIDAD FORAL DE;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Women;105 NAVARRA, COMUNIDAD FORAL DE;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Both sexes;52 NAVARRA, COMUNIDAD FORAL DE;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Men;.. NAVARRA, COMUNIDAD FORAL DE;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Women;52 NAVARRA, COMUNIDAD FORAL DE;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Both sexes;670 NAVARRA, COMUNIDAD FORAL DE;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Men;7 NAVARRA, COMUNIDAD FORAL DE;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Women;663 NAVARRA, COMUNIDAD FORAL DE;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Both sexes;6,911 NAVARRA, COMUNIDAD FORAL DE;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Men;.. NAVARRA, COMUNIDAD FORAL DE;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Women;6,911 NAVARRA, COMUNIDAD FORAL DE;Group 1501 Legally induced abortion 635;Both sexes;.. NAVARRA, COMUNIDAD FORAL DE;Group 1501 Legally induced abortion 635;Men;.. NAVARRA, COMUNIDAD FORAL DE;Group 1501 Legally induced abortion 635;Women;.. NAVARRA, COMUNIDAD FORAL DE;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Both sexes;493 NAVARRA, COMUNIDAD FORAL DE;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Men;.. NAVARRA, COMUNIDAD FORAL DE;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Women;493 NAVARRA, COMUNIDAD FORAL DE;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Both sexes;3,812 NAVARRA, COMUNIDAD FORAL DE;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Men;.. NAVARRA, COMUNIDAD FORAL DE;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Women;3,812 NAVARRA, COMUNIDAD FORAL DE;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Both sexes;1,817 NAVARRA, COMUNIDAD FORAL DE;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Men;.. NAVARRA, COMUNIDAD FORAL DE;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Women;1,817 NAVARRA, COMUNIDAD FORAL DE;Group 1505 Single spontaneous delivery 650;Both sexes;132 NAVARRA, COMUNIDAD FORAL DE;Group 1505 Single spontaneous delivery 650;Men;.. NAVARRA, COMUNIDAD FORAL DE;Group 1505 Single spontaneous delivery 650;Women;132 NAVARRA, COMUNIDAD FORAL DE;Group 1506 Other deliveries 6695-6697;Both sexes;248 NAVARRA, COMUNIDAD FORAL DE;Group 1506 Other deliveries 6695-6697;Men;.. NAVARRA, COMUNIDAD FORAL DE;Group 1506 Other deliveries 6695-6697;Women;248 NAVARRA, COMUNIDAD FORAL DE;Group 1507 Complications related to the puerperium 670-676;Both sexes;56 NAVARRA, COMUNIDAD FORAL DE;Group 1507 Complications related to the puerperium 670-676;Men;.. NAVARRA, COMUNIDAD FORAL DE;Group 1507 Complications related to the puerperium 670-676;Women;56 NAVARRA, COMUNIDAD FORAL DE;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Both sexes;353 NAVARRA, COMUNIDAD FORAL DE;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Men;.. NAVARRA, COMUNIDAD FORAL DE;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Women;353 NAVARRA, COMUNIDAD FORAL DE;Group 1600 Some disorders originating in the perinatal period 760-779;Both sexes;572 NAVARRA, COMUNIDAD FORAL DE;Group 1600 Some disorders originating in the perinatal period 760-779;Men;305 NAVARRA, COMUNIDAD FORAL DE;Group 1600 Some disorders originating in the perinatal period 760-779;Women;267 NAVARRA, COMUNIDAD FORAL DE;Group 1601 Disorders related with premature delivery and a low birth weight 765;Both sexes;166 NAVARRA, COMUNIDAD FORAL DE;Group 1601 Disorders related with premature delivery and a low birth weight 765;Men;83 NAVARRA, COMUNIDAD FORAL DE;Group 1601 Disorders related with premature delivery and a low birth weight 765;Women;83 NAVARRA, COMUNIDAD FORAL DE;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Both sexes;406 NAVARRA, COMUNIDAD FORAL DE;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Men;222 NAVARRA, COMUNIDAD FORAL DE;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Women;184 NAVARRA, COMUNIDAD FORAL DE;Grupo 1700 Congenital abnormalities 740-759;Both sexes;488 NAVARRA, COMUNIDAD FORAL DE;Grupo 1700 Congenital abnormalities 740-759;Men;254 NAVARRA, COMUNIDAD FORAL DE;Grupo 1700 Congenital abnormalities 740-759;Women;234 NAVARRA, COMUNIDAD FORAL DE;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Both sexes;2,733 NAVARRA, COMUNIDAD FORAL DE;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Men;1,470 NAVARRA, COMUNIDAD FORAL DE;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Women;1,263 NAVARRA, COMUNIDAD FORAL DE;Group 1801 Pain in throat and chest 7841, 7865;Both sexes;162 NAVARRA, COMUNIDAD FORAL DE;Group 1801 Pain in throat and chest 7841, 7865;Men;90 NAVARRA, COMUNIDAD FORAL DE;Group 1801 Pain in throat and chest 7841, 7865;Women;72 NAVARRA, COMUNIDAD FORAL DE;Group 1802 Abdominal pain 7890;Both sexes;345 NAVARRA, COMUNIDAD FORAL DE;Group 1802 Abdominal pain 7890;Men;143 NAVARRA, COMUNIDAD FORAL DE;Group 1802 Abdominal pain 7890;Women;202 NAVARRA, COMUNIDAD FORAL DE;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Both sexes;359 NAVARRA, COMUNIDAD FORAL DE;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Men;201 NAVARRA, COMUNIDAD FORAL DE;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Women;158 NAVARRA, COMUNIDAD FORAL DE;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Both sexes;1,867 NAVARRA, COMUNIDAD FORAL DE;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Men;1,036 NAVARRA, COMUNIDAD FORAL DE;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Women;831 NAVARRA, COMUNIDAD FORAL DE;Group 1900 Injuries and poisoning 800-999;Both sexes;5,771 NAVARRA, COMUNIDAD FORAL DE;Group 1900 Injuries and poisoning 800-999;Men;3,099 NAVARRA, COMUNIDAD FORAL DE;Group 1900 Injuries and poisoning 800-999;Women;2,672 NAVARRA, COMUNIDAD FORAL DE;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Both sexes;352 NAVARRA, COMUNIDAD FORAL DE;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Men;216 NAVARRA, COMUNIDAD FORAL DE;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Women;136 NAVARRA, COMUNIDAD FORAL DE;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Both sexes;182 NAVARRA, COMUNIDAD FORAL DE;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Men;125 NAVARRA, COMUNIDAD FORAL DE;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Women;57 NAVARRA, COMUNIDAD FORAL DE;Group 1903 Radius and ulna fracture 813;Both sexes;368 NAVARRA, COMUNIDAD FORAL DE;Group 1903 Radius and ulna fracture 813;Men;160 NAVARRA, COMUNIDAD FORAL DE;Group 1903 Radius and ulna fracture 813;Women;208 NAVARRA, COMUNIDAD FORAL DE;Group 1904 Femur fracture 820-821;Both sexes;866 NAVARRA, COMUNIDAD FORAL DE;Group 1904 Femur fracture 820-821;Men;218 NAVARRA, COMUNIDAD FORAL DE;Group 1904 Femur fracture 820-821;Women;648 NAVARRA, COMUNIDAD FORAL DE;Group 1905 Leg fracture, including the ankle 823-824;Both sexes;426 NAVARRA, COMUNIDAD FORAL DE;Group 1905 Leg fracture, including the ankle 823-824;Men;232 NAVARRA, COMUNIDAD FORAL DE;Group 1905 Leg fracture, including the ankle 823-824;Women;194 NAVARRA, COMUNIDAD FORAL DE;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Both sexes;1,740 NAVARRA, COMUNIDAD FORAL DE;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Men;1,120 NAVARRA, COMUNIDAD FORAL DE;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Women;620 NAVARRA, COMUNIDAD FORAL DE;Group 1907 Burns 940-949;Both sexes;37 NAVARRA, COMUNIDAD FORAL DE;Group 1907 Burns 940-949;Men;28 NAVARRA, COMUNIDAD FORAL DE;Group 1907 Burns 940-949;Women;9 NAVARRA, COMUNIDAD FORAL DE;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Both sexes;114 NAVARRA, COMUNIDAD FORAL DE;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Men;58 NAVARRA, COMUNIDAD FORAL DE;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Women;56 NAVARRA, COMUNIDAD FORAL DE;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Both sexes;1,542 NAVARRA, COMUNIDAD FORAL DE;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Men;858 NAVARRA, COMUNIDAD FORAL DE;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Women;684 NAVARRA, COMUNIDAD FORAL DE;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Both sexes;9 NAVARRA, COMUNIDAD FORAL DE;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Men;8 NAVARRA, COMUNIDAD FORAL DE;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Women;1 NAVARRA, COMUNIDAD FORAL DE;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Both sexes;135 NAVARRA, COMUNIDAD FORAL DE;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Men;76 NAVARRA, COMUNIDAD FORAL DE;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Women;59 NAVARRA, COMUNIDAD FORAL DE;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Both sexes;2,239 NAVARRA, COMUNIDAD FORAL DE;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Men;1,219 NAVARRA, COMUNIDAD FORAL DE;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Women;1,020 NAVARRA, COMUNIDAD FORAL DE;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Both sexes;119 NAVARRA, COMUNIDAD FORAL DE;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Men;77 NAVARRA, COMUNIDAD FORAL DE;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Women;42 NAVARRA, COMUNIDAD FORAL DE;Group 2102 Contraceptive management V25;Both sexes;25 NAVARRA, COMUNIDAD FORAL DE;Group 2102 Contraceptive management V25;Men;1 NAVARRA, COMUNIDAD FORAL DE;Group 2102 Contraceptive management V25;Women;24 NAVARRA, COMUNIDAD FORAL DE;Group 2103 Living newborns by type of delivery V30-V39;Both sexes;.. NAVARRA, COMUNIDAD FORAL DE;Group 2103 Living newborns by type of delivery V30-V39;Men;.. NAVARRA, COMUNIDAD FORAL DE;Group 2103 Living newborns by type of delivery V30-V39;Women;.. NAVARRA, COMUNIDAD FORAL DE;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Both sexes;858 NAVARRA, COMUNIDAD FORAL DE;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Men;540 NAVARRA, COMUNIDAD FORAL DE;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Women;318 NAVARRA, COMUNIDAD FORAL DE;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Both sexes;1,237 NAVARRA, COMUNIDAD FORAL DE;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Men;601 NAVARRA, COMUNIDAD FORAL DE;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Women;636 PA═S VASCO;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Both sexes;241,342 PA═S VASCO;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Men;120,082 PA═S VASCO;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Women;121,260 PA═S VASCO;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Both sexes;4,298 PA═S VASCO;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Men;2,412 PA═S VASCO;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Women;1,886 PA═S VASCO;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Both sexes;596 PA═S VASCO;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Men;291 PA═S VASCO;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Women;304 PA═S VASCO;Group 0102 Imprecise intestinal infections 009;Both sexes;262 PA═S VASCO;Group 0102 Imprecise intestinal infections 009;Men;127 PA═S VASCO;Group 0102 Imprecise intestinal infections 009;Women;134 PA═S VASCO;Group 0103 Tuberculosis 010-018, 137;Both sexes;230 PA═S VASCO;Group 0103 Tuberculosis 010-018, 137;Men;140 PA═S VASCO;Group 0103 Tuberculosis 010-018, 137;Women;89 PA═S VASCO;Group 0104 Septicaemia 038;Both sexes;1,673 PA═S VASCO;Group 0104 Septicaemia 038;Men;948 PA═S VASCO;Group 0104 Septicaemia 038;Women;725 PA═S VASCO;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Both sexes;235 PA═S VASCO;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Men;138 PA═S VASCO;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Women;96 PA═S VASCO;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Both sexes;1,304 PA═S VASCO;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Men;767 PA═S VASCO;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Women;537 PA═S VASCO;Group 0200 Neoplasms 140-239;Both sexes;24,041 PA═S VASCO;Group 0200 Neoplasms 140-239;Men;12,939 PA═S VASCO;Group 0200 Neoplasms 140-239;Women;11,102 PA═S VASCO;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Both sexes;2,682 PA═S VASCO;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Men;1,681 PA═S VASCO;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Women;1,001 PA═S VASCO;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Both sexes;1,650 PA═S VASCO;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Men;1,273 PA═S VASCO;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Women;377 PA═S VASCO;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Both sexes;413 PA═S VASCO;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Men;218 PA═S VASCO;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Women;195 PA═S VASCO;Group 0204 Malignant neoplasm of breast 174-175;Both sexes;1,778 PA═S VASCO;Group 0204 Malignant neoplasm of breast 174-175;Men;25 PA═S VASCO;Group 0204 Malignant neoplasm of breast 174-175;Women;1,753 PA═S VASCO;Group 0205 Malignant neoplasm of uterus 179-180, 182;Both sexes;454 PA═S VASCO;Group 0205 Malignant neoplasm of uterus 179-180, 182;Men;.. PA═S VASCO;Group 0205 Malignant neoplasm of uterus 179-180, 182;Women;454 PA═S VASCO;Group 0206 Malignant neoplasm of ovary 1830;Both sexes;234 PA═S VASCO;Group 0206 Malignant neoplasm of ovary 1830;Men;.. PA═S VASCO;Group 0206 Malignant neoplasm of ovary 1830;Women;234 PA═S VASCO;Group 0207 Malignant neoplasm of prostate 185;Both sexes;1,359 PA═S VASCO;Group 0207 Malignant neoplasm of prostate 185;Men;1,359 PA═S VASCO;Group 0207 Malignant neoplasm of prostate 185;Women;.. PA═S VASCO;Group 0208 Malignant neoplasm of bladder 188;Both sexes;2,215 PA═S VASCO;Group 0208 Malignant neoplasm of bladder 188;Men;1,793 PA═S VASCO;Group 0208 Malignant neoplasm of bladder 188;Women;422 PA═S VASCO;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Both sexes;8,623 PA═S VASCO;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Men;5,099 PA═S VASCO;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Women;3,524 PA═S VASCO;Group 0210 Carcinoma in situ 230-234;Both sexes;344 PA═S VASCO;Group 0210 Carcinoma in situ 230-234;Men;89 PA═S VASCO;Group 0210 Carcinoma in situ 230-234;Women;255 PA═S VASCO;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Both sexes;382 PA═S VASCO;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Men;242 PA═S VASCO;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Women;139 PA═S VASCO;Grupo 0212 Leiomyoma of uterus 218;Both sexes;1,058 PA═S VASCO;Grupo 0212 Leiomyoma of uterus 218;Men;.. PA═S VASCO;Grupo 0212 Leiomyoma of uterus 218;Women;1,058 PA═S VASCO;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Both sexes;2,851 PA═S VASCO;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Men;1,160 PA═S VASCO;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Women;1,691 PA═S VASCO;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Both sexes;2,605 PA═S VASCO;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Men;1,309 PA═S VASCO;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Women;1,296 PA═S VASCO;Group 0301 Anaemias 280-285;Both sexes;1,738 PA═S VASCO;Group 0301 Anaemias 280-285;Men;836 PA═S VASCO;Group 0301 Anaemias 280-285;Women;902 PA═S VASCO;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Both sexes;867 PA═S VASCO;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Men;473 PA═S VASCO;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Women;394 PA═S VASCO;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Both sexes;4,063 PA═S VASCO;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Men;1,663 PA═S VASCO;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Women;2,399 PA═S VASCO;Group 0401 Diabetes mellitus 249-250;Both sexes;1,425 PA═S VASCO;Group 0401 Diabetes mellitus 249-250;Men;830 PA═S VASCO;Group 0401 Diabetes mellitus 249-250;Women;594 PA═S VASCO;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Both sexes;2,638 PA═S VASCO;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Men;833 PA═S VASCO;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Women;1,805 PA═S VASCO;Group 0500 Mental disorders 290-319;Both sexes;7,416 PA═S VASCO;Group 0500 Mental disorders 290-319;Men;3,943 PA═S VASCO;Group 0500 Mental disorders 290-319;Women;3,473 PA═S VASCO;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Both sexes;92 PA═S VASCO;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Men;51 PA═S VASCO;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Women;41 PA═S VASCO;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Both sexes;720 PA═S VASCO;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Men;498 PA═S VASCO;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Women;222 PA═S VASCO;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Both sexes;461 PA═S VASCO;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Men;337 PA═S VASCO;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Women;124 PA═S VASCO;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Both sexes;2,335 PA═S VASCO;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Men;1,487 PA═S VASCO;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Women;847 PA═S VASCO;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Both sexes;1,820 PA═S VASCO;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Men;665 PA═S VASCO;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Women;1,155 PA═S VASCO;Group 0506 Other mental and behavioural disorders Rest of (290-319);Both sexes;1,987 PA═S VASCO;Group 0506 Other mental and behavioural disorders Rest of (290-319);Men;904 PA═S VASCO;Group 0506 Other mental and behavioural disorders Rest of (290-319);Women;1,083 PA═S VASCO;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Both sexes;5,621 PA═S VASCO;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Men;2,935 PA═S VASCO;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Women;2,686 PA═S VASCO;Group 0601 Alzheimer's disease 3310;Both sexes;114 PA═S VASCO;Group 0601 Alzheimer's disease 3310;Men;40 PA═S VASCO;Group 0601 Alzheimer's disease 3310;Women;74 PA═S VASCO;Group 0602 Multiple sclerosis 340;Both sexes;82 PA═S VASCO;Group 0602 Multiple sclerosis 340;Men;27 PA═S VASCO;Group 0602 Multiple sclerosis 340;Women;55 PA═S VASCO;Group 0603 Epilepsy 345;Both sexes;900 PA═S VASCO;Group 0603 Epilepsy 345;Men;467 PA═S VASCO;Group 0603 Epilepsy 345;Women;433 PA═S VASCO;Group 0604 Transient cerebral ischemia 435;Both sexes;740 PA═S VASCO;Group 0604 Transient cerebral ischemia 435;Men;367 PA═S VASCO;Group 0604 Transient cerebral ischemia 435;Women;373 PA═S VASCO;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Both sexes;3,785 PA═S VASCO;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Men;2,034 PA═S VASCO;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Women;1,751 PA═S VASCO;Grupo 0700 Diseases of the eye and adnexa 360-379;Both sexes;761 PA═S VASCO;Grupo 0700 Diseases of the eye and adnexa 360-379;Men;334 PA═S VASCO;Grupo 0700 Diseases of the eye and adnexa 360-379;Women;427 PA═S VASCO;Grupo 0701 Cataract 366;Both sexes;72 PA═S VASCO;Grupo 0701 Cataract 366;Men;31 PA═S VASCO;Grupo 0701 Cataract 366;Women;41 PA═S VASCO;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Both sexes;689 PA═S VASCO;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Men;303 PA═S VASCO;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Women;386 PA═S VASCO;Group 0800 Diseases of the ear and the mastoid 380-389;Both sexes;1,252 PA═S VASCO;Group 0800 Diseases of the ear and the mastoid 380-389;Men;658 PA═S VASCO;Group 0800 Diseases of the ear and the mastoid 380-389;Women;594 PA═S VASCO;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Both sexes;32,206 PA═S VASCO;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Men;18,509 PA═S VASCO;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Women;13,697 PA═S VASCO;Group 0901 Hypertensive disease 401-405;Both sexes;1,720 PA═S VASCO;Group 0901 Hypertensive disease 401-405;Men;762 PA═S VASCO;Group 0901 Hypertensive disease 401-405;Women;958 PA═S VASCO;Group 0902 Angina pectoris 4111, 413;Both sexes;737 PA═S VASCO;Group 0902 Angina pectoris 4111, 413;Men;479 PA═S VASCO;Group 0902 Angina pectoris 4111, 413;Women;259 PA═S VASCO;Group 0903 Acute myocardial infarction 410;Both sexes;2,141 PA═S VASCO;Group 0903 Acute myocardial infarction 410;Men;1,522 PA═S VASCO;Group 0903 Acute myocardial infarction 410;Women;618 PA═S VASCO;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Both sexes;2,222 PA═S VASCO;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Men;1,747 PA═S VASCO;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Women;475 PA═S VASCO;Group 0905 Diseases of the lungs circulation 415-417;Both sexes;1,053 PA═S VASCO;Group 0905 Diseases of the lungs circulation 415-417;Men;449 PA═S VASCO;Group 0905 Diseases of the lungs circulation 415-417;Women;604 PA═S VASCO;Group 0906 Heart conduction disorders and arrhytmias 426-427;Both sexes;4,632 PA═S VASCO;Group 0906 Heart conduction disorders and arrhytmias 426-427;Men;2,546 PA═S VASCO;Group 0906 Heart conduction disorders and arrhytmias 426-427;Women;2,086 PA═S VASCO;Grupo 0907 Heart failure 428;Both sexes;6,018 PA═S VASCO;Grupo 0907 Heart failure 428;Men;3,222 PA═S VASCO;Grupo 0907 Heart failure 428;Women;2,797 PA═S VASCO;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Both sexes;5,371 PA═S VASCO;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Men;2,864 PA═S VASCO;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Women;2,507 PA═S VASCO;Grupo 0909 Atherosclerosis 440;Both sexes;1,651 PA═S VASCO;Grupo 0909 Atherosclerosis 440;Men;1,304 PA═S VASCO;Grupo 0909 Atherosclerosis 440;Women;347 PA═S VASCO;Group 0910 Varicose veins of lower extremities 454;Both sexes;1,536 PA═S VASCO;Group 0910 Varicose veins of lower extremities 454;Men;555 PA═S VASCO;Group 0910 Varicose veins of lower extremities 454;Women;981 PA═S VASCO;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Both sexes;5,125 PA═S VASCO;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Men;3,059 PA═S VASCO;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Women;2,066 PA═S VASCO;Group 1000 Diseases of the respiratory system 0340, 460-519;Both sexes;26,648 PA═S VASCO;Group 1000 Diseases of the respiratory system 0340, 460-519;Men;15,529 PA═S VASCO;Group 1000 Diseases of the respiratory system 0340, 460-519;Women;11,118 PA═S VASCO;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Both sexes;850 PA═S VASCO;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Men;436 PA═S VASCO;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Women;414 PA═S VASCO;Group 1002 Pneumonia 480-486;Both sexes;5,410 PA═S VASCO;Group 1002 Pneumonia 480-486;Men;3,277 PA═S VASCO;Group 1002 Pneumonia 480-486;Women;2,132 PA═S VASCO;Group 1003 Acute bronchitis and bronchiolitis 466;Both sexes;2,818 PA═S VASCO;Group 1003 Acute bronchitis and bronchiolitis 466;Men;1,293 PA═S VASCO;Group 1003 Acute bronchitis and bronchiolitis 466;Women;1,526 PA═S VASCO;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Both sexes;1,404 PA═S VASCO;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Men;781 PA═S VASCO;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Women;623 PA═S VASCO;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Both sexes;2,187 PA═S VASCO;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Men;1,407 PA═S VASCO;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Women;780 PA═S VASCO;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Both sexes;4,992 PA═S VASCO;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Men;3,761 PA═S VASCO;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Women;1,232 PA═S VASCO;Group 1007 Asthma 4930-4931,4938-4939;Both sexes;1,704 PA═S VASCO;Group 1007 Asthma 4930-4931,4938-4939;Men;611 PA═S VASCO;Group 1007 Asthma 4930-4931,4938-4939;Women;1,093 PA═S VASCO;Group 1008 Other diseases of the respiratory system Resto of (460-519);Both sexes;7,283 PA═S VASCO;Group 1008 Other diseases of the respiratory system Resto of (460-519);Men;3,964 PA═S VASCO;Group 1008 Other diseases of the respiratory system Resto of (460-519);Women;3,319 PA═S VASCO;Group 1100 Diseases of the digestive system 520-579;Both sexes;29,961 PA═S VASCO;Group 1100 Diseases of the digestive system 520-579;Men;17,357 PA═S VASCO;Group 1100 Diseases of the digestive system 520-579;Women;12,604 PA═S VASCO;Group 1101 Disorders of the teeth and supporting structures 520-525;Both sexes;430 PA═S VASCO;Group 1101 Disorders of the teeth and supporting structures 520-525;Men;214 PA═S VASCO;Group 1101 Disorders of the teeth and supporting structures 520-525;Women;215 PA═S VASCO;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Both sexes;393 PA═S VASCO;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Men;237 PA═S VASCO;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Women;155 PA═S VASCO;Group 1103 Diseases of the esophagus 530;Both sexes;610 PA═S VASCO;Group 1103 Diseases of the esophagus 530;Men;347 PA═S VASCO;Group 1103 Diseases of the esophagus 530;Women;264 PA═S VASCO;Group 1104 Peptic ulcer 531-534;Both sexes;557 PA═S VASCO;Group 1104 Peptic ulcer 531-534;Men;390 PA═S VASCO;Group 1104 Peptic ulcer 531-534;Women;167 PA═S VASCO;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Both sexes;573 PA═S VASCO;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Men;313 PA═S VASCO;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Women;261 PA═S VASCO;Group 1106 Appendicitis 540-543;Both sexes;2,544 PA═S VASCO;Group 1106 Appendicitis 540-543;Men;1,469 PA═S VASCO;Group 1106 Appendicitis 540-543;Women;1,075 PA═S VASCO;Group 1107 Inguinal hernia 550;Both sexes;3,866 PA═S VASCO;Group 1107 Inguinal hernia 550;Men;3,451 PA═S VASCO;Group 1107 Inguinal hernia 550;Women;415 PA═S VASCO;Group 1108 Other abdominal hernia 551-553;Both sexes;2,626 PA═S VASCO;Group 1108 Other abdominal hernia 551-553;Men;1,313 PA═S VASCO;Group 1108 Other abdominal hernia 551-553;Women;1,312 PA═S VASCO;Group 1109 Crohn's disease and ulcerative colitis 555-556;Both sexes;623 PA═S VASCO;Group 1109 Crohn's disease and ulcerative colitis 555-556;Men;336 PA═S VASCO;Group 1109 Crohn's disease and ulcerative colitis 555-556;Women;288 PA═S VASCO;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Both sexes;1,214 PA═S VASCO;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Men;571 PA═S VASCO;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Women;643 PA═S VASCO;Group 1111 Intestinal obstruction without hernia 560;Both sexes;1,635 PA═S VASCO;Group 1111 Intestinal obstruction without hernia 560;Men;888 PA═S VASCO;Group 1111 Intestinal obstruction without hernia 560;Women;748 PA═S VASCO;Group 1112 Intestinal diverticulosis 562;Both sexes;1,415 PA═S VASCO;Group 1112 Intestinal diverticulosis 562;Men;673 PA═S VASCO;Group 1112 Intestinal diverticulosis 562;Women;742 PA═S VASCO;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Both sexes;2,126 PA═S VASCO;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Men;1,373 PA═S VASCO;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Women;753 PA═S VASCO;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Both sexes;1,009 PA═S VASCO;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Men;437 PA═S VASCO;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Women;571 PA═S VASCO;Group 1115 Alcoholic hepatitis 5710-5713;Both sexes;534 PA═S VASCO;Group 1115 Alcoholic hepatitis 5710-5713;Men;436 PA═S VASCO;Group 1115 Alcoholic hepatitis 5710-5713;Women;98 PA═S VASCO;Group 1116 Other diseases of the liver 570,5714-573;Both sexes;1,044 PA═S VASCO;Group 1116 Other diseases of the liver 570,5714-573;Men;692 PA═S VASCO;Group 1116 Other diseases of the liver 570,5714-573;Women;352 PA═S VASCO;Group 1117 Cholelithiasis 574;Both sexes;4,871 PA═S VASCO;Group 1117 Cholelithiasis 574;Men;2,099 PA═S VASCO;Group 1117 Cholelithiasis 574;Women;2,772 PA═S VASCO;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Both sexes;1,283 PA═S VASCO;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Men;663 PA═S VASCO;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Women;621 PA═S VASCO;Group 1119 Pancreatic diseases 577;Both sexes;1,250 PA═S VASCO;Group 1119 Pancreatic diseases 577;Men;682 PA═S VASCO;Group 1119 Pancreatic diseases 577;Women;568 PA═S VASCO;Group 1120 Other diseases of the digestive system Rest of (520-579);Both sexes;1,357 PA═S VASCO;Group 1120 Other diseases of the digestive system Rest of (520-579);Men;772 PA═S VASCO;Group 1120 Other diseases of the digestive system Rest of (520-579);Women;584 PA═S VASCO;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Both sexes;2,616 PA═S VASCO;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Men;1,528 PA═S VASCO;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Women;1,087 PA═S VASCO;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Both sexes;1,761 PA═S VASCO;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Men;1,098 PA═S VASCO;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Women;662 PA═S VASCO;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Both sexes;117 PA═S VASCO;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Men;61 PA═S VASCO;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Women;56 PA═S VASCO;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Both sexes;737 PA═S VASCO;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Men;369 PA═S VASCO;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Women;369 PA═S VASCO;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Both sexes;20,302 PA═S VASCO;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Men;10,321 PA═S VASCO;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Women;9,981 PA═S VASCO;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Both sexes;.. PA═S VASCO;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Men;.. PA═S VASCO;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Women;.. PA═S VASCO;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Both sexes;.. PA═S VASCO;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Men;.. PA═S VASCO;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Women;.. PA═S VASCO;Group 1303 Internal derangement of knee 717;Both sexes;3,648 PA═S VASCO;Group 1303 Internal derangement of knee 717;Men;2,442 PA═S VASCO;Group 1303 Internal derangement of knee 717;Women;1,206 PA═S VASCO;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Both sexes;7,339 PA═S VASCO;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Men;3,393 PA═S VASCO;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Women;3,946 PA═S VASCO;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Both sexes;272 PA═S VASCO;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Men;102 PA═S VASCO;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Women;169 PA═S VASCO;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Both sexes;923 PA═S VASCO;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Men;472 PA═S VASCO;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Women;451 PA═S VASCO;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Both sexes;1,377 PA═S VASCO;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Men;753 PA═S VASCO;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Women;623 PA═S VASCO;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Both sexes;670 PA═S VASCO;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Men;353 PA═S VASCO;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Women;316 PA═S VASCO;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Both sexes;2,972 PA═S VASCO;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Men;1,781 PA═S VASCO;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Women;1,191 PA═S VASCO;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Both sexes;3,103 PA═S VASCO;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Men;1,024 PA═S VASCO;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Women;2,079 PA═S VASCO;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Both sexes;15,452 PA═S VASCO;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Men;7,552 PA═S VASCO;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Women;7,900 PA═S VASCO;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Both sexes;1,338 PA═S VASCO;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Men;508 PA═S VASCO;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Women;829 PA═S VASCO;Group 1402 Renal failure 5836-5837, 584-586;Both sexes;1,383 PA═S VASCO;Group 1402 Renal failure 5836-5837, 584-586;Men;827 PA═S VASCO;Group 1402 Renal failure 5836-5837, 584-586;Women;555 PA═S VASCO;Group 1403 Urolithiasis 592, 594, 7880;Both sexes;2,085 PA═S VASCO;Group 1403 Urolithiasis 592, 594, 7880;Men;1,286 PA═S VASCO;Group 1403 Urolithiasis 592, 594, 7880;Women;799 PA═S VASCO;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Both sexes;4,442 PA═S VASCO;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Men;2,252 PA═S VASCO;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Women;2,190 PA═S VASCO;Group 1405 Prostatic hyperplasia 600;Both sexes;1,544 PA═S VASCO;Group 1405 Prostatic hyperplasia 600;Men;1,544 PA═S VASCO;Group 1405 Prostatic hyperplasia 600;Women;.. PA═S VASCO;Group 1406 Other diseases of the male genital organs 601-608;Both sexes;989 PA═S VASCO;Group 1406 Other diseases of the male genital organs 601-608;Men;989 PA═S VASCO;Group 1406 Other diseases of the male genital organs 601-608;Women;.. PA═S VASCO;Group 1407 Disorders of breast 610-612;Both sexes;958 PA═S VASCO;Group 1407 Disorders of breast 610-612;Men;90 PA═S VASCO;Group 1407 Disorders of breast 610-612;Women;867 PA═S VASCO;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Both sexes;360 PA═S VASCO;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Men;.. PA═S VASCO;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Women;360 PA═S VASCO;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Both sexes;99 PA═S VASCO;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Men;.. PA═S VASCO;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Women;99 PA═S VASCO;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Both sexes;2,255 PA═S VASCO;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Men;54 PA═S VASCO;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Women;2,200 PA═S VASCO;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Both sexes;21,075 PA═S VASCO;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Men;.. PA═S VASCO;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Women;21,075 PA═S VASCO;Group 1501 Legally induced abortion 635;Both sexes;167 PA═S VASCO;Group 1501 Legally induced abortion 635;Men;.. PA═S VASCO;Group 1501 Legally induced abortion 635;Women;167 PA═S VASCO;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Both sexes;632 PA═S VASCO;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Men;.. PA═S VASCO;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Women;632 PA═S VASCO;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Both sexes;12,623 PA═S VASCO;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Men;.. PA═S VASCO;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Women;12,623 PA═S VASCO;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Both sexes;3,848 PA═S VASCO;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Men;.. PA═S VASCO;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Women;3,848 PA═S VASCO;Group 1505 Single spontaneous delivery 650;Both sexes;1,830 PA═S VASCO;Group 1505 Single spontaneous delivery 650;Men;.. PA═S VASCO;Group 1505 Single spontaneous delivery 650;Women;1,830 PA═S VASCO;Group 1506 Other deliveries 6695-6697;Both sexes;420 PA═S VASCO;Group 1506 Other deliveries 6695-6697;Men;.. PA═S VASCO;Group 1506 Other deliveries 6695-6697;Women;420 PA═S VASCO;Group 1507 Complications related to the puerperium 670-676;Both sexes;197 PA═S VASCO;Group 1507 Complications related to the puerperium 670-676;Men;.. PA═S VASCO;Group 1507 Complications related to the puerperium 670-676;Women;197 PA═S VASCO;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Both sexes;1,358 PA═S VASCO;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Men;.. PA═S VASCO;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Women;1,358 PA═S VASCO;Group 1600 Some disorders originating in the perinatal period 760-779;Both sexes;2,377 PA═S VASCO;Group 1600 Some disorders originating in the perinatal period 760-779;Men;1,307 PA═S VASCO;Group 1600 Some disorders originating in the perinatal period 760-779;Women;1,070 PA═S VASCO;Group 1601 Disorders related with premature delivery and a low birth weight 765;Both sexes;728 PA═S VASCO;Group 1601 Disorders related with premature delivery and a low birth weight 765;Men;393 PA═S VASCO;Group 1601 Disorders related with premature delivery and a low birth weight 765;Women;335 PA═S VASCO;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Both sexes;1,650 PA═S VASCO;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Men;914 PA═S VASCO;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Women;736 PA═S VASCO;Grupo 1700 Congenital abnormalities 740-759;Both sexes;1,445 PA═S VASCO;Grupo 1700 Congenital abnormalities 740-759;Men;795 PA═S VASCO;Grupo 1700 Congenital abnormalities 740-759;Women;650 PA═S VASCO;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Both sexes;12,596 PA═S VASCO;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Men;7,003 PA═S VASCO;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Women;5,593 PA═S VASCO;Group 1801 Pain in throat and chest 7841, 7865;Both sexes;2,356 PA═S VASCO;Group 1801 Pain in throat and chest 7841, 7865;Men;1,323 PA═S VASCO;Group 1801 Pain in throat and chest 7841, 7865;Women;1,033 PA═S VASCO;Group 1802 Abdominal pain 7890;Both sexes;1,436 PA═S VASCO;Group 1802 Abdominal pain 7890;Men;648 PA═S VASCO;Group 1802 Abdominal pain 7890;Women;788 PA═S VASCO;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Both sexes;154 PA═S VASCO;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Men;77 PA═S VASCO;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Women;77 PA═S VASCO;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Both sexes;8,650 PA═S VASCO;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Men;4,955 PA═S VASCO;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Women;3,695 PA═S VASCO;Group 1900 Injuries and poisoning 800-999;Both sexes;20,743 PA═S VASCO;Group 1900 Injuries and poisoning 800-999;Men;10,980 PA═S VASCO;Group 1900 Injuries and poisoning 800-999;Women;9,763 PA═S VASCO;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Both sexes;1,165 PA═S VASCO;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Men;652 PA═S VASCO;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Women;513 PA═S VASCO;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Both sexes;542 PA═S VASCO;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Men;379 PA═S VASCO;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Women;163 PA═S VASCO;Group 1903 Radius and ulna fracture 813;Both sexes;1,307 PA═S VASCO;Group 1903 Radius and ulna fracture 813;Men;541 PA═S VASCO;Group 1903 Radius and ulna fracture 813;Women;766 PA═S VASCO;Group 1904 Femur fracture 820-821;Both sexes;2,965 PA═S VASCO;Group 1904 Femur fracture 820-821;Men;838 PA═S VASCO;Group 1904 Femur fracture 820-821;Women;2,127 PA═S VASCO;Group 1905 Leg fracture, including the ankle 823-824;Both sexes;1,493 PA═S VASCO;Group 1905 Leg fracture, including the ankle 823-824;Men;748 PA═S VASCO;Group 1905 Leg fracture, including the ankle 823-824;Women;745 PA═S VASCO;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Both sexes;6,145 PA═S VASCO;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Men;3,832 PA═S VASCO;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Women;2,312 PA═S VASCO;Group 1907 Burns 940-949;Both sexes;119 PA═S VASCO;Group 1907 Burns 940-949;Men;88 PA═S VASCO;Group 1907 Burns 940-949;Women;31 PA═S VASCO;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Both sexes;545 PA═S VASCO;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Men;247 PA═S VASCO;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Women;298 PA═S VASCO;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Both sexes;5,668 PA═S VASCO;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Men;3,250 PA═S VASCO;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Women;2,418 PA═S VASCO;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Both sexes;71 PA═S VASCO;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Men;38 PA═S VASCO;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Women;33 PA═S VASCO;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Both sexes;724 PA═S VASCO;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Men;366 PA═S VASCO;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Women;359 PA═S VASCO;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Both sexes;5,865 PA═S VASCO;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Men;3,009 PA═S VASCO;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Women;2,856 PA═S VASCO;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Both sexes;340 PA═S VASCO;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Men;214 PA═S VASCO;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Women;126 PA═S VASCO;Group 2102 Contraceptive management V25;Both sexes;80 PA═S VASCO;Group 2102 Contraceptive management V25;Men;2 PA═S VASCO;Group 2102 Contraceptive management V25;Women;78 PA═S VASCO;Group 2103 Living newborns by type of delivery V30-V39;Both sexes;.. PA═S VASCO;Group 2103 Living newborns by type of delivery V30-V39;Men;.. PA═S VASCO;Group 2103 Living newborns by type of delivery V30-V39;Women;.. PA═S VASCO;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Both sexes;1,736 PA═S VASCO;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Men;1,099 PA═S VASCO;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Women;637 PA═S VASCO;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Both sexes;3,708 PA═S VASCO;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Men;1,695 PA═S VASCO;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Women;2,014 Araba/┴lava;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Both sexes;35,354 Araba/┴lava;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Men;18,221 Araba/┴lava;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Women;17,133 Araba/┴lava;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Both sexes;620 Araba/┴lava;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Men;363 Araba/┴lava;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Women;257 Araba/┴lava;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Both sexes;103 Araba/┴lava;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Men;47 Araba/┴lava;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Women;56 Araba/┴lava;Group 0102 Imprecise intestinal infections 009;Both sexes;12 Araba/┴lava;Group 0102 Imprecise intestinal infections 009;Men;5 Araba/┴lava;Group 0102 Imprecise intestinal infections 009;Women;7 Araba/┴lava;Group 0103 Tuberculosis 010-018, 137;Both sexes;30 Araba/┴lava;Group 0103 Tuberculosis 010-018, 137;Men;20 Araba/┴lava;Group 0103 Tuberculosis 010-018, 137;Women;10 Araba/┴lava;Group 0104 Septicaemia 038;Both sexes;220 Araba/┴lava;Group 0104 Septicaemia 038;Men;131 Araba/┴lava;Group 0104 Septicaemia 038;Women;89 Araba/┴lava;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Both sexes;19 Araba/┴lava;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Men;11 Araba/┴lava;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Women;8 Araba/┴lava;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Both sexes;236 Araba/┴lava;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Men;149 Araba/┴lava;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Women;87 Araba/┴lava;Group 0200 Neoplasms 140-239;Both sexes;3,165 Araba/┴lava;Group 0200 Neoplasms 140-239;Men;1,741 Araba/┴lava;Group 0200 Neoplasms 140-239;Women;1,424 Araba/┴lava;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Both sexes;291 Araba/┴lava;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Men;184 Araba/┴lava;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Women;107 Araba/┴lava;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Both sexes;168 Araba/┴lava;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Men;139 Araba/┴lava;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Women;29 Araba/┴lava;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Both sexes;23 Araba/┴lava;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Men;11 Araba/┴lava;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Women;12 Araba/┴lava;Group 0204 Malignant neoplasm of breast 174-175;Both sexes;244 Araba/┴lava;Group 0204 Malignant neoplasm of breast 174-175;Men;.. Araba/┴lava;Group 0204 Malignant neoplasm of breast 174-175;Women;244 Araba/┴lava;Group 0205 Malignant neoplasm of uterus 179-180, 182;Both sexes;60 Araba/┴lava;Group 0205 Malignant neoplasm of uterus 179-180, 182;Men;.. Araba/┴lava;Group 0205 Malignant neoplasm of uterus 179-180, 182;Women;60 Araba/┴lava;Group 0206 Malignant neoplasm of ovary 1830;Both sexes;28 Araba/┴lava;Group 0206 Malignant neoplasm of ovary 1830;Men;.. Araba/┴lava;Group 0206 Malignant neoplasm of ovary 1830;Women;28 Araba/┴lava;Group 0207 Malignant neoplasm of prostate 185;Both sexes;207 Araba/┴lava;Group 0207 Malignant neoplasm of prostate 185;Men;207 Araba/┴lava;Group 0207 Malignant neoplasm of prostate 185;Women;.. Araba/┴lava;Group 0208 Malignant neoplasm of bladder 188;Both sexes;339 Araba/┴lava;Group 0208 Malignant neoplasm of bladder 188;Men;280 Araba/┴lava;Group 0208 Malignant neoplasm of bladder 188;Women;59 Araba/┴lava;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Both sexes;1,174 Araba/┴lava;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Men;689 Araba/┴lava;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Women;485 Araba/┴lava;Group 0210 Carcinoma in situ 230-234;Both sexes;34 Araba/┴lava;Group 0210 Carcinoma in situ 230-234;Men;14 Araba/┴lava;Group 0210 Carcinoma in situ 230-234;Women;20 Araba/┴lava;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Both sexes;83 Araba/┴lava;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Men;60 Araba/┴lava;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Women;23 Araba/┴lava;Grupo 0212 Leiomyoma of uterus 218;Both sexes;113 Araba/┴lava;Grupo 0212 Leiomyoma of uterus 218;Men;.. Araba/┴lava;Grupo 0212 Leiomyoma of uterus 218;Women;113 Araba/┴lava;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Both sexes;401 Araba/┴lava;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Men;157 Araba/┴lava;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Women;244 Araba/┴lava;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Both sexes;414 Araba/┴lava;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Men;218 Araba/┴lava;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Women;196 Araba/┴lava;Group 0301 Anaemias 280-285;Both sexes;261 Araba/┴lava;Group 0301 Anaemias 280-285;Men;131 Araba/┴lava;Group 0301 Anaemias 280-285;Women;130 Araba/┴lava;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Both sexes;153 Araba/┴lava;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Men;87 Araba/┴lava;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Women;66 Araba/┴lava;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Both sexes;691 Araba/┴lava;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Men;268 Araba/┴lava;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Women;423 Araba/┴lava;Group 0401 Diabetes mellitus 249-250;Both sexes;274 Araba/┴lava;Group 0401 Diabetes mellitus 249-250;Men;157 Araba/┴lava;Group 0401 Diabetes mellitus 249-250;Women;117 Araba/┴lava;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Both sexes;417 Araba/┴lava;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Men;111 Araba/┴lava;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Women;306 Araba/┴lava;Group 0500 Mental disorders 290-319;Both sexes;921 Araba/┴lava;Group 0500 Mental disorders 290-319;Men;503 Araba/┴lava;Group 0500 Mental disorders 290-319;Women;418 Araba/┴lava;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Both sexes;14 Araba/┴lava;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Men;7 Araba/┴lava;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Women;7 Araba/┴lava;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Both sexes;87 Araba/┴lava;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Men;61 Araba/┴lava;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Women;26 Araba/┴lava;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Both sexes;36 Araba/┴lava;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Men;21 Araba/┴lava;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Women;15 Araba/┴lava;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Both sexes;267 Araba/┴lava;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Men;187 Araba/┴lava;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Women;80 Araba/┴lava;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Both sexes;215 Araba/┴lava;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Men;89 Araba/┴lava;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Women;126 Araba/┴lava;Group 0506 Other mental and behavioural disorders Rest of (290-319);Both sexes;302 Araba/┴lava;Group 0506 Other mental and behavioural disorders Rest of (290-319);Men;138 Araba/┴lava;Group 0506 Other mental and behavioural disorders Rest of (290-319);Women;164 Araba/┴lava;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Both sexes;854 Araba/┴lava;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Men;447 Araba/┴lava;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Women;407 Araba/┴lava;Group 0601 Alzheimer's disease 3310;Both sexes;18 Araba/┴lava;Group 0601 Alzheimer's disease 3310;Men;7 Araba/┴lava;Group 0601 Alzheimer's disease 3310;Women;11 Araba/┴lava;Group 0602 Multiple sclerosis 340;Both sexes;18 Araba/┴lava;Group 0602 Multiple sclerosis 340;Men;5 Araba/┴lava;Group 0602 Multiple sclerosis 340;Women;13 Araba/┴lava;Group 0603 Epilepsy 345;Both sexes;183 Araba/┴lava;Group 0603 Epilepsy 345;Men;102 Araba/┴lava;Group 0603 Epilepsy 345;Women;81 Araba/┴lava;Group 0604 Transient cerebral ischemia 435;Both sexes;111 Araba/┴lava;Group 0604 Transient cerebral ischemia 435;Men;50 Araba/┴lava;Group 0604 Transient cerebral ischemia 435;Women;61 Araba/┴lava;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Both sexes;524 Araba/┴lava;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Men;283 Araba/┴lava;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Women;241 Araba/┴lava;Grupo 0700 Diseases of the eye and adnexa 360-379;Both sexes;149 Araba/┴lava;Grupo 0700 Diseases of the eye and adnexa 360-379;Men;78 Araba/┴lava;Grupo 0700 Diseases of the eye and adnexa 360-379;Women;71 Araba/┴lava;Grupo 0701 Cataract 366;Both sexes;26 Araba/┴lava;Grupo 0701 Cataract 366;Men;9 Araba/┴lava;Grupo 0701 Cataract 366;Women;17 Araba/┴lava;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Both sexes;123 Araba/┴lava;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Men;69 Araba/┴lava;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Women;54 Araba/┴lava;Group 0800 Diseases of the ear and the mastoid 380-389;Both sexes;154 Araba/┴lava;Group 0800 Diseases of the ear and the mastoid 380-389;Men;75 Araba/┴lava;Group 0800 Diseases of the ear and the mastoid 380-389;Women;79 Araba/┴lava;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Both sexes;4,574 Araba/┴lava;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Men;2,672 Araba/┴lava;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Women;1,902 Araba/┴lava;Group 0901 Hypertensive disease 401-405;Both sexes;232 Araba/┴lava;Group 0901 Hypertensive disease 401-405;Men;112 Araba/┴lava;Group 0901 Hypertensive disease 401-405;Women;120 Araba/┴lava;Group 0902 Angina pectoris 4111, 413;Both sexes;112 Araba/┴lava;Group 0902 Angina pectoris 4111, 413;Men;78 Araba/┴lava;Group 0902 Angina pectoris 4111, 413;Women;34 Araba/┴lava;Group 0903 Acute myocardial infarction 410;Both sexes;419 Araba/┴lava;Group 0903 Acute myocardial infarction 410;Men;307 Araba/┴lava;Group 0903 Acute myocardial infarction 410;Women;112 Araba/┴lava;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Both sexes;187 Araba/┴lava;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Men;147 Araba/┴lava;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Women;40 Araba/┴lava;Group 0905 Diseases of the lungs circulation 415-417;Both sexes;160 Araba/┴lava;Group 0905 Diseases of the lungs circulation 415-417;Men;77 Araba/┴lava;Group 0905 Diseases of the lungs circulation 415-417;Women;83 Araba/┴lava;Group 0906 Heart conduction disorders and arrhytmias 426-427;Both sexes;583 Araba/┴lava;Group 0906 Heart conduction disorders and arrhytmias 426-427;Men;318 Araba/┴lava;Group 0906 Heart conduction disorders and arrhytmias 426-427;Women;265 Araba/┴lava;Grupo 0907 Heart failure 428;Both sexes;729 Araba/┴lava;Grupo 0907 Heart failure 428;Men;423 Araba/┴lava;Grupo 0907 Heart failure 428;Women;306 Araba/┴lava;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Both sexes;709 Araba/┴lava;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Men;374 Araba/┴lava;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Women;335 Araba/┴lava;Grupo 0909 Atherosclerosis 440;Both sexes;294 Araba/┴lava;Grupo 0909 Atherosclerosis 440;Men;227 Araba/┴lava;Grupo 0909 Atherosclerosis 440;Women;67 Araba/┴lava;Group 0910 Varicose veins of lower extremities 454;Both sexes;416 Araba/┴lava;Group 0910 Varicose veins of lower extremities 454;Men;153 Araba/┴lava;Group 0910 Varicose veins of lower extremities 454;Women;263 Araba/┴lava;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Both sexes;733 Araba/┴lava;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Men;456 Araba/┴lava;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Women;277 Araba/┴lava;Group 1000 Diseases of the respiratory system 0340, 460-519;Both sexes;3,979 Araba/┴lava;Group 1000 Diseases of the respiratory system 0340, 460-519;Men;2,336 Araba/┴lava;Group 1000 Diseases of the respiratory system 0340, 460-519;Women;1,643 Araba/┴lava;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Both sexes;158 Araba/┴lava;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Men;81 Araba/┴lava;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Women;77 Araba/┴lava;Group 1002 Pneumonia 480-486;Both sexes;830 Araba/┴lava;Group 1002 Pneumonia 480-486;Men;507 Araba/┴lava;Group 1002 Pneumonia 480-486;Women;323 Araba/┴lava;Group 1003 Acute bronchitis and bronchiolitis 466;Both sexes;554 Araba/┴lava;Group 1003 Acute bronchitis and bronchiolitis 466;Men;276 Araba/┴lava;Group 1003 Acute bronchitis and bronchiolitis 466;Women;278 Araba/┴lava;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Both sexes;186 Araba/┴lava;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Men;103 Araba/┴lava;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Women;83 Araba/┴lava;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Both sexes;318 Araba/┴lava;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Men;192 Araba/┴lava;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Women;126 Araba/┴lava;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Both sexes;753 Araba/┴lava;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Men;585 Araba/┴lava;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Women;168 Araba/┴lava;Group 1007 Asthma 4930-4931,4938-4939;Both sexes;268 Araba/┴lava;Group 1007 Asthma 4930-4931,4938-4939;Men;86 Araba/┴lava;Group 1007 Asthma 4930-4931,4938-4939;Women;182 Araba/┴lava;Group 1008 Other diseases of the respiratory system Resto of (460-519);Both sexes;912 Araba/┴lava;Group 1008 Other diseases of the respiratory system Resto of (460-519);Men;506 Araba/┴lava;Group 1008 Other diseases of the respiratory system Resto of (460-519);Women;406 Araba/┴lava;Group 1100 Diseases of the digestive system 520-579;Both sexes;4,358 Araba/┴lava;Group 1100 Diseases of the digestive system 520-579;Men;2,568 Araba/┴lava;Group 1100 Diseases of the digestive system 520-579;Women;1,790 Araba/┴lava;Group 1101 Disorders of the teeth and supporting structures 520-525;Both sexes;70 Araba/┴lava;Group 1101 Disorders of the teeth and supporting structures 520-525;Men;37 Araba/┴lava;Group 1101 Disorders of the teeth and supporting structures 520-525;Women;33 Araba/┴lava;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Both sexes;56 Araba/┴lava;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Men;38 Araba/┴lava;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Women;18 Araba/┴lava;Group 1103 Diseases of the esophagus 530;Both sexes;125 Araba/┴lava;Group 1103 Diseases of the esophagus 530;Men;73 Araba/┴lava;Group 1103 Diseases of the esophagus 530;Women;52 Araba/┴lava;Group 1104 Peptic ulcer 531-534;Both sexes;82 Araba/┴lava;Group 1104 Peptic ulcer 531-534;Men;56 Araba/┴lava;Group 1104 Peptic ulcer 531-534;Women;26 Araba/┴lava;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Both sexes;105 Araba/┴lava;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Men;60 Araba/┴lava;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Women;45 Araba/┴lava;Group 1106 Appendicitis 540-543;Both sexes;326 Araba/┴lava;Group 1106 Appendicitis 540-543;Men;182 Araba/┴lava;Group 1106 Appendicitis 540-543;Women;144 Araba/┴lava;Group 1107 Inguinal hernia 550;Both sexes;615 Araba/┴lava;Group 1107 Inguinal hernia 550;Men;548 Araba/┴lava;Group 1107 Inguinal hernia 550;Women;67 Araba/┴lava;Group 1108 Other abdominal hernia 551-553;Both sexes;376 Araba/┴lava;Group 1108 Other abdominal hernia 551-553;Men;206 Araba/┴lava;Group 1108 Other abdominal hernia 551-553;Women;170 Araba/┴lava;Group 1109 Crohn's disease and ulcerative colitis 555-556;Both sexes;93 Araba/┴lava;Group 1109 Crohn's disease and ulcerative colitis 555-556;Men;48 Araba/┴lava;Group 1109 Crohn's disease and ulcerative colitis 555-556;Women;45 Araba/┴lava;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Both sexes;208 Araba/┴lava;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Men;105 Araba/┴lava;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Women;103 Araba/┴lava;Group 1111 Intestinal obstruction without hernia 560;Both sexes;255 Araba/┴lava;Group 1111 Intestinal obstruction without hernia 560;Men;140 Araba/┴lava;Group 1111 Intestinal obstruction without hernia 560;Women;115 Araba/┴lava;Group 1112 Intestinal diverticulosis 562;Both sexes;160 Araba/┴lava;Group 1112 Intestinal diverticulosis 562;Men;68 Araba/┴lava;Group 1112 Intestinal diverticulosis 562;Women;92 Araba/┴lava;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Both sexes;261 Araba/┴lava;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Men;172 Araba/┴lava;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Women;89 Araba/┴lava;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Both sexes;128 Araba/┴lava;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Men;61 Araba/┴lava;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Women;67 Araba/┴lava;Group 1115 Alcoholic hepatitis 5710-5713;Both sexes;67 Araba/┴lava;Group 1115 Alcoholic hepatitis 5710-5713;Men;52 Araba/┴lava;Group 1115 Alcoholic hepatitis 5710-5713;Women;15 Araba/┴lava;Group 1116 Other diseases of the liver 570,5714-573;Both sexes;142 Araba/┴lava;Group 1116 Other diseases of the liver 570,5714-573;Men;82 Araba/┴lava;Group 1116 Other diseases of the liver 570,5714-573;Women;60 Araba/┴lava;Group 1117 Cholelithiasis 574;Both sexes;683 Araba/┴lava;Group 1117 Cholelithiasis 574;Men;311 Araba/┴lava;Group 1117 Cholelithiasis 574;Women;372 Araba/┴lava;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Both sexes;211 Araba/┴lava;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Men;106 Araba/┴lava;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Women;105 Araba/┴lava;Group 1119 Pancreatic diseases 577;Both sexes;169 Araba/┴lava;Group 1119 Pancreatic diseases 577;Men;100 Araba/┴lava;Group 1119 Pancreatic diseases 577;Women;69 Araba/┴lava;Group 1120 Other diseases of the digestive system Rest of (520-579);Both sexes;226 Araba/┴lava;Group 1120 Other diseases of the digestive system Rest of (520-579);Men;123 Araba/┴lava;Group 1120 Other diseases of the digestive system Rest of (520-579);Women;103 Araba/┴lava;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Both sexes;360 Araba/┴lava;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Men;218 Araba/┴lava;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Women;142 Araba/┴lava;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Both sexes;268 Araba/┴lava;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Men;166 Araba/┴lava;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Women;102 Araba/┴lava;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Both sexes;18 Araba/┴lava;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Men;10 Araba/┴lava;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Women;8 Araba/┴lava;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Both sexes;74 Araba/┴lava;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Men;42 Araba/┴lava;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Women;32 Araba/┴lava;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Both sexes;3,597 Araba/┴lava;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Men;1,948 Araba/┴lava;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Women;1,649 Araba/┴lava;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Both sexes;.. Araba/┴lava;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Men;.. Araba/┴lava;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Women;.. Araba/┴lava;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Both sexes;.. Araba/┴lava;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Men;.. Araba/┴lava;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Women;.. Araba/┴lava;Group 1303 Internal derangement of knee 717;Both sexes;743 Araba/┴lava;Group 1303 Internal derangement of knee 717;Men;532 Araba/┴lava;Group 1303 Internal derangement of knee 717;Women;211 Araba/┴lava;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Both sexes;1,321 Araba/┴lava;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Men;660 Araba/┴lava;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Women;661 Araba/┴lava;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Both sexes;35 Araba/┴lava;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Men;11 Araba/┴lava;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Women;24 Araba/┴lava;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Both sexes;146 Araba/┴lava;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Men;79 Araba/┴lava;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Women;67 Araba/┴lava;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Both sexes;197 Araba/┴lava;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Men;111 Araba/┴lava;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Women;86 Araba/┴lava;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Both sexes;119 Araba/┴lava;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Men;69 Araba/┴lava;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Women;50 Araba/┴lava;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Both sexes;491 Araba/┴lava;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Men;313 Araba/┴lava;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Women;178 Araba/┴lava;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Both sexes;545 Araba/┴lava;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Men;173 Araba/┴lava;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Women;372 Araba/┴lava;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Both sexes;2,313 Araba/┴lava;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Men;1,271 Araba/┴lava;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Women;1,042 Araba/┴lava;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Both sexes;181 Araba/┴lava;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Men;69 Araba/┴lava;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Women;112 Araba/┴lava;Group 1402 Renal failure 5836-5837, 584-586;Both sexes;238 Araba/┴lava;Group 1402 Renal failure 5836-5837, 584-586;Men;151 Araba/┴lava;Group 1402 Renal failure 5836-5837, 584-586;Women;87 Araba/┴lava;Group 1403 Urolithiasis 592, 594, 7880;Both sexes;419 Araba/┴lava;Group 1403 Urolithiasis 592, 594, 7880;Men;279 Araba/┴lava;Group 1403 Urolithiasis 592, 594, 7880;Women;140 Araba/┴lava;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Both sexes;708 Araba/┴lava;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Men;358 Araba/┴lava;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Women;350 Araba/┴lava;Group 1405 Prostatic hyperplasia 600;Both sexes;234 Araba/┴lava;Group 1405 Prostatic hyperplasia 600;Men;234 Araba/┴lava;Group 1405 Prostatic hyperplasia 600;Women;.. Araba/┴lava;Group 1406 Other diseases of the male genital organs 601-608;Both sexes;172 Araba/┴lava;Group 1406 Other diseases of the male genital organs 601-608;Men;172 Araba/┴lava;Group 1406 Other diseases of the male genital organs 601-608;Women;.. Araba/┴lava;Group 1407 Disorders of breast 610-612;Both sexes;52 Araba/┴lava;Group 1407 Disorders of breast 610-612;Men;7 Araba/┴lava;Group 1407 Disorders of breast 610-612;Women;45 Araba/┴lava;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Both sexes;43 Araba/┴lava;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Men;.. Araba/┴lava;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Women;43 Araba/┴lava;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Both sexes;13 Araba/┴lava;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Men;.. Araba/┴lava;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Women;13 Araba/┴lava;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Both sexes;253 Araba/┴lava;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Men;1 Araba/┴lava;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Women;252 Araba/┴lava;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Both sexes;2,798 Araba/┴lava;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Men;.. Araba/┴lava;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Women;2,798 Araba/┴lava;Group 1501 Legally induced abortion 635;Both sexes;23 Araba/┴lava;Group 1501 Legally induced abortion 635;Men;.. Araba/┴lava;Group 1501 Legally induced abortion 635;Women;23 Araba/┴lava;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Both sexes;63 Araba/┴lava;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Men;.. Araba/┴lava;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Women;63 Araba/┴lava;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Both sexes;1,930 Araba/┴lava;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Men;.. Araba/┴lava;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Women;1,930 Araba/┴lava;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Both sexes;521 Araba/┴lava;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Men;.. Araba/┴lava;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Women;521 Araba/┴lava;Group 1505 Single spontaneous delivery 650;Both sexes;90 Araba/┴lava;Group 1505 Single spontaneous delivery 650;Men;.. Araba/┴lava;Group 1505 Single spontaneous delivery 650;Women;90 Araba/┴lava;Group 1506 Other deliveries 6695-6697;Both sexes;7 Araba/┴lava;Group 1506 Other deliveries 6695-6697;Men;.. Araba/┴lava;Group 1506 Other deliveries 6695-6697;Women;7 Araba/┴lava;Group 1507 Complications related to the puerperium 670-676;Both sexes;8 Araba/┴lava;Group 1507 Complications related to the puerperium 670-676;Men;.. Araba/┴lava;Group 1507 Complications related to the puerperium 670-676;Women;8 Araba/┴lava;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Both sexes;156 Araba/┴lava;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Men;.. Araba/┴lava;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Women;156 Araba/┴lava;Group 1600 Some disorders originating in the perinatal period 760-779;Both sexes;317 Araba/┴lava;Group 1600 Some disorders originating in the perinatal period 760-779;Men;180 Araba/┴lava;Group 1600 Some disorders originating in the perinatal period 760-779;Women;137 Araba/┴lava;Group 1601 Disorders related with premature delivery and a low birth weight 765;Both sexes;107 Araba/┴lava;Group 1601 Disorders related with premature delivery and a low birth weight 765;Men;61 Araba/┴lava;Group 1601 Disorders related with premature delivery and a low birth weight 765;Women;46 Araba/┴lava;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Both sexes;210 Araba/┴lava;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Men;119 Araba/┴lava;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Women;91 Araba/┴lava;Grupo 1700 Congenital abnormalities 740-759;Both sexes;138 Araba/┴lava;Grupo 1700 Congenital abnormalities 740-759;Men;57 Araba/┴lava;Grupo 1700 Congenital abnormalities 740-759;Women;81 Araba/┴lava;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Both sexes;2,404 Araba/┴lava;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Men;1,372 Araba/┴lava;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Women;1,032 Araba/┴lava;Group 1801 Pain in throat and chest 7841, 7865;Both sexes;316 Araba/┴lava;Group 1801 Pain in throat and chest 7841, 7865;Men;178 Araba/┴lava;Group 1801 Pain in throat and chest 7841, 7865;Women;138 Araba/┴lava;Group 1802 Abdominal pain 7890;Both sexes;291 Araba/┴lava;Group 1802 Abdominal pain 7890;Men;138 Araba/┴lava;Group 1802 Abdominal pain 7890;Women;153 Araba/┴lava;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Both sexes;3 Araba/┴lava;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Men;2 Araba/┴lava;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Women;1 Araba/┴lava;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Both sexes;1,794 Araba/┴lava;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Men;1,054 Araba/┴lava;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Women;740 Araba/┴lava;Group 1900 Injuries and poisoning 800-999;Both sexes;2,901 Araba/┴lava;Group 1900 Injuries and poisoning 800-999;Men;1,494 Araba/┴lava;Group 1900 Injuries and poisoning 800-999;Women;1,407 Araba/┴lava;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Both sexes;377 Araba/┴lava;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Men;196 Araba/┴lava;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Women;181 Araba/┴lava;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Both sexes;88 Araba/┴lava;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Men;53 Araba/┴lava;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Women;35 Araba/┴lava;Group 1903 Radius and ulna fracture 813;Both sexes;156 Araba/┴lava;Group 1903 Radius and ulna fracture 813;Men;63 Araba/┴lava;Group 1903 Radius and ulna fracture 813;Women;93 Araba/┴lava;Group 1904 Femur fracture 820-821;Both sexes;340 Araba/┴lava;Group 1904 Femur fracture 820-821;Men;98 Araba/┴lava;Group 1904 Femur fracture 820-821;Women;242 Araba/┴lava;Group 1905 Leg fracture, including the ankle 823-824;Both sexes;199 Araba/┴lava;Group 1905 Leg fracture, including the ankle 823-824;Men;102 Araba/┴lava;Group 1905 Leg fracture, including the ankle 823-824;Women;97 Araba/┴lava;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Both sexes;722 Araba/┴lava;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Men;421 Araba/┴lava;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Women;301 Araba/┴lava;Group 1907 Burns 940-949;Both sexes;4 Araba/┴lava;Group 1907 Burns 940-949;Men;3 Araba/┴lava;Group 1907 Burns 940-949;Women;1 Araba/┴lava;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Both sexes;140 Araba/┴lava;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Men;54 Araba/┴lava;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Women;86 Araba/┴lava;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Both sexes;794 Araba/┴lava;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Men;451 Araba/┴lava;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Women;343 Araba/┴lava;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Both sexes;2 Araba/┴lava;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Men;.. Araba/┴lava;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Women;2 Araba/┴lava;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Both sexes;79 Araba/┴lava;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Men;53 Araba/┴lava;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Women;26 Araba/┴lava;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Both sexes;647 Araba/┴lava;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Men;412 Araba/┴lava;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Women;235 Araba/┴lava;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Both sexes;19 Araba/┴lava;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Men;10 Araba/┴lava;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Women;9 Araba/┴lava;Group 2102 Contraceptive management V25;Both sexes;5 Araba/┴lava;Group 2102 Contraceptive management V25;Men;.. Araba/┴lava;Group 2102 Contraceptive management V25;Women;5 Araba/┴lava;Group 2103 Living newborns by type of delivery V30-V39;Both sexes;.. Araba/┴lava;Group 2103 Living newborns by type of delivery V30-V39;Men;.. Araba/┴lava;Group 2103 Living newborns by type of delivery V30-V39;Women;.. Araba/┴lava;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Both sexes;155 Araba/┴lava;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Men;114 Araba/┴lava;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Women;41 Araba/┴lava;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Both sexes;468 Araba/┴lava;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Men;288 Araba/┴lava;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Women;180 Bizkaia;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Both sexes;125,330 Bizkaia;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Men;61,782 Bizkaia;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Women;63,548 Bizkaia;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Both sexes;2,091 Bizkaia;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Men;1,165 Bizkaia;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Women;926 Bizkaia;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Both sexes;214 Bizkaia;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Men;107 Bizkaia;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Women;106 Bizkaia;Group 0102 Imprecise intestinal infections 009;Both sexes;157 Bizkaia;Group 0102 Imprecise intestinal infections 009;Men;75 Bizkaia;Group 0102 Imprecise intestinal infections 009;Women;81 Bizkaia;Group 0103 Tuberculosis 010-018, 137;Both sexes;126 Bizkaia;Group 0103 Tuberculosis 010-018, 137;Men;73 Bizkaia;Group 0103 Tuberculosis 010-018, 137;Women;52 Bizkaia;Group 0104 Septicaemia 038;Both sexes;856 Bizkaia;Group 0104 Septicaemia 038;Men;481 Bizkaia;Group 0104 Septicaemia 038;Women;375 Bizkaia;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Both sexes;135 Bizkaia;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Men;84 Bizkaia;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Women;50 Bizkaia;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Both sexes;605 Bizkaia;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Men;344 Bizkaia;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Women;261 Bizkaia;Group 0200 Neoplasms 140-239;Both sexes;13,128 Bizkaia;Group 0200 Neoplasms 140-239;Men;6,960 Bizkaia;Group 0200 Neoplasms 140-239;Women;6,168 Bizkaia;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Both sexes;1,535 Bizkaia;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Men;960 Bizkaia;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Women;575 Bizkaia;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Both sexes;934 Bizkaia;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Men;741 Bizkaia;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Women;193 Bizkaia;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Both sexes;230 Bizkaia;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Men;132 Bizkaia;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Women;98 Bizkaia;Group 0204 Malignant neoplasm of breast 174-175;Both sexes;1,007 Bizkaia;Group 0204 Malignant neoplasm of breast 174-175;Men;18 Bizkaia;Group 0204 Malignant neoplasm of breast 174-175;Women;989 Bizkaia;Group 0205 Malignant neoplasm of uterus 179-180, 182;Both sexes;190 Bizkaia;Group 0205 Malignant neoplasm of uterus 179-180, 182;Men;.. Bizkaia;Group 0205 Malignant neoplasm of uterus 179-180, 182;Women;190 Bizkaia;Group 0206 Malignant neoplasm of ovary 1830;Both sexes;129 Bizkaia;Group 0206 Malignant neoplasm of ovary 1830;Men;.. Bizkaia;Group 0206 Malignant neoplasm of ovary 1830;Women;129 Bizkaia;Group 0207 Malignant neoplasm of prostate 185;Both sexes;625 Bizkaia;Group 0207 Malignant neoplasm of prostate 185;Men;625 Bizkaia;Group 0207 Malignant neoplasm of prostate 185;Women;.. Bizkaia;Group 0208 Malignant neoplasm of bladder 188;Both sexes;1,234 Bizkaia;Group 0208 Malignant neoplasm of bladder 188;Men;986 Bizkaia;Group 0208 Malignant neoplasm of bladder 188;Women;248 Bizkaia;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Both sexes;4,796 Bizkaia;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Men;2,794 Bizkaia;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Women;2,002 Bizkaia;Group 0210 Carcinoma in situ 230-234;Both sexes;187 Bizkaia;Group 0210 Carcinoma in situ 230-234;Men;45 Bizkaia;Group 0210 Carcinoma in situ 230-234;Women;142 Bizkaia;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Both sexes;116 Bizkaia;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Men;67 Bizkaia;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Women;48 Bizkaia;Grupo 0212 Leiomyoma of uterus 218;Both sexes;642 Bizkaia;Grupo 0212 Leiomyoma of uterus 218;Men;.. Bizkaia;Grupo 0212 Leiomyoma of uterus 218;Women;642 Bizkaia;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Both sexes;1,505 Bizkaia;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Men;592 Bizkaia;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Women;913 Bizkaia;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Both sexes;1,319 Bizkaia;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Men;668 Bizkaia;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Women;651 Bizkaia;Group 0301 Anaemias 280-285;Both sexes;840 Bizkaia;Group 0301 Anaemias 280-285;Men;412 Bizkaia;Group 0301 Anaemias 280-285;Women;428 Bizkaia;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Both sexes;479 Bizkaia;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Men;256 Bizkaia;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Women;223 Bizkaia;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Both sexes;1,940 Bizkaia;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Men;779 Bizkaia;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Women;1,160 Bizkaia;Group 0401 Diabetes mellitus 249-250;Both sexes;590 Bizkaia;Group 0401 Diabetes mellitus 249-250;Men;327 Bizkaia;Group 0401 Diabetes mellitus 249-250;Women;262 Bizkaia;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Both sexes;1,350 Bizkaia;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Men;452 Bizkaia;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Women;898 Bizkaia;Group 0500 Mental disorders 290-319;Both sexes;4,541 Bizkaia;Group 0500 Mental disorders 290-319;Men;2,340 Bizkaia;Group 0500 Mental disorders 290-319;Women;2,201 Bizkaia;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Both sexes;37 Bizkaia;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Men;23 Bizkaia;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Women;14 Bizkaia;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Both sexes;422 Bizkaia;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Men;286 Bizkaia;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Women;136 Bizkaia;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Both sexes;315 Bizkaia;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Men;238 Bizkaia;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Women;77 Bizkaia;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Both sexes;1,447 Bizkaia;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Men;913 Bizkaia;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Women;533 Bizkaia;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Both sexes;1,232 Bizkaia;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Men;423 Bizkaia;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Women;809 Bizkaia;Group 0506 Other mental and behavioural disorders Rest of (290-319);Both sexes;1,087 Bizkaia;Group 0506 Other mental and behavioural disorders Rest of (290-319);Men;456 Bizkaia;Group 0506 Other mental and behavioural disorders Rest of (290-319);Women;631 Bizkaia;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Both sexes;3,131 Bizkaia;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Men;1,609 Bizkaia;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Women;1,522 Bizkaia;Group 0601 Alzheimer's disease 3310;Both sexes;40 Bizkaia;Group 0601 Alzheimer's disease 3310;Men;9 Bizkaia;Group 0601 Alzheimer's disease 3310;Women;31 Bizkaia;Group 0602 Multiple sclerosis 340;Both sexes;38 Bizkaia;Group 0602 Multiple sclerosis 340;Men;16 Bizkaia;Group 0602 Multiple sclerosis 340;Women;22 Bizkaia;Group 0603 Epilepsy 345;Both sexes;440 Bizkaia;Group 0603 Epilepsy 345;Men;204 Bizkaia;Group 0603 Epilepsy 345;Women;236 Bizkaia;Group 0604 Transient cerebral ischemia 435;Both sexes;383 Bizkaia;Group 0604 Transient cerebral ischemia 435;Men;199 Bizkaia;Group 0604 Transient cerebral ischemia 435;Women;184 Bizkaia;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Both sexes;2,230 Bizkaia;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Men;1,181 Bizkaia;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Women;1,049 Bizkaia;Grupo 0700 Diseases of the eye and adnexa 360-379;Both sexes;402 Bizkaia;Grupo 0700 Diseases of the eye and adnexa 360-379;Men;158 Bizkaia;Grupo 0700 Diseases of the eye and adnexa 360-379;Women;244 Bizkaia;Grupo 0701 Cataract 366;Both sexes;36 Bizkaia;Grupo 0701 Cataract 366;Men;14 Bizkaia;Grupo 0701 Cataract 366;Women;22 Bizkaia;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Both sexes;366 Bizkaia;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Men;144 Bizkaia;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Women;222 Bizkaia;Group 0800 Diseases of the ear and the mastoid 380-389;Both sexes;534 Bizkaia;Group 0800 Diseases of the ear and the mastoid 380-389;Men;297 Bizkaia;Group 0800 Diseases of the ear and the mastoid 380-389;Women;237 Bizkaia;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Both sexes;16,830 Bizkaia;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Men;9,693 Bizkaia;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Women;7,137 Bizkaia;Group 0901 Hypertensive disease 401-405;Both sexes;1,025 Bizkaia;Group 0901 Hypertensive disease 401-405;Men;432 Bizkaia;Group 0901 Hypertensive disease 401-405;Women;593 Bizkaia;Group 0902 Angina pectoris 4111, 413;Both sexes;298 Bizkaia;Group 0902 Angina pectoris 4111, 413;Men;170 Bizkaia;Group 0902 Angina pectoris 4111, 413;Women;129 Bizkaia;Group 0903 Acute myocardial infarction 410;Both sexes;1,051 Bizkaia;Group 0903 Acute myocardial infarction 410;Men;730 Bizkaia;Group 0903 Acute myocardial infarction 410;Women;320 Bizkaia;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Both sexes;1,309 Bizkaia;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Men;1,046 Bizkaia;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Women;263 Bizkaia;Group 0905 Diseases of the lungs circulation 415-417;Both sexes;588 Bizkaia;Group 0905 Diseases of the lungs circulation 415-417;Men;244 Bizkaia;Group 0905 Diseases of the lungs circulation 415-417;Women;344 Bizkaia;Group 0906 Heart conduction disorders and arrhytmias 426-427;Both sexes;2,552 Bizkaia;Group 0906 Heart conduction disorders and arrhytmias 426-427;Men;1,451 Bizkaia;Group 0906 Heart conduction disorders and arrhytmias 426-427;Women;1,101 Bizkaia;Grupo 0907 Heart failure 428;Both sexes;3,301 Bizkaia;Grupo 0907 Heart failure 428;Men;1,745 Bizkaia;Grupo 0907 Heart failure 428;Women;1,557 Bizkaia;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Both sexes;2,677 Bizkaia;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Men;1,430 Bizkaia;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Women;1,247 Bizkaia;Grupo 0909 Atherosclerosis 440;Both sexes;839 Bizkaia;Grupo 0909 Atherosclerosis 440;Men;674 Bizkaia;Grupo 0909 Atherosclerosis 440;Women;165 Bizkaia;Group 0910 Varicose veins of lower extremities 454;Both sexes;429 Bizkaia;Group 0910 Varicose veins of lower extremities 454;Men;156 Bizkaia;Group 0910 Varicose veins of lower extremities 454;Women;273 Bizkaia;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Both sexes;2,761 Bizkaia;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Men;1,615 Bizkaia;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Women;1,146 Bizkaia;Group 1000 Diseases of the respiratory system 0340, 460-519;Both sexes;13,154 Bizkaia;Group 1000 Diseases of the respiratory system 0340, 460-519;Men;7,590 Bizkaia;Group 1000 Diseases of the respiratory system 0340, 460-519;Women;5,563 Bizkaia;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Both sexes;390 Bizkaia;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Men;191 Bizkaia;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Women;199 Bizkaia;Group 1002 Pneumonia 480-486;Both sexes;2,434 Bizkaia;Group 1002 Pneumonia 480-486;Men;1,482 Bizkaia;Group 1002 Pneumonia 480-486;Women;951 Bizkaia;Group 1003 Acute bronchitis and bronchiolitis 466;Both sexes;1,875 Bizkaia;Group 1003 Acute bronchitis and bronchiolitis 466;Men;814 Bizkaia;Group 1003 Acute bronchitis and bronchiolitis 466;Women;1,062 Bizkaia;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Both sexes;646 Bizkaia;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Men;354 Bizkaia;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Women;292 Bizkaia;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Both sexes;1,053 Bizkaia;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Men;677 Bizkaia;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Women;376 Bizkaia;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Both sexes;2,601 Bizkaia;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Men;1,956 Bizkaia;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Women;646 Bizkaia;Group 1007 Asthma 4930-4931,4938-4939;Both sexes;962 Bizkaia;Group 1007 Asthma 4930-4931,4938-4939;Men;312 Bizkaia;Group 1007 Asthma 4930-4931,4938-4939;Women;650 Bizkaia;Group 1008 Other diseases of the respiratory system Resto of (460-519);Both sexes;3,193 Bizkaia;Group 1008 Other diseases of the respiratory system Resto of (460-519);Men;1,805 Bizkaia;Group 1008 Other diseases of the respiratory system Resto of (460-519);Women;1,388 Bizkaia;Group 1100 Diseases of the digestive system 520-579;Both sexes;16,056 Bizkaia;Group 1100 Diseases of the digestive system 520-579;Men;9,232 Bizkaia;Group 1100 Diseases of the digestive system 520-579;Women;6,824 Bizkaia;Group 1101 Disorders of the teeth and supporting structures 520-525;Both sexes;202 Bizkaia;Group 1101 Disorders of the teeth and supporting structures 520-525;Men;100 Bizkaia;Group 1101 Disorders of the teeth and supporting structures 520-525;Women;101 Bizkaia;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Both sexes;176 Bizkaia;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Men;99 Bizkaia;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Women;76 Bizkaia;Group 1103 Diseases of the esophagus 530;Both sexes;289 Bizkaia;Group 1103 Diseases of the esophagus 530;Men;165 Bizkaia;Group 1103 Diseases of the esophagus 530;Women;125 Bizkaia;Group 1104 Peptic ulcer 531-534;Both sexes;308 Bizkaia;Group 1104 Peptic ulcer 531-534;Men;224 Bizkaia;Group 1104 Peptic ulcer 531-534;Women;84 Bizkaia;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Both sexes;305 Bizkaia;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Men;171 Bizkaia;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Women;135 Bizkaia;Group 1106 Appendicitis 540-543;Both sexes;1,356 Bizkaia;Group 1106 Appendicitis 540-543;Men;777 Bizkaia;Group 1106 Appendicitis 540-543;Women;579 Bizkaia;Group 1107 Inguinal hernia 550;Both sexes;2,156 Bizkaia;Group 1107 Inguinal hernia 550;Men;1,930 Bizkaia;Group 1107 Inguinal hernia 550;Women;226 Bizkaia;Group 1108 Other abdominal hernia 551-553;Both sexes;1,486 Bizkaia;Group 1108 Other abdominal hernia 551-553;Men;727 Bizkaia;Group 1108 Other abdominal hernia 551-553;Women;758 Bizkaia;Group 1109 Crohn's disease and ulcerative colitis 555-556;Both sexes;305 Bizkaia;Group 1109 Crohn's disease and ulcerative colitis 555-556;Men;164 Bizkaia;Group 1109 Crohn's disease and ulcerative colitis 555-556;Women;142 Bizkaia;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Both sexes;513 Bizkaia;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Men;237 Bizkaia;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Women;276 Bizkaia;Group 1111 Intestinal obstruction without hernia 560;Both sexes;786 Bizkaia;Group 1111 Intestinal obstruction without hernia 560;Men;432 Bizkaia;Group 1111 Intestinal obstruction without hernia 560;Women;355 Bizkaia;Group 1112 Intestinal diverticulosis 562;Both sexes;806 Bizkaia;Group 1112 Intestinal diverticulosis 562;Men;364 Bizkaia;Group 1112 Intestinal diverticulosis 562;Women;442 Bizkaia;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Both sexes;1,102 Bizkaia;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Men;713 Bizkaia;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Women;389 Bizkaia;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Both sexes;586 Bizkaia;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Men;248 Bizkaia;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Women;337 Bizkaia;Group 1115 Alcoholic hepatitis 5710-5713;Both sexes;284 Bizkaia;Group 1115 Alcoholic hepatitis 5710-5713;Men;237 Bizkaia;Group 1115 Alcoholic hepatitis 5710-5713;Women;47 Bizkaia;Group 1116 Other diseases of the liver 570,5714-573;Both sexes;645 Bizkaia;Group 1116 Other diseases of the liver 570,5714-573;Men;440 Bizkaia;Group 1116 Other diseases of the liver 570,5714-573;Women;205 Bizkaia;Group 1117 Cholelithiasis 574;Both sexes;2,725 Bizkaia;Group 1117 Cholelithiasis 574;Men;1,145 Bizkaia;Group 1117 Cholelithiasis 574;Women;1,580 Bizkaia;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Both sexes;726 Bizkaia;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Men;361 Bizkaia;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Women;366 Bizkaia;Group 1119 Pancreatic diseases 577;Both sexes;699 Bizkaia;Group 1119 Pancreatic diseases 577;Men;365 Bizkaia;Group 1119 Pancreatic diseases 577;Women;334 Bizkaia;Group 1120 Other diseases of the digestive system Rest of (520-579);Both sexes;600 Bizkaia;Group 1120 Other diseases of the digestive system Rest of (520-579);Men;332 Bizkaia;Group 1120 Other diseases of the digestive system Rest of (520-579);Women;267 Bizkaia;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Both sexes;1,272 Bizkaia;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Men;778 Bizkaia;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Women;493 Bizkaia;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Both sexes;869 Bizkaia;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Men;566 Bizkaia;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Women;302 Bizkaia;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Both sexes;63 Bizkaia;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Men;34 Bizkaia;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Women;29 Bizkaia;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Both sexes;339 Bizkaia;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Men;178 Bizkaia;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Women;162 Bizkaia;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Both sexes;9,360 Bizkaia;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Men;4,604 Bizkaia;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Women;4,756 Bizkaia;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Both sexes;.. Bizkaia;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Men;.. Bizkaia;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Women;.. Bizkaia;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Both sexes;.. Bizkaia;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Men;.. Bizkaia;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Women;.. Bizkaia;Group 1303 Internal derangement of knee 717;Both sexes;1,325 Bizkaia;Group 1303 Internal derangement of knee 717;Men;884 Bizkaia;Group 1303 Internal derangement of knee 717;Women;441 Bizkaia;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Both sexes;3,620 Bizkaia;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Men;1,599 Bizkaia;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Women;2,021 Bizkaia;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Both sexes;153 Bizkaia;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Men;53 Bizkaia;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Women;99 Bizkaia;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Both sexes;375 Bizkaia;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Men;203 Bizkaia;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Women;172 Bizkaia;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Both sexes;629 Bizkaia;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Men;331 Bizkaia;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Women;297 Bizkaia;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Both sexes;253 Bizkaia;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Men;138 Bizkaia;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Women;114 Bizkaia;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Both sexes;1,470 Bizkaia;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Men;905 Bizkaia;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Women;565 Bizkaia;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Both sexes;1,537 Bizkaia;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Men;490 Bizkaia;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Women;1,047 Bizkaia;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Both sexes;8,205 Bizkaia;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Men;3,860 Bizkaia;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Women;4,345 Bizkaia;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Both sexes;821 Bizkaia;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Men;300 Bizkaia;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Women;520 Bizkaia;Group 1402 Renal failure 5836-5837, 584-586;Both sexes;810 Bizkaia;Group 1402 Renal failure 5836-5837, 584-586;Men;485 Bizkaia;Group 1402 Renal failure 5836-5837, 584-586;Women;324 Bizkaia;Group 1403 Urolithiasis 592, 594, 7880;Both sexes;923 Bizkaia;Group 1403 Urolithiasis 592, 594, 7880;Men;557 Bizkaia;Group 1403 Urolithiasis 592, 594, 7880;Women;366 Bizkaia;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Both sexes;2,198 Bizkaia;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Men;1,111 Bizkaia;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Women;1,087 Bizkaia;Group 1405 Prostatic hyperplasia 600;Both sexes;764 Bizkaia;Group 1405 Prostatic hyperplasia 600;Men;764 Bizkaia;Group 1405 Prostatic hyperplasia 600;Women;.. Bizkaia;Group 1406 Other diseases of the male genital organs 601-608;Both sexes;563 Bizkaia;Group 1406 Other diseases of the male genital organs 601-608;Men;563 Bizkaia;Group 1406 Other diseases of the male genital organs 601-608;Women;.. Bizkaia;Group 1407 Disorders of breast 610-612;Both sexes;608 Bizkaia;Group 1407 Disorders of breast 610-612;Men;49 Bizkaia;Group 1407 Disorders of breast 610-612;Women;558 Bizkaia;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Both sexes;220 Bizkaia;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Men;.. Bizkaia;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Women;220 Bizkaia;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Both sexes;44 Bizkaia;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Men;.. Bizkaia;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Women;44 Bizkaia;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Both sexes;1,255 Bizkaia;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Men;29 Bizkaia;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Women;1,225 Bizkaia;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Both sexes;10,881 Bizkaia;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Men;.. Bizkaia;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Women;10,881 Bizkaia;Group 1501 Legally induced abortion 635;Both sexes;85 Bizkaia;Group 1501 Legally induced abortion 635;Men;.. Bizkaia;Group 1501 Legally induced abortion 635;Women;85 Bizkaia;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Both sexes;296 Bizkaia;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Men;.. Bizkaia;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Women;296 Bizkaia;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Both sexes;6,199 Bizkaia;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Men;.. Bizkaia;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Women;6,199 Bizkaia;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Both sexes;1,943 Bizkaia;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Men;.. Bizkaia;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Women;1,943 Bizkaia;Group 1505 Single spontaneous delivery 650;Both sexes;1,065 Bizkaia;Group 1505 Single spontaneous delivery 650;Men;.. Bizkaia;Group 1505 Single spontaneous delivery 650;Women;1,065 Bizkaia;Group 1506 Other deliveries 6695-6697;Both sexes;229 Bizkaia;Group 1506 Other deliveries 6695-6697;Men;.. Bizkaia;Group 1506 Other deliveries 6695-6697;Women;229 Bizkaia;Group 1507 Complications related to the puerperium 670-676;Both sexes;135 Bizkaia;Group 1507 Complications related to the puerperium 670-676;Men;.. Bizkaia;Group 1507 Complications related to the puerperium 670-676;Women;135 Bizkaia;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Both sexes;929 Bizkaia;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Men;.. Bizkaia;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Women;929 Bizkaia;Group 1600 Some disorders originating in the perinatal period 760-779;Both sexes;1,164 Bizkaia;Group 1600 Some disorders originating in the perinatal period 760-779;Men;639 Bizkaia;Group 1600 Some disorders originating in the perinatal period 760-779;Women;525 Bizkaia;Group 1601 Disorders related with premature delivery and a low birth weight 765;Both sexes;354 Bizkaia;Group 1601 Disorders related with premature delivery and a low birth weight 765;Men;183 Bizkaia;Group 1601 Disorders related with premature delivery and a low birth weight 765;Women;171 Bizkaia;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Both sexes;811 Bizkaia;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Men;456 Bizkaia;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Women;355 Bizkaia;Grupo 1700 Congenital abnormalities 740-759;Both sexes;963 Bizkaia;Grupo 1700 Congenital abnormalities 740-759;Men;535 Bizkaia;Grupo 1700 Congenital abnormalities 740-759;Women;428 Bizkaia;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Both sexes;6,230 Bizkaia;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Men;3,389 Bizkaia;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Women;2,841 Bizkaia;Group 1801 Pain in throat and chest 7841, 7865;Both sexes;1,169 Bizkaia;Group 1801 Pain in throat and chest 7841, 7865;Men;639 Bizkaia;Group 1801 Pain in throat and chest 7841, 7865;Women;530 Bizkaia;Group 1802 Abdominal pain 7890;Both sexes;650 Bizkaia;Group 1802 Abdominal pain 7890;Men;294 Bizkaia;Group 1802 Abdominal pain 7890;Women;356 Bizkaia;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Both sexes;113 Bizkaia;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Men;53 Bizkaia;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Women;60 Bizkaia;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Both sexes;4,298 Bizkaia;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Men;2,403 Bizkaia;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Women;1,895 Bizkaia;Group 1900 Injuries and poisoning 800-999;Both sexes;11,252 Bizkaia;Group 1900 Injuries and poisoning 800-999;Men;6,068 Bizkaia;Group 1900 Injuries and poisoning 800-999;Women;5,184 Bizkaia;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Both sexes;392 Bizkaia;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Men;229 Bizkaia;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Women;163 Bizkaia;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Both sexes;212 Bizkaia;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Men;162 Bizkaia;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Women;50 Bizkaia;Group 1903 Radius and ulna fracture 813;Both sexes;741 Bizkaia;Group 1903 Radius and ulna fracture 813;Men;308 Bizkaia;Group 1903 Radius and ulna fracture 813;Women;433 Bizkaia;Group 1904 Femur fracture 820-821;Both sexes;1,643 Bizkaia;Group 1904 Femur fracture 820-821;Men;471 Bizkaia;Group 1904 Femur fracture 820-821;Women;1,172 Bizkaia;Group 1905 Leg fracture, including the ankle 823-824;Both sexes;799 Bizkaia;Group 1905 Leg fracture, including the ankle 823-824;Men;399 Bizkaia;Group 1905 Leg fracture, including the ankle 823-824;Women;400 Bizkaia;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Both sexes;3,716 Bizkaia;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Men;2,358 Bizkaia;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Women;1,357 Bizkaia;Group 1907 Burns 940-949;Both sexes;85 Bizkaia;Group 1907 Burns 940-949;Men;65 Bizkaia;Group 1907 Burns 940-949;Women;20 Bizkaia;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Both sexes;211 Bizkaia;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Men;95 Bizkaia;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Women;116 Bizkaia;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Both sexes;3,098 Bizkaia;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Men;1,796 Bizkaia;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Women;1,302 Bizkaia;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Both sexes;40 Bizkaia;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Men;24 Bizkaia;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Women;16 Bizkaia;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Both sexes;316 Bizkaia;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Men;160 Bizkaia;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Women;157 Bizkaia;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Both sexes;2,878 Bizkaia;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Men;1,419 Bizkaia;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Women;1,459 Bizkaia;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Both sexes;223 Bizkaia;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Men;148 Bizkaia;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Women;75 Bizkaia;Group 2102 Contraceptive management V25;Both sexes;54 Bizkaia;Group 2102 Contraceptive management V25;Men;1 Bizkaia;Group 2102 Contraceptive management V25;Women;53 Bizkaia;Group 2103 Living newborns by type of delivery V30-V39;Both sexes;.. Bizkaia;Group 2103 Living newborns by type of delivery V30-V39;Men;.. Bizkaia;Group 2103 Living newborns by type of delivery V30-V39;Women;.. Bizkaia;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Both sexes;772 Bizkaia;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Men;478 Bizkaia;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Women;294 Bizkaia;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Both sexes;1,828 Bizkaia;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Men;793 Bizkaia;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Women;1,036 Gipuzkoa;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Both sexes;80,658 Gipuzkoa;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Men;40,079 Gipuzkoa;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Women;40,579 Gipuzkoa;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Both sexes;1,587 Gipuzkoa;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Men;884 Gipuzkoa;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Women;703 Gipuzkoa;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Both sexes;279 Gipuzkoa;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Men;137 Gipuzkoa;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Women;142 Gipuzkoa;Group 0102 Imprecise intestinal infections 009;Both sexes;93 Gipuzkoa;Group 0102 Imprecise intestinal infections 009;Men;47 Gipuzkoa;Group 0102 Imprecise intestinal infections 009;Women;46 Gipuzkoa;Group 0103 Tuberculosis 010-018, 137;Both sexes;74 Gipuzkoa;Group 0103 Tuberculosis 010-018, 137;Men;47 Gipuzkoa;Group 0103 Tuberculosis 010-018, 137;Women;27 Gipuzkoa;Group 0104 Septicaemia 038;Both sexes;597 Gipuzkoa;Group 0104 Septicaemia 038;Men;336 Gipuzkoa;Group 0104 Septicaemia 038;Women;261 Gipuzkoa;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Both sexes;81 Gipuzkoa;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Men;43 Gipuzkoa;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Women;38 Gipuzkoa;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Both sexes;463 Gipuzkoa;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Men;274 Gipuzkoa;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Women;189 Gipuzkoa;Group 0200 Neoplasms 140-239;Both sexes;7,748 Gipuzkoa;Group 0200 Neoplasms 140-239;Men;4,238 Gipuzkoa;Group 0200 Neoplasms 140-239;Women;3,510 Gipuzkoa;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Both sexes;856 Gipuzkoa;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Men;537 Gipuzkoa;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Women;319 Gipuzkoa;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Both sexes;548 Gipuzkoa;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Men;393 Gipuzkoa;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Women;155 Gipuzkoa;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Both sexes;160 Gipuzkoa;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Men;75 Gipuzkoa;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Women;85 Gipuzkoa;Group 0204 Malignant neoplasm of breast 174-175;Both sexes;527 Gipuzkoa;Group 0204 Malignant neoplasm of breast 174-175;Men;7 Gipuzkoa;Group 0204 Malignant neoplasm of breast 174-175;Women;520 Gipuzkoa;Group 0205 Malignant neoplasm of uterus 179-180, 182;Both sexes;204 Gipuzkoa;Group 0205 Malignant neoplasm of uterus 179-180, 182;Men;.. Gipuzkoa;Group 0205 Malignant neoplasm of uterus 179-180, 182;Women;204 Gipuzkoa;Group 0206 Malignant neoplasm of ovary 1830;Both sexes;77 Gipuzkoa;Group 0206 Malignant neoplasm of ovary 1830;Men;.. Gipuzkoa;Group 0206 Malignant neoplasm of ovary 1830;Women;77 Gipuzkoa;Group 0207 Malignant neoplasm of prostate 185;Both sexes;527 Gipuzkoa;Group 0207 Malignant neoplasm of prostate 185;Men;527 Gipuzkoa;Group 0207 Malignant neoplasm of prostate 185;Women;.. Gipuzkoa;Group 0208 Malignant neoplasm of bladder 188;Both sexes;642 Gipuzkoa;Group 0208 Malignant neoplasm of bladder 188;Men;527 Gipuzkoa;Group 0208 Malignant neoplasm of bladder 188;Women;115 Gipuzkoa;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Both sexes;2,653 Gipuzkoa;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Men;1,616 Gipuzkoa;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Women;1,037 Gipuzkoa;Group 0210 Carcinoma in situ 230-234;Both sexes;123 Gipuzkoa;Group 0210 Carcinoma in situ 230-234;Men;30 Gipuzkoa;Group 0210 Carcinoma in situ 230-234;Women;93 Gipuzkoa;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Both sexes;183 Gipuzkoa;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Men;115 Gipuzkoa;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Women;68 Gipuzkoa;Grupo 0212 Leiomyoma of uterus 218;Both sexes;303 Gipuzkoa;Grupo 0212 Leiomyoma of uterus 218;Men;.. Gipuzkoa;Grupo 0212 Leiomyoma of uterus 218;Women;303 Gipuzkoa;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Both sexes;945 Gipuzkoa;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Men;411 Gipuzkoa;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Women;534 Gipuzkoa;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Both sexes;872 Gipuzkoa;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Men;423 Gipuzkoa;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Women;449 Gipuzkoa;Group 0301 Anaemias 280-285;Both sexes;637 Gipuzkoa;Group 0301 Anaemias 280-285;Men;293 Gipuzkoa;Group 0301 Anaemias 280-285;Women;344 Gipuzkoa;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Both sexes;235 Gipuzkoa;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Men;130 Gipuzkoa;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Women;105 Gipuzkoa;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Both sexes;1,432 Gipuzkoa;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Men;616 Gipuzkoa;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Women;816 Gipuzkoa;Group 0401 Diabetes mellitus 249-250;Both sexes;561 Gipuzkoa;Group 0401 Diabetes mellitus 249-250;Men;346 Gipuzkoa;Group 0401 Diabetes mellitus 249-250;Women;215 Gipuzkoa;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Both sexes;871 Gipuzkoa;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Men;270 Gipuzkoa;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Women;601 Gipuzkoa;Group 0500 Mental disorders 290-319;Both sexes;1,954 Gipuzkoa;Group 0500 Mental disorders 290-319;Men;1,100 Gipuzkoa;Group 0500 Mental disorders 290-319;Women;854 Gipuzkoa;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Both sexes;41 Gipuzkoa;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Men;21 Gipuzkoa;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Women;20 Gipuzkoa;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Both sexes;211 Gipuzkoa;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Men;151 Gipuzkoa;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Women;60 Gipuzkoa;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Both sexes;110 Gipuzkoa;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Men;78 Gipuzkoa;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Women;32 Gipuzkoa;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Both sexes;621 Gipuzkoa;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Men;387 Gipuzkoa;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Women;234 Gipuzkoa;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Both sexes;373 Gipuzkoa;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Men;153 Gipuzkoa;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Women;220 Gipuzkoa;Group 0506 Other mental and behavioural disorders Rest of (290-319);Both sexes;598 Gipuzkoa;Group 0506 Other mental and behavioural disorders Rest of (290-319);Men;310 Gipuzkoa;Group 0506 Other mental and behavioural disorders Rest of (290-319);Women;288 Gipuzkoa;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Both sexes;1,636 Gipuzkoa;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Men;879 Gipuzkoa;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Women;757 Gipuzkoa;Group 0601 Alzheimer's disease 3310;Both sexes;56 Gipuzkoa;Group 0601 Alzheimer's disease 3310;Men;24 Gipuzkoa;Group 0601 Alzheimer's disease 3310;Women;32 Gipuzkoa;Group 0602 Multiple sclerosis 340;Both sexes;26 Gipuzkoa;Group 0602 Multiple sclerosis 340;Men;6 Gipuzkoa;Group 0602 Multiple sclerosis 340;Women;20 Gipuzkoa;Group 0603 Epilepsy 345;Both sexes;277 Gipuzkoa;Group 0603 Epilepsy 345;Men;161 Gipuzkoa;Group 0603 Epilepsy 345;Women;116 Gipuzkoa;Group 0604 Transient cerebral ischemia 435;Both sexes;246 Gipuzkoa;Group 0604 Transient cerebral ischemia 435;Men;118 Gipuzkoa;Group 0604 Transient cerebral ischemia 435;Women;128 Gipuzkoa;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Both sexes;1,031 Gipuzkoa;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Men;570 Gipuzkoa;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Women;461 Gipuzkoa;Grupo 0700 Diseases of the eye and adnexa 360-379;Both sexes;210 Gipuzkoa;Grupo 0700 Diseases of the eye and adnexa 360-379;Men;98 Gipuzkoa;Grupo 0700 Diseases of the eye and adnexa 360-379;Women;112 Gipuzkoa;Grupo 0701 Cataract 366;Both sexes;10 Gipuzkoa;Grupo 0701 Cataract 366;Men;8 Gipuzkoa;Grupo 0701 Cataract 366;Women;2 Gipuzkoa;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Both sexes;200 Gipuzkoa;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Men;90 Gipuzkoa;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Women;110 Gipuzkoa;Group 0800 Diseases of the ear and the mastoid 380-389;Both sexes;564 Gipuzkoa;Group 0800 Diseases of the ear and the mastoid 380-389;Men;286 Gipuzkoa;Group 0800 Diseases of the ear and the mastoid 380-389;Women;278 Gipuzkoa;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Both sexes;10,802 Gipuzkoa;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Men;6,144 Gipuzkoa;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Women;4,658 Gipuzkoa;Group 0901 Hypertensive disease 401-405;Both sexes;463 Gipuzkoa;Group 0901 Hypertensive disease 401-405;Men;218 Gipuzkoa;Group 0901 Hypertensive disease 401-405;Women;245 Gipuzkoa;Group 0902 Angina pectoris 4111, 413;Both sexes;327 Gipuzkoa;Group 0902 Angina pectoris 4111, 413;Men;231 Gipuzkoa;Group 0902 Angina pectoris 4111, 413;Women;96 Gipuzkoa;Group 0903 Acute myocardial infarction 410;Both sexes;671 Gipuzkoa;Group 0903 Acute myocardial infarction 410;Men;485 Gipuzkoa;Group 0903 Acute myocardial infarction 410;Women;186 Gipuzkoa;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Both sexes;726 Gipuzkoa;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Men;554 Gipuzkoa;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Women;172 Gipuzkoa;Group 0905 Diseases of the lungs circulation 415-417;Both sexes;305 Gipuzkoa;Group 0905 Diseases of the lungs circulation 415-417;Men;128 Gipuzkoa;Group 0905 Diseases of the lungs circulation 415-417;Women;177 Gipuzkoa;Group 0906 Heart conduction disorders and arrhytmias 426-427;Both sexes;1,497 Gipuzkoa;Group 0906 Heart conduction disorders and arrhytmias 426-427;Men;777 Gipuzkoa;Group 0906 Heart conduction disorders and arrhytmias 426-427;Women;720 Gipuzkoa;Grupo 0907 Heart failure 428;Both sexes;1,988 Gipuzkoa;Grupo 0907 Heart failure 428;Men;1,054 Gipuzkoa;Grupo 0907 Heart failure 428;Women;934 Gipuzkoa;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Both sexes;1,985 Gipuzkoa;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Men;1,060 Gipuzkoa;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Women;925 Gipuzkoa;Grupo 0909 Atherosclerosis 440;Both sexes;518 Gipuzkoa;Grupo 0909 Atherosclerosis 440;Men;403 Gipuzkoa;Grupo 0909 Atherosclerosis 440;Women;115 Gipuzkoa;Group 0910 Varicose veins of lower extremities 454;Both sexes;691 Gipuzkoa;Group 0910 Varicose veins of lower extremities 454;Men;246 Gipuzkoa;Group 0910 Varicose veins of lower extremities 454;Women;445 Gipuzkoa;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Both sexes;1,631 Gipuzkoa;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Men;988 Gipuzkoa;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Women;643 Gipuzkoa;Group 1000 Diseases of the respiratory system 0340, 460-519;Both sexes;9,515 Gipuzkoa;Group 1000 Diseases of the respiratory system 0340, 460-519;Men;5,603 Gipuzkoa;Group 1000 Diseases of the respiratory system 0340, 460-519;Women;3,912 Gipuzkoa;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Both sexes;302 Gipuzkoa;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Men;164 Gipuzkoa;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Women;138 Gipuzkoa;Group 1002 Pneumonia 480-486;Both sexes;2,146 Gipuzkoa;Group 1002 Pneumonia 480-486;Men;1,288 Gipuzkoa;Group 1002 Pneumonia 480-486;Women;858 Gipuzkoa;Group 1003 Acute bronchitis and bronchiolitis 466;Both sexes;389 Gipuzkoa;Group 1003 Acute bronchitis and bronchiolitis 466;Men;203 Gipuzkoa;Group 1003 Acute bronchitis and bronchiolitis 466;Women;186 Gipuzkoa;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Both sexes;572 Gipuzkoa;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Men;324 Gipuzkoa;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Women;248 Gipuzkoa;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Both sexes;816 Gipuzkoa;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Men;538 Gipuzkoa;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Women;278 Gipuzkoa;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Both sexes;1,638 Gipuzkoa;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Men;1,220 Gipuzkoa;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Women;418 Gipuzkoa;Group 1007 Asthma 4930-4931,4938-4939;Both sexes;474 Gipuzkoa;Group 1007 Asthma 4930-4931,4938-4939;Men;213 Gipuzkoa;Group 1007 Asthma 4930-4931,4938-4939;Women;261 Gipuzkoa;Group 1008 Other diseases of the respiratory system Resto of (460-519);Both sexes;3,178 Gipuzkoa;Group 1008 Other diseases of the respiratory system Resto of (460-519);Men;1,653 Gipuzkoa;Group 1008 Other diseases of the respiratory system Resto of (460-519);Women;1,525 Gipuzkoa;Group 1100 Diseases of the digestive system 520-579;Both sexes;9,547 Gipuzkoa;Group 1100 Diseases of the digestive system 520-579;Men;5,557 Gipuzkoa;Group 1100 Diseases of the digestive system 520-579;Women;3,990 Gipuzkoa;Group 1101 Disorders of the teeth and supporting structures 520-525;Both sexes;158 Gipuzkoa;Group 1101 Disorders of the teeth and supporting structures 520-525;Men;77 Gipuzkoa;Group 1101 Disorders of the teeth and supporting structures 520-525;Women;81 Gipuzkoa;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Both sexes;161 Gipuzkoa;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Men;100 Gipuzkoa;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Women;61 Gipuzkoa;Group 1103 Diseases of the esophagus 530;Both sexes;196 Gipuzkoa;Group 1103 Diseases of the esophagus 530;Men;109 Gipuzkoa;Group 1103 Diseases of the esophagus 530;Women;87 Gipuzkoa;Group 1104 Peptic ulcer 531-534;Both sexes;167 Gipuzkoa;Group 1104 Peptic ulcer 531-534;Men;110 Gipuzkoa;Group 1104 Peptic ulcer 531-534;Women;57 Gipuzkoa;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Both sexes;163 Gipuzkoa;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Men;82 Gipuzkoa;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Women;81 Gipuzkoa;Group 1106 Appendicitis 540-543;Both sexes;862 Gipuzkoa;Group 1106 Appendicitis 540-543;Men;510 Gipuzkoa;Group 1106 Appendicitis 540-543;Women;352 Gipuzkoa;Group 1107 Inguinal hernia 550;Both sexes;1,095 Gipuzkoa;Group 1107 Inguinal hernia 550;Men;973 Gipuzkoa;Group 1107 Inguinal hernia 550;Women;122 Gipuzkoa;Group 1108 Other abdominal hernia 551-553;Both sexes;764 Gipuzkoa;Group 1108 Other abdominal hernia 551-553;Men;380 Gipuzkoa;Group 1108 Other abdominal hernia 551-553;Women;384 Gipuzkoa;Group 1109 Crohn's disease and ulcerative colitis 555-556;Both sexes;225 Gipuzkoa;Group 1109 Crohn's disease and ulcerative colitis 555-556;Men;124 Gipuzkoa;Group 1109 Crohn's disease and ulcerative colitis 555-556;Women;101 Gipuzkoa;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Both sexes;493 Gipuzkoa;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Men;229 Gipuzkoa;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Women;264 Gipuzkoa;Group 1111 Intestinal obstruction without hernia 560;Both sexes;594 Gipuzkoa;Group 1111 Intestinal obstruction without hernia 560;Men;316 Gipuzkoa;Group 1111 Intestinal obstruction without hernia 560;Women;278 Gipuzkoa;Group 1112 Intestinal diverticulosis 562;Both sexes;449 Gipuzkoa;Group 1112 Intestinal diverticulosis 562;Men;241 Gipuzkoa;Group 1112 Intestinal diverticulosis 562;Women;208 Gipuzkoa;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Both sexes;763 Gipuzkoa;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Men;488 Gipuzkoa;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Women;275 Gipuzkoa;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Both sexes;295 Gipuzkoa;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Men;128 Gipuzkoa;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Women;167 Gipuzkoa;Group 1115 Alcoholic hepatitis 5710-5713;Both sexes;183 Gipuzkoa;Group 1115 Alcoholic hepatitis 5710-5713;Men;147 Gipuzkoa;Group 1115 Alcoholic hepatitis 5710-5713;Women;36 Gipuzkoa;Group 1116 Other diseases of the liver 570,5714-573;Both sexes;257 Gipuzkoa;Group 1116 Other diseases of the liver 570,5714-573;Men;170 Gipuzkoa;Group 1116 Other diseases of the liver 570,5714-573;Women;87 Gipuzkoa;Group 1117 Cholelithiasis 574;Both sexes;1,463 Gipuzkoa;Group 1117 Cholelithiasis 574;Men;643 Gipuzkoa;Group 1117 Cholelithiasis 574;Women;820 Gipuzkoa;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Both sexes;346 Gipuzkoa;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Men;196 Gipuzkoa;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Women;150 Gipuzkoa;Group 1119 Pancreatic diseases 577;Both sexes;382 Gipuzkoa;Group 1119 Pancreatic diseases 577;Men;217 Gipuzkoa;Group 1119 Pancreatic diseases 577;Women;165 Gipuzkoa;Group 1120 Other diseases of the digestive system Rest of (520-579);Both sexes;531 Gipuzkoa;Group 1120 Other diseases of the digestive system Rest of (520-579);Men;317 Gipuzkoa;Group 1120 Other diseases of the digestive system Rest of (520-579);Women;214 Gipuzkoa;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Both sexes;984 Gipuzkoa;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Men;532 Gipuzkoa;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Women;452 Gipuzkoa;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Both sexes;624 Gipuzkoa;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Men;366 Gipuzkoa;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Women;258 Gipuzkoa;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Both sexes;36 Gipuzkoa;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Men;17 Gipuzkoa;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Women;19 Gipuzkoa;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Both sexes;324 Gipuzkoa;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Men;149 Gipuzkoa;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Women;175 Gipuzkoa;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Both sexes;7,345 Gipuzkoa;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Men;3,769 Gipuzkoa;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Women;3,576 Gipuzkoa;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Both sexes;.. Gipuzkoa;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Men;.. Gipuzkoa;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Women;.. Gipuzkoa;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Both sexes;.. Gipuzkoa;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Men;.. Gipuzkoa;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Women;.. Gipuzkoa;Group 1303 Internal derangement of knee 717;Both sexes;1,580 Gipuzkoa;Group 1303 Internal derangement of knee 717;Men;1,026 Gipuzkoa;Group 1303 Internal derangement of knee 717;Women;554 Gipuzkoa;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Both sexes;2,398 Gipuzkoa;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Men;1,134 Gipuzkoa;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Women;1,264 Gipuzkoa;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Both sexes;84 Gipuzkoa;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Men;38 Gipuzkoa;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Women;46 Gipuzkoa;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Both sexes;402 Gipuzkoa;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Men;190 Gipuzkoa;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Women;212 Gipuzkoa;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Both sexes;551 Gipuzkoa;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Men;311 Gipuzkoa;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Women;240 Gipuzkoa;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Both sexes;298 Gipuzkoa;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Men;146 Gipuzkoa;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Women;152 Gipuzkoa;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Both sexes;1,011 Gipuzkoa;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Men;563 Gipuzkoa;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Women;448 Gipuzkoa;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Both sexes;1,021 Gipuzkoa;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Men;361 Gipuzkoa;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Women;660 Gipuzkoa;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Both sexes;4,934 Gipuzkoa;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Men;2,421 Gipuzkoa;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Women;2,513 Gipuzkoa;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Both sexes;336 Gipuzkoa;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Men;139 Gipuzkoa;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Women;197 Gipuzkoa;Group 1402 Renal failure 5836-5837, 584-586;Both sexes;335 Gipuzkoa;Group 1402 Renal failure 5836-5837, 584-586;Men;191 Gipuzkoa;Group 1402 Renal failure 5836-5837, 584-586;Women;144 Gipuzkoa;Group 1403 Urolithiasis 592, 594, 7880;Both sexes;743 Gipuzkoa;Group 1403 Urolithiasis 592, 594, 7880;Men;450 Gipuzkoa;Group 1403 Urolithiasis 592, 594, 7880;Women;293 Gipuzkoa;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Both sexes;1,536 Gipuzkoa;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Men;783 Gipuzkoa;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Women;753 Gipuzkoa;Group 1405 Prostatic hyperplasia 600;Both sexes;546 Gipuzkoa;Group 1405 Prostatic hyperplasia 600;Men;546 Gipuzkoa;Group 1405 Prostatic hyperplasia 600;Women;.. Gipuzkoa;Group 1406 Other diseases of the male genital organs 601-608;Both sexes;254 Gipuzkoa;Group 1406 Other diseases of the male genital organs 601-608;Men;254 Gipuzkoa;Group 1406 Other diseases of the male genital organs 601-608;Women;.. Gipuzkoa;Group 1407 Disorders of breast 610-612;Both sexes;298 Gipuzkoa;Group 1407 Disorders of breast 610-612;Men;34 Gipuzkoa;Group 1407 Disorders of breast 610-612;Women;264 Gipuzkoa;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Both sexes;97 Gipuzkoa;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Men;.. Gipuzkoa;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Women;97 Gipuzkoa;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Both sexes;42 Gipuzkoa;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Men;.. Gipuzkoa;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Women;42 Gipuzkoa;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Both sexes;747 Gipuzkoa;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Men;24 Gipuzkoa;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Women;723 Gipuzkoa;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Both sexes;7,396 Gipuzkoa;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Men;.. Gipuzkoa;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Women;7,396 Gipuzkoa;Group 1501 Legally induced abortion 635;Both sexes;59 Gipuzkoa;Group 1501 Legally induced abortion 635;Men;.. Gipuzkoa;Group 1501 Legally induced abortion 635;Women;59 Gipuzkoa;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Both sexes;273 Gipuzkoa;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Men;.. Gipuzkoa;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Women;273 Gipuzkoa;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Both sexes;4,494 Gipuzkoa;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Men;.. Gipuzkoa;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Women;4,494 Gipuzkoa;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Both sexes;1,384 Gipuzkoa;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Men;.. Gipuzkoa;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Women;1,384 Gipuzkoa;Group 1505 Single spontaneous delivery 650;Both sexes;675 Gipuzkoa;Group 1505 Single spontaneous delivery 650;Men;.. Gipuzkoa;Group 1505 Single spontaneous delivery 650;Women;675 Gipuzkoa;Group 1506 Other deliveries 6695-6697;Both sexes;184 Gipuzkoa;Group 1506 Other deliveries 6695-6697;Men;.. Gipuzkoa;Group 1506 Other deliveries 6695-6697;Women;184 Gipuzkoa;Group 1507 Complications related to the puerperium 670-676;Both sexes;54 Gipuzkoa;Group 1507 Complications related to the puerperium 670-676;Men;.. Gipuzkoa;Group 1507 Complications related to the puerperium 670-676;Women;54 Gipuzkoa;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Both sexes;273 Gipuzkoa;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Men;.. Gipuzkoa;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Women;273 Gipuzkoa;Group 1600 Some disorders originating in the perinatal period 760-779;Both sexes;896 Gipuzkoa;Group 1600 Some disorders originating in the perinatal period 760-779;Men;488 Gipuzkoa;Group 1600 Some disorders originating in the perinatal period 760-779;Women;408 Gipuzkoa;Group 1601 Disorders related with premature delivery and a low birth weight 765;Both sexes;267 Gipuzkoa;Group 1601 Disorders related with premature delivery and a low birth weight 765;Men;149 Gipuzkoa;Group 1601 Disorders related with premature delivery and a low birth weight 765;Women;118 Gipuzkoa;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Both sexes;629 Gipuzkoa;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Men;339 Gipuzkoa;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Women;290 Gipuzkoa;Grupo 1700 Congenital abnormalities 740-759;Both sexes;344 Gipuzkoa;Grupo 1700 Congenital abnormalities 740-759;Men;203 Gipuzkoa;Grupo 1700 Congenital abnormalities 740-759;Women;141 Gipuzkoa;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Both sexes;3,962 Gipuzkoa;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Men;2,242 Gipuzkoa;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Women;1,720 Gipuzkoa;Group 1801 Pain in throat and chest 7841, 7865;Both sexes;871 Gipuzkoa;Group 1801 Pain in throat and chest 7841, 7865;Men;506 Gipuzkoa;Group 1801 Pain in throat and chest 7841, 7865;Women;365 Gipuzkoa;Group 1802 Abdominal pain 7890;Both sexes;495 Gipuzkoa;Group 1802 Abdominal pain 7890;Men;216 Gipuzkoa;Group 1802 Abdominal pain 7890;Women;279 Gipuzkoa;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Both sexes;38 Gipuzkoa;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Men;22 Gipuzkoa;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Women;16 Gipuzkoa;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Both sexes;2,558 Gipuzkoa;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Men;1,498 Gipuzkoa;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Women;1,060 Gipuzkoa;Group 1900 Injuries and poisoning 800-999;Both sexes;6,590 Gipuzkoa;Group 1900 Injuries and poisoning 800-999;Men;3,418 Gipuzkoa;Group 1900 Injuries and poisoning 800-999;Women;3,172 Gipuzkoa;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Both sexes;396 Gipuzkoa;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Men;227 Gipuzkoa;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Women;169 Gipuzkoa;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Both sexes;242 Gipuzkoa;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Men;164 Gipuzkoa;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Women;78 Gipuzkoa;Group 1903 Radius and ulna fracture 813;Both sexes;410 Gipuzkoa;Group 1903 Radius and ulna fracture 813;Men;170 Gipuzkoa;Group 1903 Radius and ulna fracture 813;Women;240 Gipuzkoa;Group 1904 Femur fracture 820-821;Both sexes;982 Gipuzkoa;Group 1904 Femur fracture 820-821;Men;269 Gipuzkoa;Group 1904 Femur fracture 820-821;Women;713 Gipuzkoa;Group 1905 Leg fracture, including the ankle 823-824;Both sexes;495 Gipuzkoa;Group 1905 Leg fracture, including the ankle 823-824;Men;247 Gipuzkoa;Group 1905 Leg fracture, including the ankle 823-824;Women;248 Gipuzkoa;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Both sexes;1,707 Gipuzkoa;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Men;1,053 Gipuzkoa;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Women;654 Gipuzkoa;Group 1907 Burns 940-949;Both sexes;30 Gipuzkoa;Group 1907 Burns 940-949;Men;20 Gipuzkoa;Group 1907 Burns 940-949;Women;10 Gipuzkoa;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Both sexes;194 Gipuzkoa;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Men;98 Gipuzkoa;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Women;96 Gipuzkoa;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Both sexes;1,776 Gipuzkoa;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Men;1,003 Gipuzkoa;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Women;773 Gipuzkoa;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Both sexes;29 Gipuzkoa;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Men;14 Gipuzkoa;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Women;15 Gipuzkoa;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Both sexes;329 Gipuzkoa;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Men;153 Gipuzkoa;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Women;176 Gipuzkoa;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Both sexes;2,340 Gipuzkoa;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Men;1,178 Gipuzkoa;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Women;1,162 Gipuzkoa;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Both sexes;98 Gipuzkoa;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Men;56 Gipuzkoa;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Women;42 Gipuzkoa;Group 2102 Contraceptive management V25;Both sexes;21 Gipuzkoa;Group 2102 Contraceptive management V25;Men;1 Gipuzkoa;Group 2102 Contraceptive management V25;Women;20 Gipuzkoa;Group 2103 Living newborns by type of delivery V30-V39;Both sexes;.. Gipuzkoa;Group 2103 Living newborns by type of delivery V30-V39;Men;.. Gipuzkoa;Group 2103 Living newborns by type of delivery V30-V39;Women;.. Gipuzkoa;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Both sexes;809 Gipuzkoa;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Men;507 Gipuzkoa;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Women;302 Gipuzkoa;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Both sexes;1,412 Gipuzkoa;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Men;614 Gipuzkoa;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Women;798 RIOJA, LA;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Both sexes;35,333 RIOJA, LA;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Men;17,319 RIOJA, LA;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Women;18,014 RIOJA, LA;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Both sexes;688 RIOJA, LA;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Men;391 RIOJA, LA;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Women;296 RIOJA, LA;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Both sexes;132 RIOJA, LA;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Men;73 RIOJA, LA;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Women;59 RIOJA, LA;Group 0102 Imprecise intestinal infections 009;Both sexes;8 RIOJA, LA;Group 0102 Imprecise intestinal infections 009;Men;3 RIOJA, LA;Group 0102 Imprecise intestinal infections 009;Women;5 RIOJA, LA;Group 0103 Tuberculosis 010-018, 137;Both sexes;35 RIOJA, LA;Group 0103 Tuberculosis 010-018, 137;Men;20 RIOJA, LA;Group 0103 Tuberculosis 010-018, 137;Women;15 RIOJA, LA;Group 0104 Septicaemia 038;Both sexes;267 RIOJA, LA;Group 0104 Septicaemia 038;Men;150 RIOJA, LA;Group 0104 Septicaemia 038;Women;117 RIOJA, LA;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Both sexes;11 RIOJA, LA;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Men;8 RIOJA, LA;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Women;3 RIOJA, LA;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Both sexes;234 RIOJA, LA;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Men;137 RIOJA, LA;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Women;97 RIOJA, LA;Group 0200 Neoplasms 140-239;Both sexes;3,083 RIOJA, LA;Group 0200 Neoplasms 140-239;Men;1,638 RIOJA, LA;Group 0200 Neoplasms 140-239;Women;1,445 RIOJA, LA;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Both sexes;322 RIOJA, LA;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Men;200 RIOJA, LA;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Women;122 RIOJA, LA;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Both sexes;201 RIOJA, LA;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Men;160 RIOJA, LA;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Women;40 RIOJA, LA;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Both sexes;107 RIOJA, LA;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Men;64 RIOJA, LA;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Women;43 RIOJA, LA;Group 0204 Malignant neoplasm of breast 174-175;Both sexes;204 RIOJA, LA;Group 0204 Malignant neoplasm of breast 174-175;Men;1 RIOJA, LA;Group 0204 Malignant neoplasm of breast 174-175;Women;203 RIOJA, LA;Group 0205 Malignant neoplasm of uterus 179-180, 182;Both sexes;69 RIOJA, LA;Group 0205 Malignant neoplasm of uterus 179-180, 182;Men;.. RIOJA, LA;Group 0205 Malignant neoplasm of uterus 179-180, 182;Women;69 RIOJA, LA;Group 0206 Malignant neoplasm of ovary 1830;Both sexes;25 RIOJA, LA;Group 0206 Malignant neoplasm of ovary 1830;Men;.. RIOJA, LA;Group 0206 Malignant neoplasm of ovary 1830;Women;25 RIOJA, LA;Group 0207 Malignant neoplasm of prostate 185;Both sexes;91 RIOJA, LA;Group 0207 Malignant neoplasm of prostate 185;Men;91 RIOJA, LA;Group 0207 Malignant neoplasm of prostate 185;Women;.. RIOJA, LA;Group 0208 Malignant neoplasm of bladder 188;Both sexes;301 RIOJA, LA;Group 0208 Malignant neoplasm of bladder 188;Men;256 RIOJA, LA;Group 0208 Malignant neoplasm of bladder 188;Women;45 RIOJA, LA;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Both sexes;1,019 RIOJA, LA;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Men;601 RIOJA, LA;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Women;418 RIOJA, LA;Group 0210 Carcinoma in situ 230-234;Both sexes;61 RIOJA, LA;Group 0210 Carcinoma in situ 230-234;Men;11 RIOJA, LA;Group 0210 Carcinoma in situ 230-234;Women;49 RIOJA, LA;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Both sexes;51 RIOJA, LA;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Men;32 RIOJA, LA;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Women;19 RIOJA, LA;Grupo 0212 Leiomyoma of uterus 218;Both sexes;163 RIOJA, LA;Grupo 0212 Leiomyoma of uterus 218;Men;.. RIOJA, LA;Grupo 0212 Leiomyoma of uterus 218;Women;163 RIOJA, LA;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Both sexes;471 RIOJA, LA;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Men;223 RIOJA, LA;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Women;248 RIOJA, LA;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Both sexes;665 RIOJA, LA;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Men;362 RIOJA, LA;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Women;303 RIOJA, LA;Group 0301 Anaemias 280-285;Both sexes;468 RIOJA, LA;Group 0301 Anaemias 280-285;Men;244 RIOJA, LA;Group 0301 Anaemias 280-285;Women;224 RIOJA, LA;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Both sexes;197 RIOJA, LA;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Men;118 RIOJA, LA;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Women;79 RIOJA, LA;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Both sexes;563 RIOJA, LA;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Men;267 RIOJA, LA;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Women;296 RIOJA, LA;Group 0401 Diabetes mellitus 249-250;Both sexes;312 RIOJA, LA;Group 0401 Diabetes mellitus 249-250;Men;172 RIOJA, LA;Group 0401 Diabetes mellitus 249-250;Women;139 RIOJA, LA;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Both sexes;252 RIOJA, LA;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Men;95 RIOJA, LA;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Women;157 RIOJA, LA;Group 0500 Mental disorders 290-319;Both sexes;632 RIOJA, LA;Group 0500 Mental disorders 290-319;Men;322 RIOJA, LA;Group 0500 Mental disorders 290-319;Women;311 RIOJA, LA;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Both sexes;30 RIOJA, LA;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Men;16 RIOJA, LA;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Women;14 RIOJA, LA;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Both sexes;40 RIOJA, LA;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Men;31 RIOJA, LA;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Women;9 RIOJA, LA;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Both sexes;34 RIOJA, LA;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Men;25 RIOJA, LA;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Women;9 RIOJA, LA;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Both sexes;183 RIOJA, LA;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Men;101 RIOJA, LA;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Women;83 RIOJA, LA;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Both sexes;107 RIOJA, LA;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Men;32 RIOJA, LA;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Women;75 RIOJA, LA;Group 0506 Other mental and behavioural disorders Rest of (290-319);Both sexes;237 RIOJA, LA;Group 0506 Other mental and behavioural disorders Rest of (290-319);Men;116 RIOJA, LA;Group 0506 Other mental and behavioural disorders Rest of (290-319);Women;121 RIOJA, LA;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Both sexes;718 RIOJA, LA;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Men;352 RIOJA, LA;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Women;366 RIOJA, LA;Group 0601 Alzheimer's disease 3310;Both sexes;25 RIOJA, LA;Group 0601 Alzheimer's disease 3310;Men;11 RIOJA, LA;Group 0601 Alzheimer's disease 3310;Women;14 RIOJA, LA;Group 0602 Multiple sclerosis 340;Both sexes;16 RIOJA, LA;Group 0602 Multiple sclerosis 340;Men;3 RIOJA, LA;Group 0602 Multiple sclerosis 340;Women;13 RIOJA, LA;Group 0603 Epilepsy 345;Both sexes;161 RIOJA, LA;Group 0603 Epilepsy 345;Men;84 RIOJA, LA;Group 0603 Epilepsy 345;Women;78 RIOJA, LA;Group 0604 Transient cerebral ischemia 435;Both sexes;138 RIOJA, LA;Group 0604 Transient cerebral ischemia 435;Men;63 RIOJA, LA;Group 0604 Transient cerebral ischemia 435;Women;76 RIOJA, LA;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Both sexes;377 RIOJA, LA;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Men;192 RIOJA, LA;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Women;185 RIOJA, LA;Grupo 0700 Diseases of the eye and adnexa 360-379;Both sexes;251 RIOJA, LA;Grupo 0700 Diseases of the eye and adnexa 360-379;Men;126 RIOJA, LA;Grupo 0700 Diseases of the eye and adnexa 360-379;Women;125 RIOJA, LA;Grupo 0701 Cataract 366;Both sexes;24 RIOJA, LA;Grupo 0701 Cataract 366;Men;13 RIOJA, LA;Grupo 0701 Cataract 366;Women;11 RIOJA, LA;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Both sexes;227 RIOJA, LA;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Men;113 RIOJA, LA;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Women;114 RIOJA, LA;Group 0800 Diseases of the ear and the mastoid 380-389;Both sexes;175 RIOJA, LA;Group 0800 Diseases of the ear and the mastoid 380-389;Men;82 RIOJA, LA;Group 0800 Diseases of the ear and the mastoid 380-389;Women;94 RIOJA, LA;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Both sexes;5,102 RIOJA, LA;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Men;2,777 RIOJA, LA;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Women;2,324 RIOJA, LA;Group 0901 Hypertensive disease 401-405;Both sexes;376 RIOJA, LA;Group 0901 Hypertensive disease 401-405;Men;190 RIOJA, LA;Group 0901 Hypertensive disease 401-405;Women;187 RIOJA, LA;Group 0902 Angina pectoris 4111, 413;Both sexes;107 RIOJA, LA;Group 0902 Angina pectoris 4111, 413;Men;66 RIOJA, LA;Group 0902 Angina pectoris 4111, 413;Women;40 RIOJA, LA;Group 0903 Acute myocardial infarction 410;Both sexes;475 RIOJA, LA;Group 0903 Acute myocardial infarction 410;Men;334 RIOJA, LA;Group 0903 Acute myocardial infarction 410;Women;141 RIOJA, LA;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Both sexes;267 RIOJA, LA;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Men;207 RIOJA, LA;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Women;60 RIOJA, LA;Group 0905 Diseases of the lungs circulation 415-417;Both sexes;218 RIOJA, LA;Group 0905 Diseases of the lungs circulation 415-417;Men;97 RIOJA, LA;Group 0905 Diseases of the lungs circulation 415-417;Women;121 RIOJA, LA;Group 0906 Heart conduction disorders and arrhytmias 426-427;Both sexes;564 RIOJA, LA;Group 0906 Heart conduction disorders and arrhytmias 426-427;Men;278 RIOJA, LA;Group 0906 Heart conduction disorders and arrhytmias 426-427;Women;286 RIOJA, LA;Grupo 0907 Heart failure 428;Both sexes;1,099 RIOJA, LA;Grupo 0907 Heart failure 428;Men;488 RIOJA, LA;Grupo 0907 Heart failure 428;Women;611 RIOJA, LA;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Both sexes;815 RIOJA, LA;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Men;443 RIOJA, LA;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Women;372 RIOJA, LA;Grupo 0909 Atherosclerosis 440;Both sexes;168 RIOJA, LA;Grupo 0909 Atherosclerosis 440;Men;112 RIOJA, LA;Grupo 0909 Atherosclerosis 440;Women;56 RIOJA, LA;Group 0910 Varicose veins of lower extremities 454;Both sexes;256 RIOJA, LA;Group 0910 Varicose veins of lower extremities 454;Men;94 RIOJA, LA;Group 0910 Varicose veins of lower extremities 454;Women;162 RIOJA, LA;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Both sexes;756 RIOJA, LA;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Men;469 RIOJA, LA;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Women;287 RIOJA, LA;Group 1000 Diseases of the respiratory system 0340, 460-519;Both sexes;4,250 RIOJA, LA;Group 1000 Diseases of the respiratory system 0340, 460-519;Men;2,547 RIOJA, LA;Group 1000 Diseases of the respiratory system 0340, 460-519;Women;1,703 RIOJA, LA;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Both sexes;137 RIOJA, LA;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Men;77 RIOJA, LA;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Women;60 RIOJA, LA;Group 1002 Pneumonia 480-486;Both sexes;822 RIOJA, LA;Group 1002 Pneumonia 480-486;Men;524 RIOJA, LA;Group 1002 Pneumonia 480-486;Women;297 RIOJA, LA;Group 1003 Acute bronchitis and bronchiolitis 466;Both sexes;164 RIOJA, LA;Group 1003 Acute bronchitis and bronchiolitis 466;Men;97 RIOJA, LA;Group 1003 Acute bronchitis and bronchiolitis 466;Women;68 RIOJA, LA;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Both sexes;215 RIOJA, LA;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Men;116 RIOJA, LA;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Women;99 RIOJA, LA;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Both sexes;240 RIOJA, LA;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Men;170 RIOJA, LA;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Women;69 RIOJA, LA;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Both sexes;907 RIOJA, LA;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Men;707 RIOJA, LA;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Women;200 RIOJA, LA;Group 1007 Asthma 4930-4931,4938-4939;Both sexes;181 RIOJA, LA;Group 1007 Asthma 4930-4931,4938-4939;Men;61 RIOJA, LA;Group 1007 Asthma 4930-4931,4938-4939;Women;120 RIOJA, LA;Group 1008 Other diseases of the respiratory system Resto of (460-519);Both sexes;1,585 RIOJA, LA;Group 1008 Other diseases of the respiratory system Resto of (460-519);Men;796 RIOJA, LA;Group 1008 Other diseases of the respiratory system Resto of (460-519);Women;790 RIOJA, LA;Group 1100 Diseases of the digestive system 520-579;Both sexes;4,709 RIOJA, LA;Group 1100 Diseases of the digestive system 520-579;Men;2,711 RIOJA, LA;Group 1100 Diseases of the digestive system 520-579;Women;1,998 RIOJA, LA;Group 1101 Disorders of the teeth and supporting structures 520-525;Both sexes;44 RIOJA, LA;Group 1101 Disorders of the teeth and supporting structures 520-525;Men;23 RIOJA, LA;Group 1101 Disorders of the teeth and supporting structures 520-525;Women;21 RIOJA, LA;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Both sexes;77 RIOJA, LA;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Men;47 RIOJA, LA;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Women;29 RIOJA, LA;Group 1103 Diseases of the esophagus 530;Both sexes;72 RIOJA, LA;Group 1103 Diseases of the esophagus 530;Men;48 RIOJA, LA;Group 1103 Diseases of the esophagus 530;Women;23 RIOJA, LA;Group 1104 Peptic ulcer 531-534;Both sexes;76 RIOJA, LA;Group 1104 Peptic ulcer 531-534;Men;45 RIOJA, LA;Group 1104 Peptic ulcer 531-534;Women;30 RIOJA, LA;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Both sexes;132 RIOJA, LA;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Men;75 RIOJA, LA;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Women;57 RIOJA, LA;Group 1106 Appendicitis 540-543;Both sexes;342 RIOJA, LA;Group 1106 Appendicitis 540-543;Men;175 RIOJA, LA;Group 1106 Appendicitis 540-543;Women;166 RIOJA, LA;Group 1107 Inguinal hernia 550;Both sexes;579 RIOJA, LA;Group 1107 Inguinal hernia 550;Men;518 RIOJA, LA;Group 1107 Inguinal hernia 550;Women;60 RIOJA, LA;Group 1108 Other abdominal hernia 551-553;Both sexes;275 RIOJA, LA;Group 1108 Other abdominal hernia 551-553;Men;121 RIOJA, LA;Group 1108 Other abdominal hernia 551-553;Women;154 RIOJA, LA;Group 1109 Crohn's disease and ulcerative colitis 555-556;Both sexes;69 RIOJA, LA;Group 1109 Crohn's disease and ulcerative colitis 555-556;Men;37 RIOJA, LA;Group 1109 Crohn's disease and ulcerative colitis 555-556;Women;31 RIOJA, LA;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Both sexes;392 RIOJA, LA;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Men;192 RIOJA, LA;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Women;200 RIOJA, LA;Group 1111 Intestinal obstruction without hernia 560;Both sexes;308 RIOJA, LA;Group 1111 Intestinal obstruction without hernia 560;Men;155 RIOJA, LA;Group 1111 Intestinal obstruction without hernia 560;Women;153 RIOJA, LA;Group 1112 Intestinal diverticulosis 562;Both sexes;309 RIOJA, LA;Group 1112 Intestinal diverticulosis 562;Men;164 RIOJA, LA;Group 1112 Intestinal diverticulosis 562;Women;144 RIOJA, LA;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Both sexes;242 RIOJA, LA;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Men;168 RIOJA, LA;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Women;74 RIOJA, LA;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Both sexes;127 RIOJA, LA;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Men;64 RIOJA, LA;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Women;64 RIOJA, LA;Group 1115 Alcoholic hepatitis 5710-5713;Both sexes;58 RIOJA, LA;Group 1115 Alcoholic hepatitis 5710-5713;Men;46 RIOJA, LA;Group 1115 Alcoholic hepatitis 5710-5713;Women;12 RIOJA, LA;Group 1116 Other diseases of the liver 570,5714-573;Both sexes;140 RIOJA, LA;Group 1116 Other diseases of the liver 570,5714-573;Men;80 RIOJA, LA;Group 1116 Other diseases of the liver 570,5714-573;Women;60 RIOJA, LA;Group 1117 Cholelithiasis 574;Both sexes;714 RIOJA, LA;Group 1117 Cholelithiasis 574;Men;298 RIOJA, LA;Group 1117 Cholelithiasis 574;Women;416 RIOJA, LA;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Both sexes;303 RIOJA, LA;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Men;180 RIOJA, LA;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Women;123 RIOJA, LA;Group 1119 Pancreatic diseases 577;Both sexes;242 RIOJA, LA;Group 1119 Pancreatic diseases 577;Men;131 RIOJA, LA;Group 1119 Pancreatic diseases 577;Women;111 RIOJA, LA;Group 1120 Other diseases of the digestive system Rest of (520-579);Both sexes;209 RIOJA, LA;Group 1120 Other diseases of the digestive system Rest of (520-579);Men;141 RIOJA, LA;Group 1120 Other diseases of the digestive system Rest of (520-579);Women;68 RIOJA, LA;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Both sexes;395 RIOJA, LA;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Men;201 RIOJA, LA;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Women;195 RIOJA, LA;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Both sexes;218 RIOJA, LA;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Men;112 RIOJA, LA;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Women;106 RIOJA, LA;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Both sexes;17 RIOJA, LA;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Men;8 RIOJA, LA;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Women;9 RIOJA, LA;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Both sexes;160 RIOJA, LA;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Men;81 RIOJA, LA;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Women;80 RIOJA, LA;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Both sexes;2,614 RIOJA, LA;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Men;1,321 RIOJA, LA;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Women;1,293 RIOJA, LA;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Both sexes;.. RIOJA, LA;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Men;.. RIOJA, LA;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Women;.. RIOJA, LA;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Both sexes;.. RIOJA, LA;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Men;.. RIOJA, LA;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Women;.. RIOJA, LA;Group 1303 Internal derangement of knee 717;Both sexes;458 RIOJA, LA;Group 1303 Internal derangement of knee 717;Men;323 RIOJA, LA;Group 1303 Internal derangement of knee 717;Women;134 RIOJA, LA;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Both sexes;930 RIOJA, LA;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Men;450 RIOJA, LA;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Women;480 RIOJA, LA;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Both sexes;56 RIOJA, LA;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Men;22 RIOJA, LA;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Women;34 RIOJA, LA;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Both sexes;72 RIOJA, LA;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Men;36 RIOJA, LA;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Women;36 RIOJA, LA;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Both sexes;256 RIOJA, LA;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Men;139 RIOJA, LA;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Women;118 RIOJA, LA;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Both sexes;60 RIOJA, LA;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Men;26 RIOJA, LA;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Women;34 RIOJA, LA;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Both sexes;345 RIOJA, LA;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Men;192 RIOJA, LA;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Women;153 RIOJA, LA;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Both sexes;436 RIOJA, LA;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Men;132 RIOJA, LA;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Women;304 RIOJA, LA;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Both sexes;2,432 RIOJA, LA;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Men;1,239 RIOJA, LA;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Women;1,192 RIOJA, LA;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Both sexes;271 RIOJA, LA;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Men;86 RIOJA, LA;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Women;185 RIOJA, LA;Group 1402 Renal failure 5836-5837, 584-586;Both sexes;132 RIOJA, LA;Group 1402 Renal failure 5836-5837, 584-586;Men;84 RIOJA, LA;Group 1402 Renal failure 5836-5837, 584-586;Women;48 RIOJA, LA;Group 1403 Urolithiasis 592, 594, 7880;Both sexes;349 RIOJA, LA;Group 1403 Urolithiasis 592, 594, 7880;Men;222 RIOJA, LA;Group 1403 Urolithiasis 592, 594, 7880;Women;127 RIOJA, LA;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Both sexes;723 RIOJA, LA;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Men;351 RIOJA, LA;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Women;372 RIOJA, LA;Group 1405 Prostatic hyperplasia 600;Both sexes;222 RIOJA, LA;Group 1405 Prostatic hyperplasia 600;Men;222 RIOJA, LA;Group 1405 Prostatic hyperplasia 600;Women;.. RIOJA, LA;Group 1406 Other diseases of the male genital organs 601-608;Both sexes;231 RIOJA, LA;Group 1406 Other diseases of the male genital organs 601-608;Men;231 RIOJA, LA;Group 1406 Other diseases of the male genital organs 601-608;Women;.. RIOJA, LA;Group 1407 Disorders of breast 610-612;Both sexes;67 RIOJA, LA;Group 1407 Disorders of breast 610-612;Men;16 RIOJA, LA;Group 1407 Disorders of breast 610-612;Women;51 RIOJA, LA;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Both sexes;59 RIOJA, LA;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Men;.. RIOJA, LA;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Women;59 RIOJA, LA;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Both sexes;27 RIOJA, LA;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Men;.. RIOJA, LA;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Women;27 RIOJA, LA;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Both sexes;350 RIOJA, LA;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Men;28 RIOJA, LA;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Women;321 RIOJA, LA;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Both sexes;3,326 RIOJA, LA;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Men;.. RIOJA, LA;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Women;3,326 RIOJA, LA;Group 1501 Legally induced abortion 635;Both sexes;19 RIOJA, LA;Group 1501 Legally induced abortion 635;Men;.. RIOJA, LA;Group 1501 Legally induced abortion 635;Women;19 RIOJA, LA;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Both sexes;132 RIOJA, LA;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Men;.. RIOJA, LA;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Women;132 RIOJA, LA;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Both sexes;1,952 RIOJA, LA;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Men;.. RIOJA, LA;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Women;1,952 RIOJA, LA;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Both sexes;932 RIOJA, LA;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Men;.. RIOJA, LA;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Women;932 RIOJA, LA;Group 1505 Single spontaneous delivery 650;Both sexes;116 RIOJA, LA;Group 1505 Single spontaneous delivery 650;Men;.. RIOJA, LA;Group 1505 Single spontaneous delivery 650;Women;116 RIOJA, LA;Group 1506 Other deliveries 6695-6697;Both sexes;13 RIOJA, LA;Group 1506 Other deliveries 6695-6697;Men;.. RIOJA, LA;Group 1506 Other deliveries 6695-6697;Women;13 RIOJA, LA;Group 1507 Complications related to the puerperium 670-676;Both sexes;20 RIOJA, LA;Group 1507 Complications related to the puerperium 670-676;Men;.. RIOJA, LA;Group 1507 Complications related to the puerperium 670-676;Women;20 RIOJA, LA;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Both sexes;142 RIOJA, LA;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Men;.. RIOJA, LA;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Women;142 RIOJA, LA;Group 1600 Some disorders originating in the perinatal period 760-779;Both sexes;241 RIOJA, LA;Group 1600 Some disorders originating in the perinatal period 760-779;Men;134 RIOJA, LA;Group 1600 Some disorders originating in the perinatal period 760-779;Women;107 RIOJA, LA;Group 1601 Disorders related with premature delivery and a low birth weight 765;Both sexes;116 RIOJA, LA;Group 1601 Disorders related with premature delivery and a low birth weight 765;Men;65 RIOJA, LA;Group 1601 Disorders related with premature delivery and a low birth weight 765;Women;51 RIOJA, LA;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Both sexes;125 RIOJA, LA;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Men;70 RIOJA, LA;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Women;55 RIOJA, LA;Grupo 1700 Congenital abnormalities 740-759;Both sexes;174 RIOJA, LA;Grupo 1700 Congenital abnormalities 740-759;Men;131 RIOJA, LA;Grupo 1700 Congenital abnormalities 740-759;Women;43 RIOJA, LA;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Both sexes;1,586 RIOJA, LA;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Men;853 RIOJA, LA;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Women;734 RIOJA, LA;Group 1801 Pain in throat and chest 7841, 7865;Both sexes;127 RIOJA, LA;Group 1801 Pain in throat and chest 7841, 7865;Men;66 RIOJA, LA;Group 1801 Pain in throat and chest 7841, 7865;Women;60 RIOJA, LA;Group 1802 Abdominal pain 7890;Both sexes;280 RIOJA, LA;Group 1802 Abdominal pain 7890;Men;119 RIOJA, LA;Group 1802 Abdominal pain 7890;Women;161 RIOJA, LA;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Both sexes;35 RIOJA, LA;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Men;22 RIOJA, LA;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Women;13 RIOJA, LA;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Both sexes;1,144 RIOJA, LA;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Men;645 RIOJA, LA;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Women;499 RIOJA, LA;Group 1900 Injuries and poisoning 800-999;Both sexes;2,959 RIOJA, LA;Group 1900 Injuries and poisoning 800-999;Men;1,483 RIOJA, LA;Group 1900 Injuries and poisoning 800-999;Women;1,477 RIOJA, LA;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Both sexes;376 RIOJA, LA;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Men;204 RIOJA, LA;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Women;172 RIOJA, LA;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Both sexes;86 RIOJA, LA;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Men;52 RIOJA, LA;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Women;33 RIOJA, LA;Group 1903 Radius and ulna fracture 813;Both sexes;101 RIOJA, LA;Group 1903 Radius and ulna fracture 813;Men;52 RIOJA, LA;Group 1903 Radius and ulna fracture 813;Women;48 RIOJA, LA;Group 1904 Femur fracture 820-821;Both sexes;518 RIOJA, LA;Group 1904 Femur fracture 820-821;Men;124 RIOJA, LA;Group 1904 Femur fracture 820-821;Women;394 RIOJA, LA;Group 1905 Leg fracture, including the ankle 823-824;Both sexes;157 RIOJA, LA;Group 1905 Leg fracture, including the ankle 823-824;Men;71 RIOJA, LA;Group 1905 Leg fracture, including the ankle 823-824;Women;87 RIOJA, LA;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Both sexes;673 RIOJA, LA;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Men;360 RIOJA, LA;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Women;313 RIOJA, LA;Group 1907 Burns 940-949;Both sexes;12 RIOJA, LA;Group 1907 Burns 940-949;Men;8 RIOJA, LA;Group 1907 Burns 940-949;Women;4 RIOJA, LA;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Both sexes;71 RIOJA, LA;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Men;42 RIOJA, LA;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Women;28 RIOJA, LA;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Both sexes;862 RIOJA, LA;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Men;513 RIOJA, LA;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Women;349 RIOJA, LA;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Both sexes;1 RIOJA, LA;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Men;1 RIOJA, LA;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Women;.. RIOJA, LA;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Both sexes;103 RIOJA, LA;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Men;55 RIOJA, LA;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Women;47 RIOJA, LA;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Both sexes;769 RIOJA, LA;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Men;382 RIOJA, LA;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Women;387 RIOJA, LA;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Both sexes;14 RIOJA, LA;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Men;9 RIOJA, LA;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Women;5 RIOJA, LA;Group 2102 Contraceptive management V25;Both sexes;13 RIOJA, LA;Group 2102 Contraceptive management V25;Men;4 RIOJA, LA;Group 2102 Contraceptive management V25;Women;9 RIOJA, LA;Group 2103 Living newborns by type of delivery V30-V39;Both sexes;.. RIOJA, LA;Group 2103 Living newborns by type of delivery V30-V39;Men;.. RIOJA, LA;Group 2103 Living newborns by type of delivery V30-V39;Women;.. RIOJA, LA;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Both sexes;187 RIOJA, LA;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Men;99 RIOJA, LA;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Women;88 RIOJA, LA;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Both sexes;555 RIOJA, LA;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Men;270 RIOJA, LA;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Women;285 Ceuta;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Both sexes;6,429 Ceuta;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Men;2,383 Ceuta;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Women;4,046 Ceuta;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Both sexes;177 Ceuta;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Men;86 Ceuta;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Women;91 Ceuta;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Both sexes;44 Ceuta;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Men;21 Ceuta;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Women;23 Ceuta;Group 0102 Imprecise intestinal infections 009;Both sexes;5 Ceuta;Group 0102 Imprecise intestinal infections 009;Men;1 Ceuta;Group 0102 Imprecise intestinal infections 009;Women;4 Ceuta;Group 0103 Tuberculosis 010-018, 137;Both sexes;18 Ceuta;Group 0103 Tuberculosis 010-018, 137;Men;11 Ceuta;Group 0103 Tuberculosis 010-018, 137;Women;7 Ceuta;Group 0104 Septicaemia 038;Both sexes;34 Ceuta;Group 0104 Septicaemia 038;Men;15 Ceuta;Group 0104 Septicaemia 038;Women;19 Ceuta;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Both sexes;5 Ceuta;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Men;4 Ceuta;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Women;1 Ceuta;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Both sexes;71 Ceuta;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Men;34 Ceuta;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Women;37 Ceuta;Group 0200 Neoplasms 140-239;Both sexes;343 Ceuta;Group 0200 Neoplasms 140-239;Men;182 Ceuta;Group 0200 Neoplasms 140-239;Women;161 Ceuta;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Both sexes;32 Ceuta;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Men;14 Ceuta;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Women;18 Ceuta;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Both sexes;55 Ceuta;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Men;48 Ceuta;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Women;7 Ceuta;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Both sexes;7 Ceuta;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Men;6 Ceuta;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Women;1 Ceuta;Group 0204 Malignant neoplasm of breast 174-175;Both sexes;29 Ceuta;Group 0204 Malignant neoplasm of breast 174-175;Men;.. Ceuta;Group 0204 Malignant neoplasm of breast 174-175;Women;29 Ceuta;Group 0205 Malignant neoplasm of uterus 179-180, 182;Both sexes;4 Ceuta;Group 0205 Malignant neoplasm of uterus 179-180, 182;Men;.. Ceuta;Group 0205 Malignant neoplasm of uterus 179-180, 182;Women;4 Ceuta;Group 0206 Malignant neoplasm of ovary 1830;Both sexes;2 Ceuta;Group 0206 Malignant neoplasm of ovary 1830;Men;.. Ceuta;Group 0206 Malignant neoplasm of ovary 1830;Women;2 Ceuta;Group 0207 Malignant neoplasm of prostate 185;Both sexes;7 Ceuta;Group 0207 Malignant neoplasm of prostate 185;Men;7 Ceuta;Group 0207 Malignant neoplasm of prostate 185;Women;.. Ceuta;Group 0208 Malignant neoplasm of bladder 188;Both sexes;21 Ceuta;Group 0208 Malignant neoplasm of bladder 188;Men;16 Ceuta;Group 0208 Malignant neoplasm of bladder 188;Women;5 Ceuta;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Both sexes;81 Ceuta;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Men;50 Ceuta;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Women;31 Ceuta;Group 0210 Carcinoma in situ 230-234;Both sexes;2 Ceuta;Group 0210 Carcinoma in situ 230-234;Men;.. Ceuta;Group 0210 Carcinoma in situ 230-234;Women;2 Ceuta;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Both sexes;7 Ceuta;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Men;3 Ceuta;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Women;4 Ceuta;Grupo 0212 Leiomyoma of uterus 218;Both sexes;21 Ceuta;Grupo 0212 Leiomyoma of uterus 218;Men;.. Ceuta;Grupo 0212 Leiomyoma of uterus 218;Women;21 Ceuta;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Both sexes;75 Ceuta;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Men;38 Ceuta;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Women;37 Ceuta;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Both sexes;59 Ceuta;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Men;34 Ceuta;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Women;25 Ceuta;Group 0301 Anaemias 280-285;Both sexes;32 Ceuta;Group 0301 Anaemias 280-285;Men;17 Ceuta;Group 0301 Anaemias 280-285;Women;15 Ceuta;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Both sexes;27 Ceuta;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Men;17 Ceuta;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Women;10 Ceuta;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Both sexes;132 Ceuta;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Men;52 Ceuta;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Women;80 Ceuta;Group 0401 Diabetes mellitus 249-250;Both sexes;72 Ceuta;Group 0401 Diabetes mellitus 249-250;Men;34 Ceuta;Group 0401 Diabetes mellitus 249-250;Women;38 Ceuta;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Both sexes;60 Ceuta;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Men;18 Ceuta;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Women;42 Ceuta;Group 0500 Mental disorders 290-319;Both sexes;131 Ceuta;Group 0500 Mental disorders 290-319;Men;90 Ceuta;Group 0500 Mental disorders 290-319;Women;41 Ceuta;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Both sexes;4 Ceuta;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Men;2 Ceuta;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Women;2 Ceuta;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Both sexes;7 Ceuta;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Men;5 Ceuta;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Women;2 Ceuta;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Both sexes;9 Ceuta;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Men;9 Ceuta;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Women;.. Ceuta;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Both sexes;37 Ceuta;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Men;28 Ceuta;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Women;9 Ceuta;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Both sexes;41 Ceuta;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Men;26 Ceuta;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Women;15 Ceuta;Group 0506 Other mental and behavioural disorders Rest of (290-319);Both sexes;33 Ceuta;Group 0506 Other mental and behavioural disorders Rest of (290-319);Men;20 Ceuta;Group 0506 Other mental and behavioural disorders Rest of (290-319);Women;13 Ceuta;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Both sexes;139 Ceuta;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Men;53 Ceuta;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Women;86 Ceuta;Group 0601 Alzheimer's disease 3310;Both sexes;.. Ceuta;Group 0601 Alzheimer's disease 3310;Men;.. Ceuta;Group 0601 Alzheimer's disease 3310;Women;.. Ceuta;Group 0602 Multiple sclerosis 340;Both sexes;2 Ceuta;Group 0602 Multiple sclerosis 340;Men;1 Ceuta;Group 0602 Multiple sclerosis 340;Women;1 Ceuta;Group 0603 Epilepsy 345;Both sexes;42 Ceuta;Group 0603 Epilepsy 345;Men;15 Ceuta;Group 0603 Epilepsy 345;Women;27 Ceuta;Group 0604 Transient cerebral ischemia 435;Both sexes;27 Ceuta;Group 0604 Transient cerebral ischemia 435;Men;12 Ceuta;Group 0604 Transient cerebral ischemia 435;Women;15 Ceuta;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Both sexes;68 Ceuta;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Men;25 Ceuta;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Women;43 Ceuta;Grupo 0700 Diseases of the eye and adnexa 360-379;Both sexes;56 Ceuta;Grupo 0700 Diseases of the eye and adnexa 360-379;Men;25 Ceuta;Grupo 0700 Diseases of the eye and adnexa 360-379;Women;31 Ceuta;Grupo 0701 Cataract 366;Both sexes;7 Ceuta;Grupo 0701 Cataract 366;Men;2 Ceuta;Grupo 0701 Cataract 366;Women;5 Ceuta;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Both sexes;49 Ceuta;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Men;23 Ceuta;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Women;26 Ceuta;Group 0800 Diseases of the ear and the mastoid 380-389;Both sexes;42 Ceuta;Group 0800 Diseases of the ear and the mastoid 380-389;Men;20 Ceuta;Group 0800 Diseases of the ear and the mastoid 380-389;Women;22 Ceuta;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Both sexes;587 Ceuta;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Men;311 Ceuta;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Women;276 Ceuta;Group 0901 Hypertensive disease 401-405;Both sexes;36 Ceuta;Group 0901 Hypertensive disease 401-405;Men;14 Ceuta;Group 0901 Hypertensive disease 401-405;Women;22 Ceuta;Group 0902 Angina pectoris 4111, 413;Both sexes;65 Ceuta;Group 0902 Angina pectoris 4111, 413;Men;31 Ceuta;Group 0902 Angina pectoris 4111, 413;Women;34 Ceuta;Group 0903 Acute myocardial infarction 410;Both sexes;83 Ceuta;Group 0903 Acute myocardial infarction 410;Men;51 Ceuta;Group 0903 Acute myocardial infarction 410;Women;32 Ceuta;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Both sexes;2 Ceuta;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Men;1 Ceuta;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Women;1 Ceuta;Group 0905 Diseases of the lungs circulation 415-417;Both sexes;15 Ceuta;Group 0905 Diseases of the lungs circulation 415-417;Men;9 Ceuta;Group 0905 Diseases of the lungs circulation 415-417;Women;6 Ceuta;Group 0906 Heart conduction disorders and arrhytmias 426-427;Both sexes;65 Ceuta;Group 0906 Heart conduction disorders and arrhytmias 426-427;Men;31 Ceuta;Group 0906 Heart conduction disorders and arrhytmias 426-427;Women;34 Ceuta;Grupo 0907 Heart failure 428;Both sexes;111 Ceuta;Grupo 0907 Heart failure 428;Men;60 Ceuta;Grupo 0907 Heart failure 428;Women;51 Ceuta;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Both sexes;130 Ceuta;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Men;68 Ceuta;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Women;62 Ceuta;Grupo 0909 Atherosclerosis 440;Both sexes;1 Ceuta;Grupo 0909 Atherosclerosis 440;Men;.. Ceuta;Grupo 0909 Atherosclerosis 440;Women;1 Ceuta;Group 0910 Varicose veins of lower extremities 454;Both sexes;6 Ceuta;Group 0910 Varicose veins of lower extremities 454;Men;4 Ceuta;Group 0910 Varicose veins of lower extremities 454;Women;2 Ceuta;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Both sexes;73 Ceuta;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Men;42 Ceuta;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Women;31 Ceuta;Group 1000 Diseases of the respiratory system 0340, 460-519;Both sexes;541 Ceuta;Group 1000 Diseases of the respiratory system 0340, 460-519;Men;327 Ceuta;Group 1000 Diseases of the respiratory system 0340, 460-519;Women;214 Ceuta;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Both sexes;48 Ceuta;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Men;24 Ceuta;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Women;24 Ceuta;Group 1002 Pneumonia 480-486;Both sexes;130 Ceuta;Group 1002 Pneumonia 480-486;Men;77 Ceuta;Group 1002 Pneumonia 480-486;Women;53 Ceuta;Group 1003 Acute bronchitis and bronchiolitis 466;Both sexes;63 Ceuta;Group 1003 Acute bronchitis and bronchiolitis 466;Men;37 Ceuta;Group 1003 Acute bronchitis and bronchiolitis 466;Women;26 Ceuta;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Both sexes;8 Ceuta;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Men;4 Ceuta;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Women;4 Ceuta;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Both sexes;34 Ceuta;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Men;23 Ceuta;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Women;11 Ceuta;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Both sexes;73 Ceuta;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Men;58 Ceuta;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Women;15 Ceuta;Group 1007 Asthma 4930-4931,4938-4939;Both sexes;10 Ceuta;Group 1007 Asthma 4930-4931,4938-4939;Men;4 Ceuta;Group 1007 Asthma 4930-4931,4938-4939;Women;6 Ceuta;Group 1008 Other diseases of the respiratory system Resto of (460-519);Both sexes;175 Ceuta;Group 1008 Other diseases of the respiratory system Resto of (460-519);Men;100 Ceuta;Group 1008 Other diseases of the respiratory system Resto of (460-519);Women;75 Ceuta;Group 1100 Diseases of the digestive system 520-579;Both sexes;680 Ceuta;Group 1100 Diseases of the digestive system 520-579;Men;341 Ceuta;Group 1100 Diseases of the digestive system 520-579;Women;339 Ceuta;Group 1101 Disorders of the teeth and supporting structures 520-525;Both sexes;7 Ceuta;Group 1101 Disorders of the teeth and supporting structures 520-525;Men;5 Ceuta;Group 1101 Disorders of the teeth and supporting structures 520-525;Women;2 Ceuta;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Both sexes;1 Ceuta;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Men;.. Ceuta;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Women;1 Ceuta;Group 1103 Diseases of the esophagus 530;Both sexes;6 Ceuta;Group 1103 Diseases of the esophagus 530;Men;4 Ceuta;Group 1103 Diseases of the esophagus 530;Women;2 Ceuta;Group 1104 Peptic ulcer 531-534;Both sexes;12 Ceuta;Group 1104 Peptic ulcer 531-534;Men;8 Ceuta;Group 1104 Peptic ulcer 531-534;Women;4 Ceuta;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Both sexes;10 Ceuta;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Men;5 Ceuta;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Women;5 Ceuta;Group 1106 Appendicitis 540-543;Both sexes;101 Ceuta;Group 1106 Appendicitis 540-543;Men;65 Ceuta;Group 1106 Appendicitis 540-543;Women;36 Ceuta;Group 1107 Inguinal hernia 550;Both sexes;17 Ceuta;Group 1107 Inguinal hernia 550;Men;15 Ceuta;Group 1107 Inguinal hernia 550;Women;2 Ceuta;Group 1108 Other abdominal hernia 551-553;Both sexes;56 Ceuta;Group 1108 Other abdominal hernia 551-553;Men;22 Ceuta;Group 1108 Other abdominal hernia 551-553;Women;34 Ceuta;Group 1109 Crohn's disease and ulcerative colitis 555-556;Both sexes;11 Ceuta;Group 1109 Crohn's disease and ulcerative colitis 555-556;Men;8 Ceuta;Group 1109 Crohn's disease and ulcerative colitis 555-556;Women;3 Ceuta;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Both sexes;97 Ceuta;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Men;46 Ceuta;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Women;51 Ceuta;Group 1111 Intestinal obstruction without hernia 560;Both sexes;26 Ceuta;Group 1111 Intestinal obstruction without hernia 560;Men;16 Ceuta;Group 1111 Intestinal obstruction without hernia 560;Women;10 Ceuta;Group 1112 Intestinal diverticulosis 562;Both sexes;14 Ceuta;Group 1112 Intestinal diverticulosis 562;Men;7 Ceuta;Group 1112 Intestinal diverticulosis 562;Women;7 Ceuta;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Both sexes;28 Ceuta;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Men;19 Ceuta;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Women;9 Ceuta;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Both sexes;29 Ceuta;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Men;14 Ceuta;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Women;15 Ceuta;Group 1115 Alcoholic hepatitis 5710-5713;Both sexes;9 Ceuta;Group 1115 Alcoholic hepatitis 5710-5713;Men;8 Ceuta;Group 1115 Alcoholic hepatitis 5710-5713;Women;1 Ceuta;Group 1116 Other diseases of the liver 570,5714-573;Both sexes;23 Ceuta;Group 1116 Other diseases of the liver 570,5714-573;Men;14 Ceuta;Group 1116 Other diseases of the liver 570,5714-573;Women;9 Ceuta;Group 1117 Cholelithiasis 574;Both sexes;142 Ceuta;Group 1117 Cholelithiasis 574;Men;36 Ceuta;Group 1117 Cholelithiasis 574;Women;106 Ceuta;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Both sexes;26 Ceuta;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Men;12 Ceuta;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Women;14 Ceuta;Group 1119 Pancreatic diseases 577;Both sexes;24 Ceuta;Group 1119 Pancreatic diseases 577;Men;16 Ceuta;Group 1119 Pancreatic diseases 577;Women;8 Ceuta;Group 1120 Other diseases of the digestive system Rest of (520-579);Both sexes;41 Ceuta;Group 1120 Other diseases of the digestive system Rest of (520-579);Men;21 Ceuta;Group 1120 Other diseases of the digestive system Rest of (520-579);Women;20 Ceuta;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Both sexes;75 Ceuta;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Men;33 Ceuta;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Women;42 Ceuta;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Both sexes;50 Ceuta;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Men;26 Ceuta;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Women;24 Ceuta;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Both sexes;1 Ceuta;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Men;.. Ceuta;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Women;1 Ceuta;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Both sexes;24 Ceuta;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Men;7 Ceuta;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Women;17 Ceuta;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Both sexes;221 Ceuta;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Men;83 Ceuta;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Women;138 Ceuta;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Both sexes;.. Ceuta;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Men;.. Ceuta;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Women;.. Ceuta;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Both sexes;.. Ceuta;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Men;.. Ceuta;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Women;.. Ceuta;Group 1303 Internal derangement of knee 717;Both sexes;7 Ceuta;Group 1303 Internal derangement of knee 717;Men;4 Ceuta;Group 1303 Internal derangement of knee 717;Women;3 Ceuta;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Both sexes;55 Ceuta;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Men;19 Ceuta;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Women;36 Ceuta;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Both sexes;5 Ceuta;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Men;2 Ceuta;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Women;3 Ceuta;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Both sexes;33 Ceuta;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Men;9 Ceuta;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Women;24 Ceuta;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Both sexes;42 Ceuta;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Men;24 Ceuta;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Women;18 Ceuta;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Both sexes;5 Ceuta;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Men;1 Ceuta;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Women;4 Ceuta;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Both sexes;30 Ceuta;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Men;12 Ceuta;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Women;18 Ceuta;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Both sexes;44 Ceuta;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Men;12 Ceuta;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Women;32 Ceuta;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Both sexes;314 Ceuta;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Men;128 Ceuta;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Women;186 Ceuta;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Both sexes;32 Ceuta;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Men;8 Ceuta;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Women;24 Ceuta;Group 1402 Renal failure 5836-5837, 584-586;Both sexes;16 Ceuta;Group 1402 Renal failure 5836-5837, 584-586;Men;12 Ceuta;Group 1402 Renal failure 5836-5837, 584-586;Women;4 Ceuta;Group 1403 Urolithiasis 592, 594, 7880;Both sexes;51 Ceuta;Group 1403 Urolithiasis 592, 594, 7880;Men;37 Ceuta;Group 1403 Urolithiasis 592, 594, 7880;Women;14 Ceuta;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Both sexes;82 Ceuta;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Men;35 Ceuta;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Women;47 Ceuta;Group 1405 Prostatic hyperplasia 600;Both sexes;17 Ceuta;Group 1405 Prostatic hyperplasia 600;Men;17 Ceuta;Group 1405 Prostatic hyperplasia 600;Women;.. Ceuta;Group 1406 Other diseases of the male genital organs 601-608;Both sexes;19 Ceuta;Group 1406 Other diseases of the male genital organs 601-608;Men;19 Ceuta;Group 1406 Other diseases of the male genital organs 601-608;Women;.. Ceuta;Group 1407 Disorders of breast 610-612;Both sexes;4 Ceuta;Group 1407 Disorders of breast 610-612;Men;.. Ceuta;Group 1407 Disorders of breast 610-612;Women;4 Ceuta;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Both sexes;11 Ceuta;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Men;.. Ceuta;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Women;11 Ceuta;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Both sexes;31 Ceuta;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Men;.. Ceuta;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Women;31 Ceuta;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Both sexes;51 Ceuta;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Men;.. Ceuta;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Women;51 Ceuta;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Both sexes;1,809 Ceuta;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Men;.. Ceuta;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Women;1,809 Ceuta;Group 1501 Legally induced abortion 635;Both sexes;.. Ceuta;Group 1501 Legally induced abortion 635;Men;.. Ceuta;Group 1501 Legally induced abortion 635;Women;.. Ceuta;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Both sexes;190 Ceuta;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Men;.. Ceuta;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Women;190 Ceuta;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Both sexes;1,182 Ceuta;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Men;.. Ceuta;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Women;1,182 Ceuta;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Both sexes;247 Ceuta;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Men;.. Ceuta;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Women;247 Ceuta;Group 1505 Single spontaneous delivery 650;Both sexes;71 Ceuta;Group 1505 Single spontaneous delivery 650;Men;.. Ceuta;Group 1505 Single spontaneous delivery 650;Women;71 Ceuta;Group 1506 Other deliveries 6695-6697;Both sexes;13 Ceuta;Group 1506 Other deliveries 6695-6697;Men;.. Ceuta;Group 1506 Other deliveries 6695-6697;Women;13 Ceuta;Group 1507 Complications related to the puerperium 670-676;Both sexes;7 Ceuta;Group 1507 Complications related to the puerperium 670-676;Men;.. Ceuta;Group 1507 Complications related to the puerperium 670-676;Women;7 Ceuta;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Both sexes;99 Ceuta;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Men;.. Ceuta;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Women;99 Ceuta;Group 1600 Some disorders originating in the perinatal period 760-779;Both sexes;127 Ceuta;Group 1600 Some disorders originating in the perinatal period 760-779;Men;73 Ceuta;Group 1600 Some disorders originating in the perinatal period 760-779;Women;54 Ceuta;Group 1601 Disorders related with premature delivery and a low birth weight 765;Both sexes;33 Ceuta;Group 1601 Disorders related with premature delivery and a low birth weight 765;Men;17 Ceuta;Group 1601 Disorders related with premature delivery and a low birth weight 765;Women;16 Ceuta;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Both sexes;94 Ceuta;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Men;56 Ceuta;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Women;38 Ceuta;Grupo 1700 Congenital abnormalities 740-759;Both sexes;33 Ceuta;Grupo 1700 Congenital abnormalities 740-759;Men;23 Ceuta;Grupo 1700 Congenital abnormalities 740-759;Women;10 Ceuta;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Both sexes;387 Ceuta;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Men;210 Ceuta;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Women;177 Ceuta;Group 1801 Pain in throat and chest 7841, 7865;Both sexes;34 Ceuta;Group 1801 Pain in throat and chest 7841, 7865;Men;19 Ceuta;Group 1801 Pain in throat and chest 7841, 7865;Women;15 Ceuta;Group 1802 Abdominal pain 7890;Both sexes;38 Ceuta;Group 1802 Abdominal pain 7890;Men;15 Ceuta;Group 1802 Abdominal pain 7890;Women;23 Ceuta;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Both sexes;18 Ceuta;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Men;10 Ceuta;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Women;8 Ceuta;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Both sexes;297 Ceuta;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Men;166 Ceuta;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Women;131 Ceuta;Group 1900 Injuries and poisoning 800-999;Both sexes;464 Ceuta;Group 1900 Injuries and poisoning 800-999;Men;252 Ceuta;Group 1900 Injuries and poisoning 800-999;Women;212 Ceuta;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Both sexes;34 Ceuta;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Men;21 Ceuta;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Women;13 Ceuta;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Both sexes;17 Ceuta;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Men;16 Ceuta;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Women;1 Ceuta;Group 1903 Radius and ulna fracture 813;Both sexes;48 Ceuta;Group 1903 Radius and ulna fracture 813;Men;29 Ceuta;Group 1903 Radius and ulna fracture 813;Women;19 Ceuta;Group 1904 Femur fracture 820-821;Both sexes;69 Ceuta;Group 1904 Femur fracture 820-821;Men;30 Ceuta;Group 1904 Femur fracture 820-821;Women;39 Ceuta;Group 1905 Leg fracture, including the ankle 823-824;Both sexes;37 Ceuta;Group 1905 Leg fracture, including the ankle 823-824;Men;17 Ceuta;Group 1905 Leg fracture, including the ankle 823-824;Women;20 Ceuta;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Both sexes;135 Ceuta;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Men;86 Ceuta;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Women;49 Ceuta;Group 1907 Burns 940-949;Both sexes;3 Ceuta;Group 1907 Burns 940-949;Men;2 Ceuta;Group 1907 Burns 940-949;Women;1 Ceuta;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Both sexes;17 Ceuta;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Men;10 Ceuta;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Women;7 Ceuta;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Both sexes;89 Ceuta;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Men;32 Ceuta;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Women;57 Ceuta;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Both sexes;2 Ceuta;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Men;2 Ceuta;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Women;.. Ceuta;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Both sexes;13 Ceuta;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Men;7 Ceuta;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Women;6 Ceuta;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Both sexes;112 Ceuta;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Men;60 Ceuta;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Women;52 Ceuta;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Both sexes;2 Ceuta;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Men;.. Ceuta;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Women;2 Ceuta;Group 2102 Contraceptive management V25;Both sexes;.. Ceuta;Group 2102 Contraceptive management V25;Men;.. Ceuta;Group 2102 Contraceptive management V25;Women;.. Ceuta;Group 2103 Living newborns by type of delivery V30-V39;Both sexes;.. Ceuta;Group 2103 Living newborns by type of delivery V30-V39;Men;.. Ceuta;Group 2103 Living newborns by type of delivery V30-V39;Women;.. Ceuta;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Both sexes;73 Ceuta;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Men;43 Ceuta;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Women;30 Ceuta;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Both sexes;37 Ceuta;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Men;17 Ceuta;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Women;20 Melilla;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Both sexes;6,828 Melilla;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Men;2,002 Melilla;Group 0000 All causes (see exceptions in methodology) 001-999 and V codes (only main diagnoses);Women;4,826 Melilla;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Both sexes;99 Melilla;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Men;61 Melilla;Group 0100 Certain infectious and parasitic diseases 001-033, 0341-0992, 042-044, 0995-134, 1360, 1362-139;Women;38 Melilla;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Both sexes;25 Melilla;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Men;15 Melilla;Group 0101 Intestinal infectious diseases, except for diarrhea 001-008;Women;10 Melilla;Group 0102 Imprecise intestinal infections 009;Both sexes;.. Melilla;Group 0102 Imprecise intestinal infections 009;Men;.. Melilla;Group 0102 Imprecise intestinal infections 009;Women;.. Melilla;Group 0103 Tuberculosis 010-018, 137;Both sexes;17 Melilla;Group 0103 Tuberculosis 010-018, 137;Men;12 Melilla;Group 0103 Tuberculosis 010-018, 137;Women;5 Melilla;Group 0104 Septicaemia 038;Both sexes;3 Melilla;Group 0104 Septicaemia 038;Men;3 Melilla;Group 0104 Septicaemia 038;Women;.. Melilla;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Both sexes;10 Melilla;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Men;9 Melilla;Group 0105 Human immunodeficiency virus infection (HIV) 042-044;Women;1 Melilla;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Both sexes;44 Melilla;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Men;22 Melilla;Grupo 0106 Other infectious and parasitic diseases Rest of (001-139, excepto 0340, 0993-0994, 135, 1361);Women;22 Melilla;Group 0200 Neoplasms 140-239;Both sexes;315 Melilla;Group 0200 Neoplasms 140-239;Men;144 Melilla;Group 0200 Neoplasms 140-239;Women;171 Melilla;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Both sexes;34 Melilla;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Men;23 Melilla;Group 0201 Malignant neoplasm of colon, rectum and anus 153-154;Women;11 Melilla;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Both sexes;28 Melilla;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Men;22 Melilla;Group 0202 Malignant neoplasm of trachea, bronchi and lungs 162;Women;6 Melilla;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Both sexes;.. Melilla;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Men;.. Melilla;Group 0203 Melanoma and other malignant neoplasms of skin 172-173;Women;.. Melilla;Group 0204 Malignant neoplasm of breast 174-175;Both sexes;39 Melilla;Group 0204 Malignant neoplasm of breast 174-175;Men;.. Melilla;Group 0204 Malignant neoplasm of breast 174-175;Women;39 Melilla;Group 0205 Malignant neoplasm of uterus 179-180, 182;Both sexes;6 Melilla;Group 0205 Malignant neoplasm of uterus 179-180, 182;Men;.. Melilla;Group 0205 Malignant neoplasm of uterus 179-180, 182;Women;6 Melilla;Group 0206 Malignant neoplasm of ovary 1830;Both sexes;.. Melilla;Group 0206 Malignant neoplasm of ovary 1830;Men;.. Melilla;Group 0206 Malignant neoplasm of ovary 1830;Women;.. Melilla;Group 0207 Malignant neoplasm of prostate 185;Both sexes;.. Melilla;Group 0207 Malignant neoplasm of prostate 185;Men;.. Melilla;Group 0207 Malignant neoplasm of prostate 185;Women;.. Melilla;Group 0208 Malignant neoplasm of bladder 188;Both sexes;44 Melilla;Group 0208 Malignant neoplasm of bladder 188;Men;35 Melilla;Group 0208 Malignant neoplasm of bladder 188;Women;9 Melilla;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Both sexes;70 Melilla;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Men;38 Melilla;Group 0209 Other malignant neoplasms. Rest of (140-208), 2090-2093;Women;32 Melilla;Group 0210 Carcinoma in situ 230-234;Both sexes;4 Melilla;Group 0210 Carcinoma in situ 230-234;Men;2 Melilla;Group 0210 Carcinoma in situ 230-234;Women;2 Melilla;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Both sexes;11 Melilla;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Men;5 Melilla;Group 0211 Benign neoplasm of colon, rectum and anus 2113-2114;Women;6 Melilla;Grupo 0212 Leiomyoma of uterus 218;Both sexes;21 Melilla;Grupo 0212 Leiomyoma of uterus 218;Men;.. Melilla;Grupo 0212 Leiomyoma of uterus 218;Women;21 Melilla;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Both sexes;58 Melilla;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Men;19 Melilla;Grupo 0213 Other benign neoplasms and neoplasms of uncertain or unknown behaviour Rest of (210-239), 2094-2099;Women;39 Melilla;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Both sexes;60 Melilla;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Men;31 Melilla;Group 0300 Blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 280-288, 2890, 2894-2899;Women;29 Melilla;Group 0301 Anaemias 280-285;Both sexes;32 Melilla;Group 0301 Anaemias 280-285;Men;17 Melilla;Group 0301 Anaemias 280-285;Women;15 Melilla;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Both sexes;28 Melilla;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Men;14 Melilla;Group 0302 Other blood and hematopoietic organ diseases, and disorders related to immunity 135, 2790-2793, 2798-2799, 286-288, 2890, 2894-2899;Women;14 Melilla;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Both sexes;141 Melilla;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Men;70 Melilla;Group 0400 Endocrine, nutritional and metabolic diseases 240-278;Women;71 Melilla;Group 0401 Diabetes mellitus 249-250;Both sexes;75 Melilla;Group 0401 Diabetes mellitus 249-250;Men;39 Melilla;Group 0401 Diabetes mellitus 249-250;Women;36 Melilla;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Both sexes;66 Melilla;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Men;31 Melilla;Group 0402 Other endocrine, nutritional and metabolic diseases Rest of (240-278);Women;35 Melilla;Group 0500 Mental disorders 290-319;Both sexes;110 Melilla;Group 0500 Mental disorders 290-319;Men;79 Melilla;Group 0500 Mental disorders 290-319;Women;31 Melilla;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Both sexes;2 Melilla;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Men;.. Melilla;Group 0501 Dementia 2900-2902, 2904-2909, 2941;Women;2 Melilla;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Both sexes;4 Melilla;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Men;4 Melilla;Group 0502 Mental and behavioural disorders due to alcohol 291, 303, 3050;Women;.. Melilla;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Both sexes;30 Melilla;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Men;24 Melilla;0503 Mental and behavioural disorders due to use of other psychoactive substances 292,2940,304,3051-3059;Women;6 Melilla;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Both sexes;30 Melilla;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Men;25 Melilla;Group 0504 Schizophrenia, schizotypal and delusional disorders 295,2970-2973,2978-2979,2983-2989;Women;5 Melilla;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Both sexes;19 Melilla;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Men;9 Melilla;Group 0505 Mood or affective disorders 296, 2980, 3004, 3011, 311;Women;10 Melilla;Group 0506 Other mental and behavioural disorders Rest of (290-319);Both sexes;25 Melilla;Group 0506 Other mental and behavioural disorders Rest of (290-319);Men;17 Melilla;Group 0506 Other mental and behavioural disorders Rest of (290-319);Women;8 Melilla;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Both sexes;79 Melilla;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Men;36 Melilla;Group 0600 Inflammatory diseases of the nervous system 320-359, 435;Women;43 Melilla;Group 0601 Alzheimer's disease 3310;Both sexes;.. Melilla;Group 0601 Alzheimer's disease 3310;Men;.. Melilla;Group 0601 Alzheimer's disease 3310;Women;.. Melilla;Group 0602 Multiple sclerosis 340;Both sexes;2 Melilla;Group 0602 Multiple sclerosis 340;Men;.. Melilla;Group 0602 Multiple sclerosis 340;Women;2 Melilla;Group 0603 Epilepsy 345;Both sexes;33 Melilla;Group 0603 Epilepsy 345;Men;20 Melilla;Group 0603 Epilepsy 345;Women;13 Melilla;Group 0604 Transient cerebral ischemia 435;Both sexes;8 Melilla;Group 0604 Transient cerebral ischemia 435;Men;1 Melilla;Group 0604 Transient cerebral ischemia 435;Women;7 Melilla;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Both sexes;36 Melilla;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Men;15 Melilla;Group 0605 Other inflammatory diseases of the nervous system. Rest of (320-359);Women;21 Melilla;Grupo 0700 Diseases of the eye and adnexa 360-379;Both sexes;25 Melilla;Grupo 0700 Diseases of the eye and adnexa 360-379;Men;10 Melilla;Grupo 0700 Diseases of the eye and adnexa 360-379;Women;15 Melilla;Grupo 0701 Cataract 366;Both sexes;4 Melilla;Grupo 0701 Cataract 366;Men;3 Melilla;Grupo 0701 Cataract 366;Women;1 Melilla;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Both sexes;21 Melilla;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Men;7 Melilla;Group 0702 Other diseases of the eye and adnexa Rest of (360-379);Women;14 Melilla;Group 0800 Diseases of the ear and the mastoid 380-389;Both sexes;12 Melilla;Group 0800 Diseases of the ear and the mastoid 380-389;Men;7 Melilla;Group 0800 Diseases of the ear and the mastoid 380-389;Women;5 Melilla;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Both sexes;589 Melilla;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Men;300 Melilla;Group 0900 Diseases of the circulatory system 2891-2893, 390-459 (except 435, 446 and 4590);Women;289 Melilla;Group 0901 Hypertensive disease 401-405;Both sexes;10 Melilla;Group 0901 Hypertensive disease 401-405;Men;2 Melilla;Group 0901 Hypertensive disease 401-405;Women;8 Melilla;Group 0902 Angina pectoris 4111, 413;Both sexes;63 Melilla;Group 0902 Angina pectoris 4111, 413;Men;38 Melilla;Group 0902 Angina pectoris 4111, 413;Women;25 Melilla;Group 0903 Acute myocardial infarction 410;Both sexes;83 Melilla;Group 0903 Acute myocardial infarction 410;Men;60 Melilla;Group 0903 Acute myocardial infarction 410;Women;23 Melilla;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Both sexes;17 Melilla;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Men;11 Melilla;Group 0904 Other ischemic heart diseases 4110, 4118, 412, 414;Women;6 Melilla;Group 0905 Diseases of the lungs circulation 415-417;Both sexes;4 Melilla;Group 0905 Diseases of the lungs circulation 415-417;Men;1 Melilla;Group 0905 Diseases of the lungs circulation 415-417;Women;3 Melilla;Group 0906 Heart conduction disorders and arrhytmias 426-427;Both sexes;65 Melilla;Group 0906 Heart conduction disorders and arrhytmias 426-427;Men;36 Melilla;Group 0906 Heart conduction disorders and arrhytmias 426-427;Women;29 Melilla;Grupo 0907 Heart failure 428;Both sexes;150 Melilla;Grupo 0907 Heart failure 428;Men;60 Melilla;Grupo 0907 Heart failure 428;Women;90 Melilla;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Both sexes;118 Melilla;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Men;53 Melilla;Grupo 0908 Cerebrovascular diseases 430-434, 436-438;Women;65 Melilla;Grupo 0909 Atherosclerosis 440;Both sexes;2 Melilla;Grupo 0909 Atherosclerosis 440;Men;1 Melilla;Grupo 0909 Atherosclerosis 440;Women;1 Melilla;Group 0910 Varicose veins of lower extremities 454;Both sexes;17 Melilla;Group 0910 Varicose veins of lower extremities 454;Men;7 Melilla;Group 0910 Varicose veins of lower extremities 454;Women;10 Melilla;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Both sexes;60 Melilla;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Men;31 Melilla;Group 0911 Other diseases of the circulatory system 2891-2893 and Rest of (390-459, except for 435, 446 and 4590);Women;29 Melilla;Group 1000 Diseases of the respiratory system 0340, 460-519;Both sexes;463 Melilla;Group 1000 Diseases of the respiratory system 0340, 460-519;Men;255 Melilla;Group 1000 Diseases of the respiratory system 0340, 460-519;Women;208 Melilla;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Both sexes;19 Melilla;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Men;8 Melilla;Group 1001 Acute upper respiratory infections and influenza 0340, 460-465,487-488;Women;11 Melilla;Group 1002 Pneumonia 480-486;Both sexes;150 Melilla;Group 1002 Pneumonia 480-486;Men;91 Melilla;Group 1002 Pneumonia 480-486;Women;59 Melilla;Group 1003 Acute bronchitis and bronchiolitis 466;Both sexes;51 Melilla;Group 1003 Acute bronchitis and bronchiolitis 466;Men;27 Melilla;Group 1003 Acute bronchitis and bronchiolitis 466;Women;24 Melilla;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Both sexes;1 Melilla;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Men;1 Melilla;Group 1004 Chronic disease of nucleos amygdala and adenoid 474;Women;.. Melilla;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Both sexes;31 Melilla;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Men;18 Melilla;Grupo 1005 Other diseases of the upper respiratory tract 470-473, 475-478;Women;13 Melilla;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Both sexes;45 Melilla;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Men;34 Melilla;Group 1006 Chronic obstructive lung disease and bronchiectasis 490-492, 4932, 494, 496;Women;11 Melilla;Group 1007 Asthma 4930-4931,4938-4939;Both sexes;31 Melilla;Group 1007 Asthma 4930-4931,4938-4939;Men;14 Melilla;Group 1007 Asthma 4930-4931,4938-4939;Women;17 Melilla;Group 1008 Other diseases of the respiratory system Resto of (460-519);Both sexes;135 Melilla;Group 1008 Other diseases of the respiratory system Resto of (460-519);Men;62 Melilla;Group 1008 Other diseases of the respiratory system Resto of (460-519);Women;73 Melilla;Group 1100 Diseases of the digestive system 520-579;Both sexes;656 Melilla;Group 1100 Diseases of the digestive system 520-579;Men;343 Melilla;Group 1100 Diseases of the digestive system 520-579;Women;313 Melilla;Group 1101 Disorders of the teeth and supporting structures 520-525;Both sexes;8 Melilla;Group 1101 Disorders of the teeth and supporting structures 520-525;Men;2 Melilla;Group 1101 Disorders of the teeth and supporting structures 520-525;Women;6 Melilla;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Both sexes;1 Melilla;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Men;1 Melilla;Group 1102 Other diseases of the oral cavity, salivary glands and jaws 526-529;Women;.. Melilla;Group 1103 Diseases of the esophagus 530;Both sexes;9 Melilla;Group 1103 Diseases of the esophagus 530;Men;4 Melilla;Group 1103 Diseases of the esophagus 530;Women;5 Melilla;Group 1104 Peptic ulcer 531-534;Both sexes;9 Melilla;Group 1104 Peptic ulcer 531-534;Men;4 Melilla;Group 1104 Peptic ulcer 531-534;Women;5 Melilla;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Both sexes;20 Melilla;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Men;10 Melilla;Group 1105 Dyspepsia and other diseases of the stomach and duodenum 535-537;Women;10 Melilla;Group 1106 Appendicitis 540-543;Both sexes;82 Melilla;Group 1106 Appendicitis 540-543;Men;50 Melilla;Group 1106 Appendicitis 540-543;Women;32 Melilla;Group 1107 Inguinal hernia 550;Both sexes;67 Melilla;Group 1107 Inguinal hernia 550;Men;62 Melilla;Group 1107 Inguinal hernia 550;Women;5 Melilla;Group 1108 Other abdominal hernia 551-553;Both sexes;65 Melilla;Group 1108 Other abdominal hernia 551-553;Men;22 Melilla;Group 1108 Other abdominal hernia 551-553;Women;43 Melilla;Group 1109 Crohn's disease and ulcerative colitis 555-556;Both sexes;7 Melilla;Group 1109 Crohn's disease and ulcerative colitis 555-556;Men;4 Melilla;Group 1109 Crohn's disease and ulcerative colitis 555-556;Women;3 Melilla;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Both sexes;35 Melilla;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Men;11 Melilla;Group 1110 Other noninfective and unespecified gastroenteritis and colitis 558;Women;24 Melilla;Group 1111 Intestinal obstruction without hernia 560;Both sexes;25 Melilla;Group 1111 Intestinal obstruction without hernia 560;Men;16 Melilla;Group 1111 Intestinal obstruction without hernia 560;Women;9 Melilla;Group 1112 Intestinal diverticulosis 562;Both sexes;20 Melilla;Group 1112 Intestinal diverticulosis 562;Men;13 Melilla;Group 1112 Intestinal diverticulosis 562;Women;7 Melilla;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Both sexes;39 Melilla;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Men;19 Melilla;Group 1113 Diseases of the anus and rectum 565-566, 5690-5694;Women;20 Melilla;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Both sexes;17 Melilla;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Men;11 Melilla;Group 1114 Other diseases of the intestine 557,564,5695,5698-5699;Women;6 Melilla;Group 1115 Alcoholic hepatitis 5710-5713;Both sexes;10 Melilla;Group 1115 Alcoholic hepatitis 5710-5713;Men;10 Melilla;Group 1115 Alcoholic hepatitis 5710-5713;Women;.. Melilla;Group 1116 Other diseases of the liver 570,5714-573;Both sexes;30 Melilla;Group 1116 Other diseases of the liver 570,5714-573;Men;20 Melilla;Group 1116 Other diseases of the liver 570,5714-573;Women;10 Melilla;Group 1117 Cholelithiasis 574;Both sexes;120 Melilla;Group 1117 Cholelithiasis 574;Men;35 Melilla;Group 1117 Cholelithiasis 574;Women;85 Melilla;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Both sexes;32 Melilla;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Men;19 Melilla;Group 1118 Other diseases of the biliary vesicle and tract 575-576;Women;13 Melilla;Group 1119 Pancreatic diseases 577;Both sexes;27 Melilla;Group 1119 Pancreatic diseases 577;Men;16 Melilla;Group 1119 Pancreatic diseases 577;Women;11 Melilla;Group 1120 Other diseases of the digestive system Rest of (520-579);Both sexes;33 Melilla;Group 1120 Other diseases of the digestive system Rest of (520-579);Men;14 Melilla;Group 1120 Other diseases of the digestive system Rest of (520-579);Women;19 Melilla;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Both sexes;61 Melilla;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Men;40 Melilla;Group 1200 Diseases of the skin and subcutaneous tissue 680-709;Women;21 Melilla;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Both sexes;49 Melilla;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Men;31 Melilla;Group 1201 Infections of the skin and the subcutaneous tissue 680-686;Women;18 Melilla;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Both sexes;1 Melilla;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Men;1 Melilla;Group 1202 Dermatitis, eczema and papulosquamous disorders 690-693, 6943, 696-6983, 6988-6989;Women;.. Melilla;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Both sexes;11 Melilla;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Men;8 Melilla;Group 1203 Other diseases of the skin and subcutaneous tissue Rest of (680-709);Women;3 Melilla;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Both sexes;84 Melilla;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Men;36 Melilla;Group 1300 Diseases of the musculoskeletal system and connective tissue 0993,1361,2794-2795, 446, 710-739;Women;48 Melilla;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Both sexes;.. Melilla;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Men;.. Melilla;Group 1301 Coxarthrosis (osteoarthritis of the hip) Just specified on a 5 digits ICD level;Women;.. Melilla;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Both sexes;.. Melilla;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Men;.. Melilla;Group 1302 Gonarthrosis (osteoarthritis of the knee) Just specified on a 5 digits ICD level;Women;.. Melilla;Group 1303 Internal derangement of knee 717;Both sexes;3 Melilla;Group 1303 Internal derangement of knee 717;Men;1 Melilla;Group 1303 Internal derangement of knee 717;Women;2 Melilla;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Both sexes;27 Melilla;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Men;7 Melilla;Group 1304 Other arthropathies 0993, 711-716, 718-719, 7271, 7284;Women;20 Melilla;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Both sexes;2 Melilla;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Men;1 Melilla;Group 1305 Systemic disorders of the connective tissue 1361, 2794-2795, 446, 710, 725, 7285;Women;1 Melilla;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Both sexes;5 Melilla;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Men;2 Melilla;Grupo 1306 Deforming spinal diseases and spondyloarthropathies 720-721, 7230, 7235, 7240, 737;Women;3 Melilla;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Both sexes;17 Melilla;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Men;9 Melilla;Group 1307 Intervertebral disc disorders 7220-7227, 7229;Women;8 Melilla;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Both sexes;2 Melilla;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Men;2 Melilla;Group 1308 Dorsalgia 7231,7234,7236,7241,7243,7245;Women;.. Melilla;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Both sexes;15 Melilla;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Men;9 Melilla;Group 1309 Soft tissue disorders 726, 7270, 7272-7279, 7280-7283, 7286-7289, 729;Women;6 Melilla;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Both sexes;13 Melilla;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Men;5 Melilla;Group 1310 Other disorders of the musculoskeletal system and connective tissue Rest of (710-739);Women;8 Melilla;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Both sexes;366 Melilla;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Men;139 Melilla;Group 1400 Diseases of the genitourinary system 0994, 580-5996, 5998-629, 7880;Women;227 Melilla;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Both sexes;30 Melilla;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Men;14 Melilla;Group 1401 Glomerular and tubulointerstitial renal diseases 580-5834, 5838-5839, 5900-5902, 5908-5909, 591, 5933-5935, 5937, 5996;Women;16 Melilla;Group 1402 Renal failure 5836-5837, 584-586;Both sexes;36 Melilla;Group 1402 Renal failure 5836-5837, 584-586;Men;18 Melilla;Group 1402 Renal failure 5836-5837, 584-586;Women;18 Melilla;Group 1403 Urolithiasis 592, 594, 7880;Both sexes;49 Melilla;Group 1403 Urolithiasis 592, 594, 7880;Men;28 Melilla;Group 1403 Urolithiasis 592, 594, 7880;Women;21 Melilla;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Both sexes;89 Melilla;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Men;35 Melilla;Group 1404 Other diseases of the urinary system 0994, 587-589, 5903, 5930-5932, 5936, 5938-5939, 595-597, 5980-5981, 5988-5989, 5990-5995, 5998-5999, 6256;Women;54 Melilla;Group 1405 Prostatic hyperplasia 600;Both sexes;14 Melilla;Group 1405 Prostatic hyperplasia 600;Men;14 Melilla;Group 1405 Prostatic hyperplasia 600;Women;.. Melilla;Group 1406 Other diseases of the male genital organs 601-608;Both sexes;26 Melilla;Group 1406 Other diseases of the male genital organs 601-608;Men;26 Melilla;Group 1406 Other diseases of the male genital organs 601-608;Women;.. Melilla;Group 1407 Disorders of breast 610-612;Both sexes;9 Melilla;Group 1407 Disorders of breast 610-612;Men;3 Melilla;Group 1407 Disorders of breast 610-612;Women;6 Melilla;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Both sexes;16 Melilla;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Men;.. Melilla;Group 1408 Inflammatory disease of the female pelvic organs 614-616;Women;16 Melilla;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Both sexes;35 Melilla;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Men;.. Melilla;Group 1409 Menstruation disorders, menopause and other diseases of the female genital organs 6250-6255, 6257-627;Women;35 Melilla;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Both sexes;62 Melilla;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Men;1 Melilla;Group 1410 Other disorders of the genitourinary system Rest of (580-629, except 5997);Women;61 Melilla;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Both sexes;2,978 Melilla;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Men;.. Melilla;Group 1500 Complications of pregnancy, labour and postpartum period 630-679;Women;2,978 Melilla;Group 1501 Legally induced abortion 635;Both sexes;.. Melilla;Group 1501 Legally induced abortion 635;Men;.. Melilla;Group 1501 Legally induced abortion 635;Women;.. Melilla;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Both sexes;259 Melilla;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Men;.. Melilla;Group 1502 Other pregnancy with abortive outcome 630-634, 636-639;Women;259 Melilla;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Both sexes;1,384 Melilla;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Men;.. Melilla;Group 1503 Complications of pregnancy mainly during the antenatal period 640-646, 651-659;Women;1,384 Melilla;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Both sexes;744 Melilla;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Men;.. Melilla;Group 1504 Complications of pregnancy and during labour 660-668, 6690-6694, 6698-6699;Women;744 Melilla;Group 1505 Single spontaneous delivery 650;Both sexes;209 Melilla;Group 1505 Single spontaneous delivery 650;Men;.. Melilla;Group 1505 Single spontaneous delivery 650;Women;209 Melilla;Group 1506 Other deliveries 6695-6697;Both sexes;34 Melilla;Group 1506 Other deliveries 6695-6697;Men;.. Melilla;Group 1506 Other deliveries 6695-6697;Women;34 Melilla;Group 1507 Complications related to the puerperium 670-676;Both sexes;16 Melilla;Group 1507 Complications related to the puerperium 670-676;Men;.. Melilla;Group 1507 Complications related to the puerperium 670-676;Women;16 Melilla;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Both sexes;332 Melilla;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Men;.. Melilla;Group 1508 Other obstetric conditions not classified elsewhere 647-649, 677-679;Women;332 Melilla;Group 1600 Some disorders originating in the perinatal period 760-779;Both sexes;187 Melilla;Group 1600 Some disorders originating in the perinatal period 760-779;Men;113 Melilla;Group 1600 Some disorders originating in the perinatal period 760-779;Women;74 Melilla;Group 1601 Disorders related with premature delivery and a low birth weight 765;Both sexes;38 Melilla;Group 1601 Disorders related with premature delivery and a low birth weight 765;Men;20 Melilla;Group 1601 Disorders related with premature delivery and a low birth weight 765;Women;18 Melilla;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Both sexes;149 Melilla;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Men;93 Melilla;Group 1602 Other conditions originating in the perinatal period Rest of (760-779);Women;56 Melilla;Grupo 1700 Congenital abnormalities 740-759;Both sexes;57 Melilla;Grupo 1700 Congenital abnormalities 740-759;Men;39 Melilla;Grupo 1700 Congenital abnormalities 740-759;Women;18 Melilla;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Both sexes;148 Melilla;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Men;66 Melilla;Signs, symptoms and abnormal clinical and laboratory findings , not classified elsewhere 780-799 (except 7880 and including 4590,5997);Women;82 Melilla;Group 1801 Pain in throat and chest 7841, 7865;Both sexes;1 Melilla;Group 1801 Pain in throat and chest 7841, 7865;Men;1 Melilla;Group 1801 Pain in throat and chest 7841, 7865;Women;.. Melilla;Group 1802 Abdominal pain 7890;Both sexes;28 Melilla;Group 1802 Abdominal pain 7890;Men;11 Melilla;Group 1802 Abdominal pain 7890;Women;17 Melilla;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Both sexes;.. Melilla;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Men;.. Melilla;1803 Other unknown and unspecified causes of morbidity and mortality 7999;Women;.. Melilla;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Both sexes;119 Melilla;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Men;54 Melilla;Group 1804 Other igns, symptoms and abnormal clinical and laboratory findings , not classified elsewhere Rest of (except 7880 and including 4590,5997);Women;65 Melilla;Group 1900 Injuries and poisoning 800-999;Both sexes;367 Melilla;Group 1900 Injuries and poisoning 800-999;Men;225 Melilla;Group 1900 Injuries and poisoning 800-999;Women;142 Melilla;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Both sexes;22 Melilla;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Men;19 Melilla;Group 1901 Intracranial injury 8001-8004, 8006-8009, 8011-8014, 8016-8019, 8031-8034, 8036-8039, 8041-8044, 8046-8049, 850-854;Women;3 Melilla;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Both sexes;20 Melilla;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Men;18 Melilla;Group 1902 Other injuries to the head 8000, 8005, 8010, 8015, 802, 8030, 8035, 8040, 8045, 830, 870-873, 900, 910, 918, 920, 921, 925, 950-951;Women;2 Melilla;Group 1903 Radius and ulna fracture 813;Both sexes;20 Melilla;Group 1903 Radius and ulna fracture 813;Men;15 Melilla;Group 1903 Radius and ulna fracture 813;Women;5 Melilla;Group 1904 Femur fracture 820-821;Both sexes;95 Melilla;Group 1904 Femur fracture 820-821;Men;37 Melilla;Group 1904 Femur fracture 820-821;Women;58 Melilla;Group 1905 Leg fracture, including the ankle 823-824;Both sexes;34 Melilla;Group 1905 Leg fracture, including the ankle 823-824;Men;26 Melilla;Group 1905 Leg fracture, including the ankle 823-824;Women;8 Melilla;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Both sexes;98 Melilla;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Men;69 Melilla;Group 1906 Other injuries 805-812, 814-819, 822, 825-829, 831-848, 860-869, 874-897, 901-904, 911-917, 919, 922-924, 926-929, 952-959;Women;29 Melilla;Group 1907 Burns 940-949;Both sexes;8 Melilla;Group 1907 Burns 940-949;Men;4 Melilla;Group 1907 Burns 940-949;Women;4 Melilla;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Both sexes;11 Melilla;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Men;5 Melilla;Group 1908 poisonings due to drugs, medicines and biological substances and toxic effects of non-medicinal substances with respect to their origin 960-989;Women;6 Melilla;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Both sexes;51 Melilla;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Men;28 Melilla;Group 1909 Complications of surgical and medical care not elsewhere classified 996-999;Women;23 Melilla;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Both sexes;.. Melilla;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Men;.. Melilla;Group 1910 Late effects of injuries, poisoning, toxic effects and other external causes 905-909;Women;.. Melilla;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Both sexes;8 Melilla;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Men;4 Melilla;Group 1911 Other and unspecified effects of external causes 930-939, 990-995;Women;4 Melilla;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Both sexes;31 Melilla;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Men;8 Melilla;Group 2100 Factors influencing health status and contact with health services Codes V (only main diagnosis);Women;23 Melilla;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Both sexes;3 Melilla;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Men;.. Melilla;Group 2101 Monitoring and assessment due to suspicion of diseases not founded V710-V712, V717-V719;Women;3 Melilla;Group 2102 Contraceptive management V25;Both sexes;11 Melilla;Group 2102 Contraceptive management V25;Men;.. Melilla;Group 2102 Contraceptive management V25;Women;11 Melilla;Group 2103 Living newborns by type of delivery V30-V39;Both sexes;.. Melilla;Group 2103 Living newborns by type of delivery V30-V39;Men;.. Melilla;Group 2103 Living newborns by type of delivery V30-V39;Women;.. Melilla;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Both sexes;6 Melilla;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Men;1 Melilla;Group 2104 Other medical care, including radiotherapy and chemotherapy sessions V071, V58;Women;5 Melilla;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Both sexes;11 Melilla;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Men;7 Melilla;Group 2105 Other factors influencing health status and contact with health services Rest of codes V (only main diagnosis);Women;4